SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 80.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 23, 2006, 11:12:18 ; Search time 7 Seconds
(without alignments)
2.991 Million cell updates/sec

Title: US-10-800-077-392
Perfect score: 4235
Sequence: 1 ctcggcccggcggcgcgagc.....cgtgtcccagctccaggggt 4235

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 145 seqs, 2472 residues

Total number of hits satisfying chosen parameters: 290

Minimum DB seq length: 5
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 145 summaries

Database : fetch392rni.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	20.4	0.5	24	1	US-09-140-378A-3	Sequence 3, Appli
	2	20.2	0.5	25	1	US-09-396-196G-24487	Sequence 24487, A
c	3	20.2	0.5	25	1	US-09-396-196G-37489	Sequence 37489, A
	4	17.4	0.4	20	1	US-09-593-711A-41	Sequence 41, Appl
c	5	16.8	0.4	21	1	US-09-226-012-91	Sequence 91, Appl
c	6	16.4	0.4	18	1	US-09-630-706-22	Sequence 22, Appl
	7	16.4	0.4	18	1	US-09-475-947A-333	Sequence 333, App
c	8	16.4	0.4	20	1	US-08-204-697-6	Sequence 6, Appli
c	9	16.4	0.4	20	1	US-08-445-291-3	Sequence 3, Appli
c	10	16.4	0.4	20	1	US-08-744-332-6	Sequence 6, Appli
c	11	16.4	0.4	20	1	US-09-198-452A-2100	Sequence 2100, Ap
c	12	16	0.4	19	1	US-09-696-791-72	Sequence 72, Appl
c	13	16	0.4	19	1	US-09-696-791-73	Sequence 73, Appl
	14	15.8	0.4	19	1	US-08-359-705B-22	Sequence 22, Appl
	15	15.8	0.4	19	1	US-08-286-846A-22	Sequence 22, Appl
	16	15.8	0.4	19	1	US-08-457-880A-22	Sequence 22, Appl
	17	15.8	0.4	19	1	US-08-444-622A-22	Sequence 22, Appl
	18	15.8	0.4	19	1	US-08-942-562-22	Sequence 22, Appl
	19	15.8	0.4	19	1	US-09-156-923-22	Sequence 22, Appl
c	20	15.8	0.4	19	1	US-10-083-246A-83	Sequence 83, Appl
	21	15.4	0.4	17	1	US-08-292-620A-1948	Sequence 1948, Ap
	22	15.4	0.4	17	1	US-09-071-845-1948	Sequence 1948, Ap
c	23	15.4	0.4	17	1	US-09-866-108A-1653	Sequence 1653, Ap
c	24	15.4	0.4	17	1	US-09-866-108A-1654	Sequence 1654, Ap
	25	15.4	0.4	17	1	US-09-818-875-3946	Sequence 3946, Ap
c	26	15.4	0.4	17	1	US-09-818-875-3947	Sequence 3947, Ap
c	27	15	0.4	17	1	US-08-937-063-15	Sequence 15, Appl
	28	15	0.4	17	1	US-09-371-772B-5010	Sequence 5010, Ap
	29	15	0.4	17	1	US-09-371-772B-5011	Sequence 5011, Ap
	30	15	0.4	17	1	US-09-371-772B-5012	Sequence 5012, Ap
c	31	15	0.4	17	1	US-09-866-108A-1651	Sequence 1651, Ap
c	32	15	0.4	17	1	US-09-866-108A-1652	Sequence 1652, Ap
c	33	15	0.4	17	1	US-09-777-732A-15	Sequence 15, Appl
	34	15	0.4	18	1	US-08-584-040-3042	Sequence 3042, Ap
	35	15	0.4	18	1	US-09-371-772B-1470	Sequence 1470, Ap
	36	15	0.4	18	1	US-09-685-664B-1470	Sequence 1470, Ap
	37	14.8	0.3	18	1	US-09-161-015-29	Sequence 29, Appl
	38	14.8	0.3	18	1	US-09-387-341-172	Sequence 172, App
	39	14.8	0.3	18	1	US-09-920-760-12	Sequence 12, Appl
	40	14.8	0.3	18	1	US-09-544-398B-517	Sequence 517, App
	41	14.8	0.3	18	1	US-09-543-771B-517	Sequence 517, App
c	42	14.4	0.3	16	1	US-09-060-299-432	Sequence 432, App
c	43	14.4	0.3	16	1	US-09-402-923A-432	Sequence 432, App
	44	14.4	0.3	16	1	US-09-371-772B-5872	Sequence 5872, Ap
	45	14.4	0.3	17	1	US-09-371-772B-4886	Sequence 4886, Ap
	46	14.4	0.3	17	1	US-09-866-108A-905	Sequence 905, App
	47	14.4	0.3	17	1	US-09-866-108A-906	Sequence 906, App
c	48	14.4	0.3	17	1	US-09-866-108A-1655	Sequence 1655, Ap
	49	14.4	0.3	17	1	US-09-866-108A-2647	Sequence 2647, Ap
	50	14.4	0.3	17	1	US-09-866-108A-2648	Sequence 2648, Ap
	51	14.4	0.3	18	1	US-07-796-106-13	Sequence 13, Appl
	52	14.4	0.3	18	1	US-09-199-859-46	Sequence 46, Appl
c	53	14.4	0.3	18	1	US-09-213-719-82	Sequence 82, Appl
	54	14.4	0.3	18	1	US-09-044-602-2	Sequence 2, Appli
	55	14.4	0.3	18	1	US-09-856-747-46	Sequence 46, Appl
	56	14.4	0.3	18	1	US-10-424-630-2	Sequence 2, Appli
c	57	14	0.3	14	1	US-08-050-073-184	Sequence 184, App
	58	14	0.3	15	1	US-08-009-075-1	Sequence 1, Appli
c	59	14	0.3	15	1	US-08-050-073-167	Sequence 167, App
c	60	14	0.3	15	1	US-09-081-646-81	Sequence 81, Appl
c	61	14	0.3	15	1	US-09-081-646-770	Sequence 770, App
c	62	14	0.3	16	1	US-08-050-073-166	Sequence 166, App
	63	14	0.3	16	1	US-09-531-000-23	Sequence 23, Appl
	64	14	0.3	17	1	US-08-050-073-75	Sequence 75, Appl
c	65	14	0.3	17	1	US-08-050-073-149	Sequence 149, App
c	66	14	0.3	17	1	US-09-160-496-6	Sequence 6, Appli
	67	14	0.3	17	1	US-09-371-772B-5013	Sequence 5013, Ap
c	68	14	0.3	17	1	US-09-866-108A-1650	Sequence 1650, Ap
c	69	14	0.3	17	1	5182195-67	Patent No. 5182195
	70	13.8	0.3	17	1	US-08-379-078-482	Sequence 482, App
c	71	13.8	0.3	17	1	US-08-261-822A-30	Sequence 30, Appl
	72	13.8	0.3	17	1	US-08-955-138-48	Sequence 48, Appl
	73	13.8	0.3	17	1	US-08-985-162-326	Sequence 326, App
	74	13.8	0.3	17	1	US-07-974-409C-96	Sequence 96, Appl
c	75	13.8	0.3	17	1	US-08-584-040-2794	Sequence 2794, Ap
	76	13.8	0.3	17	1	US-08-584-040-2824	Sequence 2824, Ap
	77	13.8	0.3	17	1	US-08-584-040-7819	Sequence 7819, Ap
c	78	13.8	0.3	17	1	US-09-673-809-98	Sequence 98, Appl
	79	13.8	0.3	17	1	US-09-474-432B-535	Sequence 535, App
	80	13.8	0.3	17	1	US-09-474-432B-559	Sequence 559, App
c	81	13.8	0.3	17	1	US-09-371-772B-1318	Sequence 1318, Ap
	82	13.8	0.3	17	1	US-09-371-772B-1348	Sequence 1348, Ap
	83	13.8	0.3	17	1	US-09-371-772B-3603	Sequence 3603, Ap
	84	13.8	0.3	17	1	US-09-371-772B-4884	Sequence 4884, Ap
	85	13.8	0.3	17	1	US-09-371-772B-4885	Sequence 4885, Ap
	86	13.8	0.3	17	1	US-09-371-772B-5092	Sequence 5092, Ap
c	87	13.8	0.3	17	1	US-09-371-772B-5545	Sequence 5545, Ap
	88	13.8	0.3	17	1	US-09-371-772B-5599	Sequence 5599, Ap
	89	13.8	0.3	17	1	US-09-371-772B-6785	Sequence 6785, Ap
	90	13.8	0.3	17	1	US-09-476-387-534	Sequence 534, App
	91	13.8	0.3	17	1	US-09-476-387-558	Sequence 558, App
	92	13.8	0.3	17	1	US-09-401-063-326	Sequence 326, App
	93	13.8	0.3	17	1	US-09-827-998-504	Sequence 504, App
	94	13.8	0.3	17	1	US-09-827-998-505	Sequence 505, App
c	95	13.8	0.3	17	1	US-09-747-391-84	Sequence 84, Appl
c	96	13.8	0.3	17	1	US-09-866-108A-2316	Sequence 2316, Ap
	97	13.8	0.3	17	1	US-09-866-108A-2464	Sequence 2464, Ap
	98	13.8	0.3	17	1	US-09-866-108A-2778	Sequence 2778, Ap
c	99	13.8	0.3	17	1	US-09-866-108A-6262	Sequence 6262, Ap
c	100	13.8	0.3	17	1	US-09-866-108A-9235	Sequence 9235, Ap
c	101	13.8	0.3	17	1	US-09-866-108A-9236	Sequence 9236, Ap
c	102	13.8	0.3	17	1	US-09-866-108A-10354	Sequence 10354, A
c	103	13.8	0.3	17	1	US-09-866-108A-10529	Sequence 10529, A
c	104	13.8	0.3	17	1	US-09-866-108A-10530	Sequence 10530, A
c	105	13.8	0.3	17	1	US-09-866-108A-10531	Sequence 10531, A
c	106	13.8	0.3	17	1	US-09-685-664B-1318	Sequence 1318, Ap

107	13.8	0.3	17	1	US-09-685-664B-1348	Sequence 1348, Ap
108	13.8	0.3	17	1	US-09-685-664B-3603	Sequence 3603, Ap
109	13.8	0.3	17	1	US-09-554-267-2	Sequence 2, Appli
110	13.8	0.3	17	1	US-09-554-267-21	Sequence 21, Appl
111	13.8	0.3	17	1	US-09-554-267-40	Sequence 40, Appl
112	13.8	0.3	17	1	PCT-US93-00977-96	Sequence 96, Appl
c 113	13.8	0.3	17	1	PCT-US95-07744A-30	Sequence 30, Appl
c 114	13.4	0.3	15	1	US-08-182-968A-3	Sequence 3, Appli
c 115	13.4	0.3	15	1	US-08-319-492B-95	Sequence 95, Appl
c 116	13.4	0.3	15	1	US-08-291-932A-95	Sequence 95, Appl
c 117	13.4	0.3	15	1	US-08-291-932A-96	Sequence 96, Appl
118	13.4	0.3	15	1	US-08-291-932A-244	Sequence 244, App
c 119	13.4	0.3	15	1	US-08-291-932A-284	Sequence 284, App
c 120	13.4	0.3	15	1	US-08-291-932A-285	Sequence 285, App
c 121	13.4	0.3	15	1	US-08-774-306A-3	Sequence 3, Appli
122	13.4	0.3	15	1	US-08-585-684B-2264	Sequence 2264, Ap
123	13.4	0.3	15	1	US-08-585-684B-2265	Sequence 2265, Ap
124	13.4	0.3	15	1	US-08-585-684B-2266	Sequence 2266, Ap
c 125	13.4	0.3	15	1	US-08-757-024-889	Sequence 889, App
c 126	13.4	0.3	15	1	US-08-757-024-946	Sequence 946, App
c 127	13.4	0.3	15	1	US-09-064-156A-3	Sequence 3, Appli
128	13.4	0.3	15	1	US-09-038-073-2264	Sequence 2264, Ap
129	13.4	0.3	15	1	US-09-038-073-2265	Sequence 2265, Ap
130	13.4	0.3	15	1	US-09-038-073-2266	Sequence 2266, Ap
c 131	13.4	0.3	15	1	US-09-081-646-122	Sequence 122, App
c 132	13.4	0.3	15	1	US-09-081-646-870	Sequence 870, App
c 133	13.4	0.3	15	1	US-09-093-972C-889	Sequence 889, App
c 134	13.4	0.3	15	1	US-09-093-972C-946	Sequence 946, App
c 135	13.4	0.3	16	1	US-08-757-024-882	Sequence 882, App
c 136	13.4	0.3	16	1	US-08-757-024-945	Sequence 945, App
137	13.4	0.3	16	1	US-09-413-452-25	Sequence 25, Appl
138	13.4	0.3	16	1	US-09-413-068-25	Sequence 25, Appl
c 139	13.4	0.3	16	1	US-09-060-299-433	Sequence 433, App
c 140	13.4	0.3	16	1	US-09-402-923A-433	Sequence 433, App
141	13.4	0.3	16	1	US-09-787-069-6	Sequence 6, Appli
142	13.4	0.3	16	1	US-09-914-841A-5	Sequence 5, Appli
c 143	13.4	0.3	16	1	US-09-093-972C-882	Sequence 882, App
c 144	13.4	0.3	16	1	US-09-093-972C-945	Sequence 945, App
145	13.4	0.3	16	1	US-10-110-502-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1
US-09-140-378A-3/c
; Sequence 3, Application US/09140378A
; Patent No. 6627733
; GENERAL INFORMATION:
; APPLICANT: Johnson, Jeffrey D.
; APPLICANT: Rutter, William J.
; APPLICANT: Edman, Jeffrey C.
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: Receptor Tyrosine Kinase With a Discoidin-Type Binding
; TITLE OF INVENTION: Domain
; FILE REFERENCE: 023070-079010US
; CURRENT APPLICATION NUMBER: US/09/140,378A
; CURRENT FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 08/077,254
; PRIOR FILING DATE: 1993-06-14
; PRIOR APPLICATION NUMBER: US 08/292,299
; PRIOR FILING DATE: 1994-08-16
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
; OTHER INFORMATION: oligonucleotide
US-09-140-378A-3

Query Match 0.5%; Score 20.4; DB 1; Length 24;
Best Local Similarity 75.0%; Pred. No. 6.9;
Matches 18; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2587 CACCGAGACCTGGCTGCTCGCAAC 2610
             ||:|| ||:|||||:||:||:|||
Db         24 CAYCGSGAYCTGGCYGCYCGSAAC 1
```

RESULT 2
US-09-396-196G-24487
; Sequence 24487, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 24487
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-24487

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 8.4;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       3005 TGATCCGGAACCCCGCCAGCCTCAA 3029
              ||||||| ||||||  |||||||||
Db          1 TGATCCGAAACCCCAACAGCCTCAA 25
```

RESULT 3
US-09-396-196G-37489/c
; Sequence 37489, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 37489
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-37489

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 8.4;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1940 ATCACAGCCAGACCCAACTGGATGA 1964
              |||||| |||||||||| ||| ||
Db         25 ATCACAACCAGACCCAACAGGAAGA 1
```

```
RESULT 4
US-09-593-711A-41
; Sequence 41, Application US/09593711A
; Patent No. 6271030
; GENERAL INFORMATION:
;  APPLICANT:    Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION:    ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
;  FILE REFERENCE:    RTS-0118
;  CURRENT APPLICATION NUMBER: US/09/593,711A
;  CURRENT FILING DATE:  2000-06-14
;  NUMBER OF SEQ ID NOS:    244
; SEQ ID NO 41
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-593-711A-41

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 18;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        214 GCCGCCGCCCGGTGCCCCG 232
              ||||||||||| ||||||
Db          1 GCCGCCGCCCGGCGCCCCG 19


RESULT 5
US-09-226-012-91/c
; Sequence 91, Application US/09226012
; Patent No. 6207383
; GENERAL INFORMATION:
;  APPLICANT: Keating, Mark T.
;  APPLICANT: Splawski, Igor
;  TITLE OF INVENTION: MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT
;  TITLE OF INVENTION: SYNDROME GENE
;  FILE REFERENCE: 2323-136
;  CURRENT APPLICATION NUMBER: US/09/226,012
;  CURRENT FILING DATE: 1999-01-06
;  EARLIER APPLICATION NUMBER: 09/122,847
;  EARLIER FILING DATE: 1998-07-27
;  NUMBER OF SEQ ID NOS: 116
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 91
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-226-012-91

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 26;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2018 GTGTGGTCCTGGTCCTGGTG 2037
              || |||||| ||||||||||
Db         20 GTCTGGTCCAGGTCCTGGTG 1


RESULT 6
US-09-630-706-22/c
; Sequence 22, Application US/09630706
; Patent No. 6277640
; GENERAL INFORMATION:
;  APPLICANT:  C. Frank Bennett
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION:  ANTISENSE MODULATION OF HER-3 EXPRESSION
;  FILE REFERENCE:  RTS-0053
;  CURRENT APPLICATION NUMBER: US/09/630,706
;  CURRENT FILING DATE:  2000-08-01
;  NUMBER OF SEQ ID NOS:  94
; SEQ ID NO 22
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-630-706-22

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 22;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        105 ACCCCAACTCCAGCCACG 122
              || ||||||||||||||||
Db         18 ACACCAACTCCAGCCACG 1


RESULT 7
US-09-475-947A-333
; Sequence 333, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
;  APPLICANT: Garner, Harold R.
;  APPLICANT:  Wren, Jonathan D.
;  APPLICANT:  Minna, John D.
;  TITLE OF INVENTION: Polymorphic Repeats in Human Genes
;  FILE REFERENCE: UTSD0667
;  CURRENT APPLICATION NUMBER: US/09/475,947A
;  CURRENT FILING DATE:  1999-12-31
;  NUMBER OF SEQ ID NOS: 346
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 333
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: human
US-09-475-947A-333

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 22;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1069 GGCCCCAGCCCCAGCCTC 1086
              ||||||||| ||||||||
Db          1 GGCCCCAGCTCCAGCCTC 18


RESULT 8
US-08-204-697-6/c
; Sequence 6, Application US/08204697
; Patent No. 5648482
;  GENERAL INFORMATION:
;    APPLICANT:  Meyer, Urs A
;    TITLE OF INVENTION:  DETECTION OF POOR METABOLIZERS OF DRUGS
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/204,697
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/716,500
;      FILING DATE:  17-JUN-1991
```

```
;       APPLICATION NUMBER:  EP 90810467.2
;       FILING DATE:  22-JUN-1990
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  EP 91108867.2
;       FILING DATE:  29-MAY-1991
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Schlager, John J.
;       REGISTRATION NUMBER:  20942
;       REFERENCE/DOCKET NUMBER:  RAN 4095/3
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  201-235-2863
;       TELEFAX:  201-235-3500
;   INFORMATION FOR SEQ ID NO:  6:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
;     HYPOTHETICAL:  NO
;     ANTI-SENSE:  NO
US-08-204-697-6

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 28;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3722 AGAAGGGGTGTCAGGGCC 3739
              |||||| ||||||||||
Db         20 AGAAGGAGTGTCAGGGCC 3


RESULT 9
US-08-445-291-3/c
; Sequence 3, Application US/08445291
; Patent No. 5649638
;  GENERAL INFORMATION:
;    APPLICANT:  Polushin, Nikolai N.
;    APPLICANT:  Efimov, Vladimir A.
;    APPLICANT:  Morocho, Alan M.
;    APPLICANT:  Cohen, Jack S.
;    TITLE OF INVENTION:  DEPROTECTION OF OLIGONUCLEOTIDES AND
;    TITLE OF INVENTION:  ANALOGS
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Oliff & Berridge
;      STREET:  P.O. Box 19928
;      CITY:  Alexandria
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22320
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/445,291
;      FILING DATE:
;      CLASSIFICATION:  102
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Berridge, William P.
;      REGISTRATION NUMBER:  30,024
;      REFERENCE/DOCKET NUMBER:  WPB/J-267
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703)836-6400
;      TELEFAX:  (703)836-2787
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-445-291-3

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 28;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3722 AGAAGGGGTGTCAGGGCC 3739
              |||||| ||||||||||
Db         20 AGAAGGAGTGTCAGGGCC 3


RESULT 10
US-08-744-332-6/c
; Sequence 6, Application US/08744332
; Patent No. 5844108
;  GENERAL INFORMATION:
;    APPLICANT:  Meyer, Urs A
;    TITLE OF INVENTION:  DETECTION OF POOR METABOLIZERS OF DRUGS
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/744,332
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/716,500
;      FILING DATE:  17-JUN-1991
;      APPLICATION NUMBER:  EP 90810467.2
;      FILING DATE:  22-JUN-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 91108867.2
;      FILING DATE:  29-MAY-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Schlager, John J.
;      REGISTRATION NUMBER:  20942
;      REFERENCE/DOCKET NUMBER:  RAN 4095/3
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-235-2863
;      TELEFAX:  201-235-3500
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-744-332-6

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 28;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3722 AGAAGGGGTGTCAGGGCC 3739
              |||||| ||||||||||
Db         20 AGAAGGAGTGTCAGGGCC 3


RESULT 11
US-09-198-452A-2100/c
; Sequence 2100, Application US/09198452A
```

; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preve
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2100
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-2100

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 28;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3134 AAATGGGAAGATACGAAG 3151
||||||||||||| |||||
Db 19 AAATGGGAAGATCCGAAG 2

RESULT 12
US-09-696-791-72/c
; Sequence 72, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 72
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk1 ribozyme binding site
US-09-696-791-72

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4188 CTTTTTGTATAAATAA 4203
||||||||||||||||
Db 19 CTTTTTGTATAAATAA 4

RESULT 13
US-09-696-791-73/c
; Sequence 73, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 73
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk1 ribozyme binding site
US-09-696-791-73

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4188 CTTTTTGTATAAATAA 4203
||||||||||||||||
Db 17 CTTTTTGTATAAATAA 2

RESULT 14
US-08-359-705B-22
; Sequence 22, Application US/08359705B
; Patent No. 5844092
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; APPLICANT: Shelton, David L.
; APPLICANT: Urfer, Roman
; TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor Inhibitors
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/359,705B
; FILING DATE: 20-Dec-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286846
; FILING DATE: 08/10/94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/215139
; FILING DATE: 03/18/94
; ATTORNEY/AGENT INFORMATION:
; NAME: Torchia, PhD., Timothy E.
; REGISTRATION NUMBER: 36,700
; REFERENCE/DOCKET NUMBER: P0873P2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-8674
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-08-359-705B-22

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 32;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3539 ACTCCAGACCAAGGGTGAG 3557
|| |||| ||||||||||
Db 1 ACGCCAGGCCAAGGGTGAG 19

RESULT 15
US-08-286-846A-22
; Sequence 22, Application US/08286846A

```
; Patent No. 5877016
;  GENERAL INFORMATION:
;    APPLICANT:  Presta, Leonard G.
;    APPLICANT:  Shelton, David L.
;    APPLICANT:  Urfer, Roman
;    TITLE OF INVENTION:  Human trk Receptors and Neurotrophic Factor Inhibitors
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genentech, Inc.
;      STREET:  460 Point San Bruno Blvd
;      CITY:  South San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94080
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44 Mb floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WinPatin (Genentech)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/286,846A
;      FILING DATE:  05-Aug-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Torchia, PhD., Timothy E.
;      REGISTRATION NUMBER:  36,700
;      REFERENCE/DOCKET NUMBER:  P0873P1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415/225-8674
;      TELEFAX:  415/952-9881
;      TELEX:  910/371-7168
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
US-08-286-846A-22

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 32;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3539 ACTCCAGACCAAGGGTGAG 3557
              || |||| ||||||||||| 
Db          1 ACGCCAGGCCAAGGGTGAG 19


RESULT 16
US-08-457-880A-22
; Sequence 22, Application US/08457880A
; Patent No. 5910574
;  GENERAL INFORMATION:
;    APPLICANT:  Leonard G. Presta
;    APPLICANT:  David L. Shelton
;    APPLICANT:  Roman Urfer
;    TITLE OF INVENTION:  HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR
;    TITLE OF INVENTION:  INHIBITORS
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genentech, Inc.
;      STREET:  1 DNA Way
;      CITY:  South San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94080
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44 Mb floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WinPatin (Genentech)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/457,880A
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/444,622
;      FILING DATE:  19-May-1995
;      APPLICATION NUMBER:  08/286846
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Torchia, PhD., Timothy E.
;      REGISTRATION NUMBER:  36,700
;      REFERENCE/DOCKET NUMBER:  P0873P1C3
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650/225-8674
;      TELEFAX:  650/952-9881
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
US-08-457-880A-22

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 32;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3539 ACTCCAGACCAAGGGTGAG 3557
              || |||| ||||||||||| 
Db          1 ACGCCAGGCCAAGGGTGAG 19


RESULT 17
US-08-444-622A-22
; Sequence 22, Application US/08444622A
; Patent No. 6025166
;  GENERAL INFORMATION:
;    APPLICANT:  Leonard G. Presta
;    APPLICANT:  David L. Shelton
;    APPLICANT:  Roman Urfer
;    TITLE OF INVENTION:  HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genentech, Inc.
;      STREET:  1 DNA Way
;      CITY:  South San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94080
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44 Mb floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WinPatin (Genentech)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/444,622A
;      FILING DATE:  19-May-1995
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/286846
;      FILING DATE:  5
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Torchia, PhD., Timothy E.
;      REGISTRATION NUMBER:  36,700
;      REFERENCE/DOCKET NUMBER:  P0873P1C3
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650/225-8674
;      TELEFAX:  650/952-9881
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
```

```
US-08-444-622A-22

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 32;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3539 ACTCCAGACCAAGGGTGAG 3557
              || |||| ||||||||||
Db          1 ACGCCAGGCCAAGGGTGAG 19


RESULT 18
US-08-942-562-22
; Sequence 22, Application US/08942562
; Patent No. 6027927
;  GENERAL INFORMATION:
;    APPLICANT:  Presta, Leonard G.
;    APPLICANT:  Shelton, David L.
;    APPLICANT:  Urfer, Roman
;    TITLE OF INVENTION:  Human trk Receptors and Neurotrophic
;    TITLE OF INVENTION:  Factor Inhibitors
;    NUMBER OF SEQUENCES:  37
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genentech, Inc.
;      STREET:  460 Point San Bruno Blvd
;      CITY:  South San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94080
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44 Mb floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WinPatin (Genentech)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/942,562
;      FILING DATE:  01-OCT-1997
;      CLASSIFICATION:  530
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/444,597
;      FILING DATE:  19-May-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Torchia, PhD., Timothy E.
;      REGISTRATION NUMBER:  36,700
;      REFERENCE/DOCKET NUMBER:  P0873P1C2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415/225-8674
;      TELEFAX:  415/952-9881
;      TELEX:  910/371-7168
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
US-08-942-562-22

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 32;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3539 ACTCCAGACCAAGGGTGAG 3557
              || |||| ||||||||||
Db          1 ACGCCAGGCCAAGGGTGAG 19


RESULT 19
US-09-156-923-22
; Sequence 22, Application US/09156923
; Patent No. 6153189
;  GENERAL INFORMATION:
;    APPLICANT:  Presta, Leonard G.
;    APPLICANT:  Shelton, David L.
;    APPLICANT:  Urfer, Roman
;    TITLE OF INVENTION:  Human trk Receptors and Neurotrophic Factor Inhibitors
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson & Bear
;      STREET:  620 Newport Center Drive 16th Floor
;      CITY:  Newport Beach
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44 Mb floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WinPatin (Genentech)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/156,923
;      FILING DATE:  18-SEP-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/359,705
;      FILING DATE:  20-DEC-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/286846
;      FILING DATE:  10-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/215139
;      FILING DATE:  18-MAR-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dreger, Ginger
;      REGISTRATION NUMBER:  33,055
;      REFERENCE/DOCKET NUMBER:  GENENT.33CP2C1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  949/760-0404
;      TELEFAX:  949/760-9502
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
US-09-156-923-22

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 32;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3539 ACTCCAGACCAAGGGTGAG 3557
              || |||| ||||||||||
Db          1 ACGCCAGGCCAAGGGTGAG 19


RESULT 20
US-10-083-246A-83/c
; Sequence 83, Application US/10083246A
; Patent No. 6916619
; GENERAL INFORMATION:
;  APPLICANT: Athena Diagnostics
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR GENETIC ANALYSIS OF POLYCYSTIC KIDNEY
;  TITLE OF INVENTION:  DISEASE
;  FILE REFERENCE: 1133/2002
;  CURRENT APPLICATION NUMBER: US/10/083,246A
;  CURRENT FILING DATE:  2002-10-15
;  NUMBER OF SEQ ID NOS: 168
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 83
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: Synthetic primer
```

```
US-10-083-246A-83

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 32;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1068 TGGCCCCAGCCCCAGCCTC 1086
              | | ||||||||||||||||
Db         19 TTGTCCCAGCCCCAGCCTC 1


RESULT 21
US-08-292-620A-1948
; Sequence 1948, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1948:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1948

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 30;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1218 AGAAGGGTCCTGCCAGC 1234
              |||||||:||:|| |||
Db          1 AGAAGGGUCCUGCAAGC 17


RESULT 22
US-09-071-845-1948
; Sequence 1948, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1948:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-1948

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 30;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1218 AGAAGGGTCCTGCCAGC 1234
              |||||||:||:|| |||
Db          1 AGAAGGGUCCUGCAAGC 17


RESULT 23
US-09-866-108A-1653/c
; Sequence 1653, Application US/09866108A
```

```
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1653
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1653

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 30;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3966 TATGGCCTCCTTTGCCC 3982
              | ||||||||||||||||
Db         17 TCTGGCCTCCTTTGCCC 1


RESULT 24
US-09-866-108A-1654/c
; Sequence 1654, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1654
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1654

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 30;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3965 CTATGGCCTCCTTTGCC 3981
              || |||||||||||||||
Db         17 CTCTGGCCTCCTTTGCC 1


RESULT 25
US-09-818-875-3946
; Sequence 3946, Application US/09818875
; Patent No. 6936467
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3946
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-3946

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 30;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2319 CCTGAAGGGTGGCTACA 2335
              |||| ||||||||||||
Db          1 CCTGGAGGGTGGCTACA 17


RESULT 26
```

```
US-09-818-875-3947/c
; Sequence 3947, Application US/09818875
; Patent No. 6936467
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3947
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-3947

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 30;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2319 CCTGAAGGGTGGCTACA 2335
              |||| ||||||||||||
Db         17 CCTGGAGGGTGGCTACA 1


RESULT 27
US-08-937-063-15/c
; Sequence 15, Application US/08937063
; Patent No. 6187534
;  GENERAL INFORMATION:
;    APPLICANT:  STROM, TERRY B.
;    APPLICANT:  VASCONCELLOS, LAURO
;    APPLICANT:  SUTHANTHIRAN, MANIKKAM
;    TITLE OF INVENTION:  METHODS OF EVALUATING TRANSPLANT
;    TITLE OF INVENTION:  REJECTION
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  HAMILTON, BROOK, SMITH & REYNOLDS
;      STREET:  TWO MILITIA DRIVE
;      CITY:  LEXINGTON
;      STATE:  MASSACHUSETTS
;      COUNTRY:  UNITED STATES
;      ZIP:  02173
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/937,063
;      FILING DATE:  24-SEP-1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  GRANAHAN, PATRICIA
;      REGISTRATION NUMBER:  32,227
;      REFERENCE/DOCKET NUMBER:  BIDMC97-01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (781) 861-6240
;      TELEFAX:  (781) 861-9540
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-937-063-15

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 35;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3961 TTCACTATGGCCTCC 3975
              |||||||||||||||
Db         15 TTCACTATGGCCTCC 1


RESULT 28
US-09-371-772B-5010
; Sequence 5010, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5010
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5010

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 35;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
              |||||||||||||:
Db          3 CCCCGCCCCCAGACU 17


RESULT 29
US-09-371-772B-5011
; Sequence 5011, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5011
```

```
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5011

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 35;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
              ||||||||||||||:
Db          2 CCCCGCCCCCAGACU 16


RESULT 30
US-09-371-772B-5012
; Sequence 5012, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5012
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5012

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 35;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
              ||||||||||||||:
Db          1 CCCCGCCCCCAGACU 15


RESULT 31
US-09-866-108A-1651/c
; Sequence 1651, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1651
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1651

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 35;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCC 3982
              |||||||||||||||
Db         17 TGGCCTCCTTTGCCC 3


RESULT 32
US-09-866-108A-1652/c
; Sequence 1652, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1652
```

```
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1652

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 35;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCC 3982
              |||||||||||||||
Db         16 TGGCCTCCTTTGCCC 2


RESULT 33
US-09-777-732A-15/c
; Sequence 15, Application US/09777732A
; Patent No. 6900015
; GENERAL INFORMATION:
;  APPLICANT: Avihingsanon, Yingyos
;  APPLICANT:  Ma, Nalli
;  APPLICANT:  Strom, Terry
;  APPLICANT:  Soares, Miguel C.
;  APPLICANT:  Ferran, Chrisiane
;  APPLICANT:  Manikkam, Suthanthiran
;  TITLE OF INVENTION: MEASUREMENT OF PROTECTIVE GENES IN ALLOGRAFT REJECTION
;  FILE REFERENCE: 01948-059001
;  CURRENT APPLICATION NUMBER: US/09/777,732A
;  CURRENT FILING DATE:  2001-02-06
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetically generated primer
US-09-777-732A-15

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 35;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3961 TTCACTATGGCCTCC 3975
              |||||||||||||||
Db         15 TTCACTATGGCCTCC 1


RESULT 34
US-08-584-040-3042
; Sequence 3042, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  3042:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-3042

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 40;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
              |||||||||||||:
Db          4 CCCCGCCCCCAGACU 18


RESULT 35
US-09-371-772B-1470
; Sequence 1470, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1470
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1470

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 40;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
              |||||||||||||:
Db          4 CCCCGCCCCCAGACU 18


RESULT 36
```

```
US-09-685-664B-1470
; Sequence 1470, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/09/685,664B
;  CURRENT FILING DATE:  2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1470
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-685-664B-1470

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 40;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
              ||||||||||||||:
Db          4 CCCCGCCCCCAGACU 18


RESULT 37
US-09-161-015-29
; Sequence 29, Application US/09161015A
; Patent No. 5965370
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF RhoG EXPRESSION
;  FILE REFERENCE: RTS-0015
;  CURRENT APPLICATION NUMBER: US/09/161,015A
;  CURRENT FILING DATE: 1998-09-25
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 29
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-015-29

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 44;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        658 CTCGAGTGCCTGTCCCTG 675
              | ||||||||||| |||||
Db          1 CGCGAGTGCCTGGCCCTG 18


RESULT 38
US-09-387-341-172
; Sequence 172, Application US/09387341
; Patent No. 6410323
; GENERAL INFORMATION:
;  APPLICANT: Roberts, M. Luisa
;  APPLICANT: Cowsert, Lex M.
;  TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
;  TITLE OF INVENTION: Expression
;  FILE REFERENCE: ISPH-0404
;  CURRENT APPLICATION NUMBER: US/09/387,341
;  CURRENT FILING DATE: 1999-08-31
;  EARLIER APPLICATION NUMBER: 09/156,424
;  EARLIER FILING DATE: 1998-09-18
;  EARLIER APPLICATION NUMBER: 09/156,979
;  EARLIER FILING DATE: 1998-09-18
;  EARLIER APPLICATION NUMBER: 09/156,807
;  EARLIER FILING DATE: 1998-09-18
;  EARLIER APPLICATION NUMBER: 09/161,015
;  EARLIER FILING DATE: 1998-09-25
;  NUMBER OF SEQ ID NOS: 233
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 172
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic
US-09-387-341-172

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 44;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        658 CTCGAGTGCCTGTCCCTG 675
              | ||||||||||| |||||
Db          1 CGCGAGTGCCTGGCCCTG 18


RESULT 39
US-09-920-760-12
; Sequence 12, Application US/09920760
; Patent No. 6492173
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CYCLIN D2 EXPRESSION
;  FILE REFERENCE: RTS-0275
;  CURRENT APPLICATION NUMBER: US/09/920,760
;  CURRENT FILING DATE:  2001-08-01
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 12
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-920-760-12

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 44;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2481 CTCCTTCCTGCGGCTAAA 2498
              |||||||||  |||||||
Db          1 CTCCTTCCTTTGGCTAAA 18


RESULT 40
US-09-544-398B-517
; Sequence 517, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-013
;  CURRENT APPLICATION NUMBER: US/09/544,398B
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: US 09/229,319
```

```
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 517
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-544-398B-517

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 44;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18


RESULT 41
US-09-543-771B-517
; Sequence 517, Application US/09543771B
; Patent No. 6780609
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-014
;  CURRENT APPLICATION NUMBER: US/09/543,771B
;  CURRENT FILING DATE:  2000-04-05
;  PRIOR APPLICATION NUMBER: US 09/229,319
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 517
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-543-771B-517

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 44;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18


RESULT 42
US-09-060-299-432/c
; Sequence 432, Application US/09060299
; Patent No. 6545137
;  GENERAL INFORMATION:
;    APPLICANT:  Todd, John A
;    APPLICANT:  Hess, John W
;    APPLICANT:  Caskey, Charles T
;    APPLICANT:  Cox, Roger D
;    APPLICANT:  Gerhold, David
;    APPLICANT:  Hammond, Holly
;    APPLICANT:  Hey, Patricia
;    APPLICANT:  Kawaguchi, Yoshihiko
;    APPLICANT:  Merriman, Tony R
;    APPLICANT:  Metzker, Michael L
;    TITLE OF INVENTION:  No. 6545137el Receptor
;    NUMBER OF SEQUENCES:  455
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Nixon and Vanderhye
;      STREET:  1100 No. 6545137th Glebe Road, Eighth Floor
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  US
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/060,299
;      FILING DATE:  15-APR-1998
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/043,553
;      FILING DATE:  15-APR-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/048,740
;      FILING DATE:  05-JUN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  B.J.Sadoff
;      REGISTRATION NUMBER:  36,663
;      REFERENCE/DOCKET NUMBER:  620-35
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703)816-4091
;      TELEFAX:  (703)816-4100
;  INFORMATION FOR SEQ ID NO:  432:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-09-060-299-432

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 40;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 CGGTCCTCACCCAGCA 1720
              ||| ||||||||||||
Db         16 CGGCCCTCACCCAGCA 1


RESULT 43
US-09-402-923A-432/c
; Sequence 432, Application US/09402923A
; Patent No. 6555654
;  GENERAL INFORMATION:
;       APPLICANT: Todd, John A
;                  Hess, John W
;                  Caskey, Charles T
;                  Cox, Roger D
;                  Gerhold, David
;                  Hammond, Holly
;                  Hey, Patricia
;                  Kawaguchi, Yoshihiko
;                  Merriman, Tony R
;                  Metzker, Michael L
;       TITLE OF INVENTION: No. 6555654el LDL-Receptor
;       NUMBER OF SEQUENCES: 455
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Nixon and Vanderhye
;            STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
;            CITY: Arlington
;            STATE: Virginia
;            COUNTRY: US
;            ZIP: VA 22201-4714
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
```

```
;               COMPUTER: IBM PC compatible
;               OPERATING SYSTEM: PC-DOS/MS-DOS
;               SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
;          CURRENT APPLICATION DATA:
;               APPLICATION NUMBER: US/09/402,923A
;               FILING DATE: 14-Feb-2001
;          PRIOR APPLICATION DATA:
;               APPLICATION NUMBER: PCT/GB98/01102
;               FILING DATE: 15-APR-1998
;               APPLICATION NUMBER: US 60/043,553
;               FILING DATE: 15-APR-1997
;               APPLICATION NUMBER: US 60/048,740
;               FILING DATE: 05-JUN-1997
;          ATTORNEY/AGENT INFORMATION:
;               NAME: B.J.Sadoff
;               REGISTRATION NUMBER: 36,663
;               REFERENCE/DOCKET NUMBER: 620-81
;          TELECOMMUNICATION INFORMATION:
;               TELEPHONE: (703)816-4091
;               TELEFAX: (703)816-4100
;     INFORMATION FOR SEQ ID NO: 432:
;          SEQUENCE CHARACTERISTICS:
;               LENGTH: 16 base pairs
;               TYPE: nucleic acid
;               STRANDEDNESS: double
;               TOPOLOGY: linear
;          SEQUENCE DESCRIPTION: SEQ ID NO: 432:
US-09-402-923A-432

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 40;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1705 CGGTCCTCACCCAGCA 1720
              ||| ||||||||||||
Db         16 CGGCCCTCACCCAGCA 1


RESULT 44
US-09-371-772B-5872
; Sequence 5872, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5872
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5872

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   68.8%;  Pred. No. 40;
  Matches   11;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGC 2947
              |:||:||||:| :|||
Db          1 AUGCUGGACUGCUGGC 16


RESULT 45
US-09-371-772B-4886
; Sequence 4886, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4886
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4886

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 46;
  Matches   11;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2933 TGCTGGACTGTTGGCA 2948
              :||:||||:| :||||
Db          1 UGCUGGACUGCUGGCA 16


RESULT 46
US-09-866-108A-905
; Sequence 905, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
```

```
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 905
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-905

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4056 GCCTGGGACCCCCAAG 4071
              || |||||||||||||
Db          2 GCTTGGGACCCCCAAG 17


RESULT 47
US-09-866-108A-906
; Sequence 906, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 906
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-906

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4056 GCCTGGGACCCCCAAG 4071
              || |||||||||||||
Db          1 GCTTGGGACCCCCAAG 16


RESULT 48
US-09-866-108A-1655/c
; Sequence 1655, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1655
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1655

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3965 CTATGGCCTCCTTTGC 3980
              || |||||||||||||
Db         16 CTCTGGCCTCCTTTGC 1


RESULT 49
US-09-866-108A-2647
; Sequence 2647, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
```

```
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2647
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2647

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1222 GGGTCCTGCCAGCCAT 1237
              ||||||||| |||||||
Db          2 GGGTCCTGGCAGCCAT 17


RESULT 50
US-09-866-108A-2648
; Sequence 2648, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2648
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2648

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 46;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1222 GGGTCCTGCCAGCCAT 1237
              ||||||||| |||||||
Db          1 GGGTCCTGGCAGCCAT 16


RESULT 51
US-07-796-106-13
; Sequence 13, Application US/07796106
; Patent No. 5389529
;  GENERAL INFORMATION:
;    APPLICANT:  PANAYOTATOS, NIKOS
;    APPLICANT:  FANDL, JAMES P.
;    TITLE OF INVENTION:  Production and Recovery of Recombinant
;    TITLE OF INVENTION:  Neurotrophins
;    NUMBER OF SEQUENCES:  25
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/796,106
;      FILING DATE:  19911121
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  6526-081
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 8698864/9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-07-796-106-13

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1100 ATGGCCAGTGGGCCGA 1115
              ||||||||| ||||||
Db          2 ATGGCCAGTCGGCCGA 17


RESULT 52
```

```
US-09-199-859-46
; Sequence 46, Application US/09199859
; Patent No. 6069008
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION
;  FILE REFERENCE: RTS-0025
;  CURRENT APPLICATION NUMBER: US/09/199,859
;  CURRENT FILING DATE: 1998-11-25
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 46
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-199-859-46

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2669 TGGAGGAGAACTCTTC 2684
              |||||||||| |||||
Db          2 TGGAGGAGAAGTCTTC 17


RESULT 53
US-09-213-719-82/c
; Sequence 82, Application US/09213719B
; Patent No. 6150162
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CD44 EXPRESSION
;  FILE REFERENCE: RTS-0006
;  CURRENT APPLICATION NUMBER: US/09/213,719B
;  CURRENT FILING DATE: 1998-12-17
;  NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 82
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-213-719-82

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2702 GCTCCCTGGGAGGAAA 2717
              | ||||||||||||||
Db         16 GGTCCCTGGGAGGAAA 1


RESULT 54
US-09-044-602-2
; Sequence 2, Application US/09044602
; Patent No. 6613750
; GENERAL INFORMATION:
;  APPLICANT: DePinho, Robert A.
;  TITLE OF INVENTION: A METHOD OF INHIBITING CELL PROLIFERATION USING AN ANTI-ONCOGENE
;  FILE REFERENCE: 96700/469
;  CURRENT APPLICATION NUMBER: US/09/044,602
;  CURRENT FILING DATE:  1998-03-19
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: primer for MDM2 mutant
US-09-044-602-2

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3598 GAAGTGCCCAACATCT 3613
              |||| ||||||||||
Db          2 GAAGGGCCCAACATCT 17


RESULT 55
US-09-856-747-46
; Sequence 46, Application US/09856747
; Patent No. 6656688
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  ISIS PHARMACEUTICALS, INC.
;  TITLE OF INVENTION: ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION
;  FILE REFERENCE: RTSP-0116
;  CURRENT APPLICATION NUMBER: US/09/856,747
;  CURRENT FILING DATE:  2001-05-24
;  PRIOR APPLICATION NUMBER: US 09/199,859
;  PRIOR FILING DATE: 1998-11-25
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 46
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-856-747-46

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2669 TGGAGGAGAACTCTTC 2684
              |||||||||| |||||
Db          2 TGGAGGAGAAGTCTTC 17


RESULT 56
US-10-424-630-2
; Sequence 2, Application US/10424630
; Patent No. 6897197
; GENERAL INFORMATION:
;  APPLICANT: DePinho, Robert A.
;  TITLE OF INVENTION: A METHOD OF INHIBITING CELL PROLIFERATION USING AN ANTI-ONCOGENE I
;  FILE REFERENCE: 96700/469
;  CURRENT APPLICATION NUMBER: US/10/424,630
;  CURRENT FILING DATE:  2003-04-28
;  PRIOR APPLICATION NUMBER: US/09/044,602
;  PRIOR FILING DATE: 1998-03-19
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: primer for MDM2 mutant
US-10-424-630-2

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       3598 GAAGTGCCCAACATCT 3613
              |||| ||||||||||
Db          2 GAAGGGCCCAACATCT 17


RESULT 57
US-08-050-073-184/c
; Sequence 184, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  184:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-184

  Query Match             0.3%;  Score 14;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2963 CCCGGCCCCGCTTC 2976
              ||||||||||||||
Db         14 CCCGGCCCCGCTTC 1


RESULT 58
US-08-009-075-1
; Sequence 1, Application US/08009075
; Patent No. 5300436
;  GENERAL INFORMATION:
;    APPLICANT:  GOLDSTEIN, Menek
;    APPLICANT:  WU, Jing
;    APPLICANT:  FILER, David
;    APPLICANT:  FRIEDHOFF, Arnold J.
;    TITLE OF INVENTION:  GENETICALLY MODIFIED TYROSINE
;    TITLE OF INVENTION:  HYDROXYLASE AND USES THEREOF
;    NUMBER OF SEQUENCES:  13
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BROWDY and NEIMARK
;      STREET:  419 Seventh Street, N.W., Suite 300
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  U.S.A.
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/009,075
;      FILING DATE:  19930126
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  TOWNSEND, GUY K.
;      REGISTRATION NUMBER:  34,033
;      REFERENCE/DOCKET NUMBER:  GOLDSTEIN=1A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-628-5197
;      TELEFAX:  202-737-3528
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-009-075-1

  Query Match             0.3%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 41;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2111 GACAGTATCTCATC 2124
              ||||||||||||||
Db          2 GACAGTATCTCATC 15


RESULT 59
US-08-050-073-167/c
; Sequence 167, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
```

```
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  167:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-167

  Query Match             0.3%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 41;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2963 CCCGGCCCCGCTTC 2976
             ||||||||||||||
Db         15 CCCGGCCCCGCTTC 2


RESULT 60
US-09-081-646-81/c
; Sequence 81, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 81
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-81

  Query Match             0.3%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 41;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2423 TCACCAACAGCATG 2436
             ||||||||||||||
Db         14 TCACCAACAGCATG 1


RESULT 61
US-09-081-646-770/c
; Sequence 770, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 770
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-770

  Query Match             0.3%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 41;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2423 TCACCAACAGCATG 2436
             ||||||||||||||
Db         14 TCACCAACAGCATG 1


RESULT 62
US-08-050-073-166/c
; Sequence 166, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  166:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-166

  Query Match             0.3%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 48;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2963 CCCGGCCCCGCTTC 2976
             ||||||||||||||
Db         15 CCCGGCCCCGCTTC 2


RESULT 63
US-09-531-000-23
; Sequence 23, Application US/09531000
```

```
; Patent No. 6461810
; GENERAL INFORMATION:
;  APPLICANT:  JOHNSON, Marion D.
;  APPLICANT:  FRESCO, Jacques R.
;  TITLE OF INVENTION:  TRIPLEX IN-SITU HYBRIDIZATION
;  FILE REFERENCE:  2448-103
;  CURRENT APPLICATION NUMBER: US/09/531,000
;  CURRENT FILING DATE:  2000-09-08
;  PRIOR APPLICATION NUMBER:  PCT/US98/23765
;  PRIOR FILING DATE:  1998-11-10
;  PRIOR APPLICATION NUMBER:  60/064,997
;  PRIOR FILING DATE:  1997-11-10
;  NUMBER OF SEQ ID NOS:  77
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 23
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target
;   OTHER INFORMATION: sequences
US-09-531-000-23

  Query Match             0.3%;  Score 14;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 48;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3587 CAGAGGAAAAGGAA 3600
              ||||||||||||||
Db          2 CAGAGGAAAAGGAA 15


RESULT 64
US-08-050-073-75
; Sequence 75, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  75:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-75

  Query Match             0.3%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2963 CCCGGCCCCGCTTC 2976
              ||||||||||||||
Db          3 CCCGGCCCCGCTTC 16


RESULT 65
US-08-050-073-149/c
; Sequence 149, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  149:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-149

  Query Match             0.3%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2963 CCCGGCCCCGCTTC 2976
              ||||||||||||||
Db         15 CCCGGCCCCGCTTC 2


RESULT 66
US-09-160-496-6/c
; Sequence 6, Application US/09160496
; Patent No. 6346613
```

```
; GENERAL INFORMATION:
;  APPLICANT: O'Mahony, Daniel J
;  APPLICANT: Cagney, Gerard
;  TITLE OF INVENTION: Composition and Method for Enhancing Paracellular
;  TITLE OF INVENTION: Transport across Cell Layers
;  FILE REFERENCE: Docket No. 6346613: 98.1070.US
;  CURRENT APPLICATION NUMBER: US/09/160,496
;  CURRENT FILING DATE: 1998-09-24
;  EARLIER APPLICATION NUMBER: US 60/059,644
;  EARLIER FILING DATE: 1997-09-24
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Human occludin
;   OTHER INFORMATION: scrambled oligonucleotide
US-09-160-496-6

  Query Match             0.3%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1561 CTACGTCCTGACTT 1574
             ||||||||||||||
Db         16 CTACGTCCTGACTT 3


RESULT 67
US-09-371-772B-5013
; Sequence 5013, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5013
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5013

  Query Match             0.3%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 54;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2895 CCCGCCCCCAGACT 2908
             |||||||||||||:
Db          1 CCCGCCCCCAGACU 14


RESULT 68
US-09-866-108A-1650/c
; Sequence 1650, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1650
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1650

  Query Match             0.3%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3969 GGCCTCCTTTGCCC 3982
             ||||||||||||||
Db         17 GGCCTCCTTTGCCC 4


RESULT 69
5182195-67/c
;Patent No. 5182195
;    APPLICANT: NAKAHAMA, KAZUO;KAISHO, YOSHIHIKO;YOSHIMURA, KOJI
;    TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
;DEFICIENT YEASTS
;    NUMBER OF SEQUENCES: 71
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/269,140
;      FILING DATE: 09-NOV-1988
;SEQ ID NO:67:
;      LENGTH: 17
5182195-67

  Query Match             0.3%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3848 TGAAGGTTTTGAG 3861
             |||||||||||||
Db         15 TGAAGGTTTTGAG 2


RESULT 70
US-08-379-078-482
```

```
; Sequence 482, Application US/08379078
; Patent No. 5639612
;  GENERAL INFORMATION:
;    APPLICANT:  Mitsuhashi, Masato
;    APPLICANT:  Cooper, Allan
;    TITLE OF INVENTION:  Gene Detection System
;    NUMBER OF SEQUENCES:  726
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  KNOBBE, MARTENS, OLSON AND BEAR
;      STREET:  620 Newport Center Drive  16th Floor
;      CITY:  Newport Beach
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/379,078
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/974,406
;      FILING DATE:  12-NOV-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Altman, Daniel E.
;      REGISTRATION NUMBER:  34,115
;      REFERENCE/DOCKET NUMBER:  HITACHI.011CP2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714-760-0404
;      TELEFAX:  714-760-9502
;  INFORMATION FOR SEQ ID NO:  482:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA to mRNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-379-078-482

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        149 CCACTGCCAGCACGCTC 165
              ||||||||| || ||||
Db          1 CCACTGCCAACATGCTC 17


RESULT 71
US-08-261-822A-30/c
; Sequence 30, Application US/08261822A
; Patent No. 5650553
;  GENERAL INFORMATION:
;    APPLICANT:  Ecker, Joseph R. et al.
;    TITLE OF INVENTION:  Plant Genes for Sensitivity to Ethylene
;    TITLE OF INVENTION:  and Pathogens
;    NUMBER OF SEQUENCES:  82
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewicz & No. 5650553ris
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/261,822A
;      FILING DATE:  17-JUN-1994
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Beardell, Lori Y.
;      REGISTRATION NUMBER:  34,293
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  YES
US-08-261-822A-30

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2586 CCACCGAGACCTGGCTG 2602
              ||||| |||||||| ||
Db         17 CCACCAAGACCTGGGTG 1


RESULT 72
US-08-955-138-48
; Sequence 48, Application US/08955138A
; Patent No. 5977435
; GENERAL INFORMATION:
;  APPLICANT: Lefebvre, Daniel D.
;  APPLICANT: Gellatly, Kevin S.
;  TITLE OF INVENTION: PLANT PHOSPHATASES
;  FILE REFERENCE: PPL97-01
;  CURRENT APPLICATION NUMBER: US/08/955,138A
;  CURRENT FILING DATE: 1997-10-21
;  NUMBER OF SEQ ID NOS: 119
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 48
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: SOLANUM TUBEROSUM
US-08-955-138-48

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3839 CCTTCATATTGAAGGTT 3855
              ||||||| |||||| ||
Db          1 CCTTCATGTTGAAGTTT 17


RESULT 73
US-08-985-162-326
; Sequence 326, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
```

```
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSEQ for Windows 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/985,162
;       FILING DATE:  04 December 1997
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/036,476
;       FILING DATE:  31 January 1997
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  230/107
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213)  955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  326:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-985-162-326

  Query Match              0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 59;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2776 AGTGATGCCTGGAGTTA 2792
              ||:||:| |:|||| :|
Db          1 AGUGAUGUCUGGAGCUA 17


RESULT 74
US-07-974-409C-96
; Sequence 96, Application US/07974409C
; Patent No. 6300058
;  GENERAL INFORMATION:
;    APPLICANT:  Akitaya, Tatsuo
;    APPLICANT:  Mitsuhashi, Masato
;    APPLICANT:  Cooper, Allan
;    TITLE OF INVENTION:  METHOD AND REAGENT
;    TITLE OF INVENTION:  FOR MEASURING MESSENGER RNA
;    NUMBER OF SEQUENCES:  457
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson, and Bear
;      STREET:  620 Newport Center Dr.  Sixteenth Floor
;      CITY:  Newport Beach
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/974,409C
;      FILING DATE:  12-NOV-1992
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Altman, Daniel E.
;      REGISTRATION NUMBER:  34,115
;      REFERENCE/DOCKET NUMBER:  HITACHI.006CP2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714-760-0404
;      TELEFAX:  714-760-9502
;  INFORMATION FOR SEQ ID NO:  96:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA to mRNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-07-974-409C-96

  Query Match              0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        149 CCACTGCCAGCACGCTC 165
              |||||||||  || ||||
Db          1 CCACTGCCAACATGCTC 17


RESULT 75
US-08-584-040-2794/c
; Sequence 2794, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2794:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
```

```
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2794

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3870 TTGGTCTTAATTTTTCT 3886
              ||  ||||||||||||||
Db         17 TTTTTCTTAATTTTTCT 1


RESULT 76
US-08-584-040-2824
; Sequence 2824, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2824:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2824

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   17.6%;  Pred. No. 59;
  Matches    3;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3892 TTCCCTTTTTGTTTCTT 3908
              ::| |:::::|::: ::
Db          1 UUCACUUUUUGUUUGUU 17


RESULT 77
US-08-584-040-7819
; Sequence 7819, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7819:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7819

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   11.8%;  Pred. No. 59;
  Matches    2;  Conservative   13;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3854 TTTTTGAGTTTTGTTTT 3870
              :::::|  ::::|::::
Db          1 UUUUUGUUUUUUGUUUU 17


RESULT 78
US-09-673-809-98/c
; Sequence 98, Application US/09673809
; Patent No. 6528261
; GENERAL INFORMATION:
;  APPLICANT:  INNOGENETICS N.V.
;  TITLE OF INVENTION:  Method for typing of HLA alleles.
;  FILE REFERENCE:  PCT99.86.HLA
;  CURRENT APPLICATION NUMBER: US/09/673,809
;  CURRENT FILING DATE:  2000-10-20
```

```
;  PRIOR APPLICATION NUMBER:  98870088.6
;  PRIOR FILING DATE:  1998-04-20
;  NUMBER OF SEQ ID NOS:  107
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 98
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-673-809-98

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2628 CCTCGTCTGCAAAGTGT 2644
              | |||||||| ||||||
Db         17 CATCGTCTGCCAAGTGT 1


RESULT 79
US-09-474-432B-535
; Sequence 535, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 535
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-535

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 59;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2776 AGTGATGCCTGGAGTTA 2792
              ||:||:|  :||||::|
Db          1 AGUGAUGUGUGGAGUUA 17


RESULT 80
US-09-474-432B-559
; Sequence 559, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleoti
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 559
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-559

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   17.6%;  Pred. No. 59;
  Matches    3;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3907 TTCGTTTTGTTTTTCTA 3923
              :: |::::|::::: :|
Db          1 UUUGUUUUGUUUUUUUA 17


RESULT 81
US-09-371-772B-1318/c
; Sequence 1318, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1318
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1318

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3870 TTGGTCTTAATTTTTCT 3886
              ||  ||||||||||||||
Db         17 TTTTTCTTAATTTTTCT 1


RESULT 82
US-09-371-772B-1348
; Sequence 1348, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
```

```
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1348
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1348

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   17.6%;  Pred. No. 59;
  Matches    3;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3892 TTCCCTTTTTGTTTCTT 3908
              ::| |:::::|::: ::
Db          1 UUCACUUUUUGUUUGUU 17


RESULT 83
US-09-371-772B-3603
; Sequence 3603, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3603

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   11.8%;  Pred. No. 59;
  Matches    2;  Conservative   13;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3854 TTTTTGAGTTTTGTTTT 3870
              :::::|  ::::|:::: 
Db          1 UUUUUGUUUUUUGUUUU 17


RESULT 84
US-09-371-772B-4884
; Sequence 4884, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4884
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4884

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 59;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2924 ACCAGCTCATGCTGGAC 2940
              | ||| :||:||:|||| 
Db          1 AUCAGAUCAUGCUGGAC 17


RESULT 85
US-09-371-772B-4885
; Sequence 4885, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4885
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4885

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 59;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2928 GCTCATGCTGGACTGTT 2944
              | :||:||:||||:| :
Db          1 GAUCAUGCUGGACUGCU 17


RESULT 86
US-09-371-772B-5092
; Sequence 5092, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
```

```
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5092
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5092

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 59;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3521 CCCCAGCCACCTCGGGG 3537
              |||| ||||||:| |||
Db             1 CCCCCGCCACCUCAGGG 17


RESULT 87
US-09-371-772B-5545/c
; Sequence 5545, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5545
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5545

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4175 TTTAAAAAAGTAACTTT 4191
              | || ||||||||||||
Db         17 TGTATAAAAGTAACTTT 1


RESULT 88
US-09-371-772B-5599
; Sequence 5599, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5599
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5599

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   29.4%;  Pred. No. 59;
  Matches    5;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3889 CCGTTCCCTTTTTGTTT 3905
              || ::| |:::::|:::
Db             1 CCUUUCACUUUUUGUUU 17


RESULT 89
US-09-371-772B-6785
; Sequence 6785, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6785
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6785

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 59;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2924 ACCAGCTCATGCTGGAC 2940
              |||||  ||:||:||||
Db             1 ACCAGACCAUGCUGGAC 17


RESULT 90
US-09-476-387-534
; Sequence 534, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
```

```
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 534
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-534

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 59;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2776 AGTGATGCCTGGAGTTA 2792
              ||:||:|  :||||::|
Db          1 AGUGAUGUGUGGAGUUA 17


RESULT 91
US-09-476-387-558
; Sequence 558, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 558
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-558

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   17.6%;  Pred. No. 59;
  Matches    3;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3907 TTCGTTTTGTTTTTCTA 3923
              :: |:::::|::::: :|
Db          1 UUUGUUUUGUUUUUUUA 17


RESULT 92
US-09-401-063-326
; Sequence 326, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  326:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-326

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 59;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2776 AGTGATGCCTGGAGTTA 2792
              ||:||:| |:|||| :|
Db          1 AGUGAUGUCUGGAGCUA 17


RESULT 93
US-09-827-998-504
; Sequence 504, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
```

```
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 504
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-504

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2700 GAGCTCCCTGGGAGGAA 2716
              |||||  ||||||||||
Db          1 GAGCTTTCTGGGAGGAA 17


RESULT 94
US-09-827-998-505
; Sequence 505, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 505
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-505

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2701 AGCTCCCTGGGAGGAAA 2717
              ||||  ||||||||||
Db          1 AGCTTTCTGGGAGGAAA 17


RESULT 95
US-09-747-391-84/c
; Sequence 84, Application US/09747391
; Patent No. 6670124
; GENERAL INFORMATION:
;  APPLICANT: Chow, Robert
;  APPLICANT:  Tonai, Richard
;  APPLICANT:  StemCyte, Inc.
;  TITLE OF INVENTION: High Throughput Methods of HLA Typing
;  FILE REFERENCE: 020035-000210US
;  CURRENT APPLICATION NUMBER: US/09/747,391
;  CURRENT FILING DATE:  2001-07-13
;  PRIOR APPLICATION NUMBER: US 60/172,768
;  PRIOR FILING DATE: 1999-12-20
;  NUMBER OF SEQ ID NOS: 278
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 84
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-747-391-84

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        161 CGCTCCGGGCCCGCCGC 177
              ||||||  ||  |||||||
Db         17 CGCTCCTGGACCGCCGC 1


RESULT 96
US-09-866-108A-2316/c
; Sequence 2316, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2316
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2316

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        374 CCATGGAGCTCCGGGTG 390
              ||||||||  |||||||
Db         17 CCATGGAGAACCGGGTG 1


RESULT 97
US-09-866-108A-2464
; Sequence 2464, Application US/09866108A
; Patent No. 6686188
```

```
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2464
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2464

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3428 GCTGGATTGCACTTTGA 3444
              ||||||||| |||| ||
Db          1 GCTGGATTGGACTTGGA 17


RESULT 98
US-09-866-108A-2778
; Sequence 2778, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2778
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2778

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1194 GGGCACCTTCAAGCCCC 1210
              || |||||||||| ||
Db          1 GGCCACCTTCAAGCACC 17


RESULT 99
US-09-866-108A-6262/c
; Sequence 6262, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
```

```
; SEQ ID NO 6262
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6262

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        564 GCAGCGTGCCCCGGGCC 580
              ||||| || ||||||||
Db         17 GCAGCTTGGCCCGGGCC 1


RESULT 100
US-09-866-108A-9235/c
; Sequence 9235, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9235
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9235

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2879 AGGACTACCGGCTGCCC 2895
              |||||| | ||||||||
Db         17 AGGACTGCAGGCTGCCC 1


RESULT 101
US-09-866-108A-9236/c
; Sequence 9236, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9236
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9236

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2878 CAGGACTACCGGCTGCC 2894
              ||||||| | |||||||
Db         17 CAGGACTGCAGGCTGCC 1


RESULT 102
US-09-866-108A-10354/c
; Sequence 10354, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
```

```
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10354
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10354

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1342 CCTCCTTCGGCTCCGCG 1358
              ||||||| ||||||| |
Db         17 CCTCCTTGGGCTCCGGG 1


RESULT 103
US-09-866-108A-10529/c
; Sequence 10529, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10529
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10529

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2603 CTCGCAACATCCTAGTC 2619
              ||||||||||| | |||
Db         17 CTCGCAACATCGTCGTC 1


RESULT 104
US-09-866-108A-10530/c
; Sequence 10530, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10530
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10530

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2602 GCTCGCAACATCCTAGT 2618
              ||||||||||| | ||
Db         17 GCTCGCAACATCGTCGT 1


RESULT 105
US-09-866-108A-10531/c
```

```
; Sequence 10531, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10531
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10531

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2601 TGCTCGCAACATCCTAG 2617
              ||||||||||||| | |
Db         17 TGCTCGCAACATCGTCG 1


RESULT 106
US-09-685-664B-1318/c
; Sequence 1318, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/09/685,664B
;  CURRENT FILING DATE:  2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1318
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-685-664B-1318

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3870 TTGGTCTTAATTTTTCT 3886
              ||  |||||||||||||
Db         17 TTTTTCTTAATTTTTCT 1


RESULT 107
US-09-685-664B-1348
; Sequence 1348, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/09/685,664B
;  CURRENT FILING DATE:  2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1348
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-685-664B-1348

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   17.6%;  Pred. No. 59;
  Matches    3;  Conservative   12;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3892 TTCCCTTTTTGTTTCTT 3908
              ::| |:::::|::: ::
Db          1 UUCACUUUUUGUUUGUU 17


RESULT 108
US-09-685-664B-3603
; Sequence 3603, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/09/685,664B
;  CURRENT FILING DATE:  2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
```

```
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-09-685-664B-3603

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   11.8%;  Pred. No. 59;
  Matches    2;  Conservative   13;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3854 TTTTTGAGTTTTGTTTT 3870
              :::::|  ::::|::::
Db          1 UUUUUGUUUUUUGUUUU 17


RESULT 109
US-09-554-267-2
; Sequence 2, Application US/09554267
; Patent No. 6878547
; GENERAL INFORMATION:
;  APPLICANT: PEYMAN, ANUSCHIRWAN
;  APPLICANT:  UHLMANN, EUGEN
;  APPLICANT:  WEISER, CAROLINE
;  TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES AGAINST TENASCIN FOR
;  TITLE OF INVENTION:  TREATING VITILIGO
;  FILE REFERENCE: 02481.1669
;  CURRENT APPLICATION NUMBER: US/09/554,267
;  CURRENT FILING DATE:  2000-07-24
;  PRIOR APPLICATION NUMBER: PCT/EP98/06868
;  PRIOR FILING DATE: 1998-10-29
;  NUMBER OF SEQ ID NOS: 58
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-09-554-267-2

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2239 GGTGCAGGTGAGTTTGG 2255
              |||| ||||| ||||||
Db          1 GGTGGAGGTGGGTTTGG 17


RESULT 110
US-09-554-267-21
; Sequence 21, Application US/09554267
; Patent No. 6878547
; GENERAL INFORMATION:
;  APPLICANT: PEYMAN, ANUSCHIRWAN
;  APPLICANT:  UHLMANN, EUGEN
;  APPLICANT:  WEISER, CAROLINE
;  TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES AGAINST TENASCIN FOR
;  TITLE OF INVENTION:  TREATING VITILIGO
;  FILE REFERENCE: 02481.1669
;  CURRENT APPLICATION NUMBER: US/09/554,267
;  CURRENT FILING DATE:  2000-07-24
;  PRIOR APPLICATION NUMBER: PCT/EP98/06868
;  PRIOR FILING DATE: 1998-10-29
;  NUMBER OF SEQ ID NOS: 58
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-09-554-267-21

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2239 GGTGCAGGTGAGTTTGG 2255
              |||| ||||| ||||||
Db          1 GGTGGAGGTGGGTTTGG 17


RESULT 111
US-09-554-267-40
; Sequence 40, Application US/09554267
; Patent No. 6878547
; GENERAL INFORMATION:
;  APPLICANT: PEYMAN, ANUSCHIRWAN
;  APPLICANT:  UHLMANN, EUGEN
;  APPLICANT:  WEISER, CAROLINE
;  TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES AGAINST TENASCIN FOR
;  TITLE OF INVENTION:  TREATING VITILIGO
;  FILE REFERENCE: 02481.1669
;  CURRENT APPLICATION NUMBER: US/09/554,267
;  CURRENT FILING DATE:  2000-07-24
;  PRIOR APPLICATION NUMBER: PCT/EP98/06868
;  PRIOR FILING DATE: 1998-10-29
;  NUMBER OF SEQ ID NOS: 58
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 40
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-09-554-267-40

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2239 GGTGCAGGTGAGTTTGG 2255
              |||| ||||| ||||||
Db          1 GGTGGAGGTGGGTTTGG 17


RESULT 112
PCT-US93-00977-96
; Sequence 96, Application PC/TUS9300977
;  GENERAL INFORMATION:
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR MEASURING MESSENGER RNA
;    NUMBER OF SEQUENCES:  711
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson, and Bear
;      STREET:  620 Newport Center Dr.  Sixteenth Floor
;      CITY:  Newport Beach
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/00977
```

```
;       FILING DATE:  19930129
;       CLASSIFICATION:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Altman, Daniel E.
;       REGISTRATION NUMBER:  34,115
;       REFERENCE/DOCKET NUMBER:  HITACHI.006H
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  714-760-0404
;       TELEFAX:  714-760-9502
;   INFORMATION FOR SEQ ID NO:  96:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  double
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA to mRNA
;     HYPOTHETICAL:  NO
;     ANTI-SENSE:  NO
PCT-US93-00977-96

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        149 CCACTGCCAGCACGCTC 165
              ||||||||| || ||||
Db          1 CCACTGCCAACATGCTC 17


RESULT 113
PCT-US95-07744A-30/c
; Sequence 30, Application PC/TUS9507744A
;  GENERAL INFORMATION:
;     APPLICANT:  Trustees of The University of Pennsylvania
;     TITLE OF INVENTION:  Plant Genes for Sensitivity to Ethylene
;     TITLE OF INVENTION:  and Pathogens
;     NUMBER OF SEQUENCES:  82
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewicz & Norris
;       STREET:  One Liberty Place, 46th floor
;       CITY:  Philadelphia
;       STATE:  PA
;       COUNTRY:  USA
;       ZIP:  19103
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US95/07744A
;       FILING DATE:  15-JUNE-1995
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/261,822
;       FILING DATE:  June 17, 1994
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Beardell, Lori Y.
;       REGISTRATION NUMBER:  34,293
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (215) 568-3100
;       TELEFAX:  (215) 568-3439
;   INFORMATION FOR SEQ ID NO:  30:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
;     HYPOTHETICAL:  NO
;     ANTI-SENSE:  YES
PCT-US95-07744A-30

  Query Match             0.3%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2586 CCACCGAGACCTGGCTG 2602
              ||||| |||||||| ||
Db         17 CCACCAAGACCTGGGTG 1


RESULT 114
US-08-182-968A-3/c
; Sequence 3, Application US/08182968A
; Patent No. 5610054
;  GENERAL INFORMATION:
;     APPLICANT:  Draper, Kenneth G.
;     TITLE OF INVENTION:  METHOD AND REAGENT FOR
;     TITLE OF INVENTION:  INHIBITING HEPATITIS C
;     TITLE OF INVENTION:  VIRUS REPLICATION
;     NUMBER OF SEQUENCES:  497
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/182,968A
;       FILING DATE:  13-JANUARY-1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  07/882,888
;       FILING DATE:  14-MAY-1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  205/277
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  3:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-182-968A-3

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          28 CTCCAGGGAGGGGGG 42
               |||| ||||||||||
Db          15 CTCCCGGGAGGGGGG 1


RESULT 115
US-08-319-492B-95/c
; Sequence 95, Application US/08319492B
; Patent No. 5616488
;  GENERAL INFORMATION:
;     APPLICANT:  Sullivan, Sean M.
;     APPLICANT:  Draper, Kenneth G.
;     APPLICANT:  McSwiggen, James
;     APPLICANT:  Stinchcomb, Dan T.
```

```
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
;    TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF IL-5
;    NUMBER OF SEQUENCES:  751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/319,492B
;      FILING DATE:  October 7, 1994
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                Two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/276
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  95:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-319-492B-95

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4166 TAAATTATATTTAAA 4180
                ||||||||||| |||
Db         15 TAAATTATATTGAAA 1


RESULT 116
US-08-291-932A-95/c
; Sequence 95, Application US/08291932A
; Patent No. 5658780
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  NF-KB
;    NUMBER OF SEQUENCES:  830
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/291,932A
;      FILING DATE:  August 15, 1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                Two
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/157
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  95:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-291-932A-95

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2670 GGAGGAGAACTCTTC 2684
                ||||||||| |||||
Db         15 GGAGGAGAAGTCTTC 1


RESULT 117
US-08-291-932A-96/c
; Sequence 96, Application US/08291932A
; Patent No. 5658780
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  NF-KB
;    NUMBER OF SEQUENCES:  830
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/291,932A
;      FILING DATE:  August 15, 1994
```

```
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    Two
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/157
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  96:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-291-932A-96

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2669 TGGAGGAGAACTCTT 2683
                ||||||||||  ||||
Db         15 TGGAGGAGAAGTCTT 1


RESULT 118
US-08-291-932A-244
; Sequence 244, Application US/08291932A
; Patent No. 5658780
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  NF-KB
;    NUMBER OF SEQUENCES:  830
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/291,932A
;      FILING DATE:  August 15, 1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    Two
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/157
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  244:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-291-932A-244

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   73.3%;  Pred. No. 54;
  Matches   11;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1474 GGAGGCTCCTGTGCG 1488
                | ||||:||:|:|||
Db          1 GCAGGCUCCUGUGCG 15


RESULT 119
US-08-291-932A-284/c
; Sequence 284, Application US/08291932A
; Patent No. 5658780
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  NF-KB
;    NUMBER OF SEQUENCES:  830
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/291,932A
;      FILING DATE:  August 15, 1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    Two
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/157
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  284:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
```

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-291-932A-284

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2670 GGAGGAGAACTCTTC 2684
              ||||||||| |||||
Db         15 GGAGGAGAAGTCTTC 1


RESULT 120
US-08-291-932A-285/c
; Sequence 285, Application US/08291932A
; Patent No. 5658780
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  NF-KB
;    NUMBER OF SEQUENCES:  830
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/291,932A
;      FILING DATE:  August 15, 1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    Two
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/157
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  285:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-291-932A-285

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2669 TGGAGGAGAACTCTT 2683
              ||||||||||| ||||
Db         15 TGGAGGAGAAGTCTT 1


RESULT 121
US-08-774-306A-3/c
; Sequence 3, Application US/08774306A
; Patent No. 5869253
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,306A
;      FILING DATE:  December 26, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/227
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-306A-3

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         28 CTCCAGGGAGGGGGG 42
              |||| ||||||||||
Db         15 CTCCCGGGAGGGGGG 1


RESULT 122
US-08-585-684B-2264
; Sequence 2264, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
```

```
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSEQ Version 1.5
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/585,684B
;       FILING DATE:  January 16, 1996
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/000,951
;       FILING DATE:  July 7, 1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/078
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2264:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-585-684B-2264

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 54;
  Matches   10;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        552 AGTGTGTGACGTGCA 566
              ||:|:|: |||:|||
Db          1 AGUGUGUUACGUGCA 15


RESULT 123
US-08-585-684B-2265
; Sequence 2265, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2265:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-2265

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 54;
  Matches   10;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        552 AGTGTGTGACGTGCA 566
              ||:|:|: |||:|||
Db          1 AGUGUGUUACGUGCA 15


RESULT 124
US-08-585-684B-2266
; Sequence 2266, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2266:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
```

```
;      TOPOLOGY:  linear
US-08-585-684B-2266

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 54;
  Matches   10;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        553 GTGTGTGACGTGCAG 567
              |:|:|: |||:|||| 
Db          1 GUGUGUUACGUGCAG 15


RESULT 125
US-08-757-024-889/c
; Sequence 889, Application US/08757024
; Patent No. 6025339
;  GENERAL INFORMATION:
;    APPLICANT:  Nyce, Jonathan W.
;    TITLE OF INVENTION:  METHOD OF TREATMENT FOR ASTHMA
;    NUMBER OF SEQUENCES:  952
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BELL, SELTZER, PARK & GIBSON
;      STREET:  P.O. Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 6025339th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,024
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5218-41
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  889:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-757-024-889

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCC 1192
              ||| ||||||||||| 
Db         15 GCCCAGCCTGTGCCC 1


RESULT 126
US-08-757-024-946/c
; Sequence 946, Application US/08757024
; Patent No. 6025339
;  GENERAL INFORMATION:
;    APPLICANT:  Nyce, Jonathan W.
;    TITLE OF INVENTION:  METHOD OF TREATMENT FOR ASTHMA
;    NUMBER OF SEQUENCES:  952
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BELL, SELTZER, PARK & GIBSON
;      STREET:  P.O. Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 6025339th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,024
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5218-41
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  946:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-757-024-946

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCC 1192
              ||| ||||||||||| 
Db         15 GCCCAGCCTGTGCCC 1


RESULT 127
US-09-064-156A-3/c
; Sequence 3, Application US/09064156A
; Patent No. 6132966
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  498
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/064,156A
;      FILING DATE:  April 21, 1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/774,306
;      FILING DATE:  December 26, 1996
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
```

```
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  234/083
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-064-156A-3

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         28 CTCCAGGGAGGGGGG 42
              |||| ||||||||||
Db         15 CTCCCGGGAGGGGGG 1


RESULT 128
US-09-038-073-2264
; Sequence 2264, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2264:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-2264

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 54;
  Matches   10;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        552 AGTGTGTGACGTGCA 566
              ||:|:|: |||:|||
Db          1 AGUGUGUUACGUGCA 15


RESULT 129
US-09-038-073-2265
; Sequence 2265, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2265:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-2265

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 54;
  Matches   10;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        552 AGTGTGTGACGTGCA 566
              ||:|:|: |||:|||
Db          1 AGUGUGUUACGUGCA 15


RESULT 130
US-09-038-073-2266
; Sequence 2266, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
```

```
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2266:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-2266

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 54;
  Matches   10;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        553 GTGTGTGACGTGCAG 567
              |:|:|: |||:||||
Db          1 GUGUGUUACGUGCAG 15


RESULT 131
US-09-081-646-122/c
; Sequence 122, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 122
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-122

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        733 GCGGACACGGCCACG 747
              ||||||||||||| |
Db         15 GCGGACACGGCCATG 1


RESULT 132
US-09-081-646-870/c
; Sequence 870, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 870
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-870

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        733 GCGGACACGGCCACG 747
              ||||||||||||| |
Db         15 GCGGACACGGCCATG 1


RESULT 133
US-09-093-972C-889/c
; Sequence 889, Application US/09093972C
; Patent No. 6825174
;   GENERAL INFORMATION:
;        APPLICANT: Nyce, Jonathan W.
;        TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
;                            & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
;                            BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION
;        NUMBER OF SEQUENCES: 996
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
;             STREET: 7 Clarke Drive
;             CITY: Cranbury
;             STATE: New Jersey
;             COUNTRY: USA
;             ZIP: 08512
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/093,972C
;             FILING DATE: 09-Jun-1998
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/472,527
;             FILING DATE: 7-June-1995
;             APPLICATION NUMBER: US 08/757,024
```

```
;             FILING DATE: 26-11-1996
;             APPLICATION NUMBER: US 08/472,527
;             FILING DATE: 7-June-1995
;             APPLICATION NUMBER: US 09/016,464
;             FILING DATE: 30-January-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Amzel, Viviana
;             REGISTRATION NUMBER: 30,930
;             REFERENCE/DOCKET NUMBER: EPI-00672
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 609-409-3035
;             TELEFAX: 413-254-9245
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 889:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 889:
US-09-093-972C-889

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCC 1192
              ||| ||||||||||||
Db         15 GCCCAGCCTGTGCCC 1


RESULT 134
US-09-093-972C-946/c
; Sequence 946, Application US/09093972C
; Patent No. 6825174
;   GENERAL INFORMATION:
;        APPLICANT: Nyce, Jonathan W.
;        TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
;                            & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
;                            BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION
;        NUMBER OF SEQUENCES: 996
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
;             STREET: 7 Clarke Drive
;             CITY: Cranbury
;             STATE: New Jersey
;             COUNTRY: USA
;             ZIP: 08512
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/093,972C
;             FILING DATE: 09-Jun-1998
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/472,527
;             FILING DATE: 7-June-1995
;             APPLICATION NUMBER: US 08/757,024
;             FILING DATE: 26-11-1996
;             APPLICATION NUMBER: US 08/472,527
;             FILING DATE: 7-June-1995
;             APPLICATION NUMBER: US 09/016,464
;             FILING DATE: 30-January-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Amzel, Viviana
;             REGISTRATION NUMBER: 30,930
;             REFERENCE/DOCKET NUMBER: EPI-00672
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 609-409-3035
;             TELEFAX: 413-254-9245
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 946:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 946:
US-09-093-972C-946

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCC 1192
              ||| ||||||||||||
Db         15 GCCCAGCCTGTGCCC 1


RESULT 135
US-08-757-024-882/c
; Sequence 882, Application US/08757024
; Patent No. 6025339
;  GENERAL INFORMATION:
;    APPLICANT:  Nyce, Jonathan W.
;    TITLE OF INVENTION:  METHOD OF TREATMENT FOR ASTHMA
;    NUMBER OF SEQUENCES:  952
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BELL, SELTZER, PARK & GIBSON
;      STREET:  P.O. Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 6025339th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,024
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5218-41
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  882:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-757-024-882

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCC 1192
              ||| ||||||||||||
Db         16 GCCCAGCCTGTGCCC 2


RESULT 136
US-08-757-024-945/c
```

```
; Sequence 945, Application US/08757024
; Patent No. 6025339
;  GENERAL INFORMATION:
;    APPLICANT:  Nyce, Jonathan W.
;    TITLE OF INVENTION:  METHOD OF TREATMENT FOR ASTHMA
;    NUMBER OF SEQUENCES:  952
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BELL, SELTZER, PARK & GIBSON
;      STREET:  P.O. Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 6025339th Carolina
;      COUNTRY:  USA
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/757,024
;      FILING DATE:  26-NOV-1996
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5218-41
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  945:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-757-024-945

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCC 1192
                ||| ||||||||||
Db         16 GCCCAGCCTGTGCCC 2


RESULT 137
US-09-413-452-25
; Sequence 25, Application US/09413452
; Patent No. 6083540
; GENERAL INFORMATION:
;  APPLICANT: Christensen, T.
;  APPLICANT: Thorsoe, H.
;  APPLICANT: Kreiberg, J.
;  APPLICANT: Buchholt, H.
;  TITLE OF INVENTION: PROCESS FOR STABILIZING PROTEINS IN AN
;  TITLE OF INVENTION: ACIDIC ENVIRONMENT WITH A HIGH-ESTER PECTIN
;  FILE REFERENCE: DYOU14.001APC
;  CURRENT APPLICATION NUMBER: US/09/413,452
;  CURRENT FILING DATE: 1999-10-06
;  EARLIER APPLICATION NUMBER: 08/983364
;  EARLIER FILING DATE: 1998-05-18
;  EARLIER APPLICATION NUMBER: PCT/EP96/03051
;  EARLIER FILING DATE: 1996-07-12
;  NUMBER OF SEQ ID NOS: 56
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 25
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: UNI (M13-20 primer)
US-09-413-452-25

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2495 TAAACGACGGACAGT 2509
                ||||||||||  ||||
Db          2 TAAACGACGGCCAGT 16


RESULT 138
US-09-413-068-25
; Sequence 25, Application US/09413068
; Patent No. 6268195
; GENERAL INFORMATION:
;  APPLICANT: Christensen, T.
;  APPLICANT: Thorsoe, H.
;  APPLICANT: Kreiberg, J.
;  APPLICANT: Buchholt, H.
;  TITLE OF INVENTION: PROCESS FOR STABILIZING PROTEINS IN AN
;  TITLE OF INVENTION: ACIDIC ENVIRONMENT WITH A HIGH-ESTER PECTIN
;  FILE REFERENCE: DYOU14.001APC
;  CURRENT APPLICATION NUMBER: US/09/413,068
;  CURRENT FILING DATE: 1999-06-06
;  EARLIER APPLICATION NUMBER: 08/983364
;  EARLIER FILING DATE: 1998-05-18
;  EARLIER APPLICATION NUMBER: PCT/EP96/03051
;  EARLIER FILING DATE: 1996-07-12
;  NUMBER OF SEQ ID NOS: 56
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 25
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: UNI (M13-20 primer)
US-09-413-068-25

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2495 TAAACGACGGACAGT 2509
                ||||||||||  ||||
Db          2 TAAACGACGGCCAGT 16


RESULT 139
US-09-060-299-433/c
; Sequence 433, Application US/09060299
; Patent No. 6545137
;  GENERAL INFORMATION:
;    APPLICANT:  Todd, John A
;    APPLICANT:  Hess, John W
;    APPLICANT:  Caskey, Charles T
;    APPLICANT:  Cox, Roger D
;    APPLICANT:  Gerhold, David
;    APPLICANT:  Hammond, Holly
;    APPLICANT:  Hey, Patricia
;    APPLICANT:  Kawaguchi, Yoshihiko
;    APPLICANT:  Merriman, Tony R
;    APPLICANT:  Metzker, Michael L
;    TITLE OF INVENTION:  No. 6545137el Receptor
;    NUMBER OF SEQUENCES:  455
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Nixon and Vanderhye
;      STREET:  1100 No. 6545137th Glebe Road, Eighth Floor
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  US
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/060,299
;      FILING DATE:  15-APR-1998
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/043,553
;      FILING DATE:  15-APR-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/048,740
;      FILING DATE:  05-JUN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  B.J.Sadoff
;      REGISTRATION NUMBER:  36,663
;      REFERENCE/DOCKET NUMBER:  620-35
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703)816-4091
;      TELEFAX:  (703)816-4100
;  INFORMATION FOR SEQ ID NO:  433:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-09-060-299-433

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3336 CTGACCTGCAGGAAC 3350
             ||||||||||| ||||
Db         15 CTGACCTGCATGAAC 1


RESULT 140
US-09-402-923A-433/c
; Sequence 433, Application US/09402923A
; Patent No. 6555654
;   GENERAL INFORMATION:
;        APPLICANT: Todd, John A
;                   Hess, John W
;                   Caskey, Charles T
;                   Cox, Roger D
;                   Gerhold, David
;                   Hammond, Holly
;                   Hey, Patricia
;                   Kawaguchi, Yoshihiko
;                   Merriman, Tony R
;                   Metzker, Michael L
;        TITLE OF INVENTION: No. 6555654el LDL-Receptor
;        NUMBER OF SEQUENCES: 455
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Nixon and Vanderhye
;             STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
;             CITY: Arlington
;             STATE: Virginia
;             COUNTRY: US
;             ZIP: VA 22201-4714
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/402,923A
;             FILING DATE: 14-Feb-2001
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: PCT/GB98/01102
;             FILING DATE: 15-APR-1998
;             APPLICATION NUMBER: US 60/043,553
;             FILING DATE: 15-APR-1997
;             APPLICATION NUMBER: US 60/048,740
;             FILING DATE: 05-JUN-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: B.J.Sadoff
;             REGISTRATION NUMBER: 36,663
;             REFERENCE/DOCKET NUMBER: 620-81
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (703)816-4091
;             TELEFAX: (703)816-4100
;   INFORMATION FOR SEQ ID NO: 433:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: double
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 433:
US-09-402-923A-433

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3336 CTGACCTGCAGGAAC 3350
             ||||||||||| ||||
Db         15 CTGACCTGCATGAAC 1


RESULT 141
US-09-787-069-6
; Sequence 6, Application US/09787069
; Patent No. 6627429
; GENERAL INFORMATION:
;  APPLICANT: Danisco A/S
;  APPLICANT:  Christensen, Tove MIE
;  APPLICANT:  Pedersen, Anette A
;  APPLICANT:  Brunstedt, Janne
;  APPLICANT:  Mikkelsen, Jorn D
;  TITLE OF INVENTION: Process
;  FILE REFERENCE: P005380WO CTH
;  CURRENT APPLICATION NUMBER: US/09/787,069
;  CURRENT FILING DATE:  2001-07-16
;  PRIOR APPLICATION NUMBER: GB 9820195.7
;  PRIOR FILING DATE: 1998-09-16
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-787-069-6

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2495 TAAACGACGGACAGT 2509
             ||||||||||| ||||
Db          2 TAAACGACGGCCAGT 16


RESULT 142
US-09-914-841A-5
; Sequence 5, Application US/09914841A
; Patent No. 6645750
; GENERAL INFORMATION:
;  APPLICANT: Amano Enzyme Inc.
;  TITLE OF INVENTION: Beta-PRIMEVEROSIDASE GENE
;  FILE REFERENCE: Q66072
;  CURRENT APPLICATION NUMBER: US/09/914,841A
;  CURRENT FILING DATE:  2001-09-04
;  PRIOR APPLICATION NUMBER: P. Hei. 11-056299
;  PRIOR FILING DATE: 1999-03-04
;  PRIOR APPLICATION NUMBER: PCT/JP00/01242
```

```
;  PRIOR FILING DATE: 2000-03-02
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic DNA PCR primer
US-09-914-841A-5

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2495 TAAACGACGGACAGT 2509
             ||||||||||| ||||
Db          2 TAAACGACGGCCAGT 16


RESULT 143
US-09-093-972C-882/c
; Sequence 882, Application US/09093972C
; Patent No. 6825174
;   GENERAL INFORMATION:
;        APPLICANT: Nyce, Jonathan W.
;        TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
;                            & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
;                            BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION
;        NUMBER OF SEQUENCES: 996
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
;             STREET: 7 Clarke Drive
;             CITY: Cranbury
;             STATE: New Jersey
;             COUNTRY: USA
;             ZIP: 08512
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/093,972C
;             FILING DATE: 09-Jun-1998
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/472,527
;             FILING DATE: 7-June-1995
;             APPLICATION NUMBER: US 08/757,024
;             FILING DATE: 26-11-1996
;             APPLICATION NUMBER: US 08/472,527
;             FILING DATE: 7-June-1995
;             APPLICATION NUMBER: US 09/016,464
;             FILING DATE: 30-January-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Amzel, Viviana
;             REGISTRATION NUMBER: 30,930
;             REFERENCE/DOCKET NUMBER: EPI-00672
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 609-409-3035
;             TELEFAX: 413-254-9245
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 882:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 882:
US-09-093-972C-882

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCC 1192
              ||| ||||||||||
Db         16 GCCCAGCCTGTGCCC 2


RESULT 144
US-09-093-972C-945/c
; Sequence 945, Application US/09093972C
; Patent No. 6825174
;   GENERAL INFORMATION:
;        APPLICANT: Nyce, Jonathan W.
;        TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
;                            & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
;                            BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION
;        NUMBER OF SEQUENCES: 996
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
;             STREET: 7 Clarke Drive
;             CITY: Cranbury
;             STATE: New Jersey
;             COUNTRY: USA
;             ZIP: 08512
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/093,972C
;             FILING DATE: 09-Jun-1998
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/472,527
;             FILING DATE: 7-June-1995
;             APPLICATION NUMBER: US 08/757,024
;             FILING DATE: 26-11-1996
;             APPLICATION NUMBER: US 08/472,527
;             FILING DATE: 7-June-1995
;             APPLICATION NUMBER: US 09/016,464
;             FILING DATE: 30-January-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Amzel, Viviana
;             REGISTRATION NUMBER: 30,930
;             REFERENCE/DOCKET NUMBER: EPI-00672
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 609-409-3035
;             TELEFAX: 413-254-9245
;             TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 945:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 945:
US-09-093-972C-945

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCC 1192
              ||| ||||||||||
Db         16 GCCCAGCCTGTGCCC 2


RESULT 145
US-10-110-502-2
```

```
; Sequence 2, Application US/10110502
; Patent No. 6872870
; GENERAL INFORMATION:
;  APPLICANT: Iturriaga de la Fuente, Gabriel
;  APPLICANT:  Thevelein, Johan M.
;  APPLICANT:  Van Dijck, Patrick
;  APPLICANT:  Mascorro-Gallardo, Jose Oscar
;  APPLICANT:  Van Vaeck, Cristophe
;  TITLE OF INVENTION: Specific Genetic Modification Of The Activity of
;  TITLE OF INVENTION:  Trehalose-6-Phosphate Synthase And Expression in a
;  TITLE OF INVENTION:  Homologous or Heterologous Environment
;  FILE REFERENCE: 702-020635
;  CURRENT APPLICATION NUMBER: US/10/110,502
;  CURRENT FILING DATE:  2002-04-12
;  PRIOR APPLICATION NUMBER: PCT/EP99/07913
;  PRIOR FILING DATE: 1999-10-15
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: Microsoft Word 97 SR-2
; SEQ ID NO 2
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Universal primer
US-10-110-502-2

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2495 TAAACGACGGACAGT 2509
                ||||||||||  ||||
Db          2 TAAACGACGGCCAGT 16


Search completed: March 23, 2006, 11:12:26
Job time : 8 secs
```

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 23, 2006, 11:22:19 ; Search time 0.001 Seconds
(without alignments)
2981.440 Million cell updates/sec

Title: US-10-800-077-392
Perfect score: 4235
Sequence: 1 ctcggcccggcggcgcgagc.....cgtgtcccagctccaggggt 4235

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 18 seqs, 352 residues

Total number of hits satisfying chosen parameters: 36

Minimum DB seq length: 5
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 18 summaries

Database : fetch392rst.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
c 1	16.8	0.4	20	1	CF306206	ACCESSION:CF306206
c 2	16.8	0.4	20	1	CF306357	ACCESSION:CF306357
c 3	16.8	0.4	20	1	CF307027	ACCESSION:CF307027
c 4	16.8	0.4	20	1	CF307105	ACCESSION:CF307105
c 5	16.8	0.4	20	1	CF307109	ACCESSION:CF307109
c 6	16.8	0.4	20	1	CF307258	ACCESSION:CF307258
c 7	16.8	0.4	21	1	CF306412	ACCESSION:CF306412
c 8	16.8	0.4	21	1	CF306419	ACCESSION:CF306419
c 9	16.8	0.4	21	1	CF306998	ACCESSION:CF306998
c 10	16.8	0.4	21	1	CF307416	ACCESSION:CF307416
c 11	16.8	0.4	21	1	CF307437	ACCESSION:CF307437
12	15.8	0.4	19	1	AI383415	ACCESSION:AI383415
c 13	15.8	0.4	19	1	CF307006	ACCESSION:CF307006
c 14	15.8	0.4	19	1	CF307304	ACCESSION:CF307304
c 15	15.8	0.4	19	1	CF307439	ACCESSION:CF307439
16	15.8	0.4	19	1	CZ283815	ACCESSION:CZ283815
c 17	13.4	0.3	16	1	BM394080	ACCESSION:BM394080
c 18	12.8	0.3	16	1	AI560058	ACCESSION:AI560058

ALIGNMENTS

RESULT 1
CF306206/c
LOCUS CF306206 20 bp mRNA linear EST 15-AUG-2003
DEFINITION HDA1--03-A04.g1 OsHDAC1-overexpressing transgenic rice lambda phage cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA clone HDA1--03-A04, mRNA sequence.
ACCESSION CF306206
VERSION CF306206.1 GI:33677967
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDA1--03-A04"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OsHDAC1-overexpressing transgenic rice lambda phage cDNA library I (HDA1)"
/note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2: XhoI; Callus was treated with ABA(20um) for 1hour. cDNA was inserted into lambda Uni-ZAP XR vector at 5' end with EcoRI and 3' end with XhoI site. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.2;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3526 GCCACCTCGGGGAACTCCAG 3545
|||||| |||||| ||||||
Db 20 GCCACCGCGGGGAGCTCCAG 1

RESULT 2
CF306357/c
LOCUS CF306357 20 bp mRNA linear EST 15-AUG-2003
DEFINITION HDA1--03-J04.g1 OsHDAC1-overexpressing transgenic rice lambda phage cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA clone HDA1--03-J04, mRNA sequence.
ACCESSION CF306357
VERSION CF306357.1 GI:33678118
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"

```
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--03-J04"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 4.2;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCAG 3545
              |||||| |||||| ||||||
Db         20 GCCACCGCGGGGAGCTCCAG 1


RESULT 3
CF307027/c
LOCUS       CF307027                  20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--05-I10.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--05-I10, mRNA sequence.
ACCESSION   CF307027
VERSION     CF307027.1  GI:33678788
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--05-I10"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 4.2;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCAG 3545
              |||||| |||||| ||||||
Db         20 GCCACCACGGGGAGCTCCAG 1


RESULT 4
CF307105/c
LOCUS       CF307105                  20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--05-M06.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--05-M06, mRNA sequence.
ACCESSION   CF307105
VERSION     CF307105.1  GI:33678866
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--05-M06"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 4.2;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCAG 3545
              |||||| |||||| ||||||
Db         20 GCCACCGCGGGGAGCTCCAG 1


RESULT 5
CF307109/c
LOCUS       CF307109                  20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--05-M12.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--05-M12, mRNA sequence.
ACCESSION   CF307109
VERSION     CF307109.1  GI:33678870
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
```

```
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--05-M12"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 4.2;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCAG 3545
              |||||| |||||| ||||||
Db         20 GCCACCGCGGGGAGCTCCAG 1


RESULT 6
CF307258/c
LOCUS       CF307258                 20 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--06-D04.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--06-D04, mRNA sequence.
ACCESSION   CF307258
VERSION     CF307258.1  GI:33679019
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--06-D04"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 4.2;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCAG 3545
              |||||| |||||| ||||||
Db         20 GCCACCACGGGGAGCTCCAG 1


RESULT 7
CF306412/c
LOCUS       CF306412                 21 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--03-M07.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--03-M07, mRNA sequence.
ACCESSION   CF306412
VERSION     CF306412.1  GI:33678173
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--03-M07"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 4;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCAG 3545
              |||||| |||||| ||||||
Db         21 GCCACCGCGGGGAGCTCCAG 2


RESULT 8
CF306419/c
LOCUS       CF306419                 21 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--03-M17.g1 OsHDAC1-overexpressing transgenic rice lambda phage
```

```
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--03-M17, mRNA sequence.
ACCESSION   CF306419
VERSION     CF306419.1  GI:33678180
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--03-M17"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 4;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCAG 3545
              |||||| |||||| ||||||
Db         21 GCCACCGCGGGGAGCTCCAG 2


RESULT 9
CF306998/c
LOCUS       CF306998                21 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--05-H01.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--05-H01, mRNA sequence.
ACCESSION   CF306998
VERSION     CF306998.1  GI:33678759
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--05-H01"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 4;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCAG 3545
              |||||| |||||| ||||||
Db         21 GCCACCGCGGGGAGCTCCAG 2


RESULT 10
CF307416/c
LOCUS       CF307416                21 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--06-K06.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--06-K06, mRNA sequence.
ACCESSION   CF307416
VERSION     CF307416.1  GI:33679177
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--06-K06"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."
```

```
  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 4;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCAG 3545
              |||||| |||||| ||||||
Db         21 GCCACCGCGGGGAGCTCCAG 2


RESULT 11
CF307437/c
LOCUS       CF307437                 21 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--06-L07.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--06-L07, mRNA sequence.
ACCESSION   CF307437
VERSION     CF307437.1  GI:33679198
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--06-L07"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 4;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCAG 3545
              |||||| |||||| ||||||
Db         21 GCCACCACGGGGAGCTCCAG 2


RESULT 12
AI383415
LOCUS       AI383415                 19 bp    mRNA    linear   EST 27-JAN-1999
DEFINITION  tc97d11.x1 NCI_CGAP_CLL1 Homo sapiens cDNA clone IMAGE:2074101 3'
            similar to SW:Y0A8_MYCTU Q50738 HYPOTHETICAL 33.1 KD PROTEIN
            CY9C4.08C. ;contains MSR1.b1 MSR1 repetitive element ;, mRNA
            sequence.
ACCESSION   AI383415
VERSION     AI383415.1  GI:4196196
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Ash Alizadeh, John Byrd, M.D., Mike Grever,
            M.D., Louis M. Staudt, M.D., Ph.D.
             cDNA Library Preparation: M. Bento Soares, Ph.D.
             cDNA Library Arrayed by: Greg Lennon, Ph.D.
             DNA Sequencing by: Washington University Genome Sequencing Center
             Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html

            Trace considered overall poor quality
            Seq primer: -40UP from Gibco
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:2074101"
                     /tissue_type="B-cell, chronic lymphotic leukemia"
                     /lab_host="DH10B"
                     /clone_lib="NCI_CGAP_CLL1"
                     /note="Vector: pT7T3D-Pac (Pharmacia) with a modified
                     polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
                     was primed with a Not I - oligo(dT) primer [5'
                     TGTTACCAATCTGAAGTGGGAGCGGCCGCATTGCTTTTTTTTTTTTTTTTTTTTTT
                     T 3']; double-stranded cDNA was ligated to Eco RI
                     adaptors (Pharmacia), digested with Not I and cloned into
                     the Not I and Eco RI sites of the modified pT7T3 vector.
                     Library is normalized, and was constructed by Bento
                     Soares and M.Patima Bonaldo."

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 6.9;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        320 GGGGGGGCGAGGGCCCCCC 338
              ||||||||| ||| |||||
Db          1 GGGGGGGCGGGGGGCCCCC 19


RESULT 13
CF307006/c
LOCUS       CF307006                 19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--05-H09.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--05-H09, mRNA sequence.
ACCESSION   CF307006
VERSION     CF307006.1  GI:33678767
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
```

```
           Yongin, Kyeonggi, Korea
           Tel: 82 31 330 6193
           Fax: 82 31 321 6355
           Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--05-H09"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 6.9;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCA 3544
              |||||| |||||| |||||
Db         19 GCCACCACGGGGAGCTCCA 1


RESULT 14
CF307304/c
LOCUS       CF307304                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--06-F05.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--06-F05, mRNA sequence.
ACCESSION   CF307304
VERSION     CF307304.1  GI:33679065
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--06-F05"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 6.9;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCA 3544
              |||||| |||||| |||||
Db         19 GCCACCACGGGGAGCTCCA 1


RESULT 15
CF307439/c
LOCUS       CF307439                19 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  HDA1--06-L09.g1 OsHDAC1-overexpressing transgenic rice lambda phage
            cDNA library I (HDA1) Oryza sativa (japonica cultivar-group) cDNA
            clone HDA1--06-L09, mRNA sequence.
ACCESSION   CF307439
VERSION     CF307439.1  GI:33679200
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="HDA1--06-L09"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 2 weeks"
                     /lab_host="E.coli SOLR"
                     /clone_lib="OsHDAC1-overexpressing transgenic rice lambda
                     phage cDNA library I (HDA1)"
                     /note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
                     XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
                     was inserted into lambda Uni-ZAP XR vector at 5' end with
                     EcoRI and 3' end with XhoI site. mRNA was derived from
                     rice Histone Deacetylase overexpression line."

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 6.9;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3526 GCCACCTCGGGGAACTCCA 3544
              |||||| |||||| |||||
Db         19 GCCACCACGGGGAGCTCCA 1


RESULT 16
CZ283815
LOCUS       CZ283815                19 bp    DNA     linear   GSS 01-JUL-2005
DEFINITION  cp31h12.f Candida parapsilosis Random Genomic Library Candida
            parapsilosis genomic clone cp31h12, genomic survey sequence.
ACCESSION   CZ283815
VERSION     CZ283815.1  GI:68455017
KEYWORDS    GSS.
SOURCE      Candida parapsilosis
```

```
  ORGANISM  Candida parapsilosis
            Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
            Saccharomycetales; mitosporic Saccharomycetales; Candida.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Logue,M.E., Wong,S., Wolfe,K.H. and Butler,G.
  TITLE     A genome sequence survey shows that the pathogenic yeast Candida
            parapsilosis has a defective MTLa1 allele at its mating type locus
  JOURNAL   Eukaryot. Cell 4 (6), 1009-1017 (2005)
   PUBMED   15947193
COMMENT     Contact: Logue M
            Department of Biochemistry, Conway Institute of Biomolecular and
            Biomedical Research
            University College Dublin
            Dublin 4, Ireland
            Tel: +353 1 7166885
            Fax: +353 1 2837211
            Email: mary.e.logue@ucd.ie
            Class: plasmid ends.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Candida parapsilosis"
                     /mol_type="genomic DNA"
                     /strain="CLIB214"
                     /db_xref="taxon:5480"
                     /clone="cp31h12"
                     /clone_lib="Candida parapsilosis Random Genomic Library"

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 6.9;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        320 GGGGGGGCGAGGGCCCCCC 338
              ||||||||| || ||||||
Db          1 GGGGGGGCGCGGCCCCCCC 19


RESULT 17
BM394080/c
LOCUS       BM394080                 16 bp    mRNA    linear   EST 17-JAN-2002
DEFINITION  50072-2-12-H02.r.1 Chilcoat/Turkewitz cDNA (large fraction)
            Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION   BM394080
VERSION     BM394080.1  GI:18194133
KEYWORDS    EST.
SOURCE      Tetrahymena thermophila
  ORGANISM  Tetrahymena thermophila
            Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
            Hymenostomatida; Tetrahymenina; Tetrahymenidae; Tetrahymena.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Turkewitz,A.P., Karrer,K.M., Jahn,C., Orias,E., Kirk,K.E.,
            Frankel,J. and Klobutcher,L.
  TITLE     EST from Tetrahymena thermophila, strain CU428.1, growing cells
  JOURNAL   Unpublished (2002)
COMMENT     Contact: Turkewitz AP
            Molecular Genetics and Cell Biology
            University of Chicago
            920 E. 58th Street, Chicago, IL 60637, USA
            Tel: 773 702 4374
            Fax: 773 702 3172
            Email: apturkew@midway.uchicago.edu
            Seq primer: T3.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Tetrahymena thermophila"
                     /mol_type="mRNA"
                     /strain="CU428.1"
                     /db_xref="taxon:5911"
                     /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
                     /note="Vector: BlueScript2 SK+; Details on library
                     preparation can be found in Chilcoat and Turkewitz (2001)
                     Proc. Natl. Acad. Sci USA, 98: 8709-8713."

  Query Match             0.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 21;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2404 ATCCGCCTGGAGGGC 2418
              ||||||||| ||||||
Db         16 ATCCGCCTTGAGGGC 2


RESULT 18
AI560058/c
LOCUS       AI560058                 16 bp    mRNA    linear   EST 13-MAY-1999
DEFINITION  tq38h11.x1 NCI_CGAP_Ut1 Homo sapiens cDNA clone IMAGE:2211141 3'
            similar to TR:Q04154 Q04154 SALIVARY PROLINE-RICH PROTEIN RP15
            PRECURSOR. ;contains MSR1.t2 MSR1 repetitive element ;, mRNA
            sequence.
ACCESSION   AI560058
VERSION     AI560058.1  GI:4510263
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
            Emmert-Buck, M.D., Ph.D.
             cDNA Library Preparation: Life Technologies, Inc.
             cDNA Library Arrayed by: Greg Lennon, Ph.D.
             DNA Sequencing by: Washington University Genome Sequencing Center
             Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html

            Trace considered overall poor quality
            Insert Length: 2104   Std Error: 0.00
            Seq primer: -40UP from Gibco
            High quality sequence stop: 1
            POLYA=No.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:2211141"
                     /tissue_type="well-differentiated endometrial
                     adenocarcinoma, 7 pooled tumors"
                     /lab_host="DH10B"
                     /clone_lib="NCI_CGAP_Ut1"
                     /note="Organ: uterus; Vector: pCMV-SPORT6; Site_1: SalI;
                     Site_2: NotI; Cloned unidirectionally.  Primer: Oligo dT.
                     Average insert size 1.75 kb. Life Technologies catalog #:
                     11538-014"

  Query Match             0.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 25;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         66 CCCCCGCCACCCGGGG 81
              ||||| || |||||||
Db         16 CCCCCTCCCCCCGGGG 1


Search completed: March 23, 2006, 11:22:21
Job time : 1 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 23, 2006, 11:14:55 ; Search time 52 Seconds
(without alignments)
3.214 Million cell updates/sec

Title: US-10-800-077-392
Perfect score: 4235
Sequence: 1 ctcggcccggcggcgcgagc.....cgtgtcccagctccaggggt 4235

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 927 seqs, 19731 residues

Total number of hits satisfying chosen parameters: 1854

Minimum DB seq length: 5
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 928 summaries

Database : fetch392rnpbm.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	48	1.1	48	1	US-10-776-399A-217	Sequence 217, App
2	40	0.9	48	1	US-10-776-399A-197	Sequence 197, App
3	38.4	0.9	48	1	US-10-776-399A-183	Sequence 183, App
4	38.4	0.9	48	1	US-10-776-399A-195	Sequence 195, App
c 5	29	0.7	36	1	US-10-800-350-2	Sequence 2, Appli
c 6	29	0.7	36	1	US-10-800-077-2	Sequence 2, Appli
7	26	0.6	26	1	US-10-440-464-40	Sequence 40, Appl
8	25	0.6	25	1	US-11-060-756-97792	Sequence 97792, A
9	25	0.6	25	1	US-11-060-756-97793	Sequence 97793, A
10	25	0.6	25	1	US-11-060-756-97794	Sequence 97794, A
11	25	0.6	25	1	US-11-060-756-97795	Sequence 97795, A
12	25	0.6	25	1	US-11-060-756-97796	Sequence 97796, A
13	25	0.6	25	1	US-11-060-756-97797	Sequence 97797, A
14	25	0.6	25	1	US-11-060-756-97798	Sequence 97798, A
15	25	0.6	25	1	US-11-060-756-97799	Sequence 97799, A
16	25	0.6	25	1	US-11-060-756-97800	Sequence 97800, A
17	25	0.6	25	1	US-11-060-756-97801	Sequence 97801, A
18	25	0.6	25	1	US-11-060-756-97802	Sequence 97802, A
19	25	0.6	25	1	US-11-060-756-97803	Sequence 97803, A
20	25	0.6	25	1	US-11-060-756-97804	Sequence 97804, A
21	25	0.6	25	1	US-11-060-756-97805	Sequence 97805, A
22	25	0.6	25	1	US-11-060-756-97806	Sequence 97806, A
23	25	0.6	25	1	US-11-060-756-97807	Sequence 97807, A
24	25	0.6	25	1	US-11-060-756-97808	Sequence 97808, A
25	25	0.6	25	1	US-11-060-756-97809	Sequence 97809, A
26	25	0.6	25	1	US-11-060-756-97810	Sequence 97810, A
27	25	0.6	25	1	US-11-060-756-97811	Sequence 97811, A
28	25	0.6	25	1	US-11-060-756-97812	Sequence 97812, A
29	25	0.6	25	1	US-11-060-756-97813	Sequence 97813, A
30	25	0.6	25	1	US-11-060-756-97814	Sequence 97814, A
31	25	0.6	25	1	US-11-060-756-97815	Sequence 97815, A
32	25	0.6	25	1	US-11-060-756-97816	Sequence 97816, A
33	25	0.6	25	1	US-11-060-756-97817	Sequence 97817, A
34	25	0.6	25	1	US-11-060-756-97818	Sequence 97818, A
35	25	0.6	25	1	US-11-060-756-97819	Sequence 97819, A
36	25	0.6	25	1	US-11-060-756-97820	Sequence 97820, A
37	25	0.6	25	1	US-11-060-756-97821	Sequence 97821, A
38	25	0.6	25	1	US-11-060-756-97822	Sequence 97822, A
39	25	0.6	25	1	US-11-060-756-97823	Sequence 97823, A
40	25	0.6	25	1	US-11-060-756-97824	Sequence 97824, A
41	25	0.6	25	1	US-11-060-756-97825	Sequence 97825, A
42	25	0.6	25	1	US-11-060-756-97826	Sequence 97826, A
43	25	0.6	25	1	US-11-060-756-97827	Sequence 97827, A
44	25	0.6	25	1	US-11-060-756-97828	Sequence 97828, A
45	25	0.6	25	1	US-11-060-756-97829	Sequence 97829, A
46	25	0.6	25	1	US-11-060-756-97830	Sequence 97830, A
47	25	0.6	25	1	US-11-060-756-97831	Sequence 97831, A
48	25	0.6	25	1	US-11-060-756-97832	Sequence 97832, A
49	25	0.6	25	1	US-11-060-756-97833	Sequence 97833, A
50	25	0.6	25	1	US-11-060-756-97834	Sequence 97834, A
51	25	0.6	25	1	US-11-060-756-97835	Sequence 97835, A
52	25	0.6	25	1	US-11-060-756-125249	Sequence 125249,
53	25	0.6	25	1	US-11-060-756-129097	Sequence 129097,
54	25	0.6	25	1	US-11-060-756-129098	Sequence 129098,
55	25	0.6	25	1	US-11-060-756-132097	Sequence 132097,
56	25	0.6	25	1	US-11-060-756-133242	Sequence 133242,
57	25	0.6	25	1	US-11-060-756-134391	Sequence 134391,
58	25	0.6	25	1	US-11-060-756-139236	Sequence 139236,
59	25	0.6	25	1	US-11-060-756-147611	Sequence 147611,
60	25	0.6	25	1	US-11-060-756-150055	Sequence 150055,
61	25	0.6	25	1	US-11-060-756-153404	Sequence 153404,
62	25	0.6	25	1	US-11-060-756-155302	Sequence 155302,
63	25	0.6	25	1	US-11-060-756-161865	Sequence 161865,
64	25	0.6	25	1	US-11-060-756-162190	Sequence 162190,
65	25	0.6	25	1	US-11-060-756-165621	Sequence 165621,
66	25	0.6	25	1	US-11-060-756-166857	Sequence 166857,
67	25	0.6	25	1	US-11-060-756-174928	Sequence 174928,
68	25	0.6	25	1	US-11-060-756-175132	Sequence 175132,
69	25	0.6	25	1	US-11-060-756-179237	Sequence 179237,
70	25	0.6	25	1	US-11-060-756-179718	Sequence 179718,
71	25	0.6	25	1	US-11-060-756-183482	Sequence 183482,
72	25	0.6	25	1	US-11-060-756-183957	Sequence 183957,
73	25	0.6	25	1	US-11-060-756-184429	Sequence 184429,
74	25	0.6	25	1	US-11-060-756-184632	Sequence 184632,
75	25	0.6	25	1	US-11-060-756-185040	Sequence 185040,
76	25	0.6	25	1	US-11-060-756-185041	Sequence 185041,
77	25	0.6	25	1	US-11-060-756-186082	Sequence 186082,
78	25	0.6	25	1	US-11-060-756-186108	Sequence 186108,
79	25	0.6	25	1	US-11-060-756-186568	Sequence 186568,
80	25	0.6	25	1	US-11-060-756-187404	Sequence 187404,
81	25	0.6	25	1	US-11-060-756-188249	Sequence 188249,
82	25	0.6	25	1	US-11-060-756-189304	Sequence 189304,
83	25	0.6	25	1	US-11-060-756-189708	Sequence 189708,
84	25	0.6	25	1	US-11-060-756-190188	Sequence 190188,
85	25	0.6	25	1	US-11-060-756-190605	Sequence 190605,
86	25	0.6	25	1	US-11-060-756-191833	Sequence 191833,
87	25	0.6	25	1	US-11-060-756-193142	Sequence 193142,
88	25	0.6	25	1	US-11-060-756-193756	Sequence 193756,
89	25	0.6	25	1	US-11-060-756-195383	Sequence 195383,
90	25	0.6	25	1	US-11-060-756-197318	Sequence 197318,
91	25	0.6	25	1	US-11-060-756-201466	Sequence 201466,
92	25	0.6	25	1	US-11-060-756-205476	Sequence 205476,
93	25	0.6	25	1	US-11-060-756-207856	Sequence 207856,
94	25	0.6	25	1	US-11-060-756-208436	Sequence 208436,
95	25	0.6	25	1	US-11-060-756-212346	Sequence 212346,
96	25	0.6	25	1	US-11-060-756-216810	Sequence 216810,
97	25	0.6	25	1	US-11-060-756-216811	Sequence 216811,
98	25	0.6	25	1	US-11-060-756-223922	Sequence 223922,
99	25	0.6	25	1	US-11-060-756-225785	Sequence 225785,
100	25	0.6	25	1	US-11-060-756-232888	Sequence 232888,
101	25	0.6	25	1	US-11-060-756-233025	Sequence 233025,
102	25	0.6	25	1	US-11-060-756-235734	Sequence 235734,
103	25	0.6	25	1	US-11-060-756-236369	Sequence 236369,
104	25	0.6	25	1	US-11-060-756-240888	Sequence 240888,
105	25	0.6	25	1	US-11-060-756-241193	Sequence 241193,
106	25	0.6	25	1	US-11-060-756-241337	Sequence 241337,

	107	25	0.6	25	1	US-11-060-756-242200	Sequence 242200,
	108	25	0.6	25	1	US-11-060-756-243194	Sequence 243194,
	109	25	0.6	25	1	US-11-060-756-244973	Sequence 244973,
	110	25	0.6	25	1	US-11-060-756-247996	Sequence 247996,
	111	25	0.6	25	1	US-11-060-756-248716	Sequence 248716,
	112	25	0.6	25	1	US-11-060-756-254719	Sequence 254719,
	113	25	0.6	25	1	US-11-060-756-260910	Sequence 260910,
	114	25	0.6	25	1	US-11-060-756-262582	Sequence 262582,
	115	25	0.6	25	1	US-11-060-756-262926	Sequence 262926,
	116	25	0.6	25	1	US-11-060-756-263974	Sequence 263974,
	117	25	0.6	25	1	US-11-060-756-264417	Sequence 264417,
	118	25	0.6	25	1	US-11-060-756-264508	Sequence 264508,
	119	25	0.6	25	1	US-11-060-756-264553	Sequence 264553,
	120	25	0.6	25	1	US-11-060-756-265308	Sequence 265308,
	121	25	0.6	25	1	US-11-060-756-266195	Sequence 266195,
	122	25	0.6	25	1	US-11-060-756-266335	Sequence 266335,
	123	25	0.6	25	1	US-11-060-756-266889	Sequence 266889,
	124	25	0.6	25	1	US-11-060-756-267083	Sequence 267083,
	125	25	0.6	25	1	US-11-060-756-268063	Sequence 268063,
	126	25	0.6	25	1	US-11-060-756-268427	Sequence 268427,
	127	25	0.6	25	1	US-11-060-756-270798	Sequence 270798,
	128	25	0.6	25	1	US-11-060-756-271627	Sequence 271627,
	129	25	0.6	25	1	US-11-060-756-275773	Sequence 275773,
	130	25	0.6	25	1	US-11-060-756-275774	Sequence 275774,
	131	25	0.6	25	1	US-11-060-756-285057	Sequence 285057,
	132	25	0.6	25	1	US-11-060-756-286007	Sequence 286007,
	133	25	0.6	25	1	US-11-060-756-286495	Sequence 286495,
	134	25	0.6	25	1	US-11-060-756-291576	Sequence 291576,
	135	25	0.6	25	1	US-11-060-756-291577	Sequence 291577,
	136	25	0.6	25	1	US-11-060-756-294522	Sequence 294522,
	137	25	0.6	25	1	US-11-060-756-294810	Sequence 294810,
	138	25	0.6	25	1	US-11-060-756-300396	Sequence 300396,
	139	25	0.6	25	1	US-11-060-756-300512	Sequence 300512,
	140	25	0.6	25	1	US-11-060-756-301519	Sequence 301519,
	141	25	0.6	25	1	US-11-060-756-301875	Sequence 301875,
	142	24.2	0.6	29	1	US-10-800-350-1	Sequence 1, Appli
	143	24.2	0.6	29	1	US-10-800-077-1	Sequence 1, Appli
	144	23.4	0.6	25	1	US-10-956-157-160391	Sequence 160391,
	145	22.4	0.5	25	1	US-10-956-157-208204	Sequence 208204,
	146	22.4	0.5	25	1	US-11-036-317-409480	Sequence 409480,
	147	21.8	0.5	25	1	US-10-719-956-644851	Sequence 644851,
	148	21.8	0.5	25	1	US-10-956-157-188189	Sequence 188189,
	149	21.8	0.5	25	1	US-11-036-317-15098	Sequence 15098, A
	150	21.8	0.5	25	1	US-11-060-756-124745	Sequence 124745,
c	151	21.8	0.5	25	1	US-11-060-756-152377	Sequence 152377,
c	152	21.8	0.5	25	1	US-11-060-756-152378	Sequence 152378,
	153	21.8	0.5	25	1	US-11-060-756-285880	Sequence 285880,
	154	21.4	0.5	25	1	US-11-036-317-39029	Sequence 39029, A
c	155	21	0.5	21	1	US-10-800-350-20	Sequence 20, Appl
c	156	21	0.5	21	1	US-10-800-350-35	Sequence 35, Appl
c	157	21	0.5	21	1	US-10-800-350-37	Sequence 37, Appl
c	158	21	0.5	21	1	US-10-800-350-39	Sequence 39, Appl
c	159	21	0.5	21	1	US-10-800-350-41	Sequence 41, Appl
c	160	21	0.5	21	1	US-10-800-350-42	Sequence 42, Appl
c	161	21	0.5	21	1	US-10-800-350-44	Sequence 44, Appl
c	162	21	0.5	21	1	US-10-800-350-45	Sequence 45, Appl
c	163	21	0.5	21	1	US-10-800-350-46	Sequence 46, Appl
c	164	21	0.5	21	1	US-10-800-350-49	Sequence 49, Appl
c	165	21	0.5	21	1	US-10-800-350-50	Sequence 50, Appl
c	166	21	0.5	21	1	US-10-800-350-52	Sequence 52, Appl
c	167	21	0.5	21	1	US-10-800-350-70	Sequence 70, Appl
c	168	21	0.5	21	1	US-10-800-350-73	Sequence 73, Appl
c	169	21	0.5	21	1	US-10-800-350-222	Sequence 222, App
c	170	21	0.5	21	1	US-10-800-350-224	Sequence 224, App
c	171	21	0.5	21	1	US-10-800-350-225	Sequence 225, App
c	172	21	0.5	21	1	US-10-800-350-226	Sequence 226, App
c	173	21	0.5	21	1	US-10-800-350-229	Sequence 229, App
c	174	21	0.5	21	1	US-10-800-350-230	Sequence 230, App
c	175	21	0.5	21	1	US-10-800-350-232	Sequence 232, App
	176	21	0.5	21	1	US-10-800-350-233	Sequence 233, App
	177	21	0.5	21	1	US-10-800-350-234	Sequence 234, App
	178	21	0.5	21	1	US-10-800-350-235	Sequence 235, App
	179	21	0.5	21	1	US-10-800-350-236	Sequence 236, App
	180	21	0.5	21	1	US-10-800-350-237	Sequence 237, App
	181	21	0.5	21	1	US-10-800-350-238	Sequence 238, App
	182	21	0.5	21	1	US-10-800-350-239	Sequence 239, App
	183	21	0.5	21	1	US-10-800-350-240	Sequence 240, App
	184	21	0.5	21	1	US-10-800-350-241	Sequence 241, App
	185	21	0.5	21	1	US-10-800-350-242	Sequence 242, App
	186	21	0.5	21	1	US-10-800-350-243	Sequence 243, App
	187	21	0.5	21	1	US-10-800-350-244	Sequence 244, App
	188	21	0.5	21	1	US-10-800-350-245	Sequence 245, App
	189	21	0.5	21	1	US-10-800-350-246	Sequence 246, App
	190	21	0.5	21	1	US-10-800-350-247	Sequence 247, App
	191	21	0.5	21	1	US-10-800-350-248	Sequence 248, App
	192	21	0.5	21	1	US-10-800-350-249	Sequence 249, App
	193	21	0.5	21	1	US-10-800-350-250	Sequence 250, App
	194	21	0.5	21	1	US-10-800-350-251	Sequence 251, App
	195	21	0.5	21	1	US-10-800-350-252	Sequence 252, App
	196	21	0.5	21	1	US-10-800-350-253	Sequence 253, App
	197	21	0.5	21	1	US-10-800-350-254	Sequence 254, App
	198	21	0.5	21	1	US-10-800-350-255	Sequence 255, App
	199	21	0.5	21	1	US-10-800-350-256	Sequence 256, App
	200	21	0.5	21	1	US-10-800-350-257	Sequence 257, App
	201	21	0.5	21	1	US-10-800-350-258	Sequence 258, App
	202	21	0.5	21	1	US-10-800-350-259	Sequence 259, App
	203	21	0.5	21	1	US-10-800-350-260	Sequence 260, App
	204	21	0.5	21	1	US-10-800-350-261	Sequence 261, App
	205	21	0.5	21	1	US-10-800-350-262	Sequence 262, App
	206	21	0.5	21	1	US-10-800-350-263	Sequence 263, App
	207	21	0.5	21	1	US-10-800-350-264	Sequence 264, App
	208	21	0.5	21	1	US-10-800-350-265	Sequence 265, App
	209	21	0.5	21	1	US-10-800-350-266	Sequence 266, App
	210	21	0.5	21	1	US-10-800-350-267	Sequence 267, App
	211	21	0.5	21	1	US-10-800-350-268	Sequence 268, App
	212	21	0.5	21	1	US-10-800-350-269	Sequence 269, App
	213	21	0.5	21	1	US-10-800-350-270	Sequence 270, App
	214	21	0.5	21	1	US-10-800-350-271	Sequence 271, App
	215	21	0.5	21	1	US-10-800-350-272	Sequence 272, App
	216	21	0.5	21	1	US-10-800-350-273	Sequence 273, App
	217	21	0.5	21	1	US-10-800-350-274	Sequence 274, App
	218	21	0.5	21	1	US-10-800-350-275	Sequence 275, App
	219	21	0.5	21	1	US-10-800-350-276	Sequence 276, App
	220	21	0.5	21	1	US-10-800-350-277	Sequence 277, App
	221	21	0.5	21	1	US-10-800-350-278	Sequence 278, App
	222	21	0.5	21	1	US-10-800-350-279	Sequence 279, App
	223	21	0.5	21	1	US-10-800-350-280	Sequence 280, App
	224	21	0.5	21	1	US-10-800-350-281	Sequence 281, App
	225	21	0.5	21	1	US-10-800-350-282	Sequence 282, App
	226	21	0.5	21	1	US-10-800-350-283	Sequence 283, App
	227	21	0.5	21	1	US-10-800-350-284	Sequence 284, App
	228	21	0.5	21	1	US-10-800-350-285	Sequence 285, App
c	229	21	0.5	21	1	US-10-800-077-20	Sequence 20, Appl
c	230	21	0.5	21	1	US-10-800-077-35	Sequence 35, Appl
c	231	21	0.5	21	1	US-10-800-077-37	Sequence 37, Appl
c	232	21	0.5	21	1	US-10-800-077-39	Sequence 39, Appl
c	233	21	0.5	21	1	US-10-800-077-41	Sequence 41, Appl
c	234	21	0.5	21	1	US-10-800-077-42	Sequence 42, Appl
c	235	21	0.5	21	1	US-10-800-077-44	Sequence 44, Appl
c	236	21	0.5	21	1	US-10-800-077-45	Sequence 45, Appl
c	237	21	0.5	21	1	US-10-800-077-46	Sequence 46, Appl
c	238	21	0.5	21	1	US-10-800-077-49	Sequence 49, Appl
c	239	21	0.5	21	1	US-10-800-077-50	Sequence 50, Appl
c	240	21	0.5	21	1	US-10-800-077-52	Sequence 52, Appl
c	241	21	0.5	21	1	US-10-800-077-70	Sequence 70, Appl
c	242	21	0.5	21	1	US-10-800-077-73	Sequence 73, Appl
c	243	21	0.5	21	1	US-10-800-077-222	Sequence 222, App
c	244	21	0.5	21	1	US-10-800-077-224	Sequence 224, App
c	245	21	0.5	21	1	US-10-800-077-225	Sequence 225, App
c	246	21	0.5	21	1	US-10-800-077-226	Sequence 226, App
c	247	21	0.5	21	1	US-10-800-077-229	Sequence 229, App
c	248	21	0.5	21	1	US-10-800-077-230	Sequence 230, App
c	249	21	0.5	21	1	US-10-800-077-232	Sequence 232, App
	250	21	0.5	21	1	US-10-800-077-233	Sequence 233, App
	251	21	0.5	21	1	US-10-800-077-234	Sequence 234, App
	252	21	0.5	21	1	US-10-800-077-235	Sequence 235, App

253	21	0.5	21	1	US-10-800-077-236	Sequence 236, App
254	21	0.5	21	1	US-10-800-077-237	Sequence 237, App
255	21	0.5	21	1	US-10-800-077-238	Sequence 238, App
256	21	0.5	21	1	US-10-800-077-239	Sequence 239, App
257	21	0.5	21	1	US-10-800-077-240	Sequence 240, App
258	21	0.5	21	1	US-10-800-077-241	Sequence 241, App
259	21	0.5	21	1	US-10-800-077-242	Sequence 242, App
260	21	0.5	21	1	US-10-800-077-243	Sequence 243, App
261	21	0.5	21	1	US-10-800-077-244	Sequence 244, App
262	21	0.5	21	1	US-10-800-077-245	Sequence 245, App
263	21	0.5	21	1	US-10-800-077-246	Sequence 246, App
264	21	0.5	21	1	US-10-800-077-247	Sequence 247, App
265	21	0.5	21	1	US-10-800-077-248	Sequence 248, App
266	21	0.5	21	1	US-10-800-077-249	Sequence 249, App
267	21	0.5	21	1	US-10-800-077-250	Sequence 250, App
268	21	0.5	21	1	US-10-800-077-251	Sequence 251, App
269	21	0.5	21	1	US-10-800-077-252	Sequence 252, App
270	21	0.5	21	1	US-10-800-077-253	Sequence 253, App
271	21	0.5	21	1	US-10-800-077-254	Sequence 254, App
272	21	0.5	21	1	US-10-800-077-255	Sequence 255, App
273	21	0.5	21	1	US-10-800-077-256	Sequence 256, App
274	21	0.5	21	1	US-10-800-077-257	Sequence 257, App
275	21	0.5	21	1	US-10-800-077-258	Sequence 258, App
276	21	0.5	21	1	US-10-800-077-259	Sequence 259, App
277	21	0.5	21	1	US-10-800-077-260	Sequence 260, App
278	21	0.5	21	1	US-10-800-077-261	Sequence 261, App
279	21	0.5	21	1	US-10-800-077-262	Sequence 262, App
280	21	0.5	21	1	US-10-800-077-263	Sequence 263, App
281	21	0.5	21	1	US-10-800-077-264	Sequence 264, App
282	21	0.5	21	1	US-10-800-077-265	Sequence 265, App
283	21	0.5	21	1	US-10-800-077-266	Sequence 266, App
284	21	0.5	21	1	US-10-800-077-267	Sequence 267, App
285	21	0.5	21	1	US-10-800-077-268	Sequence 268, App
286	21	0.5	21	1	US-10-800-077-269	Sequence 269, App
287	21	0.5	21	1	US-10-800-077-270	Sequence 270, App
288	21	0.5	21	1	US-10-800-077-271	Sequence 271, App
289	21	0.5	21	1	US-10-800-077-272	Sequence 272, App
290	21	0.5	21	1	US-10-800-077-273	Sequence 273, App
291	21	0.5	21	1	US-10-800-077-274	Sequence 274, App
292	21	0.5	21	1	US-10-800-077-275	Sequence 275, App
293	21	0.5	21	1	US-10-800-077-276	Sequence 276, App
294	21	0.5	21	1	US-10-800-077-277	Sequence 277, App
295	21	0.5	21	1	US-10-800-077-278	Sequence 278, App
296	21	0.5	21	1	US-10-800-077-279	Sequence 279, App
297	21	0.5	21	1	US-10-800-077-280	Sequence 280, App
298	21	0.5	21	1	US-10-800-077-281	Sequence 281, App
299	21	0.5	21	1	US-10-800-077-282	Sequence 282, App
300	21	0.5	21	1	US-10-800-077-283	Sequence 283, App
301	21	0.5	21	1	US-10-800-077-284	Sequence 284, App
302	21	0.5	21	1	US-10-800-077-285	Sequence 285, App
303	20.8	0.5	25	1	US-10-719-956-629839	Sequence 629839,
304	20.8	0.5	25	1	US-10-719-956-629840	Sequence 629840,
305	20.8	0.5	25	1	US-11-036-317-47943	Sequence 47943, A
306	20.8	0.5	25	1	US-11-036-317-133760	Sequence 133760,
307	20.8	0.5	25	1	US-11-036-317-479532	Sequence 479532,
c 308	20.8	0.5	25	1	US-11-060-756-121062	Sequence 121062,
c 309	20.8	0.5	25	1	US-11-060-756-121063	Sequence 121063,
c 310	20.8	0.5	25	1	US-11-060-756-142612	Sequence 142612,
c 311	20.8	0.5	25	1	US-11-060-756-142613	Sequence 142613,
312	20.8	0.5	25	1	US-11-060-756-180539	Sequence 180539,
313	20.8	0.5	25	1	US-11-060-756-256243	Sequence 256243,
314	20.4	0.5	22	1	US-10-800-350-59	Sequence 59, Appl
315	20.4	0.5	22	1	US-10-800-077-59	Sequence 59, Appl
c 316	20.4	0.5	24	1	US-09-140-378A-3	Sequence 3, Appli
317	20.2	0.5	25	1	US-10-719-956-644852	Sequence 644852,
318	20.2	0.5	25	1	US-10-809-189-24487	Sequence 24487, A
c 319	20.2	0.5	25	1	US-10-809-189-37489	Sequence 37489, A
320	20.2	0.5	25	1	US-11-036-317-105366	Sequence 105366,
321	20.2	0.5	25	1	US-11-036-317-210541	Sequence 210541,
322	20.2	0.5	25	1	US-11-036-317-341458	Sequence 341458,
323	20.2	0.5	25	1	US-11-036-317-370869	Sequence 370869,
324	20.2	0.5	25	1	US-11-036-317-373537	Sequence 373537,
325	20.2	0.5	25	1	US-11-036-317-411187	Sequence 411187,
326	20.2	0.5	25	1	US-11-036-317-456404	Sequence 456404,
327	20.2	0.5	25	1	US-11-036-317-528469	Sequence 528469,
c 328	20.2	0.5	25	1	US-11-060-756-18552	Sequence 18552, A
c 329	20.2	0.5	25	1	US-11-060-756-18556	Sequence 18556, A
c 330	20.2	0.5	25	1	US-11-060-756-18557	Sequence 18557, A
c 331	20.2	0.5	25	1	US-11-060-756-18562	Sequence 18562, A
c 332	20.2	0.5	25	1	US-11-060-756-18564	Sequence 18564, A
c 333	20.2	0.5	25	1	US-11-060-756-18574	Sequence 18574, A
c 334	20.2	0.5	25	1	US-11-060-756-18578	Sequence 18578, A
335	20.2	0.5	25	1	US-11-060-756-84138	Sequence 84138, A
336	20.2	0.5	25	1	US-11-060-756-84139	Sequence 84139, A
337	20.2	0.5	25	1	US-11-060-756-84144	Sequence 84144, A
338	20.2	0.5	25	1	US-11-060-756-84148	Sequence 84148, A
339	20.2	0.5	25	1	US-11-060-756-123826	Sequence 123826,
340	20.2	0.5	25	1	US-11-060-756-126430	Sequence 126430,
341	20.2	0.5	25	1	US-11-060-756-144910	Sequence 144910,
c 342	20.2	0.5	25	1	US-11-060-756-163425	Sequence 163425,
c 343	20.2	0.5	25	1	US-11-060-756-163426	Sequence 163426,
c 344	20.2	0.5	25	1	US-11-060-756-166073	Sequence 166073,
c 345	20.2	0.5	25	1	US-11-060-756-166074	Sequence 166074,
346	20.2	0.5	25	1	US-11-060-756-168023	Sequence 168023,
347	20.2	0.5	25	1	US-11-060-756-170191	Sequence 170191,
c 348	20.2	0.5	25	1	US-11-060-756-170358	Sequence 170358,
c 349	20.2	0.5	25	1	US-11-060-756-170359	Sequence 170359,
c 350	20.2	0.5	25	1	US-11-060-756-171498	Sequence 171498,
c 351	20.2	0.5	25	1	US-11-060-756-171499	Sequence 171499,
352	20.2	0.5	25	1	US-11-060-756-182311	Sequence 182311,
c 353	20.2	0.5	25	1	US-11-060-756-193223	Sequence 193223,
354	20.2	0.5	25	1	US-11-060-756-227416	Sequence 227416,
355	20.2	0.5	25	1	US-11-060-756-239848	Sequence 239848,
356	20.2	0.5	25	1	US-11-060-756-245548	Sequence 245548,
357	20.2	0.5	25	1	US-11-060-756-248252	Sequence 248252,
358	20.2	0.5	25	1	US-11-060-756-261475	Sequence 261475,
359	20.2	0.5	25	1	US-11-060-756-265730	Sequence 265730,
360	20.2	0.5	25	1	US-11-060-756-266448	Sequence 266448,
361	20.2	0.5	25	1	US-11-060-756-269583	Sequence 269583,
362	20.2	0.5	25	1	US-11-060-756-282968	Sequence 282968,
363	20.2	0.5	25	1	US-11-060-756-283106	Sequence 283106,
364	20.2	0.5	25	1	US-11-060-756-283608	Sequence 283608,
365	20.2	0.5	25	1	US-11-060-756-283741	Sequence 283741,
c 366	20.2	0.5	25	1	US-11-060-756-301070	Sequence 301070,
c 367	20.2	0.5	25	1	US-11-060-756-301071	Sequence 301071,
368	20	0.5	20	1	US-10-800-350-19	Sequence 19, Appl
c 369	20	0.5	20	1	US-10-800-350-21	Sequence 21, Appl
370	20	0.5	20	1	US-10-800-350-25	Sequence 25, Appl
c 371	20	0.5	20	1	US-10-800-350-27	Sequence 27, Appl
372	20	0.5	20	1	US-10-800-350-32	Sequence 32, Appl
c 373	20	0.5	20	1	US-10-800-350-33	Sequence 33, Appl
c 374	20	0.5	20	1	US-10-800-350-51	Sequence 51, Appl
375	20	0.5	20	1	US-10-800-350-55	Sequence 55, Appl
c 376	20	0.5	20	1	US-10-800-350-56	Sequence 56, Appl
c 377	20	0.5	20	1	US-10-800-350-74	Sequence 74, Appl
c 378	20	0.5	20	1	US-10-800-350-75	Sequence 75, Appl
c 379	20	0.5	20	1	US-10-800-350-76	Sequence 76, Appl
c 380	20	0.5	20	1	US-10-800-350-77	Sequence 77, Appl
c 381	20	0.5	20	1	US-10-800-350-78	Sequence 78, Appl
c 382	20	0.5	20	1	US-10-800-350-79	Sequence 79, Appl
c 383	20	0.5	20	1	US-10-800-350-80	Sequence 80, Appl
c 384	20	0.5	20	1	US-10-800-350-81	Sequence 81, Appl
c 385	20	0.5	20	1	US-10-800-350-82	Sequence 82, Appl
c 386	20	0.5	20	1	US-10-800-350-83	Sequence 83, Appl
c 387	20	0.5	20	1	US-10-800-350-84	Sequence 84, Appl
c 388	20	0.5	20	1	US-10-800-350-85	Sequence 85, Appl
c 389	20	0.5	20	1	US-10-800-350-86	Sequence 86, Appl
c 390	20	0.5	20	1	US-10-800-350-87	Sequence 87, Appl
c 391	20	0.5	20	1	US-10-800-350-88	Sequence 88, Appl
c 392	20	0.5	20	1	US-10-800-350-89	Sequence 89, Appl
c 393	20	0.5	20	1	US-10-800-350-90	Sequence 90, Appl
c 394	20	0.5	20	1	US-10-800-350-91	Sequence 91, Appl
c 395	20	0.5	20	1	US-10-800-350-92	Sequence 92, Appl
c 396	20	0.5	20	1	US-10-800-350-93	Sequence 93, Appl
c 397	20	0.5	20	1	US-10-800-350-94	Sequence 94, Appl
c 398	20	0.5	20	1	US-10-800-350-95	Sequence 95, Appl

c 399	20	0.5	20	1	US-10-800-350-96	Sequence 96, Appl
c 400	20	0.5	20	1	US-10-800-350-97	Sequence 97, Appl
c 401	20	0.5	20	1	US-10-800-350-98	Sequence 98, Appl
c 402	20	0.5	20	1	US-10-800-350-99	Sequence 99, Appl
c 403	20	0.5	20	1	US-10-800-350-100	Sequence 100, App
c 404	20	0.5	20	1	US-10-800-350-101	Sequence 101, App
c 405	20	0.5	20	1	US-10-800-350-102	Sequence 102, App
c 406	20	0.5	20	1	US-10-800-350-103	Sequence 103, App
c 407	20	0.5	20	1	US-10-800-350-104	Sequence 104, App
c 408	20	0.5	20	1	US-10-800-350-105	Sequence 105, App
c 409	20	0.5	20	1	US-10-800-350-106	Sequence 106, App
c 410	20	0.5	20	1	US-10-800-350-107	Sequence 107, App
c 411	20	0.5	20	1	US-10-800-350-108	Sequence 108, App
c 412	20	0.5	20	1	US-10-800-350-109	Sequence 109, App
c 413	20	0.5	20	1	US-10-800-350-110	Sequence 110, App
c 414	20	0.5	20	1	US-10-800-350-111	Sequence 111, App
c 415	20	0.5	20	1	US-10-800-350-112	Sequence 112, App
c 416	20	0.5	20	1	US-10-800-350-113	Sequence 113, App
c 417	20	0.5	20	1	US-10-800-350-114	Sequence 114, App
c 418	20	0.5	20	1	US-10-800-350-115	Sequence 115, App
c 419	20	0.5	20	1	US-10-800-350-116	Sequence 116, App
c 420	20	0.5	20	1	US-10-800-350-117	Sequence 117, App
c 421	20	0.5	20	1	US-10-800-350-118	Sequence 118, App
c 422	20	0.5	20	1	US-10-800-350-119	Sequence 119, App
c 423	20	0.5	20	1	US-10-800-350-120	Sequence 120, App
c 424	20	0.5	20	1	US-10-800-350-121	Sequence 121, App
c 425	20	0.5	20	1	US-10-800-350-122	Sequence 122, App
c 426	20	0.5	20	1	US-10-800-350-123	Sequence 123, App
c 427	20	0.5	20	1	US-10-800-350-124	Sequence 124, App
c 428	20	0.5	20	1	US-10-800-350-125	Sequence 125, App
c 429	20	0.5	20	1	US-10-800-350-126	Sequence 126, App
c 430	20	0.5	20	1	US-10-800-350-127	Sequence 127, App
c 431	20	0.5	20	1	US-10-800-350-128	Sequence 128, App
c 432	20	0.5	20	1	US-10-800-350-129	Sequence 129, App
c 433	20	0.5	20	1	US-10-800-350-130	Sequence 130, App
c 434	20	0.5	20	1	US-10-800-350-131	Sequence 131, App
c 435	20	0.5	20	1	US-10-800-350-132	Sequence 132, App
c 436	20	0.5	20	1	US-10-800-350-133	Sequence 133, App
c 437	20	0.5	20	1	US-10-800-350-134	Sequence 134, App
c 438	20	0.5	20	1	US-10-800-350-135	Sequence 135, App
c 439	20	0.5	20	1	US-10-800-350-136	Sequence 136, App
c 440	20	0.5	20	1	US-10-800-350-137	Sequence 137, App
c 441	20	0.5	20	1	US-10-800-350-138	Sequence 138, App
c 442	20	0.5	20	1	US-10-800-350-139	Sequence 139, App
c 443	20	0.5	20	1	US-10-800-350-140	Sequence 140, App
c 444	20	0.5	20	1	US-10-800-350-141	Sequence 141, App
c 445	20	0.5	20	1	US-10-800-350-142	Sequence 142, App
c 446	20	0.5	20	1	US-10-800-350-143	Sequence 143, App
c 447	20	0.5	20	1	US-10-800-350-144	Sequence 144, App
c 448	20	0.5	20	1	US-10-800-350-145	Sequence 145, App
c 449	20	0.5	20	1	US-10-800-350-146	Sequence 146, App
c 450	20	0.5	20	1	US-10-800-350-147	Sequence 147, App
c 451	20	0.5	20	1	US-10-800-350-148	Sequence 148, App
c 452	20	0.5	20	1	US-10-800-350-149	Sequence 149, App
c 453	20	0.5	20	1	US-10-800-350-150	Sequence 150, App
c 454	20	0.5	20	1	US-10-800-350-151	Sequence 151, App
c 455	20	0.5	20	1	US-10-800-350-152	Sequence 152, App
c 456	20	0.5	20	1	US-10-800-350-153	Sequence 153, App
c 457	20	0.5	20	1	US-10-800-350-154	Sequence 154, App
c 458	20	0.5	20	1	US-10-800-350-155	Sequence 155, App
c 459	20	0.5	20	1	US-10-800-350-156	Sequence 156, App
c 460	20	0.5	20	1	US-10-800-350-157	Sequence 157, App
c 461	20	0.5	20	1	US-10-800-350-158	Sequence 158, App
c 462	20	0.5	20	1	US-10-800-350-159	Sequence 159, App
c 463	20	0.5	20	1	US-10-800-350-160	Sequence 160, App
c 464	20	0.5	20	1	US-10-800-350-161	Sequence 161, App
c 465	20	0.5	20	1	US-10-800-350-162	Sequence 162, App
c 466	20	0.5	20	1	US-10-800-350-163	Sequence 163, App
c 467	20	0.5	20	1	US-10-800-350-164	Sequence 164, App
c 468	20	0.5	20	1	US-10-800-350-165	Sequence 165, App
c 469	20	0.5	20	1	US-10-800-350-166	Sequence 166, App
c 470	20	0.5	20	1	US-10-800-350-167	Sequence 167, App
c 471	20	0.5	20	1	US-10-800-350-168	Sequence 168, App
c 472	20	0.5	20	1	US-10-800-350-169	Sequence 169, App
c 473	20	0.5	20	1	US-10-800-350-170	Sequence 170, App
c 474	20	0.5	20	1	US-10-800-350-171	Sequence 171, App
c 475	20	0.5	20	1	US-10-800-350-172	Sequence 172, App
c 476	20	0.5	20	1	US-10-800-350-173	Sequence 173, App
c 477	20	0.5	20	1	US-10-800-350-174	Sequence 174, App
c 478	20	0.5	20	1	US-10-800-350-175	Sequence 175, App
c 479	20	0.5	20	1	US-10-800-350-176	Sequence 176, App
c 480	20	0.5	20	1	US-10-800-350-177	Sequence 177, App
c 481	20	0.5	20	1	US-10-800-350-178	Sequence 178, App
c 482	20	0.5	20	1	US-10-800-350-179	Sequence 179, App
c 483	20	0.5	20	1	US-10-800-350-180	Sequence 180, App
c 484	20	0.5	20	1	US-10-800-350-181	Sequence 181, App
c 485	20	0.5	20	1	US-10-800-350-182	Sequence 182, App
c 486	20	0.5	20	1	US-10-800-350-183	Sequence 183, App
c 487	20	0.5	20	1	US-10-800-350-184	Sequence 184, App
c 488	20	0.5	20	1	US-10-800-350-185	Sequence 185, App
c 489	20	0.5	20	1	US-10-800-350-186	Sequence 186, App
c 490	20	0.5	20	1	US-10-800-350-187	Sequence 187, App
c 491	20	0.5	20	1	US-10-800-350-188	Sequence 188, App
c 492	20	0.5	20	1	US-10-800-350-189	Sequence 189, App
c 493	20	0.5	20	1	US-10-800-350-190	Sequence 190, App
c 494	20	0.5	20	1	US-10-800-350-191	Sequence 191, App
c 495	20	0.5	20	1	US-10-800-350-192	Sequence 192, App
c 496	20	0.5	20	1	US-10-800-350-193	Sequence 193, App
c 497	20	0.5	20	1	US-10-800-350-194	Sequence 194, App
c 498	20	0.5	20	1	US-10-800-350-195	Sequence 195, App
c 499	20	0.5	20	1	US-10-800-350-196	Sequence 196, App
c 500	20	0.5	20	1	US-10-800-350-197	Sequence 197, App
c 501	20	0.5	20	1	US-10-800-350-198	Sequence 198, App
c 502	20	0.5	20	1	US-10-800-350-199	Sequence 199, App
c 503	20	0.5	20	1	US-10-800-350-200	Sequence 200, App
c 504	20	0.5	20	1	US-10-800-350-201	Sequence 201, App
c 505	20	0.5	20	1	US-10-800-350-202	Sequence 202, App
c 506	20	0.5	20	1	US-10-800-350-203	Sequence 203, App
c 507	20	0.5	20	1	US-10-800-350-204	Sequence 204, App
c 508	20	0.5	20	1	US-10-800-350-205	Sequence 205, App
c 509	20	0.5	20	1	US-10-800-350-206	Sequence 206, App
c 510	20	0.5	20	1	US-10-800-350-207	Sequence 207, App
c 511	20	0.5	20	1	US-10-800-350-208	Sequence 208, App
c 512	20	0.5	20	1	US-10-800-350-209	Sequence 209, App
c 513	20	0.5	20	1	US-10-800-350-210	Sequence 210, App
c 514	20	0.5	20	1	US-10-800-350-211	Sequence 211, App
c 515	20	0.5	20	1	US-10-800-350-212	Sequence 212, App
c 516	20	0.5	20	1	US-10-800-350-213	Sequence 213, App
c 517	20	0.5	20	1	US-10-800-350-214	Sequence 214, App
c 518	20	0.5	20	1	US-10-800-350-215	Sequence 215, App
c 519	20	0.5	20	1	US-10-800-350-216	Sequence 216, App
c 520	20	0.5	20	1	US-10-800-350-217	Sequence 217, App
c 521	20	0.5	20	1	US-10-800-350-218	Sequence 218, App
c 522	20	0.5	20	1	US-10-800-350-219	Sequence 219, App
c 523	20	0.5	20	1	US-10-800-350-220	Sequence 220, App
c 524	20	0.5	20	1	US-10-800-350-221	Sequence 221, App
c 525	20	0.5	20	1	US-10-800-350-231	Sequence 231, App
526	20	0.5	20	1	US-10-800-077-19	Sequence 19, Appl
c 527	20	0.5	20	1	US-10-800-077-21	Sequence 21, Appl
528	20	0.5	20	1	US-10-800-077-25	Sequence 25, Appl
c 529	20	0.5	20	1	US-10-800-077-27	Sequence 27, Appl
530	20	0.5	20	1	US-10-800-077-32	Sequence 32, Appl
c 531	20	0.5	20	1	US-10-800-077-33	Sequence 33, Appl
c 532	20	0.5	20	1	US-10-800-077-51	Sequence 51, Appl
533	20	0.5	20	1	US-10-800-077-55	Sequence 55, Appl
c 534	20	0.5	20	1	US-10-800-077-56	Sequence 56, Appl
c 535	20	0.5	20	1	US-10-800-077-74	Sequence 74, Appl
c 536	20	0.5	20	1	US-10-800-077-75	Sequence 75, Appl
c 537	20	0.5	20	1	US-10-800-077-76	Sequence 76, Appl
c 538	20	0.5	20	1	US-10-800-077-77	Sequence 77, Appl
c 539	20	0.5	20	1	US-10-800-077-78	Sequence 78, Appl
c 540	20	0.5	20	1	US-10-800-077-79	Sequence 79, Appl
c 541	20	0.5	20	1	US-10-800-077-80	Sequence 80, Appl
c 542	20	0.5	20	1	US-10-800-077-81	Sequence 81, Appl
c 543	20	0.5	20	1	US-10-800-077-82	Sequence 82, Appl
c 544	20	0.5	20	1	US-10-800-077-83	Sequence 83, Appl

c 545	20	0.5	20	1	US-10-800-077-84	Sequence 84, Appl
c 546	20	0.5	20	1	US-10-800-077-85	Sequence 85, Appl
c 547	20	0.5	20	1	US-10-800-077-86	Sequence 86, Appl
c 548	20	0.5	20	1	US-10-800-077-87	Sequence 87, Appl
c 549	20	0.5	20	1	US-10-800-077-88	Sequence 88, Appl
c 550	20	0.5	20	1	US-10-800-077-89	Sequence 89, Appl
c 551	20	0.5	20	1	US-10-800-077-90	Sequence 90, Appl
c 552	20	0.5	20	1	US-10-800-077-91	Sequence 91, Appl
c 553	20	0.5	20	1	US-10-800-077-92	Sequence 92, Appl
c 554	20	0.5	20	1	US-10-800-077-93	Sequence 93, Appl
c 555	20	0.5	20	1	US-10-800-077-94	Sequence 94, Appl
c 556	20	0.5	20	1	US-10-800-077-95	Sequence 95, Appl
c 557	20	0.5	20	1	US-10-800-077-96	Sequence 96, Appl
c 558	20	0.5	20	1	US-10-800-077-97	Sequence 97, Appl
c 559	20	0.5	20	1	US-10-800-077-98	Sequence 98, Appl
c 560	20	0.5	20	1	US-10-800-077-99	Sequence 99, Appl
c 561	20	0.5	20	1	US-10-800-077-100	Sequence 100, App
c 562	20	0.5	20	1	US-10-800-077-101	Sequence 101, App
c 563	20	0.5	20	1	US-10-800-077-102	Sequence 102, App
c 564	20	0.5	20	1	US-10-800-077-103	Sequence 103, App
c 565	20	0.5	20	1	US-10-800-077-104	Sequence 104, App
c 566	20	0.5	20	1	US-10-800-077-105	Sequence 105, App
c 567	20	0.5	20	1	US-10-800-077-106	Sequence 106, App
c 568	20	0.5	20	1	US-10-800-077-107	Sequence 107, App
c 569	20	0.5	20	1	US-10-800-077-108	Sequence 108, App
c 570	20	0.5	20	1	US-10-800-077-109	Sequence 109, App
c 571	20	0.5	20	1	US-10-800-077-110	Sequence 110, App
c 572	20	0.5	20	1	US-10-800-077-111	Sequence 111, App
c 573	20	0.5	20	1	US-10-800-077-112	Sequence 112, App
c 574	20	0.5	20	1	US-10-800-077-113	Sequence 113, App
c 575	20	0.5	20	1	US-10-800-077-114	Sequence 114, App
c 576	20	0.5	20	1	US-10-800-077-115	Sequence 115, App
c 577	20	0.5	20	1	US-10-800-077-116	Sequence 116, App
c 578	20	0.5	20	1	US-10-800-077-117	Sequence 117, App
c 579	20	0.5	20	1	US-10-800-077-118	Sequence 118, App
c 580	20	0.5	20	1	US-10-800-077-119	Sequence 119, App
c 581	20	0.5	20	1	US-10-800-077-120	Sequence 120, App
c 582	20	0.5	20	1	US-10-800-077-121	Sequence 121, App
c 583	20	0.5	20	1	US-10-800-077-122	Sequence 122, App
c 584	20	0.5	20	1	US-10-800-077-123	Sequence 123, App
c 585	20	0.5	20	1	US-10-800-077-124	Sequence 124, App
c 586	20	0.5	20	1	US-10-800-077-125	Sequence 125, App
c 587	20	0.5	20	1	US-10-800-077-126	Sequence 126, App
c 588	20	0.5	20	1	US-10-800-077-127	Sequence 127, App
c 589	20	0.5	20	1	US-10-800-077-128	Sequence 128, App
c 590	20	0.5	20	1	US-10-800-077-129	Sequence 129, App
c 591	20	0.5	20	1	US-10-800-077-130	Sequence 130, App
c 592	20	0.5	20	1	US-10-800-077-131	Sequence 131, App
c 593	20	0.5	20	1	US-10-800-077-132	Sequence 132, App
c 594	20	0.5	20	1	US-10-800-077-133	Sequence 133, App
c 595	20	0.5	20	1	US-10-800-077-134	Sequence 134, App
c 596	20	0.5	20	1	US-10-800-077-135	Sequence 135, App
c 597	20	0.5	20	1	US-10-800-077-136	Sequence 136, App
c 598	20	0.5	20	1	US-10-800-077-137	Sequence 137, App
c 599	20	0.5	20	1	US-10-800-077-138	Sequence 138, App
c 600	20	0.5	20	1	US-10-800-077-139	Sequence 139, App
c 601	20	0.5	20	1	US-10-800-077-140	Sequence 140, App
c 602	20	0.5	20	1	US-10-800-077-141	Sequence 141, App
c 603	20	0.5	20	1	US-10-800-077-142	Sequence 142, App
c 604	20	0.5	20	1	US-10-800-077-143	Sequence 143, App
c 605	20	0.5	20	1	US-10-800-077-144	Sequence 144, App
c 606	20	0.5	20	1	US-10-800-077-145	Sequence 145, App
c 607	20	0.5	20	1	US-10-800-077-146	Sequence 146, App
c 608	20	0.5	20	1	US-10-800-077-147	Sequence 147, App
c 609	20	0.5	20	1	US-10-800-077-148	Sequence 148, App
c 610	20	0.5	20	1	US-10-800-077-149	Sequence 149, App
c 611	20	0.5	20	1	US-10-800-077-150	Sequence 150, App
c 612	20	0.5	20	1	US-10-800-077-151	Sequence 151, App
c 613	20	0.5	20	1	US-10-800-077-152	Sequence 152, App
c 614	20	0.5	20	1	US-10-800-077-153	Sequence 153, App
c 615	20	0.5	20	1	US-10-800-077-154	Sequence 154, App
c 616	20	0.5	20	1	US-10-800-077-155	Sequence 155, App
c 617	20	0.5	20	1	US-10-800-077-156	Sequence 156, App
c 618	20	0.5	20	1	US-10-800-077-157	Sequence 157, App
c 619	20	0.5	20	1	US-10-800-077-158	Sequence 158, App
c 620	20	0.5	20	1	US-10-800-077-159	Sequence 159, App
c 621	20	0.5	20	1	US-10-800-077-160	Sequence 160, App
c 622	20	0.5	20	1	US-10-800-077-161	Sequence 161, App
c 623	20	0.5	20	1	US-10-800-077-162	Sequence 162, App
c 624	20	0.5	20	1	US-10-800-077-163	Sequence 163, App
c 625	20	0.5	20	1	US-10-800-077-164	Sequence 164, App
c 626	20	0.5	20	1	US-10-800-077-165	Sequence 165, App
c 627	20	0.5	20	1	US-10-800-077-166	Sequence 166, App
c 628	20	0.5	20	1	US-10-800-077-167	Sequence 167, App
c 629	20	0.5	20	1	US-10-800-077-168	Sequence 168, App
c 630	20	0.5	20	1	US-10-800-077-169	Sequence 169, App
c 631	20	0.5	20	1	US-10-800-077-170	Sequence 170, App
c 632	20	0.5	20	1	US-10-800-077-171	Sequence 171, App
c 633	20	0.5	20	1	US-10-800-077-172	Sequence 172, App
c 634	20	0.5	20	1	US-10-800-077-173	Sequence 173, App
c 635	20	0.5	20	1	US-10-800-077-174	Sequence 174, App
c 636	20	0.5	20	1	US-10-800-077-175	Sequence 175, App
c 637	20	0.5	20	1	US-10-800-077-176	Sequence 176, App
c 638	20	0.5	20	1	US-10-800-077-177	Sequence 177, App
c 639	20	0.5	20	1	US-10-800-077-178	Sequence 178, App
c 640	20	0.5	20	1	US-10-800-077-179	Sequence 179, App
c 641	20	0.5	20	1	US-10-800-077-180	Sequence 180, App
c 642	20	0.5	20	1	US-10-800-077-181	Sequence 181, App
c 643	20	0.5	20	1	US-10-800-077-182	Sequence 182, App
c 644	20	0.5	20	1	US-10-800-077-183	Sequence 183, App
c 645	20	0.5	20	1	US-10-800-077-184	Sequence 184, App
c 646	20	0.5	20	1	US-10-800-077-185	Sequence 185, App
c 647	20	0.5	20	1	US-10-800-077-186	Sequence 186, App
c 648	20	0.5	20	1	US-10-800-077-187	Sequence 187, App
c 649	20	0.5	20	1	US-10-800-077-188	Sequence 188, App
c 650	20	0.5	20	1	US-10-800-077-189	Sequence 189, App
c 651	20	0.5	20	1	US-10-800-077-190	Sequence 190, App
c 652	20	0.5	20	1	US-10-800-077-191	Sequence 191, App
c 653	20	0.5	20	1	US-10-800-077-192	Sequence 192, App
c 654	20	0.5	20	1	US-10-800-077-193	Sequence 193, App
c 655	20	0.5	20	1	US-10-800-077-194	Sequence 194, App
c 656	20	0.5	20	1	US-10-800-077-195	Sequence 195, App
c 657	20	0.5	20	1	US-10-800-077-196	Sequence 196, App
c 658	20	0.5	20	1	US-10-800-077-197	Sequence 197, App
c 659	20	0.5	20	1	US-10-800-077-198	Sequence 198, App
c 660	20	0.5	20	1	US-10-800-077-199	Sequence 199, App
c 661	20	0.5	20	1	US-10-800-077-200	Sequence 200, App
c 662	20	0.5	20	1	US-10-800-077-201	Sequence 201, App
c 663	20	0.5	20	1	US-10-800-077-202	Sequence 202, App
c 664	20	0.5	20	1	US-10-800-077-203	Sequence 203, App
c 665	20	0.5	20	1	US-10-800-077-204	Sequence 204, App
c 666	20	0.5	20	1	US-10-800-077-205	Sequence 205, App
c 667	20	0.5	20	1	US-10-800-077-206	Sequence 206, App
c 668	20	0.5	20	1	US-10-800-077-207	Sequence 207, App
c 669	20	0.5	20	1	US-10-800-077-208	Sequence 208, App
c 670	20	0.5	20	1	US-10-800-077-209	Sequence 209, App
c 671	20	0.5	20	1	US-10-800-077-210	Sequence 210, App
c 672	20	0.5	20	1	US-10-800-077-211	Sequence 211, App
c 673	20	0.5	20	1	US-10-800-077-212	Sequence 212, App
c 674	20	0.5	20	1	US-10-800-077-213	Sequence 213, App
c 675	20	0.5	20	1	US-10-800-077-214	Sequence 214, App
c 676	20	0.5	20	1	US-10-800-077-215	Sequence 215, App
c 677	20	0.5	20	1	US-10-800-077-216	Sequence 216, App
c 678	20	0.5	20	1	US-10-800-077-217	Sequence 217, App
c 679	20	0.5	20	1	US-10-800-077-218	Sequence 218, App
c 680	20	0.5	20	1	US-10-800-077-219	Sequence 219, App
c 681	20	0.5	20	1	US-10-800-077-220	Sequence 220, App
c 682	20	0.5	20	1	US-10-800-077-221	Sequence 221, App
c 683	20	0.5	20	1	US-10-800-077-231	Sequence 231, App
684	20	0.5	21	1	US-10-800-350-38	Sequence 38, Appl
685	20	0.5	21	1	US-10-800-350-288	Sequence 288, App
686	20	0.5	21	1	US-10-800-077-38	Sequence 38, Appl
687	20	0.5	21	1	US-10-800-077-288	Sequence 288, App
688	19.8	0.5	23	1	US-10-758-155-2633	Sequence 2633, Ap
689	19.8	0.5	23	1	US-10-831-620-2633	Sequence 2633, Ap
690	19.8	0.5	23	1	US-10-844-076-2633	Sequence 2633, Ap

	691	19.8	0.5	23	1	US-10-962-898-2237	Sequence 2237, Ap
	692	19.8	0.5	23	1	US-10-944-611-2237	Sequence 2237, Ap
c	693	19.4	0.5	21	1	US-10-800-350-43	Sequence 43, Appl
c	694	19.4	0.5	21	1	US-10-800-350-223	Sequence 223, App
c	695	19.4	0.5	21	1	US-10-800-077-43	Sequence 43, Appl
c	696	19.4	0.5	21	1	US-10-800-077-223	Sequence 223, App
c	697	19.4	0.5	22	1	US-10-635-780-16	Sequence 16, Appl
	698	19.2	0.5	24	1	US-10-309-775A-26	Sequence 26, Appl
	699	19.2	0.5	24	1	US-10-309-775A-73	Sequence 73, Appl
c	700	19	0.4	19	1	US-10-440-464-41	Sequence 41, Appl
	701	19	0.4	21	1	US-10-800-350-22	Sequence 22, Appl
	702	19	0.4	21	1	US-10-800-350-23	Sequence 23, Appl
	703	19	0.4	21	1	US-10-800-350-34	Sequence 34, Appl
	704	19	0.4	21	1	US-10-800-350-36	Sequence 36, Appl
	705	19	0.4	21	1	US-10-800-350-40	Sequence 40, Appl
	706	19	0.4	21	1	US-10-800-350-69	Sequence 69, Appl
	707	19	0.4	21	1	US-10-800-350-286	Sequence 286, App
	708	19	0.4	21	1	US-10-800-350-287	Sequence 287, App
	709	19	0.4	21	1	US-10-800-350-289	Sequence 289, App
	710	19	0.4	21	1	US-10-800-350-290	Sequence 290, App
	711	19	0.4	21	1	US-10-800-077-22	Sequence 22, Appl
	712	19	0.4	21	1	US-10-800-077-23	Sequence 23, Appl
	713	19	0.4	21	1	US-10-800-077-34	Sequence 34, Appl
	714	19	0.4	21	1	US-10-800-077-36	Sequence 36, Appl
	715	19	0.4	21	1	US-10-800-077-40	Sequence 40, Appl
	716	19	0.4	21	1	US-10-800-077-69	Sequence 69, Appl
	717	19	0.4	21	1	US-10-800-077-286	Sequence 286, App
	718	19	0.4	21	1	US-10-800-077-287	Sequence 287, App
	719	19	0.4	21	1	US-10-800-077-289	Sequence 289, App
	720	19	0.4	21	1	US-10-800-077-290	Sequence 290, App
	721	18.8	0.4	22	1	US-10-411-954-268	Sequence 268, App
	722	18.8	0.4	22	1	US-10-411-954-339	Sequence 339, App
	723	18.8	0.4	22	1	US-10-321-039-737	Sequence 737, App
	724	18.8	0.4	22	1	US-10-617-070-268	Sequence 268, App
	725	18.8	0.4	22	1	US-10-617-070-339	Sequence 339, App
	726	18.8	0.4	22	1	US-10-956-507-268	Sequence 268, App
	727	18.8	0.4	22	1	US-10-956-507-339	Sequence 339, App
	728	18.8	0.4	23	1	US-10-758-155-2627	Sequence 2627, Ap
	729	18.8	0.4	23	1	US-10-758-155-2639	Sequence 2639, Ap
	730	18.8	0.4	23	1	US-10-831-620-2627	Sequence 2627, Ap
	731	18.8	0.4	23	1	US-10-831-620-2639	Sequence 2639, Ap
	732	18.8	0.4	23	1	US-10-844-076-2627	Sequence 2627, Ap
	733	18.8	0.4	23	1	US-10-844-076-2639	Sequence 2639, Ap
	734	18.8	0.4	23	1	US-10-962-898-2232	Sequence 2232, Ap
	735	18.8	0.4	23	1	US-10-962-898-2242	Sequence 2242, Ap
	736	18.8	0.4	23	1	US-10-944-611-2232	Sequence 2232, Ap
	737	18.8	0.4	23	1	US-10-944-611-2242	Sequence 2242, Ap
c	738	18	0.4	18	1	US-10-800-350-47	Sequence 47, Appl
c	739	18	0.4	18	1	US-10-800-350-48	Sequence 48, Appl
c	740	18	0.4	18	1	US-10-800-350-227	Sequence 227, App
c	741	18	0.4	18	1	US-10-800-350-228	Sequence 228, App
c	742	18	0.4	18	1	US-10-800-077-47	Sequence 47, Appl
c	743	18	0.4	18	1	US-10-800-077-48	Sequence 48, Appl
c	744	18	0.4	18	1	US-10-800-077-227	Sequence 227, App
c	745	18	0.4	18	1	US-10-800-077-228	Sequence 228, App
	746	17.8	0.4	21	1	US-10-712-363-25	Sequence 25, Appl
c	747	17.8	0.4	21	1	US-10-810-976-5	Sequence 5, Appli
	748	17.4	0.4	19	1	US-10-411-954-236	Sequence 236, App
	749	17.4	0.4	19	1	US-10-617-070-236	Sequence 236, App
	750	17.4	0.4	19	1	US-10-617-070-361	Sequence 361, App
	751	17.4	0.4	19	1	US-10-758-155-2735	Sequence 2735, Ap
	752	17.4	0.4	19	1	US-10-831-620-2735	Sequence 2735, Ap
	753	17.4	0.4	19	1	US-10-844-076-2735	Sequence 2735, Ap
	754	17.4	0.4	19	1	US-10-956-507-236	Sequence 236, App
	755	17.4	0.4	19	1	US-10-956-507-361	Sequence 361, App
	756	17.4	0.4	20	1	US-10-188-359-13	Sequence 13, Appl
c	757	17	0.4	19	1	US-10-800-350-60	Sequence 60, Appl
c	758	17	0.4	19	1	US-10-800-077-60	Sequence 60, Appl
c	759	16.8	0.4	20	1	US-09-888-361-53	Sequence 53, Appl
c	760	16.8	0.4	20	1	US-10-705-715-53	Sequence 53, Appl
c	761	16.8	0.4	20	1	US-10-776-013-6	Sequence 6, Appli
c	762	16.8	0.4	21	1	US-09-735-995-91	Sequence 91, Appl
c	763	16.8	0.4	21	1	US-10-696-708-91	Sequence 91, Appl
	764	16.8	0.4	21	1	US-10-847-918-4062	Sequence 4062, Ap
	765	16.4	0.4	19	1	US-10-665-951-2244	Sequence 2244, Ap
	766	16.4	0.4	19	1	US-10-665-951-2265	Sequence 2265, Ap
	767	16.4	0.4	19	1	US-10-758-155-2244	Sequence 2244, Ap
	768	16.4	0.4	19	1	US-10-758-155-2265	Sequence 2265, Ap
	769	16.4	0.4	19	1	US-10-758-155-2662	Sequence 2662, Ap
	770	16.4	0.4	19	1	US-10-758-155-2663	Sequence 2663, Ap
	771	16.4	0.4	19	1	US-10-758-155-2665	Sequence 2665, Ap
	772	16.4	0.4	19	1	US-10-758-155-2729	Sequence 2729, Ap
	773	16.4	0.4	19	1	US-10-758-155-2734	Sequence 2734, Ap
	774	16.4	0.4	19	1	US-10-758-155-2737	Sequence 2737, Ap
	775	16.4	0.4	19	1	US-10-831-620-2244	Sequence 2244, Ap
	776	16.4	0.4	19	1	US-10-831-620-2265	Sequence 2265, Ap
	777	16.4	0.4	19	1	US-10-831-620-2662	Sequence 2662, Ap
	778	16.4	0.4	19	1	US-10-831-620-2663	Sequence 2663, Ap
	779	16.4	0.4	19	1	US-10-831-620-2665	Sequence 2665, Ap
	780	16.4	0.4	19	1	US-10-831-620-2729	Sequence 2729, Ap
	781	16.4	0.4	19	1	US-10-831-620-2734	Sequence 2734, Ap
	782	16.4	0.4	19	1	US-10-831-620-2737	Sequence 2737, Ap
	783	16.4	0.4	19	1	US-10-844-076-2244	Sequence 2244, Ap
	784	16.4	0.4	19	1	US-10-844-076-2265	Sequence 2265, Ap
	785	16.4	0.4	19	1	US-10-844-076-2662	Sequence 2662, Ap
	786	16.4	0.4	19	1	US-10-844-076-2663	Sequence 2663, Ap
	787	16.4	0.4	19	1	US-10-844-076-2665	Sequence 2665, Ap
	788	16.4	0.4	19	1	US-10-844-076-2729	Sequence 2729, Ap
	789	16.4	0.4	19	1	US-10-844-076-2734	Sequence 2734, Ap
	790	16.4	0.4	19	1	US-10-844-076-2737	Sequence 2737, Ap
	791	16.4	0.4	19	1	US-10-962-898-2293	Sequence 2293, Ap
	792	16.4	0.4	19	1	US-10-962-898-2421	Sequence 2421, Ap
	793	16.4	0.4	19	1	US-10-944-611-2293	Sequence 2293, Ap
	794	16.4	0.4	19	1	US-10-944-611-2421	Sequence 2421, Ap
c	795	16.4	0.4	20	1	US-10-021-707-19	Sequence 19, Appl
c	796	16.4	0.4	20	1	US-10-126-355-83	Sequence 83, Appl
c	797	16.4	0.4	20	1	US-10-289-762-2100	Sequence 2100, Ap
c	798	16.4	0.4	20	1	US-10-673-063-19	Sequence 19, Appl
	799	16	0.4	19	1	US-10-333-429-417	Sequence 417, App
	800	15.8	0.4	19	1	US-09-880-732-4	Sequence 4, Appli
	801	15.8	0.4	19	1	US-09-966-147-22	Sequence 22, Appl
c	802	15.8	0.4	19	1	US-09-904-968A-63	Sequence 63, Appl
c	803	15.8	0.4	19	1	US-10-083-246A-83	Sequence 83, Appl
	804	15.8	0.4	19	1	US-10-374-469-22	Sequence 22, Appl
	805	15.8	0.4	19	1	US-10-163-598-18	Sequence 18, Appl
	806	15.8	0.4	19	1	US-10-698-597-22	Sequence 22, Appl
	807	15.8	0.4	19	1	US-10-665-951-1677	Sequence 1677, Ap
c	808	15.8	0.4	19	1	US-10-665-951-1924	Sequence 1924, Ap
	809	15.8	0.4	19	1	US-10-665-951-2245	Sequence 2245, Ap
	810	15.8	0.4	19	1	US-10-683-990-87	Sequence 87, Appl
c	811	15.8	0.4	19	1	US-10-683-990-184	Sequence 184, App
	812	15.8	0.4	19	1	US-10-758-155-1677	Sequence 1677, Ap
c	813	15.8	0.4	19	1	US-10-758-155-1924	Sequence 1924, Ap
	814	15.8	0.4	19	1	US-10-758-155-2245	Sequence 2245, Ap
	815	15.8	0.4	19	1	US-10-758-155-2668	Sequence 2668, Ap
	816	15.8	0.4	19	1	US-10-758-155-2711	Sequence 2711, Ap
	817	15.8	0.4	19	1	US-10-758-155-2717	Sequence 2717, Ap
	818	15.8	0.4	19	1	US-10-758-155-2723	Sequence 2723, Ap
	819	15.8	0.4	19	1	US-10-758-155-2738	Sequence 2738, Ap
c	820	15.8	0.4	19	1	US-10-411-915-83	Sequence 83, Appl
	821	15.8	0.4	19	1	US-10-831-620-1677	Sequence 1677, Ap
c	822	15.8	0.4	19	1	US-10-831-620-1924	Sequence 1924, Ap
	823	15.8	0.4	19	1	US-10-831-620-2245	Sequence 2245, Ap
	824	15.8	0.4	19	1	US-10-831-620-2668	Sequence 2668, Ap
	825	15.8	0.4	19	1	US-10-831-620-2711	Sequence 2711, Ap
	826	15.8	0.4	19	1	US-10-831-620-2717	Sequence 2717, Ap
	827	15.8	0.4	19	1	US-10-831-620-2723	Sequence 2723, Ap
	828	15.8	0.4	19	1	US-10-831-620-2738	Sequence 2738, Ap
c	829	15.8	0.4	19	1	US-10-923-522-544	Sequence 544, App
	830	15.8	0.4	19	1	US-10-923-522-863	Sequence 863, App
	831	15.8	0.4	19	1	US-10-844-076-1677	Sequence 1677, Ap
c	832	15.8	0.4	19	1	US-10-844-076-1924	Sequence 1924, Ap
	833	15.8	0.4	19	1	US-10-844-076-2245	Sequence 2245, Ap
	834	15.8	0.4	19	1	US-10-844-076-2668	Sequence 2668, Ap
	835	15.8	0.4	19	1	US-10-844-076-2711	Sequence 2711, Ap
	836	15.8	0.4	19	1	US-10-844-076-2717	Sequence 2717, Ap

837	15.8	0.4	19	1	US-10-844-076-2723	Sequence 2723, Ap
838	15.8	0.4	19	1	US-10-844-076-2738	Sequence 2738, Ap
839	15.8	0.4	19	1	US-10-962-898-1677	Sequence 1677, Ap
c 840	15.8	0.4	19	1	US-10-962-898-1924	Sequence 1924, Ap
841	15.8	0.4	19	1	US-10-962-898-2294	Sequence 2294, Ap
842	15.8	0.4	19	1	US-10-944-611-1677	Sequence 1677, Ap
c 843	15.8	0.4	19	1	US-10-944-611-1924	Sequence 1924, Ap
844	15.8	0.4	19	1	US-10-944-611-2294	Sequence 2294, Ap
c 845	15.4	0.4	17	1	US-09-866-108-1653	Sequence 1653, Ap
c 846	15.4	0.4	17	1	US-09-866-108-1654	Sequence 1654, Ap
847	15.4	0.4	17	1	US-09-818-875-3946	Sequence 3946, Ap
c 848	15.4	0.4	17	1	US-09-818-875-3947	Sequence 3947, Ap
849	15.4	0.4	17	1	US-10-209-787-3946	Sequence 3946, Ap
c 850	15.4	0.4	17	1	US-10-209-787-3947	Sequence 3947, Ap
851	15.4	0.4	17	1	US-10-261-185-3946	Sequence 3946, Ap
c 852	15.4	0.4	17	1	US-10-261-185-3947	Sequence 3947, Ap
853	15.4	0.4	17	1	US-10-138-674-7739	Sequence 7739, Ap
854	15.4	0.4	17	1	US-10-138-674-7740	Sequence 7740, Ap
855	15.4	0.4	17	1	US-10-287-949A-7739	Sequence 7739, Ap
856	15.4	0.4	17	1	US-10-287-949A-7740	Sequence 7740, Ap
c 857	15.4	0.4	17	1	US-10-723-361-1653	Sequence 1653, Ap
c 858	15.4	0.4	17	1	US-10-723-361-1654	Sequence 1654, Ap
859	15.4	0.4	17	1	US-10-681-074-3946	Sequence 3946, Ap
c 860	15.4	0.4	17	1	US-10-681-074-3947	Sequence 3947, Ap
861	15.4	0.4	17	1	US-10-712-633-822	Sequence 822, App
862	15.4	0.4	17	1	US-10-712-633-823	Sequence 823, App
863	15.4	0.4	17	1	US-10-712-633-4238	Sequence 4238, Ap
c 864	15.4	0.4	18	1	US-09-969-373-1642	Sequence 1642, Ap
865	15.4	0.4	18	1	US-10-770-538-51	Sequence 51, Appl
c 866	15.4	0.4	19	1	US-10-665-951-895	Sequence 895, App
867	15.4	0.4	19	1	US-10-665-951-1219	Sequence 1219, Ap
868	15.4	0.4	19	1	US-10-665-951-2264	Sequence 2264, Ap
c 869	15.4	0.4	19	1	US-10-635-780-19	Sequence 19, Appl
c 870	15.4	0.4	19	1	US-10-758-155-895	Sequence 895, App
871	15.4	0.4	19	1	US-10-758-155-1219	Sequence 1219, Ap
872	15.4	0.4	19	1	US-10-758-155-2264	Sequence 2264, Ap
873	15.4	0.4	19	1	US-10-758-155-2669	Sequence 2669, Ap
874	15.4	0.4	19	1	US-10-758-155-2671	Sequence 2671, Ap
875	15.4	0.4	19	1	US-10-758-155-2728	Sequence 2728, Ap
876	15.4	0.4	19	1	US-10-758-155-2731	Sequence 2731, Ap
c 877	15.4	0.4	19	1	US-10-831-620-895	Sequence 895, App
878	15.4	0.4	19	1	US-10-831-620-1219	Sequence 1219, Ap
879	15.4	0.4	19	1	US-10-831-620-2264	Sequence 2264, Ap
880	15.4	0.4	19	1	US-10-831-620-2669	Sequence 2669, Ap
881	15.4	0.4	19	1	US-10-831-620-2671	Sequence 2671, Ap
882	15.4	0.4	19	1	US-10-831-620-2728	Sequence 2728, Ap
883	15.4	0.4	19	1	US-10-831-620-2731	Sequence 2731, Ap
c 884	15.4	0.4	19	1	US-10-844-076-895	Sequence 895, App
885	15.4	0.4	19	1	US-10-844-076-1219	Sequence 1219, Ap
886	15.4	0.4	19	1	US-10-844-076-2264	Sequence 2264, Ap
887	15.4	0.4	19	1	US-10-844-076-2669	Sequence 2669, Ap
888	15.4	0.4	19	1	US-10-844-076-2671	Sequence 2671, Ap
889	15.4	0.4	19	1	US-10-844-076-2728	Sequence 2728, Ap
890	15.4	0.4	19	1	US-10-844-076-2731	Sequence 2731, Ap
c 891	15.4	0.4	19	1	US-10-962-898-895	Sequence 895, App
892	15.4	0.4	19	1	US-10-962-898-1219	Sequence 1219, Ap
893	15.4	0.4	19	1	US-10-962-898-2420	Sequence 2420, Ap
c 894	15.4	0.4	19	1	US-10-962-898-3371	Sequence 3371, Ap
c 895	15.4	0.4	19	1	US-10-944-611-895	Sequence 895, App
896	15.4	0.4	19	1	US-10-944-611-1219	Sequence 1219, Ap
897	15.4	0.4	19	1	US-10-944-611-2420	Sequence 2420, Ap
c 898	15.4	0.4	19	1	US-10-944-611-3371	Sequence 3371, Ap
899	15	0.4	15	1	US-10-440-464-42	Sequence 42, Appl
c 900	15	0.4	17	1	US-09-866-108-1651	Sequence 1651, Ap
c 901	15	0.4	17	1	US-09-866-108-1652	Sequence 1652, Ap
c 902	15	0.4	17	1	US-09-777-732-15	Sequence 15, Appl
c 903	15	0.4	17	1	US-09-778-013-15	Sequence 15, Appl
904	15	0.4	17	1	US-10-138-674-5010	Sequence 5010, Ap
905	15	0.4	17	1	US-10-138-674-5011	Sequence 5011, Ap
906	15	0.4	17	1	US-10-138-674-5012	Sequence 5012, Ap
907	15	0.4	17	1	US-10-287-949A-5010	Sequence 5010, Ap
908	15	0.4	17	1	US-10-287-949A-5011	Sequence 5011, Ap
909	15	0.4	17	1	US-10-287-949A-5012	Sequence 5012, Ap
c 910	15	0.4	17	1	US-10-723-361-1651	Sequence 1651, Ap
c 911	15	0.4	17	1	US-10-723-361-1652	Sequence 1652, Ap
912	15	0.4	18	1	US-10-138-674-1470	Sequence 1470, Ap
913	15	0.4	18	1	US-10-287-949A-1470	Sequence 1470, Ap
914	15	0.4	18	1	US-10-951-303-1470	Sequence 1470, Ap
c 915	15	0.4	25	1	US-10-719-956-629839	Sequence 629839,
c 916	14.8	0.3	18	1	US-09-969-373-3074	Sequence 3074, Ap
917	14.8	0.3	18	1	US-10-178-325-172	Sequence 172, App
c 918	14.8	0.3	18	1	US-10-409-786-13	Sequence 13, Appl
c 919	14.8	0.3	18	1	US-10-378-044-8	Sequence 8, Appli
920	14.8	0.3	18	1	US-10-416-111-10	Sequence 10, Appl
921	14.8	0.3	18	1	US-10-731-739-517	Sequence 517, App
922	14.8	0.3	18	1	US-10-660-122-104	Sequence 104, App
923	14.8	0.3	18	1	US-10-477-238A-517	Sequence 517, App
924	14.8	0.3	18	1	US-10-473-126-1246	Sequence 1246, Ap
925	14.8	0.3	18	1	US-10-680-287A-517	Sequence 517, App
926	14.8	0.3	18	1	US-10-477-173-517	Sequence 517, App
c 927	14.8	0.3	18	1	US-10-182-049-49	Sequence 49, Appl
928	14.8	0.3	18	1	US-10-834-377-517	Sequence 517, App

ALIGNMENTS

RESULT 1
US-10-776-399A-217
; Sequence 217, Application US/10776399A
; Publication No. US20050026172A1
; GENERAL INFORMATION:
; APPLICANT: Li, Henry
; APPLICANT: Chatterton, Jon E.
; APPLICANT: Fan, Wufang
; APPLICANT: Ke, Ning
; APPLICANT: Wong-Staal, Flossie
; TITLE OF INVENTION: siRNA Libraries Optimized for Predetermined
; TITLE OF INVENTION: Protein Families
; FILE REFERENCE: 016556-003610US
; CURRENT APPLICATION NUMBER: US/10/776,399A
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: US 60/446,714
; PRIOR FILING DATE: 2003-02-11
; NUMBER OF SEQ ID NOS: 314
; SOFTWARE: PatentIn version 2.1
; SEQ ID NO 217
; LENGTH: 48
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:variant 5
; OTHER INFORMATION: tyrosine kinase family portion of catalytic domain
US-10-776-399A-217

Query Match 1.1%; Score 48; DB 1; Length 48;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 48; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2575 ATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 ATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 48

RESULT 2
US-10-776-399A-197
; Sequence 197, Application US/10776399A
; Publication No. US20050026172A1
; GENERAL INFORMATION:
; APPLICANT: Li, Henry
; APPLICANT: Chatterton, Jon E.
; APPLICANT: Fan, Wufang
; APPLICANT: Ke, Ning
; APPLICANT: Wong-Staal, Flossie
; TITLE OF INVENTION: siRNA Libraries Optimized for Predetermined
; TITLE OF INVENTION: Protein Families

```
;  FILE REFERENCE: 016556-003610US
;  CURRENT APPLICATION NUMBER: US/10/776,399A
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: US 60/446,714
;  PRIOR FILING DATE: 2003-02-11
;  NUMBER OF SEQ ID NOS: 314
;  SOFTWARE: PatentIn version 2.1
; SEQ ID NO 197
;   LENGTH: 48
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:variant 5
;   OTHER INFORMATION: tyrosine kinase family portion of catalytic domain
US-10-776-399A-197

  Query Match             0.9%;  Score 40;  DB 1;  Length 48;
  Best Local Similarity   89.6%;  Pred. No. 14;
  Matches   43;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       2575 ATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
                ||||  ||| ||  ||||| |||||||||||||||||||||||| ||||||
Db          1 ATGAACTATGTGCACCGCGACCTGGCTGCTCGCAACATCCTTGTCAAC 48


RESULT 3
US-10-776-399A-183
; Sequence 183, Application US/10776399A
; Publication No. US20050026172A1
; GENERAL INFORMATION:
;  APPLICANT: Li, Henry
;  APPLICANT:  Chatterton, Jon E.
;  APPLICANT:  Fan, Wufang
;  APPLICANT:  Ke, Ning
;  APPLICANT:  Wong-Staal, Flossie
;  TITLE OF INVENTION: siRNA Libraries Optimized for Predetermined
;  TITLE OF INVENTION:  Protein Families
;  FILE REFERENCE: 016556-003610US
;  CURRENT APPLICATION NUMBER: US/10/776,399A
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: US 60/446,714
;  PRIOR FILING DATE: 2003-02-11
;  NUMBER OF SEQ ID NOS: 314
;  SOFTWARE: PatentIn version 2.1
; SEQ ID NO 183
;   LENGTH: 48
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:variant 5
;   OTHER INFORMATION: tyrosine kinase family portion of catalytic domain
US-10-776-399A-183

  Query Match             0.9%;  Score 38.4;  DB 1;  Length 48;
  Best Local Similarity   87.5%;  Pred. No. 21;
  Matches   42;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       2575 ATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
                ||||  ||| ||  ||||| |||||||||||  |||||||||| ||||||
Db          1 ATGAACTATGTGCACCGTGACCTGGCTGCCCGCAACATCCTCGTCAAC 48


RESULT 4
US-10-776-399A-195
; Sequence 195, Application US/10776399A
; Publication No. US20050026172A1
; GENERAL INFORMATION:
;  APPLICANT: Li, Henry
;  APPLICANT:  Chatterton, Jon E.
;  APPLICANT:  Fan, Wufang
;  APPLICANT:  Ke, Ning
;  APPLICANT:  Wong-Staal, Flossie
;  TITLE OF INVENTION: siRNA Libraries Optimized for Predetermined
;  TITLE OF INVENTION:  Protein Families
;  FILE REFERENCE: 016556-003610US
;  CURRENT APPLICATION NUMBER: US/10/776,399A
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: US 60/446,714
;  PRIOR FILING DATE: 2003-02-11
;  NUMBER OF SEQ ID NOS: 314
;  SOFTWARE: PatentIn version 2.1
; SEQ ID NO 195
;   LENGTH: 48
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:variant 5
;   OTHER INFORMATION: tyrosine kinase family portion of catalytic domain
US-10-776-399A-195

  Query Match             0.9%;  Score 38.4;  DB 1;  Length 48;
  Best Local Similarity   87.5%;  Pred. No. 21;
  Matches   42;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       2575 ATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
                ||||  ||| ||  ||||| |||||||||||  |||||||||| ||||||
Db          1 ATGAACTATGTTCACCGTGACCTGGCTGCCCGCAACATCCTCGTCAAC 48


RESULT 5
US-10-800-350-2/c
; Sequence 2, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 36
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-2

  Query Match             0.7%;  Score 29;  DB 1;  Length 36;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   29;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 TGGATGAGAGCGAGGGCTGGCGGGAGCAG 1986
                |||||||||||||||||||||||||||||
Db         36 TGGATGAGAGCGAGGGCTGGCGGGAGCAG 8


RESULT 6
US-10-800-077-2/c
; Sequence 2, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
```

```
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 36
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-2

  Query Match             0.7%;  Score 29;  DB 1;  Length 36;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   29;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 TGGATGAGAGCGAGGGCTGGCGGGAGCAG 1986
              |||||||||||||||||||||||||||||
Db         36 TGGATGAGAGCGAGGGCTGGCGGGAGCAG 8


RESULT 7
US-10-440-464-40
; Sequence 40, Application US/10440464
; Publication No. US20040018528A1
; GENERAL INFORMATION:
;  APPLICANT: DEPRIMO, SAMUEL
;  APPLICANT:  O'FARRELL, ANNE-MARIE
;  APPLICANT:  MORIMOTO, ALYSSA
;  APPLICANT:  SMOLICH, BEVERLY
;  APPLICANT:  MANNING, WILLIAM
;  APPLICANT:  WALTER, SARAH
;  APPLICANT:  CHERRINGTON, JULIE
;  APPLICANT:  SCHILLING, JIM
;  TITLE OF INVENTION: NOVEL BIOMARKERS OF TYROSINE KINASE INHIBITOR EXPOSURE
;  TITLE OF INVENTION:  AND ACTIVITY IN MAMMALS
;  FILE REFERENCE: 038602/1592
;  CURRENT APPLICATION NUMBER: US/10/440,464
;  CURRENT FILING DATE:  2003-05-19
;  PRIOR APPLICATION NUMBER: 60/380,872
;  PRIOR FILING DATE: 2002-05-17
;  PRIOR APPLICATION NUMBER: 60/448,922
;  PRIOR FILING DATE: 2003-02-24
;  PRIOR APPLICATION NUMBER: 60/448,874
;  PRIOR FILING DATE: 2003-02-24
;  NUMBER OF SEQ ID NOS: 185
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 40
;   LENGTH: 26
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Primer
US-10-440-464-40

  Query Match             0.6%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3920 TCTACCGTCCTTGTCATAACTTTGTG 3945
              ||||||||||||||||||||||||||
Db          1 TCTACCGTCCTTGTCATAACTTTGTG 26


RESULT 8
US-11-060-756-97792
; Sequence 97792, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97792
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97792

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3918 TTTCTACCGTCCTTGTCATAACTTT 3942
              |||||||||||||||||||||||||
Db          1 TTTCTACCGTCCTTGTCATAACTTT 25


RESULT 9
US-11-060-756-97793
; Sequence 97793, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97793
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97793

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3919 TTCTACCGTCCTTGTCATAACTTTG 3943
              |||||||||||||||||||||||||
Db          1 TTCTACCGTCCTTGTCATAACTTTG 25


RESULT 10
US-11-060-756-97794
; Sequence 97794, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97794
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97794
```

```
  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3134 AAATGGGAAGATACGAAGAAAGTTT 3158
              |||||||||||||||||||||||||
Db          1 AAATGGGAAGATACGAAGAAAGTTT 25


RESULT 11
US-11-060-756-97795
; Sequence 97795, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97795
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97795

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3921 CTACCGTCCTTGTCATAACTTTGTG 3945
              |||||||||||||||||||||||||
Db          1 CTACCGTCCTTGTCATAACTTTGTG 25


RESULT 12
US-11-060-756-97796
; Sequence 97796, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97796
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97796

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3920 TCTACCGTCCTTGTCATAACTTTGT 3944
              |||||||||||||||||||||||||
Db          1 TCTACCGTCCTTGTCATAACTTTGT 25


RESULT 13
US-11-060-756-97797
; Sequence 97797, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97797
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97797

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3135 AATGGGAAGATACGAAGAAAGTTTC 3159
              |||||||||||||||||||||||||
Db          1 AATGGGAAGATACGAAGAAAGTTTC 25


RESULT 14
US-11-060-756-97798
; Sequence 97798, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97798
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97798

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3780 CTGTCACCACCAAACTCAATCATTT 3804
              |||||||||||||||||||||||||
Db          1 CTGTCACCACCAAACTCAATCATTT 25


RESULT 15
US-11-060-756-97799
; Sequence 97799, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97799
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97799
```

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3922 TACCGTCCTTGTCATAACTTTGTGT 3946
              |||||||||||||||||||||||||
Db          1 TACCGTCCTTGTCATAACTTTGTGT 25
```

RESULT 16
US-11-060-756-97800
; Sequence 97800, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97800
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97800

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3932 GTCATAACTTTGTGTTGGAGGGAAC 3956
              |||||||||||||||||||||||||
Db          1 GTCATAACTTTGTGTTGGAGGGAAC 25
```

RESULT 17
US-11-060-756-97801
; Sequence 97801, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97801
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97801

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3929 CTTGTCATAACTTTGTGTTGGAGGG 3953
              |||||||||||||||||||||||||
Db          1 CTTGTCATAACTTTGTGTTGGAGGG 25
```

RESULT 18
US-11-060-756-97802
; Sequence 97802, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97802
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97802

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3931 TGTCATAACTTTGTGTTGGAGGGAA 3955
              |||||||||||||||||||||||||
Db          1 TGTCATAACTTTGTGTTGGAGGGAA 25
```

RESULT 19
US-11-060-756-97803
; Sequence 97803, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97803
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97803

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3930 TTGTCATAACTTTGTGTTGGAGGGA 3954
              |||||||||||||||||||||||||
Db          1 TTGTCATAACTTTGTGTTGGAGGGA 25
```

RESULT 20
US-11-060-756-97804
; Sequence 97804, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97804
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97804

Query Match 0.6%; Score 25; DB 1; Length 25;

```
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3927 TCCTTGTCATAACTTTGTGTTGGAG 3951
             |||||||||||||||||||||||||
Db          1 TCCTTGTCATAACTTTGTGTTGGAG 25


RESULT 21
US-11-060-756-97805
; Sequence 97805, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97805
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97805

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3925 CGTCCTTGTCATAACTTTGTGTTGG 3949
             |||||||||||||||||||||||||
Db          1 CGTCCTTGTCATAACTTTGTGTTGG 25


RESULT 22
US-11-060-756-97806
; Sequence 97806, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97806
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97806

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3924 CCGTCCTTGTCATAACTTTGTGTTG 3948
             |||||||||||||||||||||||||
Db          1 CCGTCCTTGTCATAACTTTGTGTTG 25


RESULT 23
US-11-060-756-97807
; Sequence 97807, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97807
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97807

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3926 GTCCTTGTCATAACTTTGTGTTGGA 3950
             |||||||||||||||||||||||||
Db          1 GTCCTTGTCATAACTTTGTGTTGGA 25


RESULT 24
US-11-060-756-97808
; Sequence 97808, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97808
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97808

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3462 TTGGCAATTTGGAGAGACAGGATTT 3486
             |||||||||||||||||||||||||
Db          1 TTGGCAATTTGGAGAGACAGGATTT 25


RESULT 25
US-11-060-756-97809
; Sequence 97809, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97809
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97809

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
```

```
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3928 CCTTGTCATAACTTTGTGTTGGAGG 3952
             |||||||||||||||||||||||||
Db          1 CCTTGTCATAACTTTGTGTTGGAGG 25


RESULT 26
US-11-060-756-97810
; Sequence 97810, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97810
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97810

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3923 ACCGTCCTTGTCATAACTTTGTGTT 3947
             |||||||||||||||||||||||||
Db          1 ACCGTCCTTGTCATAACTTTGTGTT 25


RESULT 27
US-11-060-756-97811
; Sequence 97811, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97811
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97811

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3933 TCATAACTTTGTGTTGGAGGGAACC 3957
             |||||||||||||||||||||||||
Db          1 TCATAACTTTGTGTTGGAGGGAACC 25


RESULT 28
US-11-060-756-97812
; Sequence 97812, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97812
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97812

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3917 TTTTCTACCGTCCTTGTCATAACTT 3941
             |||||||||||||||||||||||||
Db          1 TTTTCTACCGTCCTTGTCATAACTT 25


RESULT 29
US-11-060-756-97813
; Sequence 97813, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97813
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97813

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3132 CAAAATGGGAAGATACGAAGAAAGT 3156
             |||||||||||||||||||||||||
Db          1 CAAAATGGGAAGATACGAAGAAAGT 25


RESULT 30
US-11-060-756-97814
; Sequence 97814, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97814
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97814

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       3131 TCAAAATGGGAAGATACGAAGAAAG 3155
             |||||||||||||||||||||||||
Db          1 TCAAAATGGGAAGATACGAAGAAAG 25


RESULT 31
US-11-060-756-97815
; Sequence 97815, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97815
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97815

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4150 TGCTTGGAGGGGTTCTTAAATTATA 4174
             |||||||||||||||||||||||||
Db          1 TGCTTGGAGGGGTTCTTAAATTATA 25


RESULT 32
US-11-060-756-97816
; Sequence 97816, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97816
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97816

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3133 AAAATGGGAAGATACGAAGAAAGTT 3157
             |||||||||||||||||||||||||
Db          1 AAAATGGGAAGATACGAAGAAAGTT 25


RESULT 33
US-11-060-756-97817
; Sequence 97817, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97817
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97817

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3461 GTTGGCAATTTGGAGAGACAGGATT 3485
             |||||||||||||||||||||||||
Db          1 GTTGGCAATTTGGAGAGACAGGATT 25


RESULT 34
US-11-060-756-97818
; Sequence 97818, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97818
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97818

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3129 CATCAAAATGGGAAGATACGAAGAA 3153
             |||||||||||||||||||||||||
Db          1 CATCAAAATGGGAAGATACGAAGAA 25


RESULT 35
US-11-060-756-97819
; Sequence 97819, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97819
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97819

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       4149 GTGCTTGGAGGGGTTCTTAAATTAT 4173
             |||||||||||||||||||||||||
Db          1 GTGCTTGGAGGGGTTCTTAAATTAT 25
```

RESULT 36
US-11-060-756-97820
; Sequence 97820, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97820
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97820

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3130 ATCAAAATGGGAAGATACGAAGAAA 3154
             |||||||||||||||||||||||||
Db          1 ATCAAAATGGGAAGATACGAAGAAA 25
```

RESULT 37
US-11-060-756-97821
; Sequence 97821, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97821
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97821

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3781 TGTCACCACCAAACTCAATCATTTT 3805
             |||||||||||||||||||||||||
Db          1 TGTCACCACCAAACTCAATCATTTT 25
```

RESULT 38
US-11-060-756-97822
; Sequence 97822, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97822
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97822

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3935 ATAACTTTGTGTTGGAGGGAACCTG 3959
             |||||||||||||||||||||||||
Db          1 ATAACTTTGTGTTGGAGGGAACCTG 25
```

RESULT 39
US-11-060-756-97823
; Sequence 97823, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97823
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97823

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3934 CATAACTTTGTGTTGGAGGGAACCT 3958
             |||||||||||||||||||||||||
Db          1 CATAACTTTGTGTTGGAGGGAACCT 25
```

RESULT 40
US-11-060-756-97824
; Sequence 97824, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97824
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97824

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       4151 GCTTGGAGGGGTTCTTAAATTATAT 4175
```

```
              ||||||||||||||||||||||||||
Db          1 GCTTGGAGGGGTTCTTAAATTATAT 25


RESULT 41
US-11-060-756-97825
; Sequence 97825, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97825
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97825

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3463 TGGCAATTTGGAGAGACAGGATTTG 3487
              |||||||||||||||||||||||||
Db          1 TGGCAATTTGGAGAGACAGGATTTG 25


RESULT 42
US-11-060-756-97826
; Sequence 97826, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97826
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97826

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3492 TTCTGCCATAATAGGAGGGGAAAAT 3516
              |||||||||||||||||||||||||
Db          1 TTCTGCCATAATAGGAGGGGAAAAT 25


RESULT 43
US-11-060-756-97827
; Sequence 97827, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97827
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97827

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3493 TCTGCCATAATAGGAGGGGAAAATC 3517
              |||||||||||||||||||||||||
Db          1 TCTGCCATAATAGGAGGGGAAAATC 25


RESULT 44
US-11-060-756-97828
; Sequence 97828, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97828
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97828

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3779 GCTGTCACCACCAAACTCAATCATT 3803
              |||||||||||||||||||||||||
Db          1 GCTGTCACCACCAAACTCAATCATT 25


RESULT 45
US-11-060-756-97829
; Sequence 97829, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97829
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97829

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3945 GTTGGAGGGAACCTGTTTCACTATG 3969
              |||||||||||||||||||||||||
```

```
Db          1 GTTGGAGGGAACCTGTTTCACTATG 25


RESULT 46
US-11-060-756-97830
; Sequence 97830, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97830
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97830

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3494 CTGCCATAATAGGAGGGGAAAATCA 3518
              |||||||||||||||||||||||||
Db          1 CTGCCATAATAGGAGGGGAAAATCA 25


RESULT 47
US-11-060-756-97831
; Sequence 97831, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97831
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97831

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3495 TGCCATAATAGGAGGGGAAAATCAC 3519
              |||||||||||||||||||||||||
Db          1 TGCCATAATAGGAGGGGAAAATCAC 25


RESULT 48
US-11-060-756-97832
; Sequence 97832, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97832
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97832

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3491 GTTCTGCCATAATAGGAGGGGAAAA 3515
              |||||||||||||||||||||||||
Db          1 GTTCTGCCATAATAGGAGGGGAAAA 25


RESULT 49
US-11-060-756-97833
; Sequence 97833, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97833
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97833

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3944 TGTTGGAGGGAACCTGTTTCACTAT 3968
              |||||||||||||||||||||||||
Db          1 TGTTGGAGGGAACCTGTTTCACTAT 25


RESULT 50
US-11-060-756-97834
; Sequence 97834, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97834
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97834

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3460 AGTTGGCAATTTGGAGAGACAGGAT 3484
              |||||||||||||||||||||||||
Db          1 AGTTGGCAATTTGGAGAGACAGGAT 25
```

```
RESULT 51
US-11-060-756-97835
; Sequence 97835, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97835
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-97835

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3465 GCAATTTGGAGAGACAGGATTTGGG 3489
             |||||||||||||||||||||||||
Db          1 GCAATTTGGAGAGACAGGATTTGGG 25


RESULT 52
US-11-060-756-125249
; Sequence 125249, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 125249
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-125249

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4007 ATGTCTGTTTCCAGAACAGTGCCTT 4031
             |||||||||||||||||||||||||
Db          1 ATGTCTGTTTCCAGAACAGTGCCTT 25


RESULT 53
US-11-060-756-129097
; Sequence 129097, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 129097
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-129097

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3950 AGGGAACCTGTTTCACTATGGCCTC 3974
             |||||||||||||||||||||||||
Db          1 AGGGAACCTGTTTCACTATGGCCTC 25


RESULT 54
US-11-060-756-129098
; Sequence 129098, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 129098
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-129098

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3950 AGGGAACCTGTTTCACTATGGCCTC 3974
             |||||||||||||||||||||||||
Db          1 AGGGAACCTGTTTCACTATGGCCTC 25


RESULT 55
US-11-060-756-132097
; Sequence 132097, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 132097
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-132097

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3984 AGTTGAAACAGGGGCCCATCATCAT 4008
             |||||||||||||||||||||||||
Db          1 AGTTGAAACAGGGGCCCATCATCAT 25
```

```
RESULT 56
US-11-060-756-133242
; Sequence 133242, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 133242
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-133242

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3390 AGAGTGGGGACTCACAGAGGCCCCC 3414
             |||||||||||||||||||||||||
Db          1 AGAGTGGGGACTCACAGAGGCCCCC 25


RESULT 57
US-11-060-756-134391
; Sequence 134391, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 134391
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-134391

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3150 AGAAAGTTTCGCAGCCGCTGGCTTT 3174
             |||||||||||||||||||||||||
Db          1 AGAAAGTTTCGCAGCCGCTGGCTTT 25


RESULT 58
US-11-060-756-139236
; Sequence 139236, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 139236
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-139236

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3923 ACCGTCCTTGTCATAACTTTGTGTT 3947
             |||||||||||||||||||||||||
Db          1 ACCGTCCTTGTCATAACTTTGTGTT 25


RESULT 59
US-11-060-756-147611
; Sequence 147611, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 147611
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-147611

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTCCAGCACAT 3278
             |||||||||||||||||||||||||
Db          1 AAATCTTGGCCAGTGTCCAGCACAT 25


RESULT 60
US-11-060-756-150055
; Sequence 150055, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 150055
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-150055

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3593 AAAAGGAAGTGCCCAACATCTCCCA 3617
             |||||||||||||||||||||||||
Db          1 AAAAGGAAGTGCCCAACATCTCCCA 25
```

```
RESULT 61
US-11-060-756-153404
; Sequence 153404, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 153404
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-153404

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3721 AAGAAGGGGTGTCAGGGCCCAGTGA 3745
             |||||||||||||||||||||||||
Db          1 AAGAAGGGGTGTCAGGGCCCAGTGA 25


RESULT 62
US-11-060-756-155302
; Sequence 155302, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 155302
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-155302

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3983 AAGTTGAAACAGGGGCCCATCATCA 4007
             |||||||||||||||||||||||||
Db          1 AAGTTGAAACAGGGGCCCATCATCA 25


RESULT 63
US-11-060-756-161865
; Sequence 161865, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 161865
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-161865

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4134 CAGAAACGGACGCCGGTGCTTGGAG 4158
             |||||||||||||||||||||||||
Db          1 CAGAAACGGACGCCGGTGCTTGGAG 25


RESULT 64
US-11-060-756-162190
; Sequence 162190, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 162190
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-162190

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3665 CAAAGAGAGTGTGACTCCCTTGCCA 3689
             |||||||||||||||||||||||||
Db          1 CAAAGAGAGTGTGACTCCCTTGCCA 25


RESULT 65
US-11-060-756-165621
; Sequence 165621, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 165621
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-165621

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3192 CAGCCAGATCTCTGCTGAGGACCTG 3216
             |||||||||||||||||||||||||
Db          1 CAGCCAGATCTCTGCTGAGGACCTG 25


RESULT 66
```

US-11-060-756-166857
; Sequence 166857, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 166857
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-166857

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3543 CAGACCAAGGGTGAGGGCGCCTTTC 3567
||||||||||||||||||||||||||
Db 1 CAGACCAAGGGTGAGGGCGCCTTTC 25

RESULT 67
US-11-060-756-174928
; Sequence 174928, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 174928
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-174928

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3921 CTACCGTCCTTGTCATAACTTTGTG 3945
||||||||||||||||||||||||||
Db 1 CTACCGTCCTTGTCATAACTTTGTG 25

RESULT 68
US-11-060-756-175132
; Sequence 175132, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 175132
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-175132

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3981 CCAAGTTGAAACAGGGGCCCATCAT 4005
||||||||||||||||||||||||||
Db 1 CCAAGTTGAAACAGGGGCCCATCAT 25

RESULT 69
US-11-060-756-179237
; Sequence 179237, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 179237
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-179237

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3177 CTCCTTCGAGCTGGTCAGCCAGATC 3201
||||||||||||||||||||||||||
Db 1 CTCCTTCGAGCTGGTCAGCCAGATC 25

RESULT 70
US-11-060-756-179718
; Sequence 179718, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 179718
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-179718

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3206 CTGAGGACCTGCTCCGAATCGGAGT 3230
||||||||||||||||||||||||||
Db 1 CTGAGGACCTGCTCCGAATCGGAGT 25

RESULT 71
US-11-060-756-183482

```
; Sequence 183482, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 183482
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-183482

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3532 TCGGGGAACTCCAGACCAAGGGTGA 3556
             |||||||||||||||||||||||||
Db          1 TCGGGGAACTCCAGACCAAGGGTGA 25


RESULT 72
US-11-060-756-183957
; Sequence 183957, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 183957
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-183957

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3652 CGTTCCCGCAGACCAAAGAGAGTGT 3676
             |||||||||||||||||||||||||
Db          1 CGTTCCCGCAGACCAAAGAGAGTGT 25


RESULT 73
US-11-060-756-184429
; Sequence 184429, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 184429
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-184429

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3925 CGTCCTTGTCATAACTTTGTGTTGG 3949
             |||||||||||||||||||||||||
Db          1 CGTCCTTGTCATAACTTTGTGTTGG 25


RESULT 74
US-11-060-756-184632
; Sequence 184632, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 184632
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-184632

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3220 CGAATCGGAGTCACTCTGGCGGGAC 3244
             |||||||||||||||||||||||||
Db          1 CGAATCGGAGTCACTCTGGCGGGAC 25


RESULT 75
US-11-060-756-185040
; Sequence 185040, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 185040
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-185040

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4132 CCCAGAAACGGACGCCGGTGCTTGG 4156
             |||||||||||||||||||||||||
Db          1 CCCAGAAACGGACGCCGGTGCTTGG 25


RESULT 76
US-11-060-756-185041
; Sequence 185041, Application US/11060756
```

```
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 185041
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-185041

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4132 CCCAGAAACGGACGCCGGTGCTTGG 4156
             |||||||||||||||||||||||||
Db          1 CCCAGAAACGGACGCCGGTGCTTGG 25


RESULT 77
US-11-060-756-186082
; Sequence 186082, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186082
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-186082

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4112 GGCGGTAGTTGGTGGTGGAACCCAG 4136
             |||||||||||||||||||||||||
Db          1 GGCGGTAGTTGGTGGTGGAACCCAG 25


RESULT 78
US-11-060-756-186108
; Sequence 186108, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186108
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-186108

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3980 CCCAAGTTGAAACAGGGGCCCATCA 4004
             |||||||||||||||||||||||||
Db          1 CCCAAGTTGAAACAGGGGCCCATCA 25


RESULT 79
US-11-060-756-186568
; Sequence 186568, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186568
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-186568

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4064 CCCCCAAGCTGTGTCCTATGAAGGG 4088
             |||||||||||||||||||||||||
Db          1 CCCCCAAGCTGTGTCCTATGAAGGG 25


RESULT 80
US-11-060-756-187404
; Sequence 187404, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 187404
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-187404

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3998 CCCATCATCATGTCTGTTTCCAGAA 4022
             |||||||||||||||||||||||||
Db          1 CCCATCATCATGTCTGTTTCCAGAA 25


RESULT 81
US-11-060-756-188249
; Sequence 188249, Application US/11060756
; Publication No. US20050221354A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188249
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-188249

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3038 CCCGGGAGAATGGCGGGGCCTCACA 3062
             |||||||||||||||||||||||||
Db          1 CCCGGGAGAATGGCGGGGCCTCACA 25


RESULT 82
US-11-060-756-189304
; Sequence 189304, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 189304
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-189304

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4133 CCAGAAACGGACGCCGGTGCTTGGA 4157
             |||||||||||||||||||||||||
Db          1 CCAGAAACGGACGCCGGTGCTTGGA 25


RESULT 83
US-11-060-756-189708
; Sequence 189708, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 189708
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-189708

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3024 CCTCAAAATCGTGGCCCGGGAGAAT 3048
             |||||||||||||||||||||||||
Db          1 CCTCAAAATCGTGGCCCGGGAGAAT 25


RESULT 84
US-11-060-756-190188
; Sequence 190188, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 190188
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-190188

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3924 CCGTCCTTGTCATAACTTTGTGTTG 3948
             |||||||||||||||||||||||||
Db          1 CCGTCCTTGTCATAACTTTGTGTTG 25


RESULT 85
US-11-060-756-190605
; Sequence 190605, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 190605
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-190605

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3371 CCTCCCCATTTTCCGGGGCAGAGTG 3395
             |||||||||||||||||||||||||
Db          1 CCTCCCCATTTTCCGGGGCAGAGTG 25


RESULT 86
US-11-060-756-191833
; Sequence 191833, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
```

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 191833
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-191833

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2919 CCTCCACCAGCTCATGCTGGACTGT 2943
||||||||||||||||||||||||||
Db 1 CCTCCACCAGCTCATGCTGGACTGT 25

RESULT 87
US-11-060-756-193142
; Sequence 193142, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193142
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-193142

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3928 CCTTGTCATAACTTTGTGTTGGAGG 3952
||||||||||||||||||||||||||
Db 1 CCTTGTCATAACTTTGTGTTGGAGG 25

RESULT 88
US-11-060-756-193756
; Sequence 193756, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193756
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-193756

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2870 CCATTGAACAGGACTACCGGCTGCC 2894
||||||||||||||||||||||||||
Db 1 CCATTGAACAGGACTACCGGCTGCC 25

RESULT 89
US-11-060-756-195383
; Sequence 195383, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 195383
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-195383

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3829 CCAGCTGCTGCCTTCATATTGAAGG 3853
||||||||||||||||||||||||||
Db 1 CCAGCTGCTGCCTTCATATTGAAGG 25

RESULT 90
US-11-060-756-197318
; Sequence 197318, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 197318
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-197318

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3686 GCCAGCTCCAGAGTGGGGGGGCTGT 3710
||||||||||||||||||||||||||
Db 1 GCCAGCTCCAGAGTGGGGGGGCTGT 25

RESULT 91
US-11-060-756-201466
; Sequence 201466, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

```
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 201466
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-201466

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3113 GCGAGTGGCTTCGGGCCATCAAAAT 3137
             |||||||||||||||||||||||||
Db          1 GCGAGTGGCTTCGGGCCATCAAAAT 25


RESULT 92
US-11-060-756-205476
; Sequence 205476, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 205476
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-205476

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4151 GCTTGGAGGGGTTCTTAAATTATAT 4175
             |||||||||||||||||||||||||
Db          1 GCTTGGAGGGGTTCTTAAATTATAT 25


RESULT 93
US-11-060-756-207856
; Sequence 207856, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 207856
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-207856

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2946 GCAGAAAGACCGGAATGCCCGGCCC 2970
             |||||||||||||||||||||||||
Db          1 GCAGAAAGACCGGAATGCCCGGCCC 25


RESULT 94
US-11-060-756-208436
; Sequence 208436, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 208436
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-208436

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3330 GCAGTACTGACCTGCAGGAACTCCC 3354
             |||||||||||||||||||||||||
Db          1 GCAGTACTGACCTGCAGGAACTCCC 25


RESULT 95
US-11-060-756-212346
; Sequence 212346, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 212346
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-212346

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4083 GAAGGGGTGTGGGGTGAGGTAGTGA 4107
             |||||||||||||||||||||||||
Db          1 GAAGGGGTGTGGGGTGAGGTAGTGA 25


RESULT 96
US-11-060-756-216810
; Sequence 216810, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
```

```
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216810
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-216810

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3988 GAAACAGGGGCCCATCATCATGTCT 4012
              |||||||||||||||||||||||||
Db          1 GAAACAGGGGCCCATCATCATGTCT 25


RESULT 97
US-11-060-756-216811
; Sequence 216811, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216811
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-216811

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3988 GAAACAGGGGCCCATCATCATGTCT 4012
              |||||||||||||||||||||||||
Db          1 GAAACAGGGGCCCATCATCATGTCT 25


RESULT 98
US-11-060-756-223922
; Sequence 223922, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 223922
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-223922

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3475 GAGACAGGATTTGGGGGTTCTGCCA 3499
              |||||||||||||||||||||||||
Db          1 GAGACAGGATTTGGGGGTTCTGCCA 25


RESULT 99
US-11-060-756-225785
; Sequence 225785, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 225785
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-225785

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3949 GAGGGAACCTGTTTCACTATGGCCT 3973
              |||||||||||||||||||||||||
Db          1 GAGGGAACCTGTTTCACTATGGCCT 25


RESULT 100
US-11-060-756-232888
; Sequence 232888, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 232888
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-232888

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3985 GTTGAAACAGGGGCCCATCATCATG 4009
              |||||||||||||||||||||||||
Db          1 GTTGAAACAGGGGCCCATCATCATG 25


RESULT 101
US-11-060-756-233025
; Sequence 233025, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
```

```
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233025
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-233025

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3945 GTTGGAGGGAACCTGTTTCACTATG 3969
             |||||||||||||||||||||||||
Db          1 GTTGGAGGGAACCTGTTTCACTATG 25


RESULT 102
US-11-060-756-235734
; Sequence 235734, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 235734
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-235734

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4013 GTTTCCAGAACAGTGCCTTGGTCAT 4037
             |||||||||||||||||||||||||
Db          1 GTTTCCAGAACAGTGCCTTGGTCAT 25


RESULT 103
US-11-060-756-236369
; Sequence 236369, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236369
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-236369

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4101 GTAGTGAAAAGGGCGGTAGTTGGTG 4125
             |||||||||||||||||||||||||
Db          1 GTAGTGAAAAGGGCGGTAGTTGGTG 25


RESULT 104
US-11-060-756-240888
; Sequence 240888, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 240888
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-240888

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4009 GTCTGTTTCCAGAACAGTGCCTTGG 4033
             |||||||||||||||||||||||||
Db          1 GTCTGTTTCCAGAACAGTGCCTTGG 25


RESULT 105
US-11-060-756-241193
; Sequence 241193, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 241193
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-241193

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4104 GTGAAAAGGGCGGTAGTTGGTGGTG 4128
             |||||||||||||||||||||||||
Db          1 GTGAAAAGGGCGGTAGTTGGTGGTG 25


RESULT 106
US-11-060-756-241337
; Sequence 241337, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
```

```
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 241337
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-241337

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3926 GTCCTTGTCATAACTTTGTGTTGGA 3950
             |||||||||||||||||||||||||
Db          1 GTCCTTGTCATAACTTTGTGTTGGA 25


RESULT 107
US-11-060-756-242200
; Sequence 242200, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 242200
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-242200

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4149 GTGCTTGGAGGGGTTCTTAAATTAT 4173
             |||||||||||||||||||||||||
Db          1 GTGCTTGGAGGGGTTCTTAAATTAT 25


RESULT 108
US-11-060-756-243194
; Sequence 243194, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 243194
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-243194

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3943 GTGTTGGAGGGAACCTGTTTCACTA 3967
             |||||||||||||||||||||||||
Db          1 GTGTTGGAGGGAACCTGTTTCACTA 25


RESULT 109
US-11-060-756-244973
; Sequence 244973, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 244973
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-244973

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3449 GTGGGGTGAGGAGTTGGCAATTTGG 3473
             |||||||||||||||||||||||||
Db          1 GTGGGGTGAGGAGTTGGCAATTTGG 25


RESULT 110
US-11-060-756-247996
; Sequence 247996, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 247996
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-247996

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3487 GGGGGTTCTGCCATAATAGGAGGGG 3511
             |||||||||||||||||||||||||
Db          1 GGGGGTTCTGCCATAATAGGAGGGG 25


RESULT 111
US-11-060-756-248716
; Sequence 248716, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
```

```
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 248716
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-248716

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4087 GGGTGTGGGGTGAGGTAGTGAAAAG 4111
              |||||||||||||||||||||||||
Db          1 GGGTGTGGGGTGAGGTAGTGAAAAG 25


RESULT 112
US-11-060-756-254719
; Sequence 254719, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 254719
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-254719

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3948 GGAGGGAACCTGTTTCACTATGGCC 3972
              |||||||||||||||||||||||||
Db          1 GGAGGGAACCTGTTTCACTATGGCC 25


RESULT 113
US-11-060-756-260910
; Sequence 260910, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 260910
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-260910

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3705 GGCTGTCCCAGGGGGCAAGAAGGGG 3729
              |||||||||||||||||||||||||
Db          1 GGCTGTCCCAGGGGGCAAGAAGGGG 25


RESULT 114
US-11-060-756-262582
; Sequence 262582, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 262582
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-262582

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCCAAGTTGAAAC 3992
              |||||||||||||||||||||||||
Db          1 TGGCCTCCTTTGCCCAAGTTGAAAC 25


RESULT 115
US-11-060-756-262926
; Sequence 262926, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 262926
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-262926

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2996 TGGACAAGATGATCCGGAACCCCGC 3020
              |||||||||||||||||||||||||
Db          1 TGGACAAGATGATCCGGAACCCCGC 25


RESULT 116
US-11-060-756-263974
; Sequence 263974, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
```

```
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 263974
;    LENGTH: 25
;    TYPE: DNA
;    ORGANISM: probe
US-11-060-756-263974

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3947 TGGAGGGAACCTGTTTCACTATGGC 3971
             |||||||||||||||||||||||||
Db          1 TGGAGGGAACCTGTTTCACTATGGC 25


RESULT 117
US-11-060-756-264417
; Sequence 264417, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 264417
;    LENGTH: 25
;    TYPE: DNA
;    ORGANISM: probe
US-11-060-756-264417

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4124 TGGTGGAACCCAGAAACGGACGCCG 4148
             |||||||||||||||||||||||||
Db          1 TGGTGGAACCCAGAAACGGACGCCG 25


RESULT 118
US-11-060-756-264508
; Sequence 264508, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 264508
;    LENGTH: 25
;    TYPE: DNA
;    ORGANISM: probe
US-11-060-756-264508

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2984 TGGTCAGCGCCCTGGACAAGATGAT 3008
             |||||||||||||||||||||||||
Db          1 TGGTCAGCGCCCTGGACAAGATGAT 25


RESULT 119
US-11-060-756-264553
; Sequence 264553, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 264553
;    LENGTH: 25
;    TYPE: DNA
;    ORGANISM: probe
US-11-060-756-264553

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3942 TGTGTTGGAGGGAACCTGTTTCACT 3966
             |||||||||||||||||||||||||
Db          1 TGTGTTGGAGGGAACCTGTTTCACT 25


RESULT 120
US-11-060-756-265308
; Sequence 265308, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 265308
;    LENGTH: 25
;    TYPE: DNA
;    ORGANISM: probe
US-11-060-756-265308

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3755 TGGGGTTTGTAGTCCCAACTTGCTG 3779
             |||||||||||||||||||||||||
Db          1 TGGGGTTTGTAGTCCCAACTTGCTG 25


RESULT 121
US-11-060-756-266195
; Sequence 266195, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
```

```
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266195
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-266195

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3920 TCTACCGTCCTTGTCATAACTTTGT 3944
             |||||||||||||||||||||||||
Db          1 TCTACCGTCCTTGTCATAACTTTGT 25


RESULT 122
US-11-060-756-266335
; Sequence 266335, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266335
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-266335

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4073 TGTGTCCTATGAAGGGGTGTGGGGT 4097
             |||||||||||||||||||||||||
Db          1 TGTGTCCTATGAAGGGGTGTGGGGT 25


RESULT 123
US-11-060-756-266889
; Sequence 266889, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266889
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-266889

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4075 TGTCCTATGAAGGGGTGTGGGGTGA 4099
             |||||||||||||||||||||||||
Db          1 TGTCCTATGAAGGGGTGTGGGGTGA 25


RESULT 124
US-11-060-756-267083
; Sequence 267083, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 267083
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-267083

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3781 TGTCACCACCAAACTCAATCATTTT 3805
             |||||||||||||||||||||||||
Db          1 TGTCACCACCAAACTCAATCATTTT 25


RESULT 125
US-11-060-756-268063
; Sequence 268063, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268063
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-268063

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4012 TGTTTCCAGAACAGTGCCTTGGTCA 4036
             |||||||||||||||||||||||||
Db          1 TGTTTCCAGAACAGTGCCTTGGTCA 25


RESULT 126
US-11-060-756-268427
; Sequence 268427, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
```

```
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268427
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-268427

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3944 TGTTGGAGGGAACCTGTTTCACTAT 3968
             |||||||||||||||||||||||||
Db          1 TGTTGGAGGGAACCTGTTTCACTAT 25


RESULT 127
US-11-060-756-270798
; Sequence 270798, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 270798
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-270798

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4105 TGAAAAGGGCGGTAGTTGGTGGTGG 4129
             |||||||||||||||||||||||||
Db          1 TGAAAAGGGCGGTAGTTGGTGGTGG 25


RESULT 128
US-11-060-756-271627
; Sequence 271627, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 271627
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-271627

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3987 TGAAACAGGGGCCCATCATCATGTC 4011
             |||||||||||||||||||||||||
Db          1 TGAAACAGGGGCCCATCATCATGTC 25


RESULT 129
US-11-060-756-275773
; Sequence 275773, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 275773
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-275773

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4016 TCCAGAACAGTGCCTTGGTCATCCC 4040
             |||||||||||||||||||||||||
Db          1 TCCAGAACAGTGCCTTGGTCATCCC 25


RESULT 130
US-11-060-756-275774
; Sequence 275774, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 275774
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-275774

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4016 TCCAGAACAGTGCCTTGGTCATCCC 4040
             |||||||||||||||||||||||||
Db          1 TCCAGAACAGTGCCTTGGTCATCCC 25


RESULT 131
US-11-060-756-285057
; Sequence 285057, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 285057
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-285057

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3087 TCACTACTCAGCTTTTGGCTCTGTG 3111
              |||||||||||||||||||||||||
Db          1 TCACTACTCAGCTTTTGGCTCTGTG 25


RESULT 132
US-11-060-756-286007
; Sequence 286007, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 286007
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-286007

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3795 TCAATCATTTTTTTCCCTTGTAAAT 3819
              |||||||||||||||||||||||||
Db          1 TCAATCATTTTTTTCCCTTGTAAAT 25


RESULT 133
US-11-060-756-286495
; Sequence 286495, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 286495
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-286495

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3922 TACCGTCCTTGTCATAACTTTGTGT 3946
              |||||||||||||||||||||||||
Db          1 TACCGTCCTTGTCATAACTTTGTGT 25


RESULT 134
US-11-060-756-291576
; Sequence 291576, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291576
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-291576

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3919 TTCTACCGTCCTTGTCATAACTTTG 3943
              |||||||||||||||||||||||||
Db          1 TTCTACCGTCCTTGTCATAACTTTG 25


RESULT 135
US-11-060-756-291577
; Sequence 291577, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291577
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-291577

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3919 TTCTACCGTCCTTGTCATAACTTTG 3943
              |||||||||||||||||||||||||
Db          1 TTCTACCGTCCTTGTCATAACTTTG 25


RESULT 136
US-11-060-756-294522
; Sequence 294522, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 294522
```

```
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-294522

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4014 TTTCCAGAACAGTGCCTTGGTCATC 4038
              |||||||||||||||||||||||||
Db          1 TTTCCAGAACAGTGCCTTGGTCATC 25


RESULT 137
US-11-060-756-294810
; Sequence 294810, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 294810
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-294810

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3564 TTTCCCTCAGGACTGGGTGTGACCA 3588
              |||||||||||||||||||||||||
Db          1 TTTCCCTCAGGACTGGGTGTGACCA 25


RESULT 138
US-11-060-756-300396
; Sequence 300396, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 300396
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-300396

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4015 TTCCAGAACAGTGCCTTGGTCATCC 4039
              |||||||||||||||||||||||||
Db          1 TTCCAGAACAGTGCCTTGGTCATCC 25


RESULT 139
US-11-060-756-300512
; Sequence 300512, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 300512
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-300512

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3977 TTGCCCAAGTTGAAACAGGGGCCCA 4001
              |||||||||||||||||||||||||
Db          1 TTGCCCAAGTTGAAACAGGGGCCCA 25


RESULT 140
US-11-060-756-301519
; Sequence 301519, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 301519
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-301519

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3930 TTGTCATAACTTTGTGTTGGAGGGA 3954
              |||||||||||||||||||||||||
Db          1 TTGTCATAACTTTGTGTTGGAGGGA 25


RESULT 141
US-11-060-756-301875
; Sequence 301875, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 301875
;   LENGTH: 25
```

```
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-301875

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3434 TTGCACTTTGAGCCCGTGGGGTGAG 3458
              |||||||||||||||||||||||||
Db          1 TTGCACTTTGAGCCCGTGGGGTGAG 25


RESULT 142
US-10-800-350-1
; Sequence 1, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 29
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-1

  Query Match             0.6%;  Score 24.2;  DB 1;  Length 29;
  Best Local Similarity   89.7%;  Pred. No. 1.9e+02;
  Matches   26;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        367 GGCGGCGCCATGGAGCTCCGGGTGCTGCT 395
              ||   |||||||||||||||||||||||||
Db          1 GGATCCGCCATGGAGCTCCGGGTGCTGCT 29


RESULT 143
US-10-800-077-1
; Sequence 1, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 29
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-1

  Query Match             0.6%;  Score 24.2;  DB 1;  Length 29;
  Best Local Similarity   89.7%;  Pred. No. 1.9e+02;
  Matches   26;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        367 GGCGGCGCCATGGAGCTCCGGGTGCTGCT 395
              ||   |||||||||||||||||||||||||
Db          1 GGATCCGCCATGGAGCTCCGGGTGCTGCT 29


RESULT 144
US-10-956-157-160391
; Sequence 160391, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William
;  TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
;  TITLE OF INVENTION:  HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
;  FILE REFERENCE: 031896-043000 (AM 101081)
;  CURRENT APPLICATION NUMBER: US/10/956,157
;  CURRENT FILING DATE:  2004-10-04
;  NUMBER OF SEQ ID NOS: 319805
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 160391
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Probe Sequence
US-10-956-157-160391

  Query Match             0.6%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 1.7e+02;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2927 AGCTCATGCTGGACTGTTGGCAGAA 2951
              | |||||||||||||||||||||||
Db          1 AACTCATGCTGGACTGTTGGCAGAA 25


RESULT 145
US-10-956-157-208204
; Sequence 208204, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William
;  TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
;  TITLE OF INVENTION:  HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
;  FILE REFERENCE: 031896-043000 (AM 101081)
;  CURRENT APPLICATION NUMBER: US/10/956,157
;  CURRENT FILING DATE:  2004-10-04
;  NUMBER OF SEQ ID NOS: 319805
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 208204
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Probe Sequence
US-10-956-157-208204

  Query Match             0.5%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 2.1e+02;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2934 GCTGGACTGTTGGCAGAAAGACCG 2957
              |||||||||||||||||| |||||
Db          1 GCTGGACTGTTGGCAGAAGGACCG 24


RESULT 146
US-11-036-317-409480
```

```
; Sequence 409480, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 409480
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-409480

  Query Match             0.5%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 2.1e+02;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2313 CAAGACCCTGAAGGGTGGCTACAC 2336
             |||||| ||||||||||||||||||
Db          1 CAAGACTCTGAAGGGTGGCTACAC 24


RESULT 147
US-10-719-956-644851
; Sequence 644851, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 644851
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-644851

  Query Match             0.5%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3781 TGTCACCACCAAACTCAATCATTTT 3805
             |||||||||||||  ||||||||||
Db          1 TGTCACCACCAAAGGCAATCATTTT 25


RESULT 148
US-10-956-157-188189
; Sequence 188189, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William
;  TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
;  TITLE OF INVENTION:  HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
;  FILE REFERENCE: 031896-043000 (AM 101081)
;  CURRENT APPLICATION NUMBER: US/10/956,157
;  CURRENT FILING DATE:  2004-10-04
;  NUMBER OF SEQ ID NOS: 319805
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188189
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Probe Sequence
US-10-956-157-188189

  Query Match             0.5%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2920 CTCCACCAGCTCATGCTGGACTGTT 2944
             || ||||| ||||||||||||||||
Db          1 CTGCACCAACTCATGCTGGACTGTT 25


RESULT 149
US-11-036-317-15098
; Sequence 15098, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 15098
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-15098

  Query Match             0.5%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGGCAGA 2950
             ||||| |||||||| ||||||||||
Db          1 CAGCTAATGCTGGATTGTTGGCAGA 25


RESULT 150
US-11-060-756-124745
; Sequence 124745, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 124745
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-124745

  Query Match             0.5%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2867 ATGCCATTGAACAGGACTACCGGCT 2891
             ||||||| || ||||||||||||||
Db          1 ATGCCATCGAGCAGGACTACCGGCT 25


RESULT 151
```

```
US-11-060-756-152377/c
; Sequence 152377, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 152377
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-152377

  Query Match             0.5%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2767 ACTTCCGCCAGTGATGCCTGGAGTT 2791
              ||||| |||||||||| ||||||||
Db         25 ACTTCTGCCAGTGATGTCTGGAGTT 1


RESULT 152
US-11-060-756-152378/c
; Sequence 152378, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 152378
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-152378

  Query Match             0.5%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2767 ACTTCCGCCAGTGATGCCTGGAGTT 2791
              ||||| |||||||||| ||||||||
Db         25 ACTTCTGCCAGTGATGTCTGGAGTT 1


RESULT 153
US-11-060-756-285880
; Sequence 285880, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 285880
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-285880

  Query Match             0.5%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2864 TCAATGCCATTGAACAGGACTACCG 2888
              |||||||||| || ||||||||||
Db          1 TCAATGCCATCGAGCAGGACTACCG 25


RESULT 154
US-11-036-317-39029
; Sequence 39029, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 39029
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-39029

  Query Match             0.5%;  Score 21.4;  DB 1;  Length 25;
  Best Local Similarity   95.7%;  Pred. No. 2.6e+02;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2605 CGCAACATCCTAGTCAACAGCAA 2627
              |||||||||||| ||||||||||
Db          2 CGCAACATCCTTGTCAACAGCAA 24


RESULT 155
US-10-800-350-20/c
; Sequence 20, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 20
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-20

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 156
US-10-800-350-35/c
; Sequence 35, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 35
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-35

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        425 AAGAGACCCTGCTGAACACAA 445
              |||||||||||||||||||||
Db         21 AAGAGACCCTGCTGAACACAA 1


RESULT 157
US-10-800-350-37/c
; Sequence 37, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 37
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-37

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAGGTGAATGTCAAGACGCTG 867
              |||||||||||||||||||||
Db         21 AAGGTGAATGTCAAGACGCTG 1


RESULT 158
US-10-800-350-39/c
; Sequence 39, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 39
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-39

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1937 AACATCACAGCCAGACCCAAC 1957
              |||||||||||||||||||||
Db         21 AACATCACAGCCAGACCCAAC 1


RESULT 159
US-10-800-350-41/c
; Sequence 41, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 41
;   LENGTH: 21
;   TYPE: RNA
```

```
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-41

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2677 AACTCTTCCGATCCCACCTAC 2697
              |||||||||||||||||||||
Db         21 AACTCTTCCGATCCCACCTAC 1


RESULT 160
US-10-800-350-42/c
; Sequence 42, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 42
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-42

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 161
US-10-800-350-44/c
; Sequence 44, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 44
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-44

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1381 GGCTCCTCCCTGCACCTGGAA 1401
              |||||||||||||||||||||
Db         21 GGCTCCTCCCTGCACCTGGAA 1


RESULT 162
US-10-800-350-45/c
; Sequence 45, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 45
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-45

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1641 TGAGCCTGTCAATGTCACCAC 1661
              |||||||||||||||||||||
Db         21 TGAGCCTGTCAATGTCACCAC 1


RESULT 163
US-10-800-350-46/c
; Sequence 46, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
```

```
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 46
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-46

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1931 GCCAGGAACATCACAGCCAGA 1951
              |||||||||||||||||||||
Db         21 GCCAGGAACATCACAGCCAGA 1


RESULT 164
US-10-800-350-49/c
; Sequence 49, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 49
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-49

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        784 AAGGTGGACACGGTGGCCGCG 804
              |||||||||||||||||||||
Db         21 AAGGTGGACACGGTGGCCGCG 1


RESULT 165
US-10-800-350-50/c
; Sequence 50, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 50
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-50

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GTGGCAATCAAGACCCTGAAG 2325
              |||||||||||||||||||||
Db         21 GTGGCAATCAAGACCCTGAAG 1


RESULT 166
US-10-800-350-52/c
; Sequence 52, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 52
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-52

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 GTCATCCAGCTCGTGGGCATG 2535
              |||||||||||||||||||||
Db         21 GTCATCCAGCTCGTGGGCATG 1


RESULT 167
US-10-800-350-70/c
; Sequence 70, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
```

```
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 70
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-70

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        425 AAGAGACCCTGCTGAACACAA 445
              |||||||||||||||||||||
Db         21 AAGAGACCCTGCTGAACACAA 1


RESULT 168
US-10-800-350-73/c
; Sequence 73, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 73
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-73

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3319 GGACCGGCCCCGCAGTACTGA 3339
              |||||||||||||||||||||
Db         21 GGACCGGCCCCGCAGTACTGA 1


RESULT 169
US-10-800-350-222/c
; Sequence 222, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 222
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-222

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 170
US-10-800-350-224/c
; Sequence 224, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 224
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-224

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1381 GGCTCCTCCCTGCACCTGGAA 1401
              |||||||||||||||||||||
Db         21 GGCTCCTCCCTGCACCTGGAA 1


RESULT 171
US-10-800-350-225/c
; Sequence 225, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
```

```
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 225
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-225

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1641 TGAGCCTGTCAATGTCACCAC 1661
             |||||||||||||||||||||
Db         21 TGAGCCTGTCAATGTCACCAC 1


RESULT 172
US-10-800-350-226/c
; Sequence 226, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 226
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-226

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1931 GCCAGGAACATCACAGCCAGA 1951
             |||||||||||||||||||||
Db         21 GCCAGGAACATCACAGCCAGA 1


RESULT 173
US-10-800-350-229/c
; Sequence 229, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 229
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-229

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        784 AAGGTGGACACGGTGGCCGCG 804
             |||||||||||||||||||||
Db         21 AAGGTGGACACGGTGGCCGCG 1


RESULT 174
US-10-800-350-230/c
; Sequence 230, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 230
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-230

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GTGGCAATCAAGACCCTGAAG 2325
             |||||||||||||||||||||
Db         21 GTGGCAATCAAGACCCTGAAG 1
```

```
RESULT 175
US-10-800-350-232/c
; Sequence 232, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 232
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-232

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 GTCATCCAGCTCGTGGGCATG 2535
             |||||||||||||||||||||
Db         21 GTCATCCAGCTCGTGGGCATG 1


RESULT 176
US-10-800-350-233
; Sequence 233, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 233
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-233

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        445 AAATTGGAAACTGCTGATCTG 465
              |||||||||||||||||||||
Db          1 AAATTGGAAACTGCTGATCTG 21


RESULT 177
US-10-800-350-234
; Sequence 234, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 234
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-234

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        446 AATTGGAAACTGCTGATCTGA 466
              |||||||||||||||||||||
Db          1 AATTGGAAACTGCTGATCTGA 21


RESULT 178
US-10-800-350-235
; Sequence 235, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 235
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-235

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        452 AAACTGCTGATCTGAAGTGGG 472
              |||||||||||||||||||||
Db          1 AAACTGCTGATCTGAAGTGGG 21


RESULT 179
US-10-800-350-236
; Sequence 236, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 236
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-236

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        453 AACTGCTGATCTGAAGTGGGT 473
              |||||||||||||||||||||
Db          1 AACTGCTGATCTGAAGTGGGT 21


RESULT 180
US-10-800-350-237
; Sequence 237, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 237
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-237

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        853 AATGTCAAGACGCTGCGTCTG 873
              |||||||||||||||||||||
Db          1 AATGTCAAGACGCTGCGTCTG 21


RESULT 181
US-10-800-350-238
; Sequence 238, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 238
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-238

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        466 AAGTGGGTGACATTCCCTCAG 486
              |||||||||||||||||||||
Db          1 AAGTGGGTGACATTCCCTCAG 21


RESULT 182
US-10-800-350-239
; Sequence 239, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 239
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
```

```
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-239

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAGGTGAATGTCAAGACGCTG 867
              |||||||||||||||||||||
Db          1 AAGGTGAATGTCAAGACGCTG 21


RESULT 183
US-10-800-350-240
; Sequence 240, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 240
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-240

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        697 AAGGAGACCTTCACCGTCTTC 717
              |||||||||||||||||||||
Db          1 AAGGAGACCTTCACCGTCTTC 21


RESULT 184
US-10-800-350-241
; Sequence 241, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 241
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-241

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        958 AAAAAGTGCGCCCAGCTGACT 978
              |||||||||||||||||||||
Db          1 AAAAAGTGCGCCCAGCTGACT 21


RESULT 185
US-10-800-350-242
; Sequence 242, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 242
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-242

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1246 AATAGCCACTCTAACACCATT 1266
              |||||||||||||||||||||
Db          1 AATAGCCACTCTAACACCATT 21


RESULT 186
US-10-800-350-243
; Sequence 243, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
```

```
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 243
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-243

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AACACCATTGGATCAGCCGTC 1278
             |||||||||||||||||||||
Db          1 AACACCATTGGATCAGCCGTC 21


RESULT 187
US-10-800-350-244
; Sequence 244, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT: Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 244
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-244

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1651 AATGTCACCACTGACCGAGAG 1671
             |||||||||||||||||||||
Db          1 AATGTCACCACTGACCGAGAG 21


RESULT 188
US-10-800-350-245
; Sequence 245, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 245
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-245

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1783 AAATACCATGAGAAGGGCGCC 1803
             |||||||||||||||||||||
Db          1 AAATACCATGAGAAGGGCGCC 21


RESULT 189
US-10-800-350-246
; Sequence 246, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 246
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-246

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1831 AAGACGTCAGAAAACCGGGCA 1851
             |||||||||||||||||||||
Db          1 AAGACGTCAGAAAACCGGGCA 21


RESULT 190
US-10-800-350-247
; Sequence 247, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
```

```
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 247
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-247

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1937 AACATCACAGCCAGACCCAAC 1957
              |||||||||||||||||||||
Db          1 AACATCACAGCCAGACCCAAC 21


RESULT 191
US-10-800-350-248
; Sequence 248, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 248
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-248

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2068 AAGCAGAGCAATGGGAGAGAA 2088
              |||||||||||||||||||||
Db          1 AAGCAGAGCAATGGGAGAGAA 21


RESULT 192
US-10-800-350-249
; Sequence 249, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 249
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-249

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2077 AATGGGAGAGAAGCAGAATAT 2097
              |||||||||||||||||||||
Db          1 AATGGGAGAGAAGCAGAATAT 21


RESULT 193
US-10-800-350-250
; Sequence 250, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 250
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-250

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2087 AAGCAGAATATTCGGACAAAC 2107
              |||||||||||||||||||||
Db          1 AAGCAGAATATTCGGACAAAC 21


RESULT 194
US-10-800-350-251
; Sequence 251, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
```

```
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 251
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-251

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2093 AATATTCGGACAAACACGGAC 2113
             |||||||||||||||||||||
Db          1 AATATTCGGACAAACACGGAC 21


RESULT 195
US-10-800-350-252
; Sequence 252, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 252
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-252

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2104 AAACACGGACAGTATCTCATC 2124
             |||||||||||||||||||||
Db          1 AAACACGGACAGTATCTCATC 21


RESULT 196
US-10-800-350-253
; Sequence 253, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 253
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-253

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2105 AACACGGACAGTATCTCATCG 2125
             |||||||||||||||||||||
Db          1 AACACGGACAGTATCTCATCG 21


RESULT 197
US-10-800-350-254
; Sequence 254, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 254
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-254

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2196 AAAAGAGATCGATGTCTCCTA 2216
             |||||||||||||||||||||
Db          1 AAAAGAGATCGATGTCTCCTA 21


RESULT 198
US-10-800-350-255
```

```
; Sequence 255, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 255
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-255

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2173 AATGAGGCTGTGAGGGAATTT 2193
             |||||||||||||||||||||
Db          1 AATGAGGCTGTGAGGGAATTT 21


RESULT 199
US-10-800-350-256
; Sequence 256, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 256
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-256

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2165 AAGACCCTAATGAGGCTGTGA 2185
             |||||||||||||||||||||
Db          1 AAGACCCTAATGAGGCTGTGA 21


RESULT 200
US-10-800-350-257
; Sequence 257, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 257
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-257

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2197 AAAGAGATCGATGTCTCCTAC 2217
             |||||||||||||||||||||
Db          1 AAAGAGATCGATGTCTCCTAC 21


RESULT 201
US-10-800-350-258
; Sequence 258, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 258
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-258

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2198 AAGAGATCGATGTCTCCTACG 2218
```

```
              ||||||||||||||||||||
Db          1 AAGAGATCGATGTCTCCTACG 21


RESULT 202
US-10-800-350-259
; Sequence 259, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 259
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-259

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2228 AAGAGGTGATTGGTGCAGGTG 2248
              |||||||||||||||||||||
Db          1 AAGAGGTGATTGGTGCAGGTG 21


RESULT 203
US-10-800-350-260
; Sequence 260, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 260
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-260

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2221 AAGATTGAAGAGGTGATTGGT 2241
              |||||||||||||||||||||
Db          1 AAGATTGAAGAGGTGATTGGT 21


RESULT 204
US-10-800-350-261
; Sequence 261, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 261
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-261

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2428 AACAGCATGCCCGTCATGATT 2448
              |||||||||||||||||||||
Db          1 AACAGCATGCCCGTCATGATT 21


RESULT 205
US-10-800-350-262
; Sequence 262, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 262
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-262
```

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2290 AAGAAGGAGAGCTGTGTGGCA 2310
              |||||||||||||||||||||
Db          1 AAGAAGGAGAGCTGTGTGGCA 21


RESULT 206
US-10-800-350-263
; Sequence 263, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 263
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-263

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2293 AAGGAGAGCTGTGTGGCAATC 2313
              |||||||||||||||||||||
Db          1 AAGGAGAGCTGTGTGGCAATC 21


RESULT 207
US-10-800-350-264
; Sequence 264, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 264
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-264

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2310 AATCAAGACCCTGAAGGGTGG 2330
              |||||||||||||||||||||
Db          1 AATCAAGACCCTGAAGGGTGG 21


RESULT 208
US-10-800-350-265
; Sequence 265, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 265
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-265

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2496 AAACGACGGACAGTTCACAGT 2516
              |||||||||||||||||||||
Db          1 AAACGACGGACAGTTCACAGT 21


RESULT 209
US-10-800-350-266
; Sequence 266, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 266
```

```
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-266

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2497 AACGACGGACAGTTCACAGTC 2517
              |||||||||||||||||||||
Db          1 AACGACGGACAGTTCACAGTC 21


RESULT 210
US-10-800-350-267
; Sequence 267, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 267
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-267

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2608 AACATCCTAGTCAACAGCAAC 2628
              |||||||||||||||||||||
Db          1 AACATCCTAGTCAACAGCAAC 21


RESULT 211
US-10-800-350-268
; Sequence 268, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 268
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-268

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2620 AACAGCAACCTCGTCTGCAAA 2640
              |||||||||||||||||||||
Db          1 AACAGCAACCTCGTCTGCAAA 21


RESULT 212
US-10-800-350-269
; Sequence 269, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 269
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-269

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2677 AACTCTTCCGATCCCACCTAC 2697
              |||||||||||||||||||||
Db          1 AACTCTTCCGATCCCACCTAC 21


RESULT 213
US-10-800-350-270
; Sequence 270, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
```

; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 270
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-270

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2639 AAGTGTCTGACTTTGGCCTTT 2659
||||||||||||||||||||
Db 1 AAGTGTCTGACTTTGGCCTTT 21

RESULT 214
US-10-800-350-271
; Sequence 271, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 271
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-271

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2626 AACCTCGTCTGCAAAGTGTCT 2646
||||||||||||||||||||
Db 1 AACCTCGTCTGCAAAGTGTCT 21

RESULT 215
US-10-800-350-272
; Sequence 272, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 272
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-272

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2638 AAAGTGTCTGACTTTGGCCTT 2658
|||||||||||||||||||||
Db 1 AAAGTGTCTGACTTTGGCCTT 21

RESULT 216
US-10-800-350-273
; Sequence 273, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 273
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-273

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2851 AATCAGGACGTGATCAATGCC 2871
||||||||||||||||||||
Db 1 AATCAGGACGTGATCAATGCC 21

RESULT 217
US-10-800-350-274
; Sequence 274, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash

```
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 274
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-274

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2715 AAAGATTCCCATCCGATGGAC 2735
             |||||||||||||||||||||
Db          1 AAAGATTCCCATCCGATGGAC 21


RESULT 218
US-10-800-350-275
; Sequence 275, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 275
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-275

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2716 AAGATTCCCATCCGATGGACT 2736
             |||||||||||||||||||||
Db          1 AAGATTCCCATCCGATGGACT 21


RESULT 219
US-10-800-350-276
; Sequence 276, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 276
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-276

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2761 AAGTTCACTTCCGCCAGTGAT 2781
             |||||||||||||||||||||
Db          1 AAGTTCACTTCCGCCAGTGAT 21


RESULT 220
US-10-800-350-277
; Sequence 277, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 277
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-277

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3141 AAGATACGAAGAAAGTTTCGC 3161
             |||||||||||||||||||||
Db          1 AAGATACGAAGAAAGTTTCGC 21


RESULT 221
US-10-800-350-278
; Sequence 278, Application US/10800350
; Publication No. US20050084873A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 278
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-278

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3135 AATGGGAAGATACGAAGAAAG 3155
             |||||||||||||||||||||
Db          1 AATGGGAAGATACGAAGAAAG 21


RESULT 222
US-10-800-350-279
; Sequence 279, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 279
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-279

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2866 AATGCCATTGAACAGGACTAC 2886
             |||||||||||||||||||||
Db          1 AATGCCATTGAACAGGACTAC 21


RESULT 223
US-10-800-350-280
; Sequence 280, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 280
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-280

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3028 AAAATCGTGGCCCGGGAGAAT 3048
             |||||||||||||||||||||
Db          1 AAAATCGTGGCCCGGGAGAAT 21


RESULT 224
US-10-800-350-281
; Sequence 281, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 281
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-281

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3253 AAAATCTTGGCCAGTGTCCAG 3273
             |||||||||||||||||||||
Db          1 AAAATCTTGGCCAGTGTCCAG 21
```

```
RESULT 225
US-10-800-350-282
; Sequence 282, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 282
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-282

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTCCAGC 3274
             |||||||||||||||||||||
Db          1 AAATCTTGGCCAGTGTCCAGC 21


RESULT 226
US-10-800-350-283
; Sequence 283, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 283
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-283

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3149 AAGAAAGTTTCGCAGCCGCTG 3169
             |||||||||||||||||||||
Db          1 AAGAAAGTTTCGCAGCCGCTG 21


RESULT 227
US-10-800-350-284
; Sequence 284, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 284
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-284

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3250 AAGAAAATCTTGGCCAGTGTC 3270
             |||||||||||||||||||||
Db          1 AAGAAAATCTTGGCCAGTGTC 21


RESULT 228
US-10-800-350-285
; Sequence 285, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 285
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-285

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3255 AATCTTGGCCAGTGTCCAGCA 3275
              |||||||||||||||||||||
Db          1 AATCTTGGCCAGTGTCCAGCA 21


RESULT 229
US-10-800-077-20/c
; Sequence 20, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 20
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-20

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 230
US-10-800-077-35/c
; Sequence 35, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 35
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-35

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        425 AAGAGACCCTGCTGAACACAA 445
              |||||||||||||||||||||
Db         21 AAGAGACCCTGCTGAACACAA 1


RESULT 231
US-10-800-077-37/c
; Sequence 37, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 37
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-37

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAGGTGAATGTCAAGACGCTG 867
              |||||||||||||||||||||
Db         21 AAGGTGAATGTCAAGACGCTG 1


RESULT 232
US-10-800-077-39/c
; Sequence 39, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 39
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-39

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1937 AACATCACAGCCAGACCCAAC 1957
              |||||||||||||||||||||
Db         21 AACATCACAGCCAGACCCAAC 1
```

```
RESULT 233
US-10-800-077-41/c
; Sequence 41, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 41
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-41

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2677 AACTCTTCCGATCCCACCTAC 2697
             |||||||||||||||||||||
Db         21 AACTCTTCCGATCCCACCTAC 1


RESULT 234
US-10-800-077-42/c
; Sequence 42, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 42
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-42

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 235
US-10-800-077-44/c
; Sequence 44, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 44
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-44

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1381 GGCTCCTCCCTGCACCTGGAA 1401
              |||||||||||||||||||||
Db         21 GGCTCCTCCCTGCACCTGGAA 1


RESULT 236
US-10-800-077-45/c
; Sequence 45, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 45
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-45

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1641 TGAGCCTGTCAATGTCACCAC 1661
              |||||||||||||||||||||
Db         21 TGAGCCTGTCAATGTCACCAC 1


RESULT 237
US-10-800-077-46/c
; Sequence 46, Application US/10800077
; Publication No. US20050164965A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 46
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-46

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1931 GCCAGGAACATCACAGCCAGA 1951
             |||||||||||||||||||||
Db         21 GCCAGGAACATCACAGCCAGA 1


RESULT 238
US-10-800-077-49/c
; Sequence 49, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 49
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-49

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        784 AAGGTGGACACGGTGGCCGCG 804
             |||||||||||||||||||||
Db         21 AAGGTGGACACGGTGGCCGCG 1


RESULT 239
US-10-800-077-50/c
; Sequence 50, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 50
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-50

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GTGGCAATCAAGACCCTGAAG 2325
             |||||||||||||||||||||
Db         21 GTGGCAATCAAGACCCTGAAG 1


RESULT 240
US-10-800-077-52/c
; Sequence 52, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 52
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-52

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 GTCATCCAGCTCGTGGGCATG 2535
             |||||||||||||||||||||
Db         21 GTCATCCAGCTCGTGGGCATG 1


RESULT 241
US-10-800-077-70/c
; Sequence 70, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
```

```
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 70
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-70

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        425 AAGAGACCCTGCTGAACACAA 445
              |||||||||||||||||||||
Db         21 AAGAGACCCTGCTGAACACAA 1


RESULT 242
US-10-800-077-73/c
; Sequence 73, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 73
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-73

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3319 GGACCGGCCCCGCAGTACTGA 3339
              |||||||||||||||||||||
Db         21 GGACCGGCCCCGCAGTACTGA 1


RESULT 243
US-10-800-077-222/c
; Sequence 222, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 222
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-222

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 244
US-10-800-077-224/c
; Sequence 224, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 224
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-224

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1381 GGCTCCTCCCTGCACCTGGAA 1401
              |||||||||||||||||||||
Db         21 GGCTCCTCCCTGCACCTGGAA 1


RESULT 245
US-10-800-077-225/c
; Sequence 225, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
```

```
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 225
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-225

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1641 TGAGCCTGTCAATGTCACCAC 1661
             |||||||||||||||||||||
Db         21 TGAGCCTGTCAATGTCACCAC 1


RESULT 246
US-10-800-077-226/c
; Sequence 226, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 226
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-226

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1931 GCCAGGAACATCACAGCCAGA 1951
             |||||||||||||||||||||
Db         21 GCCAGGAACATCACAGCCAGA 1


RESULT 247
US-10-800-077-229/c
; Sequence 229, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 229
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-229

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        784 AAGGTGGACACGGTGGCCGCG 804
              |||||||||||||||||||||
Db         21 AAGGTGGACACGGTGGCCGCG 1


RESULT 248
US-10-800-077-230/c
; Sequence 230, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 230
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-230

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GTGGCAATCAAGACCCTGAAG 2325
              |||||||||||||||||||||
Db         21 GTGGCAATCAAGACCCTGAAG 1


RESULT 249
US-10-800-077-232/c
; Sequence 232, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 232
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
```

```
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-232

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 GTCATCCAGCTCGTGGGCATG 2535
              |||||||||||||||||||||
Db         21 GTCATCCAGCTCGTGGGCATG 1


RESULT 250
US-10-800-077-233
; Sequence 233, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 233
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-233

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        445 AAATTGGAAACTGCTGATCTG 465
              |||||||||||||||||||||
Db          1 AAATTGGAAACTGCTGATCTG 21


RESULT 251
US-10-800-077-234
; Sequence 234, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 234
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-234

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        446 AATTGGAAACTGCTGATCTGA 466
              |||||||||||||||||||||
Db          1 AATTGGAAACTGCTGATCTGA 21


RESULT 252
US-10-800-077-235
; Sequence 235, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 235
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-235

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        452 AAACTGCTGATCTGAAGTGGG 472
              |||||||||||||||||||||
Db          1 AAACTGCTGATCTGAAGTGGG 21


RESULT 253
US-10-800-077-236
; Sequence 236, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 236
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-236

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
```

```
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        453 AACTGCTGATCTGAAGTGGGT 473
              |||||||||||||||||||||
Db          1 AACTGCTGATCTGAAGTGGGT 21


RESULT 254
US-10-800-077-237
; Sequence 237, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 237
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-237

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        853 AATGTCAAGACGCTGCGTCTG 873
              |||||||||||||||||||||
Db          1 AATGTCAAGACGCTGCGTCTG 21


RESULT 255
US-10-800-077-238
; Sequence 238, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 238
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-238

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        466 AAGTGGGTGACATTCCCTCAG 486
              |||||||||||||||||||||
Db          1 AAGTGGGTGACATTCCCTCAG 21


RESULT 256
US-10-800-077-239
; Sequence 239, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 239
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-239

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAGGTGAATGTCAAGACGCTG 867
              |||||||||||||||||||||
Db          1 AAGGTGAATGTCAAGACGCTG 21


RESULT 257
US-10-800-077-240
; Sequence 240, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 240
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-240

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        697 AAGGAGACCTTCACCGTCTTC 717
              |||||||||||||||||||||
Db          1 AAGGAGACCTTCACCGTCTTC 21
```

```
RESULT 258
US-10-800-077-241
; Sequence 241, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 241
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-241

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        958 AAAAAGTGCGCCCAGCTGACT 978
              |||||||||||||||||||||
Db          1 AAAAAGTGCGCCCAGCTGACT 21


RESULT 259
US-10-800-077-242
; Sequence 242, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 242
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-242

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1246 AATAGCCACTCTAACACCATT 1266
              |||||||||||||||||||||
Db          1 AATAGCCACTCTAACACCATT 21


RESULT 260
US-10-800-077-243
; Sequence 243, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 243
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-243

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AACACCATTGGATCAGCCGTC 1278
              |||||||||||||||||||||
Db          1 AACACCATTGGATCAGCCGTC 21


RESULT 261
US-10-800-077-244
; Sequence 244, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 244
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-244

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1651 AATGTCACCACTGACCGAGAG 1671
              |||||||||||||||||||||
Db          1 AATGTCACCACTGACCGAGAG 21


RESULT 262
US-10-800-077-245
; Sequence 245, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 245
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-245

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1783 AAATACCATGAGAAGGGCGCC 1803
             |||||||||||||||||||||
Db          1 AAATACCATGAGAAGGGCGCC 21


RESULT 263
US-10-800-077-246
; Sequence 246, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 246
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-246

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1831 AAGACGTCAGAAAACCGGGCA 1851
             |||||||||||||||||||||
Db          1 AAGACGTCAGAAAACCGGGCA 21


RESULT 264
US-10-800-077-247
; Sequence 247, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 247
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-247

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1937 AACATCACAGCCAGACCCAAC 1957
             |||||||||||||||||||||
Db          1 AACATCACAGCCAGACCCAAC 21


RESULT 265
US-10-800-077-248
; Sequence 248, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 248
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-248

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2068 AAGCAGAGCAATGGGAGAGAA 2088
             |||||||||||||||||||||
Db          1 AAGCAGAGCAATGGGAGAGAA 21


RESULT 266
US-10-800-077-249
; Sequence 249, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
```

```
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 249
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-249

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2077 AATGGGAGAGAAGCAGAATAT 2097
             |||||||||||||||||||||
Db          1 AATGGGAGAGAAGCAGAATAT 21


RESULT 267
US-10-800-077-250
; Sequence 250, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 250
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-250

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2087 AAGCAGAATATTCGGACAAAC 2107
             |||||||||||||||||||||
Db          1 AAGCAGAATATTCGGACAAAC 21


RESULT 268
US-10-800-077-251
; Sequence 251, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 251
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-251

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2093 AATATTCGGACAAACACGGAC 2113
             |||||||||||||||||||||
Db          1 AATATTCGGACAAACACGGAC 21


RESULT 269
US-10-800-077-252
; Sequence 252, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 252
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-252

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2104 AAACACGGACAGTATCTCATC 2124
             |||||||||||||||||||||
Db          1 AAACACGGACAGTATCTCATC 21


RESULT 270
US-10-800-077-253
; Sequence 253, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
```

```
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 253
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-253

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2105 AACACGGACAGTATCTCATCG 2125
             |||||||||||||||||||||
Db          1 AACACGGACAGTATCTCATCG 21


RESULT 271
US-10-800-077-254
; Sequence 254, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 254
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-254

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2196 AAAAGAGATCGATGTCTCCTA 2216
             |||||||||||||||||||||
Db          1 AAAAGAGATCGATGTCTCCTA 21


RESULT 272
US-10-800-077-255
; Sequence 255, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 255
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-255

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2173 AATGAGGCTGTGAGGGAATTT 2193
             |||||||||||||||||||||
Db          1 AATGAGGCTGTGAGGGAATTT 21


RESULT 273
US-10-800-077-256
; Sequence 256, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 256
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-256

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2165 AAGACCCTAATGAGGCTGTGA 2185
             |||||||||||||||||||||
Db          1 AAGACCCTAATGAGGCTGTGA 21


RESULT 274
US-10-800-077-257
; Sequence 257, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 257
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
```

```
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-257

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2197 AAAGAGATCGATGTCTCCTAC 2217
             |||||||||||||||||||||
Db          1 AAAGAGATCGATGTCTCCTAC 21


RESULT 275
US-10-800-077-258
; Sequence 258, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 258
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-258

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2198 AAGAGATCGATGTCTCCTACG 2218
             |||||||||||||||||||||
Db          1 AAGAGATCGATGTCTCCTACG 21


RESULT 276
US-10-800-077-259
; Sequence 259, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 259
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-259

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2228 AAGAGGTGATTGGTGCAGGTG 2248
             |||||||||||||||||||||
Db          1 AAGAGGTGATTGGTGCAGGTG 21


RESULT 277
US-10-800-077-260
; Sequence 260, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 260
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-260

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2221 AAGATTGAAGAGGTGATTGGT 2241
             |||||||||||||||||||||
Db          1 AAGATTGAAGAGGTGATTGGT 21


RESULT 278
US-10-800-077-261
; Sequence 261, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 261
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-261

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2428 AACAGCATGCCCGTCATGATT 2448
              ||||||||||||||||||||
Db          1 AACAGCATGCCCGTCATGATT 21
```

RESULT 279
US-10-800-077-262
; Sequence 262, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 262
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-262

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2290 AAGAAGGAGAGCTGTGTGGCA 2310
              ||||||||||||||||||||
Db          1 AAGAAGGAGAGCTGTGTGGCA 21
```

RESULT 280
US-10-800-077-263
; Sequence 263, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 263
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-263

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2293 AAGGAGAGCTGTGTGGCAATC 2313
              |||||||||||||||||||||
Db          1 AAGGAGAGCTGTGTGGCAATC 21
```

RESULT 281
US-10-800-077-264
; Sequence 264, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 264
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-264

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2310 AATCAAGACCCTGAAGGGTGG 2330
              ||||||||||||||||||||
Db          1 AATCAAGACCCTGAAGGGTGG 21
```

RESULT 282
US-10-800-077-265
; Sequence 265, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 265
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-265

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2496 AAACGACGGACAGTTCACAGT 2516
              |||||||||||||||||||||
Db          1 AAACGACGGACAGTTCACAGT 21
```

```
RESULT 283
US-10-800-077-266
; Sequence 266, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 266
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-266

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2497 AACGACGGACAGTTCACAGTC 2517
             |||||||||||||||||||||
Db          1 AACGACGGACAGTTCACAGTC 21


RESULT 284
US-10-800-077-267
; Sequence 267, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 267
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-267

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2608 AACATCCTAGTCAACAGCAAC 2628
             |||||||||||||||||||||
Db          1 AACATCCTAGTCAACAGCAAC 21


RESULT 285
US-10-800-077-268
; Sequence 268, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 268
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-268

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2620 AACAGCAACCTCGTCTGCAAA 2640
             |||||||||||||||||||||
Db          1 AACAGCAACCTCGTCTGCAAA 21


RESULT 286
US-10-800-077-269
; Sequence 269, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 269
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-269

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2677 AACTCTTCCGATCCCACCTAC 2697
             |||||||||||||||||||||
Db          1 AACTCTTCCGATCCCACCTAC 21


RESULT 287
US-10-800-077-270
; Sequence 270, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
```

```
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 270
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-270

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2639 AAGTGTCTGACTTTGGCCTTT 2659
              |||||||||||||||||||||
Db          1 AAGTGTCTGACTTTGGCCTTT 21


RESULT 288
US-10-800-077-271
; Sequence 271, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 271
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-271

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2626 AACCTCGTCTGCAAAGTGTCT 2646
              |||||||||||||||||||||
Db          1 AACCTCGTCTGCAAAGTGTCT 21


RESULT 289
US-10-800-077-272
; Sequence 272, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 272
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-272

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2638 AAAGTGTCTGACTTTGGCCTT 2658
              |||||||||||||||||||||
Db          1 AAAGTGTCTGACTTTGGCCTT 21


RESULT 290
US-10-800-077-273
; Sequence 273, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 273
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-273

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2851 AATCAGGACGTGATCAATGCC 2871
              |||||||||||||||||||||
Db          1 AATCAGGACGTGATCAATGCC 21


RESULT 291
US-10-800-077-274
; Sequence 274, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
```

```
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 274
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-274

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2715 AAAGATTCCCATCCGATGGAC 2735
              |||||||||||||||||||||
Db          1 AAAGATTCCCATCCGATGGAC 21


RESULT 292
US-10-800-077-275
; Sequence 275, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 275
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-275

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2716 AAGATTCCCATCCGATGGACT 2736
              |||||||||||||||||||||
Db          1 AAGATTCCCATCCGATGGACT 21


RESULT 293
US-10-800-077-276
; Sequence 276, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 276
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-276

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2761 AAGTTCACTTCCGCCAGTGAT 2781
              |||||||||||||||||||||
Db          1 AAGTTCACTTCCGCCAGTGAT 21


RESULT 294
US-10-800-077-277
; Sequence 277, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 277
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-277

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3141 AAGATACGAAGAAAGTTTCGC 3161
              |||||||||||||||||||||
Db          1 AAGATACGAAGAAAGTTTCGC 21


RESULT 295
US-10-800-077-278
; Sequence 278, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
```

; SEQ ID NO 278
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-278

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3135 AATGGGAAGATACGAAGAAAG 3155
||||||||||||||||||||
Db 1 AATGGGAAGATACGAAGAAAG 21

RESULT 296
US-10-800-077-279
; Sequence 279, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 279
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-279

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2866 AATGCCATTGAACAGGACTAC 2886
||||||||||||||||||||
Db 1 AATGCCATTGAACAGGACTAC 21

RESULT 297
US-10-800-077-280
; Sequence 280, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 280
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-280

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3028 AAAATCGTGGCCCGGGAGAAT 3048
||||||||||||||||||||
Db 1 AAAATCGTGGCCCGGGAGAAT 21

RESULT 298
US-10-800-077-281
; Sequence 281, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 281
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-281

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3253 AAAATCTTGGCCAGTGTCCAG 3273
||||||||||||||||||||
Db 1 AAAATCTTGGCCAGTGTCCAG 21

RESULT 299
US-10-800-077-282
; Sequence 282, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 282
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

```
US-10-800-077-282

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTCCAGC 3274
              |||||||||||||||||||||
Db          1 AAATCTTGGCCAGTGTCCAGC 21


RESULT 300
US-10-800-077-283
; Sequence 283, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 283
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-283

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3149 AAGAAAGTTTCGCAGCCGCTG 3169
              |||||||||||||||||||||
Db          1 AAGAAAGTTTCGCAGCCGCTG 21


RESULT 301
US-10-800-077-284
; Sequence 284, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 284
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-284

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3250 AAGAAAATCTTGGCCAGTGTC 3270
              |||||||||||||||||||||
Db          1 AAGAAAATCTTGGCCAGTGTC 21


RESULT 302
US-10-800-077-285
; Sequence 285, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 285
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-285

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3255 AATCTTGGCCAGTGTCCAGCA 3275
              |||||||||||||||||||||
Db          1 AATCTTGGCCAGTGTCCAGCA 21


RESULT 303
US-10-719-956-629839
; Sequence 629839, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 629839
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-629839

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        767 TGGAGAACCCCTACATCAAGGTGG 790
              |||||||| ||| ||||||||||
Db          1 TGGAGAACACCTCCATCAAGGTGG 24


RESULT 304
```

```
US-10-719-956-629840
; Sequence 629840, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 629840
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-629840

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        767 TGGAGAACCCCTACATCAAGGTGG 790
              |||||||| ||| ||||||||||||
Db          1 TGGAGAACACCTGCATCAAGGTGG 24


RESULT 305
US-11-036-317-47943
; Sequence 47943, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 47943
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-47943

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2457 GTTCATGGAGAACGGCGCCCTGGA 2480
              |||||||||||| || ||||||||
Db          1 GTTCATGGAGAATGGAGCCCTGGA 24


RESULT 306
US-11-036-317-133760
; Sequence 133760, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 133760
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-133760

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAACGGCG 2473
              ||||||| | ||||||||||||||
Db          1 TCACAGACTACATGGAGAACGGCG 24


RESULT 307
US-11-036-317-479532
; Sequence 479532, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 479532
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-479532

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2572 GAGATGAGCTACGTCCACCGAGAC 2595
              || |||||||| ||||||||||||
Db          2 GAAATGAGCTATGTCCACCGAGAC 25


RESULT 308
US-11-060-756-121062/c
; Sequence 121062, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 121062
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-121062

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2769 TTCCGCCAGTGATGCCTGGAGTTA 2792
              ||| |||||||||| |||||||||
Db         25 TTCTGCCAGTGATGTCTGGAGTTA 2
```

```
RESULT 309
US-11-060-756-121063/c
; Sequence 121063, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 121063
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-121063

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2769 TTCCGCCAGTGATGCCTGGAGTTA 2792
                ||| |||||||||| |||||||||
Db         25 TTCTGCCAGTGATGTCTGGAGTTA 2


RESULT 310
US-11-060-756-142612/c
; Sequence 142612, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 142612
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-142612

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2767 ACTTCCGCCAGTGATGCCTGGAGT 2790
                ||||| |||||||||| |||||||
Db         24 ACTTCTGCCAGTGATGTCTGGAGT 1


RESULT 311
US-11-060-756-142613/c
; Sequence 142613, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 142613
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-142613

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2767 ACTTCCGCCAGTGATGCCTGGAGT 2790
                ||||| |||||||||| |||||||
Db         24 ACTTCTGCCAGTGATGTCTGGAGT 1


RESULT 312
US-11-060-756-180539
; Sequence 180539, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 180539
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-180539

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2634 CTGCAAAGTGTCTGACTTTGGCCT 2657
                |||||||||||||||| |||||| |
Db          1 CTGCAAAGTGTCTGATTTTGGCAT 24


RESULT 313
US-11-060-756-256243
; Sequence 256243, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 256243
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-256243

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 3e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2937 GGACTGTTGGCAGAAAGACCGGAA 2960
                |||||| |||||||||||| ||||
Db          1 GGACTGCTGGCAGAAAGACAGGAA 24
```

```
RESULT 314
US-10-800-350-59
; Sequence 59, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 59
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-59

  Query Match             0.5%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   95.5%;  Pred. No. 2.5e+02;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1587 TGAGGTCACTGCATTGAACGGG 1608
             | ||||||||||||||||||||
Db          1 TCAGGTCACTGCATTGAACGGG 22


RESULT 315
US-10-800-077-59
; Sequence 59, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 59
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-59

  Query Match             0.5%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   95.5%;  Pred. No. 2.5e+02;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1587 TGAGGTCACTGCATTGAACGGG 1608
             | ||||||||||||||||||||
Db          1 TCAGGTCACTGCATTGAACGGG 22


RESULT 316
US-09-140-378A-3/c
; Sequence 3, Application US/09140378A
; Publication No. US20030124133A1
; GENERAL INFORMATION:
;  APPLICANT: Johnson, Jeffrey D.
;  APPLICANT:  Rutter, William J.
;  APPLICANT:  Edman, Jeffrey C.
;  APPLICANT:  The Regents of the University of California
;  TITLE OF INVENTION: Receptor Tyrosine Kinase With a Discoidin-Type Binding
;  TITLE OF INVENTION:  Domain
;  FILE REFERENCE: 023070-079010US
;  CURRENT APPLICATION NUMBER: US/09/140,378A
;  CURRENT FILING DATE:  1998-08-26
;  PRIOR APPLICATION NUMBER: US 08/077,254
;  PRIOR FILING DATE: 1993-06-14
;  PRIOR APPLICATION NUMBER: US 08/292,299
;  PRIOR FILING DATE: 1994-08-16
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: antisense
;   OTHER INFORMATION: oligonucleotide
US-09-140-378A-3

  Query Match             0.5%;  Score 20.4;  DB 1;  Length 24;
  Best Local Similarity   75.0%;  Pred. No. 3e+02;
  Matches   18;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2587 CACCGAGACCTGGCTGCTCGCAAC 2610
              ||:|| ||:|||||:||:||:|||
Db         24 CAYCGSGAYCTGGCYGCYCGSAAC 1


RESULT 317
US-10-719-956-644852
; Sequence 644852, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 644852
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-644852

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3781 TGTCACCACCAAACTCAATCATTTT 3805
             ||||||||||||   ||||||||||
Db          1 TGTCACCACCAATGGCAATCATTTT 25


RESULT 318
US-10-809-189-24487
; Sequence 24487, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
```

```
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 24487
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-809-189-24487

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3005 TGATCCGGAACCCCGCCAGCCTCAA 3029
              ||||||| ||||||  |||||||||
Db          1 TGATCCGAAACCCCAACAGCCTCAA 25


RESULT 319
US-10-809-189-37489/c
; Sequence 37489, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 37489
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-809-189-37489

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1940 ATCACAGCCAGACCCAACTGGATGA 1964
              |||||| |||||||||| ||| ||
Db         25 ATCACAACCAGACCCAACAGGAAGA 1


RESULT 320
US-11-036-317-105366
; Sequence 105366, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 105366
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-105366

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        769 GAGAACCCCTACATCAAGGTGGACA 793
              ||||||||||||| | || |||||||
Db          1 GAGAACCCCTACGTGAAAGTGGACA 25


RESULT 321
US-11-036-317-210541
; Sequence 210541, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 210541
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-210541

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2845 ATGAGCAATCAGGACGTGATCAATG 2869
              |||| ||||||||| |||||||| |
Db          1 ATGACCAATCAGGATGTGATCAAGG 25


RESULT 322
US-11-036-317-341458
; Sequence 341458, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 341458
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-341458

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       2233 GTGATTGGTGCAGGTGAGTTTGGCG 2257
             ||||||||||||| || ||||| |
Db          1 GTGATTGGTGCAGGAGAATTTGGAG 25


RESULT 323
US-11-036-317-370869
; Sequence 370869, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 370869
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-370869

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2846 TGAGCAATCAGGACGTGATCAATGC 2870
             ||| ||||||||| |||||||| ||
Db          1 TGACCAATCAGGATGTGATCAAGGC 25


RESULT 324
US-11-036-317-373537
; Sequence 373537, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 373537
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-373537

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2234 TGATTGGTGCAGGTGAGTTTGGCGA 2258
             |||||||||||| || ||||| ||
Db          1 TGATTGGTGCAGGAGAATTTGGAGA 25


RESULT 325
US-11-036-317-411187
; Sequence 411187, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 411187
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-411187

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        441 CACAAAATTGGAAACTGCTGATCTG 465
              ||||||| ||||||| || ||||||
Db          1 CACAAAACTGGAAACGGCGGATCTG 25


RESULT 326
US-11-036-317-456404
; Sequence 456404, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 456404
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-456404

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        850 GTGAATGTCAAGACGCTGCGTCTGG 874
              || ||| |||||||||||||| ||||
Db          1 GTTAATATCAAGACGCTGCGCCTGG 25


RESULT 327
US-11-036-317-528469
; Sequence 528469, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
;  APPLICANT: Williams, Alan
;  APPLICANT:  Blume, John
;  TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
;  FILE REFERENCE: 3654.1
;  CURRENT APPLICATION NUMBER: US/11/036,317
;  CURRENT FILING DATE:  2005-01-13
;  PRIOR APPLICATION NUMBER: US 60/536,639
;  PRIOR FILING DATE: 2004-01-13
;  NUMBER OF SEQ ID NOS: 991174
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 528469
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-11-036-317-528469
```

```
  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2390 AGCACCCCAATATCATCCGCCTGGA 2414
             ||||||||||||||| | || |||||
Db          1 AGCACCCCAATATCCTGCGGCTGGA 25


RESULT 328
US-11-060-756-18552/c
; Sequence 18552, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18552
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-18552

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2761 AAGTTCACTTCCGCCAGTGATGCCT 2785
             ||||| ||||| |||||||||| ||
Db         25 AAGTTTACTTCTGCCAGTGATGTCT 1


RESULT 329
US-11-060-756-18556/c
; Sequence 18556, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18556
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-18556

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2758 CGGAAGTTCACTTCCGCCAGTGATG 2782
             || ||||| ||||| ||||||||||
Db         25 CGAAAGTTTACTTCTGCCAGTGATG 1


RESULT 330
US-11-060-756-18557/c
; Sequence 18557, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18557
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-18557

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2762 AGTTCACTTCCGCCAGTGATGCCTG 2786
             |||| ||||| |||||||||| |||
Db         25 AGTTTACTTCTGCCAGTGATGTCTG 1


RESULT 331
US-11-060-756-18562/c
; Sequence 18562, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18562
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-18562

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2757 CCGGAAGTTCACTTCCGCCAGTGAT 2781
             ||| ||||| ||||| |||||||||
Db         25 CCGAAAGTTTACTTCTGCCAGTGAT 1


RESULT 332
US-11-060-756-18564/c
; Sequence 18564, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18564
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-18564
```

```
  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2755 TTCCGGAAGTTCACTTCCGCCAGTG 2779
              ||||| ||||| ||||| |||||||
Db         25 TTCCGAAAGTTTACTTCTGCCAGTG 1


RESULT 333
US-11-060-756-18574/c
; Sequence 18574, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18574
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-18574

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2756 TCCGGAAGTTCACTTCCGCCAGTGA 2780
              |||| ||||| ||||| ||||||||
Db         25 TCCGAAAGTTTACTTCTGCCAGTGA 1


RESULT 334
US-11-060-756-18578/c
; Sequence 18578, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18578
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-18578

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2774 CCAGTGATGCCTGGAGTTACGGGAT 2798
              ||||||||| ||||||||| || ||
Db         25 CCAGTGATGTCTGGAGTTATGGAAT 1


RESULT 335
US-11-060-756-84138
; Sequence 84138, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84138
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-84138

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2746 GCCATTGCCTTCCGGAAGTTCACTT 2770
              ||||| ||||  ||||||||||||
Db          1 GCCATAGCCTATCGGAAGTTCACTT 25


RESULT 336
US-11-060-756-84139
; Sequence 84139, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84139
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-84139

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2845 ATGAGCAATCAGGACGTGATCAATG 2869
              |||||||| ||||| || |||||||
Db          1 ATGAGCAACCAGGATGTCATCAATG 25


RESULT 337
US-11-060-756-84144
; Sequence 84144, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84144
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-84144

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
```

```
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2844 CATGAGCAATCAGGACGTGATCAAT 2868
             ||||||||| ||||| || ||||||
Db          1 CATGAGCAACCAGGATGTCATCAAT 25


RESULT 338
US-11-060-756-84148
; Sequence 84148, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84148
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-84148

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2776 AGTGATGCCTGGAGTTACGGGATTG 2800
             ||||||| |||||| ||||| ||||
Db          1 AGTGATGTCTGGAGCTACGGAATTG 25


RESULT 339
US-11-060-756-123826
; Sequence 123826, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 123826
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-123826

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGAAAGACC 2956
             |||||||||||  |||| |||||||
Db          1 ATGCTGGACTGCAGGCACAAAGACC 25


RESULT 340
US-11-060-756-126430
; Sequence 126430, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 126430
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-126430

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2803 ATGTGGGAGGTGATGTCATTTGGGG 2827
             |||||||| || |||||||||||| |
Db          1 ATGTGGGAAGTCATGTCATTTGGAG 25


RESULT 341
US-11-060-756-144910
; Sequence 144910, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 144910
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-144910

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2843 ACATGAGCAATCAGGACGTGATCAA 2867
             ||||||||||| ||||| || |||||
Db          1 ACATGAGCAACCAGGATGTCATCAA 25


RESULT 342
US-11-060-756-163425/c
; Sequence 163425, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 163425
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-163425

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
```

```
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2755 TTCCGGAAGTTCACTTCCGCCAGTG 2779
              ||||| ||||| ||||| |||||||
Db         25 TTCCGAAAGTTTACTTCTGCCAGTG 1


RESULT 343
US-11-060-756-163426/c
; Sequence 163426, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 163426
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-163426

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2755 TTCCGGAAGTTCACTTCCGCCAGTG 2779
              ||||| ||||| ||||| |||||||
Db         25 TTCCGAAAGTTTACTTCTGCCAGTG 1


RESULT 344
US-11-060-756-166073/c
; Sequence 166073, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 166073
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-166073

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2762 AGTTCACTTCCGCCAGTGATGCCTG 2786
              |||| ||||| |||||||||| |||
Db         25 AGTTTACTTCTGCCAGTGATGTCTG 1


RESULT 345
US-11-060-756-166074/c
; Sequence 166074, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 166074
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-166074

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2762 AGTTCACTTCCGCCAGTGATGCCTG 2786
              |||| ||||| |||||||||| |||
Db         25 AGTTTACTTCTGCCAGTGATGTCTG 1


RESULT 346
US-11-060-756-168023
; Sequence 168023, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 168023
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-168023

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2243 CAGGTGAGTTTGGCGAGGTGTGCCG 2267
              |||| |||||||||||||| ||| |
Db          1 CAGGGGAGTTTGGCGAGGTCTGCAG 25


RESULT 347
US-11-060-756-170191
; Sequence 170191, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 170191
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-170191

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       2931 CATGCTGGACTGTTGGCAGAAAGAC 2955
             ||||||||||||  |||| ||||||
Db          1 CATGCTGGACTGCAGGCACAAAGAC 25


RESULT 348
US-11-060-756-170358/c
; Sequence 170358, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 170358
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-170358

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2758 CGGAAGTTCACTTCCGCCAGTGATG 2782
             || ||||| ||||| ||||||||||
Db         25 CGAAAGTTTACTTCTGCCAGTGATG 1


RESULT 349
US-11-060-756-170359/c
; Sequence 170359, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 170359
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-170359

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2758 CGGAAGTTCACTTCCGCCAGTGATG 2782
             || ||||| ||||| ||||||||||
Db         25 CGAAAGTTTACTTCTGCCAGTGATG 1


RESULT 350
US-11-060-756-171498/c
; Sequence 171498, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 171498
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-171498

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2770 TCCGCCAGTGATGCCTGGAGTTACG 2794
             || |||||||||| ||||||||| |
Db         25 TCTGCCAGTGATGTCTGGAGTTATG 1


RESULT 351
US-11-060-756-171499/c
; Sequence 171499, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 171499
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-171499

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2770 TCCGCCAGTGATGCCTGGAGTTACG 2794
             || |||||||||| ||||||||| |
Db         25 TCTGCCAGTGATGTCTGGAGTTATG 1


RESULT 352
US-11-060-756-182311
; Sequence 182311, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 182311
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-182311

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       2995 CTGGACAAGATGATCCGGAACCCCG 3019
             ||||||||| | |||||||| ||||
Db          1 CTGGACAAGCTTATCCGGAATCCCG 25


RESULT 353
US-11-060-756-193223/c
; Sequence 193223, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193223
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-193223

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2771 CCGCCAGTGATGCCTGGAGTTACGG 2795
             | |||||||||| ||||||||| ||
Db         25 CTGCCAGTGATGTCTGGAGTTATGG 1


RESULT 354
US-11-060-756-227416
; Sequence 227416, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 227416
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-227416

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3003 GATGATCCGGAACCCCGCCAGCCTC 3027
             |||||||||||||| || || |||
Db          1 GATGATCCGGAACCCGGCAAGTCTC 25


RESULT 355
US-11-060-756-239848
; Sequence 239848, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 239848
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-239848

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2800 GTGATGTGGGAGGTGATGTCATTTG 2824
             || |||||||| || ||||||||||
Db          1 GTCATGTGGGAAGTCATGTCATTTG 25


RESULT 356
US-11-060-756-245548
; Sequence 245548, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 245548
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-245548

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2805 GTGGGAGGTGATGTCATTTGGGGAG 2829
             |||||| || |||||||||| |||
Db          1 GTGGGAAGTCATGTCATTTGGAGAG 25


RESULT 357
US-11-060-756-248252
; Sequence 248252, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 248252
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-248252

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2840 GGGACATGAGCAATCAGGACGTGAT 2864
```

```
              |||| ||||||||||||||| || ||
Db          1 GGGAGATGAGCAATCAGGAGGTTAT 25


RESULT 358
US-11-060-756-261475
; Sequence 261475, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 261475
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-261475

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2745 GGCCATTGCCTTCCGGAAGTTCACT 2769
              |||||| ||||  ||||||||||||
Db          1 GGCCATAGCCTATCGGAAGTTCACT 25


RESULT 359
US-11-060-756-265730
; Sequence 265730, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 265730
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-265730

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2806 TGGGAGGTGATGTCATTTGGGGAGA 2830
              ||||| || |||||||||| ||||
Db          1 TGGGAAGTCATGTCATTTGGAGAGA 25


RESULT 360
US-11-060-756-266448
; Sequence 266448, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266448
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-266448

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCATTTGGGGA 2828
              ||||||| || |||||||||| ||
Db          1 TGTGGGAAGTCATGTCATTTGGAGA 25


RESULT 361
US-11-060-756-269583
; Sequence 269583, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 269583
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-269583

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3005 TGATCCGGAACCCCGCCAGCCTCAA 3029
              |||||||||||| || || |||||
Db          1 TGATCCGGAACCCGGCAAGTCTCAA 25


RESULT 362
US-11-060-756-282968
; Sequence 282968, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 282968
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-282968

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2861 TGATCAATGCCATTGAACAGGACTA 2885
              | |||||||||||| || ||||||||
```

```
Db          1 TCATCAATGCCATCGAGCAGGACTA 25


RESULT 363
US-11-060-756-283106
; Sequence 283106, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 283106
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-283106

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGGCAGAAAGA 2954
             |||||||||||||  |||| |||||
Db          1 TCATGCTGGACTGCAGGCACAAAGA 25


RESULT 364
US-11-060-756-283608
; Sequence 283608, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 283608
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-283608

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2801 TGATGTGGGAGGTGATGTCATTTGG 2825
             | ||||||||||||||| | |||||
Db          1 TCATGTGGGAGGTGATGGCCTTTGG 25


RESULT 365
US-11-060-756-283741
; Sequence 283741, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 283741
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-283741

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2801 TGATGTGGGAGGTGATGTCATTTGG 2825
             | ||||||||| || ||||||||||
Db          1 TCATGTGGGAAGTCATGTCATTTGG 25


RESULT 366
US-11-060-756-301070/c
; Sequence 301070, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 301070
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-301070

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2773 GCCAGTGATGCCTGGAGTTACGGGA 2797
             |||||||||| ||||||||| || |
Db         25 GCCAGTGATGTCTGGAGTTATGGAA 1


RESULT 367
US-11-060-756-301071/c
; Sequence 301071, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William Martin
;  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
;  TITLE OF INVENTION:  Target Genes
;  FILE REFERENCE: AM101083 (031896-042000)
;  CURRENT APPLICATION NUMBER: US/11/060,756
;  CURRENT FILING DATE:  2005-02-18
;  NUMBER OF SEQ ID NOS: 303284
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 301071
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: probe
US-11-060-756-301071

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 3.4e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2773 GCCAGTGATGCCTGGAGTTACGGGA 2797
             |||||||||| ||||||||| || |
Db         25 GCCAGTGATGTCTGGAGTTATGGAA 1
```

```
RESULT 368
US-10-800-350-19
; Sequence 19, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-19

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        691 TCCTGCAAGGAGACCTTCAC 710
              ||||||||||||||||||||
Db          1 TCCTGCAAGGAGACCTTCAC 20


RESULT 369
US-10-800-350-21/c
; Sequence 21, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-21

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 370
US-10-800-350-25
; Sequence 25, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-25

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        697 AAGGAGACCTTCACCGTCTT 716
              ||||||||||||||||||||
Db          1 AAGGAGACCTTCACCGTCTT 20


RESULT 371
US-10-800-350-27/c
; Sequence 27, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 27
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-27

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
```

```
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 TGACTGTGAACCTGACTCGA 993
              ||||||||||||||||||||
Db         20 TGACTGTGAACCTGACTCGA 1


RESULT 372
US-10-800-350-32
; Sequence 32, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 32
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-32

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        419 CTTTGGAAGAGACCCTGCTG 438
              ||||||||||||||||||||
Db          1 CTTTGGAAGAGACCCTGCTG 20


RESULT 373
US-10-800-350-33/c
; Sequence 33, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 33
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-33

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        696 CAAGGAGACCTTCACCGTCT 715
              ||||||||||||||||||||
Db         20 CAAGGAGACCTTCACCGTCT 1


RESULT 374
US-10-800-350-51/c
; Sequence 51, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 51
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-51

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 375
US-10-800-350-55
; Sequence 55, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
```

```
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-55

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        419 CTTTGGAAGAGACCCTGCTG 438
              ||||||||||||||||||||
Db          1 CTTTGGAAGAGACCCTGCTG 20


RESULT 376
US-10-800-350-56/c
; Sequence 56, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 56
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-56

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        696 CAAGGAGACCTTCACCGTCT 715
              ||||||||||||||||||||
Db         20 CAAGGAGACCTTCACCGTCT 1


RESULT 377
US-10-800-350-74/c
; Sequence 74, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 74
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-74

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3299 GAACCCCGGGTGGGACAGGA 3318
              ||||||||||||||||||||
Db         20 GAACCCCGGGTGGGACAGGA 1


RESULT 378
US-10-800-350-75/c
; Sequence 75, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 75
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-75

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3279 GAAGTCCCAGGCCAAGCCGG 3298
              ||||||||||||||||||||
Db         20 GAAGTCCCAGGCCAAGCCGG 1


RESULT 379
US-10-800-350-76/c
; Sequence 76, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
```

```
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 76
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-76

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3259 TTGGCCAGTGTCCAGCACAT 3278
              ||||||||||||||||||||
Db         20 TTGGCCAGTGTCCAGCACAT 1


RESULT 380
US-10-800-350-77/c
; Sequence 77, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 77
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-77

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3239 CGGGACACCAGAAGAAAATC 3258
              ||||||||||||||||||||
Db         20 CGGGACACCAGAAGAAAATC 1


RESULT 381
US-10-800-350-78/c
; Sequence 78, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 78
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-78

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3219 CCGAATCGGAGTCACTCTGG 3238
              ||||||||||||||||||||
Db         20 CCGAATCGGAGTCACTCTGG 1


RESULT 382
US-10-800-350-79/c
; Sequence 79, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 79
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-79

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3199 ATCTCTGCTGAGGACCTGCT 3218
              ||||||||||||||||||||
Db         20 ATCTCTGCTGAGGACCTGCT 1


RESULT 383
US-10-800-350-80/c
; Sequence 80, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
```

```
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 80
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-80

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3179 CCTTCGAGCTGGTCAGCCAG 3198
             ||||||||||||||||||||
Db         20 CCTTCGAGCTGGTCAGCCAG 1


RESULT 384
US-10-800-350-81/c
; Sequence 81, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 81
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-81

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3159 CGCAGCCGCTGGCTTTGGCT 3178
             ||||||||||||||||||||
Db         20 CGCAGCCGCTGGCTTTGGCT 1


RESULT 385
US-10-800-350-82/c
; Sequence 82, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 82
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-82

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3139 GGAAGATACGAAGAAAGTTT 3158
             ||||||||||||||||||||
Db         20 GGAAGATACGAAGAAAGTTT 1


RESULT 386
US-10-800-350-83/c
; Sequence 83, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 83
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-83

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3119 GGCTTCGGGCCATCAAAATG 3138
             ||||||||||||||||||||
Db         20 GGCTTCGGGCCATCAAAATG 1


RESULT 387
US-10-800-350-84/c
; Sequence 84, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
```

```
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 84
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-84

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3099 TTTTGGCTCTGTGGGCGAGT 3118
             ||||||||||||||||||||
Db         20 TTTTGGCTCTGTGGGCGAGT 1


RESULT 388
US-10-800-350-85/c
; Sequence 85, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 85
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-85

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3079 CGGCAGCCTCACTACTCAGC 3098
             ||||||||||||||||||||
Db         20 CGGCAGCCTCACTACTCAGC 1


RESULT 389
US-10-800-350-86/c
; Sequence 86, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 86
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-86

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3059 CACACCCTCTCCTGGACCAG 3078
             ||||||||||||||||||||
Db         20 CACACCCTCTCCTGGACCAG 1


RESULT 390
US-10-800-350-87/c
; Sequence 87, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 87
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-87

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3039 CCGGGAGAATGGCGGGGCCT 3058
             ||||||||||||||||||||
Db         20 CCGGGAGAATGGCGGGGCCT 1
```

RESULT 391
US-10-800-350-88/c
; Sequence 88, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-88

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3019 GCCAGCCTCAAAATCGTGGC 3038
||||||||||||||||||||
Db 20 GCCAGCCTCAAAATCGTGGC 1

RESULT 392
US-10-800-350-89/c
; Sequence 89, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 89
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-89

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2999 ACAAGATGATCCGGAACCCC 3018
||||||||||||||||||||
Db 20 ACAAGATGATCCGGAACCCC 1

RESULT 393
US-10-800-350-90/c
; Sequence 90, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 90
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-90

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2979 CCAGGTGGTCAGCGCCCTGG 2998
||||||||||||||||||||
Db 20 CCAGGTGGTCAGCGCCCTGG 1

RESULT 394
US-10-800-350-91/c
; Sequence 91, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 91
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-91

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2959 AATGCCCGGCCCCGCTTCCC 2978
              ||||||||||||||||||||
Db         20 AATGCCCGGCCCCGCTTCCC 1


RESULT 395
US-10-800-350-92/c
; Sequence 92, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-92

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2939 ACTGTTGGCAGAAAGACCGG 2958
              ||||||||||||||||||||
Db         20 ACTGTTGGCAGAAAGACCGG 1


RESULT 396
US-10-800-350-93/c
; Sequence 93, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 93
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-93

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2919 CCTCCACCAGCTCATGCTGG 2938
              ||||||||||||||||||||
Db         20 CCTCCACCAGCTCATGCTGG 1


RESULT 397
US-10-800-350-94/c
; Sequence 94, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 94
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-94

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2899 CCCCCAGACTGTCCCACCTC 2918
              ||||||||||||||||||||
Db         20 CCCCCAGACTGTCCCACCTC 1


RESULT 398
US-10-800-350-95/c
; Sequence 95, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 95
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
```

```
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-95

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2879 AGGACTACCGGCTGCCCCCG 2898
              ||||||||||||||||||||
Db         20 AGGACTACCGGCTGCCCCCG 1


RESULT 399
US-10-800-350-96/c
; Sequence 96, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 96
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-96

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2859 CGTGATCAATGCCATTGAAC 2878
              ||||||||||||||||||||
Db         20 CGTGATCAATGCCATTGAAC 1


RESULT 400
US-10-800-350-97/c
; Sequence 97, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 97
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-97

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2839 TGGGACATGAGCAATCAGGA 2858
              ||||||||||||||||||||
Db         20 TGGGACATGAGCAATCAGGA 1


RESULT 401
US-10-800-350-98/c
; Sequence 98, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 98
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-98

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2819 CATTTGGGGAGAGGCCGTAC 2838
              ||||||||||||||||||||
Db         20 CATTTGGGGAGAGGCCGTAC 1


RESULT 402
US-10-800-350-99/c
; Sequence 99, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
```

```
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 99
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-99

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2799 TGTGATGTGGGAGGTGATGT 2818
             ||||||||||||||||||||
Db         20 TGTGATGTGGGAGGTGATGT 1


RESULT 403
US-10-800-350-100/c
; Sequence 100, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 100
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-100

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2779 GATGCCTGGAGTTACGGGAT 2798
             ||||||||||||||||||||
Db         20 GATGCCTGGAGTTACGGGAT 1


RESULT 404
US-10-800-350-101/c
; Sequence 101, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 101
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-101

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2759 GGAAGTTCACTTCCGCCAGT 2778
             ||||||||||||||||||||
Db         20 GGAAGTTCACTTCCGCCAGT 1


RESULT 405
US-10-800-350-102/c
; Sequence 102, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 102
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-102

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2739 CCCGGAGGCCATTGCCTTCC 2758
             ||||||||||||||||||||
Db         20 CCCGGAGGCCATTGCCTTCC 1


RESULT 406
US-10-800-350-103/c
; Sequence 103, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
```

```
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 103
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-103

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2719 ATTCCCATCCGATGGACTGC 2738
             ||||||||||||||||||||
Db         20 ATTCCCATCCGATGGACTGC 1


RESULT 407
US-10-800-350-104/c
; Sequence 104, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 104
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-104

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2699 CGAGCTCCCTGGGAGGAAAG 2718
             ||||||||||||||||||||
Db         20 CGAGCTCCCTGGGAGGAAAG 1


RESULT 408
US-10-800-350-105/c
; Sequence 105, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 105
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-105

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTACA 2698
             ||||||||||||||||||||
Db         20 CTCTTCCGATCCCACCTACA 1


RESULT 409
US-10-800-350-106/c
; Sequence 106, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 106
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-106

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2659 TCCCGATTCCTGGAGGAGAA 2678
             ||||||||||||||||||||
Db         20 TCCCGATTCCTGGAGGAGAA 1


RESULT 410
US-10-800-350-107/c
; Sequence 107, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
```

```
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 107
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-107

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2639 AAGTGTCTGACTTTGGCCTT 2658
             ||||||||||||||||||||
Db         20 AAGTGTCTGACTTTGGCCTT 1


RESULT 411
US-10-800-350-108/c
; Sequence 108, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 108
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-108

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTCTGC 2637
             ||||||||||||||||||||
Db         20 TCAACAGCAACCTCGTCTGC 1


RESULT 412
US-10-800-350-109/c
; Sequence 109, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 109
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-109

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2598 GGCTGCTCGCAACATCCTAG 2617
             ||||||||||||||||||||
Db         20 GGCTGCTCGCAACATCCTAG 1


RESULT 413
US-10-800-350-110/c
; Sequence 110, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 110
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-110

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2578 AGCTACGTCCACCGAGACCT 2597
             ||||||||||||||||||||
Db         20 AGCTACGTCCACCGAGACCT 1


RESULT 414
US-10-800-350-111/c
```

```
; Sequence 111, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 111
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-111

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2558 TGCGGTACCTTGCCGAGATG 2577
             ||||||||||||||||||||
Db         20 TGCGGTACCTTGCCGAGATG 1


RESULT 415
US-10-800-350-112/c
; Sequence 112, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 112
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-112

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2538 GCGGGGCATCGCCTCGGGCA 2557
             ||||||||||||||||||||
Db         20 GCGGGGCATCGCCTCGGGCA 1


RESULT 416
US-10-800-350-113/c
; Sequence 113, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 113
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-113

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2518 ATCCAGCTCGTGGGCATGCT 2537
             ||||||||||||||||||||
Db         20 ATCCAGCTCGTGGGCATGCT 1


RESULT 417
US-10-800-350-114/c
; Sequence 114, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 114
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-114

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2498 ACGACGGACAGTTCACAGTC 2517
```

```
                    ||||||||||||||||||||
Db         20 ACGACGGACAGTTCACAGTC 1


RESULT 418
US-10-800-350-115/c
; Sequence 115, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 115
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-115

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2478 GGACTCCTTCCTGCGGCTAA 2497
                ||||||||||||||||||||
Db         20 GGACTCCTTCCTGCGGCTAA 1


RESULT 419
US-10-800-350-116/c
; Sequence 116, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 116
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-116

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2458 TTCATGGAGAACGGCGCCCT 2477
                ||||||||||||||||||||
Db         20 TTCATGGAGAACGGCGCCCT 1


RESULT 420
US-10-800-350-117/c
; Sequence 117, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 117
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-117

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2438 CCGTCATGATTCTCACAGAG 2457
                ||||||||||||||||||||
Db         20 CCGTCATGATTCTCACAGAG 1


RESULT 421
US-10-800-350-118/c
; Sequence 118, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 118
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-118
```

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2418 CGTGGTCACCAACAGCATGC 2437
              ||||||||||||||||||||
Db         20 CGTGGTCACCAACAGCATGC 1


RESULT 422
US-10-800-350-119/c
; Sequence 119, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 119
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-119

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2398 AATATCATCCGCCTGGAGGG 2417
              ||||||||||||||||||||
Db         20 AATATCATCCGCCTGGAGGG 1


RESULT 423
US-10-800-350-120/c
; Sequence 120, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 120
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-120

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2378 TGGGCCAGTTCGAGCACCCC 2397
              ||||||||||||||||||||
Db         20 TGGGCCAGTTCGAGCACCCC 1


RESULT 424
US-10-800-350-121/c
; Sequence 121, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 121
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-121

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2358 TCTGAGCGAGGCCTCCATCA 2377
              ||||||||||||||||||||
Db         20 TCTGAGCGAGGCCTCCATCA 1


RESULT 425
US-10-800-350-122/c
; Sequence 122, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 122
```

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-122

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 GAGCGGCAGCGGCGTGAGTT 2357
              ||||||||||||||||||||
Db         20 GAGCGGCAGCGGCGTGAGTT 1


RESULT 426
US-10-800-350-123/c
; Sequence 123, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 123
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-123

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2318 CCCTGAAGGGTGGCTACACG 2337
              ||||||||||||||||||||
Db         20 CCCTGAAGGGTGGCTACACG 1


RESULT 427
US-10-800-350-124/c
; Sequence 124, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 124
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-124

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2298 GAGCTGTGTGGCAATCAAGA 2317
              ||||||||||||||||||||
Db         20 GAGCTGTGTGGCAATCAAGA 1


RESULT 428
US-10-800-350-125/c
; Sequence 125, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-125

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2278 AAGGCCCCAGGGAAGAAGGA 2297
              ||||||||||||||||||||
Db         20 AAGGCCCCAGGGAAGAAGGA 1


RESULT 429
US-10-800-350-126/c
; Sequence 126, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
```

```
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 126
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-126

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2258 AGGTGTGCCGGGGGCGGCTC 2277
              ||||||||||||||||||||
Db         20 AGGTGTGCCGGGGGCGGCTC 1


RESULT 430
US-10-800-350-127/c
; Sequence 127, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 127
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-127

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2238 TGGTGCAGGTGAGTTTGGCG 2257
              ||||||||||||||||||||
Db         20 TGGTGCAGGTGAGTTTGGCG 1


RESULT 431
US-10-800-350-128/c
; Sequence 128, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 128
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-128

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2218 GTCAAGATTGAAGAGGTGAT 2237
              ||||||||||||||||||||
Db         20 GTCAAGATTGAAGAGGTGAT 1


RESULT 432
US-10-800-350-129/c
; Sequence 129, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 129
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-129

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2198 AAGAGATCGATGTCTCCTAC 2217
              ||||||||||||||||||||
Db         20 AAGAGATCGATGTCTCCTAC 1


RESULT 433
US-10-800-350-130/c
; Sequence 130, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
```

```
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 130
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-130

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2178 GGCTGTGAGGGAATTTGCAA 2197
             ||||||||||||||||||||
Db         20 GGCTGTGAGGGAATTTGCAA 1


RESULT 434
US-10-800-350-131/c
; Sequence 131, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 131
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-131

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2158 ACTTATGAAGACCCTAATGA 2177
             ||||||||||||||||||||
Db         20 ACTTATGAAGACCCTAATGA 1


RESULT 435
US-10-800-350-132/c
; Sequence 132, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 132
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-132

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2138 AGGTCTACATCGACCCCTTC 2157
             ||||||||||||||||||||
Db         20 AGGTCTACATCGACCCCTTC 1


RESULT 436
US-10-800-350-133/c
; Sequence 133, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 133
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-133

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2118 TCTCATCGGACATGGTACTA 2137
             ||||||||||||||||||||
Db         20 TCTCATCGGACATGGTACTA 1


RESULT 437
US-10-800-350-134/c
; Sequence 134, Application US/10800350
; Publication No. US20050084873A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 134
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-134

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2098 TCGGACAAACACGGACAGTA 2117
             ||||||||||||||||||||
Db         20 TCGGACAAACACGGACAGTA 1


RESULT 438
US-10-800-350-135/c
; Sequence 135, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 135
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-135

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2078 ATGGGAGAGAAGCAGAATAT 2097
             ||||||||||||||||||||
Db         20 ATGGGAGAGAAGCAGAATAT 1


RESULT 439
US-10-800-350-136/c
; Sequence 136, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 136
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-136

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2058 CTGCCTCAGGAAGCAGAGCA 2077
             ||||||||||||||||||||
Db         20 CTGCCTCAGGAAGCAGAGCA 1


RESULT 440
US-10-800-350-137/c
; Sequence 137, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 137
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-137

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2038 GTCATTGTGGTCGCAGTTCT 2057
             ||||||||||||||||||||
Db         20 GTCATTGTGGTCGCAGTTCT 1
```

```
RESULT 441
US-10-800-350-138/c
; Sequence 138, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 138
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-138

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2018 GTGTGGTCCTGGTCCTGGTG 2037
             ||||||||||||||||||||
Db         20 GTGTGGTCCTGGTCCTGGTG 1


RESULT 442
US-10-800-350-139/c
; Sequence 139, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 139
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-139

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1998 TGCGGGCACGGCAGTCGTGG 2017
             ||||||||||||||||||||
Db         20 TGCGGGCACGGCAGTCGTGG 1


RESULT 443
US-10-800-350-140/c
; Sequence 140, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 140
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-140

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1978 CGGGAGCAGCTGGCCCTGAT 1997
             ||||||||||||||||||||
Db         20 CGGGAGCAGCTGGCCCTGAT 1


RESULT 444
US-10-800-350-141/c
; Sequence 141, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 141
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-141

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
```

```
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 TGGATGAGAGCGAGGGCTGG 1977
              ||||||||||||||||||||
Db         20 TGGATGAGAGCGAGGGCTGG 1


RESULT 445
US-10-800-350-142/c
; Sequence 142, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 142
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-142

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1938 ACATCACAGCCAGACCCAAC 1957
              ||||||||||||||||||||
Db         20 ACATCACAGCCAGACCCAAC 1


RESULT 446
US-10-800-350-143/c
; Sequence 143, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 143
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-143

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1918 TACGGGCCCTTCGGCCAGGA 1937
              ||||||||||||||||||||
Db         20 TACGGGCCCTTCGGCCAGGA 1


RESULT 447
US-10-800-350-144/c
; Sequence 144, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 144
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-144

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1898 GGGCGCGCTCTGAGGCCGGC 1917
              ||||||||||||||||||||
Db         20 GGGCGCGCTCTGAGGCCGGC 1


RESULT 448
US-10-800-350-145/c
; Sequence 145, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 145
;   LENGTH: 20
;   TYPE: DNA
```

```
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-145

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1878 CAGCTACCTGGTGCAGGTAC 1897
              ||||||||||||||||||||
Db         20 CAGCTACCTGGTGCAGGTAC 1


RESULT 449
US-10-800-350-146/c
; Sequence 146, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 146
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-146

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1858 CGGGGGCTGAAGCGGGGAGC 1877
              ||||||||||||||||||||
Db         20 CGGGGGCTGAAGCGGGGAGC 1


RESULT 450
US-10-800-350-147/c
; Sequence 147, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 147
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-147

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1838 CAGAAAACCGGGCAGAGCTG 1857
              ||||||||||||||||||||
Db         20 CAGAAAACCGGGCAGAGCTG 1


RESULT 451
US-10-800-350-148/c
; Sequence 148, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 148
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-148

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1818 CGTGCGGTTCCTGAAGACGT 1837
              ||||||||||||||||||||
Db         20 CGTGCGGTTCCTGAAGACGT 1


RESULT 452
US-10-800-350-149/c
; Sequence 149, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
```

```
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 149
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-149

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1798 GGCGCCGAGGGTCCCAGCAG 1817
             ||||||||||||||||||||
Db         20 GGCGCCGAGGGTCCCAGCAG 1


RESULT 453
US-10-800-350-150/c
; Sequence 150, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 150
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-150

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1778 AGGTCAAATACCATGAGAAG 1797
             ||||||||||||||||||||
Db         20 AGGTCAAATACCATGAGAAG 1


RESULT 454
US-10-800-350-151/c
; Sequence 151, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 151
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-151

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1758 TGGGGCTGTGCTGGACTACG 1777
             ||||||||||||||||||||
Db         20 TGGGGCTGTGCTGGACTACG 1


RESULT 455
US-10-800-350-152/c
; Sequence 152, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 152
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-152

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 GCTGTTCCCCGGGCACCCAG 1757
             ||||||||||||||||||||
Db         20 GCTGTTCCCCGGGCACCCAG 1


RESULT 456
US-10-800-350-153/c
; Sequence 153, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
```

```
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 153
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-153

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1718 GCAGCTTGAGCCTGGCCTGG 1737
             ||||||||||||||||||||
Db         20 GCAGCTTGAGCCTGGCCTGG 1


RESULT 457
US-10-800-350-154/c
; Sequence 154, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 154
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-154

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1698 GGTGACGCGGTCCTCACCCA 1717
             ||||||||||||||||||||
Db         20 GGTGACGCGGTCCTCACCCA 1


RESULT 458
US-10-800-350-155/c
; Sequence 155, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 155
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-155

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1678 CCTGCAGTGTCTGACATCCG 1697
             ||||||||||||||||||||
Db         20 CCTGCAGTGTCTGACATCCG 1


RESULT 459
US-10-800-350-156/c
; Sequence 156, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 156
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-156

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1658 CCACTGACCGAGAGGTACCT 1677
             ||||||||||||||||||||
Db         20 CCACTGACCGAGAGGTACCT 1


RESULT 460
US-10-800-350-157/c
; Sequence 157, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
```

```
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 157
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-157

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1638 ATTTGAGCCTGTCAATGTCA 1657
              ||||||||||||||||||||
Db         20 ATTTGAGCCTGTCAATGTCA 1


RESULT 461
US-10-800-350-158/c
; Sequence 158, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 158
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-158

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1618 TTAGCCACGGGGCCCGTCCC 1637
              ||||||||||||||||||||
Db         20 TTAGCCACGGGGCCCGTCCC 1


RESULT 462
US-10-800-350-159/c
; Sequence 159, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 159
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-159

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CATTGAACGGGGTATCCTCC 1617
              ||||||||||||||||||||
Db         20 CATTGAACGGGGTATCCTCC 1


RESULT 463
US-10-800-350-160/c
; Sequence 160, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 160
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-160

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1578 CTATACCTTTGAGGTCACTG 1597
              ||||||||||||||||||||
Db         20 CTATACCTTTGAGGTCACTG 1
```

```
RESULT 464
US-10-800-350-161/c
; Sequence 161, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 161
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-161

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1558 GGGCTACGTCCTGACTTCAC 1577
             ||||||||||||||||||||
Db         20 GGGCTACGTCCTGACTTCAC 1


RESULT 465
US-10-800-350-162/c
; Sequence 162, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 162
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-162

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1538 AGCCCTGGGTGGTGGTTCGA 1557
             ||||||||||||||||||||
Db         20 AGCCCTGGGTGGTGGTTCGA 1


RESULT 466
US-10-800-350-163/c
; Sequence 163, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 163
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-163

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1518 CGGCCCCCGGGACCTGGTGG 1537
             ||||||||||||||||||||
Db         20 CGGCCCCCGGGACCTGGTGG 1


RESULT 467
US-10-800-350-164/c
; Sequence 164, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 164
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-164

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1498 GGAGACCTGACTTTTGACCC 1517
              ||||||||||||||||||||
Db         20 GGAGACCTGACTTTTGACCC 1
```

RESULT 468
US-10-800-350-165/c
; Sequence 165, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 165
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-165

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1478 GCTCCTGTGCGCCCTGCGGG 1497
              ||||||||||||||||||||
Db         20 GCTCCTGTGCGCCCTGCGGG 1
```

RESULT 469
US-10-800-350-166/c
; Sequence 166, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 166
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-166

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1458 CCGGGAGTGCCGACCCGGAG 1477
              ||||||||||||||||||||
Db         20 CCGGGAGTGCCGACCCGGAG 1
```

RESULT 470
US-10-800-350-167/c
; Sequence 167, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 167
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-167

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1438 CTCACCTACGCCCTCCGCTG 1457
              ||||||||||||||||||||
Db         20 CTCACCTACGCCCTCCGCTG 1
```

RESULT 471
US-10-800-350-168/c
; Sequence 168, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 168
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:

```
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-168

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1418 AGTCTGGTGGCCGAGAGGAC 1437
              ||||||||||||||||||||
Db         20 AGTCTGGTGGCCGAGAGGAC 1


RESULT 472
US-10-800-350-169/c
; Sequence 169, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 169
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-169

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1398 GGAATGGAGTGCCCCCCTGG 1417
              ||||||||||||||||||||
Db         20 GGAATGGAGTGCCCCCCTGG 1


RESULT 473
US-10-800-350-170/c
; Sequence 170, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 170
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-170

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1378 AACGGCTCCTCCCTGCACCT 1397
              ||||||||||||||||||||
Db         20 AACGGCTCCTCCCTGCACCT 1


RESULT 474
US-10-800-350-171/c
; Sequence 171, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 171
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-171

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1358 GGAGCGTGGTTTCCCGCCTG 1377
              ||||||||||||||||||||
Db         20 GGAGCGTGGTTTCCCGCCTG 1


RESULT 475
US-10-800-350-172/c
; Sequence 172, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
```

```
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 172
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-172

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1338 CACCCCTCCTTCGGCTCCGC 1357
              ||||||||||||||||||||
Db         20 CACCCCTCCTTCGGCTCCGC 1


RESULT 476
US-10-800-350-173/c
; Sequence 173, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 173
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-173

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1318 CCCCGGGGTGCACCCTGCAC 1337
              ||||||||||||||||||||
Db         20 CCCCGGGGTGCACCCTGCAC 1


RESULT 477
US-10-800-350-174/c
; Sequence 174, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 174
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-174

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1298 ACTTCCGGGCACGCACAGAC 1317
              ||||||||||||||||||||
Db         20 ACTTCCGGGCACGCACAGAC 1


RESULT 478
US-10-800-350-175/c
; Sequence 175, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 175
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-175

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1278 CTGCCAGTGCCGCGTCGGGT 1297
              ||||||||||||||||||||
Db         20 CTGCCAGTGCCGCGTCGGGT 1


RESULT 479
US-10-800-350-176/c
; Sequence 176, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
```

```
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 176
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-176

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AACACCATTGGATCAGCCGT 1277
             ||||||||||||||||||||
Db         20 AACACCATTGGATCAGCCGT 1


RESULT 480
US-10-800-350-177/c
; Sequence 177, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 177
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-177

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1238 GCCCAGCCAATAGCCACTCT 1257
             ||||||||||||||||||||
Db         20 GCCCAGCCAATAGCCACTCT 1


RESULT 481
US-10-800-350-178/c
; Sequence 178, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 178
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-178

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1218 AGAAGGGTCCTGCCAGCCAT 1237
             ||||||||||||||||||||
Db         20 AGAAGGGTCCTGCCAGCCAT 1


RESULT 482
US-10-800-350-179/c
; Sequence 179, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 179
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-179

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1198 ACCTTCAAGCCCCTGTCAGG 1217
             ||||||||||||||||||||
Db         20 ACCTTCAAGCCCCTGTCAGG 1


RESULT 483
US-10-800-350-180/c
; Sequence 180, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
```

```
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 180
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-180

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCCAGGGC 1197
             ||||||||||||||||||||
Db         20 GCCGAGCCTGTGCCCAGGGC 1


RESULT 484
US-10-800-350-181/c
; Sequence 181, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 181
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-181

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1158 AGCTGAGGGGAACACCAAGT 1177
             ||||||||||||||||||||
Db         20 AGCTGAGGGGAACACCAAGT 1


RESULT 485
US-10-800-350-182/c
; Sequence 182, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 182
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-182

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1138 TGTGCTCCGGGGTTCGAGGC 1157
             ||||||||||||||||||||
Db         20 TGTGCTCCGGGGTTCGAGGC 1


RESULT 486
US-10-800-350-183/c
; Sequence 183, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 183
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-183

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1118 AGCCGGTCACGGGCTGCAGC 1137
             ||||||||||||||||||||
Db         20 AGCCGGTCACGGGCTGCAGC 1


RESULT 487
US-10-800-350-184/c
```

```
; Sequence 184, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 184
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-184

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1098 GGATGGCCAGTGGGCCGAAC 1117
             ||||||||||||||||||||
Db         20 GGATGGCCAGTGGGCCGAAC 1


RESULT 488
US-10-800-350-185/c
; Sequence 185, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 185
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-185

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1078 CCCAGCCTCTACTGCCGTGA 1097
             ||||||||||||||||||||
Db         20 CCCAGCCTCTACTGCCGTGA 1


RESULT 489
US-10-800-350-186/c
; Sequence 186, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 186
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-186

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1058 TCCCCGCCCCTGGCCCCAGC 1077
             ||||||||||||||||||||
Db         20 TCCCCGCCCCTGGCCCCAGC 1


RESULT 490
US-10-800-350-187/c
; Sequence 187, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 187
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-187

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1038 TAGCTGCGTGGTGGATGCCG 1057
```

```
              ||||||||||||||||||||
Db          20 TAGCTGCGTGGTGGATGCCG 1


RESULT 491
US-10-800-350-188/c
; Sequence 188, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 188
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-188

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1018 CTGGTTGTGCCCGTGGCCGG 1037
              ||||||||||||||||||||
Db         20 CTGGTTGTGCCCGTGGCCGG 1


RESULT 492
US-10-800-350-189/c
; Sequence 189, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 189
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-189

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        998 CGGAGACTGTGCCTCGGGAG 1017
              ||||||||||||||||||||
Db         20 CGGAGACTGTGCCTCGGGAG 1


RESULT 493
US-10-800-350-190/c
; Sequence 190, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 190
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-190

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        978 TGTGAACCTGACTCGATTCC 997
              ||||||||||||||||||||
Db         20 TGTGAACCTGACTCGATTCC 1


RESULT 494
US-10-800-350-191/c
; Sequence 191, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 191
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-191
```

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        958 AAAAAGTGCGCCCAGCTGAC 977
              ||||||||||||||||||||
Db         20 AAAAAGTGCGCCCAGCTGAC 1


RESULT 495
US-10-800-350-192/c
; Sequence 192, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 192
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-192

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        938 TATCCCTGCACCTCTTCTAC 957
              ||||||||||||||||||||
Db         20 TATCCCTGCACCTCTTCTAC 1


RESULT 496
US-10-800-350-193/c
; Sequence 193, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 193
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-193

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        918 GGGTGCCTGCATGGCCCTGC 937
              ||||||||||||||||||||
Db         20 GGGTGCCTGCATGGCCCTGC 1


RESULT 497
US-10-800-350-194/c
; Sequence 194, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 194
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-194

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        898 TACCTGGCCTTCCAGGACCA 917
              ||||||||||||||||||||
Db         20 TACCTGGCCTTCCAGGACCA 1


RESULT 498
US-10-800-350-195/c
; Sequence 195, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 195
```

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-195

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        878 CGCTCAGCAAGGCTGGCTTC 897
              ||||||||||||||||||||
Db         20 CGCTCAGCAAGGCTGGCTTC 1


RESULT 499
US-10-800-350-196/c
; Sequence 196, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 196
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-196

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        858 CAAGACGCTGCGTCTGGGAC 877
              ||||||||||||||||||||
Db         20 CAAGACGCTGCGTCTGGGAC 1


RESULT 500
US-10-800-350-197/c
; Sequence 197, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 197
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-197

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        838 GCCACCGGGAAGGTGAATGT 857
              ||||||||||||||||||||
Db         20 GCCACCGGGAAGGTGAATGT 1


RESULT 501
US-10-800-350-198/c
; Sequence 198, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 198
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-198

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        818 GGAAGCGCCCTGGGGCCGAG 837
              ||||||||||||||||||||
Db         20 GGAAGCGCCCTGGGGCCGAG 1


RESULT 502
US-10-800-350-199/c
; Sequence 199, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
```

```
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 199
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-199

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        798 GGCCGCGGAGCATCTCACCC 817
              ||||||||||||||||||||
Db         20 GGCCGCGGAGCATCTCACCC 1


RESULT 503
US-10-800-350-200/c
; Sequence 200, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 200
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-200

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        778 TACATCAAGGTGGACACGGT 797
              ||||||||||||||||||||
Db         20 TACATCAAGGTGGACACGGT 1


RESULT 504
US-10-800-350-201/c
; Sequence 201, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 201
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-201

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        758 CAGCCTGGATGGAGAACCCC 777
              ||||||||||||||||||||
Db         20 CAGCCTGGATGGAGAACCCC 1


RESULT 505
US-10-800-350-202/c
; Sequence 202, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 202
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-202

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        738 CACGGCCACGGCCCTCACGC 757
              ||||||||||||||||||||
Db         20 CACGGCCACGGCCCTCACGC 1


RESULT 506
US-10-800-350-203/c
; Sequence 203, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
```

```
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 203
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-203

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        718 TACTATGAGAGCGATGCGGA 737
              ||||||||||||||||||||
Db         20 TACTATGAGAGCGATGCGGA 1


RESULT 507
US-10-800-350-204/c
; Sequence 204, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 204
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-204

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        698 AGGAGACCTTCACCGTCTTC 717
              ||||||||||||||||||||
Db         20 AGGAGACCTTCACCGTCTTC 1


RESULT 508
US-10-800-350-205/c
; Sequence 205, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 205
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-205

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        678 TCGGGCTGGGCGCTCCTGCA 697
              ||||||||||||||||||||
Db         20 TCGGGCTGGGCGCTCCTGCA 1


RESULT 509
US-10-800-350-206/c
; Sequence 206, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 206
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-206

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        658 CTCGAGTGCCTGTCCCTGCC 677
              ||||||||||||||||||||
Db         20 CTCGAGTGCCTGTCCCTGCC 1


RESULT 510
US-10-800-350-207/c
; Sequence 207, Application US/10800350
; Publication No. US20050084873A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 207
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-207

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        638 CCACGCTGCGCTTCACCATG 657
              ||||||||||||||||||||
Db         20 CCACGCTGCGCTTCACCATG 1


RESULT 511
US-10-800-350-208/c
; Sequence 208, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 208
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-208

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        618 GGGCGCCGTCCACGTGTACG 637
              ||||||||||||||||||||
Db         20 GGGCGCCGTCCACGTGTACG 1


RESULT 512
US-10-800-350-209/c
; Sequence 209, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 209
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-209

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        598 ACAGGTTGGGTCCCACGGCG 617
              ||||||||||||||||||||
Db         20 ACAGGTTGGGTCCCACGGCG 1


RESULT 513
US-10-800-350-210/c
; Sequence 210, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 210
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-210

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        578 GCCAGGCCCACTGGCTTCGC 597
              ||||||||||||||||||||
Db         20 GCCAGGCCCACTGGCTTCGC 1
```

```
RESULT 514
US-10-800-350-211/c
; Sequence 211, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 211
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-211

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        558 TGACGTGCAGCGTGCCCCGG 577
              ||||||||||||||||||||
Db         20 TGACGTGCAGCGTGCCCCGG 1


RESULT 515
US-10-800-350-212/c
; Sequence 212, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 212
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-212

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        538 GTGCGCACCTACGAAGTGTG 557
              ||||||||||||||||||||
Db         20 GTGCGCACCTACGAAGTGTG 1


RESULT 516
US-10-800-350-213/c
; Sequence 213, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 213
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-213

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        518 TGGATGAGGAACAGCACAGC 537
              ||||||||||||||||||||
Db         20 TGGATGAGGAACAGCACAGC 1


RESULT 517
US-10-800-350-214/c
; Sequence 214, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 214
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-214

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
```

```
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        498 GTGGGAGGAACTGAGCGGCC 517
              ||||||||||||||||||||
Db         20 GTGGGAGGAACTGAGCGGCC 1


RESULT 518
US-10-800-350-215/c
; Sequence 215, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 215
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-215

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        478 TTCCCTCAGGTGGACGGGCA 497
              ||||||||||||||||||||
Db         20 TTCCCTCAGGTGGACGGGCA 1


RESULT 519
US-10-800-350-216/c
; Sequence 216, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 216
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-216

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        458 CTGATCTGAAGTGGGTGACA 477
              ||||||||||||||||||||
Db         20 CTGATCTGAAGTGGGTGACA 1


RESULT 520
US-10-800-350-217/c
; Sequence 217, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 217
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-217

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        438 GAACACAAAATTGGAAACTG 457
              ||||||||||||||||||||
Db         20 GAACACAAAATTGGAAACTG 1


RESULT 521
US-10-800-350-218/c
; Sequence 218, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 218
;   LENGTH: 20
;   TYPE: DNA
```

```
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-218

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        418 GCTTTGGAAGAGACCCTGCT 437
              ||||||||||||||||||||
Db         20 GCTTTGGAAGAGACCCTGCT 1


RESULT 522
US-10-800-350-219/c
; Sequence 219, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 219
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-219

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        398 GCTGGGCTTCGTTGGCCGCA 417
              ||||||||||||||||||||
Db         20 GCTGGGCTTCGTTGGCCGCA 1


RESULT 523
US-10-800-350-220/c
; Sequence 220, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 220
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-220

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        378 GGAGCTCCGGGTGCTGCTCT 397
              ||||||||||||||||||||
Db         20 GGAGCTCCGGGTGCTGCTCT 1


RESULT 524
US-10-800-350-221/c
; Sequence 221, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 221
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-221

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        376 ATGGAGCTCCGGGTGCTGCT 395
              ||||||||||||||||||||
Db         20 ATGGAGCTCCGGGTGCTGCT 1


RESULT 525
US-10-800-350-231/c
; Sequence 231, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
```

```
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 231
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-231

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 526
US-10-800-077-19
; Sequence 19, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-19

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        691 TCCTGCAAGGAGACCTTCAC 710
              ||||||||||||||||||||
Db          1 TCCTGCAAGGAGACCTTCAC 20


RESULT 527
US-10-800-077-21/c
; Sequence 21, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-21

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 528
US-10-800-077-25
; Sequence 25, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-25

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        697 AAGGAGACCTTCACCGTCTT 716
              ||||||||||||||||||||
Db          1 AAGGAGACCTTCACCGTCTT 20


RESULT 529
US-10-800-077-27/c
; Sequence 27, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 27
;   LENGTH: 20
;   TYPE: DNA
```

; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-27

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 974 TGACTGTGAACCTGACTCGA 993
||||||||||||||||||||
Db 20 TGACTGTGAACCTGACTCGA 1

RESULT 530
US-10-800-077-32
; Sequence 32, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-32

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 419 CTTTGGAAGAGACCCTGCTG 438
||||||||||||||||||||
Db 1 CTTTGGAAGAGACCCTGCTG 20

RESULT 531
US-10-800-077-33/c
; Sequence 33, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-33

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 696 CAAGGAGACCTTCACCGTCT 715
||||||||||||||||||||
Db 20 CAAGGAGACCTTCACCGTCT 1

RESULT 532
US-10-800-077-51/c
; Sequence 51, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-51

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2356 TTTCTGAGCGAGGCCTCCAT 2375
||||||||||||||||||||
Db 20 TTTCTGAGCGAGGCCTCCAT 1

RESULT 533
US-10-800-077-55
; Sequence 55, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-55

Query Match 0.5%; Score 20; DB 1; Length 20;

```
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        419 CTTTGGAAGAGACCCTGCTG 438
              ||||||||||||||||||||
Db          1 CTTTGGAAGAGACCCTGCTG 20


RESULT 534
US-10-800-077-56/c
; Sequence 56, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 56
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-56

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        696 CAAGGAGACCTTCACCGTCT 715
              ||||||||||||||||||||
Db         20 CAAGGAGACCTTCACCGTCT 1


RESULT 535
US-10-800-077-74/c
; Sequence 74, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 74
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-74

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3299 GAACCCCGGGTGGGACAGGA 3318
              ||||||||||||||||||||
Db         20 GAACCCCGGGTGGGACAGGA 1


RESULT 536
US-10-800-077-75/c
; Sequence 75, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 75
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-75

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3279 GAAGTCCCAGGCCAAGCCGG 3298
              ||||||||||||||||||||
Db         20 GAAGTCCCAGGCCAAGCCGG 1


RESULT 537
US-10-800-077-76/c
; Sequence 76, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 76
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-76

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3259 TTGGCCAGTGTCCAGCACAT 3278
              ||||||||||||||||||||
Db         20 TTGGCCAGTGTCCAGCACAT 1
```

```
RESULT 538
US-10-800-077-77/c
; Sequence 77, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 77
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-77

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3239 CGGGACACCAGAAGAAAATC 3258
             ||||||||||||||||||||
Db         20 CGGGACACCAGAAGAAAATC 1


RESULT 539
US-10-800-077-78/c
; Sequence 78, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 78
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-78

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3219 CCGAATCGGAGTCACTCTGG 3238
             ||||||||||||||||||||
Db         20 CCGAATCGGAGTCACTCTGG 1


RESULT 540
US-10-800-077-79/c
; Sequence 79, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 79
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-79

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3199 ATCTCTGCTGAGGACCTGCT 3218
             ||||||||||||||||||||
Db         20 ATCTCTGCTGAGGACCTGCT 1


RESULT 541
US-10-800-077-80/c
; Sequence 80, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 80
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-80

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3179 CCTTCGAGCTGGTCAGCCAG 3198
             ||||||||||||||||||||
Db         20 CCTTCGAGCTGGTCAGCCAG 1


RESULT 542
US-10-800-077-81/c
; Sequence 81, Application US/10800077
; Publication No. US20050164965A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 81
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-81

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3159 CGCAGCCGCTGGCTTTGGCT 3178
             ||||||||||||||||||||
Db         20 CGCAGCCGCTGGCTTTGGCT 1


RESULT 543
US-10-800-077-82/c
; Sequence 82, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 82
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-82

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3139 GGAAGATACGAAGAAAGTTT 3158
             ||||||||||||||||||||
Db         20 GGAAGATACGAAGAAAGTTT 1


RESULT 544
US-10-800-077-83/c
; Sequence 83, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 83
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-83

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3119 GGCTTCGGGCCATCAAAATG 3138
             ||||||||||||||||||||
Db         20 GGCTTCGGGCCATCAAAATG 1


RESULT 545
US-10-800-077-84/c
; Sequence 84, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 84
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-84

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3099 TTTTGGCTCTGTGGGCGAGT 3118
             ||||||||||||||||||||
Db         20 TTTTGGCTCTGTGGGCGAGT 1


RESULT 546
US-10-800-077-85/c
; Sequence 85, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
```

```
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 85
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-85

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3079 CGGCAGCCTCACTACTCAGC 3098
             ||||||||||||||||||||
Db         20 CGGCAGCCTCACTACTCAGC 1


RESULT 547
US-10-800-077-86/c
; Sequence 86, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 86
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-86

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3059 CACACCCTCTCCTGGACCAG 3078
             ||||||||||||||||||||
Db         20 CACACCCTCTCCTGGACCAG 1


RESULT 548
US-10-800-077-87/c
; Sequence 87, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 87
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-87

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3039 CCGGGAGAATGGCGGGGCCT 3058
             ||||||||||||||||||||
Db         20 CCGGGAGAATGGCGGGGCCT 1


RESULT 549
US-10-800-077-88/c
; Sequence 88, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 88
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-88

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3019 GCCAGCCTCAAAATCGTGGC 3038
             ||||||||||||||||||||
Db         20 GCCAGCCTCAAAATCGTGGC 1


RESULT 550
US-10-800-077-89/c
; Sequence 89, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
```

```
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 89
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-89

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2999 ACAAGATGATCCGGAACCCC 3018
             ||||||||||||||||||||
Db         20 ACAAGATGATCCGGAACCCC 1


RESULT 551
US-10-800-077-90/c
; Sequence 90, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 90
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-90

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2979 CCAGGTGGTCAGCGCCCTGG 2998
             ||||||||||||||||||||
Db         20 CCAGGTGGTCAGCGCCCTGG 1


RESULT 552
US-10-800-077-91/c
; Sequence 91, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 91
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-91

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2959 AATGCCCGGCCCCGCTTCCC 2978
             ||||||||||||||||||||
Db         20 AATGCCCGGCCCCGCTTCCC 1


RESULT 553
US-10-800-077-92/c
; Sequence 92, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-92

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2939 ACTGTTGGCAGAAAGACCGG 2958
             ||||||||||||||||||||
Db         20 ACTGTTGGCAGAAAGACCGG 1


RESULT 554
US-10-800-077-93/c
; Sequence 93, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 93
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
```

```
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-93

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2919 CCTCCACCAGCTCATGCTGG 2938
             ||||||||||||||||||||
Db         20 CCTCCACCAGCTCATGCTGG 1


RESULT 555
US-10-800-077-94/c
; Sequence 94, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 94
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-94

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2899 CCCCCAGACTGTCCCACCTC 2918
             ||||||||||||||||||||
Db         20 CCCCCAGACTGTCCCACCTC 1


RESULT 556
US-10-800-077-95/c
; Sequence 95, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 95
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-95

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2879 AGGACTACCGGCTGCCCCCG 2898
             ||||||||||||||||||||
Db         20 AGGACTACCGGCTGCCCCCG 1


RESULT 557
US-10-800-077-96/c
; Sequence 96, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 96
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-96

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2859 CGTGATCAATGCCATTGAAC 2878
             ||||||||||||||||||||
Db         20 CGTGATCAATGCCATTGAAC 1


RESULT 558
US-10-800-077-97/c
; Sequence 97, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 97
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-97

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
```

```
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2839 TGGGACATGAGCAATCAGGA 2858
              ||||||||||||||||||||
Db         20 TGGGACATGAGCAATCAGGA 1


RESULT 559
US-10-800-077-98/c
; Sequence 98, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 98
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-98

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2819 CATTTGGGGAGAGGCCGTAC 2838
              ||||||||||||||||||||
Db         20 CATTTGGGGAGAGGCCGTAC 1


RESULT 560
US-10-800-077-99/c
; Sequence 99, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 99
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-99

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2799 TGTGATGTGGGAGGTGATGT 2818
              ||||||||||||||||||||
Db         20 TGTGATGTGGGAGGTGATGT 1


RESULT 561
US-10-800-077-100/c
; Sequence 100, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 100
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-100

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2779 GATGCCTGGAGTTACGGGAT 2798
              ||||||||||||||||||||
Db         20 GATGCCTGGAGTTACGGGAT 1


RESULT 562
US-10-800-077-101/c
; Sequence 101, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 101
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-101

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2759 GGAAGTTCACTTCCGCCAGT 2778
              ||||||||||||||||||||
Db         20 GGAAGTTCACTTCCGCCAGT 1
```

```
RESULT 563
US-10-800-077-102/c
; Sequence 102, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 102
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-102

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2739 CCCGGAGGCCATTGCCTTCC 2758
             ||||||||||||||||||||
Db         20 CCCGGAGGCCATTGCCTTCC 1


RESULT 564
US-10-800-077-103/c
; Sequence 103, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 103
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-103

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2719 ATTCCCATCCGATGGACTGC 2738
             ||||||||||||||||||||
Db         20 ATTCCCATCCGATGGACTGC 1


RESULT 565
US-10-800-077-104/c
; Sequence 104, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 104
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-104

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2699 CGAGCTCCCTGGGAGGAAAG 2718
             ||||||||||||||||||||
Db         20 CGAGCTCCCTGGGAGGAAAG 1


RESULT 566
US-10-800-077-105/c
; Sequence 105, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 105
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-105

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTACA 2698
             ||||||||||||||||||||
Db         20 CTCTTCCGATCCCACCTACA 1


RESULT 567
US-10-800-077-106/c
; Sequence 106, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 106
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-106

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2659 TCCCGATTCCTGGAGGAGAA 2678
             ||||||||||||||||||||
Db         20 TCCCGATTCCTGGAGGAGAA 1


RESULT 568
US-10-800-077-107/c
; Sequence 107, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 107
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-107

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2639 AAGTGTCTGACTTTGGCCTT 2658
             ||||||||||||||||||||
Db         20 AAGTGTCTGACTTTGGCCTT 1


RESULT 569
US-10-800-077-108/c
; Sequence 108, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 108
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-108

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTCTGC 2637
             ||||||||||||||||||||
Db         20 TCAACAGCAACCTCGTCTGC 1


RESULT 570
US-10-800-077-109/c
; Sequence 109, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 109
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-109

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2598 GGCTGCTCGCAACATCCTAG 2617
             ||||||||||||||||||||
Db         20 GGCTGCTCGCAACATCCTAG 1


RESULT 571
US-10-800-077-110/c
; Sequence 110, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
```

```
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 110
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-110

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2578 AGCTACGTCCACCGAGACCT 2597
             ||||||||||||||||||||
Db         20 AGCTACGTCCACCGAGACCT 1


RESULT 572
US-10-800-077-111/c
; Sequence 111, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 111
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-111

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2558 TGCGGTACCTTGCCGAGATG 2577
             ||||||||||||||||||||
Db         20 TGCGGTACCTTGCCGAGATG 1


RESULT 573
US-10-800-077-112/c
; Sequence 112, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 112
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-112

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2538 GCGGGGCATCGCCTCGGGCA 2557
             ||||||||||||||||||||
Db         20 GCGGGGCATCGCCTCGGGCA 1


RESULT 574
US-10-800-077-113/c
; Sequence 113, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 113
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-113

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2518 ATCCAGCTCGTGGGCATGCT 2537
             ||||||||||||||||||||
Db         20 ATCCAGCTCGTGGGCATGCT 1


RESULT 575
US-10-800-077-114/c
; Sequence 114, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
```

```
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 114
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-114

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2498 ACGACGGACAGTTCACAGTC 2517
              ||||||||||||||||||||
Db         20 ACGACGGACAGTTCACAGTC 1


RESULT 576
US-10-800-077-115/c
; Sequence 115, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 115
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-115

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2478 GGACTCCTTCCTGCGGCTAA 2497
              ||||||||||||||||||||
Db         20 GGACTCCTTCCTGCGGCTAA 1


RESULT 577
US-10-800-077-116/c
; Sequence 116, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 116
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-116

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2458 TTCATGGAGAACGGCGCCCT 2477
              ||||||||||||||||||||
Db         20 TTCATGGAGAACGGCGCCCT 1


RESULT 578
US-10-800-077-117/c
; Sequence 117, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 117
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-117

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2438 CCGTCATGATTCTCACAGAG 2457
              ||||||||||||||||||||
Db         20 CCGTCATGATTCTCACAGAG 1


RESULT 579
US-10-800-077-118/c
; Sequence 118, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 118
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
```

; OTHER INFORMATION: Oligonucleotide
US-10-800-077-118

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2418 CGTGGTCACCAACAGCATGC 2437
||||||||||||||||||||
Db 20 CGTGGTCACCAACAGCATGC 1

RESULT 580
US-10-800-077-119/c
; Sequence 119, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 119
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-119

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2398 AATATCATCCGCCTGGAGGG 2417
||||||||||||||||||||
Db 20 AATATCATCCGCCTGGAGGG 1

RESULT 581
US-10-800-077-120/c
; Sequence 120, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 120
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-120

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2378 TGGGCCAGTTCGAGCACCCC 2397
||||||||||||||||||||
Db 20 TGGGCCAGTTCGAGCACCCC 1

RESULT 582
US-10-800-077-121/c
; Sequence 121, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 121
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-121

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2358 TCTGAGCGAGGCCTCCATCA 2377
||||||||||||||||||||
Db 20 TCTGAGCGAGGCCTCCATCA 1

RESULT 583
US-10-800-077-122/c
; Sequence 122, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-122

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2338 GAGCGGCAGCGGCGTGAGTT 2357
              ||||||||||||||||||||
Db         20 GAGCGGCAGCGGCGTGAGTT 1


RESULT 584
US-10-800-077-123/c
; Sequence 123, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 123
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-123

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2318 CCCTGAAGGGTGGCTACACG 2337
              ||||||||||||||||||||
Db         20 CCCTGAAGGGTGGCTACACG 1


RESULT 585
US-10-800-077-124/c
; Sequence 124, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 124
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-124

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2298 GAGCTGTGTGGCAATCAAGA 2317
              ||||||||||||||||||||
Db         20 GAGCTGTGTGGCAATCAAGA 1


RESULT 586
US-10-800-077-125/c
; Sequence 125, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-125

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2278 AAGGCCCCAGGGAAGAAGGA 2297
              ||||||||||||||||||||
Db         20 AAGGCCCCAGGGAAGAAGGA 1


RESULT 587
US-10-800-077-126/c
; Sequence 126, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 126
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-126

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2258 AGGTGTGCCGGGGGCGGCTC 2277
              ||||||||||||||||||||
Db         20 AGGTGTGCCGGGGGCGGCTC 1
```

```
RESULT 588
US-10-800-077-127/c
; Sequence 127, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 127
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-127

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2238 TGGTGCAGGTGAGTTTGGCG 2257
             ||||||||||||||||||||
Db         20 TGGTGCAGGTGAGTTTGGCG 1


RESULT 589
US-10-800-077-128/c
; Sequence 128, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 128
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-128

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2218 GTCAAGATTGAAGAGGTGAT 2237
             ||||||||||||||||||||
Db         20 GTCAAGATTGAAGAGGTGAT 1


RESULT 590
US-10-800-077-129/c
; Sequence 129, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 129
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-129

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2198 AAGAGATCGATGTCTCCTAC 2217
             ||||||||||||||||||||
Db         20 AAGAGATCGATGTCTCCTAC 1


RESULT 591
US-10-800-077-130/c
; Sequence 130, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 130
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-130

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2178 GGCTGTGAGGGAATTTGCAA 2197
             ||||||||||||||||||||
Db         20 GGCTGTGAGGGAATTTGCAA 1


RESULT 592
US-10-800-077-131/c
; Sequence 131, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
```

```
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 131
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-131

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2158 ACTTATGAAGACCCTAATGA 2177
              ||||||||||||||||||||
Db         20 ACTTATGAAGACCCTAATGA 1


RESULT 593
US-10-800-077-132/c
; Sequence 132, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 132
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-132

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2138 AGGTCTACATCGACCCCTTC 2157
              ||||||||||||||||||||
Db         20 AGGTCTACATCGACCCCTTC 1


RESULT 594
US-10-800-077-133/c
; Sequence 133, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 133
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-133

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2118 TCTCATCGGACATGGTACTA 2137
              ||||||||||||||||||||
Db         20 TCTCATCGGACATGGTACTA 1


RESULT 595
US-10-800-077-134/c
; Sequence 134, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 134
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-134

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2098 TCGGACAAACACGGACAGTA 2117
              ||||||||||||||||||||
Db         20 TCGGACAAACACGGACAGTA 1


RESULT 596
US-10-800-077-135/c
; Sequence 135, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
```

; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 135
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-135

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2078 ATGGGAGAGAAGCAGAATAT 2097
||||||||||||||||||||
Db 20 ATGGGAGAGAAGCAGAATAT 1

RESULT 597
US-10-800-077-136/c
; Sequence 136, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-136

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2058 CTGCCTCAGGAAGCAGAGCA 2077
||||||||||||||||||||
Db 20 CTGCCTCAGGAAGCAGAGCA 1

RESULT 598
US-10-800-077-137/c
; Sequence 137, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-137

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2038 GTCATTGTGGTCGCAGTTCT 2057
||||||||||||||||||||
Db 20 GTCATTGTGGTCGCAGTTCT 1

RESULT 599
US-10-800-077-138/c
; Sequence 138, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-138

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2018 GTGTGGTCCTGGTCCTGGTG 2037
||||||||||||||||||||
Db 20 GTGTGGTCCTGGTCCTGGTG 1

RESULT 600
US-10-800-077-139/c
; Sequence 139, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0

```
; SEQ ID NO 139
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-139

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1998 TGCGGGCACGGCAGTCGTGG 2017
              ||||||||||||||||||||
Db         20 TGCGGGCACGGCAGTCGTGG 1


RESULT 601
US-10-800-077-140/c
; Sequence 140, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 140
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-140

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1978 CGGGAGCAGCTGGCCCTGAT 1997
              ||||||||||||||||||||
Db         20 CGGGAGCAGCTGGCCCTGAT 1


RESULT 602
US-10-800-077-141/c
; Sequence 141, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 141
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-141

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 TGGATGAGAGCGAGGGCTGG 1977
              ||||||||||||||||||||
Db         20 TGGATGAGAGCGAGGGCTGG 1


RESULT 603
US-10-800-077-142/c
; Sequence 142, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 142
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-142

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1938 ACATCACAGCCAGACCCAAC 1957
              ||||||||||||||||||||
Db         20 ACATCACAGCCAGACCCAAC 1


RESULT 604
US-10-800-077-143/c
; Sequence 143, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 143
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
```

US-10-800-077-143

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1918 TACGGGCCCTTCGGCCAGGA 1937
||||||||||||||||||||
Db 20 TACGGGCCCTTCGGCCAGGA 1

RESULT 605
US-10-800-077-144/c
; Sequence 144, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 144
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-144

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1898 GGGCGCGCTCTGAGGCCGGC 1917
||||||||||||||||||||
Db 20 GGGCGCGCTCTGAGGCCGGC 1

RESULT 606
US-10-800-077-145/c
; Sequence 145, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-145

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1878 CAGCTACCTGGTGCAGGTAC 1897
||||||||||||||||||||
Db 20 CAGCTACCTGGTGCAGGTAC 1

RESULT 607
US-10-800-077-146/c
; Sequence 146, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 146
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-146

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1858 CGGGGGCTGAAGCGGGGAGC 1877
||||||||||||||||||||
Db 20 CGGGGGCTGAAGCGGGGAGC 1

RESULT 608
US-10-800-077-147/c
; Sequence 147, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-147

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1838 CAGAAAACCGGGCAGAGCTG 1857
             ||||||||||||||||||||
Db         20 CAGAAAACCGGGCAGAGCTG 1
```

RESULT 609
US-10-800-077-148/c
; Sequence 148, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 148
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-148

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1818 CGTGCGGTTCCTGAAGACGT 1837
             ||||||||||||||||||||
Db         20 CGTGCGGTTCCTGAAGACGT 1
```

RESULT 610
US-10-800-077-149/c
; Sequence 149, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 149
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-149

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1798 GGCGCCGAGGGTCCCAGCAG 1817
             ||||||||||||||||||||
Db         20 GGCGCCGAGGGTCCCAGCAG 1
```

RESULT 611
US-10-800-077-150/c
; Sequence 150, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 150
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-150

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1778 AGGTCAAATACCATGAGAAG 1797
             ||||||||||||||||||||
Db         20 AGGTCAAATACCATGAGAAG 1
```

RESULT 612
US-10-800-077-151/c
; Sequence 151, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 151
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-151

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1758 TGGGGCTGTGCTGGACTACG 1777
             ||||||||||||||||||||
Db         20 TGGGGCTGTGCTGGACTACG 1
```

RESULT 613

```
US-10-800-077-152/c
; Sequence 152, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 152
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-152

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 GCTGTTCCCCGGGCACCCAG 1757
             ||||||||||||||||||||
Db         20 GCTGTTCCCCGGGCACCCAG 1


RESULT 614
US-10-800-077-153/c
; Sequence 153, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 153
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-153

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1718 GCAGCTTGAGCCTGGCCTGG 1737
             ||||||||||||||||||||
Db         20 GCAGCTTGAGCCTGGCCTGG 1


RESULT 615
US-10-800-077-154/c
; Sequence 154, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 154
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-154

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1698 GGTGACGCGGTCCTCACCCA 1717
             ||||||||||||||||||||
Db         20 GGTGACGCGGTCCTCACCCA 1


RESULT 616
US-10-800-077-155/c
; Sequence 155, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 155
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-155

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1678 CCTGCAGTGTCTGACATCCG 1697
             ||||||||||||||||||||
Db         20 CCTGCAGTGTCTGACATCCG 1


RESULT 617
US-10-800-077-156/c
; Sequence 156, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
```

```
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 156
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-156

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1658 CCACTGACCGAGAGGTACCT 1677
             ||||||||||||||||||||
Db         20 CCACTGACCGAGAGGTACCT 1


RESULT 618
US-10-800-077-157/c
; Sequence 157, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 157
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-157

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1638 ATTTGAGCCTGTCAATGTCA 1657
             ||||||||||||||||||||
Db         20 ATTTGAGCCTGTCAATGTCA 1


RESULT 619
US-10-800-077-158/c
; Sequence 158, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 158
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-158

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1618 TTAGCCACGGGGCCCGTCCC 1637
             ||||||||||||||||||||
Db         20 TTAGCCACGGGGCCCGTCCC 1


RESULT 620
US-10-800-077-159/c
; Sequence 159, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 159
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-159

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CATTGAACGGGGTATCCTCC 1617
             ||||||||||||||||||||
Db         20 CATTGAACGGGGTATCCTCC 1


RESULT 621
US-10-800-077-160/c
; Sequence 160, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
```

```
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 160
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-160

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1578 CTATACCTTTGAGGTCACTG 1597
             ||||||||||||||||||||
Db         20 CTATACCTTTGAGGTCACTG 1


RESULT 622
US-10-800-077-161/c
; Sequence 161, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 161
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-161

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1558 GGGCTACGTCCTGACTTCAC 1577
             ||||||||||||||||||||
Db         20 GGGCTACGTCCTGACTTCAC 1


RESULT 623
US-10-800-077-162/c
; Sequence 162, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 162
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-162

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1538 AGCCCTGGGTGGTGGTTCGA 1557
             ||||||||||||||||||||
Db         20 AGCCCTGGGTGGTGGTTCGA 1


RESULT 624
US-10-800-077-163/c
; Sequence 163, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 163
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-163

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1518 CGGCCCCCGGGACCTGGTGG 1537
             ||||||||||||||||||||
Db         20 CGGCCCCCGGGACCTGGTGG 1


RESULT 625
US-10-800-077-164/c
; Sequence 164, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 164
```

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-164

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1498 GGAGACCTGACTTTTGACCC 1517
              ||||||||||||||||||||
Db         20 GGAGACCTGACTTTTGACCC 1


RESULT 626
US-10-800-077-165/c
; Sequence 165, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 165
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-165

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1478 GCTCCTGTGCGCCCTGCGGG 1497
              ||||||||||||||||||||
Db         20 GCTCCTGTGCGCCCTGCGGG 1


RESULT 627
US-10-800-077-166/c
; Sequence 166, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 166
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-166

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1458 CCGGGAGTGCCGACCCGGAG 1477
              ||||||||||||||||||||
Db         20 CCGGGAGTGCCGACCCGGAG 1


RESULT 628
US-10-800-077-167/c
; Sequence 167, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 167
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-167

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1438 CTCACCTACGCCCTCCGCTG 1457
              ||||||||||||||||||||
Db         20 CTCACCTACGCCCTCCGCTG 1


RESULT 629
US-10-800-077-168/c
; Sequence 168, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 168
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-168
```

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1418 AGTCTGGTGGCCGAGAGGAC 1437
             ||||||||||||||||||||
Db         20 AGTCTGGTGGCCGAGAGGAC 1


RESULT 630
US-10-800-077-169/c
; Sequence 169, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 169
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-169

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1398 GGAATGGAGTGCCCCCCTGG 1417
             ||||||||||||||||||||
Db         20 GGAATGGAGTGCCCCCCTGG 1


RESULT 631
US-10-800-077-170/c
; Sequence 170, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 170
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-170

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1378 AACGGCTCCTCCCTGCACCT 1397
             ||||||||||||||||||||
Db         20 AACGGCTCCTCCCTGCACCT 1


RESULT 632
US-10-800-077-171/c
; Sequence 171, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 171
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-171

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1358 GGAGCGTGGTTTCCCGCCTG 1377
             ||||||||||||||||||||
Db         20 GGAGCGTGGTTTCCCGCCTG 1


RESULT 633
US-10-800-077-172/c
; Sequence 172, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 172
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-172

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1338 CACCCCTCCTTCGGCTCCGC 1357
```

```
              ||||||||||||||||||||
Db         20 CACCCCTCCTTCGGCTCCGC 1


RESULT 634
US-10-800-077-173/c
; Sequence 173, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 173
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-173

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1318 CCCCGGGGTGCACCCTGCAC 1337
              ||||||||||||||||||||
Db         20 CCCCGGGGTGCACCCTGCAC 1


RESULT 635
US-10-800-077-174/c
; Sequence 174, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 174
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-174

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1298 ACTTCCGGGCACGCACAGAC 1317
              ||||||||||||||||||||
Db         20 ACTTCCGGGCACGCACAGAC 1


RESULT 636
US-10-800-077-175/c
; Sequence 175, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 175
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-175

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1278 CTGCCAGTGCCGCGTCGGGT 1297
              ||||||||||||||||||||
Db         20 CTGCCAGTGCCGCGTCGGGT 1


RESULT 637
US-10-800-077-176/c
; Sequence 176, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 176
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-176

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AACACCATTGGATCAGCCGT 1277
              ||||||||||||||||||||
Db         20 AACACCATTGGATCAGCCGT 1


RESULT 638
US-10-800-077-177/c
```

; Sequence 177, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 177
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-177

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1238 GCCCAGCCAATAGCCACTCT 1257
||||||||||||||||||||
Db 20 GCCCAGCCAATAGCCACTCT 1

RESULT 639
US-10-800-077-178/c
; Sequence 178, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 178
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-178

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1218 AGAAGGGTCCTGCCAGCCAT 1237
||||||||||||||||||||
Db 20 AGAAGGGTCCTGCCAGCCAT 1

RESULT 640
US-10-800-077-179/c
; Sequence 179, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 179
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-179

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1198 ACCTTCAAGCCCCTGTCAGG 1217
||||||||||||||||||||
Db 20 ACCTTCAAGCCCCTGTCAGG 1

RESULT 641
US-10-800-077-180/c
; Sequence 180, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 180
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-180

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1178 GCCGAGCCTGTGCCCAGGGC 1197
||||||||||||||||||||
Db 20 GCCGAGCCTGTGCCCAGGGC 1

RESULT 642
US-10-800-077-181/c
; Sequence 181, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING

```
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 181
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-181

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1158 AGCTGAGGGGAACACCAAGT 1177
              ||||||||||||||||||||
Db         20 AGCTGAGGGGAACACCAAGT 1


RESULT 643
US-10-800-077-182/c
; Sequence 182, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 182
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-182

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1138 TGTGCTCCGGGGTTCGAGGC 1157
              ||||||||||||||||||||
Db         20 TGTGCTCCGGGGTTCGAGGC 1


RESULT 644
US-10-800-077-183/c
; Sequence 183, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 183
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-183

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1118 AGCCGGTCACGGGCTGCAGC 1137
              ||||||||||||||||||||
Db         20 AGCCGGTCACGGGCTGCAGC 1


RESULT 645
US-10-800-077-184/c
; Sequence 184, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 184
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-184

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1098 GGATGGCCAGTGGGCCGAAC 1117
              ||||||||||||||||||||
Db         20 GGATGGCCAGTGGGCCGAAC 1


RESULT 646
US-10-800-077-185/c
; Sequence 185, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
```

```
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 185
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-185

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1078 CCCAGCCTCTACTGCCGTGA 1097
              ||||||||||||||||||||
Db         20 CCCAGCCTCTACTGCCGTGA 1


RESULT 647
US-10-800-077-186/c
; Sequence 186, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 186
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-186

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1058 TCCCCGCCCCTGGCCCCAGC 1077
              ||||||||||||||||||||
Db         20 TCCCCGCCCCTGGCCCCAGC 1


RESULT 648
US-10-800-077-187/c
; Sequence 187, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 187
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-187

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1038 TAGCTGCGTGGTGGATGCCG 1057
              ||||||||||||||||||||
Db         20 TAGCTGCGTGGTGGATGCCG 1


RESULT 649
US-10-800-077-188/c
; Sequence 188, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 188
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-188

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1018 CTGGTTGTGCCCGTGGCCGG 1037
              ||||||||||||||||||||
Db         20 CTGGTTGTGCCCGTGGCCGG 1


RESULT 650
US-10-800-077-189/c
; Sequence 189, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 189
;   LENGTH: 20
```

```
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-189

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        998 CGGAGACTGTGCCTCGGGAG 1017
              ||||||||||||||||||||
Db         20 CGGAGACTGTGCCTCGGGAG 1


RESULT 651
US-10-800-077-190/c
; Sequence 190, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 190
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-190

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        978 TGTGAACCTGACTCGATTCC 997
              ||||||||||||||||||||
Db         20 TGTGAACCTGACTCGATTCC 1


RESULT 652
US-10-800-077-191/c
; Sequence 191, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 191
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-191

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        958 AAAAAGTGCGCCCAGCTGAC 977
              ||||||||||||||||||||
Db         20 AAAAAGTGCGCCCAGCTGAC 1


RESULT 653
US-10-800-077-192/c
; Sequence 192, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 192
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-192

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        938 TATCCCTGCACCTCTTCTAC 957
              ||||||||||||||||||||
Db         20 TATCCCTGCACCTCTTCTAC 1


RESULT 654
US-10-800-077-193/c
; Sequence 193, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 193
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-193
```

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        918 GGGTGCCTGCATGGCCCTGC 937
              ||||||||||||||||||||
Db         20 GGGTGCCTGCATGGCCCTGC 1


RESULT 655
US-10-800-077-194/c
; Sequence 194, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 194
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-194

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        898 TACCTGGCCTTCCAGGACCA 917
              ||||||||||||||||||||
Db         20 TACCTGGCCTTCCAGGACCA 1


RESULT 656
US-10-800-077-195/c
; Sequence 195, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 195
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-195

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        878 CGCTCAGCAAGGCTGGCTTC 897
              ||||||||||||||||||||
Db         20 CGCTCAGCAAGGCTGGCTTC 1


RESULT 657
US-10-800-077-196/c
; Sequence 196, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 196
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-196

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        858 CAAGACGCTGCGTCTGGGAC 877
              ||||||||||||||||||||
Db         20 CAAGACGCTGCGTCTGGGAC 1


RESULT 658
US-10-800-077-197/c
; Sequence 197, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 197
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-197

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        838 GCCACCGGGAAGGTGAATGT 857
              ||||||||||||||||||||
```

```
Db         20 GCCACCGGGAAGGTGAATGT 1


RESULT 659
US-10-800-077-198/c
; Sequence 198, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 198
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-198

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        818 GGAAGCGCCCTGGGGCCGAG 837
              ||||||||||||||||||||
Db         20 GGAAGCGCCCTGGGGCCGAG 1


RESULT 660
US-10-800-077-199/c
; Sequence 199, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 199
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-199

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        798 GGCCGCGGAGCATCTCACCC 817
              ||||||||||||||||||||
Db         20 GGCCGCGGAGCATCTCACCC 1


RESULT 661
US-10-800-077-200/c
; Sequence 200, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 200
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-200

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        778 TACATCAAGGTGGACACGGT 797
              ||||||||||||||||||||
Db         20 TACATCAAGGTGGACACGGT 1


RESULT 662
US-10-800-077-201/c
; Sequence 201, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 201
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-201

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        758 CAGCCTGGATGGAGAACCCC 777
              ||||||||||||||||||||
Db         20 CAGCCTGGATGGAGAACCCC 1


RESULT 663
US-10-800-077-202/c
; Sequence 202, Application US/10800077
```

```
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 202
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-202

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        738 CACGGCCACGGCCCTCACGC 757
              ||||||||||||||||||||
Db         20 CACGGCCACGGCCCTCACGC 1


RESULT 664
US-10-800-077-203/c
; Sequence 203, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 203
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-203

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        718 TACTATGAGAGCGATGCGGA 737
              ||||||||||||||||||||
Db         20 TACTATGAGAGCGATGCGGA 1


RESULT 665
US-10-800-077-204/c
; Sequence 204, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 204
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-204

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        698 AGGAGACCTTCACCGTCTTC 717
              ||||||||||||||||||||
Db         20 AGGAGACCTTCACCGTCTTC 1


RESULT 666
US-10-800-077-205/c
; Sequence 205, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 205
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-205

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        678 TCGGGCTGGGCGCTCCTGCA 697
              ||||||||||||||||||||
Db         20 TCGGGCTGGGCGCTCCTGCA 1


RESULT 667
US-10-800-077-206/c
; Sequence 206, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
```

```
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 206
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-206

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        658 CTCGAGTGCCTGTCCCTGCC 677
              ||||||||||||||||||||
Db         20 CTCGAGTGCCTGTCCCTGCC 1


RESULT 668
US-10-800-077-207/c
; Sequence 207, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 207
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-207

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        638 CCACGCTGCGCTTCACCATG 657
              ||||||||||||||||||||
Db         20 CCACGCTGCGCTTCACCATG 1


RESULT 669
US-10-800-077-208/c
; Sequence 208, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 208
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-208

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        618 GGGCGCCGTCCACGTGTACG 637
              ||||||||||||||||||||
Db         20 GGGCGCCGTCCACGTGTACG 1


RESULT 670
US-10-800-077-209/c
; Sequence 209, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 209
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-209

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        598 ACAGGTTGGGTCCCACGGCG 617
              ||||||||||||||||||||
Db         20 ACAGGTTGGGTCCCACGGCG 1


RESULT 671
US-10-800-077-210/c
; Sequence 210, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
```

```
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 210
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-210

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        578 GCCAGGCCCACTGGCTTCGC 597
              ||||||||||||||||||||
Db         20 GCCAGGCCCACTGGCTTCGC 1


RESULT 672
US-10-800-077-211/c
; Sequence 211, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 211
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-211

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        558 TGACGTGCAGCGTGCCCCGG 577
              ||||||||||||||||||||
Db         20 TGACGTGCAGCGTGCCCCGG 1


RESULT 673
US-10-800-077-212/c
; Sequence 212, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 212
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-212

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        538 GTGCGCACCTACGAAGTGTG 557
              ||||||||||||||||||||
Db         20 GTGCGCACCTACGAAGTGTG 1


RESULT 674
US-10-800-077-213/c
; Sequence 213, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 213
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-213

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        518 TGGATGAGGAACAGCACAGC 537
              ||||||||||||||||||||
Db         20 TGGATGAGGAACAGCACAGC 1


RESULT 675
US-10-800-077-214/c
; Sequence 214, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 214
;   LENGTH: 20
;   TYPE: DNA
```

```
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-214

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        498 GTGGGAGGAACTGAGCGGCC 517
              ||||||||||||||||||||
Db         20 GTGGGAGGAACTGAGCGGCC 1


RESULT 676
US-10-800-077-215/c
; Sequence 215, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 215
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-215

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        478 TTCCCTCAGGTGGACGGGCA 497
              ||||||||||||||||||||
Db         20 TTCCCTCAGGTGGACGGGCA 1


RESULT 677
US-10-800-077-216/c
; Sequence 216, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 216
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-216

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        458 CTGATCTGAAGTGGGTGACA 477
              ||||||||||||||||||||
Db         20 CTGATCTGAAGTGGGTGACA 1


RESULT 678
US-10-800-077-217/c
; Sequence 217, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 217
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-217

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        438 GAACACAAAATTGGAAACTG 457
              ||||||||||||||||||||
Db         20 GAACACAAAATTGGAAACTG 1


RESULT 679
US-10-800-077-218/c
; Sequence 218, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 218
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-218

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
```

Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        418 GCTTTGGAAGAGACCCTGCT 437
              ||||||||||||||||||||
Db         20 GCTTTGGAAGAGACCCTGCT 1
```

RESULT 680
US-10-800-077-219/c
; Sequence 219, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 219
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-219

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        398 GCTGGGCTTCGTTGGCCGCA 417
              ||||||||||||||||||||
Db         20 GCTGGGCTTCGTTGGCCGCA 1
```

RESULT 681
US-10-800-077-220/c
; Sequence 220, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 220
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-220

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        378 GGAGCTCCGGGTGCTGCTCT 397
              ||||||||||||||||||||
Db         20 GGAGCTCCGGGTGCTGCTCT 1
```

RESULT 682
US-10-800-077-221/c
; Sequence 221, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 221
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-221

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        376 ATGGAGCTCCGGGTGCTGCT 395
              ||||||||||||||||||||
Db         20 ATGGAGCTCCGGGTGCTGCT 1
```

RESULT 683
US-10-800-077-231/c
; Sequence 231, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 231
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-231

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1
```

```
RESULT 684
US-10-800-350-38
; Sequence 38, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 38
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-38

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 2.5e+02;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACT 1958
              ||:||||||||||||||||:
Db          1 CAUCACAGCCAGACCCAACU 20


RESULT 685
US-10-800-350-288
; Sequence 288, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 288
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-288

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 2.5e+02;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACT 1958
              ||:||||||||||||||||:
Db          1 CAUCACAGCCAGACCCAACU 20


RESULT 686
US-10-800-077-38
; Sequence 38, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 38
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-38

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 2.5e+02;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACT 1958
              ||:||||||||||||||||:
Db          1 CAUCACAGCCAGACCCAACU 20


RESULT 687
US-10-800-077-288
; Sequence 288, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 288
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-288

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 2.5e+02;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACT 1958
              ||:||||||||||||||||:
Db          1 CAUCACAGCCAGACCCAACU 20
```

```
RESULT 688
US-10-758-155-2633
; Sequence 2633, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2633
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2633

  Query Match             0.5%;  Score 19.8;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 3.1e+02;
  Matches   16;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGGCA 2948
              ||| :||:||:||||:| :||||
Db          1 CAGAUCAUGCUGGACUGCUGGCA 23


RESULT 689
US-10-831-620-2633
; Sequence 2633, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2633
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2633

  Query Match             0.5%;  Score 19.8;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 3.1e+02;
  Matches   16;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGGCA 2948
              ||| :||:||:||||:| :||||
Db          1 CAGAUCAUGCUGGACUGCUGGCA 23


RESULT 690
US-10-844-076-2633
; Sequence 2633, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
```

```
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2633
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2633

  Query Match             0.5%;  Score 19.8;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 3.1e+02;
  Matches   16;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGGCA 2948
              ||| :||:||:||||:| :||||
Db          1 CAGAUCAUGCUGGACUGCUGGCA 23


RESULT 691
US-10-962-898-2237
; Sequence 2237, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2237
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
US-10-962-898-2237

  Query Match             0.5%;  Score 19.8;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 3.1e+02;
  Matches   16;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGGCA 2948
              ||| :||:||:||||:| :||||
Db          1 CAGAUCAUGCUGGACUGCUGGCA 23


RESULT 692
US-10-944-611-2237
; Sequence 2237, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2237
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
US-10-944-611-2237

  Query Match             0.5%;  Score 19.8;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 3.1e+02;
  Matches   16;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGGCA 2948
              ||| :||:||:||||:| :||||
Db          1 CAGAUCAUGCUGGACUGCUGGCA 23


RESULT 693
US-10-800-350-43/c
; Sequence 43, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
```

```
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-43

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.9e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1328 CACCCTGCACCACCCCTCCTT 1348
              |||| ||||||||||||||||
Db         21 CACCGTGCACCACCCCTCCTT 1


RESULT 694
US-10-800-350-223/c
; Sequence 223, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 223
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-223

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.9e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1328 CACCCTGCACCACCCCTCCTT 1348
              |||| ||||||||||||||||
Db         21 CACCGTGCACCACCCCTCCTT 1


RESULT 695
US-10-800-077-43/c
; Sequence 43, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-43

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.9e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1328 CACCCTGCACCACCCCTCCTT 1348
              |||| ||||||||||||||||
Db         21 CACCGTGCACCACCCCTCCTT 1


RESULT 696
US-10-800-077-223/c
; Sequence 223, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 223
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-223

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 2.9e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1328 CACCCTGCACCACCCCTCCTT 1348
              |||| ||||||||||||||||
Db         21 CACCGTGCACCACCCCTCCTT 1


RESULT 697
US-10-635-780-16/c
; Sequence 16, Application US/10635780
; Publication No. US20050032070A1
; GENERAL INFORMATION:
;  APPLICANT: EPIDAUROS Biotechnologie AG
;  TITLE OF INVENTION: Polymorphisms in the human gene for CYP2D6 and their use in
;  TITLE OF INVENTION:  diagnostic and therapeutic applications
;  FILE REFERENCE: VOS-43
;  CURRENT APPLICATION NUMBER: US/10/635,780
;  CURRENT FILING DATE:  2003-08-05
;  NUMBER OF SEQ ID NOS: 23
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
```

```
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-635-780-16

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 22;
  Best Local Similarity   95.2%;  Pred. No. 3.1e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3718 GGCAAGAAGGGGTGTCAGGGC 3738
              ||||||||||  ||||||||||
Db         21 GGCAAGAAGGAGTGTCAGGGC 1


RESULT 698
US-10-309-775A-26
; Sequence 26, Application US/10309775A
; Publication No. US20040006032A1
; GENERAL INFORMATION:
;  APPLICANT: LOPEZ, Ricardo A.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 2901/0M327
;  CURRENT APPLICATION NUMBER: US/10/309,775A
;  CURRENT FILING DATE:  2002-12-04
;  PRIOR APPLICATION NUMBER: CA 2,388,049
;  PRIOR FILING DATE: 2002-05-30
;  NUMBER OF SEQ ID NOS: 74
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer
US-10-309-775A-26

  Query Match             0.5%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 3.9e+02;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGTTTTT 3920
              |||||  |||  |||  ||||||||||
Db          1 TTTTTTTTTTTTCATTTTGTTTTT 24


RESULT 699
US-10-309-775A-73
; Sequence 73, Application US/10309775A
; Publication No. US20040006032A1
; GENERAL INFORMATION:
;  APPLICANT: LOPEZ, Ricardo A.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 2901/0M327
;  CURRENT APPLICATION NUMBER: US/10/309,775A
;  CURRENT FILING DATE:  2002-12-04
;  PRIOR APPLICATION NUMBER: CA 2,388,049
;  PRIOR FILING DATE: 2002-05-30
;  NUMBER OF SEQ ID NOS: 74
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 73
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer
US-10-309-775A-73

  Query Match             0.5%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 3.9e+02;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGTTTTT 3920
              |||||  |||  |||  ||||||||||
Db          1 TTTTTTTTTTTTCATTTTGTTTTT 24


RESULT 700
US-10-440-464-41/c
; Sequence 41, Application US/10440464
; Publication No. US20040018528A1
; GENERAL INFORMATION:
;  APPLICANT: DEPRIMO, SAMUEL
;  APPLICANT:  O'FARRELL, ANNE-MARIE
;  APPLICANT:  MORIMOTO, ALYSSA
;  APPLICANT:  SMOLICH, BEVERLY
;  APPLICANT:  MANNING, WILLIAM
;  APPLICANT:  WALTER, SARAH
;  APPLICANT:  CHERRINGTON, JULIE
;  APPLICANT:  SCHILLING, JIM
;  TITLE OF INVENTION: NOVEL BIOMARKERS OF TYROSINE KINASE INHIBITOR EXPOSURE
;  TITLE OF INVENTION:  AND ACTIVITY IN MAMMALS
;  FILE REFERENCE: 038602/1592
;  CURRENT APPLICATION NUMBER: US/10/440,464
;  CURRENT FILING DATE:  2003-05-19
;  PRIOR APPLICATION NUMBER: 60/380,872
;  PRIOR FILING DATE: 2002-05-17
;  PRIOR APPLICATION NUMBER: 60/448,922
;  PRIOR FILING DATE: 2003-02-24
;  PRIOR APPLICATION NUMBER: 60/448,874
;  PRIOR FILING DATE: 2003-02-24
;  NUMBER OF SEQ ID NOS: 185
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 41
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Primer
US-10-440-464-41

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3990 AACAGGGGCCCATCATCAT 4008
              |||||||||||||||||||
Db         19 AACAGGGGCCCATCATCAT 1


RESULT 701
US-10-800-350-22
; Sequence 22, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
```

US-10-800-350-22

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 3.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:|||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19
```

RESULT 702
US-10-800-350-23
; Sequence 23, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-23

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:|||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19
```

RESULT 703
US-10-800-350-34
; Sequence 34, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 34
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-34

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19
```

RESULT 704
US-10-800-350-36
; Sequence 36, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 36
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-36

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 3.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:|||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19
```

RESULT 705
US-10-800-350-40
; Sequence 40, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0

```
; SEQ ID NO 40
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-40

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 706
US-10-800-350-69
; Sequence 69, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 69
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-69

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 707
US-10-800-350-286
; Sequence 286, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 286
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-286

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 708
US-10-800-350-287
; Sequence 287, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 287
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-287

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 3.1e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:||||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 709
US-10-800-350-289
; Sequence 289, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
```

```
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 289
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-289

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
                |:|::||||:|||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 710
US-10-800-350-290
; Sequence 290, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 290
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-290

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
                |:|::||||:|||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 711
US-10-800-077-22
; Sequence 22, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-22

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 3.1e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
                ||:|||:|:|||||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 712
US-10-800-077-23
; Sequence 23, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-23

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
                |:|::||||:|||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 713
US-10-800-077-34
; Sequence 34, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
```

```
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 34
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-34

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              ||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 714
US-10-800-077-36
; Sequence 36, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 36
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-36

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 3.1e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:||||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 715
US-10-800-077-40
; Sequence 40, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 40
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-40

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 716
US-10-800-077-69
; Sequence 69, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 69
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-69

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              ||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 717
US-10-800-077-286
; Sequence 286, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 286
;   LENGTH: 21
;   TYPE: RNA
```

```
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-286

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              ||||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 718
US-10-800-077-287
; Sequence 287, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 287
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-287

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 3.1e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:|||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 719
US-10-800-077-289
; Sequence 289, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 289
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-289

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 720
US-10-800-077-290
; Sequence 290, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 290
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-290

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 721
US-10-411-954-268
; Sequence 268, Application US/10411954
; Publication No. US20030235848A1
; GENERAL INFORMATION:
;  APPLICANT: Neville, Matt
;  APPLICANT:  de Arruda Indig, Monika
;  TITLE OF INVENTION: Characterization of CYP2D6 Alleles
;  FILE REFERENCE: FORS-07897
;  CURRENT APPLICATION NUMBER: US/10/411,954
;  CURRENT FILING DATE:  2003-04-11
;  PRIOR APPLICATION NUMBER: 60/371,819
;  PRIOR FILING DATE: 2002-04-11
;  NUMBER OF SEQ ID NOS: 356
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-411-954-268

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 22;
  Best Local Similarity   90.9%;  Pred. No. 3.6e+02;
  Matches   20;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       3716 GGGGCAAGAAGGGGTGTCAGGG 3737
             | |||||||||| |||||||||
Db          1 GAGGCAAGAAGGAGTGTCAGGG 22
```

RESULT 722
US-10-411-954-339
; Sequence 339, Application US/10411954
; Publication No. US20030235848A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; TITLE OF INVENTION: Characterization of CYP2D6 Alleles
; FILE REFERENCE: FORS-07897
; CURRENT APPLICATION NUMBER: US/10/411,954
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 356
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 339
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-411-954-339

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3716 GGGGCAAGAAGGGGTGTCAGGG 3737
             | |||||||||| |||||||||
Db          1 GAGGCAAGAAGGAGTGTCAGGG 22
```

RESULT 723
US-10-321-039-737
; Sequence 737, Application US/10321039
; Publication No. US20040014067A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lukowiak, Andrew
; APPLICANT: Jarvis, Nancy
; APPLICANT: Kurensky, David
; TITLE OF INVENTION: Amplification Methods and Compositions
; FILE REFERENCE: FORS-06960
; CURRENT APPLICATION NUMBER: US/10/321,039
; CURRENT FILING DATE: 2002-12-17
; PRIOR APPLICATION NUMBER: 09/998,157
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: 60/329,113
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/360,489
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 759
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 737
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-321-039-737

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3716 GGGGCAAGAAGGGGTGTCAGGG 3737
             | |||||||||| |||||||||
Db          1 GAGGCAAGAAGGAGTGTCAGGG 22
```

RESULT 724
US-10-617-070-268
; Sequence 268, Application US/10617070
; Publication No. US20040096874A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; APPLICANT: Cao, Feng
; APPLICANT: Oldenburg, Mary C.
; APPLICANT: Koelbl, Jim C.
; APPLICANT: Aizenstein, Brian D.
; APPLICANT: Davey, Keith
; TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
; FILE REFERENCE: FORS-08195
; CURRENT APPLICATION NUMBER: US/10/617,070
; CURRENT FILING DATE: 2003-07-10
; PRIOR APPLICATION NUMBER: 10/411,954
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-070-268

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3716 GGGGCAAGAAGGGGTGTCAGGG 3737
             | |||||||||| |||||||||
Db          1 GAGGCAAGAAGGAGTGTCAGGG 22
```

RESULT 725
US-10-617-070-339
; Sequence 339, Application US/10617070
; Publication No. US20040096874A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; APPLICANT: Cao, Feng
; APPLICANT: Oldenburg, Mary C.
; APPLICANT: Koelbl, Jim C.
; APPLICANT: Aizenstein, Brian D.
; APPLICANT: Davey, Keith
; TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
; FILE REFERENCE: FORS-08195
; CURRENT APPLICATION NUMBER: US/10/617,070
; CURRENT FILING DATE: 2003-07-10
; PRIOR APPLICATION NUMBER: 10/411,954
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 339
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-070-339

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3716 GGGGCAAGAAGGGGTGTCAGGG 3737
              | |||||||||| |||||||||
Db          1 GAGGCAAGAAGGAGTGTCAGGG 22
```

RESULT 726
US-10-956-507-268
; Sequence 268, Application US/10956507
; Publication No. US20050196771A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; APPLICANT: Cao, Feng
; APPLICANT: Oldenburg, Mary C.
; APPLICANT: Koelbl, Jim C.
; APPLICANT: Aizenstein, Brian D.
; APPLICANT: Davey, Keith
; TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
; FILE REFERENCE: FORS-08195
; CURRENT APPLICATION NUMBER: US/10/956,507
; CURRENT FILING DATE: 2004-10-01
; PRIOR APPLICATION NUMBER: US/10/617,070
; PRIOR FILING DATE: 2003-07-10
; PRIOR APPLICATION NUMBER: 10/411,954
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-956-507-268

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3716 GGGGCAAGAAGGGGTGTCAGGG 3737
              | |||||||||| |||||||||
Db          1 GAGGCAAGAAGGAGTGTCAGGG 22
```

RESULT 727
US-10-956-507-339
; Sequence 339, Application US/10956507
; Publication No. US20050196771A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; APPLICANT: Cao, Feng
; APPLICANT: Oldenburg, Mary C.
; APPLICANT: Koelbl, Jim C.
; APPLICANT: Aizenstein, Brian D.
; APPLICANT: Davey, Keith
; TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
; FILE REFERENCE: FORS-08195
; CURRENT APPLICATION NUMBER: US/10/956,507
; CURRENT FILING DATE: 2004-10-01
; PRIOR APPLICATION NUMBER: US/10/617,070
; PRIOR FILING DATE: 2003-07-10
; PRIOR APPLICATION NUMBER: 10/411,954
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 339
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-956-507-339

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3716 GGGGCAAGAAGGGGTGTCAGGG 3737
              | |||||||||| |||||||||
Db          1 GAGGCAAGAAGGAGTGTCAGGG 22
```

RESULT 728
US-10-758-155-2627
; Sequence 2627, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2627
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2627

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 3.9e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2926 CAGCTCATGCTGGACTGTTGGC 2947
              ||| :||:||:||||:| :|||
Db          2 CAGAUCAUGCUGGACUGCUGGC 23
```

RESULT 729
US-10-758-155-2639

; Sequence 2639, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2639
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2639

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 3.9e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2927 AGCTCATGCTGGACTGTTGGCA 2948
              || :||:||:||||:| :||||
Db          1 AGAUCAUGCUGGACUGCUGGCA 22
```

RESULT 730
US-10-831-620-2627
; Sequence 2627, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2627
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2627

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 3.9e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2926 CAGCTCATGCTGGACTGTTGGC 2947
              ||| :||:||:||||:| :|||
Db          2 CAGAUCAUGCUGGACUGCUGGC 23
```

RESULT 731
US-10-831-620-2639
; Sequence 2639, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3

```
; SEQ ID NO 2639
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2639

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   68.2%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2927 AGCTCATGCTGGACTGTTGGCA 2948
              || :||:||:||||:| :||||
Db          1 AGAUCAUGCUGGACUGCUGGCA 22


RESULT 732
US-10-844-076-2627
; Sequence 2627, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2627
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2627

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   68.2%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGGC 2947
              ||| :||:||:||||:| :|||
Db          2 CAGAUCAUGCUGGACUGCUGGC 23


RESULT 733
US-10-844-076-2639
; Sequence 2639, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2639
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2639

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   68.2%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2927 AGCTCATGCTGGACTGTTGGCA 2948
              || :||:||:||||:| :||||
Db          1 AGAUCAUGCUGGACUGCUGGCA 22


RESULT 734
US-10-962-898-2232
; Sequence 2232, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
```

```
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2232
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
US-10-962-898-2232

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   68.2%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGGC 2947
              ||| :||:||:||||:| :|||
Db          2 CAGAUCAUGCUGGACUGCUGGC 23


RESULT 735
US-10-962-898-2242
; Sequence 2242, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2242
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
US-10-962-898-2242

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   68.2%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2927 AGCTCATGCTGGACTGTTGGCA 2948
              || :||:||:||||:| :||||
Db          1 AGAUCAUGCUGGACUGCUGGCA 22


RESULT 736
US-10-944-611-2232
; Sequence 2232, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2232
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
US-10-944-611-2232

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   68.2%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGGC 2947
              ||| :||:||:||||:| :|||
Db          2 CAGAUCAUGCUGGACUGCUGGC 23
```

```
RESULT 737
US-10-944-611-2242
; Sequence 2242, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2242
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA sense region
US-10-944-611-2242

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 23;
  Best Local Similarity   68.2%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2927 AGCTCATGCTGGACTGTTGGCA 2948
              || :||:||:||||:| :||||
Db          1 AGAUCAUGCUGGACUGCUGGCA 22


RESULT 738
US-10-800-350-47/c
; Sequence 47, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 47
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-47

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        499 TGGGAGGAACTGAGCGGC 516
              ||||||||||||||||||
Db         18 TGGGAGGAACTGAGCGGC 1


RESULT 739
US-10-800-350-48/c
; Sequence 48, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 48
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-48

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        692 CCTGCAAGGAGACCTTCA 709
              ||||||||||||||||||
Db         18 CCTGCAAGGAGACCTTCA 1


RESULT 740
US-10-800-350-227/c
; Sequence 227, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
```

```
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 227
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-227

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        499 TGGGAGGAACTGAGCGGC 516
              ||||||||||||||||||
Db         18 TGGGAGGAACTGAGCGGC 1


RESULT 741
US-10-800-350-228/c
; Sequence 228, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 228
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-228

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        692 CCTGCAAGGAGACCTTCA 709
              ||||||||||||||||||
Db         18 CCTGCAAGGAGACCTTCA 1


RESULT 742
US-10-800-077-47/c
; Sequence 47, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 47
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-47

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        499 TGGGAGGAACTGAGCGGC 516
              ||||||||||||||||||
Db         18 TGGGAGGAACTGAGCGGC 1


RESULT 743
US-10-800-077-48/c
; Sequence 48, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 48
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-48

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        692 CCTGCAAGGAGACCTTCA 709
              ||||||||||||||||||
Db         18 CCTGCAAGGAGACCTTCA 1


RESULT 744
US-10-800-077-227/c
; Sequence 227, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
```

```
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 227
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-227

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        499 TGGGAGGAACTGAGCGGC 516
              ||||||||||||||||||
Db         18 TGGGAGGAACTGAGCGGC 1


RESULT 745
US-10-800-077-228/c
; Sequence 228, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 228
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-228

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        692 CCTGCAAGGAGACCTTCA 709
              ||||||||||||||||||
Db         18 CCTGCAAGGAGACCTTCA 1


RESULT 746
US-10-712-363-25
; Sequence 25, Application US/10712363
; Publication No. US20040072235A1
; GENERAL INFORMATION:
;  APPLICANT: Dawson, Elliot P.
;  TITLE OF INVENTION: CYTOCHROME P450 GENETIC VARIATIONS
;  FILE REFERENCE: 13744-2
;  CURRENT APPLICATION NUMBER: US/10/712,363
;  CURRENT FILING DATE:  2003-11-12
;  PRIOR APPLICATION NUMBER: US 60/306,675
;  PRIOR FILING DATE: 2001-07-20
;  PRIOR APPLICATION NUMBER: US 10/360,790
;  PRIOR FILING DATE: 2002-07-18
;  PRIOR APPLICATION NUMBER: PCT/US03/21468
;  PRIOR FILING DATE: 2003-07-09
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: synthetic primer
US-10-712-363-25

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 4e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3715 GGGGGCAAGAAGGGGTGTCAG 3735
              || |||||||||| |||||||
Db          1 GGAGGCAAGAAGGAGTGTCAG 21


RESULT 747
US-10-810-976-5/c
; Sequence 5, Application US/10810976
; Publication No. US20040191873A1
; GENERAL INFORMATION:
;  APPLICANT: Young, Won-Bin
;  APPLICANT:  Link, Charles J.
;  TITLE OF INVENTION: METHODS FOR HIGH THROUGHPUT ELUCIDATION OF TRANSCRIPTIONAL
;  TITLE OF INVENTION:  PROFILES AND GENOME ANNOTATION
;  FILE REFERENCE: P05768US01
;  CURRENT APPLICATION NUMBER: US/10/810,976
;  CURRENT FILING DATE:  2004-03-26
;  PRIOR APPLICATION NUMBER: US 60/458,152
;  PRIOR FILING DATE: 2003-03-27
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Nested primer
US-10-810-976-5

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 4e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2410 CTGGAGGGCGTGGTCACCAAC 2430
              ||||||||||||||| | ||||
Db         21 CTGGAGGGCGTGGTGAACAAC 1


RESULT 748
US-10-411-954-236
; Sequence 236, Application US/10411954
; Publication No. US20030235848A1
; GENERAL INFORMATION:
;  APPLICANT: Neville, Matt
;  APPLICANT:  de Arruda Indig, Monika
;  TITLE OF INVENTION: Characterization of CYP2D6 Alleles
;  FILE REFERENCE: FORS-07897
;  CURRENT APPLICATION NUMBER: US/10/411,954
;  CURRENT FILING DATE:  2003-04-11
;  PRIOR APPLICATION NUMBER: 60/371,819
;  PRIOR FILING DATE: 2002-04-11
;  NUMBER OF SEQ ID NOS: 356
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
```

```
US-10-411-954-236

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 3.6e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3719 GCAAGAAGGGGTGTCAGGG 3737
              ||||||||| |||||||||
Db          1 GCAAGAAGGAGTGTCAGGG 19


RESULT 749
US-10-617-070-236
; Sequence 236, Application US/10617070
; Publication No. US20040096874A1
; GENERAL INFORMATION:
;  APPLICANT: Neville, Matt
;  APPLICANT:  de Arruda Indig, Monika
;  APPLICANT:  Cao, Feng
;  APPLICANT:  Oldenburg, Mary C.
;  APPLICANT:  Koelbl, Jim C.
;  APPLICANT:  Aizenstein, Brian D.
;  APPLICANT:  Davey, Keith
;  TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
;  FILE REFERENCE: FORS-08195
;  CURRENT APPLICATION NUMBER: US/10/617,070
;  CURRENT FILING DATE:  2003-07-10
;  PRIOR APPLICATION NUMBER: 10/411,954
;  PRIOR FILING DATE: 2003-04-11
;  PRIOR APPLICATION NUMBER: 60/371,819
;  PRIOR FILING DATE: 2002-04-11
;  NUMBER OF SEQ ID NOS: 529
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-617-070-236

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 3.6e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3719 GCAAGAAGGGGTGTCAGGG 3737
              ||||||||| |||||||||
Db          1 GCAAGAAGGAGTGTCAGGG 19


RESULT 750
US-10-617-070-361
; Sequence 361, Application US/10617070
; Publication No. US20040096874A1
; GENERAL INFORMATION:
;  APPLICANT: Neville, Matt
;  APPLICANT:  de Arruda Indig, Monika
;  APPLICANT:  Cao, Feng
;  APPLICANT:  Oldenburg, Mary C.
;  APPLICANT:  Koelbl, Jim C.
;  APPLICANT:  Aizenstein, Brian D.
;  APPLICANT:  Davey, Keith
;  TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
;  FILE REFERENCE: FORS-08195
;  CURRENT APPLICATION NUMBER: US/10/617,070
;  CURRENT FILING DATE:  2003-07-10
;  PRIOR APPLICATION NUMBER: 10/411,954
;  PRIOR FILING DATE: 2003-04-11
;  PRIOR APPLICATION NUMBER: 60/371,819
;  PRIOR FILING DATE: 2002-04-11
;  NUMBER OF SEQ ID NOS: 529
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 361
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-617-070-361

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 3.6e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3719 GCAAGAAGGGGTGTCAGGG 3737
              ||||||||| |||||||||
Db          1 GCAAGAAGGAGTGTCAGGG 19


RESULT 751
US-10-758-155-2735
; Sequence 2735, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2735
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2735

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGGCA 2948
              :||:||:||||:| :||||
Db          1 UCAUGCUGGACUGCUGGCA 19


RESULT 752
US-10-831-620-2735
```

```
; Sequence 2735, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2735
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2735

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGGCA 2948
              :||:||:||||:| :||||
Db          1 UCAUGCUGGACUGCUGGCA 19


RESULT 753
US-10-844-076-2735
; Sequence 2735, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2735
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2735

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGGCA 2948
              :||:||:||||:| :||||
Db          1 UCAUGCUGGACUGCUGGCA 19


RESULT 754
US-10-956-507-236
; Sequence 236, Application US/10956507
; Publication No. US20050196771A1
; GENERAL INFORMATION:
;  APPLICANT: Neville, Matt
;  APPLICANT:  de Arruda Indig, Monika
;  APPLICANT:  Cao, Feng
;  APPLICANT:  Oldenburg, Mary C.
;  APPLICANT:  Koelbl, Jim C.
;  APPLICANT:  Aizenstein, Brian D.
;  APPLICANT:  Davey, Keith
;  TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
;  FILE REFERENCE: FORS-08195
;  CURRENT APPLICATION NUMBER: US/10/956,507
;  CURRENT FILING DATE:  2004-10-01
;  PRIOR APPLICATION NUMBER: US/10/617,070
;  PRIOR FILING DATE: 2003-07-10
;  PRIOR APPLICATION NUMBER: 10/411,954
;  PRIOR FILING DATE: 2003-04-11
;  PRIOR APPLICATION NUMBER: 60/371,819
;  PRIOR FILING DATE: 2002-04-11
;  NUMBER OF SEQ ID NOS: 529
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-956-507-236

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 3.6e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3719 GCAAGAAGGGGTGTCAGGG 3737
              ||||||||| |||||||||
```

```
Db          1 GCAAGAAGGAGTGTCAGGG 19


RESULT 755
US-10-956-507-361
; Sequence 361, Application US/10956507
; Publication No. US20050196771A1
; GENERAL INFORMATION:
;  APPLICANT: Neville, Matt
;  APPLICANT:  de Arruda Indig, Monika
;  APPLICANT:  Cao, Feng
;  APPLICANT:  Oldenburg, Mary C.
;  APPLICANT:  Koelbl, Jim C.
;  APPLICANT:  Aizenstein, Brian D.
;  APPLICANT:  Davey, Keith
;  TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
;  FILE REFERENCE: FORS-08195
;  CURRENT APPLICATION NUMBER: US/10/956,507
;  CURRENT FILING DATE:  2004-10-01
;  PRIOR APPLICATION NUMBER: US/10/617,070
;  PRIOR FILING DATE: 2003-07-10
;  PRIOR APPLICATION NUMBER: 10/411,954
;  PRIOR FILING DATE: 2003-04-11
;  PRIOR APPLICATION NUMBER: 60/371,819
;  PRIOR FILING DATE: 2002-04-11
;  NUMBER OF SEQ ID NOS: 529
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 361
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-956-507-361

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 3.6e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3719 GCAAGAAGGGGTGTCAGGG 3737
              ||||||||| |||||||||
Db          1 GCAAGAAGGAGTGTCAGGG 19


RESULT 756
US-10-188-359-13
; Sequence 13, Application US/10188359
; Publication No. US20030215819A1
; GENERAL INFORMATION:
;  APPLICANT: DNA Print Genomics, Inc.
;  APPLICANT:  FRUDAKIS, Tony N.
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR INFERRING A RESPONSE TO A STATIN
;  FILE REFERENCE: DNA1150-3
;  CURRENT APPLICATION NUMBER: US/10/188,359
;  CURRENT FILING DATE:  2002-07-01
;  PRIOR APPLICATION NUMBER: US 60/301,867
;  PRIOR FILING DATE: 2001-06-29
;  PRIOR APPLICATION NUMBER: US 60/310,783
;  PRIOR FILING DATE: 2001-08-07
;  PRIOR APPLICATION NUMBER: US 60/322,478
;  PRIOR FILING DATE: 2001-09-13
;  NUMBER OF SEQ ID NOS: 234
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer
US-10-188-359-13

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 4e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3718 GGCAAGAAGGGGTGTCAGG 3736
              |||||||||| ||||||||
Db          2 GGCAAGAAGGAGTGTCAGG 20


RESULT 757
US-10-800-350-60/c
; Sequence 60, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-002
;  CURRENT APPLICATION NUMBER: US/10/800,350
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 60
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-350-60

  Query Match             0.4%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AACTGGATGAGAGCGAG 1971
              |||||||||||||||||
Db         19 AACTGGATGAGAGCGAG 3


RESULT 758
US-10-800-077-60/c
; Sequence 60, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
;  APPLICANT: Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P01-001
;  CURRENT APPLICATION NUMBER: US/10/800,077
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 396
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 60
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-800-077-60

  Query Match             0.4%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4e+02;
```

```
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AACTGGATGAGAGCGAG 1971
              |||||||||||||||||
Db         19 AACTGGATGAGAGCGAG 3


RESULT 759
US-09-888-361-53/c
; Sequence 53, Application US/09888361
; Publication No. US20030064944A1
; GENERAL INFORMATION:
;  APPLICANT: Susan Murray
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: RTS-0158
;  CURRENT APPLICATION NUMBER: US/09/888,361
;  CURRENT FILING DATE:  2001-06-21
;  NUMBER OF SEQ ID NOS: 163
; SEQ ID NO 53
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-888-361-53

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 4.6e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2642 TGTCTGACTTTGGCCTTTCC 2661
              ||| |||||||||| ||||||
Db         20 TGTGTGACTTTGGGCTTTCC 1


RESULT 760
US-10-705-715-53/c
; Sequence 53, Application US/10705715
; Publication No. US20040147472A1
; GENERAL INFORMATION:
;  APPLICANT: Susan Murray
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: RTS-0158
;  CURRENT APPLICATION NUMBER: US/10/705,715
;  CURRENT FILING DATE:  2003-11-10
;  PRIOR APPLICATION NUMBER: US/09/888,361
;  PRIOR FILING DATE: 2001-06-21
;  NUMBER OF SEQ ID NOS: 163
; SEQ ID NO 53
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-705-715-53

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 4.6e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2642 TGTCTGACTTTGGCCTTTCC 2661
              ||| |||||||||| ||||||
Db         20 TGTGTGACTTTGGGCTTTCC 1


RESULT 761
US-10-776-013-6/c
; Sequence 6, Application US/10776013
; Publication No. US20040226056A1
; GENERAL INFORMATION:
;  APPLICANT: MYRIAD GENETICS, INC.
;  APPLICANT:  Roch, Jean-Marc
;  APPLICANT:  Bartel, Paul
;  APPLICANT:  Heichman, Karen
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 1600.24
;  CURRENT APPLICATION NUMBER: US/10/776,013
;  CURRENT FILING DATE:  2004-02-09
;  PRIOR APPLICATION NUMBER: 09/948904
;  PRIOR FILING DATE: 2001-09-10
;  PRIOR APPLICATION NUMBER: 09/466139
;  PRIOR FILING DATE: 1999-12-21
;  PRIOR APPLICATION NUMBER: 60/113534
;  PRIOR FILING DATE: 1998-12-22
;  PRIOR APPLICATION NUMBER: 60/124120
;  PRIOR FILING DATE: 1999-03-12
;  PRIOR APPLICATION NUMBER: 60/141243
;  PRIOR FILING DATE: 1999-06-30
;  PRIOR APPLICATION NUMBER: 09/975072
;  PRIOR FILING DATE: 2001-10-12
;  PRIOR APPLICATION NUMBER: 60/240790
;  PRIOR FILING DATE: 2000-10-17
;  PRIOR APPLICATION NUMBER: 10/194967
;  PRIOR FILING DATE: 2002-07-15
;  PRIOR APPLICATION NUMBER: 60/304775
;  PRIOR FILING DATE: 2001-07-13
;  NUMBER OF SEQ ID NOS: 695
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-776-013-6

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 4.6e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        367 GGCGGCGCCATGGAGCTCCG 386
              |||  ||||||||||||||||
Db         20 GGCCCCGCCATGGAGCTCCG 1


RESULT 762
US-09-735-995-91/c
; Sequence 91, Application US/09735995
; Patent No. US20010034024A1
; GENERAL INFORMATION:
;  APPLICANT: Keating, Mark T.
;  APPLICANT:  Splawski, Igor
;  TITLE OF INVENTION: MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT
;  TITLE OF INVENTION:  SYNDROME GENE
;  FILE REFERENCE: 2323-136
;  CURRENT APPLICATION NUMBER: US/09/735,995
;  CURRENT FILING DATE:  2000-12-14
;  PRIOR APPLICATION NUMBER: 09/226,012
;  PRIOR FILING DATE: 1999-01-06
;  NUMBER OF SEQ ID NOS: 116
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 91
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-735-995-91

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 5e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2018 GTGTGGTCCTGGTCCTGGTG 2037
              || |||||| ||||||||||
```

```
Db         20 GTCTGGTCCAGGTCCTGGTG 1


RESULT 763
US-10-696-708-91/c
; Sequence 91, Application US/10696708
; Publication No. US20040078833A1
; GENERAL INFORMATION:
;  APPLICANT: Keating, Mark T.
;  APPLICANT:  Splawski, Igor
;  TITLE OF INVENTION: MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT
;  TITLE OF INVENTION:  SYNDROME GENE
;  FILE REFERENCE: 2323-164
;  CURRENT APPLICATION NUMBER: US/10/696,708
;  CURRENT FILING DATE:  2003-10-30
;  PRIOR APPLICATION NUMBER: US 09/735,995
;  PRIOR FILING DATE: 2000-12-14
;  PRIOR APPLICATION NUMBER: US 09/226,012
;  PRIOR FILING DATE: 1999-01-06
;  PRIOR APPLICATION NUMBER: 09/122,847
;  PRIOR FILING DATE: 1998-07-27
;  NUMBER OF SEQ ID NOS: 116
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 91
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-696-708-91

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 5e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2018 GTGTGGTCCTGGTCCTGGTG 2037
              || |||||| ||||||||||
Db         20 GTCTGGTCCAGGTCCTGGTG 1


RESULT 764
US-10-847-918-4062
; Sequence 4062, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Be, Xiaobing
;  APPLICANT:  Liu, Wei
;  APPLICANT:  Slonim, Donna
;  APPLICANT:  Howes, Steve
;  TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
;  FILE REFERENCE: 031896-026000 (AM101264)
;  CURRENT APPLICATION NUMBER: US/10/847,918
;  CURRENT FILING DATE:  2004-05-19
;  PRIOR APPLICATION NUMBER: US 60/471,729
;  PRIOR FILING DATE: 2003-05-20
;  NUMBER OF SEQ ID NOS: 14937
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4062
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-847-918-4062

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   65.0%;  Pred. No. 5e+02;
  Matches   13;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3823 CCTCCCCCAGCTGCTGCCTT 3842
              ||:|| |||||:||:|| ::
Db          2 CCUCCUCCAGCUGCUGCUUU 21


RESULT 765
US-10-665-951-2244
; Sequence 2244, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2244
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-665-951-2244

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 766
US-10-665-951-2265
; Sequence 2265, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
```

```
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2265
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-2265

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 767
US-10-758-155-2244
; Sequence 2244, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2244
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-758-155-2244

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 768
US-10-758-155-2265
; Sequence 2265, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2265
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-758-155-2265

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 769
```

```
US-10-758-155-2662
; Sequence 2662, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2662
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2662

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 770
US-10-758-155-2663
; Sequence 2663, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2663
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2663

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 771
US-10-758-155-2665
; Sequence 2665, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
```

```
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2665
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2665

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 772
US-10-758-155-2729
; Sequence 2729, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2729
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2729

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   66.7%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGGC 2947
              :||:||:||||:| :|||
Db          2 UCAUGCUGGACUGCUGGC 19
```

```
RESULT 773
US-10-758-155-2734
; Sequence 2734, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2734
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2734

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 774
US-10-758-155-2737
; Sequence 2737, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
```

```
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2737
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2737

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 775
US-10-831-620-2244
; Sequence 2244, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2244
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-831-620-2244

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 776
US-10-831-620-2265
; Sequence 2265, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2265
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-831-620-2265

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          2 CAUGCUGGACUGCUGGCA 19
```

```
RESULT 777
US-10-831-620-2662
; Sequence 2662, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2662
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2662

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 778
US-10-831-620-2663
; Sequence 2663, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2663
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2663

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 779
US-10-831-620-2665
; Sequence 2665, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
```

```
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2665
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2665

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 780
US-10-831-620-2729
; Sequence 2729, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2729
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2729

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   66.7%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGGC 2947
              :||:||:||||:| :|||
Db          2 UCAUGCUGGACUGCUGGC 19


RESULT 781
US-10-831-620-2734
; Sequence 2734, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2734
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2734

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 782
US-10-831-620-2737
; Sequence 2737, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
```

; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2737
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2737

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTTGGCA 2948
||:||:||||:| :||||
Db 2 CAUGCUGGACUGCUGGCA 19

RESULT 783
US-10-844-076-2244
; Sequence 2244, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2244
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-844-076-2244

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTTGGCA 2948
||:||:||||:| :||||
Db 1 CAUGCUGGACUGCUGGCA 18

RESULT 784
US-10-844-076-2265
; Sequence 2265, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2265
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-844-076-2265

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTTGGCA 2948
||:||:||||:| :||||

```
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 785
US-10-844-076-2662
; Sequence 2662, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2662
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2662

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 786
US-10-844-076-2663
; Sequence 2663, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2663
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2663

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 787
US-10-844-076-2665
; Sequence 2665, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
```

```
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2665
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2665

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 788
US-10-844-076-2729
; Sequence 2729, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2729
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2729

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   66.7%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGGC 2947
              :||:||:||||:| :|||
Db          2 UCAUGCUGGACUGCUGGC 19


RESULT 789
US-10-844-076-2734
; Sequence 2734, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2734
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2734

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 790
US-10-844-076-2737
; Sequence 2737, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
```

```
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2737
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2737

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 791
US-10-962-898-2293
; Sequence 2293, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2293
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-962-898-2293

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 792
US-10-962-898-2421
; Sequence 2421, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2421
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-962-898-2421

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
```

```
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 793
US-10-944-611-2293
; Sequence 2293, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2293
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-944-611-2293

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 794
US-10-944-611-2421
; Sequence 2421, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2421
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-944-611-2421

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 795
US-10-021-707-19/c
; Sequence 19, Application US/10021707
; Publication No. US20030186903A1
; GENERAL INFORMATION:
;  APPLICANT: James Karras
;  APPLICANT:  Kenneth Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MYD88 EXPRESSION
;  FILE REFERENCE: RTS-0330
;  CURRENT APPLICATION NUMBER: US/10/021,707
;  CURRENT FILING DATE:  2001-11-23
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-021-707-19

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 4.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2595 CCTGGCTGCTCGCAACAT 2612
              |||||||||||| ||||||
Db         19 CCTGGCTGCTCTCAACAT 2
```

```
RESULT 796
US-10-126-355-83/c
; Sequence 83, Application US/10126355
; Publication No. US20030198965A1
; GENERAL INFORMATION:
;  APPLICANT: Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF HYDROXYSTEROID
;  TITLE OF INVENTION:  11-BETA DEHYDROGENASE 1 EXPRESSION
;  FILE REFERENCE: RTS-0428
;  CURRENT APPLICATION NUMBER: US/10/126,355
;  CURRENT FILING DATE:  2002-04-19
;  NUMBER OF SEQ ID NOS: 122
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 83
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-126-355-83

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 4.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2067 GAAGCAGAGCAATGGGAG 2084
              ||||||||||||||| ||
Db         19 GAAGCAGAGCAATGGCAG 2


RESULT 797
US-10-289-762-2100/c
; Sequence 2100, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/10/289,762
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2100
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-10-289-762-2100

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 4.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3134 AAATGGGAAGATACGAAG 3151
              ||||||||||||| |||||
Db         19 AAATGGGAAGATCCGAAG 2


RESULT 798
US-10-673-063-19/c
; Sequence 19, Application US/10673063
; Publication No. US20040038926A1
; GENERAL INFORMATION:
;  APPLICANT: James Karras
;  APPLICANT:  Kenneth Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MYD88 EXPRESSION
;  FILE REFERENCE: RTS-0330
;  CURRENT APPLICATION NUMBER: US/10/673,063
;  CURRENT FILING DATE:  2003-09-26
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-673-063-19

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 4.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2595 CCTGGCTGCTCGCAACAT 2612
              |||||||||| ||||||
Db         19 CCTGGCTGCTCTCAACAT 2


RESULT 799
US-10-333-429-417
; Sequence 417, Application US/10333429
; Publication No. US20040048265A1
; GENERAL INFORMATION:
;  APPLICANT: GENSET
;  TITLE OF INVENTION: Obesity Associated Biallelic Marker Maps
;  FILE REFERENCE: G-083US02PCT
;  CURRENT APPLICATION NUMBER: US/10/333,429
;  CURRENT FILING DATE:  2003-01-17
;  PRIOR APPLICATION NUMBER: PCT/IB01/01477
;  PRIOR FILING DATE: 2001-06-28
;  PRIOR APPLICATION NUMBER: US 60/219,704
;  PRIOR FILING DATE: 2000-07-18
;  NUMBER OF SEQ ID NOS: 579
;  SOFTWARE: Patent.pm
; SEQ ID NO 417
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-38897 for SEQ 75, in complement
US-10-333-429-417

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4117 TAGTTGGTGGTGGAAC 4132
              ||||||||||||||||
Db          1 TAGTTGGTGGTGGAAC 16


RESULT 800
US-09-880-732-4
; Sequence 4, Application US/09880732
; Patent No. US20020127561A1
; GENERAL INFORMATION:
;  APPLICANT: GENICON SCIENCES CORPORATION
;  APPLICANT:  BEE, Gary
;  APPLICANT:  KOHNE, David E.
;  APPLICANT:  KORB, Linda
;  APPLICANT:  PETERSON, Todd
;  APPLICANT:  YGUERABIDE, Juan
;  TITLE OF INVENTION: ASSAY FOR GENETIC POLYMORPHISMS USING SCATTERED LIGHT DETECTABLE I
;  FILE REFERENCE: 089498/0403
;  CURRENT APPLICATION NUMBER: US/09/880,732
;  CURRENT FILING DATE:  2001-09-17
;  PRIOR APPLICATION NUMBER: US 60/210,988
;  PRIOR FILING DATE: 2000-06-12
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Primer
US-09-880-732-4

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1947 CCAGACCCAACTGGATGAG 1965
              || |||||| |||||||||
Db          1 CCTGACCCAGCTGGATGAG 19


RESULT 801
US-09-966-147-22
; Sequence 22, Application US/09966147
; Patent No. US20020146416A1
;   GENERAL INFORMATION:
;        APPLICANT: Presta, Leonard G.
;                   Shelton, David L.
;                   Urfer, Roman
;        TITLE OF INVENTION: HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
;        NUMBER OF SEQUENCES: 41
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Knobbe, Martens, Olson & Bear, LLP
;             STREET: 620 Newport Center Drive, 16th Floor
;             CITY: Newport Beach
;             STATE: California
;             COUNTRY: USA
;             ZIP: 92660
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: WinPatin (Genentech)
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/966,147
;             FILING DATE: 27-Sep-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/446172
;             FILING DATE: 19-MAY-1995
;             APPLICATION NUMBER: 08/286846
;             FILING DATE: 05-AUG-1994
;             APPLICATION NUMBER: 08/215139
;             FILING DATE: 18-MAR-1994
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Dreger, Ginger
;             REGISTRATION NUMBER: 33,055
;             REFERENCE/DOCKET NUMBER: GENENT.33CPC4C
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 954-4114
;             TELEFAX: (415) 954-4111
;   INFORMATION FOR SEQ ID NO: 22:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 19 base pairs
;             TYPE: Nucleic Acid
;             STRANDEDNESS: Single
;             TOPOLOGY: Linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-966-147-22

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3539 ACTCCAGACCAAGGGTGAG 3557
              || |||| ||||||||||
Db          1 ACGCCAGGCCAAGGGTGAG 19


RESULT 802
US-09-904-968A-63/c
; Sequence 63, Application US/09904968A
; Publication No. US20030008288A1
; GENERAL INFORMATION:
;  APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
;  APPLICANT:  GERMINO, Gregory
;  APPLICANT:  WATNICK, Terry
;  APPLICANT:  PHAKDEEKITCHAROEN, Bunyong
;  TITLE OF INVENTION: DETECTION AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE
;  FILE REFERENCE: JHU1680-2
;  CURRENT APPLICATION NUMBER: US/09/904,968A
;  CURRENT FILING DATE:  2001-07-13
;  PRIOR APPLICATION NUMBER: US 60/283,691
;  PRIOR FILING DATE: 2001-07-13
;  PRIOR APPLICATION NUMBER: US 60/218,261
;  PRIOR FILING DATE: 2000-07-13
;  NUMBER OF SEQ ID NOS: 113
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 63
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer 13R
US-09-904-968A-63

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1068 TGGCCCCAGCCCCAGCCTC 1086
              | | |||||||||||||||
Db         19 TTGTCCCAGCCCCAGCCTC 1


RESULT 803
US-10-083-246A-83/c
; Sequence 83, Application US/10083246A
; Publication No. US20030152936A1
; GENERAL INFORMATION:
;  APPLICANT: Athena Diagnostics
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR GENETIC ANALYSIS OF POLYCYSTIC KIDNEY
;  TITLE OF INVENTION:  DISEASE
;  FILE REFERENCE: 1133/2002
;  CURRENT APPLICATION NUMBER: US/10/083,246A
;  CURRENT FILING DATE:  2002-10-15
;  NUMBER OF SEQ ID NOS: 168
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 83
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: Synthetic primer
US-10-083-246A-83

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1068 TGGCCCCAGCCCCAGCCTC 1086
              | | |||||||||||||||
Db         19 TTGTCCCAGCCCCAGCCTC 1


RESULT 804
US-10-374-469-22
; Sequence 22, Application US/10374469
; Publication No. US20030157099A1
;   GENERAL INFORMATION:
;        APPLICANT: Presta, Leonard G.
;                   Shelton, David L.
```

```
;                  Urfer, Roman
;       TITLE OF INVENTION: HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
;       NUMBER OF SEQUENCES: 41
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Knobbe, Martens, Olson & Bear, LLP
;            STREET: 620 Newport Center Drive, 16th Floor
;            CITY: Newport Beach
;            STATE: California
;            COUNTRY: USA
;            ZIP: 92660
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: WinPatin (Genentech)
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/374,469
;            FILING DATE: 24-Feb-2003
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/09/966,147
;            FILING DATE: 27-Sep-2000
;            APPLICATION NUMBER: 08/446172
;            FILING DATE: 19-MAY-1995
;            APPLICATION NUMBER: 08/286846
;            FILING DATE: 05-AUG-1994
;            APPLICATION NUMBER: 08/215139
;            FILING DATE: 18-MAR-1994
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Dreger, Ginger
;            REGISTRATION NUMBER: 33,055
;            REFERENCE/DOCKET NUMBER: GENENT.33CPC4C
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 954-4114
;            TELEFAX: (415) 954-4111
;   INFORMATION FOR SEQ ID NO: 22:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 19 base pairs
;            TYPE: Nucleic Acid
;            STRANDEDNESS: Single
;            TOPOLOGY: Linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-374-469-22

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3539 ACTCCAGACCAAGGGTGAG 3557
              || |||| ||||||||||
Db          1 ACGCCAGGCCAAGGGTGAG 19


RESULT 805
US-10-163-598-18
; Sequence 18, Application US/10163598
; Publication No. US20030170651A1
; GENERAL INFORMATION:
;  APPLICANT: Guida, Marco
;  APPLICANT:  Benson, Linda
;  APPLICANT:  Hopkins, Penelope
;  TITLE OF INVENTION: Method of Identifying a Polymorphism in CYP2D6
;  FILE REFERENCE: 4389-26
;  CURRENT APPLICATION NUMBER: US/10/163,598
;  CURRENT FILING DATE:  2003-05-06
;  PRIOR APPLICATION NUMBER: US 60/296,252
;  PRIOR FILING DATE: 2001-06-05
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-163-598-18

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3718 GGCAAGAAGGGGTGTCAGG 3736
              ||||||||||  |||||||
Db          1 GGCAAGAAGGATTGTCAGG 19


RESULT 806
US-10-698-597-22
; Sequence 22, Application US/10698597
; Publication No. US20040058416A1
;  GENERAL INFORMATION:
;       APPLICANT: Presta, Leonard G.
;                  Shelton, David L.
;                  Urfer, Roman
;       TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor
;                           Inhibitors
;       NUMBER OF SEQUENCES: 41
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Knobbe, Martens, Olson & Bear
;            STREET: 620 Newport Center Drive 16th Floor
;            CITY: Newport Beach
;            STATE: California
;            COUNTRY: USA
;            ZIP: 92660
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: WinPatin (Genentech)
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/698,597
;            FILING DATE: 31-Oct-2003
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/09/724,524
;            FILING DATE: 27-No. US20040058416A1-2000
;            APPLICATION NUMBER: 09/156,923
;            FILING DATE: 18-SEP-1998
;            APPLICATION NUMBER: 08/359,705
;            FILING DATE: 20-DEC-1994
;            APPLICATION NUMBER: 08/286846
;            FILING DATE: 10-AUG-1994
;            APPLICATION NUMBER: 08/215139
;            FILING DATE: 18-MAR-1994
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Dreger, Ginger
;            REGISTRATION NUMBER: 33,055
;            REFERENCE/DOCKET NUMBER: GENENT.33CP2C2
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 949/760-0404
;            TELEFAX: 949/760-9502
;   INFORMATION FOR SEQ ID NO: 22:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 19 base pairs
;            TYPE: Nucleic Acid
;            STRANDEDNESS: Single
;            TOPOLOGY: Linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-698-597-22

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3539 ACTCCAGACCAAGGGTGAG 3557
              || |||| ||||||||||
Db          1 ACGCCAGGCCAAGGGTGAG 19
```

```
RESULT 807
US-10-665-951-1677
; Sequence 1677, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1677
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-1677

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              |:|||:||:|| ||||: |
Db          1 CUGGCUGCUCGGAACAUUC 19


RESULT 808
US-10-665-951-1924/c
; Sequence 1924, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1924
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-665-951-1924

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              |||||||||| ||||| |
Db         19 CTGGCTGCTCGGAACATTC 1


RESULT 809
US-10-665-951-2245
; Sequence 2245, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
```

```
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2245
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-2245

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGA 2950
              |:||:||||:| :|||| |
Db          1 AUGCUGGACUGCUGGCACA 19


RESULT 810
US-10-683-990-87
; Sequence 87, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
;  TITLE OF INVENTION:  Gene Expression Using SHort Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/134 (02-742-H)
;  CURRENT APPLICATION NUMBER: US/10/683,990
;  CURRENT FILING DATE:  2003-10-10
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 256
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 87
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-683-990-87

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 5.1e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        519 GGATGAGGAACAGCACAGC 537
              |||:||| ||||||  ||||
Db          1 GGAUGAGAAACAGCUCAGC 19


RESULT 811
US-10-683-990-184/c
; Sequence 184, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
;  TITLE OF INVENTION:  Gene Expression Using SHort Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/134 (02-742-H)
;  CURRENT APPLICATION NUMBER: US/10/683,990
;  CURRENT FILING DATE:  2003-10-10
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 256
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 184
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-683-990-184

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        519 GGATGAGGAACAGCACAGC 537
              ||||||| ||||||  ||||
Db         19 GGATGAGAAACAGCTCAGC 1


RESULT 812
US-10-758-155-1677
; Sequence 1677, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
```

```
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-758-155-1677

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              |:|||:||:|| ||||: |
Db          1 CUGGCUGCUCGGAACAUUC 19


RESULT 813
US-10-758-155-1924/c
; Sequence 1924, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1924
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-758-155-1924

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              |||||||||||| ||||| |
Db         19 CTGGCTGCTCGGAACATTC 1


RESULT 814
US-10-758-155-2245
; Sequence 2245, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2245
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-758-155-2245

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGA 2950
              |:||:||||:| :|||| |
Db          1 AUGCUGGACUGCUGGCACA 19
```

```
RESULT 815
US-10-758-155-2668
; Sequence 2668, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2668
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2668

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGA 2950
              |:||:||||:| :|||| |
Db          1 AUGCUGGACUGCUGGCACA 19


RESULT 816
US-10-758-155-2711
; Sequence 2711, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2711
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2711

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTT 2944
              ||| :||:||:||||:| :
Db          1 CAGAUCAUGCUGGACUGCU 19


RESULT 817
US-10-758-155-2717
; Sequence 2717, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
```

```
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2717
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2717

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2927 AGCTCATGCTGGACTGTTG 2945
              || :||:||:||||:| :|
Db          1 AGAUCAUGCUGGACUGCUG 19


RESULT 818
US-10-758-155-2723
; Sequence 2723, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2723
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2723

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2928 GCTCATGCTGGACTGTTGG 2946
              | :||:||:||||:| :||
Db          1 GAUCAUGCUGGACUGCUGG 19


RESULT 819
US-10-758-155-2738
; Sequence 2738, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2738
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2738

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGGCA 2948
              :||:||:||| :| :||||
Db          1 UCAUGCUGGAUUGCUGGCA 19


RESULT 820
US-10-411-915-83/c
; Sequence 83, Application US/10411915
; Publication No. US20050100898A1
; GENERAL INFORMATION:
;  APPLICANT: Athena Diagnostics
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR GENETIC ANALYSIS OF POLYCYSTIC KIDNEY
;  TITLE OF INVENTION:  DISEASE
;  FILE REFERENCE: 1133/2005
;  CURRENT APPLICATION NUMBER: US/10/411,915
;  CURRENT FILING DATE:  2003-04-11
;  PRIOR APPLICATION NUMBER: US 10/083,246
;  PRIOR FILING DATE: 2002-02-26
;  PRIOR APPLICATION NUMBER: US 60/328,739
;  PRIOR FILING DATE: 2001-10-12
;  NUMBER OF SEQ ID NOS: 172
```

```
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 83
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: Synthetic primer
US-10-411-915-83

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1068 TGGCCCCAGCCCCAGCCTC 1086
              | | ||||||||||||||||
Db         19 TTGTCCCAGCCCCAGCCTC 1


RESULT 821
US-10-831-620-1677
; Sequence 1677, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-831-620-1677

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              |:|||:||:|| ||||: |
Db          1 CUGGCUGCUCGGAACAUUC 19


RESULT 822
US-10-831-620-1924/c
; Sequence 1924, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1924
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-831-620-1924

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              |||||||||| ||||| |
Db         19 CTGGCTGCTCGGAACATTC 1


RESULT 823
US-10-831-620-2245
; Sequence 2245, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
```

```
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2245
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-831-620-2245

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGA 2950
              |:||:||||:| :|||| |
Db          1 AUGCUGGACUGCUGGCACA 19


RESULT 824
US-10-831-620-2668
; Sequence 2668, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2668
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2668

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGA 2950
              |:||:||||:| :|||| |
Db          1 AUGCUGGACUGCUGGCACA 19


RESULT 825
US-10-831-620-2711
; Sequence 2711, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2711
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2711

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTT 2944
              ||| :||:||:||||:| :
```

```
Db          1 CAGAUCAUGCUGGACUGCU 19


RESULT 826
US-10-831-620-2717
; Sequence 2717, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2717
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2717

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2927 AGCTCATGCTGGACTGTTG 2945
              || :||:||:||||:| :|
Db          1 AGAUCAUGCUGGACUGCUG 19


RESULT 827
US-10-831-620-2723
; Sequence 2723, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2723
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2723

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2928 GCTCATGCTGGACTGTTGG 2946
              | :||:||:||||:| :||
Db          1 GAUCAUGCUGGACUGCUGG 19


RESULT 828
US-10-831-620-2738
; Sequence 2738, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
```

```
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2738
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2738

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGGCA 2948
              :||:||:||| :| :||||
Db          1 UCAUGCUGGAUUGCUGGCA 19


RESULT 829
US-10-923-522-544/c
; Sequence 544, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Beigelman, Leonid
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/192  (MBHB03-026-B)
;  CURRENT APPLICATION NUMBER: US/10/923,522
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: PCT/US 03/05234
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/439,922
;  PRIOR FILING DATE: 2003-01-14
;  PRIOR APPLICATION NUMBER: US 60/404,039
;  PRIOR FILING DATE: 2002-08-15
;  PRIOR APPLICATION NUMBER: PCT/US 04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 1779
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 544
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-923-522-544

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        155 CCAGCACGCTCCGGGCCCG 173
              ||||| || ||||||||||
Db         19 CCAGCTCGGTCCGGGCCCG 1


RESULT 830
US-10-923-522-863
; Sequence 863, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Beigelman, Leonid
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/192  (MBHB03-026-B)
;  CURRENT APPLICATION NUMBER: US/10/923,522
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: PCT/US 03/05234
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/439,922
;  PRIOR FILING DATE: 2003-01-14
;  PRIOR APPLICATION NUMBER: US 60/404,039
;  PRIOR FILING DATE: 2002-08-15
;  PRIOR APPLICATION NUMBER: PCT/US 04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 1779
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 863
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-923-522-863

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 5.1e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        155 CCAGCACGCTCCGGGCCCG 173
              ||||| || :||||||||||
Db          1 CCAGCUCGGUCCGGGCCCG 19


RESULT 831
US-10-844-076-1677
; Sequence 1677, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
```

```
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-844-076-1677

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              |:|||:||:|| ||||: |
Db          1 CUGGCUGCUCGGAACAUUC 19


RESULT 832
US-10-844-076-1924/c
; Sequence 1924, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1924
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-844-076-1924

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              |||||||||| ||||| |
Db         19 CTGGCTGCTCGGAACATTC 1


RESULT 833
US-10-844-076-2245
; Sequence 2245, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2245
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-844-076-2245

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGA 2950
              |:||:||||:| :|||| |
```

```
Db          1 AUGCUGGACUGCUGGCACA 19


RESULT 834
US-10-844-076-2668
; Sequence 2668, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2668
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2668

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGA 2950
              |:||:||||:| :|||| |
Db          1 AUGCUGGACUGCUGGCACA 19


RESULT 835
US-10-844-076-2711
; Sequence 2711, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2711
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2711

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTT 2944
              ||| :||:||:||||:| :
Db          1 CAGAUCAUGCUGGACUGCU 19


RESULT 836
US-10-844-076-2717
; Sequence 2717, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
```

```
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2717
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2717

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2927 AGCTCATGCTGGACTGTTG 2945
                || :||:||:||||:| :|
Db          1 AGAUCAUGCUGGACUGCUG 19


RESULT 837
US-10-844-076-2723
; Sequence 2723, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2723
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2723

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2928 GCTCATGCTGGACTGTTGG 2946
                | :||:||:||||:| :||
Db          1 GAUCAUGCUGGACUGCUGG 19


RESULT 838
US-10-844-076-2738
; Sequence 2738, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2738
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2738

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGGCA 2948
                :||:||:||| :| :||||
Db          1 UCAUGCUGGAUUGCUGGCA 19


RESULT 839
US-10-962-898-1677
; Sequence 1677, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
```

```
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-962-898-1677

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
                 |:|||:||:|| ||||: |
Db          1 CUGGCUGCUCGGAACAUUC 19


RESULT 840
US-10-962-898-1924/c
; Sequence 1924, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1924
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-962-898-1924

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
                 |||||||||| ||||| |
Db         19 CTGGCTGCTCGGAACATTC 1


RESULT 841
US-10-962-898-2294
; Sequence 2294, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2294
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-962-898-2294

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGA 2950
                 |:||:||||:| :|||| |
Db          1 AUGCUGGACUGCUGGCACA 19
```

```
RESULT 842
US-10-944-611-1677
; Sequence 1677, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-944-611-1677

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              |:|||:||:|| ||||: |
Db          1 CUGGCUGCUCGGAACAUUC 19


RESULT 843
US-10-944-611-1924/c
; Sequence 1924, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1924
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-944-611-1924

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 5.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              ||||||||||| ||||| |
Db         19 CTGGCTGCTCGGAACATTC 1


RESULT 844
US-10-944-611-2294
; Sequence 2294, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
```

```
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2294
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-944-611-2294

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGA 2950
              |:||:||||:| :|||| |
Db          1 AUGCUGGACUGCUGGCACA 19


RESULT 845
US-09-866-108-1653/c
; Sequence 1653, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1653
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1653

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3966 TATGGCCTCCTTTGCCC 3982
              | |||||||||||||||
Db         17 TCTGGCCTCCTTTGCCC 1


RESULT 846
US-09-866-108-1654/c
; Sequence 1654, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1654
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1654

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
```

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       3965 CTATGGCCTCCTTTGCC 3981
              || |||||||||||||||
Db         17 CTCTGGCCTCCTTTGCC 1
```

RESULT 847
US-09-818-875-3946
; Sequence 3946, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3946
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3946

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2319 CCTGAAGGGTGGCTACA 2335
              |||| |||||||||||||
Db          1 CCTGGAGGGTGGCTACA 17
```

RESULT 848
US-09-818-875-3947/c
; Sequence 3947, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3947
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3947

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2319 CCTGAAGGGTGGCTACA 2335
              |||| |||||||||||||
Db          1 CCTGGAGGGTGGCTACA 17
```

RESULT 849
US-10-209-787-3946
; Sequence 3946, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3946
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3946

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2319 CCTGAAGGGTGGCTACA 2335
              |||| |||||||||||||
Db          1 CCTGGAGGGTGGCTACA 17
```

RESULT 850
US-10-209-787-3947/c
; Sequence 3947, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30

```
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3947
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-3947

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2319 CCTGAAGGGTGGCTACA 2335
              |||| ||||||||||||
Db         17 CCTGGAGGGTGGCTACA 1


RESULT 851
US-10-261-185-3946
; Sequence 3946, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3946
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-3946

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2319 CCTGAAGGGTGGCTACA 2335
              |||| ||||||||||||
Db          1 CCTGGAGGGTGGCTACA 17


RESULT 852
US-10-261-185-3947/c
; Sequence 3947, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3947
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-3947

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2319 CCTGAAGGGTGGCTACA 2335
              |||| ||||||||||||
Db         17 CCTGGAGGGTGGCTACA 1


RESULT 853
US-10-138-674-7739
; Sequence 7739, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7739
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7739

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTG 2942
              ||| :||:||:||||:|
Db          1 CAGAUCAUGCUGGACUG 17


RESULT 854
US-10-138-674-7740
; Sequence 7740, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 7740
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7740

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          1 CAUGCUGGACUGCUGGC 17


RESULT 855
US-10-287-949A-7739
; Sequence 7739, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7739
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7739

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTG 2942
              ||| :||:||:||||:|
Db          1 CAGAUCAUGCUGGACUG 17


RESULT 856
US-10-287-949A-7740
; Sequence 7740, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7740
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7740

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          1 CAUGCUGGACUGCUGGC 17


RESULT 857
US-10-723-361-1653/c
; Sequence 1653, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1653
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1653

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3966 TATGGCCTCCTTTGCCC 3982
              | ||||||||||||||||
Db         17 TCTGGCCTCCTTTGCCC 1


RESULT 858
US-10-723-361-1654/c
; Sequence 1654, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
```

```
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1654
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1654

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3965 CTATGGCCTCCTTTGCC 3981
              || |||||||||||||||
Db         17 CTCTGGCCTCCTTTGCC 1


RESULT 859
US-10-681-074-3946
; Sequence 3946, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3946
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-3946

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2319 CCTGAAGGGTGGCTACA 2335
              |||| |||||||||||||
Db          1 CCTGGAGGGTGGCTACA 17


RESULT 860
US-10-681-074-3947/c
; Sequence 3947, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3947
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-3947

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2319 CCTGAAGGGTGGCTACA 2335
              |||| |||||||||||||
Db         17 CCTGGAGGGTGGCTACA 1


RESULT 861
US-10-712-633-822
; Sequence 822, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Sandberg, Jennifer
;  APPLICANT:  Gordon, Gilad
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO
;  TITLE OF INVENTION:  RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND O
;  FILE REFERENCE: MBHB02-325PCT (400/047)
;  CURRENT APPLICATION NUMBER: US/10/712,633
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  PRIOR APPLICATION NUMBER: US 09/708,690
;  PRIOR FILING DATE: 2000-11-07
;  PRIOR APPLICATION NUMBER: US 09/870,161
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 60/334,461
;  PRIOR FILING DATE: 2001-11-30
;  PRIOR APPLICATION NUMBER: US 10/138,674
;  PRIOR FILING DATE: 2002-05-03
;  NUMBER OF SEQ ID NOS: 5989
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 822
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-10-712-633-822

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
```

```
  Best Local Similarity   70.6%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTG 2942
              ||| :||:||:||||:|
Db          1 CAGAUCAUGCUGGACUG 17


RESULT 862
US-10-712-633-823
; Sequence 823, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Sandberg, Jennifer
;  APPLICANT:  Gordon, Gilad
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
;  TITLE OF INVENTION:  RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
;  FILE REFERENCE: MBHB02-325PCT (400/047)
;  CURRENT APPLICATION NUMBER: US/10/712,633
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  PRIOR APPLICATION NUMBER: US 09/708,690
;  PRIOR FILING DATE: 2000-11-07
;  PRIOR APPLICATION NUMBER: US 09/870,161
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 60/334,461
;  PRIOR FILING DATE: 2001-11-30
;  PRIOR APPLICATION NUMBER: US 10/138,674
;  PRIOR FILING DATE: 2002-05-03
;  NUMBER OF SEQ ID NOS: 5989
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 823
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-10-712-633-823

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          1 CAUGCUGGACUGCUGGC 17


RESULT 863
US-10-712-633-4238
; Sequence 4238, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Sandberg, Jennifer
;  APPLICANT:  Gordon, Gilad
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
;  TITLE OF INVENTION:  RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
;  FILE REFERENCE: MBHB02-325PCT (400/047)
;  CURRENT APPLICATION NUMBER: US/10/712,633
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  PRIOR APPLICATION NUMBER: US 09/708,690
;  PRIOR FILING DATE: 2000-11-07
;  PRIOR APPLICATION NUMBER: US 09/870,161
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 60/334,461
;  PRIOR FILING DATE: 2001-11-30
;  PRIOR APPLICATION NUMBER: US 10/138,674
;  PRIOR FILING DATE: 2002-05-03
;  NUMBER OF SEQ ID NOS: 5989
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4238
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-10-712-633-4238

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          1 CAUGCUGGACUGCUGGC 17


RESULT 864
US-09-969-373-1642/c
; Sequence 1642, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1642
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-1642

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3473 GAGAGACAGGATTTGGG 3489
              |||||||||||| ||||
Db         17 GAGAGACAGGATGTGGG 1


RESULT 865
US-10-770-538-51
; Sequence 51, Application US/10770538
; Publication No. US20040241714A1
; GENERAL INFORMATION:
;  APPLICANT: BRANCH, ROBERT A.
;  APPLICANT:  ROMKES, MARJORIE
;  TITLE OF INVENTION: METHODS OF ASSESSMENT OF DRUG METABOLIZING ENZYMES
;  TITLE OF INVENTION:  FIELD OF THE INVENTION
;  FILE REFERENCE: 12405/4
;  CURRENT APPLICATION NUMBER: US/10/770,538
```

```
;  CURRENT FILING DATE:  2004-02-04
;  PRIOR APPLICATION NUMBER: US 60/444,656
;  PRIOR FILING DATE: 2003-02-04
;  NUMBER OF SEQ ID NOS: 225
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 51
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-10-770-538-51

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3718 GGCAAGAAGGGGTGTCA 3734
              ||||||||||| ||||||
Db          2 GGCAAGAAGGAGTGTCA 18


RESULT 866
US-10-665-951-895/c
; Sequence 895, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 895
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-895

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 5.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||||||||||||| |||
Db         18 AGTTTTGTTTTTGTTCT 2


RESULT 867
US-10-665-951-1219
; Sequence 1219, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1219
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-665-951-1219

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   29.4%;  Pred. No. 5.5e+02;
  Matches    5;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||:::|:::::| :|:
Db          2 AGUUUUGUUUUUGUUCU 18


RESULT 868
US-10-665-951-2264
; Sequence 2264, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
```

```
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2264
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-2264

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19


RESULT 869
US-10-635-780-19/c
; Sequence 19, Application US/10635780
; Publication No. US20050032070A1
; GENERAL INFORMATION:
;  APPLICANT: EPIDAUROS Biotechnologie AG
;  TITLE OF INVENTION: Polymorphisms in the human gene for CYP2D6 and their use in
;  TITLE OF INVENTION:  diagnostic and therapeutic applications
;  FILE REFERENCE: VOS-43
;  CURRENT APPLICATION NUMBER: US/10/635,780
;  CURRENT FILING DATE:  2003-08-05
;  NUMBER OF SEQ ID NOS: 23
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-635-780-19

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 5.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3723 GAAGGGGTGTCAGGGCC 3739
              ||||| ||||||||||
Db         19 GAAGGAGTGTCAGGGCC 3


RESULT 870
US-10-758-155-895/c
; Sequence 895, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-758-155-895

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 5.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              |||||||||||||| |||
Db         18 AGTTTTGTTTTTGTTCT 2


RESULT 871
US-10-758-155-1219
; Sequence 1219, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
```

```
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-758-155-1219

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   29.4%;  Pred. No. 5.5e+02;
  Matches    5;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||::::|:::::| :|:
Db          2 AGUUUUGUUUUUGUUCU 18


RESULT 872
US-10-758-155-2264
; Sequence 2264, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2264
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-758-155-2264

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19


RESULT 873
US-10-758-155-2669
; Sequence 2669, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/141 (MBHB02742-N)
;  CURRENT APPLICATION NUMBER: US/10/758,155
;  CURRENT FILING DATE:  2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2669
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2669

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCA 2948
              |:||:||||:| :||||
Db          1 AUGCUGGACUGCUGGCA 17


RESULT 874
US-10-758-155-2671
```

; Sequence 2671, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2671
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2671

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2932 ATGCTGGACTGTTGGCA 2948
              |:||:||||:| :||||
Db          1 AUGCUGGACUGCUGGCA 17
```

RESULT 875
US-10-758-155-2728
; Sequence 2728, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2728
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2728

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19
```

RESULT 876
US-10-758-155-2731
; Sequence 2731, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3

```
; SEQ ID NO 2731
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-758-155-2731

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
                ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19


RESULT 877
US-10-831-620-895/c
; Sequence 895, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-831-620-895

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 5.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
                ||||||||||||| |||
Db         18 AGTTTTGTTTTTGTTCT 2


RESULT 878
US-10-831-620-1219
; Sequence 1219, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-831-620-1219

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   29.4%;  Pred. No. 5.5e+02;
  Matches    5;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
                ||:::|:::::| :|:
Db          2 AGUUUUGUUUUUGUUCU 18


RESULT 879
US-10-831-620-2264
; Sequence 2264, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
```

```
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2264
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-831-620-2264

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19


RESULT 880
US-10-831-620-2669
; Sequence 2669, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2669
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2669

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCA 2948
              |:||:||||:| :||||
Db          1 AUGCUGGACUGCUGGCA 17


RESULT 881
US-10-831-620-2671
; Sequence 2671, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/152 (MBHB02-742-Q)
;  CURRENT APPLICATION NUMBER: US/10/831,620
;  CURRENT FILING DATE:  2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2751
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2671
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-831-620-2671

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCA 2948
              |:||:||||:| :||||
Db          1 AUGCUGGACUGCUGGCA 17
```

RESULT 882
US-10-831-620-2728
; Sequence 2728, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2728
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2728

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19
```

RESULT 883
US-10-831-620-2731
; Sequence 2731, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2731
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2731

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19
```

RESULT 884
US-10-844-076-895/c
; Sequence 895, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.

```
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-844-076-895

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 5.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||||||||||||| |||
Db         18 AGTTTTGTTTTTGTTCT 2


RESULT 885
US-10-844-076-1219
; Sequence 1219, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-844-076-1219

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   29.4%;  Pred. No. 5.5e+02;
  Matches    5;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||:::|:::::| :|:
Db          2 AGUUUUGUUUUUGUUCU 18


RESULT 886
US-10-844-076-2264
; Sequence 2264, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2264
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-844-076-2264

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19


RESULT 887
US-10-844-076-2669
; Sequence 2669, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
```

```
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2669
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2669

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCA 2948
              |:||:||||:| :||||
Db          1 AUGCUGGACUGCUGGCA 17


RESULT 888
US-10-844-076-2671
; Sequence 2671, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2671
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2671

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCA 2948
              |:||:||||:| :||||
Db          1 AUGCUGGACUGCUGGCA 17


RESULT 889
US-10-844-076-2728
; Sequence 2728, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2728
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2728

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19
```

```
RESULT 890
US-10-844-076-2731
; Sequence 2731, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/159 (MBHB02-742-R)
;  CURRENT APPLICATION NUMBER: US/10/844,076
;  CURRENT FILING DATE:  2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/758,155
;  PRIOR FILING DATE: 2004-01-12
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/712,633
;  PRIOR FILING DATE: 2003-11-13
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-10-23
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,951
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2755
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2731
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  target sequence
US-10-844-076-2731

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19


RESULT 891
US-10-962-898-895/c
; Sequence 895, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-962-898-895

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 5.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              |||||||||||||| |||
Db         18 AGTTTTGTTTTTGTTCT 2


RESULT 892
US-10-962-898-1219
; Sequence 1219, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-962-898-1219

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   29.4%;  Pred. No. 5.5e+02;
  Matches    5;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||:::|:::::| :|:
Db          2 AGUUUUGUUUUUGUUCU 18


RESULT 893
US-10-962-898-2420
; Sequence 2420, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2420
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-962-898-2420

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19


RESULT 894
US-10-962-898-3371/c
; Sequence 3371, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Richards, Ivan
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/236 (MBHB02-742-U)
;  CURRENT APPLICATION NUMBER: US/10/962,898
;  CURRENT FILING DATE:  2004-10-12
;  PRIOR APPLICATION NUMBER: US 10/944,644
;  PRIOR FILING DATE: 2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3371
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (2)..(3)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (6)..(6)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(8)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(11)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(13)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
```

```
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(15)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(16)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-O-methyl
US-10-962-898-3371

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 5.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||||||||||||| ||||
Db         17 CATGCTGGACTGCTGGC 1


RESULT 895
US-10-944-611-895/c
; Sequence 895, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-944-611-895

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 5.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||||||||||||| |||
Db         18 AGTTTTGTTTTTGTTCT 2


RESULT 896
US-10-944-611-1219
; Sequence 1219, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-944-611-1219

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   29.4%;  Pred. No. 5.5e+02;
  Matches    5;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||::::|:::::| :|:
Db          2 AGUUUUGUUUUUGUUCU 18


RESULT 897
US-10-944-611-2420
; Sequence 2420, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
```

```
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2420
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-944-611-2420

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 5.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19


RESULT 898
US-10-944-611-3371/c
; Sequence 3371, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Jadhav, Vasant
;  APPLICANT:  Kossen, Karl
;  APPLICANT:  Zinnen, Shawn
;  APPLICANT:  Vaish, Narendra
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor And Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/235 (MBHB02-742-S)
;  CURRENT APPLICATION NUMBER: US/10/944,611
;  CURRENT FILING DATE:  2004-09-16
;  PRIOR APPLICATION NUMBER: US 10/844,076
;  PRIOR FILING DATE: 2004-05-11
;  PRIOR APPLICATION NUMBER: US 10/831,620
;  PRIOR FILING DATE: 2004-04-23
;  PRIOR APPLICATION NUMBER: US 10/764,957
;  PRIOR FILING DATE: 2004-01-26
;  PRIOR APPLICATION NUMBER: US 10/670,011
;  PRIOR FILING DATE: 2003-09-23
;  PRIOR APPLICATION NUMBER: US 10/665,255
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: US 10/664,767
;  PRIOR FILING DATE: 2003-09-16
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4252
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3371
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (2)..(3)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (4)..(5)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (6)..(6)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(8)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (9)..(11)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (12)..(13)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (14)..(14)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(15)
;   OTHER INFORMATION: 2'-O-methyl
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(16)
;   OTHER INFORMATION: 2'-deoxy-2'-fluoro
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (17)..(18)
;   OTHER INFORMATION: 2'-O-methyl
US-10-944-611-3371

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 5.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       2931 CATGCTGGACTGTTGGC 2947
              ||||||||||| ||||
Db         17 CATGCTGGACTGCTGGC 1


RESULT 899
US-10-440-464-42
; Sequence 42, Application US/10440464
; Publication No. US20040018528A1
; GENERAL INFORMATION:
;  APPLICANT: DEPRIMO, SAMUEL
;  APPLICANT:  O'FARRELL, ANNE-MARIE
;  APPLICANT:  MORIMOTO, ALYSSA
;  APPLICANT:  SMOLICH, BEVERLY
;  APPLICANT:  MANNING, WILLIAM
;  APPLICANT:  WALTER, SARAH
;  APPLICANT:  CHERRINGTON, JULIE
;  APPLICANT:  SCHILLING, JIM
;  TITLE OF INVENTION: NOVEL BIOMARKERS OF TYROSINE KINASE INHIBITOR EXPOSURE
;  TITLE OF INVENTION:  AND ACTIVITY IN MAMMALS
;  FILE REFERENCE: 038602/1592
;  CURRENT APPLICATION NUMBER: US/10/440,464
;  CURRENT FILING DATE:  2003-05-19
;  PRIOR APPLICATION NUMBER: 60/380,872
;  PRIOR FILING DATE: 2002-05-17
;  PRIOR APPLICATION NUMBER: 60/448,922
;  PRIOR FILING DATE: 2003-02-24
;  PRIOR APPLICATION NUMBER: 60/448,874
;  PRIOR FILING DATE: 2003-02-24
;  NUMBER OF SEQ ID NOS: 185
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Probe
US-10-440-464-42

  Query Match             0.4%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3974 CCTTTGCCCAAGTTG 3988
              |||||||||||||||
Db          1 CCTTTGCCCAAGTTG 15


RESULT 900
US-09-866-108-1651/c
; Sequence 1651, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1651
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1651

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCC 3982
              |||||||||||||||
Db          17 TGGCCTCCTTTGCCC 3


RESULT 901
US-09-866-108-1652/c
; Sequence 1652, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1652
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1652

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCC 3982
              |||||||||||||||
Db         16 TGGCCTCCTTTGCCC 2


RESULT 902
US-09-777-732-15/c
; Sequence 15, Application US/09777732
; Patent No. US20020132235A1
; GENERAL INFORMATION:
;  APPLICANT: Avihingsanon, Yingyos
;  APPLICANT:  Ma, Nalli
;  APPLICANT:  Strom, Terry
;  APPLICANT:  Soares, Miguel C.
;  APPLICANT:  Ferran, Chrisiane
;  APPLICANT:  Manikkam, Suthanthiran
;  TITLE OF INVENTION: MEASUREMENT OF PROTECTIVE GENES IN ALLOGRAFT REJECTION
;  FILE REFERENCE: 01948-059001
;  CURRENT APPLICATION NUMBER: US/09/777,732
;  CURRENT FILING DATE:  2001-02-06
;  NUMBER OF SEQ ID NOS: 41
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetically generated primer
US-09-777-732-15

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3961 TTCACTATGGCCTCC 3975
              |||||||||||||||
Db         15 TTCACTATGGCCTCC 1


RESULT 903
US-09-778-013-15/c
; Sequence 15, Application US/09778013
; Publication No. US20030104371A1
; GENERAL INFORMATION:
;  APPLICANT: Strom, Terry B.
;  APPLICANT:  Suthanthiran, Manikkam
;  APPLICANT:  Vasconcellos, Lauro
;  TITLE OF INVENTION: METHOD OF EVALUATING TRANSPLANT REJECTION
;  FILE REFERENCE: 01948-061001
;  CURRENT APPLICATION NUMBER: US/09/778,013
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US 60/199,327
;  PRIOR FILING DATE: 2000-04-24
;  PRIOR APPLICATION NUMBER: US 60/240,735
;  PRIOR FILING DATE: 2000-10-16
;  PRIOR APPLICATION NUMBER: US 60/240,735
;  PRIOR FILING DATE: 2000-10-12
;  PRIOR APPLICATION NUMBER: US 60/238,718
;  PRIOR FILING DATE: 2000-10-06
;  PRIOR APPLICATION NUMBER: US 08/937,063
;  PRIOR FILING DATE: 1997-09-24
;  NUMBER OF SEQ ID NOS: 57
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: sense primer
US-09-778-013-15

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3961 TTCACTATGGCCTCC 3975
              |||||||||||||||
Db         15 TTCACTATGGCCTCC 1


RESULT 904
US-10-138-674-5010
; Sequence 5010, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5010
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-5010

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
              |||||||||||||:
Db          3 CCCCGCCCCCAGACU 17


RESULT 905
US-10-138-674-5011
; Sequence 5011, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
```

```
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5011
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-5011

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
             |||||||||||||:
Db          2 CCCCGCCCCCAGACU 16


RESULT 906
US-10-138-674-5012
; Sequence 5012, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5012
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-5012

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
             |||||||||||||:
Db          1 CCCCGCCCCCAGACU 15


RESULT 907
US-10-287-949A-5010
; Sequence 5010, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5010
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-5010

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
             |||||||||||||:
Db          3 CCCCGCCCCCAGACU 17


RESULT 908
US-10-287-949A-5011
; Sequence 5011, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5011
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-5011

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
             |||||||||||||:
Db          2 CCCCGCCCCCAGACU 16


RESULT 909
US-10-287-949A-5012
; Sequence 5012, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5012
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-5012

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
             |||||||||||||:
```

```
Db          1 CCCCGCCCCCAGACU 15


RESULT 910
US-10-723-361-1651/c
; Sequence 1651, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1651
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1651

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCC 3982
              |||||||||||||||
Db         17 TGGCCTCCTTTGCCC 3


RESULT 911
US-10-723-361-1652/c
; Sequence 1652, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1652
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1652

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCC 3982
              |||||||||||||||
Db         16 TGGCCTCCTTTGCCC 2


RESULT 912
US-10-138-674-1470
; Sequence 1470, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1470
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-1470

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 5.5e+02;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
              |||||||||||||:
Db          4 CCCCGCCCCCAGACU 18


RESULT 913
US-10-287-949A-1470
; Sequence 1470, Application US/10287949A
```

```
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1470
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-1470

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 5.5e+02;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
             ||||||||||||||:
Db          4 CCCCGCCCCCAGACU 18


RESULT 914
US-10-951-303-1470
; Sequence 1470, Application US/10951303
; Publication No. US20050227937A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/10/951,303
;  CURRENT FILING DATE:  2004-09-27
;  PRIOR APPLICATION NUMBER: US/09/685,664
;  PRIOR FILING DATE: 2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1470
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-951-303-1470

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 5.5e+02;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2894 CCCCGCCCCCAGACT 2908
             ||||||||||||||:
Db          4 CCCCGCCCCCAGACU 18


RESULT 915
US-10-719-956-629839/c
; Sequence 629839, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Rat
;  FILE REFERENCE: 3527.1
;  CURRENT APPLICATION NUMBER: US/10/719,956
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,836
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 699466
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 629839
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-10-719-956-629839

  Query Match             0.4%;  Score 15;  DB 1;  Length 25;
  Best Local Similarity   78.3%;  Pred. No. 8.9e+02;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       3636 CTCACCTTGATGGGTGCGTTCCC 3658
              | ||||||||||||  | |||| |
Db         25 CCCACCTTGATGGAGGTGTTCTC 3


RESULT 916
US-09-969-373-3074/c
; Sequence 3074, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3074
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-3074

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2225 TTGAAGAGGTGATTGGTG 2242
              |||| |||||| ||||||
Db         18 TTGAGGAGGTGTTTGGTG 1


RESULT 917
US-10-178-325-172
; Sequence 172, Application US/10178325
; Publication No. US20030199467A1
; GENERAL INFORMATION:
;  APPLICANT: Roberts, M. Luisa
;  APPLICANT:  Cowsert, Lex M.
;  TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
;  TITLE OF INVENTION:  Expression
;  FILE REFERENCE: ISPH-0404
;  CURRENT APPLICATION NUMBER: US/10/178,325
;  CURRENT FILING DATE:  2002-06-21
;  PRIOR APPLICATION NUMBER: US/09/387,341
;  PRIOR FILING DATE: 1999-08-31
;  PRIOR APPLICATION NUMBER: 09/156,424
```

```
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 09/156,979
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 09/156,807
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 09/161,015
;  PRIOR FILING DATE: 1998-09-25
;  NUMBER OF SEQ ID NOS: 233
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 172
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic
US-10-178-325-172

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        658 CTCGAGTGCCTGTCCCTG 675
              | |||||||||| |||||
Db          1 CGCGAGTGCCTGGCCCTG 18


RESULT 918
US-10-409-786-13/c
; Sequence 13, Application US/10409786
; Publication No. US20040023855A1
; GENERAL INFORMATION:
;  APPLICANT: John, Constance
;  APPLICANT:  Unger, Gretchen
;  TITLE OF INVENTION: BIOLOGIC MODULATIONS WITH NANOPARTICLES
;  FILE REFERENCE: 3157.00009
;  CURRENT APPLICATION NUMBER: US/10/409,786
;  CURRENT FILING DATE:  2003-04-08
;  PRIOR APPLICATION NUMBER: 10/378,044
;  PRIOR FILING DATE: 2003-02-28
;  PRIOR APPLICATION NUMBER: 60/394,315
;  PRIOR FILING DATE: 2002-07-08
;  PRIOR APPLICATION NUMBER: 60/370,882
;  PRIOR FILING DATE: 2002-04-08
;  PRIOR APPLICATION NUMBER: 60/428,296
;  PRIOR FILING DATE: 2002-11-22
;  PRIOR APPLICATION NUMBER: 09/877,790
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: WO 02/100343
;  PRIOR FILING DATE: 2002-06-10
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: CK2alpha Antisense
US-10-409-786-13

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1223 GGTCCTGCCAGCCATGCC 1240
              ||||| ||| ||||||||
Db         18 GGTCCCGCCCGCCATGCC 1


RESULT 919
US-10-378-044-8/c
; Sequence 8, Application US/10378044
; Publication No. US20040038303A1
; GENERAL INFORMATION:
;  APPLICANT: Genesegues, Inc.
;  TITLE OF INVENTION: Biological Modulations with Nanoparticles
;  FILE REFERENCE: 3193.03US02
;  CURRENT APPLICATION NUMBER: US/10/378,044
;  CURRENT FILING DATE:  2003-02-28
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: CK2alpha Antisense
US-10-378-044-8

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1223 GGTCCTGCCAGCCATGCC 1240
              ||||| ||| ||||||||
Db         18 GGTCCCGCCCGCCATGCC 1


RESULT 920
US-10-416-111-10
; Sequence 10, Application US/10416111
; Publication No. US20040048278A1
; GENERAL INFORMATION:
;  APPLICANT: OLEK, Alexander
;  APPLICANT:  PIEPENBROCK, Christian
;  APPLICANT:  BERLIN, Kurt
;  TITLE OF INVENTION: Diagnosis of Diseases Associated with the Human C-mos Gene
;  FILE REFERENCE: 5013.1017
;  CURRENT APPLICATION NUMBER: US/10/416,111
;  CURRENT FILING DATE:  2003-05-06
;  PRIOR APPLICATION NUMBER: PCT/EP01/12831
;  PRIOR FILING DATE: 2001-11-06
;  PRIOR APPLICATION NUMBER: DE 10054972.1
;  PRIOR FILING DATE: 2000-11-06
;  NUMBER OF SEQ ID NOS: 20
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: chemically treated genomic DNA (Homo sapiens)
US-10-416-111-10

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3782 GTCACCACCAAACTCAAT 3799
              || |||||||||||| ||
Db          1 GTTACCACCAAACTCCAT 18


RESULT 921
US-10-731-739-517
; Sequence 517, Application US/10731739
; Publication No. US20040176582A1
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-013
;  CURRENT APPLICATION NUMBER: US/10/731,739
;  CURRENT FILING DATE:  2003-12-10
;  PRIOR APPLICATION NUMBER: US/09/544,398B
;  PRIOR FILING DATE: 2002-06-10
```

```
;  PRIOR APPLICATION NUMBER: US 09/229,319
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 517
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-731-739-517

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18


RESULT 922
US-10-660-122-104
; Sequence 104, Application US/10660122
; Publication No. US20040219517A1
; GENERAL INFORMATION:
;  APPLICANT: Ecker, David J.
;  APPLICANT:  Griffey, Richard H.
;  APPLICANT:  Sampath, Rangarajan
;  APPLICANT:  Hofstadler, Steven
;  APPLICANT:  McNeil, John
;  APPLICANT:  Crooke, Stanley T.
;  TITLE OF INVENTION: Methods For Rapid Identification Of Pathogens In Humans And Anima
;  FILE REFERENCE: IBIS0061-100
;  CURRENT APPLICATION NUMBER: US/10/660,122
;  CURRENT FILING DATE:  2003-09-11
;  PRIOR APPLICATION NUMBER: 10/323,233
;  PRIOR FILING DATE: 2002-12-18
;  PRIOR APPLICATION NUMBER: 09/798,007
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/431,319
;  PRIOR FILING DATE: 2002-12-06
;  PRIOR APPLICATION NUMBER: 60/443,443
;  PRIOR FILING DATE: 2003-01-29
;  PRIOR APPLICATION NUMBER: 60/443,788
;  PRIOR FILING DATE: 2003-01-30
;  PRIOR APPLICATION NUMBER: 60/447,529
;  PRIOR FILING DATE: 2003-02-14
;  NUMBER OF SEQ ID NOS: 377
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 104
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-10-660-122-104

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        636 CGCCACGCTGCGCTTCAC 653
              || | |||||||||||||
Db          1 CGACGCGCTGCGCTTCAC 18


RESULT 923
US-10-477-238A-517
; Sequence 517, Application US/10477238A
; Publication No. US20040221326A1
; GENERAL INFORMATION:
;  APPLICANT: Babij, Philip
;  APPLICANT:  Yaworsky, Paul
;  APPLICANT:  Bex, Frederick J. III
;  APPLICANT:  Bodine, Peter Van Nest
;  TITLE OF INVENTION: Transgenic Animal Model of Bone Mass Modulation
;  FILE REFERENCE: 032796-212
;  CURRENT APPLICATION NUMBER: US/10/477,238A
;  CURRENT FILING DATE:  2003-11-10
;  PRIOR APPLICATION NUMBER: US 60/290,071
;  PRIOR FILING DATE: 2001-05-11
;  PRIOR APPLICATION NUMBER: US 60/291,311
;  PRIOR FILING DATE: 2001-05-17
;  PRIOR APPLICATION NUMBER: US 60/353,058
;  PRIOR FILING DATE: 2002-02-01
;  PRIOR APPLICATION NUMBER: US 60/361,293
;  PRIOR FILING DATE: 2002-03-04
;  NUMBER OF SEQ ID NOS: 812
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 517
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-477-238A-517

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18


RESULT 924
US-10-473-126-1246
; Sequence 1246, Application US/10473126
; Publication No. US20040234973A1
; GENERAL INFORMATION:
;  APPLICANT: Epigenomics AG
;  TITLE OF INVENTION: Methods and nucleic acids for the analysis of  hematopoietic cell
;  TITLE OF INVENTION:  proliferative disorders
;  FILE REFERENCE:
;  CURRENT APPLICATION NUMBER: US/10/473,126
;  CURRENT FILING DATE:  2003-09-26
;  NUMBER OF SEQ ID NOS: 1258
; SEQ ID NO 1246
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Detection oligonucleotide for Humos
US-10-473-126-1246

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3782 GTCACCACCAAACTCAAT 3799
              || |||||||||||| ||
Db          1 GTTACCACCAAACTCCAT 18


RESULT 925
US-10-680-287A-517
; Sequence 517, Application US/10680287A
; Publication No. US20040244069A1
; GENERAL INFORMATION:
;  APPLICANT: Babij, Philip
;  APPLICANT:  Yaworsky, Paul
;  APPLICANT:  Bex, Frederick J. III
;  APPLICANT:  Bodine, Peter Van Nest
;  TITLE OF INVENTION: Transgenic Animal Model of Bone Mass Modulation
```

```
;  FILE REFERENCE: 032796-179
;  CURRENT APPLICATION NUMBER: US/10/680,287A
;  CURRENT FILING DATE:  2003-10-08
;  PRIOR APPLICATION NUMBER: PCT/US02/14876
;  PRIOR FILING DATE: 2002-05-13
;  PRIOR APPLICATION NUMBER: US 60/290,071
;  PRIOR FILING DATE: 2001-05-11
;  PRIOR APPLICATION NUMBER: US 60/291,311
;  PRIOR FILING DATE: 2001-05-17
;  PRIOR APPLICATION NUMBER: US 60/353,058
;  PRIOR FILING DATE: 2002-02-01
;  PRIOR APPLICATION NUMBER: US 60/361,293
;  PRIOR FILING DATE: 2002-03-04
;  NUMBER OF SEQ ID NOS: 812
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 517
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-680-287A-517

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18


RESULT 926
US-10-477-173-517
; Sequence 517, Application US/10477173
; Publication No. US20050070699A1
; GENERAL INFORMATION:
;  APPLICANT: Genome Therapeutics Corporation and
;  APPLICANT:  Allen, Kristina M.
;  APPLICANT:  Yaworsky, Paul
;  APPLICANT:  Morales, Arturo J.
;  APPLICANT:  Graham, James R.
;  APPLICANT:  Anisowicz, Anthony
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: HBM Variants that Modulate Bone Mass and Lipid Levels
;  FILE REFERENCE: 032796-135
;  CURRENT APPLICATION NUMBER: US/10/477,173
;  CURRENT FILING DATE:  2003-11-10
;  PRIOR APPLICATION NUMBER: US 60/290,071
;  PRIOR FILING DATE: 2001-05-11
;  PRIOR APPLICATION NUMBER: US 60/291,311
;  PRIOR FILING DATE: 2001-05-17
;  PRIOR APPLICATION NUMBER: US 60/353,058
;  PRIOR FILING DATE: 2002-02-01
;  PRIOR APPLICATION NUMBER: US 60/361,293
;  PRIOR FILING DATE: 2002-03-04
;  NUMBER OF SEQ ID NOS: 1086
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 517
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-477-173-517

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18


RESULT 927
US-10-182-049-49/c
; Sequence 49, Application US/10182049
; Publication No. US20050113322A1
; GENERAL INFORMATION:
;  APPLICANT: Isis Pharmaceuticals, Inc.
;  APPLICANT:  C. Frank Bennett
;  APPLICANT:  Nicholas M. Dean
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION
;  FILE REFERENCE: RTSP-0360
;  CURRENT APPLICATION NUMBER: US/10/182,049
;  CURRENT FILING DATE:  2002-07-27
;  PRIOR APPLICATION NUMBER: 09/490,208
;  PRIOR FILING DATE: 2000-01-24
;  NUMBER OF SEQ ID NOS: 182
; SEQ ID NO 49
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-182-049-49

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        511 AGCGGCCTGGATGAGGAA 528
              ||| ||||||| ||||||
Db         18 AGCTGCCTGGAGGAGGAA 1


RESULT 928
US-10-834-377-517
; Sequence 517, Application US/10834377
; Publication No. US20050142617A1
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-014
;  CURRENT APPLICATION NUMBER: US/10/834,377
;  CURRENT FILING DATE:  2004-04-29
;  PRIOR APPLICATION NUMBER: US/09/543,771B
;  PRIOR FILING DATE: 2000-04-05
;  PRIOR APPLICATION NUMBER: US 09/229,319
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 517
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-834-377-517

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18


Search completed: March 23, 2006, 11:15:52
Job time : 56 secs
```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 23, 2006, 11:19:39 ; Search time 84 Seconds
(without alignments)
3.337 Million cell updates/sec

Title: US-10-800-077-392
Perfect score: 4235
Sequence: 1 ctcggcccggcggcgcgagc.....cgtgtcccagctccaggggt 4235

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1699 seqs, 33094 residues

Total number of hits satisfying chosen parameters: 3398

Minimum DB seq length: 5
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1700 summaries

Database : fetch392rnpbn.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	29	0.7	36	1	US-10-949-720-2	Sequence 2, Appli
c	2	27	0.6	27	1	US-10-310-914A-153230	Sequence 153230,
c	3	27	0.6	27	1	US-10-310-914A-153273	Sequence 153273,
c	4	27	0.6	27	1	US-10-310-914A-153276	Sequence 153276,
c	5	26	0.6	26	1	US-10-310-914A-153271	Sequence 153271,
c	6	26	0.6	26	1	US-10-310-914A-153279	Sequence 153279,
c	7	25	0.6	25	1	US-10-310-914A-153226	Sequence 153226,
c	8	25	0.6	25	1	US-10-310-914A-153237	Sequence 153237,
c	9	25	0.6	25	1	US-10-310-914A-153292	Sequence 153292,
	10	25	0.6	25	1	US-11-121-849-151566	Sequence 151566,
	11	25	0.6	25	1	US-11-121-849-151567	Sequence 151567,
	12	25	0.6	25	1	US-11-121-849-151568	Sequence 151568,
	13	25	0.6	25	1	US-11-121-849-151569	Sequence 151569,
	14	25	0.6	25	1	US-11-121-849-151570	Sequence 151570,
	15	25	0.6	25	1	US-11-121-849-151571	Sequence 151571,
	16	25	0.6	25	1	US-11-121-849-151572	Sequence 151572,
	17	25	0.6	25	1	US-11-121-849-151573	Sequence 151573,
	18	25	0.6	25	1	US-11-121-849-151575	Sequence 151575,
	19	25	0.6	25	1	US-11-121-849-151576	Sequence 151576,
	20	25	0.6	25	1	US-11-121-849-302682	Sequence 302682,
	21	25	0.6	25	1	US-11-121-849-302683	Sequence 302683,
	22	25	0.6	25	1	US-11-121-849-302684	Sequence 302684,
	23	25	0.6	25	1	US-11-121-849-302685	Sequence 302685,
	24	25	0.6	25	1	US-11-121-849-302686	Sequence 302686,
	25	25	0.6	25	1	US-11-121-849-302687	Sequence 302687,
	26	25	0.6	25	1	US-11-121-849-302688	Sequence 302688,
	27	25	0.6	25	1	US-11-121-849-302689	Sequence 302689,
	28	25	0.6	25	1	US-11-121-849-302690	Sequence 302690,
	29	25	0.6	25	1	US-11-121-849-302691	Sequence 302691,
	30	25	0.6	25	1	US-11-121-849-302692	Sequence 302692,
c	31	25	0.6	27	1	US-10-310-914A-153255	Sequence 153255,
	32	24.2	0.6	29	1	US-10-949-720-1	Sequence 1, Appli
	33	24.2	0.6	29	1	US-10-949-720-397	Sequence 397, App
c	34	24	0.6	24	1	US-10-310-914A-153219	Sequence 153219,
c	35	24	0.6	24	1	US-10-310-914A-153221	Sequence 153221,
c	36	24	0.6	24	1	US-10-310-914A-153229	Sequence 153229,
c	37	24	0.6	24	1	US-10-310-914A-153235	Sequence 153235,
c	38	24	0.6	24	1	US-10-310-914A-153238	Sequence 153238,
c	39	24	0.6	24	1	US-10-310-914A-153248	Sequence 153248,
c	40	24	0.6	24	1	US-10-310-914A-153254	Sequence 153254,
c	41	24	0.6	24	1	US-10-310-914A-153270	Sequence 153270,
c	42	24	0.6	24	1	US-10-310-914A-153280	Sequence 153280,
c	43	24	0.6	24	1	US-10-310-914A-153287	Sequence 153287,
	44	23.4	0.6	25	1	US-11-121-849-151574	Sequence 151574,
c	45	23	0.5	23	1	US-10-310-914A-153217	Sequence 153217,
c	46	23	0.5	23	1	US-10-310-914A-153223	Sequence 153223,
c	47	23	0.5	23	1	US-10-310-914A-153239	Sequence 153239,
c	48	23	0.5	23	1	US-10-310-914A-153242	Sequence 153242,
c	49	23	0.5	23	1	US-10-310-914A-153256	Sequence 153256,
c	50	23	0.5	23	1	US-10-310-914A-153259	Sequence 153259,
c	51	23	0.5	23	1	US-10-310-914A-153260	Sequence 153260,
c	52	23	0.5	23	1	US-10-310-914A-153261	Sequence 153261,
c	53	23	0.5	23	1	US-10-310-914A-153265	Sequence 153265,
c	54	23	0.5	23	1	US-10-310-914A-153266	Sequence 153266,
c	55	23	0.5	23	1	US-10-310-914A-153274	Sequence 153274,
c	56	23	0.5	23	1	US-10-310-914A-153285	Sequence 153285,
c	57	22.8	0.5	26	1	US-10-310-914A-759276	Sequence 759276,
c	58	22	0.5	22	1	US-10-310-914A-153228	Sequence 153228,
c	59	22	0.5	22	1	US-10-310-914A-153236	Sequence 153236,
c	60	22	0.5	22	1	US-10-310-914A-153246	Sequence 153246,
c	61	22	0.5	22	1	US-10-310-914A-153267	Sequence 153267,
c	62	22	0.5	22	1	US-10-310-914A-153269	Sequence 153269,
c	63	22	0.5	22	1	US-10-310-914A-153277	Sequence 153277,
c	64	22	0.5	22	1	US-10-310-914A-153281	Sequence 153281,
c	65	22	0.5	22	1	US-10-310-914A-153283	Sequence 153283,
c	66	22	0.5	22	1	US-10-310-914A-153286	Sequence 153286,
	67	21.8	0.5	25	1	US-10-310-914A-556532	Sequence 556532,
	68	21.8	0.5	25	1	US-11-136-527-49340	Sequence 49340, A
	69	21.8	0.5	25	1	US-11-136-527-243931	Sequence 243931,
	70	21.8	0.5	25	1	US-11-136-527-243935	Sequence 243935,
	71	21.8	0.5	25	1	US-11-136-527-243939	Sequence 243939,
	72	21.8	0.5	26	1	US-10-310-914A-556499	Sequence 556499,
c	73	21.4	0.5	23	1	US-10-310-914A-207826	Sequence 207826,
c	74	21.4	0.5	25	1	US-10-310-914A-916482	Sequence 916482,
c	75	21	0.5	21	1	US-10-949-720-20	Sequence 20, Appl
c	76	21	0.5	21	1	US-10-949-720-35	Sequence 35, Appl
c	77	21	0.5	21	1	US-10-949-720-37	Sequence 37, Appl
c	78	21	0.5	21	1	US-10-949-720-39	Sequence 39, Appl
c	79	21	0.5	21	1	US-10-949-720-41	Sequence 41, Appl
c	80	21	0.5	21	1	US-10-949-720-42	Sequence 42, Appl
c	81	21	0.5	21	1	US-10-949-720-44	Sequence 44, Appl
c	82	21	0.5	21	1	US-10-949-720-45	Sequence 45, Appl
c	83	21	0.5	21	1	US-10-949-720-46	Sequence 46, Appl
c	84	21	0.5	21	1	US-10-949-720-49	Sequence 49, Appl
c	85	21	0.5	21	1	US-10-949-720-50	Sequence 50, Appl
c	86	21	0.5	21	1	US-10-949-720-52	Sequence 52, Appl
c	87	21	0.5	21	1	US-10-949-720-70	Sequence 70, Appl
c	88	21	0.5	21	1	US-10-949-720-73	Sequence 73, Appl
c	89	21	0.5	21	1	US-10-949-720-222	Sequence 222, App
c	90	21	0.5	21	1	US-10-949-720-224	Sequence 224, App
c	91	21	0.5	21	1	US-10-949-720-225	Sequence 225, App
c	92	21	0.5	21	1	US-10-949-720-226	Sequence 226, App
c	93	21	0.5	21	1	US-10-949-720-229	Sequence 229, App
c	94	21	0.5	21	1	US-10-949-720-230	Sequence 230, App
c	95	21	0.5	21	1	US-10-949-720-232	Sequence 232, App
	96	21	0.5	21	1	US-10-949-720-233	Sequence 233, App
	97	21	0.5	21	1	US-10-949-720-234	Sequence 234, App
	98	21	0.5	21	1	US-10-949-720-235	Sequence 235, App
	99	21	0.5	21	1	US-10-949-720-236	Sequence 236, App
	100	21	0.5	21	1	US-10-949-720-237	Sequence 237, App
	101	21	0.5	21	1	US-10-949-720-238	Sequence 238, App
	102	21	0.5	21	1	US-10-949-720-239	Sequence 239, App
	103	21	0.5	21	1	US-10-949-720-240	Sequence 240, App
	104	21	0.5	21	1	US-10-949-720-241	Sequence 241, App
	105	21	0.5	21	1	US-10-949-720-242	Sequence 242, App
	106	21	0.5	21	1	US-10-949-720-243	Sequence 243, App

	107	21	0.5	21	1	US-10-949-720-244	Sequence 244, App
	108	21	0.5	21	1	US-10-949-720-245	Sequence 245, App
	109	21	0.5	21	1	US-10-949-720-246	Sequence 246, App
	110	21	0.5	21	1	US-10-949-720-247	Sequence 247, App
	111	21	0.5	21	1	US-10-949-720-248	Sequence 248, App
	112	21	0.5	21	1	US-10-949-720-249	Sequence 249, App
	113	21	0.5	21	1	US-10-949-720-250	Sequence 250, App
	114	21	0.5	21	1	US-10-949-720-251	Sequence 251, App
	115	21	0.5	21	1	US-10-949-720-252	Sequence 252, App
	116	21	0.5	21	1	US-10-949-720-253	Sequence 253, App
	117	21	0.5	21	1	US-10-949-720-254	Sequence 254, App
	118	21	0.5	21	1	US-10-949-720-255	Sequence 255, App
	119	21	0.5	21	1	US-10-949-720-256	Sequence 256, App
	120	21	0.5	21	1	US-10-949-720-257	Sequence 257, App
	121	21	0.5	21	1	US-10-949-720-258	Sequence 258, App
	122	21	0.5	21	1	US-10-949-720-259	Sequence 259, App
	123	21	0.5	21	1	US-10-949-720-260	Sequence 260, App
	124	21	0.5	21	1	US-10-949-720-261	Sequence 261, App
	125	21	0.5	21	1	US-10-949-720-262	Sequence 262, App
	126	21	0.5	21	1	US-10-949-720-263	Sequence 263, App
	127	21	0.5	21	1	US-10-949-720-264	Sequence 264, App
	128	21	0.5	21	1	US-10-949-720-265	Sequence 265, App
	129	21	0.5	21	1	US-10-949-720-266	Sequence 266, App
	130	21	0.5	21	1	US-10-949-720-267	Sequence 267, App
	131	21	0.5	21	1	US-10-949-720-268	Sequence 268, App
	132	21	0.5	21	1	US-10-949-720-269	Sequence 269, App
	133	21	0.5	21	1	US-10-949-720-270	Sequence 270, App
	134	21	0.5	21	1	US-10-949-720-271	Sequence 271, App
	135	21	0.5	21	1	US-10-949-720-272	Sequence 272, App
	136	21	0.5	21	1	US-10-949-720-273	Sequence 273, App
	137	21	0.5	21	1	US-10-949-720-274	Sequence 274, App
	138	21	0.5	21	1	US-10-949-720-275	Sequence 275, App
	139	21	0.5	21	1	US-10-949-720-276	Sequence 276, App
	140	21	0.5	21	1	US-10-949-720-277	Sequence 277, App
	141	21	0.5	21	1	US-10-949-720-278	Sequence 278, App
	142	21	0.5	21	1	US-10-949-720-279	Sequence 279, App
	143	21	0.5	21	1	US-10-949-720-280	Sequence 280, App
	144	21	0.5	21	1	US-10-949-720-281	Sequence 281, App
	145	21	0.5	21	1	US-10-949-720-282	Sequence 282, App
	146	21	0.5	21	1	US-10-949-720-283	Sequence 283, App
	147	21	0.5	21	1	US-10-949-720-284	Sequence 284, App
	148	21	0.5	21	1	US-10-949-720-285	Sequence 285, App
	149	21	0.5	21	1	US-10-770-726-17546	Sequence 17546, A
c	150	21	0.5	21	1	US-10-310-914A-153232	Sequence 153232,
c	151	21	0.5	21	1	US-10-310-914A-153233	Sequence 153233,
c	152	21	0.5	21	1	US-10-310-914A-153234	Sequence 153234,
c	153	21	0.5	21	1	US-10-310-914A-153240	Sequence 153240,
c	154	21	0.5	21	1	US-10-310-914A-153241	Sequence 153241,
c	155	21	0.5	21	1	US-10-310-914A-153243	Sequence 153243,
c	156	21	0.5	21	1	US-10-310-914A-153247	Sequence 153247,
c	157	21	0.5	21	1	US-10-310-914A-153249	Sequence 153249,
c	158	21	0.5	21	1	US-10-310-914A-153264	Sequence 153264,
c	159	21	0.5	21	1	US-10-310-914A-153293	Sequence 153293,
	160	20.8	0.5	25	1	US-10-310-914A-1141554	Sequence 1141554,
	161	20.8	0.5	25	1	US-11-136-527-49332	Sequence 49332, A
	162	20.8	0.5	25	1	US-11-136-527-49335	Sequence 49335, A
	163	20.4	0.5	22	1	US-10-949-720-59	Sequence 59, Appl
	164	20.4	0.5	22	1	US-10-310-914A-161890	Sequence 161890,
	165	20.4	0.5	22	1	US-10-310-914A-161891	Sequence 161891,
c	166	20.4	0.5	22	1	US-10-310-914A-916479	Sequence 916479,
c	167	20.2	0.5	25	1	US-10-932-182A-21431	Sequence 21431, A
	168	20.2	0.5	25	1	US-11-136-527-146486	Sequence 146486,
	169	20.2	0.5	25	1	US-11-136-527-146488	Sequence 146488,
	170	20.2	0.5	25	1	US-11-136-527-146494	Sequence 146494,
	171	20.2	0.5	25	1	US-11-136-527-146507	Sequence 146507,
	172	20	0.5	20	1	US-10-949-720-19	Sequence 19, Appl
c	173	20	0.5	20	1	US-10-949-720-21	Sequence 21, Appl
	174	20	0.5	20	1	US-10-949-720-25	Sequence 25, Appl
c	175	20	0.5	20	1	US-10-949-720-27	Sequence 27, Appl
	176	20	0.5	20	1	US-10-949-720-32	Sequence 32, Appl
c	177	20	0.5	20	1	US-10-949-720-33	Sequence 33, Appl
c	178	20	0.5	20	1	US-10-949-720-51	Sequence 51, Appl
	179	20	0.5	20	1	US-10-949-720-55	Sequence 55, Appl
c	180	20	0.5	20	1	US-10-949-720-56	Sequence 56, Appl
c	181	20	0.5	20	1	US-10-949-720-74	Sequence 74, Appl
c	182	20	0.5	20	1	US-10-949-720-75	Sequence 75, Appl
c	183	20	0.5	20	1	US-10-949-720-76	Sequence 76, Appl
c	184	20	0.5	20	1	US-10-949-720-77	Sequence 77, Appl
c	185	20	0.5	20	1	US-10-949-720-78	Sequence 78, Appl
c	186	20	0.5	20	1	US-10-949-720-79	Sequence 79, Appl
c	187	20	0.5	20	1	US-10-949-720-80	Sequence 80, Appl
c	188	20	0.5	20	1	US-10-949-720-81	Sequence 81, Appl
c	189	20	0.5	20	1	US-10-949-720-82	Sequence 82, Appl
c	190	20	0.5	20	1	US-10-949-720-83	Sequence 83, Appl
c	191	20	0.5	20	1	US-10-949-720-84	Sequence 84, Appl
c	192	20	0.5	20	1	US-10-949-720-85	Sequence 85, Appl
c	193	20	0.5	20	1	US-10-949-720-86	Sequence 86, Appl
c	194	20	0.5	20	1	US-10-949-720-87	Sequence 87, Appl
c	195	20	0.5	20	1	US-10-949-720-88	Sequence 88, Appl
c	196	20	0.5	20	1	US-10-949-720-89	Sequence 89, Appl
c	197	20	0.5	20	1	US-10-949-720-90	Sequence 90, Appl
c	198	20	0.5	20	1	US-10-949-720-91	Sequence 91, Appl
c	199	20	0.5	20	1	US-10-949-720-92	Sequence 92, Appl
c	200	20	0.5	20	1	US-10-949-720-93	Sequence 93, Appl
c	201	20	0.5	20	1	US-10-949-720-94	Sequence 94, Appl
c	202	20	0.5	20	1	US-10-949-720-95	Sequence 95, Appl
c	203	20	0.5	20	1	US-10-949-720-96	Sequence 96, Appl
c	204	20	0.5	20	1	US-10-949-720-97	Sequence 97, Appl
c	205	20	0.5	20	1	US-10-949-720-98	Sequence 98, Appl
c	206	20	0.5	20	1	US-10-949-720-99	Sequence 99, Appl
c	207	20	0.5	20	1	US-10-949-720-100	Sequence 100, App
c	208	20	0.5	20	1	US-10-949-720-101	Sequence 101, App
c	209	20	0.5	20	1	US-10-949-720-102	Sequence 102, App
c	210	20	0.5	20	1	US-10-949-720-103	Sequence 103, App
c	211	20	0.5	20	1	US-10-949-720-104	Sequence 104, App
c	212	20	0.5	20	1	US-10-949-720-105	Sequence 105, App
c	213	20	0.5	20	1	US-10-949-720-106	Sequence 106, App
c	214	20	0.5	20	1	US-10-949-720-107	Sequence 107, App
c	215	20	0.5	20	1	US-10-949-720-108	Sequence 108, App
c	216	20	0.5	20	1	US-10-949-720-109	Sequence 109, App
c	217	20	0.5	20	1	US-10-949-720-110	Sequence 110, App
c	218	20	0.5	20	1	US-10-949-720-111	Sequence 111, App
c	219	20	0.5	20	1	US-10-949-720-112	Sequence 112, App
c	220	20	0.5	20	1	US-10-949-720-113	Sequence 113, App
c	221	20	0.5	20	1	US-10-949-720-114	Sequence 114, App
c	222	20	0.5	20	1	US-10-949-720-115	Sequence 115, App
c	223	20	0.5	20	1	US-10-949-720-116	Sequence 116, App
c	224	20	0.5	20	1	US-10-949-720-117	Sequence 117, App
c	225	20	0.5	20	1	US-10-949-720-118	Sequence 118, App
c	226	20	0.5	20	1	US-10-949-720-119	Sequence 119, App
c	227	20	0.5	20	1	US-10-949-720-120	Sequence 120, App
c	228	20	0.5	20	1	US-10-949-720-121	Sequence 121, App
c	229	20	0.5	20	1	US-10-949-720-122	Sequence 122, App
c	230	20	0.5	20	1	US-10-949-720-123	Sequence 123, App
c	231	20	0.5	20	1	US-10-949-720-124	Sequence 124, App
c	232	20	0.5	20	1	US-10-949-720-125	Sequence 125, App
c	233	20	0.5	20	1	US-10-949-720-126	Sequence 126, App
c	234	20	0.5	20	1	US-10-949-720-127	Sequence 127, App
c	235	20	0.5	20	1	US-10-949-720-128	Sequence 128, App
c	236	20	0.5	20	1	US-10-949-720-129	Sequence 129, App
c	237	20	0.5	20	1	US-10-949-720-130	Sequence 130, App
c	238	20	0.5	20	1	US-10-949-720-131	Sequence 131, App
c	239	20	0.5	20	1	US-10-949-720-132	Sequence 132, App
c	240	20	0.5	20	1	US-10-949-720-133	Sequence 133, App
c	241	20	0.5	20	1	US-10-949-720-134	Sequence 134, App
c	242	20	0.5	20	1	US-10-949-720-135	Sequence 135, App
c	243	20	0.5	20	1	US-10-949-720-136	Sequence 136, App
c	244	20	0.5	20	1	US-10-949-720-137	Sequence 137, App
c	245	20	0.5	20	1	US-10-949-720-138	Sequence 138, App
c	246	20	0.5	20	1	US-10-949-720-139	Sequence 139, App
c	247	20	0.5	20	1	US-10-949-720-140	Sequence 140, App
c	248	20	0.5	20	1	US-10-949-720-141	Sequence 141, App
c	249	20	0.5	20	1	US-10-949-720-142	Sequence 142, App
c	250	20	0.5	20	1	US-10-949-720-143	Sequence 143, App
c	251	20	0.5	20	1	US-10-949-720-144	Sequence 144, App
c	252	20	0.5	20	1	US-10-949-720-145	Sequence 145, App

c 253	20	0.5	20	1	US-10-949-720-146	Sequence 146, App
c 254	20	0.5	20	1	US-10-949-720-147	Sequence 147, App
c 255	20	0.5	20	1	US-10-949-720-148	Sequence 148, App
c 256	20	0.5	20	1	US-10-949-720-149	Sequence 149, App
c 257	20	0.5	20	1	US-10-949-720-150	Sequence 150, App
c 258	20	0.5	20	1	US-10-949-720-151	Sequence 151, App
c 259	20	0.5	20	1	US-10-949-720-152	Sequence 152, App
c 260	20	0.5	20	1	US-10-949-720-153	Sequence 153, App
c 261	20	0.5	20	1	US-10-949-720-154	Sequence 154, App
c 262	20	0.5	20	1	US-10-949-720-155	Sequence 155, App
c 263	20	0.5	20	1	US-10-949-720-156	Sequence 156, App
c 264	20	0.5	20	1	US-10-949-720-157	Sequence 157, App
c 265	20	0.5	20	1	US-10-949-720-158	Sequence 158, App
c 266	20	0.5	20	1	US-10-949-720-159	Sequence 159, App
c 267	20	0.5	20	1	US-10-949-720-160	Sequence 160, App
c 268	20	0.5	20	1	US-10-949-720-161	Sequence 161, App
c 269	20	0.5	20	1	US-10-949-720-162	Sequence 162, App
c 270	20	0.5	20	1	US-10-949-720-163	Sequence 163, App
c 271	20	0.5	20	1	US-10-949-720-164	Sequence 164, App
c 272	20	0.5	20	1	US-10-949-720-165	Sequence 165, App
c 273	20	0.5	20	1	US-10-949-720-166	Sequence 166, App
c 274	20	0.5	20	1	US-10-949-720-167	Sequence 167, App
c 275	20	0.5	20	1	US-10-949-720-168	Sequence 168, App
c 276	20	0.5	20	1	US-10-949-720-169	Sequence 169, App
c 277	20	0.5	20	1	US-10-949-720-170	Sequence 170, App
c 278	20	0.5	20	1	US-10-949-720-171	Sequence 171, App
c 279	20	0.5	20	1	US-10-949-720-172	Sequence 172, App
c 280	20	0.5	20	1	US-10-949-720-173	Sequence 173, App
c 281	20	0.5	20	1	US-10-949-720-174	Sequence 174, App
c 282	20	0.5	20	1	US-10-949-720-175	Sequence 175, App
c 283	20	0.5	20	1	US-10-949-720-176	Sequence 176, App
c 284	20	0.5	20	1	US-10-949-720-177	Sequence 177, App
c 285	20	0.5	20	1	US-10-949-720-178	Sequence 178, App
c 286	20	0.5	20	1	US-10-949-720-179	Sequence 179, App
c 287	20	0.5	20	1	US-10-949-720-180	Sequence 180, App
c 288	20	0.5	20	1	US-10-949-720-181	Sequence 181, App
c 289	20	0.5	20	1	US-10-949-720-182	Sequence 182, App
c 290	20	0.5	20	1	US-10-949-720-183	Sequence 183, App
c 291	20	0.5	20	1	US-10-949-720-184	Sequence 184, App
c 292	20	0.5	20	1	US-10-949-720-185	Sequence 185, App
c 293	20	0.5	20	1	US-10-949-720-186	Sequence 186, App
c 294	20	0.5	20	1	US-10-949-720-187	Sequence 187, App
c 295	20	0.5	20	1	US-10-949-720-188	Sequence 188, App
c 296	20	0.5	20	1	US-10-949-720-189	Sequence 189, App
c 297	20	0.5	20	1	US-10-949-720-190	Sequence 190, App
c 298	20	0.5	20	1	US-10-949-720-191	Sequence 191, App
c 299	20	0.5	20	1	US-10-949-720-192	Sequence 192, App
c 300	20	0.5	20	1	US-10-949-720-193	Sequence 193, App
c 301	20	0.5	20	1	US-10-949-720-194	Sequence 194, App
c 302	20	0.5	20	1	US-10-949-720-195	Sequence 195, App
c 303	20	0.5	20	1	US-10-949-720-196	Sequence 196, App
c 304	20	0.5	20	1	US-10-949-720-197	Sequence 197, App
c 305	20	0.5	20	1	US-10-949-720-198	Sequence 198, App
c 306	20	0.5	20	1	US-10-949-720-199	Sequence 199, App
c 307	20	0.5	20	1	US-10-949-720-200	Sequence 200, App
c 308	20	0.5	20	1	US-10-949-720-201	Sequence 201, App
c 309	20	0.5	20	1	US-10-949-720-202	Sequence 202, App
c 310	20	0.5	20	1	US-10-949-720-203	Sequence 203, App
c 311	20	0.5	20	1	US-10-949-720-204	Sequence 204, App
c 312	20	0.5	20	1	US-10-949-720-205	Sequence 205, App
c 313	20	0.5	20	1	US-10-949-720-206	Sequence 206, App
c 314	20	0.5	20	1	US-10-949-720-207	Sequence 207, App
c 315	20	0.5	20	1	US-10-949-720-208	Sequence 208, App
c 316	20	0.5	20	1	US-10-949-720-209	Sequence 209, App
c 317	20	0.5	20	1	US-10-949-720-210	Sequence 210, App
c 318	20	0.5	20	1	US-10-949-720-211	Sequence 211, App
c 319	20	0.5	20	1	US-10-949-720-212	Sequence 212, App
c 320	20	0.5	20	1	US-10-949-720-213	Sequence 213, App
c 321	20	0.5	20	1	US-10-949-720-214	Sequence 214, App
c 322	20	0.5	20	1	US-10-949-720-215	Sequence 215, App
c 323	20	0.5	20	1	US-10-949-720-216	Sequence 216, App
c 324	20	0.5	20	1	US-10-949-720-217	Sequence 217, App
c 325	20	0.5	20	1	US-10-949-720-218	Sequence 218, App
c 326	20	0.5	20	1	US-10-949-720-219	Sequence 219, App
c 327	20	0.5	20	1	US-10-949-720-220	Sequence 220, App
c 328	20	0.5	20	1	US-10-949-720-221	Sequence 221, App
c 329	20	0.5	20	1	US-10-949-720-231	Sequence 231, App
330	20	0.5	20	1	US-10-949-720-421	Sequence 421, App
c 331	20	0.5	20	1	US-10-310-914A-153225	Sequence 153225,
c 332	20	0.5	20	1	US-10-310-914A-153251	Sequence 153251,
c 333	20	0.5	20	1	US-10-310-914A-153252	Sequence 153252,
c 334	20	0.5	20	1	US-10-310-914A-153263	Sequence 153263,
c 335	20	0.5	20	1	US-10-310-914A-153284	Sequence 153284,
336	20	0.5	21	1	US-10-949-720-38	Sequence 38, Appl
337	20	0.5	21	1	US-10-949-720-288	Sequence 288, App
338	20	0.5	21	1	US-10-770-726-17477	Sequence 17477, A
c 339	20	0.5	21	1	US-10-310-914A-153253	Sequence 153253,
c 340	20	0.5	22	1	US-10-310-914A-1353080	Sequence 1353080,
341	20	0.5	23	1	US-10-310-914A-95660	Sequence 95660, A
342	19.8	0.5	23	1	US-10-310-914A-478410	Sequence 478410,
343	19.8	0.5	23	1	US-10-310-914A-1141553	Sequence 1141553,
344	19.8	0.5	24	1	US-10-310-914A-556544	Sequence 556544,
c 345	19.4	0.5	21	1	US-10-949-720-43	Sequence 43, Appl
c 346	19.4	0.5	21	1	US-10-949-720-223	Sequence 223, App
347	19.4	0.5	21	1	US-10-770-726-16892	Sequence 16892, A
348	19.4	0.5	21	1	US-10-770-726-16916	Sequence 16916, A
349	19.4	0.5	21	1	US-10-770-726-17495	Sequence 17495, A
350	19.4	0.5	21	1	US-10-770-726-17498	Sequence 17498, A
351	19.4	0.5	21	1	US-10-770-726-17501	Sequence 17501, A
352	19.4	0.5	21	1	US-10-770-726-17534	Sequence 17534, A
353	19.4	0.5	21	1	US-10-770-726-17540	Sequence 17540, A
354	19.4	0.5	21	1	US-10-770-726-17543	Sequence 17543, A
355	19.4	0.5	21	1	US-10-310-914A-161882	Sequence 161882,
356	19.4	0.5	22	1	US-10-310-914A-161883	Sequence 161883,
c 357	19.4	0.5	22	1	US-10-310-914A-311206	Sequence 311206,
358	19.2	0.5	24	1	US-10-310-914A-390963	Sequence 390963,
c 359	19.2	0.5	24	1	US-10-310-914A-686978	Sequence 686978,
360	19.2	0.5	24	1	US-11-178-086-26	Sequence 26, Appl
361	19.2	0.5	24	1	US-11-178-086-73	Sequence 73, Appl
c 362	19	0.4	19	1	US-10-310-914A-153218	Sequence 153218,
c 363	19	0.4	19	1	US-10-310-914A-153220	Sequence 153220,
c 364	19	0.4	19	1	US-10-310-914A-153222	Sequence 153222,
c 365	19	0.4	19	1	US-10-310-914A-153224	Sequence 153224,
c 366	19	0.4	19	1	US-10-310-914A-153227	Sequence 153227,
c 367	19	0.4	19	1	US-10-310-914A-153244	Sequence 153244,
c 368	19	0.4	19	1	US-10-310-914A-153245	Sequence 153245,
c 369	19	0.4	19	1	US-10-310-914A-153250	Sequence 153250,
c 370	19	0.4	19	1	US-10-310-914A-153258	Sequence 153258,
c 371	19	0.4	19	1	US-10-310-914A-153268	Sequence 153268,
c 372	19	0.4	19	1	US-10-310-914A-153272	Sequence 153272,
c 373	19	0.4	19	1	US-10-310-914A-153282	Sequence 153282,
c 374	19	0.4	19	1	US-10-310-914A-153290	Sequence 153290,
c 375	19	0.4	19	1	US-10-310-914A-153291	Sequence 153291,
376	19	0.4	19	1	US-11-101-244-685	Sequence 685, App
377	19	0.4	19	1	US-11-101-244-686	Sequence 686, App
378	19	0.4	19	1	US-11-101-244-687	Sequence 687, App
379	19	0.4	19	1	US-11-101-244-688	Sequence 688, App
380	19	0.4	19	1	US-11-101-244-158892	Sequence 158892,
381	19	0.4	19	1	US-11-101-244-159283	Sequence 159283,
382	19	0.4	19	1	US-11-101-244-159284	Sequence 159284,
383	19	0.4	19	1	US-11-101-244-159285	Sequence 159285,
384	19	0.4	19	1	US-11-101-244-159287	Sequence 159287,
385	19	0.4	19	1	US-11-101-244-159288	Sequence 159288,
386	19	0.4	19	1	US-11-101-244-159289	Sequence 159289,
387	19	0.4	19	1	US-11-101-244-159290	Sequence 159290,
388	19	0.4	19	1	US-11-101-244-159291	Sequence 159291,
389	19	0.4	19	1	US-11-101-244-159292	Sequence 159292,
390	19	0.4	19	1	US-11-101-244-159293	Sequence 159293,
391	19	0.4	19	1	US-11-101-244-159294	Sequence 159294,
392	19	0.4	19	1	US-11-101-244-159295	Sequence 159295,
393	19	0.4	19	1	US-11-101-244-159296	Sequence 159296,
394	19	0.4	19	1	US-11-101-244-159297	Sequence 159297,
395	19	0.4	19	1	US-11-101-244-159298	Sequence 159298,
396	19	0.4	19	1	US-11-101-244-159299	Sequence 159299,
397	19	0.4	19	1	US-11-101-244-159300	Sequence 159300,
398	19	0.4	19	1	US-11-101-244-159301	Sequence 159301,

399	19	0.4	19	1	US-11-101-244-159302	Sequence 159302,
400	19	0.4	19	1	US-11-101-244-159303	Sequence 159303,
401	19	0.4	19	1	US-11-101-244-159304	Sequence 159304,
402	19	0.4	19	1	US-11-101-244-159305	Sequence 159305,
403	19	0.4	19	1	US-11-101-244-159306	Sequence 159306,
404	19	0.4	19	1	US-11-101-244-159307	Sequence 159307,
405	19	0.4	19	1	US-11-101-244-159308	Sequence 159308,
406	19	0.4	19	1	US-11-101-244-159310	Sequence 159310,
407	19	0.4	19	1	US-11-101-244-159311	Sequence 159311,
408	19	0.4	19	1	US-11-101-244-159312	Sequence 159312,
409	19	0.4	19	1	US-11-101-244-159313	Sequence 159313,
410	19	0.4	19	1	US-11-101-244-159314	Sequence 159314,
411	19	0.4	19	1	US-11-101-244-159315	Sequence 159315,
412	19	0.4	19	1	US-11-101-244-159316	Sequence 159316,
413	19	0.4	19	1	US-11-101-244-159317	Sequence 159317,
414	19	0.4	19	1	US-11-101-244-159318	Sequence 159318,
415	19	0.4	19	1	US-11-101-244-159319	Sequence 159319,
416	19	0.4	19	1	US-11-101-244-159320	Sequence 159320,
417	19	0.4	19	1	US-11-101-244-159321	Sequence 159321,
418	19	0.4	19	1	US-11-101-244-159322	Sequence 159322,
419	19	0.4	19	1	US-11-101-244-159323	Sequence 159323,
420	19	0.4	19	1	US-11-101-244-159324	Sequence 159324,
421	19	0.4	19	1	US-11-101-244-159325	Sequence 159325,
422	19	0.4	19	1	US-11-101-244-159326	Sequence 159326,
423	19	0.4	19	1	US-11-101-244-159327	Sequence 159327,
424	19	0.4	19	1	US-11-101-244-159328	Sequence 159328,
425	19	0.4	19	1	US-11-101-244-159329	Sequence 159329,
426	19	0.4	19	1	US-11-101-244-159330	Sequence 159330,
427	19	0.4	19	1	US-11-101-244-159331	Sequence 159331,
428	19	0.4	19	1	US-11-101-244-159332	Sequence 159332,
429	19	0.4	19	1	US-11-101-244-159333	Sequence 159333,
430	19	0.4	19	1	US-11-101-244-159334	Sequence 159334,
431	19	0.4	19	1	US-11-101-244-159335	Sequence 159335,
432	19	0.4	19	1	US-11-101-244-159336	Sequence 159336,
433	19	0.4	19	1	US-11-101-244-159337	Sequence 159337,
434	19	0.4	19	1	US-11-101-244-159338	Sequence 159338,
435	19	0.4	19	1	US-11-101-244-159339	Sequence 159339,
436	19	0.4	19	1	US-11-101-244-159340	Sequence 159340,
437	19	0.4	19	1	US-11-101-244-159341	Sequence 159341,
438	19	0.4	19	1	US-11-101-244-159342	Sequence 159342,
439	19	0.4	19	1	US-11-101-244-159343	Sequence 159343,
440	19	0.4	19	1	US-11-101-244-159344	Sequence 159344,
441	19	0.4	19	1	US-11-101-244-159345	Sequence 159345,
442	19	0.4	19	1	US-11-101-244-159346	Sequence 159346,
443	19	0.4	19	1	US-11-101-244-159347	Sequence 159347,
444	19	0.4	19	1	US-11-101-244-159348	Sequence 159348,
445	19	0.4	19	1	US-11-101-244-159349	Sequence 159349,
446	19	0.4	19	1	US-11-101-244-159350	Sequence 159350,
447	19	0.4	19	1	US-11-101-244-159351	Sequence 159351,
448	19	0.4	19	1	US-11-101-244-159352	Sequence 159352,
449	19	0.4	19	1	US-11-101-244-159353	Sequence 159353,
450	19	0.4	19	1	US-11-101-244-159354	Sequence 159354,
451	19	0.4	19	1	US-11-101-244-159355	Sequence 159355,
452	19	0.4	19	1	US-11-101-244-159356	Sequence 159356,
453	19	0.4	19	1	US-11-101-244-159357	Sequence 159357,
454	19	0.4	19	1	US-11-101-244-159358	Sequence 159358,
455	19	0.4	19	1	US-11-101-244-159359	Sequence 159359,
456	19	0.4	19	1	US-11-101-244-159360	Sequence 159360,
457	19	0.4	19	1	US-11-101-244-159361	Sequence 159361,
458	19	0.4	19	1	US-11-101-244-159362	Sequence 159362,
459	19	0.4	19	1	US-11-101-244-159363	Sequence 159363,
460	19	0.4	19	1	US-11-101-244-159365	Sequence 159365,
461	19	0.4	19	1	US-11-101-244-159366	Sequence 159366,
462	19	0.4	19	1	US-11-101-244-159367	Sequence 159367,
463	19	0.4	19	1	US-11-101-244-159368	Sequence 159368,
464	19	0.4	19	1	US-11-101-244-159369	Sequence 159369,
465	19	0.4	19	1	US-11-101-244-159370	Sequence 159370,
466	19	0.4	19	1	US-11-101-244-159372	Sequence 159372,
467	19	0.4	19	1	US-11-101-244-159373	Sequence 159373,
468	19	0.4	19	1	US-11-101-244-159374	Sequence 159374,
469	19	0.4	19	1	US-11-101-244-159375	Sequence 159375,
470	19	0.4	19	1	US-11-101-244-159376	Sequence 159376,
471	19	0.4	19	1	US-11-101-244-159377	Sequence 159377,
472	19	0.4	19	1	US-11-101-244-159378	Sequence 159378,
473	19	0.4	19	1	US-11-101-244-159379	Sequence 159379,
474	19	0.4	19	1	US-11-101-244-159380	Sequence 159380,
475	19	0.4	19	1	US-11-101-244-159381	Sequence 159381,
476	19	0.4	19	1	US-11-101-244-159382	Sequence 159382,
477	19	0.4	19	1	US-11-083-784-685	Sequence 685, App
478	19	0.4	19	1	US-11-083-784-686	Sequence 686, App
479	19	0.4	19	1	US-11-083-784-687	Sequence 687, App
480	19	0.4	19	1	US-11-083-784-688	Sequence 688, App
481	19	0.4	19	1	US-11-083-784-158892	Sequence 158892,
482	19	0.4	19	1	US-11-083-784-159283	Sequence 159283,
483	19	0.4	19	1	US-11-083-784-159284	Sequence 159284,
484	19	0.4	19	1	US-11-083-784-159285	Sequence 159285,
485	19	0.4	19	1	US-11-083-784-159287	Sequence 159287,
486	19	0.4	19	1	US-11-083-784-159288	Sequence 159288,
487	19	0.4	19	1	US-11-083-784-159289	Sequence 159289,
488	19	0.4	19	1	US-11-083-784-159290	Sequence 159290,
489	19	0.4	19	1	US-11-083-784-159291	Sequence 159291,
490	19	0.4	19	1	US-11-083-784-159292	Sequence 159292,
491	19	0.4	19	1	US-11-083-784-159293	Sequence 159293,
492	19	0.4	19	1	US-11-083-784-159294	Sequence 159294,
493	19	0.4	19	1	US-11-083-784-159295	Sequence 159295,
494	19	0.4	19	1	US-11-083-784-159296	Sequence 159296,
495	19	0.4	19	1	US-11-083-784-159297	Sequence 159297,
496	19	0.4	19	1	US-11-083-784-159298	Sequence 159298,
497	19	0.4	19	1	US-11-083-784-159299	Sequence 159299,
498	19	0.4	19	1	US-11-083-784-159300	Sequence 159300,
499	19	0.4	19	1	US-11-083-784-159301	Sequence 159301,
500	19	0.4	19	1	US-11-083-784-159302	Sequence 159302,
501	19	0.4	19	1	US-11-083-784-159303	Sequence 159303,
502	19	0.4	19	1	US-11-083-784-159304	Sequence 159304,
503	19	0.4	19	1	US-11-083-784-159305	Sequence 159305,
504	19	0.4	19	1	US-11-083-784-159306	Sequence 159306,
505	19	0.4	19	1	US-11-083-784-159307	Sequence 159307,
506	19	0.4	19	1	US-11-083-784-159308	Sequence 159308,
507	19	0.4	19	1	US-11-083-784-159310	Sequence 159310,
508	19	0.4	19	1	US-11-083-784-159311	Sequence 159311,
509	19	0.4	19	1	US-11-083-784-159312	Sequence 159312,
510	19	0.4	19	1	US-11-083-784-159313	Sequence 159313,
511	19	0.4	19	1	US-11-083-784-159314	Sequence 159314,
512	19	0.4	19	1	US-11-083-784-159315	Sequence 159315,
513	19	0.4	19	1	US-11-083-784-159316	Sequence 159316,
514	19	0.4	19	1	US-11-083-784-159317	Sequence 159317,
515	19	0.4	19	1	US-11-083-784-159318	Sequence 159318,
516	19	0.4	19	1	US-11-083-784-159319	Sequence 159319,
517	19	0.4	19	1	US-11-083-784-159320	Sequence 159320,
518	19	0.4	19	1	US-11-083-784-159321	Sequence 159321,
519	19	0.4	19	1	US-11-083-784-159322	Sequence 159322,
520	19	0.4	19	1	US-11-083-784-159323	Sequence 159323,
521	19	0.4	19	1	US-11-083-784-159324	Sequence 159324,
522	19	0.4	19	1	US-11-083-784-159325	Sequence 159325,
523	19	0.4	19	1	US-11-083-784-159326	Sequence 159326,
524	19	0.4	19	1	US-11-083-784-159327	Sequence 159327,
525	19	0.4	19	1	US-11-083-784-159328	Sequence 159328,
526	19	0.4	19	1	US-11-083-784-159329	Sequence 159329,
527	19	0.4	19	1	US-11-083-784-159330	Sequence 159330,
528	19	0.4	19	1	US-11-083-784-159331	Sequence 159331,
529	19	0.4	19	1	US-11-083-784-159332	Sequence 159332,
530	19	0.4	19	1	US-11-083-784-159333	Sequence 159333,
531	19	0.4	19	1	US-11-083-784-159334	Sequence 159334,
532	19	0.4	19	1	US-11-083-784-159335	Sequence 159335,
533	19	0.4	19	1	US-11-083-784-159336	Sequence 159336,
534	19	0.4	19	1	US-11-083-784-159337	Sequence 159337,
535	19	0.4	19	1	US-11-083-784-159338	Sequence 159338,
536	19	0.4	19	1	US-11-083-784-159339	Sequence 159339,
537	19	0.4	19	1	US-11-083-784-159340	Sequence 159340,
538	19	0.4	19	1	US-11-083-784-159341	Sequence 159341,
539	19	0.4	19	1	US-11-083-784-159342	Sequence 159342,
540	19	0.4	19	1	US-11-083-784-159343	Sequence 159343,
541	19	0.4	19	1	US-11-083-784-159344	Sequence 159344,
542	19	0.4	19	1	US-11-083-784-159345	Sequence 159345,
543	19	0.4	19	1	US-11-083-784-159346	Sequence 159346,
544	19	0.4	19	1	US-11-083-784-159347	Sequence 159347,

	545	19	0.4	19	1	US-11-083-784-159348	Sequence 159348,
	546	19	0.4	19	1	US-11-083-784-159349	Sequence 159349,
	547	19	0.4	19	1	US-11-083-784-159350	Sequence 159350,
	548	19	0.4	19	1	US-11-083-784-159351	Sequence 159351,
	549	19	0.4	19	1	US-11-083-784-159352	Sequence 159352,
	550	19	0.4	19	1	US-11-083-784-159353	Sequence 159353,
	551	19	0.4	19	1	US-11-083-784-159354	Sequence 159354,
	552	19	0.4	19	1	US-11-083-784-159355	Sequence 159355,
	553	19	0.4	19	1	US-11-083-784-159356	Sequence 159356,
	554	19	0.4	19	1	US-11-083-784-159357	Sequence 159357,
	555	19	0.4	19	1	US-11-083-784-159358	Sequence 159358,
	556	19	0.4	19	1	US-11-083-784-159359	Sequence 159359,
	557	19	0.4	19	1	US-11-083-784-159360	Sequence 159360,
	558	19	0.4	19	1	US-11-083-784-159361	Sequence 159361,
	559	19	0.4	19	1	US-11-083-784-159362	Sequence 159362,
	560	19	0.4	19	1	US-11-083-784-159363	Sequence 159363,
	561	19	0.4	19	1	US-11-083-784-159365	Sequence 159365,
	562	19	0.4	19	1	US-11-083-784-159366	Sequence 159366,
	563	19	0.4	19	1	US-11-083-784-159367	Sequence 159367,
	564	19	0.4	19	1	US-11-083-784-159368	Sequence 159368,
	565	19	0.4	19	1	US-11-083-784-159369	Sequence 159369,
	566	19	0.4	19	1	US-11-083-784-159370	Sequence 159370,
	567	19	0.4	19	1	US-11-083-784-159372	Sequence 159372,
	568	19	0.4	19	1	US-11-083-784-159373	Sequence 159373,
	569	19	0.4	19	1	US-11-083-784-159374	Sequence 159374,
	570	19	0.4	19	1	US-11-083-784-159375	Sequence 159375,
	571	19	0.4	19	1	US-11-083-784-159376	Sequence 159376,
	572	19	0.4	19	1	US-11-083-784-159377	Sequence 159377,
	573	19	0.4	19	1	US-11-083-784-159378	Sequence 159378,
	574	19	0.4	19	1	US-11-083-784-159379	Sequence 159379,
	575	19	0.4	19	1	US-11-083-784-159380	Sequence 159380,
	576	19	0.4	19	1	US-11-083-784-159381	Sequence 159381,
	577	19	0.4	19	1	US-11-083-784-159382	Sequence 159382,
	578	19	0.4	21	1	US-10-949-720-22	Sequence 22, Appl
	579	19	0.4	21	1	US-10-949-720-23	Sequence 23, Appl
	580	19	0.4	21	1	US-10-949-720-34	Sequence 34, Appl
	581	19	0.4	21	1	US-10-949-720-36	Sequence 36, Appl
	582	19	0.4	21	1	US-10-949-720-40	Sequence 40, Appl
	583	19	0.4	21	1	US-10-949-720-69	Sequence 69, Appl
	584	19	0.4	21	1	US-10-949-720-286	Sequence 286, App
	585	19	0.4	21	1	US-10-949-720-287	Sequence 287, App
	586	19	0.4	21	1	US-10-949-720-289	Sequence 289, App
	587	19	0.4	21	1	US-10-949-720-290	Sequence 290, App
	588	19	0.4	21	1	US-10-770-726-16917	Sequence 16917, A
	589	19	0.4	21	1	US-10-770-726-17547	Sequence 17547, A
	590	19	0.4	21	1	US-10-310-914A-1216690	Sequence 1216690,
c	591	18.8	0.4	22	1	US-10-310-914A-207817	Sequence 207817,
c	592	18.8	0.4	22	1	US-10-310-914A-287071	Sequence 287071,
	593	18.8	0.4	22	1	US-10-310-914A-1125431	Sequence 1125431,
	594	18.8	0.4	23	1	US-10-310-914A-200253	Sequence 200253,
c	595	18.8	0.4	23	1	US-10-310-914A-456565	Sequence 456565,
	596	18.8	0.4	23	1	US-10-310-914A-497207	Sequence 497207,
	597	18.8	0.4	23	1	US-10-310-914A-1141590	Sequence 1141590,
	598	18.4	0.4	20	1	US-10-310-914A-161881	Sequence 161881,
c	599	18.4	0.4	20	1	US-10-310-914A-914666	Sequence 914666,
	600	18.4	0.4	21	1	US-10-770-726-16895	Sequence 16895, A
	601	18.4	0.4	21	1	US-10-770-726-16910	Sequence 16910, A
	602	18.4	0.4	21	1	US-10-770-726-16913	Sequence 16913, A
	603	18.4	0.4	21	1	US-10-770-726-17541	Sequence 17541, A
	604	18.4	0.4	21	1	US-10-770-726-18110	Sequence 18110, A
	605	18.4	0.4	21	1	US-10-770-726-18401	Sequence 18401, A
	606	18.4	0.4	22	1	US-10-310-914A-161858	Sequence 161858,
	607	18.4	0.4	22	1	US-10-310-914A-161859	Sequence 161859,
c	608	18	0.4	18	1	US-10-949-720-47	Sequence 47, Appl
c	609	18	0.4	18	1	US-10-949-720-48	Sequence 48, Appl
c	610	18	0.4	18	1	US-10-949-720-227	Sequence 227, App
c	611	18	0.4	18	1	US-10-949-720-228	Sequence 228, App
c	612	18	0.4	18	1	US-10-310-914A-153257	Sequence 153257,
c	613	18	0.4	18	1	US-10-310-914A-153262	Sequence 153262,
c	614	18	0.4	18	1	US-10-310-914A-153275	Sequence 153275,
c	615	18	0.4	18	1	US-10-310-914A-153278	Sequence 153278,
c	616	18	0.4	18	1	US-10-310-914A-153288	Sequence 153288,
c	617	18	0.4	18	1	US-10-310-914A-153289	Sequence 153289,
	618	18	0.4	19	1	US-11-101-244-159271	Sequence 159271,
	619	18	0.4	19	1	US-11-101-244-159286	Sequence 159286,
	620	18	0.4	19	1	US-11-083-784-159271	Sequence 159271,
	621	18	0.4	19	1	US-11-083-784-159286	Sequence 159286,
	622	18	0.4	21	1	US-10-770-726-17478	Sequence 17478, A
	623	18	0.4	21	1	US-10-770-726-17544	Sequence 17544, A
	624	18	0.4	22	1	US-10-310-914A-871069	Sequence 871069,
	625	17.8	0.4	21	1	US-10-770-726-16893	Sequence 16893, A
	626	17.8	0.4	21	1	US-10-770-726-16904	Sequence 16904, A
	627	17.8	0.4	21	1	US-10-770-726-16911	Sequence 16911, A
	628	17.8	0.4	21	1	US-10-770-726-17474	Sequence 17474, A
	629	17.8	0.4	21	1	US-10-770-726-17504	Sequence 17504, A
	630	17.8	0.4	21	1	US-10-770-726-17507	Sequence 17507, A
	631	17.8	0.4	21	1	US-10-770-726-17531	Sequence 17531, A
	632	17.8	0.4	21	1	US-10-770-726-17537	Sequence 17537, A
	633	17.8	0.4	21	1	US-10-770-726-18030	Sequence 18030, A
	634	17.8	0.4	21	1	US-10-770-726-18074	Sequence 18074, A
	635	17.8	0.4	21	1	US-10-770-726-18089	Sequence 18089, A
	636	17.8	0.4	21	1	US-10-770-726-18458	Sequence 18458, A
	637	17.8	0.4	21	1	US-10-770-726-18662	Sequence 18662, A
	638	17.8	0.4	21	1	US-10-770-726-18723	Sequence 18723, A
c	639	17.8	0.4	21	1	US-10-310-914A-44767	Sequence 44767, A
	640	17.8	0.4	21	1	US-10-310-914A-332291	Sequence 332291,
	641	17.8	0.4	21	1	US-10-310-914A-332482	Sequence 332482,
	642	17.8	0.4	21	1	US-10-310-914A-471965	Sequence 471965,
	643	17.8	0.4	21	1	US-10-310-914A-556552	Sequence 556552,
c	644	17.8	0.4	21	1	US-10-310-914A-1213089	Sequence 1213089,
c	645	17.8	0.4	21	1	US-10-310-914A-1341719	Sequence 1341719,
	646	17.8	0.4	22	1	US-10-310-914A-174984	Sequence 174984,
	647	17.8	0.4	22	1	US-10-310-914A-175001	Sequence 175001,
c	648	17.8	0.4	22	1	US-10-310-914A-371300	Sequence 371300,
c	649	17.8	0.4	22	1	US-10-310-914A-494111	Sequence 494111,
	650	17.8	0.4	22	1	US-10-310-914A-497206	Sequence 497206,
	651	17.8	0.4	22	1	US-10-310-914A-549823	Sequence 549823,
	652	17.8	0.4	22	1	US-10-310-914A-765177	Sequence 765177,
	653	17.8	0.4	22	1	US-10-310-914A-1224324	Sequence 1224324,
	654	17.4	0.4	19	1	US-10-310-914A-1224348	Sequence 1224348,
	655	17.4	0.4	19	1	US-10-310-914A-1294342	Sequence 1294342,
	656	17.4	0.4	19	1	US-11-101-244-153337	Sequence 153337,
	657	17.4	0.4	19	1	US-11-101-244-153343	Sequence 153343,
	658	17.4	0.4	19	1	US-11-101-244-153383	Sequence 153383,
	659	17.4	0.4	19	1	US-11-101-244-153389	Sequence 153389,
	660	17.4	0.4	19	1	US-11-101-244-158363	Sequence 158363,
	661	17.4	0.4	19	1	US-11-101-244-158571	Sequence 158571,
	662	17.4	0.4	19	1	US-11-101-244-158800	Sequence 158800,
	663	17.4	0.4	19	1	US-11-101-244-158823	Sequence 158823,
	664	17.4	0.4	19	1	US-11-101-244-158867	Sequence 158867,
	665	17.4	0.4	19	1	US-11-101-244-158987	Sequence 158987,
	666	17.4	0.4	19	1	US-11-101-244-159004	Sequence 159004,
	667	17.4	0.4	19	1	US-11-101-244-159040	Sequence 159040,
	668	17.4	0.4	19	1	US-11-101-244-159054	Sequence 159054,
	669	17.4	0.4	19	1	US-11-101-244-159086	Sequence 159086,
	670	17.4	0.4	19	1	US-11-101-244-159100	Sequence 159100,
	671	17.4	0.4	19	1	US-11-101-244-159129	Sequence 159129,
	672	17.4	0.4	19	1	US-11-101-244-159138	Sequence 159138,
	673	17.4	0.4	19	1	US-11-101-244-159213	Sequence 159213,
	674	17.4	0.4	19	1	US-11-101-244-159231	Sequence 159231,
	675	17.4	0.4	19	1	US-11-101-244-159248	Sequence 159248,
	676	17.4	0.4	19	1	US-11-101-244-159274	Sequence 159274,
	677	17.4	0.4	19	1	US-11-101-244-159309	Sequence 159309,
	678	17.4	0.4	19	1	US-11-101-244-159364	Sequence 159364,
	679	17.4	0.4	19	1	US-11-101-244-159371	Sequence 159371,
	680	17.4	0.4	19	1	US-11-101-244-1212014	Sequence 1212014,
	681	17.4	0.4	19	1	US-11-083-784-153337	Sequence 153337,
	682	17.4	0.4	19	1	US-11-083-784-153343	Sequence 153343,
	683	17.4	0.4	19	1	US-11-083-784-153383	Sequence 153383,
	684	17.4	0.4	19	1	US-11-083-784-153389	Sequence 153389,
	685	17.4	0.4	19	1	US-11-083-784-158363	Sequence 158363,
	686	17.4	0.4	19	1	US-11-083-784-158571	Sequence 158571,
	687	17.4	0.4	19	1	US-11-083-784-158800	Sequence 158800,
	688	17.4	0.4	19	1	US-11-083-784-158823	Sequence 158823,
	689	17.4	0.4	19	1	US-11-083-784-158867	Sequence 158867,
	690	17.4	0.4	19	1	US-11-083-784-158987	Sequence 158987,

	691	17.4	0.4	19	1	US-11-083-784-159004	Sequence 159004,
	692	17.4	0.4	19	1	US-11-083-784-159040	Sequence 159040,
	693	17.4	0.4	19	1	US-11-083-784-159054	Sequence 159054,
	694	17.4	0.4	19	1	US-11-083-784-159086	Sequence 159086,
	695	17.4	0.4	19	1	US-11-083-784-159100	Sequence 159100,
	696	17.4	0.4	19	1	US-11-083-784-159129	Sequence 159129,
	697	17.4	0.4	19	1	US-11-083-784-159138	Sequence 159138,
	698	17.4	0.4	19	1	US-11-083-784-159213	Sequence 159213,
	699	17.4	0.4	19	1	US-11-083-784-159231	Sequence 159231,
	700	17.4	0.4	19	1	US-11-083-784-159248	Sequence 159248,
	701	17.4	0.4	19	1	US-11-083-784-159274	Sequence 159274,
	702	17.4	0.4	19	1	US-11-083-784-159309	Sequence 159309,
	703	17.4	0.4	19	1	US-11-083-784-159364	Sequence 159364,
	704	17.4	0.4	19	1	US-11-083-784-159371	Sequence 159371,
	705	17.4	0.4	19	1	US-11-083-784-1212014	Sequence 1212014,
	706	17.4	0.4	20	1	US-10-297-056-41	Sequence 41, Appl
c	707	17.4	0.4	20	1	US-10-310-914A-52199	Sequence 52199, A
c	708	17.4	0.4	20	1	US-10-310-914A-173994	Sequence 173994,
c	709	17.4	0.4	20	1	US-10-310-914A-173995	Sequence 173995,
c	710	17.4	0.4	20	1	US-10-310-914A-409848	Sequence 409848,
	711	17.4	0.4	20	1	US-10-310-914A-1224349	Sequence 1224349,
	712	17.4	0.4	21	1	US-10-770-726-17471	Sequence 17471, A
	713	17.4	0.4	21	1	US-10-770-726-17472	Sequence 17472, A
	714	17.4	0.4	21	1	US-10-770-726-17496	Sequence 17496, A
	715	17.4	0.4	21	1	US-10-770-726-17499	Sequence 17499, A
	716	17.4	0.4	21	1	US-10-770-726-17502	Sequence 17502, A
	717	17.4	0.4	21	1	US-10-770-726-17535	Sequence 17535, A
	718	17.4	0.4	21	1	US-10-770-726-18459	Sequence 18459, A
	719	17.4	0.4	21	1	US-10-310-914A-145348	Sequence 145348,
c	720	17.4	0.4	21	1	US-10-310-914A-176222	Sequence 176222,
c	721	17.4	0.4	21	1	US-10-310-914A-589336	Sequence 589336,
c	722	17	0.4	18	1	US-10-310-914A-153231	Sequence 153231,
	723	17	0.4	18	1	US-10-310-914A-255656	Sequence 255656,
	724	17	0.4	18	1	US-10-310-914A-687613	Sequence 687613,
c	725	17	0.4	19	1	US-10-949-720-60	Sequence 60, Appl
	726	17	0.4	19	1	US-11-101-244-4697	Sequence 4697, Ap
	727	17	0.4	19	1	US-11-083-784-4697	Sequence 4697, Ap
c	728	17	0.4	20	1	US-10-750-185-12781	Sequence 12781, A
c	729	17	0.4	20	1	US-10-750-623-12781	Sequence 12781, A
	730	17	0.4	21	1	US-10-770-726-17261	Sequence 17261, A
	731	17	0.4	21	1	US-10-770-726-17262	Sequence 17262, A
	732	17	0.4	21	1	US-10-310-914A-746199	Sequence 746199,
	733	16.8	0.4	20	1	US-10-831-286A-34263	Sequence 34263, A
	734	16.8	0.4	20	1	US-10-310-914A-103507	Sequence 103507,
c	735	16.8	0.4	20	1	US-10-310-914A-183395	Sequence 183395,
	736	16.8	0.4	20	1	US-10-310-914A-231085	Sequence 231085,
	737	16.8	0.4	20	1	US-10-310-914A-231831	Sequence 231831,
c	738	16.8	0.4	20	1	US-10-310-914A-243576	Sequence 243576,
	739	16.8	0.4	20	1	US-10-310-914A-244194	Sequence 244194,
	740	16.8	0.4	20	1	US-10-310-914A-268244	Sequence 268244,
c	741	16.8	0.4	20	1	US-10-310-914A-310780	Sequence 310780,
	742	16.8	0.4	20	1	US-10-310-914A-332290	Sequence 332290,
	743	16.8	0.4	20	1	US-10-310-914A-332481	Sequence 332481,
	744	16.8	0.4	20	1	US-10-310-914A-359152	Sequence 359152,
c	745	16.8	0.4	20	1	US-10-310-914A-409640	Sequence 409640,
c	746	16.8	0.4	20	1	US-10-310-914A-436758	Sequence 436758,
	747	16.8	0.4	20	1	US-10-310-914A-478404	Sequence 478404,
c	748	16.8	0.4	20	1	US-10-310-914A-543126	Sequence 543126,
	749	16.8	0.4	20	1	US-10-310-914A-549822	Sequence 549822,
c	750	16.8	0.4	20	1	US-10-310-914A-628964	Sequence 628964,
	751	16.8	0.4	20	1	US-10-310-914A-657369	Sequence 657369,
	752	16.8	0.4	20	1	US-10-310-914A-763042	Sequence 763042,
	753	16.8	0.4	20	1	US-10-310-914A-824483	Sequence 824483,
	754	16.8	0.4	20	1	US-10-310-914A-834462	Sequence 834462,
c	755	16.8	0.4	20	1	US-10-310-914A-846714	Sequence 846714,
	756	16.8	0.4	20	1	US-10-310-914A-930332	Sequence 930332,
	757	16.8	0.4	20	1	US-10-310-914A-1024937	Sequence 1024937,
c	758	16.8	0.4	20	1	US-10-310-914A-1025973	Sequence 1025973,
	759	16.8	0.4	20	1	US-10-310-914A-1125430	Sequence 1125430,
c	760	16.8	0.4	20	1	US-10-310-914A-1209003	Sequence 1209003,
	761	16.8	0.4	20	1	US-10-310-914A-1230235	Sequence 1230235,
	762	16.8	0.4	20	1	US-10-310-914A-1290463	Sequence 1290463,
	763	16.8	0.4	20	1	US-10-310-914A-1290469	Sequence 1290469,
c	764	16.8	0.4	20	1	US-10-310-914A-1332047	Sequence 1332047,
c	765	16.8	0.4	20	1	US-10-310-914A-1341732	Sequence 1341732,
c	766	16.8	0.4	20	1	US-11-043-752-2628	Sequence 2628, Ap
	767	16.8	0.4	21	1	US-10-770-726-16898	Sequence 16898, A
	768	16.8	0.4	21	1	US-10-770-726-17246	Sequence 17246, A
	769	16.8	0.4	21	1	US-10-770-726-17508	Sequence 17508, A
	770	16.8	0.4	21	1	US-10-770-726-18041	Sequence 18041, A
	771	16.8	0.4	21	1	US-10-770-726-18090	Sequence 18090, A
	772	16.8	0.4	21	1	US-10-770-726-18104	Sequence 18104, A
	773	16.8	0.4	21	1	US-10-770-726-18107	Sequence 18107, A
	774	16.8	0.4	21	1	US-10-770-726-26045	Sequence 26045, A
c	775	16.8	0.4	21	1	US-10-310-914A-43024	Sequence 43024, A
c	776	16.8	0.4	21	1	US-10-310-914A-94223	Sequence 94223, A
c	777	16.8	0.4	21	1	US-10-310-914A-147724	Sequence 147724,
c	778	16.8	0.4	21	1	US-10-310-914A-175830	Sequence 175830,
c	779	16.8	0.4	21	1	US-10-310-914A-239772	Sequence 239772,
c	780	16.8	0.4	21	1	US-10-310-914A-271797	Sequence 271797,
c	781	16.8	0.4	21	1	US-10-310-914A-271798	Sequence 271798,
c	782	16.8	0.4	21	1	US-10-310-914A-310403	Sequence 310403,
	783	16.8	0.4	21	1	US-10-310-914A-329952	Sequence 329952,
c	784	16.8	0.4	21	1	US-10-310-914A-340669	Sequence 340669,
c	785	16.8	0.4	21	1	US-10-310-914A-406263	Sequence 406263,
c	786	16.8	0.4	21	1	US-10-310-914A-426861	Sequence 426861,
	787	16.8	0.4	21	1	US-10-310-914A-481749	Sequence 481749,
	788	16.8	0.4	21	1	US-10-310-914A-497146	Sequence 497146,
c	789	16.8	0.4	21	1	US-10-310-914A-513444	Sequence 513444,
	790	16.8	0.4	21	1	US-10-310-914A-562705	Sequence 562705,
c	791	16.8	0.4	21	1	US-10-310-914A-572916	Sequence 572916,
c	792	16.8	0.4	21	1	US-10-310-914A-628965	Sequence 628965,
	793	16.8	0.4	21	1	US-10-310-914A-700668	Sequence 700668,
	794	16.8	0.4	21	1	US-10-310-914A-711740	Sequence 711740,
	795	16.8	0.4	21	1	US-10-310-914A-711741	Sequence 711741,
	796	16.8	0.4	21	1	US-10-310-914A-712558	Sequence 712558,
c	797	16.8	0.4	21	1	US-10-310-914A-849350	Sequence 849350,
	798	16.8	0.4	21	1	US-10-310-914A-853726	Sequence 853726,
	799	16.8	0.4	21	1	US-10-310-914A-964814	Sequence 964814,
c	800	16.8	0.4	21	1	US-10-310-914A-1044788	Sequence 1044788,
c	801	16.8	0.4	21	1	US-10-310-914A-1044846	Sequence 1044846,
	802	16.8	0.4	21	1	US-10-310-914A-1141569	Sequence 1141569,
	803	16.8	0.4	21	1	US-10-310-914A-1329403	Sequence 1329403,
	804	16.4	0.4	18	1	US-10-750-185-14487	Sequence 14487, A
	805	16.4	0.4	18	1	US-10-750-623-14487	Sequence 14487, A
c	806	16.4	0.4	18	1	US-10-310-914A-44706	Sequence 44706, A
	807	16.4	0.4	18	1	US-10-310-914A-161816	Sequence 161816,
	808	16.4	0.4	18	1	US-10-310-914A-215670	Sequence 215670,
c	809	16.4	0.4	18	1	US-10-310-914A-239735	Sequence 239735,
c	810	16.4	0.4	18	1	US-10-310-914A-263974	Sequence 263974,
	811	16.4	0.4	18	1	US-10-310-914A-346833	Sequence 346833,
	812	16.4	0.4	18	1	US-10-310-914A-486562	Sequence 486562,
	813	16.4	0.4	18	1	US-10-310-914A-562588	Sequence 562588,
c	814	16.4	0.4	18	1	US-10-310-914A-702467	Sequence 702467,
c	815	16.4	0.4	18	1	US-10-310-914A-806755	Sequence 806755,
	816	16.4	0.4	18	1	US-10-310-914A-815915	Sequence 815915,
c	817	16.4	0.4	18	1	US-10-310-914A-916487	Sequence 916487,
c	818	16.4	0.4	18	1	US-10-310-914A-937535	Sequence 937535,
c	819	16.4	0.4	18	1	US-10-310-914A-1079798	Sequence 1079798,
	820	16.4	0.4	18	1	US-10-310-914A-1251971	Sequence 1251971,
	821	16.4	0.4	19	1	US-10-310-914A-161839	Sequence 161839,
	822	16.4	0.4	19	1	US-10-310-914A-161840	Sequence 161840,
	823	16.4	0.4	19	1	US-10-310-914A-225326	Sequence 225326,
	824	16.4	0.4	19	1	US-10-310-914A-329935	Sequence 329935,
	825	16.4	0.4	19	1	US-10-310-914A-481752	Sequence 481752,
c	826	16.4	0.4	19	1	US-10-310-914A-562468	Sequence 562468,
	827	16.4	0.4	19	1	US-10-310-914A-910660	Sequence 910660,
c	828	16.4	0.4	19	1	US-10-310-914A-917658	Sequence 917658,
c	829	16.4	0.4	19	1	US-10-310-914A-1011800	Sequence 1011800,
	830	16.4	0.4	19	1	US-10-310-914A-1024936	Sequence 1024936,
	831	16.4	0.4	19	1	US-10-310-914A-1182295	Sequence 1182295,
	832	16.4	0.4	19	1	US-10-310-914A-1313753	Sequence 1313753,
	833	16.4	0.4	19	1	US-10-310-914A-1329386	Sequence 1329386,
	834	16.4	0.4	19	1	US-11-101-244-117533	Sequence 117533,
	835	16.4	0.4	19	1	US-11-101-244-158322	Sequence 158322,
	836	16.4	0.4	19	1	US-11-101-244-159024	Sequence 159024,

837	16.4	0.4	19	1	US-11-101-244-159117	Sequence 159117,
838	16.4	0.4	19	1	US-11-101-244-159229	Sequence 159229,
839	16.4	0.4	19	1	US-11-101-244-159279	Sequence 159279,
840	16.4	0.4	19	1	US-11-101-244-258796	Sequence 258796,
841	16.4	0.4	19	1	US-11-101-244-258802	Sequence 258802,
c 842	16.4	0.4	19	1	US-11-101-244-317987	Sequence 317987,
843	16.4	0.4	19	1	US-11-101-244-325732	Sequence 325732,
844	16.4	0.4	19	1	US-11-101-244-495967	Sequence 495967,
845	16.4	0.4	19	1	US-11-101-244-520914	Sequence 520914,
846	16.4	0.4	19	1	US-11-101-244-521180	Sequence 521180,
847	16.4	0.4	19	1	US-11-101-244-931315	Sequence 931315,
848	16.4	0.4	19	1	US-11-101-244-1104821	Sequence 1104821,
849	16.4	0.4	19	1	US-11-101-244-1174362	Sequence 1174362,
c 850	16.4	0.4	19	1	US-11-101-244-1393142	Sequence 1393142,
c 851	16.4	0.4	19	1	US-11-101-244-1494874	Sequence 1494874,
852	16.4	0.4	19	1	US-11-101-244-1529001	Sequence 1529001,
853	16.4	0.4	19	1	US-11-083-784-117533	Sequence 117533,
854	16.4	0.4	19	1	US-11-083-784-158322	Sequence 158322,
855	16.4	0.4	19	1	US-11-083-784-159024	Sequence 159024,
856	16.4	0.4	19	1	US-11-083-784-159117	Sequence 159117,
857	16.4	0.4	19	1	US-11-083-784-159229	Sequence 159229,
858	16.4	0.4	19	1	US-11-083-784-159279	Sequence 159279,
859	16.4	0.4	19	1	US-11-083-784-258796	Sequence 258796,
860	16.4	0.4	19	1	US-11-083-784-258802	Sequence 258802,
c 861	16.4	0.4	19	1	US-11-083-784-317987	Sequence 317987,
862	16.4	0.4	19	1	US-11-083-784-325732	Sequence 325732,
863	16.4	0.4	19	1	US-11-083-784-495967	Sequence 495967,
864	16.4	0.4	19	1	US-11-083-784-520914	Sequence 520914,
865	16.4	0.4	19	1	US-11-083-784-521180	Sequence 521180,
866	16.4	0.4	19	1	US-11-083-784-931315	Sequence 931315,
867	16.4	0.4	19	1	US-11-083-784-1104821	Sequence 1104821,
868	16.4	0.4	19	1	US-11-083-784-1174362	Sequence 1174362,
c 869	16.4	0.4	19	1	US-11-083-784-1393142	Sequence 1393142,
c 870	16.4	0.4	19	1	US-11-083-784-1494874	Sequence 1494874,
871	16.4	0.4	19	1	US-11-083-784-1529001	Sequence 1529001,
c 872	16.4	0.4	20	1	US-10-310-914A-385316	Sequence 385316,
c 873	16.4	0.4	20	1	US-10-310-914A-916483	Sequence 916483,
c 874	16.4	0.4	20	1	US-10-310-914A-1192704	Sequence 1192704,
875	16	0.4	18	1	US-10-310-914A-81546	Sequence 81546, A
876	16	0.4	18	1	US-10-310-914A-443869	Sequence 443869,
c 877	16	0.4	18	1	US-10-310-914A-916489	Sequence 916489,
878	16	0.4	18	1	US-10-310-914A-983472	Sequence 983472,
c 879	16	0.4	18	1	US-10-310-914A-1088339	Sequence 1088339,
c 880	16	0.4	18	1	US-10-310-914A-1346847	Sequence 1346847,
881	16	0.4	19	1	US-10-310-914A-196336	Sequence 196336,
882	16	0.4	19	1	US-10-310-914A-482672	Sequence 482672,
c 883	16	0.4	19	1	US-10-310-914A-1295091	Sequence 1295091,
c 884	16	0.4	19	1	US-10-310-914A-1343420	Sequence 1343420,
c 885	16	0.4	19	1	US-11-101-244-31908	Sequence 31908, A
886	16	0.4	19	1	US-11-101-244-159280	Sequence 159280,
c 887	16	0.4	19	1	US-11-101-244-704088	Sequence 704088,
c 888	16	0.4	19	1	US-11-101-244-704181	Sequence 704181,
889	16	0.4	19	1	US-11-101-244-931267	Sequence 931267,
890	16	0.4	19	1	US-11-101-244-931277	Sequence 931277,
c 891	16	0.4	19	1	US-11-101-244-1365774	Sequence 1365774,
c 892	16	0.4	19	1	US-11-083-784-31908	Sequence 31908, A
893	16	0.4	19	1	US-11-083-784-159280	Sequence 159280,
c 894	16	0.4	19	1	US-11-083-784-704088	Sequence 704088,
c 895	16	0.4	19	1	US-11-083-784-704181	Sequence 704181,
896	16	0.4	19	1	US-11-083-784-931267	Sequence 931267,
897	16	0.4	19	1	US-11-083-784-931277	Sequence 931277,
c 898	16	0.4	19	1	US-11-083-784-1365774	Sequence 1365774,
899	16	0.4	20	1	US-10-831-286A-34811	Sequence 34811, A
900	16	0.4	20	1	US-10-831-286A-37357	Sequence 37357, A
901	16	0.4	20	1	US-10-831-286A-40915	Sequence 40915, A
902	16	0.4	20	1	US-10-831-286A-48457	Sequence 48457, A
903	16	0.4	20	1	US-10-310-914A-196337	Sequence 196337,
904	15.8	0.4	19	1	US-10-922-761-87	Sequence 87, Appl
c 905	15.8	0.4	19	1	US-10-922-761-184	Sequence 184, App
906	15.8	0.4	19	1	US-10-310-914A-50195	Sequence 50195, A
c 907	15.8	0.4	19	1	US-10-310-914A-74610	Sequence 74610, A
908	15.8	0.4	19	1	US-10-310-914A-81513	Sequence 81513, A
c 909	15.8	0.4	19	1	US-10-310-914A-143107	Sequence 143107,
c 910	15.8	0.4	19	1	US-10-310-914A-143645	Sequence 143645,
c 911	15.8	0.4	19	1	US-10-310-914A-152768	Sequence 152768,
c 912	15.8	0.4	19	1	US-10-310-914A-175809	Sequence 175809,
913	15.8	0.4	19	1	US-10-310-914A-209753	Sequence 209753,
c 914	15.8	0.4	19	1	US-10-310-914A-242649	Sequence 242649,
c 915	15.8	0.4	19	1	US-10-310-914A-271792	Sequence 271792,
c 916	15.8	0.4	19	1	US-10-310-914A-376173	Sequence 376173,
c 917	15.8	0.4	19	1	US-10-310-914A-402475	Sequence 402475,
c 918	15.8	0.4	19	1	US-10-310-914A-426755	Sequence 426755,
c 919	15.8	0.4	19	1	US-10-310-914A-427119	Sequence 427119,
920	15.8	0.4	19	1	US-10-310-914A-454195	Sequence 454195,
c 921	15.8	0.4	19	1	US-10-310-914A-462107	Sequence 462107,
922	15.8	0.4	19	1	US-10-310-914A-477363	Sequence 477363,
c 923	15.8	0.4	19	1	US-10-310-914A-481676	Sequence 481676,
924	15.8	0.4	19	1	US-10-310-914A-496772	Sequence 496772,
925	15.8	0.4	19	1	US-10-310-914A-497205	Sequence 497205,
c 926	15.8	0.4	19	1	US-10-310-914A-520422	Sequence 520422,
c 927	15.8	0.4	19	1	US-10-310-914A-543953	Sequence 543953,
928	15.8	0.4	19	1	US-10-310-914A-616709	Sequence 616709,
c 929	15.8	0.4	19	1	US-10-310-914A-691544	Sequence 691544,
930	15.8	0.4	19	1	US-10-310-914A-701274	Sequence 701274,
931	15.8	0.4	19	1	US-10-310-914A-735391	Sequence 735391,
c 932	15.8	0.4	19	1	US-10-310-914A-764359	Sequence 764359,
933	15.8	0.4	19	1	US-10-310-914A-778757	Sequence 778757,
c 934	15.8	0.4	19	1	US-10-310-914A-933487	Sequence 933487,
935	15.8	0.4	19	1	US-10-310-914A-990363	Sequence 990363,
936	15.8	0.4	19	1	US-10-310-914A-1040857	Sequence 1040857,
937	15.8	0.4	19	1	US-10-310-914A-1099801	Sequence 1099801,
c 938	15.8	0.4	19	1	US-10-310-914A-1147060	Sequence 1147060,
939	15.8	0.4	19	1	US-10-310-914A-1160786	Sequence 1160786,
c 940	15.8	0.4	19	1	US-10-310-914A-1167297	Sequence 1167297,
941	15.8	0.4	19	1	US-10-310-914A-1249167	Sequence 1249167,
942	15.8	0.4	19	1	US-10-310-914A-1257401	Sequence 1257401,
943	15.8	0.4	19	1	US-11-101-244-611	Sequence 611, App
944	15.8	0.4	19	1	US-11-101-244-31906	Sequence 31906, A
945	15.8	0.4	19	1	US-11-101-244-51586	Sequence 51586, A
c 946	15.8	0.4	19	1	US-11-101-244-88135	Sequence 88135, A
947	15.8	0.4	19	1	US-11-101-244-108278	Sequence 108278,
948	15.8	0.4	19	1	US-11-101-244-108374	Sequence 108374,
949	15.8	0.4	19	1	US-11-101-244-108473	Sequence 108473,
950	15.8	0.4	19	1	US-11-101-244-108571	Sequence 108571,
951	15.8	0.4	19	1	US-11-101-244-108671	Sequence 108671,
c 952	15.8	0.4	19	1	US-11-101-244-113648	Sequence 113648,
953	15.8	0.4	19	1	US-11-101-244-149446	Sequence 149446,
954	15.8	0.4	19	1	US-11-101-244-153349	Sequence 153349,
955	15.8	0.4	19	1	US-11-101-244-158289	Sequence 158289,
956	15.8	0.4	19	1	US-11-101-244-158376	Sequence 158376,
957	15.8	0.4	19	1	US-11-101-244-158377	Sequence 158377,
958	15.8	0.4	19	1	US-11-101-244-158451	Sequence 158451,
959	15.8	0.4	19	1	US-11-101-244-158521	Sequence 158521,
960	15.8	0.4	19	1	US-11-101-244-158525	Sequence 158525,
961	15.8	0.4	19	1	US-11-101-244-158535	Sequence 158535,
962	15.8	0.4	19	1	US-11-101-244-158948	Sequence 158948,
963	15.8	0.4	19	1	US-11-101-244-158952	Sequence 158952,
964	15.8	0.4	19	1	US-11-101-244-158958	Sequence 158958,
965	15.8	0.4	19	1	US-11-101-244-159005	Sequence 159005,
966	15.8	0.4	19	1	US-11-101-244-159035	Sequence 159035,
967	15.8	0.4	19	1	US-11-101-244-159068	Sequence 159068,
968	15.8	0.4	19	1	US-11-101-244-159101	Sequence 159101,
969	15.8	0.4	19	1	US-11-101-244-159124	Sequence 159124,
970	15.8	0.4	19	1	US-11-101-244-159148	Sequence 159148,
971	15.8	0.4	19	1	US-11-101-244-159210	Sequence 159210,
972	15.8	0.4	19	1	US-11-101-244-159219	Sequence 159219,
973	15.8	0.4	19	1	US-11-101-244-159481	Sequence 159481,
c 974	15.8	0.4	19	1	US-11-101-244-182879	Sequence 182879,
c 975	15.8	0.4	19	1	US-11-101-244-183246	Sequence 183246,
976	15.8	0.4	19	1	US-11-101-244-215222	Sequence 215222,
c 977	15.8	0.4	19	1	US-11-101-244-247832	Sequence 247832,
c 978	15.8	0.4	19	1	US-11-101-244-256851	Sequence 256851,
c 979	15.8	0.4	19	1	US-11-101-244-314443	Sequence 314443,
980	15.8	0.4	19	1	US-11-101-244-351839	Sequence 351839,
981	15.8	0.4	19	1	US-11-101-244-351938	Sequence 351938,
982	15.8	0.4	19	1	US-11-101-244-351977	Sequence 351977,

983	15.8	0.4	19	1	US-11-101-244-358726	Sequence 358726,
984	15.8	0.4	19	1	US-11-101-244-358909	Sequence 358909,
985	15.8	0.4	19	1	US-11-101-244-367347	Sequence 367347,
986	15.8	0.4	19	1	US-11-101-244-368735	Sequence 368735,
987	15.8	0.4	19	1	US-11-101-244-401647	Sequence 401647,
988	15.8	0.4	19	1	US-11-101-244-463025	Sequence 463025,
989	15.8	0.4	19	1	US-11-101-244-520652	Sequence 520652,
990	15.8	0.4	19	1	US-11-101-244-553895	Sequence 553895,
991	15.8	0.4	19	1	US-11-101-244-558451	Sequence 558451,
992	15.8	0.4	19	1	US-11-101-244-588523	Sequence 588523,
993	15.8	0.4	19	1	US-11-101-244-602297	Sequence 602297,
994	15.8	0.4	19	1	US-11-101-244-632602	Sequence 632602,
c 995	15.8	0.4	19	1	US-11-101-244-633003	Sequence 633003,
c 996	15.8	0.4	19	1	US-11-101-244-645883	Sequence 645883,
c 997	15.8	0.4	19	1	US-11-101-244-665485	Sequence 665485,
998	15.8	0.4	19	1	US-11-101-244-669877	Sequence 669877,
c 999	15.8	0.4	19	1	US-11-101-244-707935	Sequence 707935,
c1000	15.8	0.4	19	1	US-11-101-244-722881	Sequence 722881,
1001	15.8	0.4	19	1	US-11-101-244-729514	Sequence 729514,
1002	15.8	0.4	19	1	US-11-101-244-729613	Sequence 729613,
1003	15.8	0.4	19	1	US-11-101-244-748070	Sequence 748070,
c1004	15.8	0.4	19	1	US-11-101-244-748086	Sequence 748086,
1005	15.8	0.4	19	1	US-11-101-244-814212	Sequence 814212,
1006	15.8	0.4	19	1	US-11-101-244-815617	Sequence 815617,
c1007	15.8	0.4	19	1	US-11-101-244-829676	Sequence 829676,
1008	15.8	0.4	19	1	US-11-101-244-858962	Sequence 858962,
1009	15.8	0.4	19	1	US-11-101-244-871328	Sequence 871328,
c1010	15.8	0.4	19	1	US-11-101-244-889071	Sequence 889071,
1011	15.8	0.4	19	1	US-11-101-244-903949	Sequence 903949,
c1012	15.8	0.4	19	1	US-11-101-244-931273	Sequence 931273,
1013	15.8	0.4	19	1	US-11-101-244-931865	Sequence 931865,
1014	15.8	0.4	19	1	US-11-101-244-943735	Sequence 943735,
1015	15.8	0.4	19	1	US-11-101-244-959149	Sequence 959149,
1016	15.8	0.4	19	1	US-11-101-244-959179	Sequence 959179,
c1017	15.8	0.4	19	1	US-11-101-244-965862	Sequence 965862,
1018	15.8	0.4	19	1	US-11-101-244-1012257	Sequence 1012257,
1019	15.8	0.4	19	1	US-11-101-244-1012356	Sequence 1012356,
c1020	15.8	0.4	19	1	US-11-101-244-1029052	Sequence 1029052,
1021	15.8	0.4	19	1	US-11-101-244-1030733	Sequence 1030733,
c1022	15.8	0.4	19	1	US-11-101-244-1033475	Sequence 1033475,
1023	15.8	0.4	19	1	US-11-101-244-1104856	Sequence 1104856,
1024	15.8	0.4	19	1	US-11-101-244-1110635	Sequence 1110635,
1025	15.8	0.4	19	1	US-11-101-244-1110844	Sequence 1110844,
1026	15.8	0.4	19	1	US-11-101-244-1111066	Sequence 1111066,
1027	15.8	0.4	19	1	US-11-101-244-1111265	Sequence 1111265,
1028	15.8	0.4	19	1	US-11-101-244-1111461	Sequence 1111461,
1029	15.8	0.4	19	1	US-11-101-244-1111653	Sequence 1111653,
1030	15.8	0.4	19	1	US-11-101-244-1111863	Sequence 1111863,
1031	15.8	0.4	19	1	US-11-101-244-1112048	Sequence 1112048,
1032	15.8	0.4	19	1	US-11-101-244-1112255	Sequence 1112255,
1033	15.8	0.4	19	1	US-11-101-244-1112450	Sequence 1112450,
1034	15.8	0.4	19	1	US-11-101-244-1112549	Sequence 1112549,
1035	15.8	0.4	19	1	US-11-101-244-1112749	Sequence 1112749,
1036	15.8	0.4	19	1	US-11-101-244-1112941	Sequence 1112941,
1037	15.8	0.4	19	1	US-11-101-244-1113149	Sequence 1113149,
1038	15.8	0.4	19	1	US-11-101-244-1113350	Sequence 1113350,
1039	15.8	0.4	19	1	US-11-101-244-1113545	Sequence 1113545,
1040	15.8	0.4	19	1	US-11-101-244-1113749	Sequence 1113749,
1041	15.8	0.4	19	1	US-11-101-244-1113949	Sequence 1113949,
1042	15.8	0.4	19	1	US-11-101-244-1114149	Sequence 1114149,
c1043	15.8	0.4	19	1	US-11-101-244-1162888	Sequence 1162888,
1044	15.8	0.4	19	1	US-11-101-244-1175693	Sequence 1175693,
1045	15.8	0.4	19	1	US-11-101-244-1207595	Sequence 1207595,
1046	15.8	0.4	19	1	US-11-101-244-1277041	Sequence 1277041,
1047	15.8	0.4	19	1	US-11-101-244-1315734	Sequence 1315734,
c1048	15.8	0.4	19	1	US-11-101-244-1355528	Sequence 1355528,
c1049	15.8	0.4	19	1	US-11-101-244-1377429	Sequence 1377429,
c1050	15.8	0.4	19	1	US-11-101-244-1380520	Sequence 1380520,
1051	15.8	0.4	19	1	US-11-101-244-1563938	Sequence 1563938,
1052	15.8	0.4	19	1	US-11-083-784-611	Sequence 611, App
1053	15.8	0.4	19	1	US-11-083-784-31906	Sequence 31906, A
1054	15.8	0.4	19	1	US-11-083-784-51586	Sequence 51586, A
c1055	15.8	0.4	19	1	US-11-083-784-88135	Sequence 88135, A
1056	15.8	0.4	19	1	US-11-083-784-108278	Sequence 108278,
1057	15.8	0.4	19	1	US-11-083-784-108374	Sequence 108374,
1058	15.8	0.4	19	1	US-11-083-784-108473	Sequence 108473,
1059	15.8	0.4	19	1	US-11-083-784-108571	Sequence 108571,
1060	15.8	0.4	19	1	US-11-083-784-108671	Sequence 108671,
c1061	15.8	0.4	19	1	US-11-083-784-113648	Sequence 113648,
1062	15.8	0.4	19	1	US-11-083-784-149446	Sequence 149446,
1063	15.8	0.4	19	1	US-11-083-784-153349	Sequence 153349,
1064	15.8	0.4	19	1	US-11-083-784-158289	Sequence 158289,
1065	15.8	0.4	19	1	US-11-083-784-158376	Sequence 158376,
1066	15.8	0.4	19	1	US-11-083-784-158377	Sequence 158377,
1067	15.8	0.4	19	1	US-11-083-784-158451	Sequence 158451,
1068	15.8	0.4	19	1	US-11-083-784-158521	Sequence 158521,
1069	15.8	0.4	19	1	US-11-083-784-158525	Sequence 158525,
1070	15.8	0.4	19	1	US-11-083-784-158535	Sequence 158535,
1071	15.8	0.4	19	1	US-11-083-784-158948	Sequence 158948,
1072	15.8	0.4	19	1	US-11-083-784-158952	Sequence 158952,
1073	15.8	0.4	19	1	US-11-083-784-158958	Sequence 158958,
1074	15.8	0.4	19	1	US-11-083-784-159005	Sequence 159005,
1075	15.8	0.4	19	1	US-11-083-784-159035	Sequence 159035,
1076	15.8	0.4	19	1	US-11-083-784-159068	Sequence 159068,
1077	15.8	0.4	19	1	US-11-083-784-159101	Sequence 159101,
1078	15.8	0.4	19	1	US-11-083-784-159124	Sequence 159124,
1079	15.8	0.4	19	1	US-11-083-784-159148	Sequence 159148,
1080	15.8	0.4	19	1	US-11-083-784-159210	Sequence 159210,
1081	15.8	0.4	19	1	US-11-083-784-159219	Sequence 159219,
1082	15.8	0.4	19	1	US-11-083-784-159481	Sequence 159481,
c1083	15.8	0.4	19	1	US-11-083-784-182879	Sequence 182879,
c1084	15.8	0.4	19	1	US-11-083-784-183246	Sequence 183246,
1085	15.8	0.4	19	1	US-11-083-784-215222	Sequence 215222,
c1086	15.8	0.4	19	1	US-11-083-784-247832	Sequence 247832,
c1087	15.8	0.4	19	1	US-11-083-784-256851	Sequence 256851,
c1088	15.8	0.4	19	1	US-11-083-784-314443	Sequence 314443,
1089	15.8	0.4	19	1	US-11-083-784-351839	Sequence 351839,
1090	15.8	0.4	19	1	US-11-083-784-351938	Sequence 351938,
1091	15.8	0.4	19	1	US-11-083-784-351977	Sequence 351977,
1092	15.8	0.4	19	1	US-11-083-784-358726	Sequence 358726,
1093	15.8	0.4	19	1	US-11-083-784-358909	Sequence 358909,
1094	15.8	0.4	19	1	US-11-083-784-367347	Sequence 367347,
1095	15.8	0.4	19	1	US-11-083-784-368735	Sequence 368735,
1096	15.8	0.4	19	1	US-11-083-784-401647	Sequence 401647,
1097	15.8	0.4	19	1	US-11-083-784-463025	Sequence 463025,
1098	15.8	0.4	19	1	US-11-083-784-520652	Sequence 520652,
1099	15.8	0.4	19	1	US-11-083-784-553895	Sequence 553895,
1100	15.8	0.4	19	1	US-11-083-784-558451	Sequence 558451,
1101	15.8	0.4	19	1	US-11-083-784-588523	Sequence 588523,
1102	15.8	0.4	19	1	US-11-083-784-602297	Sequence 602297,
1103	15.8	0.4	19	1	US-11-083-784-632602	Sequence 632602,
c1104	15.8	0.4	19	1	US-11-083-784-633003	Sequence 633003,
c1105	15.8	0.4	19	1	US-11-083-784-645883	Sequence 645883,
c1106	15.8	0.4	19	1	US-11-083-784-665485	Sequence 665485,
1107	15.8	0.4	19	1	US-11-083-784-669877	Sequence 669877,
c1108	15.8	0.4	19	1	US-11-083-784-707935	Sequence 707935,
c1109	15.8	0.4	19	1	US-11-083-784-722881	Sequence 722881,
1110	15.8	0.4	19	1	US-11-083-784-729514	Sequence 729514,
1111	15.8	0.4	19	1	US-11-083-784-729613	Sequence 729613,
1112	15.8	0.4	19	1	US-11-083-784-748070	Sequence 748070,
c1113	15.8	0.4	19	1	US-11-083-784-748086	Sequence 748086,
1114	15.8	0.4	19	1	US-11-083-784-814212	Sequence 814212,
1115	15.8	0.4	19	1	US-11-083-784-815617	Sequence 815617,
c1116	15.8	0.4	19	1	US-11-083-784-829676	Sequence 829676,
1117	15.8	0.4	19	1	US-11-083-784-858962	Sequence 858962,
1118	15.8	0.4	19	1	US-11-083-784-871328	Sequence 871328,
c1119	15.8	0.4	19	1	US-11-083-784-889071	Sequence 889071,
1120	15.8	0.4	19	1	US-11-083-784-903949	Sequence 903949,
c1121	15.8	0.4	19	1	US-11-083-784-931273	Sequence 931273,
1122	15.8	0.4	19	1	US-11-083-784-931865	Sequence 931865,
1123	15.8	0.4	19	1	US-11-083-784-943735	Sequence 943735,
1124	15.8	0.4	19	1	US-11-083-784-959149	Sequence 959149,
1125	15.8	0.4	19	1	US-11-083-784-959179	Sequence 959179,
c1126	15.8	0.4	19	1	US-11-083-784-965862	Sequence 965862,
1127	15.8	0.4	19	1	US-11-083-784-1012257	Sequence 1012257,
1128	15.8	0.4	19	1	US-11-083-784-1012356	Sequence 1012356,

c1129	15.8	0.4	19	1	US-11-083-784-1029052	Sequence 1029052,
1130	15.8	0.4	19	1	US-11-083-784-1030733	Sequence 1030733,
c1131	15.8	0.4	19	1	US-11-083-784-1033475	Sequence 1033475,
1132	15.8	0.4	19	1	US-11-083-784-1104856	Sequence 1104856,
1133	15.8	0.4	19	1	US-11-083-784-1110635	Sequence 1110635,
1134	15.8	0.4	19	1	US-11-083-784-1110844	Sequence 1110844,
1135	15.8	0.4	19	1	US-11-083-784-1111066	Sequence 1111066,
1136	15.8	0.4	19	1	US-11-083-784-1111265	Sequence 1111265,
1137	15.8	0.4	19	1	US-11-083-784-1111461	Sequence 1111461,
1138	15.8	0.4	19	1	US-11-083-784-1111653	Sequence 1111653,
1139	15.8	0.4	19	1	US-11-083-784-1111863	Sequence 1111863,
1140	15.8	0.4	19	1	US-11-083-784-1112048	Sequence 1112048,
1141	15.8	0.4	19	1	US-11-083-784-1112255	Sequence 1112255,
1142	15.8	0.4	19	1	US-11-083-784-1112450	Sequence 1112450,
1143	15.8	0.4	19	1	US-11-083-784-1112549	Sequence 1112549,
1144	15.8	0.4	19	1	US-11-083-784-1112749	Sequence 1112749,
1145	15.8	0.4	19	1	US-11-083-784-1112941	Sequence 1112941,
1146	15.8	0.4	19	1	US-11-083-784-1113149	Sequence 1113149,
1147	15.8	0.4	19	1	US-11-083-784-1113350	Sequence 1113350,
1148	15.8	0.4	19	1	US-11-083-784-1113545	Sequence 1113545,
1149	15.8	0.4	19	1	US-11-083-784-1113749	Sequence 1113749,
1150	15.8	0.4	19	1	US-11-083-784-1113949	Sequence 1113949,
1151	15.8	0.4	19	1	US-11-083-784-1114149	Sequence 1114149,
c1152	15.8	0.4	19	1	US-11-083-784-1162888	Sequence 1162888,
1153	15.8	0.4	19	1	US-11-083-784-1175693	Sequence 1175693,
1154	15.8	0.4	19	1	US-11-083-784-1207595	Sequence 1207595,
1155	15.8	0.4	19	1	US-11-083-784-1277041	Sequence 1277041,
1156	15.8	0.4	19	1	US-11-083-784-1315734	Sequence 1315734,
c1157	15.8	0.4	19	1	US-11-083-784-1355528	Sequence 1355528,
c1158	15.8	0.4	19	1	US-11-083-784-1377429	Sequence 1377429,
c1159	15.8	0.4	19	1	US-11-083-784-1380520	Sequence 1380520,
1160	15.8	0.4	19	1	US-11-083-784-1563938	Sequence 1563938,
c1161	15.4	0.4	18	1	US-10-310-914A-76027	Sequence 76027, A
c1162	15.4	0.4	18	1	US-10-310-914A-88249	Sequence 88249, A
c1163	15.4	0.4	18	1	US-10-310-914A-142074	Sequence 142074,
c1164	15.4	0.4	18	1	US-10-310-914A-194147	Sequence 194147,
c1165	15.4	0.4	18	1	US-10-310-914A-196436	Sequence 196436,
1166	15.4	0.4	18	1	US-10-310-914A-215704	Sequence 215704,
c1167	15.4	0.4	18	1	US-10-310-914A-233017	Sequence 233017,
c1168	15.4	0.4	18	1	US-10-310-914A-239452	Sequence 239452,
c1169	15.4	0.4	18	1	US-10-310-914A-277041	Sequence 277041,
1170	15.4	0.4	18	1	US-10-310-914A-291755	Sequence 291755,
c1171	15.4	0.4	18	1	US-10-310-914A-309547	Sequence 309547,
c1172	15.4	0.4	18	1	US-10-310-914A-319145	Sequence 319145,
1173	15.4	0.4	18	1	US-10-310-914A-337636	Sequence 337636,
c1174	15.4	0.4	18	1	US-10-310-914A-402474	Sequence 402474,
c1175	15.4	0.4	18	1	US-10-310-914A-482383	Sequence 482383,
c1176	15.4	0.4	18	1	US-10-310-914A-493585	Sequence 493585,
1177	15.4	0.4	18	1	US-10-310-914A-509676	Sequence 509676,
1178	15.4	0.4	18	1	US-10-310-914A-510078	Sequence 510078,
c1179	15.4	0.4	18	1	US-10-310-914A-562505	Sequence 562505,
c1180	15.4	0.4	18	1	US-10-310-914A-572035	Sequence 572035,
c1181	15.4	0.4	18	1	US-10-310-914A-572960	Sequence 572960,
c1182	15.4	0.4	18	1	US-10-310-914A-621831	Sequence 621831,
c1183	15.4	0.4	18	1	US-10-310-914A-705359	Sequence 705359,
c1184	15.4	0.4	18	1	US-10-310-914A-726118	Sequence 726118,
c1185	15.4	0.4	18	1	US-10-310-914A-736049	Sequence 736049,
c1186	15.4	0.4	18	1	US-10-310-914A-743243	Sequence 743243,
1187	15.4	0.4	18	1	US-10-310-914A-839587	Sequence 839587,
1188	15.4	0.4	18	1	US-10-310-914A-842880	Sequence 842880,
c1189	15.4	0.4	18	1	US-10-310-914A-876761	Sequence 876761,
c1190	15.4	0.4	18	1	US-10-310-914A-877410	Sequence 877410,
1191	15.4	0.4	18	1	US-10-310-914A-904313	Sequence 904313,
1192	15.4	0.4	18	1	US-10-310-914A-924563	Sequence 924563,
1193	15.4	0.4	18	1	US-10-310-914A-966189	Sequence 966189,
1194	15.4	0.4	18	1	US-10-310-914A-1029714	Sequence 1029714,
c1195	15.4	0.4	18	1	US-10-310-914A-1043266	Sequence 1043266,
1196	15.4	0.4	18	1	US-10-310-914A-1071301	Sequence 1071301,
c1197	15.4	0.4	18	1	US-10-310-914A-1175377	Sequence 1175377,
1198	15.4	0.4	18	1	US-10-310-914A-1199690	Sequence 1199690,
1199	15.4	0.4	18	1	US-10-310-914A-1214992	Sequence 1214992,
1200	15.4	0.4	18	1	US-10-310-914A-1253300	Sequence 1253300,
c1201	15.4	0.4	18	1	US-10-310-914A-1296340	Sequence 1296340,
c1202	15.4	0.4	18	1	US-10-310-914A-1312670	Sequence 1312670,
c1203	15.4	0.4	19	1	US-10-310-914A-42828	Sequence 42828, A
c1204	15.4	0.4	19	1	US-10-310-914A-42829	Sequence 42829, A
1205	15.4	0.4	19	1	US-10-310-914A-44524	Sequence 44524, A
c1206	15.4	0.4	19	1	US-10-310-914A-44732	Sequence 44732, A
c1207	15.4	0.4	19	1	US-10-310-914A-66712	Sequence 66712, A
c1208	15.4	0.4	19	1	US-10-310-914A-76028	Sequence 76028, A
1209	15.4	0.4	19	1	US-10-310-914A-124041	Sequence 124041,
c1210	15.4	0.4	19	1	US-10-310-914A-141479	Sequence 141479,
c1211	15.4	0.4	19	1	US-10-310-914A-164314	Sequence 164314,
c1212	15.4	0.4	19	1	US-10-310-914A-165319	Sequence 165319,
c1213	15.4	0.4	19	1	US-10-310-914A-165325	Sequence 165325,
1214	15.4	0.4	19	1	US-10-310-914A-174508	Sequence 174508,
c1215	15.4	0.4	19	1	US-10-310-914A-260318	Sequence 260318,
1216	15.4	0.4	19	1	US-10-310-914A-332383	Sequence 332383,
c1217	15.4	0.4	19	1	US-10-310-914A-368914	Sequence 368914,
1218	15.4	0.4	19	1	US-10-310-914A-450885	Sequence 450885,
c1219	15.4	0.4	19	1	US-10-310-914A-476139	Sequence 476139,
c1220	15.4	0.4	19	1	US-10-310-914A-478635	Sequence 478635,
1221	15.4	0.4	19	1	US-10-310-914A-567126	Sequence 567126,
c1222	15.4	0.4	19	1	US-10-310-914A-568323	Sequence 568323,
1223	15.4	0.4	19	1	US-10-310-914A-580849	Sequence 580849,
c1224	15.4	0.4	19	1	US-10-310-914A-591068	Sequence 591068,
c1225	15.4	0.4	19	1	US-10-310-914A-621832	Sequence 621832,
1226	15.4	0.4	19	1	US-10-310-914A-632545	Sequence 632545,
1227	15.4	0.4	19	1	US-10-310-914A-656960	Sequence 656960,
1228	15.4	0.4	19	1	US-10-310-914A-693048	Sequence 693048,
1229	15.4	0.4	19	1	US-10-310-914A-693049	Sequence 693049,
c1230	15.4	0.4	19	1	US-10-310-914A-724817	Sequence 724817,
c1231	15.4	0.4	19	1	US-10-310-914A-725516	Sequence 725516,
1232	15.4	0.4	19	1	US-10-310-914A-738648	Sequence 738648,
1233	15.4	0.4	19	1	US-10-310-914A-757318	Sequence 757318,
1234	15.4	0.4	19	1	US-10-310-914A-773116	Sequence 773116,
1235	15.4	0.4	19	1	US-10-310-914A-796345	Sequence 796345,
c1236	15.4	0.4	19	1	US-10-310-914A-814718	Sequence 814718,
1237	15.4	0.4	19	1	US-10-310-914A-842885	Sequence 842885,
c1238	15.4	0.4	19	1	US-10-310-914A-885145	Sequence 885145,
c1239	15.4	0.4	19	1	US-10-310-914A-900173	Sequence 900173,
1240	15.4	0.4	19	1	US-10-310-914A-906770	Sequence 906770,
1241	15.4	0.4	19	1	US-10-310-914A-912740	Sequence 912740,
1242	15.4	0.4	19	1	US-10-310-914A-933011	Sequence 933011,
1243	15.4	0.4	19	1	US-10-310-914A-949706	Sequence 949706,
c1244	15.4	0.4	19	1	US-10-310-914A-966440	Sequence 966440,
c1245	15.4	0.4	19	1	US-10-310-914A-1044765	Sequence 1044765,
c1246	15.4	0.4	19	1	US-10-310-914A-1127249	Sequence 1127249,
1247	15.4	0.4	19	1	US-10-310-914A-1150255	Sequence 1150255,
1248	15.4	0.4	19	1	US-10-310-914A-1150285	Sequence 1150285,
1249	15.4	0.4	19	1	US-10-310-914A-1154760	Sequence 1154760,
c1250	15.4	0.4	19	1	US-10-310-914A-1187331	Sequence 1187331,
c1251	15.4	0.4	19	1	US-10-310-914A-1283822	Sequence 1283822,
1252	15.4	0.4	19	1	US-11-101-244-51	Sequence 51, Appl
1253	15.4	0.4	19	1	US-11-101-244-14393	Sequence 14393, A
1254	15.4	0.4	19	1	US-11-101-244-14433	Sequence 14433, A
1255	15.4	0.4	19	1	US-11-101-244-38758	Sequence 38758, A
c1256	15.4	0.4	19	1	US-11-101-244-47494	Sequence 47494, A
1257	15.4	0.4	19	1	US-11-101-244-88064	Sequence 88064, A
1258	15.4	0.4	19	1	US-11-101-244-95986	Sequence 95986, A
1259	15.4	0.4	19	1	US-11-101-244-124920	Sequence 124920,
1260	15.4	0.4	19	1	US-11-101-244-158311	Sequence 158311,
1261	15.4	0.4	19	1	US-11-101-244-158978	Sequence 158978,
c1262	15.4	0.4	19	1	US-11-101-244-165037	Sequence 165037,
c1263	15.4	0.4	19	1	US-11-101-244-165057	Sequence 165057,
c1264	15.4	0.4	19	1	US-11-101-244-165136	Sequence 165136,
c1265	15.4	0.4	19	1	US-11-101-244-165156	Sequence 165156,
c1266	15.4	0.4	19	1	US-11-101-244-165238	Sequence 165238,
c1267	15.4	0.4	19	1	US-11-101-244-165258	Sequence 165258,
c1268	15.4	0.4	19	1	US-11-101-244-165337	Sequence 165337,
c1269	15.4	0.4	19	1	US-11-101-244-165357	Sequence 165357,
c1270	15.4	0.4	19	1	US-11-101-244-165439	Sequence 165439,
c1271	15.4	0.4	19	1	US-11-101-244-165462	Sequence 165462,
1272	15.4	0.4	19	1	US-11-101-244-223107	Sequence 223107,
c1273	15.4	0.4	19	1	US-11-101-244-249657	Sequence 249657,
c1274	15.4	0.4	19	1	US-11-101-244-249676	Sequence 249676,

1275	15.4	0.4	19	1	US-11-101-244-376141	Sequence 376141,
1276	15.4	0.4	19	1	US-11-101-244-384878	Sequence 384878,
1277	15.4	0.4	19	1	US-11-101-244-388710	Sequence 388710,
c1278	15.4	0.4	19	1	US-11-101-244-393275	Sequence 393275,
1279	15.4	0.4	19	1	US-11-101-244-405137	Sequence 405137,
1280	15.4	0.4	19	1	US-11-101-244-405183	Sequence 405183,
1281	15.4	0.4	19	1	US-11-101-244-440347	Sequence 440347,
c1282	15.4	0.4	19	1	US-11-101-244-442932	Sequence 442932,
c1283	15.4	0.4	19	1	US-11-101-244-446199	Sequence 446199,
c1284	15.4	0.4	19	1	US-11-101-244-448936	Sequence 448936,
1285	15.4	0.4	19	1	US-11-101-244-466442	Sequence 466442,
c1286	15.4	0.4	19	1	US-11-101-244-478703	Sequence 478703,
1287	15.4	0.4	19	1	US-11-101-244-488729	Sequence 488729,
1288	15.4	0.4	19	1	US-11-101-244-499341	Sequence 499341,
1289	15.4	0.4	19	1	US-11-101-244-536642	Sequence 536642,
c1290	15.4	0.4	19	1	US-11-101-244-586431	Sequence 586431,
c1291	15.4	0.4	19	1	US-11-101-244-593515	Sequence 593515,
c1292	15.4	0.4	19	1	US-11-101-244-604134	Sequence 604134,
c1293	15.4	0.4	19	1	US-11-101-244-618691	Sequence 618691,
1294	15.4	0.4	19	1	US-11-101-244-710189	Sequence 710189,
c1295	15.4	0.4	19	1	US-11-101-244-772658	Sequence 772658,
1296	15.4	0.4	19	1	US-11-101-244-778427	Sequence 778427,
1297	15.4	0.4	19	1	US-11-101-244-778438	Sequence 778438,
1298	15.4	0.4	19	1	US-11-101-244-788952	Sequence 788952,
1299	15.4	0.4	19	1	US-11-101-244-789052	Sequence 789052,
1300	15.4	0.4	19	1	US-11-101-244-789152	Sequence 789152,
1301	15.4	0.4	19	1	US-11-101-244-789248	Sequence 789248,
1302	15.4	0.4	19	1	US-11-101-244-789347	Sequence 789347,
1303	15.4	0.4	19	1	US-11-101-244-789447	Sequence 789447,
c1304	15.4	0.4	19	1	US-11-101-244-834453	Sequence 834453,
1305	15.4	0.4	19	1	US-11-101-244-837999	Sequence 837999,
1306	15.4	0.4	19	1	US-11-101-244-855576	Sequence 855576,
c1307	15.4	0.4	19	1	US-11-101-244-927801	Sequence 927801,
1308	15.4	0.4	19	1	US-11-101-244-1019444	Sequence 1019444,
c1309	15.4	0.4	19	1	US-11-101-244-1036594	Sequence 1036594,
1310	15.4	0.4	19	1	US-11-101-244-1071237	Sequence 1071237,
1311	15.4	0.4	19	1	US-11-101-244-1071275	Sequence 1071275,
1312	15.4	0.4	19	1	US-11-101-244-1104410	Sequence 1104410,
1313	15.4	0.4	19	1	US-11-101-244-1104472	Sequence 1104472,
1314	15.4	0.4	19	1	US-11-101-244-1134517	Sequence 1134517,
1315	15.4	0.4	19	1	US-11-101-244-1136133	Sequence 1136133,
1316	15.4	0.4	19	1	US-11-101-244-1207573	Sequence 1207573,
1317	15.4	0.4	19	1	US-11-101-244-1259838	Sequence 1259838,
c1318	15.4	0.4	19	1	US-11-101-244-1263543	Sequence 1263543,
c1319	15.4	0.4	19	1	US-11-101-244-1263597	Sequence 1263597,
c1320	15.4	0.4	19	1	US-11-101-244-1268095	Sequence 1268095,
c1321	15.4	0.4	19	1	US-11-101-244-1319444	Sequence 1319444,
c1322	15.4	0.4	19	1	US-11-101-244-1323046	Sequence 1323046,
c1323	15.4	0.4	19	1	US-11-101-244-1334142	Sequence 1334142,
1324	15.4	0.4	19	1	US-11-101-244-1366776	Sequence 1366776,
c1325	15.4	0.4	19	1	US-11-101-244-1372964	Sequence 1372964,
1326	15.4	0.4	19	1	US-11-101-244-1401474	Sequence 1401474,
c1327	15.4	0.4	19	1	US-11-101-244-1441103	Sequence 1441103,
c1328	15.4	0.4	19	1	US-11-101-244-1444645	Sequence 1444645,
c1329	15.4	0.4	19	1	US-11-101-244-1469620	Sequence 1469620,
c1330	15.4	0.4	19	1	US-11-101-244-1495899	Sequence 1495899,
1331	15.4	0.4	19	1	US-11-101-244-1512077	Sequence 1512077,
1332	15.4	0.4	19	1	US-11-101-244-1525042	Sequence 1525042,
c1333	15.4	0.4	19	1	US-11-101-244-1575806	Sequence 1575806,
1334	15.4	0.4	19	1	US-11-083-784-51	Sequence 51, Appl
1335	15.4	0.4	19	1	US-11-083-784-14393	Sequence 14393, A
1336	15.4	0.4	19	1	US-11-083-784-14433	Sequence 14433, A
1337	15.4	0.4	19	1	US-11-083-784-38758	Sequence 38758, A
c1338	15.4	0.4	19	1	US-11-083-784-47494	Sequence 47494, A
1339	15.4	0.4	19	1	US-11-083-784-88064	Sequence 88064, A
1340	15.4	0.4	19	1	US-11-083-784-95986	Sequence 95986, A
1341	15.4	0.4	19	1	US-11-083-784-124920	Sequence 124920,
1342	15.4	0.4	19	1	US-11-083-784-158311	Sequence 158311,
1343	15.4	0.4	19	1	US-11-083-784-158978	Sequence 158978,
c1344	15.4	0.4	19	1	US-11-083-784-165037	Sequence 165037,
c1345	15.4	0.4	19	1	US-11-083-784-165057	Sequence 165057,
c1346	15.4	0.4	19	1	US-11-083-784-165136	Sequence 165136,
c1347	15.4	0.4	19	1	US-11-083-784-165156	Sequence 165156,
c1348	15.4	0.4	19	1	US-11-083-784-165238	Sequence 165238,
c1349	15.4	0.4	19	1	US-11-083-784-165258	Sequence 165258,
c1350	15.4	0.4	19	1	US-11-083-784-165337	Sequence 165337,
c1351	15.4	0.4	19	1	US-11-083-784-165357	Sequence 165357,
c1352	15.4	0.4	19	1	US-11-083-784-165439	Sequence 165439,
c1353	15.4	0.4	19	1	US-11-083-784-165462	Sequence 165462,
1354	15.4	0.4	19	1	US-11-083-784-223107	Sequence 223107,
c1355	15.4	0.4	19	1	US-11-083-784-249657	Sequence 249657,
c1356	15.4	0.4	19	1	US-11-083-784-249676	Sequence 249676,
1357	15.4	0.4	19	1	US-11-083-784-376141	Sequence 376141,
1358	15.4	0.4	19	1	US-11-083-784-384878	Sequence 384878,
1359	15.4	0.4	19	1	US-11-083-784-388710	Sequence 388710,
c1360	15.4	0.4	19	1	US-11-083-784-393275	Sequence 393275,
1361	15.4	0.4	19	1	US-11-083-784-405137	Sequence 405137,
1362	15.4	0.4	19	1	US-11-083-784-405183	Sequence 405183,
1363	15.4	0.4	19	1	US-11-083-784-440347	Sequence 440347,
c1364	15.4	0.4	19	1	US-11-083-784-442932	Sequence 442932,
c1365	15.4	0.4	19	1	US-11-083-784-446199	Sequence 446199,
c1366	15.4	0.4	19	1	US-11-083-784-448936	Sequence 448936,
1367	15.4	0.4	19	1	US-11-083-784-466442	Sequence 466442,
c1368	15.4	0.4	19	1	US-11-083-784-478703	Sequence 478703,
1369	15.4	0.4	19	1	US-11-083-784-488729	Sequence 488729,
1370	15.4	0.4	19	1	US-11-083-784-499341	Sequence 499341,
1371	15.4	0.4	19	1	US-11-083-784-536642	Sequence 536642,
c1372	15.4	0.4	19	1	US-11-083-784-586431	Sequence 586431,
c1373	15.4	0.4	19	1	US-11-083-784-593515	Sequence 593515,
c1374	15.4	0.4	19	1	US-11-083-784-604134	Sequence 604134,
c1375	15.4	0.4	19	1	US-11-083-784-618691	Sequence 618691,
1376	15.4	0.4	19	1	US-11-083-784-710189	Sequence 710189,
c1377	15.4	0.4	19	1	US-11-083-784-772658	Sequence 772658,
1378	15.4	0.4	19	1	US-11-083-784-778427	Sequence 778427,
1379	15.4	0.4	19	1	US-11-083-784-778438	Sequence 778438,
1380	15.4	0.4	19	1	US-11-083-784-788952	Sequence 788952,
1381	15.4	0.4	19	1	US-11-083-784-789052	Sequence 789052,
1382	15.4	0.4	19	1	US-11-083-784-789152	Sequence 789152,
1383	15.4	0.4	19	1	US-11-083-784-789248	Sequence 789248,
1384	15.4	0.4	19	1	US-11-083-784-789347	Sequence 789347,
1385	15.4	0.4	19	1	US-11-083-784-789447	Sequence 789447,
c1386	15.4	0.4	19	1	US-11-083-784-834453	Sequence 834453,
1387	15.4	0.4	19	1	US-11-083-784-837999	Sequence 837999,
1388	15.4	0.4	19	1	US-11-083-784-855576	Sequence 855576,
c1389	15.4	0.4	19	1	US-11-083-784-927801	Sequence 927801,
1390	15.4	0.4	19	1	US-11-083-784-1019444	Sequence 1019444,
c1391	15.4	0.4	19	1	US-11-083-784-1036594	Sequence 1036594,
1392	15.4	0.4	19	1	US-11-083-784-1071237	Sequence 1071237,
1393	15.4	0.4	19	1	US-11-083-784-1071275	Sequence 1071275,
1394	15.4	0.4	19	1	US-11-083-784-1104410	Sequence 1104410,
1395	15.4	0.4	19	1	US-11-083-784-1104472	Sequence 1104472,
1396	15.4	0.4	19	1	US-11-083-784-1134517	Sequence 1134517,
1397	15.4	0.4	19	1	US-11-083-784-1136133	Sequence 1136133,
1398	15.4	0.4	19	1	US-11-083-784-1207573	Sequence 1207573,
1399	15.4	0.4	19	1	US-11-083-784-1259838	Sequence 1259838,
c1400	15.4	0.4	19	1	US-11-083-784-1263543	Sequence 1263543,
c1401	15.4	0.4	19	1	US-11-083-784-1263597	Sequence 1263597,
c1402	15.4	0.4	19	1	US-11-083-784-1268095	Sequence 1268095,
c1403	15.4	0.4	19	1	US-11-083-784-1319444	Sequence 1319444,
c1404	15.4	0.4	19	1	US-11-083-784-1323046	Sequence 1323046,
c1405	15.4	0.4	19	1	US-11-083-784-1334142	Sequence 1334142,
1406	15.4	0.4	19	1	US-11-083-784-1366776	Sequence 1366776,
c1407	15.4	0.4	19	1	US-11-083-784-1372964	Sequence 1372964,
1408	15.4	0.4	19	1	US-11-083-784-1401474	Sequence 1401474,
c1409	15.4	0.4	19	1	US-11-083-784-1441103	Sequence 1441103,
c1410	15.4	0.4	19	1	US-11-083-784-1444645	Sequence 1444645,
c1411	15.4	0.4	19	1	US-11-083-784-1469620	Sequence 1469620,
c1412	15.4	0.4	19	1	US-11-083-784-1495899	Sequence 1495899,
1413	15.4	0.4	19	1	US-11-083-784-1512077	Sequence 1512077,
1414	15.4	0.4	19	1	US-11-083-784-1525042	Sequence 1525042,
c1415	15.4	0.4	19	1	US-11-083-784-1575806	Sequence 1575806,
1416	15	0.4	18	1	US-10-310-914A-326990	Sequence 326990,
c1417	15	0.4	18	1	US-10-310-914A-350180	Sequence 350180,
1418	15	0.4	18	1	US-10-310-914A-392825	Sequence 392825,
1419	15	0.4	18	1	US-10-310-914A-439882	Sequence 439882,
1420	15	0.4	18	1	US-10-310-914A-492615	Sequence 492615,

c1421	15	0.4	18	1	US-10-310-914A-736192	Sequence 736192,
1422	15	0.4	18	1	US-10-310-914A-746225	Sequence 746225,
1423	15	0.4	18	1	US-10-310-914A-1154193	Sequence 1154193,
c1424	15	0.4	18	1	US-10-310-914A-1198207	Sequence 1198207,
1425	15	0.4	18	1	US-10-310-914A-1202821	Sequence 1202821,
c1426	15	0.4	18	1	US-10-310-914A-1218422	Sequence 1218422,
c1427	14.8	0.3	18	1	US-10-958-999-8	Sequence 8, Appli
1428	14.8	0.3	18	1	US-10-310-914A-41560	Sequence 41560, A
1429	14.8	0.3	18	1	US-10-310-914A-41561	Sequence 41561, A
1430	14.8	0.3	18	1	US-10-310-914A-41786	Sequence 41786, A
1431	14.8	0.3	18	1	US-10-310-914A-41980	Sequence 41980, A
1432	14.8	0.3	18	1	US-10-310-914A-44001	Sequence 44001, A
1433	14.8	0.3	18	1	US-10-310-914A-49283	Sequence 49283, A
1434	14.8	0.3	18	1	US-10-310-914A-58832	Sequence 58832, A
c1435	14.8	0.3	18	1	US-10-310-914A-64741	Sequence 64741, A
c1436	14.8	0.3	18	1	US-10-310-914A-67513	Sequence 67513, A
1437	14.8	0.3	18	1	US-10-310-914A-73628	Sequence 73628, A
1438	14.8	0.3	18	1	US-10-310-914A-73629	Sequence 73629, A
c1439	14.8	0.3	18	1	US-10-310-914A-74614	Sequence 74614, A
c1440	14.8	0.3	18	1	US-10-310-914A-76058	Sequence 76058, A
c1441	14.8	0.3	18	1	US-10-310-914A-79264	Sequence 79264, A
c1442	14.8	0.3	18	1	US-10-310-914A-85575	Sequence 85575, A
c1443	14.8	0.3	18	1	US-10-310-914A-95682	Sequence 95682, A
c1444	14.8	0.3	18	1	US-10-310-914A-98379	Sequence 98379, A
c1445	14.8	0.3	18	1	US-10-310-914A-99217	Sequence 99217, A
c1446	14.8	0.3	18	1	US-10-310-914A-107712	Sequence 107712,
c1447	14.8	0.3	18	1	US-10-310-914A-111236	Sequence 111236,
c1448	14.8	0.3	18	1	US-10-310-914A-138164	Sequence 138164,
c1449	14.8	0.3	18	1	US-10-310-914A-149256	Sequence 149256,
1450	14.8	0.3	18	1	US-10-310-914A-150479	Sequence 150479,
1451	14.8	0.3	18	1	US-10-310-914A-157171	Sequence 157171,
c1452	14.8	0.3	18	1	US-10-310-914A-168059	Sequence 168059,
c1453	14.8	0.3	18	1	US-10-310-914A-168733	Sequence 168733,
1454	14.8	0.3	18	1	US-10-310-914A-182752	Sequence 182752,
1455	14.8	0.3	18	1	US-10-310-914A-185749	Sequence 185749,
1456	14.8	0.3	18	1	US-10-310-914A-200249	Sequence 200249,
1457	14.8	0.3	18	1	US-10-310-914A-200570	Sequence 200570,
1458	14.8	0.3	18	1	US-10-310-914A-223919	Sequence 223919,
c1459	14.8	0.3	18	1	US-10-310-914A-245025	Sequence 245025,
1460	14.8	0.3	18	1	US-10-310-914A-258670	Sequence 258670,
c1461	14.8	0.3	18	1	US-10-310-914A-274408	Sequence 274408,
1462	14.8	0.3	18	1	US-10-310-914A-289024	Sequence 289024,
1463	14.8	0.3	18	1	US-10-310-914A-312199	Sequence 312199,
c1464	14.8	0.3	18	1	US-10-310-914A-316348	Sequence 316348,
c1465	14.8	0.3	18	1	US-10-310-914A-318062	Sequence 318062,
c1466	14.8	0.3	18	1	US-10-310-914A-321907	Sequence 321907,
1467	14.8	0.3	18	1	US-10-310-914A-322050	Sequence 322050,
c1468	14.8	0.3	18	1	US-10-310-914A-340689	Sequence 340689,
c1469	14.8	0.3	18	1	US-10-310-914A-343588	Sequence 343588,
c1470	14.8	0.3	18	1	US-10-310-914A-343589	Sequence 343589,
c1471	14.8	0.3	18	1	US-10-310-914A-353955	Sequence 353955,
c1472	14.8	0.3	18	1	US-10-310-914A-370347	Sequence 370347,
c1473	14.8	0.3	18	1	US-10-310-914A-374108	Sequence 374108,
c1474	14.8	0.3	18	1	US-10-310-914A-392819	Sequence 392819,
c1475	14.8	0.3	18	1	US-10-310-914A-394234	Sequence 394234,
c1476	14.8	0.3	18	1	US-10-310-914A-399085	Sequence 399085,
1477	14.8	0.3	18	1	US-10-310-914A-401700	Sequence 401700,
c1478	14.8	0.3	18	1	US-10-310-914A-407421	Sequence 407421,
c1479	14.8	0.3	18	1	US-10-310-914A-472391	Sequence 472391,
c1480	14.8	0.3	18	1	US-10-310-914A-479651	Sequence 479651,
c1481	14.8	0.3	18	1	US-10-310-914A-485967	Sequence 485967,
c1482	14.8	0.3	18	1	US-10-310-914A-487136	Sequence 487136,
c1483	14.8	0.3	18	1	US-10-310-914A-490510	Sequence 490510,
c1484	14.8	0.3	18	1	US-10-310-914A-494389	Sequence 494389,
c1485	14.8	0.3	18	1	US-10-310-914A-510815	Sequence 510815,
c1486	14.8	0.3	18	1	US-10-310-914A-519334	Sequence 519334,
c1487	14.8	0.3	18	1	US-10-310-914A-521199	Sequence 521199,
1488	14.8	0.3	18	1	US-10-310-914A-523963	Sequence 523963,
c1489	14.8	0.3	18	1	US-10-310-914A-540325	Sequence 540325,
c1490	14.8	0.3	18	1	US-10-310-914A-552910	Sequence 552910,
c1491	14.8	0.3	18	1	US-10-310-914A-559267	Sequence 559267,
c1492	14.8	0.3	18	1	US-10-310-914A-560682	Sequence 560682,
1493	14.8	0.3	18	1	US-10-310-914A-570781	Sequence 570781,
c1494	14.8	0.3	18	1	US-10-310-914A-592815	Sequence 592815,
c1495	14.8	0.3	18	1	US-10-310-914A-609105	Sequence 609105,
1496	14.8	0.3	18	1	US-10-310-914A-655587	Sequence 655587,
c1497	14.8	0.3	18	1	US-10-310-914A-661057	Sequence 661057,
c1498	14.8	0.3	18	1	US-10-310-914A-675735	Sequence 675735,
c1499	14.8	0.3	18	1	US-10-310-914A-702256	Sequence 702256,
1500	14.8	0.3	18	1	US-10-310-914A-716395	Sequence 716395,
1501	14.8	0.3	18	1	US-10-310-914A-728016	Sequence 728016,
1502	14.8	0.3	18	1	US-10-310-914A-747222	Sequence 747222,
c1503	14.8	0.3	18	1	US-10-310-914A-761086	Sequence 761086,
1504	14.8	0.3	18	1	US-10-310-914A-765180	Sequence 765180,
c1505	14.8	0.3	18	1	US-10-310-914A-771537	Sequence 771537,
1506	14.8	0.3	18	1	US-10-310-914A-778728	Sequence 778728,
c1507	14.8	0.3	18	1	US-10-310-914A-785986	Sequence 785986,
1508	14.8	0.3	18	1	US-10-310-914A-787511	Sequence 787511,
1509	14.8	0.3	18	1	US-10-310-914A-804096	Sequence 804096,
1510	14.8	0.3	18	1	US-10-310-914A-817270	Sequence 817270,
1511	14.8	0.3	18	1	US-10-310-914A-894247	Sequence 894247,
1512	14.8	0.3	18	1	US-10-310-914A-894280	Sequence 894280,
1513	14.8	0.3	18	1	US-10-310-914A-897142	Sequence 897142,
c1514	14.8	0.3	18	1	US-10-310-914A-907233	Sequence 907233,
1515	14.8	0.3	18	1	US-10-310-914A-958358	Sequence 958358,
c1516	14.8	0.3	18	1	US-10-310-914A-958514	Sequence 958514,
1517	14.8	0.3	18	1	US-10-310-914A-967635	Sequence 967635,
c1518	14.8	0.3	18	1	US-10-310-914A-974099	Sequence 974099,
c1519	14.8	0.3	18	1	US-10-310-914A-1009356	Sequence 1009356,
1520	14.8	0.3	18	1	US-10-310-914A-1014756	Sequence 1014756,
c1521	14.8	0.3	18	1	US-10-310-914A-1026764	Sequence 1026764,
c1522	14.8	0.3	18	1	US-10-310-914A-1030192	Sequence 1030192,
1523	14.8	0.3	18	1	US-10-310-914A-1059710	Sequence 1059710,
1524	14.8	0.3	18	1	US-10-310-914A-1067192	Sequence 1067192,
1525	14.8	0.3	18	1	US-10-310-914A-1067193	Sequence 1067193,
1526	14.8	0.3	18	1	US-10-310-914A-1077647	Sequence 1077647,
1527	14.8	0.3	18	1	US-10-310-914A-1077648	Sequence 1077648,
c1528	14.8	0.3	18	1	US-10-310-914A-1079848	Sequence 1079848,
1529	14.8	0.3	18	1	US-10-310-914A-1085525	Sequence 1085525,
c1530	14.8	0.3	18	1	US-10-310-914A-1087279	Sequence 1087279,
1531	14.8	0.3	18	1	US-10-310-914A-1087936	Sequence 1087936,
1532	14.8	0.3	18	1	US-10-310-914A-1090451	Sequence 1090451,
c1533	14.8	0.3	18	1	US-10-310-914A-1091850	Sequence 1091850,
c1534	14.8	0.3	18	1	US-10-310-914A-1108672	Sequence 1108672,
c1535	14.8	0.3	18	1	US-10-310-914A-1115627	Sequence 1115627,
c1536	14.8	0.3	18	1	US-10-310-914A-1134670	Sequence 1134670,
1537	14.8	0.3	18	1	US-10-310-914A-1141714	Sequence 1141714,
c1538	14.8	0.3	18	1	US-10-310-914A-1150343	Sequence 1150343,
1539	14.8	0.3	18	1	US-10-310-914A-1160776	Sequence 1160776,
c1540	14.8	0.3	18	1	US-10-310-914A-1161317	Sequence 1161317,
c1541	14.8	0.3	18	1	US-10-310-914A-1168846	Sequence 1168846,
c1542	14.8	0.3	18	1	US-10-310-914A-1183773	Sequence 1183773,
c1543	14.8	0.3	18	1	US-10-310-914A-1187035	Sequence 1187035,
1544	14.8	0.3	18	1	US-10-310-914A-1197636	Sequence 1197636,
1545	14.8	0.3	18	1	US-10-310-914A-1200184	Sequence 1200184,
c1546	14.8	0.3	18	1	US-10-310-914A-1201161	Sequence 1201161,
c1547	14.8	0.3	18	1	US-10-310-914A-1212176	Sequence 1212176,
c1548	14.8	0.3	18	1	US-10-310-914A-1214147	Sequence 1214147,
c1549	14.8	0.3	18	1	US-10-310-914A-1214571	Sequence 1214571,
c1550	14.8	0.3	18	1	US-10-310-914A-1214779	Sequence 1214779,
1551	14.8	0.3	18	1	US-10-310-914A-1228679	Sequence 1228679,
c1552	14.8	0.3	18	1	US-10-310-914A-1228949	Sequence 1228949,
1553	14.8	0.3	18	1	US-10-310-914A-1253710	Sequence 1253710,
c1554	14.8	0.3	18	1	US-10-310-914A-1258332	Sequence 1258332,
1555	14.8	0.3	18	1	US-10-310-914A-1260027	Sequence 1260027,
1556	14.8	0.3	18	1	US-10-310-914A-1263719	Sequence 1263719,
c1557	14.8	0.3	18	1	US-10-310-914A-1284973	Sequence 1284973,
1558	14.8	0.3	18	1	US-10-310-914A-1287424	Sequence 1287424,
1559	14.8	0.3	18	1	US-10-310-914A-1296859	Sequence 1296859,
1560	14.8	0.3	18	1	US-10-310-914A-1302290	Sequence 1302290,
1561	14.8	0.3	18	1	US-10-310-914A-1302291	Sequence 1302291,
c1562	14.8	0.3	18	1	US-10-310-914A-1303787	Sequence 1303787,
1563	14.8	0.3	18	1	US-10-310-914A-1305050	Sequence 1305050,
1564	14.8	0.3	18	1	US-10-310-914A-1305749	Sequence 1305749,
c1565	14.8	0.3	18	1	US-10-310-914A-1307300	Sequence 1307300,
c1566	14.8	0.3	18	1	US-10-310-914A-1313757	Sequence 1313757,

c1567	14.8	0.3	18	1	US-10-310-914A-1322817	Sequence 1322817,
c1568	14.8	0.3	18	1	US-10-310-914A-1330318	Sequence 1330318,
c1569	14.8	0.3	18	1	US-10-310-914A-1345129	Sequence 1345129,
c1570	14.8	0.3	18	1	US-10-310-914A-1360221	Sequence 1360221,
1571	14.8	0.3	18	1	US-10-310-914A-1362557	Sequence 1362557,
1572	14.8	0.3	18	1	US-10-310-914A-1368458	Sequence 1368458,
1573	14.8	0.3	18	1	US-10-310-914A-1374377	Sequence 1374377,
c1574	14.8	0.3	18	1	US-10-310-914A-1375900	Sequence 1375900,
1575	14.8	0.3	18	1	US-11-069-908-5922	Sequence 5922, Ap
c1576	14.6	0.3	25	1	US-11-121-849-151576	Sequence 151576,
1577	14.4	0.3	17	1	US-10-858-341-1384	Sequence 1384, Ap
c1578	14.4	0.3	18	1	US-10-310-914A-41907	Sequence 41907, A
1579	14.4	0.3	18	1	US-10-310-914A-56011	Sequence 56011, A
c1580	14.4	0.3	18	1	US-10-310-914A-64680	Sequence 64680, A
1581	14.4	0.3	18	1	US-10-310-914A-79204	Sequence 79204, A
c1582	14.4	0.3	18	1	US-10-310-914A-91195	Sequence 91195, A
1583	14.4	0.3	18	1	US-10-310-914A-98349	Sequence 98349, A
c1584	14.4	0.3	18	1	US-10-310-914A-111218	Sequence 111218,
c1585	14.4	0.3	18	1	US-10-310-914A-148286	Sequence 148286,
c1586	14.4	0.3	18	1	US-10-310-914A-169474	Sequence 169474,
c1587	14.4	0.3	18	1	US-10-310-914A-173307	Sequence 173307,
c1588	14.4	0.3	18	1	US-10-310-914A-174618	Sequence 174618,
c1589	14.4	0.3	18	1	US-10-310-914A-176334	Sequence 176334,
c1590	14.4	0.3	18	1	US-10-310-914A-213603	Sequence 213603,
c1591	14.4	0.3	18	1	US-10-310-914A-213974	Sequence 213974,
1592	14.4	0.3	18	1	US-10-310-914A-213993	Sequence 213993,
c1593	14.4	0.3	18	1	US-10-310-914A-216815	Sequence 216815,
c1594	14.4	0.3	18	1	US-10-310-914A-216816	Sequence 216816,
c1595	14.4	0.3	18	1	US-10-310-914A-218402	Sequence 218402,
c1596	14.4	0.3	18	1	US-10-310-914A-223481	Sequence 223481,
1597	14.4	0.3	18	1	US-10-310-914A-225022	Sequence 225022,
c1598	14.4	0.3	18	1	US-10-310-914A-246025	Sequence 246025,
c1599	14.4	0.3	18	1	US-10-310-914A-247428	Sequence 247428,
c1600	14.4	0.3	18	1	US-10-310-914A-260616	Sequence 260616,
c1601	14.4	0.3	18	1	US-10-310-914A-279451	Sequence 279451,
c1602	14.4	0.3	18	1	US-10-310-914A-281381	Sequence 281381,
c1603	14.4	0.3	18	1	US-10-310-914A-283866	Sequence 283866,
1604	14.4	0.3	18	1	US-10-310-914A-302300	Sequence 302300,
1605	14.4	0.3	18	1	US-10-310-914A-312334	Sequence 312334,
c1606	14.4	0.3	18	1	US-10-310-914A-345359	Sequence 345359,
1607	14.4	0.3	18	1	US-10-310-914A-360426	Sequence 360426,
c1608	14.4	0.3	18	1	US-10-310-914A-365250	Sequence 365250,
1609	14.4	0.3	18	1	US-10-310-914A-366631	Sequence 366631,
c1610	14.4	0.3	18	1	US-10-310-914A-384932	Sequence 384932,
1611	14.4	0.3	18	1	US-10-310-914A-400399	Sequence 400399,
c1612	14.4	0.3	18	1	US-10-310-914A-405260	Sequence 405260,
c1613	14.4	0.3	18	1	US-10-310-914A-409851	Sequence 409851,
c1614	14.4	0.3	18	1	US-10-310-914A-416008	Sequence 416008,
1615	14.4	0.3	18	1	US-10-310-914A-434918	Sequence 434918,
c1616	14.4	0.3	18	1	US-10-310-914A-444628	Sequence 444628,
1617	14.4	0.3	18	1	US-10-310-914A-449233	Sequence 449233,
c1618	14.4	0.3	18	1	US-10-310-914A-470179	Sequence 470179,
1619	14.4	0.3	18	1	US-10-310-914A-476504	Sequence 476504,
c1620	14.4	0.3	18	1	US-10-310-914A-477521	Sequence 477521,
c1621	14.4	0.3	18	1	US-10-310-914A-477522	Sequence 477522,
c1622	14.4	0.3	18	1	US-10-310-914A-502238	Sequence 502238,
c1623	14.4	0.3	18	1	US-10-310-914A-541085	Sequence 541085,
c1624	14.4	0.3	18	1	US-10-310-914A-543962	Sequence 543962,
c1625	14.4	0.3	18	1	US-10-310-914A-545257	Sequence 545257,
c1626	14.4	0.3	18	1	US-10-310-914A-551594	Sequence 551594,
c1627	14.4	0.3	18	1	US-10-310-914A-608856	Sequence 608856,
c1628	14.4	0.3	18	1	US-10-310-914A-615451	Sequence 615451,
1629	14.4	0.3	18	1	US-10-310-914A-632129	Sequence 632129,
1630	14.4	0.3	18	1	US-10-310-914A-637489	Sequence 637489,
1631	14.4	0.3	18	1	US-10-310-914A-640184	Sequence 640184,
1632	14.4	0.3	18	1	US-10-310-914A-647639	Sequence 647639,
c1633	14.4	0.3	18	1	US-10-310-914A-694211	Sequence 694211,
1634	14.4	0.3	18	1	US-10-310-914A-696304	Sequence 696304,
1635	14.4	0.3	18	1	US-10-310-914A-703730	Sequence 703730,
1636	14.4	0.3	18	1	US-10-310-914A-709308	Sequence 709308,
c1637	14.4	0.3	18	1	US-10-310-914A-715655	Sequence 715655,
1638	14.4	0.3	18	1	US-10-310-914A-722201	Sequence 722201,
c1639	14.4	0.3	18	1	US-10-310-914A-732299	Sequence 732299,
c1640	14.4	0.3	18	1	US-10-310-914A-733252	Sequence 733252,
c1641	14.4	0.3	18	1	US-10-310-914A-736940	Sequence 736940,
1642	14.4	0.3	18	1	US-10-310-914A-737419	Sequence 737419,
c1643	14.4	0.3	18	1	US-10-310-914A-738114	Sequence 738114,
1644	14.4	0.3	18	1	US-10-310-914A-750442	Sequence 750442,
1645	14.4	0.3	18	1	US-10-310-914A-759572	Sequence 759572,
1646	14.4	0.3	18	1	US-10-310-914A-778291	Sequence 778291,
1647	14.4	0.3	18	1	US-10-310-914A-790616	Sequence 790616,
c1648	14.4	0.3	18	1	US-10-310-914A-791845	Sequence 791845,
c1649	14.4	0.3	18	1	US-10-310-914A-802146	Sequence 802146,
c1650	14.4	0.3	18	1	US-10-310-914A-829295	Sequence 829295,
1651	14.4	0.3	18	1	US-10-310-914A-833421	Sequence 833421,
1652	14.4	0.3	18	1	US-10-310-914A-841274	Sequence 841274,
1653	14.4	0.3	18	1	US-10-310-914A-847213	Sequence 847213,
1654	14.4	0.3	18	1	US-10-310-914A-847214	Sequence 847214,
c1655	14.4	0.3	18	1	US-10-310-914A-853825	Sequence 853825,
c1656	14.4	0.3	18	1	US-10-310-914A-873006	Sequence 873006,
c1657	14.4	0.3	18	1	US-10-310-914A-878489	Sequence 878489,
c1658	14.4	0.3	18	1	US-10-310-914A-892826	Sequence 892826,
1659	14.4	0.3	18	1	US-10-310-914A-893437	Sequence 893437,
1660	14.4	0.3	18	1	US-10-310-914A-895138	Sequence 895138,
1661	14.4	0.3	18	1	US-10-310-914A-906603	Sequence 906603,
c1662	14.4	0.3	18	1	US-10-310-914A-912483	Sequence 912483,
c1663	14.4	0.3	18	1	US-10-310-914A-912486	Sequence 912486,
1664	14.4	0.3	18	1	US-10-310-914A-914942	Sequence 914942,
c1665	14.4	0.3	18	1	US-10-310-914A-916502	Sequence 916502,
c1666	14.4	0.3	18	1	US-10-310-914A-916686	Sequence 916686,
1667	14.4	0.3	18	1	US-10-310-914A-922634	Sequence 922634,
c1668	14.4	0.3	18	1	US-10-310-914A-929594	Sequence 929594,
1669	14.4	0.3	18	1	US-10-310-914A-964748	Sequence 964748,
c1670	14.4	0.3	18	1	US-10-310-914A-966408	Sequence 966408,
1671	14.4	0.3	18	1	US-10-310-914A-968397	Sequence 968397,
c1672	14.4	0.3	18	1	US-10-310-914A-989400	Sequence 989400,
1673	14.4	0.3	18	1	US-10-310-914A-999098	Sequence 999098,
1674	14.4	0.3	18	1	US-10-310-914A-999099	Sequence 999099,
1675	14.4	0.3	18	1	US-10-310-914A-999100	Sequence 999100,
c1676	14.4	0.3	18	1	US-10-310-914A-1002209	Sequence 1002209,
1677	14.4	0.3	18	1	US-10-310-914A-1013145	Sequence 1013145,
c1678	14.4	0.3	18	1	US-10-310-914A-1022764	Sequence 1022764,
1679	14.4	0.3	18	1	US-10-310-914A-1027936	Sequence 1027936,
c1680	14.4	0.3	18	1	US-10-310-914A-1041898	Sequence 1041898,
c1681	14.4	0.3	18	1	US-10-310-914A-1060050	Sequence 1060050,
1682	14.4	0.3	18	1	US-10-310-914A-1101002	Sequence 1101002,
c1683	14.4	0.3	18	1	US-10-310-914A-1124096	Sequence 1124096,
c1684	14.4	0.3	18	1	US-10-310-914A-1177722	Sequence 1177722,
c1685	14.4	0.3	18	1	US-10-310-914A-1187158	Sequence 1187158,
1686	14.4	0.3	18	1	US-10-310-914A-1187485	Sequence 1187485,
c1687	14.4	0.3	18	1	US-10-310-914A-1219995	Sequence 1219995,
1688	14.4	0.3	18	1	US-10-310-914A-1222014	Sequence 1222014,
c1689	14.4	0.3	18	1	US-10-310-914A-1264272	Sequence 1264272,
1690	14.4	0.3	18	1	US-10-310-914A-1264496	Sequence 1264496,
1691	14.4	0.3	18	1	US-10-310-914A-1279584	Sequence 1279584,
1692	14.4	0.3	18	1	US-10-310-914A-1289326	Sequence 1289326,
1693	14.4	0.3	18	1	US-10-310-914A-1289327	Sequence 1289327,
c1694	14.4	0.3	18	1	US-10-310-914A-1295076	Sequence 1295076,
c1695	14.4	0.3	18	1	US-10-310-914A-1296315	Sequence 1296315,
c1696	14.4	0.3	18	1	US-10-310-914A-1315876	Sequence 1315876,
c1697	14.4	0.3	18	1	US-10-310-914A-1347485	Sequence 1347485,
c1698	14.4	0.3	18	1	US-10-310-914A-1353530	Sequence 1353530,
1699	14.4	0.3	18	1	US-11-069-908-1263	Sequence 1263, Ap
1700	14.4	0.3	18	1	US-11-069-908-3629	Sequence 3629, Ap

ALIGNMENTS

RESULT 1
US-10-949-720-2/c
; Sequence 2, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey

```
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 36
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-2

  Query Match             0.7%;  Score 29;  DB 1;  Length 36;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   29;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 TGGATGAGAGCGAGGGCTGGCGGGAGCAG 1986
              |||||||||||||||||||||||||||||
Db         36 TGGATGAGAGCGAGGGCTGGCGGGAGCAG 8


RESULT 2
US-10-310-914A-153230/c
; Sequence 153230, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153230
;   LENGTH: 27
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153230

  Query Match             0.6%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   27;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3896 CTTTTTGTTTCTTCGTTTTGTTTTTCT 3922
              |||||||||||||||||||||||||||
Db         27 CTTTTTGTTTCTTCGTTTTGTTTTTCT 1


RESULT 3
US-10-310-914A-153273/c
; Sequence 153273, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153273
;   LENGTH: 27
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153273

  Query Match             0.6%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   27;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3486 TGGGGGTTCTGCCATAATAGGAGGGGA 3512
              |||||||||||||||||||||||||||
Db         27 TGGGGGTTCTGCCATAATAGGAGGGGA 1


RESULT 4
US-10-310-914A-153276/c
; Sequence 153276, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153276
;   LENGTH: 27
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153276

  Query Match             0.6%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   27;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3644 GATGGGTGCGTTCCCGCAGACCAAAGA 3670
              |||||||||||||||||||||||||||
Db         27 GATGGGTGCGTTCCCGCAGACCAAAGA 1


RESULT 5
US-10-310-914A-153271/c
; Sequence 153271, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153271
;   LENGTH: 26
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153271

  Query Match             0.6%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+02;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3419 CTGTGCCCCGCTGGATTGCACTTTGA 3444
              ||||||||||||||||||||||||||
```

```
Db         26 CTGTGCCCCGCTGGATTGCACTTTGA 1


RESULT 6
US-10-310-914A-153279/c
; Sequence 153279, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153279
;   LENGTH: 26
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153279

  Query Match             0.6%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+02;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4011 CTGTTTCCAGAACAGTGCCTTGGTCA 4036
              ||||||||||||||||||||||||||
Db         26 CTGTTTCCAGAACAGTGCCTTGGTCA 1


RESULT 7
US-10-310-914A-153226/c
; Sequence 153226, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153226
;   LENGTH: 25
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153226

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3907 TTCGTTTTGTTTTTCTACCGTCCTT 3931
              |||||||||||||||||||||||||
Db         25 TTCGTTTTGTTTTTCTACCGTCCTT 1


RESULT 8
US-10-310-914A-153237/c
; Sequence 153237, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153237
;   LENGTH: 25
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153237

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3432 GATTGCACTTTGAGCCCGTGGGGTG 3456
              |||||||||||||||||||||||||
Db         25 GATTGCACTTTGAGCCCGTGGGGTG 1


RESULT 9
US-10-310-914A-153292/c
; Sequence 153292, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153292
;   LENGTH: 25
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153292

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4046 CCCGGACCCCGCCTGGGACCCCCAA 4070
              |||||||||||||||||||||||||
Db         25 CCCGGACCCCGCCTGGGACCCCCAA 1


RESULT 10
US-11-121-849-151566
; Sequence 151566, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151566
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151566

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3912 TTTGTTTTTCTACCGTCCTTGTCAT 3936
              |||||||||||||||||||||||||
```

```
Db          1 TTTGTTTTTCTACCGTCCTTGTCAT 25


RESULT 11
US-11-121-849-151567
; Sequence 151567, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151567
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151567

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3921 CTACCGTCCTTGTCATAACTTTGTG 3945
             |||||||||||||||||||||||||
Db          1 CTACCGTCCTTGTCATAACTTTGTG 25


RESULT 12
US-11-121-849-151568
; Sequence 151568, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151568
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151568

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3926 GTCCTTGTCATAACTTTGTGTTGGA 3950
             |||||||||||||||||||||||||
Db          1 GTCCTTGTCATAACTTTGTGTTGGA 25


RESULT 13
US-11-121-849-151569
; Sequence 151569, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151569
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151569

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3941 TTGTGTTGGAGGGAACCTGTTTCAC 3965
             |||||||||||||||||||||||||
Db          1 TTGTGTTGGAGGGAACCTGTTTCAC 25


RESULT 14
US-11-121-849-151570
; Sequence 151570, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151570
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151570

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3949 GAGGGAACCTGTTTCACTATGGCCT 3973
             |||||||||||||||||||||||||
Db          1 GAGGGAACCTGTTTCACTATGGCCT 25


RESULT 15
US-11-121-849-151571
; Sequence 151571, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151571
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151571

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
```

```
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3954 AACCTGTTTCACTATGGCCTCCTTT 3978
              |||||||||||||||||||||||||
Db          1 AACCTGTTTCACTATGGCCTCCTTT 25


RESULT 16
US-11-121-849-151572
; Sequence 151572, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151572
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151572

  Query Match              0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3998 CCCATCATCATGTCTGTTTCCAGAA 4022
              |||||||||||||||||||||||||
Db          1 CCCATCATCATGTCTGTTTCCAGAA 25


RESULT 17
US-11-121-849-151573
; Sequence 151573, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151573
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151573

  Query Match              0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4013 GTTTCCAGAACAGTGCCTTGGTCAT 4037
              |||||||||||||||||||||||||
Db          1 GTTTCCAGAACAGTGCCTTGGTCAT 25


RESULT 18
US-11-121-849-151575
; Sequence 151575, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151575
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151575

  Query Match              0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4124 TGGTGGAACCCAGAAACGGACGCCG 4148
              |||||||||||||||||||||||||
Db          1 TGGTGGAACCCAGAAACGGACGCCG 25


RESULT 19
US-11-121-849-151576
; Sequence 151576, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151576
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151576

  Query Match              0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4131 ACCCAGAAACGGACGCCGGTGCTTG 4155
              |||||||||||||||||||||||||
Db          1 ACCCAGAAACGGACGCCGGTGCTTG 25


RESULT 20
US-11-121-849-302682
; Sequence 302682, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302682
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
```

```
US-11-121-849-302682

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3648 GGTGCGTTCCCGCAGACCAAAGAGA 3672
              |||||||||||||||||||||||||
Db          1 GGTGCGTTCCCGCAGACCAAAGAGA 25


RESULT 21
US-11-121-849-302683
; Sequence 302683, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302683
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-302683

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3649 GTGCGTTCCCGCAGACCAAAGAGAG 3673
              |||||||||||||||||||||||||
Db          1 GTGCGTTCCCGCAGACCAAAGAGAG 25


RESULT 22
US-11-121-849-302684
; Sequence 302684, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302684
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-302684

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3651 GCGTTCCCGCAGACCAAAGAGAGTG 3675
              |||||||||||||||||||||||||
Db          1 GCGTTCCCGCAGACCAAAGAGAGTG 25


RESULT 23
US-11-121-849-302685
; Sequence 302685, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302685
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-302685

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3653 GTTCCCGCAGACCAAAGAGAGTGTG 3677
              |||||||||||||||||||||||||
Db          1 GTTCCCGCAGACCAAAGAGAGTGTG 25


RESULT 24
US-11-121-849-302686
; Sequence 302686, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302686
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-302686

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3655 TCCCGCAGACCAAAGAGAGTGTGAC 3679
              |||||||||||||||||||||||||
Db          1 TCCCGCAGACCAAAGAGAGTGTGAC 25


RESULT 25
US-11-121-849-302687
; Sequence 302687, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
```

```
; SEQ ID NO 302687
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-302687

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3661 AGACCAAAGAGAGTGTGACTCCCTT 3685
              |||||||||||||||||||||||||
Db          1 AGACCAAAGAGAGTGTGACTCCCTT 25


RESULT 26
US-11-121-849-302688
; Sequence 302688, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302688
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-302688

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3668 AGAGAGTGTGACTCCCTTGCCAGCT 3692
              |||||||||||||||||||||||||
Db          1 AGAGAGTGTGACTCCCTTGCCAGCT 25


RESULT 27
US-11-121-849-302689
; Sequence 302689, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302689
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-302689

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3734 AGGGCCCAGTGACAAAATCATTGGG 3758
              |||||||||||||||||||||||||
Db          1 AGGGCCCAGTGACAAAATCATTGGG 25


RESULT 28
US-11-121-849-302690
; Sequence 302690, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302690
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-302690

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3762 TGTAGTCCCAACTTGCTGCTGTCAC 3786
              |||||||||||||||||||||||||
Db          1 TGTAGTCCCAACTTGCTGCTGTCAC 25


RESULT 29
US-11-121-849-302691
; Sequence 302691, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302691
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-302691

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3828 CCCAGCTGCTGCCTTCATATTGAAG 3852
              |||||||||||||||||||||||||
Db          1 CCCAGCTGCTGCCTTCATATTGAAG 25


RESULT 30
US-11-121-849-302692
; Sequence 302692, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
```

```
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302692
;    LENGTH: 25
;    TYPE: DNA
;    ORGANISM: Homo sapien
US-11-121-849-302692

  Query Match             0.6%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3829 CCAGCTGCTGCCTTCATATTGAAGG 3853
             |||||||||||||||||||||||||
Db          1 CCAGCTGCTGCCTTCATATTGAAGG 25


RESULT 31
US-10-310-914A-153255/c
; Sequence 153255, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153255
;    LENGTH: 27
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-153255

  Query Match             0.6%;  Score 25;  DB 1;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+02;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3537 GAACTCCAGACCAAGGGTGAGGGCG 3561
             |||||||||||||||||||||||||
Db         25 GAACTCCAGACCAAGGGTGAGGGCG 1


RESULT 32
US-10-949-720-1
; Sequence 1, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;    LENGTH: 29
;    TYPE: DNA
;    ORGANISM: Unknown
;    FEATURE:
;    OTHER INFORMATION: Oligonucleotide
US-10-949-720-1

  Query Match             0.6%;  Score 24.2;  DB 1;  Length 29;
  Best Local Similarity   89.7%;  Pred. No. 2.6e+02;
  Matches   26;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       367 GGCGGCGCCATGGAGCTCCGGGTGCTGCT 395
             ||   ||||||||||||||||||||||||||
Db         1 GGATCCGCCATGGAGCTCCGGGTGCTGCT 29


RESULT 33
US-10-949-720-397
; Sequence 397, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 397
;    LENGTH: 29
;    TYPE: DNA
;    ORGANISM: Unknown
;    FEATURE:
;    OTHER INFORMATION: oligonucleotide primer
US-10-949-720-397

  Query Match             0.6%;  Score 24.2;  DB 1;  Length 29;
  Best Local Similarity   89.7%;  Pred. No. 2.6e+02;
  Matches   26;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       367 GGCGGCGCCATGGAGCTCCGGGTGCTGCT 395
             ||   ||||||||||||||||||||||||||
Db         1 GGATCCGCCATGGAGCTCCGGGTGCTGCT 29


RESULT 34
US-10-310-914A-153219/c
; Sequence 153219, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153219
;    LENGTH: 24
;    TYPE: RNA
;    ORGANISM: Human
```

US-10-310-914A-153219

Query Match 0.6%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3860 AGTTTTGTTTTTGGTCTTAATTTT 3883
||||||||||||||||||||||||
Db 24 AGTTTTGTTTTTGGTCTTAATTTT 1

RESULT 35
US-10-310-914A-153221/c
; Sequence 153221, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153221
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153221

Query Match 0.6%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3846 ATTGAAGGTTTTTGAGTTTTGTTT 3869
||||||||||||||||||||||||
Db 24 ATTGAAGGTTTTTGAGTTTTGTTT 1

RESULT 36
US-10-310-914A-153229/c
; Sequence 153229, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153229
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153229

Query Match 0.6%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3899 TTTGTTTCTTCGTTTTGTTTTTCT 3922
||||||||||||||||||||||||
Db 24 TTTGTTTCTTCGTTTTGTTTTTCT 1

RESULT 37
US-10-310-914A-153235/c
; Sequence 153235, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153235
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153235

Query Match 0.6%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4075 TGTCCTATGAAGGGGTGTGGGGTG 4098
||||||||||||||||||||||||
Db 24 TGTCCTATGAAGGGGTGTGGGGTG 1

RESULT 38
US-10-310-914A-153238/c
; Sequence 153238, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153238
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153238

Query Match 0.6%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4068 CAAGCTGTGTCCTATGAAGGGGTG 4091
||||||||||||||||||||||||
Db 24 CAAGCTGTGTCCTATGAAGGGGTG 1

RESULT 39
US-10-310-914A-153248/c
; Sequence 153248, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153248
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153248

```
  Query Match             0.6%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        303 CAGGGAGAGTCAGACCTGGGGGGG 326
              ||||||||||||||||||||||||
Db         24 CAGGGAGAGTCAGACCTGGGGGGG 1


RESULT 40
US-10-310-914A-153254/c
; Sequence 153254, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153254
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153254

  Query Match             0.6%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4064 CCCCCAAGCTGTGTCCTATGAAGG 4087
              ||||||||||||||||||||||||
Db         24 CCCCCAAGCTGTGTCCTATGAAGG 1


RESULT 41
US-10-310-914A-153270/c
; Sequence 153270, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153270
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153270

  Query Match             0.6%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3837 TGCCTTCATATTGAAGGTTTTTGA 3860
              ||||||||||||||||||||||||
Db         24 TGCCTTCATATTGAAGGTTTTTGA 1


RESULT 42
US-10-310-914A-153280/c
; Sequence 153280, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153280
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153280

  Query Match             0.6%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3981 CCAAGTTGAAACAGGGGCCCATCA 4004
              ||||||||||||||||||||||||
Db         24 CCAAGTTGAAACAGGGGCCCATCA 1


RESULT 43
US-10-310-914A-153287/c
; Sequence 153287, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153287
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153287

  Query Match             0.6%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3392 AGTGGGGACTCACAGAGGCCCCCA 3415
              ||||||||||||||||||||||||
Db         24 AGTGGGGACTCACAGAGGCCCCCA 1


RESULT 44
US-11-121-849-151574
; Sequence 151574, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151574
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151574
```

```
  Query Match             0.6%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 2.5e+02;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4060 GGGACCCCCAAGCTGTGTCCTATGA 4084
              ||||||||||||| ||||||||||||
Db          1 GGGACCCCCAAGATGTGTCCTATGA 25


RESULT 45
US-10-310-914A-153217/c
; Sequence 153217, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153217
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153217

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGTTTT 3919
              |||||||||||||||||||||||
Db         23 TTTTTGTTTCTTCGTTTTGTTTT 1


RESULT 46
US-10-310-914A-153223/c
; Sequence 153223, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153223
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153223

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3882 TTTCTCCCCGTTCCCTTTTTGTT 3904
              |||||||||||||||||||||||
Db         23 TTTCTCCCCGTTCCCTTTTTGTT 1


RESULT 47
US-10-310-914A-153239/c
; Sequence 153239, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153239
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153239

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3474 AGAGACAGGATTTGGGGGTTCTG 3496
              |||||||||||||||||||||||
Db         23 AGAGACAGGATTTGGGGGTTCTG 1


RESULT 48
US-10-310-914A-153242/c
; Sequence 153242, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153242
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153242

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3556 AGGGCGCCTTTCCCTCAGGACTG 3578
              |||||||||||||||||||||||
Db         23 AGGGCGCCTTTCCCTCAGGACTG 1


RESULT 49
US-10-310-914A-153256/c
; Sequence 153256, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153256
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153256
```

```
  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3869 TTTGGTCTTAATTTTTCTCCCCG 3891
              |||||||||||||||||||||||
Db         23 TTTGGTCTTAATTTTTCTCCCCG 1


RESULT 50
US-10-310-914A-153259/c
; Sequence 153259, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153259
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153259

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3523 CCAGCCACCTCGGGGAACTCCAG 3545
              |||||||||||||||||||||||
Db         23 CCAGCCACCTCGGGGAACTCCAG 1


RESULT 51
US-10-310-914A-153260/c
; Sequence 153260, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153260
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153260

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        327 CGAGGGCCCCCCAAACTCAGTTC 349
              |||||||||||||||||||||||
Db         23 CGAGGGCCCCCCAAACTCAGTTC 1


RESULT 52
US-10-310-914A-153261/c
; Sequence 153261, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153261
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153261

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3716 GGGGCAAGAAGGGGTGTCAGGGC 3738
              |||||||||||||||||||||||
Db         23 GGGGCAAGAAGGGGTGTCAGGGC 1


RESULT 53
US-10-310-914A-153265/c
; Sequence 153265, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153265
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153265

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3344 CAGGAACTCCCCACCCCAGGGAC 3366
              |||||||||||||||||||||||
Db         23 CAGGAACTCCCCACCCCAGGGAC 1


RESULT 54
US-10-310-914A-153266/c
; Sequence 153266, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153266
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153266

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
```

```
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3856 TTTGAGTTTTGTTTTTGGTCTTA 3878
              |||||||||||||||||||||||
Db         23 TTTGAGTTTTGTTTTTGGTCTTA 1


RESULT 55
US-10-310-914A-153274/c
; Sequence 153274, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153274
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153274

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4121 TGGTGGTGGAACCCAGAAACGGA 4143
              |||||||||||||||||||||||
Db         23 TGGTGGTGGAACCCAGAAACGGA 1


RESULT 56
US-10-310-914A-153285/c
; Sequence 153285, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153285
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153285

  Query Match             0.5%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3604 CCCAACATCTCCCAGCCTCCCCA 3626
              |||||||||||||||||||||||
Db         23 CCCAACATCTCCCAGCCTCCCCA 1


RESULT 57
US-10-310-914A-759276/c
; Sequence 759276, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 759276
;   LENGTH: 26
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-759276

  Query Match             0.5%;  Score 22.8;  DB 1;  Length 26;
  Best Local Similarity   92.3%;  Pred. No. 3.1e+02;
  Matches   24;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3895 CCTTTTTGTTTCTTCGTTTTGTTTTT 3920
              |||||||||||| |||||||| |||||
Db         26 CCTTTTTGTTTGTTCGTTTTTTTTTT 1


RESULT 58
US-10-310-914A-153228/c
; Sequence 153228, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153228
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153228

  Query Match             0.5%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3939 CTTTGTGTTGGAGGGAACCTGT 3960
              ||||||||||||||||||||||
Db         22 CTTTGTGTTGGAGGGAACCTGT 1


RESULT 59
US-10-310-914A-153236/c
; Sequence 153236, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153236
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153236

  Query Match             0.5%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
```

```
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3435 TGCACTTTGAGCCCGTGGGGTG 3456
              ||||||||||||||||||||||
Db         22 TGCACTTTGAGCCCGTGGGGTG 1


RESULT 60
US-10-310-914A-153246/c
; Sequence 153246, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153246
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153246

  Query Match             0.5%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3469 TTTGGAGAGACAGGATTTGGGG 3490
              ||||||||||||||||||||||
Db         22 TTTGGAGAGACAGGATTTGGGG 1


RESULT 61
US-10-310-914A-153267/c
; Sequence 153267, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153267
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153267

  Query Match             0.5%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3946 TTGGAGGGAACCTGTTTCACTA 3967
              ||||||||||||||||||||||
Db         22 TTGGAGGGAACCTGTTTCACTA 1


RESULT 62
US-10-310-914A-153269/c
; Sequence 153269, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153269
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153269

  Query Match             0.5%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3916 TTTTTCTACCGTCCTTGTCATA 3937
              ||||||||||||||||||||||
Db         22 TTTTTCTACCGTCCTTGTCATA 1


RESULT 63
US-10-310-914A-153277/c
; Sequence 153277, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153277
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153277

  Query Match             0.5%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3943 GTGTTGGAGGGAACCTGTTTCA 3964
              ||||||||||||||||||||||
Db         22 GTGTTGGAGGGAACCTGTTTCA 1


RESULT 64
US-10-310-914A-153281/c
; Sequence 153281, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153281
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153281

  Query Match             0.5%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       3417 CCCTGTGCCCCGCTGGATTGCA 3438
             ||||||||||||||||||||||
Db         22 CCCTGTGCCCCGCTGGATTGCA 1


RESULT 65
US-10-310-914A-153283/c
; Sequence 153283, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153283
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153283

  Query Match             0.5%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3668 AGAGAGTGTGACTCCCTTGCCA 3689
             ||||||||||||||||||||||
Db         22 AGAGAGTGTGACTCCCTTGCCA 1


RESULT 66
US-10-310-914A-153286/c
; Sequence 153286, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153286
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153286

  Query Match             0.5%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3394 TGGGGACTCACAGAGGCCCCCA 3415
             ||||||||||||||||||||||
Db         22 TGGGGACTCACAGAGGCCCCCA 1


RESULT 67
US-10-310-914A-556532
; Sequence 556532, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 556532
;   LENGTH: 25
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-556532

  Query Match             0.5%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 3.7e+02;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1059 CCCCGCCCCTGGCCCCAGCCCCAGC 1083
             ||||||| | ||||||||||||||||
Db          1 CCCCGCCUCCGGCCCCAGCCCCAGC 25


RESULT 68
US-11-136-527-49340
; Sequence 49340, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
;  FILE REFERENCE: 031896-041000 (AM101086)
;  CURRENT APPLICATION NUMBER: US/11/136,527
;  CURRENT FILING DATE:  2005-05-25
;  PRIOR APPLICATION NUMBER: US 60/574,294
;  PRIOR FILING DATE: 2005-05-26
;  NUMBER OF SEQ ID NOS: 362830
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49340
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Probe
US-11-136-527-49340

  Query Match             0.5%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 3.7e+02;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3805 TTTTCCCTTGTAAATGCCCCTCCCC 3829
             |||||||||||||||| ||| |||
Db          1 TTTTCCCTTGTAAATGCTCCTTCCC 25


RESULT 69
US-11-136-527-243931
; Sequence 243931, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
;  FILE REFERENCE: 031896-041000 (AM101086)
;  CURRENT APPLICATION NUMBER: US/11/136,527
;  CURRENT FILING DATE:  2005-05-25
;  PRIOR APPLICATION NUMBER: US 60/574,294
;  PRIOR FILING DATE: 2005-05-26
;  NUMBER OF SEQ ID NOS: 362830
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 243931
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Probe
```

US-11-136-527-243931

Query Match 0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 3.7e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3837 TGCCTTCATATTGAAGGTTTTGAG 3861
             ||||||||||||||||||| | |||
Db          1 TGCCTTCATATTGAAGGTTCTGGAG 25
```

RESULT 70
US-11-136-527-243935
; Sequence 243935, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 243935
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-243935

Query Match 0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 3.7e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3839 CCTTCATATTGAAGGTTTTGAGTT 3863
             |||||||||||||||||| | |||||
Db          1 CCTTCATATTGAAGGTTCTGGAGTT 25
```

RESULT 71
US-11-136-527-243939
; Sequence 243939, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 243939
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-243939

Query Match 0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 3.7e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3838 GCCTTCATATTGAAGGTTTTGAGT 3862
             |||||||||||||||||| | ||||
Db          1 GCCTTCATATTGAAGGTTCTGGAGT 25
```

RESULT 72
US-10-310-914A-556499
; Sequence 556499, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 556499
; LENGTH: 26
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-556499

Query Match 0.5%; Score 21.8; DB 1; Length 26;
Best Local Similarity 92.0%; Pred. No. 3.9e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1059 CCCCGCCCCTGGCCCCAGCCCCAGC 1083
             ||||||| | ||||||||||||||||
Db          2 CCCCGCCUCCGGCCCCAGCCCCAGC 26
```

RESULT 73
US-10-310-914A-207826/c
; Sequence 207826, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 207826
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-207826

Query Match 0.5%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 3.5e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       3897 TTTTTGTTTCTTCGTTTTGTTTT 3919
             |||||||||||| ||||||||||
Db         23 TTTTTGTTTCTTGGTTTTGTTTT 1
```

RESULT 74
US-10-310-914A-916482/c
; Sequence 916482, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402

```
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916482
;   LENGTH: 25
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-916482

  Query Match             0.5%;  Score 21.4;  DB 1;  Length 25;
  Best Local Similarity   95.7%;  Pred. No. 4e+02;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCCCAGCCTC 1086
              |||||| ||||||||||||||||
Db         24 CCCCTGCCCCCAGCCCCAGCCTC 2


RESULT 75
US-10-949-720-20/c
; Sequence 20, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 20
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-20

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 76
US-10-949-720-35/c
; Sequence 35, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 35
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-35

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        425 AAGAGACCCTGCTGAACACAA 445
              |||||||||||||||||||||
Db         21 AAGAGACCCTGCTGAACACAA 1


RESULT 77
US-10-949-720-37/c
; Sequence 37, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 37
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-37

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAGGTGAATGTCAAGACGCTG 867
              |||||||||||||||||||||
Db         21 AAGGTGAATGTCAAGACGCTG 1


RESULT 78
US-10-949-720-39/c
; Sequence 39, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
```

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 39
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-39

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1937 AACATCACAGCCAGACCCAAC 1957
||||||||||||||||||||
Db 21 AACATCACAGCCAGACCCAAC 1

RESULT 79
US-10-949-720-41/c
; Sequence 41, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 41
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-41

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2677 AACTCTTCCGATCCCACCTAC 2697
||||||||||||||||||||
Db 21 AACTCTTCCGATCCCACCTAC 1

RESULT 80
US-10-949-720-42/c
; Sequence 42, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 42
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-42

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 928 ATGGCCCTGCTATCCCTGCAC 948
||||||||||||||||||||
Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 81
US-10-949-720-44/c
; Sequence 44, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 44
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-44

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1381 GGCTCCTCCCTGCACCTGGAA 1401

```
                    ||||||||||||||||||||
Db         21 GGCTCCTCCCTGCACCTGGAA 1


RESULT 82
US-10-949-720-45/c
; Sequence 45, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 45
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-45

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1641 TGAGCCTGTCAATGTCACCAC 1661
                ||||||||||||||||||||
Db         21 TGAGCCTGTCAATGTCACCAC 1


RESULT 83
US-10-949-720-46/c
; Sequence 46, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 46
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-46

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1931 GCCAGGAACATCACAGCCAGA 1951
                ||||||||||||||||||||
Db         21 GCCAGGAACATCACAGCCAGA 1


RESULT 84
US-10-949-720-49/c
; Sequence 49, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 49
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-49

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        784 AAGGTGGACACGGTGGCCGCG 804
                ||||||||||||||||||||
Db         21 AAGGTGGACACGGTGGCCGCG 1


RESULT 85
US-10-949-720-50/c
; Sequence 50, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
```

```
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 50
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-50

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GTGGCAATCAAGACCCTGAAG 2325
             |||||||||||||||||||||
Db         21 GTGGCAATCAAGACCCTGAAG 1


RESULT 86
US-10-949-720-52/c
; Sequence 52, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 52
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-52

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 GTCATCCAGCTCGTGGGCATG 2535
             |||||||||||||||||||||
Db         21 GTCATCCAGCTCGTGGGCATG 1


RESULT 87
US-10-949-720-70/c
; Sequence 70, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 70
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-70

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        425 AAGAGACCCTGCTGAACACAA 445
              |||||||||||||||||||||
Db         21 AAGAGACCCTGCTGAACACAA 1


RESULT 88
US-10-949-720-73/c
; Sequence 73, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 73
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-73

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3319 GGACCGGCCCCGCAGTACTGA 3339
              |||||||||||||||||||||
Db         21 GGACCGGCCCCGCAGTACTGA 1


RESULT 89
US-10-949-720-222/c
; Sequence 222, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
```

```
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 222
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-222

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 90
US-10-949-720-224/c
; Sequence 224, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 224
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-224

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1381 GGCTCCTCCCTGCACCTGGAA 1401
              |||||||||||||||||||||
Db         21 GGCTCCTCCCTGCACCTGGAA 1


RESULT 91
US-10-949-720-225/c
; Sequence 225, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 225
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-225

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1641 TGAGCCTGTCAATGTCACCAC 1661
              |||||||||||||||||||||
Db         21 TGAGCCTGTCAATGTCACCAC 1


RESULT 92
US-10-949-720-226/c
; Sequence 226, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 226
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-226

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1931 GCCAGGAACATCACAGCCAGA 1951
              ||||||||||||||||||||
Db         21 GCCAGGAACATCACAGCCAGA 1
```

```
RESULT 93
US-10-949-720-229/c
; Sequence 229, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 229
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-229

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        784 AAGGTGGACACGGTGGCCGCG 804
              ||||||||||||||||||||
Db         21 AAGGTGGACACGGTGGCCGCG 1
```

```
RESULT 94
US-10-949-720-230/c
; Sequence 230, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 230
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-230

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GTGGCAATCAAGACCCTGAAG 2325
              ||||||||||||||||||||
Db         21 GTGGCAATCAAGACCCTGAAG 1
```

```
RESULT 95
US-10-949-720-232/c
; Sequence 232, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 232
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-232

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 GTCATCCAGCTCGTGGGCATG 2535
              ||||||||||||||||||||
Db         21 GTCATCCAGCTCGTGGGCATG 1
```

```
RESULT 96
US-10-949-720-233
; Sequence 233, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
```

```
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 233
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-233

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        445 AAATTGGAAACTGCTGATCTG 465
              |||||||||||||||||||||
Db          1 AAATTGGAAACTGCTGATCTG 21


RESULT 97
US-10-949-720-234
; Sequence 234, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 234
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-234

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        446 AATTGGAAACTGCTGATCTGA 466
              |||||||||||||||||||||
Db          1 AATTGGAAACTGCTGATCTGA 21


RESULT 98
US-10-949-720-235
; Sequence 235, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 235
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-235

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        452 AAACTGCTGATCTGAAGTGGG 472
              |||||||||||||||||||||
Db          1 AAACTGCTGATCTGAAGTGGG 21


RESULT 99
US-10-949-720-236
; Sequence 236, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 236
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-236

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        453 AACTGCTGATCTGAAGTGGGT 473
              |||||||||||||||||||||
Db          1 AACTGCTGATCTGAAGTGGGT 21


RESULT 100
US-10-949-720-237
; Sequence 237, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
```

```
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 237
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-237

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        853 AATGTCAAGACGCTGCGTCTG 873
              |||||||||||||||||||||
Db          1 AATGTCAAGACGCTGCGTCTG 21


RESULT 101
US-10-949-720-238
; Sequence 238, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 238
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-238

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        466 AAGTGGGTGACATTCCCTCAG 486
              |||||||||||||||||||||
Db          1 AAGTGGGTGACATTCCCTCAG 21


RESULT 102
US-10-949-720-239
; Sequence 239, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 239
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-239

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAGGTGAATGTCAAGACGCTG 867
              |||||||||||||||||||||
Db          1 AAGGTGAATGTCAAGACGCTG 21


RESULT 103
US-10-949-720-240
; Sequence 240, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 240
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-240

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        697 AAGGAGACCTTCACCGTCTTC 717
              |||||||||||||||||||||
Db          1 AAGGAGACCTTCACCGTCTTC 21


RESULT 104
US-10-949-720-241
; Sequence 241, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 241
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-241

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        958 AAAAAGTGCGCCCAGCTGACT 978
              |||||||||||||||||||||
Db          1 AAAAAGTGCGCCCAGCTGACT 21


RESULT 105
US-10-949-720-242
; Sequence 242, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 242
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-242

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1246 AATAGCCACTCTAACACCATT 1266
              |||||||||||||||||||||
Db          1 AATAGCCACTCTAACACCATT 21


RESULT 106
US-10-949-720-243
; Sequence 243, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 243
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-243

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AACACCATTGGATCAGCCGTC 1278
              |||||||||||||||||||||
Db          1 AACACCATTGGATCAGCCGTC 21


RESULT 107
US-10-949-720-244
; Sequence 244, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
```

```
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 244
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-244

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1651 AATGTCACCACTGACCGAGAG 1671
             |||||||||||||||||||||
Db          1 AATGTCACCACTGACCGAGAG 21


RESULT 108
US-10-949-720-245
; Sequence 245, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 245
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-245

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1783 AAATACCATGAGAAGGGCGCC 1803
             |||||||||||||||||||||
Db          1 AAATACCATGAGAAGGGCGCC 21


RESULT 109
US-10-949-720-246
; Sequence 246, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 246
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-246

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1831 AAGACGTCAGAAAACCGGGCA 1851
             |||||||||||||||||||||
Db          1 AAGACGTCAGAAAACCGGGCA 21


RESULT 110
US-10-949-720-247
; Sequence 247, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 247
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-247

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1937 AACATCACAGCCAGACCCAAC 1957
             |||||||||||||||||||||
Db          1 AACATCACAGCCAGACCCAAC 21


RESULT 111
US-10-949-720-248
; Sequence 248, Application US/10949720
; Publication No. US20050249736A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 248
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-248

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2068 AAGCAGAGCAATGGGAGAGAA 2088
             |||||||||||||||||||||
Db          1 AAGCAGAGCAATGGGAGAGAA 21


RESULT 112
US-10-949-720-249
; Sequence 249, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 249
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-249

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2077 AATGGGAGAGAAGCAGAATAT 2097
             |||||||||||||||||||||
Db          1 AATGGGAGAGAAGCAGAATAT 21


RESULT 113
US-10-949-720-250
; Sequence 250, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 250
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-250

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2087 AAGCAGAATATTCGGACAAAC 2107
             |||||||||||||||||||||
Db          1 AAGCAGAATATTCGGACAAAC 21


RESULT 114
US-10-949-720-251
; Sequence 251, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 251
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-251
```

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2093 AATATTCGGACAAACACGGAC 2113
             |||||||||||||||||||||
Db          1 AATATTCGGACAAACACGGAC 21


RESULT 115
US-10-949-720-252
; Sequence 252, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 252
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-252

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2104 AAACACGGACAGTATCTCATC 2124
             |||||||||||||||||||||
Db          1 AAACACGGACAGTATCTCATC 21


RESULT 116
US-10-949-720-253
; Sequence 253, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 253
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-253

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2105 AACACGGACAGTATCTCATCG 2125
             |||||||||||||||||||||
Db          1 AACACGGACAGTATCTCATCG 21


RESULT 117
US-10-949-720-254
; Sequence 254, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 254
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-254

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2196 AAAAGAGATCGATGTCTCCTA 2216
             |||||||||||||||||||||
Db          1 AAAAGAGATCGATGTCTCCTA 21


RESULT 118
US-10-949-720-255
; Sequence 255, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
```

```
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 255
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-255

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2173 AATGAGGCTGTGAGGGAATTT 2193
             |||||||||||||||||||||
Db          1 AATGAGGCTGTGAGGGAATTT 21


RESULT 119
US-10-949-720-256
; Sequence 256, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 256
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-256

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2165 AAGACCCTAATGAGGCTGTGA 2185
             |||||||||||||||||||||
Db          1 AAGACCCTAATGAGGCTGTGA 21


RESULT 120
US-10-949-720-257
; Sequence 257, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 257
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-257

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2197 AAAGAGATCGATGTCTCCTAC 2217
             |||||||||||||||||||||
Db          1 AAAGAGATCGATGTCTCCTAC 21


RESULT 121
US-10-949-720-258
; Sequence 258, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 258
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-258

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2198 AAGAGATCGATGTCTCCTACG 2218
             |||||||||||||||||||||
Db          1 AAGAGATCGATGTCTCCTACG 21


RESULT 122
US-10-949-720-259
```

; Sequence 259, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 259
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-259

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2228 AAGAGGTGATTGGTGCAGGTG 2248
||||||||||||||||||||
Db 1 AAGAGGTGATTGGTGCAGGTG 21

RESULT 123
US-10-949-720-260
; Sequence 260, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 260
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-260

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2221 AAGATTGAAGAGGTGATTGGT 2241
|||||||||||||||||||||
Db 1 AAGATTGAAGAGGTGATTGGT 21

RESULT 124
US-10-949-720-261
; Sequence 261, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 261
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-261

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2428 AACAGCATGCCCGTCATGATT 2448
|||||||||||||||||||||
Db 1 AACAGCATGCCCGTCATGATT 21

RESULT 125
US-10-949-720-262
; Sequence 262, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 262
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:

```
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-262

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2290 AAGAAGGAGAGCTGTGTGGCA 2310
              |||||||||||||||||||||
Db          1 AAGAAGGAGAGCTGTGTGGCA 21


RESULT 126
US-10-949-720-263
; Sequence 263, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 263
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-263

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2293 AAGGAGAGCTGTGTGGCAATC 2313
              |||||||||||||||||||||
Db          1 AAGGAGAGCTGTGTGGCAATC 21


RESULT 127
US-10-949-720-264
; Sequence 264, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 264
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-264

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2310 AATCAAGACCCTGAAGGGTGG 2330
              |||||||||||||||||||||
Db          1 AATCAAGACCCTGAAGGGTGG 21


RESULT 128
US-10-949-720-265
; Sequence 265, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 265
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-265

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2496 AAACGACGGACAGTTCACAGT 2516
              |||||||||||||||||||||
Db          1 AAACGACGGACAGTTCACAGT 21


RESULT 129
US-10-949-720-266
; Sequence 266, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
```

```
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 266
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-266

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2497 AACGACGGACAGTTCACAGTC 2517
             |||||||||||||||||||||
Db          1 AACGACGGACAGTTCACAGTC 21


RESULT 130
US-10-949-720-267
; Sequence 267, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 267
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-267

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2608 AACATCCTAGTCAACAGCAAC 2628
             |||||||||||||||||||||
Db          1 AACATCCTAGTCAACAGCAAC 21


RESULT 131
US-10-949-720-268
; Sequence 268, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 268
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-268

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2620 AACAGCAACCTCGTCTGCAAA 2640
             |||||||||||||||||||||
Db          1 AACAGCAACCTCGTCTGCAAA 21


RESULT 132
US-10-949-720-269
;,Sequence 269, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 269
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-269

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2677 AACTCTTCCGATCCCACCTAC 2697
             |||||||||||||||||||||
Db          1 AACTCTTCCGATCCCACCTAC 21
```

```
RESULT 133
US-10-949-720-270
; Sequence 270, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 270
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-270

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2639 AAGTGTCTGACTTTGGCCTTT 2659
             |||||||||||||||||||||
Db          1 AAGTGTCTGACTTTGGCCTTT 21


RESULT 134
US-10-949-720-271
; Sequence 271, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 271
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-271

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2626 AACCTCGTCTGCAAAGTGTCT 2646
             |||||||||||||||||||||
Db          1 AACCTCGTCTGCAAAGTGTCT 21


RESULT 135
US-10-949-720-272
; Sequence 272, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 272
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-272

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2638 AAAGTGTCTGACTTTGGCCTT 2658
             |||||||||||||||||||||
Db          1 AAAGTGTCTGACTTTGGCCTT 21


RESULT 136
US-10-949-720-273
; Sequence 273, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 273
;   LENGTH: 21
;   TYPE: DNA
```

```
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-273

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2851 AATCAGGACGTGATCAATGCC 2871
             |||||||||||||||||||||
Db          1 AATCAGGACGTGATCAATGCC 21


RESULT 137
US-10-949-720-274
; Sequence 274, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 274
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-274

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2715 AAAGATTCCCATCCGATGGAC 2735
             |||||||||||||||||||||
Db          1 AAAGATTCCCATCCGATGGAC 21


RESULT 138
US-10-949-720-275
; Sequence 275, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 275
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-275

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2716 AAGATTCCCATCCGATGGACT 2736
             |||||||||||||||||||||
Db          1 AAGATTCCCATCCGATGGACT 21


RESULT 139
US-10-949-720-276
; Sequence 276, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 276
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-276

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2761 AAGTTCACTTCCGCCAGTGAT 2781
             |||||||||||||||||||||
Db          1 AAGTTCACTTCCGCCAGTGAT 21


RESULT 140
US-10-949-720-277
; Sequence 277, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
```

```
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 277
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-277

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3141 AAGATACGAAGAAAGTTTCGC 3161
             |||||||||||||||||||||
Db          1 AAGATACGAAGAAAGTTTCGC 21


RESULT 141
US-10-949-720-278
; Sequence 278, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 278
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-278

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3135 AATGGGAAGATACGAAGAAAG 3155
             |||||||||||||||||||||
Db          1 AATGGGAAGATACGAAGAAAG 21


RESULT 142
US-10-949-720-279
; Sequence 279, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 279
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-279

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2866 AATGCCATTGAACAGGACTAC 2886
             |||||||||||||||||||||
Db          1 AATGCCATTGAACAGGACTAC 21


RESULT 143
US-10-949-720-280
; Sequence 280, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 280
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-280

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3028 AAAATCGTGGCCCGGGAGAAT 3048
             |||||||||||||||||||||
Db          1 AAAATCGTGGCCCGGGAGAAT 21
```

```
RESULT 144
US-10-949-720-281
; Sequence 281, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 281
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-281

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3253 AAAATCTTGGCCAGTGTCCAG 3273
              |||||||||||||||||||||
Db          1 AAAATCTTGGCCAGTGTCCAG 21


RESULT 145
US-10-949-720-282
; Sequence 282, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 282
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-282

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTCCAGC 3274
              |||||||||||||||||||||
Db          1 AAATCTTGGCCAGTGTCCAGC 21


RESULT 146
US-10-949-720-283
; Sequence 283, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 283
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-283

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3149 AAGAAAGTTTCGCAGCCGCTG 3169
              |||||||||||||||||||||
Db          1 AAGAAAGTTTCGCAGCCGCTG 21


RESULT 147
US-10-949-720-284
; Sequence 284, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 284
```

```
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-284

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3250 AAGAAAATCTTGGCCAGTGTC 3270
              |||||||||||||||||||||
Db          1 AAGAAAATCTTGGCCAGTGTC 21


RESULT 148
US-10-949-720-285
; Sequence 285, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 285
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-285

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3255 AATCTTGGCCAGTGTCCAGCA 3275
              |||||||||||||||||||||
Db          1 AATCTTGGCCAGTGTCCAGCA 21


RESULT 149
US-10-770-726-17546
; Sequence 17546, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17546
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17546

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCAGAA 2951
              |||||||||||||||||||||
Db          1 CATGCTGGACTGTTGGCAGAA 21


RESULT 150
US-10-310-914A-153232/c
; Sequence 153232, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153232
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153232

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4145 GCCGGTGCTTGGAGGGGTTCT 4165
              |||||||||||||||||||||
Db         21 GCCGGTGCTTGGAGGGGTTCT 1


RESULT 151
US-10-310-914A-153233/c
; Sequence 153233, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153233
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153233

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3916 TTTTTCTACCGTCCTTGTCAT 3936
              |||||||||||||||||||||
Db         21 TTTTTCTACCGTCCTTGTCAT 1


RESULT 152
US-10-310-914A-153234/c
```

; Sequence 153234, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153234
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153234

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3444 AGCCCGTGGGGTGAGGAGTTG 3464
||||||||||||||||||||
Db 21 AGCCCGTGGGGTGAGGAGTTG 1

RESULT 153
US-10-310-914A-153240/c
; Sequence 153240, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153240
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153240

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3411 CCCCAGCCCTGTGCCCCGCTG 3431
||||||||||||||||||||
Db 21 CCCCAGCCCTGTGCCCCGCTG 1

RESULT 154
US-10-310-914A-153241/c
; Sequence 153241, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153241
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153241

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3939 CTTTGTGTTGGAGGGAACCTG 3959
||||||||||||||||||||
Db 21 CTTTGTGTTGGAGGGAACCTG 1

RESULT 155
US-10-310-914A-153243/c
; Sequence 153243, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153243
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153243

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3445 GCCCGTGGGGTGAGGAGTTGG 3465
||||||||||||||||||||
Db 21 GCCCGTGGGGTGAGGAGTTGG 1

RESULT 156
US-10-310-914A-153247/c
; Sequence 153247, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153247
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153247

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3471 TGGAGAGACAGGATTTGGGGG 3491
||||||||||||||||||||
Db 21 TGGAGAGACAGGATTTGGGGG 1

RESULT 157
US-10-310-914A-153249/c
; Sequence 153249, Application US/10310914A

```
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153249
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153249

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3699 TGGGGGGGCTGTCCCAGGGGG 3719
              |||||||||||||||||||||
Db         21 TGGGGGGGCTGTCCCAGGGGG 1


RESULT 158
US-10-310-914A-153264/c
; Sequence 153264, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153264
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153264

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3767 TCCCAACTTGCTGCTGTCACC 3787
              |||||||||||||||||||||
Db         21 TCCCAACTTGCTGCTGTCACC 1


RESULT 159
US-10-310-914A-153293/c
; Sequence 153293, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153293
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153293

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4149 GTGCTTGGAGGGGTTCTTAAA 4169
              |||||||||||||||||||||
Db         21 GTGCTTGGAGGGGTTCTTAAA 1


RESULT 160
US-10-310-914A-1141554
; Sequence 1141554, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1141554
;   LENGTH: 25
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1141554

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   87.5%;  Pred. No. 4.6e+02;
  Matches   21;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        826 CCTGGGGCCGAGGCCACCGGGAAG 849
              ||:|||||||||||||||  ||||
Db          1 CCUGGGGCCGAGGCCACCCCGAAG 24


RESULT 161
US-11-136-527-49332
; Sequence 49332, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
;  FILE REFERENCE: 031896-041000 (AM101086)
;  CURRENT APPLICATION NUMBER: US/11/136,527
;  CURRENT FILING DATE:  2005-05-25
;  PRIOR APPLICATION NUMBER: US 60/574,294
;  PRIOR FILING DATE: 2005-05-26
;  NUMBER OF SEQ ID NOS: 362830
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49332
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Probe
US-11-136-527-49332

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 4.6e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3806 TTTCCCTTGTAAATGCCCCTCCCC 3829
              |||||||||||||||| ||| |||
Db          1 TTTCCCTTGTAAATGCTCCTTCCC 24


RESULT 162
```

```
US-11-136-527-49335
; Sequence 49335, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
;  FILE REFERENCE: 031896-041000 (AM101086)
;  CURRENT APPLICATION NUMBER: US/11/136,527
;  CURRENT FILING DATE:  2005-05-25
;  PRIOR APPLICATION NUMBER: US 60/574,294
;  PRIOR FILING DATE: 2005-05-26
;  NUMBER OF SEQ ID NOS: 362830
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49335
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Probe
US-11-136-527-49335

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 4.6e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3805 TTTTCCCTTGTAAATGCCCCTCCC 3828
             |||||||||||||||||  ||| ||
Db          2 TTTTCCCTTGTAAATGCTCCTTCC 25


RESULT 163
US-10-949-720-59
; Sequence 59, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 59
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-59

  Query Match             0.5%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   95.5%;  Pred. No. 4.1e+02;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1587 TGAGGTCACTGCATTGAACGGG 1608
             | ||||||||||||||||||||
Db          1 TCAGGTCACTGCATTGAACGGG 22


RESULT 164
US-10-310-914A-161890
; Sequence 161890, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161890
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-161890

  Query Match             0.5%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   81.8%;  Pred. No. 4.1e+02;
  Matches   18;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3604 CCCAACATCTCCCAGCCTCCCC 3625
             |||||| :|:|||||||:||||
Db          1 CCCAACCUCUCCCAGCCUCCCC 22


RESULT 165
US-10-310-914A-161891
; Sequence 161891, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161891
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-161891

  Query Match             0.5%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   81.8%;  Pred. No. 4.1e+02;
  Matches   18;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3604 CCCAACATCTCCCAGCCTCCCC 3625
             |||||| :|:|||||||:||||
Db          1 CCCAACCUCUCCCAGCCUCCCC 22


RESULT 166
US-10-310-914A-916479/c
; Sequence 916479, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916479
;   LENGTH: 22
;   TYPE: RNA
```

```
;   ORGANISM: Human
US-10-310-914A-916479

  Query Match             0.5%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   95.5%;  Pred. No. 4.1e+02;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1065 CCCTGGCCCCAGCCCCAGCCTC 1086
              ||||| ||||||||||||||||
Db         22 CCCTGCCCCCAGCCCCAGCCTC 1


RESULT 167
US-10-932-182A-21431/c
; Sequence 21431, Application US/10932182A
; Publication No. US20060046253A1
; GENERAL INFORMATION:
;  APPLICANT: NAKAO, YOSHIHIRO
;  APPLICANT:  NAKAMURA, NORIHISA
;  APPLICANT:  KODAMA, YUKIKO
;  APPLICANT:  FUJIMURA, TOMOKO
;  APPLICANT:  ASHIKARI, TOSHIHIKO
;  TITLE OF INVENTION: METHODS FOR ANALYZING GENES OF INDUSTRIAL YEASTS
;  FILE REFERENCE: 030685-043
;  CURRENT APPLICATION NUMBER: US/10/932,182A
;  CURRENT FILING DATE:  2004-09-02
;  NUMBER OF SEQ ID NOS: 197023
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 21431
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Saccharomyces pastorianus
US-10-932-182A-21431

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 5.3e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2074 AGCAATGGGAGAGAAGCAGAATATT 2098
              |||||||||| |||||||  |||||
Db         25 AGCAATGGGATAGAAGCAACATATT 1


RESULT 168
US-11-136-527-146486
; Sequence 146486, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
;  FILE REFERENCE: 031896-041000 (AM101086)
;  CURRENT APPLICATION NUMBER: US/11/136,527
;  CURRENT FILING DATE:  2005-05-25
;  PRIOR APPLICATION NUMBER: US 60/574,294
;  PRIOR FILING DATE: 2005-05-26
;  NUMBER OF SEQ ID NOS: 362830
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146486
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Probe
US-11-136-527-146486

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 5.3e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2836 TACTGGGACATGAGCAATCAGGACG 2860
              |||||| |||||| ||||||||| |
Db          1 TACTGGAACATGACCAATCAGGATG 25


RESULT 169
US-11-136-527-146488
; Sequence 146488, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
;  FILE REFERENCE: 031896-041000 (AM101086)
;  CURRENT APPLICATION NUMBER: US/11/136,527
;  CURRENT FILING DATE:  2005-05-25
;  PRIOR APPLICATION NUMBER: US 60/574,294
;  PRIOR FILING DATE: 2005-05-26
;  NUMBER OF SEQ ID NOS: 362830
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146488
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Probe
US-11-136-527-146488

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 5.3e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2834 CGTACTGGGACATGAGCAATCAGGA 2858
              | |||||| |||||| |||||||||
Db          1 CCTACTGGAACATGACCAATCAGGA 25


RESULT 170
US-11-136-527-146494
; Sequence 146494, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
;  TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
;  FILE REFERENCE: 031896-041000 (AM101086)
;  CURRENT APPLICATION NUMBER: US/11/136,527
;  CURRENT FILING DATE:  2005-05-25
;  PRIOR APPLICATION NUMBER: US 60/574,294
;  PRIOR FILING DATE: 2005-05-26
;  NUMBER OF SEQ ID NOS: 362830
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146494
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Probe
US-11-136-527-146494

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 5.3e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2837 ACTGGGACATGAGCAATCAGGACGT 2861
              ||||| |||||| ||||||||| ||
Db          1 ACTGGAACATGACCAATCAGGATGT 25


RESULT 171
US-11-136-527-146507
; Sequence 146507, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Mounts, William M
```

```
;  TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
;  FILE REFERENCE: 031896-041000 (AM101086)
;  CURRENT APPLICATION NUMBER: US/11/136,527
;  CURRENT FILING DATE:  2005-05-25
;  PRIOR APPLICATION NUMBER: US 60/574,294
;  PRIOR FILING DATE: 2005-05-26
;  NUMBER OF SEQ ID NOS: 362830
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146507
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Probe
US-11-136-527-146507

  Query Match             0.5%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 5.3e+02;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2833 CCGTACTGGGACATGAGCAATCAGG 2857
              || |||||| |||||| ||||||||
Db          1 CCCTACTGGAACATGACCAATCAGG 25


RESULT 172
US-10-949-720-19
; Sequence 19, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 19
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-19

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        691 TCCTGCAAGGAGACCTTCAC 710
              ||||||||||||||||||||
Db          1 TCCTGCAAGGAGACCTTCAC 20


RESULT 173
US-10-949-720-21/c
; Sequence 21, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-21

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 174
US-10-949-720-25
; Sequence 25, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-25

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        697 AAGGAGACCTTCACCGTCTT 716
              ||||||||||||||||||||
Db          1 AAGGAGACCTTCACCGTCTT 20


RESULT 175
```

```
US-10-949-720-27/c
; Sequence 27, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 27
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-27

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        974 TGACTGTGAACCTGACTCGA 993
              ||||||||||||||||||||
Db         20 TGACTGTGAACCTGACTCGA 1


RESULT 176
US-10-949-720-32
; Sequence 32, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 32
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-32

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        419 CTTTGGAAGAGACCCTGCTG 438
              ||||||||||||||||||||
Db          1 CTTTGGAAGAGACCCTGCTG 20


RESULT 177
US-10-949-720-33/c
; Sequence 33, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 33
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-33

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        696 CAAGGAGACCTTCACCGTCT 715
              ||||||||||||||||||||
Db         20 CAAGGAGACCTTCACCGTCT 1


RESULT 178
US-10-949-720-51/c
; Sequence 51, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 51
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
```

```
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-51

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 179
US-10-949-720-55
; Sequence 55, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-55

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        419 CTTTGGAAGAGACCCTGCTG 438
              ||||||||||||||||||||
Db          1 CTTTGGAAGAGACCCTGCTG 20


RESULT 180
US-10-949-720-56/c
; Sequence 56, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 56
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-56

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        696 CAAGGAGACCTTCACCGTCT 715
              ||||||||||||||||||||
Db         20 CAAGGAGACCTTCACCGTCT 1


RESULT 181
US-10-949-720-74/c
; Sequence 74, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 74
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-74

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3299 GAACCCCGGGTGGGACAGGA 3318
              ||||||||||||||||||||
Db         20 GAACCCCGGGTGGGACAGGA 1


RESULT 182
US-10-949-720-75/c
; Sequence 75, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
```

```
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 75
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-75

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3279 GAAGTCCCAGGCCAAGCCGG 3298
              ||||||||||||||||||||
Db         20 GAAGTCCCAGGCCAAGCCGG 1


RESULT 183
US-10-949-720-76/c
; Sequence 76, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 76
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-76

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3259 TTGGCCAGTGTCCAGCACAT 3278
              ||||||||||||||||||||
Db         20 TTGGCCAGTGTCCAGCACAT 1


RESULT 184
US-10-949-720-77/c
; Sequence 77, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 77
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-77

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3239 CGGGACACCAGAAGAAAATC 3258
              ||||||||||||||||||||
Db         20 CGGGACACCAGAAGAAAATC 1


RESULT 185
US-10-949-720-78/c
; Sequence 78, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 78
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-78

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3219 CCGAATCGGAGTCACTCTGG 3238
              ||||||||||||||||||||
Db         20 CCGAATCGGAGTCACTCTGG 1
```

```
RESULT 186
US-10-949-720-79/c
; Sequence 79, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 79
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-79

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3199 ATCTCTGCTGAGGACCTGCT 3218
             ||||||||||||||||||||
Db         20 ATCTCTGCTGAGGACCTGCT 1


RESULT 187
US-10-949-720-80/c
; Sequence 80, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 80
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-80

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3179 CCTTCGAGCTGGTCAGCCAG 3198
             ||||||||||||||||||||
Db         20 CCTTCGAGCTGGTCAGCCAG 1


RESULT 188
US-10-949-720-81/c
; Sequence 81, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 81
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-81

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3159 CGCAGCCGCTGGCTTTGGCT 3178
             ||||||||||||||||||||
Db         20 CGCAGCCGCTGGCTTTGGCT 1


RESULT 189
US-10-949-720-82/c
; Sequence 82, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 82
;   LENGTH: 20
```

```
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-82

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3139 GGAAGATACGAAGAAAGTTT 3158
              ||||||||||||||||||||
Db         20 GGAAGATACGAAGAAAGTTT 1


RESULT 190
US-10-949-720-83/c
; Sequence 83, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 83
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-83

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3119 GGCTTCGGGCCATCAAAATG 3138
              ||||||||||||||||||||
Db         20 GGCTTCGGGCCATCAAAATG 1


RESULT 191
US-10-949-720-84/c
; Sequence 84, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 84
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-84

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3099 TTTTGGCTCTGTGGGCGAGT 3118
              ||||||||||||||||||||
Db         20 TTTTGGCTCTGTGGGCGAGT 1


RESULT 192
US-10-949-720-85/c
; Sequence 85, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 85
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-85

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3079 CGGCAGCCTCACTACTCAGC 3098
              ||||||||||||||||||||
Db         20 CGGCAGCCTCACTACTCAGC 1


RESULT 193
US-10-949-720-86/c
; Sequence 86, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
```

```
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 86
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-86

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3059 CACACCCTCTCCTGGACCAG 3078
             ||||||||||||||||||||
Db         20 CACACCCTCTCCTGGACCAG 1


RESULT 194
US-10-949-720-87/c
; Sequence 87, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 87
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-87

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3039 CCGGGAGAATGGCGGGGCCT 3058
             ||||||||||||||||||||
Db         20 CCGGGAGAATGGCGGGGCCT 1


RESULT 195
US-10-949-720-88/c
; Sequence 88, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 88
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-88

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3019 GCCAGCCTCAAAATCGTGGC 3038
             ||||||||||||||||||||
Db         20 GCCAGCCTCAAAATCGTGGC 1


RESULT 196
US-10-949-720-89/c
; Sequence 89, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 89
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-89

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2999 ACAAGATGATCCGGAACCCC 3018
             ||||||||||||||||||||
```

```
Db         20 ACAAGATGATCCGGAACCCC 1


RESULT 197
US-10-949-720-90/c
; Sequence 90, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 90
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-90

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2979 CCAGGTGGTCAGCGCCCTGG 2998
             ||||||||||||||||||||
Db         20 CCAGGTGGTCAGCGCCCTGG 1


RESULT 198
US-10-949-720-91/c
; Sequence 91, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 91
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-91

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2959 AATGCCCGGCCCCGCTTCCC 2978
             ||||||||||||||||||||
Db         20 AATGCCCGGCCCCGCTTCCC 1


RESULT 199
US-10-949-720-92/c
; Sequence 92, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-92

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2939 ACTGTTGGCAGAAAGACCGG 2958
             ||||||||||||||||||||
Db         20 ACTGTTGGCAGAAAGACCGG 1


RESULT 200
US-10-949-720-93/c
; Sequence 93, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
```

; SEQ ID NO 93
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-93

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2919 CCTCCACCAGCTCATGCTGG 2938
||||||||||||||||||||
Db 20 CCTCCACCAGCTCATGCTGG 1

RESULT 201
US-10-949-720-94/c
; Sequence 94, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-94

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2899 CCCCCAGACTGTCCCACCTC 2918
||||||||||||||||||||
Db 20 CCCCCAGACTGTCCCACCTC 1

RESULT 202
US-10-949-720-95/c
; Sequence 95, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 95
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-95

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2879 AGGACTACCGGCTGCCCCCG 2898
||||||||||||||||||||
Db 20 AGGACTACCGGCTGCCCCCG 1

RESULT 203
US-10-949-720-96/c
; Sequence 96, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 96
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-96

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2859 CGTGATCAATGCCATTGAAC 2878
||||||||||||||||||||
Db 20 CGTGATCAATGCCATTGAAC 1

RESULT 204
US-10-949-720-97/c
; Sequence 97, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra

```
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 97
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-97

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2839 TGGGACATGAGCAATCAGGA 2858
             ||||||||||||||||||||
Db         20 TGGGACATGAGCAATCAGGA 1


RESULT 205
US-10-949-720-98/c
; Sequence 98, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 98
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-98

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2819 CATTTGGGGAGAGGCCGTAC 2838
             ||||||||||||||||||||
Db         20 CATTTGGGGAGAGGCCGTAC 1


RESULT 206
US-10-949-720-99/c
; Sequence 99, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 99
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-99

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2799 TGTGATGTGGGAGGTGATGT 2818
             ||||||||||||||||||||
Db         20 TGTGATGTGGGAGGTGATGT 1


RESULT 207
US-10-949-720-100/c
; Sequence 100, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 100
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-100

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2779 GATGCCTGGAGTTACGGGAT 2798
              ||||||||||||||||||||
Db         20 GATGCCTGGAGTTACGGGAT 1


RESULT 208
US-10-949-720-101/c
; Sequence 101, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 101
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-101

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2759 GGAAGTTCACTTCCGCCAGT 2778
              ||||||||||||||||||||
Db         20 GGAAGTTCACTTCCGCCAGT 1


RESULT 209
US-10-949-720-102/c
; Sequence 102, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 102
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-102

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2739 CCCGGAGGCCATTGCCTTCC 2758
              ||||||||||||||||||||
Db         20 CCCGGAGGCCATTGCCTTCC 1


RESULT 210
US-10-949-720-103/c
; Sequence 103, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 103
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-103

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2719 ATTCCCATCCGATGGACTGC 2738
              ||||||||||||||||||||
Db         20 ATTCCCATCCGATGGACTGC 1


RESULT 211
US-10-949-720-104/c
; Sequence 104, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
```

```
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 104
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-104

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2699 CGAGCTCCCTGGGAGGAAAG 2718
             ||||||||||||||||||||
Db         20 CGAGCTCCCTGGGAGGAAAG 1


RESULT 212
US-10-949-720-105/c
; Sequence 105, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 105
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-105

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTACA 2698
             ||||||||||||||||||||
Db         20 CTCTTCCGATCCCACCTACA 1


RESULT 213
US-10-949-720-106/c
; Sequence 106, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 106
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-106

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2659 TCCCGATTCCTGGAGGAGAA 2678
             ||||||||||||||||||||
Db         20 TCCCGATTCCTGGAGGAGAA 1


RESULT 214
US-10-949-720-107/c
; Sequence 107, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 107
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-107

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2639 AAGTGTCTGACTTTGGCCTT 2658
             ||||||||||||||||||||
Db         20 AAGTGTCTGACTTTGGCCTT 1


RESULT 215
US-10-949-720-108/c
; Sequence 108, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
```

```
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 108
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-108

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTCTGC 2637
             ||||||||||||||||||||
Db         20 TCAACAGCAACCTCGTCTGC 1


RESULT 216
US-10-949-720-109/c
; Sequence 109, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 109
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-109

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2598 GGCTGCTCGCAACATCCTAG 2617
             ||||||||||||||||||||
Db         20 GGCTGCTCGCAACATCCTAG 1


RESULT 217
US-10-949-720-110/c
; Sequence 110, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 110
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-110

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2578 AGCTACGTCCACCGAGACCT 2597
             ||||||||||||||||||||
Db         20 AGCTACGTCCACCGAGACCT 1


RESULT 218
US-10-949-720-111/c
; Sequence 111, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 111
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-111

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
```

```
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2558 TGCGGTACCTTGCCGAGATG 2577
              ||||||||||||||||||||
Db         20 TGCGGTACCTTGCCGAGATG 1


RESULT 219
US-10-949-720-112/c
; Sequence 112, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 112
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-112

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2538 GCGGGGCATCGCCTCGGGCA 2557
              ||||||||||||||||||||
Db         20 GCGGGGCATCGCCTCGGGCA 1


RESULT 220
US-10-949-720-113/c
; Sequence 113, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 113
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-113

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2518 ATCCAGCTCGTGGGCATGCT 2537
              ||||||||||||||||||||
Db         20 ATCCAGCTCGTGGGCATGCT 1


RESULT 221
US-10-949-720-114/c
; Sequence 114, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 114
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-114

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2498 ACGACGGACAGTTCACAGTC 2517
              ||||||||||||||||||||
Db         20 ACGACGGACAGTTCACAGTC 1


RESULT 222
US-10-949-720-115/c
; Sequence 115, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
```

```
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 115
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-115

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2478 GGACTCCTTCCTGCGGCTAA 2497
             ||||||||||||||||||||
Db         20 GGACTCCTTCCTGCGGCTAA 1


RESULT 223
US-10-949-720-116/c
; Sequence 116, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 116
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-116

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2458 TTCATGGAGAACGGCGCCCT 2477
             ||||||||||||||||||||
Db         20 TTCATGGAGAACGGCGCCCT 1


RESULT 224
US-10-949-720-117/c
; Sequence 117, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 117
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-117

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2438 CCGTCATGATTCTCACAGAG 2457
             ||||||||||||||||||||
Db         20 CCGTCATGATTCTCACAGAG 1


RESULT 225
US-10-949-720-118/c
; Sequence 118, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 118
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-118

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2418 CGTGGTCACCAACAGCATGC 2437
             ||||||||||||||||||||
Db         20 CGTGGTCACCAACAGCATGC 1


RESULT 226
US-10-949-720-119/c
; Sequence 119, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 119
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-119

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2398 AATATCATCCGCCTGGAGGG 2417
             ||||||||||||||||||||
Db         20 AATATCATCCGCCTGGAGGG 1


RESULT 227
US-10-949-720-120/c
; Sequence 120, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 120
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-120

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2378 TGGGCCAGTTCGAGCACCCC 2397
             ||||||||||||||||||||
Db         20 TGGGCCAGTTCGAGCACCCC 1


RESULT 228
US-10-949-720-121/c
; Sequence 121, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 121
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-121

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2358 TCTGAGCGAGGCCTCCATCA 2377
             ||||||||||||||||||||
Db         20 TCTGAGCGAGGCCTCCATCA 1


RESULT 229
US-10-949-720-122/c
; Sequence 122, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 122
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-122
```

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 GAGCGGCAGCGGCGTGAGTT 2357
              ||||||||||||||||||||
Db         20 GAGCGGCAGCGGCGTGAGTT 1


RESULT 230
US-10-949-720-123/c
; Sequence 123, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 123
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-123

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2318 CCCTGAAGGGTGGCTACACG 2337
              ||||||||||||||||||||
Db         20 CCCTGAAGGGTGGCTACACG 1


RESULT 231
US-10-949-720-124/c
; Sequence 124, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 124
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-124

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2298 GAGCTGTGTGGCAATCAAGA 2317
              ||||||||||||||||||||
Db         20 GAGCTGTGTGGCAATCAAGA 1


RESULT 232
US-10-949-720-125/c
; Sequence 125, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-125

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2278 AAGGCCCCAGGGAAGAAGGA 2297
              ||||||||||||||||||||
Db         20 AAGGCCCCAGGGAAGAAGGA 1


RESULT 233
US-10-949-720-126/c
; Sequence 126, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
```

```
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 126
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-126

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2258 AGGTGTGCCGGGGGCGGCTC 2277
             ||||||||||||||||||||
Db         20 AGGTGTGCCGGGGGCGGCTC 1


RESULT 234
US-10-949-720-127/c
; Sequence 127, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 127
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-127

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2238 TGGTGCAGGTGAGTTTGGCG 2257
             ||||||||||||||||||||
Db         20 TGGTGCAGGTGAGTTTGGCG 1


RESULT 235
US-10-949-720-128/c
; Sequence 128, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 128
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-128

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2218 GTCAAGATTGAAGAGGTGAT 2237
             ||||||||||||||||||||
Db         20 GTCAAGATTGAAGAGGTGAT 1


RESULT 236
US-10-949-720-129/c
; Sequence 129, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 129
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-129

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2198 AAGAGATCGATGTCTCCTAC 2217
             ||||||||||||||||||||
Db         20 AAGAGATCGATGTCTCCTAC 1


RESULT 237
US-10-949-720-130/c
; Sequence 130, Application US/10949720
```

```
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 130
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-130

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2178 GGCTGTGAGGGAATTTGCAA 2197
             ||||||||||||||||||||
Db         20 GGCTGTGAGGGAATTTGCAA 1


RESULT 238
US-10-949-720-131/c
; Sequence 131, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 131
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-131

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2158 ACTTATGAAGACCCTAATGA 2177
             ||||||||||||||||||||
Db         20 ACTTATGAAGACCCTAATGA 1


RESULT 239
US-10-949-720-132/c
; Sequence 132, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 132
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-132

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2138 AGGTCTACATCGACCCCTTC 2157
             ||||||||||||||||||||
Db         20 AGGTCTACATCGACCCCTTC 1


RESULT 240
US-10-949-720-133/c
; Sequence 133, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 133
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
```

US-10-949-720-133

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2118 TCTCATCGGACATGGTACTA 2137
||||||||||||||||||||
Db 20 TCTCATCGGACATGGTACTA 1

RESULT 241
US-10-949-720-134/c
; Sequence 134, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 134
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-134

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2098 TCGGACAAACACGGACAGTA 2117
||||||||||||||||||||
Db 20 TCGGACAAACACGGACAGTA 1

RESULT 242
US-10-949-720-135/c
; Sequence 135, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 135
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-135

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2078 ATGGGAGAGAAGCAGAATAT 2097
||||||||||||||||||||
Db 20 ATGGGAGAGAAGCAGAATAT 1

RESULT 243
US-10-949-720-136/c
; Sequence 136, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-136

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2058 CTGCCTCAGGAAGCAGAGCA 2077
||||||||||||||||||||
Db 20 CTGCCTCAGGAAGCAGAGCA 1

RESULT 244
US-10-949-720-137/c
; Sequence 137, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23

```
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 137
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-137

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2038 GTCATTGTGGTCGCAGTTCT 2057
              ||||||||||||||||||||
Db         20 GTCATTGTGGTCGCAGTTCT 1


RESULT 245
US-10-949-720-138/c
; Sequence 138, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 138
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-138

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2018 GTGTGGTCCTGGTCCTGGTG 2037
              ||||||||||||||||||||
Db         20 GTGTGGTCCTGGTCCTGGTG 1


RESULT 246
US-10-949-720-139/c
; Sequence 139, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 139
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-139

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1998 TGCGGGCACGGCAGTCGTGG 2017
              ||||||||||||||||||||
Db         20 TGCGGGCACGGCAGTCGTGG 1


RESULT 247
US-10-949-720-140/c
; Sequence 140, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 140
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-140

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1978 CGGGAGCAGCTGGCCCTGAT 1997
              ||||||||||||||||||||
Db         20 CGGGAGCAGCTGGCCCTGAT 1


RESULT 248
```

US-10-949-720-141/c
; Sequence 141, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-141

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1958 TGGATGAGAGCGAGGGCTGG 1977
||||||||||||||||||||
Db 20 TGGATGAGAGCGAGGGCTGG 1

RESULT 249
US-10-949-720-142/c
; Sequence 142, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 142
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-142

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1938 ACATCACAGCCAGACCCAAC 1957
||||||||||||||||||||
Db 20 ACATCACAGCCAGACCCAAC 1

RESULT 250
US-10-949-720-143/c
; Sequence 143, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 143
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-143

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1918 TACGGGCCCTTCGGCCAGGA 1937
||||||||||||||||||||
Db 20 TACGGGCCCTTCGGCCAGGA 1

RESULT 251
US-10-949-720-144/c
; Sequence 144, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 144
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown

; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-144

 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1898 GGGCGCGCTCTGAGGCCGGC 1917
 ||||||||||||||||||||
Db 20 GGGCGCGCTCTGAGGCCGGC 1

RESULT 252
US-10-949-720-145/c
; Sequence 145, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-145

 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1878 CAGCTACCTGGTGCAGGTAC 1897
 ||||||||||||||||||||
Db 20 CAGCTACCTGGTGCAGGTAC 1

RESULT 253
US-10-949-720-146/c
; Sequence 146, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 146
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-146

 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1858 CGGGGGCTGAAGCGGGGAGC 1877
 ||||||||||||||||||||
Db 20 CGGGGGCTGAAGCGGGGAGC 1

RESULT 254
US-10-949-720-147/c
; Sequence 147, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-147

 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1838 CAGAAAACCGGGCAGAGCTG 1857
 ||||||||||||||||||||
Db 20 CAGAAAACCGGGCAGAGCTG 1

RESULT 255
US-10-949-720-148/c
; Sequence 148, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002

```
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 148
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-148

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1818 CGTGCGGTTCCTGAAGACGT 1837
             ||||||||||||||||||||
Db         20 CGTGCGGTTCCTGAAGACGT 1


RESULT 256
US-10-949-720-149/c
; Sequence 149, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 149
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-149

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1798 GGCGCCGAGGGTCCCAGCAG 1817
             ||||||||||||||||||||
Db         20 GGCGCCGAGGGTCCCAGCAG 1


RESULT 257
US-10-949-720-150/c
; Sequence 150, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 150
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-150

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1778 AGGTCAAATACCATGAGAAG 1797
             ||||||||||||||||||||
Db         20 AGGTCAAATACCATGAGAAG 1


RESULT 258
US-10-949-720-151/c
; Sequence 151, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 151
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-151

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1758 TGGGGCTGTGCTGGACTACG 1777
             ||||||||||||||||||||
Db         20 TGGGGCTGTGCTGGACTACG 1
```

```
RESULT 259
US-10-949-720-152/c
; Sequence 152, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 152
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-152

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 GCTGTTCCCCGGGCACCCAG 1757
             ||||||||||||||||||||
Db         20 GCTGTTCCCCGGGCACCCAG 1


RESULT 260
US-10-949-720-153/c
; Sequence 153, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 153
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-153

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1718 GCAGCTTGAGCCTGGCCTGG 1737
             ||||||||||||||||||||
Db         20 GCAGCTTGAGCCTGGCCTGG 1


RESULT 261
US-10-949-720-154/c
; Sequence 154, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 154
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-154

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1698 GGTGACGCGGTCCTCACCCA 1717
             ||||||||||||||||||||
Db         20 GGTGACGCGGTCCTCACCCA 1


RESULT 262
US-10-949-720-155/c
; Sequence 155, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 155
;   LENGTH: 20
```

```
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-155

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1678 CCTGCAGTGTCTGACATCCG 1697
              ||||||||||||||||||||
Db         20 CCTGCAGTGTCTGACATCCG 1


RESULT 263
US-10-949-720-156/c
; Sequence 156, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 156
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-156

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1658 CCACTGACCGAGAGGTACCT 1677
              ||||||||||||||||||||
Db         20 CCACTGACCGAGAGGTACCT 1


RESULT 264
US-10-949-720-157/c
; Sequence 157, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 157
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-157

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1638 ATTTGAGCCTGTCAATGTCA 1657
              ||||||||||||||||||||
Db         20 ATTTGAGCCTGTCAATGTCA 1


RESULT 265
US-10-949-720-158/c
; Sequence 158, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 158
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-158

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1618 TTAGCCACGGGGCCCGTCCC 1637
              ||||||||||||||||||||
Db         20 TTAGCCACGGGGCCCGTCCC 1


RESULT 266
US-10-949-720-159/c
; Sequence 159, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
```

```
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 159
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-159

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CATTGAACGGGGTATCCTCC 1617
              ||||||||||||||||||||
Db         20 CATTGAACGGGGTATCCTCC 1


RESULT 267
US-10-949-720-160/c
; Sequence 160, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 160
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-160

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1578 CTATACCTTTGAGGTCACTG 1597
              ||||||||||||||||||||
Db         20 CTATACCTTTGAGGTCACTG 1


RESULT 268
US-10-949-720-161/c
; Sequence 161, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 161
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-161

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1558 GGGCTACGTCCTGACTTCAC 1577
              ||||||||||||||||||||
Db         20 GGGCTACGTCCTGACTTCAC 1


RESULT 269
US-10-949-720-162/c
; Sequence 162, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 162
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-162

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1538 AGCCCTGGGTGGTGGTTCGA 1557
              ||||||||||||||||||||
```

```
Db         20 AGCCCTGGGTGGTGGTTCGA 1


RESULT 270
US-10-949-720-163/c
; Sequence 163, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 163
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-163

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1518 CGGCCCCCGGGACCTGGTGG 1537
             ||||||||||||||||||||
Db         20 CGGCCCCCGGGACCTGGTGG 1


RESULT 271
US-10-949-720-164/c
; Sequence 164, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 164
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-164

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1498 GGAGACCTGACTTTTGACCC 1517
             ||||||||||||||||||||
Db         20 GGAGACCTGACTTTTGACCC 1


RESULT 272
US-10-949-720-165/c
; Sequence 165, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 165
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-165

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1478 GCTCCTGTGCGCCCTGCGGG 1497
             ||||||||||||||||||||
Db         20 GCTCCTGTGCGCCCTGCGGG 1


RESULT 273
US-10-949-720-166/c
; Sequence 166, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
```

; SEQ ID NO 166
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-166

 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1458 CCGGGAGTGCCGACCCGGAG 1477
 ||||||||||||||||||||
Db 20 CCGGGAGTGCCGACCCGGAG 1

RESULT 274
US-10-949-720-167/c
; Sequence 167, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 167
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-167

 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1438 CTCACCTACGCCCTCCGCTG 1457
 ||||||||||||||||||||
Db 20 CTCACCTACGCCCTCCGCTG 1

RESULT 275
US-10-949-720-168/c
; Sequence 168, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 168
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-168

 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1418 AGTCTGGTGGCCGAGAGGAC 1437
 ||||||||||||||||||||
Db 20 AGTCTGGTGGCCGAGAGGAC 1

RESULT 276
US-10-949-720-169/c
; Sequence 169, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-169

 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1398 GGAATGGAGTGCCCCCCTGG 1417
 ||||||||||||||||||||
Db 20 GGAATGGAGTGCCCCCCTGG 1

RESULT 277
US-10-949-720-170/c
; Sequence 170, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra

```
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 170
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-170

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1378 AACGGCTCCTCCCTGCACCT 1397
             ||||||||||||||||||||
Db         20 AACGGCTCCTCCCTGCACCT 1


RESULT 278
US-10-949-720-171/c
; Sequence 171, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 171
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-171

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1358 GGAGCGTGGTTTCCCGCCTG 1377
             ||||||||||||||||||||
Db         20 GGAGCGTGGTTTCCCGCCTG 1


RESULT 279
US-10-949-720-172/c
; Sequence 172, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 172
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-172

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1338 CACCCCTCCTTCGGCTCCGC 1357
             ||||||||||||||||||||
Db         20 CACCCCTCCTTCGGCTCCGC 1


RESULT 280
US-10-949-720-173/c
; Sequence 173, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 173
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-173

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1318 CCCCGGGGTGCACCCTGCAC 1337
              ||||||||||||||||||||
Db         20 CCCCGGGGTGCACCCTGCAC 1


RESULT 281
US-10-949-720-174/c
; Sequence 174, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 174
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-174

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1298 ACTTCCGGGCACGCACAGAC 1317
              ||||||||||||||||||||
Db         20 ACTTCCGGGCACGCACAGAC 1


RESULT 282
US-10-949-720-175/c
; Sequence 175, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 175
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-175

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1278 CTGCCAGTGCCGCGTCGGGT 1297
              ||||||||||||||||||||
Db         20 CTGCCAGTGCCGCGTCGGGT 1


RESULT 283
US-10-949-720-176/c
; Sequence 176, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 176
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-176

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AACACCATTGGATCAGCCGT 1277
              ||||||||||||||||||||
Db         20 AACACCATTGGATCAGCCGT 1


RESULT 284
US-10-949-720-177/c
; Sequence 177, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
```

```
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 177
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-177

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1238 GCCCAGCCAATAGCCACTCT 1257
             ||||||||||||||||||||
Db         20 GCCCAGCCAATAGCCACTCT 1


RESULT 285
US-10-949-720-178/c
; Sequence 178, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 178
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-178

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1218 AGAAGGGTCCTGCCAGCCAT 1237
             ||||||||||||||||||||
Db         20 AGAAGGGTCCTGCCAGCCAT 1


RESULT 286
US-10-949-720-179/c
; Sequence 179, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 179
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-179

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1198 ACCTTCAAGCCCCTGTCAGG 1217
             ||||||||||||||||||||
Db         20 ACCTTCAAGCCCCTGTCAGG 1


RESULT 287
US-10-949-720-180/c
; Sequence 180, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 180
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-180

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCCAGGGC 1197
             ||||||||||||||||||||
Db         20 GCCGAGCCTGTGCCCAGGGC 1


RESULT 288
US-10-949-720-181/c
; Sequence 181, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
```

```
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 181
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-181

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1158 AGCTGAGGGGAACACCAAGT 1177
              ||||||||||||||||||||
Db         20 AGCTGAGGGGAACACCAAGT 1


RESULT 289
US-10-949-720-182/c
; Sequence 182, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 182
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-182

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1138 TGTGCTCCGGGGTTCGAGGC 1157
              ||||||||||||||||||||
Db         20 TGTGCTCCGGGGTTCGAGGC 1


RESULT 290
US-10-949-720-183/c
; Sequence 183, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 183
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-183

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1118 AGCCGGTCACGGGCTGCAGC 1137
              ||||||||||||||||||||
Db         20 AGCCGGTCACGGGCTGCAGC 1


RESULT 291
US-10-949-720-184/c
; Sequence 184, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 184
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-184

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
```

```
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1098 GGATGGCCAGTGGGCCGAAC 1117
              ||||||||||||||||||||
Db         20 GGATGGCCAGTGGGCCGAAC 1


RESULT 292
US-10-949-720-185/c
; Sequence 185, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 185
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-185

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1078 CCCAGCCTCTACTGCCGTGA 1097
              ||||||||||||||||||||
Db         20 CCCAGCCTCTACTGCCGTGA 1


RESULT 293
US-10-949-720-186/c
; Sequence 186, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 186
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-186

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1058 TCCCCGCCCCTGGCCCCAGC 1077
              ||||||||||||||||||||
Db         20 TCCCCGCCCCTGGCCCCAGC 1


RESULT 294
US-10-949-720-187/c
; Sequence 187, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 187
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-187

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1038 TAGCTGCGTGGTGGATGCCG 1057
              ||||||||||||||||||||
Db         20 TAGCTGCGTGGTGGATGCCG 1


RESULT 295
US-10-949-720-188/c
; Sequence 188, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
```

; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 188
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-188

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1018 CTGGTTGTGCCCGTGGCCGG 1037
||||||||||||||||||||
Db 20 CTGGTTGTGCCCGTGGCCGG 1

RESULT 296
US-10-949-720-189/c
; Sequence 189, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 189
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-189

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 998 CGGAGACTGTGCCTCGGGAG 1017
||||||||||||||||||||
Db 20 CGGAGACTGTGCCTCGGGAG 1

RESULT 297
US-10-949-720-190/c
; Sequence 190, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 190
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-190

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 978 TGTGAACCTGACTCGATTCC 997
||||||||||||||||||||
Db 20 TGTGAACCTGACTCGATTCC 1

RESULT 298
US-10-949-720-191/c
; Sequence 191, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 191
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-191

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 958 AAAAAGTGCGCCCAGCTGAC 977
||||||||||||||||||||
Db 20 AAAAAGTGCGCCCAGCTGAC 1

RESULT 299
US-10-949-720-192/c
; Sequence 192, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:

```
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 192
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-192

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        938 TATCCCTGCACCTCTTCTAC 957
              ||||||||||||||||||||
Db         20 TATCCCTGCACCTCTTCTAC 1


RESULT 300
US-10-949-720-193/c
; Sequence 193, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 193
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-193

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        918 GGGTGCCTGCATGGCCCTGC 937
              ||||||||||||||||||||
Db         20 GGGTGCCTGCATGGCCCTGC 1


RESULT 301
US-10-949-720-194/c
; Sequence 194, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 194
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-194

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        898 TACCTGGCCTTCCAGGACCA 917
              ||||||||||||||||||||
Db         20 TACCTGGCCTTCCAGGACCA 1


RESULT 302
US-10-949-720-195/c
; Sequence 195, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 195
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-195
```

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        878 CGCTCAGCAAGGCTGGCTTC 897
              ||||||||||||||||||||
Db         20 CGCTCAGCAAGGCTGGCTTC 1
```

RESULT 303
US-10-949-720-196/c
; Sequence 196, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 196
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-196

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        858 CAAGACGCTGCGTCTGGGAC 877
              ||||||||||||||||||||
Db         20 CAAGACGCTGCGTCTGGGAC 1
```

RESULT 304
US-10-949-720-197/c
; Sequence 197, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 197
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-197

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        838 GCCACCGGGAAGGTGAATGT 857
              ||||||||||||||||||||
Db         20 GCCACCGGGAAGGTGAATGT 1
```

RESULT 305
US-10-949-720-198/c
; Sequence 198, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 198
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-198

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        818 GGAAGCGCCCTGGGGCCGAG 837
              ||||||||||||||||||||
Db         20 GGAAGCGCCCTGGGGCCGAG 1
```

RESULT 306
US-10-949-720-199/c
; Sequence 199, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12

```
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 199
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-199

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        798 GGCCGCGGAGCATCTCACCC 817
              ||||||||||||||||||||
Db         20 GGCCGCGGAGCATCTCACCC 1


RESULT 307
US-10-949-720-200/c
; Sequence 200, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 200
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-200

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        778 TACATCAAGGTGGACACGGT 797
              ||||||||||||||||||||
Db         20 TACATCAAGGTGGACACGGT 1


RESULT 308
US-10-949-720-201/c
; Sequence 201, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 201
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-201

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        758 CAGCCTGGATGGAGAACCCC 777
              ||||||||||||||||||||
Db         20 CAGCCTGGATGGAGAACCCC 1


RESULT 309
US-10-949-720-202/c
; Sequence 202, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 202
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-202

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        738 CACGGCCACGGCCCTCACGC 757
              ||||||||||||||||||||
Db         20 CACGGCCACGGCCCTCACGC 1


RESULT 310
US-10-949-720-203/c
; Sequence 203, Application US/10949720
```

```
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 203
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-203

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        718 TACTATGAGAGCGATGCGGA 737
              ||||||||||||||||||||
Db         20 TACTATGAGAGCGATGCGGA 1


RESULT 311
US-10-949-720-204/c
; Sequence 204, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 204
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-204

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        698 AGGAGACCTTCACCGTCTTC 717
              ||||||||||||||||||||
Db         20 AGGAGACCTTCACCGTCTTC 1


RESULT 312
US-10-949-720-205/c
; Sequence 205, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 205
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-205

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        678 TCGGGCTGGGCGCTCCTGCA 697
              ||||||||||||||||||||
Db         20 TCGGGCTGGGCGCTCCTGCA 1


RESULT 313
US-10-949-720-206/c
; Sequence 206, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 206
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
```

US-10-949-720-206

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 CTCGAGTGCCTGTCCCTGCC 677
||||||||||||||||||||
Db 20 CTCGAGTGCCTGTCCCTGCC 1

RESULT 314
US-10-949-720-207/c
; Sequence 207, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 207
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-207

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 638 CCACGCTGCGCTTCACCATG 657
||||||||||||||||||||
Db 20 CCACGCTGCGCTTCACCATG 1

RESULT 315
US-10-949-720-208/c
; Sequence 208, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 208
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-208

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 618 GGGCGCCGTCCACGTGTACG 637
||||||||||||||||||||
Db 20 GGGCGCCGTCCACGTGTACG 1

RESULT 316
US-10-949-720-209/c
; Sequence 209, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 209
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-209

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 598 ACAGGTTGGGTCCCACGGCG 617
||||||||||||||||||||
Db 20 ACAGGTTGGGTCCCACGGCG 1

RESULT 317
US-10-949-720-210/c
; Sequence 210, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23

```
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 210
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-210

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        578 GCCAGGCCCACTGGCTTCGC 597
              ||||||||||||||||||||
Db         20 GCCAGGCCCACTGGCTTCGC 1


RESULT 318
US-10-949-720-211/c
; Sequence 211, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 211
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-211

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        558 TGACGTGCAGCGTGCCCCGG 577
              ||||||||||||||||||||
Db         20 TGACGTGCAGCGTGCCCCGG 1


RESULT 319
US-10-949-720-212/c
; Sequence 212, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 212
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-212

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        538 GTGCGCACCTACGAAGTGTG 557
              ||||||||||||||||||||
Db         20 GTGCGCACCTACGAAGTGTG 1


RESULT 320
US-10-949-720-213/c
; Sequence 213, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 213
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-213

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        518 TGGATGAGGAACAGCACAGC 537
              ||||||||||||||||||||
Db         20 TGGATGAGGAACAGCACAGC 1


RESULT 321
```

```
US-10-949-720-214/c
; Sequence 214, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 214
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-214

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        498 GTGGGAGGAACTGAGCGGCC 517
              ||||||||||||||||||||
Db         20 GTGGGAGGAACTGAGCGGCC 1


RESULT 322
US-10-949-720-215/c
; Sequence 215, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 215
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-215

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        478 TTCCCTCAGGTGGACGGGCA 497
              ||||||||||||||||||||
Db         20 TTCCCTCAGGTGGACGGGCA 1


RESULT 323
US-10-949-720-216/c
; Sequence 216, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 216
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-216

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        458 CTGATCTGAAGTGGGTGACA 477
              ||||||||||||||||||||
Db         20 CTGATCTGAAGTGGGTGACA 1


RESULT 324
US-10-949-720-217/c
; Sequence 217, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 217
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
```

```
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-217

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        438 GAACACAAAATTGGAAACTG 457
              ||||||||||||||||||||
Db         20 GAACACAAAATTGGAAACTG 1


RESULT 325
US-10-949-720-218/c
; Sequence 218, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 218
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-218

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        418 GCTTTGGAAGAGACCCTGCT 437
              ||||||||||||||||||||
Db         20 GCTTTGGAAGAGACCCTGCT 1


RESULT 326
US-10-949-720-219/c
; Sequence 219, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 219
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-219

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        398 GCTGGGCTTCGTTGGCCGCA 417
              ||||||||||||||||||||
Db         20 GCTGGGCTTCGTTGGCCGCA 1


RESULT 327
US-10-949-720-220/c
; Sequence 220, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 220
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-220

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        378 GGAGCTCCGGGTGCTGCTCT 397
              ||||||||||||||||||||
Db         20 GGAGCTCCGGGTGCTGCTCT 1


RESULT 328
US-10-949-720-221/c
; Sequence 221, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
```

```
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 221
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-221

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        376 ATGGAGCTCCGGGTGCTGCT 395
              ||||||||||||||||||||
Db         20 ATGGAGCTCCGGGTGCTGCT 1


RESULT 329
US-10-949-720-231/c
; Sequence 231, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 231
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-231

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 330
US-10-949-720-421
; Sequence 421, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 421
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide primer
US-10-949-720-421

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1263 CATTGGATCAGCCGTCTGCC 1282
              ||||||||||||||||||||
Db          1 CATTGGATCAGCCGTCTGCC 20


RESULT 331
US-10-310-914A-153225/c
; Sequence 153225, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153225
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153225

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3893 TCCCTTTTTGTTTCTTCGTT 3912
              ||||||||||||||||||||
Db         20 TCCCTTTTTGTTTCTTCGTT 1


RESULT 332
US-10-310-914A-153251/c
; Sequence 153251, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
```

```
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153251
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153251

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        312 TCAGACCTGGGGGGGCGAGG 331
              ||||||||||||||||||||
Db         20 TCAGACCTGGGGGGGCGAGG 1


RESULT 333
US-10-310-914A-153252/c
; Sequence 153252, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153252
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153252

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3573 GGACTGGGTGTGACCAGAGG 3592
              ||||||||||||||||||||
Db         20 GGACTGGGTGTGACCAGAGG 1


RESULT 334
US-10-310-914A-153263/c
; Sequence 153263, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153263
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153263

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3394 TGGGGACTCACAGAGGCCCC 3413
              ||||||||||||||||||||
Db         20 TGGGGACTCACAGAGGCCCC 1


RESULT 335
US-10-310-914A-153284/c
; Sequence 153284, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153284
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153284

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3964 ACTATGGCCTCCTTTGCCCA 3983
              ||||||||||||||||||||
Db         20 ACTATGGCCTCCTTTGCCCA 1


RESULT 336
US-10-949-720-38
; Sequence 38, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 38
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-38

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACT 1958
              ||:||||||||||||||||:
Db          1 CAUCACAGCCAGACCCAACU 20
```

```
RESULT 337
US-10-949-720-288
; Sequence 288, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 288
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-288

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 4.2e+02;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACT 1958
             ||:||||||||||||||||:
Db          1 CAUCACAGCCAGACCCAACU 20


RESULT 338
US-10-770-726-17477
; Sequence 17477, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17477
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17477

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2506 CAGTTCACAGTCATCCAGCT 2525
             ||||||||||||||||||||
Db          1 CAGTTCACAGTCATCCAGCT 20


RESULT 339
US-10-310-914A-153253/c
; Sequence 153253, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153253
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153253

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3463 TGGCAATTTGGAGAGACAGG 3482
             ||||||||||||||||||||
Db         20 TGGCAATTTGGAGAGACAGG 1


RESULT 340
US-10-310-914A-1353080/c
; Sequence 1353080, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1353080
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1353080

  Query Match             0.5%;  Score 20;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1065 CCCTGGCCCCAGCCCCAGCC 1084
             ||||||||||||||||||||
Db         22 CCCTGGCCCCAGCCCCAGCC 3


RESULT 341
US-10-310-914A-95660
; Sequence 95660, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 95660
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
```

```
US-10-310-914A-95660

  Query Match             0.5%;  Score 20;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        169 GCCCGCCGCCCGCGCGCGCG 188
              ||||||||||||||||||||
Db          2 GCCCGCCGCCCGCGCGCGCG 21


RESULT 342
US-10-310-914A-478410
; Sequence 478410, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 478410
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-478410

  Query Match             0.5%;  Score 19.8;  DB 1;  Length 23;
  Best Local Similarity   13.0%;  Pred. No. 5.1e+02;
  Matches    3;  Conservative   18;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGTTTT 3919
              :::::|::: :: |::::|::::
Db          1 UUUUUGUUUGUUUGUUUUGUUUU 23


RESULT 343
US-10-310-914A-1141553
; Sequence 1141553, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1141553
;   LENGTH: 23
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1141553

  Query Match             0.5%;  Score 19.8;  DB 1;  Length 23;
  Best Local Similarity   87.0%;  Pred. No. 5.1e+02;
  Matches   20;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        826 CCTGGGGCCGAGGCCACCGGGAA 848
              ||:|||||||||||||||  |||
Db          1 CCUGGGGCCGAGGCCACCCCGAA 23


RESULT 344
US-10-310-914A-556544
; Sequence 556544, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 556544
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-556544

  Query Match             0.5%;  Score 19.8;  DB 1;  Length 24;
  Best Local Similarity   91.3%;  Pred. No. 5.5e+02;
  Matches   21;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1062 CGCCCCTGGCCCCAGCCCCAGCC 1084
              |||| | ||||||||||||||||
Db          1 CGCCUCCGGCCCCAGCCCCAGCC 23


RESULT 345
US-10-949-720-43/c
; Sequence 43, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 43
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-43

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1328 CACCCTGCACCACCCCTCCTT 1348
              |||| ||||||||||||||||
Db         21 CACCGTGCACCACCCCTCCTT 1


RESULT 346
US-10-949-720-223/c
; Sequence 223, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
```

```
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 223
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-223

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1328 CACCCTGCACCACCCCTCCTT 1348
              |||| ||||||||||||||||
Db         21 CACCGTGCACCACCCCTCCTT 1


RESULT 347
US-10-770-726-16892
; Sequence 16892, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16892
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-16892

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2608 AACATCCTAGTCAACAGCAAC 2628
              |||||||| ||||||||||||
Db          1 AACATCCTCGTCAACAGCAAC 21


RESULT 348
US-10-770-726-16916
; Sequence 16916, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16916
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-16916

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2927 AGCTCATGCTGGACTGTTGGC 2947
              | ||||||||||||||||||||
Db          1 AACTCATGCTGGACTGTTGGC 21


RESULT 349
US-10-770-726-17495
; Sequence 17495, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17495
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17495

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2607 CAACATCCTAGTCAACAGCAA 2627
              ||||||||| ||||||||||||
Db          1 CAACATCCTCGTCAACAGCAA 21


RESULT 350
US-10-770-726-17498
; Sequence 17498, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17498
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17498

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       2610 CATCCTAGTCAACAGCAACCT 2630
             |||||| ||||||||||||||||
Db          1 CATCCTCGTCAACAGCAACCT 21


RESULT 351
US-10-770-726-17501
; Sequence 17501, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17501
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17501

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2619 CAACAGCAACCTCGTCTGCAA 2639
             |||||||||||| ||||||||
Db          1 CAACAGCAACCTGGTCTGCAA 21


RESULT 352
US-10-770-726-17534
; Sequence 17534, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17534
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17534

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2865 CAATGCCATTGAACAGGACTA 2885
             |||||||||||| ||||||||
Db          1 CAATGCCATTGAGCAGGACTA 21


RESULT 353
US-10-770-726-17540
; Sequence 17540, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17540
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17540

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2923 CACCAGCTCATGCTGGACTGT 2943
             ||||| ||||||||||||||||
Db          1 CACCAACTCATGCTGGACTGT 21


RESULT 354
US-10-770-726-17543
; Sequence 17543, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17543
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17543

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 4.8e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGG 2946
             || ||||||||||||||||||
Db          1 CAACTCATGCTGGACTGTTGG 21


RESULT 355
US-10-310-914A-161882
; Sequence 161882, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161882
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-161882
```

```
  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 4.8e+02;
  Matches   17;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3605 CCAACATCTCCCAGCCTCCCC 3625
              ||||| :|:|||||||:||||
Db          1 CCAACCUCUCCCAGCCUCCCC 21


RESULT 356
US-10-310-914A-161883
; Sequence 161883, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161883
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-161883

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 5.2e+02;
  Matches   17;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3605 CCAACATCTCCCAGCCTCCCC 3625
              ||||| :|:|||||||:||||
Db          1 CCAACCUCUCCCAGCCUCCCC 21


RESULT 357
US-10-310-914A-311206/c
; Sequence 311206, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 311206
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-311206

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 22;
  Best Local Similarity   95.2%;  Pred. No. 5.2e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3929 CTTGTCATAACTTTGTGTTGG 3949
              |||||| ||||||||||||||
Db         21 CTTGTCTTAACTTTGTGTTGG 1


RESULT 358
US-10-310-914A-390963
; Sequence 390963, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 390963
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-390963

  Query Match             0.5%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   8.3%;  Pred. No. 6.3e+02;
  Matches    2;  Conservative   19;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGTTTTT 3920
              ::::: :::|::  ::::|:::::
Db          1 UUUUUCUUUCUUUUUUUUGUUUUU 24


RESULT 359
US-10-310-914A-686978/c
; Sequence 686978, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 686978
;   LENGTH: 24
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-686978

  Query Match             0.5%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 6.3e+02;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGTTTTT 3920
              |||||| || ||| ||||||||||
Db         24 TTTTTGCTTTTTCTTTTTGTTTTT 1


RESULT 360
US-11-178-086-26
; Sequence 26, Application US/11178086
; Publication No. US20050276789A1
; GENERAL INFORMATION:
;  APPLICANT: LOPEZ, Ricardo A.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 2901/0M327
;  CURRENT APPLICATION NUMBER: US/11/178,086
;  CURRENT FILING DATE:  2005-07-08
;  PRIOR APPLICATION NUMBER: US/10/309,775
;  PRIOR FILING DATE: 2002-12-04
;  PRIOR APPLICATION NUMBER: CA 2,388,049
;  PRIOR FILING DATE: 2002-05-30
;  NUMBER OF SEQ ID NOS: 74
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: PCR primer
US-11-178-086-26

  Query Match             0.5%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 6.3e+02;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGTTTTT 3920
              ||||| ||| ||| ||||||||||
Db          1 TTTTTTTTTTTTCATTTTGTTTTT 24


RESULT 361
US-11-178-086-73
; Sequence 73, Application US/11178086
; Publication No. US20050276789A1
; GENERAL INFORMATION:
;  APPLICANT: LOPEZ, Ricardo A.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
;  FILE REFERENCE: 2901/0M327
;  CURRENT APPLICATION NUMBER: US/11/178,086
;  CURRENT FILING DATE:  2005-07-08
;  PRIOR APPLICATION NUMBER: US/10/309,775
;  PRIOR FILING DATE: 2002-12-04
;  PRIOR APPLICATION NUMBER: CA 2,388,049
;  PRIOR FILING DATE: 2002-05-30
;  NUMBER OF SEQ ID NOS: 74
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 73
;   LENGTH: 24
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer
US-11-178-086-73

  Query Match             0.5%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 6.3e+02;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGTTTTT 3920
              ||||| ||| ||| ||||||||||
Db          1 TTTTTTTTTTTTCATTTTGTTTTT 24


RESULT 362
US-10-310-914A-153218/c
; Sequence 153218, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153218
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153218

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3852 GGTTTTTGAGTTTTGTTTT 3870
              |||||||||||||||||||
Db         19 GGTTTTTGAGTTTTGTTTT 1


RESULT 363
US-10-310-914A-153220/c
; Sequence 153220, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153220
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153220

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3887 CCCCGTTCCCTTTTTGTTT 3905
              |||||||||||||||||||
Db         19 CCCCGTTCCCTTTTTGTTT 1


RESULT 364
US-10-310-914A-153222/c
; Sequence 153222, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153222
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153222

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4159 GGGTTCTTAAATTATATTT 4177
              |||||||||||||||||||
Db         19 GGGTTCTTAAATTATATTT 1


RESULT 365
US-10-310-914A-153224/c
; Sequence 153224, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 153224
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153224

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3899 TTTGTTTCTTCGTTTTGTT 3917
              |||||||||||||||||||
Db         19 TTTGTTTCTTCGTTTTGTT 1


RESULT 366
US-10-310-914A-153227/c
; Sequence 153227, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153227
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153227

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3885 CTCCCCGTTCCCTTTTTGT 3903
              |||||||||||||||||||
Db         19 CTCCCCGTTCCCTTTTTGT 1


RESULT 367
US-10-310-914A-153244/c
; Sequence 153244, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153244
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153244

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3414 CAGCCCTGTGCCCCGCTGG 3432
              |||||||||||||||||||
Db         19 CAGCCCTGTGCCCCGCTGG 1


RESULT 368
US-10-310-914A-153245/c
; Sequence 153245, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153245
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153245

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3471 TGGAGAGACAGGATTTGGG 3489
              |||||||||||||||||||
Db         19 TGGAGAGACAGGATTTGGG 1


RESULT 369
US-10-310-914A-153250/c
; Sequence 153250, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153250
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153250

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3700 GGGGGGGCTGTCCCAGGGG 3718
              |||||||||||||||||||
Db         19 GGGGGGGCTGTCCCAGGGG 1


RESULT 370
US-10-310-914A-153258/c
; Sequence 153258, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153258
```

```
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153258

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4082 TGAAGGGGTGTGGGGTGAG 4100
              |||||||||||||||||||
Db         19 TGAAGGGGTGTGGGGTGAG 1


RESULT 371
US-10-310-914A-153268/c
; Sequence 153268, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153268
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153268

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3828 CCCAGCTGCTGCCTTCATA 3846
              |||||||||||||||||||
Db         19 CCCAGCTGCTGCCTTCATA 1


RESULT 372
US-10-310-914A-153272/c
; Sequence 153272, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153272
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153272

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4112 GGCGGTAGTTGGTGGTGGA 4130
              |||||||||||||||||||
Db         19 GGCGGTAGTTGGTGGTGGA 1


RESULT 373
US-10-310-914A-153282/c
; Sequence 153282, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153282
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153282

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3671 GAGTGTGACTCCCTTGCCA 3689
              |||||||||||||||||||
Db         19 GAGTGTGACTCCCTTGCCA 1


RESULT 374
US-10-310-914A-153290/c
; Sequence 153290, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153290
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153290

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3799 TCATTTTTTCCCTTGTAA 3817
              |||||||||||||||||||
Db         19 TCATTTTTTCCCTTGTAA 1


RESULT 375
US-10-310-914A-153291/c
; Sequence 153291, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153291
;   LENGTH: 19
```

```
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153291

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4004 ATCATGTCTGTTTCCAGAA 4022
              ||||||||||||||||||
Db         19 ATCATGTCTGTTTCCAGAA 1


RESULT 376
US-11-101-244-685
; Sequence 685, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 685
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-685

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 4.5e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2100 GGACAAACACGGACAGTAT 2118
              |||||||||||||||:|:
Db          1 GGACAAACACGGACAGUAU 19


RESULT 377
US-11-101-244-686
; Sequence 686, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 686
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-686

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2132 GTACTAAGGTCTACATCGA 2150
              |:||:||||:|:|||:|||
Db          1 GUACUAAGGUCUACAUCGA 19


RESULT 378
US-11-101-244-687
; Sequence 687, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 687
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-687

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2081 GGAGAGAAGCAGAATATTC 2099
              ||||||||||||||:|::|
Db          1 GGAGAGAAGCAGAAUAUUC 19


RESULT 379
US-11-101-244-688
; Sequence 688, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 688
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
```

US-11-101-244-688

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1243 GCCAATAGCCACTCTAACA 1261
              |||||:|||||||:|:||||
Db          1 GCCAAUAGCCACUCUAACA 19
```

RESULT 380
US-11-101-244-158892
; Sequence 158892, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158892
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158892

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||||::||:||||||
Db          1 UCACAGAGUUCAUGGAGAA 19
```

RESULT 381
US-11-101-244-159283
; Sequence 159283, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159283
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159283

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3786 CCACCAAACTCAATCATTT 3804
              |||||||||:|||:||:::
Db          1 CCACCAAACUCAAUCAUUU 19
```

RESULT 382
US-11-101-244-159284
; Sequence 159284, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159284
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159284

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3949 GAGGGAACCTGTTTCACTA 3967
              |||||||||:|:::|||:|
Db          1 GAGGGAACCUGUUUCACUA 19
```

RESULT 383
US-11-101-244-159285
; Sequence 159285, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159285
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159285

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2100 GGACAAACACGGACAGTAT 2118
              |||||||||||||||:|:
Db          1 GGACAAACACGGACAGUAU 19
```

RESULT 384
US-11-101-244-159287
; Sequence 159287, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159287
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159287

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||||::||:||||||
Db          1 UCACAGAGUUCAUGGAGAA 19
```

RESULT 385
US-11-101-244-159288
; Sequence 159288, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159288
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159288

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy        424 GAAGAGACCCTGCTGAACA 442
              ||||||||||:||:|||||
Db          1 GAAGAGACCCUGCUGAACA 19
```

RESULT 386
US-11-101-244-159289
; Sequence 159289, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159289
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159289

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2132 GTACTAAGGTCTACATCGA 2150
              |:||:||||:|:|||:|||
Db          1 GUACUAAGGUCUACAUCGA 19
```

RESULT 387
US-11-101-244-159290
; Sequence 159290, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159290
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159290

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;

Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy        450 GGAAACTGCTGATCTGAAG 468
              ||||||:||:||:|:||||
Db          1 GGAAACUGCUGAUCUGAAG 19
```

RESULT 388
US-11-101-244-159291
; Sequence 159291, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159291
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159291

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2081 GGAGAGAAGCAGAATATTC 2099
              ||||||||||||||:|::|
Db          1 GGAGAGAAGCAGAAUAUUC 19
```

RESULT 389
US-11-101-244-159292
; Sequence 159292, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159292
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159292

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3333 GTACTGACCTGCAGGAACT 3351
              |:||:||||:||||||||:
Db          1 GUACUGACCUGCAGGAACU 19
```

RESULT 390
US-11-101-244-159293
; Sequence 159293, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159293
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159293

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3454 GTGAGGAGTTGGCAATTTG 3472
              |:||||||::|||||:::|
Db          1 GUGAGGAGUUGGCAAUUUG 19
```

RESULT 391
US-11-101-244-159294
; Sequence 159294, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159294
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159294

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3453 GGTGAGGAGTTGGCAATTT 3471
              ||:||||||::|||||:::
Db          1 GGUGAGGAGUUGGCAAUUU 19
```

RESULT 392
US-11-101-244-159295
; Sequence 159295, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159295
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159295

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.5e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2070 GCAGAGCAATGGGAGAGAA 2088
              |||||||||:|||||||||
Db          1 GCAGAGCAAUGGGAGAGAA 19
```

RESULT 393
US-11-101-244-159296
; Sequence 159296, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159296
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159296

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3832 GCTGCTGCCTTCATATTGA 3850
              ||:||:|||::||:|::||
Db          1 GCUGCUGCCUUCAUAUUGA 19
```

RESULT 394
US-11-101-244-159297
; Sequence 159297, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159297
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159297

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2361 GAGCGAGGCCTCCATCATG 2379
              ||||||||||:|||:||:|
Db          1 GAGCGAGGCCUCCAUCAUG 19
```

RESULT 395
US-11-101-244-159298
; Sequence 159298, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159298
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159298

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       4020 GAACAGTGCCTTGGTCATC 4038
              |||||||:|||::||:||:|
```

```
Db          1 GAACAGUGCCUUGGUCAUC 19


RESULT 396
US-11-101-244-159299
; Sequence 159299, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159299
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159299

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1243 GCCAATAGCCACTCTAACA 1261
              |||||:||||||:|:||||
Db          1 GCCAAUAGCCACUCUAACA 19


RESULT 397
US-11-101-244-159300
; Sequence 159300, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159300
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159300

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1770 GGACTACGAGGTCAAATAC 1788
              ||||:||||||:||||:||
Db          1 GGACUACGAGGUCAAAUAC 19


RESULT 398
US-11-101-244-159301
; Sequence 159301, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159301
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159301

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCATT 2822
              :|:||||||:||:|:||::
Db          1 UGUGGGAGGUGAUGUCAUU 19


RESULT 399
US-11-101-244-159302
; Sequence 159302, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159302
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159302

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2493 GCTAAACGACGGACAGTTC 2511
              ||:||||||||||||::|
Db          1 GCUAAACGACGGACAGUUC 19
```

```
RESULT 400
US-11-101-244-159303
; Sequence 159303, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159303
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159303

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1496 GGGGAGACCTGACTTTTGA 1514
              |||||||||:|||::::||
Db          1 GGGGAGACCUGACUUUUGA 19


RESULT 401
US-11-101-244-159304
; Sequence 159304, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159304
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159304

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        965 GCGCCCAGCTGACTGTGAA 983
              |||||||||:|||:|:|||
Db          1 GCGCCCAGCUGACUGUGAA 19


RESULT 402
US-11-101-244-159305
; Sequence 159305, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159305
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159305

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4156 GAGGGGTTCTTAAATTATA 4174
              ||||||::|::|||::|:|
Db          1 GAGGGGUUCUUAAAUUAUA 19


RESULT 403
US-11-101-244-159306
; Sequence 159306, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159306
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159306

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4066 CCCAAGCTGTGTCCTATGA 4084
              |||||||:|:|:||:|:||
Db          1 CCCAAGCUGUGUCCUAUGA 19


RESULT 404
```

```
US-11-101-244-159307
; Sequence 159307, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159307
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159307

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2082 GAGAGAAGCAGAATATTCG 2100
              ||||||||||||||:|::||
Db          1 GAGAGAAGCAGAAUAUUCG 19


RESULT 405
US-11-101-244-159308
; Sequence 159308, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159308
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159308

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1777 GAGGTCAAATACCATGAGA 1795
              ||||:||||:||||:||||
Db          1 GAGGUCAAAUACCAUGAGA 19


RESULT 406
US-11-101-244-159310
; Sequence 159310, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159310
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159310

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1779 GGTCAAATACCATGAGAAG 1797
              ||:||||:||||:||||||
Db          1 GGUCAAAUACCAUGAGAAG 19


RESULT 407
US-11-101-244-159311
; Sequence 159311, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159311
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159311

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3951 GGGAACCTGTTTCACTATG 3969
              |||||||:|:::|||:|:|
Db          1 GGGAACCUGUUUCACUAUG 19


RESULT 408
US-11-101-244-159312
; Sequence 159312, Application US/11101244
```

```
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159312
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159312

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3363 GGACACCGCCTCCCCATTT 3381
             ||||||||||:|||||:::
Db          1 GGACACCGCCUCCCCAUUU 19


RESULT 409
US-11-101-244-159313
; Sequence 159313, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159313
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159313

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2295 GGAGAGCTGTGTGGCAATC 2313
             |||||||:|:|:|||||:|
Db          1 GGAGAGCUGUGUGGCAAUC 19


RESULT 410
US-11-101-244-159314
; Sequence 159314, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159314
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159314

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3948 GGAGGGAACCTGTTTCACT 3966
             ||||||||||:|:::|||:
Db          1 GGAGGGAACCUGUUUCACU 19


RESULT 411
US-11-101-244-159315
; Sequence 159315, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159315
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159315

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2288 GGAAGAAGGAGAGCTGTGT 2306
             ||||||||||||||:|:|:
Db          1 GGAAGAAGGAGAGCUGUGU 19


RESULT 412
US-11-101-244-159316
; Sequence 159316, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159316
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159316

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2090 CAGAATATTCGGACAAACA 2108
              |||||:|::||||||||||
Db          1 CAGAAUAUUCGGACAAACA 19


RESULT 413
US-11-101-244-159317
; Sequence 159317, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159317
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159317

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 GAGCAGCTGGCCCTGATTG 1999
              |||||||:|||||:||::|
Db          1 GAGCAGCUGGCCCUGAUUG 19


RESULT 414
US-11-101-244-159318
; Sequence 159318, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159318
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159318

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        460 GATCTGAAGTGGGTGACAT 478
              ||:|:||||:|||:||||:
Db          1 GAUCUGAAGUGGGUGACAU 19


RESULT 415
US-11-101-244-159319
; Sequence 159319, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159319
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159319

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2500 GACGGACAGTTCACAGTCA 2518
              |||||||||::|||||:||
Db          1 GACGGACAGUUCACAGUCA 19


RESULT 416
US-11-101-244-159320
; Sequence 159320, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
```

```
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159320
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159320

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2121 CATCGGACATGGTACTAAG 2139
              ||:||||||:||:||:|||
Db          1 CAUCGGACAUGGUACUAAG 19


RESULT 417
US-11-101-244-159321
; Sequence 159321, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159321
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159321

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1583 CCTTTGAGGTCACTGCATT 1601
              ||:::||||:|||:|||::
Db          1 CCUUUGAGGUCACUGCAUU 19


RESULT 418
US-11-101-244-159322
; Sequence 159322, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159322
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159322

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 4.5e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        428 AGACCCTGCTGAACACAAA 446
              ||||||:||:|||||||||
Db          1 AGACCCUGCUGAACACAAA 19


RESULT 419
US-11-101-244-159323
; Sequence 159323, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159323
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159323

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        542 GCACCTACGAAGTGTGTGA 560
              |||||:||||||:|:|:||
Db          1 GCACCUACGAAGUGUGUGA 19


RESULT 420
US-11-101-244-159324
; Sequence 159324, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
```

```
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159324
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159324

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4154 TGGAGGGGTTCTTAAATTA 4172
              :|||||||::|::|||::|
Db          1 UGGAGGGGUUCUUAAAUUA 19


RESULT 421
US-11-101-244-159325
; Sequence 159325, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159325
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159325

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2807 GGGAGGTGATGTCATTTGG 2825
              ||||||:||:|:||:::||
Db          1 GGGAGGUGAUGUCAUUUGG 19


RESULT 422
US-11-101-244-159326
; Sequence 159326, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159326
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159326

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||:||:|:||||
Db          1 ACAGCAACCUCGUCUGCAA 19


RESULT 423
US-11-101-244-159327
; Sequence 159327, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159327
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159327

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2116 TATCTCATCGGACATGGTA 2134
              :|:|:||:||||||:||:|
Db          1 UAUCUCAUCGGACAUGGUA 19


RESULT 424
US-11-101-244-159328
; Sequence 159328, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
```

```
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159328
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159328

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1570 GACTTCACCTATACCTTTG 1588
              |||::||||:|:|||:::|
Db          1 GACUUCACCUAUACCUUUG 19


RESULT 425
US-11-101-244-159329
; Sequence 159329, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159329
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159329

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4068 CAAGCTGTGTCCTATGAAG 4086
              |||||:|:|:||:|:||||
Db          1 CAAGCUGUGUCCUAUGAAG 19


RESULT 426
US-11-101-244-159330
; Sequence 159330, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159330
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159330

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3952 GGAACCTGTTTCACTATGG 3970
              ||||||:|:::|||:|:||
Db          1 GGAACCUGUUUCACUAUGG 19


RESULT 427
US-11-101-244-159331
; Sequence 159331, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159331
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159331

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3078 GCGGCAGCCTCACTACTCA 3096
              |||||||||:|||:||:||
Db          1 GCGGCAGCCUCACUACUCA 19


RESULT 428
US-11-101-244-159332
; Sequence 159332, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
```

```
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159332
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159332

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2441 TCATGATTCTCACAGAGTT 2459
              :||:||::|:|||||||::
Db          1 UCAUGAUUCUCACAGAGUU 19


RESULT 429
US-11-101-244-159333
; Sequence 159333, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159333
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159333

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2235 GATTGGTGCAGGTGAGTTT 2253
              ||::||:|||||:|||:::
Db          1 GAUUGGUGCAGGUGAGUUU 19


RESULT 430
US-11-101-244-159334
; Sequence 159334, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159334
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159334

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1602 GAACGGGGTATCCTCCTTA 1620
              ||||||||:|:||:||::|
Db          1 GAACGGGGUAUCCUCCUUA 19


RESULT 431
US-11-101-244-159335
; Sequence 159335, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159335
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159335

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2934 GCTGGACTGTTGGCAGAAA 2952
              ||:||||:|::||||||||
Db          1 GCUGGACUGUUGGCAGAAA 19


RESULT 432
US-11-101-244-159336
; Sequence 159336, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
```

```
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159336
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159336

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2156 TCACTTATGAAGACCCTAA 2174
              :|||::|:|||||||||:||
Db          1 UCACUUAUGAAGACCCUAA 19


RESULT 433
US-11-101-244-159337
; Sequence 159337, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159337
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159337

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1587 TGAGGTCACTGCATTGAAC 1605
              :||||:|||:|||::||||
Db          1 UGAGGUCACUGCAUUGAAC 19


RESULT 434
US-11-101-244-159338
; Sequence 159338, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159338
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159338

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        707 TCACCGTCTTCTACTATGA 725
              :|||||:|::|:||:|:||
Db          1 UCACCGUCUUCUACUAUGA 19


RESULT 435
US-11-101-244-159339
; Sequence 159339, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159339
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159339

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2789 GTTACGGGATTGTGATGTG 2807
              |::||||||::|:||:|:|
Db          1 GUUACGGGAUUGUGAUGUG 19


RESULT 436
US-11-101-244-159340
; Sequence 159340, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
```

```
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159340
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-11-101-244-159340

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2079 TGGGAGAGAAGCAGAATAT 2097
              :|||||||||||||||:|:
Db          1 UGGGAGAGAAGCAGAAUAU 19


RESULT 437
US-11-101-244-159341
; Sequence 159341, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159341
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-11-101-244-159341

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3932 GTCATAACTTTGTGTTGGA 3950
              |:||:|||:::|:|::|||
Db          1 GUCAUAACUUUGUGUUGGA 19


RESULT 438
US-11-101-244-159342
; Sequence 159342, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159342
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-11-101-244-159342

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3426 CCGCTGGATTGCACTTTGA 3444
              ||||:|||::||||:::||
Db          1 CCGCUGGAUUGCACUUUGA 19


RESULT 439
US-11-101-244-159343
; Sequence 159343, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159343
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-11-101-244-159343

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAACAG 2624
              ||||||:||:||:||||||
Db          1 GCAACAUCCUAGUCAACAG 19


RESULT 440
US-11-101-244-159344
; Sequence 159344, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
```

```
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159344
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159344

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1248 TAGCCACTCTAACACCATT 1266
              :||||||:|:|||||||::
Db          1 UAGCCACUCUAACACCAUU 19


RESULT 441
US-11-101-244-159345
; Sequence 159345, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159345
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159345

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1241 CAGCCAATAGCCACTCTAA 1259
              |||||||:||||||:|:||
Db          1 CAGCCAAUAGCCACUCUAA 19


RESULT 442
US-11-101-244-159346
; Sequence 159346, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159346
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159346

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        842 CCGGGAAGGTGAATGTCAA 860
              |||||||||:|||:|:|||
Db          1 CCGGGAAGGUGAAUGUCAA 19


RESULT 443
US-11-101-244-159347
; Sequence 159347, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159347
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159347

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3206 CTGAGGACCTGCTCCGAAT 3224
              |:|||||||:||:|||||:
Db          1 CUGAGGACCUGCUCCGAAU 19


RESULT 444
US-11-101-244-159348
; Sequence 159348, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
```

```
; SEQ ID NO 159348
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159348

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2987 TCAGCGCCCTGGACAAGAT 3005
              :||||||||:||||||||:
Db          1 UCAGCGCCCUGGACAAGAU 19


RESULT 445
US-11-101-244-159349
; Sequence 159349, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159349
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159349

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2625 CAACCTCGTCTGCAAAGTG 2643
              |||||:|||:|:||||||:|
Db          1 CAACCUCGUCUGCAAAGUG 19


RESULT 446
US-11-101-244-159350
; Sequence 159350, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159350
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159350

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2602 GCTCGCAACATCCTAGTCA 2620
              ||:|||||||:||:||:||
Db          1 GCUCGCAACAUCCUAGUCA 19


RESULT 447
US-11-101-244-159351
; Sequence 159351, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159351
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159351

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2126 GACATGGTACTAAGGTCTA 2144
              ||||:||:||:||||:|:|
Db          1 GACAUGGUACUAAGGUCUA 19


RESULT 448
US-11-101-244-159352
; Sequence 159352, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159352
;   LENGTH: 19
```

```
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159352

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2220 CAAGATTGAAGAGGTGATT 2238
              |||||::|||||||:||::
Db          1 CAAGAUUGAAGAGGUGAUU 19


RESULT 449
US-11-101-244-159353
; Sequence 159353, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159353
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159353

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2104 AAACACGGACAGTATCTCA 2122
              ||||||||||||:|:|:||
Db          1 AAACACGGACAGUAUCUCA 19


RESULT 450
US-11-101-244-159354
; Sequence 159354, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159354
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159354

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4106 GAAAAGGGCGGTAGTTGGT 4124
              ||||||||||:||::||:
Db          1 GAAAAGGGCGGUAGUUGGU 19


RESULT 451
US-11-101-244-159355
; Sequence 159355, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159355
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159355

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3758 GGTTTGTAGTCCCAACTTG 3776
              ||:::|:||:||||||::|
Db          1 GGUUUGUAGUCCCAACUUG 19


RESULT 452
US-11-101-244-159356
; Sequence 159356, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159356
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
```

US-11-101-244-159356

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy        422 TGGAAGAGACCCTGCTGAA 440
              :||||||||||||:||:|||
Db          1 UGGAAGAGACCCUGCUGAA 19
```

RESULT 453
US-11-101-244-159357
; Sequence 159357, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159357
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159357

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy        411 GGCCGCAGCTTTGGAAGAG 429
              |||||||||:::|||||||
Db          1 GGCCGCAGCUUUGGAAGAG 19
```

RESULT 454
US-11-101-244-159358
; Sequence 159358, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159358
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159358

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy        702 GACCTTCACCGTCTTCTAC 720
              ||||::|||||:|::|:||
Db          1 GACCUUCACCGUCUUCUAC 19
```

RESULT 455
US-11-101-244-159359
; Sequence 159359, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159359
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159359

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy        977 CTGTGAACCTGACTCGATT 995
              |:|:|||||:|||:|||::
Db          1 CUGUGAACCUGACUCGAUU 19
```

RESULT 456
US-11-101-244-159360
; Sequence 159360, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159360
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159360

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2786 GGAGTTACGGGATTGTGAT 2804
              ||||::||||||::|:||:
Db          1 GGAGUUACGGGAUUGUGAU 19
```

RESULT 457
US-11-101-244-159361
; Sequence 159361, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159361
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159361

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2159 CTTATGAAGACCCTAATGA 2177
              |::|:|||||||:||:||
Db          1 CUUAUGAAGACCCUAAUGA 19
```

RESULT 458
US-11-101-244-159362
; Sequence 159362, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159362
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159362

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2101 GACAAACACGGACAGTATC 2119
              |||||||||||||||:|:|
Db          1 GACAAACACGGACAGUAUC 19
```

RESULT 459
US-11-101-244-159363
; Sequence 159363, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159363
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159363

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1769 TGGACTACGAGGTCAAATA 1787
              :||||:||||||:||||:|
Db          1 UGGACUACGAGGUCAAAUA 19
```

RESULT 460
US-11-101-244-159365
; Sequence 159365, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159365
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159365

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.5e+02;

Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3998 CCCATCATCATGTCTGTTT 4016
              |||||:||:||:|:|:|:::
Db          1 CCCAUCAUCAUGUCUGUUU 19
```

RESULT 461
US-11-101-244-159366
; Sequence 159366, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159366
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159366

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3262 GCCAGTGTCCAGCACATGA 3280
              |||||:|:||||||||:||
Db          1 GCCAGUGUCCAGCACAUGA 19
```

RESULT 462
US-11-101-244-159367
; Sequence 159367, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159367
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159367

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3082 CAGCCTCACTACTCAGCTT 3100
              |||||:|||:||:||||::
Db          1 CAGCCUCACUACUCAGCUU 19
```

RESULT 463
US-11-101-244-159368
; Sequence 159368, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159368
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159368

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2559 GCGGTACCTTGCCGAGATG 2577
              ||||:|||::|||||||:|
Db          1 GCGGUACCUUGCCGAGAUG 19
```

RESULT 464
US-11-101-244-159369
; Sequence 159369, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159369
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159369

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy        452 AAACTGCTGATCTGAAGTG 470
              ||||:||:||:|:||||:|
Db          1 AAACUGCUGAUCUGAAGUG 19
```

RESULT 465
US-11-101-244-159370
; Sequence 159370, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159370
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159370

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy        423 GGAAGAGACCCTGCTGAAC 441
              ||||||||||:||:||||
Db          1 GGAAGAGACCCUGCUGAAC 19
```

RESULT 466
US-11-101-244-159372
; Sequence 159372, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159372
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159372

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2183 TGAGGGAATTTGCAAAAGA 2201
              :|||||||:::|||||||||
Db          1 UGAGGGAAUUUGCAAAAGA 19
```

RESULT 467
US-11-101-244-159373
; Sequence 159373, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159373
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159373

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3969 GGCCTCCTTTGCCCAAGTT 3987
              ||||:||:::||||||||::
Db          1 GGCCUCCUUUGCCCAAGUU 19
```

RESULT 468
US-11-101-244-159374
; Sequence 159374, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159374
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159374

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3779 GCTGTCACCACCAAACTCA 3797
              ||:|:||||||||||:||
```

```
Db          1 GCUGUCACCACCAAACUCA 19
```

RESULT 469
US-11-101-244-159375
; Sequence 159375, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159375
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159375

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2622 CAGCAACCTCGTCTGCAAA 2640
              ||||||||:||:|:|||||
Db          1 CAGCAACCUCGUCUGCAAA 19
```

RESULT 470
US-11-101-244-159376
; Sequence 159376, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159376
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159376

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2088 AGCAGAATATTCGGACAAA 2106
              |||||||:|::||||||||
Db          1 AGCAGAAUAUUCGGACAAA 19
```

RESULT 471
US-11-101-244-159377
; Sequence 159377, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159377
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159377

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       4136 GAAACGGACGCCGGTGCTT 4154
              |||||||||||||||:||::
Db          1 GAAACGGACGCCGGUGCUU 19
```

RESULT 472
US-11-101-244-159378
; Sequence 159378, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159378
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159378

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       3593 AAAAGGAAGTGCCCAACAT 3611
              |||||||||:||||||||:
Db          1 AAAAGGAAGUGCCCAACAU 19
```

```
RESULT 473
US-11-101-244-159379
; Sequence 159379, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159379
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159379

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        845 GGAAGGTGAATGTCAAGAC 863
              ||||||:|||:|:||||||
Db          1 GGAAGGUGAAUGUCAAGAC 19


RESULT 474
US-11-101-244-159380
; Sequence 159380, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159380
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159380

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        504 GGAACTGAGCGGCCTGGAT 522
              |||||:||||||||:|||:
Db          1 GGAACUGAGCGGCCUGGAU 19


RESULT 475
US-11-101-244-159381
; Sequence 159381, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159381
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159381

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        540 GCGCACCTACGAAGTGTGT 558
              |||||||:||||||:|:|:
Db          1 GCGCACCUACGAAGUGUGU 19


RESULT 476
US-11-101-244-159382
; Sequence 159382, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159382
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159382

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 4.5e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2063 TCAGGAAGCAGAGCAATGG 2081
              :||||||||||||||||:||
Db          1 UCAGGAAGCAGAGCAAUGG 19


RESULT 477
```

US-11-083-784-685
; Sequence 685, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 685
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-685

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 GGACAAACACGGACAGTAT 2118
||||||||||||||||:|:
Db 1 GGACAAACACGGACAGUAU 19

RESULT 478
US-11-083-784-686
; Sequence 686, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 686
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-686

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2132 GTACTAAGGTCTACATCGA 2150
|:||:||||:|:|||:|||
Db 1 GUACUAAGGUCUACAUCGA 19

RESULT 479
US-11-083-784-687
; Sequence 687, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 687
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-687

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2081 GGAGAGAAGCAGAATATTC 2099
|||||||||||||:|::|
Db 1 GGAGAGAAGCAGAAUAUUC 19

RESULT 480
US-11-083-784-688
; Sequence 688, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 688
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-688

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1243 GCCAATAGCCACTCTAACA 1261
              |||||:||||||:|:||||
Db          1 GCCAAUAGCCACUCUAACA 19


RESULT 481
US-11-083-784-158892
; Sequence 158892, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158892
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158892

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||||::||:||||||
Db          1 UCACAGAGUUCAUGGAGAA 19


RESULT 482
US-11-083-784-159283
; Sequence 159283, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159283
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159283

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3786 CCACCAAACTCAATCATTT 3804
              |||||||||:|||:||:::
Db          1 CCACCAAACUCAAUCAUUU 19


RESULT 483
US-11-083-784-159284
; Sequence 159284, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159284
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159284

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3949 GAGGGAACCTGTTTCACTA 3967
              |||||||||:|:::|||:|
Db          1 GAGGGAACCUGUUUCACUA 19


RESULT 484
US-11-083-784-159285
; Sequence 159285, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159285
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
```

US-11-083-784-159285

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 GGACAAACACGGACAGTAT 2118
||||||||||||||||:|:
Db 1 GGACAAACACGGACAGUAU 19

RESULT 485
US-11-083-784-159287
; Sequence 159287, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159287
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159287

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 2450 TCACAGAGTTCATGGAGAA 2468
:||||||::||:||||||
Db 1 UCACAGAGUUCAUGGAGAA 19

RESULT 486
US-11-083-784-159288
; Sequence 159288, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159288
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159288

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 424 GAAGAGACCCTGCTGAACA 442
||||||||||:||:|||||
Db 1 GAAGAGACCCUGCUGAACA 19

RESULT 487
US-11-083-784-159289
; Sequence 159289, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159289
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159289

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2132 GTACTAAGGTCTACATCGA 2150
|:||:||||:|:|||:|||
Db 1 GUACUAAGGUCUACAUCGA 19

RESULT 488
US-11-083-784-159290
; Sequence 159290, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

```
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159290
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159290

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        450 GGAAACTGCTGATCTGAAG 468
              ||||||:||:||:|:||||
Db          1 GGAAACUGCUGAUCUGAAG 19


RESULT 489
US-11-083-784-159291
; Sequence 159291, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159291
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159291

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2081 GGAGAGAAGCAGAATATTC 2099
              ||||||||||||||:|::|
Db          1 GGAGAGAAGCAGAAUAUUC 19


RESULT 490
US-11-083-784-159292
; Sequence 159292, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159292
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159292

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3333 GTACTGACCTGCAGGAACT 3351
              |:||:||||:||||||||:
Db          1 GUACUGACCUGCAGGAACU 19


RESULT 491
US-11-083-784-159293
; Sequence 159293, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159293
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159293

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3454 GTGAGGAGTTGGCAATTTG 3472
              |:||||||::||||||:::|
Db          1 GUGAGGAGUUGGCAAUUUG 19


RESULT 492
US-11-083-784-159294
; Sequence 159294, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
```

```
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159294
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159294

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3453 GGTGAGGAGTTGGCAATTT 3471
              ||:|||||::|||||:::
Db          1 GGUGAGGAGUUGGCAAUUU 19


RESULT 493
US-11-083-784-159295
; Sequence 159295, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159295
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159295

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 4.5e+02;
  Matches   18;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2070 GCAGAGCAATGGGAGAGAA 2088
              |||||||||:|||||||||
Db          1 GCAGAGCAAUGGGAGAGAA 19


RESULT 494
US-11-083-784-159296
; Sequence 159296, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159296
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159296

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3832 GCTGCTGCCTTCATATTGA 3850
              ||:||:|||::||:::||
Db          1 GCUGCUGCCUUCAUAUUGA 19


RESULT 495
US-11-083-784-159297
; Sequence 159297, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159297
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159297

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2361 GAGCGAGGCCTCCATCATG 2379
              ||||||||||:|||:||:|
Db          1 GAGCGAGGCCUCCAUCAUG 19


RESULT 496
US-11-083-784-159298
; Sequence 159298, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
```

```
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159298
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159298

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4020 GAACAGTGCCTTGGTCATC 4038
              ||||||:|||::||:||:|
Db          1 GAACAGUGCCUUGGUCAUC 19


RESULT 497
US-11-083-784-159299
; Sequence 159299, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159299
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159299

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1243 GCCAATAGCCACTCTAACA 1261
              |||||:||||||:|:||||
Db          1 GCCAAUAGCCACUCUAACA 19


RESULT 498
US-11-083-784-159300
; Sequence 159300, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159300
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159300

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1770 GGACTACGAGGTCAAATAC 1788
              ||||:||||||:||||:||
Db          1 GGACUACGAGGUCAAAUAC 19


RESULT 499
US-11-083-784-159301
; Sequence 159301, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159301
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159301

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCATT 2822
              :|:||||||:||:|:||::
Db          1 UGUGGGAGGUGAUGUCAUU 19


RESULT 500
US-11-083-784-159302
; Sequence 159302, Application US/11083784
```

```
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159302
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159302

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2493 GCTAAACGACGGACAGTTC 2511
              ||:|||||||||||||::|
Db          1 GCUAAACGACGGACAGUUC 19


RESULT 501
US-11-083-784-159303
; Sequence 159303, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159303
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159303

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1496 GGGGAGACCTGACTTTTGA 1514
              |||||||||:|||::::||
Db          1 GGGGAGACCUGACUUUUGA 19


RESULT 502
US-11-083-784-159304
; Sequence 159304, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159304
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159304

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        965 GCGCCCAGCTGACTGTGAA 983
              |||||||||:|||:|:|||
Db          1 GCGCCCAGCUGACUGUGAA 19


RESULT 503
US-11-083-784-159305
; Sequence 159305, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159305
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159305

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4156 GAGGGGTTCTTAAATTATA 4174
              ||||||::|::|||::|:|
```

```
Db          1 GAGGGGUUCUUAAAUUAUA 19


RESULT 504
US-11-083-784-159306
; Sequence 159306, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159306
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159306

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4066 CCCAAGCTGTGTCCTATGA 4084
              |||||||:|:|:||:|:||
Db          1 CCCAAGCUGUGUCCUAUGA 19


RESULT 505
US-11-083-784-159307
; Sequence 159307, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159307
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159307

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2082 GAGAGAAGCAGAATATTCG 2100
              |||||||||||||:|::||
Db          1 GAGAGAAGCAGAAUAUUCG 19


RESULT 506
US-11-083-784-159308
; Sequence 159308, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159308
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159308

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1777 GAGGTCAAATACCATGAGA 1795
              ||||:||||:||||:||||
Db          1 GAGGUCAAAUACCAUGAGA 19


RESULT 507
US-11-083-784-159310
; Sequence 159310, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159310
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159310
```

```
  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1779 GGTCAAATACCATGAGAAG 1797
              ||:||||:||||:||||||
Db          1 GGUCAAAUACCAUGAGAAG 19


RESULT 508
US-11-083-784-159311
; Sequence 159311, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159311
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159311

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3951 GGGAACCTGTTTCACTATG 3969
              |||||||:|:::|||:|:|
Db          1 GGGAACCUGUUUCACUAUG 19


RESULT 509
US-11-083-784-159312
; Sequence 159312, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159312
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159312

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3363 GGACACCGCCTCCCCATTT 3381
              ||||||||||:|||||:::
Db          1 GGACACCGCCUCCCCAUUU 19


RESULT 510
US-11-083-784-159313
; Sequence 159313, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159313
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159313

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2295 GGAGAGCTGTGTGGCAATC 2313
              |||||||:|:|:|||||:|
Db          1 GGAGAGCUGUGUGGCAAUC 19


RESULT 511
US-11-083-784-159314
; Sequence 159314, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
```

; SEQ ID NO 159314
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159314

 Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 73.7%; Pred. No. 4.5e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 3948 GGAGGGAACCTGTTTCACT 3966
 ||||||||||:|:::|||:
Db 1 GGAGGGAACCUGUUUCACU 19

RESULT 512
US-11-083-784-159315
; Sequence 159315, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159315
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159315

 Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 4.5e+02;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2288 GGAAGAAGGAGAGCTGTGT 2306
 ||||||||||||||:|:|:
Db 1 GGAAGAAGGAGAGCUGUGU 19

RESULT 513
US-11-083-784-159316
; Sequence 159316, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159316
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159316

 Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 4.5e+02;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2090 CAGAATATTCGGACAAACA 2108
 |||||:|::||||||||||
Db 1 CAGAAUAUUCGGACAAACA 19

RESULT 514
US-11-083-784-159317
; Sequence 159317, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159317
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159317

 Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 78.9%; Pred. No. 4.5e+02;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1981 GAGCAGCTGGCCCTGATTG 1999
 |||||||:|||||:||::|
Db 1 GAGCAGCUGGCCCUGAUUG 19

RESULT 515
US-11-083-784-159318
; Sequence 159318, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14

```
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159318
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159318

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        460 GATCTGAAGTGGGTGACAT 478
              ||:|:||||:|||:||||:
Db          1 GAUCUGAAGUGGGUGACAU 19


RESULT 516
US-11-083-784-159319
; Sequence 159319, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159319
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159319

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2500 GACGGACAGTTCACAGTCA 2518
              ||||||||||::|||||:||
Db          1 GACGGACAGUUCACAGUCA 19


RESULT 517
US-11-083-784-159320
; Sequence 159320, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159320
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159320

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2121 CATCGGACATGGTACTAAG 2139
              ||:||||||:||:||:|||
Db          1 CAUCGGACAUGGUACUAAG 19


RESULT 518
US-11-083-784-159321
; Sequence 159321, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159321
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159321

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1583 CCTTTGAGGTCACTGCATT 1601
              ||:::||||:|||:|||::
Db          1 CCUUUGAGGUCACUGCAUU 19


RESULT 519
US-11-083-784-159322
; Sequence 159322, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
```

```
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159322
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159322

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 4.5e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        428 AGACCCTGCTGAACACAAA 446
              ||||||:||:|||||||||
Db          1 AGACCCUGCUGAACACAAA 19


RESULT 520
US-11-083-784-159323
; Sequence 159323, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159323
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159323

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        542 GCACCTACGAAGTGTGTGA 560
              |||||:||||||:|:|:||
Db          1 GCACCUACGAAGUGUGUGA 19


RESULT 521
US-11-083-784-159324
; Sequence 159324, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159324
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159324

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4154 TGGAGGGGTTCTTAAATTA 4172
              :|||||||::|::|||::|
Db          1 UGGAGGGGUUCUUAAAUUA 19


RESULT 522
US-11-083-784-159325
; Sequence 159325, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159325
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159325

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2807 GGGAGGTGATGTCATTTGG 2825
              ||||||:||:|:||:::||
Db          1 GGGAGGUGAUGUCAUUUGG 19


RESULT 523
US-11-083-784-159326
; Sequence 159326, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159326
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159326

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||:||:|:||||
Db          1 ACAGCAACCUCGUCUGCAA 19


RESULT 524
US-11-083-784-159327
; Sequence 159327, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159327
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159327

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2116 TATCTCATCGGACATGGTA 2134
              :|:|:||:||||||:||:|
Db          1 UAUCUCAUCGGACAUGGUA 19


RESULT 525
US-11-083-784-159328
; Sequence 159328, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159328
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159328

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1570 GACTTCACCTATACCTTTG 1588
              |||::||||:|:|||:::|
Db          1 GACUUCACCUAUACCUUUG 19


RESULT 526
US-11-083-784-159329
; Sequence 159329, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159329
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159329

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4068 CAAGCTGTGTCCTATGAAG 4086
              |||||:|:|:||:|:||||
Db          1 CAAGCUGUGUCCUAUGAAG 19
```

```
RESULT 527
US-11-083-784-159330
; Sequence 159330, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159330
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159330

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3952 GGAACCTGTTTCACTATGG 3970
              ||||||:|:::|||:|:||
Db          1 GGAACCUGUUUCACUAUGG 19


RESULT 528
US-11-083-784-159331
; Sequence 159331, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159331
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159331

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3078 GCGGCAGCCTCACTACTCA 3096
              |||||||||:|||:||:||
Db          1 GCGGCAGCCUCACUACUCA 19


RESULT 529
US-11-083-784-159332
; Sequence 159332, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159332
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159332

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2441 TCATGATTCTCACAGAGTT 2459
              :||:||::|:|||||||::
Db          1 UCAUGAUUCUCACAGAGUU 19


RESULT 530
US-11-083-784-159333
; Sequence 159333, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159333
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159333

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
```

Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2235 GATTGGTGCAGGTGAGTTT 2253
              ||::||:|||||:|||:::
Db          1 GAUUGGUGCAGGUGAGUUU 19
```

RESULT 531
US-11-083-784-159334
; Sequence 159334, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159334
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159334

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1602 GAACGGGGTATCCTCCTTA 1620
              ||||||||:|:||:|||::|
Db          1 GAACGGGGUAUCCUCCUUA 19
```

RESULT 532
US-11-083-784-159335
; Sequence 159335, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159335
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159335

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2934 GCTGGACTGTTGGCAGAAA 2952
              ||:||||:|::||||||||
Db          1 GCUGGACUGUUGGCAGAAA 19
```

RESULT 533
US-11-083-784-159336
; Sequence 159336, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159336
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159336

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2156 TCACTTATGAAGACCCTAA 2174
              :|||::|:|||||||:||
Db          1 UCACUUAUGAAGACCCUAA 19
```

RESULT 534
US-11-083-784-159337
; Sequence 159337, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159337
; LENGTH: 19

```
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159337

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1587 TGAGGTCACTGCATTGAAC 1605
              :||||:|||:|||::||||
Db          1 UGAGGUCACUGCAUUGAAC 19


RESULT 535
US-11-083-784-159338
; Sequence 159338, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159338
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159338

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        707 TCACCGTCTTCTACTATGA 725
              :||||||:|::|:||:|:||
Db          1 UCACCGUCUUCUACUAUGA 19


RESULT 536
US-11-083-784-159339
; Sequence 159339, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159339
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159339

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2789 GTTACGGGATTGTGATGTG 2807
              |::||||||::|:||:|:|
Db          1 GUUACGGGAUUGUGAUGUG 19


RESULT 537
US-11-083-784-159340
; Sequence 159340, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159340
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159340

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2079 TGGGAGAGAAGCAGAATAT 2097
              :|||||||||||||||:|:
Db          1 UGGGAGAGAAGCAGAAUAU 19


RESULT 538
US-11-083-784-159341
; Sequence 159341, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
```

```
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159341
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159341

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3932 GTCATAACTTTGTGTTGGA 3950
              |:||:|||:::|:|::|||
Db          1 GUCAUAACUUUGUGUUGGA 19


RESULT 539
US-11-083-784-159342
; Sequence 159342, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159342
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159342

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3426 CCGCTGGATTGCACTTTGA 3444
              ||||:|||::||||:::||
Db          1 CCGCUGGAUUGCACUUUGA 19


RESULT 540
US-11-083-784-159343
; Sequence 159343, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159343
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159343

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAACAG 2624
              ||||||:||:||:||||||
Db          1 GCAACAUCCUAGUCAACAG 19


RESULT 541
US-11-083-784-159344
; Sequence 159344, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159344
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159344

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1248 TAGCCACTCTAACACCATT 1266
              :||||||:|:|||||||::
Db          1 UAGCCACUCUAACACCAUU 19


RESULT 542
US-11-083-784-159345
; Sequence 159345, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
```

```
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159345
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159345

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1241 CAGCCAATAGCCACTCTAA 1259
              ||||||:||||||:|:||
Db          1 CAGCCAAUAGCCACUCUAA 19


RESULT 543
US-11-083-784-159346
; Sequence 159346, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159346
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159346

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        842 CCGGGAAGGTGAATGTCAA 860
              |||||||||:|||:|:|||
Db          1 CCGGGAAGGUGAAUGUCAA 19


RESULT 544
US-11-083-784-159347
; Sequence 159347, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159347
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159347

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3206 CTGAGGACCTGCTCCGAAT 3224
              |:||||||:||:|||||:
Db          1 CUGAGGACCUGCUCCGAAU 19


RESULT 545
US-11-083-784-159348
; Sequence 159348, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159348
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159348

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2987 TCAGCGCCCTGGACAAGAT 3005
              :||||||||:||||||||:
Db          1 UCAGCGCCCUGGACAAGAU 19


RESULT 546
US-11-083-784-159349
; Sequence 159349, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
```

```
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159349
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159349

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2625 CAACCTCGTCTGCAAAGTG 2643
              |||||:||:|:|||||:|
Db          1 CAACCUCGUCUGCAAAGUG 19


RESULT 547
US-11-083-784-159350
; Sequence 159350, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159350
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159350

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2602 GCTCGCAACATCCTAGTCA 2620
              ||:|||||||:||:||:||
Db          1 GCUCGCAACAUCCUAGUCA 19


RESULT 548
US-11-083-784-159351
; Sequence 159351, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159351
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159351

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2126 GACATGGTACTAAGGTCTA 2144
              ||||:||:||:||||:|:|
Db          1 GACAUGGUACUAAGGUCUA 19


RESULT 549
US-11-083-784-159352
; Sequence 159352, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159352
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159352

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2220 CAAGATTGAAGAGGTGATT 2238
              |||||::|||||||:||::
Db          1 CAAGAUUGAAGAGGUGAUU 19


RESULT 550
```

```
US-11-083-784-159353
; Sequence 159353, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159353
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159353

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2104 AAACACGGACAGTATCTCA 2122
              ||||||||||||:|:|:||
Db          1 AAACACGGACAGUAUCUCA 19


RESULT 551
US-11-083-784-159354
; Sequence 159354, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159354
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159354

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4106 GAAAAGGGCGGTAGTTGGT 4124
              ||||||||||||:||::||:
Db          1 GAAAAGGGCGGUAGUUGGU 19


RESULT 552
US-11-083-784-159355
; Sequence 159355, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159355
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159355

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3758 GGTTTGTAGTCCCAACTTG 3776
              ||:::|:||:||||||::|
Db          1 GGUUUGUAGUCCCAACUUG 19


RESULT 553
US-11-083-784-159356
; Sequence 159356, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159356
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159356

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        422 TGGAAGAGACCCTGCTGAA 440
              :||||||||||||:||:|||
Db          1 UGGAAGAGACCCUGCUGAA 19
```

RESULT 554
US-11-083-784-159357
; Sequence 159357, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159357
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159357

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy        411 GGCCGCAGCTTTGGAAGAG 429
              |||||||||:::|||||||
Db          1 GGCCGCAGCUUUGGAAGAG 19
```

RESULT 555
US-11-083-784-159358
; Sequence 159358, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159358
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159358

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy        702 GACCTTCACCGTCTTCTAC 720
              ||||::|||||:|::|:||
Db          1 GACCUUCACCGUCUUCUAC 19
```

RESULT 556
US-11-083-784-159359
; Sequence 159359, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159359
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159359

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```
Qy        977 CTGTGAACCTGACTCGATT 995
              |:|:|||||:|||:|||::
Db          1 CUGUGAACCUGACUCGAUU 19
```

RESULT 557
US-11-083-784-159360
; Sequence 159360, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159360
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-083-784-159360

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 2786 GGAGTTACGGGATTGTGAT 2804
||||::|||||::|:||:
Db 1 GGAGUUACGGGAUUGUGAU 19

RESULT 558
US-11-083-784-159361
; Sequence 159361, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159361
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159361

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2159 CTTATGAAGACCCTAATGA 2177
|::|:|||||||:||:||
Db 1 CUUAUGAAGACCCUAAUGA 19

RESULT 559
US-11-083-784-159362
; Sequence 159362, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159362
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159362

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2101 GACAAACACGGACAGTATC 2119
|||||||||||||||:|:|
Db 1 GACAAACACGGACAGUAUC 19

RESULT 560
US-11-083-784-159363
; Sequence 159363, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159363
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159363

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1769 TGGACTACGAGGTCAAATA 1787
:||||:||||||:||||:|
Db 1 UGGACUACGAGGUCAAAUA 19

RESULT 561
US-11-083-784-159365
; Sequence 159365, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

```
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159365
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-11-083-784-159365

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3998 CCCATCATCATGTCTGTTT 4016
              ||||:||:||:|:|:|:::
Db          1 CCCAUCAUCAUGUCUGUUU 19


RESULT 562
US-11-083-784-159366
; Sequence 159366, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159366
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-11-083-784-159366

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3262 GCCAGTGTCCAGCACATGA 3280
              |||||:|:||||||||:||
Db          1 GCCAGUGUCCAGCACAUGA 19


RESULT 563
US-11-083-784-159367
; Sequence 159367, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159367
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-11-083-784-159367

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3082 CAGCCTCACTACTCAGCTT 3100
              |||||:|||:||:||||::
Db          1 CAGCCUCACUACUCAGCUU 19


RESULT 564
US-11-083-784-159368
; Sequence 159368, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159368
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-11-083-784-159368

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2559 GCGGTACCTTGCCGAGATG 2577
              ||||:|||::|||||||:|
Db          1 GCGGUACCUUGCCGAGAUG 19


RESULT 565
US-11-083-784-159369
; Sequence 159369, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
```

```
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159369
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159369

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        452 AAACTGCTGATCTGAAGTG 470
              ||||:||:||:|:||||:|
Db          1 AAACUGCUGAUCUGAAGUG 19


RESULT 566
US-11-083-784-159370
; Sequence 159370, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159370
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159370

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 4.5e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        423 GGAAGAGACCCTGCTGAAC 441
              ||||||||||||:||:||||
Db          1 GGAAGAGACCCUGCUGAAC 19


RESULT 567
US-11-083-784-159372
; Sequence 159372, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159372
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159372

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2183 TGAGGGAATTTGCAAAAGA 2201
              :|||||||:::||||||||
Db          1 UGAGGGAAUUUGCAAAAGA 19


RESULT 568
US-11-083-784-159373
; Sequence 159373, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159373
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159373

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3969 GGCCTCCTTTGCCCAAGTT 3987
              ||||:||:::|||||||::
Db          1 GGCCUCCUUUGCCCAAGUU 19


RESULT 569
US-11-083-784-159374
; Sequence 159374, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
```

```
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159374
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159374

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3779 GCTGTCACCACCAAACTCA 3797
              ||:|:|||||||||||:||
Db          1 GCUGUCACCACCAAACUCA 19


RESULT 570
US-11-083-784-159375
; Sequence 159375, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159375
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159375

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2622 CAGCAACCTCGTCTGCAAA 2640
              ||||||||:||:|:|||||
Db          1 CAGCAACCUCGUCUGCAAA 19


RESULT 571
US-11-083-784-159376
; Sequence 159376, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159376
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159376

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2088 AGCAGAATATTCGGACAAA 2106
              |||||||:|::||||||||
Db          1 AGCAGAAUAUUCGGACAAA 19


RESULT 572
US-11-083-784-159377
; Sequence 159377, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159377
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159377

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4136 GAAACGGACGCCGGTGCTT 4154
              ||||||||||||||:||::
Db          1 GAAACGGACGCCGGUGCUU 19


RESULT 573
US-11-083-784-159378
; Sequence 159378, Application US/11083784
```

```
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159378
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159378

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 4.5e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3593 AAAAGGAAGTGCCCAACAT 3611
              |||||||||:||||||||:
Db          1 AAAAGGAAGUGCCCAACAU 19


RESULT 574
US-11-083-784-159379
; Sequence 159379, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159379
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159379

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        845 GGAAGGTGAATGTCAAGAC 863
              ||||||:|||:|:||||||
Db          1 GGAAGGUGAAUGUCAAGAC 19


RESULT 575
US-11-083-784-159380
; Sequence 159380, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159380
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159380

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 4.5e+02;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        504 GGAACTGAGCGGCCTGGAT 522
              |||||:||||||||:|||:
Db          1 GGAACUGAGCGGCCUGGAU 19


RESULT 576
US-11-083-784-159381
; Sequence 159381, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159381
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159381

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4.5e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        540 GCGCACCTACGAAGTGTGT 558
              |||||||:||||||:|:|:
```

```
Db          1 GCGCACCUACGAAGUGUGU 19


RESULT 577
US-11-083-784-159382
; Sequence 159382, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159382
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-11-083-784-159382

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 4.5e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2063 TCAGGAAGCAGAGCAATGG 2081
              :|||||||||||||||:||
Db          1 UCAGGAAGCAGAGCAAUGG 19


RESULT 578
US-10-949-720-22
; Sequence 22, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Unknown
;    FEATURE:
;    OTHER INFORMATION: Oligonucleotide
US-10-949-720-22

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 5.3e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:|||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 579
US-10-949-720-23
; Sequence 23, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
;    LENGTH: 21
;    TYPE: RNA
;    ORGANISM: Unknown
;    FEATURE:
;    OTHER INFORMATION: Oligonucleotide
US-10-949-720-23

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 580
US-10-949-720-34
; Sequence 34, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 34
;    LENGTH: 21
```

```
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-34

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 5.3e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 581
US-10-949-720-36
; Sequence 36, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 36
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-36

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 5.3e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:|||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 582
US-10-949-720-40
; Sequence 40, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 40
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-40

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 583
US-10-949-720-69
; Sequence 69, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 69
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-69

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 5.3e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 584
US-10-949-720-286
; Sequence 286, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
```

```
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 286
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-286

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 5.3e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 585
US-10-949-720-287
; Sequence 287, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 287
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-287

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 5.3e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:|||||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 586
US-10-949-720-289
; Sequence 289, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 289
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-289

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 587
US-10-949-720-290
; Sequence 290, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 290
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-290

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
```

```
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 588
US-10-770-726-16917
; Sequence 16917, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16917
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-16917

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   68.4%;  Pred. No. 5.3e+02;
  Matches   13;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2929 CTCATGCTGGACTGTTGGC 2947
              |:||:||:||||:|::|||
Db          1 CUCAUGCUGGACUGUUGGC 19


RESULT 589
US-10-770-726-17547
; Sequence 17547, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17547
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-17547

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 5.3e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2933 TGCTGGACTGTTGGCAGAA 2951
              :||:||||:|::|||||||
Db          1 UGCUGGACUGUUGGCAGAA 19


RESULT 590
US-10-310-914A-1216690
; Sequence 1216690, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1216690
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1216690

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 5.3e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3407 AGGCCCCCAGCCCTGTGCC 3425
              |||||||||||||:|:|||
Db          3 AGGCCCCCAGCCCUGUGCC 21


RESULT 591
US-10-310-914A-207817/c
; Sequence 207817, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 207817
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-207817

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 22;
  Best Local Similarity   90.9%;  Pred. No. 6e+02;
  Matches   20;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3901 TGTTTCTTCGTTTTGTTTTTCT 3922
              |||||||| |||||||||| |
Db         22 TGTTTCTTGGTTTTGTTTTTTT 1


RESULT 592
US-10-310-914A-287071/c
; Sequence 287071, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 287071
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-287071

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 22;
  Best Local Similarity   90.9%;  Pred. No. 6e+02;
  Matches   20;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1414 CTGGAGTCTGGTGGCCGAGAGG 1435
```

```
              || |||||||| ||||||||||
Db         22 CTAGAGTCTGGCGGCCGAGAGG 1
```

RESULT 593
US-10-310-914A-1125431
; Sequence 1125431, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1125431
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1125431

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 13.6%; Pred. No. 6e+02;
Matches 3; Conservative 17; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3897 TTTTTGTTTCTTCGTTTTGTTT 3918
              :::::|::: :: |::::|:::
Db          1 UUUUUGUUUGUUUGUUUUGUUU 22
```

RESULT 594
US-10-310-914A-200253
; Sequence 200253, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 200253
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-200253

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 81.8%; Pred. No. 6.4e+02;
Matches 18; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3614 CCCAGCCTCCCCAGGTGCCCCC 3635
              |||| ||:|||||| :||||||
Db          1 CCCACCCUCCCCCAGCUGCCCCC 22
```

RESULT 595
US-10-310-914A-456565/c
; Sequence 456565, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 456565
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-456565

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 6.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1572 CTTCACCTATACCTTTGAGGTC 1593
              | ||||| ||||||||||||||
Db         23 CATCACCAATACCTTTGAGGTC 2
```

RESULT 596
US-10-310-914A-497207
; Sequence 497207, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 497207
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-497207

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 6.4e+02;
Matches 19; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1064 CCCCTGGCCCCAGCCCCAGCCT 1085
              ||||  ||||||||||||||:
Db          1 CCCCCAGCCCCAGCCCCAGCCU 22
```

RESULT 597
US-10-310-914A-1141590
; Sequence 1141590, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1141590
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1141590

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 6.4e+02;
Matches 19; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```
Qy        828 TGGGGCCGAGGCCACCGGGAAG 849
              :|||||||||||||||  ||||
```

```
Db          1 UGGGGCCGAGGCCACCCCGAAG 22


RESULT 598
US-10-310-914A-161881
; Sequence 161881, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161881
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-161881

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 5.7e+02;
  Matches   16;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3605 CCAACATCTCCCAGCCTCCC 3624
             ||||| :|:|||||||:|||
Db          1 CCAACCUCUCCCAGCCUCCC 20


RESULT 599
US-10-310-914A-914666/c
; Sequence 914666, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 914666
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-914666

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 20;
  Best Local Similarity   95.0%;  Pred. No. 5.7e+02;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        170 CCCGCCGCCCGCGCGCGCGG 189
              |||||||||||| ||||||||
Db         20 CCCGCCGCCCGAGCGCGCGG 1


RESULT 600
US-10-770-726-16895
; Sequence 16895, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16895
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-16895

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 6.1e+02;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2620 AACAGCAACCTCGTCTGCAA 2639
              |||||||||||| ||||||||
Db          1 AACAGCAACCTGGTCTGCAA 20


RESULT 601
US-10-770-726-16910
; Sequence 16910, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16910
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-16910

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 6.1e+02;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2863 ATCAATGCCATTGAACAGGA 2882
              |||||||||||||| |||||
Db          2 ATCAATGCCATTGAGCAGGA 21


RESULT 602
US-10-770-726-16913
; Sequence 16913, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16913
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-16913

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 6.1e+02;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       2866 AATGCCATTGAACAGGACTA 2885
              |||||||||||| ||||||||
Db          1 AATGCCATTGAGCAGGACTA 20


RESULT 603
US-10-770-726-17541
; Sequence 17541, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17541
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-17541

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   65.0%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2925 CCAGCTCATGCTGGACTGTT 2944
              ||| |:||:||:||||:|::
Db          1 CCAACUCAUGCUGGACUGUU 20


RESULT 604
US-10-770-726-18110
; Sequence 18110, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18110
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-18110

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 6.1e+02;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2938 GACTGTTGGCAGAAAGACCG 2957
              |||||||||||||| |||||
Db          1 GACTGTTGGCAGAAGGACCG 20


RESULT 605
US-10-770-726-18401
; Sequence 18401, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18401
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-18401

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 6.1e+02;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        898 TACCTGGCCTTCCAGGACCA 917
              |||||||||||||||||| |
Db          1 TACCTGGCCTTCCAGGACTA 20


RESULT 606
US-10-310-914A-161858
; Sequence 161858, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161858
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-161858

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 22;
  Best Local Similarity   80.0%;  Pred. No. 6.6e+02;
  Matches   16;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3606 CAACATCTCCCAGCCTCCCC 3625
              |||| :|:|||||||:||||
Db          1 CAACCUCUCCCAGCCUCCCC 20


RESULT 607
US-10-310-914A-161859
; Sequence 161859, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161859
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-161859

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 22;
  Best Local Similarity   80.0%;  Pred. No. 6.6e+02;
```

```
  Matches   16;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3606 CAACATCTCCCAGCCTCCCC 3625
              |||| :|:|||||||:|||| 
Db          1 CAACCUCUCCCAGCCUCCCC 20


RESULT 608
US-10-949-720-47/c
; Sequence 47, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 47
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-47

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        499 TGGGAGGAACTGAGCGGC 516
              ||||||||||||||||||
Db         18 TGGGAGGAACTGAGCGGC 1


RESULT 609
US-10-949-720-48/c
; Sequence 48, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 48
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-48

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        692 CCTGCAAGGAGACCTTCA 709
              ||||||||||||||||||
Db         18 CCTGCAAGGAGACCTTCA 1


RESULT 610
US-10-949-720-227/c
; Sequence 227, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 227
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-227

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        499 TGGGAGGAACTGAGCGGC 516
              ||||||||||||||||||
Db         18 TGGGAGGAACTGAGCGGC 1


RESULT 611
US-10-949-720-228/c
; Sequence 228, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
```

```
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 228
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-228

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        692 CCTGCAAGGAGACCTTCA 709
              ||||||||||||||||||
Db         18 CCTGCAAGGAGACCTTCA 1


RESULT 612
US-10-310-914A-153257/c
; Sequence 153257, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153257
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153257

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4039 CCACATCCCCGGACCCCG 4056
              ||||||||||||||||||
Db         18 CCACATCCCCGGACCCCG 1


RESULT 613
US-10-310-914A-153262/c
; Sequence 153262, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153262
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153262

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3358 CCCAGGGACACCGCCTCC 3375
              ||||||||||||||||||
Db         18 CCCAGGGACACCGCCTCC 1


RESULT 614
US-10-310-914A-153275/c
; Sequence 153275, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153275
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153275

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3459 GAGTTGGCAATTTGGAGA 3476
              ||||||||||||||||||
Db         18 GAGTTGGCAATTTGGAGA 1


RESULT 615
US-10-310-914A-153278/c
; Sequence 153278, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153278
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153278

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3827 CCCCAGCTGCTGCCTTCA 3844
              ||||||||||||||||||
Db         18 CCCCAGCTGCTGCCTTCA 1


RESULT 616
US-10-310-914A-153288/c
; Sequence 153288, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
```

```
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153288
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153288

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3508 GGGGAAAATCACCCCCCA 3525
              ||||||||||||||||||
Db         18 GGGGAAAATCACCCCCCA 1


RESULT 617
US-10-310-914A-153289/c
; Sequence 153289, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153289
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153289

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3344 CAGGAACTCCCCACCCCA 3361
              ||||||||||||||||||
Db         18 CAGGAACTCCCCACCCCA 1


RESULT 618
US-11-101-244-159271
; Sequence 159271, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159271
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159271

  Query Match             0.4%;  Score 18;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 5.7e+02;
  Matches   15;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2362 AGCGAGGCCTCCATCATG 2379
              |||||||||:|||:||:|
Db          2 AGCGAGGCCUCCAUCAUG 19


RESULT 619
US-11-101-244-159286
; Sequence 159286, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159286
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159286

  Query Match             0.4%;  Score 18;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 5.7e+02;
  Matches   11;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1570 GACTTCACCTATACCTTT 1587
              |||::||||:|:|||:::
Db          2 GACUUCACCUAUACCUUU 19


RESULT 620
US-11-083-784-159271
; Sequence 159271, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159271
;   LENGTH: 19
```

```
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159271

  Query Match             0.4%;  Score 18;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 5.7e+02;
  Matches   15;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2362 AGCGAGGCCTCCATCATG 2379
              ||||||||:|||:||:|
Db          2 AGCGAGGCCUCCAUCAUG 19


RESULT 621
US-11-083-784-159286
; Sequence 159286, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159286
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159286

  Query Match             0.4%;  Score 18;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 5.7e+02;
  Matches   11;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1570 GACTTCACCTATACCTTT 1587
              |||::||||:|:|||:::
Db          2 GACUUCACCUAUACCUUU 19


RESULT 622
US-10-770-726-17478
; Sequence 17478, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17478
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-17478

  Query Match             0.4%;  Score 18;  DB 1;  Length 21;
  Best Local Similarity   72.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2508 GTTCACAGTCATCCAGCT 2525
              |::|||||:||:|||||:
Db          1 GUUCACAGUCAUCCAGCU 18


RESULT 623
US-10-770-726-17544
; Sequence 17544, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17544
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-17544

  Query Match             0.4%;  Score 18;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 6.7e+02;
  Matches   12;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2929 CTCATGCTGGACTGTTGG 2946
              |:||:||:||||:|::||
Db          2 CUCAUGCUGGACUGUUGG 19


RESULT 624
US-10-310-914A-871069
; Sequence 871069, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 871069
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-871069

  Query Match             0.4%;  Score 18;  DB 1;  Length 22;
  Best Local Similarity   88.9%;  Pred. No. 7.2e+02;
  Matches   16;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1070 GCCCCAGCCCCAGCCTCT 1087
              ||||||||||||||||:|:
Db          5 GCCCCAGCCCCAGCCUCU 22


RESULT 625
US-10-770-726-16893
; Sequence 16893, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
```

```
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16893
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-16893

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 7e+02;
  Matches   15;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2610 CATCCTAGTCAACAGCAACCT 2630
              ||:||: |:|||||||||| :
Db          1 CAUCCUCGUCAACAGCAACUU 21


RESULT 626
US-10-770-726-16904
; Sequence 16904, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16904
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-16904

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2761 AAGTTCACTTCCGCCAGTGAT 2781
              |||||||| || |||||||||
Db          1 AAGTTCACCTCGGCCAGTGAT 21


RESULT 627
US-10-770-726-16911
; Sequence 16911, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16911
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-16911

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 7e+02;
  Matches   14;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2864 TCAATGCCATTGAACAGGACT 2884
              :|||:||||::|| ||||| :
Db          1 UCAAUGCCAUUGAGCAGGAUU 21


RESULT 628
US-10-770-726-17474
; Sequence 17474, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17474
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17474

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2451 CACAGAGTTCATGGAGAACGG 2471
              ||| ||||||||||||| ||
Db          1 CACCGAGTTCATGGAGAATGG 21


RESULT 629
US-10-770-726-17504
; Sequence 17504, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17504
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17504

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2622 CAGCAACCTCGTCTGCAAAGT 2642
              ||||||||| |||||||| ||
Db          1 CAGCAACCTGGTCTGCAAGGT 21


RESULT 630
US-10-770-726-17507
```

```
; Sequence 17507, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17507
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17507

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2625 CAACCTCGTCTGCAAAGTGTC 2645
              |||||| |||||||| |||||
Db          1 CAACCTGGTCTGCAAGGTGTC 21


RESULT 631
US-10-770-726-17531
; Sequence 17531, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17531
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17531

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2854 CAGGACGTGATCAATGCCATT 2874
              ||||| || ||||||||||||
Db          1 CAGGATGTAATCAATGCCATT 21


RESULT 632
US-10-770-726-17537
; Sequence 17537, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17537
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17537

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2871 CATTGAACAGGACTACCGGCT 2891
              |||||| |||||||| |||||
Db          1 CATTGAGCAGGACTATCGGCT 21


RESULT 633
US-10-770-726-18030
; Sequence 18030, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18030
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-18030

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   57.1%;  Pred. No. 7e+02;
  Matches   12;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2141 TCTACATCGACCCCTTCACTT 2161
              :|:|||:||| || ::|||::
Db          1 UCUACAUCGAUCCUUUCACUU 21


RESULT 634
US-10-770-726-18074
; Sequence 18074, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18074
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-18074

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2455 GAGTTCATGGAGAACGGCGCC 2475
              ||||||||||||| ||| ||
Db          1 GAGTTCATGGAGAATGGCTCC 21
```

```
RESULT 635
US-10-770-726-18089
; Sequence 18089, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18089
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-18089

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2760 GAAGTTCACTTCCGCCAGTGA 2780
             ||||||||| || ||||||||
Db          1 GAAGTTCACCTCGGCCAGTGA 21


RESULT 636
US-10-770-726-18458
; Sequence 18458, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18458
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-18458

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2861 TGATCAATGCCATTGAACAGG 2881
             | ||||||||||||| ||||
Db          1 TAATCAATGCCATTGAGCAGG 21


RESULT 637
US-10-770-726-18662
; Sequence 18662, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18662
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-18662

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2871 CATTGAACAGGACTACCGGCT 2891
             |||||| |||||||| |||||
Db          1 CATTGAGCAGGACTATCGGCT 21


RESULT 638
US-10-770-726-18723
; Sequence 18723, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18723
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-18723

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   57.1%;  Pred. No. 7e+02;
  Matches   12;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2141 TCTACATCGACCCCTTCACTT 2161
             :|:|||:||| || ::|||::
Db          1 UCUACAUCGAUCCUUUCACUU 21


RESULT 639
US-10-310-914A-44767/c
; Sequence 44767, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44767
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-44767

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       2907 CTGTCCCACCTCCCTCCACCA 2927
              ||| ||| ||||||||||||||
Db         21 CTGCCCCCCCTCCCTCCACCA 1


RESULT 640
US-10-310-914A-332291
; Sequence 332291, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 332291
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-332291

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 7e+02;
  Matches   18;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1060 CCCGCCCCTGGCCCCAGCCCC 1080
              ||| ||||: ||||||||||||
Db          1 CCCACCCCUAGCCCCAGCCCC 21


RESULT 641
US-10-310-914A-332482
; Sequence 332482, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 332482
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-332482

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 7e+02;
  Matches   18;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1060 CCCGCCCCTGGCCCCAGCCCC 1080
              ||| ||||: ||||||||||||
Db          1 CCCACCCCUAGCCCCAGCCCC 21


RESULT 642
US-10-310-914A-471965
; Sequence 471965, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 471965
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-471965

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 7e+02;
  Matches   16;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        124 CTTGCTGCGCGCCCGCCCGGC 144
              |::||:|||| ||||||| ||
Db          1 CUUGCUGCGCCCCCGCCCCGC 21


RESULT 643
US-10-310-914A-556552
; Sequence 556552, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 556552
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-556552

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 7e+02;
  Matches   18;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1065 CCCTGGCCCCAGCCCCAGCCT 1085
              | | ||||||||||||||||:
Db          1 CUCCGGCCCCAGCCCCAGCCU 21


RESULT 644
US-10-310-914A-1213089/c
; Sequence 1213089, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1213089
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1213089

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3850 AAGGTTTTGAGTTTTGTTTT 3870
```

```
              ||||||||| ||||||||||
Db         21 AAGGTTTTTTTGTTTTGTTTT 1


RESULT 645
US-10-310-914A-1341719/c
; Sequence 1341719, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1341719
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1341719

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        665 GCCTGTCCCTGCCTCGGGCTG 685
              ||||||||||||  ||| ||||
Db         21 GCCTGTCCCTGCTTCGAGCTG 1


RESULT 646
US-10-310-914A-174984
; Sequence 174984, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 174984
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-174984

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 7.5e+02;
  Matches   17;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3521 CCCCAGCCACCTCGGGGAACT 3541
              ||||||||||:|||| | |:
Db          1 CCCCAGCCACCUCGGGCACCU 21


RESULT 647
US-10-310-914A-175001
; Sequence 175001, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 175001
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-175001

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 7.5e+02;
  Matches   17;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3521 CCCCAGCCACCTCGGGGAACT 3541
              ||||||||||:|||| | |:
Db          2 CCCCAGCCACCUCGGGCACCU 22


RESULT 648
US-10-310-914A-371300/c
; Sequence 371300, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 371300
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-371300

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 7.5e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4189 TTTTTGTATAAATAAAAGAAA 4209
              |||||||||||| |||| |||
Db         21 TTTTTGTATAAAAAAAAAAAA 1


RESULT 649
US-10-310-914A-494111/c
; Sequence 494111, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 494111
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-494111

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 7.5e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACTG 1959
              ||||||| |||||||||||  |
```

```
Db         21 CATCACACCCAGACCCAACGG 1


RESULT 650
US-10-310-914A-497206
; Sequence 497206, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 497206
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-497206

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 7.5e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCCCAGCC 1084
              ||||  ||||||||||||||||
Db          1 CCCCCAGCCCCAGCCCCAGCC 21


RESULT 651
US-10-310-914A-549823
; Sequence 549823, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 549823
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-549823

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 7.5e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCCCAGCC 1084
              |||  ||||||||||||||||
Db          1 CCCUCGGCCCCAGCCCCAGCC 21


RESULT 652
US-10-310-914A-765177
; Sequence 765177, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 765177
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-765177

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 7.5e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1059 CCCCGCCCCTGGCCCCAGCCC 1079
              ||||| ||| ||||||||||||
Db          2 CCCCGACCCCGGCCCCAGCCC 22


RESULT 653
US-10-310-914A-1224324
; Sequence 1224324, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1224324
;   LENGTH: 22
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1224324

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   61.9%;  Pred. No. 7.5e+02;
  Matches   13;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3158 TCGCAGCCGCTGGCTTTGGCT 3178
              :||||||  |:|||:::|||:
Db          2 UCGCAGCGCCUGGCUUUGGCU 22


RESULT 654
US-10-310-914A-1224348
; Sequence 1224348, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1224348
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1224348

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 6.6e+02;
  Matches   16;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1852 GAGCTGCGGGGGCTGAAGC 1870
              ||||:|| |||||:|||||
Db          1 GAGCUGCUGGGGCUGAAGC 19
```

```
RESULT 655
US-10-310-914A-1294342
; Sequence 1294342, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1294342
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1294342

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3336 CTGACCTGCAGGAACTCCC 3354
              |:|| |:|||||||:|||
Db          1 CUGAGCUGCAGGAACUCCC 19


RESULT 656
US-11-101-244-153337
; Sequence 153337, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 153337
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-153337

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAACAG 2624
              ||||||:||: |:||||||
Db          1 GCAACAUCCUCGUCAACAG 19


RESULT 657
US-11-101-244-153343
; Sequence 153343, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 153343
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-153343

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||: |:|:||||
Db          1 ACAGCAACCUGGUCUGCAA 19


RESULT 658
US-11-101-244-153383
; Sequence 153383, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 153383
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-153383

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 6.6e+02;
  Matches   12;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2636 GCAAAGTGTCTGACTTTGG 2654
              |||| |:|:|:|||:::||
Db          1 GCAAGGUGUCUGACUUUGG 19


RESULT 659
US-11-101-244-153389
; Sequence 153389, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
```

```
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 153389
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-153389

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 6.6e+02;
  Matches   11;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2633 TCTGCAAAGTGTCTGACTT 2651
              :|:|||| |:|:|:|||:: 
Db          1 UCUGCAAGGUGUCUGACUU 19


RESULT 660
US-11-101-244-158363
; Sequence 158363, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158363
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158363

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 6.6e+02;
  Matches   12;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2636 GCAAAGTGTCTGACTTTGG 2654
              |||| |:|:|:|||:::|| 
Db          1 GCAAGGUGUCUGACUUUGG 19


RESULT 661
US-11-101-244-158571
; Sequence 158571, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158571
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158571

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 6.6e+02;
  Matches   11;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2633 TCTGCAAAGTGTCTGACTT 2651
              :|:||||||:|:|:|| :: 
Db          1 UCUGCAAAGUGUCUGAUUU 19


RESULT 662
US-11-101-244-158800
; Sequence 158800, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158800
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158800

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2361 GAGCGAGGCCTCCATCATG 2379
              ||||||||| :|||:||:| 
Db          1 GAGCGAGGCGUCCAUCAUG 19


RESULT 663
US-11-101-244-158823
; Sequence 158823, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
```

```
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158823
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158823

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||: |:|:|||| 
Db          1 ACAGCAACCUGGUCUGCAA 19


RESULT 664
US-11-101-244-158867
; Sequence 158867, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158867
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158867

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 6.6e+02;
  Matches   11;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2633 TCTGCAAAGTGTCTGACTT 2651
              :|:|||| |:|:|:|||:: 
Db          1 UCUGCAAGGUGUCUGACUU 19


RESULT 665
US-11-101-244-158987
; Sequence 158987, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158987
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158987

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2361 GAGCGAGGCCTCCATCATG 2379
              |||||| |||:|||:||:| 
Db          1 GAGCGAAGCCUCCAUCAUG 19


RESULT 666
US-11-101-244-159004
; Sequence 159004, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159004
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159004

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.6e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :||| |||::||:|||||| 
Db          1 UCACCGAGUUCAUGGAGAA 19


RESULT 667
US-11-101-244-159040
; Sequence 159040, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
```

```
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159040
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159040

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAACAG 2624
              ||||||:||: |:||||||
Db          1 GCAACAUCCUCGUCAACAG 19


RESULT 668
US-11-101-244-159054
; Sequence 159054, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159054
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159054

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||: |:|:||||
Db          1 ACAGCAACCUGGUCUGCAA 19


RESULT 669
US-11-101-244-159086
; Sequence 159086, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159086
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159086

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2361 GAGCGAGGCCTCCATCATG 2379
              |||||| |||:|||:||:|
Db          1 GAGCGAAGCCUCCAUCAUG 19


RESULT 670
US-11-101-244-159100
; Sequence 159100, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159100
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159100

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.6e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :||| |||::||:||||||
Db          1 UCACCGAGUUCAUGGAGAA 19


RESULT 671
US-11-101-244-159129
; Sequence 159129, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
```

```
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159129
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159129

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAACAG 2624
              ||||||:||: |:||||||
Db          1 GCAACAUCCUCGUCAACAG 19


RESULT 672
US-11-101-244-159138
; Sequence 159138, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159138
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159138

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||: |:|:||||
Db          1 ACAGCAACCUGGUCUGCAA 19


RESULT 673
US-11-101-244-159213
; Sequence 159213, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159213
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159213

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAACAG 2624
              ||||||:||: |:||||||
Db          1 GCAACAUCCUUGUCAACAG 19


RESULT 674
US-11-101-244-159231
; Sequence 159231, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159231
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159231

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||: |:|:||||
Db          1 ACAGCAACCUGGUCUGCAA 19


RESULT 675
US-11-101-244-159248
; Sequence 159248, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
```

```
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159248
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159248

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.6e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2602 GCTCGCAACATCCTAGTCA 2620
              ||:|||||||:||: |:||
Db          1 GCUCGCAACAUCCUUGUCA 19


RESULT 676
US-11-101-244-159274
; Sequence 159274, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159274
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159274

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.6e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2624 GCAACCTCGTCTGCAAAGT 2642
              ||||||: |:|:||||||:
Db          1 GCAACCUGGUCUGCAAAGU 19


RESULT 677
US-11-101-244-159309
; Sequence 159309, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159309
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159309

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 6.6e+02;
  Matches   13;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||:|| |||::||||:|:|
Db          1 CGUCCGGACUUCACCUAUA 19


RESULT 678
US-11-101-244-159364
; Sequence 159364, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159364
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159364

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 6.6e+02;
  Matches   13;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        546 CTACGAAGTGTGTGACGTG 564
              |:|||||:|:|:|| |:|
Db          1 CUACGAAGUGUGUGAAGUG 19


RESULT 679
US-11-101-244-159371
; Sequence 159371, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
```

```
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159371
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159371

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 6.6e+02;
  Matches   13;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1565 GTCCTGACTTCACCTATAC 1583
              |:|| |||::||||:|:||
Db          1 GUCCGGACUUCACCUAUAC 19


RESULT 680
US-11-101-244-1212014
; Sequence 1212014, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1212014
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1212014

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 6.6e+02;
  Matches   13;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        941 CCCTGCACCTCTTCTACAA 959
              |||:| |||:|::|:||||
Db          1 CCCUGGACCUCUUCUACAA 19


RESULT 681
US-11-083-784-153337
; Sequence 153337, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 153337
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-153337

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAACAG 2624
              ||||||:||: |:||||||
Db          1 GCAACAUCCUCGUCAACAG 19


RESULT 682
US-11-083-784-153343
; Sequence 153343, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 153343
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-153343

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||: |:|:||||
Db          1 ACAGCAACCUGGUCUGCAA 19


RESULT 683
US-11-083-784-153383
; Sequence 153383, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
```

```
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 153383
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-153383

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 6.6e+02;
  Matches   12;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2636 GCAAAGTGTCTGACTTTGG 2654
              |||| |:|:|:|||:::||
Db          1 GCAAGGUGUCUGACUUUGG 19


RESULT 684
US-11-083-784-153389
; Sequence 153389, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 153389
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-153389

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 6.6e+02;
  Matches   11;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2633 TCTGCAAAGTGTCTGACTT 2651
              :|:|||| |:|:|:|||::
Db          1 UCUGCAAGGUGUCUGACUU 19


RESULT 685
US-11-083-784-158363
; Sequence 158363, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158363
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158363

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 6.6e+02;
  Matches   12;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2636 GCAAAGTGTCTGACTTTGG 2654
              |||| |:|:|:|||:::||
Db          1 GCAAGGUGUCUGACUUUGG 19


RESULT 686
US-11-083-784-158571
; Sequence 158571, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158571
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158571

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 6.6e+02;
  Matches   11;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2633 TCTGCAAAGTGTCTGACTT 2651
              :|:||||||:|:|:|| ::
Db          1 UCUGCAAAGUGUCUGAUUU 19


RESULT 687
US-11-083-784-158800
; Sequence 158800, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
```

```
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158800
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158800

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2361 GAGCGAGGCCTCCATCATG 2379
              ||||||||| :|||:||:|
Db          1 GAGCGAGGCGUCCAUCAUG 19


RESULT 688
US-11-083-784-158823
; Sequence 158823, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158823
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158823

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||: |:|:||||
Db          1 ACAGCAACCUGGUCUGCAA 19


RESULT 689
US-11-083-784-158867
; Sequence 158867, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158867
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158867

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 6.6e+02;
  Matches   11;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2633 TCTGCAAAGTGTCTGACTT 2651
              :|:|||| |:|:|:|||::
Db          1 UCUGCAAGGUGUCUGACUU 19


RESULT 690
US-11-083-784-158987
; Sequence 158987, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158987
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158987

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2361 GAGCGAGGCCTCCATCATG 2379
              |||||| |||:|||:||:|
Db          1 GAGCGAAGCCUCCAUCAUG 19


RESULT 691
US-11-083-784-159004
; Sequence 159004, Application US/11083784
```

; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159004
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159004

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.6e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2450 TCACAGAGTTCATGGAGAA 2468
:||| |||:::||:||||||
Db 1 UCACCGAGUUCAUGGAGAA 19

RESULT 692
US-11-083-784-159040
; Sequence 159040, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159040
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159040

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2606 GCAACATCCTAGTCAACAG 2624
||||||:||: |:||||||
Db 1 GCAACAUCCUCGUCAACAG 19

RESULT 693
US-11-083-784-159054
; Sequence 159054, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159054
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159054

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2621 ACAGCAACCTCGTCTGCAA 2639
||||||||:|:|:||||
Db 1 ACAGCAACCUGGUCUGCAA 19

RESULT 694
US-11-083-784-159086
; Sequence 159086, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159086
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159086

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2361 GAGCGAGGCCTCCATCATG 2379
|||||| |||:|||:||:|

```
Db          1 GAGCGAAGCCUCCAUCAUG 19


RESULT 695
US-11-083-784-159100
; Sequence 159100, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159100
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159100

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.6e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :||| |||::||:||||||
Db          1 UCACCGAGUUCAUGGAGAA 19


RESULT 696
US-11-083-784-159129
; Sequence 159129, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159129
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159129

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAACAG 2624
              ||||||:||: |:||||||
Db          1 GCAACAUCCUCGUCAACAG 19


RESULT 697
US-11-083-784-159138
; Sequence 159138, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159138
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159138

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||: |:|:||||
Db          1 ACAGCAACCUGGUCUGCAA 19


RESULT 698
US-11-083-784-159213
; Sequence 159213, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159213
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159213
```

```
  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAACAG 2624
              ||||||:||: |:||||||
Db          1 GCAACAUCCUUGUCAACAG 19


RESULT 699
US-11-083-784-159231
; Sequence 159231, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159231
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159231

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 6.6e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||: |:|:||||
Db          1 ACAGCAACCUGGUCUGCAA 19


RESULT 700
US-11-083-784-159248
; Sequence 159248, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159248
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159248

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.6e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2602 GCTCGCAACATCCTAGTCA 2620
              ||:|||||||:||: |:||
Db          1 GCUCGCAACAUCCUUGUCA 19


RESULT 701
US-11-083-784-159274
; Sequence 159274, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159274
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159274

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 6.6e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2624 GCAACCTCGTCTGCAAAGT 2642
              ||||||: |:|:|||||||:
Db          1 GCAACCUGGUCUGCAAAGU 19


RESULT 702
US-11-083-784-159309
; Sequence 159309, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
```

; SEQ ID NO 159309
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159309

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1564 CGTCCTGACTTCACCTATA 1582
||:|| |||::||||:|:|
Db 1 CGUCCGGACUUCACCUAUA 19

RESULT 703
US-11-083-784-159364
; Sequence 159364, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159364
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159364

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 546 CTACGAAGTGTGTGACGTG 564
|:||||||:|:|:|| |:|
Db 1 CUACGAAGUGUGUGAAGUG 19

RESULT 704
US-11-083-784-159371
; Sequence 159371, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159371
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159371

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1565 GTCCTGACTTCACCTATAC 1583
|:|| |||::||||:|:||
Db 1 GUCCGGACUUCACCUAUAC 19

RESULT 705
US-11-083-784-1212014
; Sequence 1212014, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1212014
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1212014

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 941 CCCTGCACCTCTTCTACAA 959
|||:| |||:|::|:||||
Db 1 CCCUGGACCUCUUCUACAA 19

RESULT 706
US-10-297-056-41
; Sequence 41, Application US/10297056
; Publication No. US20060030045A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Isis Pharmaceuticals, Inc.
; TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
; FILE REFERENCE: RTSP-0150
; CURRENT APPLICATION NUMBER: US/10/297,056
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 09/593,711
; PRIOR FILING DATE: 2000-06-13
; NUMBER OF SEQ ID NOS: 244
; SEQ ID NO 41

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-297-056-41

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 7.1e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        214 GCCGCCGCCCGGTGCCCCG 232
              ||||||||||||| ||||||
Db          1 GCCGCCGCCCGGCGCCCCG 19


RESULT 707
US-10-310-914A-52199/c
; Sequence 52199, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 52199
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-52199

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 7.1e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        138 GCCCGGCGCGGCCACTGCC 156
              ||||||||| |||||||||
Db         20 GCCCGGCGCCGCCACTGCC 2


RESULT 708
US-10-310-914A-173994/c
; Sequence 173994, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 173994
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-173994

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 7.1e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1069 GGCCCCAGCCCCAGCCTCT 1087
              | ||||||||||||||||||
Db         19 GCCCCCAGCCCCAGCCTCT 1


RESULT 709
US-10-310-914A-173995/c
; Sequence 173995, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 173995
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-173995

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 7.1e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1069 GGCCCCAGCCCCAGCCTCT 1087
              | ||||||||||||||||||
Db         19 GCCCCCAGCCCCAGCCTCT 1


RESULT 710
US-10-310-914A-409848/c
; Sequence 409848, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 409848
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-409848

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 7.1e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1069 GGCCCCAGCCCCAGCCTCT 1087
              |||||||||||| ||||||
Db         19 GGCCCCAGCCCCTGCCTCT 1


RESULT 711
US-10-310-914A-1224349
; Sequence 1224349, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
```

; SEQ ID NO 1224349
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1224349

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 7.1e+02;
Matches 16; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1852 GAGCTGCGGGGGCTGAAGC 1870
||||:|| |||||:|||||
Db 1 GAGCUGCUGGGGCUGAAGC 19

RESULT 712
US-10-770-726-17471
; Sequence 17471, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17471
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17471

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 7.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2450 TCACAGAGTTCATGGAGAA 2468
|||| ||||||||||||||
Db 3 TCACCGAGTTCATGGAGAA 21

RESULT 713
US-10-770-726-17472
; Sequence 17472, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17472
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-17472

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 7.7e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2450 TCACAGAGTTCATGGAGAA 2468
:||| |||::||:||||||
Db 1 UCACCGAGUUCAUGGAGAA 19

RESULT 714
US-10-770-726-17496
; Sequence 17496, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17496
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-17496

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 7.7e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2609 ACATCCTAGTCAACAGCAA 2627
|||:||: |:||||||||
Db 1 ACAUCCUCGUCAACAGCAA 19

RESULT 715
US-10-770-726-17499
; Sequence 17499, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17499
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-17499

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 7.7e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2612 TCCTAGTCAACAGCAACCT 2630
:||: |:||||||||||:
Db 1 UCCUCGUCAACAGCAACCU 19

RESULT 716
US-10-770-726-17502
; Sequence 17502, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)

```
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17502
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-17502

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 7.7e+02;
  Matches   15;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2621 ACAGCAACCTCGTCTGCAA 2639
              |||||||||: |:|:||||
Db          1 ACAGCAACCUGGUCUGCAA 19


RESULT 717
US-10-770-726-17535
; Sequence 17535, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17535
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-17535

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 7.7e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2867 ATGCCATTGAACAGGACTA 2885
              |:||||::|| |||||||:|
Db          1 AUGCCAUUGAGCAGGACUA 19


RESULT 718
US-10-770-726-18459
; Sequence 18459, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18459
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-18459

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 7.7e+02;
  Matches   14;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2863 ATCAATGCCATTGAACAGG 2881
              |:|||:||||::|| ||||
Db          1 AUCAAUGCCAUUGAGCAGG 19


RESULT 719
US-10-310-914A-145348
; Sequence 145348, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 145348
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-145348

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 7.7e+02;
  Matches   17;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         99 GGAGGGACCCCAACTCCAG 117
              |||||||||||||:||||
Db          1 GGAGGGACCCCAAGUCCAG 19


RESULT 720
US-10-310-914A-176222/c
; Sequence 176222, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 176222
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-176222

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 7.7e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4089 GTGTGGGGTGAGGTAGTGA 4107
              |||||||||||||| |||||
Db         19 GTGTGGGGTGAGGCAGTGA 1


RESULT 721
US-10-310-914A-589336/c
; Sequence 589336, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
```

```
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 589336
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-589336

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 7.7e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        742 GCCACGGCCCTCACGCCAG 760
              ||||||||||||||| ||||
Db         20 GCCACGGCCCTCACACCAG 2


RESULT 722
US-10-310-914A-153231/c
; Sequence 153231, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153231
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-153231

  Query Match             0.4%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 6.6e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3891 GTTCCCTTTTTGTTTCT 3907
              |||||||||||||||||
Db         17 GTTCCCTTTTTGTTTCT 1


RESULT 723
US-10-310-914A-255656
; Sequence 255656, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 255656
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-255656

  Query Match             0.4%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 6.6e+02;
  Matches   16;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3014 ACCCCGCCAGCCTCAAA 3030
              |||||||||||||:||||
Db          1 ACCCCGCCAGCCUCAAA 17


RESULT 724
US-10-310-914A-687613
; Sequence 687613, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 687613
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-687613

  Query Match             0.4%;  Score 17;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 6.6e+02;
  Matches   16;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1847 GGGCAGAGCTGCGGGGG 1863
              ||||||||||:|||||||
Db          2 GGGCAGAGCUGCGGGGG 18


RESULT 725
US-10-949-720-60/c
; Sequence 60, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
;  APPLICANT: Krasnoperov, Valery
;  APPLICANT:  Zozulya, Sergey
;  APPLICANT:  Kertesz, Nathalie
;  APPLICANT:  Reddy, Ramachandra
;  APPLICANT:  Gill, Parkash
;  TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
;  TITLE OF INVENTION:  ANGIOGENESIS AND TUMOR GROWTH
;  FILE REFERENCE: VASG-P02-002
;  CURRENT APPLICATION NUMBER: US/10/949,720
;  CURRENT FILING DATE:  2004-09-23
;  PRIOR APPLICATION NUMBER: US 60/454,432
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/454,300
;  PRIOR FILING DATE: 2003-03-12
;  PRIOR APPLICATION NUMBER: US 10/800,350
;  PRIOR FILING DATE: 2004-03-12
;  NUMBER OF SEQ ID NOS: 425
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 60
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-949-720-60

  Query Match             0.4%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 7.2e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AACTGGATGAGAGCGAG 1971
              |||||||||||||||||
Db         19 AACTGGATGAGAGCGAG 3
```

```
RESULT 726
US-11-101-244-4697
; Sequence 4697, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 4697
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-4697

  Query Match             0.4%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 7.2e+02;
  Matches   13;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        995 TCCCGGAGACTGTGCCT 1011
              :|||||||||:|:|||:
Db          1 UCCCGGAGACUGUGCCU 17


RESULT 727
US-11-083-784-4697
; Sequence 4697, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 4697
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-4697

  Query Match             0.4%;  Score 17;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 7.2e+02;
  Matches   13;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        995 TCCCGGAGACTGTGCCT 1011
              :|||||||||:|:|||:
Db          1 UCCCGGAGACUGUGCCU 17


RESULT 728
US-10-750-185-12781/c
; Sequence 12781, Application US/10750185
; Publication No. US20050260603A1
; GENERAL INFORMATION:
;  APPLICANT: MMI GENOMICS, INC.
;  APPLICANT:  DeNISE, Sue K.
;  APPLICANT:  KERR, Richard
;  APPLICANT:  ROSENFELD, David
;  APPLICANT:  HOLM, Tom
;  APPLICANT:  BATES, Stephen
;  APPLICANT:  FANTIN, Dennis
;  TITLE OF INVENTION: COMPOSITIONS FOR INFERRING BOVINE TRAITS
;  FILE REFERENCE: MMI1100-2
;  CURRENT APPLICATION NUMBER: US/10/750,185
;  CURRENT FILING DATE:  2003-12-31
;  PRIOR APPLICATION NUMBER: US 60/437,482
;  PRIOR FILING DATE: 2002-12-31
;  NUMBER OF SEQ ID NOS: 64922
;  SOFTWARE: PatentIN version 3.1
; SEQ ID NO 12781
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Reverse Primer
US-10-750-185-12781

  Query Match             0.4%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        497 AGTGGGAGGAACTGAGC 513
              |||||||||||||||||
Db         19 AGTGGGAGGAACTGAGC 3


RESULT 729
US-10-750-623-12781/c
; Sequence 12781, Application US/10750623
; Publication No. US20050287531A1
; GENERAL INFORMATION:
;  APPLICANT: MMI GENOMICS, INC.
;  APPLICANT:  DeNISE, Sue K.
;  APPLICANT:  KERR, Richard
;  APPLICANT:  ROSENFELD, David
;  APPLICANT:  HOLM, Tom
;  APPLICANT:  BATES, Stephen
;  APPLICANT:  FANTIN, Dennis
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR INFERRING BOVINE TRAITS
;  FILE REFERENCE: MMI1100-1
;  CURRENT APPLICATION NUMBER: US/10/750,623
;  CURRENT FILING DATE:  2003-12-31
;  PRIOR APPLICATION NUMBER: US 60/437,482
;  PRIOR FILING DATE: 2002-12-31
;  NUMBER OF SEQ ID NOS: 64922
;  SOFTWARE: PatentIN version 3.1
; SEQ ID NO 12781
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Reverse Primer
US-10-750-623-12781

  Query Match             0.4%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        497 AGTGGGAGGAACTGAGC 513
              |||||||||||||||||
```

```
Db         19 AGTGGGAGGAACTGAGC 3


RESULT 730
US-10-770-726-17261
; Sequence 17261, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17261
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17261

  Query Match             0.4%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 8.4e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        892 GGCTTCTACCTGGCCTT 908
              |||||||||||||||||
Db          5 GGCTTCTACCTGGCCTT 21


RESULT 731
US-10-770-726-17262
; Sequence 17262, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17262
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-17262

  Query Match             0.4%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   64.7%;  Pred. No. 8.4e+02;
  Matches   11;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        892 GGCTTCTACCTGGCCTT 908
              |||::|:|||:||||::
Db          3 GGCUUCUACCUGGCCUU 19


RESULT 732
US-10-310-914A-746199
; Sequence 746199, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 746199
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-746199

  Query Match             0.4%;  Score 17;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 8.4e+02;
  Matches   15;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2966 GGCCCCGCTTCCCCCAG 2982
              ||||||||::|||||||
Db          1 GGCCCCGCUUCCCCCAG 17


RESULT 733
US-10-831-286A-34263
; Sequence 34263, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
;  APPLICANT: ZENG, QIANDONG
;  APPLICANT:  CHATELLIER, SONIA
;  APPLICANT:  MOIR, DONALD T.
;  APPLICANT:  LACROIX, BRUNA
;  APPLICANT:  CHILDRESS, DARRELL
;  TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
;  FILE REFERENCE: 032796-174.001
;  CURRENT APPLICATION NUMBER: US/10/831,286A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/464,955
;  PRIOR FILING DATE: 2003-04-24
;  NUMBER OF SEQ ID NOS: 48788
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34263
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Veillonella atypica
US-10-831-286A-34263

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        449 TGGAAACTGCTGATCTGAAG 468
              ||||||||||||||||  ||
Db          1 TGGAAACTGCTGATCTAGAG 20


RESULT 734
US-10-310-914A-103507
; Sequence 103507, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 103507
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-103507

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
```

```
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1061 CCGCCCCTGGCCCCAGCCCC 1080
              ||||||| |||||| |||||
Db          1 CCGCCCCGGGCCCCCGCCCC 20


RESULT 735
US-10-310-914A-183395/c
; Sequence 183395, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 183395
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-183395

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3702 GGGGGCTGTCCCAGGGGGCA 3721
              |||||||| ||| |||||||
Db         20 GGGGGCTGCCCCGGGGGGCA 1


RESULT 736
US-10-310-914A-231085
; Sequence 231085, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 231085
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-231085

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   15.0%;  Pred. No. 8.1e+02;
  Matches    3;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3900 TTGTTTCTTCGTTTTGTTTT 3919
              ::|::: :: |::::|::::
Db          1 UUGUUUGUUUGUUUUGUUUU 20


RESULT 737
US-10-310-914A-231831
; Sequence 231831, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 231831
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-231831

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 8.1e+02;
  Matches   15;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3824 CTCCCCCAGCTGCTGCCTTC 3843
              |:|||||||:|| |||: |
Db          1 CUCCCCCAGCUGCAGCCUCC 20


RESULT 738
US-10-310-914A-243576/c
; Sequence 243576, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 243576
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-243576

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1061 CCGCCCCTGGCCCCAGCCCC 1080
              |||||||||||||  ||||
Db         20 CCGCCCCTGGCCCCGCCCCC 1


RESULT 739
US-10-310-914A-244194
; Sequence 244194, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 244194
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-244194

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 8.1e+02;
```

```
  Matches   15;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1330 CCCTGCACCACCCCTCCTTC 1349
              |||:||||| ||||:||: |
Db          1 CCCUGCACCUCCCCUCCUCC 20


RESULT 740
US-10-310-914A-268244
; Sequence 268244, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 268244
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-268244

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   15.0%;  Pred. No. 8.1e+02;
  Matches    3;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGT 3916
              :::::|::: :: |::::|:
Db          1 UUUUUGUUUGUUUGUUUUGU 20


RESULT 741
US-10-310-914A-310780/c
; Sequence 310780, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 310780
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-310780

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGT 3916
              |||||||||  || |||||||
Db         20 TTTTTGTTTGTTTGTTTTGT 1


RESULT 742
US-10-310-914A-332290
; Sequence 332290, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 332290
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-332290

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 8.1e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1060 CCCGCCCCTGGCCCCAGCCC 1079
              ||| ||||: ||||||||||
Db          1 CCCACCCCUAGCCCCAGCCC 20


RESULT 743
US-10-310-914A-332481
; Sequence 332481, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 332481
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-332481

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 8.1e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1060 CCCGCCCCTGGCCCCAGCCC 1079
              ||| ||||: ||||||||||
Db          1 CCCACCCCUAGCCCCAGCCC 20


RESULT 744
US-10-310-914A-359152
; Sequence 359152, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 359152
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-359152

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   15.0%;  Pred. No. 8.1e+02;
  Matches    3;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       3900 TTGTTTCTTCGTTTTGTTTT 3919
              ::|::: :: |::::|::::
Db          1 UUGUUUGUUUGUUUUGUUUU 20


RESULT 745
US-10-310-914A-409640/c
; Sequence 409640, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 409640
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-409640

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1726 AGCCTGGCCTGGGCTGTTCC 1745
              |||||||||||| |||| ||
Db         20 AGCCTGGCCTGGTCTGTGCC 1


RESULT 746
US-10-310-914A-436758/c
; Sequence 436758, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 436758
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-436758

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3404 CAGAGGCCCCCAGCCCTGTG 3423
              | |||||||||||||| |||
Db         20 CCGAGGCCCCCAGCCCAGTG 1


RESULT 747
US-10-310-914A-478404
; Sequence 478404, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 478404
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-478404

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   15.0%;  Pred. No. 8.1e+02;
  Matches    3;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3900 TTGTTTCTTCGTTTTGTTTT 3919
              ::|::: :: |::::|::::
Db          1 UUGUUUGUUUGUUUUGUUUU 20


RESULT 748
US-10-310-914A-543126/c
; Sequence 543126, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 543126
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-543126

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3852 GGTTTTTGAGTTTTGTTTTT 3871
              | |||||| ||||||||||||
Db         20 GTTTTTTGGGTTTTGTTTTT 1


RESULT 749
US-10-310-914A-549822
; Sequence 549822, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 549822
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-549822

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1064 CCCCTGGCCCCAGCCCCAGC 1083
              |||  ||||||||||||||||
Db          1 CCCUCGGCCCCAGCCCCAGC 20


RESULT 750
US-10-310-914A-628964/c
; Sequence 628964, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 628964
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-628964

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1851 AGAGCTGCGGGGGCTGAAGC 1870
              |||||||  ||||||||||||
Db         20 AGAGCTGATGGGGCTGAAGC 1


RESULT 751
US-10-310-914A-657369
; Sequence 657369, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 657369
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-657369

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 8.1e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4039 CCACATCCCCGGACCCCGCC 4058
              |||| :||||||||||| |||
Db          1 CCACGUCCCCGGACCCUGCC 20


RESULT 752
US-10-310-914A-763042
; Sequence 763042, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 763042
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-763042

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         58 CGGCTCAGCCCCCGCCACCC 77
              |||| | ||||||||||||||
Db          1 CGGCCCGGCCCCCGCCACCC 20


RESULT 753
US-10-310-914A-824483
; Sequence 824483, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 824483
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-824483

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 8.1e+02;
  Matches   15;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2366 AGGCCTCCATCATGGGCCAG 2385
              |||||:|||:| : ||||||
Db          1 AGGCCUCCAUCCUAGGCCAG 20


RESULT 754
US-10-310-914A-834462
; Sequence 834462, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 834462
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-834462

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   15.0%;  Pred. No. 8.1e+02;
  Matches    3;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3900 TTGTTTCTTCGTTTTGTTTT 3919
```

```
              ::|::: :: |::::|::::
Db          1 UUGUUUGUUUGUUUUGUUUU 20


RESULT 755
US-10-310-914A-846714/c
; Sequence 846714, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 846714
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-846714

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1067 CTGGCCCCAGCCCCAGCCTC 1086
              |||| ||||||| |||||||
Db         20 CTGGGCCCAGCCGCAGCCTC 1


RESULT 756
US-10-310-914A-930332
; Sequence 930332, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 930332
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-930332

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   15.0%;  Pred. No. 8.1e+02;
  Matches    3;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3900 TTGTTTCTTCGTTTTGTTTT 3919
              ::|::: :: |::::|::::
Db          1 UUGUUUGUUUGUUUUGUUUU 20


RESULT 757
US-10-310-914A-1024937
; Sequence 1024937, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1024937
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1024937

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   70.0%;  Pred. No. 8.1e+02;
  Matches   14;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3775 TGCTGCTGTCACCACCAAAC 3794
              :||:||:|:||||| ||| |
Db          1 UGCUGCUGUCACCAUCAACC 20


RESULT 758
US-10-310-914A-1025973/c
; Sequence 1025973, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1025973
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1025973

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCTTAA 3879
              | |||||||||||| ||||
Db         20 ATTTTTGTTTTTGGTTTTAA 1


RESULT 759
US-10-310-914A-1125430
; Sequence 1125430, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1125430
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1125430

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   15.0%;  Pred. No. 8.1e+02;
  Matches    3;  Conservative   15;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3900 TTGTTTCTTCGTTTTGTTTT 3919
              ::|::: :: |::::|::::
```

```
Db          1 UUGUUUGUUUGUUUUGUUUU 20


RESULT 760
US-10-310-914A-1209003/c
; Sequence 1209003, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1209003
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1209003

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1066 CCTGGCCCCAGCCCCAGCCT 1085
              ||| |||||||||||  ||||
Db         20 CCTTGCCCCAGCCCCTGCCT 1


RESULT 761
US-10-310-914A-1230235
; Sequence 1230235, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1230235
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1230235

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 8.1e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2886 CCGGCTGCCCCCGCCCCCAG 2905
              |||||:||||||  ||||||
Db          1 CCGGCUGCCCCCCGCCCCAG 20


RESULT 762
US-10-310-914A-1290463
; Sequence 1290463, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1290463
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1290463

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 8.1e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1061 CCGCCCCTGGCCCCAGCCCC 1080
              | |||||:||||||||| ||
Db          1 CAGCCCCUGGCCCCAGCGCC 20


RESULT 763
US-10-310-914A-1290469
; Sequence 1290469, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1290469
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1290469

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 8.1e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1060 CCCGCCCCTGGCCCCAGCCC 1079
              || |||||:|||||||||| |
Db          1 CCAGCCCCUGGCCCCAGCGC 20


RESULT 764
US-10-310-914A-1332047/c
; Sequence 1332047, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1332047
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1332047

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3702 GGGGGCTGTCCCAGGGGGCA 3721
              |||||||| ||| |||||||
Db         20 GGGGGCTGCCCCGGGGGGCA 1
```

```
RESULT 765
US-10-310-914A-1341732/c
; Sequence 1341732, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1341732
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1341732

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        667 CTGTCCCTGCCTCGGGCTGG 686
              |||||||||| ||| |||||
Db         20 CTGTCCCTGCTTCGAGCTGG 1


RESULT 766
US-11-043-752-2628/c
; Sequence 2628, Application US/11043752
; Publication No. US20060014165A1
; GENERAL INFORMATION:
;  APPLICANT: Hakonarson,  Hakon
;  APPLICANT:  Gurney, Mark E.
;  APPLICANT:  Halapi, Eva
;  TITLE OF INVENTION: METHODS OF DIAGNOSIS AND TREATMENT FOR
;  TITLE OF INVENTION:  ASTHMA AND OTHER RESPIRATORY DISEASES BASED ON HAPLOTYPE
;  TITLE OF INVENTION:  ASSOCIATION
;  FILE REFERENCE: 2345.2044-003
;  CURRENT APPLICATION NUMBER: US/11/043,752
;  CURRENT FILING DATE:  2005-01-26
;  PRIOR APPLICATION NUMBER: PCT/US04/022446
;  PRIOR FILING DATE: 2004-07-14
;  PRIOR APPLICATION NUMBER: 60/487,072
;  PRIOR FILING DATE: 2003-07-14
;  PRIOR APPLICATION NUMBER: 60/559,611
;  PRIOR FILING DATE: 2004-04-05
;  NUMBER OF SEQ ID NOS: 4326
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2628
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-11-043-752-2628

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 8.1e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2065 AGGAAGCAGAGCAATGGGAG 2084
              |||||| ||||||| |||||
Db         20 AGGAAGGAGAGCAAAGGGAG 1


RESULT 767
US-10-770-726-16898
; Sequence 16898, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16898
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-16898

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2626 AACCTCGTCTGCAAAGTGTC 2645
              ||||| |||||||| |||||
Db          1 AACCTGGTCTGCAAGGTGTC 20


RESULT 768
US-10-770-726-17246
; Sequence 17246, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17246
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-17246

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        696 CAAGGAGACCTTCACCGTCT 715
              |||||||||||||| | |||
Db          1 CAAGGAGACCTTCAACCTCT 20


RESULT 769
US-10-770-726-17508
; Sequence 17508, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17508
;   LENGTH: 21
;   TYPE: RNA
```

```
;   ORGANISM: RNAi
US-10-770-726-17508

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   60.0%;  Pred. No. 8.8e+02;
  Matches   12;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2627 ACCTCGTCTGCAAAGTGTCT 2646
              |||: |:|:|||| |:|:|:
Db          1 ACCUGGUCUGCAAGGUGUCU 20


RESULT 770
US-10-770-726-18041
; Sequence 18041, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18041
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-18041

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2248 GAGTTTGGCGAGGTGTGCCG 2267
              |||||||||||||| ||| |
Db          1 GAGTTTGGCGAGGTCTGCAG 20


RESULT 771
US-10-770-726-18090
; Sequence 18090, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18090
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-770-726-18090

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   65.0%;  Pred. No. 8.8e+02;
  Matches   13;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2762 AGTTCACTTCCGCCAGTGAT 2781
              ||::||| :| |||||:||:
Db          1 AGUUCACCUCGGCCAGUGAU 20


RESULT 772
US-10-770-726-18104
; Sequence 18104, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18104
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-18104

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2857 GACGTGATCAATGCCATTGA 2876
              || || ||||||||||||||
Db          1 GATGTAATCAATGCCATTGA 20


RESULT 773
US-10-770-726-18107
; Sequence 18107, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18107
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-18107

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2875 GAACAGGACTACCGGCTGCC 2894
              || |||||||| ||||||||
Db          1 GAGCAGGACTATCGGCTGCC 20


RESULT 774
US-10-770-726-26045
; Sequence 26045, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM101079 (031896-010000)
;  CURRENT APPLICATION NUMBER: US/10/770,726
;  CURRENT FILING DATE:  2004-02-04
;  NUMBER OF SEQ ID NOS: 48640
```

```
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26045
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-770-726-26045

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1787 ACCATGAGAAGGGCGCCGAG 1806
              |||||||||| || ||||||
Db          2 ACCATGAGAATGGAGCCGAG 21


RESULT 775
US-10-310-914A-43024/c
; Sequence 43024, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 43024
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-43024

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1063 GCCCCTGGCCCCAGCCCCAG 1082
              ||||| ||| ||||||||||
Db         21 GCCCCAGGCACCAGCCCCAG 2


RESULT 776
US-10-310-914A-94223/c
; Sequence 94223, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 94223
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-94223

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3855 TTTTGAGTTTTGTTTTTGGT 3874
              ||||| ||||||||||| ||
Db         21 TTTTGGGTTTTGTTTTTTGT 2


RESULT 777
US-10-310-914A-147724/c
; Sequence 147724, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 147724
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-147724

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3853 GTTTTTGAGTTTTGTTTTTG 3872
              |||||||  ||||||||||||
Db         21 GTTTTTGTTTTTTGTTTTTG 2


RESULT 778
US-10-310-914A-175830/c
; Sequence 175830, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 175830
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-175830

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3898 TTTTGTTTCTTCGTTTTGTT 3917
              |||||||||||| || |||||
Db         21 TTTTGTTTCTTGGTGTTGTT 2


RESULT 779
US-10-310-914A-239772/c
; Sequence 239772, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
```

; SEQ ID NO 239772
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-239772

 Query Match 0.4%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 8.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1070 GCCCCAGCCCCAGCCTCTAC 1089
 ||||||||||| |||||| |
Db 21 GCCCCAGCCCCTGCCTCTGC 2

RESULT 780
US-10-310-914A-271797/c
; Sequence 271797, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 271797
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-271797

 Query Match 0.4%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 8.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1061 CCGCCCCTGGCCCCAGCCCC 1080
 || |||||| ||||||||||
Db 20 CCCCCCCTGTCCCCAGCCCC 1

RESULT 781
US-10-310-914A-271798/c
; Sequence 271798, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 271798
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-271798

 Query Match 0.4%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 8.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1061 CCGCCCCTGGCCCCAGCCCC 1080
 || |||||| ||||||||||
Db 20 CCCCCCCTGTCCCCAGCCCC 1

RESULT 782
US-10-310-914A-310403/c
; Sequence 310403, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 310403
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-310403

 Query Match 0.4%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 8.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1065 CCCTGGCCCCAGCCCCAGCC 1084
 ||||| |||||||||| |||
Db 21 CCCTGACCCCAGCCCCTGCC 2

RESULT 783
US-10-310-914A-329952
; Sequence 329952, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 329952
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-329952

 Query Match 0.4%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 80.0%; Pred. No. 8.8e+02;
 Matches 16; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 3720 CAAGAAGGGGTGTCAGGGCC 3739
 | |||||||||:|:||||| |
Db 1 CCAGAAGGGGUGUCAGGGGC 20

RESULT 784
US-10-310-914A-340669/c
; Sequence 340669, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 340669

```
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-340669

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1129 GGCTGCAGCTGTGCTCCGGG 1148
              ||||| |||||||||| |||
Db         20 GGCTGTAGCTGTGCTCTGGG 1


RESULT 785
US-10-310-914A-406263/c
; Sequence 406263, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 406263
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-406263

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        747 GGCCCTCACGCCAGCCTGGA 766
              |||||||  ||||||||||||
Db         21 GGCCCTCTGGCCAGCCTGGA 2


RESULT 786
US-10-310-914A-426861/c
; Sequence 426861, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 426861
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-426861

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3899 TTTGTTTCTTCGTTTTGTTT 3918
              |||||||||| ||||| |||
Db         21 TTTGTTTCTTTGTTTTATTT 2


RESULT 787
US-10-310-914A-481749
; Sequence 481749, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 481749
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-481749

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        166 CGGGCCCGCCGCCCGCGCGC 185
              | ||||||  ||||||||||||
Db          2 CUGGCCCGUCGCCCGCGCGC 21


RESULT 788
US-10-310-914A-497146
; Sequence 497146, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 497146
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-497146

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCCCAGC 1083
              ||||  ||||||||||||||
Db          2 CCCCCAGCCCCAGCCCCAGC 21


RESULT 789
US-10-310-914A-513444/c
; Sequence 513444, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 513444
;   LENGTH: 21
```

```
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-513444

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         37 GGGGGGGAGACCGCGAGCGG 56
              ||||| ||| ||||||||||
Db         21 GGGGGAGAGGCCGCGAGCGG 2


RESULT 790
US-10-310-914A-562705
; Sequence 562705, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 562705
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-562705

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   60.0%;  Pred. No. 8.8e+02;
  Matches   12;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1132 TGCAGCTGTGCTCCGGGGTT 1151
              : ||||:|:||:|| |||::
Db          2 UCCAGCUGUGCUCCUGGGUU 21


RESULT 791
US-10-310-914A-572916/c
; Sequence 572916, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 572916
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-572916

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1716 CAGCAGCTTGAGCCTGGCCT 1735
              |||||||||| ||||||| |
Db         21 CAGCAGCTTGTGCCTGGCAT 2


RESULT 792
US-10-310-914A-628965/c
; Sequence 628965, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 628965
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-628965

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1851 AGAGCTGCGGGGGCTGAAGC 1870
              |||||||  ||||||||||||
Db         20 AGAGCTGATGGGGCTGAAGC 1


RESULT 793
US-10-310-914A-700668
; Sequence 700668, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 700668
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-700668

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   85.0%;  Pred. No. 8.8e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1060 CCCGCCCCTGGCCCCAGCCC 1079
              ||||||||:|| |||| |||
Db          2 CCCGCCCCUGGUCCCACCCC 21


RESULT 794
US-10-310-914A-711740
; Sequence 711740, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 711740
;   LENGTH: 21
;   TYPE: RNA
```

```
;   ORGANISM: Human
US-10-310-914A-711740

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   85.0%;  Pred. No. 8.8e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        308 AGAGTCAGACCTGGGGGGGC 327
              |||| ||||||:|||| |||
Db          1 AGAGACAGACCUGGGGAGGC 20


RESULT 795
US-10-310-914A-711741
; Sequence 711741, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 711741
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-711741

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   85.0%;  Pred. No. 8.8e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        308 AGAGTCAGACCTGGGGGGGC 327
              |||| ||||||:|||| |||
Db          1 AGAGACAGACCUGGGGAGGC 20


RESULT 796
US-10-310-914A-712558
; Sequence 712558, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 712558
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-712558

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   85.0%;  Pred. No. 8.8e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1063 GCCCCTGGCCCCAGCCCCAG 1082
              |||||:||||||  ||||||
Db          2 GCCCCUGGCCCCCACCCCAG 21


RESULT 797
US-10-310-914A-849350/c
; Sequence 849350, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 849350
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-849350

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        498 GTGGGAGGAACTGAGCGGCC 517
              ||||| ||||| ||||||||
Db         21 GTGGGTGGAACAGAGCGGCC 2


RESULT 798
US-10-310-914A-853726
; Sequence 853726, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 853726
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-853726

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   70.0%;  Pred. No. 8.8e+02;
  Matches   14;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3056 CCTCACACCCTCTCCTGGAC 3075
              ||:|| ||||:|:||:|| |
Db          2 CCUCAGACCCUCUCCUGGGC 21


RESULT 799
US-10-310-914A-964814
; Sequence 964814, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 964814
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
```

```
US-10-310-914A-964814

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   85.0%;  Pred. No. 8.8e+02;
  Matches   17;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1067 CTGGCCCCAGCCCCAGCCTC 1086
              |:|||||| ||||||||| |
Db          2 CUGGCCCCGGCCCCAGCCCC 21


RESULT 800
US-10-310-914A-1044788/c
; Sequence 1044788, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1044788
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1044788

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1073 CCAGCCCCAGCCTCTACTGC 1092
              | |||||||||| ||||||||
Db         21 CTAGCCCCAGCTTCTACTGC 2


RESULT 801
US-10-310-914A-1044846/c
; Sequence 1044846, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1044846
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1044846

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1072 CCCAGCCCCAGCCTCTACTG 1091
              || |||||||||| |||||||
Db         20 CCTAGCCCCAGCTTCTACTG 1


RESULT 802
US-10-310-914A-1141569
; Sequence 1141569, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1141569
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1141569

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 8.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        830 GGGCCGAGGCCACCGGGAAG 849
              |||||||||||||||  ||||
Db          1 GGGCCGAGGCCACCCCGAAG 20


RESULT 803
US-10-310-914A-1329403
; Sequence 1329403, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1329403
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1329403

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   80.0%;  Pred. No. 8.8e+02;
  Matches   16;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3720 CAAGAAGGGGTGTCAGGGCC 3739
              | |||||||||:|:||||| |
Db          1 CCAGAAGGGGUGUCAGGGGC 20


RESULT 804
US-10-750-185-14487
; Sequence 14487, Application US/10750185
; Publication No. US20050260603A1
; GENERAL INFORMATION:
;  APPLICANT: MMI GENOMICS, INC.
;  APPLICANT:  DeNISE, Sue K.
;  APPLICANT:  KERR, Richard
;  APPLICANT:  ROSENFELD, David
;  APPLICANT:  HOLM, Tom
;  APPLICANT:  BATES, Stephen
;  APPLICANT:  FANTIN, Dennis
;  TITLE OF INVENTION: COMPOSITIONS FOR INFERRING BOVINE TRAITS
;  FILE REFERENCE: MMI1100-2
;  CURRENT APPLICATION NUMBER: US/10/750,185
;  CURRENT FILING DATE:  2003-12-31
;  PRIOR APPLICATION NUMBER: US 60/437,482
;  PRIOR FILING DATE: 2002-12-31
;  NUMBER OF SEQ ID NOS: 64922
```

```
;  SOFTWARE: PatentIN version 3.1
; SEQ ID NO 14487
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Reverse Primer
US-10-750-185-14487

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1532 TGGTGGAGCCCTGGGTGG 1549
              ||||||||||||| ||||
Db          1 TGGTGGAGCCCTGTGTGG 18


RESULT 805
US-10-750-623-14487
; Sequence 14487, Application US/10750623
; Publication No. US20050287531A1
; GENERAL INFORMATION:
;  APPLICANT: MMI GENOMICS, INC.
;  APPLICANT:  DeNISE, Sue K.
;  APPLICANT:  KERR, Richard
;  APPLICANT:  ROSENFELD, David
;  APPLICANT:  HOLM, Tom
;  APPLICANT:  BATES, Stephen
;  APPLICANT:  FANTIN, Dennis
;  TITLE OF INVENTION: METHODS AND SYSTEMS FOR INFERRING BOVINE TRAITS
;  FILE REFERENCE: MMI1100-1
;  CURRENT APPLICATION NUMBER: US/10/750,623
;  CURRENT FILING DATE:  2003-12-31
;  PRIOR APPLICATION NUMBER: US 60/437,482
;  PRIOR FILING DATE: 2002-12-31
;  NUMBER OF SEQ ID NOS: 64922
;  SOFTWARE: PatentIN version 3.1
; SEQ ID NO 14487
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Reverse Primer
US-10-750-623-14487

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1532 TGGTGGAGCCCTGGGTGG 1549
              ||||||||||||| ||||
Db          1 TGGTGGAGCCCTGTGTGG 18


RESULT 806
US-10-310-914A-44706/c
; Sequence 44706, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44706
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-44706

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2911 CCCACCTCCCTCCACCAG 2928
              ||| ||||||||||||||
Db         18 CCCCCCTCCCTCCACCAG 1


RESULT 807
US-10-310-914A-161816
; Sequence 161816, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161816
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-161816

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 7.6e+02;
  Matches   14;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3607 AACATCTCCCAGCCTCCC 3624
              ||| :|:|||||||:|||
Db          1 AACCUCUCCCAGCCUCCC 18


RESULT 808
US-10-310-914A-215670
; Sequence 215670, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 215670
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-215670

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        171 CCGCCGCCCGCGCGCGCG 188
              |||||||||||| |||||
Db          1 CCGCCGCCCGCGGGCGCG 18


RESULT 809
US-10-310-914A-239735/c
; Sequence 239735, Application US/10310914A
; Publication No. US20060003322A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 239735
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-239735

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1070 GCCCCAGCCCCAGCCTCT 1087
              ||||||||||| ||||||
Db         18 GCCCCAGCCCCTGCCTCT 1


RESULT 810
US-10-310-914A-263974/c
; Sequence 263974, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 263974
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-263974

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2964 CCGGCCCCGCTTCCCCCA 2981
              || ||||||||||||||
Db         18 CCCGCCCCGCTTCCCCCA 1


RESULT 811
US-10-310-914A-346833
; Sequence 346833, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 346833
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-346833

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 7.6e+02;
  Matches   16;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2963 CCCGGCCCCGCTTCCCCC 2980
              |||||||||||| :|||||
Db          1 CCCGGCCCCGCCUCCCCC 18


RESULT 812
US-10-310-914A-486562
; Sequence 486562, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 486562
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-486562

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 7.6e+02;
  Matches   16;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3351 TCCCCACCCCAGGGACAC 3368
              :|||||||||||||||| |
Db          1 UCCCCACCCCAGGGACCC 18


RESULT 813
US-10-310-914A-562588
; Sequence 562588, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 562588
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-562588

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   66.7%;  Pred. No. 7.6e+02;
  Matches   12;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1134 CAGCTGTGCTCCGGGGTT 1151
              ||||:|:||:|| |||::
Db          1 CAGCUGUGCUCCUGGGUU 18


RESULT 814
US-10-310-914A-702467/c
; Sequence 702467, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 702467
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-702467

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3774 TTGCTGCTGTCACCACCA 3791
              || ||||||||||||||||
Db         18 TTTCTGCTGTCACCACCA 1


RESULT 815
US-10-310-914A-806755/c
; Sequence 806755, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 806755
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-806755

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3381 TTCCGGGGCAGAGTGGGG 3398
              ||| ||||||||||||||||
Db         18 TTCGGGGGCAGAGTGGGG 1


RESULT 816
US-10-310-914A-815915
; Sequence 815915, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 815915
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-815915

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 7.6e+02;
  Matches   14;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1376 TGAACGGCTCCTCCCTGC 1393
              :|||||||:||:||| ||
Db          1 UGAACGGCUCCUCCCCGC 18


RESULT 817
US-10-310-914A-916487/c
; Sequence 916487, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916487
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-916487

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1067 CTGGCCCCAGCCCCAGCC 1084
              ||| ||||||||||||||||
Db         18 CTGCCCCCAGCCCCAGCC 1


RESULT 818
US-10-310-914A-937535/c
; Sequence 937535, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 937535
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-937535

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        267 GAGGAGTCCCGCGCGGAG 284
              |||||||||||||| |||
Db         18 GAGGAGTCCCGCGCAGAG 1


RESULT 819
US-10-310-914A-1079798/c
; Sequence 1079798, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
```

```
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1079798
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1079798

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 7.6e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1062 CGCCCCTGGCCCCAGCCC 1079
              |||||||| |||||||||
Db         18 CGCCCCTGTCCCCAGCCC 1


RESULT 820
US-10-310-914A-1251971
; Sequence 1251971, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1251971
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1251971

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 7.6e+02;
  Matches   16;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2075 GCAATGGGAGAGAAGCAG 2092
              ||||:||||| |||||||
Db          1 GCAAUGGGAGGGAAGCAG 18


RESULT 821
US-10-310-914A-161839
; Sequence 161839, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161839
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-161839

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 8.2e+02;
  Matches   14;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3608 ACATCTCCCAGCCTCCCC 3625
              || :|:|||||||:||||
Db          1 ACCUCUCCCAGCCUCCCC 18


RESULT 822
US-10-310-914A-161840
; Sequence 161840, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161840
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-161840

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 8.2e+02;
  Matches   14;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3608 ACATCTCCCAGCCTCCCC 3625
              || :|:|||||||:||||
Db          1 ACCUCUCCCAGCCUCCCC 18


RESULT 823
US-10-310-914A-225326
; Sequence 225326, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 225326
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-225326

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 8.2e+02;
  Matches   15;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        754 ACGCCAGCCTGGATGGAG 771
              ||||||| |:|||:||||
Db          1 ACGCCAGGCUGGAUGGAG 18


RESULT 824
US-10-310-914A-329935
; Sequence 329935, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
```

```
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 329935
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-329935

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 8.2e+02;
  Matches   15;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3722 AGAAGGGGTGTCAGGGCC 3739
              ||||||||:|:||||| |
Db          2 AGAAGGGGUGUCAGGGGC 19


RESULT 825
US-10-310-914A-481752
; Sequence 481752, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 481752
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-481752

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        168 GGCCCGCCGCCCGCGCGC 185
              |||||| ||||||||||
Db          1 GGCCCGUCGCCCGCGCGC 18


RESULT 826
US-10-310-914A-562468/c
; Sequence 562468, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 562468
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-562468

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1059 CCCCGCCCCTGGCCCCAG 1076
              ||||| ||||||||||||
Db         19 CCCCGACCCTGGCCCCAG 2


RESULT 827
US-10-310-914A-910660
; Sequence 910660, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 910660
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-910660

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 8.2e+02;
  Matches   15;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1979 GGGAGCAGCTGGCCCTGA 1996
              |||||||||:|| ||:||
Db          2 GGGAGCAGCUGGGCCUGA 19


RESULT 828
US-10-310-914A-917658/c
; Sequence 917658, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 917658
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-917658

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 CTTGAGCCTGGCCTGGGC 1739
              ||| ||||||||||||||
Db         19 CTTCAGCCTGGCCTGGGC 2


RESULT 829
US-10-310-914A-1011800/c
; Sequence 1011800, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
```

```
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1011800
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1011800

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1069 GGCCCCAGCCCCAGCCTC 1086
              ||| ||||||||||||||
Db         18 GGCACCAGCCCCAGCCTC 1


RESULT 830
US-10-310-914A-1024936
; Sequence 1024936, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1024936
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1024936

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 8.2e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3775 TGCTGCTGTCACCACCAA 3792
              :||:||:|:||||| |||
Db          1 UGCUGCUGUCACCAUCAA 18


RESULT 831
US-10-310-914A-1182295
; Sequence 1182295, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1182295
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1182295

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        219 CGCCCGGTGCCCCGCACG 236
              ||||||| ||||||||||
Db          1 CGCCCGGGGCCCCGCACG 18


RESULT 832
US-10-310-914A-1313753
; Sequence 1313753, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1313753
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1313753

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3095 CAGCTTTTGGCTCTGTGG 3112
              |||| :::|||:|:|:||
Db          1 CAGCAUUUGGCUCUGUGG 18


RESULT 833
US-10-310-914A-1329386
; Sequence 1329386, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1329386
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1329386

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 8.2e+02;
  Matches   15;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3722 AGAAGGGGTGTCAGGGCC 3739
              ||||||||:|:||||| |
Db          2 AGAAGGGGUGUCAGGGGC 19


RESULT 834
US-11-101-244-117533
; Sequence 117533, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
```

```
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 117533
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-117533

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 8.2e+02;
  Matches   15;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2592 AGACCTGGCTGCTCGCAA 2609
              |||||:|||:|| |||||
Db          1 AGACCUGGCUGCCCGCAA 18


RESULT 835
US-11-101-244-158322
; Sequence 158322, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158322
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158322

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2634 CTGCAAAGTGTCTGACTT 2651
              |:|||| |:|:|:|||:: 
Db          2 CUGCAAGGUGUCUGACUU 19


RESULT 836
US-11-101-244-159024
; Sequence 159024, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159024
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159024

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCAT 2821
              :|:||||||:||:|:| :
Db          1 UGUGGGAGGUGAUGUCCU 18


RESULT 837
US-11-101-244-159117
; Sequence 159117, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159117
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159117

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCAT 2821
              :|:||||||:||:|:| :
Db          1 UGUGGGAGGUGAUGUCCU 18


RESULT 838
US-11-101-244-159229
; Sequence 159229, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
```

```
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159229
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159229

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 8.2e+02;
  Matches   16;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2841 GGACATGAGCAATCAGGA 2858
              |||||:||||||  |||||
Db          1 GGACAUGAGCAACCAGGA 18


RESULT 839
US-11-101-244-159279
; Sequence 159279, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159279
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159279

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 8.2e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2625 CAACCTCGTCTGCAAAGT 2642
              |||||: |:|:||||||:
Db          1 CAACCUGGUCUGCAAAGU 18


RESULT 840
US-11-101-244-258796
; Sequence 258796, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 258796
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-258796

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1565 GTCCTGACTTCACCTATA 1582
              |:||:|||::|| |:|:|
Db          2 GUCCUGACUUCAACUAUA 19


RESULT 841
US-11-101-244-258802
; Sequence 258802, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 258802
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-258802

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1565 GTCCTGACTTCACCTATA 1582
              |:||:|||::|| |:|:|
Db          1 GUCCUGACUUCAACUAUA 18


RESULT 842
US-11-101-244-317987/c
; Sequence 317987, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
```

```
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 317987
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-317987

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2801 TGATGTGGGAGGTGATGT 2818
              |||||||||||.||||||
Db         19 TGATGTGGGAGTTGATGT 2

RESULT 843
US-11-101-244-325732
; Sequence 325732, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 325732
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-325732

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 8.2e+02;
  Matches   16;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3276 CATGAAGTCCCAGGCCAA 3293
              || ||||:||||||||||
Db          1 CAAGAAGUCCCAGGCCAA 18

RESULT 844
US-11-101-244-495967
; Sequence 495967, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 495967
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-495967

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 8.2e+02;
  Matches   15;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2987 TCAGCGCCCTGGACAAGA 3004
              :||||| ||:||||||||
Db          1 UCAGCGGCCUGGACAAGA 18

RESULT 845
US-11-101-244-520914
; Sequence 520914, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 520914
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-520914

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 8.2e+02;
  Matches   14;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2580 CTACGTCCACCGAGACCT 2597
              |:|| :|||||||||||:
Db          1 CUACAUCCACCGAGACCU 18

RESULT 846
US-11-101-244-521180
; Sequence 521180, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
```

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 521180
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-521180

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 8.2e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2592 AGACCTGGCTGCTCGCAA 2609
||||||:|||:||:|| ||
Db 1 AGACCUGGCUGCUCGGAA 18

RESULT 847
US-11-101-244-931315
; Sequence 931315, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 931315
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-931315

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 8.2e+02;
Matches 10; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy 3962 TCACTATGGCCTCCTTTG 3979
: ||:|:||||:||:::|
Db 1 UGACUAUGGCCUCCUUUG 18

RESULT 848
US-11-101-244-1104821
; Sequence 1104821, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1104821
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1104821

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 8.2e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2157 CACTTATGAAGACCCTAA 2174
|||: |:||||||||:||
Db 2 CACUAAUGAAGACCCUAA 19

RESULT 849
US-11-101-244-1174362
; Sequence 1174362, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1174362
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1174362

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 8.2e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1386 CTCCCTGCACCTGGAATG 1403
|:|||:|| ||:||||:|
Db 2 CUCCCUGCUCCUGGAAUG 19

RESULT 850
US-11-101-244-1393142/c
; Sequence 1393142, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10

```
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1393142
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1393142

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2165 AAGACCCTAATGAGGCTG 2182
              ||||||| ||||||||||
Db         18 AAGACCCGAATGAGGCTG 1


RESULT 851
US-11-101-244-1494874/c
; Sequence 1494874, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1494874
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1494874

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1937 AACATCACAGCCAGACCC 1954
              |||| ||||||||||||||
Db         18 AACACCACAGCCAGACCC 1


RESULT 852
US-11-101-244-1529001
; Sequence 1529001, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1529001
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1529001

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 8.2e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2298 GAGCTGTGTGGCAATCAA 2315
              ||||:|:|: ||||:|||
Db          1 GAGCUGUGUUGCAAUCAA 18


RESULT 853
US-11-083-784-117533
; Sequence 117533, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 117533
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-117533

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 8.2e+02;
  Matches   15;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2592 AGACCTGGCTGCTCGCAA 2609
              |||||:|||:|| |||||
Db          1 AGACCUGGCUGCCCGCAA 18


RESULT 854
US-11-083-784-158322
; Sequence 158322, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
```

```
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158322
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158322

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2634 CTGCAAAGTGTCTGACTT 2651
              |:|||| |:|:|:|||::
Db          2 CUGCAAGGUGUCUGACUU 19


RESULT 855
US-11-083-784-159024
; Sequence 159024, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159024
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159024

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCAT 2821
              :|:||||||:||:|:| :
Db          1 UGUGGGAGGUGAUGUCCU 18


RESULT 856
US-11-083-784-159117
; Sequence 159117, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159117
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159117

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCAT 2821
              :|:||||||:||:|:| :
Db          1 UGUGGGAGGUGAUGUCCU 18


RESULT 857
US-11-083-784-159229
; Sequence 159229, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159229
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159229

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 8.2e+02;
  Matches   16;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2841 GGACATGAGCAATCAGGA 2858
              |||||:|||||| |||||
Db          1 GGACAUGAGCAACCAGGA 18


RESULT 858
US-11-083-784-159279
; Sequence 159279, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
```

```
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159279
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159279

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 8.2e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2625 CAACCTCGTCTGCAAAGT 2642
              |||||: |:|:||||||:
Db          1 CAACCUGGUCUGCAAAGU 18


RESULT 859
US-11-083-784-258796
; Sequence 258796, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 258796
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-258796

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1565 GTCCTGACTTCACCTATA 1582
              |:||:|||::|| |:|:|
Db          2 GUCCUGACUUCAACUAUA 19


RESULT 860
US-11-083-784-258802
; Sequence 258802, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 258802
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-258802

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 8.2e+02;
  Matches   11;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1565 GTCCTGACTTCACCTATA 1582
              |:||:|||::|| |:|:|
Db          1 GUCCUGACUUCAACUAUA 18


RESULT 861
US-11-083-784-317987/c
; Sequence 317987, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 317987
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-317987

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2801 TGATGTGGGAGGTGATGT 2818
              |||||||||| ||||||
Db         19 TGATGTGGGAGTTGATGT 2


RESULT 862
US-11-083-784-325732
; Sequence 325732, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 325732
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-325732

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 8.2e+02;
  Matches   16;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3276 CATGAAGTCCCAGGCCAA 3293
              || ||||:||||||||||
Db          1 CAAGAAGUCCCAGGCCAA 18


RESULT 863
US-11-083-784-495967
; Sequence 495967, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 495967
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-495967

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 8.2e+02;
  Matches   15;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2987 TCAGCGCCCTGGACAAGA 3004
              :||||| ||:||||||||
Db          1 UCAGCGGCCUGGACAAGA 18


RESULT 864
US-11-083-784-520914
; Sequence 520914, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 520914
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-520914

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 8.2e+02;
  Matches   14;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2580 CTACGTCCACCGAGACCT 2597
              |:|| :||||||||||:
Db          1 CUACAUCCACCGAGACCU 18


RESULT 865
US-11-083-784-521180
; Sequence 521180, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 521180
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-521180

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 8.2e+02;
  Matches   14;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2592 AGACCTGGCTGCTCGCAA 2609
              |||||:|||:||:|| ||
Db          1 AGACCUGGCUGCUCGGAA 18
```

```
RESULT 866
US-11-083-784-931315
; Sequence 931315, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 931315
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-931315

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   55.6%;  Pred. No. 8.2e+02;
  Matches   10;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3962 TCACTATGGCCTCCTTTG 3979
              : ||:|:||||:||:::|
Db          1 UGACUAUGGCCUCCUUUG 18


RESULT 867
US-11-083-784-1104821
; Sequence 1104821, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1104821
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1104821

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 8.2e+02;
  Matches   14;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2157 CACTTATGAAGACCCTAA 2174
              |||: |:||||||:||
Db          2 CACUAAUGAAGACCCUAA 19


RESULT 868
US-11-083-784-1174362
; Sequence 1174362, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1174362
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1174362

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 8.2e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1386 CTCCCTGCACCTGGAATG 1403
              |:|||:|| ||:||||:|
Db          2 CUCCCUGCUCCUGGAAUG 19


RESULT 869
US-11-083-784-1393142/c
; Sequence 1393142, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1393142
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1393142

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
```

```
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2165 AAGACCCTAATGAGGCTG 2182
              ||||||| ||||||||||
Db         18 AAGACCCGAATGAGGCTG 1


RESULT 870
US-11-083-784-1494874/c
; Sequence 1494874, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1494874
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1494874

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 8.2e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1937 AACATCACAGCCAGACCC 1954
              |||| ||||||||||||||
Db         18 AACACCACAGCCAGACCC 1


RESULT 871
US-11-083-784-1529001
; Sequence 1529001, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1529001
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1529001

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 8.2e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2298 GAGCTGTGTGGCAATCAA 2315
              ||||:|:|: ||||:|||
Db          1 GAGCUGUGUUGCAAUCAA 18


RESULT 872
US-10-310-914A-385316/c
; Sequence 385316, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 385316
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-385316

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 8.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2885 ACCGGCTGCCCCCGCCCC 2902
              |||| ||||||||||||||
Db         20 ACCGCCTGCCCCCGCCCC 3


RESULT 873
US-10-310-914A-916483/c
; Sequence 916483, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916483
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-916483

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 8.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1069 GGCCCCAGCCCCAGCCTC 1086
              | ||||||||||||||||
Db         19 GCCCCCAGCCCCAGCCTC 2


RESULT 874
US-10-310-914A-1192704/c
; Sequence 1192704, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1192704
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1192704

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 8.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        453 AACTGCTGATCTGAAGTG 470
              |||| ||||||||||||||
Db         19 AACTCCTGATCTGAAGTG 2


RESULT 875
US-10-310-914A-81546
; Sequence 81546, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 81546
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-81546

  Query Match             0.4%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 8.3e+02;
  Matches   15;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1065 CCCTGGCCCCAGCCCC 1080
              |||:|||||||||||||
Db          3 CCCUGGCCCCAGCCCC 18


RESULT 876
US-10-310-914A-443869
; Sequence 443869, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 443869
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-443869

  Query Match             0.4%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 8.3e+02;
  Matches   15;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1071 CCCCAGCCCCAGCCTC 1086
              ||||||||||||||:|
Db          3 CCCCAGCCCCAGCCUC 18


RESULT 877
US-10-310-914A-916489/c
; Sequence 916489, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916489
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-916489

  Query Match             0.4%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 8.3e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1071 CCCCAGCCCCAGCCTC 1086
              ||||||||||||||||
Db         18 CCCCAGCCCCAGCCTC 3


RESULT 878
US-10-310-914A-983472
; Sequence 983472, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 983472
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-983472

  Query Match             0.4%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 8.3e+02;
  Matches   15;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1065 CCCTGGCCCCAGCCCC 1080
              |||:|||||||||||||
Db          2 CCCUGGCCCCAGCCCC 17


RESULT 879
US-10-310-914A-1088339/c
; Sequence 1088339, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
```

```
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1088339
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1088339

  Query Match             0.4%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 8.3e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2050 GCAGTTCTCTGCCTCA 2065
             ||||||||||||||||
Db         16 GCAGTTCTCTGCCTCA 1


RESULT 880
US-10-310-914A-1346847/c
; Sequence 1346847, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1346847
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1346847

  Query Match             0.4%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 8.3e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCC 1079
             ||||||||||||||||
Db         17 CCCCTGGCCCCAGCCC 2


RESULT 881
US-10-310-914A-196336
; Sequence 196336, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 196336
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-196336

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2285 CAGGGAAGAAGGAGAG 2300
             ||||||||||||||||
Db          3 CAGGGAAGAAGGAGAG 18


RESULT 882
US-10-310-914A-482672
; Sequence 482672, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 482672
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-482672

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   68.8%;  Pred. No. 9e+02;
  Matches   11;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2051 CAGTTCTCTGCCTCAG 2066
             |||::|:|:|||:|||
Db          1 CAGUUCUCUGCCUCAG 16


RESULT 883
US-10-310-914A-1295091/c
; Sequence 1295091, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1295091
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1295091

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3821 CCCCTCCCCCAGCTGC 3836
             ||||||||||||||||
Db         17 CCCCTCCCCCAGCTGC 2


RESULT 884
US-10-310-914A-1343420/c
; Sequence 1343420, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
```

```
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1343420
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1343420

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        180 GCGCGCGCGGCACAGA 195
              ||||||||||||||||
Db         16 GCGCGCGCGGCACAGA 1


RESULT 885
US-11-101-244-31908/c
; Sequence 31908, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 31908
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-31908

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3264 CAGTGTCCAGCACATG 3279
              ||||||||||||||||
Db         18 CAGTGTCCAGCACATG 3


RESULT 886
US-11-101-244-159280
; Sequence 159280, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159280
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159280

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   75.0%;  Pred. No. 9e+02;
  Matches   12;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        885 CAAGGCTGGCTTCTAC 900
              ||||||:|||::|:||
Db          4 CAAGGCUGGCUUCUAC 19


RESULT 887
US-11-101-244-704088/c
; Sequence 704088, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 704088
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-704088

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3608 ACATCTCCCAGCCTCC 3623
              ||||||||||||||||
Db         19 ACATCTCCCAGCCTCC 4


RESULT 888
US-11-101-244-704181/c
; Sequence 704181, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
```

```
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 704181
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-704181

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3608 ACATCTCCCAGCCTCC 3623
              ||||||||||||||||
Db         19 ACATCTCCCAGCCTCC 4


RESULT 889
US-11-101-244-931267
; Sequence 931267, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 931267
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-931267

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   62.5%;  Pred. No. 9e+02;
  Matches   10;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3964 ACTATGGCCTCCTTTG 3979
              ||:|:||||:|:::|
Db          2 ACUAUGGCCUCCUUUG 17


RESULT 890
US-11-101-244-931277
; Sequence 931277, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 931277
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-931277

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   62.5%;  Pred. No. 9e+02;
  Matches   10;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3964 ACTATGGCCTCCTTTG 3979
              ||:|:||||:|:::|
Db          1 ACUAUGGCCUCCUUUG 16


RESULT 891
US-11-101-244-1365774/c
; Sequence 1365774, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1365774
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1365774

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2656 CTTTCCCGATTCCTGG 2671
              ||||||||||||||||
Db         16 CTTTCCCGATTCCTGG 1


RESULT 892
US-11-083-784-31908/c
; Sequence 31908, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
```

```
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 31908
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-31908

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3264 CAGTGTCCAGCACATG 3279
              ||||||||||||||||
Db         18 CAGTGTCCAGCACATG 3


RESULT 893
US-11-083-784-159280
; Sequence 159280, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159280
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159280

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   75.0%;  Pred. No. 9e+02;
  Matches   12;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        885 CAAGGCTGGCTTCTAC 900
              ||||||:|||::|:||
Db          4 CAAGGCUGGCUUCUAC 19


RESULT 894
US-11-083-784-704088/c
; Sequence 704088, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 704088
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-704088

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3608 ACATCTCCCAGCCTCC 3623
              ||||||||||||||||
Db         19 ACATCTCCCAGCCTCC 4


RESULT 895
US-11-083-784-704181/c
; Sequence 704181, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 704181
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-704181

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3608 ACATCTCCCAGCCTCC 3623
              ||||||||||||||||
Db         19 ACATCTCCCAGCCTCC 4


RESULT 896
US-11-083-784-931267
; Sequence 931267, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 931267
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-931267

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   62.5%;  Pred. No. 9e+02;
  Matches   10;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3964 ACTATGGCCTCCTTTG 3979
              ||:|:||||:||:::|
Db          2 ACUAUGGCCUCCUUUG 17


RESULT 897
US-11-083-784-931277
; Sequence 931277, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 931277
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-931277

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   62.5%;  Pred. No. 9e+02;
  Matches   10;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3964 ACTATGGCCTCCTTTG 3979
              ||:|:||||:||:::|
Db          1 ACUAUGGCCUCCUUUG 16


RESULT 898
US-11-083-784-1365774/c
; Sequence 1365774, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1365774
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1365774

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 9e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2656 CTTTCCCGATTCCTGG 2671
              ||||||||||||||||
Db         16 CTTTCCCGATTCCTGG 1


RESULT 899
US-10-831-286A-34811
; Sequence 34811, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
;  APPLICANT: ZENG, QIANDONG
;  APPLICANT:  CHATELLIER, SONIA
;  APPLICANT:  MOIR, DONALD T.
;  APPLICANT:  LACROIX, BRUNA
;  APPLICANT:  CHILDRESS, DARRELL
;  TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
;  FILE REFERENCE: 032796-174.001
;  CURRENT APPLICATION NUMBER: US/10/831,286A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/464,955
;  PRIOR FILING DATE: 2003-04-24
;  NUMBER OF SEQ ID NOS: 48788
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34811
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Veillonella atypica
US-10-831-286A-34811

  Query Match             0.4%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 9.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        449 TGGAAACTGCTGATCT 464
              ||||||||||||||||
Db          2 TGGAAACTGCTGATCT 17


RESULT 900
US-10-831-286A-37357
; Sequence 37357, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
;  APPLICANT: ZENG, QIANDONG
;  APPLICANT:  CHATELLIER, SONIA
;  APPLICANT:  MOIR, DONALD T.
;  APPLICANT:  LACROIX, BRUNA
;  APPLICANT:  CHILDRESS, DARRELL
;  TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
```

```
;  FILE REFERENCE: 032796-174.001
;  CURRENT APPLICATION NUMBER: US/10/831,286A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/464,955
;  PRIOR FILING DATE: 2003-04-24
;  NUMBER OF SEQ ID NOS: 48788
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37357
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Veillonella atypica
US-10-831-286A-37357

  Query Match             0.4%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 9.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        449 TGGAAACTGCTGATCT 464
              ||||||||||||||||
Db          4 TGGAAACTGCTGATCT 19


RESULT 901
US-10-831-286A-40915
; Sequence 40915, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
;  APPLICANT: ZENG, QIANDONG
;  APPLICANT:  CHATELLIER, SONIA
;  APPLICANT:  MOIR, DONALD T.
;  APPLICANT:  LACROIX, BRUNA
;  APPLICANT:  CHILDRESS, DARRELL
;  TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
;  FILE REFERENCE: 032796-174.001
;  CURRENT APPLICATION NUMBER: US/10/831,286A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/464,955
;  PRIOR FILING DATE: 2003-04-24
;  NUMBER OF SEQ ID NOS: 48788
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40915
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Veillonella atypica
US-10-831-286A-40915

  Query Match             0.4%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 9.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        449 TGGAAACTGCTGATCT 464
              ||||||||||||||||
Db          3 TGGAAACTGCTGATCT 18


RESULT 902
US-10-831-286A-48457
; Sequence 48457, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
;  APPLICANT: ZENG, QIANDONG
;  APPLICANT:  CHATELLIER, SONIA
;  APPLICANT:  MOIR, DONALD T.
;  APPLICANT:  LACROIX, BRUNA
;  APPLICANT:  CHILDRESS, DARRELL
;  TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
;  FILE REFERENCE: 032796-174.001
;  CURRENT APPLICATION NUMBER: US/10/831,286A
;  CURRENT FILING DATE:  2004-04-26
;  PRIOR APPLICATION NUMBER: 60/464,955
;  PRIOR FILING DATE: 2003-04-24
;  NUMBER OF SEQ ID NOS: 48788
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 48457
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Veillonella atypica
US-10-831-286A-48457

  Query Match             0.4%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 9.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        449 TGGAAACTGCTGATCT 464
              ||||||||||||||||
Db          5 TGGAAACTGCTGATCT 20


RESULT 903
US-10-310-914A-196337
; Sequence 196337, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 196337
;   LENGTH: 20
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-196337

  Query Match             0.4%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 9.7e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2285 CAGGGAAGAAGGAGAG 2300
              ||||||||||||||||
Db          3 CAGGGAAGAAGGAGAG 18


RESULT 904
US-10-922-761-87
; Sequence 87, Application US/10922761
; Publication No. US20050267058A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/223  (MBHB 04-736-A)
;  CURRENT APPLICATION NUMBER: US/10/922,761
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: US 10/683,990
;  PRIOR FILING DATE: 2003-10-10
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-11-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2004-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 320
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 87
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-922-761-87

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        519 GGATGAGGAACAGCACAGC 537
              |||:||| |||||| ||||
Db          1 GGAUGAGAAACAGCUCAGC 19


RESULT 905
US-10-922-761-184/c
; Sequence 184, Application US/10922761
; Publication No. US20050267058A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/223  (MBHB 04-736-A)
;  CURRENT APPLICATION NUMBER: US/10/922,761
;  CURRENT FILING DATE:  2004-08-20
;  PRIOR APPLICATION NUMBER: US 10/683,990
;  PRIOR FILING DATE: 2003-10-10
;  PRIOR APPLICATION NUMBER: PCT/US04/16390
;  PRIOR FILING DATE: 2004-05-24
;  PRIOR APPLICATION NUMBER: US 10/826,966
;  PRIOR FILING DATE: 2004-04-16
;  PRIOR APPLICATION NUMBER: US 10/757,803
;  PRIOR FILING DATE: 2004-01-14
;  PRIOR APPLICATION NUMBER: US 10/720,448
;  PRIOR FILING DATE: 2003-11-24
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2003-11-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2004-05-23
;  PRIOR APPLICATION NUMBER: PCT/US03/05346
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: PCT/US03/05028
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 320
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 184
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-922-761-184

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        519 GGATGAGGAACAGCACAGC 537
              ||||||| |||||| ||||
Db         19 GGATGAGAAACAGCTCAGC 1


RESULT 906
US-10-310-914A-50195
; Sequence 50195, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 50195
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-50195

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2276 TCAAGGCCCCAGGGAAGAA 2294
              :||| |||||| |||||||
Db          1 UCAAUGCCCCACGGAAGAA 19


RESULT 907
US-10-310-914A-74610/c
; Sequence 74610, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 74610
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-74610

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3896 CTTTTTGTTTCTTCGTTTT 3914
              |||||||||| || |||||
Db         19 CTTTTTGTTTGTTTGTTTT 1


RESULT 908
US-10-310-914A-81513
; Sequence 81513, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
```

```
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 81513
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-81513

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3357 CCCCAGGGACACCGCCTCC 3375
              ||||||||||  || ||:||
Db          1 CCCCAGGGACUCCACCUCC 19


RESULT 909
US-10-310-914A-143107/c
; Sequence 143107, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 143107
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-143107

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1669 GAGGTACCTCCTGCAGTGT 1687
              | ||| |||||||||||||
Db         19 GTGGTCCCTCCTGCAGTGT 1


RESULT 910
US-10-310-914A-143645/c
; Sequence 143645, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 143645
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-143645

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        571 GCCCCGGGCCAGGCCCACT 589
              |||||||||||||||  ||
Db         19 GCCCCGGGCCAGGCCACCT 1


RESULT 911
US-10-310-914A-152768/c
; Sequence 152768, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 152768
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-152768

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        131 CGCGCCCGCCCGGCGCGGC 149
              | ||||||||||||| ||||
Db         19 CCCGCCCGCCCGGCCCGGC 1


RESULT 912
US-10-310-914A-175809/c
; Sequence 175809, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 175809
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-175809

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3898 TTTTGTTTCTTCGTTTTGT 3916
              ||||||||||| || ||||
Db         19 TTTTGTTTCTTGGTGTTGT 1


RESULT 913
US-10-310-914A-209753
; Sequence 209753, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
```

```
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 209753
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-209753

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3408 GGCCCCCAGCCCTGTGCCC 3426
              || ||||||||| |:||||
Db          1 GGACCCCAGCCCAGUGCCC 19


RESULT 914
US-10-310-914A-242649/c
; Sequence 242649, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 242649
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-242649

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        494 GGCAGTGGGAGGAACTGAG 512
              ||||||||| |||| ||||
Db         19 GGCAGTGGGTGGAAGTGAG 1


RESULT 915
US-10-310-914A-271792/c
; Sequence 271792, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 271792
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-271792

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1061 CCGCCCCTGGCCCCAGCCC 1079
              || |||||| |||||||||
Db         19 CCCCCCCTGTCCCCAGCCC 1


RESULT 916
US-10-310-914A-376173/c
; Sequence 376173, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 376173
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-376173

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1959 GGATGAGAGCGAGGGCTGG 1977
              ||| ||||||| |||||||
Db         19 GGAGGAGAGCGCGGGCTGG 1


RESULT 917
US-10-310-914A-402475/c
; Sequence 402475, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 402475
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-402475

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         85 GACCCCGAGGCCCCGGAGG 103
              | || ||||||||||||||
Db         19 GCCCTCGAGGCCCCGGAGG 1


RESULT 918
US-10-310-914A-426755/c
; Sequence 426755, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
```

```
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 426755
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-426755

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3899 TTTGTTTCTTCGTTTTGTT 3917
              |||||||||| ||||| ||
Db         19 TTTGTTTCTTTGTTTTATT 1


RESULT 919
US-10-310-914A-427119/c
; Sequence 427119, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 427119
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-427119

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3161 CAGCCGCTGGCTTTGGCTC 3179
              |||| ||||| ||||||||
Db         19 CAGCTGCTGGATTTGGCTC 1


RESULT 920
US-10-310-914A-454195
; Sequence 454195, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 454195
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-454195

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        130 GCGCGCCCGCCCGGCGCGG 148
              ||||| |||||||||| ||
Db          1 GCGCGGCCGCCCGGCGGGG 19


RESULT 921
US-10-310-914A-462107/c
; Sequence 462107, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 462107
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-462107

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTG 3915
              ||||||||| || ||||||
Db         19 TTTTTGTTTGTTTGTTTTG 1


RESULT 922
US-10-310-914A-477363
; Sequence 477363, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 477363
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-477363

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2227 GAAGAGGTGATTGGTGCAG 2245
              |||||||:||:  |:||||
Db          1 GAAGAGGUGAUGAGUGCAG 19


RESULT 923
US-10-310-914A-481676/c
; Sequence 481676, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
```

```
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 481676
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-481676

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1964 AGAGCGAGGGCTGGCGGGA 1982
              |||| |||||| |||||||
Db         19 AGAGGGAGGGCAGGCGGGA 1


RESULT 924
US-10-310-914A-496772
; Sequence 496772, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 496772
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-496772

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1753 CCCAGTGGGGCTGTGCTGG 1771
              |||||:|| ||:| ||:||
Db          1 CCCAGUGGUGCUGGGCUGG 19


RESULT 925
US-10-310-914A-497205
; Sequence 497205, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 497205
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-497205

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCCCAG 1082
              ||||  ||||||||||||||
Db          1 CCCCCAGCCCCAGCCCCAG 19


RESULT 926
US-10-310-914A-520422/c
; Sequence 520422, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 520422
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-520422

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3896 CTTTTTGTTTCTTCGTTTT 3914
              |||||||||| || |||||
Db         19 CTTTTTGTTTGTTTGTTTT 1


RESULT 927
US-10-310-914A-543953/c
; Sequence 543953, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 543953
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-543953

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2799 TGTGATGTGGGAGGTGATG 2817
              ||||||| |||||||| ||
Db         19 TGTGATGGGGGAGGTGGTG 1


RESULT 928
US-10-310-914A-616709
; Sequence 616709, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
```

```
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 616709
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-616709

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1061 CCGCCCCTGGCCCCAGCCC 1079
              ||||||| || ||||||||
Db          1 CCGCCCCCGGGCCCAGCCC 19


RESULT 929
US-10-310-914A-691544/c
; Sequence 691544, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 691544
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-691544

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1055 CCGTCCCCGCCCCTGGCCC 1073
              |||||||||||| | |||||
Db         19 CCGTCCCCGCCTCGGGCCC 1


RESULT 930
US-10-310-914A-701274
; Sequence 701274, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 701274
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-701274

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3571 CAGGACTGGGTGTGACCAG 3589
              ||||||:|||: :|||| |
Db          1 CAGGACUGGGUCUGACCUG 19


RESULT 931
US-10-310-914A-735391
; Sequence 735391, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 735391
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-735391

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1531 CTGGTGGAGCCCTGGGTGG 1549
              |:||:||||||| ||| ||
Db          1 CUGGUGGAGCCCCGGGCGG 19


RESULT 932
US-10-310-914A-764359/c
; Sequence 764359, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 764359
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-764359

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1847 GGGCAGAGCTGCGGGGGCT 1865
              |||| |||||| |||||||
Db         19 GGGCGGAGCTGTGGGGGCT 1


RESULT 933
US-10-310-914A-778757
; Sequence 778757, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
```

; SEQ ID NO 778757
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-778757

 Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 9.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 184 GCGCGGCACAGACGCGGGG 202
 ||||||||||| ||| |||
Db 1 GCGCGGCACAGGCGCAGGG 19

RESULT 934
US-10-310-914A-933487/c
; Sequence 933487, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 933487
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-933487

 Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 9.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1057 GTCCCCGCCCCTGGCCCCA 1075
 | |||||||| |||||||
Db 19 GGCCCCGCCCCGGGCCCCA 1

RESULT 935
US-10-310-914A-990363
; Sequence 990363, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 990363
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-990363

 Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 9.4e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 170 CCCGCCGCCCCGCGCGCGCG 188
 ||||||||||||||| | ||
Db 1 CCCGCCGCCCGCGCCCUCG 19

RESULT 936
US-10-310-914A-1040857
; Sequence 1040857, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1040857
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1040857

 Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 9.4e+02;
 Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 572 CCCCGGGCCAGGCCCACTG 590
 |||| |||||||||| |:|
Db 1 CCCCUGGCCAGGCCCUCUG 19

RESULT 937
US-10-310-914A-1099801
; Sequence 1099801, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1099801
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1099801

 Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 15.8%; Pred. No. 9.4e+02;
 Matches 3; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

Qy 3904 TTCTTCGTTTTGTTTTTCT 3922
 ::|::| :::: :::::|:
Db 1 UUCUUCCUUUUCUUUUUCU 19

RESULT 938
US-10-310-914A-1147060/c
; Sequence 1147060, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1147060

```
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1147060

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1530 CCTGGTGGAGCCCTGGGTG 1548
              |||||  ||||||||||||
Db         19 CCTGGGCGAGCCCTGGGTG 1


RESULT 939
US-10-310-914A-1160786
; Sequence 1160786, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1160786
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1160786

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1057 GTCCCCGCCCCTGGCCCCA 1075
              |:||||| ||| |||||||
Db          1 GUCCCCGACCCAGGCCCCA 19


RESULT 940
US-10-310-914A-1167297/c
; Sequence 1167297, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1167297
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1167297

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTG 3915
              |||||||||  ||  ||||||
Db         19 TTTTTGTTTGTTTGTTTTG 1


RESULT 941
US-10-310-914A-1249167
; Sequence 1249167, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1249167
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1249167

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1074 CAGCCCCAGCCTCTACTGC 1092
              ||||||||||:  ||:||
Db          1 CAGCCCCAGCCUUCACUGC 19


RESULT 942
US-10-310-914A-1257401
; Sequence 1257401, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1257401
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1257401

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   15.8%;  Pred. No. 9.4e+02;
  Matches    3;  Conservative   14;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3904 TTCTTCGTTTTGTTTTTCT 3922
              ::|:: |:::: :::::|:
Db          1 UUCUUUGUUUUCUUUUUCU 19


RESULT 943
US-11-101-244-611
; Sequence 611, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
```

```
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 611
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-611

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2985 GGTCAGCGCCCTGGACAAG 3003
              ||:||||||||  ||||||
Db          1 GGUCAGCGCCCAAGACAAG 19


RESULT 944
US-11-101-244-31906
; Sequence 31906, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 31906
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-31906

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3952 GGAACCTGTTTCACTATGG 3970
              |||| |:| ::|||:|:||
Db          1 GGAAGCUGAUUCACUAUGG 19


RESULT 945
US-11-101-244-51586
; Sequence 51586, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 51586
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-51586

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2985 GGTCAGCGCCCTGGACAAG 3003
              ||:||||||||  ||||||
Db          1 GGUCAGCGCCCAAGACAAG 19


RESULT 946
US-11-101-244-88135/c
; Sequence 88135, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 88135
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-88135

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2032 CTGGTGGTCATTGTGGTCG 2050
              || |||||||| ||||||
Db         19 CTTGTGGTCATTCTGGTCG 1


RESULT 947
US-11-101-244-108278
; Sequence 108278, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
```

```
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 108278
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-108278

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| ::| :||||||
Db          1 UCACAGACUUCCUGGAGAA 19


RESULT 948
US-11-101-244-108374
; Sequence 108374, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 108374
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-108374

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| ::| :||||||
Db          1 UCACAGACUUCCUGGAGAA 19


RESULT 949
US-11-101-244-108473
; Sequence 108473, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 108473
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-108473

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| ::| :||||||
Db          1 UCACAGACUUCCUGGAGAA 19


RESULT 950
US-11-101-244-108571
; Sequence 108571, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 108571
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-108571

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| ::| :||||||
Db          1 UCACAGACUUCCUGGAGAA 19


RESULT 951
US-11-101-244-108671
; Sequence 108671, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
```

```
;  SOFTWARE: Proprietary
; SEQ ID NO 108671
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-108671

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| ::| :|||||||
Db          1 UCACAGACUUCCUGGAGAA 19


RESULT 952
US-11-101-244-113648/c
; Sequence 113648, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 113648
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-113648

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        974 TGACTGTGAACCTGACTCG 992
              ||| |||||||||| ||||
Db         19 TGAGTGTGAACCTGGCTCG 1


RESULT 953
US-11-101-244-149446
; Sequence 149446, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 149446
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-149446

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1979 GGGAGCAGCTGGCCCTGAT 1997
              |||||| ||:||| |:||:
Db          1 GGGAGCUGCUGGCACUGAU 19


RESULT 954
US-11-101-244-153349
; Sequence 153349, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 153349
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-153349

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :||| |||: ||:|||||
Db          1 UCACUGAGUACAUGGAGAA 19


RESULT 955
US-11-101-244-158289
; Sequence 158289, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158289
```

```
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158289

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| :: |:|||||||
Db          1 UCACAGAAUUUAUGGAGAA 19


RESULT 956
US-11-101-244-158376
; Sequence 158376, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158376
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158376

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2846 TGAGCAATCAGGACGTGAT 2864
              :||||||:||||| |: |:
Db          1 UGAGCAAUCAGGAGGUUAU 19


RESULT 957
US-11-101-244-158377
; Sequence 158377, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158377
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158377

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2710 GGAGGAAAGATTCCCATCC 2728
              ||||||||||: || |:||
Db          1 GGAGGAAAGAUCCCUAUCC 19


RESULT 958
US-11-101-244-158451
; Sequence 158451, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158451
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158451

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1777 GAGGTCAAATACCATGAGA 1795
              ||||:||||:|| |:|| |
Db          1 GAGGUCAAAUACUAUGAAA 19


RESULT 959
US-11-101-244-158521
; Sequence 158521, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158521
;   LENGTH: 19
;   TYPE: RNA
```

```
;   ORGANISM: Homo sapiens
US-11-101-244-158521

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              : |||||| ||:||||||
Db          1 UAACAGAGUACAUGGAGAA 19


RESULT 960
US-11-101-244-158525
; Sequence 158525, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158525
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158525

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2453 CAGAGTTCATGGAGAACGG 2471
              |||||: ||:|||||| ||
Db          1 CAGAGUACAUGGAGAAUGG 19


RESULT 961
US-11-101-244-158535
; Sequence 158535, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158535
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158535

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2411 TGGAGGGCGTGGTCACCAA 2429
              :||| |||||:||:||| ||
Db          1 UGGAAGGCGUGGUCACUAA 19


RESULT 962
US-11-101-244-158948
; Sequence 158948, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158948
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158948

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCATT 2822
              :|:|||| |: |:|:||::
Db          1 UGUGGGAAGUCAUGUCAUU 19


RESULT 963
US-11-101-244-158952
; Sequence 158952, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158952
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158952
```

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2445 GATTCTCACAGAGTTCATG 2463
              ||:  :|||||||::||:|
Db          1 GAUCAUCACAGAGUUCAUG 19
```

RESULT 964
US-11-101-244-158958
; Sequence 158958, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158958
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158958

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2807 GGGAGGTGATGTCATTTGG 2825
              |||| |: |:|:||:::||
Db          1 GGGAAGUCAUGUCAUUUGG 19
```

RESULT 965
US-11-101-244-159005
; Sequence 159005, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159005
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159005

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2500 GACGGACAGTTCACAGTCA 2518
              || || |||::|||||:||
Db          1 GAUGGGCAGUUCACAGUCA 19
```

RESULT 966
US-11-101-244-159035
; Sequence 159035, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159035
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159035

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2807 GGGAGGTGATGTCATTTGG 2825
              ||||||:||:|:| : :||
Db          1 GGGAGGUGAUGUCCUAUGG 19
```

RESULT 967
US-11-101-244-159068
; Sequence 159068, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159068
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159068

Query Match 0.4%; Score 15.8; DB 1; Length 19;

```
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2998 GACAAGATGATCCGGAACC 3016
              |||||||:||:||| || |
Db          1 GACAAGAUGAUCCGCAAUC 19


RESULT 968
US-11-101-244-159101
; Sequence 159101, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159101
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159101

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2500 GACGGACAGTTCACAGTCA 2518
              || || |||::||||||:||
Db          1 GAUGGGCAGUUCACAGUCA 19


RESULT 969
US-11-101-244-159124
; Sequence 159124, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159124
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159124

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2807 GGGAGGTGATGTCATTTGG 2825
              ||||||:||:|:| : :||
Db          1 GGGAGGUGAUGUCCUAUGG 19


RESULT 970
US-11-101-244-159148
; Sequence 159148, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159148
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159148

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2998 GACAAGATGATCCGGAACC 3016
              |||||||:||:||| || |
Db          1 GACAAGAUGAUCCGCAAUC 19


RESULT 971
US-11-101-244-159210
; Sequence 159210, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159210
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-159210

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy        704 CCTTCACCGTCTTCTACTA 722
              ||::|| | :|::|:||:|
Db          1 CCUUCAACCUCUUCUACUA 19
```

RESULT 972
US-11-101-244-159219
; Sequence 159219, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159219
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159219

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :||| |||::||:||| ||
Db          1 UCACUGAGUUCAUGGAAAA 19
```

RESULT 973
US-11-101-244-159481
; Sequence 159481, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159481
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159481

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2220 CAAGATTGAAGAGGTGATT 2238
              |||||::|| ||||: |::
Db          1 CAAGAUUGAGGAGGUCAUU 19
```

RESULT 974
US-11-101-244-182879/c
; Sequence 182879, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 182879
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-182879

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3876 TTAATTTTTCTCCCCGTTC 3894
              |||||||| || |||||||
Db         19 TTAATTTTCCTACCCGTTC 1
```

RESULT 975
US-11-101-244-183246/c
; Sequence 183246, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 183246
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-183246

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1585 TTTGAGGTCACTGCATTGA 1603
```

```
              |||||||| ||| ||||||
Db         19 TTTGAGGTGACTTCATTGA 1


RESULT 976
US-11-101-244-215222
; Sequence 215222, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 215222
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-215222

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3730 TGTCAGGGCCCAGTGACAA 3748
              :|:|||||||||| || ||
Db          1 UGUCAGGGCCCAGAGAGAA 19


RESULT 977
US-11-101-244-247832/c
; Sequence 247832, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 247832
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-247832

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1612 TCCTCCTTAGCCACGGGGC 1630
              || |||||||||||||| ||
Db         19 TCATCCTTAGCCACGGTGC 1


RESULT 978
US-11-101-244-256851/c
; Sequence 256851, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 256851
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-256851

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2019 TGTGGTCCTGGTCCTGGTG 2037
              | ||||||||||||||| ||
Db         19 TTTGGTCCTGGTCCTGTTG 1


RESULT 979
US-11-101-244-314443/c
; Sequence 314443, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 314443
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-314443

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1124 TCACGGGCTGCAGCTGTGC 1142
              ||| ||||| |||||||||
Db         19 TCATGGGCTTCAGCTGTGC 1
```

```
RESULT 980
US-11-101-244-351839
; Sequence 351839, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 351839
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-351839

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3779 GCTGTCACCACCAAACTCA 3797
              ||:|:|| ||||||| :||
Db          1 GCUGUCAUCACCAAAGUCA 19


RESULT 981
US-11-101-244-351938
; Sequence 351938, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 351938
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-351938

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3779 GCTGTCACCACCAAACTCA 3797
              ||:|:|| ||||||| :||
Db          1 GCUGUCAUCACCAAAGUCA 19


RESULT 982
US-11-101-244-351977
; Sequence 351977, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 351977
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-351977

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3779 GCTGTCACCACCAAACTCA 3797
              ||:|:|| ||||||| :||
Db          1 GCUGUCAUCACCAAAGUCA 19


RESULT 983
US-11-101-244-358726
; Sequence 358726, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 358726
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-358726

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19
```

```
RESULT 984
US-11-101-244-358909
; Sequence 358909, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 358909
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-358909

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 985
US-11-101-244-367347
; Sequence 367347, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 367347
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-367347

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCATT 2822
              :|:|||  |:||:|:||::
Db          1 UGUGGGCAGUGAUGUCAUU 19


RESULT 986
US-11-101-244-368735
; Sequence 368735, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 368735
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-368735

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        510 GAGCGGCCTGGATGAGGAA 528
              |||| |||:|||:||| ||
Db          1 GAGCUGCCUGGAUGAGAAA 19


RESULT 987
US-11-101-244-401647
; Sequence 401647, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 401647
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-401647

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        109 CAACTCCAGCCACGTCTTG 127
              |||| |||||||||:| :|
Db          1 CAACACCAGCCACGUCAUG 19


RESULT 988
US-11-101-244-463025
```

```
; Sequence 463025, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 463025
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-463025

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 GATGTCTCCTACGTCAAGA 2224
              ||:|:| | :|||:|||||
Db          1 GAUGUCACUUACGUCAAGA 19


RESULT 989
US-11-101-244-520652
; Sequence 520652, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 520652
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-520652

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              : ||||||::||:||| ||
Db          1 UGACAGAGUUCAUGGAAAA 19


RESULT 990
US-11-101-244-553895
; Sequence 553895, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 553895
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-553895

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3593 AAAAGGAAGTGCCCAACAT 3611
              |||||||||:| |||| |:
Db          1 AAAAGGAAGUGUCCAAUAU 19


RESULT 991
US-11-101-244-558451
; Sequence 558451, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 558451
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-558451

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2288 GGAAGAAGGAGAGCTGTGT 2306
              |||||||||||||  |:|:
Db          1 GGAAGAAGGAGAGGAGUGU 19


RESULT 992
US-11-101-244-588523
; Sequence 588523, Application US/11101244
; Publication No. US20050246794A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 588523
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-588523

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 993
US-11-101-244-602297
; Sequence 602297, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 602297
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-602297

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3239 CGGGACACCAGAAGAAAAT 3257
              || |||||||||||| |:
Db          1 CGUGACACCAGAAGAAUAU 19


RESULT 994
US-11-101-244-632602
; Sequence 632602, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 632602
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-632602

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        704 CCTTCACCGTCTTCTACTA 722
              | ::|| ||:|::|:||:|
Db          1 CAUUCAACGUCUUCUACUA 19


RESULT 995
US-11-101-244-633003/c
; Sequence 633003, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 633003
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-633003

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2801 TGATGTGGGAGGTGATGTC 2819
              |||||  ||||||||||||
Db         19 TGATGGTGGAGGTGATGTC 1


RESULT 996
US-11-101-244-645883/c
; Sequence 645883, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
```

```
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 645883
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-645883

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3243 ACACCAGAAGAAAATCTTG 3261
              ||| |||||| ||||||||
Db         19 ACAACAGAAGCAAATCTTG 1


RESULT 997
US-11-101-244-665485/c
; Sequence 665485, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 665485
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-665485

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2607 CAACATCCTAGTCAACAGC 2625
              |||||||| |||||| |||
Db         19 CAACATCCCAGTCAATAGC 1


RESULT 998
US-11-101-244-669877
; Sequence 669877, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 669877
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-669877

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 999
US-11-101-244-707935/c
; Sequence 707935, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 707935
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-707935

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2029 GTCCTGGTGGTCATTGTGG 2047
              || ||||||||| ||||||
Db         19 GTACTGGTGGTCCTTGTGG 1


RESULT 1000
US-11-101-244-722881/c
; Sequence 722881, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
```

```
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 722881
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-722881

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2801 TGATGTGGGAGGTGATGTC 2819
              ||||||||| | |||||||
Db         19 TGATGTGGGCGTTGATGTC 1


RESULT 1001
US-11-101-244-729514
; Sequence 729514, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 729514
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-729514

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4003 CATCATGTCTGTTTCCAGA 4021
              ||: |:|:|:|:::| |||
Db          1 CAUGAUGUCUGUUUCUAGA 19


RESULT 1002
US-11-101-244-729613
; Sequence 729613, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 729613
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-729613

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4003 CATCATGTCTGTTTCCAGA 4021
              ||: |:|:|:|:::| |||
Db          1 CAUGAUGUCUGUUUCUAGA 19


RESULT 1003
US-11-101-244-748070
; Sequence 748070, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 748070
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-748070

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        455 CTGCTGATCTGAAGTGGGT 473
              |:||:||:|:| ||:|| :
Db          1 CUGCUGAUCUGUAGUGGUU 19


RESULT 1004
US-11-101-244-748086/c
; Sequence 748086, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
```

```
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 748086
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-748086

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3598 GAAGTGCCCAACATCTCCC 3616
              |||||  ||||||||||||
Db         19 GAAGTTTCCAACATCTCCC 1


RESULT 1005
US-11-101-244-814212
; Sequence 814212, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 814212
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-814212

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        893 GCTTCTACCTGGCCTTCCA 911
              ||::|:|||:|||| :| |
Db          1 GCUUCUACCUGGCCCUCUA 19


RESULT 1006
US-11-101-244-815617
; Sequence 815617, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 815617
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-815617

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2292 GAAGGAGAGCTGTGTGGCA 2310
              |||||| |||:|:|:| ||
Db          1 GAAGGAAAGCUGUGUGACA 19


RESULT 1007
US-11-101-244-829676/c
; Sequence 829676, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 829676
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-829676

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2375 TCATGGGCCAGTTCGAGCA 2393
              |||||| |||| |||||||
Db         19 TCATGGTCCAGCTCGAGCA 1


RESULT 1008
US-11-101-244-858962
; Sequence 858962, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 858962
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-858962

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        504 GGAACTGAGCGGCCTGGAT 522
              |||| : |||||||:|||:
Db          1 GGAAGUCAGCGGCCUGGAU 19


RESULT 1009
US-11-101-244-871328
; Sequence 871328, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 871328
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-871328

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1010
US-11-101-244-889071/c
; Sequence 889071, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 889071
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-889071

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2644 TCTGACTTTGGCCTTTCCC 2662
              |||||||| ||||| ||||
Db         19 TCTGACTTGGGCCTCTCCC 1


RESULT 1011
US-11-101-244-903949
; Sequence 903949, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 903949
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-903949

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3012 GAACCCCGCCAGCCTCAAA 3030
              |||||| |||||||:|| |
Db          1 GAACCCAGCCAGCCUCAUA 19


RESULT 1012
US-11-101-244-931273/c
; Sequence 931273, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
```

```
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 931273
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-931273

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        447 ATTGGAAACTGCTGATCTG 465
              ||||||||||||| | |||
Db         19 ATTGGAAACTGCTCAGCTG 1


RESULT 1013
US-11-101-244-931865
; Sequence 931865, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 931865
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-931865

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3625 CAGGTGCCCCCCTCACCTT 3643
              ||| :|||| ||:||||::
Db          1 CAGCUGCCCUCCUCACCUU 19


RESULT 1014
US-11-101-244-943735
; Sequence 943735, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 943735
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-943735

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        835 GAGGCCACCGGGAAGGTGA 853
              |||||||| |||| |:||
Db          1 GAGGCCACCAGGAAUGUGA 19


RESULT 1015
US-11-101-244-959149
; Sequence 959149, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 959149
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-959149

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        768 GGAGAACCCCTACATCAAG 786
              ||||||  ||:|||:||||
Db          1 GGAGAAGGCCUACAUCAAG 19


RESULT 1016
US-11-101-244-959179
; Sequence 959179, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
```

```
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 959179
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-959179

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        767 TGGAGAACCCCTACATCAA 785
              :||||||  ||:|||:|||
Db          1 UGGAGAAGGCCUACAUCAA 19


RESULT 1017
US-11-101-244-965862/c
; Sequence 965862, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 965862
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-965862

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTCTG 2636
              |||||||||||||||  |||
Db         19 TCAACAGCAACCTCAACTG 1


RESULT 1018
US-11-101-244-1012257
; Sequence 1012257, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1012257
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1012257

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2619 CAACAGCAACCTCGTCTGC 2637
              ||||||||||:| :|: |
Db          1 CAACAGCAACCUCUUCUUC 19


RESULT 1019
US-11-101-244-1012356
; Sequence 1012356, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1012356
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1012356

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2619 CAACAGCAACCTCGTCTGC 2637
              ||||||||||:| :|: |
Db          1 CAACAGCAACCUCUUCUUC 19


RESULT 1020
US-11-101-244-1029052/c
; Sequence 1029052, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
```

```
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1029052
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1029052

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2644 TCTGACTTTGGCCTTTCCC 2662
              ||||||| |||||||| ||
Db         19 TCTGACTCTGGCCTTTGCC 1


RESULT 1021
US-11-101-244-1030733
; Sequence 1030733, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1030733
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1030733

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2176 GAGGCTGTGAGGGAATTTG 2194
              |||||:|:| | |||:::|
Db          1 GAGGCUGUGUGAGAAUUUG 19


RESULT 1022
US-11-101-244-1033475/c
; Sequence 1033475, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1033475
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1033475

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3960 TTTCACTATGGCCTCCTTT 3978
              ||||  |||||||||||||
Db         19 TTTCTGTATGGCCTCCTTT 1


RESULT 1023
US-11-101-244-1104856
; Sequence 1104856, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1104856
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1104856

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2159 CTTATGAAGACCCTAATGA 2177
              |: |:|||||||:|| ||
Db          1 CUAAUGAAGACCCUAAAGA 19


RESULT 1024
US-11-101-244-1110635
; Sequence 1110635, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
```

```
;  SOFTWARE: Proprietary
; SEQ ID NO 1110635
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1110635

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1025
US-11-101-244-1110844
; Sequence 1110844, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1110844
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1110844

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1026
US-11-101-244-1111066
; Sequence 1111066, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1111066
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1111066

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1027
US-11-101-244-1111265
; Sequence 1111265, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1111265
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1111265

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1028
US-11-101-244-1111461
; Sequence 1111461, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1111461
```

```
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1111461

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1029
US-11-101-244-1111653
; Sequence 1111653, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1111653
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1111653

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1030
US-11-101-244-1111863
; Sequence 1111863, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1111863
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1111863

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1031
US-11-101-244-1112048
; Sequence 1112048, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112048
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1112048

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1032
US-11-101-244-1112255
; Sequence 1112255, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112255
;   LENGTH: 19
;   TYPE: RNA
```

```
;   ORGANISM: Homo sapiens
US-11-101-244-1112255

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1033
US-11-101-244-1112450
; Sequence 1112450, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112450
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1112450

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1034
US-11-101-244-1112549
; Sequence 1112549, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112549
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1112549

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1035
US-11-101-244-1112749
; Sequence 1112749, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112749
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1112749

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1036
US-11-101-244-1112941
; Sequence 1112941, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112941
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1112941
```

```
  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1037
US-11-101-244-1113149
; Sequence 1113149, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1113149
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1113149

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1038
US-11-101-244-1113350
; Sequence 1113350, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1113350
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1113350

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1039
US-11-101-244-1113545
; Sequence 1113545, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1113545
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1113545

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1040
US-11-101-244-1113749
; Sequence 1113749, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1113749
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1113749

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
```

```
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1041
US-11-101-244-1113949
; Sequence 1113949, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1113949
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1113949

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1042
US-11-101-244-1114149
; Sequence 1114149, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1114149
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1114149

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1043
US-11-101-244-1162888/c
; Sequence 1162888, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1162888
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1162888

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        452 AAACTGCTGATCTGAAGTG 470
              ||||| ||||||| |||||
Db         19 AAACTCCTGATCTCAAGTG 1


RESULT 1044
US-11-101-244-1175693
; Sequence 1175693, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1175693
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1175693

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy        452 AAACTGCTGATCTGAAGTG 470
              ||||:||:|| |: |||:|
Db          1 AAACUGCUGACCUCAAGUG 19
```

RESULT 1045
US-11-101-244-1207595
; Sequence 1207595, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1207595
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1207595

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2808 GGAGGTGATGTCATTTGGG 2826
              |||||:| :|:||:::| |
Db          1 GGAGGUGGUGUCAUUUGUG 19
```

RESULT 1046
US-11-101-244-1277041
; Sequence 1277041, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1277041
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1277041

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2746 GCCATTGCCTTCCGGAAGT 2764
              ||||::|||::| | |||:
Db          1 GCCAUUGCCUUCAGAAAGU 19
```

RESULT 1047
US-11-101-244-1315734
; Sequence 1315734, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1315734
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1315734

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3828 CCCAGCTGCTGCCTTCATA 3846
              ||||||: |:|||::| :|
Db          1 CCCAGCUCCUGCCUUCUUA 19
```

RESULT 1048
US-11-101-244-1355528/c
; Sequence 1355528, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1355528
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1355528

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3469 TTTGGAGAGACAGGATTTG 3487
```

```
                    | ||||||||||||| |||
Db         19 TATGGAGAGACAGGAGTTG 1


RESULT 1049
US-11-101-244-1377429/c
; Sequence 1377429, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1377429
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1377429

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        466 AAGTGGGTGACATTCCCTC 484
              |||| ||||||| ||||||
Db         19 AAGTAGGTGACACTCCCTC 1


RESULT 1050
US-11-101-244-1380520/c
; Sequence 1380520, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1380520
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1380520

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2799 TGTGATGTGGGAGGTGATG 2817
              |||||||| || |||||||
Db         19 TGTGATGTCGGTGGTGATG 1


RESULT 1051
US-11-101-244-1563938
; Sequence 1563938, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1563938
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1563938

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        702 GACCTTCACCGTCTTCTAC 720
              ||||::|| ||:|: |:||
Db          1 GACCUUCAACGUCUACUAC 19


RESULT 1052
US-11-083-784-611
; Sequence 611, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 611
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-611

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2985 GGTCAGCGCCCTGGACAAG 3003
```

```
              ||:||||||||  ||||||
Db          1 GGUCAGCGCCCAAGACAAG 19
```

RESULT 1053
US-11-083-784-31906
; Sequence 31906, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 31906
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-31906

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy       3952 GGAACCTGTTTCACTATGG 3970
              |||| |:| ::|||:|:||
Db          1 GGAAGCUGAUUCACUAUGG 19
```

RESULT 1054
US-11-083-784-51586
; Sequence 51586, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 51586
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-51586

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2985 GGTCAGCGCCCTGGACAAG 3003
              ||:||||||||  ||||||
Db          1 GGUCAGCGCCCAAGACAAG 19
```

RESULT 1055
US-11-083-784-88135/c
; Sequence 88135, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 88135
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-88135

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2032 CTGGTGGTCATTGTGGTCG 2050
              || |||||||||  ||||||
Db         19 CTTGTGGTCATTCTGGTCG 1
```

RESULT 1056
US-11-083-784-108278
; Sequence 108278, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 108278
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-108278

```
  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| ::| :|||||||
Db          1 UCACAGACUUCCUGGAGAA 19


RESULT 1057
US-11-083-784-108374
; Sequence 108374, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 108374
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-108374

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| ::| :|||||||
Db          1 UCACAGACUUCCUGGAGAA 19


RESULT 1058
US-11-083-784-108473
; Sequence 108473, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 108473
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-108473

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| ::| :|||||||
Db          1 UCACAGACUUCCUGGAGAA 19


RESULT 1059
US-11-083-784-108571
; Sequence 108571, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 108571
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-108571

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| ::| :|||||||
Db          1 UCACAGACUUCCUGGAGAA 19


RESULT 1060
US-11-083-784-108671
; Sequence 108671, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
```

```
;  SOFTWARE: Proprietary
; SEQ ID NO 108671
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-108671

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| ::| :||||||
Db             1 UCACAGACUUCCUGGAGAA 19


RESULT 1061
US-11-083-784-113648/c
; Sequence 113648, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 113648
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-113648

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        974 TGACTGTGAACCTGACTCG 992
              ||| |||||||||| ||||
Db         19 TGAGTGTGAACCTGGCTCG 1


RESULT 1062
US-11-083-784-149446
; Sequence 149446, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 149446
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-149446

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1979 GGGAGCAGCTGGCCCTGAT 1997
              |||||| ||:||| |:||:
Db             1 GGGAGCUGCUGGCACUGAU 19


RESULT 1063
US-11-083-784-153349
; Sequence 153349, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 153349
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-153349

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :||| |||: ||:||||||
Db             1 UCACUGAGUACAUGGAGAA 19


RESULT 1064
US-11-083-784-158289
; Sequence 158289, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
```

```
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158289
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158289

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :|||||| :: |:|||||||
Db          1 UCACAGAAUUUAUGGAGAA 19


RESULT 1065
US-11-083-784-158376
; Sequence 158376, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158376
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158376

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2846 TGAGCAATCAGGACGTGAT 2864
              :||||||:||||| |: |:
Db          1 UGAGCAAUCAGGAGGUUAU 19


RESULT 1066
US-11-083-784-158377
; Sequence 158377, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158377
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158377

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2710 GGAGGAAAGATTCCCATCC 2728
              ||||||||||: || |:||
Db          1 GGAGGAAAGAUCCCUAUCC 19


RESULT 1067
US-11-083-784-158451
; Sequence 158451, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158451
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158451

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1777 GAGGTCAAATACCATGAGA 1795
              ||||:||||:|| |:|| |
Db          1 GAGGUCAAAUACUAUGAAA 19


RESULT 1068
US-11-083-784-158521
; Sequence 158521, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
```

```
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158521
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158521

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              : |||||| : ||:||||||
Db          1 UAACAGAGUACAUGGAGAA 19


RESULT 1069
US-11-083-784-158525
; Sequence 158525, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158525
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158525

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2453 CAGAGTTCATGGAGAACGG 2471
              ||||| : ||:|||||| ||
Db          1 CAGAGUACAUGGAGAAUGG 19


RESULT 1070
US-11-083-784-158535
; Sequence 158535, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158535
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158535

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2411 TGGAGGGCGTGGTCACCAA 2429
              :||| |||| :||:||| ||
Db          1 UGGAAGGCGUGGUCACUAA 19


RESULT 1071
US-11-083-784-158948
; Sequence 158948, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158948
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158948

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCATT 2822
              :|:|||| |: |:|:||::
Db          1 UGUGGGAAGUCAUGUCAUU 19


RESULT 1072
US-11-083-784-158952
; Sequence 158952, Application US/11083784
; Publication No. US20050245475A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158952
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158952

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2445 GATTCTCACAGAGTTCATG 2463
              ||:  :|||||||::||:|
Db          1 GAUCAUCACAGAGUUCAUG 19


RESULT 1073
US-11-083-784-158958
; Sequence 158958, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158958
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-158958

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2807 GGGAGGTGATGTCATTTGG 2825
              |||| |: |:|:||:::||
Db          1 GGGAAGUCAUGUCAUUUGG 19


RESULT 1074
US-11-083-784-159005
; Sequence 159005, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159005
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159005

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2500 GACGGACAGTTCACAGTCA 2518
              || || |||::||||||:||
Db          1 GAUGGGCAGUUCACAGUCA 19


RESULT 1075
US-11-083-784-159035
; Sequence 159035, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159035
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159035

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2807 GGGAGGTGATGTCATTTGG 2825
              ||||||:||:|:| : :||
Db          1 GGGAGGUGAUGUCCUAUGG 19
```

RESULT 1076
US-11-083-784-159068
; Sequence 159068, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159068
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159068

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2998 GACAAGATGATCCGGAACC 3016
||||||:||:||| || |
Db 1 GACAAGAUGAUCCGCAAUC 19

RESULT 1077
US-11-083-784-159101
; Sequence 159101, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159101
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159101

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2500 GACGGACAGTTCACAGTCA 2518
|| || |||::|||||:||
Db 1 GAUGGGCAGUUCACAGUCA 19

RESULT 1078
US-11-083-784-159124
; Sequence 159124, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159124
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159124

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2807 GGGAGGTGATGTCATTTGG 2825
||||||:||:|:| : :||
Db 1 GGGAGGUGAUGUCCUAUGG 19

RESULT 1079
US-11-083-784-159148
; Sequence 159148, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159148
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159148

Query Match 0.4%; Score 15.8; DB 1; Length 19;

```
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2998 GACAAGATGATCCGGAACC 3016
              ||||||:||:||| || |
Db          1 GACAAGAUGAUCCGCAAUC 19


RESULT 1080
US-11-083-784-159210
; Sequence 159210, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159210
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159210

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        704 CCTTCACCGTCTTCTACTA 722
              ||::|| | :|::|:||:|
Db          1 CCUUCAACCUCUUCUACUA 19


RESULT 1081
US-11-083-784-159219
; Sequence 159219, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159219
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159219

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              :||| |||::||:||| ||
Db          1 UCACUGAGUUCAUGGAAAA 19


RESULT 1082
US-11-083-784-159481
; Sequence 159481, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 159481
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-159481

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2220 CAAGATTGAAGAGGTGATT 2238
              |||||::|| ||||: |::
Db          1 CAAGAUUGAGGAGGUCAUU 19


RESULT 1083
US-11-083-784-182879/c
; Sequence 182879, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 182879
```

```
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-182879

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3876 TTAATTTTTCTCCCCGTTC 3894
              ||||||||  || |||||||
Db         19 TTAATTTTCCTACCCGTTC 1


RESULT 1084
US-11-083-784-183246/c
; Sequence 183246, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 183246
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-183246

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1585 TTTGAGGTCACTGCATTGA 1603
              ||||||||  ||| ||||||
Db         19 TTTGAGGTGACTTCATTGA 1


RESULT 1085
US-11-083-784-215222
; Sequence 215222, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 215222
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-215222

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3730 TGTCAGGGCCCAGTGACAA 3748
              :|:||||||||||  || ||
Db          1 UGUCAGGGCCCAGAGAGAA 19


RESULT 1086
US-11-083-784-247832/c
; Sequence 247832, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 247832
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-247832

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1612 TCCTCCTTAGCCACGGGGC 1630
              ||  |||||||||||||  ||
Db         19 TCATCCTTAGCCACGGTGC 1


RESULT 1087
US-11-083-784-256851/c
; Sequence 256851, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
```

```
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 256851
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-256851

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2019 TGTGGTCCTGGTCCTGGTG 2037
              | ||||||||||||||| ||
Db         19 TTTGGTCCTGGTCCTGTTG 1


RESULT 1088
US-11-083-784-314443/c
; Sequence 314443, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 314443
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-314443

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1124 TCACGGGCTGCAGCTGTGC 1142
              ||| ||||| |||||||||
Db         19 TCATGGGCTTCAGCTGTGC 1


RESULT 1089
US-11-083-784-351839
; Sequence 351839, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 351839
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-351839

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3779 GCTGTCACCACCAAACTCA 3797
              ||:|:|| ||||||| :||
Db          1 GCUGUCAUCACCAAAGUCA 19


RESULT 1090
US-11-083-784-351938
; Sequence 351938, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 351938
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-351938

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3779 GCTGTCACCACCAAACTCA 3797
              ||:|:|| ||||||| :||
Db          1 GCUGUCAUCACCAAAGUCA 19


RESULT 1091
US-11-083-784-351977
; Sequence 351977, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 351977
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-351977

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3779 GCTGTCACCACCAAACTCA 3797
              ||:|:|| ||||||| :||
Db          1 GCUGUCAUCACCAAAGUCA 19


RESULT 1092
US-11-083-784-358726
; Sequence 358726, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 358726
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-358726

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1093
US-11-083-784-358909
; Sequence 358909, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 358909
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-358909

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1094
US-11-083-784-367347
; Sequence 367347, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 367347
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-367347

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2804 TGTGGGAGGTGATGTCATT 2822
              :|:||| |:||:|:||::
Db          1 UGUGGGCAGUGAUGUCAUU 19


RESULT 1095
US-11-083-784-368735
; Sequence 368735, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
```

```
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 368735
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-368735

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        510 GAGCGGCCTGGATGAGGAA 528
              |||| |||:|||:||| ||
Db          1 GAGCUGCCUGGAUGAGAAA 19


RESULT 1096
US-11-083-784-401647
; Sequence 401647, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 401647
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-401647

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        109 CAACTCCAGCCACGTCTTG 127
              |||| |||||||||:| :|
Db          1 CAACACCAGCCACGUCAUG 19


RESULT 1097
US-11-083-784-463025
; Sequence 463025, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 463025
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-463025

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2206 GATGTCTCCTACGTCAAGA 2224
              ||:|:| | :|||:|||||
Db          1 GAUGUCACUUACGUCAAGA 19


RESULT 1098
US-11-083-784-520652
; Sequence 520652, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 520652
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-520652

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2450 TCACAGAGTTCATGGAGAA 2468
              : ||||||::||:||| ||
Db          1 UGACAGAGUUCAUGGAAAA 19
```

```
RESULT 1099
US-11-083-784-553895
; Sequence 553895, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 553895
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-553895

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3593 AAAAGGAAGTGCCCAACAT 3611
              ||||||||||:| |||| |:
Db          1 AAAAGGAAGUGUCCAAUAU 19


RESULT 1100
US-11-083-784-558451
; Sequence 558451, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 558451
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-558451

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2288 GGAAGAAGGAGAGCTGTGT 2306
              |||||||||||||  |:|:
Db          1 GGAAGAAGGAGAGGAGUGU 19


RESULT 1101
US-11-083-784-588523
; Sequence 588523, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 588523
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-588523

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1102
US-11-083-784-602297
; Sequence 602297, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 602297
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-602297

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       3239 CGGGACACCAGAAGAAAAT 3257
              || |||||||||||||  |:
Db          1 CGUGACACCAGAAGAAUAU 19


RESULT 1103
US-11-083-784-632602
; Sequence 632602, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 632602
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-632602

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        704 CCTTCACCGTCTTCTACTA 722
              | ::|| ||:|::|:||:|
Db          1 CAUUCAACGUCUUCUACUA 19


RESULT 1104
US-11-083-784-633003/c
; Sequence 633003, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 633003
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-633003

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2801 TGATGTGGGAGGTGATGTC 2819
              |||||  ||||||||||||
Db         19 TGATGGTGGAGGTGATGTC 1


RESULT 1105
US-11-083-784-645883/c
; Sequence 645883, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 645883
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-645883

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3243 ACACCAGAAGAAAATCTTG 3261
              ||| |||||| ||||||||
Db         19 ACAACAGAAGCAAATCTTG 1


RESULT 1106
US-11-083-784-665485/c
; Sequence 665485, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 665485
;   LENGTH: 19
;   TYPE: RNA
```

```
;   ORGANISM: Homo sapiens
US-11-083-784-665485

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2607 CAACATCCTAGTCAACAGC 2625
              ||||||| |||||| |||
Db         19 CAACATCCCAGTCAATAGC 1


RESULT 1107
US-11-083-784-669877
; Sequence 669877, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 669877
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-669877

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1108
US-11-083-784-707935/c
; Sequence 707935, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 707935
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-707935

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2029 GTCCTGGTGGTCATTGTGG 2047
              || ||||||||| ||||||
Db         19 GTACTGGTGGTCCTTGTGG 1


RESULT 1109
US-11-083-784-722881/c
; Sequence 722881, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 722881
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-722881

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2801 TGATGTGGGAGGTGATGTC 2819
              ||||||||| | |||||||
Db         19 TGATGTGGGCGTTGATGTC 1


RESULT 1110
US-11-083-784-729514
; Sequence 729514, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
```

```
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 729514
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-729514

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4003 CATCATGTCTGTTTCCAGA 4021
              ||: |:|:|:|:::| |||
Db          1 CAUGAUGUCUGUUUCUAGA 19


RESULT 1111
US-11-083-784-729613
; Sequence 729613, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 729613
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-729613

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 9.4e+02;
  Matches   10;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4003 CATCATGTCTGTTTCCAGA 4021
              ||: |:|:|:|:::| |||
Db          1 CAUGAUGUCUGUUUCUAGA 19


RESULT 1112
US-11-083-784-748070
; Sequence 748070, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 748070
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-748070

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        455 CTGCTGATCTGAAGTGGGT 473
              |:||:||:|:| ||:|| :
Db          1 CUGCUGAUCUGUAGUGGUU 19


RESULT 1113
US-11-083-784-748086/c
; Sequence 748086, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 748086
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-748086

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3598 GAAGTGCCCAACATCTCCC 3616
              |||||  ||||||||||||
Db         19 GAAGTTTCCAACATCTCCC 1


RESULT 1114
US-11-083-784-814212
; Sequence 814212, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
```

```
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 814212
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-814212

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        893 GCTTCTACCTGGCCTTCCA 911
              ||::|:|||:|||| :| |
Db          1 GCUUCUACCUGGCCCUCUA 19


RESULT 1115
US-11-083-784-815617
; Sequence 815617, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 815617
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-815617

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2292 GAAGGAGAGCTGTGTGGCA 2310
              |||||| |||:|:|:| ||
Db          1 GAAGGAAAGCUGUGUGACA 19


RESULT 1116
US-11-083-784-829676/c
; Sequence 829676, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 829676
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-829676

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2375 TCATGGGCCAGTTCGAGCA 2393
              |||||| |||| |||||||
Db         19 TCATGGTCCAGCTCGAGCA 1


RESULT 1117
US-11-083-784-858962
; Sequence 858962, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 858962
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-858962

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        504 GGAACTGAGCGGCCTGGAT 522
              |||| : |||||||:|||:
Db          1 GGAAGUCAGCGGCCUGGAU 19


RESULT 1118
US-11-083-784-871328
; Sequence 871328, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
```

```
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 871328
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-871328

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1119
US-11-083-784-889071/c
; Sequence 889071, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 889071
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-889071

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2644 TCTGACTTTGGCCTTTCCC 2662
              |||||||| ||||| ||||
Db         19 TCTGACTTGGGCCTCTCCC 1


RESULT 1120
US-11-083-784-903949
; Sequence 903949, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 903949
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-903949

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3012 GAACCCCGCCAGCCTCAAA 3030
              |||||| |||||||:|| |
Db          1 GAACCCAGCCAGCCUCAUA 19


RESULT 1121
US-11-083-784-931273/c
; Sequence 931273, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 931273
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-931273

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        447 ATTGGAAACTGCTGATCTG 465
              |||||||||||| | |||
Db         19 ATTGGAAACTGCTCAGCTG 1


RESULT 1122
US-11-083-784-931865
```

```
; Sequence 931865, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 931865
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-931865

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3625 CAGGTGCCCCCCTCACCTT 3643
              ||| :|||| ||:||||::
Db          1 CAGCUGCCCUCCUCACCUU 19


RESULT 1123
US-11-083-784-943735
; Sequence 943735, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 943735
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-943735

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 9.4e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        835 GAGGCCACCGGGAAGGTGA 853
              ||||||||| |||| |:||
Db          1 GAGGCCACCAGGAAUGUGA 19


RESULT 1124
US-11-083-784-959149
; Sequence 959149, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 959149
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-959149

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 9.4e+02;
  Matches   15;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        768 GGAGAACCCCTACATCAAG 786
              ||||||  ||:|||:||||
Db          1 GGAGAAGGCCUACAUCAAG 19


RESULT 1125
US-11-083-784-959179
; Sequence 959179, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 959179
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-959179

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        767 TGGAGAACCCCTACATCAA 785
```

```
              :|||||| ||:|||:|||
Db          1 UGGAGAAGGCCUACAUCAA 19
```

RESULT 1126
US-11-083-784-965862/c
; Sequence 965862, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 965862
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-965862

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2618 TCAACAGCAACCTCGTCTG 2636
              |||||||||||||| |||
Db         19 TCAACAGCAACCTCAACTG 1
```

RESULT 1127
US-11-083-784-1012257
; Sequence 1012257, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1012257
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1012257

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2619 CAACAGCAACCTCGTCTGC 2637
              ||||||||||:| :|: |
Db          1 CAACAGCAACCUCUUCUUC 19
```

RESULT 1128
US-11-083-784-1012356
; Sequence 1012356, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1012356
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1012356

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2619 CAACAGCAACCTCGTCTGC 2637
              ||||||||||:| :|: |
Db          1 CAACAGCAACCUCUUCUUC 19
```

RESULT 1129
US-11-083-784-1029052/c
; Sequence 1029052, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1029052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1029052

```
  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2644 TCTGACTTTGGCCTTTCCC 2662
              ||||||| |||||||| ||
Db         19 TCTGACTCTGGCCTTTGCC 1


RESULT 1130
US-11-083-784-1030733
; Sequence 1030733, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1030733
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1030733

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2176 GAGGCTGTGAGGGAATTTG 2194
              |||||:|:| | |||:::|
Db          1 GAGGCUGUGUGAGAAUUUG 19


RESULT 1131
US-11-083-784-1033475/c
; Sequence 1033475, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1033475
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1033475

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3960 TTTCACTATGGCCTCCTTT 3978
              ||||  |||||||||||||
Db         19 TTTCTGTATGGCCTCCTTT 1


RESULT 1132
US-11-083-784-1104856
; Sequence 1104856, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1104856
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1104856

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 9.4e+02;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2159 CTTATGAAGACCCTAATGA 2177
              |: |:||||||||:|| ||
Db          1 CUAAUGAAGACCCUAAAGA 19


RESULT 1133
US-11-083-784-1110635
; Sequence 1110635, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
```

```
;  SOFTWARE: Proprietary
; SEQ ID NO 1110635
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1110635

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1134
US-11-083-784-1110844
; Sequence 1110844, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1110844
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1110844

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1135
US-11-083-784-1111066
; Sequence 1111066, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1111066
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1111066

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1136
US-11-083-784-1111265
; Sequence 1111265, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1111265
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1111265

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1137
US-11-083-784-1111461
; Sequence 1111461, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
```

```
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1111461
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1111461

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1138
US-11-083-784-1111653
; Sequence 1111653, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1111653
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1111653

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1139
US-11-083-784-1111863
; Sequence 1111863, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1111863
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1111863

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1140
US-11-083-784-1112048
; Sequence 1112048, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112048
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1112048

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1141
US-11-083-784-1112255
; Sequence 1112255, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
```

```
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112255
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1112255

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1142
US-11-083-784-1112450
; Sequence 1112450, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112450
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1112450

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1143
US-11-083-784-1112549
; Sequence 1112549, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112549
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1112549

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1144
US-11-083-784-1112749
; Sequence 1112749, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112749
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1112749

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1145
US-11-083-784-1112941
; Sequence 1112941, Application US/11083784
; Publication No. US20050245475A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1112941
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1112941

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1146
US-11-083-784-1113149
; Sequence 1113149, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1113149
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1113149

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1147
US-11-083-784-1113350
; Sequence 1113350, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1113350
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1113350

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19


RESULT 1148
US-11-083-784-1113545
; Sequence 1113545, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1113545
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1113545

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1564 CGTCCTGACTTCACCTATA 1582
              ||: |:|||::| ||:|:|
Db          1 CGUACUGACUUCUCCUAUA 19
```

RESULT 1149
US-11-083-784-1113749
; Sequence 1113749, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1113749
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1113749

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 CGTCCTGACTTCACCTATA 1582
||: |:|||::| ||:|:|
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1150
US-11-083-784-1113949
; Sequence 1113949, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1113949
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1113949

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 CGTCCTGACTTCACCTATA 1582
||: |:|||::| ||:|:|
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1151
US-11-083-784-1114149
; Sequence 1114149, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1114149
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1114149

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 CGTCCTGACTTCACCTATA 1582
||: |:|||::| ||:|:|
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1152
US-11-083-784-1162888/c
; Sequence 1162888, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1162888
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1162888

Query Match 0.4%; Score 15.8; DB 1; Length 19;

```
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        452 AAACTGCTGATCTGAAGTG 470
              ||||| ||||||| |||||
Db         19 AAACTCCTGATCTCAAGTG 1


RESULT 1153
US-11-083-784-1175693
; Sequence 1175693, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1175693
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1175693

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 9.4e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        452 AAACTGCTGATCTGAAGTG 470
              ||||:||:|| |: |||:|
Db          1 AAACUGCUGACCUCAAGUG 19


RESULT 1154
US-11-083-784-1207595
; Sequence 1207595, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1207595
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1207595

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 9.4e+02;
  Matches   11;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2808 GGAGGTGATGTCATTTGGG 2826
              |||||:| :|:||:::| |
Db          1 GGAGGUGGUGUCAUUUGUG 19


RESULT 1155
US-11-083-784-1277041
; Sequence 1277041, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1277041
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1277041

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2746 GCCATTGCCTTCCGGAAGT 2764
              ||||::|||::| | |||:
Db          1 GCCAUUGCCUUCAGAAAGU 19


RESULT 1156
US-11-083-784-1315734
; Sequence 1315734, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1315734
```

```
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1315734

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3828 CCCAGCTGCTGCCTTCATA 3846
              |||||| |:|||::| :|
Db          1 CCCAGCUCCUGCCUUCUUA 19


RESULT 1157
US-11-083-784-1355528/c
; Sequence 1355528, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1355528
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1355528

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3469 TTTGGAGAGACAGGATTTG 3487
              | ||||||||||||| |||
Db         19 TATGGAGAGACAGGAGTTG 1


RESULT 1158
US-11-083-784-1377429/c
; Sequence 1377429, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1377429
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1377429

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        466 AAGTGGGTGACATTCCCTC 484
              |||| ||||||| ||||||
Db         19 AAGTAGGTGACACTCCCTC 1


RESULT 1159
US-11-083-784-1380520/c
; Sequence 1380520, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1380520
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1380520

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 9.4e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2799 TGTGATGTGGGAGGTGATG 2817
              |||||||| || |||||||
Db         19 TGTGATGTCGGTGGTGATG 1


RESULT 1160
US-11-083-784-1563938
; Sequence 1563938, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
```

```
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1563938
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1563938

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 9.4e+02;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        702 GACCTTCACCGTCTTCTAC 720
              ||||::|| ||:|: |:||
Db          1 GACCUUCAACGUCUACUAC 19


RESULT 1161
US-10-310-914A-76027/c
; Sequence 76027, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 76027
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-76027

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4086 GGGGTGTGGGGTGAGGT 4102
              ||||||||||||| |||
Db         17 GGGGTGTGGGGTGGGGT 1


RESULT 1162
US-10-310-914A-88249/c
; Sequence 88249, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 88249
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-88249

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        169 GCCCGCCGCCCGCGCGC 185
              ||||||||||||||| |
Db         17 GCCCGCCGCCCGCGCCC 1


RESULT 1163
US-10-310-914A-142074/c
; Sequence 142074, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 142074
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-142074

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3820 GCCCCTCCCCCAGCTGC 3836
              ||||||||||||||| |
Db         18 GCCCCTCCCCCAGCTCC 2


RESULT 1164
US-10-310-914A-194147/c
; Sequence 194147, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 194147
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-194147

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1530 CCTGGTGGAGCCCTGGG 1546
              || |||||||||||||||
Db         18 CCAGGTGGAGCCCTGGG 2


RESULT 1165
US-10-310-914A-196436/c
; Sequence 196436, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
```

```
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 196436
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-196436

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1230 CCAGCCATGCCCAGCCA 1246
              ||||||| |||||||||
Db         18 CCAGCCAGGCCCAGCCA 2


RESULT 1166
US-10-310-914A-215704
; Sequence 215704, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 215704
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-215704

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        171 CCGCCGCCCGCGCGCGC 187
              ||||||||||||| ||||
Db          2 CCGCCGCCCGCGGGCGC 18


RESULT 1167
US-10-310-914A-233017/c
; Sequence 233017, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 233017
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-233017

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3891 GTTCCCTTTTTGTTTCT 3907
              ||||||| |||||||||
Db         17 GTTCCCTCTTTGTTTCT 1


RESULT 1168
US-10-310-914A-239452/c
; Sequence 239452, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 239452
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-239452

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1059 CCCCGCCCCTGGCCCCA 1075
              ||||||||||||| ||||
Db         18 CCCCGCCCCTGGTCCCA 2


RESULT 1169
US-10-310-914A-277041/c
; Sequence 277041, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 277041
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-277041

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        144 CGCGGCCACTGCCAGCA 160
              |||||| ||||||||||
Db         18 CGCGGCTACTGCCAGCA 2


RESULT 1170
US-10-310-914A-291755
; Sequence 291755, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
```

```
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 291755
;    LENGTH: 18
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-291755

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   23.5%;  Pred. No. 9.5e+02;
  Matches    4;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3861 GTTTTGTTTTTGGTCTT 3877
              |::::|::::: |:|::
Db          2 GUUUUGUUUUUUGUCUU 18


RESULT 1171
US-10-310-914A-309547/c
; Sequence 309547, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 309547
;    LENGTH: 18
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-309547

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         52 AGCGGCCGGCTCAGCCC 68
              ||||||  ||||||||||
Db         17 AGCGGCTGGCTCAGCCC 1


RESULT 1172
US-10-310-914A-319145/c
; Sequence 319145, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 319145
;    LENGTH: 18
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-319145

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCCC 1080
              ||||| ||||||||||

Db         18 CCCCTTGCCCCAGCCCC 2


RESULT 1173
US-10-310-914A-337636
; Sequence 337636, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 337636
;    LENGTH: 18
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-337636

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        574 CCGGGCCAGGCCCACTG 590
              ||||||||||||||| |
Db          2 CCGGGCCAGGCCCACAG 18


RESULT 1174
US-10-310-914A-402474/c
; Sequence 402474, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 402474
;    LENGTH: 18
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-402474

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         87 CCCCGAGGCCCCGGAGG 103
              || ||||||||||||||
Db         17 CCTCGAGGCCCCGGAGG 1


RESULT 1175
US-10-310-914A-482383/c
; Sequence 482383, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
```

```
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 482383
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-482383

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        169 GCCCGCCGCCCGCGCGC 185
              ||||||||||||||| |
Db         18 GCCCGCCGCCCGCGCCC 2


RESULT 1176
US-10-310-914A-493585/c
; Sequence 493585, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 493585
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-493585

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        184 GCGCGGCACAGACGCGG 200
              |||||||||||| |||||
Db         18 GCGCGGCACAGGCGCGG 2


RESULT 1177
US-10-310-914A-509676
; Sequence 509676, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 509676
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-509676

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 9.5e+02;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3823 CCTCCCCCAGCTGCTGC 3839
              ||:|| |||||:||:||
Db          2 CCUCCUCCAGCUGCUGC 18


RESULT 1178
US-10-310-914A-510078
; Sequence 510078, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 510078
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-510078

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        572 CCCCGGGCCAGGCCCAC 588
              || |||||||||||||
Db          2 CCACGGGCCAGGCCCAC 18


RESULT 1179
US-10-310-914A-562505/c
; Sequence 562505, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 562505
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-562505

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1059 CCCCGCCCCTGGCCCCA 1075
              ||||| ||||||||||
Db         17 CCCCGACCCTGGCCCCA 1


RESULT 1180
US-10-310-914A-572035/c
; Sequence 572035, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
```

```
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 572035
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-572035

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         66 CCCCCGCCACCCGGGGC 82
              ||||||||||||||| |
Db         17 CCCCCGCCACCCGGGCC 1


RESULT 1181
US-10-310-914A-572960/c
; Sequence 572960, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 572960
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-572960

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1717 AGCAGCTTGAGCCTGGC 1733
              ||||||||| |||||||
Db         18 AGCAGCTTGTGCCTGGC 2


RESULT 1182
US-10-310-914A-621831/c
; Sequence 621831, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 621831
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-621831

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3820 GCCCCTCCCCCAGCTGC 3836
              ||||||| |||||||||
Db         18 GCCCCTCTCCCAGCTGC 2


RESULT 1183
US-10-310-914A-705359/c
; Sequence 705359, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 705359
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-705359

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1833 GACGTCAGAAAACCGGG 1849
              || |||||||||||||||
Db         17 GAGGTCAGAAAACCGGG 1


RESULT 1184
US-10-310-914A-726118/c
; Sequence 726118, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 726118
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-726118

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3614 CCCAGCCTCCCCAGGTG 3630
              |||| ||||||||||||
Db         17 CCCACCCTCCCCAGGTG 1


RESULT 1185
US-10-310-914A-736049/c
; Sequence 736049, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 736049
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-736049

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1067 CTGGCCCCAGCCCCAGC 1083
              ||| ||||||||||||||
Db         18 CTGCCCCCAGCCCCAGC 2


RESULT 1186
US-10-310-914A-743243/c
; Sequence 743243, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 743243
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-743243

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1970 AGGGCTGGCGGGAGCAG 1986
              ||||||||| |||||||
Db         17 AGGGCTGGCAGGAGCAG 1


RESULT 1187
US-10-310-914A-839587
; Sequence 839587, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 839587
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-839587

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 9.5e+02;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1340 CCCCTCCTTCGGCTCCG 1356
              ||||:||: ||||:|||
Db          2 CCCCUCCUCCGGCUCCG 18


RESULT 1188
US-10-310-914A-842880
; Sequence 842880, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 842880
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-842880

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   70.6%;  Pred. No. 9.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        921 TGCCTGCATGGCCCTGC 937
              :|| :|||:|||||:||
Db          1 UGCGUGCAUGGCCCUGC 17


RESULT 1189
US-10-310-914A-876761/c
; Sequence 876761, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 876761
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-876761

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3832 GCTGCTGCCTTCATATT 3848
              ||||||||||||||| ||
Db         18 GCTGCTGCCTTCATTTT 2


RESULT 1190
US-10-310-914A-877410/c
; Sequence 877410, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 877410
```

```
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-877410

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCCAG 1194
              ||| ||||||||||||||
Db         18 GCCTAGCCTGTGCCCAG 2


RESULT 1191
US-10-310-914A-904313
; Sequence 904313, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 904313
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-904313

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 9.5e+02;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1329 ACCCTGCACCACCCCTC 1345
              ||||:|||||||||| |
Db          1 ACCCUGCACCACCCCAC 17


RESULT 1192
US-10-310-914A-924563
; Sequence 924563, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 924563
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-924563

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 9.5e+02;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1927 TTCGGCCAGGAACATCA 1943
              ::|||||||||| ||:||
Db          1 UUCGGCCAGGAGCAUCA 17


RESULT 1193
US-10-310-914A-966189
; Sequence 966189, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 966189
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-966189

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   70.6%;  Pred. No. 9.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2935 CTGGACTGTTGGCAGAA 2951
              |:||||:|::||| |||
Db          2 CUGGACUGUUGGCGGAA 18


RESULT 1194
US-10-310-914A-1029714
; Sequence 1029714, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1029714
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1029714

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 9.5e+02;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1068 TGGCCCCAGCCCCAGCC 1084
              :|||||| |||||||||
Db          1 UGGCCCCUGCCCCAGCC 17


RESULT 1195
US-10-310-914A-1043266/c
; Sequence 1043266, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1043266
;   LENGTH: 18
```

```
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1043266

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        577 GGCCAGGCCCACTGGCT 593
              ||||||||||| |||||
Db         17 GGCCAGGCCCAGTGGCT 1


RESULT 1196
US-10-310-914A-1071301
; Sequence 1071301, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1071301
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1071301

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   17.6%;  Pred. No. 9.5e+02;
  Matches    3;  Conservative   13;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3898 TTTTGTTTCTTCGTTTT 3914
              ::::|:::|:: |::::
Db          1 UUUUGUUUCUUUGUUUU 17


RESULT 1197
US-10-310-914A-1175377/c
; Sequence 1175377, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1175377
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1175377

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1059 CCCCGCCCCTGGCCCCA 1075
              ||||||||| |||||||
Db         17 CCCCGCCCCGGGCCCCA 1


RESULT 1198
US-10-310-914A-1199690
; Sequence 1199690, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1199690
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1199690

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   70.6%;  Pred. No. 9.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3680 TCCCTTGCCAGCTCCAG 3696
              : ||::||||||:||||
Db          1 UACCUUGCCAGCUCCAG 17


RESULT 1199
US-10-310-914A-1214992
; Sequence 1214992, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1214992
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1214992

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 9.5e+02;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3612 CTCCCAGCCTCCCCAGG 3628
              |:|||| ||:|||||||
Db          1 CUCCCAACCUCCCCAGG 17


RESULT 1200
US-10-310-914A-1253300
; Sequence 1253300, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1253300
;   LENGTH: 18
;   TYPE: RNA
```

```
;   ORGANISM: Human
US-10-310-914A-1253300

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 9.5e+02;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1069 GGCCCCAGCCCCAGCCT 1085
              ||||||||||||  |||:
Db          1 GGCCCCAGCCCCCGCCU 17


RESULT 1201
US-10-310-914A-1296340/c
; Sequence 1296340, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1296340
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1296340

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        644 TGCGCTTCACCATGCTC 660
              || |||||||||||||||
Db         18 TGTGCTTCACCATGCTC 2


RESULT 1202
US-10-310-914A-1312670/c
; Sequence 1312670, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1312670
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1312670

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 9.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3517 CACCCCCCAGCCACCTC 3533
              ||||| ||||||||||||
Db         17 CACCCGCCAGCCACCTC 1


RESULT 1203
US-10-310-914A-42828/c
; Sequence 42828, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 42828
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-42828

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1536 GGAGCCCTGGGTGGTGG 1552
              || |||||||||||||||
Db         18 GGCGCCCTGGGTGGTGG 2


RESULT 1204
US-10-310-914A-42829/c
; Sequence 42829, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 42829
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-42829

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1536 GGAGCCCTGGGTGGTGG 1552
              || |||||||||||||||
Db         18 GGCGCCCTGGGTGGTGG 2


RESULT 1205
US-10-310-914A-44524
; Sequence 44524, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44524
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
```

```
US-10-310-914A-44524

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1e+03;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1864 CTGAAGCGGGGAGCCAG 1880
              |:||||| |||||||||
Db          1 CUGAAGCCGGGAGCCAG 17


RESULT 1206
US-10-310-914A-44732/c
; Sequence 44732, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44732
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-44732

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2912 CCACCTCCCTCCACCAG 2928
              || |||||||||||||||
Db         19 CCCCCTCCCTCCACCAG 3


RESULT 1207
US-10-310-914A-66712/c
; Sequence 66712, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 66712
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-66712

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4086 GGGGTGTGGGGTGAGGT 4102
              |||| ||||||||||||
Db         18 GGGGGGTGGGGTGAGGT 2


RESULT 1208
US-10-310-914A-76028/c
; Sequence 76028, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 76028
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-76028

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4086 GGGGTGTGGGGTGAGGT 4102
              |||||||||||||| |||
Db         17 GGGGTGTGGGGTGGGGT 1


RESULT 1209
US-10-310-914A-124041
; Sequence 124041, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 124041
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-124041

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1e+03;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        730 GATGCGGACACGGCCAC 746
              ||:||||||| |||||
Db          2 GAUGCGGACACAGCCAC 18


RESULT 1210
US-10-310-914A-141479/c
; Sequence 141479, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 141479
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-141479
```

```
  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1384 TCCTCCCTGCACCTGGA 1400
              ||||||||||  ||||||
Db         17 TCCTCCCTGCCCCTGGA 1


RESULT 1211
US-10-310-914A-164314/c
; Sequence 164314, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 164314
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-164314

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1531 CTGGTGGAGCCCTGGGT 1547
              ||||  ||||||||||||
Db         17 CTGGGGGAGCCCTGGGT 1


RESULT 1212
US-10-310-914A-165319/c
; Sequence 165319, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 165319
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-165319

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3823 CCTCCCCCAGCTGCTGC 3839
              ||||||||  ||||||||
Db         18 CCTCCCCCTGCTGCTGC 2


RESULT 1213
US-10-310-914A-165325/c
; Sequence 165325, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 165325
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-165325

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3823 CCTCCCCCAGCTGCTGC 3839
              ||||||||  ||||||||
Db         19 CCTCCCCCTGCTGCTGC 3


RESULT 1214
US-10-310-914A-174508
; Sequence 174508, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 174508
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-174508

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1e+03;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3383 CCGGGGCAGAGTGGGGA 3399
              | ||||||||||:|||||
Db          3 CGGGGGCAGAGUGGGGA 19


RESULT 1215
US-10-310-914A-260318/c
; Sequence 260318, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 260318
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-260318
```

```
  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        681 GGCTGGGCGCTCCTGCA 697
              |||||||||| ||||||
Db         19 GGCTGGGCGCCCCTGCA 3


RESULT 1216
US-10-310-914A-332383
; Sequence 332383, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 332383
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-332383

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1e+03;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCCC 1080
              ||||: ||||||||||
Db          3 CCCCUAGCCCCAGCCCC 19


RESULT 1217
US-10-310-914A-368914/c
; Sequence 368914, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 368914
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-368914

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        933 CCTGCTATCCCTGCACC 949
              ||||||||||||||| |
Db         19 CCTGCTATCCCTGCAGC 3


RESULT 1218
US-10-310-914A-450885
; Sequence 450885, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 450885
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-450885

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   23.5%;  Pred. No. 1e+03;
  Matches    4;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3892 TTCCCTTTTTGTTTCTT 3908
              ::|||::::: :::|::
Db          2 UUCCCUUUUUCUUUCUU 18


RESULT 1219
US-10-310-914A-476139/c
; Sequence 476139, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 476139
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-476139

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3351 TCCCCACCCCAGGGACA 3367
              |||||||||||||| ||
Db         17 TCCCCACCCCAGGGTCA 1


RESULT 1220
US-10-310-914A-478635/c
; Sequence 478635, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 478635
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-478635

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
```

```
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         79 GGGCGGGACCCCGAGGC 95
              || ||||||||||||||
Db         17 GGCCGGGACCCCGAGGC 1


RESULT 1221
US-10-310-914A-567126
; Sequence 567126, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 567126
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-567126

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1e+03;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        494 GGCAGTGGGAGGAACTG 510
              ||||| |||||||||:|
Db          2 GGCAGGGGGAGGAACUG 18


RESULT 1222
US-10-310-914A-568323/c
; Sequence 568323, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 568323
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-568323

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         17 GAGCAGAGCCACTCCAG 33
              ||||||| |||||||||
Db         17 GAGCAGACCCACTCCAG 1


RESULT 1223
US-10-310-914A-580849
; Sequence 580849, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 580849
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-580849

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1e+03;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3409 GCCCCCAGCCCTGTGCC 3425
              ||||||||||:| |||
Db          2 GCCCCCAGCCCUGGGCC 18


RESULT 1224
US-10-310-914A-591068/c
; Sequence 591068, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 591068
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-591068

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3862 TTTTGTTTTTGGTCTTA 3878
              ||||||||||||| |||
Db         19 TTTTGTTTTTGGTTTTA 3


RESULT 1225
US-10-310-914A-621832/c
; Sequence 621832, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 621832
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-621832

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
```

```
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3820 GCCCCTCCCCCAGCTGC 3836
              ||||||| |||||||||
Db         18 GCCCCTCTCCCAGCTGC 2


RESULT 1226
US-10-310-914A-632545
; Sequence 632545, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 632545
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-632545

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         74 ACCCGGGGCGGGACCCC 90
              |||||||||||||| |||
Db          2 ACCCGGGGCGGGAACCC 18


RESULT 1227
US-10-310-914A-656960
; Sequence 656960, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 656960
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-656960

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3730 TGTCAGGGCCCAGTGAC 3746
              : :|||||||||||:|||
Db          1 UCUCAGGGCCCAGUGAC 17


RESULT 1228
US-10-310-914A-693048
; Sequence 693048, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 693048
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-693048

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1e+03;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         212 GCGCCGCCGCCCGGTGC 228
               ||||||||||||| :||
Db           3 GCGCCGCCGCCCGCUGC 19


RESULT 1229
US-10-310-914A-693049
; Sequence 693049, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 693049
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-693049

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1e+03;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         212 GCGCCGCCGCCCGGTGC 228
               ||||||||||||| :||
Db           3 GCGCCGCCGCCCGCUGC 19


RESULT 1230
US-10-310-914A-724817/c
; Sequence 724817, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 724817
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-724817

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       4085 AGGGGTGTGGGGTGAGG 4101
              ||| |||||||||||||
Db         17 AGGTGTGTGGGGTGAGG 1
```

RESULT 1231
US-10-310-914A-725516/c
; Sequence 725516, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 725516
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-725516

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       3351 TCCCCACCCCAGGGACA 3367
              ||||||||||||||| ||
Db         17 TCCCCACCCCAGGGCCA 1
```

RESULT 1232
US-10-310-914A-738648
; Sequence 738648, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 738648
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-738648

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1e+03;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1071 CCCCAGCCCCAGCCTCT 1087
              ||||||||||||||| |:
Db          1 CCCCAGCCCCAGCCGCU 17
```

RESULT 1233
US-10-310-914A-757318
; Sequence 757318, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 757318
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-757318

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1e+03;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy       4056 GCCTGGGACCCCCAAGC 4072
              |||:|||| |||||||||
Db          2 GCCUGGGAGCCCCAAGC 18
```

RESULT 1234
US-10-310-914A-773116
; Sequence 773116, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 773116
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-773116

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

```
Qy        923 CCTGCATGGCCCTGCTA 939
              ||:|||:|||||:|| |
Db          1 CCUGCAUGGCCCUGCAA 17
```

RESULT 1235
US-10-310-914A-796345
; Sequence 796345, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 796345
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-796345

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 23.5%; Pred. No. 1e+03;
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

```
Qy       3856 TTTGAGTTTTGTTTTTG 3872
              :::| |::::|:::::|
Db          3 UUUGUGUUUUGUUUUUG 19


RESULT 1236
US-10-310-914A-814718/c
; Sequence 814718, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 814718
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-814718

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1228 TGCCAGCCATGCCCAGC 1244
              ||||||||| |||||||
Db         19 TGCCAGCCAGGCCCAGC 3


RESULT 1237
US-10-310-914A-842885
; Sequence 842885, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 842885
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-842885

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 1e+03;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        921 TGCCTGCATGGCCCTGC 937
              :|| :|||:|||||:||
Db          2 UGCGUGCAUGGCCCUGC 18


RESULT 1238
US-10-310-914A-885145/c
; Sequence 885145, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 885145
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-885145

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        106 CCCCAACTCCAGCCACG 122
              ||||||||||||||| ||
Db         17 CCCCAACTCCAGCCCCG 1


RESULT 1239
US-10-310-914A-900173/c
; Sequence 900173, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 900173
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-900173

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1725 GAGCCTGGCCTGGGCTG 1741
              | ||||||||||||||||
Db         17 GCGCCTGGCCTGGGCTG 1


RESULT 1240
US-10-310-914A-906770
; Sequence 906770, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 906770
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-906770

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         77 CGGGGCGGGACCCCGAG 93
```

```
              |||||||||| ||||||
Db          1 CGGGGCGGGAACCCGAG 17


RESULT 1241
US-10-310-914A-912740
; Sequence 912740, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 912740
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-912740

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1330 CCCTGCACCACCCCTCC 1346
              |||:|| |||||||:||
Db          1 CCCUGCCCCACCCCUCC 17


RESULT 1242
US-10-310-914A-933011
; Sequence 933011, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 933011
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-933011

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   47.1%;  Pred. No. 1e+03;
  Matches    8;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4189 TTTTTGTATAAATAAAA 4205
              :::::|:|:|||:|| |
Db          2 UUUUUGUAUAAAUAACA 18


RESULT 1243
US-10-310-914A-949706
; Sequence 949706, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 949706
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-949706

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 1e+03;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3192 CAGCCAGATCTCTGCTG 3208
              ||||||| :|:|:||:|
Db          1 CAGCCAGUUCUCUGCUG 17


RESULT 1244
US-10-310-914A-966440/c
; Sequence 966440, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 966440
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-966440

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1230 CCAGCCATGCCCAGCCA 1246
              ||||||| |||||||||
Db         17 CCAGCCAAGCCCAGCCA 1


RESULT 1245
US-10-310-914A-1044765/c
; Sequence 1044765, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1044765
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1044765

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1076 GCCCCAGCCTCTACTGC 1092
              |||||||| ||||||||
```

```
Db         19 GCCCCAGCTTCTACTGC 3


RESULT 1246
US-10-310-914A-1127249/c
; Sequence 1127249, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1127249
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1127249

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1070 GCCCCAGCCCCAGCCTC 1086
              |||||||||||||||| |
Db         18 GCCCCAGCCCCAGCCCC 2


RESULT 1247
US-10-310-914A-1150255
; Sequence 1150255, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1150255
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1150255

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   64.7%;  Pred. No. 1e+03;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3106 TCTGTGGGCGAGTGGCT 3122
              :|:|:|||| ||:|||:
Db          1 UCUGUGGGCAAGUGGCU 17


RESULT 1248
US-10-310-914A-1150285
; Sequence 1150285, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1150285
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1150285

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   64.7%;  Pred. No. 1e+03;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3106 TCTGTGGGCGAGTGGCT 3122
              :|:|:|||| ||:|||:
Db          1 UCUGUGGGCAAGUGGCU 17


RESULT 1249
US-10-310-914A-1154760
; Sequence 1154760, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1154760
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1154760

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2910 TCCCACCTCCCTCCACC 2926
              :||||||:|||:||| |
Db          1 UCCCACCUCCCUCCAGC 17


RESULT 1250
US-10-310-914A-1187331/c
; Sequence 1187331, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1187331
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1187331

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCCC 1080
              |||||| ||||||||||
Db         18 CCCCTGCCCCCAGCCCC 2
```

```
RESULT 1251
US-10-310-914A-1283822/c
; Sequence 1283822, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1283822
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1283822

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4002 TCATCATGTCTGTTTCC 4018
              ||||||||| |||||||
Db         19 TCATCATGTTTGTTTCC 3


RESULT 1252
US-11-101-244-51
; Sequence 51, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 51
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-51

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3472 GGAGAGACAGGATTTGG 3488
              ||||||| ||||:::||
Db          2 GGAGAGAAAGGAUUUGG 18


RESULT 1253
US-11-101-244-14393
; Sequence 14393, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 14393
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-14393

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAAC 2622
              ||||||:||:||:|| |
Db          1 GCAACAUCCUAGUCAUC 17


RESULT 1254
US-11-101-244-14433
; Sequence 14433, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 14433
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-14433

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAAC 2622
              ||||||:||:||:|| |
Db          3 GCAACAUCCUAGUCAUC 19


RESULT 1255
US-11-101-244-38758
; Sequence 38758, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
```

```
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 38758
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-38758

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1191 CCAGGGCACCTTCAAGC 1207
              ||||||||||::||| |
Db          1 CCAGGGCACCUUCAAAC 17


RESULT 1256
US-11-101-244-47494/c
; Sequence 47494, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 47494
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-47494

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2120 TCATCGGACATGGTACT 2136
              ||||||||||| ||||
Db         19 TCATCGGACATGTTACT 3


RESULT 1257
US-11-101-244-88064
; Sequence 88064, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 88064
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-88064

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        708 CACCGTCTTCTACTATG 724
              || ||:|::|:||:|:|
Db          3 CAACGUCUUCUACUAUG 19


RESULT 1258
US-11-101-244-95986
; Sequence 95986, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 95986
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-95986

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3946 TTGGAGGGAACCTGTTT 3962
              ::|||||| |||:|:::
Db          3 UUGGAGGGUACCUGUUU 19


RESULT 1259
US-11-101-244-124920
; Sequence 124920, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
```

```
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 124920
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-124920

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   64.7%;  Pred. No. 1e+03;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2222 AGATTGAAGAGGTGATT 2238
              |||::||| |||:||::
Db          3 AGAUUGAACAGGUGAUU 19


RESULT 1260
US-11-101-244-158311
; Sequence 158311, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158311
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158311

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2845 ATGAGCAATCAGGACGT 2861
              |:||||||:||||| |:
Db          2 AUGAGCAAUCAGGAGGU 18


RESULT 1261
US-11-101-244-158978
; Sequence 158978, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 158978
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-158978

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   64.7%;  Pred. No. 1e+03;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2815 ATGTCATTTGGGGAGAG 2831
              |:|:||:::|| |||||
Db          2 AUGUCAUUUGGAGAGAG 18


RESULT 1262
US-11-101-244-165037/c
; Sequence 165037, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165037
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-165037

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||| ||||
Db         18 AAATCTTGGCCATTGTC 2


RESULT 1263
US-11-101-244-165057/c
; Sequence 165057, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
```

```
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165057
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-165057

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||| ||||
Db         17 AAATCTTGGCCATTGTC 1


RESULT 1264
US-11-101-244-165136/c
; Sequence 165136, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165136
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-165136

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||| ||||
Db         18 AAATCTTGGCCATTGTC 2


RESULT 1265
US-11-101-244-165156/c
; Sequence 165156, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165156
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-165156

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||| ||||
Db         17 AAATCTTGGCCATTGTC 1


RESULT 1266
US-11-101-244-165238/c
; Sequence 165238, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165238
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-165238

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||| ||||
Db         18 AAATCTTGGCCATTGTC 2


RESULT 1267
US-11-101-244-165258/c
; Sequence 165258, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
```

; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165258
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165258

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTC 3270
||||||||||||| ||||
Db 17 AAATCTTGGCCATTGTC 1

RESULT 1268
US-11-101-244-165337/c
; Sequence 165337, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165337
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165337

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTC 3270
||||||||||||| ||||
Db 18 AAATCTTGGCCATTGTC 2

RESULT 1269
US-11-101-244-165357/c
; Sequence 165357, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165357
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165357

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTC 3270
||||||||||||| ||||
Db 17 AAATCTTGGCCATTGTC 1

RESULT 1270
US-11-101-244-165439/c
; Sequence 165439, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165439
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165439

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTC 3270
||||||||||||| ||||
Db 18 AAATCTTGGCCATTGTC 2

RESULT 1271
US-11-101-244-165462/c
; Sequence 165462, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07

```
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165462
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-165462

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||  ||||
Db         17 AAATCTTGGCCATTGTC 1


RESULT 1272
US-11-101-244-223107
; Sequence 223107, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 223107
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-223107

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   64.7%;  Pred. No. 1e+03;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        449 TGGAAACTGCTGATCTG 465
              :||||||: |:||:|:|
Db          3 UGGAAACUUCUGAUCUG 19


RESULT 1273
US-11-101-244-249657/c
; Sequence 249657, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 249657
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-249657

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2411 TGGAGGGCGTGGTCACC 2427
              |||||||||||||||  |
Db         17 TGGAGGGCGTGGTCATC 1


RESULT 1274
US-11-101-244-249676/c
; Sequence 249676, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 249676
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-249676

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2411 TGGAGGGCGTGGTCACC 2427
              |||||||||||||||  |
Db         17 TGGAGGGCGTGGTCATC 1


RESULT 1275
US-11-101-244-376141
; Sequence 376141, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
```

```
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 376141
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-376141

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        520 GATGAGGAACAGCACAG 536
              || ||||||||||||||
Db          1 GAAGAGGAACAGCACAG 17


RESULT 1276
US-11-101-244-384878
; Sequence 384878, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 384878
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-384878

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 1e+03;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2158 ACTTATGAAGACCCTAA 2174
              ||::|:||| ||||:||
Db          3 ACUUAUGAACACCCUAA 19


RESULT 1277
US-11-101-244-388710
; Sequence 388710, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 388710
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-388710

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3472 GGAGAGACAGGATTTGG 3488
              ||||||| ||||:::||
Db          1 GGAGAGAAAGGAUUUGG 17


RESULT 1278
US-11-101-244-393275/c
; Sequence 393275, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 393275
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-393275

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3133 AAAATGGGAAGATACGA 3149
              ||| ||||||||||||||
Db         19 AAAGTGGGAAGATACGA 3


RESULT 1279
US-11-101-244-405137
; Sequence 405137, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
```

```
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 405137
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-405137

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 1e+03;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4066 CCCAAGCTGTGTCCTAT 4082
              |||||||:|:|:|| |:
Db          3 CCCAAGCUGUGUCCAAU 19


RESULT 1280
US-11-101-244-405183
; Sequence 405183, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 405183
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-405183

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 1e+03;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4066 CCCAAGCTGTGTCCTAT 4082
              |||||||:|:|:|| |:
Db          1 CCCAAGCUGUGUCCAAU 17


RESULT 1281
US-11-101-244-440347
; Sequence 440347, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 440347
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-440347

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        438 GAACACAAAATTGGAAA 454
              ||||| ||||::|||||
Db          1 GAACAGAAAAUUGGAAA 17


RESULT 1282
US-11-101-244-442932/c
; Sequence 442932, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 442932
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-442932

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2423 TCACCAACAGCATGCCC 2439
              |||||||||||||| ||
Db         17 TCACCAACAGCATGACC 1


RESULT 1283
US-11-101-244-446199/c
; Sequence 446199, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
```

```
; SEQ ID NO 446199
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-446199

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1612 TCCTCCTTAGCCACGGG 1628
              ||||||  ||||||||||
Db         18 TCCTCCATAGCCACGGG 2


RESULT 1284
US-11-101-244-448936/c
; Sequence 448936, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 448936
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-448936

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1933 CAGGAACATCACAGCCA 1949
              ||||||||||| ||||
Db         17 CAGGAACATCACTGCCA 1


RESULT 1285
US-11-101-244-466442
; Sequence 466442, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 466442
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-466442

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2187 GGAATTTGCAAAAGAGA 2203
              ||||:::||| ||||||
Db          1 GGAAUUUGCACAAGAGA 17


RESULT 1286
US-11-101-244-478703/c
; Sequence 478703, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 478703
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-478703

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2803 ATGTGGGAGGTGATGTC 2819
              ||||| ||||||||||
Db         18 ATGTGTGAGGTGATGTC 2


RESULT 1287
US-11-101-244-488729
; Sequence 488729, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 488729
;   LENGTH: 19
```

```
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-488729

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1877 CCAGCTACCTGGTGCAG 1893
              ||| |:|||:||:|||| 
Db          1 CCAACUACCUGGUGCAG 17


RESULT 1288
US-11-101-244-499341
; Sequence 499341, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 499341
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-499341

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2290 AAGAAGGAGAGCTGTGT 2306
              |||||||||| |:|:|:
Db          3 AAGAAGGAGAACUGUGU 19


RESULT 1289
US-11-101-244-536642
; Sequence 536642, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 536642
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-536642

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        438 GAACACAAAATTGGAAA 454
              ||||| ||||::|||||
Db          1 GAACAGAAAAUUGGAAA 17


RESULT 1290
US-11-101-244-586431/c
; Sequence 586431, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 586431
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-586431

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1587 TGAGGTCACTGCATTGA 1603
              |||||||||||| ||||
Db         17 TGAGGTCACTGCGTTGA 1


RESULT 1291
US-11-101-244-593515/c
; Sequence 593515, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 593515
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
```

US-11-101-244-593515

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2475 CCTGGACTCCTTCCTGC 2491
||||| ||||||||||
Db 17 CCTGGCCTCCTTCCTGC 1

RESULT 1292
US-11-101-244-604134/c
; Sequence 604134, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 604134
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-604134

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3247 CAGAAGAAAATCTTGGC 3263
|||||| ||||||||||
Db 17 CAGAAGGAAATCTTGGC 1

RESULT 1293
US-11-101-244-618691/c
; Sequence 618691, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 618691
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-618691

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2338 GAGCGGCAGCGGCGTGA 2354
|||| ||||||||||||
Db 17 GAGCAGCAGCGGCGTGA 1

RESULT 1294
US-11-101-244-710189
; Sequence 710189, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 710189
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-710189

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2593 GACCTGGCTGCTCGCAA 2609
||||:|||:|| |||||
Db 2 GACCUGGCUGCCCGCAA 18

RESULT 1295
US-11-101-244-772658/c
; Sequence 772658, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 772658
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-772658

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2029 GTCCTGGTGGTCATTGT 2045
              ||||||||||||  ||||
Db         17 GTCCTGGTGGTCTTTGT 1
```

RESULT 1296
US-11-101-244-778427
; Sequence 778427, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 778427
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-778427

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 1e+03;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

```
Qy       3934 CATAACTTTGTGTTGGA 3950
              ||:|||:::|: ::|||
Db          3 CAUAACUUUGUCUUGGA 19
```

RESULT 1297
US-11-101-244-778438
; Sequence 778438, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 778438
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-778438

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 1e+03;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

```
Qy       3934 CATAACTTTGTGTTGGA 3950
              ||:|||:::|: ::|||
Db          2 CAUAACUUUGUCUUGGA 18
```

RESULT 1298
US-11-101-244-788952
; Sequence 788952, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 788952
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-788952

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2618 TCAACAGCAACCTCGTC 2634
              :||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19
```

RESULT 1299
US-11-101-244-789052
; Sequence 789052, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-789052

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;

```
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19


RESULT 1300
US-11-101-244-789152
; Sequence 789152, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 789152
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-789152

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19


RESULT 1301
US-11-101-244-789248
; Sequence 789248, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 789248
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-789248

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19


RESULT 1302
US-11-101-244-789347
; Sequence 789347, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 789347
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-789347

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19


RESULT 1303
US-11-101-244-789447
; Sequence 789447, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 789447
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-789447

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19
```

RESULT 1304
US-11-101-244-834453/c
; Sequence 834453, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 834453
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-834453

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2205 CGATGTCTCCTACGTCA 2221
              |||||||||||||  |||
Db         17 CGATGTCTCCTACTTCA 1
```

RESULT 1305
US-11-101-244-837999
; Sequence 837999, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 837999
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-837999

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1e+03;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy       3073 GACCAGCGGCAGCCTCA 3089
              |||||||||| ||:||
Db          1 GACCAGCGGCAACCUCA 17
```

RESULT 1306
US-11-101-244-855576
; Sequence 855576, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 855576
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-855576

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 1e+03;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

```
Qy        452 AAACTGCTGATCTGAAG 468
              ||| :||:||:|:||||
Db          3 AAAUUGCUGAUCUGAAG 19
```

RESULT 1307
US-11-101-244-927801/c
; Sequence 927801, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 927801
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-927801

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       3168 TGGCTTTGGCTCCTTCG 3184
              |||||| ||||||||||
```

```
Db         17 TGGCTTCGGCTCCTTCG 1


RESULT 1308
US-11-101-244-1019444
; Sequence 1019444, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1019444
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1019444

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        109 CAACTCCAGCCACGTCT 125
              ||||:|||| ||||:|:
Db          1 CAACUCCAGUCACGUCU 17


RESULT 1309
US-11-101-244-1036594/c
; Sequence 1036594, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1036594
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1036594

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2669 TGGAGGAGAACTCTTCC 2685
              ||| ||||||||||||
Db         17 TGGTGGAGAACTCTTCC 1


RESULT 1310
US-11-101-244-1071237
; Sequence 1071237, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1071237
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1071237

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3831 AGCTGCTGCCTTCATAT 3847
              |||:||:|||::||: :
Db          2 AGCUGCUGCCUUCAUUU 18


RESULT 1311
US-11-101-244-1071275
; Sequence 1071275, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1071275
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1071275

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3831 AGCTGCTGCCTTCATAT 3847
              |||:||:|||::||: :
Db          3 AGCUGCUGCCUUCAUUU 19
```

```
RESULT 1312
US-11-101-244-1104410
; Sequence 1104410, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1104410
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1104410

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1233 GCCATGCCCAGCCAATA 1249
              ||||:|||||  ||||:|
Db          2 GCCAUGCCCAACCAAUA 18


RESULT 1313
US-11-101-244-1104472
; Sequence 1104472, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1104472
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1104472

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1233 GCCATGCCCAGCCAATA 1249
              ||||:|||||  ||||:|
Db          3 GCCAUGCCCAACCAAUA 19


RESULT 1314
US-11-101-244-1134517
; Sequence 1134517, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1134517
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1134517

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3595 AAGGAAGTGCCCAACAT 3611
              |||||||:||| ||||:
Db          2 AAGGAAGUGCCAAACAU 18


RESULT 1315
US-11-101-244-1136133
; Sequence 1136133, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1136133
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1136133

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3832 GCTGCTGCCTTCATATT 3848
              ||:||:|||::|| |::
Db          1 GCUGCUGCCUUCACAUU 17


RESULT 1316
```

```
US-11-101-244-1207573
; Sequence 1207573, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1207573
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1207573

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2808 GGAGGTGATGTCATTTG 2824
              |||||:| :|:||:::|
Db          3 GGAGGUGGUGUCAUUUG 19


RESULT 1317
US-11-101-244-1259838
; Sequence 1259838, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1259838
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1259838

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        451 GAAACTGCTGATCTGAA 467
              ||||| ||:||:|:|||
Db          2 GAAACAGCUGAUCUGAA 18


RESULT 1318
US-11-101-244-1263543/c
; Sequence 1263543, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1263543
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1263543

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        445 AAATTGGAAACTGCTGA 461
              |||||||||||| ||||
Db         19 AAATTGGAAACTTCTGA 3


RESULT 1319
US-11-101-244-1263597/c
; Sequence 1263597, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1263597
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1263597

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        445 AAATTGGAAACTGCTGA 461
              |||||||||||| ||||
Db         17 AAATTGGAAACTTCTGA 1


RESULT 1320
US-11-101-244-1268095/c
; Sequence 1268095, Application US/11101244
```

```
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1268095
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1268095

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1044 CGTGGTGGATGCCGTCC 1060
              | ||||||||||||||||
Db         17 CATGGTGGATGCCGTCC 1


RESULT 1321
US-11-101-244-1319444/c
; Sequence 1319444, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1319444
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1319444

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3780 CTGTCACCACCAAACTC 3796
              |||||||||||||| ||
Db         18 CTGTCACCACCAAAGTC 2


RESULT 1322
US-11-101-244-1323046/c
; Sequence 1323046, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1323046
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1323046

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGG 2946
              ||||||||||||||| |
Db         19 TCATGCTGGACTGTTTG 3


RESULT 1323
US-11-101-244-1334142/c
; Sequence 1334142, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1334142
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1334142

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4134 CAGAAACGGACGCCGGT 4150
              ||||||| |||||||||
Db         18 CAGAAACAGACGCCGGT 2


RESULT 1324
US-11-101-244-1366776
; Sequence 1366776, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1366776
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1366776

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        305 GGGAGAGTCAGACCTGG 321
              |||||||:| ||||:||
Db          1 GGGAGAGUCUGACCUGG 17


RESULT 1325
US-11-101-244-1372964/c
; Sequence 1372964, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1372964
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1372964

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2110 GGACAGTATCTCATCGG 2126
              |||||||||||||||| |
Db         17 GGACAGTATCTCATCAG 1


RESULT 1326
US-11-101-244-1401474
; Sequence 1401474, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1401474
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1401474

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3639 ACCTTGATGGGTGCGTT 3655
              |||::||:|||:|| ::
Db          3 ACCUUGAUGGGUGCUUU 19


RESULT 1327
US-11-101-244-1441103/c
; Sequence 1441103, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1441103
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1441103

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3272 AGCACATGAAGTCCCAG 3288
              || ||||||||||||||
Db         18 AGAACATGAAGTCCCAG 2


RESULT 1328
US-11-101-244-1444645/c
; Sequence 1444645, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
```

```
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1444645
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1444645

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1885 CTGGTGCAGGTACGGGC 1901
              ||||||||||||| |||
Db         17 CTGGTGCAGGTACTGGC 1


RESULT 1329
US-11-101-244-1469620/c
; Sequence 1469620, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1469620
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1469620

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        859 AAGACGCTGCGTCTGGG 875
              |||| ||||||||||||
Db         18 AAGAAGCTGCGTCTGGG 2


RESULT 1330
US-11-101-244-1495899/c
; Sequence 1495899, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1495899
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1495899

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2446 ATTCTCACAGAGTTCAT 2462
              |||||||||||| |||||
Db         18 ATTCTCACAGACTTCAT 2


RESULT 1331
US-11-101-244-1512077
; Sequence 1512077, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1512077
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1512077

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   64.7%;  Pred. No. 1e+03;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2348 GGCGTGAGTTTCTGAGC 2364
              ||||:|||:::|: |||
Db          2 GGCGUGAGUUUCUUAGC 18


RESULT 1332
US-11-101-244-1525042
; Sequence 1525042, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
```

```
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1525042
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1525042

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4017 CCAGAACAGTGCCTTGG 4033
              |||||||||:|||:: |
Db          1 CCAGAACAGUGCCUUAG 17


RESULT 1333
US-11-101-244-1575806/c
; Sequence 1575806, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/101,244
;  CURRENT FILING DATE:  2005-04-07
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1575806
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-101-244-1575806

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3134 AAATGGGAAGATACGAA 3150
              |||||||||||||| |||
Db         18 AAATGGGAAGATAAGAA 2


RESULT 1334
US-11-083-784-51
; Sequence 51, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 51
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-51

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3472 GGAGAGACAGGATTTGG 3488
              ||||||| ||||:::||
Db          2 GGAGAGAAAGGAUUUGG 18


RESULT 1335
US-11-083-784-14393
; Sequence 14393, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 14393
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-14393

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAAC 2622
              ||||||:||:||:|| |
Db          1 GCAACAUCCUAGUCAUC 17


RESULT 1336
US-11-083-784-14433
; Sequence 14433, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
```

```
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 14433
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-14433

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2606 GCAACATCCTAGTCAAC 2622
              ||||||:||:||:|| |
Db          3 GCAACAUCCUAGUCAUC 19


RESULT 1337
US-11-083-784-38758
; Sequence 38758, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 38758
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-38758

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1191 CCAGGGCACCTTCAAGC 1207
              ||||||||||::||| |
Db          1 CCAGGGCACCUUCAAAC 17


RESULT 1338
US-11-083-784-47494/c
; Sequence 47494, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 47494
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-47494

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2120 TCATCGGACATGGTACT 2136
              ||||||||||||:||||
Db         19 TCATCGGACATGTTACT 3


RESULT 1339
US-11-083-784-88064
; Sequence 88064, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 88064
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-88064

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        708 CACCGTCTTCTACTATG 724
              || ||:|::|:||:|:|
Db          3 CAACGUCUUCUACUAUG 19


RESULT 1340
```

US-11-083-784-95986
; Sequence 95986, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 95986
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-95986

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 3946 TTGGAGGGAACCTGTTT 3962
::|||||| |||:|:::
Db 3 UUGGAGGGUACCUGUUU 19

RESULT 1341
US-11-083-784-124920
; Sequence 124920, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 124920
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-124920

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 1e+03;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2222 AGATTGAAGAGGTGATT 2238
|||::||| |||:||::
Db 3 AGAUUGAACAGGUGAUU 19

RESULT 1342
US-11-083-784-158311
; Sequence 158311, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158311
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158311

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2845 ATGAGCAATCAGGACGT 2861
|:||||||:||||| |:
Db 2 AUGAGCAAUCAGGAGGU 18

RESULT 1343
US-11-083-784-158978
; Sequence 158978, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158978
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158978

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 1e+03;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2815 ATGTCATTTGGGGAGAG 2831
              |:|:||:::|| |||||
Db          2 AUGUCAUUUGGAGAGAG 18


RESULT 1344
US-11-083-784-165037/c
; Sequence 165037, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165037
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-165037

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||| ||||
Db         18 AAATCTTGGCCATTGTC 2


RESULT 1345
US-11-083-784-165057/c
; Sequence 165057, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165057
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-165057

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||| ||||
Db         17 AAATCTTGGCCATTGTC 1


RESULT 1346
US-11-083-784-165136/c
; Sequence 165136, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165136
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-165136

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||| ||||
Db         18 AAATCTTGGCCATTGTC 2


RESULT 1347
US-11-083-784-165156/c
; Sequence 165156, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165156
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
```

US-11-083-784-165156

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTC 3270
||||||||||||| ||||
Db 17 AAATCTTGGCCATTGTC 1

RESULT 1348
US-11-083-784-165238/c
; Sequence 165238, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165238
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-165238

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTC 3270
||||||||||||| ||||
Db 18 AAATCTTGGCCATTGTC 2

RESULT 1349
US-11-083-784-165258/c
; Sequence 165258, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165258
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-165258

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTC 3270
||||||||||||| ||||
Db 17 AAATCTTGGCCATTGTC 1

RESULT 1350
US-11-083-784-165337/c
; Sequence 165337, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165337
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-165337

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTC 3270
||||||||||||| ||||
Db 18 AAATCTTGGCCATTGTC 2

RESULT 1351
US-11-083-784-165357/c
; Sequence 165357, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

```
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165357
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-165357

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||  ||||
Db         17 AAATCTTGGCCATTGTC 1


RESULT 1352
US-11-083-784-165439/c
; Sequence 165439, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165439
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-165439

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||  ||||
Db         18 AAATCTTGGCCATTGTC 2


RESULT 1353
US-11-083-784-165462/c
; Sequence 165462, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 165462
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-165462

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTC 3270
              ||||||||||||  ||||
Db         17 AAATCTTGGCCATTGTC 1


RESULT 1354
US-11-083-784-223107
; Sequence 223107, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 223107
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-223107

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   64.7%;  Pred. No. 1e+03;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        449 TGGAAACTGCTGATCTG 465
              :||||||: |:||:|:|
Db          3 UGGAAACUUCUGAUCUG 19


RESULT 1355
US-11-083-784-249657/c
; Sequence 249657, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
```

```
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 249657
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-249657

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2411 TGGAGGGCGTGGTCACC 2427
              ||||||||||||||| |
Db         17 TGGAGGGCGTGGTCATC 1


RESULT 1356
US-11-083-784-249676/c
; Sequence 249676, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 249676
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-249676

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2411 TGGAGGGCGTGGTCACC 2427
              ||||||||||||||| |
Db         17 TGGAGGGCGTGGTCATC 1


RESULT 1357
US-11-083-784-376141
; Sequence 376141, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 376141
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-376141

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        520 GATGAGGAACAGCACAG 536
              || ||||||||||||||
Db          1 GAAGAGGAACAGCACAG 17


RESULT 1358
US-11-083-784-384878
; Sequence 384878, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 384878
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-384878

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 1e+03;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2158 ACTTATGAAGACCCTAA 2174
              ||::|:||| |||||:||
Db          3 ACUUAUGAACACCCUAA 19


RESULT 1359
US-11-083-784-388710
; Sequence 388710, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
```

```
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 388710
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-388710

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3472 GGAGAGACAGGATTTGG 3488
              ||||||| ||||:::||
Db          1 GGAGAGAAAGGAUUUGG 17


RESULT 1360
US-11-083-784-393275/c
; Sequence 393275, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 393275
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-393275

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3133 AAAATGGGAAGATACGA 3149
              ||| ||||||||||||||
Db         19 AAAGTGGGAAGATACGA 3


RESULT 1361
US-11-083-784-405137
; Sequence 405137, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 405137
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-405137

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 1e+03;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4066 CCCAAGCTGTGTCCTAT 4082
              |||||||:|:|:|| |:
Db          3 CCCAAGCUGUGUCCAAU 19


RESULT 1362
US-11-083-784-405183
; Sequence 405183, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 405183
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-405183

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 1e+03;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4066 CCCAAGCTGTGTCCTAT 4082
              |||||||:|:|:|| |:
Db          1 CCCAAGCUGUGUCCAAU 17


RESULT 1363
US-11-083-784-440347
; Sequence 440347, Application US/11083784
```

```
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 440347
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-440347

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        438 GAACACAAAATTGGAAA 454
              ||||| ||||::|||||
Db          1 GAACAGAAAAUUGGAAA 17


RESULT 1364
US-11-083-784-442932/c
; Sequence 442932, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 442932
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-442932

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2423 TCACCAACAGCATGCCC 2439
              ||||||||||||||| ||
Db         17 TCACCAACAGCATGACC 1


RESULT 1365
US-11-083-784-446199/c
; Sequence 446199, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 446199
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-446199

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1612 TCCTCCTTAGCCACGGG 1628
              |||||| ||||||||||
Db         18 TCCTCCATAGCCACGGG 2


RESULT 1366
US-11-083-784-448936/c
; Sequence 448936, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 448936
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-448936

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1933 CAGGAACATCACAGCCA 1949
              |||||||||||| ||||
```

```
Db         17 CAGGAACATCACTGCCA 1
```

```
RESULT 1367
US-11-083-784-466442
; Sequence 466442, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 466442
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-466442

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2187 GGAATTTGCAAAAGAGA 2203
              ||||:::||| ||||||
Db          1 GGAAUUUGCACAAGAGA 17
```

```
RESULT 1368
US-11-083-784-478703/c
; Sequence 478703, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 478703
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-478703

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2803 ATGTGGGAGGTGATGTC 2819
              ||||| ||||||||||
Db         18 ATGTGTGAGGTGATGTC 2
```

```
RESULT 1369
US-11-083-784-488729
; Sequence 488729, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 488729
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-488729

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1877 CCAGCTACCTGGTGCAG 1893
              ||| |:|||:||:||||
Db          1 CCAACUACCUGGUGCAG 17
```

```
RESULT 1370
US-11-083-784-499341
; Sequence 499341, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 499341
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-499341
```

```
  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2290 AAGAAGGAGAGCTGTGT 2306
              ||||||||| |:|:|:
Db          3 AAGAAGGAGAACUGUGU 19


RESULT 1371
US-11-083-784-536642
; Sequence 536642, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 536642
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-536642

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        438 GAACACAAAATTGGAAA 454
              ||||| ||||::|||||
Db          1 GAACAGAAAAUUGGAAA 17


RESULT 1372
US-11-083-784-586431/c
; Sequence 586431, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 586431
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-586431

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1587 TGAGGTCACTGCATTGA 1603
              ||||||||||| ||||
Db         17 TGAGGTCACTGCGTTGA 1


RESULT 1373
US-11-083-784-593515/c
; Sequence 593515, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 593515
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-593515

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2475 CCTGGACTCCTTCCTGC 2491
              ||||| ||||||||||||
Db         17 CCTGGCCTCCTTCCTGC 1


RESULT 1374
US-11-083-784-604134/c
; Sequence 604134, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
```

```
; SEQ ID NO 604134
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-604134

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3247 CAGAAGAAAATCTTGGC 3263
              ||||||  ||||||||||
Db         17 CAGAAGGAAATCTTGGC 1


RESULT 1375
US-11-083-784-618691/c
; Sequence 618691, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 618691
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-618691

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2338 GAGCGGCAGCGGCGTGA 2354
              ||||  ||||||||||||
Db         17 GAGCAGCAGCGGCGTGA 1


RESULT 1376
US-11-083-784-710189
; Sequence 710189, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 710189
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-710189

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2593 GACCTGGCTGCTCGCAA 2609
              ||||:|||:|| |||||
Db          2 GACCUGGCUGCCCGCAA 18


RESULT 1377
US-11-083-784-772658/c
; Sequence 772658, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 772658
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-772658

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2029 GTCCTGGTGGTCATTGT 2045
              ||||||||||||  ||||
Db         17 GTCCTGGTGGTCTTTGT 1


RESULT 1378
US-11-083-784-778427
; Sequence 778427, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
```

```
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 778427
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-778427

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   52.9%;  Pred. No. 1e+03;
  Matches    9;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3934 CATAACTTTGTGTTGGA 3950
              ||:|||:::|: ::|||
Db          3 CAUAACUUUGUCUUGGA 19


RESULT 1379
US-11-083-784-778438
; Sequence 778438, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 778438
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-778438

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   52.9%;  Pred. No. 1e+03;
  Matches    9;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3934 CATAACTTTGTGTTGGA 3950
              ||:|||:::|: ::|||
Db          2 CAUAACUUUGUCUUGGA 18


RESULT 1380
US-11-083-784-788952
; Sequence 788952, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 788952
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-788952

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19


RESULT 1381
US-11-083-784-789052
; Sequence 789052, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 789052
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-789052

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19


RESULT 1382
US-11-083-784-789152
; Sequence 789152, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
```

```
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 789152
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-789152

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19


RESULT 1383
US-11-083-784-789248
; Sequence 789248, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 789248
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-789248

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19


RESULT 1384
US-11-083-784-789347
; Sequence 789347, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 789347
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-789347

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19


RESULT 1385
US-11-083-784-789447
; Sequence 789447, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 789447
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-789447

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2618 TCAACAGCAACCTCGTC 2634
              :|||||||||||:| :|
Db          3 UCAACAGCAACCUCUUC 19


RESULT 1386
US-11-083-784-834453/c
; Sequence 834453, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 834453
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-834453

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2205 CGATGTCTCCTACGTCA 2221
              ||||||||||||| |||
Db         17 CGATGTCTCCTACTTCA 1


RESULT 1387
US-11-083-784-837999
; Sequence 837999, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 837999
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-837999

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1e+03;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3073 GACCAGCGGCAGCCTCA 3089
              |||||||||||  ||:||
Db          1 GACCAGCGGCAACCUCA 17


RESULT 1388
US-11-083-784-855576
; Sequence 855576, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 855576
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-855576

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 1e+03;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        452 AAACTGCTGATCTGAAG 468
              ||| :||:||:|:||||
Db          3 AAAUUGCUGAUCUGAAG 19


RESULT 1389
US-11-083-784-927801/c
; Sequence 927801, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 927801
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-927801

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3168 TGGCTTTGGCTCCTTCG 3184
              |||||| ||||||||||
Db         17 TGGCTTCGGCTCCTTCG 1
```

```
RESULT 1390
US-11-083-784-1019444
; Sequence 1019444, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1019444
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1019444

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        109 CAACTCCAGCCACGTCT 125
              ||||:|||| ||||:|:
Db          1 CAACUCCAGUCACGUCU 17


RESULT 1391
US-11-083-784-1036594/c
; Sequence 1036594, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1036594
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1036594

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2669 TGGAGGAGAACTCTTCC 2685
              ||| ||||||||||||
Db         17 TGGTGGAGAACTCTTCC 1


RESULT 1392
US-11-083-784-1071237
; Sequence 1071237, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1071237
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1071237

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3831 AGCTGCTGCCTTCATAT 3847
              |||:||:|||::||: :
Db          2 AGCUGCUGCCUUCAUUU 18


RESULT 1393
US-11-083-784-1071275
; Sequence 1071275, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1071275
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1071275

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
```

```
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3831 AGCTGCTGCCTTCATAT 3847
              |||:||:|||::||: :
Db          3 AGCUGCUGCCUUCAUUU 19


RESULT 1394
US-11-083-784-1104410
; Sequence 1104410, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1104410
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1104410

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1233 GCCATGCCCAGCCAATA 1249
              ||||:||||| ||||:|
Db          2 GCCAUGCCCAACCAAUA 18


RESULT 1395
US-11-083-784-1104472
; Sequence 1104472, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1104472
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1104472

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1233 GCCATGCCCAGCCAATA 1249
              ||||:||||| ||||:|
Db          3 GCCAUGCCCAACCAAUA 19


RESULT 1396
US-11-083-784-1134517
; Sequence 1134517, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1134517
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1134517

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3595 AAGGAAGTGCCCAACAT 3611
              |||||||:||| ||||:
Db          2 AAGGAAGUGCCAAACAU 18


RESULT 1397
US-11-083-784-1136133
; Sequence 1136133, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1136133
;   LENGTH: 19
```

```
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1136133

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3832 GCTGCTGCCTTCATATT 3848
              ||:||:|||::|| |::
Db          1 GCUGCUGCCUUCACAUU 17


RESULT 1398
US-11-083-784-1207573
; Sequence 1207573, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1207573
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1207573

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2808 GGAGGTGATGTCATTTG 2824
              |||||:| :|:||:::|
Db          3 GGAGGUGGUGUCAUUUG 19


RESULT 1399
US-11-083-784-1259838
; Sequence 1259838, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1259838
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1259838

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        451 GAAACTGCTGATCTGAA 467
              ||||| ||:||:|:|||
Db          2 GAAACAGCUGAUCUGAA 18


RESULT 1400
US-11-083-784-1263543/c
; Sequence 1263543, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1263543
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1263543

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        445 AAATTGGAAACTGCTGA 461
              |||||||||||| ||||
Db         19 AAATTGGAAACTTCTGA 3


RESULT 1401
US-11-083-784-1263597/c
; Sequence 1263597, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
```

```
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1263597
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1263597

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        445 AAATTGGAAACTGCTGA 461
              ||||||||||||  ||||
Db         17 AAATTGGAAACTTCTGA 1


RESULT 1402
US-11-083-784-1268095/c
; Sequence 1268095, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1268095
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1268095

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1044 CGTGGTGGATGCCGTCC 1060
              | ||||||||||||||||
Db         17 CATGGTGGATGCCGTCC 1


RESULT 1403
US-11-083-784-1319444/c
; Sequence 1319444, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1319444
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1319444

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3780 CTGTCACCACCAAACTC 3796
              |||||||||||||| ||
Db         18 CTGTCACCACCAAAGTC 2


RESULT 1404
US-11-083-784-1323046/c
; Sequence 1323046, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1323046
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1323046

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2930 TCATGCTGGACTGTTGG 2946
              ||||||||||||||| |
Db         19 TCATGCTGGACTGTTTG 3


RESULT 1405
US-11-083-784-1334142/c
; Sequence 1334142, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
```

```
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1334142
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1334142

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4134 CAGAAACGGACGCCGGT 4150
              ||||||| |||||||||
Db         18 CAGAAACAGACGCCGGT 2


RESULT 1406
US-11-083-784-1366776
; Sequence 1366776, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1366776
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1366776

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 1e+03;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        305 GGGAGAGTCAGACCTGG 321
              |||||||:| ||||:||
Db          1 GGGAGAGUCUGACCUGG 17


RESULT 1407
US-11-083-784-1372964/c
; Sequence 1372964, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1372964
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1372964

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2110 GGACAGTATCTCATCGG 2126
              ||||||||||||||| |
Db         17 GGACAGTATCTCATCAG 1


RESULT 1408
US-11-083-784-1401474
; Sequence 1401474, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1401474
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1401474

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   58.8%;  Pred. No. 1e+03;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3639 ACCTTGATGGGTGCGTT 3655
              |||::||:|||:|| ::
Db          3 ACCUUGAUGGGUGCUUU 19


RESULT 1409
US-11-083-784-1441103/c
; Sequence 1441103, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
```

```
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1441103
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1441103

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3272 AGCACATGAAGTCCCAG 3288
              || ||||||||||||||
Db         18 AGAACATGAAGTCCCAG 2


RESULT 1410
US-11-083-784-1444645/c
; Sequence 1444645, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1444645
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1444645

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1885 CTGGTGCAGGTACGGGC 1901
              ||||||||||||| |||
Db         17 CTGGTGCAGGTACTGGC 1


RESULT 1411
US-11-083-784-1469620/c
; Sequence 1469620, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1469620
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1469620

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        859 AAGACGCTGCGTCTGGG 875
              |||| ||||||||||||
Db         18 AAGAAGCTGCGTCTGGG 2


RESULT 1412
US-11-083-784-1495899/c
; Sequence 1495899, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1495899
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1495899

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2446 ATTCTCACAGAGTTCAT 2462
              |||||||||| |||||
Db         18 ATTCTCACAGACTTCAT 2


RESULT 1413
```

```
US-11-083-784-1512077
; Sequence 1512077, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1512077
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1512077

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   64.7%;  Pred. No. 1e+03;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2348 GGCGTGAGTTTCTGAGC 2364
              ||||:|||:::|: |||
Db          2 GGCGUGAGUUUCUUAGC 18


RESULT 1414
US-11-083-784-1525042
; Sequence 1525042, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1525042
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1525042

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 1e+03;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4017 CCAGAACAGTGCCTTGG 4033
              |||||||||:|||:: |
Db          1 CCAGAACAGUGCCUUAG 17


RESULT 1415
US-11-083-784-1575806/c
; Sequence 1575806, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
;  APPLICANT: Dharmacon, Inc.
;  APPLICANT:  Khvorova, Anastasia
;  APPLICANT:  Reynolds, Angela
;  APPLICANT:  Leake, Devin
;  APPLICANT:  Marshall, William
;  APPLICANT:  Scaringe, Stephen
;  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;  FILE REFERENCE: 13499US
;  CURRENT APPLICATION NUMBER: US/11/083,784
;  CURRENT FILING DATE:  2005-03-18
;  PRIOR APPLICATION NUMBER: US/10/714,333
;  PRIOR FILING DATE: 2003-11-14
;  PRIOR APPLICATION NUMBER: 60/502,050
;  PRIOR FILING DATE: 2003-09-10
;  PRIOR APPLICATION NUMBER: 60/426,137
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 1591911
;  SOFTWARE: Proprietary
; SEQ ID NO 1575806
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-11-083-784-1575806

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1e+03;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3134 AAATGGGAAGATACGAA 3150
              ||||||||||||| |||
Db         18 AAATGGGAAGATAAGAA 2


RESULT 1416
US-10-310-914A-326990
; Sequence 326990, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 326990
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-326990

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         12 GGCGCGAGCAGAGCC 26
              |||||||||||||||
Db          3 GGCGCGAGCAGAGCC 17


RESULT 1417
US-10-310-914A-350180/c
; Sequence 350180, Application US/10310914A
; Publication No. US20060003322A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 350180
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-350180

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        430 ACCCTGCTGAACACA 444
              |||||||||||||||
Db         18 ACCCTGCTGAACACA 4


RESULT 1418
US-10-310-914A-392825
; Sequence 392825, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 392825
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-392825

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   66.7%;  Pred. No. 1e+03;
  Matches   10;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        389 TGCTGCTCTGCTGGG 403
              :||:||:|:||:|||
Db          4 UGCUGCUCUGCUGGG 18


RESULT 1419
US-10-310-914A-439882
; Sequence 439882, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 439882
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-439882

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 1e+03;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        147 GGCCACTGCCAGCAC 161
              ||||||:||||||||
Db          4 GGCCACUGCCAGCAC 18


RESULT 1420
US-10-310-914A-492615
; Sequence 492615, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 492615
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-492615

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 1e+03;
  Matches   13;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 CCTCACCCAGCAGCT 1723
              ||:||||||||||:
Db          3 CCUCACCCAGCAGCU 17


RESULT 1421
US-10-310-914A-736192/c
; Sequence 736192, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 736192
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-736192

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1072 CCCAGCCCCAGCCTC 1086
              |||||||||||||||
Db         18 CCCAGCCCCAGCCTC 4


RESULT 1422
US-10-310-914A-746225
; Sequence 746225, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 746225
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-746225

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 1e+03;
  Matches   13;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2966 GGCCCCGCTTCCCCC 2980
              |||||||::|||||
Db          4 GGCCCCGCUUCCCCC 18


RESULT 1423
US-10-310-914A-1154193
; Sequence 1154193, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1154193
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1154193

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 1e+03;
  Matches   13;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2913 CACCTCCCTCCACCA 2927
              ||||:|||:||||||
Db          3 CACCUCCCUCCACCA 17


RESULT 1424
US-10-310-914A-1198207/c
; Sequence 1198207, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1198207
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1198207

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1070 GCCCCAGCCCCAGCC 1084
              |||||||||||||||
Db         16 GCCCCAGCCCCAGCC 2


RESULT 1425
US-10-310-914A-1202821
; Sequence 1202821, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1202821
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1202821

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 1e+03;
  Matches   14;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1743 TCCCCGGGCACCCAG 1757
              :|||||||||||||
Db          1 UCCCCGGGCACCCAG 15


RESULT 1426
US-10-310-914A-1218422/c
; Sequence 1218422, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1218422
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1218422

  Query Match             0.4%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2985 GGTCAGCGCCCTGGA 2999
              |||||||||||||||
Db         17 GGTCAGCGCCCTGGA 3


RESULT 1427
US-10-958-999-8/c
; Sequence 8, Application US/10958999
; Publication No. US20060018826A1
; GENERAL INFORMATION:
;  APPLICANT: Genesegues, Inc.
```

```
;  APPLICANT:  Oligos Etc, Inc.
;  TITLE OF INVENTION: Biological Modulations with Nanoparticles
;  FILE REFERENCE: 3193.03wo01
;  CURRENT APPLICATION NUMBER: US/10/958,999
;  CURRENT FILING DATE:  2004-10-05
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: CK2alpha Antisense
US-10-958-999-8

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1223 GGTCCTGCCAGCCATGCC 1240
              ||||| ||| ||||||||
Db         18 GGTCCCGCCCGCCATGCC 1


RESULT 1428
US-10-310-914A-41560
; Sequence 41560, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 41560
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-41560

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 TCCCCGGGCACCCAGTGG 1760
              :|||||||||  ||  |:||
Db          1 UCCCCGGGCAGCCUGUGG 18


RESULT 1429
US-10-310-914A-41561
; Sequence 41561, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 41561
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-41561

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 TCCCCGGGCACCCAGTGG 1760
              :|||||||||  ||  |:||
Db          1 UCCCCGGGCAGCCUGUGG 18


RESULT 1430
US-10-310-914A-41786
; Sequence 41786, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 41786
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-41786

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        485 AGGTGGACGGGCAGTGGG 502
              |||:|| |||||||  |||
Db          1 AGGUGGGCGGGCAGGGGG 18


RESULT 1431
US-10-310-914A-41980
; Sequence 41980, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 41980
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-41980

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         87 CCCCGAGGCCCCGGAGGG 104
              ||||| |||||||  ||||
Db          1 CCCCGCGGCCCCGCAGGG 18


RESULT 1432
US-10-310-914A-44001
; Sequence 44001, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
```

```
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44001
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-44001

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1966 AGCGAGGGCTGGCGGGAG 1983
              || |||||| ||||||||
Db          1 AGGGAGGGCGGGCGGGAG 18


RESULT 1433
US-10-310-914A-49283
; Sequence 49283, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 49283
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-49283

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        170 CCCGCCGCCCGCGCGCGC 187
              |||||||||| |||| ||
Db          1 CCCGCCGCCCCCGCGGGC 18


RESULT 1434
US-10-310-914A-58832
; Sequence 58832, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 58832
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-58832

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   66.7%;  Pred. No. 1.1e+03;
  Matches   12;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        942 CCTGCACCTCTTCTACAA 959
              ||:|||||:|::|  |||
Db          1 CCUGCACCUCUUCCCCAA 18


RESULT 1435
US-10-310-914A-64741/c
; Sequence 64741, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 64741
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-64741

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2887 CGGCTGCCCCCGCCCCCA 2904
              | |||||| |||||||||
Db         18 CCGCTGCCGCCGCCCCCA 1


RESULT 1436
US-10-310-914A-67513/c
; Sequence 67513, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 67513
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-67513

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3856 TTTGAGTTTTGTTTTTGG 3873
              |||||||||| ||||| |
Db         18 TTTGAGTTTTTTTTTTG 1


RESULT 1437
US-10-310-914A-73628
; Sequence 73628, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
```

```
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 73628
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-73628

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2979 CCAGGTGGTCAGCGCCCT 2996
              ||||| ||:||| ||||:
Db          1 CCAGGGGGUCAGAGCCCU 18


RESULT 1438
US-10-310-914A-73629
; Sequence 73629, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 73629
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-73629

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2979 CCAGGTGGTCAGCGCCCT 2996
              ||||| ||:||| ||||:
Db          1 CCAGGGGGUCAGAGCCCU 18


RESULT 1439
US-10-310-914A-74614/c
; Sequence 74614, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 74614
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-74614

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3896 CTTTTTGTTTCTTCGTTT 3913
              |||||||||| || ||||
Db         18 CTTTTTGTTTGTTTGTTT 1


RESULT 1440
US-10-310-914A-76058/c
; Sequence 76058, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 76058
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-76058

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4087 GGGTGTGGGGTGAGGTAG 4104
              |||||||||||| ||| |
Db         18 GGGTGTGGGGTGGGGTGG 1


RESULT 1441
US-10-310-914A-79264/c
; Sequence 79264, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 79264
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-79264

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1383 CTCCTCCCTGCACCTGGA 1400
              |||||||||| || |||
Db         18 CTCCTCCCTGCCCCAGGA 1


RESULT 1442
US-10-310-914A-85575/c
; Sequence 85575, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
```

```
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 85575
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-85575

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3898 TTTTGTTTCTTCGTTTTG 3915
              ||||||||  ||  ||||||
Db         18 TTTTGTTTGTTTGTTTTG 1


RESULT 1443
US-10-310-914A-95682/c
; Sequence 95682, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 95682
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-95682

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3168 TGGCTTTGGCTCCTTCGA 3185
              ||||||||||| ||| ||
Db         18 TGGCTTTGGCTTCTTGGA 1


RESULT 1444
US-10-310-914A-98379/c
; Sequence 98379, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 98379
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-98379

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3861 GTTTTGTTTTTGGTCTTA 3878
              ||||||||||| ||| |
Db         18 GTTTTGTTTTTGTTCTGA 1


RESULT 1445
US-10-310-914A-99217/c
; Sequence 99217, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 99217
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-99217

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3853 GTTTTTGAGTTTTGTTTT 3870
              ||||||  ||| |||||||
Db         18 GTTTTTTAGTCTTGTTTT 1


RESULT 1446
US-10-310-914A-107712/c
; Sequence 107712, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 107712
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-107712

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        133 CGCCCGCCCGGCGCGGCC 150
              ||||||||||| ||| |||
Db         18 CGCCCGCCCGCCGCCGCC 1


RESULT 1447
US-10-310-914A-111236/c
; Sequence 111236, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
```

```
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 111236
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-111236

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1230 CCAGCCATGCCCAGCCAA 1247
              ||||||| |||||||| |
Db         18 CCAGCCAGGCCCAGCCGA 1


RESULT 1448
US-10-310-914A-138164/c
; Sequence 138164, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 138164
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-138164

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        134 GCCCGCCCGGCGCGGCCA 151
              |||||||||||| || |||
Db         18 GCCCGCCCGGCCCGCCCA 1


RESULT 1449
US-10-310-914A-149256/c
; Sequence 149256, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 149256
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-149256

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3622 CCCCAGGTGCCCCCCTCA 3639
              |||| || ||||||||||
Db         18 CCCCCGGAGCCCCCCTCA 1


RESULT 1450
US-10-310-914A-150479
; Sequence 150479, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 150479
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-150479

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   72.2%;  Pred. No. 1.1e+03;
  Matches   13;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3823 CCTCCCCCAGCTGCTGCC 3840
              ||:|| |||||: |:|||
Db          1 CCUCCUCCAGCUUCUGCC 18


RESULT 1451
US-10-310-914A-157171
; Sequence 157171, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 157171
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-157171

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1442 CCTACGCCCTCCGCTGCC 1459
              ||: ||||| ||||:|||
Db          1 CCUGCGCCCGCCGCUGCC 18


RESULT 1452
US-10-310-914A-168059/c
; Sequence 168059, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
```

```
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 168059
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-168059

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        133 CGCCCGCCCGGCGCGGCC 150
              |||||||||| ||| |||
Db         18 CGCCCGCCCGCCGCCGCC 1


RESULT 1453
US-10-310-914A-168733/c
; Sequence 168733, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 168733
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-168733

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3056 CCTCACACCCTCTCCTGG 3073
              ||||||| ||||||| ||
Db         18 CCTCACATCCTCTCCAGG 1


RESULT 1454
US-10-310-914A-182752
; Sequence 182752, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 182752
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-182752

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2963 CCCGGCCCCGCTTCCCCC 2980
              |||||||||| ||| |
Db          1 CCCGGCCCCGCUCCCCAC 18


RESULT 1455
US-10-310-914A-185749
; Sequence 185749, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 185749
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-185749

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   66.7%;  Pred. No. 1.1e+03;
  Matches   12;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1128 GGGCTGCAGCTGTGCTCC 1145
              | ||:|| ||:|:||:||
Db          1 GAGCUGCUGCUGUGCUCC 18


RESULT 1456
US-10-310-914A-200249
; Sequence 200249, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 200249
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-200249

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3616 CAGCCTCCCCAGGTGCCC 3633
              || ||:|||||| :||||
Db          1 CACCCUCCCCCAGCUGCCC 18


RESULT 1457
US-10-310-914A-200570
; Sequence 200570, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
```

```
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 200570
;    LENGTH: 18
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-200570

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1056 CGTCCCCGCCCCTGGCCC 1073
              || ||||| |||:|||||
Db          1 CGGCCCCGGCCCUGGCCC 18


RESULT 1458
US-10-310-914A-223919
; Sequence 223919, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 223919
;    LENGTH: 18
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-223919

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCCCA 1081
              |||| |||||||| ||||
Db          1 CCCCAGGCCCCAGGCCCA 18


RESULT 1459
US-10-310-914A-245025/c
; Sequence 245025, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 245025
;    LENGTH: 18
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-245025

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1330 CCCTGCACCACCCCTCCT 1347
              |||||| |||| ||||||
Db         18 CCCTGCCCCACACCTCCT 1


RESULT 1460
US-10-310-914A-258670
; Sequence 258670, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 258670
;    LENGTH: 18
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-258670

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2282 CCCCAGGGAAGAAGGAGA 2299
              ||||||| ||| ||||||
Db          1 CCCCAGGAAAGCAGGAGA 18


RESULT 1461
US-10-310-914A-274408/c
; Sequence 274408, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 274408
;    LENGTH: 18
;    TYPE: RNA
;    ORGANISM: Human
US-10-310-914A-274408

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1521 CCCCCGGGACCTGGTGGA 1538
              | ||||||| ||||||||
Db         18 CTCCCGGGAGCTGGTGGA 1


RESULT 1462
US-10-310-914A-289024
; Sequence 289024, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
```

```
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 289024
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-289024

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 1.1e+03;
  Matches    9;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3877 TAATTTTTCTCCCCGTTC 3894
              :||::: :|:||||| :|
Db          1 UAAUUUCUCUCCCCGCUC 18


RESULT 1463
US-10-310-914A-312199
; Sequence 312199, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 312199
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-312199

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1705 CGGTCCTCACCCAGCAGC 1722
              | |:|| ||||||||||
Db          1 CUGUCCCCACCCAGCAGC 18


RESULT 1464
US-10-310-914A-316348/c
; Sequence 316348, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 316348
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-316348

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3072 GGACCAGCGGCAGCCTCA 3089
              || |||||| ||||||||
Db         18 GGGCCAGCGCCAGCCTCA 1


RESULT 1465
US-10-310-914A-318062/c
; Sequence 318062, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 318062
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-318062

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4149 GTGCTTGGAGGGGTTCTT 4166
              ||||||||| | ||||||
Db         18 GTGCTTGGACGTGTTCTT 1


RESULT 1466
US-10-310-914A-321907/c
; Sequence 321907, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 321907
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-321907

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2886 CCGGCTGCCCCCGCCCCC 2903
              |||||||||| |||| |
Db         18 CCGGCTGCCCCTGCCCGC 1


RESULT 1467
US-10-310-914A-322050
; Sequence 322050, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
```

```
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 322050
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-322050

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1062 CGCCCCTGGCCCCAGCCC 1079
              | ||||:|||| ||||||
Db          1 CUCCCCUGGCCUCAGCCC 18


RESULT 1468
US-10-310-914A-340689/c
; Sequence 340689, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 340689
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-340689

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1127 CGGGCTGCAGCTGTGCTC 1144
              | ||||| ||||||||||
Db         18 CTGGCTGTAGCTGTGCTC 1


RESULT 1469
US-10-310-914A-343588/c
; Sequence 343588, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 343588
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-343588

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1326 TGCACCCTGCACCACCCC 1343
              ||| |||||| |||||||
Db         18 TGCCCCCTGCCCCACCCC 1


RESULT 1470
US-10-310-914A-343589/c
; Sequence 343589, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 343589
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-343589

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1326 TGCACCCTGCACCACCCC 1343
              ||| |||||| |||||||
Db         18 TGCCCCCTGCCCCACCCC 1


RESULT 1471
US-10-310-914A-353955/c
; Sequence 353955, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 353955
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-353955

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2089 GCAGAATATTCGGACAAA 2106
              | |||||||||| ||||||
Db         18 GTAGAATATTCAGACAAA 1


RESULT 1472
US-10-310-914A-370347/c
; Sequence 370347, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 370347
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-370347

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        158 GCACGCTCCGGGCCCGCC 175
              |||||| |||| ||||||
Db         18 GCACGCCCCGGCCCCGCC 1


RESULT 1473
US-10-310-914A-374108/c
; Sequence 374108, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 374108
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-374108

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4015 TTCCAGAACAGTGCCTTG 4032
              ||| || ||||||||||
Db         18 TTCTAGCACAGTGCCTTG 1


RESULT 1474
US-10-310-914A-392819/c
; Sequence 392819, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 392819
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-392819

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1801 GCCGAGGGTCCCAGCAGC 1818
              ||| |||| |||||||||
Db         18 GCCTAGGGCCCCAGCAGC 1


RESULT 1475
US-10-310-914A-394234/c
; Sequence 394234, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 394234
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-394234

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        245 GGCCCGCGCTGAGGGCCC 262
              |||||| |||| ||||||
Db         18 GGCCCGGGCTGGGGGCCC 1


RESULT 1476
US-10-310-914A-399085/c
; Sequence 399085, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 399085
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-399085

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        128 CTGCGCGCCCGCCCGGCG 145
              | |||||||||||||| ||
Db         18 CCGCGCGCCCGCCCGCCG 1


RESULT 1477
US-10-310-914A-401700
; Sequence 401700, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 401700
```

```
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-401700

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   66.7%;  Pred. No. 1.1e+03;
  Matches   12;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1128 GGGCTGCAGCTGTGCTCC 1145
              || |:|||||:|:| :||
Db          1 GGCCUGCAGCUGUGAUCC 18


RESULT 1478
US-10-310-914A-407421/c
; Sequence 407421, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 407421
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-407421

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        419 CTTTGGAAGAGACCCTGC 436
              ||||||||||||  ||||
Db         18 CTTTGGAAGAGATTCTGC 1


RESULT 1479
US-10-310-914A-472391/c
; Sequence 472391, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 472391
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-472391

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2043 TGTGGTCGCAGTTCTCTG 2060
              ||||||  ||||||||||
Db         18 TGTGGTTACAGTTCTCTG 1


RESULT 1480
US-10-310-914A-479651/c
; Sequence 479651, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 479651
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-479651

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1905 CTCTGAGGCCGGCTACGG 1922
              ||||||||||||||| | |
Db         18 CTCTGAGGCCGGCTCCTG 1


RESULT 1481
US-10-310-914A-485967/c
; Sequence 485967, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 485967
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-485967

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3879 ATTTTTCTCCCCGTTCCC 3896
              ||||||| |||| |||||
Db         18 ATTTTTCCCCCCTTTCCC 1


RESULT 1482
US-10-310-914A-487136/c
; Sequence 487136, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 487136
;   LENGTH: 18
```

```
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-487136

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3898 TTTTGTTTCTTCGTTTTG 3915
              ||||||||  ||  ||||||
Db         18 TTTTGTTTGTTTGTTTTG 1


RESULT 1483
US-10-310-914A-490510/c
; Sequence 490510, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 490510
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-490510

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1957 CTGGATGAGAGCGAGGGC 1974
              | |||  ||||||||||||
Db         18 CAGGAGGAGAGCGAGGGC 1


RESULT 1484
US-10-310-914A-494389/c
; Sequence 494389, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 494389
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-494389

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1151 TCGAGGCAGCTGAGGGGA 1168
              ||  ||||||||||||||
Db         18 TCTGGGCAGCTGAGGGGA 1


RESULT 1485
US-10-310-914A-510815/c
; Sequence 510815, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 510815
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-510815

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        384 CCGGGTGCTGCTCTGCTG 401
              | |||  ||||||||||||
Db         18 CTGGGGGCTGCTCTGCTG 1


RESULT 1486
US-10-310-914A-519334/c
; Sequence 519334, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 519334
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-519334

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        156 CAGCACGCTCCGGGCCCG 173
              ||||||  ||  ||||||||
Db         18 CAGCACCCTGCGGGCCCG 1


RESULT 1487
US-10-310-914A-521199/c
; Sequence 521199, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 521199
;   LENGTH: 18
;   TYPE: RNA
```

```
;   ORGANISM: Human
US-10-310-914A-521199

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3604 CCCAACATCTCCCAGCCT 3621
              ||||||||| ||||| ||
Db         18 CCCAACATCACCCAGTCT 1


RESULT 1488
US-10-310-914A-523963
; Sequence 523963, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 523963
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-523963

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   61.1%;  Pred. No. 1.1e+03;
  Matches   11;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2225 TTGAAGAGGTGATTGGTG 2242
              ::||||| | ||::||:|
Db          1 UUGAAGAAGAGAUUGGUG 18


RESULT 1489
US-10-310-914A-540325/c
; Sequence 540325, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 540325
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-540325

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         20 CAGAGCCACTCCAGGGAG 37
              ||||||||||||||  ||
Db         18 CAGAGCCACTCCAGCCAG 1


RESULT 1490
US-10-310-914A-552910/c
; Sequence 552910, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 552910
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-552910

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       4054 CCGCCTGGGACCCCCAAG 4071
              |||||||||| ||||| |
Db         18 CCGCCTGGGATCCCCAGG 1


RESULT 1491
US-10-310-914A-559267/c
; Sequence 559267, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 559267
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-559267

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3609 CATCTCCCAGCCTCCCCA 3626
              | ||||||| ||||||||
Db         18 CCTCTCCCACCCTCCCCA 1


RESULT 1492
US-10-310-914A-560682/c
; Sequence 560682, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 560682
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
```

US-10-310-914A-560682

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1330 CCCTGCACCACCCCTCCT 1347
||| ||||| ||||||||
Db 18 CCCAGCACCGCCCCTCCT 1

RESULT 1493
US-10-310-914A-570781
; Sequence 570781, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 570781
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-570781

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 1.1e+03;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2290 AAGAAGGAGAGCTGTGTG 2307
||||| ||||||:| |:|
Db 1 AAGAAAGAGAGCUGGGUG 18

RESULT 1494
US-10-310-914A-592815/c
; Sequence 592815, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 592815
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-592815

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3449 GTGGGGTGAGGAGTTGGC 3466
|||| ||||||||| |||
Db 18 GTGGCGTGAGGAGTGGGC 1

RESULT 1495
US-10-310-914A-609105/c
; Sequence 609105, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 609105
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-609105

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1847 GGGCAGAGCTGCGGGGGC 1864
|| ||||||||| |||||
Db 18 GGACAGAGCTGCTGGGGC 1

RESULT 1496
US-10-310-914A-655587
; Sequence 655587, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 655587
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-655587

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 1.1e+03;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1782 CAAATACCATGAGAAGGG 1799
||||:||||:||| |||
Db 1 CAAAUACCAUGAGCUGGG 18

RESULT 1497
US-10-310-914A-661057/c
; Sequence 661057, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 661057
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-661057

```
  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1326 TGCACCCTGCACCACCCC 1343
              ||| |||||| |||||||
Db         18 TGCCCCCTGCCCCACCCC 1


RESULT 1498
US-10-310-914A-675735/c
; Sequence 675735, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 675735
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-675735

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3852 GGTTTTTGAGTTTTGTTT 3869
              |||||||  |||||||||
Db         18 GGTTTTTTGGTTTTGTTT 1


RESULT 1499
US-10-310-914A-702256/c
; Sequence 702256, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 702256
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-702256

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        170 CCCGCCGCCCCGCGCGCGC 187
              | ||||||||||||| |||
Db         18 CTCGCCGCCCCGCGCCCGC 1


RESULT 1500
US-10-310-914A-716395
; Sequence 716395, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 716395
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-716395

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2286 AGGGAAGAAGGAGAGCTG 2303
              ||| | ||||||||||:|
Db          1 AGGCAGGAAGGAGAGCUG 18


RESULT 1501
US-10-310-914A-728016
; Sequence 728016, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 728016
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-728016

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1227 CTGCCAGCCATGCCCAGC 1244
              |: |||||| :|||||||
Db          1 CUUCCAGCCCUGCCCAGC 18


RESULT 1502
US-10-310-914A-747222
; Sequence 747222, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 747222
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-747222
```

```
  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         85 GACCCCGAGGCCCCGGAG 102
              ||||| | ||||||||||
Db          1 GACCCAGGGGCCCCGGAG 18


RESULT 1503
US-10-310-914A-761086/c
; Sequence 761086, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 761086
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-761086

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2977 CCCCAGGTGGTCAGCGCC 2994
              ||||||||| |||| |||
Db         18 CCCCAGGTGCTCAGGGCC 1


RESULT 1504
US-10-310-914A-765180
; Sequence 765180, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 765180
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-765180

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1066 CCTGGCCCCAGCCCCAGC 1083
              || |||||||||||||| |
Db          1 CCCGGCCCCAGCCCCACC 18


RESULT 1505
US-10-310-914A-771537/c
; Sequence 771537, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 771537
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-771537

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1089 CTGCCGTGAGGATGGCCA 1106
              |||  ||||||||||||||
Db         18 CTGGGGTGAGGATGGCCA 1


RESULT 1506
US-10-310-914A-778728
; Sequence 778728, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 778728
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-778728

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        187 CGGCACAGACGCGGGGCC 204
              |||||||| ||| |||||
Db          1 CGGCACAGGCGCAGGGCC 18


RESULT 1507
US-10-310-914A-785986/c
; Sequence 785986, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 785986
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-785986

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
```

```
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1064 CCCCTGGCCCCAGCCCCA 1081
              |||||| |||||||| ||
Db         18 CCCCTGACCCCAGCCTCA 1


RESULT 1508
US-10-310-914A-787511
; Sequence 787511, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 787511
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-787511

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3342 TGCAGGAACTCCCCACCC 3359
              :||||| || ||||||||
Db          1 UGCAGGUACCCCCCACCC 18


RESULT 1509
US-10-310-914A-804096
; Sequence 804096, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 804096
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-804096

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   72.2%;  Pred. No. 1.1e+03;
  Matches   13;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3824 CTCCCCCAGCTGCTGCCT 3841
              |:|| ||||| ||:|||:
Db          1 CUCCUCCAGCCGCUGCCU 18


RESULT 1510
US-10-310-914A-817270
; Sequence 817270, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 817270
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-817270

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 1.1e+03;
  Matches    9;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3095 CAGCTTTTGGCTCTGTGG 3112
              ||| :::: ||:|:|:||
Db          1 CAGGUUUUUGCUCUGUGG 18


RESULT 1511
US-10-310-914A-894247
; Sequence 894247, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 894247
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-894247

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1329 ACCCTGCACCACCCCTCC 1346
              ||||:|||| | |||:||
Db          1 ACCCUGCACAAGCCCUCC 18


RESULT 1512
US-10-310-914A-894280
; Sequence 894280, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 894280
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-894280

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   72.2%;  Pred. No. 1.1e+03;
```

```
  Matches   13;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1330 CCCTGCACCACCCCTCCT 1347
              |||:|||| | |||:||:
Db          1 CCCUGCACAAGCCCUCCU 18


RESULT 1513
US-10-310-914A-897142
; Sequence 897142, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 897142
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-897142

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1844 ACCGGGCAGAGCTGCGGG 1861
              ||| |||||||||:|| ||
Db          1 ACCAGGCAGAGCUGCUGG 18


RESULT 1514
US-10-310-914A-907233/c
; Sequence 907233, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 907233
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-907233

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1070 GCCCCAGCCCCAGCCTCT 1087
              |||||| |||| ||||||
Db         18 GCCCCACCCCCTGCCTCT 1


RESULT 1515
US-10-310-914A-958358
; Sequence 958358, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 958358
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-958358

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2910 TCCCACCTCCCTCCACCA 2927
              :||||||:||| || |||
Db          1 UCCCACCUCCCCCCUCCA 18


RESULT 1516
US-10-310-914A-958514/c
; Sequence 958514, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 958514
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-958514

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2968 CCCCGCTTCCCCCAGGTG 2985
              ||| || ||||||||||
Db         18 CCCAGCATCCCCCAGGTG 1


RESULT 1517
US-10-310-914A-967635
; Sequence 967635, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 967635
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-967635

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   72.2%;  Pred. No. 1.1e+03;
  Matches   13;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       2306 TGGCAATCAAGACCCTGA 2323
              :|||||:  ||||||:||
Db          1 UGGCAAUGUAGACCCUGA 18


RESULT 1518
US-10-310-914A-974099/c
; Sequence 974099, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 974099
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-974099

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1067 CTGGCCCCAGCCCCAGCC 1084
              | ||||||||||||| |||
Db         18 CGGGCCCCAGCCCCGGCC 1


RESULT 1519
US-10-310-914A-1009356/c
; Sequence 1009356, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1009356
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1009356

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1319 CCCGGGGTGCACCCTGCA 1336
              |||| | ||||||||||||
Db         18 CCCGTGTTGCACCCTGCA 1


RESULT 1520
US-10-310-914A-1014756
; Sequence 1014756, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1014756
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1014756

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2963 CCCGGCCCCGCTTCCCCC 2980
              | |||||||||| :|||||
Db         1 CGCGGCCCCGCAUCCCCC 18


RESULT 1521
US-10-310-914A-1026764/c
; Sequence 1026764, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1026764
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1026764

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3903 TTTCTTCGTTTTGTTTTT 3920
              |||||  ||||||||||||
Db         18 TTTCTCTGTTTTGTTTTT 1


RESULT 1522
US-10-310-914A-1030192/c
; Sequence 1030192, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1030192
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1030192

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       3823 CCTCCCCCAGCTGCTGCC 3840
              || ||||||||||||| |
Db         18 CCACCCCCAGCTGCTGTC 1


RESULT 1523
US-10-310-914A-1059710
; Sequence 1059710, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1059710
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1059710

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        675 GCCTCGGGCTGGGCGCTC 692
              |||:||||| |||||| |
Db          1 GCCUCGGGCCGGGCGCGC 18


RESULT 1524
US-10-310-914A-1067192
; Sequence 1067192, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1067192
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1067192

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3517 CACCCCCCAGCCACCTCG 3534
              || ||||| ||||||:||
Db          1 CAGCCCCCUGCCACCUCG 18


RESULT 1525
US-10-310-914A-1067193
; Sequence 1067193, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1067193
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1067193

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3517 CACCCCCCAGCCACCTCG 3534
              || ||||| ||||||:||
Db          1 CAGCCCCCUGCCACCUCG 18


RESULT 1526
US-10-310-914A-1077647
; Sequence 1077647, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1077647
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1077647

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3517 CACCCCCCAGCCACCTCG 3534
              || ||||| ||||||:||
Db          1 CAGCCCCCUGCCACCUCG 18


RESULT 1527
US-10-310-914A-1077648
; Sequence 1077648, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1077648
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1077648

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3517 CACCCCCCAGCCACCTCG 3534
```

```
              || ||||| ||||||:||
Db          1 CAGCCCCCUGCCACCUCG 18


RESULT 1528
US-10-310-914A-1079848/c
; Sequence 1079848, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1079848
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1079848

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2964 CCGGCCCCGCTTCCCCCA 2981
              ||||||||||| |||||
Db         18 CCGGCCCCGCTGGCCCCA 1


RESULT 1529
US-10-310-914A-1085525
; Sequence 1085525, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1085525
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1085525

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   72.2%;  Pred. No. 1.1e+03;
  Matches   13;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3260 TGGCCAGTGTCCAGCACA 3277
              :| ||||:|: |||||||
Db          1 UGCCCAGUGUGCAGCACA 18


RESULT 1530
US-10-310-914A-1087279/c
; Sequence 1087279, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1087279
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1087279

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2811 GGTGATGTCATTTGGGGA 2828
              | ||||||| ||||||||
Db         18 GTTGATGTCTTTTGGGGA 1


RESULT 1531
US-10-310-914A-1087936
; Sequence 1087936, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1087936
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1087936

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        568 CGTGCCCCGGGCCAGGCC 585
              | :|||||||| ||||||
Db          1 CCUGCCCCGGGACAGGCC 18


RESULT 1532
US-10-310-914A-1090451
; Sequence 1090451, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1090451
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1090451

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2963 CCCGGCCCCGCTTCCCCC 2980
              ||| |||||||: |||||
```

```
Db          1 CCCCGCCCCGCUCCCCCC 18


RESULT 1533
US-10-310-914A-1091850/c
; Sequence 1091850, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1091850
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1091850

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3765 AGTCCCAACTTGCTGCTG 3782
              ||||||| | ||||||||
Db         18 AGTCCCACCCTGCTGCTG 1


RESULT 1534
US-10-310-914A-1108672/c
; Sequence 1108672, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1108672
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1108672

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3765 AGTCCCAACTTGCTGCTG 3782
              ||||||| | ||||||||
Db         18 AGTCCCACCCTGCTGCTG 1


RESULT 1535
US-10-310-914A-1115627/c
; Sequence 1115627, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1115627
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1115627

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3821 CCCCTCCCCCAGCTGCTG 3838
              ||||||| || |||||||
Db         18 CCCCTCCGCCCGCTGCTG 1


RESULT 1536
US-10-310-914A-1134670/c
; Sequence 1134670, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1134670
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1134670

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        381 GCTCCGGGTGCTGCTCTG 398
              |||| |||||||||| ||
Db         18 GCTCTGGGTGCTGCTTTG 1


RESULT 1537
US-10-310-914A-1141714
; Sequence 1141714, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1141714
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1141714

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3603 GCCCAACATCTCCCAGCC 3620
              || |||| :|:|||||||
Db          1 GCACAACCUCUCCCAGCC 18
```

```
RESULT 1538
US-10-310-914A-1150343/c
; Sequence 1150343, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1150343
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1150343

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3765 AGTCCCAACTTGCTGCTG 3782
              ||||||| | ||||||||
Db         18 AGTCCCACCCTGCTGCTG 1


RESULT 1539
US-10-310-914A-1160776
; Sequence 1160776, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1160776
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1160776

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1060 CCCGCCCCTGGCCCCAGC 1077
              |||| ||| |||||||||
Db          1 CCCGACCCAGGCCCCAGC 18


RESULT 1540
US-10-310-914A-1161317/c
; Sequence 1161317, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1161317
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1161317

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2419 GTGGTCACCAACAGCATG 2436
              ||||||| ||||| ||||
Db         18 GTGGTCAGCAACACCATG 1


RESULT 1541
US-10-310-914A-1168846/c
; Sequence 1168846, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1168846
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1168846

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        244 GGGCCCGCGCTGAGGGCC 261
              ||||||| |||| |||||
Db         18 GGGCCCGGGCTGCGGGCC 1


RESULT 1542
US-10-310-914A-1183773/c
; Sequence 1183773, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1183773
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1183773

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1866 GAAGCGGGGAGCCAGCTA 1883
              ||| |||||||||||| |
Db         18 GAACCGGGGAGCCAGCGA 1
```

```
RESULT 1543
US-10-310-914A-1187035/c
; Sequence 1187035, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1187035
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1187035

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2964 CCGGCCCCGCTTCCCCCA 2981
              || |||||||| ||||||
Db         18 CCAGCCCCGCTGCCCCCA 1


RESULT 1544
US-10-310-914A-1197636
; Sequence 1197636, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1197636
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1197636

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1062 CGCCCCTGGCCCCAGCCC 1079
              | ||||:|||| ||||||
Db          1 CUCCCCUGGCCUCAGCCC 18


RESULT 1545
US-10-310-914A-1200184
; Sequence 1200184, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1200184
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1200184

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   55.6%;  Pred. No. 1.1e+03;
  Matches   10;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3469 TTTGGAGAGACAGGATTT 3486
              :::| ||||||||| :::
Db          1 UUUGUAGAGACAGGGUUU 18


RESULT 1546
US-10-310-914A-1201161/c
; Sequence 1201161, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1201161
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1201161

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1066 CCTGGCCCCAGCCCCAGC 1083
              ||||| | ||||||||||
Db         18 CCTGGTCGCAGCCCCAGC 1


RESULT 1547
US-10-310-914A-1212176/c
; Sequence 1212176, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1212176
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1212176

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1062 CGCCCCTGGCCCCAGCCC 1079
              | |||| ||||||||||
Db         18 CTCCCCCGGCCCCAGCCC 1
```

```
RESULT 1548
US-10-310-914A-1214147/c
; Sequence 1214147, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1214147
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1214147

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3819 TGCCCCTCCCCCAGCTGC 3836
              ||||||| ||||||  |||
Db         18 TGCCCCTGCCCCAGGTGC 1


RESULT 1549
US-10-310-914A-1214571/c
; Sequence 1214571, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1214571
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1214571

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        381 GCTCCGGGTGCTGCTCTG 398
              ||||  |||||||||| ||
Db         18 GCTCTGGGTGCTGCTTTG 1


RESULT 1550
US-10-310-914A-1214779/c
; Sequence 1214779, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1214779
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1214779

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1557 AGGGCTACGTCCTGACTT 1574
              ||||||||  |||||  |||
Db         18 AGGGCTACCTCCTGTCTT 1


RESULT 1551
US-10-310-914A-1228679
; Sequence 1228679, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1228679
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1228679

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   72.2%;  Pred. No. 1.1e+03;
  Matches   13;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        763 TGGATGGAGAACCCCTAC 780
              :|||:||||| || |:||
Db          1 UGGAUGGAGAGCCUCUAC 18


RESULT 1552
US-10-310-914A-1228949/c
; Sequence 1228949, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1228949
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1228949

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTT 3914
              |||||||||  ||  |||||
Db         18 TTTTTGTTTGTTTGTTTT 1


RESULT 1553
```

US-10-310-914A-1253710
; Sequence 1253710, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1253710
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1253710

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 1.1e+03;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 3469 TTTGGAGAGACAGGATTT 3486
:::| ||||||||| :::
Db 1 UUUGUAGAGACAGGGUUU 18

RESULT 1554
US-10-310-914A-1258332/c
; Sequence 1258332, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1258332
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1258332

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3892 TTCCCTTTTTGTTTCTTC 3909
|||||||| | |||||||
Db 18 TTCCCTTTGTCTTTCTTC 1

RESULT 1555
US-10-310-914A-1260027
; Sequence 1260027, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1260027
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1260027

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 66.7%; Pred. No. 1.1e+03;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1127 CGGGCTGCAGCTGTGCTC 1144
| |||:| |||:|:||:|
Db 1 CAGGCUGUAGCUGUGCUC 18

RESULT 1556
US-10-310-914A-1263719
; Sequence 1263719, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1263719
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1263719

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 86 ACCCCGAGGCCCCGGAGG 103
|| ||| ||||||||||
Db 1 ACGCCGGGGCCCCGGAGG 18

RESULT 1557
US-10-310-914A-1284973/c
; Sequence 1284973, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1284973
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1284973

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 172 CGCCGCCCGCGCGCGCGG 189
|| | ||||||||||||||
Db 18 CGGCCCCCGCGCGCGCGG 1

RESULT 1558
US-10-310-914A-1287424

```
; Sequence 1287424, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1287424
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1287424

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        675 GCCTCGGGCTGGGCGCTC 692
              |||:||||| |||||| |
Db          1 GCCUCGGGCCGGGCGCGC 18


RESULT 1559
US-10-310-914A-1296859
; Sequence 1296859, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1296859
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1296859

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1072 CCCAGCCCCAGCCTCTAC 1089
              ||| |||||||||:|: |
Db          1 CCCUGCCCCAGCCUCUCC 18


RESULT 1560
US-10-310-914A-1302290
; Sequence 1302290, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1302290
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1302290

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3517 CACCCCCCAGCCACCTCG 3534
              || ||||| ||||||:||
Db          1 CAGCCCCCUGCCACCUCG 18


RESULT 1561
US-10-310-914A-1302291
; Sequence 1302291, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1302291
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1302291

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3517 CACCCCCCAGCCACCTCG 3534
              || ||||| ||||||:||
Db          1 CAGCCCCCUGCCACCUCG 18


RESULT 1562
US-10-310-914A-1303787/c
; Sequence 1303787, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1303787
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1303787

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2279 AGGCCCCAGGGAAGAAGG 2296
              |||||||||| || |||||
Db         18 AGGCCCCAGAGAGGAAGG 1


RESULT 1563
US-10-310-914A-1305050
; Sequence 1305050, Application US/10310914A
```

```
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1305050
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1305050

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 1.1e+03;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1803 CGAGGGTCCCAGCAGCGT 1820
              ||||||:||||| ||| :
Db          1 CGAGGGUCCCAGGAGCCU 18


RESULT 1564
US-10-310-914A-1305749
; Sequence 1305749, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1305749
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1305749

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        568 CGTGCCCCGGGCCAGGCC 585
              | :||||||| ||||||
Db          1 CCUGCCCCGGGACAGGCC 18


RESULT 1565
US-10-310-914A-1307300/c
; Sequence 1307300, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1307300
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1307300

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3822 CCCTCCCCCAGCTGCTGC 3839
              ||| ||||| ||||||||
Db         18 CCCGCCCCCTGCTGCTGC 1


RESULT 1566
US-10-310-914A-1313757/c
; Sequence 1313757, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1313757
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1313757

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1531 CTGGTGGAGCCCTGGGTG 1548
              |||||||||| ||||| |
Db         18 CTGGTGGAGCTCTGGGGG 1


RESULT 1567
US-10-310-914A-1322817/c
; Sequence 1322817, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1322817
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1322817

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3412 CCCAGCCCTGTGCCCCGC 3429
              ||||||||||||||  ||
Db         18 CCCAGCCCTGTGCCAGGC 1


RESULT 1568
US-10-310-914A-1330318/c
; Sequence 1330318, Application US/10310914A
; Publication No. US20060003322A1
```

; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1330318
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1330318

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1959 GGATGAGAGCGAGGGCTG 1976
||| ||||||| ||||||
Db 18 GGAGGAGAGCGCGGGCTG 1

RESULT 1569
US-10-310-914A-1345129/c
; Sequence 1345129, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1345129
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1345129

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3578 GGGTGTGACCAGAGGAAA 3595
||||||| ||||||| ||
Db 18 GGGTGTGCCCAGAGGCAA 1

RESULT 1570
US-10-310-914A-1360221/c
; Sequence 1360221, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1360221
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1360221

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1062 CGCCCCTGGCCCCAGCCC 1079
|||||||| |||| ||||
Db 18 CGCCCCTGTCCCCTGCCC 1

RESULT 1571
US-10-310-914A-1362557
; Sequence 1362557, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1362557
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1362557

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 1.1e+03;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 3469 TTTGGAGAGACAGGATTT 3486
:::| ||||||||| :::
Db 1 UUUGUAGAGACAGGGUUU 18

RESULT 1572
US-10-310-914A-1368458
; Sequence 1368458, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1368458
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1368458

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3514 AATCACCCCCCAGCCACC 3531
|| |||||| ||||||||
Db 1 AACCACCCCACAGCCACC 18

RESULT 1573
US-10-310-914A-1374377
; Sequence 1374377, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

```
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1374377
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1374377

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         76 CCGGGGCGGGACCCCGAG 93
              ||||||| ||||||| ||
Db          1 CCGGGGCAGGACCCCCAG 18


RESULT 1574
US-10-310-914A-1375900/c
; Sequence 1375900, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1375900
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1375900

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1131 CTGCAGCTGTGCTCCGGG 1148
              |||||| |||||||| ||
Db         18 CTGCAGGTGTGCTCCAGG 1


RESULT 1575
US-11-069-908-5922
; Sequence 5922, Application US/11069908
; Publication No. US20050266432A1
; GENERAL INFORMATION:
;  APPLICANT: OLIPHANT, ARNOLD
;  APPLICANT:  MURRAY, SARAH
;  TITLE OF INVENTION: HAPLOTYPE MARKERS FOR DIAGNOSING SUSCEPTIBILITY TO IMMUNOLOGICAL
;  TITLE OF INVENTION:  CONDITIONS
;  FILE REFERENCE: 029011-0402
;  CURRENT APPLICATION NUMBER: US/11/069,908
;  CURRENT FILING DATE:  2005-02-28
;  PRIOR APPLICATION NUMBER: 60/547,823
;  PRIOR FILING DATE: 2004-02-26
;  NUMBER OF SEQ ID NOS: 7098
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 5922
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-11-069-908-5922

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+03;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1793 AGAAGGGCGCCGAGGGTC 1810
              ||||||| || |||||||
Db          1 AGAAGGGTGCAGAGGGTC 18


RESULT 1576
US-11-121-849-151576/c
; Sequence 151576, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
;  APPLICANT: John Palma
;  TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
;  TITLE OF INVENTION:  Microarrays
;  FILE REFERENCE: 3684.1
;  CURRENT APPLICATION NUMBER: US/11/121,849
;  CURRENT FILING DATE:  2005-05-03
;  PRIOR APPLICATION NUMBER: 60/567,949
;  PRIOR FILING DATE: 2004-05-03
;  NUMBER OF SEQ ID NOS: 673904
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151576
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-11-121-849-151576

  Query Match             0.3%;  Score 14.6;  DB 1;  Length 25;
  Best Local Similarity   81.0%;  Pred. No. 1.6e+03;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2343 GCAGCGGCGTGAGTTTCTGAG 2363
              ||| ||||||  ||||||| |
Db         22 GCACCGGCGTCCGTTTCTGGG 2


RESULT 1577
US-10-858-341-1384
; Sequence 1384, Application US/10858341
; Publication No. US20050287667A1
; GENERAL INFORMATION:
;  APPLICANT: Sheikhnejad, Reza
;  APPLICANT:  Sooch, Mina P.
;  APPLICANT:  Goodwin, Neal
;  APPLICANT:  Olson, David
;  TITLE OF INVENTION: Methods and Compositions for the Inhibition of Gene Expression
;  FILE REFERENCE: PRONAI-09053
;  CURRENT APPLICATION NUMBER: US/10/858,341
;  CURRENT FILING DATE:  2004-06-01
;  NUMBER OF SEQ ID NOS: 1439
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1384
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: methylated C nucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (10)..(10)
;   OTHER INFORMATION: methylated C nucleotide
;   FEATURE:
```

```
;   NAME/KEY: modified_base
;   LOCATION: (12)..(12)
;   OTHER INFORMATION: methylated C nucleotide
;   FEATURE:
;   NAME/KEY: modified_base
;   LOCATION: (17)..(17)
;   OTHER INFORMATION: methylated C nucleotide
US-10-858-341-1384

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          5 GCCCGGCGGCGCGAGC 20
              ||| ||||||||||||
Db          1 GCCTGGCGGCGCGAGC 16


RESULT 1578
US-10-310-914A-41907/c
; Sequence 41907, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 41907
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-41907

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1866 GAAGCGGGGAGCCAGC 1881
              |||||||| |||||||
Db         17 GAAGCGGGAAGCCAGC 2


RESULT 1579
US-10-310-914A-56011
; Sequence 56011, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 56011
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-56011

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2286 AGGGAAGAAGGAGAGC 2301
              ||| ||||||||||||
Db          1 AGGCAAGAAGGAGAGC 16


RESULT 1580
US-10-310-914A-64680/c
; Sequence 64680, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 64680
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-64680

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2890 CTGCCCCCGCCCCCAG 2905
              ||||| ||||||||||
Db         18 CTGCCGCCGCCCCCAG 3


RESULT 1581
US-10-310-914A-79204
; Sequence 79204, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 79204
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-79204

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3612 CTCCCAGCCTCCCCAG 3627
              |:|||||||:|||| |
Db          1 CUCCCAGCCUCCCCGG 16


RESULT 1582
US-10-310-914A-91195/c
; Sequence 91195, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
```

```
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 91195
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-91195

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1058 TCCCCGCCCCTGGCCC 1073
              ||||||||||||  |||
Db         17 TCCCCGCCCCTGCCCC 2


RESULT 1583
US-10-310-914A-98349
; Sequence 98349, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 98349
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-98349

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2282 CCCCAGGGAAGAAGGA 2297
              |||||||| |||||||
Db          1 CCCCAGGGCAGAAGGA 16


RESULT 1584
US-10-310-914A-111218/c
; Sequence 111218, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 111218
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-111218

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1230 CCAGCCATGCCCAGCC 1245
              |||||||  ||||||||
Db         17 CCAGCCAGGCCCAGCC 2


RESULT 1585
US-10-310-914A-148286/c
; Sequence 148286, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 148286
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-148286

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3821 CCCCTCCCCCAGCTGC 3836
              | ||||||||||||||
Db         18 CTCCTCCCCCAGCTGC 3


RESULT 1586
US-10-310-914A-169474/c
; Sequence 169474, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 169474
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-169474

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        170 CCCGCCGCCCGCGCGC 185
              | ||||||||||||||
Db         18 CGCGCCGCCCGCGCGC 3


RESULT 1587
US-10-310-914A-173307/c
; Sequence 173307, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
```

```
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 173307
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-173307

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1071 CCCCAGCCCCAGCCTC 1086
              ||||||||||||||| |
Db         18 CCCCAGCCCCAGCCCC 3


RESULT 1588
US-10-310-914A-174618/c
; Sequence 174618, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 174618
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-174618

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2467 AACGGCGCCCTGGACT 2482
              | ||||||||||||||
Db         18 AGCGGCGCCCTGGACT 3


RESULT 1589
US-10-310-914A-176334/c
; Sequence 176334, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 176334
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-176334

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3822 CCCTCCCCCAGCTGCT 3837
              || |||||||||||||
Db         17 CCTTCCCCCAGCTGCT 2


RESULT 1590
US-10-310-914A-213603/c
; Sequence 213603, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 213603
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-213603

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3352 CCCCACCCCAGGGACA 3367
              |||||||||||||| ||
Db         18 CCCCACCCCAGGGGCA 3


RESULT 1591
US-10-310-914A-213974/c
; Sequence 213974, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 213974
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-213974

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        135 CCCGCCCGGCGCGGCC 150
              |||||||||||||| ||
Db         17 CCCGCCCGGCGCGCCC 2


RESULT 1592
US-10-310-914A-213993
; Sequence 213993, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 213993
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-213993

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+03;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        164 TCCGGGCCCGCCGCCC 179
              :|||||| ||||||||
Db          1 UCCGGGCGCGCCGCCC 16


RESULT 1593
US-10-310-914A-216815/c
; Sequence 216815, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 216815
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-216815

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1071 CCCCAGCCCCAGCCTC 1086
              |||||||||||||| |
Db         16 CCCCAGCCCCAGCCCC 1


RESULT 1594
US-10-310-914A-216816/c
; Sequence 216816, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 216816
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-216816

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1071 CCCCAGCCCCAGCCTC 1086
              |||||||||||||| |
Db         16 CCCCAGCCCCAGCCCC 1


RESULT 1595
US-10-310-914A-218402/c
; Sequence 218402, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 218402
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-218402

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1980 GGAGCAGCTGGCCCTG 1995
              |||||||||||| |||
Db         16 GGAGCAGCTGGCTCTG 1


RESULT 1596
US-10-310-914A-223481/c
; Sequence 223481, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 223481
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-223481

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3523 CCAGCCACCTCGGGGA 3538
              ||||||| ||||||||
Db         16 CCAGCCAACTCGGGGA 1


RESULT 1597
US-10-310-914A-225022
; Sequence 225022, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 225022
```

```
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-225022

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3609 CATCTCCCAGCCTCCC 3624
              || |:|||||||:|||
Db          3 CACCUCCCAGCCUCCC 18


RESULT 1598
US-10-310-914A-246025/c
; Sequence 246025, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 246025
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-246025

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3856 TTTGAGTTTTGTTTTT 3871
              |||| ||||||||||||
Db         18 TTTGGGTTTTGTTTTT 3


RESULT 1599
US-10-310-914A-247428/c
; Sequence 247428, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 247428
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-247428

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3517 CACCCCCCAGCCACCT 3532
              ||||||||| ||||||
Db         16 CACCCCCCACCCACCT 1


RESULT 1600
US-10-310-914A-260616/c
; Sequence 260616, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 260616
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-260616

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3799 TCATTTTTTTCCCTTG 3814
              |||||||||||||| |
Db         17 TCATTTTTTTCCCTGG 2


RESULT 1601
US-10-310-914A-279451/c
; Sequence 279451, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 279451
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-279451

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        169 GCCCGCCGCCCGCGCG 184
              ||||||| ||||||||
Db         16 GCCCGCCACCCGCGCG 1


RESULT 1602
US-10-310-914A-281381/c
; Sequence 281381, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 281381
;   LENGTH: 18
```

```
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-281381

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2064 CAGGAAGCAGAGCAAT 2079
              ||||||||| ||||||
Db         18 CAGGAAGCAAAGCAAT 3


RESULT 1603
US-10-310-914A-283866/c
; Sequence 283866, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 283866
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-283866

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1230 CCAGCCATGCCCAGCC 1245
              |||||| |||||||||
Db         16 CCAGCCCTGCCCAGCC 1


RESULT 1604
US-10-310-914A-302300
; Sequence 302300, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 302300
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-302300

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2700 GAGCTCCCTGGGAGGA 2715
              ||||:|||:||||| |
Db          1 GAGCUCCCUGGGAGCA 16


RESULT 1605
US-10-310-914A-312334
; Sequence 312334, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 312334
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-312334

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        835 GAGGCCACCGGGAAGG 850
              | ||||||||||||||
Db          2 GCGGCCACCGGGAAGG 17


RESULT 1606
US-10-310-914A-345359/c
; Sequence 345359, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 345359
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-345359

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        974 TGACTGTGAACCTGAC 989
              || ||||||||||||
Db         16 TGGCTGTGAACCTGAC 1


RESULT 1607
US-10-310-914A-360426
; Sequence 360426, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 360426
;   LENGTH: 18
;   TYPE: RNA
```

```
;   ORGANISM: Human
US-10-310-914A-360426

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   18.8%;  Pred. No. 1.2e+03;
  Matches    3;  Conservative   12;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3907 TTCGTTTTGTTTTTCT 3922
              ::| :::|:::::|:
Db          1 UUCAUUUUGUUUUUCU 16


RESULT 1608
US-10-310-914A-365250/c
; Sequence 365250, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 365250
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-365250

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 GGCGCGAGCAGAGCCA 27
              |||||||||||||| ||
Db         18 GGCGCGAGCAGAGACA 3


RESULT 1609
US-10-310-914A-366631
; Sequence 366631, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 366631
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-366631

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+03;
  Matches    8;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4190 TTTTGTATAAATAAAA 4205
              ::::|:|:|||:| ||
Db          3 UUUUGUAUAAAUAUAA 18


RESULT 1610
US-10-310-914A-384932/c
; Sequence 384932, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 384932
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-384932

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1134 CAGCTGTGCTCCGGGG 1149
              |||||||||||| |||
Db         18 CAGCTGTGCTCCTGGG 3


RESULT 1611
US-10-310-914A-400399
; Sequence 400399, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 400399
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-400399

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1058 TCCCCGCCCCTGGCCC 1073
              :|||||||||: ||||
Db          1 UCCCCGCCCCUCGCCC 16


RESULT 1612
US-10-310-914A-405260/c
; Sequence 405260, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 405260
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
```

```
US-10-310-914A-405260

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         25 CCACTCCAGGGAGGGG 40
              ||||||| ||||||||
Db         18 CCACTCCCGGGAGGGG 3


RESULT 1613
US-10-310-914A-409851/c
; Sequence 409851, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 409851
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-409851

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1070 GCCCCAGCCCCAGCCT 1085
              ||||||||| ||||||
Db         16 GCCCCAGCCTCAGCCT 1


RESULT 1614
US-10-310-914A-416008/c
; Sequence 416008, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 416008
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-416008

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2269 GGGCGGCTCAAGGCCC 2284
              ||||||||| ||||||
Db         16 GGGCGGCTCCAGGCCC 1


RESULT 1615
US-10-310-914A-434918
; Sequence 434918, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 434918
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-434918

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         57 CCGGCTCAGCCCCCGC 72
              ||||| ||||||||||
Db          3 CCGGCCCAGCCCCCGC 18


RESULT 1616
US-10-310-914A-444628/c
; Sequence 444628, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 444628
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-444628

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3759 GTTTGTAGTCCCAACT 3774
              | ||||||||||||||
Db         18 GCTTGTAGTCCCAACT 3


RESULT 1617
US-10-310-914A-449233
; Sequence 449233, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 449233
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-449233
```

```
  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        831 GGCCGAGGCCACCGGG 846
              ||||||||||||| ||
Db          2 GGCCGAGGCCACCCGG 17


RESULT 1618
US-10-310-914A-470179/c
; Sequence 470179, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 470179
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-470179

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3904 TTCTTCGTTTTGTTTT 3919
              ||||| ||||||||||
Db         17 TTCTTGGTTTTGTTTT 2


RESULT 1619
US-10-310-914A-476504
; Sequence 476504, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 476504
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-476504

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+03;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1063 GCCCCTGGCCCCAGCC 1078
              |||||:|||||| |||
Db          3 GCCCCUGGCCCCCGCC 18


RESULT 1620
US-10-310-914A-477521/c
; Sequence 477521, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 477521
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-477521

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        896 TCTACCTGGCCTTCCA 911
              ||| ||||||||||||
Db         18 TCTCCCTGGCCTTCCA 3


RESULT 1621
US-10-310-914A-477522/c
; Sequence 477522, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 477522
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-477522

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        896 TCTACCTGGCCTTCCA 911
              ||| ||||||||||||
Db         18 TCTCCCTGGCCTTCCA 3


RESULT 1622
US-10-310-914A-502238/c
; Sequence 502238, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 502238
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-502238
```

```
  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1071 CCCCAGCCCCAGCCTC 1086
              ||||||||||||||| |
Db         16 CCCCAGCCCCAGCCCC 1


RESULT 1623
US-10-310-914A-541085/c
; Sequence 541085, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 541085
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-541085

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3852 GGTTTTTGAGTTTTGT 3867
              |||||||| |||||||
Db         16 GGTTTTTGGGTTTTGT 1


RESULT 1624
US-10-310-914A-543962/c
; Sequence 543962, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 543962
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-543962

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2799 TGTGATGTGGGAGGTG 2814
              ||||||| ||||||||
Db         16 TGTGATGGGGGAGGTG 1


RESULT 1625
US-10-310-914A-545257/c
; Sequence 545257, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 545257
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-545257

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        680 GGGCTGGGCGCTCCTG 695
              |||| ||||||||||||
Db         16 GGGCCGGGCGCTCCTG 1


RESULT 1626
US-10-310-914A-551594/c
; Sequence 551594, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 551594
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-551594

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        753 CACGCCAGCCTGGATG 768
              ||| ||||||||||||
Db         17 CACTCCAGCCTGGATG 2


RESULT 1627
US-10-310-914A-608856/c
; Sequence 608856, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 608856
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-608856

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
```

Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 166 CGGGCCCGCCGCCCGC 181
||||||.|||||||||
Db 18 CGGGCCGGCCGCCCGC 3

RESULT 1628
US-10-310-914A-615451/c
; Sequence 615451, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 615451
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-615451

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 61 CTCAGCCCCCGCCACC 76
|.|||||||||||||
Db 17 CCCAGCCCCCGCCACC 2

RESULT 1629
US-10-310-914A-632129
; Sequence 632129, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 632129
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-632129

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.2e+03;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 512 GCGGCCTGGATGAGGA 527
||||||:|||.|||||
Db 2 GCGGCCUGGAGGAGGA 17

RESULT 1630
US-10-310-914A-637489
; Sequence 637489, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 637489
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-637489

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.2e+03;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 816 CCGGAAGCGCCCTGGG 831
||||||||||.|:|||
Db 3 CCGGAAGCGCGCUGGG 18

RESULT 1631
US-10-310-914A-640184
; Sequence 640184, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 640184
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-640184

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.2e+03;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 485 AGGTGGACGGGCAGTG 500
|||:||||||||| |
Db 3 AGGUGGACGGGCAGAG 18

RESULT 1632
US-10-310-914A-647639
; Sequence 647639, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 647639
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-647639

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;

```
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3717 GGGCAAGAAGGGGTGT 3732
              ||||| |||||||:|:
Db          2 GGGCAUGAAGGGGUGU 17


RESULT 1633
US-10-310-914A-694211/c
; Sequence 694211, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 694211
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-694211

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3057 CTCACACCCTCTCCTG 3072
              | ||||||||||||||
Db         16 CCCACACCCTCTCCTG 1


RESULT 1634
US-10-310-914A-696304
; Sequence 696304, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 696304
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-696304

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        128 CTGCGCGCCCGCCCGG 143
              | ||||||||||||||
Db          1 CCGCGCGCCCGCCCGG 16


RESULT 1635
US-10-310-914A-703730
; Sequence 703730, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 703730
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-703730

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2102 ACAAACACGGACAGTA 2117
              |||||||||||||| |
Db          2 ACAAACACGGACAGGA 17


RESULT 1636
US-10-310-914A-709308
; Sequence 709308, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 709308
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-709308

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   75.0%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4195 TATAAATAAAAGAAAA 4210
              :|:|||:|| ||||||
Db          1 UAUAAAUAAUAGAAAA 16


RESULT 1637
US-10-310-914A-715655/c
; Sequence 715655, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 715655
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-715655

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       3774 TTGCTGCTGTCACCAC 3789
              |||||||||||||| ||
Db         18 TTGCTGCTGTCACGAC 3


RESULT 1638
US-10-310-914A-722201
; Sequence 722201, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 722201
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-722201

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        879 GCTCAGCAAGGCTGGC 894
              ||: |||||||||:|||
Db          2 GCUGAGCAAGGCUGGC 17


RESULT 1639
US-10-310-914A-732299/c
; Sequence 732299, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 732299
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-732299

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3679 CTCCCTTGCCAGCTCC 3694
              ||||||| ||||||||
Db         16 CTCCCTTTCCAGCTCC 1


RESULT 1640
US-10-310-914A-733252/c
; Sequence 733252, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 733252
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-733252

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2968 CCCCGCTTCCCCCAGG 2983
              ||| ||||||||||||
Db         18 CCCTGCTTCCCCCAGG 3


RESULT 1641
US-10-310-914A-736940/c
; Sequence 736940, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 736940
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-736940

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3857 TTGAGTTTTGTTTTTG 3872
              ||| ||||||||||||
Db         16 TTGTGTTTTGTTTTTG 1


RESULT 1642
US-10-310-914A-737419
; Sequence 737419, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 737419
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-737419

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy         31 CAGGGAGGGGGGGAGA 46
              |||||||| |||||||
Db          3 CAGGGAGGCGGGGAGA 18


RESULT 1643
US-10-310-914A-738114/c
; Sequence 738114, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 738114
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-738114

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3821 CCCCTCCCCCAGCTGC 3836
              |||||||||||||| |
Db         16 CCCCTCCCCCAGCTCC 1


RESULT 1644
US-10-310-914A-750442
; Sequence 750442, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 750442
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-750442

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         85 GACCCCGAGGCCCCGG 100
              | ||||||||||||||
Db          3 GGCCCCGAGGCCCCGG 18


RESULT 1645
US-10-310-914A-759572
; Sequence 759572, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 759572
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-759572

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+03;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        824 GCCCTGGGGCCGAGGC 839
              ||||:||||||| |||
Db          2 GCCCUGGGGCCGGGGC 17


RESULT 1646
US-10-310-914A-778291
; Sequence 778291, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 778291
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-778291

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3688 CAGCTCCAGAGTGGGG 3703
              ||||: |||||:||||
Db          3 CAGCUUCAGAGUGGGG 18


RESULT 1647
US-10-310-914A-790616
; Sequence 790616, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 790616
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-790616

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3821 CCCCTCCCCCAGCTGC 3836
```

```
              ||||:||||||||: |
Db          3 CCCCUCCCCCAGCUCC 18


RESULT 1648
US-10-310-914A-791845/c
; Sequence 791845, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 791845
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-791845

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1530 CCTGGTGGAGCCCTGG 1545
              ||||| ||||||||||
Db         18 CCTGGGGGAGCCCTGG 3


RESULT 1649
US-10-310-914A-802146/c
; Sequence 802146, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 802146
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-802146

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        390 GCTGCTCTGCTGGGCT 405
              |||||||||||| ||||
Db         16 GCTGCTCTGCTTGGCT 1


RESULT 1650
US-10-310-914A-829295/c
; Sequence 829295, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 829295
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-829295

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1382 GCTCCTCCCTGCACCT 1397
              |||||||||||| |||
Db         18 GCTCCTCCCTGCTCCT 3


RESULT 1651
US-10-310-914A-833421
; Sequence 833421, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 833421
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-833421

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1069 GGCCCCAGCCCCAGCC 1084
              || ||||||||||||||
Db          2 GGACCCAGCCCCAGCC 17


RESULT 1652
US-10-310-914A-841274
; Sequence 841274, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 841274
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-841274

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        750 CCTCACGCCAGCCTGG 765
              ||:||| ||||||:||
```

```
Db          2 CCUCACUCCAGCCUGG 17


RESULT 1653
US-10-310-914A-847213
; Sequence 847213, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 847213
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-847213

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   75.0%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4083 GAAGGGGTGTGGGGTG 4098
              | |||||:|:||||:|
Db          3 GGAGGGGUGUGGGGUG 18


RESULT 1654
US-10-310-914A-847214
; Sequence 847214, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 847214
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-847214

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   75.0%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4083 GAAGGGGTGTGGGGTG 4098
              | |||||:|:||||:|
Db          3 GGAGGGGUGUGGGGUG 18


RESULT 1655
US-10-310-914A-853825/c
; Sequence 853825, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 853825
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-853825

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         10 GCGGCGCGAGCAGAGC 25
              |||||||||||||| ||
Db         18 GCGGCGCGAGCAGGGC 3


RESULT 1656
US-10-310-914A-873006/c
; Sequence 873006, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 873006
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-873006

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1727 GCCTGGCCTGGGCTGT 1742
              | ||||||||||||||
Db         17 GGCTGGCCTGGGCTGT 2


RESULT 1657
US-10-310-914A-878489/c
; Sequence 878489, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 878489
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-878489

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3828 CCCAGCTGCTGCCTTC 3843
              |||||||||||||| ||
Db         16 CCCAGCTGCTGCCCTC 1
```

```
RESULT 1658
US-10-310-914A-892826/c
; Sequence 892826, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 892826
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-892826

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3823 CCTCCCCCAGCTGCTG 3838
              ||||||||  |||||||
Db         18 CCTCCCCCTGCTGCTG 3


RESULT 1659
US-10-310-914A-893437
; Sequence 893437, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 893437
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-893437

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2704 TCCCTGGGAGGAAAGA 2719
              :|||:||||||||  ||
Db          1 UCCCUGGGAGGAAUGA 16


RESULT 1660
US-10-310-914A-895138
; Sequence 895138, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895138
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-895138

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+03;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1071 CCCCAGCCCCAGCCTC 1086
              ||||||||  |||||:|
Db          3 CCCCAGCCUCAGCCUC 18


RESULT 1661
US-10-310-914A-906603
; Sequence 906603, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 906603
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-906603

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+03;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2893 CCCCCGCCCCCAGACT 2908
              |||||  |||||||||:
Db          2 CCCCCUCCCCCAGACU 17


RESULT 1662
US-10-310-914A-912483/c
; Sequence 912483, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 912483
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-912483

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3862 TTTTGTTTTTGGTCTT 3877
              ||||||||||||  ||
Db         18 TTTTGTTTTTGGTTTT 3
```

```
RESULT 1663
US-10-310-914A-912486/c
; Sequence 912486, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 912486
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-912486

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3862 TTTTGTTTTTGGTCTT 3877
              ||||||||||||| ||
Db         16 TTTTGTTTTTGGTTTT 1


RESULT 1664
US-10-310-914A-914942
; Sequence 914942, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 914942
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-914942

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+03;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        210 TGGCGCCGCCGCCCGG 225
              :|||||||| ||||||
Db          3 UGGCGCCGCGGCCCGG 18


RESULT 1665
US-10-310-914A-916502/c
; Sequence 916502, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916502
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-916502

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2890 CTGCCCCCGCCCCCAG 2905
              ||||||| ||||||||
Db         18 CTGCCCCAGCCCCCAG 3


RESULT 1666
US-10-310-914A-916686/c
; Sequence 916686, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916686
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-916686

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3402 CACAGAGGCCCCCAGC 3417
              |||||||||||| ||||
Db         17 CACAGAGGCCCTCAGC 2


RESULT 1667
US-10-310-914A-922634
; Sequence 922634, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 922634
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-922634

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2879 AGGACTACCGGCTGCC 2894
              |||||:|| |||:|||
Db          2 AGGACUACAGGCUGCC 17
```

```
RESULT 1668
US-10-310-914A-929594/c
; Sequence 929594, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 929594
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-929594

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3855 TTTTGAGTTTTGTTTT 3870
                || ||||||||||||
Db         18 TTCTGAGTTTTGTTTT 3


RESULT 1669
US-10-310-914A-964748
; Sequence 964748, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 964748
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-964748

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   62.5%;  Pred. No. 1.2e+03;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4177 TAAAAAAGTAACTTTT 4192
              :|||||||:|||: ::
Db          1 UAAAAAAGUAACUCUU 16


RESULT 1670
US-10-310-914A-966408/c
; Sequence 966408, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 966408
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-966408

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1230 CCAGCCATGCCCAGCC 1245
              ||||||| ||||||||
Db         16 CCAGCCAAGCCCAGCC 1


RESULT 1671
US-10-310-914A-968397
; Sequence 968397, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 968397
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-968397

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   75.0%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3185 AGCTGGTCAGCCAGAT 3200
              |||:||:||| ||||:
Db          2 AGCUGGUCAGGCAGAU 17


RESULT 1672
US-10-310-914A-989400/c
; Sequence 989400, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 989400
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-989400

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3907 TTCGTTTTGTTTTTCT 3922
              ||| ||||||||||||
Db         17 TTCTTTTTGTTTTTCT 2


RESULT 1673
```

```
US-10-310-914A-999098
; Sequence 999098, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 999098
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-999098

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1331 CCTGCACCACCCCTCC 1346
              ||:|| |||||||:||
Db          1 CCUGCUCCACCCCUCC 16


RESULT 1674
US-10-310-914A-999099
; Sequence 999099, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 999099
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-999099

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1331 CCTGCACCACCCCTCC 1346
              ||:|| |||||||:||
Db          1 CCUGCUCCACCCCUCC 16


RESULT 1675
US-10-310-914A-999100
; Sequence 999100, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 999100
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-999100

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1331 CCTGCACCACCCCTCC 1346
              ||:|| |||||||:||
Db          1 CCUGCUCCACCCCUCC 16


RESULT 1676
US-10-310-914A-1002209/c
; Sequence 1002209, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1002209
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1002209

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3372 CTCCCCATTTTCCGGG 3387
              |||||||| |||||||
Db         17 CTCCCCATCTTCCGGG 2


RESULT 1677
US-10-310-914A-1013145
; Sequence 1013145, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1013145
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1013145

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        137 CGCCCGGCGCGGCCAC 152
              |||||||||||||| |
Db          2 CGCCCGGCGCGGCCGC 17


RESULT 1678
US-10-310-914A-1022764/c
```

; Sequence 1022764, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1022764
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1022764

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3907 TTCGTTTTGTTTTTCT 3922
||| ||||||||||||
Db 17 TTCCTTTTGTTTTTCT 2

RESULT 1679
US-10-310-914A-1027936
; Sequence 1027936, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1027936
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1027936

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 3983 AAGTTGAAACAGGGGC 3998
|||::|||||||| |
Db 2 AAGUUGAAACAGGGUC 17

RESULT 1680
US-10-310-914A-1041898/c
; Sequence 1041898, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1041898
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1041898

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 681 GGCTGGGCGCTCCTGC 696
|||||||| |||||||
Db 18 GGCTGGGCTCTCCTGC 3

RESULT 1681
US-10-310-914A-1060050/c
; Sequence 1060050, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1060050
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1060050

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1070 GCCCCAGCCCCAGCCT 1085
||||||||||||| |||
Db 17 GCCCCAGCCCCATCCT 2

RESULT 1682
US-10-310-914A-1101002
; Sequence 1101002, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1101002
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1101002

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 56.2%; Pred. No. 1.2e+03;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 3882 TTTCTCCCCGTTCCCT 3897
:::|:|||||: |||:
Db 1 UUUCUCCCCGUCCCCU 16

RESULT 1683
US-10-310-914A-1124096/c
; Sequence 1124096, Application US/10310914A

```
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1124096
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1124096

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1425 TGGCCGAGAGGACCTC 1440
              |||| ||||||||||
Db         16 TGGCGGAGAGGACCTC 1


RESULT 1684
US-10-310-914A-1177722/c
; Sequence 1177722, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1177722
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1177722

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1070 GCCCCAGCCCCAGCCT 1085
              |||||||||||| |||
Db         17 GCCCCAGCCCCATCCT 2


RESULT 1685
US-10-310-914A-1187158/c
; Sequence 1187158, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1187158
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1187158

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1063 GCCCCTGGCCCCAGCC 1078
              ||||| ||||||||||
Db         16 GCCCCGGGCCCCAGCC 1


RESULT 1686
US-10-310-914A-1187485
; Sequence 1187485, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1187485
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1187485

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+03;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1070 GCCCCAGCCCCAGCCT 1085
              | ||||||||||||||:
Db          3 GACCCAGCCCCAGCCU 18


RESULT 1687
US-10-310-914A-1219995/c
; Sequence 1219995, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219995
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1219995

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3800 CATTTTTTTCCCTTGT 3815
              |||||| |||||||||
Db         18 CATTTTATTCCCTTGT 3


RESULT 1688
US-10-310-914A-1222014
; Sequence 1222014, Application US/10310914A
; Publication No. US20060003322A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1222014
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1222014

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2407 CGCCTGGAGGGCGTGG 2422
                | ||:|||||||||:||
Db          1 CCCCUGGAGGGCGUGG 16


RESULT 1689
US-10-310-914A-1264272/c
; Sequence 1264272, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1264272
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1264272

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        680 GGGCTGGGCGCTCCTG 695
                |||| ||||||||||
Db         16 GGGCCGGGCGCTCCTG 1


RESULT 1690
US-10-310-914A-1264496
; Sequence 1264496, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1264496
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1264496

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   81.2%;  Pred. No. 1.2e+03;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        750 CCTCACGCCAGCCTGG 765
                ||:||| ||||||:||
Db          2 CCUCACUCCAGCCUGG 17


RESULT 1691
US-10-310-914A-1279584
; Sequence 1279584, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1279584
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1279584

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        131 CGCGCCCGCCCGGCGC 146
                ||||||||||||  |||
Db          2 CGCGCCCGCCCGCCGC 17


RESULT 1692
US-10-310-914A-1289326
; Sequence 1289326, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1289326
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1289326

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   75.0%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3611 TCTCCCAGCCTCCCCA 3626
                :|:|||||||:| |||
Db          1 UCUCCCAGCCUCUCCA 16


RESULT 1693
US-10-310-914A-1289327
; Sequence 1289327, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1289327
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1289327

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   75.0%;  Pred. No. 1.2e+03;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3611 TCTCCCAGCCTCCCCA 3626
              :|:|||||||:| |||
Db          1 UCUCCCAGCCUCUCCA 16


RESULT 1694
US-10-310-914A-1295076/c
; Sequence 1295076, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1295076
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1295076

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3823 CCTCCCCCAGCTGCTG 3838
              |||||||||||||| |
Db         18 CCTCCCCCAGCTGCAG 3


RESULT 1695
US-10-310-914A-1296315/c
; Sequence 1296315, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1296315
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1296315

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        647 GCTTCACCATGCTCGA 662
              |||||||||||||| |
Db         17 GCTTCACCATGCTCCA 2


RESULT 1696
US-10-310-914A-1315876/c
; Sequence 1315876, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1315876
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1315876

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1071 CCCCAGCCCCAGCCTC 1086
              | ||||||||||||||
Db         18 CACCAGCCCCAGCCTC 3


RESULT 1697
US-10-310-914A-1347485/c
; Sequence 1347485, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
;  APPLICANT:  Shiler, Kvuzat
;  TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;  TITLE OF INVENTION:  uses thereof
;  FILE REFERENCE: 06087.0200.CPUS01
;  CURRENT APPLICATION NUMBER: US/10/310,914A
;  CURRENT FILING DATE:  2002-12-06
;  NUMBER OF SEQ ID NOS: 1388402
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1347485
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Human
US-10-310-914A-1347485

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+03;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1515 CCCCGGCCCCCGGGAC 1530
              |||||||||||||| |
Db         16 CCCCGGCCCCCGGGCC 1


RESULT 1698
US-10-310-914A-1353530/c
; Sequence 1353530, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
;  APPLICANT: Bentwich, Isaac
```

; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1353530
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1353530

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        753 CACGCCAGCCTGGATG 768
              ||| |||||||||||||
Db         17 CACTCCAGCCTGGATG 2
```

RESULT 1699
US-11-069-908-1263
; Sequence 1263, Application US/11069908
; Publication No. US20050266432A1
; GENERAL INFORMATION:
; APPLICANT: OLIPHANT, ARNOLD
; APPLICANT: MURRAY, SARAH
; TITLE OF INVENTION: HAPLOTYPE MARKERS FOR DIAGNOSING SUSCEPTIBILITY TO IMMUNOLOGICAL
; TITLE OF INVENTION: CONDITIONS
; FILE REFERENCE: 029011-0402
; CURRENT APPLICATION NUMBER: US/11/069,908
; CURRENT FILING DATE: 2005-02-28
; PRIOR APPLICATION NUMBER: 60/547,823
; PRIOR FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 7098
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1263
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-11-069-908-1263

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1068 TGGCCCCAGCCCCAGC 1083
              ||| |||||||||||||
Db          1 TGGGCCCAGCCCCAGC 16
```

RESULT 1700
US-11-069-908-3629
; Sequence 3629, Application US/11069908
; Publication No. US20050266432A1
; GENERAL INFORMATION:
; APPLICANT: OLIPHANT, ARNOLD
; APPLICANT: MURRAY, SARAH
; TITLE OF INVENTION: HAPLOTYPE MARKERS FOR DIAGNOSING SUSCEPTIBILITY TO IMMUNOLOGICAL
; TITLE OF INVENTION: CONDITIONS
; FILE REFERENCE: 029011-0402
; CURRENT APPLICATION NUMBER: US/11/069,908
; CURRENT FILING DATE: 2005-02-28
; PRIOR APPLICATION NUMBER: 60/547,823
; PRIOR FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 7098
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3629
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-11-069-908-3629

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1068 TGGCCCCAGCCCCAGC 1083
              ||| |||||||||||||
Db          1 TGGGCCCAGCCCCAGC 16
```

Search completed: March 23, 2006, 11:21:11
Job time : 92 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 23, 2006, 11:09:46 ; Search time 39 Seconds
(without alignments)
3.281 Million cell updates/sec

Title: US-10-800-077-392
Perfect score: 4235
Sequence: 1 ctcggcccggcggcgcgagc.....cgtgtcccagctccaggggt 4235

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 756 seqs, 15107 residues

Total number of hits satisfying chosen parameters: 1512

Minimum DB seq length: 5
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 758 summaries

Database : fetch392rng.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	50	1.2	50	1	AAI78874	Human silent SNP c
	2	48	1.1	48	1	ADR52551	Small interfering
	3	40	0.9	48	1	ADR52531	Small interfering
	4	38.4	0.9	48	1	ADR52529	Small interfering
	5	38.4	0.9	48	1	ADR52517	Small interfering
c	6	29	0.7	36	1	ADR86708	Human ephrin B4 PC
c	7	29	0.7	36	1	ADR82277	Human EphB4 PCR pr
	8	26	0.6	26	1	ADH17041	Forward PCR primer
	9	24.2	0.6	29	1	ADR86707	Human ephrin B4 PC
	10	24.2	0.6	29	1	ADR82276	Human EphB4 PCR pr
	11	22	0.5	22	1	ADT00082	Novel mutant prote
c	12	21	0.5	21	1	ADR86751	Human ephrin B4 an
	13	21	0.5	21	1	ADR86956	Human ephrinB4 sho
	14	21	0.5	21	1	ADR86972	Human ephrinB4 sho
	15	21	0.5	21	1	ADR86981	Human ephrinB4 sho
c	16	21	0.5	21	1	ADR86772	Human ephrinB4 sho
	17	21	0.5	21	1	ADR86950	Human ephrinB4 sho
	18	21	0.5	21	1	ADR86963	Human ephrinB4 sho
	19	21	0.5	21	1	ADR86971	Human ephrinB4 sho
	20	21	0.5	21	1	ADR86979	Human ephrinB4 sho
c	21	21	0.5	21	1	ADR86726	Human ephrin B4 an
	22	21	0.5	21	1	ADR86936	Human ephrinB4 sho
	23	21	0.5	21	1	ADR86938	Human ephrinB4 sho
	24	21	0.5	21	1	ADR86957	Human ephrinB4 sho
	25	21	0.5	21	1	ADR86965	Human ephrinB4 sho
	26	21	0.5	21	1	ADR86967	Human ephrinB4 sho
	27	21	0.5	21	1	ADR86983	Human ephrinB4 sho
	28	21	0.5	21	1	ADR86941	Human ephrinB4 sho
	29	21	0.5	21	1	ADR86953	Human ephrinB4 sho
	30	21	0.5	21	1	ADR86966	Human ephrinB4 sho
	31	21	0.5	21	1	ADR86969	Human ephrinB4 sho
	32	21	0.5	21	1	ADR86980	Human ephrinB4 sho
c	33	21	0.5	21	1	ADR86746	Human ephrin B4 an
c	34	21	0.5	21	1	ADR86924	Human ephrin B4 an
c	35	21	0.5	21	1	ADR86927	Human ephrin B4 an
	36	21	0.5	21	1	ADR86944	Human ephrinB4 sho
	37	21	0.5	21	1	ADR86945	Human ephrinB4 sho
	38	21	0.5	21	1	ADR86954	Human ephrinB4 sho
	39	21	0.5	21	1	ADR86961	Human ephrinB4 sho
	40	21	0.5	21	1	ADR86948	Human ephrinB4 sho
	41	21	0.5	21	1	ADR86968	Human ephrinB4 sho
	42	21	0.5	21	1	ADR86987	Human ephrinB4 sho
c	43	21	0.5	21	1	ADR86775	Human ephrin B4 an
c	44	21	0.5	21	1	ADR86928	Human ephrin B4 an
	45	21	0.5	21	1	ADR86940	Human ephrinB4 sho
	46	21	0.5	21	1	ADR86973	Human ephrinB4 sho
	47	21	0.5	21	1	ADR86975	Human ephrinB4 sho
	48	21	0.5	21	1	ADR86952	Human ephrinB4 sho
	49	21	0.5	21	1	ADR86955	Human ephrinB4 sho
	50	21	0.5	21	1	ADR86960	Human ephrinB4 sho
	51	21	0.5	21	1	ADR86962	Human ephrinB4 sho
	52	21	0.5	21	1	ADR86976	Human ephrinB4 sho
c	53	21	0.5	21	1	ADR86748	Human ephrin B4 an
c	54	21	0.5	21	1	ADR86931	Human ephrin B4 an
	55	21	0.5	21	1	ADR86935	Human ephrinB4 sho
	56	21	0.5	21	1	ADR86977	Human ephrinB4 sho
	57	21	0.5	21	1	ADR86978	Human ephrinB4 sho
	58	21	0.5	21	1	ADR86985	Human ephrinB4 sho
c	59	21	0.5	21	1	ADR86932	Human ephrin B4 an
	60	21	0.5	21	1	ADR86943	Human ephrinB4 sho
	61	21	0.5	21	1	ADR86958	Human ephrinB4 sho
	62	21	0.5	21	1	ADR86982	Human ephrinB4 sho
	63	21	0.5	21	1	ADR86986	Human ephrinB4 sho
c	64	21	0.5	21	1	ADR86739	Human ephrinB4 sho
c	65	21	0.5	21	1	ADR86743	Human ephrinB4 sho
c	66	21	0.5	21	1	ADR86752	Human ephrin B4 an
	67	21	0.5	21	1	ADR86937	Human ephrinB4 sho
	68	21	0.5	21	1	ADR86939	Human ephrinB4 sho
	69	21	0.5	21	1	ADR86959	Human ephrinB4 sho
	70	21	0.5	21	1	ADR86964	Human ephrinB4 sho
c	71	21	0.5	21	1	ADR86737	Human ephrinB4 sho
c	72	21	0.5	21	1	ADR86741	Human ephrinB4 sho
	73	21	0.5	21	1	ADR86942	Human ephrinB4 sho
c	74	21	0.5	21	1	ADR86754	Human ephrin B4 an
c	75	21	0.5	21	1	ADR86926	Human ephrin B4 an
	76	21	0.5	21	1	ADR86947	Human ephrinB4 sho
	77	21	0.5	21	1	ADR86949	Human ephrinB4 sho
c	78	21	0.5	21	1	ADR86744	Human ephrin B4 an
c	79	21	0.5	21	1	ADR86934	Human ephrin B4 an
	80	21	0.5	21	1	ADR86946	Human ephrinB4 sho
	81	21	0.5	21	1	ADR86951	Human ephrinB4 sho
	82	21	0.5	21	1	ADR86970	Human ephrinB4 sho
	83	21	0.5	21	1	ADR86984	Human ephrinB4 sho
c	84	21	0.5	21	1	ADR86747	Human ephrin B4 an
	85	21	0.5	21	1	ADR86974	Human ephrinB4 sho
c	86	21	0.5	21	1	ADR82292	Human EphB4 antise
	87	21	0.5	21	1	ADR82495	Human EphB4 antise
	88	21	0.5	21	1	ADR82516	Human EphB4 antise
	89	21	0.5	21	1	ADR82524	Human EphB4 antise
	90	21	0.5	21	1	ADR82527	Human EphB4 antise
	91	21	0.5	21	1	ADR82532	Human EphB4 antise
	92	21	0.5	21	1	ADR82512	Human EphB4 antise
	93	21	0.5	21	1	ADR82531	Human EphB4 antise
c	94	21	0.5	21	1	ADR82319	Human EphB4 antise
	95	21	0.5	21	1	ADR82493	Human EphB4 antise
	96	21	0.5	21	1	ADR82494	Human EphB4 antise
	97	21	0.5	21	1	ADR82519	Human EphB4 antise
	98	21	0.5	21	1	ADR82525	Human EphB4 antise
	99	21	0.5	21	1	ADR82534	Human EphB4 antise
	100	21	0.5	21	1	ADR82506	Human EphB4 antise
	101	21	0.5	21	1	ADR82513	Human EphB4 antise
	102	21	0.5	21	1	ADR82540	Human EphB4 antise
c	103	21	0.5	21	1	ADR82479	Human EphB4 antise
c	104	21	0.5	21	1	ADR82483	Human EphB4 antise
	105	21	0.5	21	1	ADR82507	Human EphB4 antise
	106	21	0.5	21	1	ADR82514	Human EphB4 antise

	107	21	0.5	21	1	ADR82518	Human EphB4 antise
	108	21	0.5	21	1	ADR82529	Human EphB4 antise
	109	21	0.5	21	1	ADR82537	Human EphB4 antise
c	110	21	0.5	21	1	ADR82316	Human EphB4 antise
	111	21	0.5	21	1	ADR82496	Human EphB4 antise
	112	21	0.5	21	1	ADR82503	Human EphB4 antise
	113	21	0.5	21	1	ADR82508	Human EphB4 antise
	114	21	0.5	21	1	ADR82510	Human EphB4 antise
	115	21	0.5	21	1	ADR82542	Human EphB4 antise
c	116	21	0.5	21	1	ADR82311	Human EphB4 antise
c	117	21	0.5	21	1	ADR82317	Human EphB4 antise
	118	21	0.5	21	1	ADR82499	Human EphB4 antise
	119	21	0.5	21	1	ADR82509	Human EphB4 antise
	120	21	0.5	21	1	ADR82520	Human EphB4 antise
	121	21	0.5	21	1	ADR82492	Human EphB4 antise
	122	21	0.5	21	1	ADR82504	Human EphB4 antise
c	123	21	0.5	21	1	ADR82308	Human EphB4 siRNA
c	124	21	0.5	21	1	ADR82313	Human EphB4 antise
c	125	21	0.5	21	1	ADR82482	Human EphB4 antise
c	126	21	0.5	21	1	ADR82486	Human EphB4 antise
c	127	21	0.5	21	1	ADR82302	Human EphB4 siRNA
c	128	21	0.5	21	1	ADR82327	Human EphB4 siRNA
	129	21	0.5	21	1	ADR82498	Human EphB4 antise
	130	21	0.5	21	1	ADR82500	Human EphB4 antise
	131	21	0.5	21	1	ADR82505	Human EphB4 antise
	132	21	0.5	21	1	ADR82538	Human EphB4 antise
c	133	21	0.5	21	1	ADR82487	Human EphB4 antise
	134	21	0.5	21	1	ADR82491	Human EphB4 antise
	135	21	0.5	21	1	ADR82517	Human EphB4 antise
	136	21	0.5	21	1	ADR82522	Human EphB4 antise
	137	21	0.5	21	1	ADR82528	Human EphB4 antise
	138	21	0.5	21	1	ADR82530	Human EphB4 antise
c	139	21	0.5	21	1	ADR82304	Human EphB4 siRNA
c	140	21	0.5	21	1	ADR82306	Human EphB4 siRNA
c	141	21	0.5	21	1	ADR82312	Human EphB4 antise
	142	21	0.5	21	1	ADR82511	Human EphB4 antise
	143	21	0.5	21	1	ADR82533	Human EphB4 antise
c	144	21	0.5	21	1	ADR82330	Human EphB4 antise
c	145	21	0.5	21	1	ADR82481	Human EphB4 antise
	146	21	0.5	21	1	ADR82490	Human EphB4 antise
	147	21	0.5	21	1	ADR82501	Human EphB4 antise
	148	21	0.5	21	1	ADR82502	Human EphB4 antise
	149	21	0.5	21	1	ADR82523	Human EphB4 antise
	150	21	0.5	21	1	ADR82535	Human EphB4 antise
	151	21	0.5	21	1	ADR82536	Human EphB4 antise
	152	21	0.5	21	1	ADR82541	Human EphB4 antise
	153	21	0.5	21	1	ADR82515	Human EphB4 antise
c	154	21	0.5	21	1	ADR82309	Human EphB4 antise
	155	21	0.5	21	1	ADR82497	Human EphB4 antise
	156	21	0.5	21	1	ADR82521	Human EphB4 antise
	157	21	0.5	21	1	ADR82539	Human EphB4 antise
c	158	21	0.5	21	1	ADR82489	Human EphB4 antise
	159	21	0.5	21	1	ADR82526	Human EphB4 antise
c	160	20.8	0.5	24	1	ADU79893	Antisense oligonuc
	161	20.4	0.5	22	1	ADR86761	Human ephrin B4 RT
	162	20.4	0.5	22	1	ADR82667	Human EphB4 RT-PCR
c	163	20.4	0.5	24	1	ADE79941	Tyrosine kinase an
c	164	20	0.5	20	1	ADR86727	Human ephrin B4 an
c	165	20	0.5	20	1	ADR86801	Human ephrin B4 an
c	166	20	0.5	20	1	ADR86860	Human ephrin B4 an
c	167	20	0.5	20	1	ADR86901	Human ephrin B4 an
c	168	20	0.5	20	1	ADR87091	Human ephrin B4 PC
c	169	20	0.5	20	1	ADR86753	Human ephrin B4 an
c	170	20	0.5	20	1	ADR86782	Human ephrin B4 an
c	171	20	0.5	20	1	ADR86823	Human ephrin B4 an
c	172	20	0.5	20	1	ADR86871	Human ephrin B4 an
c	173	20	0.5	20	1	ADR86877	Human ephrin B4 an
c	174	20	0.5	20	1	ADR86894	Human ephrin B4 an
c	175	20	0.5	20	1	ADR86902	Human ephrin B4 an
c	176	20	0.5	20	1	ADR86910	Human ephrin B4 an
c	177	20	0.5	20	1	ADR86915	Human ephrin B4 an
c	178	20	0.5	20	1	ADR86921	Human ephrin B4 an
c	179	20	0.5	20	1	ADR86790	Human ephrin B4 an
c	180	20	0.5	20	1	ADR86805	Human ephrin B4 an
c	181	20	0.5	20	1	ADR86809	Human ephrin B4 an
c	182	20	0.5	20	1	ADR86821	Human ephrin B4 an
c	183	20	0.5	20	1	ADR86824	Human ephrin B4 an
c	184	20	0.5	20	1	ADR86840	Human ephrin B4 an
c	185	20	0.5	20	1	ADR86841	Human ephrin B4 an
c	186	20	0.5	20	1	ADR86777	Human ephrin B4 an
c	187	20	0.5	20	1	ADR86787	Human ephrin B4 an
c	188	20	0.5	20	1	ADR86808	Human ephrin B4 an
c	189	20	0.5	20	1	ADR86813	Human ephrin B4 an
c	190	20	0.5	20	1	ADR86814	Human ephrin B4 an
c	191	20	0.5	20	1	ADR86815	Human ephrin B4 an
c	192	20	0.5	20	1	ADR86819	Human ephrin B4 an
c	193	20	0.5	20	1	ADR86822	Human ephrin B4 an
c	194	20	0.5	20	1	ADR86838	Human ephrin B4 an
c	195	20	0.5	20	1	ADR86873	Human ephrin B4 an
c	196	20	0.5	20	1	ADR86899	Human ephrin B4 an
c	197	20	0.5	20	1	ADR86923	Human ephrin B4 an
c	198	20	0.5	20	1	ADR86758	Human ephrin B4 pr
c	199	20	0.5	20	1	ADR86778	Human ephrin B4 an
c	200	20	0.5	20	1	ADR86796	Human ephrin B4 an
c	201	20	0.5	20	1	ADR86803	Human ephrin B4 an
c	202	20	0.5	20	1	ADR86832	Human ephrin B4 an
c	203	20	0.5	20	1	ADR86848	Human ephrin B4 an
c	204	20	0.5	20	1	ADR86850	Human ephrin B4 an
c	205	20	0.5	20	1	ADR86856	Human ephrin B4 an
c	206	20	0.5	20	1	ADR86862	Human ephrin B4 an
c	207	20	0.5	20	1	ADR86884	Human ephrin B4 an
c	208	20	0.5	20	1	ADR86895	Human ephrin B4 an
c	209	20	0.5	20	1	ADR86905	Human ephrin B4 an
c	210	20	0.5	20	1	ADR86906	Human ephrin B4 an
c	211	20	0.5	20	1	ADR86908	Human ephrin B4 an
c	212	20	0.5	20	1	ADR86918	Human ephrin B4 an
	213	20	0.5	20	1	ADR86725	Human ephrin B4 an
c	214	20	0.5	20	1	ADR86785	Human ephrin B4 an
c	215	20	0.5	20	1	ADR86835	Human ephrin B4 an
c	216	20	0.5	20	1	ADR86851	Human ephrin B4 an
c	217	20	0.5	20	1	ADR86864	Human ephrin B4 an
c	218	20	0.5	20	1	ADR86875	Human ephrin B4 an
c	219	20	0.5	20	1	ADR86879	Human ephrin B4 an
c	220	20	0.5	20	1	ADR86880	Human ephrin B4 an
c	221	20	0.5	20	1	ADR86900	Human ephrin B4 an
c	222	20	0.5	20	1	ADR86907	Human ephrin B4 an
	223	20	0.5	20	1	ADR86731	Human ephrin B4 RT
c	224	20	0.5	20	1	ADR86779	Human ephrin B4 an
c	225	20	0.5	20	1	ADR86784	Human ephrin B4 an
c	226	20	0.5	20	1	ADR86792	Human ephrin B4 an
c	227	20	0.5	20	1	ADR86804	Human ephrin B4 an
c	228	20	0.5	20	1	ADR86807	Human ephrin B4 an
c	229	20	0.5	20	1	ADR86867	Human ephrin B4 an
c	230	20	0.5	20	1	ADR86874	Human ephrin B4 an
c	231	20	0.5	20	1	ADR86881	Human ephrin B4 an
c	232	20	0.5	20	1	ADR86892	Human ephrin B4 an
c	233	20	0.5	20	1	ADR86893	Human ephrin B4 an
c	234	20	0.5	20	1	ADR86917	Human ephrin B4 an
c	235	20	0.5	20	1	ADR86794	Human ephrin B4 an
c	236	20	0.5	20	1	ADR86827	Human ephrin B4 an
c	237	20	0.5	20	1	ADR86839	Human ephrin B4 an
c	238	20	0.5	20	1	ADR86847	Human ephrin B4 an
c	239	20	0.5	20	1	ADR86854	Human ephrin B4 an
c	240	20	0.5	20	1	ADR86855	Human ephrin B4 an
c	241	20	0.5	20	1	ADR86888	Human ephrin B4 an
	242	20	0.5	20	1	ADR86757	Human ephrin B4 pr
c	243	20	0.5	20	1	ADR86793	Human ephrin B4 an
c	244	20	0.5	20	1	ADR86802	Human ephrin B4 an
c	245	20	0.5	20	1	ADR86806	Human ephrin B4 an
c	246	20	0.5	20	1	ADR86830	Human ephrin B4 an
c	247	20	0.5	20	1	ADR86831	Human ephrin B4 an
c	248	20	0.5	20	1	ADR86878	Human ephrin B4 an
c	249	20	0.5	20	1	ADR86909	Human ephrin B4 an
c	250	20	0.5	20	1	ADR86795	Human ephrin B4 an
c	251	20	0.5	20	1	ADR86818	Human ephrin B4 an
c	252	20	0.5	20	1	ADR86842	Human ephrin B4 an

c 253	20	0.5	20	1	ADR86859	Human ephrin B4 an
c 254	20	0.5	20	1	ADR86872	Human ephrin B4 an
c 255	20	0.5	20	1	ADR86885	Human ephrin B4 an
c 256	20	0.5	20	1	ADR86886	Human ephrin B4 an
c 257	20	0.5	20	1	ADR86898	Human ephrin B4 an
c 258	20	0.5	20	1	ADR86903	Human ephrin B4 an
c 259	20	0.5	20	1	ADR86911	Human ephrin B4 an
c 260	20	0.5	20	1	ADR86933	Human ephrin B4 an
c 261	20	0.5	20	1	ADR86800	Human ephrin B4 an
c 262	20	0.5	20	1	ADR86811	Human ephrin B4 an
c 263	20	0.5	20	1	ADR86846	Human ephrin B4 an
c 264	20	0.5	20	1	ADR86882	Human ephrin B4 an
c 265	20	0.5	20	1	ADR86890	Human ephrin B4 an
c 266	20	0.5	20	1	ADR86913	Human ephrin B4 an
c 267	20	0.5	20	1	ADR86914	Human ephrin B4 an
c 268	20	0.5	20	1	ADR86922	Human ephrin B4 an
c 269	20	0.5	20	1	ADR86733	Human ephrin B4 RT
c 270	20	0.5	20	1	ADR86780	Human ephrin B4 an
c 271	20	0.5	20	1	ADR86781	Human ephrin B4 an
c 272	20	0.5	20	1	ADR86798	Human ephrin B4 an
c 273	20	0.5	20	1	ADR86812	Human ephrin B4 an
c 274	20	0.5	20	1	ADR86845	Human ephrin B4 an
c 275	20	0.5	20	1	ADR86865	Human ephrin B4 an
c 276	20	0.5	20	1	ADR86876	Human ephrin B4 an
c 277	20	0.5	20	1	ADR86889	Human ephrin B4 an
c 278	20	0.5	20	1	ADR86891	Human ephrin B4 an
c 279	20	0.5	20	1	ADR86904	Human ephrin B4 an
c 280	20	0.5	20	1	ADR86919	Human ephrin B4 an
c 281	20	0.5	20	1	ADR86920	Human ephrin B4 an
c 282	20	0.5	20	1	ADR86776	Human ephrin B4 an
c 283	20	0.5	20	1	ADR86797	Human ephrin B4 an
c 284	20	0.5	20	1	ADR86820	Human ephrin B4 an
c 285	20	0.5	20	1	ADR86825	Human ephrin B4 an
c 286	20	0.5	20	1	ADR86852	Human ephrin B4 an
c 287	20	0.5	20	1	ADR86866	Human ephrin B4 an
c 288	20	0.5	20	1	ADR86869	Human ephrin B4 an
c 289	20	0.5	20	1	ADR86870	Human ephrin B4 an
c 290	20	0.5	20	1	ADR86883	Human ephrin B4 an
c 291	20	0.5	20	1	ADR86887	Human ephrin B4 an
c 292	20	0.5	20	1	ADR86896	Human ephrin B4 an
c 293	20	0.5	20	1	ADR86897	Human ephrin B4 an
294	20	0.5	20	1	ADR87090	Human ephrin B4 PC
c 295	20	0.5	20	1	ADR86788	Human ephrin B4 an
c 296	20	0.5	20	1	ADR86789	Human ephrin B4 an
c 297	20	0.5	20	1	ADR86791	Human ephrin B4 an
c 298	20	0.5	20	1	ADR86817	Human ephrin B4 an
c 299	20	0.5	20	1	ADR86833	Human ephrin B4 an
c 300	20	0.5	20	1	ADR86834	Human ephrin B4 an
c 301	20	0.5	20	1	ADR86836	Human ephrin B4 an
c 302	20	0.5	20	1	ADR86837	Human ephrin B4 an
c 303	20	0.5	20	1	ADR86849	Human ephrin B4 an
c 304	20	0.5	20	1	ADR86863	Human ephrin B4 an
c 305	20	0.5	20	1	ADR86783	Human ephrin B4 an
c 306	20	0.5	20	1	ADR86786	Human ephrin B4 an
c 307	20	0.5	20	1	ADR86828	Human ephrin B4 an
c 308	20	0.5	20	1	ADR86843	Human ephrin B4 an
c 309	20	0.5	20	1	ADR86844	Human ephrin B4 an
c 310	20	0.5	20	1	ADR86858	Human ephrin B4 an
c 311	20	0.5	20	1	ADR86868	Human ephrin B4 an
c 312	20	0.5	20	1	ADR86916	Human ephrin B4 an
c 313	20	0.5	20	1	ADR86799	Human ephrin B4 an
c 314	20	0.5	20	1	ADR86810	Human ephrin B4 an
c 315	20	0.5	20	1	ADR86816	Human ephrin B4 an
c 316	20	0.5	20	1	ADR86826	Human ephrin B4 an
c 317	20	0.5	20	1	ADR86829	Human ephrin B4 an
c 318	20	0.5	20	1	ADR86853	Human ephrin B4 an
c 319	20	0.5	20	1	ADR86857	Human ephrin B4 an
c 320	20	0.5	20	1	ADR86861	Human ephrin B4 an
c 321	20	0.5	20	1	ADR86912	Human ephrin B4 an
c 322	20	0.5	20	1	ADR82356	Human EphB4 antise
c 323	20	0.5	20	1	ADR82384	Human EphB4 antise
c 324	20	0.5	20	1	ADR82395	Human EphB4 antise
c 325	20	0.5	20	1	ADR82438	Human EphB4 antise
c 326	20	0.5	20	1	ADR82474	Human EphB4 antise
c 327	20	0.5	20	1	ADR82361	Human EphB4 antise
c 328	20	0.5	20	1	ADR82367	Human EphB4 antise
c 329	20	0.5	20	1	ADR82387	Human EphB4 antise
c 330	20	0.5	20	1	ADR82388	Human EphB4 antise
c 331	20	0.5	20	1	ADR82390	Human EphB4 antise
c 332	20	0.5	20	1	ADR82393	Human EphB4 antise
c 333	20	0.5	20	1	ADR82410	Human EphB4 antise
c 334	20	0.5	20	1	ADR82439	Human EphB4 antise
c 335	20	0.5	20	1	ADR82440	Human EphB4 antise
c 336	20	0.5	20	1	ADR82452	Human EphB4 antise
c 337	20	0.5	20	1	ADR82463	Human EphB4 antise
c 338	20	0.5	20	1	ADR82335	Human EphB4 antise
c 339	20	0.5	20	1	ADR82340	Human EphB4 antise
c 340	20	0.5	20	1	ADR82348	Human EphB4 antise
c 341	20	0.5	20	1	ADR82353	Human EphB4 antise
c 342	20	0.5	20	1	ADR82408	Human EphB4 antise
c 343	20	0.5	20	1	ADR82415	Human EphB4 antise
c 344	20	0.5	20	1	ADR82416	Human EphB4 antise
c 345	20	0.5	20	1	ADR82441	Human EphB4 antise
c 346	20	0.5	20	1	ADR82442	Human EphB4 antise
c 347	20	0.5	20	1	ADR82462	Human EphB4 antise
c 348	20	0.5	20	1	ADR82471	Human EphB4 antise
c 349	20	0.5	20	1	ADR82476	Human EphB4 antise
c 350	20	0.5	20	1	ADR82336	Human EphB4 antise
c 351	20	0.5	20	1	ADR82343	Human EphB4 antise
c 352	20	0.5	20	1	ADR82345	Human EphB4 antise
c 353	20	0.5	20	1	ADR82359	Human EphB4 antise
c 354	20	0.5	20	1	ADR82365	Human EphB4 antise
c 355	20	0.5	20	1	ADR82370	Human EphB4 antise
c 356	20	0.5	20	1	ADR82423	Human EphB4 antise
c 357	20	0.5	20	1	ADR82432	Human EphB4 antise
c 358	20	0.5	20	1	ADR82446	Human EphB4 antise
c 359	20	0.5	20	1	ADR82455	Human EphB4 antise
c 360	20	0.5	20	1	ADR82459	Human EphB4 antise
c 361	20	0.5	20	1	ADR82466	Human EphB4 antise
c 362	20	0.5	20	1	ADR82472	Human EphB4 antise
c 363	20	0.5	20	1	ADR82318	Human EphB4 antise
c 364	20	0.5	20	1	ADR82363	Human EphB4 antise
c 365	20	0.5	20	1	ADR82406	Human EphB4 antise
c 366	20	0.5	20	1	ADR82429	Human EphB4 antise
367	20	0.5	20	1	ADR82291	Human EphB4 sense
c 368	20	0.5	20	1	ADR82338	Human EphB4 antise
c 369	20	0.5	20	1	ADR82396	Human EphB4 antise
c 370	20	0.5	20	1	ADR82413	Human EphB4 antise
c 371	20	0.5	20	1	ADR82419	Human EphB4 antise
c 372	20	0.5	20	1	ADR82424	Human EphB4 antise
c 373	20	0.5	20	1	ADR82444	Human EphB4 antise
c 374	20	0.5	20	1	ADR82450	Human EphB4 antise
c 375	20	0.5	20	1	ADR82465	Human EphB4 antise
376	20	0.5	20	1	ADR82663	Human EphB4 PCR pr
c 377	20	0.5	20	1	ADR82333	Human EphB4 antise
c 378	20	0.5	20	1	ADR82347	Human EphB4 antise
c 379	20	0.5	20	1	ADR82355	Human EphB4 antise
c 380	20	0.5	20	1	ADR82376	Human EphB4 antise
c 381	20	0.5	20	1	ADR82378	Human EphB4 antise
c 382	20	0.5	20	1	ADR82383	Human EphB4 antise
c 383	20	0.5	20	1	ADR82421	Human EphB4 antise
c 384	20	0.5	20	1	ADR82426	Human EphB4 antise
c 385	20	0.5	20	1	ADR82443	Human EphB4 antise
c 386	20	0.5	20	1	ADR82445	Human EphB4 antise
c 387	20	0.5	20	1	ADR82447	Human EphB4 antise
c 388	20	0.5	20	1	ADR82469	Human EphB4 antise
c 389	20	0.5	20	1	ADR82475	Human EphB4 antise
c 390	20	0.5	20	1	ADR82293	Human EphB4 antise
c 391	20	0.5	20	1	ADR82344	Human EphB4 antise
c 392	20	0.5	20	1	ADR82352	Human EphB4 antise
c 393	20	0.5	20	1	ADR82368	Human EphB4 antise
c 394	20	0.5	20	1	ADR82386	Human EphB4 antise
c 395	20	0.5	20	1	ADR82401	Human EphB4 antise
c 396	20	0.5	20	1	ADR82402	Human EphB4 antise
c 397	20	0.5	20	1	ADR82417	Human EphB4 antise
c 398	20	0.5	20	1	ADR82425	Human EphB4 antise

c 399	20	0.5	20	1	ADR82431	Human EphB4 antise
c 400	20	0.5	20	1	ADR82434	Human EphB4 antise
c 401	20	0.5	20	1	ADR82435	Human EphB4 antise
c 402	20	0.5	20	1	ADR82449	Human EphB4 antise
c 403	20	0.5	20	1	ADR82331	Human EphB4 antise
c 404	20	0.5	20	1	ADR82360	Human EphB4 antise
c 405	20	0.5	20	1	ADR82371	Human EphB4 antise
c 406	20	0.5	20	1	ADR82389	Human EphB4 antise
c 407	20	0.5	20	1	ADR82454	Human EphB4 antise
c 408	20	0.5	20	1	ADR82470	Human EphB4 antise
409	20	0.5	20	1	ADR82658	Human EphB4 PCR pr
c 410	20	0.5	20	1	ADR82332	Human EphB4 antise
c 411	20	0.5	20	1	ADR82346	Human EphB4 antise
c 412	20	0.5	20	1	ADR82364	Human EphB4 antise
c 413	20	0.5	20	1	ADR82369	Human EphB4 antise
c 414	20	0.5	20	1	ADR82381	Human EphB4 antise
c 415	20	0.5	20	1	ADR82385	Human EphB4 antise
c 416	20	0.5	20	1	ADR82409	Human EphB4 antise
c 417	20	0.5	20	1	ADR82412	Human EphB4 antise
c 418	20	0.5	20	1	ADR82420	Human EphB4 antise
c 419	20	0.5	20	1	ADR82430	Human EphB4 antise
c 420	20	0.5	20	1	ADR82437	Human EphB4 antise
c 421	20	0.5	20	1	ADR82451	Human EphB4 antise
c 422	20	0.5	20	1	ADR82458	Human EphB4 antise
c 423	20	0.5	20	1	ADR82460	Human EphB4 antise
c 424	20	0.5	20	1	ADR82477	Human EphB4 antise
c 425	20	0.5	20	1	ADR82664	Human EphB4 PCR pr
c 426	20	0.5	20	1	ADR82342	Human EphB4 antise
c 427	20	0.5	20	1	ADR82354	Human EphB4 antise
c 428	20	0.5	20	1	ADR82372	Human EphB4 antise
c 429	20	0.5	20	1	ADR82373	Human EphB4 antise
c 430	20	0.5	20	1	ADR82379	Human EphB4 antise
c 431	20	0.5	20	1	ADR82391	Human EphB4 antise
c 432	20	0.5	20	1	ADR82407	Human EphB4 antise
c 433	20	0.5	20	1	ADR82411	Human EphB4 antise
c 434	20	0.5	20	1	ADR82414	Human EphB4 antise
c 435	20	0.5	20	1	ADR82418	Human EphB4 antise
c 436	20	0.5	20	1	ADR82334	Human EphB4 antise
c 437	20	0.5	20	1	ADR82351	Human EphB4 antise
c 438	20	0.5	20	1	ADR82357	Human EphB4 antise
c 439	20	0.5	20	1	ADR82362	Human EphB4 antise
c 440	20	0.5	20	1	ADR82374	Human EphB4 antise
c 441	20	0.5	20	1	ADR82394	Human EphB4 antise
c 442	20	0.5	20	1	ADR82399	Human EphB4 antise
c 443	20	0.5	20	1	ADR82422	Human EphB4 antise
c 444	20	0.5	20	1	ADR82427	Human EphB4 antise
c 445	20	0.5	20	1	ADR82464	Human EphB4 antise
c 446	20	0.5	20	1	ADR82467	Human EphB4 antise
c 447	20	0.5	20	1	ADR82468	Human EphB4 antise
c 448	20	0.5	20	1	ADR82488	Human EphB4 antise
449	20	0.5	20	1	ADR82297	Human beta-actin R
c 450	20	0.5	20	1	ADR82377	Human EphB4 antise
c 451	20	0.5	20	1	ADR82392	Human EphB4 antise
c 452	20	0.5	20	1	ADR82403	Human EphB4 antise
c 453	20	0.5	20	1	ADR82433	Human EphB4 antise
c 454	20	0.5	20	1	ADR82453	Human EphB4 antise
c 455	20	0.5	20	1	ADR82456	Human EphB4 antise
c 456	20	0.5	20	1	ADR82339	Human EphB4 antise
c 457	20	0.5	20	1	ADR82341	Human EphB4 antise
c 458	20	0.5	20	1	ADR82358	Human EphB4 antise
c 459	20	0.5	20	1	ADR82382	Human EphB4 antise
c 460	20	0.5	20	1	ADR82659	Human EphB4 PCR pr
c 461	20	0.5	20	1	ADR82337	Human EphB4 antise
c 462	20	0.5	20	1	ADR82349	Human EphB4 antise
c 463	20	0.5	20	1	ADR82366	Human EphB4 antise
c 464	20	0.5	20	1	ADR82375	Human EphB4 antise
c 465	20	0.5	20	1	ADR82380	Human EphB4 antise
c 466	20	0.5	20	1	ADR82398	Human EphB4 antise
c 467	20	0.5	20	1	ADR82404	Human EphB4 antise
c 468	20	0.5	20	1	ADR82405	Human EphB4 antise
c 469	20	0.5	20	1	ADR82428	Human EphB4 antise
c 470	20	0.5	20	1	ADR82448	Human EphB4 antise
c 471	20	0.5	20	1	ADR82457	Human EphB4 antise
c 472	20	0.5	20	1	ADR82461	Human EphB4 antise
c 473	20	0.5	20	1	ADR82473	Human EphB4 antise
c 474	20	0.5	20	1	ADR82350	Human EphB4 antise
c 475	20	0.5	20	1	ADR82397	Human EphB4 antise
c 476	20	0.5	20	1	ADR82400	Human EphB4 antise
c 477	20	0.5	20	1	ADR82436	Human EphB4 antise
c 478	20	0.5	20	1	ADR82478	Human EphB4 antise
479	20	0.5	21	1	ADR86990	Human ephrinB4 sho
480	20	0.5	21	1	ADR86740	Human ephrinB4 sho
481	20	0.5	21	1	ADR82545	Human EphB4 antise
482	20	0.5	21	1	ADR82305	Human EphB4 siRNA
483	19.8	0.5	23	1	ADY89201	VEGF/VEGFR siRNA S
c 484	19.4	0.5	21	1	ADR86925	Human ephrin B4 an
c 485	19.4	0.5	21	1	ADR86745	Human ephrin B4 an
c 486	19.4	0.5	21	1	ADR82480	Human EphB4 antise
c 487	19.4	0.5	21	1	ADR82310	Human EphB4 antise
488	19.4	0.5	21	1	ADU31805	Knock-down target
489	19.4	0.5	21	1	ADU31803	Knock-down target
490	19.4	0.5	21	1	ADU31804	Knock-down target
c 491	19.4	0.5	22	1	ADX00839	Human CYP2D6 gene
492	19.2	0.5	24	1	ADG75924	Immunostimulatory
493	19.2	0.5	24	1	ADG75971	Immunostimulatory
c 494	19	0.4	19	1	ADH17042	Reverse PCR primer
495	19	0.4	19	1	ADQ60986	Anti-EPHB4 siRNA r
496	19	0.4	19	1	ADQ60983	Anti-EPHB4 siRNA r
497	19	0.4	19	1	ADQ60984	Anti-EPHB4 siRNA r
498	19	0.4	19	1	ADQ60985	Anti-EPHB4 siRNA r
499	19	0.4	21	1	ADR86728	Human ephrinB4 sho
500	19	0.4	21	1	ADR86742	Human ephrinB4 sho
501	19	0.4	21	1	ADR86992	Human ephrinB4 sho
502	19	0.4	21	1	ADR86989	Human ephrinB4 sho
503	19	0.4	21	1	ADR86771	Human ephrinB4 sho
504	19	0.4	21	1	ADR86736	Human ephrinB4 sho
505	19	0.4	21	1	ADR86729	Human ephrinB4 sho
506	19	0.4	21	1	ADR86991	Human ephrinB4 sho
507	19	0.4	21	1	ADR86738	Human ephrinB4 sho
508	19	0.4	21	1	ADR86988	Human ephrinB4 sho
509	19	0.4	21	1	ADR82303	Human EphB4 siRNA
510	19	0.4	21	1	ADR82543	Human EphB4 antise
511	19	0.4	21	1	ADR82544	Human EphB4 antise
512	19	0.4	21	1	ADR82307	Human EphB4 siRNA
513	19	0.4	21	1	ADR82301	Human EphB4 siRNA
514	19	0.4	21	1	ADR82326	Human EphB4 siRNA
515	19	0.4	21	1	ADR82295	Human beta-actin R
516	19	0.4	21	1	ADR82294	Human EphB4 siRNA
517	19	0.4	21	1	ADR82546	Human EphB4 antise
518	19	0.4	21	1	ADR82547	Human EphB4 antise
519	19	0.4	21	1	ADR82660	Human EphB4 siRNA
520	18.8	0.4	22	1	ADJ14704	Debrisoquine 4-hyd
521	18.8	0.4	22	1	ADJ14787	Debrisoquine 4-hyd
522	18.8	0.4	22	1	ADO60807	Human debrisoquine
523	18.8	0.4	22	1	ADO60878	Human debrisoquine
524	18.8	0.4	22	1	ADZ71126	Human CYP2D6 gene-
525	18.8	0.4	23	1	ADY89206	VEGF/VEGFR siRNA S
526	18.8	0.4	23	1	ADY89196	VEGF/VEGFR siRNA S
527	18.4	0.4	23	1	ADY50241	Human beta-globin
c 528	18	0.4	18	1	ADR86930	Human ephrin B4 an
c 529	18	0.4	18	1	ADR86749	Human ephrin B4 an
c 530	18	0.4	18	1	ADR86750	Human ephrin B4 an
c 531	18	0.4	18	1	ADR86929	Human ephrin B4 an
c 532	18	0.4	18	1	ADR82314	Human EphB4 antise
c 533	18	0.4	18	1	ADR82484	Human EphB4 antise
c 534	18	0.4	18	1	ADR82315	Human EphB4 antise
c 535	18	0.4	18	1	ADR82485	Human EphB4 antise
c 536	18	0.4	22	1	ADC16452	Short interfering
537	17.8	0.4	21	1	ADJ78587	Human cytochrome P
538	17.8	0.4	21	1	ADM28915	PCR primer #1 for
c 539	17.8	0.4	21	1	ADS00674	Nested PCR primer
540	17.4	0.4	19	1	ADJ14673	Debrisoquine 4-hyd
541	17.4	0.4	19	1	ADO60900	Human debrisoquine
542	17.4	0.4	19	1	ADO60775	Human debrisoquine
c 543	17.4	0.4	19	1	ADT01293	Novel mutant prote
544	17.4	0.4	20	1	ABL94275	Human C/EBP beta p

545	17.4	0.4	20	1	ADC26603	CYP2D6-specific pr
c 546	17	0.4	19	1	ADR86762	Human ephrin B4 RT
c 547	17	0.4	19	1	ADR82668	Human EphB4 RT-PCR
548	17	0.4	20	1	AAQ27541	PCR Primer P5(1) c
549	17	0.4	20	1	AAQ64160	Primer for amplify
550	16.8	0.4	20	1	AAZ18209	Tyrosine kinase ge
c 551	16.8	0.4	20	1	AAZ02532	PCR primer used to
c 552	16.8	0.4	20	1	ADC65757	Human TGF-beta rec
c 553	16.8	0.4	20	1	ADU78633	Antisense oligonuc
c 554	16.8	0.4	20	1	ADW83103	MAP3K9 marker ampl
c 555	16.8	0.4	21	1	AAZ18182	PTK 26 gene specif
c 556	16.8	0.4	21	1	AAZ18188	PTK 30 gene specif
c 557	16.8	0.4	21	1	AAZ18166	PTK 17 gene specif
c 558	16.8	0.4	21	1	AAZ18172	PTK 20 gene specif
c 559	16.8	0.4	21	1	AAZ18178	PTK 23 gene specif
c 560	16.8	0.4	21	1	AAA07689	Reverse primer for
561	16.8	0.4	21	1	ABZ58380	Human protein phos
562	16.8	0.4	21	1	ACL42990	CACNA1D siRNA anti
c 563	16.4	0.4	18	1	AAH47543	Human Her-3 mRNA i
564	16.4	0.4	18	1	ABX80008	EST polymorphic DN
565	16.4	0.4	19	1	ADY89257	VEGFR siRNA target
566	16.4	0.4	19	1	ADY89385	VEGFR siRNA target
c 567	16.4	0.4	20	1	AAQ20433	Debrisoquine polym
c 568	16.4	0.4	20	1	AAX92799	PCR primer used to
c 569	16.4	0.4	20	1	AAL60967	Human MyD88 antise
c 570	16.4	0.4	20	1	ADE14481	HSD11B1 antisense
c 571	16.4	0.4	20	1	ADY59502	Oligonucleotide of
572	16.4	0.4	20	1	AEB22981	SCN5A gene exon 2
c 573	16	0.4	17	1	ACA99868	G-protein coupled
c 574	16	0.4	17	1	ACA99867	G-protein coupled
c 575	16	0.4	17	1	ABT37713	Tumour suppression
c 576	16	0.4	17	1	ADI48271	Human tumour suppr
c 577	16	0.4	17	1	ACC53159	Human tumour suppr
c 578	16	0.4	19	1	AAA82487	cdk1 ribozyme bind
c 579	16	0.4	19	1	AAA82486	cdk1 ribozyme bind
c 580	16	0.4	19	1	AAH57648	Cell-cycle depende
c 581	16	0.4	19	1	AAH57649	Cell-cycle depende
582	16	0.4	19	1	ABK41169	Human obesity-asso
583	16	0.4	19	1	ADT01526	Novel mutant prote
584	16	0.4	20	1	ABZ99246	Human PDE4C oligon
585	16	0.4	20	1	ABD32277	Human PDE4C-derive
586	16	0.4	20	1	ADJ61131	Oligonucleotide as
587	15.8	0.4	19	1	AAT00705	Human trkC recepto
588	15.8	0.4	19	1	AAZ88855	Human trkC recepto
c 589	15.8	0.4	19	1	AAD30287	Human PKD1 gene mu
590	15.8	0.4	19	1	ABK30165	CYP2D6 gene polymo
591	15.8	0.4	19	1	ABZ24394	Human cytochrome P
592	15.8	0.4	19	1	ADF37388	Human VEGFR3 short
c 593	15.8	0.4	19	1	ADF37635	Human VEGFR3 short
c 594	15.8	0.4	19	1	ADF84250	Human ABL1-targete
595	15.8	0.4	19	1	ADF84569	Human ABL1-targete
c 596	15.8	0.4	19	1	ADI00303	PCR primer SEQ ID
597	15.8	0.4	19	1	ADO16340	4 synthesis-period
598	15.8	0.4	19	1	ADQ60909	Anti-BLK siRNA rel
c 599	15.8	0.4	19	1	ADU03887	Human polycystic k
c 600	15.8	0.4	19	1	ADY88888	VEGFR siRNA SEQ ID
601	15.8	0.4	19	1	ADY89258	VEGFR siRNA target
602	15.8	0.4	19	1	ADY88641	VEGFR siRNA SEQ ID
603	15.6	0.4	18	1	ADX58087	Primer Gamma 10 fo
604	15.6	0.4	18	1	ADX58086	Primer Gamma 9 for
605	15.4	0.4	17	1	AAT53779	Rat ICAM hammerhea
606	15.4	0.4	17	1	AAV92591	Human A-Raf substr
607	15.4	0.4	17	1	AAF06056	Hammerhead ribozym
c 608	15.4	0.4	17	1	ABA81101	LDLR mutation corr
609	15.4	0.4	17	1	ABA81100	LDLR mutation corr
c 610	15.4	0.4	17	1	ABN01661	Human GDMLP-1 17-m
c 611	15.4	0.4	17	1	ABN01662	Human GDMLP-1 17-m
c 612	15.4	0.4	17	1	ABQ63403	Human KTOM1a porti
613	15.4	0.4	17	1	ACN02004	WNV Inozyme substr
c 614	15.4	0.4	17	1	ACN11465	WNV minus strand I
615	15.4	0.4	17	1	AEB58244	Human VEGF recepto
616	15.4	0.4	17	1	AEB58245	Human VEGF recepto
617	15.4	0.4	17	1	AEB61660	Human VEGF recepto
c 618	15.4	0.4	17	1	ACN64751	Human GDMLP-1 prob
c 619	15.4	0.4	17	1	ACN64752	Human GDMLP-1 prob
620	15.4	0.4	18	1	ADR87873	Biotinylated prime
c 621	15.4	0.4	19	1	ADF36606	Human VEGFR2 short
622	15.4	0.4	19	1	ADF36930	Human VEGFR2 short
623	15.4	0.4	19	1	ADO16519	4 synthesis-period
624	15.4	0.4	19	1	ADQ60352	Anti-Cyclophilin s
c 625	15.4	0.4	19	1	ADR79853	Human apolipoprote
c 626	15.4	0.4	19	1	ADR79854	Human apolipoprote
c 627	15.4	0.4	19	1	ADR76909	Human apolipoprote
c 628	15.4	0.4	19	1	ADR76910	Human apolipoprote
c 629	15.4	0.4	19	1	ADT81353	Apolipoprotein B (
c 630	15.4	0.4	19	1	ADT84297	Apolipoprotein B (
c 631	15.4	0.4	19	1	ADT84296	Apolipoprotein B (
c 632	15.4	0.4	19	1	ADT81352	Apolipoprotein B (
c 633	15.4	0.4	19	1	ADX00842	Human CYP2D6 gene
634	15.4	0.4	19	1	ADY88183	VEGFR siRNA SEQ ID
c 635	15.4	0.4	19	1	ADY87859	VEGFR siRNA SEQ ID
636	15.4	0.4	19	1	ADY89384	VEGFR siRNA target
c 637	15.4	0.4	19	1	ADY90334	VEGFR siRNA SEQ ID
638	15	0.4	15	1	ADH17043	Taqman probe used
c 639	15	0.4	17	1	AAX35184	PCR primer used am
c 640	15	0.4	17	1	ABN01660	Human GDMLP-1 17-m
c 641	15	0.4	17	1	ABN01659	Human GDMLP-1 17-m
c 642	15	0.4	17	1	ABA02896	Human IL-17 RT-PCR
c 643	15	0.4	17	1	ACA99869	G-protein coupled
c 644	15	0.4	17	1	ACA99866	G-protein coupled
645	15	0.4	17	1	ADO13871	dbv gene cluster p
c 646	15	0.4	17	1	ACN64750	Human GDMLP-1 prob
c 647	15	0.4	17	1	ACN64749	Human GDMLP-1 prob
648	15	0.4	17	1	ADS73574	tcp gene cluster i
649	15	0.4	18	1	AAX70292	Human flt1 VEGF re
650	14.8	0.3	18	1	AAQ65270	Antisense oligonuc
c 651	14.8	0.3	18	1	AAX09464	Human biallelic po
652	14.8	0.3	18	1	AAV25485	Primer 39DRD4.SB.P
653	14.8	0.3	18	1	AAZ25567	Human RhoG antisen
c 654	14.8	0.3	18	1	AAX55193	Multiple antisense
c 655	14.8	0.3	18	1	AAA34640	Human adenosine re
656	14.8	0.3	18	1	AAA09486	Antisense primer f
c 657	14.8	0.3	18	1	AAF20762	Human multiple tar
c 658	14.8	0.3	18	1	AAF21465	Human multiple tar
c 659	14.8	0.3	18	1	AAH75205	Human inducible NO
660	14.8	0.3	18	1	AAF94748	Rho G antisense ph
661	14.8	0.3	18	1	ABA82492	Zmax1 gene region
662	14.8	0.3	18	1	ABL44014	Human chromosome 1
663	14.8	0.3	18	1	AAL48393	Human c-mos gene P
664	14.8	0.3	18	1	ABK23289	Human Zmax1 cDNA f
665	14.8	0.3	18	1	ABZ11106	Haematopoietic cel
666	14.8	0.3	18	1	ACC45872	Human HBM STS mark
667	14.8	0.3	18	1	ADB98570	Sequence tagged si
c 668	14.8	0.3	18	1	ADE85865	Casein kinase 2 an
c 669	14.8	0.3	18	1	ADD93278	CK2-alpha'(Prime-1
c 670	14.8	0.3	18	1	ABZ96456	Human nucleic acid
c 671	14.8	0.3	18	1	ABZ97159	Human MTA oligonuc
672	14.8	0.3	18	1	ABX10913	Novel human membra
673	14.8	0.3	18	1	ACA60574	Antisense inhibiti
c 674	14.8	0.3	18	1	ABD20418	Human pulmonary an
c 675	14.8	0.3	18	1	ABD32442	Human MTA oligo SE
676	14.8	0.3	18	1	ADI34784	Kidney injury mole
677	14.8	0.3	18	1	ADI20875	MS SnuPE detection
678	14.8	0.3	18	1	ADP47449	Intelligent PCR pr
679	14.8	0.3	18	1	ADQ59807	Intelligent PCR pr
680	14.8	0.3	18	1	ADR17435	Human chromosome 1
681	14.8	0.3	18	1	ADR48086	Human chromosome 1
c 682	14.8	0.3	18	1	ADW37806	Human GPR4 DNA RT-
683	14.8	0.3	18	1	ADV66866	S. carnosus secA P
684	14.8	0.3	18	1	AEB69814	Human chromosome 1
c 685	14.8	0.3	48	1	ADR52529	Small interfering
c 686	14.8	0.3	48	1	ADR52517	Small interfering
c 687	14.6	0.3	15	1	ABQ72285	Human CYP2D6 allel
688	14.6	0.3	17	1	AAA29598	Human insulin sens
689	14.6	0.3	17	1	ADH23252	Degenerate sense P
690	14.4	0.3	16	1	AAQ65268	Antisense oligonuc

c	691	14.4	0.3	16	1	ADC13653	Human NOVX reverse
	692	14.4	0.3	16	1	AEB18973	Human leukocyte an
	693	14.4	0.3	17	1	AAQ65269	Antisense oligonuc
	694	14.4	0.3	17	1	AAQ65253	Antisense oligonuc
	695	14.4	0.3	17	1	AAV92592	Human A-Raf substr
	696	14.4	0.3	17	1	AAF06057	Hammerhead ribozym
	697	14.4	0.3	17	1	AAF02029	Hammerhead ribozym
	698	14.4	0.3	17	1	ADV06123	Human BACE DNAzyme
	699	14.4	0.3	17	1	ADU94065	Human TERT NCH rib
	700	14.4	0.3	17	1	ADV00664	Human TERT DNAzyme
c	701	14.4	0.3	17	1	ADM89524	Human PTP-1B NCH r
c	702	14.4	0.3	17	1	ADM89525	Human PTP-1B NCH r
	703	14.4	0.3	17	1	ADV07544	Human BACE amberzy
c	704	14.4	0.3	17	1	ADV01226	Human TERT DNAzyme
	705	14.4	0.3	17	1	ADU94064	Human TERT NCH rib
	706	14.4	0.3	17	1	ADV05221	Human BACE zinzyme
	707	14.4	0.3	17	1	ADV07126	Human BACE amberzy
	708	14.4	0.3	17	1	ABN02655	Human GDMLP-1 17-m
c	709	14.4	0.3	17	1	ABN01663	Human GDMLP-1 17-m
	710	14.4	0.3	17	1	ABN02656	Human GDMLP-1 17-m
	711	14.4	0.3	17	1	ABN00913	Human GDMLP-1 17-m
	712	14.4	0.3	17	1	ABN00914	Human GDMLP-1 17-m
c	713	14.4	0.3	17	1	ABQ63402	Human KTOM1a porti
c	714	14.4	0.3	17	1	ABQ63404	Human KTOM1a porti
	715	14.4	0.3	17	1	ABL31121	Human HLA genotypi
c	716	14.4	0.3	17	1	ACN04226	WNV Zinzyme substr
	717	14.4	0.3	17	1	ACN12772	WNV minus strand Z
c	718	14.4	0.3	17	1	ACN13224	WNV minus strand Z
	719	14.4	0.3	17	1	ACN05992	WNV Amberzyme subs
c	720	14.4	0.3	17	1	ACN11464	WNV minus strand I
	721	14.4	0.3	17	1	ABT35221	Tumour suppression
	722	14.4	0.3	17	1	ACA06540	NFKB sub-unit modu
	723	14.4	0.3	17	1	ACA06539	NFKB sub-unit modu
c	724	14.4	0.3	17	1	ABZ62068	Human H-Ras DNAzym
	725	14.4	0.3	17	1	ABZ61986	Human H-Ras DNAzym
	726	14.4	0.3	17	1	ACC66601	Murine oligonucleo
c	727	14.4	0.3	17	1	ACC63709	Murine oligonucleo
	728	14.4	0.3	17	1	ADB44084	Tumour suppression
	729	14.4	0.3	17	1	ADE25202	Plant growth assoc
c	730	14.4	0.3	17	1	ACC53156	Human tumour suppr
c	731	14.4	0.3	17	1	ADL48219	Human IKK-gamma su
c	732	14.4	0.3	17	1	AEB60994	Human VEGF recepto
	733	14.4	0.3	17	1	ADL82216	Human ER+ breast c
	734	14.4	0.3	17	1	ADL60384	Human organic anio
	735	14.4	0.3	17	1	ADR27266	Human single nucle
	736	14.4	0.3	17	1	ACN64003	Human GDMLP-1 prob
c	737	14.4	0.3	17	1	ACN64753	Human GDMLP-1 prob
	738	14.4	0.3	17	1	ACN64004	Human GDMLP-1 prob
	739	14.4	0.3	17	1	ACN65746	Human GDMLP-1 prob
	740	14.4	0.3	17	1	ACN65745	Human GDMLP-1 prob
c	741	14.4	0.3	17	1	ADZ31142	Human H-Ras substr
	742	14.4	0.3	17	1	ADZ31060	Human H-Ras substr
	743	14.4	0.3	18	1	AAQ65238	Antisense oligonuc
	744	14.4	0.3	18	1	AAQ65254	Antisense oligonuc
c	745	14.4	0.3	18	1	AAV48676	junB gene antisens
c	746	14.4	0.3	18	1	AAA52892	Human CD44 antisen
	747	14.4	0.3	18	1	AAA30403	Human NF-kappa-B p
c	748	14.4	0.3	18	1	ADI94534	Human IL-10 associ
c	749	14.4	0.3	18	1	ADI93071	ARRESTOR oligonucl
	750	14.4	0.3	18	1	ACA62538	Human MDM2 mutant
	751	14.4	0.3	18	1	ADB54472	Hybridisation olig
	752	14.4	0.3	18	1	ADF90215	Human NF-kappa-B p
c	753	14.4	0.3	18	1	ADH94506	Human gene PCR pri
	754	14.4	0.3	18	1	ADH71082	Human Vbeta micros
	755	14.4	0.3	18	1	ADM83057	Human NF-kappa-B p
c	756	14.4	0.3	18	1	ADS90640	Oligonucleotide of
c	757	14.4	0.3	18	1	ADZ66354	DNA methylation an
c	758	14.4	0.3	18	1	AEA12272	Human KIR allele 2

ALIGNMENTS

RESULT 1
AAI78874/c
ID AAI78874 standard; DNA; 50 BP.
XX
AC AAI78874;
XX
DT 09-NOV-2001 (first entry)
XX
DE Human silent SNP containing nucleic acid SEQ:5815.
XX
KW Human; single nucleotide polymorphism; SNP; genome; gene therapy;
KW protein therapy; vaccine; probe; diagnostic assay; detection;
KW quantitation; restorative therapy; polymorphic; ds.
XX
OS Homo sapiens.
XX
PN WO200140521-A2.
XX
PD 07-JUN-2001.
XX
PF 30-NOV-2000; 2000WO-US032758.
XX
PR 30-NOV-1999; 99US-0168138P.
PR 29-NOV-2000; 2000US-00726173.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach M;
XX
DR WPI; 2001-356160/37.
XX
PT Polymorphic nucleic acid sequences, useful in genetic testing and
PT therapy.
XX
PS Claim 1; Page 2290; 2653pp; English.
XX
CC AAI73060 to AAI79867 represent isolated human polymorphic polynucleotide
CC sequences (I), which contain single nucleotide polymorphisms (SNPs).
CC AAM53114 to AAM53329 represent peptides related to human polymorphic
CC polynucleotide sequences. The sequences can be used in gene and protein
CC therapy, and in vaccine production. (I) and the polypeptides encoded by
CC them may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate expression of polymorphic polypeptides. For
CC example, (I) may be used to treat disorders by rectifying mutations or
CC deletions in a patient's genome that affect the activity of polypeptides
CC by expressing inactive proteins or to supplement the patients own
CC production of polypeptide. Additionally, (I) and its complementary
CC sequences may also be used as DNA probes in diagnostic assays to detect
CC and quantitate the presence of similar nucleic acids in samples, and
CC therefore which patients may be in need of restorative therapy. The
CC polypeptides encoded by (I) may be used as antigens in the production of
CC antibodies specific for polymorphic polypeptides. The antibodies may also
CC be used to down regulate expression and activity. The antibodies may also
CC be used as diagnostic agents for detecting the presence of polymorphic
CC polypeptides in samples
XX
SQ Sequence 50 BP; 24 A; 11 C; 8 G; 7 T; 0 U; 0 Other;

Query Match 1.2%; Score 50; DB 1; Length 50;
Best Local Similarity 100.0%; Pred. No. 0.037;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3829 CCAGCTGCTGCCTTCATATTGAAGGTTTTTGAGTTTTGTTTTTGGTCTTA 3878
||||||||||||||||||||||||||||||||||||||||||||||||||
Db 50 CCAGCTGCTGCCTTCATATTGAAGGTTTTTGAGTTTTGTTTTTGGTCTTA 1

RESULT 2
ADR52551
ID ADR52551 standard; DNA; 48 BP.
XX
AC ADR52551;
XX

```
DT   18-NOV-2004  (first entry)
XX
DE   Small interfering RNA expression library oligonucleotide #109.
XX
KW   ss; siRNA; small interfering RNA; gene expression; gene silencing;
KW   expression library; silencing; G coupled receptor; ion channel;
KW   receptor tyrosine kinase; non-receptor tyrosine kinases;
KW   nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase;
KW   protease; matrix metalloproteinase; E3 ubiquitin ligase.
XX
OS   Synthetic.
XX
PN   WO2004072261-A2.
XX
PD   26-AUG-2004.
XX
PF   10-FEB-2004; 2004WO-US003949.
XX
PR   11-FEB-2003; 2003US-0446714P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Li H,  Chatterton JE,  Fan W,  Ke N,  Wong-Staal F;
XX
DR   WPI; 2004-625862/60.
DR   P-PSDB; ADR52552.
XX
PT   Generating a siRNA expression library for selective post-transcriptional
PT   silencing of genes encoding a family of proteins comprises identifying a
PT   consensus sequence for protein families.
XX
PS   Example 2; SEQ ID NO 217; 44pp; English.
XX
CC   The invention relates to a method for generating a siRNA expression
CC   library for selective post-transcriptional silencing of genes encoding a
CC   family of proteins comprising identifying a consensus sequence for the
CC   family of proteins. The method comprises: (a) identifying a consensus
CC   sequence for the family of proteins; and (b) generating an siRNA
CC   expression library whose members encode siRNA molecules that target at
CC   least all mRNA encoding all known members of the family of proteins. The
CC   family of proteins is G coupled receptors, ion channels, receptor
CC   tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone
CC   receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix
CC   metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases.
CC   Identifying a consensus sequences comprises identifying at least one, two
CC   or more signature motif for the family of proteins. The method is useful
CC   for generating a siRNA expression library for selective post-
CC   transcriptional silencing of genes encoding a family of proteins. The
CC   library is useful for identifying genes involved in disease processes.
CC   This sequence corresponds to an oligonucleotide used in the method of the
CC   invention.
XX
SQ   Sequence 48 BP; 12 A; 17 C; 10 G; 9 T; 0 U; 0 Other;

  Query Match             1.1%;  Score 48;  DB 1;  Length 48;
  Best Local Similarity   100.0%;  Pred. No. 0.065;
  Matches   48;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2575 ATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
             ||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 ATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 48


RESULT 3
ADR52531
ID   ADR52531 standard; DNA; 48 BP.
XX
AC   ADR52531;
XX
DT   18-NOV-2004  (first entry)
XX
DE   Small interfering RNA expression library oligonucleotide #99.
XX
KW   ss; siRNA; small interfering RNA; gene expression; gene silencing;
KW   expression library; silencing; G coupled receptor; ion channel;
KW   receptor tyrosine kinase; non-receptor tyrosine kinases;
KW   nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase;
KW   protease; matrix metalloproteinase; E3 ubiquitin ligase.
XX
OS   Synthetic.
XX
PN   WO2004072261-A2.
XX
PD   26-AUG-2004.
XX
PF   10-FEB-2004; 2004WO-US003949.
XX
PR   11-FEB-2003; 2003US-0446714P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Li H,  Chatterton JE,  Fan W,  Ke N,  Wong-Staal F;
XX
DR   WPI; 2004-625862/60.
DR   P-PSDB; ADR52532.
XX
PT   Generating a siRNA expression library for selective post-transcriptional
PT   silencing of genes encoding a family of proteins comprises identifying a
PT   consensus sequence for protein families.
XX
PS   Example 2; SEQ ID NO 197; 44pp; English.
XX
CC   The invention relates to a method for generating a siRNA expression
CC   library for selective post-transcriptional silencing of genes encoding a
CC   family of proteins comprising identifying a consensus sequence for the
CC   family of proteins. The method comprises: (a) identifying a consensus
CC   sequence for the family of proteins; and (b) generating an siRNA
CC   expression library whose members encode siRNA molecules that target at
CC   least all mRNA encoding all known members of the family of proteins. The
CC   family of proteins is G coupled receptors, ion channels, receptor
CC   tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone
CC   receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix
CC   metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases.
CC   Identifying a consensus sequences comprises identifying at least one, two
CC   or more signature motif for the family of proteins. The method is useful
CC   for generating a siRNA expression library for selective post-
CC   transcriptional silencing of genes encoding a family of proteins. The
CC   library is useful for identifying genes involved in disease processes.
CC   This sequence corresponds to an oligonucleotide used in the method of the
CC   invention.
XX
SQ   Sequence 48 BP; 11 A; 16 C; 10 G; 11 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 40;  DB 1;  Length 48;
  Best Local Similarity   89.6%;  Pred. No. 0.86;
  Matches   43;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       2575 ATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
             |||| ||| || ||||| ||||||||||||||||||||||| ||||||
Db          1 ATGAACTATGTGCACCGCGACCTGGCTGCTCGCAACATCCTTGTCAAC 48


RESULT 4
ADR52529
ID   ADR52529 standard; DNA; 48 BP.
XX
AC   ADR52529;
XX
DT   18-NOV-2004  (first entry)
XX
DE   Small interfering RNA expression library oligonucleotide #98.
XX
KW   ss; siRNA; small interfering RNA; gene expression; gene silencing;
KW   expression library; silencing; G coupled receptor; ion channel;
KW   receptor tyrosine kinase; non-receptor tyrosine kinases;
KW   nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase;
```

KW protease; matrix metalloproteinase; E3 ubiquitin ligase.
XX
OS Synthetic.
XX
PN WO2004072261-A2.
XX
PD 26-AUG-2004.
XX
PF 10-FEB-2004; 2004WO-US003949.
XX
PR 11-FEB-2003; 2003US-0446714P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Li H, Chatterton JE, Fan W, Ke N, Wong-Staal F;
XX
DR WPI; 2004-625862/60.
DR P-PSDB; ADR52530.
XX
PT Generating a siRNA expression library for selective post-transcriptional
PT silencing of genes encoding a family of proteins comprises identifying a
PT consensus sequence for protein families.
XX
PS Example 2; SEQ ID NO 195; 44pp; English.
XX
CC The invention relates to a method for generating a siRNA expression
CC library for selective post-transcriptional silencing of genes encoding a
CC family of proteins comprising identifying a consensus sequence for the
CC family of proteins. The method comprises: (a) identifying a consensus
CC sequence for the family of proteins; and (b) generating an siRNA
CC expression library whose members encode siRNA molecules that target at
CC least all mRNA encoding all known members of the family of proteins. The
CC family of proteins is G coupled receptors, ion channels, receptor
CC tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone
CC receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix
CC metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases.
CC Identifying a consensus sequences comprises identifying at least one, two
CC or more signature motif for the family of proteins. The method is useful
CC for generating a siRNA expression library for selective post-
CC transcriptional silencing of genes encoding a family of proteins. The
CC library is useful for identifying genes involved in disease processes.
CC This sequence corresponds to an oligonucleotide used in the method of the
CC invention.
XX
SQ Sequence 48 BP; 11 A; 17 C; 9 G; 11 T; 0 U; 0 Other;

Query Match 0.9%; Score 38.4; DB 1; Length 48;
Best Local Similarity 87.5%; Pred. No. 1.4;
Matches 42; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 2575 ATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
|||| ||| || ||||| |||||||||||| |||||||||||| ||||||
Db 1 ATGAACTATGTTCACCGTGACCTGGCTGCCCGCAACATCCTCGTCAAC 48

RESULT 5
ADR52517
ID ADR52517 standard; DNA; 48 BP.
XX
AC ADR52517;
XX
DT 18-NOV-2004 (first entry)
XX
DE Small interfering RNA expression library oligonucleotide #92.
XX
KW ss; siRNA; small interfering RNA; gene expression; gene silencing;
KW expression library; silencing; G coupled receptor; ion channel;
KW receptor tyrosine kinase; non-receptor tyrosine kinases;
KW nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase;
KW protease; matrix metalloproteinase; E3 ubiquitin ligase.
XX
OS Synthetic.
XX
PN WO2004072261-A2.
XX
PD 26-AUG-2004.
XX
PF 10-FEB-2004; 2004WO-US003949.
XX
PR 11-FEB-2003; 2003US-0446714P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Li H, Chatterton JE, Fan W, Ke N, Wong-Staal F;
XX
DR WPI; 2004-625862/60.
DR P-PSDB; ADR52518.
XX
PT Generating a siRNA expression library for selective post-transcriptional
PT silencing of genes encoding a family of proteins comprises identifying a
PT consensus sequence for protein families.
XX
PS Example 2; SEQ ID NO 183; 44pp; English.
XX
CC The invention relates to a method for generating a siRNA expression
CC library for selective post-transcriptional silencing of genes encoding a
CC family of proteins comprising identifying a consensus sequence for the
CC family of proteins. The method comprises: (a) identifying a consensus
CC sequence for the family of proteins; and (b) generating an siRNA
CC expression library whose members encode siRNA molecules that target at
CC least all mRNA encoding all known members of the family of proteins. The
CC family of proteins is G coupled receptors, ion channels, receptor
CC tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone
CC receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix
CC metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases.
CC Identifying a consensus sequences comprises identifying at least one, two
CC or more signature motif for the family of proteins. The method is useful
CC for generating a siRNA expression library for selective post-
CC transcriptional silencing of genes encoding a family of proteins. The
CC library is useful for identifying genes involved in disease processes.
CC This sequence corresponds to an oligonucleotide used in the method of the
CC invention.
XX
SQ Sequence 48 BP; 11 A; 17 C; 10 G; 10 T; 0 U; 0 Other;

Query Match 0.9%; Score 38.4; DB 1; Length 48;
Best Local Similarity 87.5%; Pred. No. 1.4;
Matches 42; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 2575 ATGAGCTACGTCCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
|||| ||| || ||||| |||||||||||| |||||||||||| ||||||
Db 1 ATGAACTATGTGCACCGTGACCTGGCTGCCCGCAACATCCTCGTCAAC 48

RESULT 6
ADR86708/c
ID ADR86708 standard; DNA; 36 BP.
XX
AC ADR86708;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 PCR primer seqid 13.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.

```
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 1; Page 44; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a primer used in the isolation of human ephrin B4 cDNA used in
CC   the creation of an expression vector for producing a soluble Eph B4
CC   derivative.
XX
SQ   Sequence 36 BP; 4 A; 18 C; 6 G; 8 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 29;  DB 1;  Length 36;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   29;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 TGGATGAGAGCGAGGGCTGGCGGGAGCAG 1986
              |||||||||||||||||||||||||||||
Db         36 TGGATGAGAGCGAGGGCTGGCGGGAGCAG 8


RESULT 7
ADR82277/c
ID   ADR82277 standard; DNA; 36 BP.
XX
AC   ADR82277;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 PCR primer #2.
XX
KW   human; ss; PCR; primer; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 1; Page 49; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   PCR primer.
XX
SQ   Sequence 36 BP; 4 A; 18 C; 6 G; 8 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 29;  DB 1;  Length 36;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   29;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 TGGATGAGAGCGAGGGCTGGCGGGAGCAG 1986
              |||||||||||||||||||||||||||||
Db         36 TGGATGAGAGCGAGGGCTGGCGGGAGCAG 8


RESULT 8
ADH17041
ID   ADH17041 standard; DNA; 26 BP.
XX
AC   ADH17041;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Forward PCR primer used to amplify human EphB4 sequence.
XX
KW   tyrosine kinase activity; type 1 plasminogen activator inhibitor; PAI-1;
KW   TIMP-1; tissue inhibitor of metalloproteinase 1; vinculin;
KW   vascular endothelial growth factor; VEGF; placental growth factor; PLGF;
KW   migration inhibitory factor; MIG; PCR; primer; ss; human; RT-PCR; EphB4.
XX
OS   Homo sapiens.
XX
PN   WO2003097854-A2.
XX
PD   27-NOV-2003.
XX
PF   19-MAY-2003; 2003WO-US015711.
XX
PR   17-MAY-2002; 2002US-0380872P.
PR   24-FEB-2003; 2003US-0448874P.
PR   24-FEB-2003; 2003US-0448922P.
XX
PA   (SUGE-) SUGEN INC.
XX
PI   Morimoto A,  Deprimo S,  O'farrell A,  Smolich BD,  Manning WC;
```

```
PI   Walter SA,  Schilling JW,  Cherrington J;
XX
DR   WPI; 2004-042604/04.
XX
PT   Determining whether a test compound inhibits tyrosine kinase activity in
PT   a mammal by exposing the mammal to the test compound and measuring in the
PT   mammal the level of at least one of the measured proteins or mRNA
PT   transcripts.
XX
PS   Example K; SEQ ID NO 40; 408pp; English.
XX
CC   The invention relates to a novel method for determining whether a test
CC   compound inhibits tyrosine kinase activity in a mammal comprising
CC   measuring in the mammal the level of at least one of the proteins and/or
CC   mRNA transcripts or genes for such proteins comprising type 1 plasminogen
CC   activator inhibitor (PAI-1), TIMP-1 (tissue inhibitor of
CC   metalloproteinase 1), vinculin, vascular endothelial growth factor
CC   (VEGF), placental growth factor (PLGF), VEGF/PLGF heterodimers or
CC   migration inhibitory factor (MIG), exposing the mammal to the test
CC   compound and then measuring in the mammal the level of at least one of
CC   the proteins and/or mRNA transcripts previously measured. The method of
CC   the invention may be useful for determining whether a test compound
CC   inhibits tyrosine kinase activity in a mammal. The current sequence is
CC   that of the PCR primer which was used in the exemplification of the
CC   invention.
XX
SQ   Sequence 26 BP; 4 A; 7 C; 4 G; 11 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3920 TCTACCGTCCTTGTCATAACTTTGTG 3945
             ||||||||||||||||||||||||||
Db          1 TCTACCGTCCTTGTCATAACTTTGTG 26


RESULT 9
ADR86707
ID   ADR86707 standard; DNA; 29 BP.
XX
AC   ADR86707;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 PCR primer seqid 12.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 1; Page 44; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a primer used in the isolation of human ephrin B4 cDNA used in
CC   the creation of an expression vector for producing a soluble Eph B4
CC   derivative.
XX
SQ   Sequence 29 BP; 3 A; 9 C; 11 G; 6 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 24.2;  DB 1;  Length 29;
  Best Local Similarity   89.7%;  Pred. No. 52;
  Matches   26;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        367 GGCGGCGCCATGGAGCTCCGGGTGCTGCT 395
              ||   ||||||||||||||||||||||||
Db          1 GGATCCGCCATGGAGCTCCGGGTGCTGCT 29


RESULT 10
ADR82276
ID   ADR82276 standard; DNA; 29 BP.
XX
AC   ADR82276;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 PCR primer #1.
XX
KW   human; ss; PCR; primer; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
```

PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 1; Page 49; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC PCR primer.
XX
SQ Sequence 29 BP; 3 A; 9 C; 11 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 24.2; DB 1; Length 29;
Best Local Similarity 89.7%; Pred. No. 52;
Matches 26; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 367 GGCGGCGCCATGGAGCTCCGGGTGCTGCT 395
|| |||||||||||||||||||||||||||
Db 1 GGATCCGCCATGGAGCTCCGGGTGCTGCT 29

RESULT 11
ADT00082
ID ADT00082 standard; DNA; 22 BP.
XX
AC ADT00082;
XX
DT 16-DEC-2004 (first entry)
XX
DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID70.
XX
KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
KW tumourigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
KW GUCY2F; MCCK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;
KW guanylate cyclase stimulator; ss.
XX
OS Homo sapiens.
XX
PN WO2004082458-A2.
XX
PD 30-SEP-2004.
XX
PF 18-FEB-2004; 2004WO-US004452.
XX
PR 21-FEB-2003; 2003US-0448537P.
PR 29-MAY-2003; 2003US-0473895P.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
XX
DR WPI; 2004-718702/70.
XX
PT Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCCK) and
PT associated methods for diagnosing cancer and screening for anti-cancer
PT agents.
XX
PS Disclosure; SEQ ID NO 70; 363pp; English.
XX
CC This invention relates to a novel activated mutant protein tyrosine
CC kinases and associated methods for diagnosing cancer and screening for
CC anti-cancer agents. Protein kinases are signalling molecules involved in
CC tumourigenesis. Mutational analysis of the human tyrosine kinase gene
CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
CC MCCK/MLK4 genes. Most were identified in the kinase domain. The invention
CC may be useful for the production of compounds with a cytostatic activity
CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
CC stimulators. The invention may be useful for developing methods for
CC detecting mutations involved in cancer or screening for anti-cancer
CC agents. The present sequence is that of a human-derived oligonucleotide
CC which is related to the invention.
XX
SQ Sequence 22 BP; 7 A; 1 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2219 TCAAGATTGAAGAGGTGATTGG 2240
||||||||||||||||||||||
Db 1 TCAAGATTGAAGAGGTGATTGG 22

RESULT 12
ADR86751/c
ID ADR86751 standard; DNA; 21 BP.
XX
AC ADR86751;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 56.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 79; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 21 BP; 2 A; 10 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 784 AAGGTGGACACGGTGGCCGCG 804
||||||||||||||||||||||
Db 21 AAGGTGGACACGGTGGCCGCG 1

RESULT 13
ADR86956
ID ADR86956 standard; DNA; 21 BP.
XX
AC ADR86956;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 261.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2196 AAAAGAGATCGATGTCTCCTA 2216
||||||||||||||||||||||
Db 1 AAAAGAGATCGATGTCTCCTA 21

RESULT 14
ADR86972
ID ADR86972 standard; DNA; 21 BP.
XX
AC ADR86972;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 277.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 3 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2639 AAGTGTCTGACTTTGGCCTTT 2659
||||||||||||||||||||||
Db 1 AAGTGTCTGACTTTGGCCTTT 21

RESULT 15
ADR86981
ID ADR86981 standard; DNA; 21 BP.
XX
AC ADR86981;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 286.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2866 AATGCCATTGAACAGGACTAC 2886
||||||||||||||||||||||
Db 1 AATGCCATTGAACAGGACTAC 21

RESULT 16
ADR86772/c
ID ADR86772 standard; DNA; 21 BP.
XX
AC ADR86772;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 77.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 6; Page 89; 198pp; English.
XX

```
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 2 A; 4 C; 6 G; 0 T; 9 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        425 AAGAGACCCTGCTGAACACAA 445
              |||||||||||||||||||||
Db         21 AAGAGACCCTGCTGAACACAA 1


RESULT 17
ADR86950
ID   ADR86950 standard; DNA; 21 BP.
XX
AC   ADR86950;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 255.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 10 A; 2 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2068 AAGCAGAGCAATGGGAGAGAA 2088
              |||||||||||||||||||||
Db          1 AAGCAGAGCAATGGGAGAGAA 21


RESULT 18
ADR86963
ID   ADR86963 standard; DNA; 21 BP.
XX
AC   ADR86963;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 268.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
```

```
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2428 AACAGCATGCCCGTCATGATT 2448
             |||||||||||||||||||||
Db          1 AACAGCATGCCCGTCATGATT 21


RESULT 19
ADR86971
ID   ADR86971 standard; DNA; 21 BP.
XX
AC   ADR86971;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 276.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 5 A; 10 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2677 AACTCTTCCGATCCCACCTAC 2697
             |||||||||||||||||||||
Db          1 AACTCTTCCGATCCCACCTAC 21


RESULT 20
ADR86979
ID   ADR86979 standard; DNA; 21 BP.
XX
AC   ADR86979;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 284.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
```

XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 9 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3141 AAGATACGAAGAAAGTTTCGC 3161
              |||||||||||||||||||||
Db          1 AAGATACGAAGAAAGTTTCGC 21
```

RESULT 21
ADR86726/c
ID ADR86726 standard; DNA; 21 BP.
XX
AC ADR86726;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 31.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 3; Page 62; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1
```

RESULT 22
ADR86936
ID ADR86936 standard; DNA; 21 BP.
XX
AC ADR86936;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 241.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX

PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 446 AATTGGAAACTGCTGATCTGA 466
||||||||||||||||||||
Db 1 AATTGGAAACTGCTGATCTGA 21

RESULT 23
ADR86938
ID ADR86938 standard; DNA; 21 BP.
XX
AC ADR86938;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 243.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 453 AACTGCTGATCTGAAGTGGGT 473
||||||||||||||||||||
Db 1 AACTGCTGATCTGAAGTGGGT 21

RESULT 24
ADR86957
ID ADR86957 standard; DNA; 21 BP.
XX
AC ADR86957;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 262.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX

OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 6 A; 1 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2173 AATGAGGCTGTGAGGGAATTT 2193
||||||||||||||||||||
Db 1 AATGAGGCTGTGAGGGAATTT 21

RESULT 25
ADR86965
ID ADR86965 standard; DNA; 21 BP.
XX
AC ADR86965;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 270.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 6 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2293 AAGGAGAGCTGTGTGGCAATC 2313
||||||||||||||||||||
Db 1 AAGGAGAGCTGTGTGGCAATC 21

RESULT 26
ADR86967
ID ADR86967 standard; DNA; 21 BP.
XX
AC ADR86967;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 272.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 8 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2496 AAACGACGGACAGTTCACAGT 2516
||||||||||||||||||||
Db 1 AAACGACGGACAGTTCACAGT 21

RESULT 27
ADR86983
ID ADR86983 standard; DNA; 21 BP.
XX
AC ADR86983;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 288.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3253 AAAATCTTGGCCAGTGTCCAG 3273
||||||||||||||||||||
Db 1 AAAATCTTGGCCAGTGTCCAG 21

RESULT 28
ADR86941
ID ADR86941 standard; DNA; 21 BP.
XX
AC ADR86941;
XX

```
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 246.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAGGTGAATGTCAAGACGCTG 867
              |||||||||||||||||||||
Db          1 AAGGTGAATGTCAAGACGCTG 21


RESULT 29
ADR86953
ID   ADR86953 standard; DNA; 21 BP.
XX
AC   ADR86953;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 258.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2093 AATATTCGGACAAACACGGAC 2113
              |||||||||||||||||||||
Db          1 AATATTCGGACAAACACGGAC 21
```

```
RESULT 30
ADR86966
ID   ADR86966 standard; DNA; 21 BP.
XX
AC   ADR86966;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 271.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2310 AATCAAGACCCTGAAGGGTGG 2330
             |||||||||||||||||||||
Db          1 AATCAAGACCCTGAAGGGTGG 21


RESULT 31
ADR86969
ID   ADR86969 standard; DNA; 21 BP.
XX
AC   ADR86969;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 274.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 9 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2608 AACATCCTAGTCAACAGCAAC 2628
              |||||||||||||||||||||
Db          1 AACATCCTAGTCAACAGCAAC 21


RESULT 32
ADR86980
ID   ADR86980 standard; DNA; 21 BP.
XX
AC   ADR86980;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 285.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 11 A; 1 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3135 AATGGGAAGATACGAAGAAAG 3155
              |||||||||||||||||||||
Db          1 AATGGGAAGATACGAAGAAAG 21


RESULT 33
ADR86746/c
ID   ADR86746 standard; DNA; 21 BP.
XX
AC   ADR86746;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 51.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 5; Page 79; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
```

```
XX
SQ   Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1381 GGCTCCTCCCTGCACCTGGAA 1401
              |||||||||||||||||||||
Db         21 GGCTCCTCCCTGCACCTGGAA 1

RESULT 34
ADR86924/c
ID   ADR86924 standard; DNA; 21 BP.
XX
AC   ADR86924;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 229.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 35
ADR86927/c
ID   ADR86927 standard; DNA; 21 BP.
XX
AC   ADR86927;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 232.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
```

```
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1641 TGAGCCTGTCAATGTCACCAC 1661
              |||||||||||||||||||||
Db         21 TGAGCCTGTCAATGTCACCAC 1


RESULT 36
ADR86944
ID   ADR86944 standard; DNA; 21 BP.
XX
AC   ADR86944;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 249.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 8 A; 7 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1246 AATAGCCACTCTAACACCATT 1266
              |||||||||||||||||||||
Db          1 AATAGCCACTCTAACACCATT 21


RESULT 37
ADR86945
ID   ADR86945 standard; DNA; 21 BP.
XX
AC   ADR86945;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 250.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
```

```
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 6 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AACACCATTGGATCAGCCGTC 1278
              |||||||||||||||||||||
Db          1 AACACCATTGGATCAGCCGTC 21


RESULT 38
ADR86954
ID   ADR86954 standard; DNA; 21 BP.
XX
AC   ADR86954;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 259.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 8 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2104 AAACACGGACAGTATCTCATC 2124
              |||||||||||||||||||||
Db          1 AAACACGGACAGTATCTCATC 21


RESULT 39
ADR86961
ID   ADR86961 standard; DNA; 21 BP.
XX
AC   ADR86961;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 266.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
```

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 1 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2228 AAGAGGTGATTGGTGCAGGTG 2248
||||||||||||||||||||
Db 1 AAGAGGTGATTGGTGCAGGTG 21

RESULT 40
ADR86948
ID ADR86948 standard; DNA; 21 BP.
XX
AC ADR86948;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 253.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 9 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1831 AAGACGTCAGAAAACCGGGCA 1851
||||||||||||||||||||
Db 1 AAGACGTCAGAAAACCGGGCA 21

RESULT 41
ADR86968
ID ADR86968 standard; DNA; 21 BP.
XX
AC ADR86968;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 273.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX

PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2497 AACGACGGACAGTTCACAGTC 2517
||||||||||||||||||||
Db 1 AACGACGGACAGTTCACAGTC 21

RESULT 42
ADR86987
ID ADR86987 standard; DNA; 21 BP.
XX
AC ADR86987;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 292.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 96; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3255 AATCTTGGCCAGTGTCCAGCA 3275
||||||||||||||||||||
Db 1 AATCTTGGCCAGTGTCCAGCA 21

RESULT 43
ADR86775/c
ID ADR86775 standard; DNA; 21 BP.
XX
AC ADR86775;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 80.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.

XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 91; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 21 BP; 2 A; 7 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3319 GGACCGGCCCCGCAGTACTGA 3339
||||||||||||||||||||
Db 21 GGACCGGCCCCGCAGTACTGA 1

RESULT 44
ADR86928/c
ID ADR86928 standard; DNA; 21 BP.
XX
AC ADR86928;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 233.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 21 BP; 1 A; 5 C; 7 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1931 GCCAGGAACATCACAGCCAGA 1951
||||||||||||||||||||
Db 21 GCCAGGAACATCACAGCCAGA 1

RESULT 45
ADR86940
ID ADR86940 standard; DNA; 21 BP.
XX
AC ADR86940;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 245.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.

XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 466 AAGTGGGTGACATTCCCTCAG 486
||||||||||||||||||||
Db 1 AAGTGGGTGACATTCCCTCAG 21

RESULT 46
ADR86973
ID ADR86973 standard; DNA; 21 BP.
XX
AC ADR86973;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 278.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2626 AACCTCGTCTGCAAAGTGTCT 2646
||||||||||||||||||||
Db 1 AACCTCGTCTGCAAAGTGTCT 21

RESULT 47
ADR86975
ID ADR86975 standard; DNA; 21 BP.
XX
AC ADR86975;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 280.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX

PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2851 AATCAGGACGTGATCAATGCC 2871
||||||||||||||||||||
Db 1 AATCAGGACGTGATCAATGCC 21

RESULT 48
ADR86952
ID ADR86952 standard; DNA; 21 BP.
XX
AC ADR86952;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 257.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2087 AAGCAGAATATTCGGACAAAC 2107
||||||||||||||||||||
Db 1 AAGCAGAATATTCGGACAAAC 21

RESULT 49
ADR86955
ID ADR86955 standard; DNA; 21 BP.
XX
AC ADR86955;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 260.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;

KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2105 AACACGGACAGTATCTCATCG 2125
             |||||||||||||||||||||
Db          1 AACACGGACAGTATCTCATCG 21
```

RESULT 50
ADR86960
ID ADR86960 standard; DNA; 21 BP.
XX
AC ADR86960;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 265.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2198 AAGAGATCGATGTCTCCTACG 2218
             |||||||||||||||||||||
Db          1 AAGAGATCGATGTCTCCTACG 21
```

RESULT 51
ADR86962
ID ADR86962 standard; DNA; 21 BP.
XX
AC ADR86962;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 267.
XX

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 0 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2221 AAGATTGAAGAGGTGATTGGT 2241
||||||||||||||||||||
Db 1 AAGATTGAAGAGGTGATTGGT 21

RESULT 52
ADR86976
ID ADR86976 standard; DNA; 21 BP.
XX
AC ADR86976;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 281.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2715 AAAGATTCCCATCCGATGGAC 2735
||||||||||||||||||||
Db 1 AAAGATTCCCATCCGATGGAC 21

RESULT 53
ADR86748/c
ID ADR86748 standard; DNA; 21 BP.
XX

```
AC   ADR86748;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 53.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 5; Page 79; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 1 A; 5 C; 7 G; 8 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1931 GCCAGGAACATCACAGCCAGA 1951
              |||||||||||||||||||||
Db         21 GCCAGGAACATCACAGCCAGA 1

RESULT 54
```

```
ADR86931/c
ID   ADR86931 standard; DNA; 21 BP.
XX
AC   ADR86931;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 236.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 2 A; 10 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        784 AAGGTGGACACGGTGGCCGCG 804
              |||||||||||||||||||||
Db         21 AAGGTGGACACGGTGGCCGCG 1
```

```
RESULT 55
ADR86935
ID   ADR86935 standard; DNA; 21 BP.
XX
AC   ADR86935;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 240.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        445 AAATTGGAAACTGCTGATCTG 465
              |||||||||||||||||||||
Db          1 AAATTGGAAACTGCTGATCTG 21


RESULT 56
ADR86977
ID   ADR86977 standard; DNA; 21 BP.
XX
AC   ADR86977;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 282.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2716 AAGATTCCCATCCGATGGACT 2736
              |||||||||||||||||||||
Db          1 AAGATTCCCATCCGATGGACT 21


RESULT 57
ADR86978
ID   ADR86978 standard; DNA; 21 BP.
XX
AC   ADR86978;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 283.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2761 AAGTTCACTTCCGCCAGTGAT 2781
              |||||||||||||||||||||
Db          1 AAGTTCACTTCCGCCAGTGAT 21


RESULT 58
ADR86985
ID   ADR86985 standard; DNA; 21 BP.
XX
AC   ADR86985;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 290.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 96; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
```

CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 6 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3149 AAGAAAGTTTCGCAGCCGCTG 3169
||||||||||||||||||||
Db 1 AAGAAAGTTTCGCAGCCGCTG 21

RESULT 59
ADR86932/c
ID ADR86932 standard; DNA; 21 BP.
XX
AC ADR86932;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 237.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 21 BP; 3 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2305 GTGGCAATCAAGACCCTGAAG 2325
||||||||||||||||||||
Db 21 GTGGCAATCAAGACCCTGAAG 1

RESULT 60
ADR86943
ID ADR86943 standard; DNA; 21 BP.
XX
AC ADR86943;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 248.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 958 AAAAAGTGCGCCCAGCTGACT 978
||||||||||||||||||||
Db 1 AAAAAGTGCGCCCAGCTGACT 21

RESULT 61
ADR86958
ID ADR86958 standard; DNA; 21 BP.
XX
AC ADR86958;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 263.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2165 AAGACCCTAATGAGGCTGTGA 2185
||||||||||||||||||||
Db 1 AAGACCCTAATGAGGCTGTGA 21

RESULT 62
ADR86982
ID ADR86982 standard; DNA; 21 BP.
XX
AC ADR86982;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 287.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3028 AAAATCGTGGCCCGGGAGAAT 3048
||||||||||||||||||||
Db 1 AAAATCGTGGCCCGGGAGAAT 21

RESULT 63
ADR86986
ID ADR86986 standard; DNA; 21 BP.
XX
AC ADR86986;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 291.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 96; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3250 AAGAAAATCTTGGCCAGTGTC 3270
||||||||||||||||||||
Db 1 AAGAAAATCTTGGCCAGTGTC 21

RESULT 64
ADR86739/c
ID ADR86739 standard; RNA; 21 BP.
XX
AC ADR86739;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 44.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 75; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

```
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 4 A; 7 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAGGTGAATGTCAAGACGCTG 867
              |||||||||||||||||||||
Db         21 AAGGTGAATGTCAAGACGCTG 1


RESULT 65
ADR86743/c
ID   ADR86743 standard; RNA; 21 BP.
XX
AC   ADR86743;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 48.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 5; Page 75; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 5 A; 1 C; 10 G; 0 T; 5 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2677 AACTCTTCCGATCCCACCTAC 2697
              |||||||||||||||||||||
Db         21 AACTCTTCCGATCCCACCTAC 1


RESULT 66
ADR86752/c
ID   ADR86752 standard; DNA; 21 BP.
XX
AC   ADR86752;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 57.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
```

```
PT   scleroderma.
XX
PS   Example 5; Page 79; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 3 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GTGGCAATCAAGACCCTGAAG 2325
              |||||||||||||||||||||
Db         21 GTGGCAATCAAGACCCTGAAG 1


RESULT 67
ADR86937
ID   ADR86937 standard; DNA; 21 BP.
XX
AC   ADR86937;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 242.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        452 AAACTGCTGATCTGAAGTGGG 472
              |||||||||||||||||||||
Db          1 AAACTGCTGATCTGAAGTGGG 21


RESULT 68
ADR86939
ID   ADR86939 standard; DNA; 21 BP.
XX
AC   ADR86939;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 244.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
```

```
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        853 AATGTCAAGACGCTGCGTCTG 873
              |||||||||||||||||||||
Db          1 AATGTCAAGACGCTGCGTCTG 21


RESULT 69
ADR86959
ID   ADR86959 standard; DNA; 21 BP.
XX
AC   ADR86959;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 264.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2197 AAAGAGATCGATGTCTCCTAC 2217
              |||||||||||||||||||||
Db          1 AAAGAGATCGATGTCTCCTAC 21


RESULT 70
ADR86964
ID   ADR86964 standard; DNA; 21 BP.
XX
AC   ADR86964;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 269.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
```

PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2290 AAGAAGGAGAGCTGTGTGGCA 2310
              |||||||||||||||||||||
Db          1 AAGAAGGAGAGCTGTGTGGCA 21
```

RESULT 71
ADR86737/c
ID ADR86737 standard; RNA; 21 BP.
XX
AC ADR86737;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 42.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 75; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 2 A; 4 C; 6 G; 0 T; 9 U; 0 Other;

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        425 AAGAGACCCTGCTGAACACAA 445
              |||||||||||||||||||||
Db         21 AAGAGACCCTGCTGAACACAA 1
```

RESULT 72
ADR86741/c
ID ADR86741 standard; RNA; 21 BP.
XX
AC ADR86741;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 46.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX

PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 75; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 1 A; 2 C; 9 G; 0 T; 9 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1937 AACATCACAGCCAGACCCAAC 1957
||||||||||||||||||||
Db 21 AACATCACAGCCAGACCCAAC 1

RESULT 73
ADR86942
ID ADR86942 standard; DNA; 21 BP.
XX
AC ADR86942;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 247.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 697 AAGGAGACCTTCACCGTCTTC 717
||||||||||||||||||||
Db 1 AAGGAGACCTTCACCGTCTTC 21

RESULT 74
ADR86754/c
ID ADR86754 standard; DNA; 21 BP.
XX
AC ADR86754;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 59.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;

```
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 5; Page 79; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 GTCATCCAGCTCGTGGGCATG 2535
              |||||||||||||||||||||
Db         21 GTCATCCAGCTCGTGGGCATG 1


RESULT 75
ADR86926/c
ID   ADR86926 standard; DNA; 21 BP.
XX
AC   ADR86926;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 231.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1381 GGCTCCTCCCTGCACCTGGAA 1401
              |||||||||||||||||||||
Db         21 GGCTCCTCCCTGCACCTGGAA 1


RESULT 76
ADR86947
ID   ADR86947 standard; DNA; 21 BP.
XX
AC   ADR86947;
XX
DT   16-DEC-2004  (first entry)
XX
```

```
DE   Human ephrinB4 short interferance RNA seqid 252.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1783 AAATACCATGAGAAGGGCGCC 1803
             |||||||||||||||||||||
Db          1 AAATACCATGAGAAGGGCGCC 21


RESULT 77
ADR86949
ID   ADR86949 standard; DNA; 21 BP.
XX
AC   ADR86949;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 254.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 9 A; 9 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1937 AACATCACAGCCAGACCCAAC 1957
             |||||||||||||||||||||
Db          1 AACATCACAGCCAGACCCAAC 21


RESULT 78
ADR86744/c
```

```
ID   ADR86744 standard; DNA; 21 BP.
XX
AC   ADR86744;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 49.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 5; Page 79; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1
```

```
RESULT 79
ADR86934/c
ID   ADR86934 standard; DNA; 21 BP.
XX
AC   ADR86934;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 239.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 GTCATCCAGCTCGTGGGCATG 2535
```

```
                    ||||||||||||||||||||
Db         21 GTCATCCAGCTCGTGGGCATG 1

RESULT 80
ADR86946
ID   ADR86946 standard; DNA; 21 BP.
XX
AC   ADR86946;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 251.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1651 AATGTCACCACTGACCGAGAG 1671
                ||||||||||||||||||||
Db          1 AATGTCACCACTGACCGAGAG 21


RESULT 81
ADR86951
ID   ADR86951 standard; DNA; 21 BP.
XX
AC   ADR86951;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 256.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 10 A; 1 C; 7 G; 3 T; 0 U; 0 Other;
```

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2077 AATGGGAGAGAAGCAGAATAT 2097
              |||||||||||||||||||||
Db          1 AATGGGAGAGAAGCAGAATAT 21


RESULT 82
ADR86970
ID   ADR86970 standard; DNA; 21 BP.
XX
AC   ADR86970;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 275.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 95; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 8 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2620 AACAGCAACCTCGTCTGCAAA 2640
              |||||||||||||||||||||
Db          1 AACAGCAACCTCGTCTGCAAA 21


RESULT 83
ADR86984
ID   ADR86984 standard; DNA; 21 BP.
XX
AC   ADR86984;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 289.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 96; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
```

CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTCCAGC 3274
||||||||||||||||||||
Db 1 AAATCTTGGCCAGTGTCCAGC 21

RESULT 84
ADR86747/c
ID ADR86747 standard; DNA; 21 BP.
XX
AC ADR86747;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 52.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 79; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1641 TGAGCCTGTCAATGTCACCAC 1661
||||||||||||||||||||
Db 21 TGAGCCTGTCAATGTCACCAC 1

RESULT 85
ADR86974
ID ADR86974 standard; DNA; 21 BP.
XX
AC ADR86974;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 279.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for

```
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2638 AAAGTGTCTGACTTTGGCCTT 2658
              |||||||||||||||||||||
Db          1 AAAGTGTCTGACTTTGGCCTT 21


RESULT 86
ADR82292/c
ID   ADR82292 standard; DNA; 21 BP.
XX
AC   ADR82292;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #1.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 3; Page 68; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 87
ADR82495
ID   ADR82495 standard; DNA; 21 BP.
XX
AC   ADR82495;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #6.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        466 AAGTGGGTGACATTCCCTCAG 486
              |||||||||||||||||||||
Db          1 AAGTGGGTGACATTCCCTCAG 21
```

```
RESULT 88
ADR82516
ID   ADR82516 standard; DNA; 21 BP.
XX
AC   ADR82516;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #27.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 5 A; 1 C; 10 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2228 AAGAGGTGATTGGTGCAGGTG 2248
             |||||||||||||||||||||
Db          1 AAGAGGTGATTGGTGCAGGTG 21


RESULT 89
ADR82524
ID   ADR82524 standard; DNA; 21 BP.
XX
AC   ADR82524;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #35.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 9 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2608 AACATCCTAGTCAACAGCAAC 2628
             |||||||||||||||||||||
Db          1 AACATCCTAGTCAACAGCAAC 21


RESULT 90
ADR82527
ID   ADR82527 standard; DNA; 21 BP.
XX
AC   ADR82527;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #38.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
```

```
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 3 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2639 AAGTGTCTGACTTTGGCCTTT 2659
             |||||||||||||||||||||
Db          1 AAGTGTCTGACTTTGGCCTTT 21


RESULT 91
ADR82532
ID   ADR82532 standard; DNA; 21 BP.
XX
AC   ADR82532;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #43.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2716 AAGATTCCCATCCGATGGACT 2736
             |||||||||||||||||||||
Db          1 AAGATTCCCATCCGATGGACT 21


RESULT 92
ADR82512
ID   ADR82512 standard; DNA; 21 BP.
XX
AC   ADR82512;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #23.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
```

```
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 6 A; 1 C; 8 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2173 AATGAGGCTGTGAGGGAATTT 2193
             |||||||||||||||||||||
Db          1 AATGAGGCTGTGAGGGAATTT 21


RESULT 93
ADR82531
ID   ADR82531 standard; DNA; 21 BP.
XX
AC   ADR82531;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #42.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2715 AAAGATTCCCATCCGATGGAC 2735
             |||||||||||||||||||||
Db          1 AAAGATTCCCATCCGATGGAC 21


RESULT 94
ADR82319/c
ID   ADR82319 standard; DNA; 21 BP.
XX
AC   ADR82319;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #13.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 GTCATCCAGCTCGTGGGCATG 2535
             |||||||||||||||||||||
Db         21 GTCATCCAGCTCGTGGGCATG 1


RESULT 95
ADR82493
```

```
ID   ADR82493 standard; DNA; 21 BP.
XX
AC   ADR82493;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #4.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 5 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        453 AACTGCTGATCTGAAGTGGGT 473
              |||||||||||||||||||||
Db          1 AACTGCTGATCTGAAGTGGGT 21


RESULT 96
ADR82494
ID   ADR82494 standard; DNA; 21 BP.
XX
AC   ADR82494;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #5.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        853 AATGTCAAGACGCTGCGTCTG 873
              |||||||||||||||||||||
Db          1 AATGTCAAGACGCTGCGTCTG 21


RESULT 97
ADR82519
ID   ADR82519 standard; DNA; 21 BP.
XX
AC   ADR82519;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #30.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
```

PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 102; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 7 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2290 AAGAAGGAGAGCTGTGTGGCA 2310
||||||||||||||||||||
Db 1 AAGAAGGAGAGCTGTGTGGCA 21

RESULT 98
ADR82525
ID ADR82525 standard; DNA; 21 BP.
XX
AC ADR82525;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense RNAi probe #36.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 102; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 8 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2620 AACAGCAACCTCGTCTGCAAA 2640
|||||||||||||||||||||
Db 1 AACAGCAACCTCGTCTGCAAA 21

RESULT 99
ADR82534
ID ADR82534 standard; DNA; 21 BP.
XX
AC ADR82534;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense RNAi probe #45.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 103; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or

```
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 9 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3141 AAGATACGAAGAAAGTTTCGC 3161
              |||||||||||||||||||||
Db          1 AAGATACGAAGAAAGTTTCGC 21


RESULT 100
ADR82506
ID   ADR82506 standard; DNA; 21 BP.
XX
AC   ADR82506;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #17.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 10 A; 1 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2077 AATGGGAGAGAAGCAGAATAT 2097
              |||||||||||||||||||||
Db          1 AATGGGAGAGAAGCAGAATAT 21


RESULT 101
ADR82513
ID   ADR82513 standard; DNA; 21 BP.
XX
AC   ADR82513;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #24.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2165 AAGACCCTAATGAGGCTGTGA 2185
              |||||||||||||||||||||
Db          1 AAGACCCTAATGAGGCTGTGA 21


RESULT 102
ADR82540
ID   ADR82540 standard; DNA; 21 BP.
XX
AC   ADR82540;
XX
```

```
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #51.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 6 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3149 AAGAAAGTTTCGCAGCCGCTG 3169
              |||||||||||||||||||||
Db          1 AAGAAAGTTTCGCAGCCGCTG 21


RESULT 103
ADR82479/c
ID   ADR82479 standard; DNA; 21 BP.
XX
AC   ADR82479;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #150.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 104
ADR82483/c
ID   ADR82483 standard; DNA; 21 BP.
XX
AC   ADR82483;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #154.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
```

```
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 21 BP; 1 A; 5 C; 7 G; 8 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1931 GCCAGGAACATCACAGCCAGA 1951
             |||||||||||||||||||||
Db         21 GCCAGGAACATCACAGCCAGA 1


RESULT 105
ADR82507
ID   ADR82507 standard; DNA; 21 BP.
XX
AC   ADR82507;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #18.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2087 AAGCAGAATATTCGGACAAAC 2107
             |||||||||||||||||||||
Db          1 AAGCAGAATATTCGGACAAAC 21


RESULT 106
ADR82514
ID   ADR82514 standard; DNA; 21 BP.
XX
AC   ADR82514;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #25.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
```

```
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2197 AAAGAGATCGATGTCTCCTAC 2217
              |||||||||||||||||||||
Db          1 AAAGAGATCGATGTCTCCTAC 21


RESULT 107
ADR82518
ID   ADR82518 standard; DNA; 21 BP.
XX
AC   ADR82518;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #29.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2428 AACAGCATGCCCGTCATGATT 2448
              |||||||||||||||||||||
Db          1 AACAGCATGCCCGTCATGATT 21


RESULT 108
ADR82529
ID   ADR82529 standard; DNA; 21 BP.
XX
AC   ADR82529;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #40.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 4 A; 4 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2638 AAAGTGTCTGACTTTGGCCTT 2658
              |||||||||||||||||||||
Db          1 AAAGTGTCTGACTTTGGCCTT 21


RESULT 109
ADR82537
ID   ADR82537 standard; DNA; 21 BP.
XX
AC   ADR82537;
XX
DT   16-DEC-2004  (first entry)
XX
```

```
DE   Human EphB4 antisense RNAi probe #48.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3028 AAAATCGTGGCCCGGGAGAAT 3048
              |||||||||||||||||||||
Db          1 AAAATCGTGGCCCGGGAGAAT 21


RESULT 110
ADR82316/c
ID   ADR82316 standard; DNA; 21 BP.
XX
AC   ADR82316;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #10.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 21 BP; 2 A; 10 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        784 AAGGTGGACACGGTGGCCGCG 804
              |||||||||||||||||||||
Db         21 AAGGTGGACACGGTGGCCGCG 1


RESULT 111
ADR82496
ID   ADR82496 standard; DNA; 21 BP.
XX
AC   ADR82496;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #7.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
```

```
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAGGTGAATGTCAAGACGCTG 867
              |||||||||||||||||||||
Db          1 AAGGTGAATGTCAAGACGCTG 21


RESULT 112
ADR82503
ID   ADR82503 standard; DNA; 21 BP.
XX
AC   ADR82503;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #14.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 9 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1831 AAGACGTCAGAAAACCGGGCA 1851
              |||||||||||||||||||||
Db          1 AAGACGTCAGAAAACCGGGCA 21


RESULT 113
ADR82508
ID   ADR82508 standard; DNA; 21 BP.
XX
AC   ADR82508;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #19.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
```

```
SQ   Sequence 21 BP; 9 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2093 AATATTCGGACAAACACGGAC 2113
              |||||||||||||||||||||
Db          1 AATATTCGGACAAACACGGAC 21


RESULT 114
ADR82510
ID   ADR82510 standard; DNA; 21 BP.
XX
AC   ADR82510;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #21.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2105 AACACGGACAGTATCTCATCG 2125
              |||||||||||||||||||||
Db          1 AACACGGACAGTATCTCATCG 21


RESULT 115
ADR82542
ID   ADR82542 standard; DNA; 21 BP.
XX
AC   ADR82542;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #53.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3255 AATCTTGGCCAGTGTCCAGCA 3275
              |||||||||||||||||||||
Db          1 AATCTTGGCCAGTGTCCAGCA 21


RESULT 116
ADR82311/c
ID   ADR82311 standard; DNA; 21 BP.
XX
AC   ADR82311;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #5.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
```

```
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1381 GGCTCCTCCCTGCACCTGGAA 1401
             |||||||||||||||||||||
Db         21 GGCTCCTCCCTGCACCTGGAA 1


RESULT 117
ADR82317/c
ID   ADR82317 standard; DNA; 21 BP.
XX
AC   ADR82317;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #11.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 21 BP; 3 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GTGGCAATCAAGACCCTGAAG 2325
             |||||||||||||||||||||
Db         21 GTGGCAATCAAGACCCTGAAG 1


RESULT 118
ADR82499
ID   ADR82499 standard; DNA; 21 BP.
XX
AC   ADR82499;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #10.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
```

```
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 8 A; 7 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1246 AATAGCCACTCTAACACCATT 1266
              |||||||||||||||||||||
Db          1 AATAGCCACTCTAACACCATT 21


RESULT 119
ADR82509
ID   ADR82509 standard; DNA; 21 BP.
XX
AC   ADR82509;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #20.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 8 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2104 AAACACGGACAGTATCTCATC 2124
              |||||||||||||||||||||
Db          1 AAACACGGACAGTATCTCATC 21


RESULT 120
ADR82520
ID   ADR82520 standard; DNA; 21 BP.
XX
AC   ADR82520;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #31.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 6 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
```

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2293 AAGGAGAGCTGTGTGGCAATC 2313
              |||||||||||||||||||||
Db          1 AAGGAGAGCTGTGTGGCAATC 21


RESULT 121
ADR82492
ID   ADR82492 standard; DNA; 21 BP.
XX
AC   ADR82492;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #3.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        452 AAACTGCTGATCTGAAGTGGG 472
              |||||||||||||||||||||
Db          1 AAACTGCTGATCTGAAGTGGG 21


RESULT 122
ADR82504
ID   ADR82504 standard; DNA; 21 BP.
XX
AC   ADR82504;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #15.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 9 A; 9 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1937 AACATCACAGCCAGACCCAAC 1957
              |||||||||||||||||||||
Db          1 AACATCACAGCCAGACCCAAC 21


RESULT 123
ADR82308/c
ID   ADR82308 standard; RNA; 21 BP.
XX
AC   ADR82308;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #10.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
```

```
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 81; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 5 A; 1 C; 10 G; 0 T; 5 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2677 AACTCTTCCGATCCCACCTAC 2697
              |||||||||||||||||||||
Db         21 AACTCTTCCGATCCCACCTAC 1


RESULT 124
ADR82313/c
ID   ADR82313 standard; DNA; 21 BP.
XX
AC   ADR82313;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #7.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 21 BP; 1 A; 5 C; 7 G; 8 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1931 GCCAGGAACATCACAGCCAGA 1951
              |||||||||||||||||||||
Db         21 GCCAGGAACATCACAGCCAGA 1


RESULT 125
ADR82482/c
ID   ADR82482 standard; DNA; 21 BP.
XX
AC   ADR82482;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #153.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
```

```
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1641 TGAGCCTGTCAATGTCACCAC 1661
             |||||||||||||||||||||
Db         21 TGAGCCTGTCAATGTCACCAC 1


RESULT 126
ADR82486/c
ID   ADR82486 standard; DNA; 21 BP.
XX
AC   ADR82486;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #157.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 21 BP; 2 A; 10 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        784 AAGGTGGACACGGTGGCCGCG 804
              |||||||||||||||||||||
Db         21 AAGGTGGACACGGTGGCCGCG 1


RESULT 127
ADR82302/c
ID   ADR82302 standard; RNA; 21 BP.
XX
AC   ADR82302;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #4.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 81; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 2 A; 4 C; 6 G; 0 T; 9 U; 0 Other;
```

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        425 AAGAGACCCTGCTGAACACAA 445
              |||||||||||||||||||||
Db         21 AAGAGACCCTGCTGAACACAA 1


RESULT 128
ADR82327/c
ID   ADR82327 standard; RNA; 21 BP.
XX
AC   ADR82327;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #12.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 6; Page 96; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 2 A; 4 C; 6 G; 0 T; 9 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        425 AAGAGACCCTGCTGAACACAA 445
              |||||||||||||||||||||
Db         21 AAGAGACCCTGCTGAACACAA 1


RESULT 129
ADR82498
ID   ADR82498 standard; DNA; 21 BP.
XX
AC   ADR82498;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #9.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        958 AAAAAGTGCGCCCAGCTGACT 978
              |||||||||||||||||||||
Db          1 AAAAAGTGCGCCCAGCTGACT 21


RESULT 130
ADR82500
ID   ADR82500 standard; DNA; 21 BP.
XX
AC   ADR82500;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #11.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
```

```
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 6 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1258 AACACCATTGGATCAGCCGTC 1278
              |||||||||||||||||||||
Db          1 AACACCATTGGATCAGCCGTC 21


RESULT 131
ADR82505
ID   ADR82505 standard; DNA; 21 BP.
XX
AC   ADR82505;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #16.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 10 A; 2 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2068 AAGCAGAGCAATGGGAGAGAA 2088
              |||||||||||||||||||||
Db          1 AAGCAGAGCAATGGGAGAGAA 21


RESULT 132
ADR82538
ID   ADR82538 standard; DNA; 21 BP.
XX
AC   ADR82538;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #49.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
```

```
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3253 AAAATCTTGGCCAGTGTCCAG 3273
              |||||||||||||||||||||
Db          1 AAAATCTTGGCCAGTGTCCAG 21


RESULT 133
ADR82487/c
ID   ADR82487 standard; DNA; 21 BP.
XX
AC   ADR82487;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #158.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 21 BP; 3 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2305 GTGGCAATCAAGACCCTGAAG 2325
              |||||||||||||||||||||
Db         21 GTGGCAATCAAGACCCTGAAG 1


RESULT 134
ADR82491
ID   ADR82491 standard; DNA; 21 BP.
XX
AC   ADR82491;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #2.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        446 AATTGGAAACTGCTGATCTGA 466
              |||||||||||||||||||||
Db          1 AATTGGAAACTGCTGATCTGA 21


RESULT 135
ADR82517
ID   ADR82517 standard; DNA; 21 BP.
XX
AC   ADR82517;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #28.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 0 C; 8 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2221 AAGATTGAAGAGGTGATTGGT 2241
              |||||||||||||||||||||
Db          1 AAGATTGAAGAGGTGATTGGT 21


RESULT 136
ADR82522
ID   ADR82522 standard; DNA; 21 BP.
XX
AC   ADR82522;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #33.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2496 AAACGACGGACAGTTCACAGT 2516
              |||||||||||||||||||||
Db          1 AAACGACGGACAGTTCACAGT 21


RESULT 137
ADR82528
ID   ADR82528 standard; DNA; 21 BP.
XX
AC   ADR82528;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #39.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
```

KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 102; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2626 AACCTCGTCTGCAAAGTGTCT 2646
             |||||||||||||||||||||
Db          1 AACCTCGTCTGCAAAGTGTCT 21
```

RESULT 138
ADR82530
ID ADR82530 standard; DNA; 21 BP.
XX
AC ADR82530;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense RNAi probe #41.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 102; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 7 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2851 AATCAGGACGTGATCAATGCC 2871
             |||||||||||||||||||||
Db          1 AATCAGGACGTGATCAATGCC 21
```

RESULT 139
ADR82304/c
ID ADR82304 standard; RNA; 21 BP.
XX
AC ADR82304;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 siRNA #6.
XX
KW human; ss; siRNA; small interference RNA; RNA interference;
KW gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW inflammatory disorder; chronic articular rheumatism; psoriasis;
KW ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW angiogenesis inhibitor.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

```
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 81; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 4 A; 7 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        847 AAGGTGAATGTCAAGACGCTG 867
              |||||||||||||||||||||
Db         21 AAGGTGAATGTCAAGACGCTG 1


RESULT 140
ADR82306/c
ID   ADR82306 standard; RNA; 21 BP.
XX
AC   ADR82306;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #8.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 81; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 1 A; 2 C; 9 G; 0 T; 9 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1937 AACATCACAGCCAGACCCAAC 1957
              |||||||||||||||||||||
Db         21 AACATCACAGCCAGACCCAAC 1


RESULT 141
ADR82312/c
ID   ADR82312 standard; DNA; 21 BP.
XX
AC   ADR82312;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #6.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
```

```
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1641 TGAGCCTGTCAATGTCACCAC 1661
              |||||||||||||||||||||
Db         21 TGAGCCTGTCAATGTCACCAC 1


RESULT 142
ADR82511
ID   ADR82511 standard; DNA; 21 BP.
XX
AC   ADR82511;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #22.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2196 AAAAGAGATCGATGTCTCCTA 2216
              |||||||||||||||||||||
Db          1 AAAAGAGATCGATGTCTCCTA 21


RESULT 143
ADR82533
ID   ADR82533 standard; DNA; 21 BP.
XX
AC   ADR82533;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #44.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2761 AAGTTCACTTCCGCCAGTGAT 2781
              |||||||||||||||||||||
Db          1 AAGTTCACTTCCGCCAGTGAT 21


RESULT 144
ADR82330/c
ID   ADR82330 standard; DNA; 21 BP.
XX
AC   ADR82330;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #1.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
```

```
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 98; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 21 BP; 2 A; 7 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3319 GGACCGGCCCCGCAGTACTGA 3339
              |||||||||||||||||||||
Db         21 GGACCGGCCCCGCAGTACTGA 1


RESULT 145
ADR82481/c
ID   ADR82481 standard; DNA; 21 BP.
XX
AC   ADR82481;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #152.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1381 GGCTCCTCCCTGCACCTGGAA 1401
              |||||||||||||||||||||
Db         21 GGCTCCTCCCTGCACCTGGAA 1


RESULT 146
ADR82490
ID   ADR82490 standard; DNA; 21 BP.
XX
AC   ADR82490;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #1.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
```

```
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        445 AAATTGGAAACTGCTGATCTG 465
              |||||||||||||||||||||
Db          1 AAATTGGAAACTGCTGATCTG 21


RESULT 147
ADR82501
ID   ADR82501 standard; DNA; 21 BP.
XX
AC   ADR82501;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #12.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1651 AATGTCACCACTGACCGAGAG 1671
              |||||||||||||||||||||
Db          1 AATGTCACCACTGACCGAGAG 21


RESULT 148
ADR82502
ID   ADR82502 standard; DNA; 21 BP.
XX
AC   ADR82502;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #13.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1783 AAATACCATGAGAAGGGCGCC 1803
              |||||||||||||||||||||
Db          1 AAATACCATGAGAAGGGCGCC 21


RESULT 149
ADR82523
ID   ADR82523 standard; DNA; 21 BP.
XX
AC   ADR82523;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #34.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2497 AACGACGGACAGTTCACAGTC 2517
              |||||||||||||||||||||
Db          1 AACGACGGACAGTTCACAGTC 21


RESULT 150
ADR82535
ID   ADR82535 standard; DNA; 21 BP.
XX
AC   ADR82535;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #46.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 11 A; 1 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3135 AATGGGAAGATACGAAGAAAG 3155
              |||||||||||||||||||||
Db          1 AATGGGAAGATACGAAGAAAG 21


RESULT 151
ADR82536
ID   ADR82536 standard; DNA; 21 BP.
XX
AC   ADR82536;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #47.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
```

```
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2866 AATGCCATTGAACAGGACTAC 2886
             |||||||||||||||||||||
Db          1 AATGCCATTGAACAGGACTAC 21


RESULT 152
ADR82541
ID   ADR82541 standard; DNA; 21 BP.
XX
AC   ADR82541;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #52.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3250 AAGAAAATCTTGGCCAGTGTC 3270
             |||||||||||||||||||||
Db          1 AAGAAAATCTTGGCCAGTGTC 21


RESULT 153
ADR82515
ID   ADR82515 standard; DNA; 21 BP.
XX
AC   ADR82515;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #26.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
```

```
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2198 AAGAGATCGATGTCTCCTACG 2218
              |||||||||||||||||||||
Db          1 AAGAGATCGATGTCTCCTACG 21


RESULT 154
ADR82309/c
ID   ADR82309 standard; DNA; 21 BP.
XX
AC   ADR82309;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #3.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        928 ATGGCCCTGCTATCCCTGCAC 948
              |||||||||||||||||||||
Db         21 ATGGCCCTGCTATCCCTGCAC 1


RESULT 155
ADR82497
ID   ADR82497 standard; DNA; 21 BP.
XX
AC   ADR82497;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #8.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 5 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        697 AAGGAGACCTTCACCGTCTTC 717
              |||||||||||||||||||||
Db          1 AAGGAGACCTTCACCGTCTTC 21
```

```
RESULT 156
ADR82521
ID   ADR82521 standard; DNA; 21 BP.
XX
AC   ADR82521;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #32.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2310 AATCAAGACCCTGAAGGGTGG 2330
              |||||||||||||||||||||
Db          1 AATCAAGACCCTGAAGGGTGG 21


RESULT 157
ADR82539
ID   ADR82539 standard; DNA; 21 BP.
XX
AC   ADR82539;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #50.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3254 AAATCTTGGCCAGTGTCCAGC 3274
              |||||||||||||||||||||
Db          1 AAATCTTGGCCAGTGTCCAGC 21


RESULT 158
ADR82489/c
ID   ADR82489 standard; DNA; 21 BP.
XX
AC   ADR82489;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #160.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
```

```
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2515 GTCATCCAGCTCGTGGGCATG 2535
              |||||||||||||||||||||
Db         21 GTCATCCAGCTCGTGGGCATG 1


RESULT 159
ADR82526
ID   ADR82526 standard; DNA; 21 BP.
XX
AC   ADR82526;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #37.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 102; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 5 A; 10 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2677 AACTCTTCCGATCCCACCTAC 2697
              |||||||||||||||||||||
Db          1 AACTCTTCCGATCCCACCTAC 21


RESULT 160
ADU79893/c
ID   ADU79893 standard; DNA; 24 BP.
XX
AC   ADU79893;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Antisense oligonucleotide #7 specific for human EphA7.
XX
KW   Prostrate cancer; breast cancer; colon cancer; cytostatic;
KW   bone metastasis; EphA2; EphA2 inhibitor; bone injury; bone pain;
KW   analgesic; spinal cord compression; bone surgery; hypercalcemia;
KW   diagnosis; antisense therapy; antibody therapy; antimetastatic;
KW   Erythropoietin-producing hepatocellular A2 receptor tyrosine kinase; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004101764-A2.
XX
PD   25-NOV-2004.
XX
PF   12-MAY-2004; 2004WO-US014830.
XX
PR   13-MAY-2003; 2003US-0470006P.
PR   18-SEP-2003; 2003US-0504324P.
XX
PA   (CHIR ) CHIRON CORP.
XX
PI   Zimmerman DL,  Hansen R,  Winter J,  Reinhard C,  Fang S;
XX
DR   WPI; 2005-039350/04.
XX
PT   Inhibiting one or more skeletal related events such as bone fracture,
PT   spinal cord compression, bone surgery, bone metastasis or hypercalcemia
PT   of malignancy in cancer patient, involves administering EphA2 inhibitors
PT   to patient.
XX
PS   Example 10; SEQ ID NO 77; 115pp; English.
XX
CC   The present invention relates to metastasis of cancer to bone,
```

```
CC   identifying molecules that play a role in skeletal related events (SREs)
CC   and metastasis, identifying modulators of skeletal related events and
CC   metastasis, and inhibiting one or more SREs in a patient. Determining the
CC   susceptibility of a cancer patient to one or more SREs comprises
CC   detecting evidence of Erythropoietin-producing hepatocellular A2 receptor
CC   tyrosine kinase (EphA2) expression in a patient's cancer sample. Evidence
CC   of EphA2 expression is indicative of the patient's susceptibility to one
CC   or more SREs. The cancer prostate, breast or colon cancer. Inhibiting
CC   SREs comprises administering one or more EphA2 inhibitors to the patient.
CC   One inhibitor is an antibody that binds EphA2, where the antibody
CC   inhibits bone SREs in a patient having bone metastasis, or the antibody
CC   is identified by testing for its effectiveness for treating metastasis in
CC   bone. The antibody binds at least one region of the EphA2 sequence, and
CC   the regions are chosen from 60 sequences given in the specification. The
CC   EphA2 inhibitor can also be an oligonucleotide, small molecule, mimetic,
CC   or decoy. The methods are useful for determining the susceptibility of a
CC   cancer patient to one or more SREs chosen from bone fracture, radiation
CC   for bone pain or fracture prevention or treatment, spinal cord
CC   compression, bone surgery, bone metastasis or hypercalcemia of
CC   malignancy. The methods are useful for ameliorating symptoms of
CC   metastasis to bone in a cancer patient, inhibiting interactions of a
CC   cancer cell and a host cell, inhibiting anchorage-dependent cell growth,
CC   and inhibiting migration of cancer cell or inhibiting adhesion of cancer
CC   cell. The symptoms of metastasis to bone is chosen from pain and bone
CC   fractures. The present sequence is antisense oligonucleotide #7 specific
CC   for human EphA2.
XX
SQ   Sequence 24 BP; 4 A; 4 C; 9 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20.8;  DB 1;  Length 24;
  Best Local Similarity   91.7%;  Pred. No. 1.1e+02;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2609 ACATCCTAGTCAACAGCAACCTCG 2632
             ||||||| ||||||||||||||| |
Db         24 ACATCCTCGTCAACAGCAACCTGG 1


RESULT 161
ADR86761
ID   ADR86761 standard; DNA; 22 BP.
XX
AC   ADR86761;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 RT-PCR primer seqid 66.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; reverse transcriptase PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 6; Page 86; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a primer used in the isolation of human ephrin B4 cDNA.
XX
SQ   Sequence 22 BP; 5 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20.4;  DB 1;  Length 22;
  Best Local Similarity   95.5%;  Pred. No. 1e+02;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1587 TGAGGTCACTGCATTGAACGGG 1608
              | ||||||||||||||||||||
Db          1 TCAGGTCACTGCATTGAACGGG 22


RESULT 162
ADR82667
ID   ADR82667 standard; DNA; 22 BP.
XX
AC   ADR82667;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 RT-PCR primer #3.
XX
KW   human; ss; RT-PCR; primer; reverse transcriptase; EphB4; EphrinB2;
KW   cancer; angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
```

PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 6; Page 93; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC reverse transcriptase (RT)-PCR primer.
XX
SQ Sequence 22 BP; 5 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 1e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1587 TGAGGTCACTGCATTGAACGGG 1608
|||||||||||||||||||||
Db 1 TCAGGTCACTGCATTGAACGGG 22

RESULT 163
ADE79941/c
ID ADE79941 standard; cDNA; 24 BP.
XX
AC ADE79941;
XX
DT 29-JAN-2004 (first entry)
XX
DE Tyrosine kinase antisene oligonculeotide.
XX
KW ss; antisense; tyrosine kinase; epithelial type cell tumour.
XX
OS Synthetic.
XX
PN US2003124133-A1.
XX
PD 03-JUL-2003.
XX
PF 26-AUG-1998; 98US-00140378.
XX
PR 14-JUN-1993; 93US-00077254.
PR 16-AUG-1994; 94US-00292299.
XX
PA (JOHN/) JOHNSON J D.
PA (RUTT/) RUTTER W J.
PA (EDMA/) EDMAN J C.
XX
PI Johnson JD, Rutter WJ, Edman JC;
XX
DR WPI; 2004-009136/01.
XX
PT A new polypeptide has a discoidin-type ligand binding domain and a
PT tyrosine kinase domain and is useful to diagnose and treat a patient
PT having tumors of epithelial type cells which express the polypeptide on
PT their surface.
XX
PS Example 1; SEQ ID NO 3; 27pp; English.
XX
CC The invention relates to a composition comprising a polypeptide having a
CC first domain with carbohydrate binding activity and a second domain with
CC kinase activity, a first domain with discoidin-type ligand binding
CC characteristics and a second domain with tyrosine kinase activity. The
CC invention is useful to diagnose, prognose and treat a patient having
CC tumours of epithelial type cells which express the polypeptide on their
CC surface. The present sequence represents a tyrosine kinase antisene
CC oligonculeotide.
XX
SQ Sequence 24 BP; 1 A; 6 C; 7 G; 4 T; 0 U; 6 Other;

Query Match 0.5%; Score 20.4; DB 1; Length 24;
Best Local Similarity 75.0%; Pred. No. 1.2e+02;
Matches 18; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2587 CACCGAGACCTGGCTGCTCGCAAC 2610
||:|| ||:|||||:||:||:|||
Db 24 CAYCGSGAYCTGGCYGCYCGSAAC 1

RESULT 164
ADR86727/c
ID ADR86727 standard; DNA; 20 BP.
XX
AC ADR86727;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 32.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 3; Page 62; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated

```
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 165
ADR86801/c
ID   ADR86801 standard; DNA; 20 BP.
XX
AC   ADR86801;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 106.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 7 A; 10 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2799 TGTGATGTGGGAGGTGATGT 2818
              ||||||||||||||||||||
Db         20 TGTGATGTGGGAGGTGATGT 1


RESULT 166
ADR86860/c
ID   ADR86860 standard; DNA; 20 BP.
XX
AC   ADR86860;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 165.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
```

CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1618 TTAGCCACGGGGCCCGTCCC 1637
||||||||||||||||||||
Db 20 TTAGCCACGGGGCCCGTCCC 1

RESULT 167
ADR86901/c
ID ADR86901 standard; DNA; 20 BP.
XX
AC ADR86901;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 206.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 798 GGCCGCGGAGCATCTCACCC 817
||||||||||||||||||||
Db 20 GGCCGCGGAGCATCTCACCC 1

RESULT 168
ADR87091/c
ID ADR87091 standard; DNA; 20 BP.
XX
AC ADR87091;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 PCR primer seqid 396.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 4; Page 69; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a primer used in the isolation of human ephrin B4 cDNA used in
CC the creation of an expression vector for producing a soluble Eph B4
CC derivative.
XX
SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 696 CAAGGAGACCTTCACCGTCT 715
||||||||||||||||||||
Db 20 CAAGGAGACCTTCACCGTCT 1

RESULT 169
ADR86753/c
ID ADR86753 standard; DNA; 20 BP.
XX
AC ADR86753;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 58.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 79; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2356 TTTCTGAGCGAGGCCTCCAT 2375
||||||||||||||||||||
Db 20 TTTCTGAGCGAGGCCTCCAT 1

RESULT 170
ADR86782/c
ID ADR86782 standard; DNA; 20 BP.
XX
AC ADR86782;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 87.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 91; 198pp; English.
XX

```
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3179 CCTTCGAGCTGGTCAGCCAG 3198
              ||||||||||||||||||||
Db         20 CCTTCGAGCTGGTCAGCCAG 1


RESULT 171
ADR86823/c
ID   ADR86823 standard; DNA; 20 BP.
XX
AC   ADR86823;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 128.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2358 TCTGAGCGAGGCCTCCATCA 2377
              ||||||||||||||||||||
Db         20 TCTGAGCGAGGCCTCCATCA 1


RESULT 172
ADR86871/c
ID   ADR86871 standard; DNA; 20 BP.
XX
AC   ADR86871;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 176.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
```

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1398 GGAATGGAGTGCCCCCCTGG 1417
||||||||||||||||||||
Db 20 GGAATGGAGTGCCCCCCTGG 1

RESULT 173
ADR86877/c
ID ADR86877 standard; DNA; 20 BP.
XX
AC ADR86877;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 182.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1278 CTGCCAGTGCCGCGTCGGGT 1297
||||||||||||||||||||
Db 20 CTGCCAGTGCCGCGTCGGGT 1

RESULT 174
ADR86894/c
ID ADR86894 standard; DNA; 20 BP.
XX
AC ADR86894;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 199.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.

XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 7 A; 1 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 938 TATCCCTGCACCTCTTCTAC 957
||||||||||||||||||||
Db 20 TATCCCTGCACCTCTTCTAC 1

RESULT 175
ADR86902/c
ID ADR86902 standard; DNA; 20 BP.
XX
AC ADR86902;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 207.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 778 TACATCAAGGTGGACACGGT 797
||||||||||||||||||||
Db 20 TACATCAAGGTGGACACGGT 1

RESULT 176
ADR86910/c
ID ADR86910 standard; DNA; 20 BP.
XX
AC ADR86910;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 215.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX

PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 618 GGGCGCCGTCCACGTGTACG 637
||||||||||||||||||||
Db 20 GGGCGCCGTCCACGTGTACG 1

RESULT 177
ADR86915/c
ID ADR86915 standard; DNA; 20 BP.
XX
AC ADR86915;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 220.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 518 TGGATGAGGAACAGCACAGC 537
||||||||||||||||||||
Db 20 TGGATGAGGAACAGCACAGC 1

RESULT 178
ADR86921/c
ID ADR86921 standard; DNA; 20 BP.
XX
AC ADR86921;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 226.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX

OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 398 GCTGGGCTTCGTTGGCCGCA 417
||||||||||||||||||||
Db 20 GCTGGGCTTCGTTGGCCGCA 1

RESULT 179
ADR86790/c
ID ADR86790 standard; DNA; 20 BP.
XX
AC ADR86790;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 95.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3019 GCCAGCCTCAAAATCGTGGC 3038
||||||||||||||||||||
Db 20 GCCAGCCTCAAAATCGTGGC 1

RESULT 180
ADR86805/c
ID ADR86805 standard; DNA; 20 BP.
XX
AC ADR86805;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 110.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

```
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2719 ATTCCCATCCGATGGACTGC 2738
              ||||||||||||||||||||
Db         20 ATTCCCATCCGATGGACTGC 1


RESULT 181
ADR86809/c
ID   ADR86809 standard; DNA; 20 BP.
XX
AC   ADR86809;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 114.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2639 AAGTGTCTGACTTTGGCCTT 2658
              ||||||||||||||||||||
Db         20 AAGTGTCTGACTTTGGCCTT 1


RESULT 182
ADR86821/c
ID   ADR86821 standard; DNA; 20 BP.
XX
AC   ADR86821;
XX
```

DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 126.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2398 AATATCATCCGCCTGGAGGG 2417
              ||||||||||||||||||||
Db         20 AATATCATCCGCCTGGAGGG 1
```

RESULT 183
ADR86824/c
ID ADR86824 standard; DNA; 20 BP.
XX
AC ADR86824;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 129.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 GAGCGGCAGCGGCGTGAGTT 2357
              ||||||||||||||||||||
Db         20 GAGCGGCAGCGGCGTGAGTT 1
```

```
RESULT 184
ADR86840/c
ID   ADR86840 standard; DNA; 20 BP.
XX
AC   ADR86840;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 145.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 7 A; 9 C; 4 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2018 GTGTGGTCCTGGTCCTGGTG 2037
             ||||||||||||||||||||
Db         20 GTGTGGTCCTGGTCCTGGTG 1


RESULT 185
ADR86841/c
ID   ADR86841 standard; DNA; 20 BP.
XX
AC   ADR86841;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 146.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 10 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1998 TGCGGGCACGGCAGTCGTGG 2017
              ||||||||||||||||||||
Db         20 TGCGGGCACGGCAGTCGTGG 1
```

RESULT 186
ADR86777/c
ID ADR86777 standard; DNA; 20 BP.
XX
AC ADR86777;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 82.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 91; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 1 A; 7 C; 7 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3279 GAAGTCCCAGGCCAAGCCGG 3298
              ||||||||||||||||||||
Db         20 GAAGTCCCAGGCCAAGCCGG 1
```

RESULT 187
ADR86787/c
ID ADR86787 standard; DNA; 20 BP.
XX
AC ADR86787;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 92.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

```
XX
SQ   Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3079 CGGCAGCCTCACTACTCAGC 3098
              ||||||||||||||||||||
Db         20 CGGCAGCCTCACTACTCAGC 1


RESULT 188
ADR86808/c
ID   ADR86808 standard; DNA; 20 BP.
XX
AC   ADR86808;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 113.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2659 TCCCGATTCCTGGAGGAGAA 2678
              ||||||||||||||||||||
Db         20 TCCCGATTCCTGGAGGAGAA 1


RESULT 189
ADR86813/c
ID   ADR86813 standard; DNA; 20 BP.
XX
AC   ADR86813;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 118.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
```

CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2558 TGCGGTACCTTGCCGAGATG 2577
||||||||||||||||||||
Db 20 TGCGGTACCTTGCCGAGATG 1

RESULT 190
ADR86814/c
ID ADR86814 standard; DNA; 20 BP.
XX
AC ADR86814;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 119.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 9 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2538 GCGGGGCATCGCCTCGGGCA 2557
||||||||||||||||||||
Db 20 GCGGGGCATCGCCTCGGGCA 1

RESULT 191
ADR86815/c
ID ADR86815 standard; DNA; 20 BP.
XX
AC ADR86815;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 120.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2518 ATCCAGCTCGTGGGCATGCT 2537
||||||||||||||||||||
Db 20 ATCCAGCTCGTGGGCATGCT 1

RESULT 192
ADR86819/c
ID ADR86819 standard; DNA; 20 BP.
XX
AC ADR86819;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 124.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2438 CCGTCATGATTCTCACAGAG 2457
||||||||||||||||||||
Db 20 CCGTCATGATTCTCACAGAG 1

RESULT 193
ADR86822/c
ID ADR86822 standard; DNA; 20 BP.
XX
AC ADR86822;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 127.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2378 TGGGCCAGTTCGAGCACCCC 2397
||||||||||||||||||||
Db 20 TGGGCCAGTTCGAGCACCCC 1

RESULT 194
ADR86838/c
ID ADR86838 standard; DNA; 20 BP.
XX
AC ADR86838;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 143.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2058 CTGCCTCAGGAAGCAGAGCA 2077
||||||||||||||||||||
Db 20 CTGCCTCAGGAAGCAGAGCA 1

RESULT 195
ADR86873/c
ID ADR86873 standard; DNA; 20 BP.
XX
AC ADR86873;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 178.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX

PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1358 GGAGCGTGGTTTCCCGCCTG 1377
||||||||||||||||||||
Db 20 GGAGCGTGGTTTCCCGCCTG 1

RESULT 196
ADR86899/c
ID ADR86899 standard; DNA; 20 BP.
XX
AC ADR86899;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 204.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 838 GCCACCGGGAAGGTGAATGT 857
||||||||||||||||||||
Db 20 GCCACCGGGAAGGTGAATGT 1

RESULT 197
ADR86923/c
ID ADR86923 standard; DNA; 20 BP.
XX
AC ADR86923;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 228.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.

```
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        376 ATGGAGCTCCGGGTGCTGCT 395
              ||||||||||||||||||||
Db         20 ATGGAGCTCCGGGTGCTGCT 1


RESULT 198
ADR86758/c
ID   ADR86758 standard; DNA; 20 BP.
XX
AC   ADR86758;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 probe seqid 63.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 6; Page 86; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 probe that can be used to detect EphB4
CC   expression.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        696 CAAGGAGACCTTCACCGTCT 715
              ||||||||||||||||||||
Db         20 CAAGGAGACCTTCACCGTCT 1


RESULT 199
ADR86778/c
ID   ADR86778 standard; DNA; 20 BP.
XX
AC   ADR86778;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 83.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
```

PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 91; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3259 TTGGCCAGTGTCCAGCACAT 3278
||||||||||||||||||||
Db 20 TTGGCCAGTGTCCAGCACAT 1

RESULT 200
ADR86796/c
ID ADR86796 standard; DNA; 20 BP.
XX
AC ADR86796;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 101.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 2 C; 12 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2899 CCCCCAGACTGTCCCACCTC 2918
||||||||||||||||||||
Db 20 CCCCCAGACTGTCCCACCTC 1

RESULT 201
ADR86803/c
ID ADR86803 standard; DNA; 20 BP.
XX
AC ADR86803;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 108.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.

XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2759 GGAAGTTCACTTCCGCCAGT 2778
||||||||||||||||||||
Db 20 GGAAGTTCACTTCCGCCAGT 1

RESULT 202
ADR86832/c
ID ADR86832 standard; DNA; 20 BP.
XX
AC ADR86832;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 137.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX

PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 8 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2178 GGCTGTGAGGGAATTTGCAA 2197
||||||||||||||||||||
Db 20 GGCTGTGAGGGAATTTGCAA 1

RESULT 203
ADR86848/c
ID ADR86848 standard; DNA; 20 BP.
XX
AC ADR86848;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 153.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.

```
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 1 A; 12 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1858 CGGGGGCTGAAGCGGGGAGC 1877
             ||||||||||||||||||||
Db         20 CGGGGGCTGAAGCGGGGAGC 1


RESULT 204
ADR86850/c
ID   ADR86850 standard; DNA; 20 BP.
XX
AC   ADR86850;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 155.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1818 CGTGCGGTTCCTGAAGACGT 1837
             ||||||||||||||||||||
Db         20 CGTGCGGTTCCTGAAGACGT 1


RESULT 205
ADR86856/c
ID   ADR86856 standard; DNA; 20 BP.
XX
AC   ADR86856;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 161.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
```

```
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1698 GGTGACGCGGTCCTCACCCA 1717
              ||||||||||||||||||||
Db         20 GGTGACGCGGTCCTCACCCA 1


RESULT 206
ADR86862/c
ID   ADR86862 standard; DNA; 20 BP.
XX
AC   ADR86862;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 167.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1578 CTATACCTTTGAGGTCACTG 1597
              ||||||||||||||||||||
Db         20 CTATACCTTTGAGGTCACTG 1


RESULT 207
ADR86884/c
ID   ADR86884 standard; DNA; 20 BP.
XX
AC   ADR86884;
```

```
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 189.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1138 TGTGCTCCGGGGTTCGAGGC 1157
              ||||||||||||||||||||
Db         20 TGTGCTCCGGGGTTCGAGGC 1


RESULT 208
ADR86895/c
ID   ADR86895 standard; DNA; 20 BP.
XX
AC   ADR86895;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 200.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        918 GGGTGCCTGCATGGCCCTGC 937
              ||||||||||||||||||||
Db         20 GGGTGCCTGCATGGCCCTGC 1
```

```
RESULT 209
ADR86905/c
ID   ADR86905 standard; DNA; 20 BP.
XX
AC   ADR86905;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 210.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        718 TACTATGAGAGCGATGCGGA 737
              ||||||||||||||||||||
Db         20 TACTATGAGAGCGATGCGGA 1


RESULT 210
ADR86906/c
ID   ADR86906 standard; DNA; 20 BP.
XX
AC   ADR86906;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 211.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
```

```
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        698 AGGAGACCTTCACCGTCTTC 717
              ||||||||||||||||||||
Db         20 AGGAGACCTTCACCGTCTTC 1


RESULT 211
ADR86908/c
ID   ADR86908 standard; DNA; 20 BP.
XX
AC   ADR86908;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 213.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        658 CTCGAGTGCCTGTCCCTGCC 677
              ||||||||||||||||||||
Db         20 CTCGAGTGCCTGTCCCTGCC 1


RESULT 212
ADR86918/c
ID   ADR86918 standard; DNA; 20 BP.
XX
AC   ADR86918;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 223.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
```

```
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        458 CTGATCTGAAGTGGGTGACA 477
              ||||||||||||||||||||
Db         20 CTGATCTGAAGTGGGTGACA 1


RESULT 213
ADR86725
ID   ADR86725 standard; DNA; 20 BP.
XX
AC   ADR86725;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 30.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 3; Page 62; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        691 TCCTGCAAGGAGACCTTCAC 710
              ||||||||||||||||||||
Db          1 TCCTGCAAGGAGACCTTCAC 20


RESULT 214
ADR86785/c
ID   ADR86785 standard; DNA; 20 BP.
XX
AC   ADR86785;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 90.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
```

```
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3119 GGCTTCGGGCCATCAAAATG 3138
              ||||||||||||||||||||
Db         20 GGCTTCGGGCCATCAAAATG 1


RESULT 215
ADR86835/c
ID   ADR86835 standard; DNA; 20 BP.
XX
AC   ADR86835;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 140.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2118 TCTCATCGGACATGGTACTA 2137
              ||||||||||||||||||||
Db         20 TCTCATCGGACATGGTACTA 1


RESULT 216
ADR86851/c
ID   ADR86851 standard; DNA; 20 BP.
XX
AC   ADR86851;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 156.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
```

```
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 1 A; 9 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1798 GGCGCCGAGGGTCCCAGCAG 1817
              ||||||||||||||||||||
Db         20 GGCGCCGAGGGTCCCAGCAG 1


RESULT 217
ADR86864/c
ID   ADR86864 standard; DNA; 20 BP.
XX
AC   ADR86864;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 169.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1538 AGCCCTGGGTGGTGGTTCGA 1557
              ||||||||||||||||||||
Db         20 AGCCCTGGGTGGTGGTTCGA 1


RESULT 218
ADR86875/c
ID   ADR86875 standard; DNA; 20 BP.
XX
AC   ADR86875;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 180.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
```

```
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1318 CCCCGGGGTGCACCCTGCAC 1337
              ||||||||||||||||||||
Db         20 CCCCGGGGTGCACCCTGCAC 1


RESULT 219
ADR86879/c
ID   ADR86879 standard; DNA; 20 BP.
XX
AC   ADR86879;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 184.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 3 C; 9 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1238 GCCCAGCCAATAGCCACTCT 1257
              ||||||||||||||||||||
Db         20 GCCCAGCCAATAGCCACTCT 1


RESULT 220
ADR86880/c
ID   ADR86880 standard; DNA; 20 BP.
XX
AC   ADR86880;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 185.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
```

```
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1218 AGAAGGGTCCTGCCAGCCAT 1237
              ||||||||||||||||||||
Db         20 AGAAGGGTCCTGCCAGCCAT 1


RESULT 221
ADR86900/c
ID   ADR86900 standard; DNA; 20 BP.
XX
AC   ADR86900;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 205.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 1 A; 10 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        818 GGAAGCGCCCTGGGGCCGAG 837
              ||||||||||||||||||||
Db         20 GGAAGCGCCCTGGGGCCGAG 1


RESULT 222
ADR86907/c
ID   ADR86907 standard; DNA; 20 BP.
XX
AC   ADR86907;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 212.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
```

DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 678 TCGGGCTGGGCGCTCCTGCA 697
||||||||||||||||||||
Db 20 TCGGGCTGGGCGCTCCTGCA 1

RESULT 223
ADR86731
ID ADR86731 standard; DNA; 20 BP.
XX
AC ADR86731;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 RT-PCR primer seqid 36.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; reverse transcriptase PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 3; Page 63; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a primer used in the isolation of human ephrin B4 cDNA.
XX
SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 697 AAGGAGACCTTCACCGTCTT 716
||||||||||||||||||||
Db 1 AAGGAGACCTTCACCGTCTT 20

RESULT 224
ADR86779/c
ID ADR86779 standard; DNA; 20 BP.
XX
AC ADR86779;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 84.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX

PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 91; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 1 A; 5 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3239 CGGGACACCAGAAGAAAATC 3258
||||||||||||||||||||
Db 20 CGGGACACCAGAAGAAAATC 1

RESULT 225
ADR86784/c
ID ADR86784 standard; DNA; 20 BP.
XX
AC ADR86784;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 89.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 6 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3139 GGAAGATACGAAGAAAGTTT 3158
||||||||||||||||||||
Db 20 GGAAGATACGAAGAAAGTTT 1

RESULT 226
ADR86792/c
ID ADR86792 standard; DNA; 20 BP.
XX
AC ADR86792;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 97.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.

XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2979 CCAGGTGGTCAGCGCCCTGG 2998
||||||||||||||||||||
Db 20 CCAGGTGGTCAGCGCCCTGG 1

RESULT 227
ADR86804/c
ID ADR86804 standard; DNA; 20 BP.
XX
AC ADR86804;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 109.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 5 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2739 CCCGGAGGCCATTGCCTTCC 2758
||||||||||||||||||||
Db 20 CCCGGAGGCCATTGCCTTCC 1

RESULT 228
ADR86807/c
ID ADR86807 standard; DNA; 20 BP.
XX
AC ADR86807;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 112.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.

XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 1 C; 10 G; 4 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTACA 2698
              ||||||||||||||||||||
Db         20 CTCTTCCGATCCCACCTACA 1
```

RESULT 229
ADR86867/c
ID ADR86867 standard; DNA; 20 BP.
XX
AC ADR86867;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 172.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 8 C; 8 G; 0 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1478 GCTCCTGTGCGCCCTGCGGG 1497
              ||||||||||||||||||||
Db         20 GCTCCTGTGCGCCCTGCGGG 1
```

RESULT 230
ADR86874/c
ID ADR86874 standard; DNA; 20 BP.
XX
AC ADR86874;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 179.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

```
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 3 C; 12 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1338 CACCCCTCCTTCGGCTCCGC 1357
             ||||||||||||||||||||
Db         20 CACCCCTCCTTCGGCTCCGC 1


RESULT 231
ADR86881/c
ID   ADR86881 standard; DNA; 20 BP.
XX
AC   ADR86881;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 186.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1198 ACCTTCAAGCCCCTGTCAGG 1217
             ||||||||||||||||||||
Db         20 ACCTTCAAGCCCCTGTCAGG 1


RESULT 232
ADR86892/c
ID   ADR86892 standard; DNA; 20 BP.
XX
AC   ADR86892;
```

```
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 197.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        978 TGTGAACCTGACTCGATTCC 997
              ||||||||||||||||||||
Db         20 TGTGAACCTGACTCGATTCC 1


RESULT 233
ADR86893/c
ID   ADR86893 standard; DNA; 20 BP.
XX
AC   ADR86893;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 198.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        958 AAAAAGTGCGCCCAGCTGAC 977
              ||||||||||||||||||||
Db         20 AAAAAGTGCGCCCAGCTGAC 1
```

```
RESULT 234
ADR86917/c
ID   ADR86917 standard; DNA; 20 BP.
XX
AC   ADR86917;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 222.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        478 TTCCCTCAGGTGGACGGGCA 497
              ||||||||||||||||||||
Db         20 TTCCCTCAGGTGGACGGGCA 1


RESULT 235
ADR86794/c
ID   ADR86794 standard; DNA; 20 BP.
XX
AC   ADR86794;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 99.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
```

```
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2939 ACTGTTGGCAGAAAGACCGG 2958
              ||||||||||||||||||||
Db         20 ACTGTTGGCAGAAAGACCGG 1


RESULT 236
ADR86827/c
ID   ADR86827 standard; DNA; 20 BP.
XX
AC   ADR86827;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 132.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 0 A; 8 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2278 AAGGCCCCAGGGAAGAAGGA 2297
              ||||||||||||||||||||
Db         20 AAGGCCCCAGGGAAGAAGGA 1


RESULT 237
ADR86839/c
ID   ADR86839 standard; DNA; 20 BP.
XX
AC   ADR86839;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 144.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
```

```
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2038 GTCATTGTGGTCGCAGTTCT 2057
              ||||||||||||||||||||
Db         20 GTCATTGTGGTCGCAGTTCT 1


RESULT 238
ADR86847/c
ID   ADR86847 standard; DNA; 20 BP.
XX
AC   ADR86847;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 152.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1878 CAGCTACCTGGTGCAGGTAC 1897
              ||||||||||||||||||||
Db         20 CAGCTACCTGGTGCAGGTAC 1


RESULT 239
ADR86854/c
ID   ADR86854 standard; DNA; 20 BP.
XX
AC   ADR86854;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 159.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
```

```
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 GCTGTTCCCCGGGCACCCAG 1757
              ||||||||||||||||||||
Db         20 GCTGTTCCCCGGGCACCCAG 1

RESULT 240
ADR86855/c
ID   ADR86855 standard; DNA; 20 BP.
XX
AC   ADR86855;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 160.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1718 GCAGCTTGAGCCTGGCCTGG 1737
              ||||||||||||||||||||
Db         20 GCAGCTTGAGCCTGGCCTGG 1

RESULT 241
ADR86888/c
ID   ADR86888 standard; DNA; 20 BP.
XX
AC   ADR86888;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 193.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
```

```
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 2 A; 4 C; 13 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1058 TCCCCGCCCCTGGCCCCAGC 1077
              ||||||||||||||||||||
Db         20 TCCCCGCCCCTGGCCCCAGC 1


RESULT 242
ADR86757
ID   ADR86757 standard; DNA; 20 BP.
XX
AC   ADR86757;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 probe seqid 62.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 6; Page 86; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 probe that can be used to detect EphB4
CC   expression.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        419 CTTTGGAAGAGACCCTGCTG 438
              ||||||||||||||||||||
Db          1 CTTTGGAAGAGACCCTGCTG 20


RESULT 243
ADR86793/c
ID   ADR86793 standard; DNA; 20 BP.
XX
AC   ADR86793;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 98.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
```

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 4 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2959 AATGCCCGGCCCCGCTTCCC 2978
||||||||||||||||||||
Db 20 AATGCCCGGCCCCGCTTCCC 1

RESULT 244
ADR86802/c
ID ADR86802 standard; DNA; 20 BP.
XX
AC ADR86802;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 107.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2779 GATGCCTGGAGTTACGGGAT 2798
||||||||||||||||||||
Db 20 GATGCCTGGAGTTACGGGAT 1

RESULT 245
ADR86806/c
ID ADR86806 standard; DNA; 20 BP.
XX
AC ADR86806;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 111.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX

PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2699 CGAGCTCCCTGGGAGGAAAG 2718
||||||||||||||||||||
Db 20 CGAGCTCCCTGGGAGGAAAG 1

RESULT 246
ADR86830/c
ID ADR86830 standard; DNA; 20 BP.
XX
AC ADR86830;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 135.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 7 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2218 GTCAAGATTGAAGAGGTGAT 2237
||||||||||||||||||||
Db 20 GTCAAGATTGAAGAGGTGAT 1

RESULT 247
ADR86831/c
ID ADR86831 standard; DNA; 20 BP.
XX
AC ADR86831;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 136.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.

XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2198 AAGAGATCGATGTCTCCTAC 2217
||||||||||||||||||||
Db 20 AAGAGATCGATGTCTCCTAC 1

RESULT 248
ADR86878/c
ID ADR86878 standard; DNA; 20 BP.
XX
AC ADR86878;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 183.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1258 AACACCATTGGATCAGCCGT 1277
||||||||||||||||||||
Db 20 AACACCATTGGATCAGCCGT 1

RESULT 249
ADR86909/c
ID ADR86909 standard; DNA; 20 BP.
XX
AC ADR86909;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 214.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.

XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 638 CCACGCTGCGCTTCACCATG 657
||||||||||||||||||||
Db 20 CCACGCTGCGCTTCACCATG 1

RESULT 250
ADR86795/c
ID ADR86795 standard; DNA; 20 BP.
XX
AC ADR86795;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 100.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2919 CCTCCACCAGCTCATGCTGG 2938
||||||||||||||||||||
Db 20 CCTCCACCAGCTCATGCTGG 1

RESULT 251
ADR86818/c
ID ADR86818 standard; DNA; 20 BP.
XX
AC ADR86818;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 123.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX

PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2458 TTCATGGAGAACGGCGCCCT 2477
||||||||||||||||||||
Db 20 TTCATGGAGAACGGCGCCCT 1

RESULT 252
ADR86842/c
ID ADR86842 standard; DNA; 20 BP.
XX
AC ADR86842;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 147.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.

XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1978 CGGGAGCAGCTGGCCCTGAT 1997
||||||||||||||||||||
Db 20 CGGGAGCAGCTGGCCCTGAT 1

RESULT 253
ADR86859/c
ID ADR86859 standard; DNA; 20 BP.
XX
AC ADR86859;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 164.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;

KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1638 ATTTGAGCCTGTCAATGTCA 1657
              ||||||||||||||||||||
Db         20 ATTTGAGCCTGTCAATGTCA 1
```

RESULT 254
ADR86872/c
ID ADR86872 standard; DNA; 20 BP.
XX
AC ADR86872;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 177.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 3 C; 10 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1378 AACGGCTCCTCCCTGCACCT 1397
              ||||||||||||||||||||
Db         20 AACGGCTCCTCCCTGCACCT 1
```

RESULT 255
ADR86885/c
ID ADR86885 standard; DNA; 20 BP.
XX
AC ADR86885;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 190.
XX

```
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1118 AGCCGGTCACGGGCTGCAGC 1137
              ||||||||||||||||||||
Db         20 AGCCGGTCACGGGCTGCAGC 1


RESULT 256
ADR86886/c
ID   ADR86886 standard; DNA; 20 BP.
XX
AC   ADR86886;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 191.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1098 GGATGGCCAGTGGGCCGAAC 1117
              ||||||||||||||||||||
Db         20 GGATGGCCAGTGGGCCGAAC 1


RESULT 257
ADR86898/c
ID   ADR86898 standard; DNA; 20 BP.
XX
```

```
AC   ADR86898;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 203.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        858 CAAGACGCTGCGTCTGGGAC 877
              ||||||||||||||||||||
Db         20 CAAGACGCTGCGTCTGGGAC 1

RESULT 258
ADR86903/c
ID   ADR86903 standard; DNA; 20 BP.
XX
AC   ADR86903;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 208.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        758 CAGCCTGGATGGAGAACCCC 777
              ||||||||||||||||||||
Db         20 CAGCCTGGATGGAGAACCCC 1
```

```
RESULT 259
ADR86911/c
ID   ADR86911 standard; DNA; 20 BP.
XX
AC   ADR86911;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 216.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        598 ACAGGTTGGGTCCCACGGCG 617
              ||||||||||||||||||||
Db         20 ACAGGTTGGGTCCCACGGCG 1


RESULT 260
ADR86933/c
ID   ADR86933 standard; DNA; 20 BP.
XX
AC   ADR86933;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 238.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
```

```
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 261
ADR86800/c
ID   ADR86800 standard; DNA; 20 BP.
XX
AC   ADR86800;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 105.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2819 CATTTGGGGAGAGGCCGTAC 2838
              ||||||||||||||||||||
Db         20 CATTTGGGGAGAGGCCGTAC 1


RESULT 262
ADR86811/c
ID   ADR86811 standard; DNA; 20 BP.
XX
AC   ADR86811;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 116.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
```

```
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2598 GGCTGCTCGCAACATCCTAG 2617
              ||||||||||||||||||||
Db         20 GGCTGCTCGCAACATCCTAG 1


RESULT 263
ADR86846/c
ID   ADR86846 standard; DNA; 20 BP.
XX
AC   ADR86846;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 151.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 2 A; 10 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1898 GGGCGCGCTCTGAGGCCGGC 1917
              ||||||||||||||||||||
Db         20 GGGCGCGCTCTGAGGCCGGC 1


RESULT 264
ADR86882/c
ID   ADR86882 standard; DNA; 20 BP.
XX
AC   ADR86882;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 187.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
```

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 8 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1178 GCCGAGCCTGTGCCCAGGGC 1197
||||||||||||||||||||
Db 20 GCCGAGCCTGTGCCCAGGGC 1

RESULT 265
ADR86890/c
ID ADR86890 standard; DNA; 20 BP.
XX
AC ADR86890;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 195.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 9 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1018 CTGGTTGTGCCCGTGGCCGG 1037
||||||||||||||||||||
Db 20 CTGGTTGTGCCCGTGGCCGG 1

RESULT 266
ADR86913/c
ID ADR86913 standard; DNA; 20 BP.
XX
AC ADR86913;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 218.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 558 TGACGTGCAGCGTGCCCCGG 577
||||||||||||||||||||
Db 20 TGACGTGCAGCGTGCCCCGG 1

RESULT 267
ADR86914/c
ID ADR86914 standard; DNA; 20 BP.
XX
AC ADR86914;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 219.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 538 GTGCGCACCTACGAAGTGTG 557
||||||||||||||||||||
Db 20 GTGCGCACCTACGAAGTGTG 1

RESULT 268
ADR86922/c
ID ADR86922 standard; DNA; 20 BP.
XX
AC ADR86922;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 227.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 378 GGAGCTCCGGGTGCTGCTCT 397
||||||||||||||||||||
Db 20 GGAGCTCCGGGTGCTGCTCT 1

RESULT 269
ADR86733/c
ID ADR86733 standard; DNA; 20 BP.
XX
AC ADR86733;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 RT-PCR primer seqid 38.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; reverse transcriptase PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 3; Page 63; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a primer used in the isolation of human ephrin B4 cDNA.
XX
SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 974 TGACTGTGAACCTGACTCGA 993
||||||||||||||||||||
Db 20 TGACTGTGAACCTGACTCGA 1

RESULT 270
ADR86780/c
ID ADR86780 standard; DNA; 20 BP.
XX
AC ADR86780;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 85.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX

PS Example 8; Page 91; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3219 CCGAATCGGAGTCACTCTGG 3238
||||||||||||||||||||
Db 20 CCGAATCGGAGTCACTCTGG 1

RESULT 271
ADR86781/c
ID ADR86781 standard; DNA; 20 BP.
XX
AC ADR86781;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 86.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 91; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3199 ATCTCTGCTGAGGACCTGCT 3218
||||||||||||||||||||
Db 20 ATCTCTGCTGAGGACCTGCT 1

RESULT 272
ADR86798/c
ID ADR86798 standard; DNA; 20 BP.
XX
AC ADR86798;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 103.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.

XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2859 CGTGATCAATGCCATTGAAC 2878
||||||||||||||||||||
Db 20 CGTGATCAATGCCATTGAAC 1

RESULT 273
ADR86812/c
ID ADR86812 standard; DNA; 20 BP.
XX
AC ADR86812;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 117.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2578 AGCTACGTCCACCGAGACCT 2597
||||||||||||||||||||
Db 20 AGCTACGTCCACCGAGACCT 1

RESULT 274
ADR86845/c
ID ADR86845 standard; DNA; 20 BP.
XX
AC ADR86845;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 150.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.

XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1918 TACGGGCCCTTCGGCCAGGA 1937
||||||||||||||||||||
Db 20 TACGGGCCCTTCGGCCAGGA 1

RESULT 275
ADR86865/c
ID ADR86865 standard; DNA; 20 BP.
XX
AC ADR86865;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 170.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 9 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1518 CGGCCCCCGGGACCTGGTGG 1537
||||||||||||||||||||
Db 20 CGGCCCCCGGGACCTGGTGG 1

RESULT 276
ADR86876/c
ID ADR86876 standard; DNA; 20 BP.
XX
AC ADR86876;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 181.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX

PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1298 ACTTCCGGGCACGCACAGAC 1317
||||||||||||||||||||
Db 20 ACTTCCGGGCACGCACAGAC 1

RESULT 277
ADR86889/c
ID ADR86889 standard; DNA; 20 BP.
XX
AC ADR86889;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 194.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.

XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TAGCTGCGTGGTGGATGCCG 1057
||||||||||||||||||||
Db 20 TAGCTGCGTGGTGGATGCCG 1

RESULT 278
ADR86891/c
ID ADR86891 standard; DNA; 20 BP.
XX
AC ADR86891;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 196.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;

KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 998 CGGAGACTGTGCCTCGGGAG 1017
||||||||||||||||||||
Db 20 CGGAGACTGTGCCTCGGGAG 1

RESULT 279
ADR86904/c
ID ADR86904 standard; DNA; 20 BP.
XX
AC ADR86904;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 209.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 1 A; 5 C; 11 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 738 CACGGCCACGGCCCTCACGC 757
||||||||||||||||||||
Db 20 CACGGCCACGGCCCTCACGC 1

RESULT 280
ADR86919/c
ID ADR86919 standard; DNA; 20 BP.
XX
AC ADR86919;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 224.
XX

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 4 C; 3 G; 10 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        438 GAACACAAAATTGGAAACTG 457
              ||||||||||||||||||||
Db         20 GAACACAAAATTGGAAACTG 1
```

RESULT 281
ADR86920/c
ID ADR86920 standard; DNA; 20 BP.
XX
AC ADR86920;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 225.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        418 GCTTTGGAAGAGACCCTGCT 437
              ||||||||||||||||||||
Db         20 GCTTTGGAAGAGACCCTGCT 1
```

RESULT 282
ADR86776/c
ID ADR86776 standard; DNA; 20 BP.
XX

```
AC   ADR86776;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 81.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 91; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3299 GAACCCCGGGTGGGACAGGA 3318
              ||||||||||||||||||||
Db         20 GAACCCCGGGTGGGACAGGA 1

RESULT 283
```

```
ADR86797/c
ID   ADR86797 standard; DNA; 20 BP.
XX
AC   ADR86797;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 102.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2879 AGGACTACCGGCTGCCCCCG 2898
              ||||||||||||||||||||
Db         20 AGGACTACCGGCTGCCCCCG 1
```

```
RESULT 284
ADR86820/c
ID   ADR86820 standard; DNA; 20 BP.
XX
AC   ADR86820;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 125.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2418 CGTGGTCACCAACAGCATGC 2437
              ||||||||||||||||||||
Db         20 CGTGGTCACCAACAGCATGC 1


RESULT 285
ADR86825/c
ID   ADR86825 standard; DNA; 20 BP.
XX
AC   ADR86825;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 130.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
```

```
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2318 CCCTGAAGGGTGGCTACACG 2337
              ||||||||||||||||||||
Db         20 CCCTGAAGGGTGGCTACACG 1


RESULT 286
ADR86852/c
ID   ADR86852 standard; DNA; 20 BP.
XX
AC   ADR86852;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 157.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1778 AGGTCAAATACCATGAGAAG 1797
              ||||||||||||||||||||
Db         20 AGGTCAAATACCATGAGAAG 1


RESULT 287
ADR86866/c
ID   ADR86866 standard; DNA; 20 BP.
XX
AC   ADR86866;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 171.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
```

```
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1498 GGAGACCTGACTTTTGACCC 1517
              ||||||||||||||||||||
Db         20 GGAGACCTGACTTTTGACCC 1


RESULT 288
ADR86869/c
ID   ADR86869 standard; DNA; 20 BP.
XX
AC   ADR86869;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 174.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1438 CTCACCTACGCCCTCCGCTG 1457
              ||||||||||||||||||||
Db         20 CTCACCTACGCCCTCCGCTG 1


RESULT 289
ADR86870/c
ID   ADR86870 standard; DNA; 20 BP.
XX
AC   ADR86870;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 175.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
```

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1418 AGTCTGGTGGCCGAGAGGAC 1437
||||||||||||||||||||
Db 20 AGTCTGGTGGCCGAGAGGAC 1

RESULT 290
ADR86883/c
ID ADR86883 standard; DNA; 20 BP.
XX
AC ADR86883;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 188.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1158 AGCTGAGGGGAACACCAAGT 1177
||||||||||||||||||||
Db 20 AGCTGAGGGGAACACCAAGT 1

RESULT 291
ADR86887/c
ID ADR86887 standard; DNA; 20 BP.
XX
AC ADR86887;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 192.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

```
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1078 CCCAGCCTCTACTGCCGTGA 1097
              ||||||||||||||||||||
Db         20 CCCAGCCTCTACTGCCGTGA 1


RESULT 292
ADR86896/c
ID   ADR86896 standard; DNA; 20 BP.
XX
AC   ADR86896;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 201.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        898 TACCTGGCCTTCCAGGACCA 917
              ||||||||||||||||||||
Db         20 TACCTGGCCTTCCAGGACCA 1


RESULT 293
ADR86897/c
ID   ADR86897 standard; DNA; 20 BP.
XX
AC   ADR86897;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 202.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
```

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 878 CGCTCAGCAAGGCTGGCTTC 897
||||||||||||||||||||
Db 20 CGCTCAGCAAGGCTGGCTTC 1

RESULT 294
ADR87090
ID ADR87090 standard; DNA; 20 BP.
XX
AC ADR87090;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 PCR primer seqid 395.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 4; Page 69; 198pp; English.
XX

CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a primer used in the isolation of human ephrin B4 cDNA used in
CC the creation of an expression vector for producing a soluble Eph B4
CC derivative.
XX
SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 419 CTTTGGAAGAGACCCTGCTG 438
||||||||||||||||||||
Db 1 CTTTGGAAGAGACCCTGCTG 20

RESULT 295
ADR86788/c
ID ADR86788 standard; DNA; 20 BP.
XX
AC ADR86788;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 93.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or

```
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3059 CACACCCTCTCCTGGACCAG 3078
              ||||||||||||||||||||
Db         20 CACACCCTCTCCTGGACCAG 1


RESULT 296
ADR86789/c
ID   ADR86789 standard; DNA; 20 BP.
XX
AC   ADR86789;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 94.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 2 A; 10 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3039 CCGGGAGAATGGCGGGGCCT 3058
              ||||||||||||||||||||
Db         20 CCGGGAGAATGGCGGGGCCT 1


RESULT 297
ADR86791/c
ID   ADR86791 standard; DNA; 20 BP.
XX
AC   ADR86791;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 96.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
```

```
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2999 ACAAGATGATCCGGAACCCC 3018
              ||||||||||||||||||||
Db         20 ACAAGATGATCCGGAACCCC 1


RESULT 298
ADR86817/c
ID   ADR86817 standard; DNA; 20 BP.
XX
AC   ADR86817;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 122.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2478 GGACTCCTTCCTGCGGCTAA 2497
              ||||||||||||||||||||
Db         20 GGACTCCTTCCTGCGGCTAA 1


RESULT 299
ADR86833/c
ID   ADR86833 standard; DNA; 20 BP.
XX
AC   ADR86833;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 138.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
```

PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2158 ACTTATGAAGACCCTAATGA 2177
||||||||||||||||||||
Db 20 ACTTATGAAGACCCTAATGA 1

RESULT 300
ADR86834/c
ID ADR86834 standard; DNA; 20 BP.
XX
AC ADR86834;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 139.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2138 AGGTCTACATCGACCCCTTC 2157
||||||||||||||||||||
Db 20 AGGTCTACATCGACCCCTTC 1

RESULT 301
ADR86836/c
ID ADR86836 standard; DNA; 20 BP.
XX
AC ADR86836;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 141.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX

PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2098 TCGGACAAACACGGACAGTA 2117
||||||||||||||||||||
Db 20 TCGGACAAACACGGACAGTA 1

RESULT 302
ADR86837/c
ID ADR86837 standard; DNA; 20 BP.
XX
AC ADR86837;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 142.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 7 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2078 ATGGGAGAGAAGCAGAATAT 2097
||||||||||||||||||||
Db 20 ATGGGAGAGAAGCAGAATAT 1

RESULT 303
ADR86849/c
ID ADR86849 standard; DNA; 20 BP.
XX
AC ADR86849;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 154.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;

```
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 1 A; 7 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1838 CAGAAAACCGGGCAGAGCTG 1857
             ||||||||||||||||||||
Db         20 CAGAAAACCGGGCAGAGCTG 1


RESULT 304
ADR86863/c
ID   ADR86863 standard; DNA; 20 BP.
XX
AC   ADR86863;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 168.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1558 GGGCTACGTCCTGACTTCAC 1577
             ||||||||||||||||||||
Db         20 GGGCTACGTCCTGACTTCAC 1


RESULT 305
ADR86783/c
ID   ADR86783 standard; DNA; 20 BP.
XX
AC   ADR86783;
XX
DT   16-DEC-2004  (first entry)
XX
```

DE Human ephrin B4 antisense oligonucleotide seqid 88.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 7 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3159 CGCAGCCGCTGGCTTTGGCT 3178
||||||||||||||||||||
Db 20 CGCAGCCGCTGGCTTTGGCT 1

RESULT 306
ADR86786/c
ID ADR86786 standard; DNA; 20 BP.
XX
AC ADR86786;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 91.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 8 A; 8 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3099 TTTTGGCTCTGTGGGCGAGT 3118
||||||||||||||||||||
Db 20 TTTTGGCTCTGTGGGCGAGT 1

RESULT 307
ADR86828/c

```
ID   ADR86828 standard; DNA; 20 BP.
XX
AC   ADR86828;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 133.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 92; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 11 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2258 AGGTGTGCCGGGGGCGGCTC 2277
              ||||||||||||||||||||
Db         20 AGGTGTGCCGGGGGCGGCTC 1
```

```
RESULT 308
ADR86843/c
ID   ADR86843 standard; DNA; 20 BP.
XX
AC   ADR86843;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 148.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 3 A; 11 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 TGGATGAGAGCGAGGGCTGG 1977
```

```
                    ||||||||||||||||||||
Db         20 TGGATGAGAGCGAGGGCTGG 1
```

RESULT 309
ADR86844/c
ID ADR86844 standard; DNA; 20 BP.
XX
AC ADR86844;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 149.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 1 A; 2 C; 9 G; 8 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1938 ACATCACAGCCAGACCCAAC 1957
              ||||||||||||||||||||
Db         20 ACATCACAGCCAGACCCAAC 1
```

RESULT 310
ADR86858/c
ID ADR86858 standard; DNA; 20 BP.
XX
AC ADR86858;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 163.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1658 CCACTGACCGAGAGGTACCT 1677
              ||||||||||||||||||||
Db         20 CCACTGACCGAGAGGTACCT 1

RESULT 311
ADR86868/c
ID   ADR86868 standard; DNA; 20 BP.
XX
AC   ADR86868;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 173.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 1 A; 9 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1458 CCGGGAGTGCCGACCCGGAG 1477
              ||||||||||||||||||||
Db         20 CCGGGAGTGCCGACCCGGAG 1

RESULT 312
ADR86916/c
ID   ADR86916 standard; DNA; 20 BP.
XX
AC   ADR86916;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 221.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
```

CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 10 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 498 GTGGGAGGAACTGAGCGGCC 517
||||||||||||||||||||
Db 20 GTGGGAGGAACTGAGCGGCC 1

RESULT 313
ADR86799/c
ID ADR86799 standard; DNA; 20 BP.
XX
AC ADR86799;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 104.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2839 TGGGACATGAGCAATCAGGA 2858
||||||||||||||||||||
Db 20 TGGGACATGAGCAATCAGGA 1

RESULT 314
ADR86810/c
ID ADR86810 standard; DNA; 20 BP.
XX
AC ADR86810;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 115.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2618 TCAACAGCAACCTCGTCTGC 2637
||||||||||||||||||||
Db 20 TCAACAGCAACCTCGTCTGC 1

RESULT 315
ADR86816/c
ID ADR86816 standard; DNA; 20 BP.
XX
AC ADR86816;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 121.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2498 ACGACGGACAGTTCACAGTC 2517
||||||||||||||||||||
Db 20 ACGACGGACAGTTCACAGTC 1

RESULT 316
ADR86826/c
ID ADR86826 standard; DNA; 20 BP.
XX
AC ADR86826;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 131.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2298 GAGCTGTGTGGCAATCAAGA 2317
||||||||||||||||||||
Db 20 GAGCTGTGTGGCAATCAAGA 1

RESULT 317
ADR86829/c
ID ADR86829 standard; DNA; 20 BP.
XX
AC ADR86829;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 134.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 6 A; 10 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2238 TGGTGCAGGTGAGTTTGGCG 2257
||||||||||||||||||||
Db 20 TGGTGCAGGTGAGTTTGGCG 1

RESULT 318
ADR86853/c
ID ADR86853 standard; DNA; 20 BP.
XX
AC ADR86853;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 158.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX

```
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1758 TGGGGCTGTGCTGGACTACG 1777
              ||||||||||||||||||||
Db         20 TGGGGCTGTGCTGGACTACG 1


RESULT 319
ADR86857/c
ID   ADR86857 standard; DNA; 20 BP.
XX
AC   ADR86857;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 162.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 93; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1678 CCTGCAGTGTCTGACATCCG 1697
              ||||||||||||||||||||
Db         20 CCTGCAGTGTCTGACATCCG 1


RESULT 320
ADR86861/c
ID   ADR86861 standard; DNA; 20 BP.
XX
AC   ADR86861;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 166.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
```

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1598 CATTGAACGGGGTATCCTCC 1617
||||||||||||||||||||
Db 20 CATTGAACGGGGTATCCTCC 1

RESULT 321
ADR86912/c
ID ADR86912 standard; DNA; 20 BP.
XX
AC ADR86912;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 217.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 578 GCCAGGCCCACTGGCTTCGC 597
||||||||||||||||||||
Db 20 GCCAGGCCCACTGGCTTCGC 1

RESULT 322
ADR82356/c
ID ADR82356 standard; DNA; 20 BP.
XX
AC ADR82356;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #27.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX

```
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 7 A; 10 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2799 TGTGATGTGGGAGGTGATGT 2818
              ||||||||||||||||||||
Db         20 TGTGATGTGGGAGGTGATGT 1


RESULT 323
ADR82384/c
ID   ADR82384 standard; DNA; 20 BP.
XX
AC   ADR82384;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #55.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 6 A; 10 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2238 TGGTGCAGGTGAGTTTGGCG 2257
              ||||||||||||||||||||
Db         20 TGGTGCAGGTGAGTTTGGCG 1


RESULT 324
ADR82395/c
ID   ADR82395 standard; DNA; 20 BP.
XX
AC   ADR82395;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #66.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
```

```
CC   antisense probe.
XX
SQ   Sequence 20 BP; 7 A; 9 C; 4 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2018 GTGTGGTCCTGGTCCTGGTG 2037
              ||||||||||||||||||||
Db         20 GTGTGGTCCTGGTCCTGGTG 1


RESULT 325
ADR82438/c
ID   ADR82438 standard; DNA; 20 BP.
XX
AC   ADR82438;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #109.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1158 AGCTGAGGGGAACACCAAGT 1177
              ||||||||||||||||||||
Db         20 AGCTGAGGGGAACACCAAGT 1


RESULT 326
ADR82474/c
ID   ADR82474 standard; DNA; 20 BP.
XX
AC   ADR82474;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #145.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 4 C; 3 G; 10 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        438 GAACACAAAATTGGAAACTG 457
              ||||||||||||||||||||
Db         20 GAACACAAAATTGGAAACTG 1


RESULT 327
ADR82361/c
ID   ADR82361 standard; DNA; 20 BP.
XX
AC   ADR82361;
XX
DT   16-DEC-2004  (first entry)
```

```
XX
DE   Human EphB4 antisense probe #32.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2699 CGAGCTCCCTGGGAGGAAAG 2718
             ||||||||||||||||||||
Db         20 CGAGCTCCCTGGGAGGAAAG 1


RESULT 328
ADR82367/c
ID   ADR82367 standard; DNA; 20 BP.
XX
AC   ADR82367;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #38.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2578 AGCTACGTCCACCGAGACCT 2597
             ||||||||||||||||||||
Db         20 AGCTACGTCCACCGAGACCT 1


RESULT 329
ADR82387/c
ID   ADR82387 standard; DNA; 20 BP.
XX
AC   ADR82387;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #58.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
```

```
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 8 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2178 GGCTGTGAGGGAATTTGCAA 2197
              ||||||||||||||||||||
Db         20 GGCTGTGAGGGAATTTGCAA 1


RESULT 330
ADR82388/c
ID   ADR82388 standard; DNA; 20 BP.
XX
AC   ADR82388;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #59.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2158 ACTTATGAAGACCCTAATGA 2177
              ||||||||||||||||||||
Db         20 ACTTATGAAGACCCTAATGA 1


RESULT 331
ADR82390/c
ID   ADR82390 standard; DNA; 20 BP.
XX
AC   ADR82390;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #61.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
```

```
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2118 TCTCATCGGACATGGTACTA 2137
              ||||||||||||||||||||
Db         20 TCTCATCGGACATGGTACTA 1


RESULT 332
ADR82393/c
ID   ADR82393 standard; DNA; 20 BP.
XX
AC   ADR82393;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #64.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2058 CTGCCTCAGGAAGCAGAGCA 2077
              ||||||||||||||||||||
Db         20 CTGCCTCAGGAAGCAGAGCA 1


RESULT 333
ADR82410/c
ID   ADR82410 standard; DNA; 20 BP.
XX
AC   ADR82410;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #81.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1718 GCAGCTTGAGCCTGGCCTGG 1737
              ||||||||||||||||||||
Db         20 GCAGCTTGAGCCTGGCCTGG 1


RESULT 334
ADR82439/c
ID   ADR82439 standard; DNA; 20 BP.
XX
```

```
AC   ADR82439;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #110.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1138 TGTGCTCCGGGGTTCGAGGC 1157
              ||||||||||||||||||||
Db         20 TGTGCTCCGGGGTTCGAGGC 1


RESULT 335
ADR82440/c
ID   ADR82440 standard; DNA; 20 BP.
XX
AC   ADR82440;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #111.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1118 AGCCGGTCACGGGCTGCAGC 1137
              ||||||||||||||||||||
Db         20 AGCCGGTCACGGGCTGCAGC 1


RESULT 336
ADR82452/c
ID   ADR82452 standard; DNA; 20 BP.
XX
AC   ADR82452;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #123.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
```

```
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        878 CGCTCAGCAAGGCTGGCTTC 897
              ||||||||||||||||||||
Db         20 CGCTCAGCAAGGCTGGCTTC 1


RESULT 337
ADR82463/c
ID   ADR82463 standard; DNA; 20 BP.
XX
AC   ADR82463;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #134.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        658 CTCGAGTGCCTGTCCCTGCC 677
              ||||||||||||||||||||
Db         20 CTCGAGTGCCTGTCCCTGCC 1


RESULT 338
ADR82335/c
ID   ADR82335 standard; DNA; 20 BP.
XX
AC   ADR82335;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #6.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 98; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
```

```
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3219 CCGAATCGGAGTCACTCTGG 3238
              ||||||||||||||||||||
Db         20 CCGAATCGGAGTCACTCTGG 1


RESULT 339
ADR82340/c
ID   ADR82340 standard; DNA; 20 BP.
XX
AC   ADR82340;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #11.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 98; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3119 GGCTTCGGGCCATCAAAATG 3138
              ||||||||||||||||||||
Db         20 GGCTTCGGGCCATCAAAATG 1


RESULT 340
ADR82348/c
ID   ADR82348 standard; DNA; 20 BP.
XX
AC   ADR82348;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #19.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 4 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2959 AATGCCCGGCCCCGCTTCCC 2978
              ||||||||||||||||||||
Db         20 AATGCCCGGCCCCGCTTCCC 1


RESULT 341
```

```
ADR82353/c
ID   ADR82353 standard; DNA; 20 BP.
XX
AC   ADR82353;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #24.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2859 CGTGATCAATGCCATTGAAC 2878
             ||||||||||||||||||||
Db         20 CGTGATCAATGCCATTGAAC 1


RESULT 342
ADR82408/c
ID   ADR82408 standard; DNA; 20 BP.
XX
AC   ADR82408;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #79.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1758 TGGGGCTGTGCTGGACTACG 1777
              ||||||||||||||||||||
Db         20 TGGGGCTGTGCTGGACTACG 1


RESULT 343
ADR82415/c
ID   ADR82415 standard; DNA; 20 BP.
XX
AC   ADR82415;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #86.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
```

```
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1618 TTAGCCACGGGGCCCGTCCC 1637
             ||||||||||||||||||||
Db         20 TTAGCCACGGGGCCCGTCCC 1


RESULT 344
ADR82416/c
ID   ADR82416 standard; DNA; 20 BP.
XX
AC   ADR82416;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #87.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CATTGAACGGGGTATCCTCC 1617
             ||||||||||||||||||||
Db         20 CATTGAACGGGGTATCCTCC 1


RESULT 345
ADR82441/c
ID   ADR82441 standard; DNA; 20 BP.
XX
AC   ADR82441;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #112.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
```

```
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1098 GGATGGCCAGTGGGCCGAAC 1117
             ||||||||||||||||||||
Db         20 GGATGGCCAGTGGGCCGAAC 1


RESULT 346
ADR82442/c
ID   ADR82442 standard; DNA; 20 BP.
XX
AC   ADR82442;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #113.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1078 CCCAGCCTCTACTGCCGTGA 1097
             ||||||||||||||||||||
Db         20 CCCAGCCTCTACTGCCGTGA 1


RESULT 347
ADR82462/c
ID   ADR82462 standard; DNA; 20 BP.
XX
AC   ADR82462;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #133.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        678 TCGGGCTGGGCGCTCCTGCA 697
              ||||||||||||||||||||
Db         20 TCGGGCTGGGCGCTCCTGCA 1
```

```
RESULT 348
ADR82471/c
ID   ADR82471 standard; DNA; 20 BP.
XX
AC   ADR82471;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #142.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 10 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        498 GTGGGAGGAACTGAGCGGCC 517
              ||||||||||||||||||||
Db         20 GTGGGAGGAACTGAGCGGCC 1


RESULT 349
ADR82476/c
ID   ADR82476 standard; DNA; 20 BP.
XX
AC   ADR82476;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #147.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        398 GCTGGGCTTCGTTGGCCGCA 417
              ||||||||||||||||||||
Db         20 GCTGGGCTTCGTTGGCCGCA 1


RESULT 350
ADR82336/c
ID   ADR82336 standard; DNA; 20 BP.
XX
AC   ADR82336;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #7.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
```

XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 98; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3199 ATCTCTGCTGAGGACCTGCT 3218
||||||||||||||||||||
Db 20 ATCTCTGCTGAGGACCTGCT 1

RESULT 351
ADR82343/c
ID ADR82343 standard; DNA; 20 BP.
XX
AC ADR82343;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #14.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3059 CACACCCTCTCCTGGACCAG 3078
||||||||||||||||||||
Db 20 CACACCCTCTCCTGGACCAG 1

RESULT 352
ADR82345/c
ID ADR82345 standard; DNA; 20 BP.
XX
AC ADR82345;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #16.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

```
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3019 GCCAGCCTCAAAATCGTGGC 3038
              ||||||||||||||||||||
Db         20 GCCAGCCTCAAAATCGTGGC 1


RESULT 353
ADR82359/c
ID   ADR82359 standard; DNA; 20 BP.
XX
AC   ADR82359;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #30.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2739 CCCGGAGGCCATTGCCTTCC 2758
              ||||||||||||||||||||
Db         20 CCCGGAGGCCATTGCCTTCC 1


RESULT 354
ADR82365/c
ID   ADR82365 standard; DNA; 20 BP.
XX
AC   ADR82365;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #36.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2618 TCAACAGCAACCTCGTCTGC 2637
              ||||||||||||||||||||
Db         20 TCAACAGCAACCTCGTCTGC 1
```

RESULT 355
ADR82370/c
ID ADR82370 standard; DNA; 20 BP.
XX
AC ADR82370;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #41.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2518 ATCCAGCTCGTGGGCATGCT 2537
              ||||||||||||||||||||
Db         20 ATCCAGCTCGTGGGCATGCT 1
```

RESULT 356
ADR82423/c
ID ADR82423 standard; DNA; 20 BP.
XX
AC ADR82423;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #94.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 1 A; 9 C; 7 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1458 CCGGGAGTGCCGACCCGGAG 1477
              ||||||||||||||||||||
Db         20 CCGGGAGTGCCGACCCGGAG 1
```

RESULT 357
ADR82432/c
ID ADR82432 standard; DNA; 20 BP.
XX
AC ADR82432;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #103.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

```
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1278 CTGCCAGTGCCGCGTCGGGT 1297
             ||||||||||||||||||||
Db         20 CTGCCAGTGCCGCGTCGGGT 1


RESULT 358
ADR82446/c
ID   ADR82446 standard; DNA; 20 BP.
XX
AC   ADR82446;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #117.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        998 CGGAGACTGTGCCTCGGGAG 1017
              ||||||||||||||||||||
Db         20 CGGAGACTGTGCCTCGGGAG 1


RESULT 359
ADR82455/c
ID   ADR82455 standard; DNA; 20 BP.
XX
AC   ADR82455;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #126.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
```

```
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 1 A; 10 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        818 GGAAGCGCCCTGGGGCCGAG 837
              ||||||||||||||||||||
Db         20 GGAAGCGCCCTGGGGCCGAG 1


RESULT 360
ADR82459/c
ID   ADR82459 standard; DNA; 20 BP.
XX
AC   ADR82459;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #130.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 1 A; 5 C; 11 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        738 CACGGCCACGGCCCTCACGC 757
              ||||||||||||||||||||
Db         20 CACGGCCACGGCCCTCACGC 1


RESULT 361
ADR82466/c
ID   ADR82466 standard; DNA; 20 BP.
XX
AC   ADR82466;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #137.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
```

```
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        598 ACAGGTTGGGTCCCACGGCG 617
              ||||||||||||||||||||
Db         20 ACAGGTTGGGTCCCACGGCG 1


RESULT 362
ADR82472/c
ID   ADR82472 standard; DNA; 20 BP.
XX
AC   ADR82472;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #143.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        478 TTCCCTCAGGTGGACGGGCA 497
              ||||||||||||||||||||
Db         20 TTCCCTCAGGTGGACGGGCA 1


RESULT 363
ADR82318/c
ID   ADR82318 standard; DNA; 20 BP.
XX
AC   ADR82318;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #12.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 364
ADR82363/c
ID   ADR82363 standard; DNA; 20 BP.
XX
AC   ADR82363;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #34.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
```

```
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2659 TCCCGATTCCTGGAGGAGAA 2678
             ||||||||||||||||||||
Db         20 TCCCGATTCCTGGAGGAGAA 1


RESULT 365
ADR82406/c
ID   ADR82406 standard; DNA; 20 BP.
XX
AC   ADR82406;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #77.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 1 A; 9 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1798 GGCGCCGAGGGTCCCAGCAG 1817
             ||||||||||||||||||||
Db         20 GGCGCCGAGGGTCCCAGCAG 1


RESULT 366
ADR82429/c
ID   ADR82429 standard; DNA; 20 BP.
XX
AC   ADR82429;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #100.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
```

DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 4 A; 3 C; 12 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1338 CACCCCTCCTTCGGCTCCGC 1357
||||||||||||||||||||
Db 20 CACCCCTCCTTCGGCTCCGC 1

RESULT 367
ADR82291
ID ADR82291 standard; DNA; 20 BP.
XX
AC ADR82291;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 sense ODN.
XX
KW human; ss; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW inflammatory disorder; chronic articular rheumatism; psoriasis;
KW ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW angiogenesis inhibitor.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 3; Page 68; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC sense oligodeoxynucleotide (ODN).
XX
SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 TCCTGCAAGGAGACCTTCAC 710
||||||||||||||||||||
Db 1 TCCTGCAAGGAGACCTTCAC 20

RESULT 368
ADR82338/c
ID ADR82338 standard; DNA; 20 BP.
XX
AC ADR82338;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #9.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 98; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX

```
SQ   Sequence 20 BP; 5 A; 7 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3159 CGCAGCCGCTGGCTTTGGCT 3178
              ||||||||||||||||||||
Db         20 CGCAGCCGCTGGCTTTGGCT 1


RESULT 369
ADR82396/c
ID   ADR82396 standard; DNA; 20 BP.
XX
AC   ADR82396;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #67.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 10 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1998 TGCGGGCACGGCAGTCGTGG 2017
              ||||||||||||||||||||
Db         20 TGCGGGCACGGCAGTCGTGG 1


RESULT 370
ADR82413/c
ID   ADR82413 standard; DNA; 20 BP.
XX
AC   ADR82413;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #84.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1658 CCACTGACCGAGAGGTACCT 1677
              ||||||||||||||||||||
Db         20 CCACTGACCGAGAGGTACCT 1


RESULT 371
ADR82419/c
ID   ADR82419 standard; DNA; 20 BP.
XX
AC   ADR82419;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #90.
```

XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1538 AGCCCTGGGTGGTGGTTCGA 1557
||||||||||||||||||||
Db 20 AGCCCTGGGTGGTGGTTCGA 1

RESULT 372
ADR82424/c
ID ADR82424 standard; DNA; 20 BP.
XX
AC ADR82424;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #95.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1438 CTCACCTACGCCCTCCGCTG 1457
||||||||||||||||||||
Db 20 CTCACCTACGCCCTCCGCTG 1

RESULT 373
ADR82444/c
ID ADR82444 standard; DNA; 20 BP.
XX
AC ADR82444;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #115.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.

```
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1038 TAGCTGCGTGGTGGATGCCG 1057
              ||||||||||||||||||||
Db         20 TAGCTGCGTGGTGGATGCCG 1


RESULT 374
ADR82450/c
ID   ADR82450 standard; DNA; 20 BP.
XX
AC   ADR82450;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #121.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        918 GGGTGCCTGCATGGCCCTGC 937
              ||||||||||||||||||||
Db         20 GGGTGCCTGCATGGCCCTGC 1


RESULT 375
ADR82465/c
ID   ADR82465 standard; DNA; 20 BP.
XX
AC   ADR82465;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #136.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
```

```
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        618 GGGCGCCGTCCACGTGTACG 637
              ||||||||||||||||||||
Db         20 GGGCGCCGTCCACGTGTACG 1


RESULT 376
ADR82663
ID   ADR82663 standard; DNA; 20 BP.
XX
AC   ADR82663;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 PCR primer #14.
XX
KW   human; ss; PCR; primer; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 6; Page 93; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   PCR primer.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        419 CTTTGGAAGAGACCCTGCTG 438
              ||||||||||||||||||||
Db          1 CTTTGGAAGAGACCCTGCTG 20


RESULT 377
ADR82333/c
ID   ADR82333 standard; DNA; 20 BP.
XX
AC   ADR82333;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #4.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 98; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3259 TTGGCCAGTGTCCAGCACAT 3278
              ||||||||||||||||||||
Db         20 TTGGCCAGTGTCCAGCACAT 1


RESULT 378
ADR82347/c
ID   ADR82347 standard; DNA; 20 BP.
XX
AC   ADR82347;
XX
DT   16-DEC-2004  (first entry)
```

```
XX
DE   Human EphB4 antisense probe #18.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2979 CCAGGTGGTCAGCGCCCTGG 2998
             ||||||||||||||||||||
Db         20 CCAGGTGGTCAGCGCCCTGG 1


RESULT 379
ADR82355/c
ID   ADR82355 standard; DNA; 20 BP.
XX
AC   ADR82355;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #26.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2819 CATTTGGGGAGAGGCCGTAC 2838
             ||||||||||||||||||||
Db         20 CATTTGGGGAGAGGCCGTAC 1


RESULT 380
ADR82376/c
ID   ADR82376 standard; DNA; 20 BP.
XX
AC   ADR82376;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #47.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
```

```
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2398 AATATCATCCGCCTGGAGGG 2417
              ||||||||||||||||||||
Db         20 AATATCATCCGCCTGGAGGG 1


RESULT 381
ADR82378/c
ID   ADR82378 standard; DNA; 20 BP.
XX
AC   ADR82378;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #49.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2358 TCTGAGCGAGGCCTCCATCA 2377
              ||||||||||||||||||||
Db         20 TCTGAGCGAGGCCTCCATCA 1


RESULT 382
ADR82383/c
ID   ADR82383 standard; DNA; 20 BP.
XX
AC   ADR82383;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #54.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
```

```
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 11 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2258 AGGTGTGCCGGGGGCGGCTC 2277
              ||||||||||||||||||||
Db         20 AGGTGTGCCGGGGGCGGCTC 1


RESULT 383
ADR82421/c
ID   ADR82421 standard; DNA; 20 BP.
XX
AC   ADR82421;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #92.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1498 GGAGACCTGACTTTTGACCC 1517
              ||||||||||||||||||||
Db         20 GGAGACCTGACTTTTGACCC 1


RESULT 384
ADR82426/c
ID   ADR82426 standard; DNA; 20 BP.
XX
AC   ADR82426;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #97.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1398 GGAATGGAGTGCCCCCCTGG 1417
              ||||||||||||||||||||
Db         20 GGAATGGAGTGCCCCCCTGG 1


RESULT 385
ADR82443/c
ID   ADR82443 standard; DNA; 20 BP.
XX
```

```
AC   ADR82443;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #114.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 4 C; 13 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1058 TCCCCGCCCCTGGCCCCAGC 1077
              ||||||||||||||||||||
Db         20 TCCCCGCCCCTGGCCCCAGC 1


RESULT 386
ADR82445/c
ID   ADR82445 standard; DNA; 20 BP.
XX
AC   ADR82445;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #116.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 6 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1018 CTGGTTGTGCCCGTGGCCGG 1037
              ||||||||||||||||||||
Db         20 CTGGTTGTGCCCGTGGCCGG 1


RESULT 387
ADR82447/c
ID   ADR82447 standard; DNA; 20 BP.
XX
AC   ADR82447;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #118.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
```

```
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        978 TGTGAACCTGACTCGATTCC 997
              ||||||||||||||||||||
Db         20 TGTGAACCTGACTCGATTCC 1


RESULT 388
ADR82469/c
ID   ADR82469 standard; DNA; 20 BP.
XX
AC   ADR82469;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #140.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        538 GTGCGCACCTACGAAGTGTG 557
              ||||||||||||||||||||
Db         20 GTGCGCACCTACGAAGTGTG 1


RESULT 389
ADR82475/c
ID   ADR82475 standard; DNA; 20 BP.
XX
AC   ADR82475;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #146.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
```

```
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        418 GCTTTGGAAGAGACCCTGCT 437
              ||||||||||||||||||||
Db         20 GCTTTGGAAGAGACCCTGCT 1


RESULT 390
ADR82293/c
ID   ADR82293 standard; DNA; 20 BP.
XX
AC   ADR82293;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #2.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 3; Page 68; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 391
ADR82344/c
ID   ADR82344 standard; DNA; 20 BP.
XX
AC   ADR82344;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #15.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 10 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3039 CCGGGAGAATGGCGGGGCCT 3058
              ||||||||||||||||||||
Db         20 CCGGGAGAATGGCGGGGCCT 1


RESULT 392
```

```
ADR82352/c
ID   ADR82352 standard; DNA; 20 BP.
XX
AC   ADR82352;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #23.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2879 AGGACTACCGGCTGCCCCCG 2898
             ||||||||||||||||||||
Db         20 AGGACTACCGGCTGCCCCCG 1


RESULT 393
ADR82368/c
ID   ADR82368 standard; DNA; 20 BP.
XX
AC   ADR82368;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #39.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2558 TGCGGTACCTTGCCGAGATG 2577
             ||||||||||||||||||||
Db         20 TGCGGTACCTTGCCGAGATG 1


RESULT 394
ADR82386/c
ID   ADR82386 standard; DNA; 20 BP.
XX
AC   ADR82386;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #57.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
```

PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2198 AAGAGATCGATGTCTCCTAC 2217
||||||||||||||||||||
Db 20 AAGAGATCGATGTCTCCTAC 1

RESULT 395
ADR82401/c
ID ADR82401 standard; DNA; 20 BP.
XX
AC ADR82401;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #72.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 2 A; 10 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1898 GGGCGCGCTCTGAGGCCGGC 1917
||||||||||||||||||||
Db 20 GGGCGCGCTCTGAGGCCGGC 1

RESULT 396
ADR82402/c
ID ADR82402 standard; DNA; 20 BP.
XX
AC ADR82402;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #73.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX

```
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1878 CAGCTACCTGGTGCAGGTAC 1897
             ||||||||||||||||||||
Db         20 CAGCTACCTGGTGCAGGTAC 1


RESULT 397
ADR82417/c
ID   ADR82417 standard; DNA; 20 BP.
XX
AC   ADR82417;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #88.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1578 CTATACCTTTGAGGTCACTG 1597
             ||||||||||||||||||||
Db         20 CTATACCTTTGAGGTCACTG 1


RESULT 398
ADR82425/c
ID   ADR82425 standard; DNA; 20 BP.
XX
AC   ADR82425;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #96.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1418 AGTCTGGTGGCCGAGAGGAC 1437
             ||||||||||||||||||||
Db         20 AGTCTGGTGGCCGAGAGGAC 1
```

```
RESULT 399
ADR82431/c
ID   ADR82431 standard; DNA; 20 BP.
XX
AC   ADR82431;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #102.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1298 ACTTCCGGGCACGCACAGAC 1317
              ||||||||||||||||||||
Db         20 ACTTCCGGGCACGCACAGAC 1


RESULT 400
ADR82434/c
ID   ADR82434 standard; DNA; 20 BP.
XX
AC   ADR82434;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #105.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 3 C; 9 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1238 GCCCAGCCAATAGCCACTCT 1257
              ||||||||||||||||||||
Db         20 GCCCAGCCAATAGCCACTCT 1


RESULT 401
ADR82435/c
ID   ADR82435 standard; DNA; 20 BP.
XX
AC   ADR82435;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #106.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
```

XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1218 AGAAGGGTCCTGCCAGCCAT 1237
||||||||||||||||||||
Db 20 AGAAGGGTCCTGCCAGCCAT 1

RESULT 402
ADR82449/c
ID ADR82449 standard; DNA; 20 BP.
XX
AC ADR82449;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #120.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 7 A; 1 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 938 TATCCCTGCACCTCTTCTAC 957
||||||||||||||||||||
Db 20 TATCCCTGCACCTCTTCTAC 1

RESULT 403
ADR82331/c
ID ADR82331 standard; DNA; 20 BP.
XX
AC ADR82331;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #2.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

```
XX
PS   Example 8; Page 98; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3299 GAACCCCGGGTGGGACAGGA 3318
              ||||||||||||||||||||
Db         20 GAACCCCGGGTGGGACAGGA 1


RESULT 404
ADR82360/c
ID   ADR82360 standard; DNA; 20 BP.
XX
AC   ADR82360;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #31.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2719 ATTCCCATCCGATGGACTGC 2738
              ||||||||||||||||||||
Db         20 ATTCCCATCCGATGGACTGC 1


RESULT 405
ADR82371/c
ID   ADR82371 standard; DNA; 20 BP.
XX
AC   ADR82371;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #42.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2498 ACGACGGACAGTTCACAGTC 2517
              ||||||||||||||||||||
Db         20 ACGACGGACAGTTCACAGTC 1
```

RESULT 406
ADR82389/c
ID ADR82389 standard; DNA; 20 BP.
XX
AC ADR82389;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #60.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2138 AGGTCTACATCGACCCCTTC 2157
              ||||||||||||||||||||
Db         20 AGGTCTACATCGACCCCTTC 1
```

RESULT 407
ADR82454/c
ID ADR82454 standard; DNA; 20 BP.
XX
AC ADR82454;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #125.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        838 GCCACCGGGAAGGTGAATGT 857
              ||||||||||||||||||||
Db         20 GCCACCGGGAAGGTGAATGT 1
```

RESULT 408
ADR82470/c
ID ADR82470 standard; DNA; 20 BP.
XX
AC ADR82470;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #141.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

```
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        518 TGGATGAGGAACAGCACAGC 537
              ||||||||||||||||||||
Db         20 TGGATGAGGAACAGCACAGC 1


RESULT 409
ADR82658
ID   ADR82658 standard; DNA; 20 BP.
XX
AC   ADR82658;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 PCR primer #12.
XX
KW   human; ss; PCR; primer; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 4; Page 75; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   PCR primer.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        419 CTTTGGAAGAGACCCTGCTG 438
              ||||||||||||||||||||
Db          1 CTTTGGAAGAGACCCTGCTG 20


RESULT 410
ADR82332/c
ID   ADR82332 standard; DNA; 20 BP.
XX
AC   ADR82332;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #3.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
```

PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 98; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 1 A; 7 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3279 GAAGTCCCAGGCCAAGCCGG 3298
||||||||||||||||||||
Db 20 GAAGTCCCAGGCCAAGCCGG 1

RESULT 411
ADR82346/c
ID ADR82346 standard; DNA; 20 BP.
XX
AC ADR82346;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #17.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2999 ACAAGATGATCCGGAACCCC 3018
||||||||||||||||||||
Db 20 ACAAGATGATCCGGAACCCC 1

RESULT 412
ADR82364/c
ID ADR82364 standard; DNA; 20 BP.
XX
AC ADR82364;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #35.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;

```
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2639 AAGTGTCTGACTTTGGCCTT 2658
              ||||||||||||||||||||
Db         20 AAGTGTCTGACTTTGGCCTT 1


RESULT 413
ADR82369/c
ID   ADR82369 standard; DNA; 20 BP.
XX
AC   ADR82369;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #40.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 9 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2538 GCGGGGCATCGCCTCGGGCA 2557
              ||||||||||||||||||||
Db         20 GCGGGGCATCGCCTCGGGCA 1


RESULT 414
ADR82381/c
ID   ADR82381 standard; DNA; 20 BP.
XX
AC   ADR82381;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #52.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2298 GAGCTGTGTGGCAATCAAGA 2317
              ||||||||||||||||||||
Db         20 GAGCTGTGTGGCAATCAAGA 1


RESULT 415
ADR82385/c
ID   ADR82385 standard; DNA; 20 BP.
XX
AC   ADR82385;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #56.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
```

```
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 7 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2218 GTCAAGATTGAAGAGGTGAT 2237
              ||||||||||||||||||||
Db         20 GTCAAGATTGAAGAGGTGAT 1


RESULT 416
ADR82409/c
ID   ADR82409 standard; DNA; 20 BP.
XX
AC   ADR82409;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #80.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 GCTGTTCCCCGGGCACCCAG 1757
              ||||||||||||||||||||
Db         20 GCTGTTCCCCGGGCACCCAG 1


RESULT 417
ADR82412/c
ID   ADR82412 standard; DNA; 20 BP.
XX
AC   ADR82412;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #83.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
```

```
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1678 CCTGCAGTGTCTGACATCCG 1697
              ||||||||||||||||||||
Db         20 CCTGCAGTGTCTGACATCCG 1


RESULT 418
ADR82420/c
ID   ADR82420 standard; DNA; 20 BP.
XX
AC   ADR82420;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #91.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 9 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1518 CGGCCCCCGGGACCTGGTGG 1537
              ||||||||||||||||||||
Db         20 CGGCCCCCGGGACCTGGTGG 1


RESULT 419
ADR82430/c
ID   ADR82430 standard; DNA; 20 BP.
XX
AC   ADR82430;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #101.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 10 G; 2 T; 0 U; 0 Other;
```

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1318 CCCCGGGGTGCACCCTGCAC 1337
              ||||||||||||||||||||
Db         20 CCCCGGGGTGCACCCTGCAC 1


RESULT 420
ADR82437/c
ID   ADR82437 standard; DNA; 20 BP.
XX
AC   ADR82437;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #108.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 8 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1178 GCCGAGCCTGTGCCCAGGGC 1197
              ||||||||||||||||||||
Db         20 GCCGAGCCTGTGCCCAGGGC 1


RESULT 421
ADR82451/c
ID   ADR82451 standard; DNA; 20 BP.
XX
AC   ADR82451;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #122.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        898 TACCTGGCCTTCCAGGACCA 917
              ||||||||||||||||||||
Db         20 TACCTGGCCTTCCAGGACCA 1


RESULT 422
ADR82458/c
ID   ADR82458 standard; DNA; 20 BP.
XX
AC   ADR82458;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #129.
XX
```

```
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        758 CAGCCTGGATGGAGAACCCC 777
              ||||||||||||||||||||
Db         20 CAGCCTGGATGGAGAACCCC 1


RESULT 423
ADR82460/c
ID   ADR82460 standard; DNA; 20 BP.
XX
AC   ADR82460;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #131.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        718 TACTATGAGAGCGATGCGGA 737
              ||||||||||||||||||||
Db         20 TACTATGAGAGCGATGCGGA 1


RESULT 424
ADR82477/c
ID   ADR82477 standard; DNA; 20 BP.
XX
AC   ADR82477;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #148.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
```

PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 378 GGAGCTCCGGGTGCTGCTCT 397
||||||||||||||||||||
Db 20 GGAGCTCCGGGTGCTGCTCT 1

RESULT 425
ADR82664/c
ID ADR82664 standard; DNA; 20 BP.
XX
AC ADR82664;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 PCR primer #15.
XX
KW human; ss; PCR; primer; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 6; Page 93; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC PCR primer.
XX
SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 696 CAAGGAGACCTTCACCGTCT 715
||||||||||||||||||||
Db 20 CAAGGAGACCTTCACCGTCT 1

RESULT 426
ADR82342/c
ID ADR82342 standard; DNA; 20 BP.
XX
AC ADR82342;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #13.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 98; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

```
XX
SQ   Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3079 CGGCAGCCTCACTACTCAGC 3098
              ||||||||||||||||||||
Db         20 CGGCAGCCTCACTACTCAGC 1


RESULT 427
ADR82354/c
ID   ADR82354 standard; DNA; 20 BP.
XX
AC   ADR82354;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #25.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2839 TGGGACATGAGCAATCAGGA 2858
              ||||||||||||||||||||
Db         20 TGGGACATGAGCAATCAGGA 1


RESULT 428
ADR82372/c
ID   ADR82372 standard; DNA; 20 BP.
XX
AC   ADR82372;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #43.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2478 GGACTCCTTCCTGCGGCTAA 2497
              ||||||||||||||||||||
Db         20 GGACTCCTTCCTGCGGCTAA 1


RESULT 429
ADR82373/c
ID   ADR82373 standard; DNA; 20 BP.
XX
AC   ADR82373;
XX
DT   16-DEC-2004  (first entry)
XX
```

```
DE   Human EphB4 antisense probe #44.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2458 TTCATGGAGAACGGCGCCCT 2477
              ||||||||||||||||||||
Db         20 TTCATGGAGAACGGCGCCCT 1


RESULT 430
ADR82379/c
ID   ADR82379 standard; DNA; 20 BP.
XX
AC   ADR82379;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #50.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2338 GAGCGGCAGCGGCGTGAGTT 2357
              ||||||||||||||||||||
Db         20 GAGCGGCAGCGGCGTGAGTT 1


RESULT 431
ADR82391/c
ID   ADR82391 standard; DNA; 20 BP.
XX
AC   ADR82391;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #62.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
```

PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2098 TCGGACAAACACGGACAGTA 2117
||||||||||||||||||||
Db 20 TCGGACAAACACGGACAGTA 1

RESULT 432
ADR82407/c
ID ADR82407 standard; DNA; 20 BP.
XX
AC ADR82407;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #78.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1778 AGGTCAAATACCATGAGAAG 1797
||||||||||||||||||||
Db 20 AGGTCAAATACCATGAGAAG 1

RESULT 433
ADR82411/c
ID ADR82411 standard; DNA; 20 BP.
XX
AC ADR82411;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #82.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory

```
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1698 GGTGACGCGGTCCTCACCCA 1717
              ||||||||||||||||||||
Db         20 GGTGACGCGGTCCTCACCCA 1


RESULT 434
ADR82414/c
ID   ADR82414 standard; DNA; 20 BP.
XX
AC   ADR82414;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #85.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1638 ATTTGAGCCTGTCAATGTCA 1657
              ||||||||||||||||||||
Db         20 ATTTGAGCCTGTCAATGTCA 1


RESULT 435
ADR82418/c
ID   ADR82418 standard; DNA; 20 BP.
XX
AC   ADR82418;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #89.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1558 GGGCTACGTCCTGACTTCAC 1577
              ||||||||||||||||||||
Db         20 GGGCTACGTCCTGACTTCAC 1


RESULT 436
ADR82334/c
ID   ADR82334 standard; DNA; 20 BP.
XX
AC   ADR82334;
```

```
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #5.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 98; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 1 A; 5 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3239 CGGGACACCAGAAGAAAATC 3258
             ||||||||||||||||||||
Db         20 CGGGACACCAGAAGAAAATC 1


RESULT 437
ADR82351/c
ID   ADR82351 standard; DNA; 20 BP.
XX
AC   ADR82351;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #22.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 2 C; 12 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2899 CCCCCAGACTGTCCCACCTC 2918
             ||||||||||||||||||||
Db         20 CCCCCAGACTGTCCCACCTC 1


RESULT 438
ADR82357/c
ID   ADR82357 standard; DNA; 20 BP.
XX
AC   ADR82357;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #28.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
```

PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2779 GATGCCTGGAGTTACGGGAT 2798
||||||||||||||||||||
Db 20 GATGCCTGGAGTTACGGGAT 1

RESULT 439
ADR82362/c
ID ADR82362 standard; DNA; 20 BP.
XX
AC ADR82362;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #33.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 1 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2679 CTCTTCCGATCCCACCTACA 2698
||||||||||||||||||||
Db 20 CTCTTCCGATCCCACCTACA 1

RESULT 440
ADR82374/c
ID ADR82374 standard; DNA; 20 BP.
XX
AC ADR82374;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #45.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

```
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2438 CCGTCATGATTCTCACAGAG 2457
              ||||||||||||||||||||
Db         20 CCGTCATGATTCTCACAGAG 1


RESULT 441
ADR82394/c
ID   ADR82394 standard; DNA; 20 BP.
XX
AC   ADR82394;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #65.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2038 GTCATTGTGGTCGCAGTTCT 2057
              ||||||||||||||||||||
Db         20 GTCATTGTGGTCGCAGTTCT 1


RESULT 442
ADR82399/c
ID   ADR82399 standard; DNA; 20 BP.
XX
AC   ADR82399;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #70.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 1 A; 2 C; 9 G; 8 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1938 ACATCACAGCCAGACCCAAC 1957
              ||||||||||||||||||||
Db         20 ACATCACAGCCAGACCCAAC 1


RESULT 443
ADR82422/c
```

```
ID   ADR82422 standard; DNA; 20 BP.
XX
AC   ADR82422;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #93.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 8 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1478 GCTCCTGTGCGCCCTGCGGG 1497
              ||||||||||||||||||||
Db         20 GCTCCTGTGCGCCCTGCGGG 1


RESULT 444
ADR82427/c
ID   ADR82427 standard; DNA; 20 BP.
XX
AC   ADR82427;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #98.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 3 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1378 AACGGCTCCTCCCTGCACCT 1397
              ||||||||||||||||||||
Db         20 AACGGCTCCTCCCTGCACCT 1


RESULT 445
ADR82464/c
ID   ADR82464 standard; DNA; 20 BP.
XX
AC   ADR82464;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #135.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
```

XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 638 CCACGCTGCGCTTCACCATG 657
||||||||||||||||||||
Db 20 CCACGCTGCGCTTCACCATG 1

RESULT 446
ADR82467/c
ID ADR82467 standard; DNA; 20 BP.
XX
AC ADR82467;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #138.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 578 GCCAGGCCCACTGGCTTCGC 597
||||||||||||||||||||
Db 20 GCCAGGCCCACTGGCTTCGC 1

RESULT 447
ADR82468/c
ID ADR82468 standard; DNA; 20 BP.
XX
AC ADR82468;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #139.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at

```
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        558 TGACGTGCAGCGTGCCCCGG 577
              ||||||||||||||||||||
Db         20 TGACGTGCAGCGTGCCCCGG 1


RESULT 448
ADR82488/c
ID   ADR82488 standard; DNA; 20 BP.
XX
AC   ADR82488;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #159.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2356 TTTCTGAGCGAGGCCTCCAT 2375
              ||||||||||||||||||||
Db         20 TTTCTGAGCGAGGCCTCCAT 1


RESULT 449
ADR82297
ID   ADR82297 standard; DNA; 20 BP.
XX
AC   ADR82297;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human beta-actin RT-PCR primer #2.
XX
KW   human; ss; RT-PCR; primer; beta-actin; reverse transcriptase; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 3; Page 69; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human beta-
CC   actin reverse transcriptase (RT)-PCR primer.
XX
SQ   Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        697 AAGGAGACCTTCACCGTCTT 716
              ||||||||||||||||||||
Db          1 AAGGAGACCTTCACCGTCTT 20
```

```
RESULT 450
ADR82377/c
ID   ADR82377 standard; DNA; 20 BP.
XX
AC   ADR82377;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #48.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2378 TGGGCCAGTTCGAGCACCCC 2397
              ||||||||||||||||||||
Db         20 TGGGCCAGTTCGAGCACCCC 1


RESULT 451
ADR82392/c
ID   ADR82392 standard; DNA; 20 BP.
XX
AC   ADR82392;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #63.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2078 ATGGGAGAGAAGCAGAATAT 2097
              ||||||||||||||||||||
Db         20 ATGGGAGAGAAGCAGAATAT 1


RESULT 452
ADR82403/c
ID   ADR82403 standard; DNA; 20 BP.
XX
AC   ADR82403;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #74.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
```

XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 1 A; 12 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1858 CGGGGGCTGAAGCGGGGAGC 1877
||||||||||||||||||||
Db 20 CGGGGGCTGAAGCGGGGAGC 1

RESULT 453
ADR82433/c
ID ADR82433 standard; DNA; 20 BP.
XX
AC ADR82433;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #104.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1258 AACACCATTGGATCAGCCGT 1277
||||||||||||||||||||
Db 20 AACACCATTGGATCAGCCGT 1

RESULT 454
ADR82453/c
ID ADR82453 standard; DNA; 20 BP.
XX
AC ADR82453;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #124.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 101; 206pp; English.

```
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        858 CAAGACGCTGCGTCTGGGAC 877
              ||||||||||||||||||||
Db         20 CAAGACGCTGCGTCTGGGAC 1


RESULT 455
ADR82456/c
ID   ADR82456 standard; DNA; 20 BP.
XX
AC   ADR82456;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #127.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        798 GGCCGCGGAGCATCTCACCC 817
              ||||||||||||||||||||
Db         20 GGCCGCGGAGCATCTCACCC 1


RESULT 456
ADR82339/c
ID   ADR82339 standard; DNA; 20 BP.
XX
AC   ADR82339;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #10.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 98; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3139 GGAAGATACGAAGAAAGTTT 3158
              ||||||||||||||||||||
```

```
Db         20 GGAAGATACGAAGAAAGTTT 1


RESULT 457
ADR82341/c
ID   ADR82341 standard; DNA; 20 BP.
XX
AC   ADR82341;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #12.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 98; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 8 A; 8 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3099 TTTTGGCTCTGTGGGCGAGT 3118
             ||||||||||||||||||||
Db         20 TTTTGGCTCTGTGGGCGAGT 1


RESULT 458
ADR82358/c
ID   ADR82358 standard; DNA; 20 BP.
XX
AC   ADR82358;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #29.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2759 GGAAGTTCACTTCCGCCAGT 2778
             ||||||||||||||||||||
Db         20 GGAAGTTCACTTCCGCCAGT 1


RESULT 459
ADR82382/c
ID   ADR82382 standard; DNA; 20 BP.
XX
AC   ADR82382;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #53.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
```

OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 0 A; 8 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2278 AAGGCCCCAGGGAAGAAGGA 2297
||||||||||||||||||||
Db 20 AAGGCCCCAGGGAAGAAGGA 1

RESULT 460
ADR82659/c
ID ADR82659 standard; DNA; 20 BP.
XX
AC ADR82659;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 PCR primer #13.
XX
KW human; ss; PCR; primer; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 4; Page 75; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC PCR primer.
XX
SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 696 CAAGGAGACCTTCACCGTCT 715
||||||||||||||||||||
Db 20 CAAGGAGACCTTCACCGTCT 1

RESULT 461
ADR82337/c
ID ADR82337 standard; DNA; 20 BP.
XX
AC ADR82337;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #8.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

```
XX
PS   Example 8; Page 98; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3179 CCTTCGAGCTGGTCAGCCAG 3198
              ||||||||||||||||||||
Db         20 CCTTCGAGCTGGTCAGCCAG 1


RESULT 462
ADR82349/c
ID   ADR82349 standard; DNA; 20 BP.
XX
AC   ADR82349;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #20.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2939 ACTGTTGGCAGAAAGACCGG 2958
              ||||||||||||||||||||
Db         20 ACTGTTGGCAGAAAGACCGG 1


RESULT 463
ADR82366/c
ID   ADR82366 standard; DNA; 20 BP.
XX
AC   ADR82366;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #37.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2598 GGCTGCTCGCAACATCCTAG 2617
              ||||||||||||||||||||
Db         20 GGCTGCTCGCAACATCCTAG 1
```

RESULT 464
ADR82375/c
ID ADR82375 standard; DNA; 20 BP.
XX
AC ADR82375;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #46.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2418 CGTGGTCACCAACAGCATGC 2437
              ||||||||||||||||||||
Db         20 CGTGGTCACCAACAGCATGC 1
```

RESULT 465
ADR82380/c
ID ADR82380 standard; DNA; 20 BP.
XX
AC ADR82380;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #51.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

```
  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2318 CCCTGAAGGGTGGCTACACG 2337
              ||||||||||||||||||||
Db         20 CCCTGAAGGGTGGCTACACG 1
```

RESULT 466
ADR82398/c
ID ADR82398 standard; DNA; 20 BP.
XX
AC ADR82398;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #69.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 11 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1958 TGGATGAGAGCGAGGGCTGG 1977
||||||||||||||||||||
Db 20 TGGATGAGAGCGAGGGCTGG 1

RESULT 467
ADR82404/c
ID ADR82404 standard; DNA; 20 BP.
XX
AC ADR82404;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #75.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 1 A; 7 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1838 CAGAAAACCGGGCAGAGCTG 1857
||||||||||||||||||||
Db 20 CAGAAAACCGGGCAGAGCTG 1

RESULT 468
ADR82405/c
ID ADR82405 standard; DNA; 20 BP.
XX
AC ADR82405;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #76.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1818 CGTGCGGTTCCTGAAGACGT 1837
||||||||||||||||||||
Db 20 CGTGCGGTTCCTGAAGACGT 1

RESULT 469
ADR82428/c
ID ADR82428 standard; DNA; 20 BP.
XX
AC ADR82428;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #99.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1358 GGAGCGTGGTTTCCCGCCTG 1377
||||||||||||||||||||
Db 20 GGAGCGTGGTTTCCCGCCTG 1

RESULT 470
ADR82448/c
ID ADR82448 standard; DNA; 20 BP.
XX
AC ADR82448;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #119.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

```
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        958 AAAAAGTGCGCCCAGCTGAC 977
              ||||||||||||||||||||
Db         20 AAAAAGTGCGCCCAGCTGAC 1


RESULT 471
ADR82457/c
ID   ADR82457 standard; DNA; 20 BP.
XX
AC   ADR82457;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #128.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        778 TACATCAAGGTGGACACGGT 797
              ||||||||||||||||||||
Db         20 TACATCAAGGTGGACACGGT 1


RESULT 472
ADR82461/c
ID   ADR82461 standard; DNA; 20 BP.
XX
AC   ADR82461;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #132.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        698 AGGAGACCTTCACCGTCTTC 717
              ||||||||||||||||||||
Db         20 AGGAGACCTTCACCGTCTTC 1


RESULT 473
ADR82473/c
ID   ADR82473 standard; DNA; 20 BP.
XX
AC   ADR82473;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #144.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
```

```
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        458 CTGATCTGAAGTGGGTGACA 477
              ||||||||||||||||||||
Db         20 CTGATCTGAAGTGGGTGACA 1


RESULT 474
ADR82350/c
ID   ADR82350 standard; DNA; 20 BP.
XX
AC   ADR82350;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #21.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 99; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2919 CCTCCACCAGCTCATGCTGG 2938
              ||||||||||||||||||||
Db         20 CCTCCACCAGCTCATGCTGG 1


RESULT 475
ADR82397/c
ID   ADR82397 standard; DNA; 20 BP.
XX
AC   ADR82397;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #68.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
```

```
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1978 CGGGAGCAGCTGGCCCTGAT 1997
              ||||||||||||||||||||
Db         20 CGGGAGCAGCTGGCCCTGAT 1


RESULT 476
ADR82400/c
ID   ADR82400 standard; DNA; 20 BP.
XX
AC   ADR82400;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #71.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1918 TACGGGCCCTTCGGCCAGGA 1937
              ||||||||||||||||||||
Db         20 TACGGGCCCTTCGGCCAGGA 1


RESULT 477
ADR82436/c
ID   ADR82436 standard; DNA; 20 BP.
XX
AC   ADR82436;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #107.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
```

```
SQ   Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1198 ACCTTCAAGCCCCTGTCAGG 1217
              ||||||||||||||||||||
Db         20 ACCTTCAAGCCCCTGTCAGG 1


RESULT 478
ADR82478/c
ID   ADR82478 standard; DNA; 20 BP.
XX
AC   ADR82478;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #149.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 96;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        376 ATGGAGCTCCGGGTGCTGCT 395
              ||||||||||||||||||||
Db         20 ATGGAGCTCCGGGTGCTGCT 1


RESULT 479
ADR86990
ID   ADR86990 standard; DNA; 21 BP.
XX
AC   ADR86990;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 295.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 96; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 7 A; 9 C; 2 G; 0 T; 3 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 1.1e+02;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACT 1958
```

```
              ||:||||||||||||||||:
Db          1 CAUCACAGCCAGACCCAACU 20


RESULT 480
ADR86740
ID   ADR86740 standard; RNA; 21 BP.
XX
AC   ADR86740;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 45.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 5; Page 75; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 7 A; 9 C; 2 G; 0 T; 3 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 1.1e+02;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACT 1958
              ||:||||||||||||||||:
Db          1 CAUCACAGCCAGACCCAACU 20


RESULT 481
ADR82545
ID   ADR82545 standard; RNA; 21 BP.
XX
AC   ADR82545;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #56.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 9 C; 2 G; 0 T; 3 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 1.1e+02;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACT 1958
              ||:||||||||||||||||:
Db          1 CAUCACAGCCAGACCCAACU 20


RESULT 482
ADR82305
ID   ADR82305 standard; RNA; 21 BP.
XX
```

```
AC   ADR82305;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #7.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 81; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 7 A; 9 C; 2 G; 0 T; 3 U; 0 Other;

  Query Match             0.5%;  Score 20;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 1.1e+02;
  Matches   18;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1939 CATCACAGCCAGACCCAACT 1958
              ||:||||||||||||||||:
Db          1 CAUCACAGCCAGACCCAACU 20


RESULT 483
ADY89201
ID   ADY89201 standard; RNA; 23 BP.
XX
AC   ADY89201;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGF/VEGFR siRNA SEQ ID NO 2237.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW   pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2237; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGF/VEGFR siRNA.
XX
SQ   Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             0.5%;  Score 19.8;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 1.3e+02;
  Matches   16;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTGTTGGCA 2948
              ||| :||:||:||||:| :||||
Db          1 CAGAUCAUGCUGGACUGCUGGCA 23


RESULT 484
ADR86925/c
ID   ADR86925 standard; DNA; 21 BP.
XX
AC   ADR86925;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 230.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
```

```
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 4 A; 2 C; 12 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.3e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1328 CACCCTGCACCACCCCTCCTT 1348
              |||| ||||||||||||||||
Db         21 CACCGTGCACCACCCCTCCTT 1


RESULT 485
ADR86745/c
ID   ADR86745 standard; DNA; 21 BP.
XX
AC   ADR86745;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 50.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 5; Page 79; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 21 BP; 4 A; 2 C; 12 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.3e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1328 CACCCTGCACCACCCCTCCTT 1348
              |||| ||||||||||||||||
Db         21 CACCGTGCACCACCCCTCCTT 1


RESULT 486
ADR82480/c
ID   ADR82480 standard; DNA; 21 BP.
XX
AC   ADR82480;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #151.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
```

```
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 21 BP; 4 A; 2 C; 12 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.3e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1328 CACCCTGCACCACCCCTCCTT 1348
              |||| ||||||||||||||||
Db         21 CACCGTGCACCACCCCTCCTT 1


RESULT 487
ADR82310/c
ID   ADR82310 standard; DNA; 21 BP.
XX
AC   ADR82310;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #4.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 21 BP; 4 A; 2 C; 12 G; 3 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.3e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1328 CACCCTGCACCACCCCTCCTT 1348
              |||| ||||||||||||||||
Db         21 CACCGTGCACCACCCCTCCTT 1


RESULT 488
ADU31805
ID   ADU31805 standard; DNA; 21 BP.
XX
AC   ADU31805;
XX
DT   27-JAN-2005  (first entry)
XX
DE   Knock-down target sequence #5203.
XX
KW   ds; RNA production; protein production; drug development;
KW   knock-down target.
XX
OS   Unidentified.
XX
PN   WO2004094636-A1.
XX
PD   04-NOV-2004.
XX
PF   24-APR-2003; 2003WO-EP004362.
XX
PR   24-APR-2003; 2003WO-EP004362.
XX
PA   (GALA-) GALAPAGOS GENOMICS NV.
PA   (VSCH/) VAN DER SCHUEREN J.
XX
PI   Arts GJF,  Lambrecht MJY,  Djokic K,  Clasen RJ,  Mesic E;
PI   Griffioen S,  Bergs CJL;
XX
DR   WPI; 2004-775940/76.
XX
PT   New knockdown sequences, useful in lowering the amount of RNA and/or
PT   protein production in cells used in drug development process.
XX
```

```
PS   Claim 11; SEQ ID NO 5219; 402pp; English.
XX
CC   The invention relates to a polynucleotide comprising an RNA sequence. The
CC   polynucleotides, vector, libraries, and method are useful in lowering the
CC   amount of RNA and/or protein production in cells used in drug development
CC   process. The present sequence represents a knock-down target sequence.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.3e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2851 AATCAGGACGTGATCAATGCC 2871
              | ||||||||||||||||||||
Db          1 ACTCAGGACGTGATCAATGCC 21


RESULT 489
ADU31803
ID   ADU31803 standard; DNA; 21 BP.
XX
AC   ADU31803;
XX
DT   27-JAN-2005  (first entry)
XX
DE   Knock-down target sequence #5201.
XX
KW   ds; RNA production; protein production; drug development;
KW   knock-down target.
XX
OS   Unidentified.
XX
PN   WO2004094636-A1.
XX
PD   04-NOV-2004.
XX
PF   24-APR-2003; 2003WO-EP004362.
XX
PR   24-APR-2003; 2003WO-EP004362.
XX
PA   (GALA-) GALAPAGOS GENOMICS NV.
PA   (VSCH/) VAN DER SCHUEREN J.
XX
PI   Arts GJF,  Lambrecht MJY,  Djokic K,  Clasen RJ,  Mesic E;
PI   Griffioen S,  Bergs CJL;
XX
DR   WPI; 2004-775940/76.
XX
PT   New knockdown sequences, useful in lowering the amount of RNA and/or
PT   protein production in cells used in drug development process.
XX
PS   Claim 11; SEQ ID NO 5217; 402pp; English.
XX
CC   The invention relates to a polynucleotide comprising an RNA sequence. The
CC   polynucleotides, vector, libraries, and method are useful in lowering the
CC   amount of RNA and/or protein production in cells used in drug development
CC   process. The present sequence represents a knock-down target sequence.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.3e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1783 AAATACCATGAGAAGGGCGCC 1803
              | ||||||||||||||||||||
Db          1 ACATACCATGAGAAGGGCGCC 21


RESULT 490
ADU31804
ID   ADU31804 standard; DNA; 21 BP.
XX
AC   ADU31804;
XX
DT   27-JAN-2005  (first entry)
XX
DE   Knock-down target sequence #5202.
XX
KW   ds; RNA production; protein production; drug development;
KW   knock-down target.
XX
OS   Unidentified.
XX
PN   WO2004094636-A1.
XX
PD   04-NOV-2004.
XX
PF   24-APR-2003; 2003WO-EP004362.
XX
PR   24-APR-2003; 2003WO-EP004362.
XX
PA   (GALA-) GALAPAGOS GENOMICS NV.
PA   (VSCH/) VAN DER SCHUEREN J.
XX
PI   Arts GJF,  Lambrecht MJY,  Djokic K,  Clasen RJ,  Mesic E;
PI   Griffioen S,  Bergs CJL;
XX
DR   WPI; 2004-775940/76.
XX
PT   New knockdown sequences, useful in lowering the amount of RNA and/or
PT   protein production in cells used in drug development process.
XX
PS   Claim 11; SEQ ID NO 5218; 402pp; English.
XX
CC   The invention relates to a polynucleotide comprising an RNA sequence. The
CC   polynucleotides, vector, libraries, and method are useful in lowering the
CC   amount of RNA and/or protein production in cells used in drug development
CC   process. The present sequence represents a knock-down target sequence.
XX
SQ   Sequence 21 BP; 6 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 19.4;  DB 1;  Length 21;
  Best Local Similarity   95.2%;  Pred. No. 1.3e+02;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2715 AAAGATTCCCATCCGATGGAC 2735
              | ||||||||||||||||||||
Db          1 ACAGATTCCCATCCGATGGAC 21


RESULT 491
ADX00839/c
ID   ADX00839 standard; DNA; 22 BP.
XX
AC   ADX00839;
XX
DT   21-APR-2005  (first entry)
XX
DE   Human CYP2D6 gene 2988GtoA mutation detection reverse PCR primer #3.
XX
KW   DNA purification; SNP detection; cardiovascular-gen.; hypotensive;
KW   neuroleptic; antiarrhythmic; antiemetic; analgesic; anorectic;
KW   tranquilizer; antimanic; antidepressant; allelic variant; CYP2D6 gene;
KW   diagnosis; codeine dependence; depression; hepatitis C virus infection;
KW   psychosis; schizophrenia; Parkinsons disease; forensic; primer; PCR; ss.
XX
OS   Homo sapiens.
XX
PN   US2005032070-A1.
XX
PD   10-FEB-2005.
XX
PF   05-AUG-2003; 2003US-00635780.
XX
```

PR 05-AUG-2003; 2003US-00635780.
XX
PA (RAIM/) RAIMUNDO S.
PA (ZANG/) ZANGER U.
XX
PI Raimundo S, Zanger U;
XX
DR WPI; 2005-161644/17.
XX
PT Novel polynucleotide of molecular variants of Cytochrome P450 2D6
PT (CYP2D6) gene, capable of hybridizing to CYP2D6 gene, is useful in
PT diagnosing disease related to presence of molecular variant of CYP2D6
PT gene.
XX
PS Example 1; SEQ ID NO 16; 33pp; English.
XX
CC The invention relates to a polynucleotide (I) of molecular variants of
CC CYP2D6 gene, chosen from polynucleotide capable of hybridizing to CYP2D6
CC gene, where the polynucleotide consists of substitution of one or more
CC nucleotides at position corresponding to 4784, 4735 or 4087 of the CYP2D6
CC gene having a fully defined sequence (S1) of 9609 base pairs as given in
CC the specification. (I) is useful for identifying a diagnostic
CC composition, which involves (a) isolating (I) from several subgroups of
CC individuals, where one subgroup has no prevalence for CYP2D6 associated
CC disease, and one or more further subgroup(s) do have prevalence for a
CC CYP2D6 associated disease, and (b) identifying a single nucleotide
CC polymorphism by comparing the nucleic acid sequence of the polynucleotide
CC or the gene of one subgroup having no prevalence for a CYP2D6 associated
CC disease, with one or more further subgroup(s) having a prevalence for a
CC CYP2D6 associated disease. (I) is useful for diagnosing a disease related
CC to the presence of a molecular variant of a CYP2D6 gene or susceptibility
CC to such a disorder, which involves determining the presence of (I) in a
CC sample from a subject. (I) is useful for diagnosing whether a subject has
CC EM, IM or PM phenotype, and for determining whether an individual is at
CC risk for a toxic reaction, non-response, insufficient response, or
CC reduced metabolic activity of CYP2D6 to treatment with a CYP2D6
CC substrate. (I) is useful in selecting a subject suffering from a CYP2D6
CC substrate treatable disease for treatment with the substrate, and in
CC treating a subject suffering from a CYP2D6 substrate treatable disease.
CC (I) is useful for detecting variant polynucleotide of CYP2D6 gene in a
CC sample, which involves contacting (I) with the sample under conditions
CC allowing interaction of variant of CYP2D6 gene with several immobilized
CC targets on (I), and determining the binding of the polynucleotide or the
CC gene to the immobilized targets on (I). (I) is useful for diagnosing a
CC disease, which involves binding of the variant polynucleotide of CYP2D6
CC gene or the gene to the immobilized targets on (IV), where the binding
CC indicates the presence or the absence of the disease or a prevalence for
CC the disease. The disease is codeine dependence, depression, hepatitis C,
CC psychosis, schizophrenia or Parkinson's disease. (I) is useful for
CC diagnosing an altered activity of the CYP2D6 enzyme, and for diagnosing a
CC polynucleotide associated with IM phenotype of CYP2D6. (I) is useful in
CC diagnosing individual's genetic constitution of the CYP2D6 status, useful
CC in personalized medicine. (I) is used for prediction of the therapeutic
CC outcome of an individual with an established drug and for avoidance of
CC side effects/toxicity due to altered activity of CYP2D6 mediated by
CC different CYP2D6 alleles. (I) is useful as forensic markers. This
CC sequence corresponds to a PCR primer to amplify the exon 6 region of the
CC CYP2D6 gene for detection polymorphisms.
XX
SQ Sequence 22 BP; 2 A; 10 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3718 GGCAAGAAGGGGTGTCAGGGC 3738
||||||||||| ||||||||||
Db 21 GGCAAGAAGGAGTGTCAGGGC 1

RESULT 492
ADG75924
ID ADG75924 standard; DNA; 24 BP.
XX
AC ADG75924;
XX
DT 11-MAR-2004 (first entry)
XX
DE Immunostimulatory non-CpG oligonucleotide IMT 179 SeqID 26.
XX
KW ss; non-CpG; immunostimulatory; non-palindromic; immune response;
KW proliferation; differentiation; cytokine; antibody production; B-cell;
KW plasmacytoid dendritic cell; immunomodulator; gene therapy;
KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
KW renal cell carcinoma.
XX
OS Synthetic.
XX
PN WO2003101375-A2.
XX
PD 11-DEC-2003.
XX
PF 30-MAY-2003; 2003WO-EP005691.
XX
PR 30-MAY-2002; 2002CA-02388049.
XX
PA (IMMU-) IMMUNOTECH SA.
XX
PI Lopez RA;
XX
DR WPI; 2004-053333/05.
XX
PT New immunostimulatory oligonucleotide comprising non-palindromic nucleic
PT acid sequence motif, useful for inducing B-cell activation, treating,
PT preventing or ameliorating immune system disorder or tumoral disease e.g.
PT melanoma.
XX
PS Claim 14; SEQ ID NO 26; 139pp; English.
XX
CC This invention relates to novel immunostimulatory oligonucleotides that
CC contain a non-palindromic sequence motif. Specifically, it refers to DNA
CC oligonucleotides (without a CpG motif), which can stimulate an immune
CC response in animals of the order of primate, including humans. The immune
CC response is characterised by the proliferation, differentiation, cytokine
CC and antibody production in B-cells, as well as cell differentiation and
CC cytokine production in plasmacytoid dendritic cells. The present
CC invention describes immunomodulator compositions that also comprise an
CC antigen selected from, for example, viruses, bacteria, parasites, tumour
CC cells and glycolipids. As such, these DNA oligos can be used in gene
CC therapy for inducing B-cell activation, treating, preventing or
CC ameliorating an immune system disorder or a tumoural disease including
CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
CC carcinoma. This oligonucleotide sequence is an immunostimulatory non-CpG
CC variant DNA oligo, used in an exemplification of the invention.
XX
SQ Sequence 24 BP; 1 A; 1 C; 1 G; 21 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3897 TTTTTGTTTCTTCGTTTTGTTTTT 3920
||||| ||| ||| ||||||||||
Db 1 TTTTTTTTTTTTCATTTTGTTTTT 24

RESULT 493
ADG75971
ID ADG75971 standard; DNA; 24 BP.
XX
AC ADG75971;
XX
DT 11-MAR-2004 (first entry)
XX
DE Immunostimulatory non-CpG phosphorothioate DNA oligo IMT179 SeqID73.
XX

```
KW   ss; non-CpG; immunostimulatory; non-palindromic; immune response;
KW   proliferation; differentiation; cytokine; antibody production; B-cell;
KW   plasmacytoid dendritic cell; immunomodulator; gene therapy;
KW   chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
KW   renal cell carcinoma.
XX
OS   Synthetic.
XX
PN   WO2003101375-A2.
XX
PD   11-DEC-2003.
XX
PF   30-MAY-2003; 2003WO-EP005691.
XX
PR   30-MAY-2002; 2002CA-02388049.
XX
PA   (IMMU-) IMMUNOTECH SA.
XX
PI   Lopez RA;
XX
DR   WPI; 2004-053333/05.
XX
PT   New immunostimulatory oligonucleotide comprising non-palindromic nucleic
PT   acid sequence motif, useful for inducing B-cell activation, treating,
PT   preventing or ameliorating immune system disorder or tumoral disease e.g.
PT   melanoma.
XX
PS   Example 5; SEQ ID NO 73; 139pp; English.
XX
CC   This invention relates to novel immunostimulatory oligonucleotides that
CC   contain a non-palindromic sequence motif. Specifically, it refers to DNA
CC   oligonucleotides (without a CpG motif), which can stimulate an immune
CC   response in animals of the order of primate, including humans. The immune
CC   response is characterised by the proliferation, differentiation, cytokine
CC   and antibody production in B-cells, as well as cell differentiation and
CC   cytokine production in plasmacytoid dendritic cells. The present
CC   invention describes immunomodulator compositions that also comprise an
CC   antigen selected from, for example, viruses, bacteria, parasites, tumour
CC   cells and glycolipids. As such, these DNA oligos can be used in gene
CC   therapy for inducing B-cell activation, treating, preventing or
CC   ameliorating an immune system disorder or a tumoural disease including
CC   chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
CC   carcinoma. This oligonucleotide sequence is an immunostimulatory
CC   phosphorothioate non-CpG variant DNA oligo, used to determine the effect
CC   of oligo size on B cell proliferation and IL6 secretion in an
CC   exemplification of the invention.
XX
SQ   Sequence 24 BP; 1 A; 1 C; 1 G; 21 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 19.2;  DB 1;  Length 24;
  Best Local Similarity   87.5%;  Pred. No. 1.7e+02;
  Matches   21;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       3897 TTTTTGTTTCTTCGTTTTGTTTTT 3920
              ||||| ||| ||| ||||||||||
Db          1 TTTTTTTTTTTTCATTTTGTTTTT 24


RESULT 494
ADH17042/c
ID   ADH17042 standard; DNA; 19 BP.
XX
AC   ADH17042;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Reverse PCR primer used to amplify human EphB4 sequence.
XX
KW   tyrosine kinase activity; type 1 plasminogen activator inhibitor; PAI-1;
KW   TIMP-1; tissue inhibitor of metalloproteinase 1; vinculin;
KW   vascular endothelial growth factor; VEGF; placental growth factor; PLGF;
KW   migration inhibitory factor; MIG; PCR; primer; ss; human; RT-PCR; EphB4.
XX
OS   Homo sapiens.
XX
PN   WO2003097854-A2.
XX
PD   27-NOV-2003.
XX
PF   19-MAY-2003; 2003WO-US015711.
XX
PR   17-MAY-2002; 2002US-0380872P.
PR   24-FEB-2003; 2003US-0448874P.
PR   24-FEB-2003; 2003US-0448922P.
XX
PA   (SUGE-) SUGEN INC.
XX
PI   Morimoto A,  Deprimo S,  O'farrell A,  Smolich BD,  Manning WC;
PI   Walter SA,  Schilling JW,  Cherrington J;
XX
DR   WPI; 2004-042604/04.
XX
PT   Determining whether a test compound inhibits tyrosine kinase activity in
PT   a mammal by exposing the mammal to the test compound and measuring in the
PT   mammal the level of at least one of the measured proteins or mRNA
PT   transcripts.
XX
PS   Example K; SEQ ID NO 41; 408pp; English.
XX
CC   The invention relates to a novel method for determining whether a test
CC   compound inhibits tyrosine kinase activity in a mammal comprising
CC   measuring in the mammal the level of at least one of the proteins and/or
CC   mRNA transcripts or genes for such proteins comprising type 1 plasminogen
CC   activator inhibitor (PAI-1), TIMP-1 (tissue inhibitor of
CC   metalloproteinase 1), vinculin, vascular endothelial growth factor
CC   (VEGF), placental growth factor (PLGF), VEGF/PLGF heterodimers or
CC   migration inhibitory factor (MIG), exposing the mammal to the test
CC   compound and then measuring in the mammal the level of at least one of
CC   the proteins and/or mRNA transcripts previously measured. The method of
CC   the invention may be useful for determining whether a test compound
CC   inhibits tyrosine kinase activity in a mammal. The current sequence is
CC   that of the PCR primer which was used in the exemplification of the
CC   invention.
XX
SQ   Sequence 19 BP; 3 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3990 AACAGGGGCCCATCATCAT 4008
              ||||||||||||||||||
Db         19 AACAGGGGCCCATCATCAT 1


RESULT 495
ADQ60986
ID   ADQ60986 standard; RNA; 19 BP.
XX
AC   ADQ60986;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Anti-EPHB4 siRNA related DNA sequence SEQ ID NO:688.
XX
KW   ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW   RNA interference.
XX
OS   Synthetic.
XX
PN   WO2004045543-A2.
XX
PD   03-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-US036787.
XX
```

PR 14-NOV-2002; 2002US-0426137P.
PR 10-SEP-2003; 2003US-0502050P.
XX
PA (DHAR-) DHARMACON INC.
XX
PI Anastasia K, Angela R, Devin L, William M, Stephen S;
XX
DR WPI; 2004-420527/39.
XX
PT Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT by selecting a target gene and measuring the functionality of the
PT nucleotide sequences that are complementary to a stretch of nucleotides
PT of the target sequence.
XX
PS Example 12; SEQ ID NO 688; 199pp; English.
XX
CC The invention relates to a novel method for selecting siRNA (short
CC interfering RNA) comprising selecting an siRNA molecule of 19-25
CC nucleoside bases by selecting a target gene and measuring the
CC functionality of sequences of 19-25 nucleotides in length that are
CC substantially complementary to a stretch of nucleotides of the target
CC sequence, where the functionality is dependent upon non-target specific
CC criteria. Also claimed are methods for gene-silencing, developing an
CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC sequence consisting of GGGAGAUAGUGAUGAAGUA; GAAGUACAUCCAUUAUAAG;
CC GUACGACAACCGGGAGAUA; AGAUAGUGAUGAAGUACAU; UGAAGACUCUGCUCAGUUU;
CC CAUGCGGCCUCUGUUUGA; UGCGGCCUCUGUUUGAUUU; GAGAUAGUGAUGAAGUACA;
CC GGAGAUAGUGAUGAAGUAC; and GAAGACUCUGCUCAGUUUG. The siRNA molecule
CC comprises a sense strand and an anti-sense strand. The siRNA molecule
CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC pairs. The kit comprises at least two siRNA, comprising a first optimised
CC siRNA and a second optimised siRNA. The method is useful in selecting
CC siRNA for generating a gene silencing reagent. The present sequence is
CC used in the exemplification of the invention. The sequence is shown in
CC the specification as DNA, but described as siRNA.
XX
SQ Sequence 19 BP; 7 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1243 GCCAATAGCCACTCTAACA 1261
||||||||||||||||||
Db 1 GCCAATAGCCACTCTAACA 19

RESULT 496
ADQ60983
ID ADQ60983 standard; RNA; 19 BP.
XX
AC ADQ60983;
XX
DT 09-SEP-2004 (first entry)
XX
DE Anti-EPHB4 siRNA related DNA sequence SEQ ID NO:685.
XX
KW ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW RNA interference.
XX
OS Synthetic.
XX
PN WO2004045543-A2.
XX
PD 03-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-US036787.
XX
PR 14-NOV-2002; 2002US-0426137P.
PR 10-SEP-2003; 2003US-0502050P.
XX
PA (DHAR-) DHARMACON INC.
XX
PI Anastasia K, Angela R, Devin L, William M, Stephen S;
XX
DR WPI; 2004-420527/39.
XX
PT Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT by selecting a target gene and measuring the functionality of the
PT nucleotide sequences that are complementary to a stretch of nucleotides
PT of the target sequence.
XX
PS Example 12; SEQ ID NO 685; 199pp; English.
XX
CC The invention relates to a novel method for selecting siRNA (short
CC interfering RNA) comprising selecting an siRNA molecule of 19-25
CC nucleoside bases by selecting a target gene and measuring the
CC functionality of sequences of 19-25 nucleotides in length that are
CC substantially complementary to a stretch of nucleotides of the target
CC sequence, where the functionality is dependent upon non-target specific
CC criteria. Also claimed are methods for gene-silencing, developing an
CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC sequence consisting of GGGAGAUAGUGAUGAAGUA; GAAGUACAUCCAUUAUAAG;
CC GUACGACAACCGGGAGAUA; AGAUAGUGAUGAAGUACAU; UGAAGACUCUGCUCAGUUU;
CC CAUGCGGCCUCUGUUUGA; UGCGGCCUCUGUUUGAUUU; GAGAUAGUGAUGAAGUACA;
CC GGAGAUAGUGAUGAAGUAC; and GAAGACUCUGCUCAGUUUG. The siRNA molecule
CC comprises a sense strand and an anti-sense strand. The siRNA molecule
CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC pairs. The kit comprises at least two siRNA, comprising a first optimised
CC siRNA and a second optimised siRNA. The method is useful in selecting
CC siRNA for generating a gene silencing reagent. The present sequence is
CC used in the exemplification of the invention. The sequence is shown in
CC the specification as DNA, but described as siRNA.
XX
SQ Sequence 19 BP; 8 A; 4 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 GGACAAACACGGACAGTAT 2118
||||||||||||||||||
Db 1 GGACAAACACGGACAGTAT 19

RESULT 497
ADQ60984
ID ADQ60984 standard; RNA; 19 BP.
XX
AC ADQ60984;
XX
DT 09-SEP-2004 (first entry)
XX
DE Anti-EPHB4 siRNA related DNA sequence SEQ ID NO:686.
XX
KW ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW RNA interference.
XX
OS Synthetic.
XX
PN WO2004045543-A2.
XX
PD 03-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-US036787.
XX
PR 14-NOV-2002; 2002US-0426137P.
PR 10-SEP-2003; 2003US-0502050P.
XX
PA (DHAR-) DHARMACON INC.

XX
PI Anastasia K, Angela R, Devin L, William M, Stephen S;
XX
DR WPI; 2004-420527/39.
XX
PT Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT by selecting a target gene and measuring the functionality of the
PT nucleotide sequences that are complementary to a stretch of nucleotides
PT of the target sequence.
XX
PS Example 12; SEQ ID NO 686; 199pp; English.
XX
CC The invention relates to a novel method for selecting siRNA (short
CC interfering RNA) comprising selecting an siRNA molecule of 19-25
CC nucleoside bases by selecting a target gene and measuring the
CC functionality of sequences of 19-25 nucleotides in length that are
CC substantially complementary to a stretch of nucleotides of the target
CC sequence, where the functionality is dependent upon non-target specific
CC criteria. Also claimed are methods for gene-silencing, developing an
CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC sequence consisting of GGGAGAUAGUGAUGAAGUA; GAAGUACAUCCAUUAUAAG;
CC GUACGACAACCGGGAGAUA; AGAUAGUGAUGAAGUACAU; UGAAGACUCUGCUCAGUUU;
CC CAUGCGGCCUCUGUUUGA; UGCGGCCUCUGUUUGAUUU; GAGAUAGUGAUGAAGUACA;
CC GGAGAUAGUGAUGAAGUAC; and GAAGACUCUGCUCAGUUUG. The siRNA molecule
CC comprises a sense strand and an anti-sense strand. The siRNA molecule
CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC pairs. The kit comprises at least two siRNA, comprising a first optimised
CC siRNA and a second optimised siRNA. The method is useful in selecting
CC siRNA for generating a gene silencing reagent. The present sequence is
CC used in the exemplification of the invention. The sequence is shown in
CC the specification as DNA, but described as siRNA.
XX
SQ Sequence 19 BP; 6 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2132 GTACTAAGGTCTACATCGA 2150
||||||||||||||||||||
Db 1 GTACTAAGGTCTACATCGA 19

RESULT 498
ADQ60985
ID ADQ60985 standard; RNA; 19 BP.
XX
AC ADQ60985;
XX
DT 09-SEP-2004 (first entry)
XX
DE Anti-EPHB4 siRNA related DNA sequence SEQ ID NO:687.
XX
KW ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW RNA interference.
XX
OS Synthetic.
XX
PN WO2004045543-A2.
XX
PD 03-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-US036787.
XX
PR 14-NOV-2002; 2002US-0426137P.
PR 10-SEP-2003; 2003US-0502050P.
XX
PA (DHAR-) DHARMACON INC.
XX
PI Anastasia K, Angela R, Devin L, William M, Stephen S;
XX
DR WPI; 2004-420527/39.
XX
PT Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT by selecting a target gene and measuring the functionality of the
PT nucleotide sequences that are complementary to a stretch of nucleotides
PT of the target sequence.
XX
PS Example 12; SEQ ID NO 687; 199pp; English.
XX
CC The invention relates to a novel method for selecting siRNA (short
CC interfering RNA) comprising selecting an siRNA molecule of 19-25
CC nucleoside bases by selecting a target gene and measuring the
CC functionality of sequences of 19-25 nucleotides in length that are
CC substantially complementary to a stretch of nucleotides of the target
CC sequence, where the functionality is dependent upon non-target specific
CC criteria. Also claimed are methods for gene-silencing, developing an
CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC sequence consisting of GGGAGAUAGUGAUGAAGUA; GAAGUACAUCCAUUAUAAG;
CC GUACGACAACCGGGAGAUA; AGAUAGUGAUGAAGUACAU; UGAAGACUCUGCUCAGUUU;
CC CAUGCGGCCUCUGUUUGA; UGCGGCCUCUGUUUGAUUU; GAGAUAGUGAUGAAGUACA;
CC GGAGAUAGUGAUGAAGUAC; and GAAGACUCUGCUCAGUUUG. The siRNA molecule
CC comprises a sense strand and an anti-sense strand. The siRNA molecule
CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC pairs. The kit comprises at least two siRNA, comprising a first optimised
CC siRNA and a second optimised siRNA. The method is useful in selecting
CC siRNA for generating a gene silencing reagent. The present sequence is
CC used in the exemplification of the invention. The sequence is shown in
CC the specification as DNA, but described as siRNA.
XX
SQ Sequence 19 BP; 8 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2081 GGAGAGAAGCAGAATATTC 2099
||||||||||||||||||||
Db 1 GGAGAGAAGCAGAATATTC 19

RESULT 499
ADR86728
ID ADR86728 standard; RNA; 21 BP.
XX
AC ADR86728;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 33.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX

PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 3; Page 62; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 3 C; 7 G; 0 T; 6 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 849 GGTGAATGTCAAGACGCTG 867
||:|||:|:|||||||:|
Db 1 GGUGAAUGUCAAGACGCUG 19

RESULT 500
ADR86742
ID ADR86742 standard; RNA; 21 BP.
XX
AC ADR86742;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 47.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 75; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.4e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2679 CTCTTCCGATCCCACCTAC 2697
|:|::||||:||||||:||
Db 1 CUCUUCCGAUCCCACCUAC 19

RESULT 501
ADR86992
ID ADR86992 standard; DNA; 21 BP.
XX
AC ADR86992;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 297.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.

XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 96; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;

```
  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19
```

RESULT 502
ADR86989
ID ADR86989 standard; DNA; 21 BP.
XX
AC ADR86989;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 294.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX

PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 96; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 3 C; 7 G; 0 T; 6 U; 0 Other;

```
  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:||||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19
```

RESULT 503
ADR86771
ID ADR86771 standard; DNA; 21 BP.
XX
AC ADR86771;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 76.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.

XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 6; Page 89; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

```
  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19
```

RESULT 504
ADR86736
ID ADR86736 standard; RNA; 21 BP.
XX
AC ADR86736;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 41.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW RNA interferance; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 75; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

```
  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19
```

RESULT 505
ADR86729
ID ADR86729 standard; RNA; 21 BP.
XX
AC ADR86729;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interferance RNA seqid 34.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

```
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 3; Page 62; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 506
ADR86991
ID   ADR86991 standard; DNA; 21 BP.
XX
AC   ADR86991;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 296.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 96; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 507
ADR86738
ID   ADR86738 standard; RNA; 21 BP.
XX
AC   ADR86738;
```

```
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 43.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 5; Page 75; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 5 A; 3 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:|||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 508
ADR86988
ID   ADR86988 standard; DNA; 21 BP.
XX
AC   ADR86988;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrinB4 short interferance RNA seqid 293.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; short interferance RNA; siRNA;
KW   RNA interferance; gene silencing; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 96; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 siRNA that can be used to control EphB4
CC   expression.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19
```

```
RESULT 509
ADR82303
ID   ADR82303 standard; RNA; 21 BP.
XX
AC   ADR82303;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #5.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 81; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 5 A; 3 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:||||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 510
ADR82543
ID   ADR82543 standard; RNA; 21 BP.
XX
AC   ADR82543;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #54.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 511
ADR82544
ID   ADR82544 standard; RNA; 21 BP.
XX
AC   ADR82544;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #55.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
```

```
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 5 A; 3 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:|||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 512
ADR82307
ID   ADR82307 standard; RNA; 21 BP.
XX
AC   ADR82307;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #9.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 81; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 513
ADR82301
ID   ADR82301 standard; RNA; 21 BP.
XX
AC   ADR82301;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #3.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 81; 206pp; English.
XX
```

```
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 514
ADR82326
ID   ADR82326 standard; RNA; 21 BP.
XX
AC   ADR82326;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #11.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 6; Page 96; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        427 GAGACCCTGCTGAACACAA 445
              |||||||:||:||||||||
Db          1 GAGACCCUGCUGAACACAA 19


RESULT 515
ADR82295
ID   ADR82295 standard; DNA; 21 BP.
XX
AC   ADR82295;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human beta-actin RT-PCR primer #1.
XX
KW   human; ss; RT-PCR; primer; beta-actin; reverse transcriptase; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 3; Page 69; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human beta-
CC   actin reverse transcriptase (RT)-PCR primer.
XX
SQ   Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19
```

```
RESULT 516
ADR82294
ID   ADR82294 standard; RNA; 21 BP.
XX
AC   ADR82294;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #1.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 3; Page 68; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   siRNA.
XX
SQ   Sequence 21 BP; 5 A; 3 C; 7 G; 0 T; 6 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   78.9%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        849 GGTGAATGTCAAGACGCTG 867
              ||:|||:|:|||||||:|
Db          1 GGUGAAUGUCAAGACGCUG 19


RESULT 517
ADR82546
ID   ADR82546 standard; RNA; 21 BP.
XX
AC   ADR82546;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #57.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 518
ADR82547
ID   ADR82547 standard; RNA; 21 BP.
XX
AC   ADR82547;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense RNAi probe #58.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
```

```
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 103; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense RNAi probe.
XX
SQ   Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 519
ADR82660
ID   ADR82660 standard; RNA; 21 BP.
XX
AC   ADR82660;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 siRNA #2.
XX
KW   human; ss; siRNA; small interference RNA; RNA interference;
KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW   angiogenesis inhibitor.
XX
OS   Homo sapiens.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 3; Page 68; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   PCR primer.
XX
SQ   Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             0.4%;  Score 19;  DB 1;  Length 21;
  Best Local Similarity   73.7%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2679 CTCTTCCGATCCCACCTAC 2697
              |:|::||||:||||||:||
Db          1 CUCUUCCGAUCCCACCUAC 19


RESULT 520
ADJ14704
ID   ADJ14704 standard; DNA; 22 BP.
XX
AC   ADJ14704;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Debrisoquine 4-hydroxylase (CYP2D6)-related  PCR primer - SEQ ID 268.
XX
KW   SNP; single nucleotide polymorphism; cytochrome p450; CYP allele;
KW   debrisoquine 4-hydroxylase; 2D6; CYP2D6; human; ss; PCR; primer.
XX
OS   Unidentified.
XX
PN   US2003235848-A1.
XX
PD   25-DEC-2003.
XX
PF   11-APR-2003; 2003US-00411954.
XX
PR   11-APR-2002; 2002US-0371819P.
XX
PA   (NEVI/) NEVILLE M.
PA   (INDI/) INDIG M D A.
XX
PI   Neville M,  Indig MDA;
XX
DR   WPI; 2004-070577/07.
XX
PT   Characterizing a cytochrome p450 allele by amplifying Y target sequences
PT   with the primer set and detecting at least one of the footprint regions
PT   with the assay probe.
XX
PS   Example 3; SEQ ID NO 268; 55pp; English.
XX
CC   The invention relates to a novel method for characterising a cytochrome
CC   p450 (CYP) allele (or single nucleotide polymorphism [SNP]) which
CC   comprises providing a sample with at least Y target sequences, a primer
CC   set comprising a forward and a reverse primer sequence for each of the Y
CC   target sequences and at least one assay probe configured to detect a
```

```
CC   footprint region, amplifying the Y target sequences with the primer set
CC   and detecting at least one of the footprint regions with the assay probe.
CC   The method of the invention may be useful for characterising a cytochrome
CC   p450 allele. The current sequence is that of a debrisoquine 4-hydroxylase
CC   (cytochrome p450 2D6; CYP2D6)-related PCR primer of the invention.
XX
SQ   Sequence 22 BP; 7 A; 2 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 22;
  Best Local Similarity   90.9%;  Pred. No. 1.7e+02;
  Matches   20;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3716 GGGGCAAGAAGGGGTGTCAGGG 3737
              | ||||||||||  |||||||||
Db          1 GAGGCAAGAAGGAGTGTCAGGG 22


RESULT 521
ADJ14787
ID   ADJ14787 standard; DNA; 22 BP.
XX
AC   ADJ14787;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Debrisoquine 4-hydroxylase (CYP2D6)-related PCR primer 19.
XX
KW   SNP; single nucleotide polymorphism; cytochrome p450; CYP allele;
KW   debrisoquine 4-hydroxylase; 2D6; CYP2D6; human; ss; PCR; primer.
XX
OS   Unidentified.
XX
PN   US2003235848-A1.
XX
PD   25-DEC-2003.
XX
PF   11-APR-2003; 2003US-00411954.
XX
PR   11-APR-2002; 2002US-0371819P.
XX
PA   (NEVI/) NEVILLE M.
PA   (INDI/) INDIG M D A.
XX
PI   Neville M,  Indig MDA;
XX
DR   WPI; 2004-070577/07.
XX
PT   Characterizing a cytochrome p450 allele by amplifying Y target sequences
PT   with the primer set and detecting at least one of the footprint regions
PT   with the assay probe.
XX
PS   Example 1; Fig 5A; 55pp; English.
XX
CC   The invention relates to a novel method for characterising a cytochrome
CC   p450 (CYP) allele (or single nucleotide polymorphism [SNP]) which
CC   comprises providing a sample with at least Y target sequences, a primer
CC   set comprising a forward and a reverse primer sequence for each of the Y
CC   target sequences and at least one assay probe configured to detect a
CC   footprint region, amplifying the Y target sequences with the primer set
CC   and detecting at least one of the footprint regions with the assay probe.
CC   The method of the invention may be useful for characterising a cytochrome
CC   p450 allele. The current sequence is that of a debrisoquine 4-hydroxylase
CC   (cytochrome p450 2D6; CYP2D6)-related PCR primer of the invention.
XX
SQ   Sequence 22 BP; 7 A; 2 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 22;
  Best Local Similarity   90.9%;  Pred. No. 1.7e+02;
  Matches   20;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3716 GGGGCAAGAAGGGGTGTCAGGG 3737
              | ||||||||||  |||||||||
Db          1 GAGGCAAGAAGGAGTGTCAGGG 22


RESULT 522
ADO60807
ID   ADO60807 standard; DNA; 22 BP.
XX
AC   ADO60807;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human debrisoquine 4-hydroxylase, CYP2D6 PCR primer #5.
XX
KW   oligonucleotide detection assay; debrisoquine 4-hydroxylase; CYP2D6;
KW   cytochrome p450; human; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   US2004096874-A1.
XX
PD   20-MAY-2004.
XX
PF   10-JUL-2003; 2003US-00617070.
XX
PR   11-APR-2002; 2002US-0371819P.
PR   11-APR-2003; 2003US-00411954.
XX
PA   (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
PI   Neville M,  Indig MDA,  Cao F,  Oldenburg MC,  Koelbl JA;
PI   Aizenstein BD,  Davey K;
XX
DR   WPI; 2004-447680/42.
XX
PT   New kit comprising an oligonucleotide detection assay for detecting the
PT   number of CYP2D6 gene copies in a sample and for identifying CYP2D6
PT   associated polymorphisms.
XX
PS   Example 1; SEQ ID NO 268; 172pp; English.
XX
CC   The invention relates to a kit which comprises an oligonucleotide
CC   detection assay configured for detecting the number of debrisoquine 4-
CC   hydroxylase, CYP2D6, gene copies present in a sample and configured to
CC   identify the presence or absence of at least two CYP2D6 associated
CC   polymorphisms. The kit and methods are useful for characterising
CC   cytochrome p450 genes and alleles or for developing and optimising
CC   nucleic acid detection assays for use in basic research, clinical
CC   research and for the development of clinical detection assays. The
CC   present sequence represents a human debrisoquine 4-hydroxylase, CYP2D6
CC   PCR primer.
XX
SQ   Sequence 22 BP; 7 A; 2 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 18.8;  DB 1;  Length 22;
  Best Local Similarity   90.9%;  Pred. No. 1.7e+02;
  Matches   20;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3716 GGGGCAAGAAGGGGTGTCAGGG 3737
              | ||||||||||  |||||||||
Db          1 GAGGCAAGAAGGAGTGTCAGGG 22


RESULT 523
ADO60878
ID   ADO60878 standard; DNA; 22 BP.
XX
AC   ADO60878;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human debrisoquine 4-hydroxylase, CYP2D6 associated oligonucleotide #7.
XX
KW   oligonucleotide detection assay; debrisoquine 4-hydroxylase; CYP2D6;
KW   cytochrome p450; human; ss.
```

XX
OS Homo sapiens.
XX
PN US2004096874-A1.
XX
PD 20-MAY-2004.
XX
PF 10-JUL-2003; 2003US-00617070.
XX
PR 11-APR-2002; 2002US-0371819P.
PR 11-APR-2003; 2003US-00411954.
XX
PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
PI Neville M, Indig MDA, Cao F, Oldenburg MC, Koelbl JA;
PI Aizenstein BD, Davey K;
XX
DR WPI; 2004-447680/42.
XX
PT New kit comprising an oligonucleotide detection assay for detecting the
PT number of CYP2D6 gene copies in a sample and for identifying CYP2D6
PT associated polymorphisms.
XX
PS Disclosure; SEQ ID NO 339; 172pp; English.
XX
CC The invention relates to a kit which comprises an oligonucleotide
CC detection assay configured for detecting the number of debrisoquine 4-
CC hydroxylase, CYP2D6, gene copies present in a sample and configured to
CC identify the presence or absence of at least two CYP2D6 associated
CC polymorphisms. The kit and methods are useful for characterising
CC cytochrome p450 genes and alleles or for developing and optimising
CC nucleic acid detection assays for use in basic research, clinical
CC research and for the development of clinical detection assays. The
CC present sequence represents a human debrisoquine 4-hydroxylase, CYP2D6
CC associated oligonucleotide.
XX
SQ Sequence 22 BP; 7 A; 2 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3716 GGGGCAAGAAGGGGTGTCAGGG 3737
| |||||||||| |||||||||
Db 1 GAGGCAAGAAGGAGTGTCAGGG 22

RESULT 524
ADZ71126
ID ADZ71126 standard; DNA; 22 BP.
XX
AC ADZ71126;
XX
DT 14-JUL-2005 (first entry)
XX
DE Human CYP2D6 gene-specific PCR primer - SEQ ID 9.
XX
KW diabetic retinopathy; antidiabetic; ophthalmological; hepatotoxicity;
KW CYP2D6; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2005040415-A1.
XX
PD 06-MAY-2005.
XX
PF 05-OCT-2004; 2004WO-EP011123.
XX
PR 06-OCT-2003; 2003US-0508972P.
XX
PA (NOVS) NOVARTIS AG.
PA (NOVS) NOVARTIS PHARMA GMBH.
XX
PI Mccullough K, Wolfgang CD;
XX
DR WPI; 2005-346738/35.
XX
PT Use of N-benzoyl-staurosporine in manufacture of medicament for treatment
PT of diabetic retinopathy with reduced hepatotoxicity in patients selected
PT based on genotype of patients at IL1A genetic locus predictive of
PT hepatotoxicity.
XX
PS Example; SEQ ID NO 9; 55pp; English.
XX
CC The invention comprises a method of using N-benzoyl-staurosporine in the
CC manufacture of a medicament for the treatment of diabetic retinopathy
CC with reduced hepatotoxicity in a selected patient population. The patient
CC population is selected on the basis of the genotype of the patients at a
CC genetic locus within the IL1A gene - the IL1A genetic locus is predictive
CC of hepatotoxicity. The method of the invention is useful in the
CC manufacture of a medicament for the treatment of diabetic retinopathy
CC with reduced hepatotoxicity in a selected patient population. The present
CC DNA sequence represents a PCR primer that was used to amplify exons 7, 8
CC and 9 of the human CYP2D6 gene.
XX
SQ Sequence 22 BP; 7 A; 2 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3716 GGGGCAAGAAGGGGTGTCAGGG 3737
| |||||||||| |||||||||
Db 1 GAGGCAAGAAGGAGTGTCAGGG 22

RESULT 525
ADY89206
ID ADY89206 standard; RNA; 23 BP.
XX
AC ADY89206;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGF/VEGFR siRNA SEQ ID NO 2242.
XX
KW ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX

DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2242; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGF/VEGFR siRNA.
XX
SQ Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2927 AGCTCATGCTGGACTGTTGGCA 2948
|| :||:||:||||:| :||||
Db 1 AGAUCAUGCUGGACUGCUGGCA 22

RESULT 526
ADY89196
ID ADY89196 standard; RNA; 23 BP.
XX
AC ADY89196;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGF/VEGFR siRNA SEQ ID NO 2232.
XX
KW ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2232; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGF/VEGFR siRNA.
XX
SQ Sequence 23 BP; 4 A; 6 C; 7 G; 0 T; 6 U; 0 Other;

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2926 CAGCTCATGCTGGACTGTTGGC 2947
||| :||:||:||||:| :|||
Db 2 CAGAUCAUGCUGGACUGCUGGC 23

RESULT 527
ADY50241
ID ADY50241 standard; DNA; 23 BP.
XX
AC ADY50241;
XX
DT 05-MAY-2005 (first entry)
XX
DE Human beta-globin PCR primer SEQ ID NO 7.
XX
KW DNA purification; elution; beta-globin; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2005007852-A2.
XX
PD 27-JAN-2005.
XX
PF 09-JUL-2004; 2004WO-US022391.
XX
PR 09-JUL-2003; 2003US-0485972P.
XX
PA (GENV-) GENVAULT CORP.
XX
PI Davis JC, Hogan M;
XX
DR WPI; 2005-112868/12.
XX
PT Eluting nucleic acid from nucleic acid-containing sample e.g., human
PT blood sample on storage media, by contacting sample on storage media with
PT elution buffer, eluting nucleic acid from sample and recovering eluted
PT nucleic acid.
XX
PS Example 1; SEQ ID NO 7; 54pp; English.
XX
CC The invention describes a method of eluting nucleic acid from a nucleic
CC acid-containing sample e.g., human blood sample on storage media. The
CC method involves providing a nucleic acid containing sample, preferably
CC human blood sample on storage media, contacting the sample on storage
CC media with an elution buffer comprising 10 mM Tris having a pH of 11.0-
CC 12.0, preferably 11.5-11.7, eluting nucleic acid from the sample on
CC storage media, and recovering eluted nucleic acid, where the human blood
CC sample is contacted with a wash buffer which is then removed before being
CC contacted with the elution buffer. Also described is a kit (I) for
CC eluting nucleic acid from a nucleic acid containing sample on storage
CC media, comprising an elution buffer having a pH of 11.0-12.0 and
CC instruction unit for eluting nucleic acid from a sample on storage media.
CC (M1) is useful for eluting nucleic acid such as DNA or RNA from a nucleic
CC acid-containing sample, preferably a human blood sample on storage media.
CC (M1) and (I) are useful for optimizing nucleic acid recovery depending on
CC the sample storage media and the intended use. The DNA eluted by (M1) is
CC useful for numerous downstream applications including PCR based

```
CC   applications, short tandem repeat (STR) marker analysis, single
CC   nucleotide polymorphism (SNP) analysis and whole genome amplification
CC   (WGA). (M1) is simple, inexpensive and can be performed rapidly (30-60
CC   minutes). (M1) provides high quality DNA that can be used in various
CC   applications. (M1) avoids the use of toxic materials and is automation-
CC   compatible. This sequence represents a primer used to detect beta-globin
CC   from blood samples.
XX
SQ   Sequence 23 BP; 7 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 18.4;  DB 1;  Length 23;
  Best Local Similarity   95.0%;  Pred. No. 2e+02;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3720 CAAGAAGGGGTGTCAGGGCC 3739
              |||||||| ||||||||||
Db          1 CAAGAAGGAGTGTCAGGGCC 20


RESULT 528
ADR86930/c
ID   ADR86930 standard; DNA; 18 BP.
XX
AC   ADR86930;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 235.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 8; Page 94; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        692 CCTGCAAGGAGACCTTCA 709
              ||||||||||||||||||
Db         18 CCTGCAAGGAGACCTTCA 1


RESULT 529
ADR86749/c
ID   ADR86749 standard; DNA; 18 BP.
XX
AC   ADR86749;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 antisense oligonucleotide seqid 54.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; antisense technology;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
PT   scleroderma.
XX
PS   Example 5; Page 79; 198pp; English.
XX
CC   The invention describes an isolated soluble polypeptide comprising an
CC   amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC   protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
```

CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 499 TGGGAGGAACTGAGCGGC 516
||||||||||||||||||
Db 18 TGGGAGGAACTGAGCGGC 1

RESULT 530
ADR86750/c
ID ADR86750 standard; DNA; 18 BP.
XX
AC ADR86750;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 55.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 79; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 692 CCTGCAAGGAGACCTTCA 709
||||||||||||||||||
Db 18 CCTGCAAGGAGACCTTCA 1

RESULT 531
ADR86929/c
ID ADR86929 standard; DNA; 18 BP.
XX
AC ADR86929;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 234.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

```
CC   polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC   Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC   described are: an antagonist antibody that binds to an extracellular
CC   domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC   EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC   diagnostic kit, comprising the above soluble polypeptide or antagonist
CC   antibody, and a pharmaceutical carrier; methods of inhibiting
CC   angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC   cell; a method of reducing the growth rate of a tumour; methods for
CC   treating a patient suffering from a cancer or an angiogenesis-associated
CC   disease; and a method for identifying a tumor that is suitable for
CC   treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC   antibody is useful for manufacturing a medicament for the treatment of
CC   cancer or an angiogenesis-associated disease. The composition and methods
CC   are useful for diagnosing or treating cancer or angiogenesis-associated
CC   diseases, such as inflammatory disorders, chronic articular rheumatism,
CC   psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC   represents a human ephrin B4 antisense oligonucleotide that can be used
CC   to control EphB4 expression.
XX
SQ   Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        499 TGGGAGGAACTGAGCGGC 516
              ||||||||||||||||||
Db         18 TGGGAGGAACTGAGCGGC 1


RESULT 532
ADR82314/c
ID   ADR82314 standard; DNA; 18 BP.
XX
AC   ADR82314;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #8.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        499 TGGGAGGAACTGAGCGGC 516
              ||||||||||||||||||
Db         18 TGGGAGGAACTGAGCGGC 1


RESULT 533
ADR82484/c
ID   ADR82484 standard; DNA; 18 BP.
XX
AC   ADR82484;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #155.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
```

```
SQ   Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        499 TGGGAGGAACTGAGCGGC 516
              ||||||||||||||||||
Db         18 TGGGAGGAACTGAGCGGC 1


RESULT 534
ADR82315/c
ID   ADR82315 standard; DNA; 18 BP.
XX
AC   ADR82315;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense ODN #9.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 5; Page 85; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense oligodeoxynucleotide (ODN).
XX
SQ   Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        692 CCTGCAAGGAGACCTTCA 709
              ||||||||||||||||||
Db         18 CCTGCAAGGAGACCTTCA 1


RESULT 535
ADR82485/c
ID   ADR82485 standard; DNA; 18 BP.
XX
AC   ADR82485;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human EphB4 antisense probe #156.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R,  Gill P;
XX
DR   WPI; 2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 101; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        692 CCTGCAAGGAGACCTTCA 709
              ||||||||||||||||||
Db         18 CCTGCAAGGAGACCTTCA 1


RESULT 536
ADC16452/c
ID   ADC16452 standard; RNA; 22 BP.
XX
AC   ADC16452;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Short interfering double-stranded RNA oligonucleotide SEQ ID NO:177.
```

```
XX
KW   expression interference; expression inhibition; target gene;
KW   short interfering double stranded RNA; cytostatic; gene therapy;
KW   proliferative disease; cancer; ds.
XX
OS   Synthetic.
XX
PN   WO2003012052-A2.
XX
PD   13-FEB-2003.
XX
PF   30-JUL-2002; 2002WO-US024226.
XX
PR   30-JUL-2001; 2001US-0308640P.
PR   08-APR-2002; 2002US-0370970P.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
PA   (CARN-) CARNEGIE INST WASHINGTON.
PA   (IMCO-) IMPERIAL COLLEGE INNOVATIONS LTD.
XX
PI   Caplen NJ, Morgan RA, Fire A, Parrish S, Mousses S;
PI   Kallioniemi O, Cornelison JR, Alton EW, Griesenbach U;
XX
DR   WPI; 2003-248169/24.
XX
PT   New RNA comprising double stranded RNA and a 3' or 5' overhang having a
PT   length of 0-nucleotide to 5-nucleotides on each strand, useful as reverse
PT   genetic and/or therapeutic tools for interfering or inhibiting expression
PT   of a target gene.
XX
PS   Claim 71; SEQ ID NO 177; 176pp; English.
XX
CC   The present invention describes an RNA (I) used for the interference or
CC   inhibition of expression of a target gene, where (I) comprises double
CC   stranded RNA of 15-40 nucleotides in length and a 3' or 5' overhang
CC   having a length of 0-nucleotide to 5-nucleotides on each strand, where
CC   the sequence of the double stranded RNA is substantially identical to a
CC   portion of a mRNA or transcript of the target gene. Also described: (1)
CC   interfering with or inhibiting the expression of a target gene in a cell
CC   by exposing the cell to an amount of (I); (2) a gene silencing array
CC   comprising a substantially flat substrate, and addressably arrayed
CC   different double-stranded RNAs; (3) an array-based method of assessing a
CC   phenotypic effect of a double-stranded RNA on a target gene; (4)
CC   validating a gene as a potential drug target for a disease or condition;
CC   (5) selecting an optimised sequence of a double-stranded RNA for
CC   interference with or inhibition of expression of a target gene in a cell;
CC   and (6) a short double-stranded RNA effective for interfering with or
CC   inhibiting expression of a target gene comprising any of 311 20-78
CC   nucleotide sequences (see ADC16276 to ADC16586). (I) has cytostatic
CC   activity, and can be used in gene therapy. The RNAs are useful as reverse
CC   genetic and/or therapeutic tools for interfering or inhibiting expression
CC   of a target gene. They are useful for treating proliferative diseases,
CC   e.g. cancer.
XX
SQ   Sequence 22 BP; 3 A; 6 C; 6 G; 0 T; 7 U; 0 Other;

  Query Match             0.4%;  Score 18;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        516 CCTGGATGAGGAACAGCA 533
              ||||||||||||||||||
Db         21 CCTGGATGAGGAACAGCA 4


RESULT 537
ADJ78587
ID   ADJ78587 standard; DNA; 21 BP.
XX
AC   ADJ78587;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human cytochrome P450 isoenzyme 2D6 PCR primer SeqID25.
XX
KW   primer set; variant identification; cytochrome P450 isoenzyme 2D6;
KW   CYP2D6; chromosome 22q13.1; single nucleotide polymorphism; SNP;
KW   low frequency variant; pharmaceutical drugs metabolism; human; PCR;
KW   primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004009760-A2.
XX
PD   29-JAN-2004.
XX
PF   09-JUL-2003; 2003WO-US021468.
XX
PR   18-JUL-2002; 2002US-0397010P.
XX
PA   (BIOV-) BIOVENTURES INC.
XX
PI   Dawson EP;
XX
DR   WPI; 2004-132938/13.
XX
PT   New primer set useful for screening a polynucleotide sample to detect and
PT   identify variants in the cytochrome P450 isoenzyme 2D6 gene, and for
PT   detecting low frequency variants affecting pharmaceutical drugs
PT   metabolism.
XX
PS   Claim 1; SEQ ID NO 25; 51pp; English.
XX
CC   This invention relates to novel primer sets that can be used to screen a
CC   polynucleotide sample to detect and identify variants in the cytochrome
CC   P450 isoenzyme 2D6 (CYP2D6) gene. The gene is located on chromosome
CC   22q13.1 and contains several single nucleotide polymorphisms, the details
CC   of which are disclosed in the specification. The methods and compositions
CC   of the present invention are useful for screening a polynucleotide sample
CC   to detect and identify variants in the cytochrome P450 isoenzyme 2D6 gene
CC   and detecting low frequency variants affecting pharmaceutical drugs
CC   metabolism. The present sequence is that of a PCR primer which may be
CC   used in the primer sets of the invention.
XX
SQ   Sequence 21 BP; 7 A; 2 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 2.1e+02;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3715 GGGGGCAAGAAGGGGTGTCAG 3735
              || |||||||||| |||||||
Db          1 GGAGGCAAGAAGGAGTGTCAG 21


RESULT 538
ADM28915
ID   ADM28915 standard; DNA; 21 BP.
XX
AC   ADM28915;
XX
DT   01-JUL-2004  (first entry)
XX
DE   PCR primer #1 for human CYP2D6 gene exon 7-9.
XX
KW   Human; cytochrome P450 isoenzyme 2D6; CYP2D6 isoenzyme;
KW   altered metabolism; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   US2004072235-A1.
XX
PD   15-APR-2004.
XX
PF   12-NOV-2003; 2003US-00712363.
XX
```

PR 20-JUL-2001; 2001US-0306675P.
PR 18-JUL-2002; 2002US-00360790.
PR 09-JUL-2003; 2003WO-US021468.
XX
PA (DAWS/) DAWSON E P.
XX
PI Dawson EP;
XX
DR WPI; 2004-328568/30.
XX
PT Novel primer set for screening a polynucleotide sample to detect and
PT identify variants in the cytochrome P450 isoenzyme 2D6 (CYP2D6) gene in a
PT polynucleotide sample or a population.
XX
PS Claim 1; SEQ ID NO 25; 47pp; English.
XX
CC The present invention relates to a primer set that can be used to screen
CC a polynucleotide sample to detect and identify variants in the human
CC cytochrome P450 isoenzyme 2D6 (CYP2D6) gene. Also disclosed is a kit for
CC the above screening method, a method for predicting the potential for
CC altered metabolism of a substance, including one or more than one
CC pharmaceutical drug, by a first individual compared to a second control
CC individual, where the substance is metabolised by the CYP2D6 isoenzyme, a
CC purified or isolated variant of wild-type CYP2D6 isoenzyme having one or
CC more than one of the alterations chosen from F-I at position 120, F-F at
CC position 120, E-K at position 155, R-R at position 194, F-F at position
CC 219, L-L at position 276, H-H at position 324, R-STOP at position 344, Y-
CC C at position 355, H-H at position 361, V-FRAMESHIFT at position 363, E-K
CC at position 418, H-Y at position 478 and F-F at position 483. The primer
CC set is useful for screening a polynucleotide sample to detect and
CC identify the presence of one or more than one variant in the CYP2D6 gene
CC in the sample. The primer set permits amplification from a small
CC polynucleotide sample of selected portions of the coding portion of the
CC CYP2D6 gene, or amplification of the entire coding portion of CYP2D6, as
CC well as the flanking intronic sequences that are relevant to recognition
CC of splice sites. The primer set further permits the detection of genetic
CC variants of CYP2D6 without interference from pseudogenes or from
CC homologous or paralogous genes of non-CYP2D6 cytochrome p450 genes. The
CC primer set also permits the detection of low frequency variants that
CC affect pharmaceutical drugs metabolism, thereby decreasing the false
CC negative rate in variant screening. The present sequence represents a PCR
CC primer of the invention.
XX
SQ Sequence 21 BP; 7 A; 2 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3715 GGGGGCAAGAAGGGGTGTCAG 3735
|| |||||||||| |||||||
Db 1 GGAGGCAAGAAGGAGTGTCAG 21

RESULT 539
ADS00674/c
ID ADS00674 standard; DNA; 21 BP.
XX
AC ADS00674;
XX
DT 16-DEC-2004 (first entry)
XX
DE Nested PCR primer SAVI#9.
XX
KW PCR; ss; RNA transcription profile; exon marker; reverse transcription;
KW Type IIS restriction enzyme; exon tag; viral vector;
KW green fluorescent protein; SAVI; Serial analysis of vector integration;
KW functional genome annotation; high throughput sequencing;
KW exon-intron boundary; primer.
XX
OS Unidentified.
XX
PN US2004191873-A1.
XX
PD 30-SEP-2004.
XX
PF 26-MAR-2004; 2004US-00810976.
XX
PR 27-MAR-2003; 2003US-0458152P.
XX
PA (YOUN/) YOUNG W.
PA (LINK/) LINK C J.
XX
PI Young W, Link CJ;
XX
DR WPI; 2004-698722/68.
XX
PT Elucidating RNA transcription profile in eukaryotic cell by producing
PT cloned tags using construct having exon marker sequence and comparing
PT sequence tags to sequence database and identifying RNA transcript
PT specific to sequenced tags.
XX
PS Example 2; SEQ ID NO 5; 32pp; English.
XX
CC The invention relates to elucidating the RNA transcription profile in a
CC eukaryotic cell by introducing into the cell a polynucleotide construct
CC comprising an exon marker sequence, subjecting cDNA obtained by reverse
CC transcription to digestion with a first Type IIS restriction enzyme, self
CC -ligating the fragments, amplifying a region of the fragment containing
CC the exon tags, cloning the fragments, and comparing sequence tags to
CC sequence database. The tags obtained are typically 40 nucleotides in
CC length compared to 20 nucleotides obtained from prior art methods. Also
CC included are a polynucleotide construct (comprising, in a 5' to 3'
CC orientation, a splice acceptor sequence, a type IIS restriction enzyme
CC recognition site oriented so that it is capable of cleaving DNA fused
CC upstream of the 5' end of a marker exon, restriction enzyme recognition
CC site, marker exon, a type IIS restriction enzyme recognition site
CC oriented so that it is capable of cleaving sequences located downstream
CC of the 3' end of the marker exon, and splice donor sequence or comprising
CC a marker exon sequence flanked by a functional 5' splice acceptor
CC sequences and a 3' splice donor sequence, and where the marker exon
CC contains at least two RER sites at the 5' end of the marker exon, at
CC least one the 5' RER sites is recognized by a type IIS restriction enzyme
CC and oriented in such a way that a type IIS restriction enzyme cuts the
CC DNA outside the boundaries that define the marker exon, and the marker
CC exon contains at least two RER sites at the 3' end of the marker exon,
CC where at least one of the 3' RER sites is recognized by a Type IIS
CC restriction enzyme and oriented in such a way that a Type IIS restriction
CC enzyme cuts the DNA outside the boundaries that define the marker exon,
CC and where the restriction recognition sites are located close from the
CC border of the marker exon such that after cutting flanking exons generate
CC sequence tags of at least 8 nucleotides), a vector comprising the above
CC construct, a polynucleotide construct Pgt13, and a polynucleotide
CC construct pGTfso-M. The method further involves ligating the amplified
CC fragments together to form a concatamer prior to cloning. In the method,
CC the polynucleotide construct is contained within a (viral) vector (e.g. a
CC retroviral vector, a lentiviral vector and an adeno-associated viral
CC vector, preferably retroviral vector). The marker exon marker sequence
CC encodes a fluorescent protein, preferably a green fluorescent protein.
CC The method, referred to as SAVI (Serial analysis of vector (or viral)
CC integration) is useful for elucidating a RNA transcription profile in a
CC eukaryotic cell. The method is also useful for functional genome
CC annotation, high throughput sequencing and characterisation of exon-
CC intron boundaries, and for determining the relative transcriptional level
CC of tagged RNA variant. The method of the invention was used to analyse
CC the RNA transcription profile of 107 (unidentified) cells. The present
CC sequence is a nested PCR primer used to amplify the tags in the above
CC experiment.
XX
SQ Sequence 21 BP; 3 A; 9 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2410 CTGGAGGGCGTGGTCACCAAC 2430

```
                ||||||||||||||| | ||||
Db         21 CTGGAGGGCGTGGTGAACAAC 1


RESULT 540
ADJ14673
ID   ADJ14673 standard; DNA; 19 BP.
XX
AC   ADJ14673;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Debrisoquine 4-hydroxylase (CYP2D6)-related  PCR primer - SEQ ID 236.
XX
KW   SNP; single nucleotide polymorphism; cytochrome p450; CYP allele;
KW   debrisoquine 4-hydroxylase; 2D6; CYP2D6; human; ss; PCR; primer.
XX
OS   Unidentified.
XX
PN   US2003235848-A1.
XX
PD   25-DEC-2003.
XX
PF   11-APR-2003; 2003US-00411954.
XX
PR   11-APR-2002; 2002US-0371819P.
XX
PA   (NEVI/) NEVILLE M.
PA   (INDI/) INDIG M D A.
XX
PI   Neville M,  Indig MDA;
XX
DR   WPI; 2004-070577/07.
XX
PT   Characterizing a cytochrome p450 allele by amplifying Y target sequences
PT   with the primer set and detecting at least one of the footprint regions
PT   with the assay probe.
XX
PS   Example 3; SEQ ID NO 236; 55pp; English.
XX
CC   The invention relates to a novel method for characterising a cytochrome
CC   p450 (CYP) allele (or single nucleotide polymorphism [SNP]) which
CC   comprises providing a sample with at least Y target sequences, a primer
CC   set comprising a forward and a reverse primer sequence for each of the Y
CC   target sequences and at least one assay probe configured to detect a
CC   footprint region, amplifying the Y target sequences with the primer set
CC   and detecting at least one of the footprint regions with the assay probe.
CC   The method of the invention may be useful for characterising a cytochrome
CC   p450 allele. The current sequence is that of a debrisoquine 4-hydroxylase
CC   (cytochrome p450 2D6; CYP2D6)-related PCR primer of the invention.
XX
SQ   Sequence 19 BP; 6 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3719 GCAAGAAGGGGTGTCAGGG 3737
                ||||||||| |||||||||
Db          1 GCAAGAAGGAGTGTCAGGG 19


RESULT 541
ADO60900
ID   ADO60900 standard; DNA; 19 BP.
XX
AC   ADO60900;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human debrisoquine 4-hydroxylase, CYP2D6 associated oligonucleotide #29.
XX
KW   oligonucleotide detection assay; debrisoquine 4-hydroxylase; CYP2D6;
KW   cytochrome p450; human; ss.
XX
OS   Homo sapiens.
XX
PN   US2004096874-A1.
XX
PD   20-MAY-2004.
XX
PF   10-JUL-2003; 2003US-00617070.
XX
PR   11-APR-2002; 2002US-0371819P.
PR   11-APR-2003; 2003US-00411954.
XX
PA   (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
PI   Neville M,  Indig MDA,  Cao F,  Oldenburg MC,  Koelbl JA;
PI   Aizenstein BD,  Davey K;
XX
DR   WPI; 2004-447680/42.
XX
PT   New kit comprising an oligonucleotide detection assay for detecting the
PT   number of CYP2D6 gene copies in a sample and for identifying CYP2D6
PT   associated polymorphisms.
XX
PS   Disclosure; SEQ ID NO 361; 172pp; English.
XX
CC   The invention relates to a kit which comprises an oligonucleotide
CC   detection assay configured for detecting the number of debrisoquine 4-
CC   hydroxylase, CYP2D6, gene copies present in a sample and configured to
CC   identify the presence or absence of at least two CYP2D6 associated
CC   polymorphisms. The kit and methods are useful for characterising
CC   cytochrome p450 genes and alleles or for developing and optimising
CC   nucleic acid detection assays for use in basic research, clinical
CC   research and for the development of clinical detection assays. The
CC   present sequence represents a human debrisoquine 4-hydroxylase, CYP2D6
CC   associated oligonucleotide.
XX
SQ   Sequence 19 BP; 6 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3719 GCAAGAAGGGGTGTCAGGG 3737
                ||||||||| |||||||||
Db          1 GCAAGAAGGAGTGTCAGGG 19


RESULT 542
ADO60775
ID   ADO60775 standard; DNA; 19 BP.
XX
AC   ADO60775;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human debrisoquine 4-hydroxylase, CYP2D6 oligonucleotide #1.
XX
KW   oligonucleotide detection assay; debrisoquine 4-hydroxylase; CYP2D6;
KW   cytochrome p450; human; ss.
XX
OS   Homo sapiens.
XX
PN   US2004096874-A1.
XX
PD   20-MAY-2004.
XX
PF   10-JUL-2003; 2003US-00617070.
XX
PR   11-APR-2002; 2002US-0371819P.
PR   11-APR-2003; 2003US-00411954.
XX
PA   (THIR-) THIRD WAVE TECHNOLOGIES INC.
```

```
XX
PI   Neville M,  Indig MDA,  Cao F,  Oldenburg MC,  Koelbl JA;
PI   Aizenstein BD,  Davey K;
XX
DR   WPI; 2004-447680/42.
XX
PT   New kit comprising an oligonucleotide detection assay for detecting the
PT   number of CYP2D6 gene copies in a sample and for identifying CYP2D6
PT   associated polymorphisms.
XX
PS   Example 3; SEQ ID NO 236; 172pp; English.
XX
CC   The invention relates to a kit which comprises an oligonucleotide
CC   detection assay configured for detecting the number of debrisoquine 4-
CC   hydroxylase, CYP2D6, gene copies present in a sample and configured to
CC   identify the presence or absence of at least two CYP2D6 associated
CC   polymorphisms. The kit and methods are useful for characterising
CC   cytochrome p450 genes and alleles or for developing and optimising
CC   nucleic acid detection assays for use in basic research, clinical
CC   research and for the development of clinical detection assays. The
CC   present sequence represents a human debrisoquine 4-hydroxylase, CYP2D6
CC   oligonucleotide.
XX
SQ   Sequence 19 BP; 6 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3719 GCAAGAAGGGGTGTCAGGG 3737
              ||||||||| |||||||||
Db          1 GCAAGAAGGAGTGTCAGGG 19


RESULT 543
ADT01293/c
ID   ADT01293 standard; DNA; 19 BP.
XX
AC   ADT01293;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Novel mutant protein tyrosine kinase-related oligonucleotide SeqID1281.
XX
KW   tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
KW   tumourigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
KW   GUCY2F; MCCK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;
KW   guanylate cyclase stimulator; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004082458-A2.
XX
PD   30-SEP-2004.
XX
PF   18-FEB-2004; 2004WO-US004452.
XX
PR   21-FEB-2003; 2003US-0448537P.
PR   29-MAY-2003; 2003US-0473895P.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Bardelli A,  Parsons W,  Velculescu V,  Kinzler KW,  Vogelstein B;
XX
DR   WPI; 2004-718702/70.
XX
PT   Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCCK) and
PT   associated methods for diagnosing cancer and screening for anti-cancer
PT   agents.
XX
PS   Disclosure; SEQ ID NO 1281; 363pp; English.
XX
CC   This invention relates to a novel activated mutant protein tyrosine
CC   kinases and associated methods for diagnosing cancer and screening for
CC   anti-cancer agents. Protein kinases are signalling molecules involved in
CC   tumourigenesis. Mutational analysis of the human tyrosine kinase gene
CC   family identified somatic alteration sin 1 in 5 colorectal cancers, with
CC   the majority of mutations occurring in the NTRK3, FES, GUCY2F and
CC   MCCK/MLK4 genes. Most were identified in the kinase domain. The invention
CC   may be useful for the production of compounds with a cytostatic activity
CC   acting as protein tyrosine kinase inhibitors or guanylate cyclase
CC   stimulators. The invention may be useful for developing methods for
CC   detecting mutations involved in cancer or screening for anti-cancer
CC   agents. The present sequence is that of a human-derived oligonucleotide
CC   which is related to the invention.
XX
SQ   Sequence 19 BP; 6 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 19;
  Best Local Similarity   94.7%;  Pred. No. 2e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2928 GCTCATGCTGGACTGTTGG 2946
              ||||||||| |||||||||
Db         19 GCTCATGCTCGACTGTTGG 1


RESULT 544
ABL94275
ID   ABL94275 standard; DNA; 20 BP.
XX
AC   ABL94275;
XX
DT   29-JUL-2002  (first entry)
XX
DE   Human C/EBP beta phosphorothioate antisense oligonucleotide, SEQ ID:41.
XX
KW   Human; C/EBP beta; CCAAT/enhancer-binding protein beta; C/EPB2; LAP;
KW   TCF5; CRP2; NFIL6; IL6DBP; NF-M; AGP/EBP; Apc/EBP; transcription factor;
KW   tissue development; cellular function; proliferation; differentiation;
KW   hormone responsiveness; oxidative stress response;
KW   IL-6 signalling mediator; interleukin-6; carbohydrate metabolism;
KW   immunity; Th1 response; female fertility; gluconeogenesis; ovarian;
KW   cancer; tumour formation; type II; diabetes; infection; inflammation;
KW   expression inhibition; phosphorothioate; antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
FT                   cytosines are 5-methylcytosine"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
FT                   cytosines are 5-methylcytosine"
XX
PN   US6271030-B1.
XX
PD   07-AUG-2001.
XX
PF   14-JUN-2000; 2000US-00593711.
XX
PR   14-JUN-2000; 2000US-00593711.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Butler MM,  Wyatt J;
XX
```

```
DR   WPI; 2002-214451/27.
XX
PT   Novel antisense compound targeted to nucleic acids encoding human or
PT   mouse CCAAT/enhancer binding protein (C/EBP) beta, useful in vitro for
PT   inhibiting expression of human or mouse C/EBP beta in cells/tissues.
XX
PS   Claim 1; Col 42; 69pp; English.
XX
CC   Sequences ABL94252-ABL94476 represent antisense oligonucleotides targeted
CC   to the human or mouse CCAAT/enhancer-binding protein alpha (C/EBP alpha)
CC   gene, which inhibit its expression. The antisense oligonucleotides were
CC   designed to target different regions of the human and/or mouse C/EBP
CC   alpha RNA, and were analysed for their effect on C/EBP alpha mRNA levels
CC   by quantitative real-time PCR. The C/EBP family of proteins are a family
CC   of transcription factors which regulate the expression of a wide range of
CC   genes that control normal tissue development, cellular function, cellular
CC   proliferation and functional differentiation. C/EBP beta (also known as
CC   C/EPB2, LAP, TCF5, CRP2, NFIL6, IL6DBP, NF-M, AGP/EBP and Apc/EBP)
CC   primarily regulates hormone responsiveness and oxidative stress responses
CC   and is a mediator of IL-6 (interleukin-6) signalling. C/EBP beta is
CC   thought to be involved in carbohydrate metabolism, immunity, the Th1
CC   response, female fertility and gluconeogenic pathways. C/EBP beta is
CC   expressed in the liver, lung, spleen, kidney, brain, and testis, with the
CC   highest expression found in the lung. It is also expressed at a higher
CC   level in malignant ovarian tissue compared with normal ovarian tissue,
CC   and its expression in pancreas is upregulated in response to chronically
CC   elevated levels of glucose, indicating that it is involved in the
CC   impairment of insulin secretion in type II diabetes. The oligonucleotides
CC   of the invention are useful for diagnosis, prevention and treatment of
CC   conditions associated with C/EBP beta expression, such as cancer
CC   (particularly ovarian cancer), tumour formation, diabetes (particularly
CC   type II diabetes), infection, or inflammation
XX
SQ   Sequence 20 BP; 0 A; 12 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        214 GCCGCCGCCCGGTGCCCCG 232
              ||||||||||||  ||||||
Db          1 GCCGCCGCCCGGCGCCCCG 19


RESULT 545
ADC26603
ID   ADC26603 standard; DNA; 20 BP.
XX
AC   ADC26603;
XX
DT   18-DEC-2003  (first entry)
XX
DE   CYP2D6-specific primer 1 used to identify CYP2D6E7_339 polymorphism.
XX
KW   statin response; cytochrome p450 3A4; CYP3A4; 2D6; CYP2D6;
KW   3-hydroxy-3-methylglutaryl-coenzyme A reductase; HMGCR; atorvastatin;
KW   simvastatin; serum cholesterol level; heart attack; human; ss; PCR;
KW   primer.
XX
OS   Homo sapiens.
XX
PN   WO2003002721-A2.
XX
PD   09-JAN-2003.
XX
PF   01-JUL-2002; 2002WO-US020847.
XX
PR   29-JUN-2001; 2001US-0301867P.
PR   07-AUG-2001; 2001US-0310783P.
PR   13-SEP-2001; 2001US-0322478P.
XX
PA   (DNAP-) DNAPRINT GENOMICS INC.
XX
PI   Frudakis T;
XX
DR   WPI; 2003-239174/23.
XX
PT   Inferring a statin response from a nucleic acid sample, by haplotype
PT   allele indicative of statin response, a decrease in total cholesterol, or
PT   in low density lipoprotein infers a statin response of the subject.
XX
PS   Example 1; SEQ ID NO 13; 323pp; English.
XX
CC   The invention relates to a novel method for inferring a statin response
CC   from a nucleic acid sample comprising identifying in the nucleic acid
CC   sample, at least one haplotype allele indicative of a statin response.
CC   The haplotype allele may comprise nucleotides of the cytochrome p450 3A4
CC   (CYP3A4) gene, nucleotides of the cytochrome p450 2D6 (CYP2D6) gene or
CC   nucleotides of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase
CC   (HMGCR) gene. The method of the invention may be useful for inferring a
CC   statin response of a human subject from a nucleic acid sample, where the
CC   human subject is a Caucasian subject and the statin is atorvastatin or
CC   simvastatin. The method may also be useful for determining whether to
CC   prescribe statin to a patient with elevated serum cholesterol levels in
CC   order to prevent heart attack. The current sequence is that of the PCR
CC   primer of the invention which was used to identify the human CYP2D6E7_339
CC   polymorphism DNA.
XX
SQ   Sequence 20 BP; 7 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 2.1e+02;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3718 GGCAAGAAGGGGTGTCAGG 3736
              ||||||||||  ||||||||
Db          2 GGCAAGAAGGAGTGTCAGG 20


RESULT 546
ADR86762/c
ID   ADR86762 standard; DNA; 19 BP.
XX
AC   ADR86762;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human ephrin B4 RT-PCR primer seqid 67.
XX
KW   cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW   pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; human; ephrin B4; reverse transcriptase PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080425-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007755.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Krasnoperov V,  Zozulya S,  Keretesz N,  Reddy R,  Gill P;
XX
DR   WPI; 2004-668883/65.
XX
PT   New soluble polypeptides comprising an extracellular domain of EphB4 or
PT   Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT   associated diseases, such as inflammatory disorders, psoriasis or
```

PT scleroderma.
XX
PS Example 6; Page 86; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a primer used in the isolation of human ephrin B4 cDNA.
XX
SQ Sequence 19 BP; 4 A; 7 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1955 AACTGGATGAGAGCGAG 1971
||||||||||||||||||
Db 19 AACTGGATGAGAGCGAG 3

RESULT 547
ADR82668/c
ID ADR82668 standard; DNA; 19 BP.
XX
AC ADR82668;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 RT-PCR primer #4.
XX
KW human; ss; RT-PCR; primer; reverse transcriptase; EphB4; EphrinB2;
KW cancer; angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 6; Page 93; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC reverse transcriptase (RT)-PCR primer.
XX
SQ Sequence 19 BP; 4 A; 7 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1955 AACTGGATGAGAGCGAG 1971
||||||||||||||||||
Db 19 AACTGGATGAGAGCGAG 3

RESULT 548
AAQ27541
ID AAQ27541 standard; DNA; 20 BP.
XX
AC AAQ27541;
XX
DT 29-JAN-1993 (first entry)
XX
DE PCR Primer P5(1) corresponds to TKF receptor nts. 628-647.
XX
KW TKF; tumour diagnosis; polymerase chain reaction; PCR;
KW fibroblast growth factor; human; Tyrosine Kinase receptor; ss.
XX
OS Synthetic.
XX
PN DE4104240-A.
XX
PD 13-AUG-1992.
XX
PF 12-FEB-1991; 91DE-04104240.
XX
PR 12-FEB-1991; 91DE-04104240.
XX
PA (GEOR-) GEORG-SPEYER-HAUS CHEMOTHERAPEUTISCHES.
XX
PI Holtrich U, Braeuninger A, Strebhardt K, Ruebsamen-Waigmann H;
XX
DR WPI; 1992-277527/34.
XX
PT New tyrosine kinase receptor protein related to FGF receptor proteins -
PT and corresponding DNA sequences, used in treatment and diagnosis of lung
PT tumours.
XX
PS Example 1; Page 11; 12pp; German.
XX
CC Primer P5(1) corresponds to nucleotides 628-647 of a human TKF receptor
CC (see AAQ27537). P5(1) was used with a second primer (AAQ27540) to amplify
CC partial sequences of previously unknown TKF receptor genes from cDNA
CC prepared from human lung tissue RNA. The two primers are based on
CC sequences which are highly conserved among known members of the TKF
CC receptor family. See AAQ27539-Q27544
XX
SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2584 GTCCACCGAGACCTGGC 2600
              |||||||||||||||||
Db          4 GTCCACCGAGACCTGGC 20


RESULT 549
AAQ64160
ID   AAQ64160 standard; DNA; 20 BP.
XX
AC   AAQ64160;
XX
DT   25-MAR-2003  (revised)
DT   03-FEB-1995  (first entry)
XX
DE   Primer for amplifying tyrosine kinase receptor coding sequence.
XX
KW   Tyrosine kinase; receptor; proto-oncogene; trk; detection; diagnosis;
KW   antibody; treatment; tumour; antisense; ss.
XX
OS   Synthetic.
XX
PN   DE4239817-A1.
XX
PD   01-JUN-1994.
XX
PF   26-NOV-1992;   92DE-04239817.
XX
PR   26-NOV-1992;   92DE-04239817.
XX
PA   (CHEM-) CHEMOTHERAPEUTISCHES FORSCHUNG.
XX
PI   Strebhardt K,  Ruebsamen-Waigmann H,  Holtrich U;
XX
DR   WPI; 1994-184380/23.
XX
PT   New protein tyrosine kinase and related nucleic acid - vectors,
PT   transformed cells, etc., useful for diagnosis and treatment of tumours.
XX
PS   Example 1; Page 9; 9pp; German.
XX
CC   Three primers (AAQ64159-Q64161) were used to amplify regions of the
CC   protein tyrosine kinase receptor. The gene encoding the receptor is
CC   related to the trk proto-oncogene. Antibodies against the encoded
CC   polypeptide are useful for diagnosis and for the treatment of tumours.
CC   The antibodies may also be radiolabelled or coupled to a cytotoxin for
CC   destruction of cancer cells. Antisense nucleic acid can be used to
CC   inhibit gene expression. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 17;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2584 GTCCACCGAGACCTGGC 2600
              |||||||||||||||||
Db          4 GTCCACCGAGACCTGGC 20


RESULT 550
AAZ18209
ID   AAZ18209 standard; DNA; 20 BP.
XX
AC   AAZ18209;
XX
DT   11-OCT-1999  (first entry)
XX
DE   Tyrosine kinase gene specific primer 400.
XX
KW   Genetic proximity; gene expression; cell characterisation; homeobox gene;
KW   genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KW   kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KW   primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9934016-A2.
XX
PD   08-JUL-1999.
XX
PF   28-DEC-1998;   98WO-IL000625.
XX
PR   29-DEC-1997;   97IL-00122793.
PR   16-OCT-1998;   98IL-00126627.
XX
PA   (GENE-) GENENA LTD.
XX
PI   Vider B;
XX
DR   WPI; 1999-419113/35.
DR   P-PSDB; AAY14743.
XX
PT   Identifying and characterizing cells by comparing the pattern of gene
PT   expression in a selected gene family.
XX
PS   Claim 4; Page 48; 102pp; English.
XX
CC   The invention provides a new method for identifying and characterising
CC   cells. The method for determining the genetic proximity of a first cell
CC   and a second cell comprises: (a) obtaining the first cell and the second
CC   cell; (b) determining in the first cell and the second cell the pattern
CC   of expression of genes in a selected gene family; and (c) calculating a
CC   proximity index using a specified formula. The methods can be used for
CC   characterising cells, e.g. for determining the origin of a cell, its
CC   genetic status, whether it carries a genetic defect, or whether it is
CC   transformed. They can be used for detecting a selected genetic defect in
CC   an individual, e.g. a fetus. They can also be used for determining the
CC   effect of a selected treatment on a test cell. They can also be used for
CC   obtaining cells capable of expressing an homeobox related desired
CC   property. The method uses reverse transcriptase polymerase chain reaction
CC   (RT-PCR) for determining the pattern of gene expression in a selected
CC   gene family. Sequences AAZ17803-Z18342 represent primers that can be used
CC   in the RT-PCR reactions to determine the pattern of gene expression. The
CC   gene family can be selected from a set of homeobox genes, kinase genes,
CC   protein phosphatase genes, P450 enzyme genes, steroid receptor
CC   superfamily genes or cadherin superfamily genes
XX
SQ   Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2.6e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2638 AAAGTGTCTGACTTTGGCCT 2657
              ||||| || ||||||||||
Db          1 AAAGTCTCAGACTTTGGCCT 20


RESULT 551
AAZ02532/c
ID   AAZ02532 standard; DNA; 20 BP.
XX
AC   AAZ02532;
XX
DT   07-OCT-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KW   Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW   paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;
KW   nongonococcal uretritis; epidymitis; cervicitis; salpingitis; PCR primer;
KW   bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS   Synthetic.
```

```
OS   Chlamydia trachomatis.
XX
PN   WO9928475-A2.
XX
PD   10-JUN-1999.
XX
PF   27-NOV-1998;   98WO-IB001939.
XX
PR   28-NOV-1997;   97FR-00015041.
PR   17-DEC-1997;   97FR-00016034.
PR   04-NOV-1998;   98US-0107077P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-371125/31.
XX
PT   Genome sequence of Chlamydia trachomatis.
XX
PS   Disclosure; Page 1532; 1755pp; English.
XX
CC   PCR primers AAZ01426-Z06209 were used to amplify open reading frames
CC   (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC   encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC   against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC   be used to control growth of the microorganism. Chlamydia trachomatis is
CC   responsible for a large number of diseases, e.g. eye diseases such as
CC   conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC   conjunctivitis; genital diseases such as nongonococcal uretritis,
CC   epidymitis, cervicitis, salpingitis, perihepatitis, bartholinitis;
CC   pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC   The polypeptides of the invention may be of use in treating these
CC   diseases
XX
SQ   Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2.6e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2714 GAAAGATTCCCATCCGATGG 2733
                ||||||| ||| ||||||||
Db         20 GAAAGATACCCTTCCGATGG 1


RESULT 552
ADC65757/c
ID   ADC65757 standard; DNA; 20 BP.
XX
AC   ADC65757;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human TGF-beta receptor II targeted antisense oligonucleotide #34.
XX
KW   human; antisense oligonucleotide;
KW   transforming growth factor beta receptor II; TGF-beta receptor II;
KW   hyperproliferative disorder; breast cancer; autoimmune disorder;
KW   rheumatoid arthritis; 2'-O-methoxyethyl gapmer;
KW   phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003000656-A2.
XX
PD   03-JAN-2003.
XX
PF   19-JUN-2002; 2002WO-US019665.
XX
PR   21-JUN-2001; 2001US-00888361.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Murray SF,  Wyatt JR;
XX
DR   WPI; 2003-175279/17.
XX
PT   New compound having a sequence targeted to a nucleic acid encoding
PT   Transforming growth factor beta-receptor II, useful for preparing a
PT   composition for treating hyperproliferative disorder e.g., lung, liver,
PT   colon or gastric cancer.
XX
PS   Claim 3; SEQ ID NO 53; 141pp; English.
XX
CC   The invention comprises antisense oligonucleotides that are targeted to
CC   the nucleic acid encoding transforming growth factor beta (TGF-beta)
CC   receptor II. The antisense oligonucleotides of the invention are useful
CC   for treating: hyperproliferative disorders (e.g. breast cancer), or an
CC   autoimmune disorder (e.g. rheumatoid arthritis). The present DNA sequence
CC   represents a 2'-O-methoxyethyl gapmer oligonucleotide with a
CC   phosphorothioate backbone that is targeted to human TGF-beta receptor II.
XX
SQ   Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 20;
  Best Local Similarity   90.0%;  Pred. No. 2.6e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2642 TGTCTGACTTTGGCCTTTCC 2661
                ||| ||||||||| ||||||
Db         20 TGTGTGACTTTGGGCTTTCC 1


RESULT 553
ADU78633/c
ID   ADU78633 standard; DNA; 20 BP.
XX
AC   ADU78633;
XX
DT   27-JAN-2005  (first entry)
XX
DE   Antisense oligonucleotide, SEQ ID 6.
XX
KW   Neuroprotective; Antidepressant; Neuroleptic; Tranquilizer;
KW   Antiparkinsonian; Nootropic; Antidiabetic; Anorectic;
KW   Cardiovascular-Gen.; Antiarteriosclerotic; Antilipemic;
KW   Alzheimer's disease; neurological disorder; phosphatase; enzyme;
KW   antisense; ss.
XX
OS   Homo sapiens.
XX
PN   US2004226056-A1.
XX
PD   11-NOV-2004.
XX
PF   09-FEB-2004; 2004US-00776013.
XX
PR   22-DEC-1998;   98US-0113534P.
PR   12-MAR-1999;   99US-0124120P.
PR   30-JUN-1999;   99US-0141243P.
PR   21-DEC-1999;   99US-00466139.
PR   17-OCT-2000; 2000US-0240790P.
PR   13-JUL-2001; 2001US-0304775P.
PR   10-SEP-2001; 2001US-00948904.
PR   12-OCT-2001; 2001US-00975072.
PR   15-JUL-2002; 2002US-00194967.
XX
PA   (MYRI-) MYRIAD GENETICS INC.
XX
PI   Roch J,  Bartel P,  Heichman K;
XX
DR   WPI; 2004-794772/78.
XX
PT   Selecting agents useful for treating Alzheimer's disease comprises
PT   contacting focal adhesion kinase 2 with a test agent and measuring a
```

PT biological activity related to focal adhesion kinase 2 function with or
PT without the test agent.
XX
PS Disclosure; SEQ ID NO 6; 247pp; English.
XX
CC The present invention relates to a method for selecting agents that are
CC potentially useful for the treatment of Alzheimer's disease. The method
CC comprises contacting Focal Adhesion Kinase 2 (FAK2) with a test agent and
CC measuring a biological activity related to FAK2 function in the presence
CC and absence of the test agent. The method is useful for screening
CC compounds or agents that can be used to treat neurological disorders,
CC ailments and diseases including mild cognitive impairment, depression,
CC schizophrenia, obsessive-compulsive disorder, bipolar disorder, and
CC neurodegenerative diseases and disorders and motor neuron diseases and
CC disorders such as Alzheimer's disease, Parkinson's disease, dementia with
CC Lewy bodies, amyotrophic lateral sclerosis or Lou Gehrig's disease,
CC Alpers' disease, Leigh's disease, Pelizaeus-Merbacher disease,
CC Olivopontocerebellar atrophy, Friedreich's ataxia, leukodystrophies, Rett
CC syndrome, Ramsay Hunt syndrome type II, and Down's syndrome, as well as
CC for treating or preventing other diseases such as dislipidemia, diabetes,
CC obesity, cardiovascular diseases such as atherosclerosis and coronary
CC heart disease. Also disclosed is the coding sequence for a novel human
CC phosphatase called PN7740 (ADU78628 and ADU78629). PN7740 contains a
CC protein phosphatase 2C domain, which likely acts to dephosphorylate
CC specific phospho-serine or phospho-threonine residues on particular
CC protein substrates. Although the precise role played by protein
CC phosphatase 2Cs in Alzheimer's disease pathogenesis has yet to be
CC defined, the inventors have discovered that fragments of PN7740 interact
CC with the first phosphotyrosine binding domain (PTB) domain of Fe65 (also
CC known as APBB1(710) or amyloid beta (A4) precursor protein-binding,
CC family B, member 1, isoform E9 (710)), suggesting that PN7740 may well be
CC involved somehow. Fe65 is known to interact with the cytosolic C-terminal
CC region of Amyloid beta (A4) precursor protein (APP) and APP metabolism is
CC critical to the pathogenesis of Alzheimer's disease, because it leads to
CC the release of either toxic Abeta or trophic secreted APP (sAPP)
CC metabolites. The present sequence is an antisense oligonucleotide which
CC can be used in antisense therapy for Alzheimer's disease.
XX
SQ Sequence 20 BP; 2 A; 7 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 367 GGCGGCGCCATGGAGCTCCG 386
||| ||||||||||||||||
Db 20 GGCCCCGCCATGGAGCTCCG 1

RESULT 554
ADW83103/c
ID ADW83103 standard; DNA; 20 BP.
XX
AC ADW83103;
XX
DT 07-APR-2005 (first entry)
XX
DE MAP3K9 marker amplification reverse primer #571.
XX
KW mixed lineage kinase; MLK; asthma; at-risk haplotype; MAP3K9;
KW antiasthmatic; respiratory-gen.; antiinflammatory; antirheumatic;
KW antiarthritic; antipsoriatic; neuroprotective; gastrointestinal-gen.;
KW respiratory disease; chronic obstructive pulmonary disease;
KW chronic bronchitis; inflammation; ss; primer; PCR.
XX
OS Unidentified.
XX
PN WO2005007144-A2.
XX
PD 27-JAN-2005.
XX
PF 14-JUL-2004; 2004WO-US022446.
XX
PR 14-JUL-2003; 2003US-0487072P.
PR 05-APR-2004; 2004US-0559611P.
XX
PA (DECO-) DECODE GENETICS EHF.
XX
PI Hakonarson H, Gurney ME, Halapi E;
XX
DR WPI; 2005-122681/13.
XX
PT Use of mixed lineage kinase family kinase inhibitor in the manufacture of
PT a medicament for treatment of asthma associated at-risk haplotype for
PT asthma, at-risk haplotype in MAP3K9 gene or increased MLK1 protein
PT expression or activity.
XX
PS Disclosure; Fig 12; 640pp; English.
XX
CC The invention relates to the novel use of a mixed lineage kinase (MLK)
CC family kinase inhibitor for treating asthma. Where the asthma is
CC associated with a risk factor selected from an at-risk haplotype for
CC asthma, at-risk haplotype in MAP3K9 gene, polymorphism in MAP3K9 nucleic
CC acid, dysregulation of MAP3K9 mRNA expression, dysregulation of a MAP3K9
CC mRNA isoform, and/or increased MLK1 protein expression. The invention
CC further comprises: a method for the diagnosis or identification of
CC susceptibility to asthma; a method for the use of a first nucleic acid
CC molecule for diagnosing asthma or susceptibility to asthma in a sample; a
CC method for assaying the presence of a first nucleic acid molecule in a
CC sample; a method for assessing the response to treatment with an MLK
CC family kinase nucleic acid inhibitor in a target population or in an
CC individual with an at-risk haplotype for asthma, at-risk haplotype in the
CC MAP3K9 gene, polymorphism in the MAP3K9 nucleic acid, dysregulation of
CC MAP3K9 mRNA expression, dysregulation of MAP3K9 mRNA isoform, increased
CC MLK1 protein expression, increased MLK1 biochemical activity or increased
CC MLK1 protein isoform expression; a method for assessing the response to
CC treatment with an MLK1 inhibitor in a target population including an
CC individual with an at-risk haplotype for asthma, as above; a kit for
CC assaying a sample for the presence or absence of at least one haplotype
CC comprising 2 or more alleles associated with asthma comprising: at least
CC one nucleic acid capable of detecting the presence or absence of at least
CC one specific allele; a reagent kit for assaying the presence of at least
CC one haplotype comprising 2 or more alleles comprising: at least one
CC labeled nucleic acid capable of detecting at least one specific allele of
CC the haplotype, and reagents for detection of the label; and a reagent kit
CC for assaying a sample for the presence of at least one haplotype
CC comprising 2 or more alleles comprising: at least one nucleic acid
CC comprising at least one nucleotide sequence that is at least partially
CC complementary to a part of nucleotide sequence of MAP3K9, capable of
CC acting as a primer for a primer extension reaction and capable of
CC detecting 2 or more specific alleles of the haplotype. The MLK family
CC kinase inhibitor has the following activities: antiasthmatic, respiratory
CC -gen., antiinflammatory, antirheumatic, antiarthritic, antipsoriatic,
CC neuroprotective, and gastrointestinal-gen. The MLK family kinase
CC inhibitor is useful for the treatment of asthma associated with a risk
CC factor selected from at-risk haplotype for asthma, at-risk haplotype in
CC MAP3K9 gene, polymorphism in MAP3K9 nucleic acid, dysregulation of MAP3K9
CC mRNA expression, dysregulation of MAP3K9 mRNA isoform, increased MLK1
CC protein expression, increased MLK1 biochemical activity and/or increased
CC MLK1 protein isoform expression; and in diagnosis or identification of
CC susceptibility to asthma. The inhibitor is also useful for the treatment
CC of other respiratory diseases associated with MAP3K9 or other members of
CC the JNK pathway such as chronic obstructive pulmonary disease, chronic
CC bronchitis and other inflammatory diseases such as rheumatoid arthritis,
CC psoriasis, multiple sclerosis and inflammatory bowel disease. This
CC polynucleotide sequence represents a reverse primer which is used in
CC amplifying a marker of the MAP3K9 kinase, where MAP3K9 is a part of
CC Mitogen-Activated Protein Kinase (MAPK) signal transduction pathways, of
CC the invention.
XX
SQ Sequence 20 BP; 0 A; 10 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2065 AGGAAGCAGAGCAATGGGAG 2084
              |||||| ||||||| |||||
Db         20 AGGAAGGAGAGCAAAGGGAG 1
```

RESULT 555
AAZ18182/c
ID AAZ18182 standard; DNA; 21 BP.
XX
AC AAZ18182;
XX
DT 11-OCT-1999 (first entry)
XX
DE PTK 26 gene specific primer.
XX
KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KW primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9934016-A2.
XX
PD 08-JUL-1999.
XX
PF 28-DEC-1998; 98WO-IL000625.
XX
PR 29-DEC-1997; 97IL-00122793.
PR 16-OCT-1998; 98IL-00126627.
XX
PA (GENE-) GENENA LTD.
XX
PI Vider B;
XX
DR WPI; 1999-419113/35.
DR P-PSDB; AAY14717.
XX
PT Identifying and characterizing cells by comparing the pattern of gene
PT expression in a selected gene family.
XX
PS Claim 4; Page 46; 102pp; English.
XX
CC The invention provides a new method for identifying and characterising
CC cells. The method for determining the genetic proximity of a first cell
CC and a second cell comprises: (a) obtaining the first cell and the second
CC cell; (b) determining in the first cell and the second cell the pattern
CC of expression of genes in a selected gene family; and (c) calculating a
CC proximity index using a specified formula. The methods can be used for
CC characterising cells, e.g. for determining the origin of a cell, its
CC genetic status, whether it carries a genetic defect, or whether it is
CC transformed. They can be used for detecting a selected genetic defect in
CC an individual, e.g. a fetus. They can also be used for determining the
CC effect of a selected treatment on a test cell. They can also be used for
CC obtaining cells capable of expressing an homeobox related desired
CC property. The method uses reverse transcriptase polymerase chain reaction
CC (RT-PCR) for determining the pattern of gene expression in a selected
CC gene family. Sequences AAZ17803-Z18342 represent primers that can be used
CC in the RT-PCR reactions to determine the pattern of gene expression. The
CC gene family can be selected from a set of homeobox genes, kinase genes,
CC protein phosphatase genes, P450 enzyme genes, steroid receptor
CC superfamily genes or cadherin superfamily genes
XX
SQ Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2776 AGTGATGCCTGGAGTTACGG 2795
              ||||||| |||||| |||||
Db         21 AGTGATGTCTGGAGCTACGG 2
```

RESULT 556
AAZ18188/c
ID AAZ18188 standard; DNA; 21 BP.
XX
AC AAZ18188;
XX
DT 11-OCT-1999 (first entry)
XX
DE PTK 30 gene specific primer.
XX
KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KW primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9934016-A2.
XX
PD 08-JUL-1999.
XX
PF 28-DEC-1998; 98WO-IL000625.
XX
PR 29-DEC-1997; 97IL-00122793.
PR 16-OCT-1998; 98IL-00126627.
XX
PA (GENE-) GENENA LTD.
XX
PI Vider B;
XX
DR WPI; 1999-419113/35.
DR P-PSDB; AAY14723.
XX
PT Identifying and characterizing cells by comparing the pattern of gene
PT expression in a selected gene family.
XX
PS Claim 4; Page 46; 102pp; English.
XX
CC The invention provides a new method for identifying and characterising
CC cells. The method for determining the genetic proximity of a first cell
CC and a second cell comprises: (a) obtaining the first cell and the second
CC cell; (b) determining in the first cell and the second cell the pattern
CC of expression of genes in a selected gene family; and (c) calculating a
CC proximity index using a specified formula. The methods can be used for
CC characterising cells, e.g. for determining the origin of a cell, its
CC genetic status, whether it carries a genetic defect, or whether it is
CC transformed. They can be used for detecting a selected genetic defect in
CC an individual, e.g. a fetus. They can also be used for determining the
CC effect of a selected treatment on a test cell. They can also be used for
CC obtaining cells capable of expressing an homeobox related desired
CC property. The method uses reverse transcriptase polymerase chain reaction
CC (RT-PCR) for determining the pattern of gene expression in a selected
CC gene family. Sequences AAZ17803-Z18342 represent primers that can be used
CC in the RT-PCR reactions to determine the pattern of gene expression. The
CC gene family can be selected from a set of homeobox genes, kinase genes,
CC protein phosphatase genes, P450 enzyme genes, steroid receptor
CC superfamily genes or cadherin superfamily genes
XX
SQ Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2776 AGTGATGCCTGGAGTTACGG 2795
              ||||||| |||||| |||||
Db         21 AGTGATGTCTGGAGCTACGG 2
```

RESULT 557

```
AAZ18166/c
ID   AAZ18166 standard; DNA; 21 BP.
XX
AC   AAZ18166;
XX
DT   11-OCT-1999  (first entry)
XX
DE   PTK 17 gene specific primer.
XX
KW   Genetic proximity; gene expression; cell characterisation; homeobox gene;
KW   genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KW   kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KW   primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9934016-A2.
XX
PD   08-JUL-1999.
XX
PF   28-DEC-1998;   98WO-IL000625.
XX
PR   29-DEC-1997;   97IL-00122793.
PR   16-OCT-1998;   98IL-00126627.
XX
PA   (GENE-) GENENA LTD.
XX
PI   Vider B;
XX
DR   WPI; 1999-419113/35.
DR   P-PSDB; AAY14701.
XX
PT   Identifying and characterizing cells by comparing the pattern of gene
PT   expression in a selected gene family.
XX
PS   Claim 4; Page 46; 102pp; English.
XX
CC   The invention provides a new method for identifying and characterising
CC   cells. The method for determining the genetic proximity of a first cell
CC   and a second cell comprises: (a) obtaining the first cell and the second
CC   cell; (b) determining in the first cell and the second cell the pattern
CC   of expression of genes in a selected gene family; and (c) calculating a
CC   proximity index using a specified formula. The methods can be used for
CC   characterising cells, e.g. for determining the origin of a cell, its
CC   genetic status, whether it carries a genetic defect, or whether it is
CC   transformed. They can be used for detecting a selected genetic defect in
CC   an individual, e.g. a fetus. They can also be used for determining the
CC   effect of a selected treatment on a test cell. They can also be used for
CC   obtaining cells capable of expressing an homeobox related desired
CC   property. The method uses reverse transcriptase polymerase chain reaction
CC   (RT-PCR) for determining the pattern of gene expression in a selected
CC   gene family. Sequences AAZ17803-Z18342 represent primers that can be used
CC   in the RT-PCR reactions to determine the pattern of gene expression. The
CC   gene family can be selected from a set of homeobox genes, kinase genes,
CC   protein phosphatase genes, P450 enzyme genes, steroid receptor
CC   superfamily genes or cadherin superfamily genes
XX
SQ   Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 2.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2776 AGTGATGCCTGGAGTTACGG 2795
              ||||||| |||||| |||||
Db         21 AGTGATGTCTGGAGCTACGG 2


RESULT 558
AAZ18172/c
ID   AAZ18172 standard; DNA; 21 BP.
XX
AC   AAZ18172;
XX
DT   11-OCT-1999  (first entry)
XX
DE   PTK 20 gene specific primer.
XX
KW   Genetic proximity; gene expression; cell characterisation; homeobox gene;
KW   genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KW   kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KW   primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9934016-A2.
XX
PD   08-JUL-1999.
XX
PF   28-DEC-1998;   98WO-IL000625.
XX
PR   29-DEC-1997;   97IL-00122793.
PR   16-OCT-1998;   98IL-00126627.
XX
PA   (GENE-) GENENA LTD.
XX
PI   Vider B;
XX
DR   WPI; 1999-419113/35.
DR   P-PSDB; AAY14707.
XX
PT   Identifying and characterizing cells by comparing the pattern of gene
PT   expression in a selected gene family.
XX
PS   Claim 4; Page 46; 102pp; English.
XX
CC   The invention provides a new method for identifying and characterising
CC   cells. The method for determining the genetic proximity of a first cell
CC   and a second cell comprises: (a) obtaining the first cell and the second
CC   cell; (b) determining in the first cell and the second cell the pattern
CC   of expression of genes in a selected gene family; and (c) calculating a
CC   proximity index using a specified formula. The methods can be used for
CC   characterising cells, e.g. for determining the origin of a cell, its
CC   genetic status, whether it carries a genetic defect, or whether it is
CC   transformed. They can be used for detecting a selected genetic defect in
CC   an individual, e.g. a fetus. They can also be used for determining the
CC   effect of a selected treatment on a test cell. They can also be used for
CC   obtaining cells capable of expressing an homeobox related desired
CC   property. The method uses reverse transcriptase polymerase chain reaction
CC   (RT-PCR) for determining the pattern of gene expression in a selected
CC   gene family. Sequences AAZ17803-Z18342 represent primers that can be used
CC   in the RT-PCR reactions to determine the pattern of gene expression. The
CC   gene family can be selected from a set of homeobox genes, kinase genes,
CC   protein phosphatase genes, P450 enzyme genes, steroid receptor
CC   superfamily genes or cadherin superfamily genes
XX
SQ   Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 2.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2776 AGTGATGCCTGGAGTTACGG 2795
              ||||||| |||||| |||||
Db         21 AGTGATGTCTGGAGCTACGG 2


RESULT 559
AAZ18178/c
ID   AAZ18178 standard; DNA; 21 BP.
XX
AC   AAZ18178;
XX
DT   11-OCT-1999  (first entry)
```

```
XX
DE   PTK 23 gene specific primer.
XX
KW   Genetic proximity; gene expression; cell characterisation; homeobox gene;
KW   genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KW   kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KW   primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9934016-A2.
XX
PD   08-JUL-1999.
XX
PF   28-DEC-1998;   98WO-IL000625.
XX
PR   29-DEC-1997;   97IL-00122793.
PR   16-OCT-1998;   98IL-00126627.
XX
PA   (GENE-) GENENA LTD.
XX
PI   Vider B;
XX
DR   WPI; 1999-419113/35.
DR   P-PSDB; AAY14713.
XX
PT   Identifying and characterizing cells by comparing the pattern of gene
PT   expression in a selected gene family.
XX
PS   Claim 4; Page 46; 102pp; English.
XX
CC   The invention provides a new method for identifying and characterising
CC   cells. The method for determining the genetic proximity of a first cell
CC   and a second cell comprises: (a) obtaining the first cell and the second
CC   cell; (b) determining in the first cell and the second cell the pattern
CC   of expression of genes in a selected gene family; and (c) calculating a
CC   proximity index using a specified formula. The methods can be used for
CC   characterising cells, e.g. for determining the origin of a cell, its
CC   genetic status, whether it carries a genetic defect, or whether it is
CC   transformed. They can be used for detecting a selected genetic defect in
CC   an individual, e.g. a fetus. They can also be used for determining the
CC   effect of a selected treatment on a test cell. They can also be used for
CC   obtaining cells capable of expressing an homeobox related desired
CC   property. The method uses reverse transcriptase polymerase chain reaction
CC   (RT-PCR) for determining the pattern of gene expression in a selected
CC   gene family. Sequences AAZ17803-Z18342 represent primers that can be used
CC   in the RT-PCR reactions to determine the pattern of gene expression. The
CC   gene family can be selected from a set of homeobox genes, kinase genes,
CC   protein phosphatase genes, P450 enzyme genes, steroid receptor
CC   superfamily genes or cadherin superfamily genes
XX
SQ   Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 2.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2776 AGTGATGCCTGGAGTTACGG 2795
              ||||||| |||||| |||||
Db         21 AGTGATGTCTGGAGCTACGG 2


RESULT 560
AAA07689/c
ID   AAA07689 standard; DNA; 21 BP.
XX
AC   AAA07689;
XX
DT   19-JUN-2000  (first entry)
XX
DE   Reverse primer for amplifying HERG gene exon 13.
XX
KW   HERG; mutation; long QT syndrome; LQT syndrome; gene therapy; human;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200006772-A1.
XX
PD   10-FEB-2000.
XX
PF   20-JUL-1999;   99WO-US016337.
XX
PR   27-JUL-1998;   98US-00122847.
PR   06-JAN-1999;   99US-00226012.
XX
PA   (UTAH ) UNIV UTAH RES FOUND.
XX
PI   Keating MT,  Splawski I;
XX
DR   WPI; 2000-195319/17.
XX
PT   New isolated mutant HERG nucleic acids, useful for developing products
PT   for the diagnosis, prevention and treatment of long QT syndrome.
XX
PS   Claim 7; Page 72; 163pp; English.
XX
CC   The invention relates to a HERG protein having a mutation compared to
CC   wild-type HERG, and is useful for developing products for the diagnosis,
CC   prevention and treatment of long QT (LQT) syndrome. The products and
CC   methods can be used for the diagnosis of subjects with LQT syndrome. They
CC   can also be used to screen for drugs for treating or preventing LQT
CC   syndrome. The HERG nucleic acids can also be used for gene therapy and
CC   HERG peptides can be used for peptide therapy. Sequences AAA07654-693
CC   represent primers for amplifying HERG exons
XX
SQ   Sequence 21 BP; 6 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 2.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2018 GTGTGGTCCTGGTCCTGGTG 2037
              || |||||| ||||||||||
Db         20 GTCTGGTCCAGGTCCTGGTG 1


RESULT 561
ABZ58380
ID   ABZ58380 standard; DNA; 21 BP.
XX
AC   ABZ58380;
XX
DT   28-APR-2003  (first entry)
XX
DE   Human protein phosphatase 2C-like enzyme forward PCR primer.
XX
KW   Human; protein phosphatase 2C-like enzyme; enzyme; nootropic;
KW   neuroprotective; pulmonary; anorectic; antidiabetic; analgesic;
KW   antiparkinsonian; gene therapy; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297074-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-EP005874.
XX
PR   30-MAY-2001; 2001US-0294006P.
PR   11-FEB-2002; 2002US-0354928P.
XX
PA   (FARB ) BAYER AG.
XX
PI   Zhu Z;
```

```
XX
DR   WPI; 2003-041414/03.
XX
PT   Reagent for modulating the activity of a protein phosphatase 2C-like
PT   enzyme, used for treating diseases, such as, obesity or diabetes,
PT   comprises e.g. a polynucleotide, polypeptide, ribozyme, or antisense
PT   oligonucleotide.
XX
PS   Example 10; Page 83; 121pp; English.
XX
CC   The present sequence is a forward primer for the human protein
CC   phosphatase 2C-like enzyme (PP2CLE) gene (see ABZ58379). The primer was
CC   used in a Taqman quantitative analysis to determine expression of PP2CLE
CC   in different tissues and cell lines. High expression was observed in
CC   spinal cord, uterus, skeletal muscle, mammary gland, kidney, trachea,
CC   colon and brain, in primary cultured alveolar type II cells, cultured
CC   small airway epithelial cells and in cultured human bronchial epithelial
CC   cells. The invention provides PP2CLE polynucleotides, polypeptides,
CC   expression vectors, host cells and methods of producing PP2CLE
CC   polypeptides and detecting PP2CLE polynucleotides. Also provided are
CC   methods of using the polypeptides and polynucleotides to screen for
CC   reagents which decrease or modulate the activity of PP2CLE. Claimed
CC   pharmaceutical compositions comprising an expression vector or an
CC   identified reagent are used to modulate the activity of PP2CLE in a
CC   disease, especially central nervous system (CNS) disorders, chronic
CC   obstructive pulmonary disorder, obesity and diabetes (claimed). Other
CC   diseases that can be treated include Alzheimer's disease, Parkinson's
CC   disease, and pain associated with CNS disorders
XX
SQ   Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 2.8e+02;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        585 CCACTGGCTTCGCACAGGTT 604
              ||||||||| |||| |||||
Db          1 CCACTGGCTACGCAGAGGTT 20


RESULT 562
ACL42990
ID   ACL42990 standard; RNA; 21 BP.
XX
AC   ACL42990;
XX
DT   24-MAR-2005  (first entry)
XX
DE   CACNA1D siRNA antisense sequence, SEQ ID 4062.
XX
KW   Cytostatic; Gene therapy; Vaccine; RNA Interference; cancer; ss;
KW   short interfering RNA; gene silencing.
XX
OS   Synthetic.
XX
PN   WO2005001092-A2.
XX
PD   06-JAN-2005.
XX
PF   19-MAY-2004; 2004WO-US015645.
XX
PR   20-MAY-2003; 2003US-0471729P.
XX
PA   (AMHP ) WYETH.
XX
PI   Be X,  Wei L,  Slonim DK,  Howes SH;
XX
DR   WPI; 2005-075568/08.
XX
PT   Pharmaceutical composition comprising an agent capable of modulating an
PT   expression level or protein activity of a gene, e.g. ABCC4, or a T cell
PT   activated by the polypeptide or antibody, and a carrier, useful for
PT   treating cancer.
XX
PS   Claim 3; SEQ ID NO 4062; 113pp; English.
XX
CC   The present invention relates to a novel pharmaceutical composition
CC   comprising: (a) an agent capable of modulating an expression level or
CC   protein activity of a cancer-related transmembrane protein (CRTP) or gene
CC   ; an antibody specific for a CRTP, or a T cell activated by a CRTP; and
CC   (b) a carrier. The pharmaceutical composition may also comprise a
CC   polynucleotide capable of inhibiting or decreasing the expression of the
CC   CRTP by RNA interference or an antisense mechanism. The CRTPs of the
CC   invention are selected from ABCC4, C20orf103, CACNA1D, CDH6, CST, ENPP3,
CC   FLJ11856, GPR54, HAVCR1, SLC6A3, SLC30A4, TRG, and TRPM4. The
CC   pharmaceutical composition is useful for treating cancer, e.g. colon
CC   cancer, lung cancer, breast cancer, prostate cancer, liver cancer, kidney
CC   cancer, stomach cancer, and esophageal cancer. The present sequence is a
CC   CRTP short interfering RNAs (siRNA) oligonucleotide. Note: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 21 BP; 1 A; 9 C; 3 G; 0 T; 8 U; 0 Other;

  Query Match             0.4%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   65.0%;  Pred. No. 2.8e+02;
  Matches   13;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3823 CCTCCCCCAGCTGCTGCCTT 3842
              ||:|| |||||:||:|| ::
Db          2 CCUCCUCCAGCUGCUGCUUU 21


RESULT 563
AAH47543/c
ID   AAH47543 standard; DNA; 18 BP.
XX
AC   AAH47543;
XX
DT   30-NOV-2001  (first entry)
XX
DE   Human Her-3 mRNA inhibiting antisense oligo ISIS # 19558.
XX
KW   Her-3; epidermal growth factor; EGF; receptor/tyrosine kinase; human;
KW   antiinflammatory; cytostatic; antibacterial; antisense; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US6277640-B1.
XX
PD   21-AUG-2001.
XX
PF   31-JUL-2000; 2000US-00630706.
XX
PR   31-JUL-2000; 2000US-00630706.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Cowsert LM;
XX
DR   WPI; 2001-535134/59.
XX
PT   Antisense compounds capable of modulating expression of human Her-3,
PT   member of epidermal growth factor family of receptor/tyrosine kinases,
PT   useful for preventing or delaying infection, inflammation or tumor
PT   formation.
XX
PS   Claim 1; Col 42; 49pp; English.
XX
CC   The invention provides antisense compounds capable of inhibiting the
CC   expression of human Her-3, a member of epidermal growth factor (EGF)
CC   family of receptor/tyrosine kinases. The antisense oligonucleotides are
CC   useful for inhibiting the expression of Her-3 in cells or tissues. They
CC   are commonly used as research reagents and in diagnostics for example, to
```

```
CC   elucidate the function of particular genes. The antisense compounds are
CC   also useful for distinguishing between functions of various members of a
CC   biological pathway and for research use. They are also utilized for
CC   diagnostics, therapeutics, prophylaxis and in kits. They are useful
CC   prophylactically, e.g. to prevent or delay infection, inflammation or
CC   tumor formation. Sequences AAH47532-47615 represent chimeric antisense
CC   phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap,
CC   used for the inhibition of Her-3 mRNA expression
XX
SQ   Sequence 18 BP; 1 A; 2 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 2.4e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        105 ACCCCAACTCCAGCCACG 122
              || |||||||||||||||
Db         18 ACACCAACTCCAGCCACG 1


RESULT 564
ABX80008
ID   ABX80008 standard; cDNA; 18 BP.
XX
AC   ABX80008;
XX
DT   17-APR-2003  (first entry)
XX
DE   EST polymorphic DNA repeat polynucleotide #333.
XX
KW   EST; expressed sequence tag; ss; polymorphic repeat; tandem repeat;
KW   polymorphic marker prediction of ubiquitous simple sequences; POMPOUS;
KW   Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;
KW   Haw River syndrome; Huntington's disease; fragile-X syndrome;
KW   Fredreich's ataxis; myotonic dystrophy; hyperandrogenaemia;
KW   spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
XX
OS   Homo sapiens.
XX
PN   US6472154-B1.
XX
PD   29-OCT-2002.
XX
PF   31-DEC-1999;   99US-00475947.
XX
PR   31-DEC-1999;   99US-00475947.
XX
PA   (TEXA ) UNIV TEXAS SYSTEM.
XX
PI   Garner HR,  Wren JD,  Minna JD,  Fondon JW;
XX
DR   WPI; 2003-208818/20.
XX
PT   Identifying a candidate polymorphic repeat within a coding sequence, for
PT   understanding or treating genetic disease, comprises detecting tandem
PT   repeats in a target coding sequence and scoring the repeats for
PT   polymorphic probability.
XX
PS   Example; Col 1165; 588pp; English.
XX
CC   The invention discloses a method for identifying a candidate polymorphic
CC   repeat within a coding sequence (expressed sequence tag, EST), which
CC   comprises detecting tandem repeats in a target coding sequence, scoring
CC   the repeats for polymorphic probability and generating a dataset
CC   correlating the repeats with polymorphic probability to identify a
CC   candidate polymorphic repeat. The computational methods (polymorphic
CC   marker prediction of ubiquitous simple sequences, POMPOUS, and Rep-X) are
CC   useful for identifying and detecting candidate polymorphic repeats in
CC   human genes, which can be used to understand, treat or eliminate genetic
CC   diseases, predispositions or adverse drug-treatment reactions. Examples
CC   of diseases linked to nucleotide repeats are Machado-Joseph, Haw River
CC   syndrome, Huntington's disease, fragile-X syndrome, Fredreich's ataxis,
CC   myotonic dystrophy, hyperandrogenaemia, spinal and bulbar atrophy and
CC   spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are
CC   the polymorphic repeats identified for a search of human ESTs
XX
SQ   Sequence 18 BP; 2 A; 10 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 2.4e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1069 GGCCCCAGCCCCAGCCTC 1086
              ||||||||| ||||||||
Db          1 GGCCCCAGCTCCAGCCTC 18


RESULT 565
ADY89257
ID   ADY89257 standard; RNA; 19 BP.
XX
AC   ADY89257;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2293.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2293; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 19 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 2.6e+02;
```

```
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          1 CAUGCUGGACUGCUGGCA 18


RESULT 566
ADY89385
ID   ADY89385 standard; RNA; 19 BP.
XX
AC   ADY89385;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2421.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2421; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 19 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGCA 2948
              ||:||:||||:| :||||
Db          2 CAUGCUGGACUGCUGGCA 19


RESULT 567
AAQ20433/c
ID   AAQ20433 standard; DNA; 20 BP.
XX
AC   AAQ20433;
XX
DT   07-APR-1992  (first entry)
XX
DE   Debrisoquine polymorphism PCR primer.
XX
KW   Polymerase chain reaction; ss.
XX
OS   Synthetic.
XX
PN   EP463395-A.
XX
PD   02-JAN-1992.
XX
PF   29-MAY-1991;   91EP-00108867.
XX
PR   22-JUN-1990;   90EP-00810467.
XX
PA   (HOFF ) HOFFMANN-LA ROCHE AG.
XX
DR   WPI; 1992-009068/02.
XX
PT   New PCR primers for detecting poor metaboliser of drugs - useful to
PT   highlight cases of debrisoquine, mephenytoin-and acetylation-
PT   polymorphism.
XX
PS   Claim 11; Page 18; 31pp; English.
XX
CC   The sequence is that of an oligonucleotide primer which is used in a
CC   polymerase chain reaction (PCR) for the detection of normal and genes
CC   coding for drug metabolising enzymes which allow the phenotyping of poor
CC   metabolisers. Detection of debrisoquone polymorphism (CY2D6 gene -
CC   encodes the P450IID6 enzyme) is possible using this primer. See also
CC   AAQ20421-Q20436
XX
SQ   Sequence 20 BP; 2 A; 10 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 2.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3722 AGAAGGGGTGTCAGGGCC 3739
              |||||| ||||||||||
Db         20 AGAAGGAGTGTCAGGGCC 3


RESULT 568
AAX92799/c
ID   AAX92799 standard; DNA; 20 BP.
XX
AC   AAX92799;
XX
DT   13-SEP-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW   Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW   sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW   neutralising epitope; PCR primer; ss.
XX
OS   Synthetic.
OS   Chlamydophila pneumoniae.
XX
PN   WO9927105-A2.
XX
PD   03-JUN-1999.
XX
PF   20-NOV-1998;   98WO-IB001890.
XX
```

```
PR   21-NOV-1997;   97FR-00014673.
PR   04-NOV-1998;   98US-0107078P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-357842/30.
XX
PT   Genome sequence of Chlamydia pneumoniae.
XX
PS   Page 1540; Disclosure; 1912pp; English.
XX
CC   AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC   and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC   (see AAX91990). C. pneumoniae causes respiratory disease such as
CC   pneumonia and bronchitis and is thought to be a contributing factor in
CC   heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC   nodosum or pharyngitis. The polypeptides encoded by the open reading
CC   frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC   in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC   nucleotides sequences can also be used as immunogenic compositions,
CC   especially where the vector directs the expression of a neutralising
CC   epitope of C. pneumoniae
XX
SQ   Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 2.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3134 AAATGGGAAGATACGAAG 3151
              ||||||||||| |||||
Db         19 AAATGGGAAGATCCGAAG 2


RESULT 569
AAL60967/c
ID   AAL60967 standard; DNA; 20 BP.
XX
AC   AAL60967;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human MyD88 antisense oligonucleotide, ISIS #190947.
XX
KW   Antisense; human; myeloid differentiation primary response gene 88;
KW   MyD88; Alzheimer's disease; neurodegenerative disease; schizophrenia;
KW   gene therapy; Down's syndrome; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidine residues
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003046132-A2.
XX
PD   05-JUN-2003.
XX
PF   20-NOV-2002; 2002WO-US037411.
XX
PR   23-NOV-2001; 2001US-00021707.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Karras JG,  Dobie K;
XX
DR   WPI; 2003-505193/47.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding MyD88, useful for preparing a composition for treating
PT   neurodegenerative disease, e.g. Alzheimer's disease.
XX
PS   Claim 3; Page 76; 106pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   encoding human MyD88 (myeloid differentiation primary response gene 88)
CC   to inhibits its expression. Antisense compounds of the invention are
CC   useful for preparing a composition for treating neurodegenerative disease
CC   e.g. Alzheimer's disease, Down's syndrome or schizophrenia. The invention
CC   is also useful in gene therapy. The present sequence is an antisense
CC   oligonucleotide targetted to human MyD88 DNA
XX
SQ   Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 2.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2595 CCTGGCTGCTCGCAACAT 2612
              |||||||||| ||||||
Db         19 CCTGGCTGCTCTCAACAT 2


RESULT 570
ADE14481/c
ID   ADE14481 standard; DNA; 20 BP.
XX
AC   ADE14481;
XX
DT   29-JAN-2004  (first entry)
XX
DE   HSD11B1 antisense oligonucleotide seq id 83.
XX
KW   osteopathic; antidepressant; anorectic; antidiabetic;
KW   antiarteriosclerotic; antilipemic; antisense-therapy;
KW   hydroxysteroid 11-beta dehydrogenase 1; osteoporosis; depression;
KW   metabolic disorder; obesity; HSD11B1; diabetes; atherosclerosis;
KW   hyperlipidaemia; antisense technology; mouse; ss.
XX
OS   Mus sp.
XX
PN   US2003198965-A1.
XX
PD   23-OCT-2003.
XX
PF   19-APR-2002; 2002US-00126355.
XX
PR   19-APR-2002; 2002US-00126355.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Freier SM;
XX
DR   WPI; 2003-852782/79.
XX
PT   New antisense compounds useful for treating disorders associated with
PT   hydroxysteroid 11-beta dehydrogenase 1 expression, such as osteoporosis,
PT   depression and metabolic disorders like obesity, diabetes and
PT   atherosclerosis.
XX
PS   Example 16; SEQ ID NO 83; 53pp; English.
XX
```

```
CC   The invention describes a compound (I) 8-80 nucleobases in length
CC   targeted to a nucleic acid molecule encoding hydroxysteroid 11-beta
CC   dehydrogenase 1, inhibiting expression of hydroxysteroid 11-beta
CC   dehydrogenase 1. The methods and compositions of the present invention
CC   are useful for treating disorders associated with hydroxysteroid 11-beta
CC   dehydrogenase 1 expression, such as osteoporosis, depression and
CC   metabolic disorders like obesity, diabetes, atherosclerosis and
CC   hyperlipidaemia. This sequence represents an antisense oligonucleotide
CC   used to control the expression of mouse hydroxysteroid 11-beta
CC   dehydrogenase 1.
XX
SQ   Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 2.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2067 GAAGCAGAGCAATGGGAG 2084
              ||||||||||||||| ||
Db         19 GAAGCAGAGCAATGGCAG 2


RESULT 571
ADY59502/c
ID   ADY59502 standard; DNA; 20 BP.
XX
AC   ADY59502;
XX
DT   19-MAY-2005  (first entry)
XX
DE   Oligonucleotide of the invention PN09.
XX
KW   ss; diagnosis; tumor; cytostatic; neoplasm; DNA microarray.
XX
OS   Unidentified.
XX
PN   CN1472338-A.
XX
PD   04-FEB-2004.
XX
PF   01-AUG-2002; 2002CN-00125892.
XX
PR   01-AUG-2002; 2002CN-00125892.
XX
PA   (JUNX-) JUNXUAN BIOLOGICAL TECHNOLOGY CO LTD SHE.
XX
PI   Liang P,  Ding Y,  Zhang X;
XX
DR   WPI; 2004-317417/30.
XX
PT   Tumor related gene testing method.
XX
PS   Disclosure; Page 10; 14pp; Chinese.
XX
CC   The invention relates to a novel process for detecting a tumor associated
CC   gene in order to diagnose early tumor. The method comprises artificially
CC   synthesizing a specific cDNA fragment as a probe, on a solid support to
CC   form a DNA array of a tumor associated gene, reverse transcription and
CC   labeling, hybridizing the labeled specimen cDNA fragment and tumor
CC   associated gene DNA array, and direct quantitative analysis. The present
CC   sequence is used in the invention.
XX
SQ   Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 2.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        256 AGGGCCCCGACGAGGAGT 273
              ||||||||| ||||||||
Db         18 AGGGCCCCGCCGAGGAGT 1


RESULT 572
AEB22981
ID   AEB22981 standard; DNA; 20 BP.
XX
AC   AEB22981;
XX
DT   22-SEP-2005  (first entry)
XX
DE   SCN5A gene exon 2 forward primer.
XX
KW   SCN5A; sodium channel; Brugada syndrome; heart arrhythmia;
KW   antiarrhythmic; selectable marker; ventricular fibrillation; ss; PCR;
KW   primer.
XX
OS   Synthetic.
XX
PN   JP2005192413-A.
XX
PD   21-JUL-2005.
XX
PF   26-DEC-2003; 2003JP-00435234.
XX
PR   26-DEC-2003; 2003JP-00435234.
XX
PA   (DOKU-) DOKURITSU GYOSEI HOJIN KAGAKU GIJUTSU SH.
XX
PI   Matsunaga A;
XX
DR   WPI; 2005-501993/51.
XX
PT   Novel SCN5A gene of sodium channel alpha subunit, with mutations in which
PT   glycine being substituted by serine, and serine being substituted by
PT   leucine, at specific positions, useful as marker for diagnosing Brugada
PT   syndrome.
XX
PS   Example 1; Page; 30pp; Japanese.
XX
CC   The invention relates to an novel SCN5A gene of a sodium channel alpha
CC   subunit. The novel SCN5A gene comprises the mutation G292S between the
CC   fifth and sixth membrane passing-through subunits of the first domain;
CC   and/or the mutation S835L of the intracellular loop between the fourth
CC   and fifth membrane passing-through subunits of the second domain. The
CC   novel SCN5A gene can be used as a Brugada syndrome marker, for diagnosing
CC   Brugada syndrome. Brugada syndrome causes idiopathic ventricular
CC   fibrillation, thus the gene/marker allow for the prevention or treatment
CC   of the syndrome. This oligo sequence represents a primer used to amplify
CC   an exon of the SCN5A gene of the invention.
XX
SQ   Sequence 20 BP; 4 A; 12 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 2.9e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2915 CCTCCCTCCACCAGCTCA 2932
              ||||||||||||||| ||
Db          1 CCTCCCTCCACCAGCACA 18


RESULT 573
ACA99868/c
ID   ACA99868 standard; DNA; 17 BP.
XX
AC   ACA99868;
XX
DT   28-JUL-2003  (first entry)
XX
DE   G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #361.
XX
KW   Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW   G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS   Homo sapiens.
```

XX
PN WO2003031621-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032599.
XX
PR 12-OCT-2001; 2001US-0329000P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Zhang J;
XX
DR WPI; 2003-381720/36.
XX
PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS Example 2; SEQ ID NO 385; 156pp; English.
XX
CC The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 3 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1190 CCCAGGGCACCTTCAA 1205
||||||||||||||||
Db 16 CCCAGGGCACCTTCAA 1

RESULT 574
ACA99867/c
ID ACA99867 standard; DNA; 17 BP.
XX
AC ACA99867;
XX
DT 28-JUL-2003 (first entry)
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #360.
XX
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO2003031621-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032599.
XX
PR 12-OCT-2001; 2001US-0329000P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Zhang J;
XX
DR WPI; 2003-381720/36.
XX
PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS Example 2; SEQ ID NO 384; 156pp; English.
XX
CC The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1190 CCCAGGGCACCTTCAA 1205
||||||||||||||||
Db 17 CCCAGGGCACCTTCAA 2

RESULT 575
ABT37713/c
ID ABT37713 standard; DNA; 17 BP.
XX
AC ABT37713;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 3350.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 425; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,

```
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 4 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3469 TTTGGAGAGACAGGAT 3484
             ||||||||||||||||
Db         17 TTTGGAGAGACAGGAT 2


RESULT 576
ADI48271/c
ID   ADI48271 standard; DNA; 17 BP.
XX
AC   ADI48271;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID774.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 774; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 4 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3469 TTTGGAGAGACAGGAT 3484
             ||||||||||||||||
Db         17 TTTGGAGAGACAGGAT 2


RESULT 577
ACC53159/c
ID   ACC53159 standard; DNA; 17 BP.
XX
AC   ACC53159;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #1926.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 485; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 4 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3469 TTTGGAGAGACAGGAT 3484
             ||||||||||||||||
Db         17 TTTGGAGAGACAGGAT 2
```

```
RESULT 578
AAA82487/c
ID   AAA82487 standard; DNA; 19 BP.
XX
AC   AAA82487;
XX
DT   04-DEC-2000  (first entry)
XX
DE   cdk1 ribozyme binding site #73.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 47; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 11 A; 1 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4188 CTTTTTGTATAAATAA 4203
              ||||||||||||||||
Db         17 CTTTTTGTATAAATAA 2


RESULT 579
AAA82486/c
ID   AAA82486 standard; DNA; 19 BP.
XX
AC   AAA82486;
XX
DT   04-DEC-2000  (first entry)
XX
DE   cdk1 ribozyme binding site #72.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 47; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 10 A; 1 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4188 CTTTTTGTATAAATAA 4203
              ||||||||||||||||
Db         19 CTTTTTGTATAAATAA 4


RESULT 580
AAH57648/c
ID   AAH57648 standard; DNA; 19 BP.
XX
AC   AAH57648;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cell-cycle dependent kinase cdk1 ribozyme binding site SEQ ID NO:72.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
```

```
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 77; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 10 A; 1 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4188 CTTTTTGTATAAATAA 4203
              ||||||||||||||||
Db         19 CTTTTTGTATAAATAA 4


RESULT 581
AAH57649/c
ID   AAH57649 standard; DNA; 19 BP.
XX
AC   AAH57649;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cell-cycle dependent kinase cdk1 ribozyme binding site SEQ ID NO:73.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 77; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 11 A; 1 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4188 CTTTTTGTATAAATAA 4203
              ||||||||||||||||
Db         17 CTTTTTGTATAAATAA 2


RESULT 582
ABK41169
ID   ABK41169 standard; DNA; 19 BP.
XX
AC   ABK41169;
XX
DT   21-MAY-2002  (first entry)
XX
DE   Human obesity-associated biallelic marker downstream PCR primer #75.
XX
KW   Human; obesity associated-biallelic marker; chromosome 10; obesity; ss;
KW   drug response; hyperuricaemia; digestive pathology; hypertension; cancer;
KW   hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;
KW   insulin disorder; atheromatous disease; cardiac insufficiency; primer.
XX
OS   Homo sapiens.
XX
PN   WO200206525-A2.
XX
PD   24-JAN-2002.
XX
PF   28-JUN-2001; 2001WO-IB001477.
XX
PR   18-JUL-2000; 2000US-0219704P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I,  Abderrahim H,  Bihain B;
XX
DR   WPI; 2002-155043/20.
XX
PT   Set of novel map-related biallelic markers, preferably located on obesity
PT   disorder-associated chromosomal regions on chromosomes 3, 10 and 19,
```

PT useful, for e.g. detecting statistical correlations between marker allele
PT and a phenotype.
XX
PS Example 2; Page 278; 311pp; English.
XX
CC The invention relates to a set of novel map-related biallelic markers,
CC preferably located on obesity disorder-associated chromosomal regions on
CC chromosomes 3, 10 and 19. The markers are useful for genotyping or
CC estimating the frequency of an allele in a population, for detecting an
CC association between a genotype or haplotype and a phenotype, e.g. a
CC disease involving drug responses, obesity or disorders related to
CC obesity, such as hyperuricaemia, digestive pathology, hepatic function
CC disorders, cancer, cardiovascular disease, hypertension, hyperlipidaemia,
CC insulin disorders, atheromatous disease and cardiac insufficiency. The
CC markers are useful for detecting a statistical correlation between a
CC biallelic marker allele and a phenotype and/or between a biallelic marker
CC haplotype and a phenotype. This sequence represents a PCR primer used to
CC amplify a human obesity-associated biallelic marker
XX
SQ Sequence 19 BP; 3 A; 1 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4117 TAGTTGGTGGTGGAAC 4132
||||||||||||||||
Db 1 TAGTTGGTGGTGGAAC 16

RESULT 583
ADT01526
ID ADT01526 standard; DNA; 19 BP.
XX
AC ADT01526;
XX
DT 16-DEC-2004 (first entry)
XX
DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID1514.
XX
KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
KW tumourigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
KW GUCY2F; MCCK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;
KW guanylate cyclase stimulator; ss.
XX
OS Homo sapiens.
XX
PN WO2004082458-A2.
XX
PD 30-SEP-2004.
XX
PF 18-FEB-2004; 2004WO-US004452.
XX
PR 21-FEB-2003; 2003US-0448537P.
PR 29-MAY-2003; 2003US-0473895P.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
XX
DR WPI; 2004-718702/70.
XX
PT Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCCK) and
PT associated methods for diagnosing cancer and screening for anti-cancer
PT agents.
XX
PS Disclosure; SEQ ID NO 1514; 363pp; English.
XX
CC This invention relates to a novel activated mutant protein tyrosine
CC kinases and associated methods for diagnosing cancer and screening for
CC anti-cancer agents. Protein kinases are signalling molecules involved in
CC tumourigenesis. Mutational analysis of the human tyrosine kinase gene
CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
CC MCCK/MLK4 genes. Most were identified in the kinase domain. The invention
CC may be useful for the production of compounds with a cytostatic activity
CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
CC stimulators. The invention may be useful for developing methods for
CC detecting mutations involved in cancer or screening for anti-cancer
CC agents. The present sequence is that of a human-derived oligonucleotide
CC which is related to the invention.
XX
SQ Sequence 19 BP; 4 A; 2 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2235 GATTGGTGCAGGTGAG 2250
||||||||||||||||
Db 1 GATTGGTGCAGGTGAG 16

RESULT 584
ABZ99246
ID ABZ99246 standard; DNA; 20 BP.
XX
AC ABZ99246;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human PDE4C oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 14488; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an

```
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2048 TCGCAGTTCTCTGCCT 2063
              ||||||||||||||||
Db          1 TCGCAGTTCTCTGCCT 16


RESULT 585
ABD32277
ID   ABD32277 standard; DNA; 20 BP.
XX
AC   ABD32277;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human PDE4C-derived oligonucleotide SEQ ID 14488.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 14488; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2048 TCGCAGTTCTCTGCCT 2063
              ||||||||||||||||
Db          1 TCGCAGTTCTCTGCCT 16


RESULT 586
ADJ61131
ID   ADJ61131 standard; DNA; 20 BP.
XX
AC   ADJ61131;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Oligonucleotide associated to PDE4C #197.
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2004011613-A2.
XX
PD   05-FEB-2004.
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
PR   29-JUL-2002; 2002US-0399076P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Tang L,  Sandrasagra A,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-203534/19.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
PS   Claim 2; SEQ ID NO 1987; 85pp; English.
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
```

```
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 16;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2048 TCGCAGTTCTCTGCCT 2063
              ||||||||||||||||
Db          1 TCGCAGTTCTCTGCCT 16


RESULT 587
AAT00705
ID   AAT00705 standard; DNA; 19 BP.
XX
AC   AAT00705;
XX
DT   08-JUL-1996  (first entry)
XX
DE   Human trkC receptor TK insert sense DNA primer.
XX
KW   trkC receptor; tyrosine-kinase; enzyme; protease; inflammation; pain;
KW   diagnosis; neurotrophic factor; kidney; lung; psychiatric disorder;
KW   DNA primer; PCR; polymerase chain reaction; ss.
XX
OS   Synthetic.
XX
PN   WO9525795-A1.
XX
PD   28-SEP-1995.
XX
PF   17-MAR-1995;   95WO-US003426.
XX
PR   18-MAR-1994;   94US-00215139.
PR   05-AUG-1994;   94US-00286846.
PR   20-DEC-1994;   94US-00359705.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Presta LG,  Shelton DL,  Urfer R;
XX
DR   WPI; 1995-344616/44.
XX
PT   New human trkB and trkC poly:peptide(s) and fusion proteins contg. them -
PT   also DNA, vectors and transformed cells useful in treatment and diagnosis
PT   of abnormal neurotrophic factor expression, e.g. inflammatory pain.
XX
PS   Disclosure; Page 70; 117pp; English.
XX
CC   This TK insert sense DNA primer was used in a Northern blot analysis to
CC   examine expression patterns of the trkC receptor in human tissue
XX
SQ   Sequence 19 BP; 5 A; 5 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3539 ACTCCAGACCAAGGGTGAG 3557
              || |||| ||||||||||
Db          1 ACGCCAGGCCAAGGGTGAG 19


RESULT 588
AAZ88855
ID   AAZ88855 standard; DNA; 19 BP.
XX
AC   AAZ88855;
XX
DT   30-MAY-2000  (first entry)
XX
DE   Human trkC receptor TK insert sense primer.
XX
KW   trkB; human; receptor tyrosine kinase; trkC; diagnosis; neurotrophin;
KW   neurotrophic factor; primer; trkA; ss.
XX
OS   Homo sapiens.
XX
PN   US6027927-A.
XX
PD   22-FEB-2000.
XX
PF   01-OCT-1997;   97US-00942562.
XX
PR   18-MAR-1994;   94US-00215139.
PR   05-AUG-1994;   94US-00286846.
PR   19-MAY-1995;   95US-00444597.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Urfer R,  Shelton DL,  Presta LG;
XX
DR   WPI; 2000-194832/17.
XX
PT   New human trk receptors useful in the diagnosis of various human
PT   pathological conditions associated with elevated or reduced levels of
PT   neurotrophins capable of binding trkB and/or trkC.
XX
PS   Disclosure; Col 93-94; 78pp; English.
XX
CC   This invention describes a novel isolated and purified polypeptide (I),
CC   belonging to the trk family of receptor tyrosine kinases, trkB and trkC.
CC   (I) are useful in the purification of human neurotrophic factors and in
CC   the diagnosis of various human pathological conditions associated with
CC   elevated or reduced levels of neurotrophins capable of binding trkB
CC   and/or trkC. AAZ88843-Z88868 represent primers used in the isolation of
CC   the trkA, trkB and trkC receptor proteins described in the method of the
CC   invention
XX
SQ   Sequence 19 BP; 5 A; 5 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3539 ACTCCAGACCAAGGGTGAG 3557
              || |||| ||||||||||
Db          1 ACGCCAGGCCAAGGGTGAG 19


RESULT 589
AAD30287/c
ID   AAD30287 standard; DNA; 19 BP.
XX
AC   AAD30287;
XX
DT   17-MAY-2002  (first entry)
XX
DE   Human PKD1 gene mutation detecting nested PCR primer, 13R.
XX
```

KW Human; PKD1 gene; autosomal dominant polycystic kidney disease; ADPKD;
KW acquired cystic disease; transgenic animal; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200206529-A2.
XX
PD 24-JAN-2002.
XX
PF 13-JUL-2001; 2001WO-US022035.
XX
PR 13-JUL-2000; 2000US-0218261P.
PR 13-APR-2001; 2001US-0283691P.
XX
PA (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
PI Germino GG, Watnick TJ, Phakdeekitcharoen B;
XX
DR WPI; 2002-179805/23.
XX
PT Novel primer for diagnosing polycystic kidney disease-associated
PT disorder, comprises regions having sequence that selectively hybridizes
PT to polycystic kidney disease gene sequence.
XX
PS Claim 6; Page 101; 192pp; English.
XX
CC The present invention relates to compositions and methods useful for the
CC identification and detection of polycystic kidney disease (PKD1) gene
CC mutations. The invention also relates to primers comprising a 5' region
CC having a sequence that selectively hybridises to a PKD1 gene sequence and
CC optionally, to a PKD1 homologue sequence and an adjacent 3' region having
CC a sequence that selectively hybridises to a PKD1 gene sequence and not to
CC a PKD1 homologue sequence. Primer pairs of the invention are useful for
CC detecting the presence or absence of a mutation in a PKD1 polynucleotide
CC in a sample, for identifying a subject at risk for a PKD1-associated
CC disorder such as autosomal dominant polycystic kidney disease (ADPKD) or
CC acquired cystic disease and for diagnosing a PKD1- associated disorder in
CC a subject. They are useful for selectively amplifying a region of a PKD1
CC gene. PKD1 DNA fragments are useful detecting the presence of a mutant
CC PKD1 polynucleotide in a sample, as a probe for an amplification
CC reaction, in hybridisation or amplification assays of biological samples
CC to detect abnormalities of PKD1 expression and for engineering transgenic
CC animals. The present sequence is a PCR primer used to detect mutation in
CC human PKD1 gene
XX
SQ Sequence 19 BP; 4 A; 3 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1068 TGGCCCCAGCCCCAGCCTC 1086
|| | ||||||||||||||||
Db 19 TTGTCCCAGCCCCAGCCTC 1

RESULT 590
ABK30165
ID ABK30165 standard; DNA; 19 BP.
XX
AC ABK30165;
XX
DT 23-APR-2002 (first entry)
XX
DE CYP2D6 gene polymorphism detection primer #4.
XX
KW Human; CYP2D6; primer; single nucleotide polymorphism detection; SNP; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200196604-A2.
XX
PD 20-DEC-2001.
XX
PF 11-JUN-2001; 2001WO-US018912.
XX
PR 12-JUN-2000; 2000US-0210988P.
XX
PA (GENI-) GENICON SCI CORP.
XX
PI Bee G, Kohne DE, Korb L, Peterson T, Yguerabide J;
XX
DR WPI; 2002-130745/17.
XX
PT Determining the presence of a CYP2D6 target sequence in a DNA sample
PT containing CYP2D6 nucleic acid, for detecting mutations or polymorphisms,
PT comprises detecting the scattered light from a particle bound to the
PT target sequence.
XX
PS Claim 14; Page 50; 66pp; English.
XX
CC The invention relates to a method of determining the presence or absence
CC of a CYP2D6 target sequence in a DNA sample containing CYP2D6 nucleic
CC acid. Determining the presence or absence of a CYP2D6 target sequence in
CC a sample of DNA containing CYP2D6 nucleic acid comprises contacting the
CC nucleic acid with a probe under stringent binding conditions, and
CC detecting the presence or absence of the target sequence bound with the
CC probe with a scattered light detectable particle, by observing light
CC scattered from the particle which indicates the presence of the target
CC sequence. The method is useful for determining the presence or absence of
CC particular single nucleotide polymorphisms or alleles in genomic nucleic
CC acid, especially in a pharmacogenetically relevant gene or genes in a DNA
CC sample, and to detect and measure one or more target sequences in a
CC sample. The method may also be used to detect specific mutations to
CC identify the phenotypic classification of an individual. ABK30162-
CC ABK30230 represent CYP2D6 target sequence-specific primers of the
CC invention
XX
SQ Sequence 19 BP; 4 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1947 CCAGACCCAACTGGATGAG 1965
|| |||||| |||||||||
Db 1 CCTGACCCAGCTGGATGAG 19

RESULT 591
ABZ24394
ID ABZ24394 standard; DNA; 19 BP.
XX
AC ABZ24394;
XX
DT 18-MAR-2003 (first entry)
XX
DE Human cytochrome P450 CYP2D6*36 specific forward PCR primer.
XX
KW Human; cytochrome P450; CYP2D6; CYP2D6*36; enzyme; genotyping; SNP;
KW single nucleotide polymorphism; drug metabolism; antidepressant;
KW antiarrhythmic; neuroleptic; morphine; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200299118-A2.
XX
PD 12-DEC-2002.
XX
PF 05-JUN-2002; 2002WO-US017938.
XX
PR 05-JUN-2001; 2001US-0296252P.
XX
PA (DNAS-) DNA LAB SCI INC.
XX

PI Guida M, Benson L, Hopkins P;
XX
DR WPI; 2003-148673/14.
XX
PT Determining a cytochrome P450 2D6 (CYP2D6) genotype of an individual,
PT useful for identifying polymorphisms in the CYP2D6 metabolic enzyme, by
PT using primers that hybridize to genomic DNA comprising a CYP2D6 exon 1
PT C188T polymorphisms.
XX
PS Example 1; Page 13; 32pp; English.
XX
CC The present sequence is a forward primer specific to the human human
CC cytochrome P450 CYP2D6*36 allele. CYP2D6 enzyme catalyses the oxidation
CC of e.g. tricyclic antidepressants, antiarrhythmics, neuroleptics and
CC morphine derivatives. 68 Alleles have been identified, over 30 of them
CC associated with alterations in drug metabolism. The CYP2D6*10 haplotype
CC consists of 4 single nucleotide polymorphisms, including a C188T mutation
CC in exon 1 that results in an unstable enzyme with lower metabolic
CC activity. The invention provides a method of determining the CYP2D6
CC genotype of an individual, especially an Asian, by amplification of
CC genomic DNA using primers specific for the exon 1 C188T polymorphism or
CC for the wild-type sequence and analysis of amplification products. In
CC examples from the invention, a CYP2D6*10 duplication was identified.
CC CYP2D6*36 is a subvariant of CYP2D6*10, and PCR amplification of
CC CYP2D6*36 was used to examine the structure of the CYP2D6*10-associated
CC gene duplication
XX
SQ Sequence 19 BP; 6 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3718 GGCAAGAAGGGGTGTCAGG 3736
||||||||| |||||||
Db 1 GGCAAGAAGGATTGTCAGG 19

RESULT 592
ADF37388
ID ADF37388 standard; RNA; 19 BP.
XX
AC ADF37388;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR3 short interfering nucleic acid (siNA) SEQ ID NO:1677.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 1677; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 19 BP; 3 A; 6 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 3.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2596 CTGGCTGCTCGCAACATCC 2614
|:|||:||:|| ||||: |
Db 1 CUGGCUGCUCGGAACAUUC 19

RESULT 593
ADF37635/c
ID ADF37635 standard; RNA; 19 BP.
XX
AC ADF37635;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR3 short interfering nucleic acid (siNA) SEQ ID NO:1924.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.

```
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 1924; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 5 A; 5 C; 6 G; 0 T; 3 U; 0 Other;

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              ||||||||||| ||||| |
Db         19 CTGGCTGCTCGGAACATTC 1


RESULT 594
ADF84250/c
ID   ADF84250 standard; RNA; 19 BP.
XX
AC   ADF84250;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human ABL1-targeted siRNA - SEQ ID 544.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005234.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   15-AUG-2002; 2002US-0404039P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   14-JAN-2003; 2003US-0439922P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-679889/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT   cluster region-Abelson (BCR-ABL) gene.
XX
PS   Example 7; SEQ ID NO 544; 197pp; English.
XX
CC   The invention relates to a novel double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the breakpoint
CC   cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC   (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC   activity and may be useful for modulating expression of the BCR-ABL gene,
CC   as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC   screening, target identification and validation, genetic engineering,
CC   gene function studies and gene mapping. The current sequence is that of
CC   the human ABL1-targeted siRNA of the invention.
XX
SQ   Sequence 19 BP; 2 A; 7 C; 9 G; 0 T; 1 U; 0 Other;

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        155 CCAGCACGCTCCGGGCCCG 173
              ||||| || ||||||||||
Db         19 CCAGCTCGGTCCGGGCCCG 1


RESULT 595
ADF84569
ID   ADF84569 standard; RNA; 19 BP.
XX
AC   ADF84569;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human ABL1-targeted siRNA - SEQ ID 863.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005234.
XX
PR   20-FEB-2002; 2002US-0358580P.
```

```
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   15-AUG-2002; 2002US-0404039P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   14-JAN-2003; 2003US-0439922P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-679889/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT   cluster region-Abelson (BCR-ABL) gene.
XX
PS   Example 7; SEQ ID NO 863; 197pp; English.
XX
CC   The invention relates to a novel double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the breakpoint
CC   cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC   (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC   activity and may be useful for modulating expression of the BCR-ABL gene,
CC   as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC   screening, target identification and validation, genetic engineering,
CC   gene function studies and gene mapping. The current sequence is that of
CC   the human ABL1-targeted siRNA of the invention.
XX
SQ   Sequence 19 BP; 1 A; 9 C; 7 G; 0 T; 2 U; 0 Other;

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 3.1e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        155 CCAGCACGCTCCGGGCCCG 173
              ||||| || :|||||||||
Db          1 CCAGCUCGGUCCGGGCCCG 19


RESULT 596
ADI00303/c
ID   ADI00303 standard; DNA; 19 BP.
XX
AC   ADI00303;
XX
DT   22-APR-2004  (first entry)
XX
DE   PCR primer SEQ ID 83 used to amplify human PKD-1 exon 13 DNA.
XX
KW   mutation analysis; PKD; polycystic kidney disease; human; PKD-1; ss; PCR;
KW   primer.
XX
OS   Homo sapiens.
XX
PN   US2003152936-A1.
XX
PD   14-AUG-2003.
XX
PF   26-FEB-2002; 2002US-00083246.
XX
PR   12-OCT-2001; 2001US-0328739P.
XX
PA   (ATHE-) ATHENA DIAGNOSTICS INC.
XX
PI   Jones JG,  Hennigan AN,  Curran JA,  Allen SK,  Robichaud NJ,  Wang J;
PI   Flynn KE,  Garces JA,  Palatucci CM;
XX
DR   WPI; 2003-897708/82.
XX
PT   Analyzing mutations of a target nucleic acid by detecting heteroduplexes
PT   from generated duplexes, useful for diagnosing patients affected with
PT   polycystic kidney disease.
XX
PS   Disclosure; SEQ ID NO 83; 126pp; English.
XX
CC   The invention relates to a novel method of mutation analysis of a target
CC   nucleic acid which comprises incubating a sample having the target
CC   nucleic acid in a reaction mixture, in the presence of at least one first
CC   and second nucleic acid, where incubation produces amplified products,
CC   generating duplexes in the amplified products and detecting the presence
CC   or absence of a heteroduplex from the duplexes, where its presence
CC   indicates a potential mutation in the target nucleic acid and its absence
CC   indicates the absence of mutation in the target nucleic acid. The method
CC   and compositions of the invention may be useful for analysing mutation
CC   and diagnosing patients affected with PKD (polycystic kidney disease).
CC   The current sequence is that of a PCR primer of the invention which was
CC   used to amplify human polycystic kidney disease PKD-1 DNA.
XX
SQ   Sequence 19 BP; 4 A; 3 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1068 TGGCCCCAGCCCCAGCCTC 1086
              | | ||||||||||||||||
Db         19 TTGTCCCAGCCCCAGCCTC 1


RESULT 597
ADO16340
ID   ADO16340 standard; DNA; 19 BP.
XX
AC   ADO16340;
XX
DT   29-JUL-2004  (first entry)
XX
DE   4 synthesis-period of neuroblastoma related primer, SEQ ID 602.
XX
KW   Human; 4 synthesis-period; neuroblastoma; stage 4S; primer; ss.
XX
OS   Synthetic.
XX
PN   WO2004039975-A1.
XX
PD   13-MAY-2004.
XX
PF   30-OCT-2003; 2003WO-JP013932.
XX
PR   30-OCT-2002; 2002JP-00316586.
XX
PA   (HISM ) HISAMITSU PHARM CO LTD.
PA   (CHIB-) CHIBA PREFECTURE.
XX
PI   Nakagawara A,  Ohira M;
XX
DR   WPI; 2004-390323/36.
XX
PT   Novel nucleic acid obtained from 4 synthesis-period of neuroblastoma
PT   cells useful for prognosing and determining progress stage of
PT   neuroblastomas.
XX
PS   Claim 8; SEQ ID NO 602; 455pp; Japanese.
XX
CC   The present invention relates to human nucleic acid sequences (I;
CC   ADO15739-ADO15912) obtained from 4 synthesis-period (stage 4S) of
CC   neuroblastoma cell. (I) is useful for prognosing and determining the
CC   progress stage of 4 synthesis-period of neuroblastoma. The present
CC   sequence is a primer, used to illustrate the invention.
XX
SQ   Sequence 19 BP; 7 A; 7 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
```

```
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         18 AGCAGAGCCACTCCAGGGA 36
              ||||||||||||||||  ||
Db          1 AGCAGAGCCACTCCACAGA 19
```

RESULT 598
ADQ60909
ID ADQ60909 standard; RNA; 19 BP.
XX
AC ADQ60909;
XX
DT 09-SEP-2004 (first entry)
XX
DE Anti-BLK siRNA related DNA sequence SEQ ID NO:611.
XX
KW ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW RNA interference.
XX
OS Synthetic.
XX
PN WO2004045543-A2.
XX
PD 03-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-US036787.
XX
PR 14-NOV-2002; 2002US-0426137P.
PR 10-SEP-2003; 2003US-0502050P.
XX
PA (DHAR-) DHARMACON INC.
XX
PI Anastasia K, Angela R, Devin L, William M, Stephen S;
XX
DR WPI; 2004-420527/39.
XX
PT Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT by selecting a target gene and measuring the functionality of the
PT nucleotide sequences that are complementary to a stretch of nucleotides
PT of the target sequence.
XX
PS Example 12; SEQ ID NO 611; 199pp; English.
XX
CC The invention relates to a novel method for selecting siRNA (short
CC interfering RNA) comprising selecting an siRNA molecule of 19-25
CC nucleoside bases by selecting a target gene and measuring the
CC functionality of sequences of 19-25 nucleotides in length that are
CC substantially complementary to a stretch of nucleotides of the target
CC sequence, where the functionality is dependent upon non-target specific
CC criteria. Also claimed are methods for gene-silencing, developing an
CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC sequence consisting of GGGAGAUAGUGAUGAAGUA; GAAGUACAUCCAUUAUAAG;
CC GUACGACAACCGGGAGAUA; AGAUAGUGAUGAAGUACAU; UGAAGACUCUGCUCAGUUU;
CC CAUGCGGCCUCUGUUUGA; UGCGGCCUCUGUUUGAUUU; GAGAUAGUGAUGAAGUACA;
CC GGAGAUAGUGAUGAAGUAC; and GAAGACUCUGCUCAGUUUG. The siRNA molecule
CC comprises a sense strand and an anti-sense strand. The siRNA molecule
CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC pairs. The kit comprises at least two siRNA, comprising a first optimised
CC siRNA and a second optimised siRNA. The method is useful in selecting
CC siRNA for generating a gene silencing reagent. The present sequence is
CC used in the exemplification of the invention. The sequence is shown in
CC the specification as DNA, but described as siRNA.
XX
SQ Sequence 19 BP; 6 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

```
  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2985 GGTCAGCGCCCTGGACAAG 3003
              ||||||||||  ||||||
Db          1 GGTCAGCGCCCAAGACAAG 19
```

RESULT 599
ADU03887/c
ID ADU03887 standard; DNA; 19 BP.
XX
AC ADU03887;
XX
DT 30-DEC-2004 (first entry)
XX
DE Human polycystic kidney disease 1 (PKD-1) gene specific primer, 1X13R.
XX
KW mutation detection; polycystic kidney disease; PKD; PKD-1; PKD-2;
KW biomarker; autosomal dominant polycystic kidney disease; ADPKD; primer;
KW ss.
XX
OS Homo sapiens.
XX
PN CA2461106-A1.
XX
PD 11-OCT-2004.
XX
PF 08-APR-2004; 2004CA-02461106.
XX
PR 11-APR-2003; 2003US-00411915.
XX
PA (ATHE-) ATHENA DIAGNOSTICS INC.
XX
PI Jones JG, Hennigan AN, Flynn KE, Garces JA, Seltzer WK;
PI Palatucci CM, Wang J, Curran JA, Allen SK, Robichaud NJ;
XX
DR WPI; 2004-776219/77.
XX
PT Novel nucleic acid comprising specific sequence capable of detecting
PT mutations in polycystic kidney disease-1 (PKD-1) or PKD-2 gene, useful
PT for detecting biomarkers of autosomal dominant polycystic kidney disease.
XX
PS Disclosure; Page 41; 195pp; English.
XX
CC The invention relates to a novel isolated nucleic acid capable of
CC detecting mutations in polycystic kidney disease (PKD-1) or PKD-2 gene,
CC comprising a specific sequence. The invention further comprises: a
CC nucleic acid biomarker for autosomal dominant polycystic kidney disease
CC (ADPKD), comprising a PKD-1 or PKD-2 nucleic acid sequence having one or
CC more novel nucleotide alterations chosen from identified ADPKD associated
CC alterations, as given in the specification; a polypeptide biomarker for
CC ADPKD, comprising a PKD-1 or PKD-2 polypeptide sequence having one or
CC more novel amino acid alterations chosen from identified ADPKD associated
CC alterations, as given in the specification; a method for diagnosing ADPKD
CC in an individual; and a method for determining in an individual the
CC presence or absence of a mutant PKD gene. The PKD mutation detecting
CC isolated nucleic acid or the ADPKD nucleic acid biomarker is useful in
CC diagnosing ADPKD in an individual, or determining the presence or absence
CC of a mutant PKD gene in an individual. This polynucleotide sequence
CC represents a human polycystic kidney disease specific primer used in the
CC detection method of the invention.
XX
SQ Sequence 19 BP; 4 A; 3 C; 10 G; 2 T; 0 U; 0 Other;

```
  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1068 TGGCCCCAGCCCCAGCCTC 1086
              | | ||||||||||||||||
Db         19 TTGTCCCAGCCCCAGCCTC 1
```

RESULT 600

```
ADY88888/c
ID   ADY88888 standard; RNA; 19 BP.
XX
AC   ADY88888;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA SEQ ID NO 1924.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing;
KW   VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 1924; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA.
XX
SQ   Sequence 19 BP; 5 A; 5 C; 6 G; 0 T; 3 U; 0 Other;

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 3.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2596 CTGGCTGCTCGCAACATCC 2614
              ||||||||||| ||||| |
Db         19 CTGGCTGCTCGGAACATTC 1


RESULT 601
ADY89258
ID   ADY89258 standard; RNA; 19 BP.
XX
AC   ADY89258;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2294.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2294; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 19 BP; 4 A; 5 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2932 ATGCTGGACTGTTGGCAGA 2950
              |:||:||||:| :|||| |
Db          1 AUGCUGGACUGCUGGCACA 19


RESULT 602
ADY88641
ID   ADY88641 standard; RNA; 19 BP.
XX
AC   ADY88641;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA SEQ ID NO 1677.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing;
KW   VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
```

XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 1677; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA.
XX
SQ Sequence 19 BP; 3 A; 6 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 3.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2596 CTGGCTGCTCGCAACATCC 2614
|:|||:||:|| ||||: |
Db 1 CUGGCUGCUCGGAACAUUC 19

RESULT 603
ADX58087
ID ADX58087 standard; DNA; 18 BP.
XX
AC ADX58087;
XX
DT 21-APR-2005 (first entry)
XX
DE Primer Gamma 10 for single chain antibody heavy chain variable fragment.
XX
KW virucide; vaccine; single chain antibody; HSV; glycoprotein;
KW glycoprotein D; herpes simplex virus; HSV infection; RT-PCR; primer; ss;
KW heavy chain.
XX
OS Synthetic.
XX
PN WO2005011580-A2.
XX
PD 10-FEB-2005.
XX
PF 26-JUL-2004; 2004WO-US024013.
XX
PR 25-JUL-2003; 2003US-0489984P.
XX
PA (TEXA) UNIV TEXAS SYSTEM.
XX
PI Simmons A, Chen J;
XX
DR WPI; 2005-142827/15.
XX
PT New single chain antibody that specifically binds to a Herpes Simplex
PT Virus (HSV) glycoprotein, useful in preparing a composition for
PT preventing or treating a HSV infection.
XX
PS Example 1; SEQ ID NO 25; 99pp; English.
XX
CC The specification describes a single chain antibody that specifically
CC binds to a herpes simplex virus (HSV) glycoprotein, e.g. glycoprotein D.
CC The single chain antibody of the invention is useful for preparing a
CC composition for preventing or treating a HSV infection. C region RT-PCR
CC primer ADX58077 with gamma degenerate signal sequence RT-PCR primers
CC ADX58078-ADX58094 were used to amplify cDNA encoding single chain
CC antibody heavy chain variable fragments. The amplicons were used to
CC generate single chain antibodies of the invention.
XX
SQ Sequence 18 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 1 Other;

Query Match 0.4%; Score 15.6; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 4067 CCAAGCTGTGTCCTAT 4082
|||||||||||||:|
Db 1 CCAAGCTGTGTCCTRT 16

RESULT 604
ADX58086
ID ADX58086 standard; DNA; 18 BP.
XX
AC ADX58086;
XX
DT 21-APR-2005 (first entry)
XX
DE Primer Gamma 9 for a single chain antibody heavy chain variable fragment.
XX
KW virucide; vaccine; single chain antibody; HSV; glycoprotein;
KW glycoprotein D; herpes simplex virus; HSV infection; RT-PCR; primer; ss;
KW heavy chain.
XX
OS Synthetic.
XX
PN WO2005011580-A2.
XX
PD 10-FEB-2005.
XX
PF 26-JUL-2004; 2004WO-US024013.
XX
PR 25-JUL-2003; 2003US-0489984P.
XX
PA (TEXA) UNIV TEXAS SYSTEM.
XX
PI Simmons A, Chen J;
XX
DR WPI; 2005-142827/15.
XX
PT New single chain antibody that specifically binds to a Herpes Simplex
PT Virus (HSV) glycoprotein, useful in preparing a composition for
PT preventing or treating a HSV infection.
XX
PS Example 1; SEQ ID NO 24; 99pp; English.
XX
CC The specification describes a single chain antibody that specifically

```
CC   binds to a herpes simplex virus (HSV) glycoprotein, e.g. glycoprotein D.
CC   The single chain antibody of the invention is useful for preparing a
CC   composition for preventing or treating a HSV infection. C region RT-PCR
CC   primer ADX58077 with gamma degenerate signal sequence RT-PCR primers
CC   ADX58078-ADX58094 were used to amplify cDNA encoding single chain
CC   antibody heavy chain variable fragments. The amplicons were used to
CC   generate single chain antibodies of the invention.
XX
SQ   Sequence 18 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 1 Other;

  Query Match             0.4%;  Score 15.6;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 3e+02;
  Matches   15;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       4067 CCAAGCTGTGTCCTAT 4082
              ||||||||||||||:|
Db          1 CCAAGCTGTGTCCTRT 16


RESULT 605
AAT53779
ID   AAT53779 standard; RNA; 17 BP.
XX
AC   AAT53779;
XX
DT   25-MAR-2003  (revised)
DT   03-APR-1997  (first entry)
XX
DE   Rat ICAM hammerhead ribozyme target sequence (nt. position 2659).
XX
KW   Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW   gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW   intercellular adhesion molecule; rel A; tumour necrosis factor;
KW   TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW   translocation; chronic myelogenous leukaemia; CML; cancer;
KW   Philadelphia chromosome; inflammation; autoimmune disease;
KW   atherosclerosis; myocardial infarction; stroke; restenosis;
KW   transplant rejection; rheumatoid arthritis; psoriasis;
KW   myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW   human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW   ss.
XX
OS   Rattus rattus.
XX
PN   WO9523225-A2.
XX
PD   31-AUG-1995.
XX
PF   23-FEB-1995;   95WO-IB000156.
XX
PR   23-FEB-1994;   94US-00201109.
PR   29-MAR-1994;   94US-00218934.
PR   04-APR-1994;   94US-00222795.
PR   07-APR-1994;   94US-00224483.
PR   15-APR-1994;   94US-00227958.
PR   15-APR-1994;   94US-00228041.
PR   18-MAY-1994;   94US-00245736.
PR   06-JUL-1994;   94US-00271280.
PR   15-AUG-1994;   94US-00291932.
PR   16-AUG-1994;   94US-00291433.
PR   17-AUG-1994;   94US-00292620.
PR   19-AUG-1994;   94US-00293520.
PR   02-SEP-1994;   94US-00300000.
PR   08-SEP-1994;   94US-00303039.
PR   23-SEP-1994;   94US-00311486.
PR   23-SEP-1994;   94US-00311749.
PR   28-SEP-1994;   94US-00314397.
PR   03-OCT-1994;   94US-00316771.
PR   07-OCT-1994;   94US-00319492.
PR   11-OCT-1994;   94US-00321993.
PR   04-NOV-1994;   94US-00334847.
PR   10-NOV-1994;   94US-00337608.
PR   28-NOV-1994;   94US-00345516.
PR   16-DEC-1994;   94US-00357577.
PR   23-DEC-1994;   94US-00363233.
PR   30-JAN-1995;   95US-00380734.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Chowrira B,  Direnzo A,  Draper KG,  Dudycz LW;
PI   Grimm S,  Karpeisky A,  Kisich K,  Matulic-Adamic J,  Mcswiggen JA;
PI   Modak A,  Pavco P,  Beigleman L,  Sullivan SM,  Sweedler D,  Thompson JD;
PI   Tracz D,  Usman N,  Wincott FE,  Woolf T;
XX
DR   WPI; 1995-351090/45.
XX
PT   Ribozymes having modified bases and methods for producing them - for use
PT   in inhibiting disease related genes.
XX
PS   Claim 2; Page 204; 407pp; English.
XX
CC   The present sequence represents a preferred target sequence for an
CC   enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC   nucleotide base position indicated in the DE line. Regions of the mRNA
CC   that do not form secondary folding structures and that contain potential
CC   hammerhead and hairpin ribozyme cleavage sites were identified by
CC   computer analysis. Ribozymes directed against these mRNA sequences were
CC   designed and synthesised with modifications that improve their nuclease
CC   resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC   inhibit ICAM-1 expression, making them useful for reducing transplant
CC   rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC   asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC   correct PI field.)
XX
SQ   Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1218 AGAAGGGTCCTGCCAGC 1234
              |||||||:||:|| |||
Db          1 AGAAGGGUCCUGCAAGC 17


RESULT 606
AAV92591
ID   AAV92591 standard; RNA; 17 BP.
XX
AC   AAV92591;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human A-Raf substrate position 1871.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
```

```
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T,  Matulic-Adamic J,  Reynolds M,  Kisich K,  Bellon L;
PI   Parry T,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Burgin A;
PI   Thompson J,  Workman CT,  Beaudry A,  Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 160; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 1 A; 11 C; 2 G; 0 T; 3 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2965 CGGCCCCGCTTCCCCCA 2981
              ||||||| |::|||||
Db          1 CGGCCCCUCUUCCCCCA 17


RESULT 607
AAF06056
ID   AAF06056 standard; DNA; 17 BP.
XX
AC   AAF06056;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #2853.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 121; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 5 A; 5 C; 1 G; 0 T; 6 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 2.9e+02;
  Matches   10;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1566 TCCTGACTTCACCTATA 1582
              :||:|||::|| |:|:|
Db          1 UCCUGACUUCAACUAUA 17


RESULT 608
ABA81101/c
ID   ABA81101 standard; DNA; 17 BP.
XX
AC   ABA81101;
XX
DT   24-JAN-2002  (first entry)
XX
DE   LDLR mutation correcting oligonucleotide SEQ ID NO: 3947.
XX
KW   Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW   retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW   cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW   adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW   haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW   mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW   familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW   UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW   Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW   antilipemic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200173002-A2.
XX
PD   04-OCT-2001.
XX
PF   27-MAR-2001; 2001WO-US009761.
XX
PR   27-MAR-2000; 2000US-0192176P.
PR   27-MAR-2000; 2000US-0192179P.
PR   01-JUN-2000; 2000US-0208538P.
PR   30-OCT-2000; 2000US-0244989P.
XX
PA   (UYDE ) UNIV DELAWARE.
XX
PI   Kmiec EB,  Gamper HB,  Rice MC;
XX
DR   WPI; 2001-639230/73.
XX
PT   Oligonucleotide for targeted alterations of genetic sequences and for
PT   treating cystic fibrosis, comprises at least one mismatch and chemical
PT   modification.
```

```
XX
PS   Claim 7; Page 256; 294pp; English.
XX
CC   The present invention provides single-stranded oligonucleotides which can
CC   be used for the targeted alteration of genomic sequences, where the
CC   oligonucleotide has at least one mismatch compared with the genomic
CC   sequence to be altered. In particular, these sequences are directed at
CC   the following genes: adenosine deaminase, p53, beta-globin,
CC   retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC   (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC   1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC   apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC   (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC   presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC   such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC   haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC   Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC   various syndromes. The present sequence is one of the gene correcting
CC   oligonucleotides of the invention
XX
SQ   Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2319 CCTGAAGGGTGGCTACA 2335
                ||||  ||||||||||||
Db         17 CCTGGAGGGTGGCTACA 1


RESULT 609
ABA81100
ID   ABA81100 standard; DNA; 17 BP.
XX
AC   ABA81100;
XX
DT   24-JAN-2002  (first entry)
XX
DE   LDLR mutation correcting oligonucleotide SEQ ID NO: 3946.
XX
KW   Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW   retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW   cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW   adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW   haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW   mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW   familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW   UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW   Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW   antilipemic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200173002-A2.
XX
PD   04-OCT-2001.
XX
PF   27-MAR-2001; 2001WO-US009761.
XX
PR   27-MAR-2000; 2000US-0192176P.
PR   27-MAR-2000; 2000US-0192179P.
PR   01-JUN-2000; 2000US-0208538P.
PR   30-OCT-2000; 2000US-0244989P.
XX
PA   (UYDE ) UNIV DELAWARE.
XX
PI   Kmiec EB,  Gamper HB,  Rice MC;
XX
DR   WPI; 2001-639230/73.
XX
PT   Oligonucleotide for targeted alterations of genetic sequences and for
PT   treating cystic fibrosis, comprises at least one mismatch and chemical
PT   modification.
XX
PS   Claim 7; Page 256; 294pp; English.
XX
CC   The present invention provides single-stranded oligonucleotides which can
CC   be used for the targeted alteration of genomic sequences, where the
CC   oligonucleotide has at least one mismatch compared with the genomic
CC   sequence to be altered. In particular, these sequences are directed at
CC   the following genes: adenosine deaminase, p53, beta-globin,
CC   retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC   (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC   1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC   apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC   (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC   presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC   such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC   haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC   Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC   various syndromes. The present sequence is one of the gene correcting
CC   oligonucleotides of the invention
XX
SQ   Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2319 CCTGAAGGGTGGCTACA 2335
                ||||  ||||||||||||
Db          1 CCTGGAGGGTGGCTACA 17


RESULT 610
ABN01661/c
ID   ABN01661 standard; DNA; 17 BP.
XX
AC   ABN01661;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1653.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
```

```
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 1653; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3966 TATGGCCTCCTTTGCCC 3982
              | ||||||||||||||||
Db         17 TCTGGCCTCCTTTGCCC 1


RESULT 611
ABN01662/c
ID   ABN01662 standard; DNA; 17 BP.
XX
AC   ABN01662;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1654.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 1654; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3965 CTATGGCCTCCTTTGCC 3981
              || |||||||||||||||
Db         17 CTCTGGCCTCCTTTGCC 1


RESULT 612
ABQ63403/c
ID   ABQ63403 standard; DNA; 17 BP.
XX
AC   ABQ63403;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 116.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
```

```
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 172; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 2 A; 2 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4039 CCACATCCCCGGACCCC 4055
              ||||||||||||||| ||
Db         17 CCACATCCCCGGACTCC 1


RESULT 613
ACN02004
ID   ACN02004 standard; RNA; 17 BP.
XX
AC   ACN02004;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Inozyme substrate SEQ ID NO 1994.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 1994; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3228 AGTCACTCTGGCGGGAC 3244
              ||:||| |:||||||||
Db          1 AGUCACACUGGCGGGAC 17


RESULT 614
ACN11465/c
ID   ACN11465 standard; RNA; 17 BP.
XX
AC   ACN11465;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 11468.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
```

```
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 11468; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3228 AGTCACTCTGGCGGGAC 3244
              |||||| ||||||||||
Db         17 AGTCACACTGGCGGGAC 1


RESULT 615
AEB58244
ID   AEB58244 standard; mRNA; 17 BP.
XX
AC   AEB58244;
XX
DT   22-SEP-2005  (first entry)
XX
DE   Human VEGF receptor 1 (flt-1) DNAzyme target sequence SEQ ID 822.
XX
KW   VEGF receptor; angiogenesis; cancer; tumor; ocular disease;
KW   diabetic retinopathy; age related macular degeneration;
KW   angiogenesis disorder; rheumatoid arthritis; psoriasis; wound healing;
KW   endometriosis; endometroid carcinoma; gynecological bleeding disorder;
KW   menstruation disorder; premenstrual syndrome; menopause; Gynecological;
KW   Cytostatic; Ophthalmological; Antidiabetic; antiangiogenic;
KW   Antipsoriatic; Antirheumatic; Antiarthritic; Vulnerary; Hemostatic;
KW   Contraceptive; ss; enzymatic nucleic acid.
XX
OS   Homo sapiens.
XX
PN   WO200296927-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US017674.
XX
PR   29-MAY-2001; 2001US-00870161.
PR   30-NOV-2001; 2001US-0334461P.
PR   03-MAY-2002; 2002US-00138674.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Escobedo J,  Mcswiggen J,  Pavco P,  Stinchcomb D,  Sandberg J;
PI   Gordon G;
XX
DR   WPI; 2003-140439/13.
XX
PT   Novel enzymatic nucleic acids, ribozymes, which modulate expression of
PT   genes encoding vascular endothelial growth factor and/or VEGF receptor,
PT   useful for inhibiting tumor angiogenesis in cell, and for treating
PT   cancer.
XX
PS   Disclosure; SEQ ID NO 822; 172pp; English.
XX
CC   The invention relates to enzymatic nucleic acids (I) i.e.
CC   ribozymes/DNAzymes/Zinzymes that target and modulate expression of, genes
CC   encoding vascular endothelial growth factor (VEGF) and/or VEGF receptor
CC   (VEGFR1 and 2 encode by the Flt-1 and Kdr genes respectively). Also
CC   included are a composition comprising (I) and a carrier, administering
CC   (I) to a cell (by contacting the cell with the compound under conditions
CC   suitable for the administration), administering (I) to a cell (in
CC   conjunction with one or more other drug by contacting the cell with the
CC   compound and the other drug under conditions suitable for the
CC   administration), administering (I) to a mammal (by contacting the mammal
CC   with the compound under conditions suitable for the administration),
CC   treating (M1) a subject having endometriosis (by contacting a subject
CC   with, or administering to subject, a nucleic acid molecule (II) that
CC   modulates expression of VEGF, VEGFR1, and/or VEGFR2), a mammalian cell
CC   (III) comprising (I) and administering to a mammal (I) (in conjunction
CC   with a chemotherapeutic agent comprising contacting the mammal with the
CC   compound and the chemotherapeutic agent under conditions suitable for the
CC   administration). (I) is administered to a mammalian cell, preferably
CC   human cell in the presence of a delivery reagent which is a lipid such as
CC   cationic lipid or phospholipid, or a liposome. The enzymatic nucleic acid
CC   molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1
CC   and/or VEGFR2 gene, and is in a hammerhead, inozyme, DNAzyme, G-cleaver,
CC   or Amberzyme configuration. The enzymatic nucleic acids are useful for
CC   inhibiting ocular angiogenesis associated with diabetic retinopathy or
CC   age-related diabetic retinopathy, in a subject. They are also useful for
CC   inhibiting angiogenesis, preferably tumor angiogenesis in cell, and for
CC   treating a subject having a condition associated with an increased level
CC   of VEGF receptor, where the condition is cancer, e.g. breast cancer, lung
CC   cancer (such as non-small cell lung carcinoma), colorectal cancer, renal
CC   cancer (such as renal cell carcinoma), pancreatic cancer. The enzymatic
CC   nucleic acids are useful for treating a subject (preferably human) having
CC   endometriosis, psoriasis, age-related macular degeneration, proliferative
CC   diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis,
CC   wound healing, endometrial carcinoma, gynecologic bleeding disorders,
CC   irregular menstrual cycles, ovulation, premenstrual syndrome, and
CC   menopausal dysfunction. The enzymatic nucleic acids are useful for birth
CC   control by inhibiting ovulation or embryonic uterine implantation. The
CC   present sequence is a target sequence from the human VEGFR1/flt-1 mRNA.
XX
SQ   Sequence 17 BP; 4 A; 4 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 2.9e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2926 CAGCTCATGCTGGACTG 2942
              ||| :||:||:||||:|
Db          1 CAGAUCAUGCUGGACUG 17


RESULT 616
AEB58245
ID   AEB58245 standard; mRNA; 17 BP.
XX
AC   AEB58245;
XX
DT   22-SEP-2005  (first entry)
XX
DE   Human VEGF receptor 1 (flt-1) DNAzyme target sequence SEQ ID 823.
```

XX
KW VEGF receptor; angiogenesis; cancer; tumor; ocular disease;
KW diabetic retinopathy; age related macular degeneration;
KW angiogenesis disorder; rheumatoid arthritis; psoriasis; wound healing;
KW endometriosis; endometroid carcinoma; gynecological bleeding disorder;
KW menstruation disorder; premenstrual syndrome; menopause; Gynecological;
KW Cytostatic; Ophthalmological; Antidiabetic; antiangiogenic;
KW Antipsoriatic; Antirheumatic; Antiarthritic; Vulnerary; Hemostatic;
KW Contraceptive; ss; enzymatic nucleic acid.
XX
OS Homo sapiens.
XX
PN WO200296927-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US017674.
XX
PR 29-MAY-2001; 2001US-00870161.
PR 30-NOV-2001; 2001US-0334461P.
PR 03-MAY-2002; 2002US-00138674.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Escobedo J, Mcswiggen J, Pavco P, Stinchcomb D, Sandberg J;
PI Gordon G;
XX
DR WPI; 2003-140439/13.
XX
PT Novel enzymatic nucleic acids, ribozymes, which modulate expression of
PT genes encoding vascular endothelial growth factor and/or VEGF receptor,
PT useful for inhibiting tumor angiogenesis in cell, and for treating
PT cancer.
XX
PS Disclosure; SEQ ID NO 823; 172pp; English.
XX
CC The invention relates to enzymatic nucleic acids (I) i.e.
CC ribozymes/DNAzymes/Zinzymes that target and modulate expression of, genes
CC encoding vascular endothelial growth factor (VEGF) and/or VEGF receptor
CC (VEGFR1 and 2 encode by the Flt-1 and Kdr genes respectively). Also
CC included are a composition comprising (I) and a carrier, administering
CC (I) to a cell (by contacting the cell with the compound under conditions
CC suitable for the administration), administering (I) to a cell (in
CC conjunction with one or more other drug by contacting the cell with the
CC compound and the other drug under conditions suitable for the
CC administration), administering (I) to a mammal (by contacting the mammal
CC with the compound under conditions suitable for the administration),
CC treating (M1) a subject having endometriosis (by contacting a subject
CC with, or administering to subject, a nucleic acid molecule (II) that
CC modulates expression of VEGF, VEGFR1, and/or VEGFR2), a mammalian cell
CC (III) comprising (I) and administering to a mammal (I) (in conjunction
CC with a chemotherapeutic agent comprising contacting the mammal with the
CC compound and the chemotherapeutic agent under conditions suitable for the
CC administration). (I) is administered to a mammalian cell, preferably
CC human cell in the presence of a delivery reagent which is a lipid such as
CC cationic lipid or phospholipid, or a liposome. The enzymatic nucleic acid
CC molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1
CC and/or VEGFR2 gene, and is in a hammerhead, inozyme, DNAzyme, G-cleaver,
CC or Amberzyme configuration. The enzymatic nucleic acids are useful for
CC inhibiting ocular angiogenesis associated with diabetic retinopathy or
CC age-related diabetic retinopathy, in a subject. They are also useful for
CC inhibiting angiogenesis, preferably tumor angiogenesis in cell, and for
CC treating a subject having a condition associated with an increased level
CC of VEGF receptor, where the condition is cancer, e.g. breast cancer, lung
CC cancer (such as non-small cell lung carcinoma), colorectal cancer, renal
CC cancer (such as renal cell carcinoma), pancreatic cancer. The enzymatic
CC nucleic acids are useful for treating a subject (preferably human) having
CC endometriosis, psoriasis, age-related macular degeneration, proliferative
CC diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis,
CC wound healing, endometrial carcinoma, gynecologic bleeding disorders,
CC irregular menstrual cycles, ovulation, premenstrual syndrome, and
CC menopausal dysfunction. The enzymatic nucleic acids are useful for birth
CC control by inhibiting ovulation or embryonic uterine implantation. The
CC present sequence is a target sequence from the human VEGFR1/flt-1 mRNA.
XX
SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.9e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTTGGC 2947
||:||:||||:| :|||
Db 1 CAUGCUGGACUGCUGGC 17

RESULT 617
AEB61660
ID AEB61660 standard; mRNA; 17 BP.
XX
AC AEB61660;
XX
DT 22-SEP-2005 (first entry)
XX
DE Human VEGF receptor 21 (Kdr) DNAzyme target sequence SEQ ID 4238.
XX
KW VEGF receptor; angiogenesis; cancer; tumor; ocular disease;
KW diabetic retinopathy; age related macular degeneration;
KW angiogenesis disorder; rheumatoid arthritis; psoriasis; wound healing;
KW endometriosis; endometroid carcinoma; gynecological bleeding disorder;
KW menstruation disorder; premenstrual syndrome; menopause; Gynecological;
KW Cytostatic; Ophthalmological; Antidiabetic; antiangiogenic;
KW Antipsoriatic; Antirheumatic; Antiarthritic; Vulnerary; Hemostatic;
KW Contraceptive; ss; enzymatic nucleic acid.
XX
OS Homo sapiens.
XX
PN WO200296927-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US017674.
XX
PR 29-MAY-2001; 2001US-00870161.
PR 30-NOV-2001; 2001US-0334461P.
PR 03-MAY-2002; 2002US-00138674.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Escobedo J, Mcswiggen J, Pavco P, Stinchcomb D, Sandberg J;
PI Gordon G;
XX
DR WPI; 2003-140439/13.
XX
PT Novel enzymatic nucleic acids, ribozymes, which modulate expression of
PT genes encoding vascular endothelial growth factor and/or VEGF receptor,
PT useful for inhibiting tumor angiogenesis in cell, and for treating
PT cancer.
XX
PS Disclosure; SEQ ID NO 4238; 172pp; English.
XX
CC The invention relates to enzymatic nucleic acids (I) i.e.
CC ribozymes/DNAzymes/Zinzymes that target and modulate expression of, genes
CC encoding vascular endothelial growth factor (VEGF) and/or VEGF receptor
CC (VEGFR1 and 2 encode by the Flt-1 and Kdr genes respectively). Also
CC included are a composition comprising (I) and a carrier, administering
CC (I) to a cell (by contacting the cell with the compound under conditions
CC suitable for the administration), administering (I) to a cell (in
CC conjunction with one or more other drug by contacting the cell with the
CC compound and the other drug under conditions suitable for the
CC administration), administering (I) to a mammal (by contacting the mammal
CC with the compound under conditions suitable for the administration),
CC treating (M1) a subject having endometriosis (by contacting a subject
CC with, or administering to subject, a nucleic acid molecule (II) that

```
CC   modulates expression of VEGF, VEGFR1, and/or VEGFR2), a mammalian cell
CC   (III) comprising (I) and administering to a mammal (I) (in conjunction
CC   with a chemotherapeutic agent comprising contacting the mammal with the
CC   compound and the chemotherapeutic agent under conditions suitable for the
CC   administration). (I) is administered to a mammalian cell, preferably
CC   human cell in the presence of a delivery reagent which is a lipid such as
CC   cationic lipid or phospholipid, or a liposome. The enzymatic nucleic acid
CC   molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1
CC   and/or VEGFR2 gene, and is in a hammerhead, inozyme, DNAzyme, G-cleaver,
CC   or Amberzyme configuration. The enzymatic nucleic acids are useful for
CC   inhibiting ocular angiogenesis associated with diabetic retinopathy or
CC   age-related diabetic retinopathy, in a subject. They are also useful for
CC   inhibiting angiogenesis, preferably tumor angiogenesis in cell, and for
CC   treating a subject having a condition associated with an increased level
CC   of VEGF receptor, where the condition is cancer, e.g. breast cancer, lung
CC   cancer (such as non-small cell lung carcinoma), colorectal cancer, renal
CC   cancer (such as renal cell carcinoma), pancreatic cancer. The enzymatic
CC   nucleic acids are useful for treating a subject (preferably human) having
CC   endometriosis, psoriasis, age-related macular degeneration, proliferative
CC   diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis,
CC   wound healing, endometrial carcinoma, gynecologic bleeding disorders,
CC   irregular menstrual cycles, ovulation, premenstrual syndrome, and
CC   menopausal dysfunction. The enzymatic nucleic acids are useful for birth
CC   control by inhibiting ovulation or embryonic uterine implantation. The
CC   present sequence is a target sequence from the human VEGFR2/Kdr mRNA.
XX
SQ   Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 2.9e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          1 CAUGCUGGACUGCUGGC 17


RESULT 618
ACN64751/c
ID   ACN64751 standard; DNA; 17 BP.
XX
AC   ACN64751;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:1653.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 1653; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3966 TATGGCCTCCTTTGCCC 3982
              | ||||||||||||||||
Db         17 TCTGGCCTCCTTTGCCC 1


RESULT 619
ACN64752/c
ID   ACN64752 standard; DNA; 17 BP.
XX
AC   ACN64752;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:1654.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
```

```
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 1654; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 2.9e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3965 CTATGGCCTCCTTTGCC 3981
              || |||||||||||||||
Db         17 CTCTGGCCTCCTTTGCC 1


RESULT 620
ADR87873
ID   ADR87873 standard; DNA; 18 BP.
XX
AC   ADR87873;
XX
DT   04-NOV-2004  (first entry)
XX
DE   Biotinylated primer used to amplify human CYP2D6 exon 7 DNA - SEQ ID 51.
XX
KW   SNP detection; drug therapy; PCR; primer; ss; human;
KW   cytochrome P450 isoenzyme; debrisoquine 4-hydroxylase; CYP2D6 exon 7.
XX
OS   Homo sapiens.
XX
PN   WO2004069189-A2.
XX
PD   19-AUG-2004.
XX
PF   04-FEB-2004; 2004WO-US002941.
XX
PR   04-FEB-2003; 2003US-0444656P.
XX
PA   (INNO-) INNOVACEUTICALS INC.
XX
PI   Branch RA,  Romkes M;
XX
DR   WPI; 2004-604340/58.
XX
PT   Measuring the expression or activity of a CYP enzyme in a subject by
PT   measuring the expression of the CYP enzyme gene or mRNA expression for
PT   the CYP enzyme in whole blood and normalizing the measured CYP enzyme
PT   gene or mRNA expression.
XX
PS   Example 5; SEQ ID NO 51; 73pp; English.
XX
CC   The invention relates to a novel method for measuring the expression or
CC   activity of a CYP (cytochrome P450), NAT1 (N-acetyltransferase 1) or NAT2
CC   (N-acetyltransferase 2) enzyme in a subject comprising measuring the
CC   expression of the enzyme gene or mRNA in whole blood and normalising the
CC   measured enzyme gene or mRNA expression, respectively. The method may be
CC   useful in measuring the expression or activity of an enzyme in a subject
CC   and for detecting and quantifying the presence of SNPs (single nucleotide
CC   polymorphisms) within an enzyme. Thus, the method of the invention may be
CC   utilised in order to predict the effectiveness or safety of a drug
CC   therapy, since the drug metabolising capability of an individual is
CC   affected by the isoenzymes present within that individual. The current
CC   sequence is that of a 5' biotinylated PCR primer which was used to
CC   amplify human CYP2D6 (debrisoquine 4-hydroxylase) DNA of the invention.
XX
SQ   Sequence 18 BP; 7 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 18;
  Best Local Similarity   94.1%;  Pred. No. 3.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3718 GGCAAGAAGGGGTGTCA 3734
              |||||||||| ||||||
Db          2 GGCAAGAAGGAGTGTCA 18


RESULT 621
ADF36606/c
ID   ADF36606 standard; RNA; 19 BP.
XX
AC   ADF36606;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:895.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
```

```
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 895; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 12 A; 3 C; 3 G; 0 T; 1 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||||||||||||| |||
Db         18 AGTTTTGTTTTTGTTCT 2


RESULT 622
ADF36930
ID   ADF36930 standard; RNA; 19 BP.
XX
AC   ADF36930;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:1219.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 1219; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 1 A; 3 C; 3 G; 0 T; 12 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   29.4%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative   11;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||::::|:::::| :|:
Db          2 AGUUUUGUUUUUGUUCU 18


RESULT 623
ADO16519
ID   ADO16519 standard; DNA; 19 BP.
XX
AC   ADO16519;
XX
DT   29-JUL-2004  (first entry)
XX
DE   4 synthesis-period of neuroblastoma related primer, SEQ ID 781.
XX
KW   Human; 4 synthesis-period; neuroblastoma; stage 4S; primer; ss.
XX
```

OS Synthetic.
XX
PN WO2004039975-A1.
XX
PD 13-MAY-2004.
XX
PF 30-OCT-2003; 2003WO-JP013932.
XX
PR 30-OCT-2002; 2002JP-00316586.
XX
PA (HISM) HISAMITSU PHARM CO LTD.
PA (CHIB-) CHIBA PREFECTURE.
XX
PI Nakagawara A, Ohira M;
XX
DR WPI; 2004-390323/36.
XX
PT Novel nucleic acid obtained from 4 synthesis-period of neuroblastoma
PT cells useful for prognosing and determining progress stage of
PT neuroblastomas.
XX
PS Claim 8; SEQ ID NO 781; 455pp; Japanese.
XX
CC The present invention relates to human nucleic acid sequences (I;
CC ADO15739-ADO15912) obtained from 4 synthesis-period (stage 4S) of
CC neuroblastoma cell. (I) is useful for prognosing and determining the
CC progress stage of 4 synthesis-period of neuroblastoma. The present
CC sequence is a primer, used to illustrate the invention.
XX
SQ Sequence 19 BP; 8 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1935 GGAACATCACAGCCAGA 1951
||||||| ||||||||||
Db 3 GGAACACCACAGCCAGA 19

RESULT 624
ADQ60352
ID ADQ60352 standard; RNA; 19 BP.
XX
AC ADQ60352;
XX
DT 09-SEP-2004 (first entry)
XX
DE Anti-Cyclophilin siRNA Cyclo 20 SEQ ID NO:51.
XX
KW ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW RNA interference; cyclophilin.
XX
OS Synthetic.
XX
PN WO2004045543-A2.
XX
PD 03-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-US036787.
XX
PR 14-NOV-2002; 2002US-0426137P.
PR 10-SEP-2003; 2003US-0502050P.
XX
PA (DHAR-) DHARMACON INC.
XX
PI Anastasia K, Angela R, Devin L, William M, Stephen S;
XX
DR WPI; 2004-420527/39.
XX
PT Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT by selecting a target gene and measuring the functionality of the
PT nucleotide sequences that are complementary to a stretch of nucleotides
PT of the target sequence.
XX
PS Example 1; SEQ ID NO 51; 199pp; English.
XX
CC The invention relates to a novel method for selecting siRNA (short
CC interfering RNA) comprising selecting an siRNA molecule of 19-25
CC nucleoside bases by selecting a target gene and measuring the
CC functionality of sequences of 19-25 nucleotides in length that are
CC substantially complementary to a stretch of nucleotides of the target
CC sequence, where the functionality is dependent upon non-target specific
CC criteria. Also claimed are methods for gene-silencing, developing an
CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC sequence consisting of GGGAGAUAGUGAUGAAGUA; GAAGUACAUCCAUUAUAAG;
CC GUACGACAACCGGGAGAUA; AGAUAGUGAUGAAGUACAU; UGAAGACUCUGCUCAGUUU;
CC CAUGCGGCCUCUGUUUGA; UGCGGCCUCUGUUUGAUUU; GAGAUAGUGAUGAAGUACA;
CC GGAGAUAGUGAUGAAGUAC; and GAAGACUCUGCUCAGUUUG. The siRNA molecule
CC comprises a sense strand and an anti-sense strand. The siRNA molecule
CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC pairs. The kit comprises at least two siRNA, comprising a first optimised
CC siRNA and a second optimised siRNA. The method is useful in selecting
CC siRNA for generating a gene silencing reagent. The present sequence is
CC used in the exemplification of the invention.
XX
SQ Sequence 19 BP; 7 A; 1 C; 8 G; 0 T; 3 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 3.5e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 3472 GGAGAGACAGGATTTGG 3488
||||||| ||||:::||
Db 2 GGAGAGAAAGGAUUUGG 18

RESULT 625
ADR79853/c
ID ADR79853 standard; DNA; 19 BP.
XX
AC ADR79853;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human apolipoprotein B (ApoB) oligonucleotide seqid 4349.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX
OS Homo sapiens.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 13-MAR-2003; 2003US-0455050P.
PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.

PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX
DR WPI; 2004-677362/66.
XX
PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
PS Example 5; SEQ ID NO 4349; 378pp; English.
XX
CC The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or disregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholestorolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC can be used to control ApoB gene expression.
XX
SQ Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3553 GTGAGGGCGCCTTTCCC 3569
||||||||| |||||||
Db 18 GTGAGGGCGGCTTTCCC 2

RESULT 626
ADR79854/c
ID ADR79854 standard; DNA; 19 BP.
XX
AC ADR79854;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human apolipoprotein B (ApoB) oligonucleotide seqid 4350.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX
OS Homo sapiens.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 13-MAR-2003; 2003US-0455050P.
PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX
DR WPI; 2004-677362/66.
XX
PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
PS Example 5; SEQ ID NO 4350; 378pp; English.
XX
CC The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or disregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholestorolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC can be used to control ApoB gene expression.
XX
SQ Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

```
  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3553 GTGAGGGCGCCTTTCCC 3569
              ||||||||| |||||||
Db         19 GTGAGGGCGGCTTTCCC 3

RESULT 627
ADR76909/c
ID   ADR76909 standard; DNA; 19 BP.
XX
AC   ADR76909;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human apolipoprotein B (ApoB) oligonucleotide seqid 1394.
XX
KW   antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW   cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW   RNA interference; iRNA; antisense technology; lipid metabolism;
KW   cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW   coronary artery disease; CAD; coronary heart disease; CHD;
KW   atherosclerosis; hepatic glucose production;
KW   glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW   colon cancer; lung cancer; neurological disease; Huntington disease;
KW   spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080406-A2.
XX
PD   23-SEP-2004.
XX
PF   08-MAR-2004; 2004WO-US007070.
XX
PR   07-MAR-2003; 2003US-0452682P.
PR   12-MAR-2003; 2003US-0454265P.
PR   13-MAR-2003; 2003US-0454962P.
PR   13-MAR-2003; 2003US-0455050P.
PR   14-APR-2003; 2003US-0462894P.
PR   17-APR-2003; 2003US-0463772P.
PR   25-APR-2003; 2003US-0465665P.
PR   25-APR-2003; 2003US-0465802P.
PR   09-MAY-2003; 2003US-0469612P.
PR   08-AUG-2003; 2003US-0493986P.
PR   11-AUG-2003; 2003US-0494597P.
PR   26-SEP-2003; 2003US-0506341P.
PR   09-OCT-2003; 2003US-0510246P.
PR   10-OCT-2003; 2003US-0510318P.
PR   07-NOV-2003; 2003US-0518453P.
XX
PA   (ALNY-) ALNYLAM PHARM.
XX
PI   Manoharan M,  Bumcrot D;
XX
DR   WPI; 2004-677362/66.
XX
PT   Interference RNA agent useful for treating dyslipidemias, coronary artery
PT   disease, diabetes, cancer or neurological disease, comprises sense
PT   sequence and antisense sequence which has specific modifications.
XX
PS   Example 5; SEQ ID NO 1394; 378pp; English.
XX
CC   The invention describes a RNA interference (iRNA) agent (I) comprising a
CC   sense sequence and an antisense sequence, where the sense sequences have
CC   one or more asymmetrical 2'-O alkyl modifications, the antisense
CC   sequences have one or more asymmetrical phosphorothioate modifications
CC   and the antisense sequence targets a human gene sequence. Also described
CC   are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC   levels or glucose-6-phosphatase levels in a subject; producing (I);
CC   stabilising (I), involves selecting a sequence with activity and
CC   introducing one or more asymmetrical modification in the sequence, where
CC   the modification decreases nuclease sensitivity while not decreasing its
CC   activity; a kit comprising (I) and instruction for its use; and a device
CC   that can be dispense or administer a composition comprising (I). (I) is
CC   useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC   is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC   The subject is suffering from a disorder characterised by elevated or
CC   otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC   levels of cholesterol, and/or disregulation of lipid metabolism. The
CC   disorder is chosen from the HDL/LDL cholesterol imbalance,
CC   dyslipidaemias, hypercholestorolaemia, statin-resistant
CC   hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC   disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC   inhibit hepatic glucose production or for treating glucose-metabolism-
CC   related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC   treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC   lung cancer), neurological disease (e.g., Huntington disease or
CC   spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC   represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC   can be used to control ApoB gene expression.
XX
SQ   Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3553 GTGAGGGCGCCTTTCCC 3569
              ||||||||| |||||||
Db         18 GTGAGGGCGGCTTTCCC 2

RESULT 628
ADR76910/c
ID   ADR76910 standard; DNA; 19 BP.
XX
AC   ADR76910;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human apolipoprotein B (ApoB) oligonucleotide seqid 1395.
XX
KW   antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW   cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW   RNA interference; iRNA; antisense technology; lipid metabolism;
KW   cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW   coronary artery disease; CAD; coronary heart disease; CHD;
KW   atherosclerosis; hepatic glucose production;
KW   glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW   colon cancer; lung cancer; neurological disease; Huntington disease;
KW   spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080406-A2.
XX
PD   23-SEP-2004.
XX
PF   08-MAR-2004; 2004WO-US007070.
XX
PR   07-MAR-2003; 2003US-0452682P.
PR   12-MAR-2003; 2003US-0454265P.
PR   13-MAR-2003; 2003US-0454962P.
PR   13-MAR-2003; 2003US-0455050P.
PR   14-APR-2003; 2003US-0462894P.
PR   17-APR-2003; 2003US-0463772P.
PR   25-APR-2003; 2003US-0465665P.
PR   25-APR-2003; 2003US-0465802P.
PR   09-MAY-2003; 2003US-0469612P.
PR   08-AUG-2003; 2003US-0493986P.
PR   11-AUG-2003; 2003US-0494597P.
PR   26-SEP-2003; 2003US-0506341P.
```

```
PR   09-OCT-2003; 2003US-0510246P.
PR   10-OCT-2003; 2003US-0510318P.
PR   07-NOV-2003; 2003US-0518453P.
XX
PA   (ALNY-) ALNYLAM PHARM.
XX
PI   Manoharan M,  Bumcrot D;
XX
DR   WPI; 2004-677362/66.
XX
PT   Interference RNA agent useful for treating dyslipidemias, coronary artery
PT   disease, diabetes, cancer or neurological disease, comprises sense
PT   sequence and antisense sequence which has specific modifications.
XX
PS   Example 5; SEQ ID NO 1395; 378pp; English.
XX
CC   The invention describes a RNA interference (iRNA) agent (I) comprising a
CC   sense sequence and an antisense sequence, where the sense sequences have
CC   one or more asymmetrical 2'-O alkyl modifications, the antisense
CC   sequences have one or more asymmetrical phosphorothioate modifications
CC   and the antisense sequence targets a human gene sequence. Also described
CC   are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC   levels or glucose-6-phosphatase levels in a subject; producing (I);
CC   stabilising (I), involves selecting a sequence with activity and
CC   introducing one or more asymmetrical modification in the sequence, where
CC   the modification decreases nuclease sensitivity while not decreasing its
CC   activity; a kit comprising (I) and instruction for its use; and a device
CC   that can be dispense or administer a composition comprising (I). (I) is
CC   useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC   is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC   The subject is suffering from a disorder characterised by elevated or
CC   otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC   levels of cholesterol, and/or disregulation of lipid metabolism. The
CC   disorder is chosen from the HDL/LDL cholesterol imbalance,
CC   dyslipidaemias, hypercholestorolaemia, statin-resistant
CC   hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC   disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC   inhibit hepatic glucose production or for treating glucose-metabolism-
CC   related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC   treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC   lung cancer), neurological disease (e.g., Huntington disease or
CC   spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC   represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC   can be used to control ApoB gene expression.
XX
SQ   Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3553 GTGAGGGCGCCTTTCCC 3569
              ||||||||| |||||||
Db         19 GTGAGGGCGGCTTTCCC 3


RESULT 629
ADT81353/c
ID   ADT81353 standard; DNA; 19 BP.
XX
AC   ADT81353;
XX
DT   13-JAN-2005  (first entry)
XX
DE   Apolipoprotein B (apoB) antisense inhibition target seqid 1395.
XX
KW   antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW   interference RNA; iRNA; cholesterol moiety; apoB; glucose-6-phosphatase;
KW   lipid metabolism; cholesterol imbalance; dyslipidaemia;
KW   familial combined hyperlipidaemia; acquired hyperlipidaemia;
KW   hypercholesterolaemia; statin-resistant hypercholesterolaemia;
KW   coronary artery disease; coronary heart disease; atherosclerosis;
KW   hepatic glucose production; glucose-metabolism-related disorder;
KW   type-2 diabetes; glitaxzone-resistant diabetes; human; apolipoprotein B;
KW   antisense inhibition; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004091515-A2.
XX
PD   28-OCT-2004.
XX
PF   09-APR-2004; 2004WO-US011255.
XX
PR   09-APR-2003; 2003US-0462097P.
PR   10-APR-2003; 2003US-0461915P.
PR   14-APR-2003; 2003US-0462894P.
PR   17-APR-2003; 2003US-0463772P.
PR   25-APR-2003; 2003US-0465665P.
PR   25-APR-2003; 2003US-0465802P.
PR   09-MAY-2003; 2003US-0469612P.
PR   08-AUG-2003; 2003US-0493986P.
PR   11-AUG-2003; 2003US-0494597P.
PR   26-SEP-2003; 2003US-0506341P.
PR   09-OCT-2003; 2003US-0510246P.
PR   10-OCT-2003; 2003US-0510318P.
PR   07-NOV-2003; 2003US-0518453P.
PR   08-MAR-2004; 2004WO-US007070.
PR   05-APR-2004; 2004WO-US010586.
XX
PA   (ALNY-) ALNYLAM PHARM INC.
XX
PI   Manoharan M,  Elbashir S,  Harborth J;
XX
DR   WPI; 2004-766693/75.
XX
PT   New interference RNA agent comprising sense sequence and antisense
PT   sequence having cholesterol moieties, useful for reducing apoB-100 levels
PT   or glucose-6-phosphatase levels.
XX
PS   Claim 2; SEQ ID NO 1395; 324pp; English.
XX
CC   The invention describes an interference RNA (iRNA) agent (I) comprising a
CC   sense sequence and an antisense sequence, where the sense sequence
CC   comprises one or more cholesterol moieties, and the antisense sequence
CC   targets a human gene sequence. The following are disclosed: a
CC   pharmaceutical composition comprising (I); and a device for administering
CC   (I) into a patient. (I) is useful for reducing apoB-100 levels or glucose
CC   -6-phosphatase levels in a subject. (I) targets a sequence identical to
CC   any one of sequences as given in the specification. (I) comprises a
CC   cholesterol moiety. The cholesterol moiety is coupled to a sense strand.
CC   (I) further comprises a second cholesterol moiety. The second cholesterol
CC   moiety is coupled to a sense strand. (I) has 21 or more nucleotides. The
CC   duplex region of (I) is 19 nucleotides in length. The subject is
CC   suffering from a disorder having elevated or otherwise unwanted
CC   expression of apo-B-100, elevated or otherwise unwanted levels of
CC   cholesterol, and/or disregulation of lipid metabolism. The disorder is
CC   chosen from HDL/LDL cholesterol imbalance, dyslipidaemia (e.g., familial
CC   combined hyperlipidaemia or acquired hyperlipidaemia),
CC   hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary
CC   artery disease, coronary heart disease and atherosclerosis, preferably
CC   statin-resistant hypercholesterolaemia. (I) is administered to a subject
CC   to inhibit hepatic glucose production or for treating glucose-metabolism-
CC   related disorders e.g., type-2 diabetes or glitaxzone-resistant diabetes.
CC   (I) has endonuclease or exonuclease resistance. This sequence represents
CC   a human apolipoprotein B (apoB) pallindromic sequence that may be useful
CC   as a target for antisense inhibition.
XX
SQ   Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3553 GTGAGGGCGCCTTTCCC 3569
              ||||||||| |||||||
```

```
Db         19 GTGAGGGCGGCTTTCCC 3


RESULT 630
ADT84297/c
ID   ADT84297 standard; DNA; 19 BP.
XX
AC   ADT84297;
XX
DT   13-JAN-2005  (first entry)
XX
DE   Apolipoprotein B (apoB) antisense inhibition target seqid 4339.
XX
KW   antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW   interference RNA; iRNA; cholesterol moiety; apoB; glucose-6-phosphatase;
KW   lipid metabolism; cholesterol imbalance; dyslipidaemia;
KW   familial combined hyperlipidaemia; acquired hyperlipidaemia;
KW   hypercholesterolaemia; statin-resistant hypercholesterolaemia;
KW   coronary artery disease; coronary heart disease; atherosclerosis;
KW   hepatic glucose production; glucose-metabolism-related disorder;
KW   type-2 diabetes; glitaxzone-resistant diabetes; human; apolipoprotein B;
KW   antisense inhibition; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004091515-A2.
XX
PD   28-OCT-2004.
XX
PF   09-APR-2004; 2004WO-US011255.
XX
PR   09-APR-2003; 2003US-0462097P.
PR   10-APR-2003; 2003US-0461915P.
PR   14-APR-2003; 2003US-0462894P.
PR   17-APR-2003; 2003US-0463772P.
PR   25-APR-2003; 2003US-0465665P.
PR   25-APR-2003; 2003US-0465802P.
PR   09-MAY-2003; 2003US-0469612P.
PR   08-AUG-2003; 2003US-0493986P.
PR   11-AUG-2003; 2003US-0494597P.
PR   26-SEP-2003; 2003US-0506341P.
PR   09-OCT-2003; 2003US-0510246P.
PR   10-OCT-2003; 2003US-0510318P.
PR   07-NOV-2003; 2003US-0518453P.
PR   08-MAR-2004; 2004WO-US007070.
PR   05-APR-2004; 2004WO-US010586.
XX
PA   (ALNY-) ALNYLAM PHARM INC.
XX
PI   Manoharan M,  Elbashir S,  Harborth J;
XX
DR   WPI; 2004-766693/75.
XX
PT   New interference RNA agent comprising sense sequence and antisense
PT   sequence having cholesterol moieties, useful for reducing apoB-100 levels
PT   or glucose-6-phosphatase levels.
XX
PS   Claim 2; SEQ ID NO 4339; 324pp; English.
XX
CC   The invention describes an interference RNA (iRNA) agent (I) comprising a
CC   sense sequence and an antisense sequence, where the sense sequence
CC   comprises one or more cholesterol moieties, and the antisense sequence
CC   targets a human gene sequence. The following are disclosed: a
CC   pharmaceutical composition comprising (I); and a device for administering
CC   (I) into a patient. (I) is useful for reducing apoB-100 levels or glucose
CC   -6-phosphatase levels in a subject. (I) targets a sequence identical to
CC   any one of sequences as given in the specification. (I) comprises a
CC   cholesterol moiety. The cholesterol moiety is coupled to a sense strand.
CC   (I) further comprises a second cholesterol moiety. The second cholesterol
CC   moiety is coupled to a sense strand. (I) has 21 or more nucleotides. The
CC   duplex region of (I) is 19 nucleotides in length. The subject is
CC   suffering from a disorder having elevated or otherwise unwanted
CC   expression of apo-B-100, elevated or otherwise unwanted levels of
CC   cholesterol, and/or disregulation of lipid metabolism. The disorder is
CC   chosen from HDL/LDL cholesterol imbalance, dyslipidaemia (e.g., familial
CC   combined hyperlipidaemia or acquired hyperlipidaemia),
CC   hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary
CC   artery disease, coronary heart disease and atherosclerosis, preferably
CC   statin-resistant hypercholesterolaemia. (I) is administered to a subject
CC   to inhibit hepatic glucose production or for treating glucose-metabolism-
CC   related disorders e.g., type-2 diabetes or glitaxzone-resistant diabetes.
CC   (I) has endonuclease or exonuclease resistance. This sequence represents
CC   a human apolipoprotein B (apoB) pallindromic sequence that may be useful
CC   as a target for antisense inhibition.
XX
SQ   Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3553 GTGAGGGCGCCTTTCCC 3569
              ||||||||| |||||||
Db         19 GTGAGGGCGGCTTTCCC 3


RESULT 631
ADT84296/c
ID   ADT84296 standard; DNA; 19 BP.
XX
AC   ADT84296;
XX
DT   13-JAN-2005  (first entry)
XX
DE   Apolipoprotein B (apoB) antisense inhibition target seqid 4338.
XX
KW   antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW   interference RNA; iRNA; cholesterol moiety; apoB; glucose-6-phosphatase;
KW   lipid metabolism; cholesterol imbalance; dyslipidaemia;
KW   familial combined hyperlipidaemia; acquired hyperlipidaemia;
KW   hypercholesterolaemia; statin-resistant hypercholesterolaemia;
KW   coronary artery disease; coronary heart disease; atherosclerosis;
KW   hepatic glucose production; glucose-metabolism-related disorder;
KW   type-2 diabetes; glitaxzone-resistant diabetes; human; apolipoprotein B;
KW   antisense inhibition; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004091515-A2.
XX
PD   28-OCT-2004.
XX
PF   09-APR-2004; 2004WO-US011255.
XX
PR   09-APR-2003; 2003US-0462097P.
PR   10-APR-2003; 2003US-0461915P.
PR   14-APR-2003; 2003US-0462894P.
PR   17-APR-2003; 2003US-0463772P.
PR   25-APR-2003; 2003US-0465665P.
PR   25-APR-2003; 2003US-0465802P.
PR   09-MAY-2003; 2003US-0469612P.
PR   08-AUG-2003; 2003US-0493986P.
PR   11-AUG-2003; 2003US-0494597P.
PR   26-SEP-2003; 2003US-0506341P.
PR   09-OCT-2003; 2003US-0510246P.
PR   10-OCT-2003; 2003US-0510318P.
PR   07-NOV-2003; 2003US-0518453P.
PR   08-MAR-2004; 2004WO-US007070.
PR   05-APR-2004; 2004WO-US010586.
XX
PA   (ALNY-) ALNYLAM PHARM INC.
XX
PI   Manoharan M,  Elbashir S,  Harborth J;
XX
DR   WPI; 2004-766693/75.
XX
```

```
PT   New interference RNA agent comprising sense sequence and antisense
PT   sequence having cholesterol moieties, useful for reducing apoB-100 levels
PT   or glucose-6-phosphatase levels.
XX
PS   Claim 2; SEQ ID NO 4338; 324pp; English.
XX
CC   The invention describes an interference RNA (iRNA) agent (I) comprising a
CC   sense sequence and an antisense sequence, where the sense sequence
CC   comprises one or more cholesterol moieties, and the antisense sequence
CC   targets a human gene sequence. The following are disclosed: a
CC   pharmaceutical composition comprising (I); and a device for administering
CC   (I) into a patient. (I) is useful for reducing apoB-100 levels or glucose
CC   -6-phosphatase levels in a subject. (I) targets a sequence identical to
CC   any one of sequences as given in the specification. (I) comprises a
CC   cholesterol moiety. The cholesterol moiety is coupled to a sense strand.
CC   (I) further comprises a second cholesterol moiety. The second cholesterol
CC   moiety is coupled to a sense strand. (I) has 21 or more nucleotides. The
CC   duplex region of (I) is 19 nucleotides in length. The subject is
CC   suffering from a disorder having elevated or otherwise unwanted
CC   expression of apo-B-100, elevated or otherwise unwanted levels of
CC   cholesterol, and/or disregulation of lipid metabolism. The disorder is
CC   chosen from HDL/LDL cholesterol imbalance, dyslipidaemia (e.g., familial
CC   combined hyperlipidaemia or acquired hyperlipidaemia),
CC   hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary
CC   artery disease, coronary heart disease and atherosclerosis, preferably
CC   statin-resistant hypercholesterolaemia. (I) is administered to a subject
CC   to inhibit hepatic glucose production or for treating glucose-metabolism-
CC   related disorders e.g., type-2 diabetes or glitaxzone-resistant diabetes.
CC   (I) has endonuclease or exonuclease resistance. This sequence represents
CC   a human apolipoprotein B (apoB) pallindromic sequence that may be useful
CC   as a target for antisense inhibition.
XX
SQ   Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3553 GTGAGGGCGCCTTTCCC 3569
              ||||||||| |||||||
Db         18 GTGAGGGCGGCTTTCCC 2


RESULT 632
ADT81352/c
ID   ADT81352 standard; DNA; 19 BP.
XX
AC   ADT81352;
XX
DT   13-JAN-2005  (first entry)
XX
DE   Apolipoprotein B (apoB) antisense inhibition target seqid 1394.
XX
KW   antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW   interference RNA; iRNA; cholesterol moiety; apoB; glucose-6-phosphatase;
KW   lipid metabolism; cholesterol imbalance; dyslipidaemia;
KW   familial combined hyperlipidaemia; acquired hyperlipidaemia;
KW   hypercholesterolaemia; statin-resistant hypercholesterolaemia;
KW   coronary artery disease; coronary heart disease; atherosclerosis;
KW   hepatic glucose production; glucose-metabolism-related disorder;
KW   type-2 diabetes; glitaxzone-resistant diabetes; human; apolipoprotein B;
KW   antisense inhibition; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004091515-A2.
XX
PD   28-OCT-2004.
XX
PF   09-APR-2004; 2004WO-US011255.
XX
PR   09-APR-2003; 2003US-0462097P.
PR   10-APR-2003; 2003US-0461915P.
PR   14-APR-2003; 2003US-0462894P.
PR   17-APR-2003; 2003US-0463772P.
PR   25-APR-2003; 2003US-0465665P.
PR   25-APR-2003; 2003US-0465802P.
PR   09-MAY-2003; 2003US-0469612P.
PR   08-AUG-2003; 2003US-0493986P.
PR   11-AUG-2003; 2003US-0494597P.
PR   26-SEP-2003; 2003US-0506341P.
PR   09-OCT-2003; 2003US-0510246P.
PR   10-OCT-2003; 2003US-0510318P.
PR   07-NOV-2003; 2003US-0518453P.
PR   08-MAR-2004; 2004WO-US007070.
PR   05-APR-2004; 2004WO-US010586.
XX
PA   (ALNY-) ALNYLAM PHARM INC.
XX
PI   Manoharan M,  Elbashir S,  Harborth J;
XX
DR   WPI; 2004-766693/75.
XX
PT   New interference RNA agent comprising sense sequence and antisense
PT   sequence having cholesterol moieties, useful for reducing apoB-100 levels
PT   or glucose-6-phosphatase levels.
XX
PS   Claim 2; SEQ ID NO 1394; 324pp; English.
XX
CC   The invention describes an interference RNA (iRNA) agent (I) comprising a
CC   sense sequence and an antisense sequence, where the sense sequence
CC   comprises one or more cholesterol moieties, and the antisense sequence
CC   targets a human gene sequence. The following are disclosed: a
CC   pharmaceutical composition comprising (I); and a device for administering
CC   (I) into a patient. (I) is useful for reducing apoB-100 levels or glucose
CC   -6-phosphatase levels in a subject. (I) targets a sequence identical to
CC   any one of sequences as given in the specification. (I) comprises a
CC   cholesterol moiety. The cholesterol moiety is coupled to a sense strand.
CC   (I) further comprises a second cholesterol moiety. The second cholesterol
CC   moiety is coupled to a sense strand. (I) has 21 or more nucleotides. The
CC   duplex region of (I) is 19 nucleotides in length. The subject is
CC   suffering from a disorder having elevated or otherwise unwanted
CC   expression of apo-B-100, elevated or otherwise unwanted levels of
CC   cholesterol, and/or disregulation of lipid metabolism. The disorder is
CC   chosen from HDL/LDL cholesterol imbalance, dyslipidaemia (e.g., familial
CC   combined hyperlipidaemia or acquired hyperlipidaemia),
CC   hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary
CC   artery disease, coronary heart disease and atherosclerosis, preferably
CC   statin-resistant hypercholesterolaemia. (I) is administered to a subject
CC   to inhibit hepatic glucose production or for treating glucose-metabolism-
CC   related disorders e.g., type-2 diabetes or glitaxzone-resistant diabetes.
CC   (I) has endonuclease or exonuclease resistance. This sequence represents
CC   a human apolipoprotein B (apoB) pallindromic sequence that may be useful
CC   as a target for antisense inhibition.
XX
SQ   Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3553 GTGAGGGCGCCTTTCCC 3569
              ||||||||| |||||||
Db         18 GTGAGGGCGGCTTTCCC 2


RESULT 633
ADX00842/c
ID   ADX00842 standard; DNA; 19 BP.
XX
AC   ADX00842;
XX
DT   21-APR-2005  (first entry)
XX
DE   Human CYP2D6 gene 2988GtoA mutation detection reverse PCR primer #6.
XX
```

KW DNA purification; SNP detection; cardiovascular-gen.; hypotensive;
KW neuroleptic; antiarrhythmic; antiemetic; analgesic; anorectic;
KW tranquilizer; antimanic; antidepressant; allelic variant; CYP2D6 gene;
KW diagnosis; codeine dependence; depression; hepatitis C virus infection;
KW psychosis; schizophrenia; Parkinsons disease; forensic; primer; PCR; ss.
XX
OS Homo sapiens.
XX
PN US2005032070-A1.
XX
PD 10-FEB-2005.
XX
PF 05-AUG-2003; 2003US-00635780.
XX
PR 05-AUG-2003; 2003US-00635780.
XX
PA (RAIM/) RAIMUNDO S.
PA (ZANG/) ZANGER U.
XX
PI Raimundo S, Zanger U;
XX
DR WPI; 2005-161644/17.
XX
PT Novel polynucleotide of molecular variants of Cytochrome P450 2D6
PT (CYP2D6) gene, capable of hybridizing to CYP2D6 gene, is useful in
PT diagnosing disease related to presence of molecular variant of CYP2D6
PT gene.
XX
PS Example 1; SEQ ID NO 19; 33pp; English.
XX
CC The invention relates to a polynucleotide (I) of molecular variants of
CC CYP2D6 gene, chosen from polynucleotide capable of hybridizing to CYP2D6
CC gene, where the polynucleotide consists of substitution of one or more
CC nucleotides at position corresponding to 4784, 4735 or 4087 of the CYP2D6
CC gene having a fully defined sequence (S1) of 9609 base pairs as given in
CC the specification. (I) is useful for identifying a diagnostic
CC composition, which involves (a) isolating (I) from several subgroups of
CC individuals, where one subgroup has no prevalence for CYP2D6 associated
CC disease, and one or more further subgroup(s) do have prevalence for a
CC CYP2D6 associated disease, and (b) identifying a single nucleotide
CC polymorphism by comparing the nucleic acid sequence of the polynucleotide
CC or the gene of one subgroup having no prevalence for a CYP2D6 associated
CC disease, with one or more further subgroup(s) having a prevalence for a
CC CYP2D6 associated disease. (I) is useful for diagnosing a disease related
CC to the presence of a molecular variant of a CYP2D6 gene or susceptibility
CC to such a disorder, which involves determining the presence of (I) in a
CC sample from a subject. (I) is useful for diagnosing whether a subject has
CC EM, IM or PM phenotype, and for determining whether an individual is at
CC risk for a toxic reaction, non-response, insufficient response, or
CC reduced metabolic activity of CYP2D6 to treatment with a CYP2D6
CC substrate. (I) is useful in selecting a subject suffering from a CYP2D6
CC substrate treatable disease for treatment with the substrate, and in
CC treating a subject suffering from a CYP2D6 substrate treatable disease.
CC (I) is useful for detecting variant polynucleotide of CYP2D6 gene in a
CC sample, which involves contacting (I) with the sample under conditions
CC allowing interaction of variant of CYP2D6 gene with several immobilized
CC targets on (I), and determining the binding of the polynucleotide or the
CC gene to the immobilized targets on (I). (I) is useful for diagnosing a
CC disease, which involves binding of the variant polynucleotide of CYP2D6
CC gene or the gene to the immobilized targets on (IV), where the binding
CC indicates the presence or the absence of the disease or a prevalence for
CC the disease. The disease is codeine dependence, depression, hepatitis C,
CC psychosis, schizophrenia or Parkinson's disease. (I) is useful for
CC diagnosing an altered activity of the CYP2D6 enzyme, and for diagnosing a
CC polynucleotide associated with IM phenotype of CYP2D6. (I) is useful in
CC diagnosing individual's genetic constitution of the CYP2D6 status, useful
CC in personalized medicine. (I) is used for prediction of the therapeutic
CC outcome of an individual with an established drug and for avoidance of
CC side effects/toxicity due to altered activity of CYP2D6 mediated by
CC different CYP2D6 alleles. (I) is useful as forensic markers. This
CC sequence corresponds to a PCR primer to amplify the exon 6 region of the
CC CYP2D6 gene for detection polymorphisms.
XX
SQ Sequence 19 BP; 2 A; 10 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3723 GAAGGGGTGTCAGGGCC 3739
||||| |||||||||||
Db 19 GAAGGAGTGTCAGGGCC 3

RESULT 634
ADY88183
ID ADY88183 standard; RNA; 19 BP.
XX
AC ADY88183;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA SEQ ID NO 1219.
XX
KW ss; siRNA; short interfering RNA; RNA interference; gene silencing;
KW VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 1219; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA.
XX
SQ Sequence 19 BP; 1 A; 3 C; 3 G; 0 T; 12 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 29.4%; Pred. No. 3.5e+02;
Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

```
Qy       3860 AGTTTTGTTTTTGGTCT 3876
              ||:::|:::::| :|:
Db          2 AGUUUUGUUUUUGUUCU 18


RESULT 635
ADY87859/c
ID   ADY87859 standard; RNA; 19 BP.
XX
AC   ADY87859;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA SEQ ID NO 895.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing;
KW   VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 895; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA.
XX
SQ   Sequence 19 BP; 12 A; 3 C; 3 G; 0 T; 1 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTCT 3876
              |||||||||||| |||
Db         18 AGTTTTGTTTTTGTTCT 2


RESULT 636
ADY89384
ID   ADY89384 standard; RNA; 19 BP.
XX
AC   ADY89384;
XX
DT   16-JUN-2005  (first entry)
XX
DE   VEGFR siRNA target sequence SEQ ID NO 2420.
XX
KW   ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 2420; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA target sequence.
XX
SQ   Sequence 19 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 3.5e+02;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||:||:||||:| :|||
Db          3 CAUGCUGGACUGCUGGC 19


RESULT 637
ADY90334/c
ID   ADY90334 standard; RNA; 19 BP.
XX
AC   ADY90334;
XX
DT   16-JUN-2005  (first entry)
XX
```

```
DE   VEGFR siRNA SEQ ID NO 3371.
XX
KW   ss; siRNA; short interfering RNA; RNA interference; gene silencing;
KW   VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS   Synthetic.
XX
PN   WO2005028649-A1.
XX
PD   31-MAR-2005.
XX
PF   16-SEP-2004; 2004WO-US030488.
XX
PR   16-SEP-2003; 2003US-00664767.
PR   16-SEP-2003; 2003US-00665255.
PR   23-SEP-2003; 2003US-00670011.
PR   23-OCT-2003; 2003US-00693059.
PR   24-NOV-2003; 2003US-00720448.
PR   03-DEC-2003; 2003US-00727780.
PR   14-JAN-2004; 2004US-00757803.
PR   26-JAN-2004; 2004US-00764957.
PR   10-FEB-2004; 2004US-0543480P.
PR   13-FEB-2004; 2004US-00780447.
PR   16-APR-2004; 2004US-00826966.
PR   23-APR-2004; 2004US-00831620.
PR   30-APR-2004; 2004US-00013456.
PR   11-MAY-2004; 2004US-00844076.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Jadhav V,  Kossen K,  Zinnen S,  Vaish N,  Mcswiggen J;
XX
DR   WPI; 2005-254128/26.
XX
PT   New multifunctional siNA molecule that directs cleavage of the first and
PT   second VEGF or VEGFR target sequences via RNA interference, useful in
PT   preparing a composition for treating cell proliferative disorders e.g.
PT   cancers.
XX
PS   Disclosure; SEQ ID NO 3371; 396pp; English.
XX
CC   The invention relates to a multifunctional siNA molecule comprising a
CC   structure having Formula MF-III and which directs cleavage of the first
CC   and second VEGF or VEGFR target sequences via RNA interference. The
CC   multifunctional siNA molecule is useful in preparing a pharmaceutical
CC   composition for treating cell proliferative disorders, e.g. cancer. The
CC   present sequence represents a VEGFR siRNA.
XX
SQ   Sequence 19 BP; 4 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

  Query Match             0.4%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 3.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2931 CATGCTGGACTGTTGGC 2947
              ||||||||||| ||||
Db         17 CATGCTGGACTGCTGGC 1


RESULT 638
ADH17043
ID   ADH17043 standard; DNA; 15 BP.
XX
AC   ADH17043;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Taqman probe used to analyse human EphB4 sequence.
XX
KW   tyrosine kinase activity; type 1 plasminogen activator inhibitor; PAI-1;
KW   TIMP-1; tissue inhibitor of metalloproteinase 1; vinculin;
KW   vascular endothelial growth factor; VEGF; placental growth factor; PLGF;
KW   migration inhibitory factor; MIG; probe; ss; human; EphB4.
XX
OS   Homo sapiens.
XX
PN   WO2003097854-A2.
XX
PD   27-NOV-2003.
XX
PF   19-MAY-2003; 2003WO-US015711.
XX
PR   17-MAY-2002; 2002US-0380872P.
PR   24-FEB-2003; 2003US-0448874P.
PR   24-FEB-2003; 2003US-0448922P.
XX
PA   (SUGE-) SUGEN INC.
XX
PI   Morimoto A,  Deprimo S,  O'farrell A,  Smolich BD,  Manning WC;
PI   Walter SA,  Schilling JW,  Cherrington J;
XX
DR   WPI; 2004-042604/04.
XX
PT   Determining whether a test compound inhibits tyrosine kinase activity in
PT   a mammal by exposing the mammal to the test compound and measuring in the
PT   mammal the level of at least one of the measured proteins or mRNA
PT   transcripts.
XX
PS   Example K; SEQ ID NO 42; 408pp; English.
XX
CC   The invention relates to a novel method for determining whether a test
CC   compound inhibits tyrosine kinase activity in a mammal comprising
CC   measuring in the mammal the level of at least one of the proteins and/or
CC   mRNA transcripts or genes for such proteins comprising type 1 plasminogen
CC   activator inhibitor (PAI-1), TIMP-1 (tissue inhibitor of
CC   metalloproteinase 1), vinculin, vascular endothelial growth factor
CC   (VEGF), placental growth factor (PLGF), VEGF/PLGF heterodimers or
CC   migration inhibitory factor (MIG), exposing the mammal to the test
CC   compound and then measuring in the mammal the level of at least one of
CC   the proteins and/or mRNA transcripts previously measured. The method of
CC   the invention may be useful for determining whether a test compound
CC   inhibits tyrosine kinase activity in a mammal. The current sequence is
CC   that of the Taqman probe which was used in the exemplification of the
CC   invention.
XX
SQ   Sequence 15 BP; 2 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 2.7e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3974 CCTTTGCCCAAGTTG 3988
              |||||||||||||||
Db          1 CCTTTGCCCAAGTTG 15


RESULT 639
AAX35184/c
ID   AAX35184 standard; DNA; 17 BP.
XX
AC   AAX35184;
XX
DT   01-JUL-1999  (first entry)
XX
DE   PCR primer used amplify and thus quantify an interleukin-17 gene.
XX
KW   Evaluation; transplant rejection; immune activation marker gene;
KW   perforin; granzyme B; Fas ligand; acute rejection; renal allograft;
KW   sequential evaluation; simultaneous evaluation; infection;
KW   interleukin-17; IL-17; PCR primer; ss.
XX
OS   Synthetic.
XX
PN   WO9915700-A1.
XX
PD   01-APR-1999.
```

```
XX
PF   22-SEP-1998;   98WO-US019549.
XX
PR   24-SEP-1997;   97US-00937063.
XX
PA   (BETH-) BETH ISRAEL DEACONESS MEDICAL CENT.
PA   (CORR ) CORNELL RES FOUND INC.
XX
PI   Strom TB,  Vasconcellos L,  Suthanthiran M;
XX
DR   WPI; 1999-254724/21.
XX
PT   Methods of evaluating transplant rejection.
XX
PS   Example 1; Page 17; 40pp; English.
XX
CC   The specification describes a method for evaluating transplant rejection
CC   in a host by detecting up-regulation of the expression of at least two
CC   immune activation marker genes chosen from perforin, granzyme B and Fas
CC   ligand. The method is particularly used for evaluation of acute rejection
CC   of a renal allograft. Simultaneous, or sequential evaluation of the
CC   biological sample for the presence or absence of an infectious agent acts
CC   a screening test, which is useful to differentially distinguish between
CC   acute rejection of the transplant or infection. PCR primers AAX35184-85
CC   were used to quantify the expression of a specific gene transcript
XX
SQ   Sequence 17 BP; 5 A; 2 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3961 TTCACTATGGCCTCC 3975
              |||||||||||||||
Db         15 TTCACTATGGCCTCC 1


RESULT 640
ABN01660/c
ID   ABN01660 standard; DNA; 17 BP.
XX
AC   ABN01660;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1652.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 1652; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCC 3982
              |||||||||||||||
Db         16 TGGCCTCCTTTGCCC 2


RESULT 641
ABN01659/c
ID   ABN01659 standard; DNA; 17 BP.
XX
AC   ABN01659;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1651.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
```

```
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 1651; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCC 3982
              |||||||||||||||
Db         17 TGGCCTCCTTTGCCC 3


RESULT 642
ABA02896/c
ID   ABA02896 standard; DNA; 17 BP.
XX
AC   ABA02896;
XX
DT   15-FEB-2002  (first entry)
XX
DE   Human IL-17 RT-PCR primer SEQ ID NO 15.
XX
KW   Human; acute transplant rejection; gene expression;
KW   pro-apoptotic gene cluster; cytoprotective; IL-7/17; IL-8; IL-10; IL-15;
KW   T cell; urinary system; renal graft; antimicrobial; antiviral;
KW   antifungal; competitive template RT-PCR; PCR primer; ss.
XX
OS   Synthetic.
XX
PN   WO200181916-A2.
XX
PD   01-NOV-2001.
XX
PF   23-APR-2001; 2001WO-US013014.
XX
PR   24-APR-2000; 2000US-0199327P.
PR   06-OCT-2000; 2000US-0238718P.
PR   12-OCT-2000; 2000US-0239635P.
PR   16-OCT-2000; 2000US-0240735P.
PR   06-FEB-2001; 2001US-00778013.
XX
PA   (BETH-) BETH ISRAEL DEACONESS MEDICAL CENT.
XX
PI   Ma N,  Strom T,  Soares MC,  Ferran C,  Suthanthiran M;
PI   Vasconcellos L,  Avihingsanon Y;
XX
DR   WPI; 2002-034457/04.
XX
PT   Evaluating acute transplant rejection in a host especially in a recipient
PT   of a urinary system graft, by determining a heightened magnitude of
PT   expression of genes in rejection-associated gene clusters.
XX
PS   Example 1; Fig 1; 101pp; English.
XX
CC   The invention relates to evaluating acute transplant rejection in a host,
CC   comprising obtaining a sample, determining the magnitude of gene
CC   expression of at least two genes from one or more rejection associated-
CC   gene clusters, where the genes were selected from the pro-apoptotic
CC   cluster, the cytoprotective cluster, the IL-7/17, IL-8, IL-10, IL-15 and
CC   T cell clusters, comparing the results to a baseline magnitude of gene
CC   expression of the two genes and detecting upregulation of the two genes.
CC   The method is useful for evaluating acute transplant rejection in a host
CC   especially in a recipient of a urinary system (renal) graft, where gene
CC   expression in the urine sample of at least two genes of a pro-apoptotic
CC   gene cluster is determined. The method is further useful for treating a
CC   transplantation-related condition in a host. The method comprises
CC   choosing a therapy comprising adding to the host's baseline therapeutic
CC   regimen an effective dose of an anti-rejection agent appropriate, for
CC   treating rejection state. The anti-rejection agent is selected from
CC   azathioprine, cyclosporine, FK506, mycophenolate mofetil, anti-CD25
CC   antibody, antithymocyte globulin, rapamycin, ACE inhibitors, perillyl
CC   alcohol, anti-CTLA4 antibody, anti-CD40L antibody, anti-thrombin III,
CC   tissue plasminogen activator, antioxidants, anti-CD154, anti-CD3
CC   antibody. The therapy may further comprise modifying the host's baseline
CC   therapeutic regimen by adding pharmacological agent selected from
CC   antimicrobial agents, antiviral agents and antifungal agents or by
CC   reducing a dose of a baseline anti-rejection agent. The method accurately
CC   quantitate marker gene expression in biopsy tissue, urine, urine
CC   sediment, peripheral blood mononuclear and other body fluids and
CC   correlates the magnitude of expression of these genes with rejection of
CC   allografts. Moreover, the evaluation of the expression of marker genes in
CC   a post-transplant sample, along with the evaluation of the expression of
CC   an infectious agent gene also accurately detects allografts rejection.
CC   The is rapid and reliable for diagnosing acute rejection, even in cases
CC   where allograft biopsies show only mild cellular infiltrates. The present
CC   sequence is that of a PCR primer used for quantitation of gene expression
CC   by competitive template RT-PCR in a method of the invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3961 TTCACTATGGCCTCC 3975
              |||||||||||||||
Db         15 TTCACTATGGCCTCC 1
```

```
RESULT 643
ACA99869/c
ID   ACA99869 standard; DNA; 17 BP.
XX
AC   ACA99869;
XX
DT   28-JUL-2003  (first entry)
XX
DE   G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #362.
XX
KW   Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW   G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003031621-A2.
XX
PD   17-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032599.
XX
PR   12-OCT-2001; 2001US-0329000P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Zhang J;
XX
DR   WPI; 2003-381720/36.
XX
PT   New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT   investigating and/or treating disorders associated with aberrant
PT   expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS   Example 2; SEQ ID NO 386; 156pp; English.
XX
CC   The invention describes an isolated nucleic acid encoding a G protein
CC   coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC   2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC   409 residue amino acid sequence, all given in the specification, with or
CC   without conservative amino acid substitutions, or complements of the
CC   sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC   length. The methods and compositions of the present invention are useful
CC   for diagnosing, investigating and/or treating disorders associated with
CC   aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC   This sequence represents an oligonucleotide used to analyse the gene
CC   encoding human G-protein coupled receptor GPCR-A-1
XX
SQ   Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1190 CCCAGGGCACCTTCA 1204
             |||||||||||||||
Db         15 CCCAGGGCACCTTCA 1


RESULT 644
ACA99866/c
ID   ACA99866 standard; DNA; 17 BP.
XX
AC   ACA99866;
XX
DT   28-JUL-2003  (first entry)
XX
DE   G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #359.
XX
KW   Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW   G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003031621-A2.
XX
PD   17-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032599.
XX
PR   12-OCT-2001; 2001US-0329000P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Zhang J;
XX
DR   WPI; 2003-381720/36.
XX
PT   New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT   investigating and/or treating disorders associated with aberrant
PT   expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS   Example 2; SEQ ID NO 383; 156pp; English.
XX
CC   The invention describes an isolated nucleic acid encoding a G protein
CC   coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC   2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC   409 residue amino acid sequence, all given in the specification, with or
CC   without conservative amino acid substitutions, or complements of the
CC   sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC   length. The methods and compositions of the present invention are useful
CC   for diagnosing, investigating and/or treating disorders associated with
CC   aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC   This sequence represents an oligonucleotide used to analyse the gene
CC   encoding human G-protein coupled receptor GPCR-A-1
XX
SQ   Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1191 CCAGGGCACCTTCAA 1205
             |||||||||||||||
Db         17 CCAGGGCACCTTCAA 3


RESULT 645
ADO13871
ID   ADO13871 standard; DNA; 17 BP.
XX
AC   ADO13871;
XX
DT   15-JUL-2004  (first entry)
XX
DE   dbv gene cluster probe dpgA, primer #2.
XX
KW   ss; dbv; gene cluster; Actinomadura sp.; biosynthesis; glycopeptide;
KW   A40926; 4-hydroxy-phenylglycine; 3; 5-dihydroxy-phenylglycine;
KW   heptapeptide skeleton; chlorination; aromatic residue;
KW   beta-hydroxylation; tyrosine; cross-linking; N-acetyl glucuroamine;
KW   mannosyl; export; antibiotic; primer.
XX
OS   Actinomadura sp. ATCC 39727.
OS   Synthetic.
XX
PN   EP1413626-A1.
XX
PD   28-APR-2004.
XX
PF   23-OCT-2002; 2002EP-00023597.
XX
PR   23-OCT-2002; 2002EP-00023597.
XX
PA   (VICU-) VICURON PHARM INC.
XX
PI   Donadio S,  Sosio M,  Beltrametti F;
```

```
XX
DR   WPI; 2004-332813/31.
XX
PT   Novel isolated polypeptide A40926, comprising polypeptide sequence or
PT   open reading frame polypeptide involved in biosynthetic pathway of
PT   A409626, useful for synthesizing glycopeptide antibiotic A409626.
XX
PS   Example 1; Page 16; 164pp; English.
XX
CC   This sequence is a primer which as used in the amplification of a probe
CC   which was used in the isolation of the dbv gene cluster from Nonomuria
CC   sp. ATCC39727 (formerly Actinomadura sp. ATCC39727). The 37 proteins
CC   encoded by the dbv gene cluster are involved in the biosynthesis of the
CC   glycopeptide A40926. dbv ORF 1, 2, 5, and 37 encode polypeptides required
CC   for the synthesis of 4-hydroxy-phenylglycine residues of A40926. dbv ORF
CC   30-34 and 37 encode polypeptides required for the synthesis of 3, 5-
CC   dihydroxy-phenylglycine residues of A40926. dbv ORF 16, 17, 25, 26 and 36
CC   encode polypeptides required for the synthesis of heptapeptide skeleton
CC   of A40926. dbv ORF 10 encodes polypeptide required for the chlorination
CC   of the aromatic residues of A40926. dbv ORF 28 encodes a polypeptide
CC   required for the beta-hydroxylation of the tyrosine residue of amino acid
CC   6 of A40926. dbv ORF 11-14 encode polypeptides required for cross-linking
CC   of the aromatic residues of amino acids at positions 2 and 4, 4 and 6, 1
CC   and 3, and 5 and 7 of A40926. dbv ORF 9, 23 and 29 encode polypeptides
CC   required for addition and formation of N-acetyl glucuroamine residue of
CC   A40926. dbv ORF 20 or 27 encode polypeptides required for the attachment
CC   of mannosyl residues or N-methylation of A40926. dbv ORF 7, 18, 19, 24
CC   and 35 encode polypeptides required for the export of A40926 or its
CC   precursors. dbv ORF 3, 4, 6, and 22 encode polypeptides required for
CC   regulating the expression of one or more genes of the dbv gene cluster.
CC   The dbv gene cluster and the proteins encoded by it are useful for
CC   producing glycopeptide antibiotic A40926 or its precursor.
XX
SQ   Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1260 CACCATTGGATCAGC 1274
              |||||||||||||||
Db          2 CACCATTGGATCAGC 16


RESULT 646
ACN64750/c
ID   ACN64750 standard; DNA; 17 BP.
XX
AC   ACN64750;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:1652.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 1652; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCC 3982
              |||||||||||||||
Db         16 TGGCCTCCTTTGCCC 2


RESULT 647
ACN64749/c
ID   ACN64749 standard; DNA; 17 BP.
XX
AC   ACN64749;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:1651.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
```

```
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 1651; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       3968 TGGCCTCCTTTGCCC 3982
              |||||||||||||||
Db         17 TGGCCTCCTTTGCCC 3


RESULT 648
ADS73574
ID   ADS73574 standard; DNA; 17 BP.
XX
AC   ADS73574;
XX
DT   02-DEC-2004  (first entry)
XX
DE   tcp gene cluster isolation probe dpgA, primer #2.
XX
KW   ss; tcp; gene cluster; biosynthesis; glycopeptide; teicoplanin;
KW   antibiotic; bal; cep; com; sta; 4-hydroxy-phenylglycine; 3;
KW   5-dihydroxy-phenylglycine; heptapeptide skeleton; cross-linking;
KW   aromatic residue; N-acyl-beta-D-glucosamine; core structure; export;
KW   resistance; chlorination; alpha-hydroxylation; mannosyl attachment;
KW   primer; probe.
XX
OS   Actinoplanes teichomyceticus; ATCC31121.
OS   Synthetic.
XX
PN   EP1460085-A1.
XX
PD   22-SEP-2004.
XX
PF   20-MAR-2003; 2003EP-00006341.
XX
PR   20-MAR-2003; 2003EP-00006341.
XX
PA   (VICU-) VICURON PHARM INC.
XX
PI   Donadio S, Sosio M, Bianchi A;
XX
DR   WPI; 2004-663557/65.
XX
PT   Novel open reading frame polypeptide involved in biosynthetic pathway of
PT   teicoplanin, useful for producing glycopeptide antibiotic teicoplanin.
XX
PS   Example 1; SEQ ID NO 44; 175pp; English.
XX
CC   This sequence represents a primer which was used in the amplification of
CC   the probe dpgA. The amplified probe was used in the isolation of the tcp
CC   gene cluster which is involved in the biosynthesis of the glycopeptide
CC   teicoplanin. The isolated tcp sequence consists of 39 ORFs. Teicoplanin
CC   is a complex of closely related glycopeptide antibiotics produced by A.
CC   teichomyceticus. The tcp cluster is characterised by the presence of
CC   several ORFs that do not find homologues in the bal, cep, com and sta
CC   clusters. The glycopeptides encoded by the tcp cluster are useful for
CC   producing glycopeptide antibiotic teicoplanin. Fragments of the tcp
CC   cluster may be used for synthesizing 4-hydroxy-phenylglycine residues of
CC   teicoplanin, 3,5-dihydroxy-phenylglycine residue, heptapeptide skeleton
CC   of teicoplanin, for cross-linking of the aromatic residues of amino acids
CC   of teicoplanin, for the addition and formation of the two N-acyl-beta-D-
CC   glucosamine residues to the core structure of teicoplanin, for exporting
CC   teicoplanin or some of its precursors outside of the cytoplasm and for
CC   conferring resistance to teicoplanin to the producing strain, for
CC   regulating the expression of one or more genes of the tcp gene cluster,
CC   for the chlorination of the aromatic residues of amino acids of
CC   teicoplanin, for alpha-hydroxylation of the tyrosine residue of amino
CC   acid of teicoplanin, for attaching mannosyl residue of teicoplanin, and
CC   for the synthesis of teicoplanin.
XX
SQ   Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.4%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1260 CACCATTGGATCAGC 1274
              |||||||||||||||
Db          2 CACCATTGGATCAGC 16


RESULT 649
AAX70292
ID   AAX70292 standard; RNA; 18 BP.
XX
AC   AAX70292;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human flt1 VEGF receptor hairpin ribozyme substrate #60.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
```

KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 94; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 18 BP; 2 A; 11 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 3.6e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2894 CCCCGCCCCCAGACT 2908
||||||||||||||:
Db 4 CCCCGCCCCCAGACU 18

RESULT 650
AAQ65270
ID AAQ65270 standard; DNA; 18 BP.
XX
AC AAQ65270;
XX
DT 23-DEC-1994 (first entry)
XX
DE Antisense oligonucleotide complementary to Hepatitis C Virus genome.
XX
KW Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
KW inhibition; viral protein precursor; ss.
XX
OS Synthetic.
XX
PN CA2104649-A.
XX
PD 26-FEB-1994.
XX
PF 23-AUG-1993; 93CA-02104649.
XX
PR 25-AUG-1992; 92JP-00248796.
PR 03-MAR-1993; 93JP-00042736.
XX
PA (SEKI/) SEKI M.
XX
PI Seki M, Honda Y, Yamada E;
XX
DR WPI; 1994-151836/19.
XX
PT Anti:sense oligo:nucleotide(s) complementary to the hepatitis C virus
PT genome - are useful as antiviral agents.
XX
PS Claim 5; Page 219; 262pp; English.
XX
CC This oligonucleotide is an example of a preferred antisense compound i.e.
CC it has a base sequence of 15-30 bases which is included within the 49
CC bases from G at position 127 to C at position 175 of AAQ64913 and which
CC contains at least 7 bases from C at position 147 to C at position 153.
CC The antisense oligonucleotide is useful for inhibiting translation of HCV
CC genes
XX
SQ Sequence 18 BP; 1 A; 5 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 26 CACTCCAGGGAGGGGGGG 43
| |||| ||||||||||||
Db 1 CTCTCCCGGGAGGGGGGG 18

RESULT 651
AAX09464/c
ID AAX09464 standard; DNA; 18 BP.
XX
AC AAX09464;
XX
DT 24-MAR-1999 (first entry)
XX
DE Human biallelic polymorphic marker upstream primer #344.
XX
KW Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW detection; phenotypic typing; characteristic; infection; hereditary;
KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW treatment; marker; primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9820165-A2.
XX
PD 14-MAY-1998.
XX
PF 05-NOV-1997; 97WO-US020313.
XX
PR 06-NOV-1996; 96US-0030455P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX
PI Lander ES, Wang D, Hudson T;
XX
DR WPI; 1998-286974/25.
XX
PT New isolated nucleic acid segments from the human genome - used for
PT determining polymorphic forms for use in e.g. forensics, paternity
PT testing or phenotypic typing for disease.
XX
PS Claim 15; Page 94; 310pp; English.
XX
CC AAX09121-X10268 are allele-specific oligonucleotide primers used in the
CC isolation of various biallelic polymorphic markers found in the human
CC genome (represented in AAX10269-X12937). These primers can be used in a
CC method for determining polymorphic forms in an individual for use in e.g.
CC forensics, paternity testing or for phenotypic typing for diseases such
CC as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial

```
CC   hypercholesterolemia, polycystic kidney disease, hereditary
CC   spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC   haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC   syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC   autoimmune diseases, inflammation, cancer, diseases of the nervous
CC   system, infection by pathogenic microorganisms, and characteristics such
CC   as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC   endurance, fertility, and susceptibility or receptivity to particular
CC   drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC   segments can also be used to produce medicaments for the treatment or
CC   prophylaxis of such diseases
XX
SQ   Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3990 AACAGGGGCCCATCATCA 4007
              ||||||| ||||| ||||
Db         18 AACAGGGCCCCATTATCA 1


RESULT 652
AAV25485
ID   AAV25485 standard; DNA; 18 BP.
XX
AC   AAV25485;
XX
DT   09-JUL-1998  (first entry)
XX
DE   Primer 39DRD4.SB.PCR4 for DRD4 gene.
XX
KW   PCR primer; dopaminergic gene; DRD4; susceptibility diagnosis;
KW   migraine with aura; depression; anxiety; variant allele detection;
KW   differentiation; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9807426-A1.
XX
PD   26-FEB-1998.
XX
PF   21-AUG-1997;   97WO-US014830.
XX
PR   22-AUG-1996;   96US-0024399P.
PR   17-JAN-1997;   97US-0036091P.
XX
PA   (GLAX ) GLAXO GROUP LTD.
XX
PI   Peroutka SJ;
XX
DR   WPI; 1998-168887/15.
XX
PT   Assessing susceptibility to syndromes including migraine with aura,
PT   depression and anxiety - by detecting variant alleles in genes for
PT   dopaminergic receptors or transporter, also treatment using agents that
PT   antagonise binding of dopamine to these proteins.
XX
PS   Example; Page 18; 54pp; English.
XX
CC   The present sequence is a primer for the dopaminergic gene DRD4, which
CC   can be used in a novel method assess susceptibility to a syndrome having
CC   symptoms of migraine with aura (MWA), depression and/or anxiety. The
CC   method comprises detecting a variant allele of at least 1 dopaminergic
CC   gene. Analysis of variant dopaminergic gene alleles may also
CC   differentiate between patients with MWA, and those with migraine without
CC   aura (MO) or other conditions, e.g. stroke, that produce similar symptoms
XX
SQ   Sequence 18 BP; 1 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        387 GGTGCTGCTCTGCTGGGC 404
              | ||||||||| ||||||
Db          1 GCTGCTGCTCTACTGGGC 18


RESULT 653
AAZ25567
ID   AAZ25567 standard; DNA; 18 BP.
XX
AC   AAZ25567;
XX
DT   21-DEC-1999  (first entry)
XX
DE   Human RhoG antisense phosphorothioate oligonucleotide #15.
XX
KW   Human; RhoG; inhibition; antisense; phosphorothioate; expression; GTPase;
KW   mitosis; mitogen; DNA synthesis; cell cycle; cancer;
KW   dynamic organisation; actin cytoskeleton; ras-mediated transformation;
KW   diagnosis; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /note= "phosphorothioate linkages"
XX
PN   US5965370-A.
XX
PD   12-OCT-1999.
XX
PF   25-SEP-1998;   98US-00161015.
XX
PR   25-SEP-1998;   98US-00161015.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM;
XX
DR   WPI; 1999-579906/49.
XX
PT   Antisense oligonucleotides useful for inhibiting the expression of the
PT   human RhoG gene.
XX
PS   Claim 3; Col 27; 24pp; English.
XX
CC   AAZ25553 to AAZ25582 represent specifically claimed antisense
CC   oligonucleotides targeted to, and capable of inhibiting the expression of
CC   nucleic acids encoding human RhoG. RhoG is a member of the Rho subfamily
CC   of small GTPases the expression of which is associated with the induction
CC   of mitosis by mitogens. RhoG is thought to be required for entry into the
CC   DNA synthesis step of the cell cycle. It also effects the dynamic
CC   organisation of the actin cytoskeleton which regulates changes during
CC   cell cycle progression (e.g. cell rounding and pinching off during
CC   mitosis) and with determining the density to which cells will proliferate
CC   (RhoG affects an actin-dependent signal transduction pathway mediating
CC   the level of contact inhibition through surface signals). Additionally,
CC   RhoG is associated with the development of cancers (RhoG participates in
CC   a signalling pathway involving ras-mediated transformation). Antisense
CC   compounds from the present invention may be used for inhibiting the
CC   expression of human RhoG in cells and tissues in vitro and may be used
CC   diagnostically to determine the role of RhoG in various biochemical
CC   pathways (e.g. its role in mitosis, the organisation of the actin
CC   cytoskeleton and in cancer development)
XX
SQ   Sequence 18 BP; 1 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
```

```
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        658 CTCGAGTGCCTGTCCCTG 675
              | |||||||||| |||||
Db          1 CGCGAGTGCCTGGCCCTG 18


RESULT 654
AAX55193/c
ID   AAX55193 standard; DNA; 18 BP.
XX
AC   AAX55193;
XX
DT   05-JUL-1999  (first entry)
XX
DE   Multiple antisense oligonucleotide 14.
XX
KW   Antisense oligonucleotide; multiple target; antisense treatment;
KW   impaired respiration; inflammation; lung disease;
KW   pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW   acute asthma; allergy; asthma; impeded respiration;
KW   respiratory distress syndrome; pain; cystic fibrosis;
KW   pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW   chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW   colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW   hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW   prostate cancer; ss.
XX
OS   Synthetic.
XX
PN   WO9913886-A1.
XX
PD   25-MAR-1999.
XX
PF   17-SEP-1998;   98WO-US019419.
XX
PR   17-SEP-1997;   97US-0059160P.
PR   09-JUN-1998;   98US-00093972.
XX
PA   (UYEC-) UNIV EAST CAROLINA.
XX
PI   Nyce JW;
XX
DR   WPI; 1999-229400/19.
XX
PT   New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT   vasoconstriction.
XX
PS   Disclosure; Page 74; 120pp; English.
XX
CC   The specification describes antisense oligonucleotides (AAX52869-X55271)
CC   directed against at least 2 mRNAs selected from target genes, coding and
CC   non-coding regions of RNAs corresponding to target genes, gene initiation
CC   codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'
CC   -end and the juxta-section between coding and non-coding regions and all
CC   segments of RNAs encoding proteins associated with one or more diseases,
CC   conditions or mixtures. The antisense oligonucleotides may be derived
CC   from sequences AAX55272-74. These multiple target oligonucleotides
CC   (specifically AAX55180-271) can be used for the antisense treatment of
CC   diseases and conditions. Typical diseases and conditions are those
CC   associated with impaired respiration and inflammation, including lung
CC   diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC   acute asthma, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC   pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC   disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC   colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC   hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC   well as all types of cancers which may metastasize or have metastasized
CC   to the lungs, including breast and prostate cancer
XX
SQ   Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1063 GCCCCTGGCCCCAGCCCC 1080
              | ||| ||||||||||||
Db         18 GGCCCAGGCCCCAGCCCC 1


RESULT 655
AAA34640/c
ID   AAA34640 standard; DNA; 18 BP.
XX
AC   AAA34640;
XX
DT   28-JUL-2000  (first entry)
XX
DE   Human adenosine receptor related polynucleotide SEQ ID NO:2329.
XX
KW   Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW   phosphorothioate; impaired respiration; inflammation; allergy;
KW   allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW   antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW   lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW   respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW   pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW   cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
OS   Homo sapiens.
XX
PN   WO200009525-A2.
XX
PD   24-FEB-2000.
XX
PF   03-AUG-1999;   99WO-US017712.
XX
PR   03-AUG-1998;   98US-0095212P.
XX
PA   (UYEC-) UNIV EAST CAROLINA.
XX
PI   Nyce JW;
XX
DR   WPI; 2000-205971/18.
XX
PT   New antisense oligonucleotides useful for treating e.g. pulmonary
PT   vasoconstruction, inflammation, allergies, asthma, hypertension,
PT   bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT   cancers.
XX
PS   Disclosure; Page 556; 1343pp; English.
XX
CC   The present invention describes a new composition comprising an antisense
CC   oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC   nucleic acids involved in bronchoconstriction, allergies, and/or
CC   inflammation. The ON can have antiinflammatory, antiallergic,
CC   antiasthmatic, cytostatic and analgesic activities. The compositions are
CC   useful for the treatment of diseases associated with inflammation,
CC   impaired airways, including lung disease and diseases whose secondary
CC   effects afflict the lungs of a subject. They can be used for treating
CC   e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC   impeded respiration, respiratory distress syndrome, pain, cystic
CC   fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC   pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC   carcinomas, and cancers which may metastasise to the lungs, including
CC   breast and prostate cancer. The reduction of the adenosine content of the
CC   ONs reduces side effects. The A-containing ONs break down with the
CC   release of deoxyadenosine which activates adenosine receptors causing
CC   bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC   nucleotide sequences given in the sequence listing from the present
CC   invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC   sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC   from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
CC   AAA33992) are specifically claimed ONs from the present invention. N.B.
```

```
CC   Sequences given in the disclosure of the present invention do not match
CC   up with their corresponding SEQ ID NO: sequences given in the sequence
CC   listing
XX
SQ   Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1063 GCCCCTGGCCCCAGCCCC 1080
              | ||| ||||||||||||
Db         18 GGCCCAGGCCCCAGCCCC 1


RESULT 656
AAA09486
ID   AAA09486 standard; DNA; 18 BP.
XX
AC   AAA09486;
XX
DT   29-AUG-2000  (first entry)
XX
DE   Antisense primer for human Zsig24 gene mapping.
XX
KW   Zsig24; membrane-associated; glucose metabolism; chromosome 11q23-24;
KW   obesity; diabetes; antigenic peptide; antibody; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200024767-A2.
XX
PD   04-MAY-2000.
XX
PF   20-OCT-1999;   99WO-US024662.
XX
PR   23-OCT-1998;   98US-00178009.
PR   23-JUN-1999;   99US-00339395.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Sheppard PO,  Jelinek LJ,  Whitmore TE;
XX
DR   WPI; 2000-350689/30.
XX
PT   Zsig24 nucleic acids and peptides useful for detecting chromosome 11
PT   abnormalities associated with glucose metabolism such as diabetes and
PT   obesity.
XX
PS   Example 2; Page 70; 81pp; English.
XX
CC   The human Zsig24 gene encodes a membrane associated protein, and is
CC   linked to defects in glucose metabolism. The gene has been mapped to
CC   chromosome 11q23-24. The nucleic acids and the proteins they encode may
CC   be used to screen for defects in chromosome 11 that are associated with
CC   glucose metabolism and therefore may be involved in the development of
CC   obesity and diabetes. For example the peptides may be used to produce
CC   antibodies that may be used in immunoassays and the nucleic acids may be
CC   used as probes/primers for polymerase chain reaction analysis
XX
SQ   Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3629 TGCCCCCCTCACCTTGAT 3646
              ||||||| |||||| |||
Db          1 TGCCCCCTTCACCTGGAT 18


RESULT 657
AAF20762/c
ID   AAF20762 standard; DNA; 18 BP.
XX
AC   AAF20762;
XX
DT   14-MAR-2001  (first entry)
XX
DE   Human multiple target antisense (MTA) oligonucleotide #2329.
XX
KW   Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW   human; airway disorder; bronchoconstriction; lung inflammation;
KW   surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW   immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW   respiratory obstruction; pulmonary obstruction; impeded respiration;
KW   surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW   respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW   pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW   chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW   cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200062736-A2.
XX
PD   26-OCT-2000.
XX
PF   24-MAR-2000; 2000WO-US008020.
XX
PR   06-APR-1999;   99US-0127958P.
XX
PA   (UYEC-) UNIV EAST CAROLINA.
PA   (NYCE/) NYCE J W.
XX
PI   Nyce JW;
XX
DR   WPI; 2000-679539/66.
XX
PT   Low adenosine (A) content antisense oligonucleotides which do not trigger
PT   adenosine receptors during metabolism, useful e.g. for treating cancers
PT   and respiratory obstructions.
XX
PS   Claim 14; Page 624; 1592pp; English.
XX
CC   The present invention describes low adenosine (A) content antisense
CC   oligonucleotides and compositions (I) comprising them. In the antisense
CC   oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC   (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC   immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC   The antisense oligonucleotides and (I) can be used to down-regulate the
CC   expression and or activity of target polypeptides associated with
CC   lung/respiratory disorders and malignancies, such as stimulating and
CC   activating peptide factors and transmitters, transcription factors,
CC   immunoglobulins and antibodies, antibody receptors, cytokines and
CC   chemokines, endogenously produced specific and non-specific enzymes,
CC   binding proteins, adhesion molecules and their receptors, cytokine and
CC   chemokine receptors, adenosine receptors, bradykinin receptors, central
CC   nervous system (CNS) and peripheral nervous and non-nervous system
CC   receptors, CNS and peripheral nervous and non-nervous system peptide
CC   transmitters, defensins, growth factors, vasoactive peptides and
CC   receptors, binding proteins and malignancy associated proteins. The
CC   antisense oligonucleotides may be used in this way to treat disorders
CC   including respiratory obstruction (especially pulmonary obstruction
CC   and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC   surfactant hypoproduction which are associated with a disease or
CC   condition selected from pulmonary vasoconstriction, inflammation,
CC   allergies, asthma, impeded respiration, respiratory distress syndrome
CC   (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC   pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC   and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC   fragments and antisense oligonucleotides used in the exemplification of
CC   the present invention
XX
SQ   Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
```

```
  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1063 GCCCCTGGCCCCAGCCCC 1080
              | ||| ||||||||||||
Db         18 GGCCCAGGCCCCAGCCCC 1


RESULT 658
AAF21465/c
ID   AAF21465 standard; DNA; 18 BP.
XX
AC   AAF21465;
XX
DT   14-MAR-2001  (first entry)
XX
DE   Human multiple target antisense (MTA) oligonucleotide #3032.
XX
KW   Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW   human; airway disorder; bronchoconstriction; lung inflammation;
KW   surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW   immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW   respiratory obstruction; pulmonary obstruction; impeded respiration;
KW   surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW   respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW   pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW   chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW   cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200062736-A2.
XX
PD   26-OCT-2000.
XX
PF   24-MAR-2000; 2000WO-US008020.
XX
PR   06-APR-1999;   99US-0127958P.
XX
PA   (UYEC-) UNIV EAST CAROLINA.
PA   (NYCE/) NYCE J W.
XX
PI   Nyce JW;
XX
DR   WPI; 2000-679539/66.
XX
PT   Low adenosine (A) content antisense oligonucleotides which do not trigger
PT   adenosine receptors during metabolism, useful e.g. for treating cancers
PT   and respiratory obstructions.
XX
PS   Disclosure; Page 297; 1592pp; English.
XX
CC   The present invention describes low adenosine (A) content antisense
CC   oligonucleotides and compositions (I) comprising them. In the antisense
CC   oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC   (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC   immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC   The antisense oligonucleotides and (I) can be used to down-regulate the
CC   expression and or activity of target polypeptides associated with
CC   lung/respiratory disorders and malignancies, such as stimulating and
CC   activating peptide factors and transmitters, transcription factors,
CC   immunoglobulins and antibodies, antibody receptors, cytokines and
CC   chemokines, endogenously produced specific and non-specific enzymes,
CC   binding proteins, adhesion molecules and their receptors, cytokine and
CC   chemokine receptors, adenosine receptors, bradykinin receptors, central
CC   nervous system (CNS) and peripheral nervous and non-nervous system
CC   receptors, CNS and peripheral nervous and non-nervous system peptide
CC   transmitters, defensins, growth factors, vasoactive peptides and
CC   receptors, binding proteins and malignancy associated proteins. The
CC   antisense oligonucleotides may be used in this way to treat disorders
CC   including respiratory obstruction (especially pulmonary obstruction
CC   and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC   surfactant hypoproduction which are associated with a disease or
CC   condition selected from pulmonary vasoconstriction, inflammation,
CC   allergies, asthma, impeded respiration, respiratory distress syndrome
CC   (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC   pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC   and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC   fragments and antisense oligonucleotides used in the exemplification of
CC   the present invention
XX
SQ   Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1063 GCCCCTGGCCCCAGCCCC 1080
              | ||| ||||||||||||
Db         18 GGCCCAGGCCCCAGCCCC 1


RESULT 659
AAH75205/c
ID   AAH75205 standard; DNA; 18 BP.
XX
AC   AAH75205;
XX
DT   02-OCT-2001  (first entry)
XX
DE   Human inducible NOS antisense oligonucleotide SEQ ID NO 49.
XX
KW   Antisense oligonucleotide; inducible nitric oxide synthase; NOS;
KW   modulate expression; immunomodulator; antidiabetic; cardiovascular;
KW   cardiant; neuroprotective; vasotropic; ischaemia; reperfusion injury;
KW   2'-O-methoxyethyl; phosphorothioate; human; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate backbone, 5' and 3' four
FT                   nucleotide 2'-MOE (2'-O-methoxyethyl) wings (the cytidine
FT                   residues in the 2'-MOE wings are 5-methylcytidines) and a
FT                   deoxy gap"
XX
PN   WO200152902-A1.
XX
PD   26-JUL-2001.
XX
PF   15-JAN-2001; 2001WO-US001381.
XX
PR   24-JAN-2000; 2000US-00490208.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Dean NM,  Cowsert LM;
XX
DR   WPI; 2001-465340/50.
XX
PT   New antisense oligonucleotides for modulating the expression of inducible
PT   nitric oxide synthase in cells or tissues, particularly useful for
PT   treating e.g. immunological, cardiovascular or neurological disorders, or
PT   ischemia.
XX
PS   Claim 3; Page 84; 144pp; English.
XX
CC   The invention relates to antisense compounds, especially
CC   oligonucleotides, which are targeted to a nucleic acid encoding inducible
CC   nitric oxide synthase and which specifically hybridise to and modulate
CC   expression of inducible nitric oxide synthase. The antisense compounds
```

```
CC   have immunomodulator, antidiabetic, cardiovascular, cardiant,
CC   neuroprotective, disorder and vasotropic activity. The antisense
CC   oligonucleotides are useful for inhibiting the expression of inducible
CC   nitric oxide synthase in cells or tissues. In particular, the antisense
CC   oligonucleotides are useful for treating diseases or disorders associated
CC   with inducible nitric oxide synthase, e.g. diabetes, immunological
CC   disorder, cardiovascular disorder, neurological disorder or
CC   ischaemia/reperfusion injury. The antisense oligonucleotides are also
CC   useful for research and diagnostics. The present sequence is that of an
CC   antisense 2'-O-methoxyethyl gapmer oligonucleotide with a
CC   phosphorothioate backbone, a central "gap" region of ten nucleotides
CC   flanked by four nucleotide 2'-MOE (2'-methoxyethyl) wings (cytidine
CC   residues in the 2'-MOE wings are 5-methylcytidines) and targeted to human
CC   inducible nitric oxide synthase (NOS) mRNA (AAH47959)
XX
SQ   Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        511 AGCGGCCTGGATGAGGAA 528
              ||| ||||||| ||||||
Db         18 AGCTGCCTGGAGGAGGAA 1


RESULT 660
AAF94748
ID   AAF94748 standard; DNA; 18 BP.
XX
AC   AAF94748;
XX
DT   23-MAY-2001  (first entry)
XX
DE   Rho G antisense phosphorothioate oligonucleotide SEQ ID 172.
XX
KW   Rho; GTP binding protein; phosphorothioate antisense oligonucleotide;
KW   RhoA; RhoB; RhoC; RhoG; Rac 1; cdc42; hyperproliferative condition;
KW   cancer; wound healing; clotting; ischaemia; reperfusion; reoxygenation;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO200115739-A1.
XX
PD   08-MAR-2001.
XX
PF   18-AUG-2000; 2000WO-US022808.
XX
PR   31-AUG-1999;   99US-00387341.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Roberts ML,  Cowsert LM;
XX
DR   WPI; 2001-191677/19.
XX
PT   An antisense compound targeted to a nucleic acid molecule encoding a
PT   member of the human Rho family of small GTP binding proteins useful for
PT   treating e.g. cancer and ischemia.
XX
PS   Example 18; Page 81; 156pp; English.
XX
CC   This invention relates to an antisense compound targeted to a nucleic
CC   acid molecule encoding a member of the human Rho family of small GTP
CC   binding proteins, where the antisense compound inhibits the expression of
CC   the member of the human Rho family. The invention includes antisense
CC   oligonucleotides AAF94580 - AAF94637 which target a RhoA nucleotide
CC   sequence, AAF94645 - AAF94684 which target a RhoB nucleotide sequence,
CC   AAF94686 - AAF94725 which target a RhoC nucleotide sequence, AAF94727 -
CC   AAF94766 which target RhoG nucleotide sequence, AAF94769 - AAF94790 which
CC   target a Rac 1 nucleotide sequence and AAF94795 - AAF94809 which target
CC   cdc42 nucleotide sequence. The antisense compound is useful for treating
CC   hyperproliferative conditions, especially cancer, abnormal wound healing
CC   or clotting conditions and ischaemia/reperfusion or reoxygenation injury.
CC   The compound may also be used to diagnose the above conditions
XX
SQ   Sequence 18 BP; 1 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        658 CTCGAGTGCCTGTCCCTG 675
              | ||||||||||| |||||
Db          1 CGCGAGTGCCTGGCCCTG 18


RESULT 661
ABA82492
ID   ABA82492 standard; DNA; 18 BP.
XX
AC   ABA82492;
XX
DT   25-JAN-2002  (first entry)
XX
DE   Zmax1 gene region physical map preparation STS marker #451.
XX
KW   Human; high bone mass; HBM gene; Zmax1 gene; chromosome 11; 11q13.3;
KW   sequence tagged site; STS; osteoporosis; osteopathic; gene therapy;
KW   antisense therapy; vaccine; bone disorder; Paget's disease; adapter;
KW   sclerostosis; osteomalacia; fibrous dysplasia; PCR primer; linker; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200177327-A1.
XX
PD   18-OCT-2001.
XX
PF   21-JUN-2000; 2000WO-US016951.
XX
PR   05-APR-2000; 2000US-00543771.
PR   05-APR-2000; 2000US-00544398.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Carulli JP,  Little RD,  Recker RR,  Johnson ML;
XX
DR   WPI; 2001-657171/75.
XX
PT   New high bone mass (HBM) and Zmax1 genes and proteins useful for
PT   modulating bone mass for the treatment of e.g. osteoporosis.
XX
PS   Disclosure; Page 36; 443pp; English.
XX
CC   The present invention describes the human Zmax1 gene and the high bone
CC   mass (HBM) gene,which are found on chromosome 11q13.3. The Zmax1 and HBM
CC   genes have osteopathic activities. The genes can be used in gene therapy,
CC   antisense therapy and in the production of vaccines. They can be used in
CC   the diagnosis and treatment of bone disorders including osteoporosis,
CC   Paget's disease, sclerostosis, osteomalacia and fibrous dysplasia.
CC   ABA82038 to ABA82700 and AAG68168 to AAG68193 represent sequences used in
CC   the exemplification of the present invention
XX
SQ   Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18
```

```
RESULT 662
ABL44014
ID   ABL44014 standard; DNA; 18 BP.
XX
AC   ABL44014;
XX
DT   11-APR-2002  (first entry)
XX
DE   Human chromosome 1p36-35 PCR primer SEQ ID NO:1058.
XX
KW   Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   JP2001321190-A.
XX
PD   20-NOV-2001.
XX
PF   12-MAR-2001; 2001JP-00068285.
XX
PR   10-MAR-2000; 2000JP-00066716.
XX
PA   (RIKA ) RIKAGAKU KENKYUSHO.
PA   (GENO-) GENOTEX YG.
XX
DR   WPI; 2002-144136/19.
XX
PT   Arraying genome clones.
XX
PS   Claim 4; Page 25; 528pp; Japanese.
XX
CC   The present invention describes a method of arraying genome clones. The
CC   method comprises: (a) clones of the genomic libraries contained in
CC   multiwell plates numbered for discrimination are mixed in each of the
CC   multiwell plates; (b) a primer designed based on the chromosome marker
CC   sequence is added to the mixture to carry out an amplification reaction;
CC   (c) a signal corresponding to the marker is detected from the resultant
CC   amplified product to specify the discrimination Nos. of the multiwell
CC   plates containing the clones having said marker sequence; (d) the order
CC   of the markers is changed so that the same discrimination Nos. succeed to
CC   the maximum in the specified discrimination Nos. to array the multiwell
CC   plates; (e) the clones in the multiwell plates of the specified
CC   discrimination Nos. are mixed respectively in each wells of longitudinal
CC   and lateral directions; (f) the mixed clones are cultured and the
CC   resultant cultures are amplified by using the above primer; (g) signals
CC   are detected from the amplified products; (h) the clones in the multiwell
CC   plates are specified from the detected result; and (i) the clones are
CC   reconstituted as the positions on the chromosome and arrayed. The
CC   microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC   PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC   represent PCR primers for human chromosome 21q22.1, which are
CC   specifically claimed for use in the present invention
XX
SQ   Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2554 GGCATGCGGTACCTTGCC 2571
              |||||| |||||| ||||
Db          1 GGCATGAGGTACCATGCC 18


RESULT 663
AAL48393
ID   AAL48393 standard; DNA; 18 BP.
XX
AC   AAL48393;
XX
DT   01-OCT-2002  (first entry)
XX
DE   Human c-mos gene PCR primer SEQ ID NO: 10.
XX
KW   Human; c-mos; cytosine methylation; cytostatic; cancer; carcinoma;
KW   cytostatic; leukaemia; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200236604-A2.
XX
PD   10-MAY-2002.
XX
PF   06-NOV-2001; 2001WO-EP012831.
XX
PR   06-NOV-2000; 2000DE-01054972.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2002-566498/60.
XX
PT   New chemically pretreated nucleic acid of the human c-mos gene, useful in
PT   diagnosis and treatment of e.g. cancers, and related oligomers for
PT   determining cytosine methylation.
XX
PS   Claim 29; Page 36; 42pp; German.
XX
CC   The present invention provides chemically pretreated DNA sequences
CC   derived from the human c-mos gene. These can be used in the diagnosis and
CC   treatment of lung carcinoma, throat cancer, acute myeloid leukaemia,
CC   chronic mylocystic leukaemia and Burkitt lymphoma, and to differentiate
CC   between different forms and stages of acute lymphatic leukaemia. The
CC   present sequence is a PCR primer for the human c-mos sequence
XX
SQ   Sequence 18 BP; 6 A; 7 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3782 GTCACCACCAAACTCAAT 3799
              || |||||||||||| ||
Db          1 GTTACCACCAAACTCCAT 18


RESULT 664
ABK23289
ID   ABK23289 standard; DNA; 18 BP.
XX
AC   ABK23289;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human Zmax1 cDNA forward PCR primer #226.
XX
KW   Human; mouse; Zmax1; HBM; high bone mass gene; lipid regulation; stroke;
KW   lipid-associated condition; arteriosclerosis; cardiovascular disease; ss;
KW   osteoporosis; atherosclerosis; diabetic atherosclerosis; plaque build-up;
KW   neurovascular condition; wound healing; gene therapy; PCR primer; probe;
KW   bone development disorder; antiarteriosclerotic; cardiovascular;
KW   osteopathic; cerebroprotective.
XX
OS   Homo sapiens.
XX
PN   WO200192891-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016946.
XX
PR   26-MAY-2000; 2000US-00578900.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
```

PA (UYCR-) UNIV CREIGHTON SCHOOL MEDICINE.
XX
PI Carulli JP, Little RD, Recker RR, Johnson ML;
XX
DR WPI; 2002-097784/13.
XX
PT Identifying molecules involved in lipid regulation, useful for
PT diagnosing, treating or preventing e.g., arteriosclerosis, comprises
PT identifying a molecule that binds to high bone mass gene or its
PT corresponding wild type gene.
XX
PS Disclosure; Page 41; 409pp; English.
XX
CC The invention relates to a method for identifying a molecule involved in
CC lipid regulation comprising identifying a molecule that binds to or
CC inhibits binding of a molecule to high bone mass (HBM) or its wild type
CC gene, Zmax1. Compounds identified by the method are useful for treating,
CC diagnosing, preventing or screening for normal and abnormal lipid-
CC associated conditions, including arteriosclerosis, cardiovascular
CC disease, stroke, and osteoporosis. The compounds may also be used in the
CC treatment or prevention of diabetic atherosclerosis, neurovascular
CC conditions caused by plaque build-up, poor circulation due to plaque
CC build-up and associated poor wound healing. The methods may be used in
CC gene therapy, pharmaceutical development, and diagnostic assays for bone
CC development disorders. Molecules identified by comparison of Zmax1 and
CC HBM systems can be used as surrogate markers in pharmaceutical
CC development, in diagnosis of human or animal bone disease, and in the
CC treatment of bone diseases. Sequences ABK22776-ABK23411 represent cDNA
CC molecules encoding human Zmax1 and HBM, and PCR primers, probes, linkers
CC and adapters of the invention
XX
SQ Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3093 CTCAGCTTTTGGCTCTGT 3110
|| |||||||||| ||||
Db 1 CTGAGCTTTTGGCACTGT 18

RESULT 665
ABZ11106
ID ABZ11106 standard; DNA; 18 BP.
XX
AC ABZ11106;
XX
DT 16-JAN-2003 (first entry)
XX
DE Haematopoietic cell proliferation disorder related oligonucleotide #1246.
XX
KW Human; haematopoietic cell proliferation disorder; cytostatic;
KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW cytosine methylation state; probe; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200277272-A2.
XX
PD 03-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-EP003401.
XX
PR 26-MAR-2001; 2001US-0278333P.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T, Pelet C;
PI Schwope I, Ziebarth H;
XX
DR WPI; 2003-018942/01.
XX
PT Detecting and differentiating between hematopoietic cell proliferative
PT disorders, comprises contacting a target nucleic acid with a reagent that
PT distinguishes between methylated and non-methylated CpG dinucleotides.
XX
PS Claim 15; Page 76; 117pp; English.
XX
CC The present invention describes a method for detecting and
CC differentiating between haematopoietic cell proliferative disorders
CC associated with at least 1 gene and/or their regulatory regions in a
CC subject. The method comprises contacting a target nucleic acid in a
CC biological sample obtained from the subject with at least 1 reagent,
CC which distinguishes between methylated and non-methylated CpG
CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC represent specifically claimed nucleotide sequences from the present
CC invention. Oligonucleotides from the present invention can be used: for
CC differentiating between healthy haematopoietic cells and proliferative
CC disorder haematopoietic cells; for differentiating between acute
CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC determining the cytosine methylation state and/or single nucleotide
CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC related sequences and their complements; and as primers for the
CC amplification of haematopoietic cell proliferation disorder related DNA
CC sequences. The nucleotide sequences from the present invention can also
CC be used for detecting a predisposition to, differentiation between
CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC haematopoietic cell proliferative disorders. The present method enables a
CC highly specific classification of haematopoietic cell proliferative
CC disorders allowing for improved and informed treatment of patients
XX
SQ Sequence 18 BP; 6 A; 7 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3782 GTCACCACCAAACTCAAT 3799
|| |||||||||||| ||
Db 1 GTTACCACCAAACTCCAT 18

RESULT 666
ACC45872
ID ACC45872 standard; DNA; 18 BP.
XX
AC ACC45872;
XX
DT 02-JUN-2003 (first entry)
XX
DE Human HBM STS marker forward primer #226.
XX
KW Human; high bone mass; HBM; LRP5; LRP6; transgenic; bone mass modulation;
KW gene therapy; bone density modulation; bone strength; trabecular number;
KW bone size; bone tissue connectivity; bone disease; osteoporosis; PCR;
KW osteomalacia; rickets; Paget's disease; neoplasm of the bone; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200292764-A2.
XX
PD 21-NOV-2002.
XX
PF 13-MAY-2002; 2002WO-US014876.
XX
PR 11-MAY-2001; 2001US-0290071P.
PR 17-MAY-2001; 2001US-0291311P.
PR 01-FEB-2002; 2002US-0353058P.
PR 04-MAR-2002; 2002US-0361293P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PA (AMHP) WYETH.

```
XX
PI   Babij P,  Bex PJ,  Yaworsky PJ,  Bodine PV;
XX
DR   WPI; 2003-129278/12.
XX
PT   New transgenic animals (e.g. mice), useful as models for studying bone
PT   density modulation, developing drugs for treating or preventing bone
PT   diseases (e.g. osteoporosis), or diagnosing diseases characterized by
PT   reduced bone density.
XX
PS   Disclosure; Page 57; 603pp; English.
XX
CC   The invention relates to novel transgenic animals expressing the high
CC   bone mass (HBM) gene, expressing the corresponding wild type HBM gene,
CC   comprising an alteration of the gene encoding LRP5 or LRP6, or expressing
CC   an LRP5 that is modulated by an altered gene control sequence introduced
CC   by homologous or non-homologous recombination. The transgenic animals are
CC   for the study of bone density modulation or bone mass modulation. The
CC   invention has osteopathic and cytostatic activity. The polynucleotides of
CC   the invention may have a use in gene therapy. The transgenic animals and
CC   nucleic acids are for the study of bone density modulation, where the
CC   bone mass is modulated relative to non-transgenic animals of the same
CC   species in more than one parameter selected from bone density, bone
CC   strength, trabecular number, bone size, or bone tissue connectivity. The
CC   transgenic animals, nucleic acids and methods are useful for identifying
CC   molecules involved in bone development, and for developing pharmaceutical
CC   compositions, which may be employed for treating or preventing bone
CC   diseases, e.g. osteoporosis, osteomalacia, rickets, Paget's disease, or
CC   neoplasms of the bone. The transgenic animals and nucleic acids are also
CC   useful in methods for diagnosing diseases involved in bone development,
CC   or characterised by reduced bone density or mass. The present sequence is
CC   used in the exemplification of the invention
XX
SQ   Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18


RESULT 667
ADB98570
ID   ADB98570 standard; DNA; 18 BP.
XX
AC   ADB98570;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Sequence tagged site #451 used to prepare Zmax1 (LRP5) gene region map.
XX
KW   Osteopathic; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
KW   bone mass modulation; osteoporosis; STS; sequence tagged site; ds.
XX
OS   Homo sapiens.
XX
PN   WO200292000-A2.
XX
PD   21-NOV-2002.
XX
PF   13-MAY-2002; 2002WO-US014877.
XX
PR   11-MAY-2001; 2001US-0290071P.
PR   17-MAY-2001; 2001US-0291311P.
PR   01-FEB-2002; 2002US-0353058P.
PR   04-MAR-2002; 2002US-0361293P.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
PA   (AMHP ) WYETH.
XX
PI   Allen K,  Anisowicz A,  Graham JR,  Morales A,  Yaworsky PJ,  Liu W;
XX
DR   WPI; 2003-129214/12.
XX
PT   New nucleic acid comprising a mutation in LRP5 or LRP6, useful for
PT   diagnosing a HBM-like phenotype in a subject and for preparing a
PT   composition for modulating bone mass and/or lipid levels in a subject
PT   suffering from e.g. osteoporosis.
XX
PS   Example 2; Page 64; 629pp; English.
XX
CC   The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and
CC   LRP6 mutants, which results in a HBM-like phenotype when expressed in a
CC   cell. The HBM-like phenotype results in bone mass modulation and/or lipid
CC   level modulation. The invention is useful for diagnosing a HBM-like
CC   phenotype in a subject and for preparing a composition for modulating
CC   bone mass and/or lipid levels in a subject suffering from e.g.
CC   osteoporosis. The present sequence is a Sequence Tagged Site (STS)
CC   marker, which was used to prepare a physical map of the Zmax1 (LRP5) gene
CC   region.
XX
SQ   Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18


RESULT 668
ADE85865/c
ID   ADE85865 standard; DNA; 18 BP.
XX
AC   ADE85865;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Casein kinase 2 antisense oligonucleotide.
XX
KW   Casein kinase 2; protein kinase; enzyme; antisense; antitumour;
KW   gene therapy; nanoparticle; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' O-methylated"
FT   modified_base   18
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 3' butanol"
XX
PN   WO2003087389-A2.
XX
PD   23-OCT-2003.
XX
PF   08-APR-2003; 2003WO-US010729.
XX
PR   08-APR-2002; 2002US-0370882P.
PR   08-JUL-2002; 2002US-0394315P.
PR   22-NOV-2002; 2002US-0428296P.
PR   28-FEB-2003; 2003US-00378044.
XX
PA   (GENE-) GENESEGUES INC.
PA   (OLIG-) OLIGOS ETC INC.
XX
PI   Unger GM,  Dale RMK,  Thompson TL;
XX
```

```
DR   WPI; 2003-845336/78.
XX
PT   New nanoparticles of less than 100 nm comprising an antisense
PT   polynucleotide, useful for targeted treatment of cancerous cells, e.g.
PT   leukemic blasts, ovarian or breast cancer cells or other
PT   hyperproliferative disorders.
XX
PS   Example 6; SEQ ID NO 8; 92pp; English.
XX
CC   The present sequence is that of a 3' butanol end-blocked antisense
CC   oligonucleotide targeted to the casein kinase 2 alpha' subunit. In an
CC   example from the invention, this oligonucleotide was encapsulated in
CC   nanoparticles and examined for antitumour activity. An IC50 value against
CC   chemoresistant head neck carcinoma SCC-15 cells of 5.5% cisplatin IC50
CC   (molar basis) was determined. This is an example of antisense
CC   oligonucleotides of the invention that suppress the expression of protein
CC   kinase CK2 alpha', CK2 beta or CK2 alpha. Such oligonucleotides can be
CC   encapsulated in nanoparticles and delivered to a cell or tissue for use
CC   in cancer therapy. The cells are selected from glial cells, astrocytes,
CC   smooth muscle cells, myofibroblasts, vascular endothelial cells,
CC   leukaemic blasts, vascular endothelial cells in solid tumours, B-cell
CC   lymphoproliferative disease cells, acute myeloid leukaemic cells, glial
CC   tumour cells, breast cancer cells, small-cell lung cancer cells, ovarian
CC   cancer cells, colorectal cancer cells, blood vessel media cells, squamous
CC   cell carcinoma cells or epithelial-derived cancer cells (claimed).
XX
SQ   Sequence 18 BP; 2 A; 5 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1223 GGTCCTGCCAGCCATGCC 1240
              ||||| ||| ||||||||
Db         18 GGTCCCGCCCGCCATGCC 1


RESULT 669
ADD93278/c
ID   ADD93278 standard; RNA; 18 BP.
XX
AC   ADD93278;
XX
DT   29-JAN-2004  (first entry)
XX
DE   CK2-alpha'(Prime-1) target for growth inhibition.
XX
KW   ss; casein kinase II; CK2; alpha subunit; molecular target;
KW   growth inhibition; cell adhesion molecule; immunoglobulin superfamily;
KW   cell adhesion molecule; integrin; cadherin; selectin;
KW   growth factor receptor; collagen receptor; laminin receptor;
KW   fibronectin receptor; chondroitin sulphate receptor;
KW   dermatan sulphate receptor; heparin sulphate receptor;
KW   keratan sulphate receptor; elastin receptor; vitronectin receptor;
KW   cancer; antisense; doxorubicin; apoptosis.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   18
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER = c-butanol"
XX
PN   WO2003087323-A2.
XX
PD   23-OCT-2003.
XX
PF   08-APR-2003; 2003WO-US010850.
XX
PR   08-APR-2002; 2002US-0370882P.
PR   08-JUL-2002; 2002US-0394315P.
PR   22-NOV-2002; 2002US-0428296P.
PR   28-FEB-2003; 2003US-00378044.
XX
PA   (GENE-) GENESEGUES INC.
XX
PI   Unger GM;
XX
DR   WPI; 2003-853949/79.
XX
PT   New collection of particles comprising a bioactive component, a
PT   surfactant molecule having an HLB value of less than about 6.0 units, a
PT   biocompatible polymer, and a cell recognition component, useful for
PT   treating cancer.
XX
PS   Example 6; Page 64; 90pp; English.
XX
CC   This sequence represents a fragment of a human casein kinase II (CK2)
CC   alpha subunit gene which was used as a molecular target for growth
CC   inhibition. These sequences were used in the new collection of particles
CC   of the invention which comprises a bioactive component, a surfactant
CC   molecule having an HLB value of less than about 6.0 units, a
CC   biocompatible polymer, and a cell recognition component. The collection
CC   has an average diameter of less than about 200 nanometers as measured by
CC   atomic force microscopy following drying of the collection of particles.
CC   The cell recognition component has a binding affinity for a cell
CC   recognition target consisting of cell adhesion molecules, immunoglobulin
CC   superfamily, cell adhesion molecules, integrins, cadherins, selectins,
CC   growth factor receptors, collagen receptors, laminin receptors,
CC   fibronectin receptors, chondroitin sulphate receptors, dermatan sulphate
CC   receptors, heparin sulphate receptors, keratan sulphate receptors,
CC   elastin receptors or vitronectin receptors. The particles may be used for
CC   delivering an anti-cancer agent to cancer cells by contacting the cancer
CC   cells with the collection of particles comprising the anticancer agents,
CC   a surfactant having an HLB value less than about 6.0 milts and a
CC   biocompatible polymer. The anticancer agent comprises a nucleic acid. The
CC   nucleic acid comprises an antisense sequence to a native human nucleic
CC   acid sequence. The antisense sequence is effective to inhibit expression
CC   of CK2. The anticancer agent comprises doxorubicin or an apoptotic agent.
XX
SQ   Sequence 18 BP; 2 A; 5 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1223 GGTCCTGCCAGCCATGCC 1240
              ||||| ||| ||||||||
Db         18 GGTCCCGCCCGCCATGCC 1


RESULT 670
ABZ96456/c
ID   ABZ96456 standard; DNA; 18 BP.
XX
AC   ABZ96456;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human nucleic acid sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
```

XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 11698; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1063 GCCCCTGGCCCCAGCCCC 1080
| ||| ||||||||||||
Db 18 GGCCCAGGCCCCAGCCCC 1

RESULT 671
ABZ97159/c
ID ABZ97159 standard; DNA; 18 BP.
XX
AC ABZ97159;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human MTA oligonucleotide.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.

XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 12401; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1063 GCCCCTGGCCCCAGCCCC 1080
| ||| ||||||||||||
Db 18 GGCCCAGGCCCCAGCCCC 1

RESULT 672
ABX10913
ID ABX10913 standard; DNA; 18 BP.
XX
AC ABX10913;
XX
DT 28-APR-2003 (first entry)
XX
DE Novel human membrane associated protein Zsig24, antisense primer.
XX
KW Human; membrane associated protein; Zsig24; metabolic disease; obesity;
KW diabetes; type II diabetes; Pima Indian; polymorphism identification;
KW chromosome 11q23-q24; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN US2002164701-A1.
XX
PD 07-NOV-2002.
XX
PF 25-OCT-2001; 2001US-00001631.
XX
PR 23-OCT-1998; 98US-0105450P.
PR 23-JUN-1999; 99US-0141519P.

PR 20-OCT-1999; 99US-00422052.
XX
PA (SHEP/) SHEPPARD P O.
PA (JELI/) JELINEK L J.
PA (WHIT/) WHITMORE T E.
XX
PI Sheppard PO, Jelinek LJ, Whitmore TE;
XX
DR WPI; 2003-247256/24.
XX
PT New isolated Zsig24 polypeptide and polynucleotides encoding the
PT polypeptide, useful for diagnosing chromosome 11 abnormalities, or for
PT diagnosing obesity or type II diabetes in an individual e.g., Pima
PT Indian.
XX
PS Example 2; Page 29; 34pp; English.
XX
CC The invention describes an isolated polypeptide (I) comprising an amino
CC acid sequence which shares at least 70% or greater than 95% percent
CC identity with a fully defined human Zsig24 polypeptide sequence (S1). The
CC polynucleotide encoding Zsig24 is useful as a diagnostic reagent for
CC detecting a chromosome 11 abnormality in a subject, involving amplifying
CC nucleic acid molecules that encode Zsig24 from RNA isolated from a
CC biological sample of the subject, and detecting a mutation in the
CC amplified nucleic acid molecules, where the presence of a mutation
CC indicates a chromosome 11 abnormality. The polynucleotide is also useful
CC for diagnosing a metabolic disease (e.g., obesity or diabetes, preferably
CC type II diabetes) or susceptibility to a metabolic disease in an
CC individual (e.g., Pima Indian), where the disease is related to the
CC expression or activity of Zsig24 polypeptide comprising sequence of (S1)
CC in that individual. The method optionally involves amplifying nucleic
CC acid molecules that encode Zsig24 from RNA isolated from a biological
CC sample of the individual, and detecting a mutation in the amplified
CC nucleic acid molecules, where the presence of a mutation indicates
CC metabolic disease or susceptibility to a metabolic disease or amplifying
CC nucleic acid molecules that encode Zsig24 from RNA isolated from a
CC biological sample of the subject, and transcribing the amplified nucleic
CC acid molecules to produce Zsig24 mRNA, translating Zsig24 mRNA to produce
CC (I), and detecting a mutation (I). The methods are for identifying
CC polymorphisms in a new human gene that resides on chromosome 11q23-q24, a
CC locus linked with a heritable form of diabetes. This sequence represents
CC a primer used to locate the novel human membrane associated protein
CC Zsig24 gene to chromosome 11
XX
SQ Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3629 TGCCCCCCTCACCTTGAT 3646
||||||| |||||| |||
Db 1 TGCCCCCTTCACCTGGAT 18

RESULT 673
ACA60574
ID ACA60574 standard; DNA; 18 BP.
XX
AC ACA60574;
XX
DT 11-JUN-2003 (first entry)
XX
DE Antisense inhibition of human cyclin D2 related oligonucleotide #11.
XX
KW Human; cyclin D2; diagnostic; therapeutic; prophylaxis;
KW cyclin 2 inhibition; ss.
XX
OS Homo sapiens.
XX
PN US6492173-B1.
XX
PD 10-DEC-2002.
XX
PF 01-AUG-2001; 2001US-00920760.
XX
PR 01-AUG-2001; 2001US-00920760.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowsert LM;
XX
DR WPI; 2003-361492/34.
XX
PT Novel antisense compound useful for treating diseases associated with
PT Cyclin D2 expression, comprises an oligonucleotide comprising up to 50
PT nucleobases in length, which inhibits expression of Cyclin D2 in cells or
PT tissues in vitro.
XX
PS Example 15; Col 45-46; 40pp; English.
XX
CC The invention describes a compound (I) of up to 50 nucleobases in length,
CC which inhibits the expression of Cyclin D2. (I) is useful for inhibiting
CC the expression of Cyclin D2 in cells or tissues in vitro. (I) is thus
CC useful for treating disease associated with Cyclin D2 expression. (I) is
CC useful for diagnostics, therapeutics, prophylaxis and as research
CC reagents and kits. This sequence represents human cyclin D2 inhibition
CC associated oligonucleotide
XX
SQ Sequence 18 BP; 3 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2481 CTCCTTCCTGCGGCTAAA 2498
||||||||| |||||||
Db 1 CTCCTTCCTTTGGCTAAA 18

RESULT 674
ABD20418/c
ID ABD20418 standard; DNA; 18 BP.
XX
AC ABD20418;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human pulmonary and inflammatory target DNA #29.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ds.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX

```
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 11699; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1063 GCCCCTGGCCCCAGCCCC 1080
              | ||| ||||||||||||
Db         18 GGCCCAGGCCCCAGCCCC 1


RESULT 675
ABD32442/c
ID   ABD32442 standard; DNA; 18 BP.
XX
AC   ABD32442;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human MTA oligo SEQ ID 12401.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 12401; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1063 GCCCCTGGCCCCAGCCCC 1080
              | ||| ||||||||||||
Db         18 GGCCCAGGCCCCAGCCCC 1


RESULT 676
ADI34784
ID   ADI34784 standard; DNA; 18 BP.
XX
AC   ADI34784;
XX
DT   22-APR-2004  (first entry)
XX
DE   Kidney injury molecule 1 (KIM-1) PCR primer rKIM1.reverse.
XX
KW   KIM-1; marker gene; renal toxicity; calbindin-D28k;
KW   kidney injury molecule 1; OPN; osteopontin; EGF1;
```

```
KW   epidermal growth factor; clusterin; VEGF;
KW   vascular endothelial growth factor; alpha-2u globulin related-protein;
KW   complement component 4; C4; kidney-specific organic anion transporter-K1;
KW   OAT-K1; aldolase A; aldolase B; podocin; lipocalin 2; nephrotropic; PCR;
KW   primer; ss.
XX
OS   Rattus sp.
OS   Synthetic.
XX
PN   WO2004005544-A2.
XX
PD   15-JAN-2004.
XX
PF   03-JUL-2003; 2003WO-EP007111.
XX
PR   04-JUL-2002; 2002GB-00015509.
XX
PA   (NOVS ) NOVARTIS AG.
PA   (NOVS ) NOVARTIS PHARMA GMBH.
XX
PI   Chibout S,  Grenet O,  Imbert G,  Kehren J,  Staedtler F;
PI   Wolfgang CD;
XX
DR   WPI; 2004-091386/09.
XX
PT   Use of marker genes for monitoring, prognosing, diagnosing or treating
PT   renal disorders, e.g. renal diseases, injuries or toxicities, or for
PT   identifying agents for treating renal toxicity.
XX
PS   Example 1; Page 36; 58pp; English.
XX
CC   The invention relates to the use of marker genes for monitoring,
CC   prognosing, diagnosing or treating renal toxicity, identifying agents for
CC   treatment of renal toxicity or identifying agents that do not induce
CC   renal toxicity. The marker genes are selected from Calbindin-D28k, KIM-1
CC   (kidney injury molecule 1), OPN (osteopontin), EGF1 (epidermal growth
CC   factor), Clusterin, VEGF (Vascular Endothelial Growth Factor), Alpha-2u
CC   globulin related-protein, Complement component 4 (C4), Kidney-specific
CC   Organic Anion Transporter-K1 (OAT-K1), Aldolase A, Aldolase B, Podocin
CC   and Alpha-2u (lipocalin 2). The marker genes are useful for monitoring,
CC   prognosing, diagnosing or treating renal toxicity, identifying agents for
CC   treatment of renal toxicity or identifying agents that do not induce
CC   renal toxicity. The polymorphism in a gene is useful for the diagnostic
CC   of renal toxicity. The method also provides a test useful for determining
CC   whether a renal toxicity in a patient will respond to therapy. The
CC   present sequence represents a primer used in real-time quantitative PCR
CC   analysis of KIM-1 gene.
XX
SQ   Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1377 GAACGGCTCCTCCCTGCA 1394
              | ||| ||||||||||||
Db          1 GCACGTCTCCTCCCTGCA 18


RESULT 677
ADI20875
ID   ADI20875 standard; DNA; 18 BP.
XX
AC   ADI20875;
XX
DT   06-MAY-2004  (first entry)
XX
DE   MS SnuPE detection oligonucleotide for DD3 #15.
XX
KW   DD3; CpG dinucleotide; cell proliferative disorder; ss.
XX
OS   Synthetic.
XX
PN   WO2004005543-A1.
XX
PD   15-JAN-2004.
XX
PF   25-JUN-2003; 2003WO-EP006690.
XX
PR   08-JUL-2002; 2002DE-01030692.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Horns T;
XX
DR   WPI; 2004-091385/09.
XX
PT   Detecting methylation of 5' and promoter region of DD3 gene for
PT   diagnosing proliferative disorders comprising contacting target nucleic
PT   acid with a reagent that distinguishes between methylated and non-
PT   methylated CpG dinucleotide.
XX
PS   Claim 6; SEQ ID NO 78; 56pp; English.
XX
CC   The present invention relates to detecting the methylation state of the
CC   5' and promoter region of the gene DD3 within a subject comprising
CC   contacting a target nucleic acid having one or more sequences selected
CC   from 5 3581 base pair sequences in a biological sample with at least one
CC   reagent or a series of reagents. The method is useful for detecting the
CC   methylation state of the 5' and promoter region of the gene DD3 within a
CC   subject. The set of oligonucleotides comprising at least three of the
CC   oligomers is useful for detecting the cytosine methylation state and/or
CC   single nucleotide polymorphisms (SNPs) within SEQ. ID NO. 1-5 and its
CC   complementary sequences. The set of oligomers is also useful for
CC   detecting the methylation state of all CpG dinucleotides within SEQ ID
CC   NO. 1 and its complementary sequences. The set of at least two
CC   oligonucleotides can be used as primer oligonucleotides for the
CC   amplification of DNA sequences selected from SEQ ID NO. 1-5 and its
CC   complementary sequences. The DNA- and/or PNA-array is useful for
CC   analyzing diseases associated with the methylation state of the gene DD3
CC   comprising at least one nucleic acid. The methods, nucleic acids,
CC   oligonucleotide or PNA-oligomer, kit, array or the set of
CC   oligonucleotides is useful for the characterization, classification,
CC   differentiation, grading, staging, and/or diagnosis of cell proliferative
CC   disorders, or the predisposition to cell proliferative disorders. It can
CC   also be used for the therapy of cell proliferative disorders. The present
CC   sequence represents a detection oligonucleotide of the invention.
XX
SQ   Sequence 18 BP; 1 A; 0 C; 5 G; 12 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3857 TTGAGTTTTGTTTTTGGT 3874
              ||||| ||| ||||||||
Db          1 TTGAGGTTTTTTTTTGGT 18


RESULT 678
ADP47449
ID   ADP47449 standard; DNA; 18 BP.
XX
AC   ADP47449;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Intelligent PCR primer for the identification of bacteria SeqID 104.
XX
KW   PCR; ss; primer; pharmacogenetic analysis; medical diagnosis; cancer;
KW   blood typing; virus stereotyping; pathogen; mass spectroscopy;
KW   etiologic agent.
XX
OS   Synthetic.
XX
PN   WO2004052175-A2.
```

XX
PD 24-JUN-2004.
XX
PF 05-DEC-2003; 2003WO-US038830.
XX
PR 06-DEC-2002; 2002US-0431319P.
PR 18-DEC-2002; 2002US-00323233.
PR 18-DEC-2002; 2002US-00325526.
PR 18-DEC-2002; 2002US-00325527.
PR 18-DEC-2002; 2002US-00326051.
PR 29-JAN-2003; 2003US-0443443P.
PR 30-JAN-2003; 2003US-0443788P.
PR 14-FEB-2003; 2003US-0447529P.
PR 11-SEP-2003; 2003US-00660122.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey RH, Hofstadler SA, Sampath R, Mcneil J;
PI Crooke ST;
XX
DR WPI; 2004-468672/44.
XX
PT Identifying a pathogen in a biological sample, useful in medical
PT diagnosis, comprises amplifying a nucleic acid from the sample with a
PT pair of intelligent primers, and determining the molecular mass of the
PT amplification product.
XX
PS Example 15; SEQ ID NO 104; 228pp; English.
XX
CC This invention relates to a novel method for the rapid identification of
CC pathogens occurring in environmental samples or biological samples
CC derived from humans and animals. Specifically, it refers to using
CC intelligent primers to obtain an amplification product in order that the
CC molecular mass of the amplicon can be determined by mass spectroscopy,
CC which in turn identifies the pathogen found in the sample. The present
CC invention describes the rapid detection and identification of an
CC etiologic agent that does not required nucleic acid sequencing, and
CC instead relies on the use of intelligent primers to target ribosomal RNA
CC or housekeeping genes. Accordingly, this method can be used to identify a
CC pathogen or infectious agent in a biological sample, which is useful in
CC pharmacogenetic analysis and medical diagnosis (including cancer
CC diagnosis based on mutations and polymorphisms), or for detecting single
CC nucleotide polymorphisms in blood typing or stereotyping of viruses. This
CC oligonucleotide sequence is an intelligent PCR primer used to identify
CC different bacterial strains, given in an exemplification of the
CC invention.
XX
SQ Sequence 18 BP; 2 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 636 CGCCACGCTGCGCTTCAC 653
|| | ||||||||||||||
Db 1 CGACGCGCTGCGCTTCAC 18

RESULT 679
ADQ59807
ID ADQ59807 standard; DNA; 18 BP.
XX
AC ADQ59807;
XX
DT 07-OCT-2004 (first entry)
XX
DE Intelligent PCR primer VALS_EC_1833_1943 forward SEQ ID NO:104.
XX
KW ss; etiologic agent; disease; intelligent primer;
KW pathogen identification; PCR; primer.
XX
OS Synthetic.
XX
PN WO2004060278-A2.
XX
PD 22-JUL-2004.
XX
PF 05-DEC-2003; 2003WO-US038761.
XX
PR 06-DEC-2002; 2002US-0431319P.
PR 18-DEC-2002; 2002US-00323233.
PR 18-DEC-2002; 2002US-00325526.
PR 18-DEC-2002; 2002US-00325527.
PR 18-DEC-2002; 2002US-00326051.
PR 29-JAN-2003; 2003US-0443443P.
PR 30-JAN-2003; 2003US-0443788P.
PR 14-FEB-2003; 2003US-0447529P.
PR 11-SEP-2003; 2003US-0501926P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey RH, Sampath R, Hofstadler SA, Mcneil J;
PI Crooke ST, Blyn LB, Ranken R, Hall TA;
XX
DR WPI; 2004-534302/51.
XX
PT Identifying pathogens in humans or animals comprises amplifying a nucleic
PT acid molecule from the individual with intelligent primers to obtain
PT amplification products, and determining molecular masses of the
PT amplification products.
XX
PS Claim 40; SEQ ID NO 104; 184pp; English.
XX
CC The invention relates to a novel method for identifying etiologic agents
CC of disease in an individual comprising amplifying a nucleic acid from a
CC biological sample of the individual with intelligent primers to obtain
CC amplification products corresponding to the etiologic agents, and
CC determining the molecular masses of the amplification products. The
CC composition and methods of the invention are useful for identifying
CC pathogens in biological samples from humans and animals, resolving
CC etiologic agents present in samples obtained from humans and animals,
CC determining detailed genetic information about such pathogens or
CC etiologic agents, and for rapidly detecting and identifying bioagents
CC from environmental, clinical or other samples. The present sequence
CC represents an intelligent PCR primer of the invention.
XX
SQ Sequence 18 BP; 2 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 636 CGCCACGCTGCGCTTCAC 653
|| | ||||||||||||||
Db 1 CGACGCGCTGCGCTTCAC 18

RESULT 680
ADR17435
ID ADR17435 standard; DNA; 18 BP.
XX
AC ADR17435;
XX
DT 04-NOV-2004 (first entry)
XX
DE Human chromosome 11 Zmax1 region forward mapping primer #226.
XX
KW Human; high bone mass; Zmax1; ss; primer; HBM; osteoporosis; osteopathic;
KW LDL receptor; bone development; metabolic bone disease; PCR.
XX
OS Homo sapiens.
XX
PN US6780609-B1.
XX
PD 24-AUG-2004.
XX

PF 05-APR-2000; 2000US-00543771.
XX
PR 13-JAN-1998; 98US-0071449P.
PR 23-OCT-1998; 98US-0105511P.
PR 13-JAN-1999; 99US-00229319.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Carulli JP, Little RD, Recker RR, Johnson ML;
XX
DR WPI; 2004-623529/60.
XX
PT New high bone mass gene of chromosome 1.1Q13.3, encoding protein useful
PT for treating, diagnosing, preventing, or screening for normal and
PT abnormal conditions of bone, including metabolic bone diseases, e.g.
PT osteoporosis.
XX
PS Disclosure; SEQ ID NO 517; 284pp; English.
XX
CC The invention relates to an isolated amino acid protein sequence selected
CC from an amino acid sequence appearing as ADR16922 or an amino acid
CC sequence comprising or consisting of the extracellular domain of
CC ADR16922(amino acids 23-1385). ADR16922 is encoded by the HBM (high bone
CC mass) allele of the human Zmax1 gene and has sequence similarity to LDL
CC receptors. Also disclosed are nucleic acids, proteins, cloning vectors,
CC expression vectors, transformed hosts, methods of developing
CC pharmaceutical compositions, methods of identifying molecules involved in
CC bone development, and methods of diagnosing and treating diseases
CC involved in bone development. Specifically disclosed is the Zmax1 gene
CC and the high bone mass (HBM) allele on chromosome 11q13.3 encoding
CC ADR16922. The protein is useful for treating, diagnosing, preventing, or
CC screening for normal and abnormal conditions of bone, including metabolic
CC bone diseases, e.g. osteoporosis. The present sequence is a PCR primer
CC used in the mapping of the Zmax1/HBM gene.
XX
SQ Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3093 CTCAGCTTTTGGCTCTGT 3110
|| |||||||||| ||||
Db 1 CTGAGCTTTTGGCACTGT 18

RESULT 681
ADR48086
ID ADR48086 standard; DNA; 18 BP.
XX
AC ADR48086;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human chromosome 11 Zmax1 region forward mapping primer #226.
XX
KW Human; ss; PCR; high bone mass; Zmax1; HBM; bone modulation;
KW bone development disorder; osteoporosis; chromosome 11; gene therapy;
KW primer.
XX
OS Homo sapiens.
XX
PN US2004176582-A1.
XX
PD 09-SEP-2004.
XX
PF 10-DEC-2003; 2003US-00731739.
XX
PR 13-JAN-1998; 98US-0071449P.
PR 23-OCT-1998; 98US-0105511P.
PR 13-JAN-1999; 99US-00229319.
PR 05-APR-2000; 2000US-00544398.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PA (UYCR-) UNIV CREIGHTON.
XX
PI Carulli JP, Little RD, Recker RR, Johnson ML;
XX
DR WPI; 2004-661408/64.
XX
PT New nucleic acid sequence encoding high bone mass, useful in diagnosing,
PT treating and/or preventing osteoporosis.
XX
PS Disclosure; SEQ ID NO 517; 303pp; English.
XX
CC The invention relates to an isolated nucleic acid sequence encoding a
CC high bone mass protein (HBM). The gene exists in two alleles, Zmax1, the
CC notional wild-type (the cDNA for which appears as ADR47570 encoding
CC ADR47572) and the HBM allele (the cDNA for which appears as ADR47571
CC encoding ADR47573). The two alleles differ by a single nucleotide
CC polymorphism (G to T at position 582 of ADR47570) causing a Gly to Val
CC change at position 171 of the protein. Also included are a replicative
CC cloning vector comprising HBM/Zmax1 (and a replicon operative in an
CC isolated host cell), an expression vector comprising HBM/Zmax1 operably
CC linked to a transcription regulatory region, an isolated host cell
CC transformed with the vector(s), a method for testing a substance as a
CC therapeutic agent for bone modulation in a host, a method of identifying
CC a molecule involved in bone modulation, a method for identifying a
CC (candidate) protein involved in bone modulation,a method of testing for
CC HBM activity, a method of developing a pharmaceutical for the treatment
CC of bone development disorders, a method for treating a bone development
CC disorder in an animal, a method of altering bone development in a host, a
CC method for diagnostic screening for a genetic predisposition to a bone
CC development disorder, a diagnostic assay for bone development disorders,
CC a method of expressing the HBM protein in bone tissue, a bacterial
CC artificial chromosome comprising HBM/Zmax1 sequence (appearing as
CC ADR47574-ADR47580), a method for amplifying a nucleotide polymorphism in
CC the Zmax1 or HBM gene, a method for identifying a regulatory element of a
CC HBM gene and an isolated nucleic acid segment of at least 15 contiguous
CC nucleotides including a polymorphic site from HBM/Zmax1. The nucleic acid
CC molecule and the encoded polypeptide, composition, and methods are useful
CC in diagnosing, treating and preventing a bone development disorder, i.e.
CC osteoporosis. The gene for HBM/Zmax1 is located on chromosome 11q13.3.
CC The present sequence is a primer used in the mapping of the HBM/Zmax1
CC gene.
XX
SQ Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3093 CTCAGCTTTTGGCTCTGT 3110
|| |||||||||| ||||
Db 1 CTGAGCTTTTGGCACTGT 18

RESULT 682
ADW37806/c
ID ADW37806 standard; DNA; 18 BP.
XX
AC ADW37806;
XX
DT 10-MAR-2005 (first entry)
XX
DE Human GPR4 DNA RT-PCR primer #2.
XX
KW GPR4; osteoporosis; osteopathic; degeneration; endocrine disease;
KW musculoskeletal disease; diagnosis; RT-PCR; primer; ss;
KW reverse transcriptase PCR.
XX
OS Homo sapiens.
XX
PN WO2004112823-A1.
XX
PD 29-DEC-2004.

XX
PF 18-JUN-2004; 2004WO-EP006625.
XX
PR 20-JUN-2003; 2003US-0480245P.
PR 02-SEP-2003; 2003US-0499549P.
XX
PA (NOVS) NOVARTIS AG.
PA (NOVS) NOVARTIS PHARMA GMBH.
XX
PI Baumgarten B, Jones CE, Ludwig M, Martiny-Baron G, Seuwen K;
PI Wolf R, Wyder L, Suply T;
XX
DR WPI; 2005-048763/05.
XX
PT Use of an isolated proton-sensing GPCR polypeptide or polynucleotide in
PT developing a medicament for treating medical conditions in which proton
PT homeostasis is imbalanced.
XX
PS Example 11; Page 42; 83pp; English.
XX
CC The invention relates to isolated proton-sensing GPCR polypeptides and
CC polynucleotides useful in developing a medicament for treating diseases
CC and medical conditions in which proton homeostasis is imbalanced. The
CC invention also relates to a pharmaceutical composition comprising the
CC antibody, or agonist or antagonist of a proton-sensing GPCR polypeptide
CC for treating or preventing diseases and medical conditions in which
CC proton homeostasis is imbalanced, a method of screening for compounds
CC that stimulate or inhibit the function or expression level of the proton-
CC sensing GPCR polypeptides, a method of screening for compounds that
CC agonize or antagonize the proton-sensing activity of the GPCR
CC polypeptides and a diagnostic kit comprising the antibody against a
CC proton-sensing GPCR polypeptide or pharmaceutical preparation comprising
CC the antibody. Treating or preventing diseases and medical conditions in
CC which proton homeostasis is imbalanced comprises administering to a
CC subject the antibody, or agonist or antagonist of a proton-sensing GPCR
CC polypeptide. Screening for compounds that stimulate or inhibit the
CC function or expression level of a proton-sensing GPCR polypeptide
CC comprises measuring or detecting, quantitatively or qualitatively, the
CC binding of a candidate compound to the polypeptide (or to the cells or
CC membranes expressing the polypeptide) or its fusion protein by means of a
CC label directly or indirectly associated with the candidate compound,
CC measuring the competition of binding of a candidate compound to the
CC polypeptide (or to the cells or membranes expressing the polypeptide) or
CC a fusion protein thereof in the presence of a labeled competitor, testing
CC whether the candidate compound results in a signal generated by
CC activation or inhibition of the polypeptide using detection systems
CC appropriate to the cells or cell membranes expressing the polypeptide,
CC and detecting the effect of a candidate compound on the production of
CC mRNA encoding the polypeptide or the polypeptide in cells, using for
CC instance, an ELISA assay. The isolated proton-sensing GPCR polypeptides,
CC polynucleotides and antibodies that bind to the polypeptides are useful
CC in developing a medicament for treating or preventing diseases and
CC medical conditions in which proton homeostasis is imbalanced, e.g.,
CC osteoporosis. This sequence represents a reverse transcriptase PCR (RT-
CC PCR) primer used in expression profiling of human GPR4, used in the scope
CC of the invention.
XX
SQ Sequence 18 BP; 0 A; 2 C; 8 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1937 AACATCACAGCCAGACCC 1954
||||.|||||||.||||
Db 18 AACAGCACAGCCAAACCC 1

RESULT 683
ADV66866
ID ADV66866 standard; DNA; 18 BP.
XX
AC ADV66866;
XX
DT 10-MAR-2005 (first entry)
XX
DE S. carnosus secA PCR primer SecAS.c.H4.
XX
KW SecA; translocation ATPase; protein secretion; protein purification; ss;
KW primer; PCR.
XX
OS Staphylococcus carnosus.
XX
PN WO2004108932-A1.
XX
PD 16-DEC-2004.
XX
PF 28-MAY-2004; 2004WO-DE001107.
XX
PR 02-JUN-2003; 2003DE-01025026.
XX
PA (KERJ) FORSCHUNGSZENTRUM JUELICH GMBH.
XX
PI Koeberling O, Freudl R;
XX
DR WPI; 2005-031709/03.
XX
PT New modified SecA protein, useful in microbial production of proteins,
PT provides a higher level of protein secretion than wild-type protein.
XX
PS Example; Page 33; 71pp; German.
XX
CC This invention describes a novel variant SecA protein (a translocation
CC ATPase) and its encoding polynucleotide which provides an increased level
CC of protein secretion, particularly hormones, enzymes, growth factors,
CC pharmaceutical proteins, or cytokines. The protein includes at least one
CC alteration in the amino acid regions that form the regulatory elements
CC IRA-1 and/or IRA-2, and is derived from Bacillus subtilis, B.
CC licheniformis, B. amyloliquefaciens, Staphylococcus carnosus, Escherichia
CC coli or Corynebacterium glutamicum. Most preferably the alterations are
CC in the 198-772 region of the S. carnosus protein or in region 442-767 of
CC the B. subtilis protein. Even a single mutation in secA can significantly
CC improve secretory activity. The invention also describes a method for
CC microbial production of proteins that includes expression of mutant secA
CC in a host cell which improves secretion and yield of the protein, and may
CC make possible secretion of proteins that are not normally secreted at
CC all. Preferably the microorganisms are the same species as those from
CC which the secA polypeptides are derived. The secA polynucleotides can be
CC labeled and used as probes for identification and/or isolation of genes
CC that encode proteins involved in protein secretion. A strain of B.
CC subtilis, designated RMA, was constructed in which the normal secA gene
CC was replaced by secA from S. carnosus. Suppressor mutants of RMA were
CC selected for inability to grow at 25degC and/or inability to produce
CC spores, indicative of changes in the inserted secA gene. The mutations
CC present in the suppressor mutants were identified, then transferred to
CC the secA gene of B. subtilis. The mutant strains of B. subtilis were then
CC tested for expression of alkaline phosphatase PhoB containing the
CC Leu15Gln mutation, which is normally secreted only very inefficiently in
CC the wild-type. This protein was secreted much more effectively by the
CC mutant strain. This sequence represents a PCR primer used to amplify the
CC S. carnosus wild type secA gene.
XX
SQ Sequence 18 BP; 5 A; 4 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 790 GACACGGTGGCCGCGGAG 807
||||.||||.||||||||
Db 1 GACAAGGTGACCGCGGAG 18

RESULT 684
AEB69814
ID AEB69814 standard; DNA; 18 BP.

```
XX
AC   AEB69814;
XX
DT   22-SEP-2005  (first entry)
XX
DE   Human chromosome 11 Zmax1 region forward mapping primer, SEQ ID 517.
XX
KW   Osteopathic; high bone mass; Zmax1; bone disease; osteoporosis;
KW   osteomalacia; bone injury; Pagets disease; PCR; primer; ss;
KW   sequence-tagged site.
XX
OS   Homo sapiens.
XX
PN   US2005142617-A1.
XX
PD   30-JUN-2005.
XX
PF   29-APR-2004; 2004US-00834377.
XX
PR   13-JAN-1998;   98US-0071449P.
PR   23-OCT-1998;   98US-0105511P.
PR   13-JAN-1999;   99US-00229319.
PR   05-APR-2000; 2000US-00543771.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
PA   (UYCR-) UNIV CREIGHTON SCHOOL MEDICINE.
XX
PI   Carulli JP,  Little RD,  Recker RR,  Johnson ML;
XX
DR   WPI; 2005-496364/50.
XX
PT   Identifying candidate molecule involved in bone modulation, comprises
PT   identifying molecule that binds to Zmax1, high bone mass (HBM) protein,
PT   or both Zmax1 and HBM protein.
XX
PS   Disclosure; SEQ ID NO 517; 308pp; English.
XX
CC   The present invention relates to a method (M1) for identifying a
CC   candidate molecule involved in bone modulation. The method comprises
CC   identifying a molecule that binds to High Bone Mass protein (HBM) and/ or
CC   Zmax1 protein. The HBM gene exists in two alleles: Zmax1, the notional
CC   wild-type (the cDNA for which appears as AEB69299 encoding AEB69301 and
CC   AEB69939 encoding AEB69940) and the HBM allele (the cDNA for which
CC   appears as AEB69300 encoding AEB69302). The two alleles differ by a
CC   single nucleotide polymorphism (T to G at position 582 of AEB69299)
CC   causing a Gly to Val change at position 171 of the protein. The HBM
CC   protein has the property of causing elevated bone mass, while the Zmax1
CC   protein does not. The gene for HBM/Zmax1 is located on chromosome
CC   11q13.3. Also claimed is a method of pharmaceutical development for
CC   treating of bone development disorders, such as osteoporosis,
CC   osteomalacia, bone fractures, Paget's disease, etc., which comprises
CC   identifying a molecule that binds to the Zmax1 protein, or to HBM, or
CC   both. PCR primers AEB69364 - AEB69923 are for sequence-tagged site (STS)
CC   markers in the HBM region on chromosome 11q13.3, which were used to
CC   prepare a physical map of the Zmax1 region.
XX
SQ   Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 3.8e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       3093 CTCAGCTTTTGGCTCTGT 3110
              || |||||||||| ||||
Db          1 CTGAGCTTTTGGCACTGT 18


RESULT 685
ADR52529/c
ID   ADR52529 standard; DNA; 48 BP.
XX
AC   ADR52529;
XX
DT   18-NOV-2004  (first entry)
XX
DE   Small interfering RNA expression library oligonucleotide #98.
XX
KW   ss; siRNA; small interfering RNA; gene expression; gene silencing;
KW   expression library; silencing; G coupled receptor; ion channel;
KW   receptor tyrosine kinase; non-receptor tyrosine kinases;
KW   nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase;
KW   protease; matrix metalloproteinase; E3 ubiquitin ligase.
XX
OS   Synthetic.
XX
PN   WO2004072261-A2.
XX
PD   26-AUG-2004.
XX
PF   10-FEB-2004; 2004WO-US003949.
XX
PR   11-FEB-2003; 2003US-0446714P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Li H,  Chatterton JE,  Fan W,  Ke N,  Wong-Staal F;
XX
DR   WPI; 2004-625862/60.
DR   P-PSDB; ADR52530.
XX
PT   Generating a siRNA expression library for selective post-transcriptional
PT   silencing of genes encoding a family of proteins comprises identifying a
PT   consensus sequence for protein families.
XX
PS   Example 2; SEQ ID NO 195; 44pp; English.
XX
CC   The invention relates to a method for generating a siRNA expression
CC   library for selective post-transcriptional silencing of genes encoding a
CC   family of proteins comprising identifying a consensus sequence for the
CC   family of proteins. The method comprises: (a) identifying a consensus
CC   sequence for the family of proteins; and (b) generating an siRNA
CC   expression library whose members encode siRNA molecules that target at
CC   least all mRNA encoding all known members of the family of proteins. The
CC   family of proteins is G coupled receptors, ion channels, receptor
CC   tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone
CC   receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix
CC   metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases.
CC   Identifying a consensus sequences comprises identifying at least one, two
CC   or more signature motif for the family of proteins. The method is useful
CC   for generating a siRNA expression library for selective post-
CC   transcriptional silencing of genes encoding a family of proteins. The
CC   library is useful for identifying genes involved in disease processes.
CC   This sequence corresponds to an oligonucleotide used in the method of the
CC   invention.
XX
SQ   Sequence 48 BP; 11 A; 17 C; 9 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.8;  DB 1;  Length 48;
  Best Local Similarity   64.7%;  Pred. No. 6.2e+02;
  Matches   22;  Conservative    0;  Mismatches   12;  Indels    0;  Gaps    0;

Qy       1854 GCTGCGGGGGCTGAAGCGGGGAGCCAGCTACCTG 1887
                | ||  | || ||  ||||| ||||| |  | |
Db         48 GTTGACGAGGATGTTGCGGGCAGCCAGGTCACGG 15


RESULT 686
ADR52517/c
ID   ADR52517 standard; DNA; 48 BP.
XX
AC   ADR52517;
XX
DT   18-NOV-2004  (first entry)
XX
DE   Small interfering RNA expression library oligonucleotide #92.
XX
```

KW ss; siRNA; small interfering RNA; gene expression; gene silencing;
KW expression library; silencing; G coupled receptor; ion channel;
KW receptor tyrosine kinase; non-receptor tyrosine kinases;
KW nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase;
KW protease; matrix metalloproteinase; E3 ubiquitin ligase.
XX
OS Synthetic.
XX
PN WO2004072261-A2.
XX
PD 26-AUG-2004.
XX
PF 10-FEB-2004; 2004WO-US003949.
XX
PR 11-FEB-2003; 2003US-0446714P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Li H, Chatterton JE, Fan W, Ke N, Wong-Staal F;
XX
DR WPI; 2004-625862/60.
DR P-PSDB; ADR52518.
XX
PT Generating a siRNA expression library for selective post-transcriptional
PT silencing of genes encoding a family of proteins comprises identifying a
PT consensus sequence for protein families.
XX
PS Example 2; SEQ ID NO 183; 44pp; English.
XX
CC The invention relates to a method for generating a siRNA expression
CC library for selective post-transcriptional silencing of genes encoding a
CC family of proteins comprising identifying a consensus sequence for the
CC family of proteins. The method comprises: (a) identifying a consensus
CC sequence for the family of proteins; and (b) generating an siRNA
CC expression library whose members encode siRNA molecules that target at
CC least all mRNA encoding all known members of the family of proteins. The
CC family of proteins is G coupled receptors, ion channels, receptor
CC tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone
CC receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix
CC metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases.
CC Identifying a consensus sequences comprises identifying at least one, two
CC or more signature motif for the family of proteins. The method is useful
CC for generating a siRNA expression library for selective post-
CC transcriptional silencing of genes encoding a family of proteins. The
CC library is useful for identifying genes involved in disease processes.
CC This sequence corresponds to an oligonucleotide used in the method of the
CC invention.
XX
SQ Sequence 48 BP; 11 A; 17 C; 10 G; 10 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 48;
Best Local Similarity 64.7%; Pred. No. 6.2e+02;
Matches 22; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 1854 GCTGCGGGGGCTGAAGCGGGGAGCCAGCTACCTG 1887
| || | || || ||||| |||||| | | |
Db 48 GTTGACGAGGATGTTGCGGGCAGCCAGGTCACGG 15

RESULT 687
ABQ72285/c
ID ABQ72285 standard; DNA; 15 BP.
XX
AC ABQ72285;
XX
DT 02-SEP-2002 (first entry)
XX
DE Human CYP2D6 allele-specific oligonucleotide (ASO) primer, SEQ ID NO:72.
XX
KW Human; cytochrome P450; subfamily IID polypeptide 6; CYP2D6; enzyme;
KW chromosome 22q13.1; drug metabolism; detoxification; mono-oxygenase;
KW antiarrhythmic; arrhythmia; adrenoreceptor antagonist; hypertension;
KW tricyclic antidepressant; procainamide; drug induced lupus syndrome;
KW environmentally linked disease; Parkinsons's disease; haplotyping;
KW genotyping; haplotype; genetic variant; single nucleotide polymorphism;
KW SNP; drug screening; drug discovery; allele-specific oligonucleotide;
KW ASO; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200238589-A2.
XX
PD 16-MAY-2002.
XX
PF 09-NOV-2001; 2001WO-US047396.
XX
PR 09-NOV-2000; 2000US-0247943P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Anastasio AE, Chew A, Choi JY, Denton RR, Nandabalan K;
PI Petersen N, Rounds E;
XX
DR WPI; 2002-519292/55.
XX
PT Novel genetic variants of Cytochrome P450, Subfamily IID, Polypeptide 6
PT isogenes, useful for improving efficiency and reliability in drug
PT development for treating hypertension, arrhythmias and Parkinson's
PT disease.
XX
PS Claim 15; Page 18; 158pp; English.
XX
CC The invention relates to a method for haplotyping the cytochrome P450,
CC subfamily IID, polypeptide 6 (CYP2D6) gene (ABQ72215, ABQ72364) of an
CC individual, and also describes 29 novel polymorphic sites within the
CC human CYP2D6 gene. The CYP2D6 gene is located on chromosome 22q13.1 and
CC contains 9 exons which encode a 497 amino acid protein (ABB09563). CYP2D6
CC is a mono-oxygenase involved in the detoxification of many drugs and
CC environmental chemicals. It plays a role in the metabolism of drugs such
CC as antiarrhythmics, adrenoreceptor antagonists and tricyclic
CC antidepressants, and is also involved in the formation of a metabolite
CC linked to the drug-induced lupus syndrome observed with procainamide.
CC Variations in CYP2D6 activity or expression may also influence an
CC individual's susceptibility to environmentally-linked diseases, and it
CC has been demonstrated that CYP2D6 activity may be involved in the
CC pathogenesis of Parkinsons's disease, with individuals with a less active
CC form of the enzyme tending to have an earlier onset of this condition.
CC CYP2D6 nucleic acid sequences are useful in studying the expression and
CC function of CYP2D6, and in expressing CYP2D6 protein for use in screening
CC drugs for the treatment of CYP2D6-associated diseases (e.g.,
CC hypertension, atrial and ventricular arrhythmias, Parkinson's disease,
CC and drug-induced lupus syndrome) or which are metabolised by CYP2D6.
CC CYP2D6 nucleic acids and proteins are also useful in studying the effect
CC of polymorphisms on the biological activity of CYP2D6. Polymorphisms in
CC the target region may be determined by the use of allele-specific
CC oligonucleotides (ASOs; ABQ72217-ABQ72303) as probes and primers, and by
CC primer extension using oligonucleotide primers comprising sequences
CC ABQ72304-ABQ72361. The method of the invention is useful for haplotyping
CC the CYP2D6 gene in populations and in individuals, enabling decisions to
CC be made as to whether CYP2D6 is a likely therapeutic target for a disease
CC of interest, and to control for genetically-based bias in the design of
CC drugs that target or are metabolised by CYP2D6. In addition, transgenic
CC animals comprising a human CYP2D6 gene are useful for studying the
CC expression of CYP2D6 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted to or metabolised by CYP2D6, and for testing the
CC efficacy of therapeutic agents and compounds for treating CYP2D6-
CC associated conditions in a biological system. Sequences ABQ72246-
CC ABQ72303 represent specifically claimed allele-specific oligonucleotide
CC (ASO) primers used for detecting polymorphisms in the CYP2D6 gene
XX
SQ Sequence 15 BP; 0 A; 8 C; 3 G; 3 T; 0 U; 1 Other;

Query Match 0.3%; Score 14.6; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy         10 GCGGCGCGAGCAGAG 24
              |:|||||||||||||
Db         15 GYGGCGCGAGCAGAG 1


RESULT 688
AAA29598
ID   AAA29598 standard; DNA; 17 BP.
XX
AC   AAA29598;
XX
DT   10-AUG-2000  (first entry)
XX
DE   Human insulin sense PCR primer.
XX
KW   Hormone dependent cancer; hormone independent cancer; hormonal drug;
KW   prostate cancer; breast cancer; cervical cancer; ovarian cancer;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200020034-A1.
XX
PD   13-APR-2000.
XX
PF   07-OCT-1999;   99WO-JP005533.
XX
PR   08-OCT-1998;   98JP-00286793.
XX
PA   (TAKE ) TAKEDA CHEM IND LTD.
XX
PI   Matsutani E,  Naito K;
XX
DR   WPI; 2000-303644/26.
XX
PT   Hormonal drug-containing agents for retarding conversion of hormone-
PT   dependent cancers into hormone-independent cancers, useful e.g. for
PT   treating prostate and breast cancers.
XX
PS   Example 1; Page 19; 31pp; Japanese.
XX
CC   The present invention describes a hormonal drug-containing agent (I) for
CC   retarding the conversion of a hormone-dependent cancer into a hormone-
CC   independent cancer. The agents can be used to treat prostate, breast,
CC   cervical and ovarian cancers and to make hormonal drugs for retarding the
CC   conversion of a hormone-dependent cancer into a hormone-independent
CC   cancer. The drug can retard the change of hormone-dependent cancers into
CC   hormone-independent cancers effectively. The present sequence represents
CC   a PCR primer which is used in an example from the present invention
XX
SQ   Sequence 17 BP; 2 A; 4 C; 4 G; 1 T; 0 U; 6 Other;

  Query Match             0.3%;  Score 14.6;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2587 CACCGAGACCTGGCTGC 2603
              ||::|:|||:|:||:||
Db          1 CAYMGRGACYTKGCWGC 17


RESULT 689
ADH23252
ID   ADH23252 standard; DNA; 17 BP.
XX
AC   ADH23252;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Degenerate sense PCR primer used to amplify the insulin receptor.
XX
KW   hormone dependent cancer; hormone; differentiation inducing agent;
KW   luteinising hormone-releasing hormone; LH-RH; fat soluble vitamin;
KW   prostate; ovarian; uterine; breast cancer; hormone independent cancer;
KW   anti-tumour; PCR; primer; ss; insulin receptor.
XX
OS   Synthetic.
OS   Unidentified.
XX
PN   JP2004002240-A.
XX
PD   08-JAN-2004.
XX
PF   31-MAY-2002; 2002JP-00160837.
XX
PR   31-MAY-2002; 2002JP-00160837.
XX
PA   (TAKE ) TAKEDA CHEM IND LTD.
XX
DR   WPI; 2004-113108/12.
XX
PT   Novel therapeutic agent of hormone dependent cancer, comprising hormone
PT   group, chemical agent and differentiation inducing agent, useful for
PT   treating hormone dependent cancer in mammal.
XX
PS   Example 1; Page 14; 15pp; Japanese.
XX
CC   This invention relates to a novel therapeutic agent for the treatment of
CC   hormone dependent cancer that comprises a hormone group chemical agent
CC   and a differentiation inducing agent. Specifically, the hormone group
CC   chemical agent refers to an agonist derived from the luteinising hormone-
CC   releasing hormone (LH-RH), whereas the differentiation inducing agent is
CC   preferably a fat soluble vitamin, or can be a nuclear receptor ligand,
CC   histone acetylation regulation drug or a DNA methylation regulation drug.
CC   The present invention describes using the LH-RH agonist as a preventative
CC   or therapeutic agent for hormone dependent prostate, ovarian, uterine or
CC   breast cancer, and can also delay change in hormone independent cancer.
CC   Accordingly, the compositions of the invention are described as
CC   exhibiting high anti-tumour activity. This oligonucleotide sequence is a
CC   degenerate PCR primer used to amplify the insulin receptor, in an
CC   exemplification of the invention.
XX
SQ   Sequence 17 BP; 2 A; 4 C; 4 G; 1 T; 0 U; 6 Other;

  Query Match             0.3%;  Score 14.6;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2587 CACCGAGACCTGGCTGC 2603
              ||::|:|||:|:||:||
Db          1 CAYMGRGACYTKGCWGC 17


RESULT 690
AAQ65268
ID   AAQ65268 standard; DNA; 16 BP.
XX
AC   AAQ65268;
XX
DT   23-DEC-1994  (first entry)
XX
DE   Antisense oligonucleotide complementary to Hepatitis C Virus genome.
XX
KW   Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
KW   inhibition; viral protein precursor; ss.
XX
OS   Synthetic.
XX
PN   CA2104649-A.
XX
PD   26-FEB-1994.
XX
PF   23-AUG-1993;   93CA-02104649.
XX
PR   25-AUG-1992;   92JP-00248796.
PR   03-MAR-1993;   93JP-00042736.
```

XX
PA (SEKI/) SEKI M.
XX
PI Seki M, Honda Y, Yamada E;
XX
DR WPI; 1994-151836/19.
XX
PT Anti:sense oligo:nucleotide(s) complementary to the hepatitis C virus
PT genome - are useful as antiviral agents.
XX
PS Claim 5; Page 218; 262pp; English.
XX
CC This oligonucleotide is an example of a preferred antisense compound i.e.
CC it has a base sequence of 15-30 bases which is included within the 49
CC bases from G at position 127 to C at position 175 of AAQ64913 and which
CC contains at least 7 bases from C at position 147 to C at position 153.
CC The antisense oligonucleotide is useful for inhibiting translation of HCV
CC genes
XX
SQ Sequence 16 BP; 1 A; 4 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 28 CTCCAGGGAGGGGGGG 43
|||| ||||||||||
Db 1 CTCCCGGGAGGGGGGG 16

RESULT 691
ADC13653/c
ID ADC13653 standard; DNA; 16 BP.
XX
AC ADC13653;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human NOVX reverse primer, SEQ ID No 138.
XX
KW NOVX; FADD interacting protein; ATPase; H+ Transporting; Lysosomal;
KW FGF 17; Single Pass Transmembrane; Beta-Ketoacyl Synthase; Neuralin 2;
KW Glutamate Receptor Interacting Protein 2; ChR-Methyltransferase;
KW NP25 Variant; GTPase-Activating Protein; ELKS; Sim2; RhoGAP;
KW Phospholipase; Scavenger Receptor Domain Containing Protein;
KW Metallothionein IA; NOGO receptor; FYVE; NOELIN;
KW Cyclin Regulatory Subunit; Tetratrico Peptide Repeat Protein;
KW Immunoglobulin Domain Containing Protein; PA Domain Containing Protein;
KW Phenylalanine; Histidine Ammonia-Lyase; Cellular Retinaldehyde-Binding;
KW Glutamine Repeat Containing Protein; TNF Receptor Associated Factor2;
KW Vacuolar Protein Sorting Homologue R-VPS33A;
KW Bola Domain Containing Protein; Neurotrophin Receptor;
KW RAL Guanine Nucleotide Dissociation Stimulator; Armadillo/Beta-Catenin;
KW Metalloprotease; T10 Ser/Thr-rich; Ring finger-like; cytostatic;
KW gene therapy; vaccine; cancer; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003004617-A2.
XX
PD 16-JAN-2003.
XX
PF 03-JUL-2002; 2002WO-US021359.
XX
PR 05-JUL-2001; 2001US-0303046P.
PR 09-JUL-2001; 2001US-0303828P.
PR 11-JUL-2001; 2001US-0304502P.
PR 12-JUL-2001; 2001US-0305011P.
PR 13-JUL-2001; 2001US-0305262P.
PR 17-JUL-2001; 2001US-0306085P.
PR 24-JUL-2001; 2001US-0307536P.
PR 27-JUL-2001; 2001US-0308228P.
PR 30-JUL-2001; 2001US-0308877P.
PR 01-AUG-2001; 2001US-0309255P.
PR 10-AUG-2001; 2001US-0311753P.
PR 19-SEP-2001; 2001US-0323449P.
PR 22-FEB-2002; 2002US-0358932P.
PR 05-MAR-2002; 2002US-0361765P.
PR 02-JUL-2002; 2002US-00188248.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Patturajan M, Gerlach VL, Anderson DW, Taupier RJ, Zerhusen BD;
PI Guo X, Casman SJ, Hjalt T, Miller CE, Kekuda R, Shimkets RA;
PI Malyankar UM, Zhong M, Padigaru M, Li L, Shenoy SG, Gorman L;
PI Edinger SR;
XX
DR WPI; 2003-201550/19.
XX
PT New NOVX polypeptide, useful for preparing a composition for treating or
PT preventing cancer.
XX
PS Example 37; Page 241; 393pp; English.
XX
CC The invention relates to a novel isolated NOVX polypeptide comprising: a
CC sequence of 57-1149 amino acids as defined in the specification, or its
CC mature form; a sequence that is at least 95% identical to the 57-1149
CC amino acid polypeptide; or a sequence comprising one or more conservative
CC substitutions in the 57-1149 amino acid polypeptide. The NOVX proteins of
CC the invention include the following protein families: FADD interacting
CC protein-like, ATPase, H+ Transporting, Lysosomal (vacuolar Proton Pump)-
CC like, FGF 17-like, Single Pass Transmembrane-like, Beta-Ketoacyl Synthase
CC -like, Neuralin 2-like, Glutamate Receptor Interacting Protein 2-like,
CC ChR-Methyltransferase-like, NP25 Variant-like, GTPase-Activating Protein-
CC like, ELKS-like, Sim2-like, RhoGAP-like, Phospholipase-like, Scavenger
CC Receptor Domain Containing Protein-like, Metallothionein IA-like, NOGO
CC receptor-like, FYVE-protein, NOELIN-like, Cyclin Regulatory Subunit-like,
CC Tetratrico Peptide Repeat Protein-like, Immunoglobulin Domain Containing
CC Protein-like, PA Domain Containing Protein-like, Phenylalanine and
CC Histidine Ammonia-Lyase-like, Cellular Retinaldehyde-Binding-like,
CC Glutamine Repeat Containing Protein-like, TNF Receptor Associated Factor2
CC -like, Vacuolar Protein Sorting Homologue R-VPS33A, Bola Domain
CC Containing Protein-like, Neurotrophin Receptor-like, RAL Guanine
CC Nucleotide Dissociation Stimulator-like, Armadillo/Beta-Catenin-like,
CC Metalloprotease-like, T10 Ser/Thr-rich-like, and Ring finger-like
CC protein. The NOVX proteins and the encoding polynucleotides have
CC cytostatic activity and can be used in gene therapy or a vaccine. The
CC NOVX polypeptide is useful for preparing a composition for treating or
CC preventing cancer. This polynucleotide sequence represents a reverse
CC primer of a gene encoding a NOVX protein of the invention.
XX
SQ Sequence 16 BP; 5 A; 7 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2019 TGTGGTCCTGGTCCTG 2034
||||||||||| ||||
Db 16 TGTGGTCCTGGGCCTG 1

RESULT 692
AEB18973
ID AEB18973 standard; DNA; 16 BP.
XX
AC AEB18973;
XX
DT 22-SEP-2005 (first entry)
XX
DE Human leukocyte antigen-DR allele probe SeqID749.
XX
KW human leukocyte antigen; hla; diagnostic; transplant rejection; cancer;
KW diabetes; ss; probe.
XX
OS Homo sapiens.

```
XX
PN   JP2005185171-A.
XX
PD   14-JUL-2005.
XX
PF   25-DEC-2003; 2003JP-00430553.
XX
PR   25-DEC-2003; 2003JP-00430553.
XX
PA   (CANO ) CANON KK.
XX
PI   Tsukada M;
XX
DR   WPI; 2005-483346/49.
XX
PT   Probe set for identifying human leukocyte antigen-DR allele in test
PT   sample of patients with e.g. cancer and diabetes, comprises probes
PT   corresponding to sequences such as DRB1.010101 or DRB1.0104.
XX
PS   Claim 2; SEQ ID NO 749; 87pp; Japanese.
XX
CC   This invention relates to a novel probe set for identifying a human
CC   leukocyte antigen (HLA)-DR allele in a test substance, which comprises
CC   probes with partial sequence containing base written in capital letter as
CC   fully defined in the HLA-DR allele list given in the specification. The
CC   invention is useful for identifying HLA-DR allele in a test sample. The
CC   probe set can identify HLA-DR alleles in patients with organ transplant,
CC   cancer, diabetes and other multiple-factor diseases, and enables
CC   provision of tailored medical treatment to individual patients. The
CC   present sequence is that of a probe which is a member of a novel probe
CC   set of the invention.
XX
SQ   Sequence 16 BP; 2 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 3.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1819 GTGCGGTTCCTGAAGA 1834
                ||||||||||||  |||
Db          1 GTGCGGTTCCTGGAGA 16


RESULT 693
AAQ65269
ID   AAQ65269 standard; DNA; 17 BP.
XX
AC   AAQ65269;
XX
DT   23-DEC-1994  (first entry)
XX
DE   Antisense oligonucleotide complementary to Hepatitis C Virus genome.
XX
KW   Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
KW   inhibition; viral protein precursor; ss.
XX
OS   Synthetic.
XX
PN   CA2104649-A.
XX
PD   26-FEB-1994.
XX
PF   23-AUG-1993;   93CA-02104649.
XX
PR   25-AUG-1992;   92JP-00248796.
PR   03-MAR-1993;   93JP-00042736.
XX
PA   (SEKI/) SEKI M.
XX
PI   Seki M,  Honda Y,  Yamada E;
XX
DR   WPI; 1994-151836/19.
XX
PT   Anti:sense oligo:nucleotide(s) complementary to the hepatitis C virus
PT   genome - are useful as antiviral agents.
XX
PS   Claim 5; Page 219; 262pp; English.
XX
CC   This oligonucleotide is an example of a preferred antisense compound i.e.
CC   it has a base sequence of 15-30 bases which is included within the 49
CC   bases from G at position 127 to C at position 175 of AAQ64913 and which
CC   contains at least 7 bases from C at position 147 to C at position 153.
CC   The antisense oligonucleotide is useful for inhibiting translation of HCV
CC   genes
XX
SQ   Sequence 17 BP; 1 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         28 CTCCAGGGAGGGGGGG 43
              |||| ||||||||||
Db          2 CTCCCGGGAGGGGGGG 17


RESULT 694
AAQ65253
ID   AAQ65253 standard; DNA; 17 BP.
XX
AC   AAQ65253;
XX
DT   21-DEC-1994  (first entry)
XX
DE   Antisense oligonucleotide complementary to Hepatitis C Virus genome.
XX
KW   Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
KW   inhibition; viral protein precursor; ss.
XX
OS   Synthetic.
XX
PN   CA2104649-A.
XX
PD   26-FEB-1994.
XX
PF   23-AUG-1993;   93CA-02104649.
XX
PR   25-AUG-1992;   92JP-00248796.
PR   03-MAR-1993;   93JP-00042736.
XX
PA   (SEKI/) SEKI M.
XX
PI   Seki M,  Honda Y,  Yamada E;
XX
DR   WPI; 1994-151836/19.
XX
PT   Anti:sense oligo:nucleotide(s) complementary to the hepatitis C virus
PT   genome - are useful as antiviral agents.
XX
PS   Claim 5; Page 212; 262pp; English.
XX
CC   This oligonucleotide is an example of a preferred antisense compound i.e.
CC   it has a base sequence of 15-30 bases which is included within the 49
CC   bases from G at position 127 to C at position 175 of AAQ64913 and which
CC   contains at least 7 bases from C at position 147 to C at position 153.
CC   The antisense oligonucleotide is useful for inhibiting translation of HCV
CC   genes
XX
SQ   Sequence 17 BP; 1 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         28 CTCCAGGGAGGGGGGG 43
              |||| ||||||||||
```

```
Db          1 CTCCCGGGAGGGGGGG 16


RESULT 695
AAV92592
ID   AAV92592 standard; RNA; 17 BP.
XX
AC   AAV92592;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human A-Raf substrate position 1873.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T,  Matulic-Adamic J,  Reynolds M,  Kisich K,  Bellon L;
PI   Parry T,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Burgin A;
PI   Thompson J,  Workman CT,  Beaudry A,  Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 160; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 2 A; 10 C; 2 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2967 GCCCCGCTTCCCCCAG 2982
              ||||| |::|||||||
Db          1 GCCCCUCUUCCCCCAG 16


RESULT 696
AAF06057
ID   AAF06057 standard; DNA; 17 BP.
XX
AC   AAF06057;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #2854.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 121; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 6 A; 5 C; 1 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 3.9e+02;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1567 CCTGACTTCACCTATA 1582
              ||:|||::|| |:|:|
Db          1 CCUGACUUCAACUAUA 16


RESULT 697
AAF02029
ID   AAF02029 standard; DNA; 17 BP.
XX
AC   AAF02029;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #324.
```

```
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 63; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3059 CACACCCTCTCCTGGA 3074
              ||| ||||||||||||
Db          1 CACCCCCTCTCCTGGA 16


RESULT 698
ADV06123
ID   ADV06123 standard; RNA; 17 BP.
XX
AC   ADV06123;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Human BACE DNAzyme substrate sequence #287.
XX
KW   Enzymatic nucleic acid molecule; gene expression; down regulation;
KW   protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW   MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW   beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW   c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW   hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW   amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW   diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW   hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO200116312-A2.
XX
PD   08-MAR-2001.
XX
PF   30-AUG-2000; 2000WO-US023998.
XX
PR   31-AUG-1999;   99US-0151713P.
PR   27-SEP-1999;   99US-00406643.
PR   27-SEP-1999;   99US-0156236P.
PR   27-SEP-1999;   99US-0156467P.
PR   08-NOV-1999;   99US-00436430.
PR   06-DEC-1999;   99US-0169100P.
PR   29-DEC-1999;   99US-00474432.
PR   29-DEC-1999;   99US-0173612P.
PR   30-DEC-1999;   99US-00476387.
PR   04-FEB-2000; 2000US-00498824.
PR   20-MAR-2000; 2000US-00531025.
PR   14-APR-2000; 2000US-0197769P.
PR   23-MAY-2000; 2000US-00578223.
PR   09-AUG-2000; 2000US-00636385.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Usman N,  Blatt L,  Beigelman L,  Burgin A;
PI   Karpeisky A,  Matulic-Adamic J,  Sweedler D,  Draper K,  Chowrira B;
PI   Stinchcomb D,  Beaudry A,  Zinnen S,  Lugwig J,  Sproat BS;
XX
DR   WPI; 2001-244406/25.
XX
PT   Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT   are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT   obesity and heart disease.
XX
PS   Example 4; Page 382; 717pp; English.
XX
CC   The present invention relates to the use of enzymatic nucleic acid
CC   molecules (e.g. ribozymes) to modulate gene expression. The invention
CC   also methods for their use to down regulate or inhibit the expression of
CC   genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC   aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC   alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC   receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC   presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC   nucleic acid molecules used to inhibit the expression of the said genes
CC   include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC   zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC   for treating cancer, in particular breast cancer, Alzheimer's disease,
CC   diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC   diseases, hepatitis B infections, and hepatitis and hepatocellular
CC   carcinoma. The enzymatic nucleic acid molecules can also be used as
CC   diagnostic tools to examine genetic drift and mutations within diseased
CC   cells and to detect the presence of specific RNA in a cell. The present
CC   sequence represents a substrate/target sequence for a DNAzyme used in the
CC   examples of the present invention. Note: Some SEQ ID Nos are repeated
CC   more than once in the specification, but these have different sequences
CC   associated with them.
XX
SQ   Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3702 GGGGGCTGTCCCAGGG 3717
              ||||||:| |||||||
Db          1 GGGGGCUGGCCCAGGG 16


RESULT 699
ADU94065
ID   ADU94065 standard; DNA; 17 BP.
XX
AC   ADU94065;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Human TERT NCH ribozyme substrate sequence #888.
```

```
XX
KW   Enzymatic nucleic acid molecule; gene expression; down regulation;
KW   protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW   MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW   beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW   c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW   hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW   amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW   diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW   hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW   ds.
XX
OS   Homo sapiens.
XX
PN   WO200116312-A2.
XX
PD   08-MAR-2001.
XX
PF   30-AUG-2000; 2000WO-US023998.
XX
PR   31-AUG-1999;   99US-0151713P.
PR   27-SEP-1999;   99US-00406643.
PR   27-SEP-1999;   99US-0156236P.
PR   27-SEP-1999;   99US-0156467P.
PR   08-NOV-1999;   99US-00436430.
PR   06-DEC-1999;   99US-0169100P.
PR   29-DEC-1999;   99US-00474432.
PR   29-DEC-1999;   99US-0173612P.
PR   30-DEC-1999;   99US-00476387.
PR   04-FEB-2000; 2000US-00498824.
PR   20-MAR-2000; 2000US-00531025.
PR   14-APR-2000; 2000US-0197769P.
PR   23-MAY-2000; 2000US-00578223.
PR   09-AUG-2000; 2000US-00636385.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Usman N,  Blatt L,  Beigelman L,  Burgin A;
PI   Karpeisky A,  Matulic-Adamic J,  Sweedler D,  Draper K,  Chowrira B;
PI   Stinchcomb D,  Beaudry A,  Zinnen S,  Lugwig J,  Sproat BS;
XX
DR   WPI; 2001-244406/25.
XX
PT   Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT   are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT   obesity and heart disease.
XX
PS   Example 1; Page 294; 717pp; English.
XX
CC   The present invention relates to the use of enzymatic nucleic acid
CC   molecules (e.g. ribozymes) to modulate gene expression. The invention
CC   also methods for their use to down regulate or inhibit the expression of
CC   genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC   aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC   alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC   receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC   presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC   nucleic acid molecules used to inhibit the expression of the said genes
CC   include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC   zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC   for treating cancer, in particular breast cancer, Alzheimer's disease,
CC   diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC   diseases, hepatitis B infections, and hepatitis and hepatocellular
CC   carcinoma. The enzymatic nucleic acid molecules can also be used as
CC   diagnostic tools to examine genetic drift and mutations within diseased
CC   cells and to detect the presence of specific RNA in a cell. The present
CC   sequence represents a substrate/target sequence for a ribozyme used in
CC   the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC   more than once in the specification, but these have different sequences
CC   associated with them.
XX
SQ   Sequence 17 BP; 2 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2733 GACTGCCCCGGAGGCC 2748
              ||||||| |||||||
Db          1 GACTGCCCTGGAGGCC 16


RESULT 700
ADV00664
ID   ADV00664 standard; DNA; 17 BP.
XX
AC   ADV00664;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Human TERT DNAzyme substrate sequence #214.
XX
KW   Enzymatic nucleic acid molecule; gene expression; down regulation;
KW   protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW   MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW   beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW   c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW   hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW   amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW   diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW   hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW   ds.
XX
OS   Homo sapiens.
XX
PN   WO200116312-A2.
XX
PD   08-MAR-2001.
XX
PF   30-AUG-2000; 2000WO-US023998.
XX
PR   31-AUG-1999;   99US-0151713P.
PR   27-SEP-1999;   99US-00406643.
PR   27-SEP-1999;   99US-0156236P.
PR   27-SEP-1999;   99US-0156467P.
PR   08-NOV-1999;   99US-00436430.
PR   06-DEC-1999;   99US-0169100P.
PR   29-DEC-1999;   99US-00474432.
PR   29-DEC-1999;   99US-0173612P.
PR   30-DEC-1999;   99US-00476387.
PR   04-FEB-2000; 2000US-00498824.
PR   20-MAR-2000; 2000US-00531025.
PR   14-APR-2000; 2000US-0197769P.
PR   23-MAY-2000; 2000US-00578223.
PR   09-AUG-2000; 2000US-00636385.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Usman N,  Blatt L,  Beigelman L,  Burgin A;
PI   Karpeisky A,  Matulic-Adamic J,  Sweedler D,  Draper K,  Chowrira B;
PI   Stinchcomb D,  Beaudry A,  Zinnen S,  Lugwig J,  Sproat BS;
XX
DR   WPI; 2001-244406/25.
XX
PT   Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT   are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT   obesity and heart disease.
XX
PS   Example 1; Page 319; 717pp; English.
XX
CC   The present invention relates to the use of enzymatic nucleic acid
CC   molecules (e.g. ribozymes) to modulate gene expression. The invention
CC   also methods for their use to down regulate or inhibit the expression of
CC   genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC   aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC   alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
```

```
CC   receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC   presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC   nucleic acid molecules used to inhibit the expression of the said genes
CC   include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC   zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC   for treating cancer, in particular breast cancer, Alzheimer's disease,
CC   diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC   diseases, hepatitis B infections, and hepatitis and hepatocellular
CC   carcinoma. The enzymatic nucleic acid molecules can also be used as
CC   diagnostic tools to examine genetic drift and mutations within diseased
CC   cells and to detect the presence of specific RNA in a cell. The present
CC   sequence represents a substrate/target sequence for a DNAzyme used in the
CC   examples of the present invention. Note: Some SEQ ID Nos are repeated
CC   more than once in the specification, but these have different sequences
CC   associated with them.
XX
SQ   Sequence 17 BP; 3 A; 7 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         72 CCACCCGGGGCGGGAC 87
              ||||||||||| ||||
Db          1 CCACCCGGGGCAGGAC 16


RESULT 701
ADM89524/c
ID   ADM89524 standard; DNA; 17 BP.
XX
AC   ADM89524;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Human PTP-1B NCH ribozyme substrate sequence #390.
XX
KW   Enzymatic nucleic acid molecule; gene expression; down regulation;
KW   protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW   MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW   beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW   c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW   hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW   amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW   diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW   hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW   ds.
XX
OS   Homo sapiens.
XX
PN   WO200116312-A2.
XX
PD   08-MAR-2001.
XX
PF   30-AUG-2000; 2000WO-US023998.
XX
PR   31-AUG-1999;   99US-0151713P.
PR   27-SEP-1999;   99US-00406643.
PR   27-SEP-1999;   99US-0156236P.
PR   27-SEP-1999;   99US-0156467P.
PR   08-NOV-1999;   99US-00436430.
PR   06-DEC-1999;   99US-0169100P.
PR   29-DEC-1999;   99US-00474432.
PR   29-DEC-1999;   99US-0173612P.
PR   30-DEC-1999;   99US-00476387.
PR   04-FEB-2000; 2000US-00498824.
PR   20-MAR-2000; 2000US-00531025.
PR   14-APR-2000; 2000US-0197769P.
PR   23-MAY-2000; 2000US-00578223.
PR   09-AUG-2000; 2000US-00636385.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Usman N,  Blatt L,  Beigelman L,  Burgin A;
PI   Karpeisky A,  Matulic-Adamic J,  Sweedler D,  Draper K,  Chowrira B;
PI   Stinchcomb D,  Beaudry A,  Zinnen S,  Lugwig J,  Sproat BS;
XX
DR   WPI; 2001-244406/25.
XX
PT   Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT   are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT   obesity and heart disease.
XX
PS   Example 2; Page 200; 717pp; English.
XX
CC   The present invention relates to the use of enzymatic nucleic acid
CC   molecules (e.g. ribozymes) to modulate gene expression. The invention
CC   also methods for their use to down regulate or inhibit the expression of
CC   genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC   aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC   alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC   receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC   presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC   nucleic acid molecules used to inhibit the expression of the said genes
CC   include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC   zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC   for treating cancer, in particular breast cancer, Alzheimer's disease,
CC   diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC   diseases, hepatitis B infections, and hepatitis and hepatocellular
CC   carcinoma. The enzymatic nucleic acid molecules can also be used as
CC   diagnostic tools to examine genetic drift and mutations within diseased
CC   cells and to detect the presence of specific RNA in a cell. The present
CC   sequence represents a substrate/target sequence for a ribozyme used in
CC   the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC   more than once in the specification, but these have different sequences
CC   associated with them.
XX
SQ   Sequence 17 BP; 2 A; 10 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1536 GGAGCCCTGGGTGGTG 1551
              ||||||||||||||  |
Db         17 GGAGCCCTGGGTGGGG 2


RESULT 702
ADM89525/c
ID   ADM89525 standard; DNA; 17 BP.
XX
AC   ADM89525;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Human PTP-1B NCH ribozyme substrate sequence #391.
XX
KW   Enzymatic nucleic acid molecule; gene expression; down regulation;
KW   protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW   MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW   beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW   c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW   hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW   amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW   diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW   hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW   ds.
XX
OS   Homo sapiens.
XX
PN   WO200116312-A2.
XX
PD   08-MAR-2001.
XX
PF   30-AUG-2000; 2000WO-US023998.
```

```
XX
PR   31-AUG-1999;   99US-0151713P.
PR   27-SEP-1999;   99US-00406643.
PR   27-SEP-1999;   99US-0156236P.
PR   27-SEP-1999;   99US-0156467P.
PR   08-NOV-1999;   99US-00436430.
PR   06-DEC-1999;   99US-0169100P.
PR   29-DEC-1999;   99US-00474432.
PR   29-DEC-1999;   99US-0173612P.
PR   30-DEC-1999;   99US-00476387.
PR   04-FEB-2000; 2000US-00498824.
PR   20-MAR-2000; 2000US-00531025.
PR   14-APR-2000; 2000US-0197769P.
PR   23-MAY-2000; 2000US-00578223.
PR   09-AUG-2000; 2000US-00636385.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Usman N,  Blatt L,  Beigelman L,  Burgin A;
PI   Karpeisky A,  Matulic-Adamic J,  Sweedler D,  Draper K,  Chowrira B;
PI   Stinchcomb D,  Beaudry A,  Zinnen S,  Lugwig J,  Sproat BS;
XX
DR   WPI; 2001-244406/25.
XX
PT   Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT   are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT   obesity and heart disease.
XX
PS   Example 2; Page 200; 717pp; English.
XX
CC   The present invention relates to the use of enzymatic nucleic acid
CC   molecules (e.g. ribozymes) to modulate gene expression. The invention
CC   also methods for their use to down regulate or inhibit the expression of
CC   genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC   aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC   alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC   receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC   presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC   nucleic acid molecules used to inhibit the expression of the said genes
CC   include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC   zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC   for treating cancer, in particular breast cancer, Alzheimer's disease,
CC   diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC   diseases, hepatitis B infections, and hepatitis and hepatocellular
CC   carcinoma. The enzymatic nucleic acid molecules can also be used as
CC   diagnostic tools to examine genetic drift and mutations within diseased
CC   cells and to detect the presence of specific RNA in a cell. The present
CC   sequence represents a substrate/target sequence for a ribozyme used in
CC   the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC   more than once in the specification, but these have different sequences
CC   associated with them.
XX
SQ   Sequence 17 BP; 2 A; 11 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1536 GGAGCCCTGGGTGGTG 1551
              ||||||||||||||| |
Db         16 GGAGCCCTGGGTGGGG 1


RESULT 703
ADV07544
ID   ADV07544 standard; RNA; 17 BP.
XX
AC   ADV07544;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Human BACE amberzyme ribozyme substrate sequence #425.
XX
KW   Enzymatic nucleic acid molecule; gene expression; down regulation;
KW   protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW   MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW   beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW   c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW   hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW   amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW   diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW   hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO200116312-A2.
XX
PD   08-MAR-2001.
XX
PF   30-AUG-2000; 2000WO-US023998.
XX
PR   31-AUG-1999;   99US-0151713P.
PR   27-SEP-1999;   99US-00406643.
PR   27-SEP-1999;   99US-0156236P.
PR   27-SEP-1999;   99US-0156467P.
PR   08-NOV-1999;   99US-00436430.
PR   06-DEC-1999;   99US-0169100P.
PR   29-DEC-1999;   99US-00474432.
PR   29-DEC-1999;   99US-0173612P.
PR   30-DEC-1999;   99US-00476387.
PR   04-FEB-2000; 2000US-00498824.
PR   20-MAR-2000; 2000US-00531025.
PR   14-APR-2000; 2000US-0197769P.
PR   23-MAY-2000; 2000US-00578223.
PR   09-AUG-2000; 2000US-00636385.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Usman N,  Blatt L,  Beigelman L,  Burgin A;
PI   Karpeisky A,  Matulic-Adamic J,  Sweedler D,  Draper K,  Chowrira B;
PI   Stinchcomb D,  Beaudry A,  Zinnen S,  Lugwig J,  Sproat BS;
XX
DR   WPI; 2001-244406/25.
XX
PT   Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT   are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT   obesity and heart disease.
XX
PS   Example 4; Page 401; 717pp; English.
XX
CC   The present invention relates to the use of enzymatic nucleic acid
CC   molecules (e.g. ribozymes) to modulate gene expression. The invention
CC   also methods for their use to down regulate or inhibit the expression of
CC   genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC   aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC   alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC   receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC   presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC   nucleic acid molecules used to inhibit the expression of the said genes
CC   include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC   zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC   for treating cancer, in particular breast cancer, Alzheimer's disease,
CC   diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC   diseases, hepatitis B infections, and hepatitis and hepatocellular
CC   carcinoma. The enzymatic nucleic acid molecules can also be used as
CC   diagnostic tools to examine genetic drift and mutations within diseased
CC   cells and to detect the presence of specific RNA in a cell. The present
CC   sequence represents a substrate/target sequence for a ribozyme used in
CC   the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC   more than once in the specification, but these have different sequences
CC   associated with them.
XX
SQ   Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
```

```
  Best Local Similarity   87.5%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3702 GGGGGCTGTCCCAGGG 3717
              ||||||:| |||||||
Db          2 GGGGGCUGGCCCAGGG 17


RESULT 704
ADV01226/c
ID   ADV01226 standard; DNA; 17 BP.
XX
AC   ADV01226;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Human TERT DNAzyme substrate sequence #497.
XX
KW   Enzymatic nucleic acid molecule; gene expression; down regulation;
KW   protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW   MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW   beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW   c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW   hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW   amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW   diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW   hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW   ds.
XX
OS   Homo sapiens.
XX
PN   WO200116312-A2.
XX
PD   08-MAR-2001.
XX
PF   30-AUG-2000; 2000WO-US023998.
XX
PR   31-AUG-1999;   99US-0151713P.
PR   27-SEP-1999;   99US-00406643.
PR   27-SEP-1999;   99US-0156236P.
PR   27-SEP-1999;   99US-0156467P.
PR   08-NOV-1999;   99US-00436430.
PR   06-DEC-1999;   99US-0169100P.
PR   29-DEC-1999;   99US-00474432.
PR   29-DEC-1999;   99US-0173612P.
PR   30-DEC-1999;   99US-00476387.
PR   04-FEB-2000; 2000US-00498824.
PR   20-MAR-2000; 2000US-00531025.
PR   14-APR-2000; 2000US-0197769P.
PR   23-MAY-2000; 2000US-00578223.
PR   09-AUG-2000; 2000US-00636385.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Usman N,  Blatt L,  Beigelman L,  Burgin A;
PI   Karpeisky A,  Matulic-Adamic J,  Sweedler D,  Draper K,  Chowrira B;
PI   Stinchcomb D,  Beaudry A,  Zinnen S,  Lugwig J,  Sproat BS;
XX
DR   WPI; 2001-244406/25.
XX
PT   Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT   are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT   obesity and heart disease.
XX
PS   Example 1; Page 328; 717pp; English.
XX
CC   The present invention relates to the use of enzymatic nucleic acid
CC   molecules (e.g. ribozymes) to modulate gene expression. The invention
CC   also methods for their use to down regulate or inhibit the expression of
CC   genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC   aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC   alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC   receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC   presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC   nucleic acid molecules used to inhibit the expression of the said genes
CC   include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC   zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC   for treating cancer, in particular breast cancer, Alzheimer's disease,
CC   diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC   diseases, hepatitis B infections, and hepatitis and hepatocellular
CC   carcinoma. The enzymatic nucleic acid molecules can also be used as
CC   diagnostic tools to examine genetic drift and mutations within diseased
CC   cells and to detect the presence of specific RNA in a cell. The present
CC   sequence represents a substrate/target sequence for a DNAzyme used in the
CC   examples of the present invention. Note: Some SEQ ID Nos are repeated
CC   more than once in the specification, but these have different sequences
CC   associated with them.
XX
SQ   Sequence 17 BP; 1 A; 6 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        211 GGCGCCGCCGCCCGGT 226
              ||||||||||||||| |
Db         17 GGCGCCGCCGCCCGCT 2


RESULT 705
ADU94064
ID   ADU94064 standard; DNA; 17 BP.
XX
AC   ADU94064;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Human TERT NCH ribozyme substrate sequence #887.
XX
KW   Enzymatic nucleic acid molecule; gene expression; down regulation;
KW   protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW   MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW   beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW   c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW   hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW   amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW   diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW   hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW   ds.
XX
OS   Homo sapiens.
XX
PN   WO200116312-A2.
XX
PD   08-MAR-2001.
XX
PF   30-AUG-2000; 2000WO-US023998.
XX
PR   31-AUG-1999;   99US-0151713P.
PR   27-SEP-1999;   99US-00406643.
PR   27-SEP-1999;   99US-0156236P.
PR   27-SEP-1999;   99US-0156467P.
PR   08-NOV-1999;   99US-00436430.
PR   06-DEC-1999;   99US-0169100P.
PR   29-DEC-1999;   99US-00474432.
PR   29-DEC-1999;   99US-0173612P.
PR   30-DEC-1999;   99US-00476387.
PR   04-FEB-2000; 2000US-00498824.
PR   20-MAR-2000; 2000US-00531025.
PR   14-APR-2000; 2000US-0197769P.
PR   23-MAY-2000; 2000US-00578223.
PR   09-AUG-2000; 2000US-00636385.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Usman N,  Blatt L,  Beigelman L,  Burgin A;
```

```
PI   Karpeisky A,  Matulic-Adamic J,  Sweedler D,  Draper K,  Chowrira B;
PI   Stinchcomb D,  Beaudry A,  Zinnen S,  Lugwig J,  Sproat BS;
XX
DR   WPI; 2001-244406/25.
XX
PT   Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT   are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT   obesity and heart disease.
XX
PS   Example 1; Page 294; 717pp; English.
XX
CC   The present invention relates to the use of enzymatic nucleic acid
CC   molecules (e.g. ribozymes) to modulate gene expression. The invention
CC   also methods for their use to down regulate or inhibit the expression of
CC   genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC   aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC   alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC   receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC   presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC   nucleic acid molecules used to inhibit the expression of the said genes
CC   include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC   zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC   for treating cancer, in particular breast cancer, Alzheimer's disease,
CC   diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC   diseases, hepatitis B infections, and hepatitis and hepatocellular
CC   carcinoma. The enzymatic nucleic acid molecules can also be used as
CC   diagnostic tools to examine genetic drift and mutations within diseased
CC   cells and to detect the presence of specific RNA in a cell. The present
CC   sequence represents a substrate/target sequence for a ribozyme used in
CC   the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC   more than once in the specification, but these have different sequences
CC   associated with them.
XX
SQ   Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2733 GACTGCCCCGGAGGCC 2748
              ||||||||  |||||||
Db          2 GACTGCCCTGGAGGCC 17


RESULT 706
ADV05221
ID   ADV05221 standard; RNA; 17 BP.
XX
AC   ADV05221;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Human BACE zinzyme ribozyme substrate sequence #163.
XX
KW   Enzymatic nucleic acid molecule; gene expression; down regulation;
KW   protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW   MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW   beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW   c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW   hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW   amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW   diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW   hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO200116312-A2.
XX
PD   08-MAR-2001.
XX
PF   30-AUG-2000; 2000WO-US023998.
XX
PR   31-AUG-1999;   99US-0151713P.
PR   27-SEP-1999;   99US-00406643.
PR   27-SEP-1999;   99US-0156236P.
PR   27-SEP-1999;   99US-0156467P.
PR   08-NOV-1999;   99US-00436430.
PR   06-DEC-1999;   99US-0169100P.
PR   29-DEC-1999;   99US-00474432.
PR   29-DEC-1999;   99US-0173612P.
PR   30-DEC-1999;   99US-00476387.
PR   04-FEB-2000; 2000US-00498824.
PR   20-MAR-2000; 2000US-00531025.
PR   14-APR-2000; 2000US-0197769P.
PR   23-MAY-2000; 2000US-00578223.
PR   09-AUG-2000; 2000US-00636385.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Usman N,  Blatt L,  Beigelman L,  Burgin A;
PI   Karpeisky A,  Matulic-Adamic J,  Sweedler D,  Draper K,  Chowrira B;
PI   Stinchcomb D,  Beaudry A,  Zinnen S,  Lugwig J,  Sproat BS;
XX
DR   WPI; 2001-244406/25.
XX
PT   Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT   are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT   obesity and heart disease.
XX
PS   Example 4; Page 373; 717pp; English.
XX
CC   The present invention relates to the use of enzymatic nucleic acid
CC   molecules (e.g. ribozymes) to modulate gene expression. The invention
CC   also methods for their use to down regulate or inhibit the expression of
CC   genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC   aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC   alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC   receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC   presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC   nucleic acid molecules used to inhibit the expression of the said genes
CC   include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC   zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC   for treating cancer, in particular breast cancer, Alzheimer's disease,
CC   diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC   diseases, hepatitis B infections, and hepatitis and hepatocellular
CC   carcinoma. The enzymatic nucleic acid molecules can also be used as
CC   diagnostic tools to examine genetic drift and mutations within diseased
CC   cells and to detect the presence of specific RNA in a cell. The present
CC   sequence represents a substrate/target sequence for a ribozyme used in
CC   the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC   more than once in the specification, but these have different sequences
CC   associated with them.
XX
SQ   Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3702 GGGGGCTGTCCCAGGG 3717
              ||||||:| |||||||
Db          1 GGGGGCUGGCCCAGGG 16


RESULT 707
ADV07126
ID   ADV07126 standard; RNA; 17 BP.
XX
AC   ADV07126;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Human BACE amberzyme ribozyme substrate sequence #211.
XX
KW   Enzymatic nucleic acid molecule; gene expression; down regulation;
```

```
KW   protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW   MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW   beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW   c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW   hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW   amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW   diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW   hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO200116312-A2.
XX
PD   08-MAR-2001.
XX
PF   30-AUG-2000; 2000WO-US023998.
XX
PR   31-AUG-1999;   99US-0151713P.
PR   27-SEP-1999;   99US-00406643.
PR   27-SEP-1999;   99US-0156236P.
PR   27-SEP-1999;   99US-0156467P.
PR   08-NOV-1999;   99US-00436430.
PR   06-DEC-1999;   99US-0169100P.
PR   29-DEC-1999;   99US-00474432.
PR   29-DEC-1999;   99US-0173612P.
PR   30-DEC-1999;   99US-00476387.
PR   04-FEB-2000; 2000US-00498824.
PR   20-MAR-2000; 2000US-00531025.
PR   14-APR-2000; 2000US-0197769P.
PR   23-MAY-2000; 2000US-00578223.
PR   09-AUG-2000; 2000US-00636385.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Usman N,  Blatt L,  Beigelman L,  Burgin A;
PI   Karpeisky A,  Matulic-Adamic J,  Sweedler D,  Draper K,  Chowrira B;
PI   Stinchcomb D,  Beaudry A,  Zinnen S,  Lugwig J,  Sproat BS;
XX
DR   WPI; 2001-244406/25.
XX
PT   Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT   are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT   obesity and heart disease.
XX
PS   Example 4; Page 395; 717pp; English.
XX
CC   The present invention relates to the use of enzymatic nucleic acid
CC   molecules (e.g. ribozymes) to modulate gene expression. The invention
CC   also methods for their use to down regulate or inhibit the expression of
CC   genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC   aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC   alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC   receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC   presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC   nucleic acid molecules used to inhibit the expression of the said genes
CC   include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC   zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC   for treating cancer, in particular breast cancer, Alzheimer's disease,
CC   diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC   diseases, hepatitis B infections, and hepatitis and hepatocellular
CC   carcinoma. The enzymatic nucleic acid molecules can also be used as
CC   diagnostic tools to examine genetic drift and mutations within diseased
CC   cells and to detect the presence of specific RNA in a cell. The present
CC   sequence represents a substrate/target sequence for a ribozyme used in
CC   the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC   more than once in the specification, but these have different sequences
CC   associated with them.
XX
SQ   Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.9e+02;
    Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3702 GGGGGCTGTCCCAGGG 3717
              ||||||:| |||||||
Db          1 GGGGGCUGGCCCAGGG 16


RESULT 708
ABN02655
ID   ABN02655 standard; DNA; 17 BP.
XX
AC   ABN02655;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2647.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2647; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
```

```
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1222 GGGTCCTGCCAGCCAT 1237
              |||||||| |||||||
Db          2 GGGTCCTGGCAGCCAT 17


RESULT 709
ABN01663/c
ID   ABN01663 standard; DNA; 17 BP.
XX
AC   ABN01663;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1655.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 1655; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 4 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3965 CTATGGCCTCCTTTGC 3980
              || |||||||||||||
Db         16 CTCTGGCCTCCTTTGC 1


RESULT 710
ABN02656
ID   ABN02656 standard; DNA; 17 BP.
XX
AC   ABN02656;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2648.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
```

```
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2648; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1222 GGGTCCTGCCAGCCAT 1237
              ||||||||.|||||||
Db          1 GGGTCCTGGCAGCCAT 16


RESULT 711
ABN00913
ID   ABN00913 standard; DNA; 17 BP.
XX
AC   ABN00913;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:905.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 905; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4056 GCCTGGGACCCCCAAG 4071
              || |||||||||||||
Db          2 GCTTGGGACCCCCAAG 17


RESULT 712
ABN00914
ID   ABN00914 standard; DNA; 17 BP.
XX
AC   ABN00914;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:906.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
```

```
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 906; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4056 GCCTGGGACCCCCAAG 4071
              || |||||||||||||
Db          1 GCTTGGGACCCCCAAG 16


RESULT 713
ABQ63402/c
ID   ABQ63402 standard; DNA; 17 BP.
XX
AC   ABQ63402;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 115.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 172; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 2 A; 2 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4040 CACATCCCCGGACCCC 4055
              |||||||||||||  ||
Db         17 CACATCCCCGGACTCC 2


RESULT 714
ABQ63404/c
ID   ABQ63404 standard; DNA; 17 BP.
XX
AC   ABQ63404;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 117.
XX
```

```
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 173; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 2 A; 2 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4039 CCACATCCCCGGACCC 4054
              ||||||||||||||| |
Db         16 CCACATCCCCGGACTC 1


RESULT 715
ABL31121
ID   ABL31121 standard; DNA; 17 BP.
XX
AC   ABL31121;
XX
DT   21-MAR-2002  (first entry)
XX
DE   Human HLA genotyping oligonucleotide SEQ ID NO 610.
XX
KW   Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW   immunogenetic; transplantation; genetic disease; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192572-A1.
XX
PD   06-DEC-2001.
XX
PF   01-JUN-2001; 2001WO-JP004662.
XX
PR   01-JUN-2000; 2000JP-00164798.
XX
PA   (NISN ) NISSHINBO IND INC.
PA   (SYST-) SYSTEM RES INC.
XX
PI   Inoko H,  Kagiya T,  Ichihara T,  Matsumura Y,  Moriya S,  Nishida M;
XX
DR   WPI; 2002-122074/16.
XX
PT   Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
PT   individuals e.g. by determining immunogenetic differences when
PT   transplanting between them.
XX
PS   Claim 10; Page 209; 345pp; Japanese.
XX
CC   The invention relates to a typing kit for judging human leukocyte antigen
CC   (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC   oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC   genes e.g. belonging to HLA class I antigens on human genome and
CC   containing gene polymorphisms as alloantigens have been immobilised as
CC   primers for amplification of cleaved nucleic acids relating to gene
CC   polymorphisms. The method is useful for judging HLA genotypes of
CC   individuals by determining immunogenetic differences before transplanting
CC   between them, providing genetic information to decide compatibility of
CC   organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC   pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC   diagnosis of genetic diseases and identifying individuals
XX
SQ   Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1819 GTGCGGTTCCTGAAGA 1834
              |||||||||||| |||
Db          1 GTGCGGTTCCTGGAGA 16


RESULT 716
ACN04226/c
ID   ACN04226 standard; RNA; 17 BP.
XX
AC   ACN04226;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Zinzyme substrate SEQ ID NO 4229.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
```

PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 4229; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;

```
  Query Match              0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2054 TTCTCTGCCTCAGGAA 2069
                ||||||| ||||||||
Db         17 TTCTCTGGCTCAGGAA 2
```

RESULT 717
ACN12772
ID ACN12772 standard; RNA; 17 BP.
XX
AC ACN12772;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Zinzyme substrate SEQ ID NO 12775.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 12775; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;

```
  Query Match              0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 3.9e+02;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2054 TTCTCTGCCTCAGGAA 2069
                ::|:|:| |:||||||
Db          2 UUCUCUGGCUCAGGAA 17
```

RESULT 718
ACN13224/c
ID ACN13224 standard; RNA; 17 BP.
XX
AC ACN13224;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Zinzyme substrate SEQ ID NO 13227.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.

```
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 13227; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3228 AGTCACTCTGGCGGGA 3243
              |||||| |||||||||
Db         16 AGTCACACTGGCGGGA 1


RESULT 719
ACN05992
ID   ACN05992 standard; RNA; 17 BP.
XX
AC   ACN05992;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Amberzyme substrate SEQ ID NO 5995.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 5995; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3229 GTCACTCTGGCGGGAC 3244
              |:||| |:||||||||
Db          1 GUCACACUGGCGGGAC 16


RESULT 720
ACN11464/c
ID   ACN11464 standard; RNA; 17 BP.
XX
AC   ACN11464;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 11467.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 11467; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
```

```
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3229 GTCACTCTGGCGGGAC 3244
              ||||| ||||||||||
Db         17 GTCACACTGGCGGGAC 2


RESULT 721
ABT35221
ID   ABT35221 standard; DNA; 17 BP.
XX
AC   ABT35221;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 858.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 133; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 9 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4174 ATTTAAAAAAGTAACT 4189
              || ||||||||||||
Db          2 ATCTAAAAAAGTAACT 17


RESULT 722
ACA06540
ID   ACA06540 standard; RNA; 17 BP.
XX
AC   ACA06540;
XX
DT   03-JUN-2003  (first entry)
XX
DE   NFKB sub-unit modulating inozyme substrate #359.
XX
KW   Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW   G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW   lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW   oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW   cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW   lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW   chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW   cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW   gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW   rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW   gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW   transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW   allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS   Homo sapiens.
XX
PN   US2002177568-A1.
XX
PD   28-NOV-2002.
XX
PF   23-MAY-2001; 2001US-00864785.
XX
PR   07-DEC-1992;   92US-00987132.
PR   18-MAY-1994;   94US-00245466.
PR   15-AUG-1994;   94US-00291932.
PR   23-DEC-1996;   96US-00777916.
XX
PA   (STIN/) STINCHCOMB D T.
PA   (MCSW/) MCSWIGGEN J.
PA   (DRAP/) DRAPER K G.
XX
PI   Stinchcomb DT,  Mcswiggen J,  Draper KG;
XX
DR   WPI; 2003-340953/32.
XX
PT   Novel enzymatic nucleic acid molecules which down regulates expression of
PT   a sequence encoding a subunit of nuclear factor kappa B useful for
PT   treating cancer, inflammatory disorders and autoimmune diseases.
XX
PS   Claim 3; Page 32; 72pp; English.
XX
CC   The invention describes an enzymatic nucleic acid molecule (I) which down
CC   regulates expression of a sequence encoding a subunit of nuclear factor
CC   kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC   configuration. The enzymatic nucleic acid molecule is adapted to treat
CC   cancer and is useful for down-regulating REL-A activity in a cell, for
CC   treating a patient having a condition associated with the level of REL-A.
CC   (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC   the presence of a divalent cation, especially Mg^2^+. The enzymatic and
```

```
CC   antisense nucleic acid molecules are useful for treating breast, lung,
CC   prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC   cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC   multidrug resistant cancer. The method involves use of other drug
CC   therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC   chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC   cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC   gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC   acid molecules are also useful for treating inflammatory disease such as
CC   rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC   obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC   rejection, gene therapy applications, ischaemia/reperfusion injury
CC   (central nervous system (CNS) and myocardial), glomerulonephritis,
CC   sepsis, allergic airway inflammation, inflammatory bowel disease or
CC   infection. This sequence represents the substrate of a novel enzymatic
CC   nucleic acid molecule
XX
SQ   Sequence 17 BP; 2 A; 11 C; 3 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1065 CCCTGGCCCCAGCCCC 1080
              ||| ||||||||||||
Db          1 CCCAGGCCCCAGCCCC 16


RESULT 723
ACA06539
ID   ACA06539 standard; RNA; 17 BP.
XX
AC   ACA06539;
XX
DT   03-JUN-2003  (first entry)
XX
DE   NFKB sub-unit modulating inozyme substrate #358.
XX
KW   Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW   G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW   lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW   oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW   cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW   lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW   chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW   cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW   gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW   rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW   gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW   transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW   allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS   Homo sapiens.
XX
PN   US2002177568-A1.
XX
PD   28-NOV-2002.
XX
PF   23-MAY-2001; 2001US-00864785.
XX
PR   07-DEC-1992;   92US-00987132.
PR   18-MAY-1994;   94US-00245466.
PR   15-AUG-1994;   94US-00291932.
PR   23-DEC-1996;   96US-00777916.
XX
PA   (STIN/) STINCHCOMB D T.
PA   (MCSW/) MCSWIGGEN J.
PA   (DRAP/) DRAPER K G.
XX
PI   Stinchcomb DT,  Mcswiggen J,  Draper KG;
XX
DR   WPI; 2003-340953/32.
XX
PT   Novel enzymatic nucleic acid molecules which down regulates expression of
PT   a sequence encoding a subunit of nuclear factor kappa B useful for
PT   treating cancer, inflammatory disorders and autoimmune diseases.
XX
PS   Claim 3; Page 32; 72pp; English.
XX
CC   The invention describes an enzymatic nucleic acid molecule (I) which down
CC   regulates expression of a sequence encoding a subunit of nuclear factor
CC   kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC   configuration. The enzymatic nucleic acid molecule is adapted to treat
CC   cancer and is useful for down-regulating REL-A activity in a cell, for
CC   treating a patient having a condition associated with the level of REL-A.
CC   (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC   the presence of a divalent cation, especially Mg^2^+. The enzymatic and
CC   antisense nucleic acid molecules are useful for treating breast, lung,
CC   prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC   cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC   multidrug resistant cancer. The method involves use of other drug
CC   therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC   chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC   cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC   gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC   acid molecules are also useful for treating inflammatory disease such as
CC   rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC   obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC   rejection, gene therapy applications, ischaemia/reperfusion injury
CC   (central nervous system (CNS) and myocardial), glomerulonephritis,
CC   sepsis, allergic airway inflammation, inflammatory bowel disease or
CC   infection. This sequence represents the substrate of a novel enzymatic
CC   nucleic acid molecule
XX
SQ   Sequence 17 BP; 2 A; 11 C; 4 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1065 CCCTGGCCCCAGCCCC 1080
              ||| ||||||||||||
Db          2 CCCAGGCCCCAGCCCC 17


RESULT 724
ABZ62068/c
ID   ABZ62068 standard; RNA; 17 BP.
XX
AC   ABZ62068;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human H-Ras DNAzyme target #859.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
```

```
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 129; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1668 AGAGGTACCTCCTGCA 1683
                ||||  ||||||||||
Db         16 AGAGATACCTCCTGCA 1


RESULT 725
ABZ61986
ID   ABZ61986 standard; RNA; 17 BP.
XX
AC   ABZ61986;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human H-Ras DNAzyme target #777.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 126; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 1 A; 6 C; 7 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        576 GGGCCAGGCCCACTGG 591
              ||||||||||| |:||
Db          2 GGGCCAGGCCCUCUGG 17


RESULT 726
ACC66601
ID   ACC66601 standard; DNA; 17 BP.
XX
AC   ACC66601;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 3848.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 480; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 2 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       3798 ATCATTTTTTTCCCTT 3813
              ||||| ||||||||||
Db          2 ATCATGTTTTTCCCTT 17
```

RESULT 727
ACC63709/c
ID ACC63709 standard; DNA; 17 BP.
XX
AC ACC63709;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour supression, SEQ ID 956.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 142; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2850 CAATCAGGACGTGATC 2865
              ||||||| ||||||||
Db         16 CAATCAGAACGTGATC 1
```

RESULT 728
ADB44084
ID ADB44084 standard; DNA; 17 BP.
XX
AC ADB44084;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #4407.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 547; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

```
  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2545 ATCGCCTCGGGCATGC 2560
              |||||||| |||||||
Db          2 ATCGCCTCCGGCATGC 17
```

RESULT 729
ADE25202
ID ADE25202 standard; DNA; 17 BP.
XX
AC ADE25202;
XX
DT 29-JAN-2004 (first entry)
XX
DE Plant growth associated polynucleotide seq id 177.
XX
KW plant growth; plant growth trait modulation; Brassicaceae; Arabidopsis;

KW Brassica; Zea; Oryza; Triticum; Hordeum; Lolium; Sorghum; Glycine;
KW Medicago; Helianthus; Lactuca; Beta; Vitis; Solanum; Lycopersicon;
KW Capsicum; Gossypium; Hevea; Linum; Prunus; Citrus; Populus; Pinus;
KW Quercus; ss.
XX
OS Magnoliophyta.
XX
PN US2003188343-A1.
XX
PD 02-OCT-2003.
XX
PF 07-JAN-2003; 2003US-00338777.
XX
PR 09-JAN-2002; 2002US-0347288P.
XX
PA (LYNX-) LYNX THERAPEUTICS INC.
XX
PI Bowen BA, Haudenschild CD, Buckler ES;
XX
DR WPI; 2003-803305/75.
XX
PT New isolated or recombinant polypeptide for use in modulating a plant
PT growth trait in a flowering plant e.g. in Arabidopsis, Brassica, Zea, or
PT Oryza.
XX
PS Example 2; SEQ ID NO 177; 81pp; English.
XX
CC The invention describes an isolated or recombinant polypeptide (I)
CC comprising a sequence: (a) comprising 1 of 30 sequences (S1), as given in
CC the specification, or a conservative variant; (b) encoded by 1 of 30
CC sequences (S2), as given in the specification, or a conservative variant;
CC (c) encoded by a sequence that hybridises under stringent conditions to
CC S2; and (d) encoded by a sequence 70 % identical to S2. The expression or
CC activity of (I) is modulated to modulate a plant growth trait in a
CC flowering plant, of the family Brassicaceae, preferably in a plant that
CC is Arabidopsis, Brassica, Zea, Oryza, Triticum, Hordeum, Lolium, Sorghum,
CC Glycine, Medicago, Helianthus, Lactuca, Beta, Vitis, Solanum,
CC Lycopersicon, Capsicum, Gossypium, Hevea, Linum, Prunus, Citrus, Populus,
CC Pinus, or Quercus. A new method is used to detect genes for a plant
CC growth trait. This sequence represents a polynucleotide isolated from the
CC plant growth associated genes of the invention that can be used a a
CC primer, probe or genetic marker.
XX
SQ Sequence 17 BP; 7 A; 3 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2862 GATCAATGCCATTGAA 2877
||||||| |||||||||
Db 1 GATCAAAGCCATTGAA 16

RESULT 730
ACC53156/c
ID ACC53156 standard; DNA; 17 BP.
XX
AC ACC53156;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #1923.
XX
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
OS Homo sapiens.
XX
PN FR2826373-A1.
XX
PD 27-DEC-2002.
XX
PF 20-JUN-2001; 2001FR-00008139.
XX
PR 20-JUN-2001; 2001FR-00008139.
XX
PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI Tuijnder M, Telerman A, Amson R;
XX
DR WPI; 2003-250498/25.
XX
PT New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
PS Claim 1; Page 484; 798pp; French.
XX
CC This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX
SQ Sequence 17 BP; 5 A; 5 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3469 TTTGGAGAGACAGGAT 3484
|||| ||||||||||
Db 17 TTTGTAGAGACAGGAT 2

RESULT 731
ADL48219/c
ID ADL48219 standard; RNA; 17 BP.
XX
AC ADL48219;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #729.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX

```
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 1752; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human IKK-
CC   gamma substrate sequence.
XX
SQ   Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        882 CAGCAAGGCTGGCTTC 897
              ||||| ||||||||||
Db         17 CAGCATGGCTGGCTTC 2


RESULT 732
AEB60994/c
ID   AEB60994 standard; mRNA; 17 BP.
XX
AC   AEB60994;
XX
DT   22-SEP-2005  (first entry)
XX
DE   Human VEGF receptor 21 (Kdr) DNAzyme target sequence SEQ ID 3572.
XX
KW   VEGF receptor; angiogenesis; cancer; tumor; ocular disease;
KW   diabetic retinopathy; age related macular degeneration;
KW   angiogenesis disorder; rheumatoid arthritis; psoriasis; wound healing;
KW   endometriosis; endometroid carcinoma; gynecological bleeding disorder;
KW   menstruation disorder; premenstrual syndrome; menopause; Gynecological;
KW   Cytostatic; Ophthalmological; Antidiabetic; antiangiogenic;
KW   Antipsoriatic; Antirheumatic; Antiarthritic; Vulnerary; Hemostatic;
KW   Contraceptive; ss; enzymatic nucleic acid.
XX
OS   Homo sapiens.
XX
PN   WO200296927-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US017674.
XX
PR   29-MAY-2001; 2001US-00870161.
PR   30-NOV-2001; 2001US-0334461P.
PR   03-MAY-2002; 2002US-00138674.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Escobedo J,  Mcswiggen J,  Pavco P,  Stinchcomb D,  Sandberg J;
PI   Gordon G;
XX
DR   WPI; 2003-140439/13.
XX
PT   Novel enzymatic nucleic acids, ribozymes, which modulate expression of
PT   genes encoding vascular endothelial growth factor and/or VEGF receptor,
PT   useful for inhibiting tumor angiogenesis in cell, and for treating
PT   cancer.
XX
PS   Disclosure; SEQ ID NO 3572; 172pp; English.
XX
CC   The invention relates to enzymatic nucleic acids (I) i.e.
CC   ribozymes/DNAzymes/Zinzymes that target and modulate expression of, genes
CC   encoding vascular endothelial growth factor (VEGF) and/or VEGF receptor
CC   (VEGFR1 and 2 encode by the Flt-1 and Kdr genes respectively). Also
CC   included are a composition comprising (I) and a carrier, administering
CC   (I) to a cell (by contacting the cell with the compound under conditions
CC   suitable for the administration), administering (I) to a cell (in
CC   conjunction with one or more other drug by contacting the cell with the
CC   compound and the other drug under conditions suitable for the
CC   administration), administering (I) to a mammal (by contacting the mammal
CC   with the compound under conditions suitable for the administration),
CC   treating (M1) a subject having endometriosis (by contacting a subject
CC   with, or administering to subject, a nucleic acid molecule (II) that
CC   modulates expression of VEGF, VEGFR1, and/or VEGFR2), a mammalian cell
CC   (III) comprising (I) and administering to a mammal (I) (in conjunction
CC   with a chemotherapeutic agent comprising contacting the mammal with the
CC   compound and the chemotherapeutic agent under conditions suitable for the
CC   administration). (I) is administered to a mammalian cell, preferably
CC   human cell in the presence of a delivery reagent which is a lipid such as
CC   cationic lipid or phospholipid, or a liposome. The enzymatic nucleic acid
CC   molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1
CC   and/or VEGFR2 gene, and is in a hammerhead, inozyme, DNAzyme, G-cleaver,
CC   or Amberzyme configuration. The enzymatic nucleic acids are useful for
CC   inhibiting ocular angiogenesis associated with diabetic retinopathy or
CC   age-related diabetic retinopathy, in a subject. They are also useful for
CC   inhibiting angiogenesis, preferably tumor angiogenesis in cell, and for
CC   treating a subject having a condition associated with an increased level
CC   of VEGF receptor, where the condition is cancer, e.g. breast cancer, lung
CC   cancer (such as non-small cell lung carcinoma), colorectal cancer, renal
CC   cancer (such as renal cell carcinoma), pancreatic cancer. The enzymatic
CC   nucleic acids are useful for treating a subject (preferably human) having
CC   endometriosis, psoriasis, age-related macular degeneration, proliferative
CC   diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis,
CC   wound healing, endometrial carcinoma, gynecologic bleeding disorders,
CC   irregular menstrual cycles, ovulation, premenstrual syndrome, and
CC   menopausal dysfunction. The enzymatic nucleic acids are useful for birth
CC   control by inhibiting ovulation or embryonic uterine implantation. The
CC   present sequence is a target sequence from the human VEGFR2/Kdr mRNA.
XX
SQ   Sequence 17 BP; 11 A; 3 C; 2 G; 0 T; 1 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3860 AGTTTTGTTTTTGGTC 3875
              ||||||||||||| ||
Db         16 AGTTTTGTTTTTGTTC 1


RESULT 733
ADL82216
ID   ADL82216 standard; DNA; 17 BP.
XX
AC   ADL82216;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human ER+ breast cancer differentially expressed sequence #186.
XX
KW   gene therapy; ds; breast cancer; human; ER+ breast cancer.
XX
OS   Homo sapiens.
XX
```

PN US2003166026-A1.
XX
PD 04-SEP-2003.
XX
PF 08-JAN-2003; 2003US-00339782.
XX
PR 09-JAN-2002; 2002US-0348053P.
XX
PA (LYNX-) LYNX THERAPEUTICS INC.
XX
PI Goodman LJ, Bowen BA;
XX
DR WPI; 2004-069003/07.
XX
PT Vector containing nucleic acid associated with breast cancer, useful for
PT treating, diagnosing and characterizing breast cancer, also related
PT polypeptides and antibodies.
XX
PS Claim 1; SEQ ID NO 187; 61pp; English.
XX
CC The invention relates to a composition which contains at least one vector
CC (B) containing a nucleic acid (I) associated with breast cancer. The
CC vector (B), also polypeptides (II) encoded by (I), are used for treatment
CC of breast cancer. Arrays based on (I), (II), or their fragments, and (II)
CC -specific antibodies (Ab) are used to predict characteristics (e.g.
CC invasiveness or stage) of breast cancer, and (I), or its fragments, are
CC used to modulate characteristics of such cells; to identify breast cancer
CC genes and to detect breast cancer (by detecting polymorphic nucleic acid
CC or its products). The present sequence represents a human ER+ breast
CC cancer differentially expressed sequence.
XX
SQ Sequence 17 BP; 9 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 4174 ATTTAAAAAAGTAACT 4189
|| ||||||||||||||
Db 2 ATCTAAAAAAGTAACT 17

RESULT 734
ADL60384
ID ADL60384 standard; DNA; 17 BP.
XX
AC ADL60384;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human organic anion transport protein SNP region #110.
XX
KW gene therapy; human; OATP2; cMOAT; hepatic disease; metabolic disease;
KW inflammatory disease; cardiovascular disease; hyperproliferative disease;
KW neurological disease; infectious disease; liver disease;
KW high cholesterol; hypertension; congestive heart failure;
KW coronary heart disease; cancer; wound healing; ds; SNP;
KW single nucleotide polymorphism.
XX
OS Homo sapiens.
XX
PN US2004068096-A1.
XX
PD 08-APR-2004.
XX
PF 20-SEP-2002; 2002US-00252155.
XX
PR 21-SEP-2001; 2001US-0324172P.
PR 27-NOV-2001; 2001US-0333700P.
XX
PA (TSUC/) TSUCHIHASHI Z.
PA (HUIL/) HUI L.
PA (KIRC/) KIRCHGESSNER T.
XX
PI Tsuchihashi Z, Hui L, Kirchgessner T;
XX
DR WPI; 2004-304621/28.
XX
PT New nucleic acid encoding human OATP2 or cMOAT protein, useful in
PT diagnosing, treating or preventing diseases or disorders, e.g.
PT inflammatory, cardiovascular, hyperproliferative, neurological or
PT infectious diseases.
XX
PS Claim 3; SEQ ID NO 160; 296pp; English.
XX
CC The invention relates to an isolated nucleic acid derived from a human
CC gene encoding a protein, i.e. human OATP2 protein or human cMOAT protein,
CC where the nucleic acid comprises at least one polymorphic position The
CC nucleic acid and the encoded protein, kits and composition are useful in
CC diagnosing, treating or preventing diseases or disorders, e.g. hepatic,
CC metabolic, inflammatory, cardiovascular, hyperproliferative,
CC neurological, infectious diseases, liver disease, high cholesterol,
CC hypertension, congestive heart failure or coronary heart disease and
CC cancer and promotes wound healing. The present sequence represents the a
CC human organic anion transport protein SNP region.
XX
SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3073 GACCAGCGGCAGCCTC 3088
||||| ||||||||||
Db 2 GACCACCGGCAGCCTC 17

RESULT 735
ADR27266
ID ADR27266 standard; DNA; 17 BP.
XX
AC ADR27266;
XX
DT 04-NOV-2004 (first entry)
XX
DE Human single nucleotide polymorphism detection primer #356.
XX
KW ss; primer; single nucleotide polymorphism; SNP; diagnosis;
KW disease association; linkage analysis; autoimmune disease;
KW rheumatoid arthritis; diabetes; multiple sclerosis;
KW systemic lupus erythematosus; inflammatory bowel disease; psoriasis;
KW thyroiditis; celiac disease; pernicious anaemia; asthma; vitiligo;
KW glomerulonephritis; Graves' disease; myocarditis; Sjogren disease;
KW primary systemic vasculitis; genotyping; gene therapy; PCR primer.
XX
OS Homo sapiens.
XX
PN WO2004067779-A2.
XX
PD 12-AUG-2004.
XX
PF 30-JAN-2004; 2004WO-US002652.
XX
PR 30-JAN-2003; 2003US-0443566P.
PR 18-MAR-2003; 2003US-0455444P.
PR 25-APR-2003; 2003US-0465241P.
PR 15-AUG-2003; 2003US-0495115P.
PR 13-NOV-2003; 2003US-0519270P.
XX
PA (APPL-) APPLERA CORP.
XX
PI Cargill M, Begovich AB, Carlton VE, Schrodi SJ, Alexander HC;
XX
DR WPI; 2004-594223/57.
XX
PT New single nucleotide polymorphisms (SNPs) associated with rheumatoid

```
PT   arthritis (RA), useful in identification of individuals at risk of
PT   developing RA or other autoimmune disease, and in development of
PT   therapeutic agents.
XX
PS   Claim 21; SEQ ID NO 49938; 141pp; English.
XX
CC   The invention relates to an isolated nucleic acid molecule comprising at
CC   least 8 contiguous nucleotides where one of the nucleotides is a single
CC   nucleotide polymorphism (SNP) selected from any one of the nucleotide
CC   sequences of SEQ ID NOs:1-669 and 1339-49582, or their complements. The
CC   SNPs are useful as targets for the design of diagnostic reagents and the
CC   development of therapeutic agents, as well as for disease association and
CC   linkage analysis. In particular, the SNPs are useful for identifying an
CC   individual who is at an increased or decreased risk for developing an
CC   autoimmune disease such as rheumatoid arthritis, type 1 diabetes,
CC   multiple sclerosis, systemic lupus erythematosus, inflammatory bowel
CC   diseases, psoriasis, thyroiditis, celiac disease, pernicious anaemia,
CC   asthma, vitiligo, glomerulonephritis, Graves' disease, myocarditis,
CC   Sjogren disease, or primary systemic vasculitis. Methods associated with
CC   the SNPs are useful for early detection of the disease, for providing
CC   clinically important information for the prevention and/or treatment of
CC   the autoimmune diseases particularly rheumatoid arthritis, and for
CC   screening and selecting therapeutic agents. The SNPs are useful for human
CC   identification applications. The genes containing the SNPs are useful for
CC   treating the diseases defined above. The nucleic acid molecules are
CC   useful as hybridization probes for genotyping SNPs in messenger RNA,
CC   cDNA, genomic DNA, and genomic clones. The nucleic acid molecules are
CC   useful for constructing host cells expressing a part or all of the
CC   nucleic acid molecules and variant peptides, for constructing transgenic
CC   animals, for assaying or screening drugs that modulate nucleic acid
CC   expression, or for gene therapy in patients whose cells have aberrant
CC   gene expression. This sequence corresponds to a PCR primer which
CC   hybridises to the nucleic acids of the invention to amplify the SNP
CC   containing region. (Note: SEQ ID NOs 1-49582 are claimed and stated as
CC   being provided in the specification, however these sequences are not
CC   provided in the printed specification).
XX
SQ   Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3062 ACCCTCTCCTGGACCA 3077
              | ||||||||||||||
Db          2 AGCCTCTCCTGGACCA 17


RESULT 736
ACN64003
ID   ACN64003 standard; DNA; 17 BP.
XX
AC   ACN64003;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:905.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 905; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4056 GCCTGGGACCCCCAAG 4071
              || ||||||||||||||
Db          2 GCTTGGGACCCCCAAG 17


RESULT 737
ACN64753/c
ID   ACN64753 standard; DNA; 17 BP.
XX
AC   ACN64753;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:1655.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
```

```
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 1655; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 6 A; 4 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3965 CTATGGCCTCCTTTGC 3980
              || |||||||||||||
Db         16 CTCTGGCCTCCTTTGC 1


RESULT 738
ACN64004
ID   ACN64004 standard; DNA; 17 BP.
XX
AC   ACN64004;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:906.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 906; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       4056 GCCTGGGACCCCCAAG 4071
              || |||||||||||||
Db          1 GCTTGGGACCCCCAAG 16


RESULT 739
```

```
ACN65746
ID   ACN65746 standard; DNA; 17 BP.
XX
AC   ACN65746;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:2648.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 2648; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1222 GGGTCCTGCCAGCCAT 1237
              ||||||| |||||||
Db          1 GGGTCCTGGCAGCCAT 16


RESULT 740
ACN65745
ID   ACN65745 standard; DNA; 17 BP.
XX
AC   ACN65745;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:2647.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 2647; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
```

```
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1222 GGGTCCTGCCAGCCAT 1237
              |||||||| |||||||
Db          2 GGGTCCTGGCAGCCAT 17


RESULT 741
ADZ31142/c
ID   ADZ31142 standard; RNA; 17 BP.
XX
AC   ADZ31142;
XX
DT   30-JUN-2005  (first entry)
XX
DE   Human H-Ras substrate RNA sequence SEQ ID NO:2180.
XX
KW   short interfering RNA; siRNA; RNA interference; gene silencing;
KW   cytostatic; cancer; Ras gene; substrate; ss.
XX
OS   Homo sapiens.
XX
PN   US2005080031-A1.
XX
PD   14-APR-2005.
XX
PF   26-NOV-2003; 2003US-00724270.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   10-SEP-2001; 2001US-0318471P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   20-MAY-2002; 2002WO-US015876.
PR   29-MAY-2002; 2002US-00157580.
PR   29-MAY-2002; 2002WO-US016840.
PR   06-JUN-2002; 2002US-00163552.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   10-SEP-2002; 2002US-00238700.
PR   15-JAN-2003; 2003US-0440129P.
PR   20-FEB-2003; 2003WO-US005028.
PR   20-FEB-2003; 2003WO-US005346.
PR   16-APR-2003; 2003US-00417012.
PR   24-APR-2003; 2003US-00422704.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   29-AUG-2003; 2003US-00652791.
PR   23-OCT-2003; 2003US-00693059.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2005-331166/34.
XX
PT   Novel double-stranded short interfering RNA molecule having first
PT   nucleotide sequence complementary to RNA encoding HER2 or its portion,
PT   and second nucleotide sequence having complementarity to first sequence,
PT   useful for treating cancer.
XX
PS   Example 1; SEQ ID NO 2180; 143pp; English.
XX
CC   The invention relates to a double-stranded short interfering RNA (siRNA)
CC   molecule (I) comprising a first nucleotide sequence having 19-23
CC   nucleotides complementary to an RNA sequence encoding HER2 or its
CC   portion, and a second nucleotide sequence having 19-23 nucleotides
CC   exhibiting complementarity to the first sequence, and including at least
CC   one nucleotide that is not a 2'-OH containing ribonucleotide. Also
CC   described is a method of producing a class of nucleic acid-based gene
CC   modulating agents that exhibit a high degree of specificity for RNA of a
CC   desired target. (I) is useful for modulating HER2 activity in a cell, and
CC   for treating diseases or conditions related to levels of HER2 gene
CC   expression. (I) is useful for treating cancer, such as pancreatic cancer,
CC   bladder cancer, lung cancer, breast cancer or prostrate cancer. The
CC   present sequence represents a human H-Ras substrate RNA sequence for a
CC   DNAzyme (ribozyme), which is used in an example from the present
CC   invention for the identification of potential target sites in human Ras
CC   RNA.
XX
SQ   Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 3.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1668 AGAGGTACCTCCTGCA 1683
              |||| ||||||||||||
Db         16 AGAGATACCTCCTGCA 1


RESULT 742
ADZ31060
ID   ADZ31060 standard; RNA; 17 BP.
XX
AC   ADZ31060;
XX
DT   30-JUN-2005  (first entry)
XX
DE   Human H-Ras substrate RNA sequence SEQ ID NO:2098.
XX
KW   short interfering RNA; siRNA; RNA interference; gene silencing;
KW   cytostatic; cancer; Ras gene; substrate; ss.
XX
OS   Homo sapiens.
XX
PN   US2005080031-A1.
XX
PD   14-APR-2005.
XX
PF   26-NOV-2003; 2003US-00724270.
XX
PR   18-MAY-2001; 2001US-0292217P.
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   20-JUL-2001; 2001US-0306883P.
PR   13-AUG-2001; 2001US-0311865P.
PR   10-SEP-2001; 2001US-0318471P.
PR   20-FEB-2002; 2002US-0358580P.
PR   06-MAR-2002; 2002US-0362016P.
PR   11-MAR-2002; 2002US-0363124P.
PR   20-MAY-2002; 2002WO-US015876.
PR   29-MAY-2002; 2002US-00157580.
PR   29-MAY-2002; 2002WO-US016840.
PR   06-JUN-2002; 2002US-00163552.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   10-SEP-2002; 2002US-00238700.
PR   15-JAN-2003; 2003US-0440129P.
PR   20-FEB-2003; 2003WO-US005028.
```

```
PR   20-FEB-2003; 2003WO-US005346.
PR   16-APR-2003; 2003US-00417012.
PR   24-APR-2003; 2003US-00422704.
PR   30-APR-2003; 2003US-00427160.
PR   23-MAY-2003; 2003US-00444853.
PR   29-AUG-2003; 2003US-00652791.
PR   23-OCT-2003; 2003US-00693059.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2005-331166/34.
XX
PT   Novel double-stranded short interfering RNA molecule having first
PT   nucleotide sequence complementary to RNA encoding HER2 or its portion,
PT   and second nucleotide sequence having complementarity to first sequence,
PT   useful for treating cancer.
XX
PS   Example 1; SEQ ID NO 2098; 143pp; English.
XX
CC   The invention relates to a double-stranded short interfering RNA (siRNA)
CC   molecule (I) comprising a first nucleotide sequence having 19-23
CC   nucleotides complementary to an RNA sequence encoding HER2 or its
CC   portion, and a second nucleotide sequence having 19-23 nucleotides
CC   exhibiting complementarity to the first sequence, and including at least
CC   one nucleotide that is not a 2'-OH containing ribonucleotide. Also
CC   described is a method of producing a class of nucleic acid-based gene
CC   modulating agents that exhibit a high degree of specificity for RNA of a
CC   desired target. (I) is useful for modulating HER2 activity in a cell, and
CC   for treating diseases or conditions related to levels of HER2 gene
CC   expression. (I) is useful for treating cancer, such as pancreatic cancer,
CC   bladder cancer, lung cancer, breast cancer or prostrate cancer. The
CC   present sequence represents a human H-Ras substrate RNA sequence for a
CC   DNAzyme (ribozyme), which is used in an example from the present
CC   invention for the identification of potential target sites in human Ras
CC   RNA.
XX
SQ   Sequence 17 BP; 1 A; 6 C; 7 G; 0 T; 3 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        576 GGGCCAGGCCCACTGG 591
              ||||||||||| |:||
Db          2 GGGCCAGGCCCUCUGG 17


RESULT 743
AAQ65238
ID   AAQ65238 standard; DNA; 18 BP.
XX
AC   AAQ65238;
XX
DT   21-DEC-1994  (first entry)
XX
DE   Antisense oligonucleotide complementary to Hepatitis C Virus genome.
XX
KW   Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
KW   inhibition; viral protein precursor; ss.
XX
OS   Synthetic.
XX
PN   CA2104649-A.
XX
PD   26-FEB-1994.
XX
PF   23-AUG-1993;   93CA-02104649.
XX
PR   25-AUG-1992;   92JP-00248796.
PR   03-MAR-1993;   93JP-00042736.
XX
PA   (SEKI/) SEKI M.
XX
PI   Seki M,  Honda Y,  Yamada E;
XX
DR   WPI; 1994-151836/19.
XX
PT   Anti:sense oligo:nucleotide(s) complementary to the hepatitis C virus
PT   genome - are useful as antiviral agents.
XX
PS   Claim 5; Page 205; 262pp; English.
XX
CC   This oligonucleotide is an example of a preferred antisense compound i.e.
CC   it has a base sequence of 15-30 bases which is included within the 49
CC   bases from G at position 127 to C at position 175 of AAQ64913 and which
CC   contains at least 7 bases from C at position 147 to C at position 153.
CC   The antisense oligonucleotide is useful for inhibiting translation of HCV
CC   genes
XX
SQ   Sequence 18 BP; 1 A; 5 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         28 CTCCAGGGAGGGGGGG 43
              |||| ||||||||||
Db          1 CTCCCGGGAGGGGGGG 16


RESULT 744
AAQ65254
ID   AAQ65254 standard; DNA; 18 BP.
XX
AC   AAQ65254;
XX
DT   21-DEC-1994  (first entry)
XX
DE   Antisense oligonucleotide complementary to Hepatitis C Virus genome.
XX
KW   Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
KW   inhibition; viral protein precursor; ss.
XX
OS   Synthetic.
XX
PN   CA2104649-A.
XX
PD   26-FEB-1994.
XX
PF   23-AUG-1993;   93CA-02104649.
XX
PR   25-AUG-1992;   92JP-00248796.
PR   03-MAR-1993;   93JP-00042736.
XX
PA   (SEKI/) SEKI M.
XX
PI   Seki M,  Honda Y,  Yamada E;
XX
DR   WPI; 1994-151836/19.
XX
PT   Anti:sense oligo:nucleotide(s) complementary to the hepatitis C virus
PT   genome - are useful as antiviral agents.
XX
PS   Claim 5; Page 212; 262pp; English.
XX
CC   This oligonucleotide is an example of a preferred antisense compound i.e.
CC   it has a base sequence of 15-30 bases which is included within the 49
CC   bases from G at position 127 to C at position 175 of AAQ64913 and which
CC   contains at least 7 bases from C at position 147 to C at position 153.
CC   The antisense oligonucleotide is useful for inhibiting translation of HCV
CC   genes
XX
SQ   Sequence 18 BP; 1 A; 4 C; 10 G; 3 T; 0 U; 0 Other;
```

```
  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         28 CTCCAGGGAGGGGGGG 43
              |||| ||||||||||
Db          2 CTCCCGGGAGGGGGGG 17


RESULT 745
AAV48676/c
ID   AAV48676 standard; DNA; 18 BP.
XX
AC   AAV48676;
XX
DT   15-OCT-1998  (first entry)
XX
DE   junB gene antisense oligonucleotide JunB-T-5.
XX
KW   junB; junD; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP856579-A1.
XX
PD   05-AUG-1998.
XX
PF   31-JAN-1997;   97EP-00101531.
XX
PR   31-JAN-1997;   97EP-00101531.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Schlingensiepen K,  Brysch W;
XX
DR   WPI; 1998-400910/35.
XX
PT   Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT   consecutive guanosine or inosine - and have specific ratio of residues
PT   able to form two or three hydrogen bonds, have greater activity and
PT   reduced toxicity, used therapeutically or to modulate growth of cells in
PT   culture.
XX
PS   Example 3; Fig 5c; 286pp; English.
XX
CC   AAV48564-708 represent antisense oligonucleotides directed against the
CC   junB and junD genes. Of these, only oligonucleotides AAV48565-614
CC   resulted in effective downregulation of negative growth control by JunB
CC   or JunD, while AAV48615-708 had little effect. The oligonucleotides
CC   exemplify the invention. The specification describes oligonucleotides
CC   that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC   can each form three hydrogen bonds to cytosine; do not contain four
CC   consecutive nucleotides able to form three H-bonds each to four
CC   consecutive cytosines; do not contain two sequences of three consecutive
CC   nucleotides each able to form three H-bonds to three consecutive
CC   cytosines, and the ratio between residues able to form two H-bonds each
CC   (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
CC   oligonucleotides are used to modulate expression of genes, particularly
CC   the genes for p53, ErbB-2, junB, junD, TGF-beta 1 or beta 2 to control
CC   proliferation of primary cell cultures (e.g. bone marrow stem, liver or
CC   kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC   oligonucleotides can also be used to analyse function of proteins (by
CC   altering their expression or activity) and therapeutically, e.g. in cases
CC   of cancer or (targeting TGF) for stimulating the immune system
XX
SQ   Sequence 18 BP; 1 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         93 GGCCCCGGAGGGACCC 108
              ||||||| ||||||||
Db         17 GGCCCCGCAGGGACCC 2


RESULT 746
AAA52892/c
ID   AAA52892 standard; DNA; 18 BP.
XX
AC   AAA52892;
XX
DT   15-SEP-2000  (first entry)
XX
DE   Human CD44 antisense oligonucleotide ISIS# 18781.
XX
KW   Human; CD44; cell surface adhesion receptor; cytostatic; antirheumatic;
KW   antiinflammatory; antiarthritic; CD44 antisense inhibition;
KW   hyperproliferative disorder; cancer; inflammatory disorder;
KW   rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO200035935-A1.
XX
PD   22-JUN-2000.
XX
PF   14-DEC-1999;   99WO-US029576.
XX
PR   17-DEC-1998;   98US-00213719.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Cowsert LM;
XX
DR   WPI; 2000-431564/37.
XX
PT   New antisense compound, that inhibits the expression of human cell
PT   surface adhesion receptor CD44, for treating hyperproliferative disorders
PT   and inflammatory conditions, such as cancer and rheumatoid arthritis.
XX
PS   Example 15; Page 77; 105pp; English.
XX
CC   The present sequence is one of a large number of antisense
CC   oligonucleotides designed to target different regions of the human CD44
CC   mRNA. CD44 is a multifunctional human cell surface adhesion receptor. The
CC   oligonucleotides were analysed for effect on CD44 mRNA levels by
CC   quantitative real-time PCR analysis. Antisense oligonucleotides that
CC   inhibit CD44 expression can be used to treat CD44-associated conditions
CC   including hyperproliferative disorders, such as cancer, and inflammatory
CC   conditions, such as rheumatoid arthritis. The antisense compounds
CC   hybridise to CD44 nucleic acids, thus allowing sandwich and other assays
CC   to be easily constructed. Note: The sequence has a phosphorothioate
CC   backbone and may be either an oligodeoxynucleotide or a chimeric
CC   oligonucleotide containing 2'-methoxyethyl (2'-MOE) wings and a deoxy
CC   gap. The ISIS number given above corresponds to the oligodeoxynucleotide
CC   sequence
XX
SQ   Sequence 18 BP; 3 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2702 GCTCCCTGGGAGGAAA 2717
              | ||||||||||||||
Db         16 GGTCCCTGGGAGGAAA 1


RESULT 747
AAA30403
ID   AAA30403 standard; DNA; 18 BP.
XX
AC   AAA30403;
XX
```

```
DT   21-AUG-2000  (first entry)
XX
DE   Human NF-kappa-B p65 subunit antisense oligodeoxynucleotide ISIS# 23770.
XX
KW   Human; anti-inflammatory; cytostatic; antimicrobial; infection;
KW   antisense inhibition; inflammation; transcription factor; apoptosis;
KW   cancer; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /note= "all or some internucleoside bonds are
FT                   phosphorothioate and optionally some sugars may be 2'
FT                   methoxyethyl"
XX
PN   US6069008-A.
XX
PD   30-MAY-2000.
XX
PF   25-NOV-1998;   98US-00199859.
XX
PR   25-NOV-1998;   98US-00199859.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Cowsert LM,  Monia BP;
XX
DR   WPI; 2000-410858/35.
XX
PT   Antisense compounds which inhibit the expression of the human NF-kappa-B
PT   p65 subunit (p65) useful for treating diseases associated with p65
PT   expression and as prophylaxis to prevent of delay infection, inflammation
PT   or tumor formation.
XX
PS   Example 15; Col 41; 33pp; English.
XX
CC   The present sequence is one of a number of oligonucleotides designed to
CC   target different regions of the human NF-kappa-B p65 subunit, which is a
CC   member of the Rel/NF-kappa-B family of transcription factors. Rel/NF-
CC   kappa-B proteins are involved in a diverse set of signaling pathways
CC   involving stress, apoptosis, cancer, growth, infection and inflammation.
CC   Antisense oligonucleotides are able to inhibit expression of the p65
CC   subunit and may therefore be used in the treatment of disorders
CC   associated with NF-kappa-B p65 subunit expression. They may be used as a
CC   prophylaxis to prevent or delay infection, inflammation or tumour
CC   formation. Antisense compounds may also be used for research and
CC   diagnostics because they hybridise to nucleic acids encoding NF-kappa-B
CC   p65 subunit. The effect of antisense oligonucleotides on NF-kappa-B p65
CC   subunit mRNA levels was measured using real-time quantitative PCR and
CC   Northern blot analysis. Antisense oligonucleotides were synthesised on an
CC   automated DNA synthesiser
XX
SQ   Sequence 18 BP; 6 A; 2 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2669 TGGAGGAGAACTCTTC 2684
              |||||||||| |||||
Db          2 TGGAGGAGAAGTCTTC 17


RESULT 748
ADI94534/c
ID   ADI94534 standard; DNA; 18 BP.
XX
AC   ADI94534;
XX
DT   04-NOV-2004  (first entry)
XX
DE   Human IL-10 associated probe SEQ ID 2087.
XX
KW   functional domain; nucleic acid cleavage assay; nuclease; polymerase;
KW   detection; microorganism; RNA genome; hepatitis C;
KW   human immunodeficiency virus; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO200190337-A2.
XX
PD   29-NOV-2001.
XX
PF   24-MAY-2001; 2001WO-US017086.
XX
PR   24-MAY-2000; 2000US-00577304.
PR   11-JAN-2001; 2001US-00758282.
PR   24-MAY-2001; 2001US-00864426.
PR   24-MAY-2001; 2001US-00864636.
XX
PA   (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
PI   Allawi H,  Bartholomay CT,  Chehak L,  Curtis ML,  Eis PS,  Hall JG;
PI   Ip HS,  Kaiser M,  Kwiatkowski RW,  Lukowiak AA,  Lyamichev V,  Ma W;
PI   Olson-Munoz MC,  Olson SM,  Schaefer JJ,  Skrzypczynski Z,  Takova TY;
PI   Vedvik KL,  Lyamichev NE,  Neri BP;
XX
DR   WPI; 2002-083110/11.
XX
PT   Composition comprising enzyme which comprises heterologous functional
PT   domain that provides altered functionality in nucleic acid cleavage
PT   assay, useful for cleaving nucleic acid, and detecting presence of RNA
PT   target.
XX
PS   Claim 95; SEQ ID NO 2087; 1266pp; English.
XX
CC   This invention describes a novel composition comprising an enzyme which
CC   contains a heterologous functional domain that provides altered
CC   functionality in a nucleic acid cleavage assay. The enzyme comprises a 5'
CC   nuclease, preferably a thermostable 5' nuclease, or a polymerase which is
CC   altered in sequence related to a naturally occurring sequence of a
CC   polymerase such that it exhibits reduced DNA synthetic activity from that
CC   of the naturally occurring polymerase. Preferably the polymerase is a
CC   thermostable polymerase from a Thermus species such as T. aquaticus, T.
CC   flavus, T. thermophilus, T. filiformus or T. scotoductus. The enzyme
CC   comprises a heterologous functional domain, an amino acid sequence that
CC   provides an improved substrate binding activity in the nucleic acid
CC   cleavage assay and an amino acid sequence that provides improved
CC   background specificity in the nucleic acid cleavage assay. The invasive
CC   cleavage structure comprises a RNA target nucleic acid (a cytochrome
CC   P450, or cytokine RNA). Cleavage of the invasive cleavage structure
CC   generates an non-target cleavage product, which is then detected by
CC   detecting fluorescence, mass or fluorescence energy transfer or by
CC   detecting radioactivity luminescence, phosphorescence, fluorescence
CC   polarisation or charge. The enzyme is useful for cleaving a nucleic acid
CC   which involves exposing a sample (a cell lysate) comprising substrate
CC   nucleic acid to the enzyme which produces at least one detectable
CC   cleavage product. The enzyme is employed for detecting target DNAs and
CC   RNAs comprising wild-type and mutant alleles of genes including genes
CC   from humans, other animal or plants that are or may be associated with
CC   disease or other conditions. In addition, the enzymes may be useful for
CC   detecting and identifying strains of microorganisms including bacteria,
CC   fungi, protozoa, ciliates and viruses, preferably detecting and
CC   identifying viruses having RNA genomes, such as hepatitis C and human
CC   immunodeficiency virus.
XX
SQ   Sequence 18 BP; 3 A; 1 C; 8 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3787 CACCAAACTCAATCAT 3802
              |||||||||| ||||
```

```
Db         16 CACCAAACTCACTCAT 1


RESULT 749
ADI93071/c
ID   ADI93071 standard; DNA; 18 BP.
XX
AC   ADI93071;
XX
DT   04-NOV-2004  (first entry)
XX
DE   ARRESTOR oligonucleotide SEQ ID 624.
XX
KW   functional domain; nucleic acid cleavage assay; nuclease; polymerase;
KW   detection; microorganism; RNA genome; hepatitis C;
KW   human immunodeficiency virus; ss; probe.
XX
OS   Synthetic.
XX
PN   WO200190337-A2.
XX
PD   29-NOV-2001.
XX
PF   24-MAY-2001; 2001WO-US017086.
XX
PR   24-MAY-2000; 2000US-00577304.
PR   11-JAN-2001; 2001US-00758282.
PR   24-MAY-2001; 2001US-00864426.
PR   24-MAY-2001; 2001US-00864636.
XX
PA   (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
PI   Allawi H, Bartholomay CT, Chehak L, Curtis ML, Eis PS, Hall JG;
PI   Ip HS, Kaiser M, Kwiatkowski RW, Lukowiak AA, Lyamichev V, Ma W;
PI   Olson-Munoz MC, Olson SM, Schaefer JJ, Skrzypczynski Z, Takova TY;
PI   Vedvik KL, Lyamichev NE, Neri BP;
XX
DR   WPI; 2002-083110/11.
XX
PT   Composition comprising enzyme which comprises heterologous functional
PT   domain that provides altered functionality in nucleic acid cleavage
PT   assay, useful for cleaving nucleic acid, and detecting presence of RNA
PT   target.
XX
PS   Claim 96; SEQ ID NO 624; 1266pp; English.
XX
CC   This invention describes a novel composition comprising an enzyme which
CC   contains a heterologous functional domain that provides altered
CC   functionality in a nucleic acid cleavage assay. The enzyme comprises a 5'
CC   nuclease, preferably a thermostable 5' nuclease, or a polymerase which is
CC   altered in sequence related to a naturally occurring sequence of a
CC   polymerase such that it exhibits reduced DNA synthetic activity from that
CC   of the naturally occurring polymerase. Preferably the polymerase is a
CC   thermostable polymerase from a Thermus species such as T. aquaticus, T.
CC   flavus, T. thermophilus, T. filiformus or T. scotoductus. The enzyme
CC   comprises a heterologous functional domain, an amino acid sequence that
CC   provides an improved substrate binding activity in the nucleic acid
CC   cleavage assay and an amino acid sequence that provides improved
CC   background specificity in the nucleic acid cleavage assay. The invasive
CC   cleavage structure comprises a RNA target nucleic acid (a cytochrome
CC   P450, or cytokine RNA). Cleavage of the invasive cleavage structure
CC   generates an non-target cleavage product, which is then detected by
CC   detecting fluorescence, mass or fluorescence energy transfer or by
CC   detecting radioactivity luminescence, phosphorescence, fluorescence
CC   polarisation or charge. The enzyme is useful for cleaving a nucleic acid
CC   which involves exposing a sample (a cell lysate) comprising substrate
CC   nucleic acid to the enzyme which produces at least one detectable
CC   cleavage product. The enzyme is employed for detecting target DNAs and
CC   RNAs comprising wild-type and mutant alleles of genes including genes
CC   from humans, other animal or plants that are or may be associated with
CC   disease or other conditions. In addition, the enzymes may be useful for
CC   detecting and identifying strains of microorganisms including bacteria,
CC   fungi, protozoa, ciliates and viruses, preferably detecting and
CC   identifying viruses having RNA genomes, such as hepatitis C and human
CC   immunodeficiency virus.
XX
SQ   Sequence 18 BP; 3 A; 1 C; 8 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3787 CACCAAACTCAATCAT 3802
                ||||||||||| ||||
Db         16 CACCAAACTCACTCAT 1


RESULT 750
ACA62538
ID   ACA62538 standard; DNA; 18 BP.
XX
AC   ACA62538;
XX
DT   18-AUG-2003  (first entry)
XX
DE   Human MDM2 mutant 156-221 PCR primer #2.
XX
KW   Human; ss; PCR; primer; MDM2; cancer; tumour; cytostatic; p19(ARF); p53;
KW   Rb; oncoprotein; oncogenic transformation; proteosomal degradation.
XX
OS   Homo sapiens.
XX
PN   US2002193325-A1.
XX
PD   19-DEC-2002.
XX
PF   19-MAR-1998;   98US-00044602.
XX
PR   19-MAR-1998;   98US-00044602.
XX
PA   (DEPI/) DEPINHO R A.
XX
PI   Depinho RA;
XX
DR   WPI; 2003-512091/48.
XX
PT   Inhibiting growth of a tumor cell, involves introducing to the cell, an
PT   antioncogene protein or nucleic acid encoding the proteins, to inhibit
PT   growth of the tumor cell.
XX
PS   Disclosure; Page 7; 28pp; English.
XX
CC   The invention relates to inhibiting growth of a tumour cell, involving
CC   introducing to the cell, p19(ARF) (or its mimetics), and p53 to inhibit
CC   growth of the tumour cell. p19(ARF) acts as a suppressor of oncogenic
CC   transformation by binding to the MDM2 (not defined) oncoprotein and
CC   blocking its ability to target associated proteins (such as Rb and p53)
CC   for proteosomal degradation. Also included is a pharmaceutical
CC   composition comprising p19(ARF), or comprising a nucleic acid encoding
CC   p19(ARF). The method is useful for inhibiting the growth of a tumour
CC   cell, and the treatment of cancer. A mutant of MDM2 was created (lacking
CC   amino acids 156-221) which was used to investigate the binding of
CC   p19(ARF) to MDM2. The present sequence is a PCR primer used to create a
CC   nucleic acid encoding the MDM2 mutant protein
XX
SQ   Sequence 18 BP; 5 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3598 GAAGTGCCCAACATCT 3613
                |||| ||||||||||
Db          2 GAAGGGCCCAACATCT 17
```

```
RESULT 751
ADB54472
ID   ADB54472 standard; DNA; 18 BP.
XX
AC   ADB54472;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Hybridisation oligonucleotide 10 used to analyse genomic DNA region.
XX
KW   colon cell proliferative disorder; non methylated CpG dinucleotide;
KW   cytostatic; cancer; adenoma; carcinoma; cytosine methylation state; ss;
KW   probe.
XX
OS   Unidentified.
XX
PN   WO2003072821-A2.
XX
PD   04-SEP-2003.
XX
PF   27-FEB-2003; 2003WO-EP002035.
XX
PR   27-FEB-2002; 2002EP-00004551.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Adorjan P,  Burger M,  Maier S,  Nimmrich I,  Becker E,  Lesche R;
PI   Rujan T,  Schmitt A;
XX
DR   WPI; 2003-731620/69.
XX
PT   Detecting and differentiating between colon cell proliferative disorders
PT   associated with a gene or its regulatory regions comprises contacting a
PT   target nucleic acid in a biological sample obtained from the subject with
PT   a reagent.
XX
PS   Claim 36; Page 27; 74pp; English.
XX
CC   The invention relates to a novel method for detecting and differentiating
CC   between colon cell proliferative disorders associated with at least one
CC   gene or its regulatory regions. The method comprises contacting a target
CC   nucleic acid in a biological sample obtained from the subject with at
CC   least one reagent or a series of reagents, where the reagent or series of
CC   reagents, distinguishes between methylated and non methylated CpG
CC   dinucleotides within the target nucleic acid. The molecules of the
CC   invention demonstrate cytostatic activity whilst the method may useful
CC   for detecting and differentiating between colon cell proliferative
CC   disorders, including cancers such as colon adenoma and colon carcinoma.
CC   The PNA (peptide nucleic acid)-oligomers are useful as probes for
CC   determining cytosine methylation state or single nucleotide
CC   polymorphisms. The current sequence is that of the hybridisation
CC   oligonucleotide of the invention which was used to analyse the genomic
CC   DNA region.
XX
SQ   Sequence 18 BP; 2 A; 0 C; 5 G; 11 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3859 GAGTTTTGTTTTTGGT 3874
              ||||||||||||||  |
Db          3 GAGTTTTGTTTTTGTT 18


RESULT 752
ADF90215
ID   ADF90215 standard; DNA; 18 BP.
XX
AC   ADF90215;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human NF-kappa-B p65 subunit antisense oligonucleotide #39.
XX
KW   Human; NF-kappa-B p65 subunit; ss; antisense; stress; cancer;
KW   autoimmune disease; multiple sclerosis; hyperproliferative disorder;
KW   apoptosis-related disease; inflammation; infection; growth disorder.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxtethyl residue and all cytidines are 5-
FT                   methylcytidines"
FT   modified_base   15. .18
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxtethyl residue and all cytidines are 5-
FT                   methylcytidines"
XX
PN   US2003175793-A1.
XX
PD   18-SEP-2003.
XX
PF   25-APR-2003; 2003US-00424211.
XX
PR   25-NOV-1998;   98US-00199859.
PR   23-NOV-1999;   99WO-US027762.
PR   24-MAY-2001; 2001US-00856747.
XX
PA   (BENN/) BENNETT C F.
PA   (MONI/) MONIA B P.
PA   (COWS/) COWSERT L M.
XX
PI   Bennett CF,  Monia BP,  Cowsert LM;
XX
DR   WPI; 2003-898531/82.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding human NF-kappa-B p65 subunit, useful for preparing a composition
PT   for treating e.g., autoimmune disease or hyperproliferative disorder.
XX
PS   Claim 3; SEQ ID NO 46; 33pp; English.
XX
CC   The invention relates a new antisense compound, having a sequence
CC   comprising 8-50 bp targeted to a nucleic acid encoding human NF-kappa-B
CC   p65 subunit, specifically hybridises with the nucleic acid encoding human
CC   NF-kappa-B p65 subunit and inhibits its expression. Also included are a
CC   pharmaceutical composition, a method of inhibiting the expression of
CC   human NF-kappa-B p65 subunit in cells or tissues, and a method of
CC   treating an animal having or suspected of having a disease or condition
CC   associated with human NF-kappa-B p65 subunit. The compound is useful for
CC   preparing a composition for treating autoimmune disease e.g., multiple
CC   sclerosis or hyperproliferative disorder e.g., cancer, stress, apoptosis-
CC   related disease, inflammation, infection and growth disorders. The
CC   present sequence is a Human NF-kappa-B p65 subunit antisense
CC   oligonucleotide of the invention.
XX
SQ   Sequence 18 BP; 6 A; 2 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2669 TGGAGGAGAACTCTTC 2684
              ||||||||||  |||||
Db          2 TGGAGGAGAAGTCTTC 17
```

```
RESULT 753
ADH94506/c
ID   ADH94506 standard; DNA; 18 BP.
XX
AC   ADH94506;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human gene PCR primer #1351.
XX
KW   human; gene sequence; single nucleotide polymorphism; SNP;
KW   disease diagnosis; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   JP2003174883-A.
XX
PD   24-JUN-2003.
XX
PF   11-DEC-2001; 2001JP-00377637.
XX
PR   11-DEC-2001; 2001JP-00377637.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR   WPI; 2003-819215/77.
XX
PT   Polynucleotide for detecting single nucleotide polymorphisms existing in
PT   human gene, contains isolated human gene having specified sequence.
XX
PS   Claim 2; SEQ ID NO 2343; 529pp; Japanese.
XX
CC   The invention comprises isolated human gene sequences and PCR primer
CC   sequences which can be used to detect single nucleotide polymorphisms
CC   (SNPs). The DNA sequences of the invention are useful for detecting SNPs
CC   existing in human genes and for the diagnosis of human disease. The
CC   present DNA sequence represents a human gene PCR primer of the invention.
XX
SQ   Sequence 18 BP; 5 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3769 CCAACTTGCTGCTGTC 3784
              ||||||||||||||| |
Db         16 CCAACTTGCTGCTGCC 1


RESULT 754
ADH71082
ID   ADH71082 standard; DNA; 18 BP.
XX
AC   ADH71082;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Vbeta microsatellite primer #25.
XX
KW   human; T-cell associated disease; Vbeta; autoimmune disease;
KW   degenerative nervous system disease; graft versus host disease;
KW   hypersensitivity disease; infectious disease; neoplastic disease;
KW   Addison's disease; atrophic gastritis;
KW   degenerative nervous system disease; multiple sclerosis;
KW   Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW   allergy; type II hypersensitivity; Goodpasture's syndrome;
KW   type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW   HIV; fungal infection; Candida; parasitic infection; schistosome;
KW   filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW   lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW   breast cancer; ss; primer; microsatellite.
XX
OS   Homo sapiens.
XX
PN   US2002150891-A1.
XX
PD   17-OCT-2002.
XX
PF   05-MAR-1999;   99US-00263959.
XX
PR   19-SEP-1994;   94US-00309335.
PR   19-SEP-1995;   95US-00531241.
XX
PA   (HOOD/) HOOD L E.
PA   (ROWE/) ROWEN L.
XX
PI   Hood LE,  Rowen L;
XX
DR   WPI; 2004-059052/06.
XX
PT   Kit for diagnozing and treating T-cell associated diseases e.g.
PT   autoimmune, degenerative nervous system and infectious disease, comprises
PT   nucleic acid primers specifically priming and allowing amplification of a
PT   Vbeta gene.
XX
PS   Disclosure; SEQ ID NO 1276; 164pp; English.
XX
CC   The invention relates to a kit for diagnosing and treating T-cell
CC   associated diseases which comprises a panel of nucleic acid primers
CC   specifically priming and allowing amplification of each Vbeta gene,
CC   VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
CC   rejection and diagnosing and treating T-cell associated diseases
CC   including autoimmune diseases, degenerative nervous system diseases,
CC   graft versus host disease, hypersensitivity diseases, infectious diseases
CC   and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC   atrophic gastritis. Degenerative nervous system diseases include multiple
CC   sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
CC   I hypersensitivities such as contact with allergens that lead to
CC   allergies, Type II hypersensitivities such as those present in
CC   Goodpasture's syndrome and Type IV hypersensitivities such as those
CC   manifested in leprosy. Infectious diseases include viral infections
CC   caused by viruses such as HIV, fungal infections such as those caused by
CC   the yeast genus Candida, parasitic infections such as those caused by
CC   schistosomes, filaria and bacterial infections such as those caused by
CC   Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC   such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC   breast. The present sequence represents a Vbeta microsatellite primer.
XX
SQ   Sequence 18 BP; 3 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        753 CACGCCAGCCTGGATG 768
              ||| ||||||||||||
Db          3 CACTCCAGCCTGGATG 18


RESULT 755
ADM83057
ID   ADM83057 standard; DNA; 18 BP.
XX
AC   ADM83057;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human NF-kappa-B p65 sub-unit antisense oligonucleotide ISIS 23770.
XX
KW   ss; antisense; human; NF-kappa-B p65 sub-unit; infection; inflammation;
KW   tumour formation.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
```

```
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER = phosphorothioate backbone. Optionally 1-4
FT                   and 15-18 are 2'-methoxyethyl (2'-MOE) nucleotides. All
FT                   2'-MOE cytidines are 5-methylcytidines"
XX
PN   US6656688-B1.
XX
PD   02-DEC-2003.
XX
PF   24-MAY-2001; 2001US-00856747.
XX
PR   25-NOV-1998;   98US-00199859.
PR   23-NOV-1999;   99WO-US027762.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Monia BP,  Cowsert LM;
XX
DR   WPI; 2004-058362/06.
XX
PT   New antisense oligonucleotides inhibiting the expression of human NF-
PT   kappa-B p65 subunit, useful for treating diseases associated with p65
PT   expression, or for preventing or delaying infection, inflammation or
PT   tumor formation.
XX
PS   Example 15; SEQ ID NO 46; 32pp; English.
XX
CC   The invention relates to an antisense compound targeted to a nucleic acid
CC   molecule encoding human NF-kappa-B p65 sub-unit. The antisense compound
CC   may used as a prophylaxis to prevent or delay infection, inflammation or
CC   tumour formation; used for the treatment of disease or disorder
CC   associated with the expression of NF-kappa-B p65 sub-unit; for research
CC   and diagnostics; or as reagents and kits. Antisense compounds may be used
CC   as research reagents and diagnostics, to elucidate the function of
CC   particular genes, to distinguish between functions of various members of
CC   biological pathway and in treatment regimes of cells, tissues, and
CC   animals. The present sequence represents a human NF-kappa-B p65 sub-unit
CC   antisense oligonucleotide.
XX
SQ   Sequence 18 BP; 6 A; 2 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2669 TGGAGGAGAACTCTTC 2684
             ||||||||||  |||||
Db          2 TGGAGGAGAAGTCTTC 17


RESULT 756
ADS90640/c
ID   ADS90640 standard; DNA; 18 BP.
XX
AC   ADS90640;
XX
DT   18-NOV-2004  (first entry)
XX
DE   Oligonucleotide of the invention SEQ ID NO:1656.
XX
KW   ss; cell proliferative disorder; breast; methylation; cytostatic;
KW   gene therapy; single nucleotide polymorphism; SNP.
XX
OS   Unidentified.
XX
PN   WO2004035803-A2.
XX
PD   29-APR-2004.
XX
PF   01-OCT-2003; 2003WO-EP010881.
XX
PR   01-OCT-2002; 2002DE-01045779.
PR   07-JAN-2003; 2003DE-01000096.
PR   17-APR-2003; 2003DE-01017955.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Foekens J,  Harbeck N,  Koenig T,  Maier S,  Martens J,  Model F;
PI   Nimmrich I,  Rujan T,  Schmitt A,  Schmitt M,  Look MP,  Marx A;
XX
DR   WPI; 2004-348468/32.
XX
PT   Predicting responsiveness of a subject with breast cell proliferative
PT   disorder, useful for treating or differentiating breast cell
PT   proliferative disorders comprises analyzing methylation pattern of a
PT   genomic DNA from the subject.
XX
PS   Disclosure; SEQ ID NO 1656; 104pp; English.
XX
CC   The invention relates to a novel method for predicting the responsiveness
CC   of a subject with a cell proliferative disorder of the breast tissues to
CC   a therapy comprising analysing the methylation pattern of a target
CC   nucleic acid by contacting at least one of the target nucleic acids in a
CC   biological sample obtained from the subject prior to or during treatment.
CC   The method of the invention has cytostatic activity, and may have a use
CC   in gene therapy. The set of oligonucleotides comprising at least two of
CC   the oligomers are useful for detecting the cytosine methylation state
CC   and/or single nucleotide polymorphisms (SNPs) within the sequences. The
CC   methods, nucleic acid, oligonucleotide, and kit are useful for the
CC   treatment, characterisation, classification and/or differentiation, of
CC   breast cell proliferative disorders. The method is also useful for
CC   predicting the responsiveness of a subject with a cell proliferative
CC   disorder of the breast tissues to a therapy. The present sequence is used
CC   in the exemplification of the invention.
XX
SQ   Sequence 18 BP; 7 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       3789 CCAAACTCAATCATTT 3804
              |||||  ||||||||||
Db         16 CCAAATTCAATCATTT 1


RESULT 757
ADZ66354/c
ID   ADZ66354 standard; DNA; 18 BP.
XX
AC   ADZ66354;
XX
DT   14-JUL-2005  (first entry)
XX
DE   DNA methylation analysis method-related human CBFA2T3 PCR primer SeqID37.
XX
KW   DNA methylation; gene expression; cancer; breast tumor; prostate tumor;
KW   ovary tumor; hepatocellular carcinoma; CBFA2T3; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2005038046-A1.
XX
PD   28-APR-2005.
XX
PF   14-OCT-2004; 2004WO-AU001398.
XX
PR   14-OCT-2003; 2003AU-00905593.
XX
PA   (BION-) BIONOMICS LTD.
XX
PI   Bais AJ,  Kremmidiotis G;
XX
DR   WPI; 2005-322870/33.
XX
```

```
PT   Identifying normal cell methylation range in locus of interest by
PT   modifying nucleic acids by cytosine-conversion, identifying sample with
PT   methylated CpG sites, producing methylation map, quantifying methylation
PT   ratio, establishing range.
XX
PS   Example 1; SEQ ID NO 37; 80pp; English.
XX
CC   This invention relates to a novel method of identifying a normal cell
CC   methylation range in a locus of interest. The method involves providing
CC   separately nucleic acids from samples and modifying the nucleic acids by
CC   cytosine-conversion, identifying samples with high to moderately
CC   methylated CpG sites, generating a methylation map, performing
CC   amplification of specific CpG sites, quantifying the unmethylated to
CC   methylated ratio and establishing a correlation between methylation and
CC   mRNA expression levels. The method is useful for identifying a normal
CC   cell methylation range, in order to allow for the detection of aberrant
CC   methylation, in a locus of interest in a nucleic acid, particularly at a
CC   CpG island. The invention is useful for detecting aberrant methylation in
CC   a locus of interest in a nucleic acid, particularly at a CpG island, of a
CC   subject and may be useful for diagnosis or prognosis of a disease in a
CC   subject. The disease is cancer chosen from breast cancer, prostate
CC   cancer, ovarian cancer, hepatocellular cancer and primitive
CC   neuroectodermal cancer. The invented method is preferably useful for
CC   screening samples for aberrant methylation of the CBFA2T3 gene and
CC   enables high sensitive and accurate quantification of CpG methylation at
CC   any given genetics locus. The present sequence is that of a PCR primer
CC   which was used for amplification of a region of the human CBFA2T3 gene in
CC   the exemplification of the invention.
XX
SQ   Sequence 18 BP; 2 A; 10 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2700 GAGCTCCCTGGGAGGA 2715
                ||||| ||||||||||
Db         18 GAGCTGCCTGGGAGGA 3


RESULT 758
AEA12272/c
ID   AEA12272 standard; DNA; 18 BP.
XX
AC   AEA12272;
XX
DT   28-JUL-2005  (first entry)
XX
DE   Human KIR allele 2DS4*00101/00102/002 sense PCR primer.
XX
KW   ss; primer; PCR; killer-cell immunoglobulin-like receptor;
KW   allelic variation; DNA detection.
XX
OS   Homo sapiens.
XX
PN   WO2005046459-A2.
XX
PD   26-MAY-2005.
XX
PF   15-MAR-2004; 2004WO-US007925.
XX
PR   22-OCT-2003; 2003US-0513307P.
XX
PA   (PELF-) PEL-FREEZ CLINICAL SYSTEMS INC.
XX
PI   Dinauer D,  Wang L;
XX
DR   WPI; 2005-417488/42.
XX
PT   Primer set for identifying killer-cell immunoglobulin-like receptor KIR
PT   allele or all of presently known KIR alleles, comprises primer pairs
PT   capable of producing amplicon having specific length from nucleic acid
PT   encoding KIR.
XX
PS   Example 1; Page 23; 32pp; English.
XX
CC   The invention relates to a novel primer set for identifying a killer-cell
CC   immunoglobulin-like receptor (KIR) allele or identifying all of the
CC   presently known KIR alleles, comprising a first primer pair that
CC   comprises a first primer and second primer, or several primer pairs
CC   capable of identifying all presently known KIR alleles, where the primer
CC   pairs are capable of producing an amplicon that is less than or 1000
CC   bases in length from a nucleic acid that encodes a KIR. The primer set is
CC   useful for detecting a KIR allele, in carrying out reverse transcriptase
CC   (RT)-PCR of KIR mRNA for expression analysis, and for identifying single
CC   KIR allele. The primer set is useful for defining or identifying KIR
CC   haplotypes, genotypes and polymorphic variations in an individual or in
CC   different populations, for identifying KIR compatible and incompatible
CC   stem cell transplant donor-recipient pairs and for studying if KIR
CC   mismatching between donor and recipient correlates with KIR epitope
CC   mismatch predicted by human leukocyte antigen (HLA). The primer set
CC   provides high resolution or allele level genotyping that primarily target
CC   polymorphism in the extracellular domains of the KIR genes. The sequences
CC   shown in (AEA12251-AEA12290) represent the primer set of the invention.
XX
SQ   Sequence 18 BP; 3 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.3%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       378 GGAGCTCCGGGTGCTG 393
                ||||||||||| ||||
Db        16 GGAGCTCCGGGAGCTG 1


Search completed: March 23, 2006, 11:10:29
Job time : 43 secs
```

THIS PAGE BLANK (USPTO)